PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	[Anonymous]				[Anonymous]			Hypnotism (Reprint from JAMA vol 121, pg 1250, 1943)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		ERICKSON MH, 1943, JAMA-J AM MED ASSOC, V121, P1250	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2018	319	14					1512	1512		10.1001/jama.2018.0761	http://dx.doi.org/10.1001/jama.2018.0761			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC2CR	29634820				2023-01-03	WOS:000429590200032
J	Abu-Gharbieh, E; Shehab, NG; Almasri, IM; Bustanji, Y				Abu-Gharbieh, Eman; Shehab, Naglaa G.; Almasri, Ihab M.; Bustanji, Yasser			Antihyperuricemic and xanthine oxidase inhibitory activities of Tribulus arabicus and its isolated compound, ursolic acid: In vitro and in vivo investigation and docking simulations	PLOS ONE			English	Article							CRYSTAL-STRUCTURE; ALLOPURINOL; OXIDOREDUCTASE; MECHANISM; ANTITUMOR; COMPLEX; LEAVES	Background Hyperurecemia is usually associated with gout and various metabolic arthritis disorders. Limited medications are available to manage such conditions. This study aimed to isolate the triterpenes constituent of the plant and to assess xanthine oxidase (XO) inhibitory and antihyperuricemic activities of Tribulus arabicus ethanolic extract, its fractions and the isolated compound using in vitro and in vivo approaches. Methods The ethanolic extract, fractions; n-hexane, chloroform and n-butanol and the isolated compound (ursolic acid) were evaluated in vitro for their XO inhibitory activity. Those that demonstrated significant activity were further evaluated for their antihyperuricemic activity on potassium oxonate-induced hyperuricemia in mice. Results The ethanolic extract was found to be safe up to 5000 mg/kg. The extract and its n-hexane fraction exhibited significant inhibitory activity on XO, whilst only a modest reduction in the enzymatic activity was noticed with n-butanol and chloroform fractions. Furthermore, administration of the ethanolic extract at low and high doses significantly reduced serum urate levels in mice by 31.1 and 64.6% respectively. The isolated active constituent, ursolic acid, showed potent XO inhibition activity (Half maximal inhibitory concentration, IC50 = 10.3 mu g/mL), and significantly reduced uric acid level in vivo by 79.9%. Virtually, the binding mode of ursolic acid with XO was determined using molecular docking simulations. Conclusions The activity of the ethanolic extract of T. arabicus and its n-hexane fraction can be attributed to the isolated compound, ursolic acid. Ursolic acid has good hypouricemic activity and therefore has high potential to be used for the treatment of gout and hyperuricemia-related diseases.	[Abu-Gharbieh, Eman] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates; [Abu-Gharbieh, Eman] Dubai Pharm Coll, Dept Pharmacol & Toxicol, Dubai, U Arab Emirates; [Shehab, Naglaa G.] Dubai Pharm Coll, Dept Pharmaceut Chem & Nat Prod, Dubai, U Arab Emirates; [Shehab, Naglaa G.] Cairo Univ, Fac Pharm, Dept Pharmacognosy, Cairo, Egypt; [Almasri, Ihab M.] Al Azhar Univ, Fac Pharm, Dept Pharmaceut Chem & Pharmacognosy, Gaza, Palestine; [Bustanji, Yasser] Univ Jordan, Fac Pharm, Dept Biopharmaceut & Clin Pharm, Amman, Jordan; [Bustanji, Yasser] Univ Jordan, Hamdi Mango Ctr Sci Res, Amman, Jordan	University of Sharjah; Egyptian Knowledge Bank (EKB); Cairo University; University of Jordan; University of Jordan	Abu-Gharbieh, E (corresponding author), Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates.; Abu-Gharbieh, E (corresponding author), Dubai Pharm Coll, Dept Pharmacol & Toxicol, Dubai, U Arab Emirates.	eabugharbieh@sharjah.ac.ae	Almasri, Ihab/AAK-5245-2021; Abu-Gharbieh, Eman/F-3635-2010; Bustanji, Yasser/C-2626-2015	Abu-Gharbieh, Eman/0000-0002-5972-0681; shehab, naglaa/0000-0002-7514-4055; Bustanji, Yasser/0000-0003-1315-0609				Abu-Gharbieh E, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1729-9; Akhtari E, 2014, DARU, V22, DOI 10.1186/2008-2231-22-40; Al-Bayati FA, 2008, J ZHEJIANG UNIV-SC B, V9, P154, DOI 10.1631/jzus.B0720251; [Anonymous], 2014, MARVINSKETCH CALCULA; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Berry CE, 2004, J PHYSIOL-LONDON, V555, P589, DOI 10.1113/jphysiol.2003.055913; Cao HN, 2014, J NAT PROD, V77, P1693, DOI 10.1021/np500320g; Chhatre Saurabh, 2014, Pharmacogn Rev, V8, P45, DOI 10.4103/0973-7847.125530; de Faria ELP, 2017, ACS SUSTAIN CHEM ENG, V5, P7344, DOI 10.1021/acssuschemeng.7b01616; Fried R. FLW., 1974, IMETHODS ENZYMATIC A, P644; Hille R, 1985, MOLYBDENUM ENZYMES; Hu XY, 2018, RSC ADV, V8, P6532, DOI 10.1039/c7ra11856b; Jongbloed M., 2003, COMPREHENSIVE GUIDE; Kamboj P, 2011, Indian J Nephrol, V21, P154, DOI 10.4103/0971-4065.83727; Kong LD, 2001, PHYTOCHEMISTRY, V58, P645, DOI 10.1016/S0031-9422(01)00176-5; Ksiksi Taoufik, 2017, Current Bioactive Compounds, V13, P82, DOI 10.2174/1573407212666161014130546; Landmesser U, 2002, CIRCULATION, V106, P3073, DOI 10.1161/01.CIR.0000041431.57222.AF; Lewis CT, 1963, LATIN DICT BASED AND; LORKE D, 1983, ARCH TOXICOL, V54, P275, DOI 10.1007/BF01234480; Lu J, 2010, FOOD SCI, V30, P250, DOI [10.7506/spkx1002-6630-200913057, DOI 10.7506/SPKX1002-6630-200913057]; Mohammad MK, 2010, PHARM BIOL, V48, P1376, DOI 10.3109/13880209.2010.483521; National Research Council of the National Academies, 2011, GUIDE CARE USE LAB A, V8th, DOI DOI 10.17226/12910; Duong NT, 2017, ASIAN PAC J TROP MED, V10, P619, DOI 10.1016/j.apjtm.2017.06.002; Okamoto K, 2003, J BIOL CHEM, V278, P1848, DOI 10.1074/jbc.M208307200; Okamoto K, 2008, NUCLEOS NUCLEOT NUCL, V27, P888, DOI 10.1080/15257770802146577; OMEGA, 2013, OMEGA2514; Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6; Pai PG, 2012, NEPHROPROTECTIVE EFF; Shan JZ, 2016, PROTEIN CELL, V7, P571, DOI 10.1007/s13238-016-0295-0; Sheng HM, 2011, NAT PROD REP, V28, P543, DOI 10.1039/c0np00059k; STAVRIC B, 1975, PHARMACOL RES COMMUN, V7, P117, DOI 10.1016/S0031-6989(75)80015-4; Sultana N, 2011, J ENZYM INHIB MED CH, V26, P616, DOI 10.3109/14756366.2010.546793; Tapsell LC, 2006, MED J AUSTRALIA, V185, pS4; Umpierrez A, 1998, J ALLERGY CLIN IMMUN, V101, P286, DOI 10.1016/S0091-6749(98)70396-3; Unno T, 2004, J ETHNOPHARMACOL, V93, P391, DOI 10.1016/j.jep.2004.04.012; Wallach SL, 1998, HOSP PRACT, V33, P22; Yang G, 2014, J AGR FOOD CHEM, V62, P2207, DOI 10.1021/jf405675g; Zhou XJ, 2009, DRUG DEV IND PHARM, V35, P305, DOI [10.1080/03639040802302165, 10.1080/03639040802302165 ]	38	21	21	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0202572	10.1371/journal.pone.0202572	http://dx.doi.org/10.1371/journal.pone.0202572			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ6RF	30114281	gold, Green Published, Green Submitted			2023-01-03	WOS:000441850400086
J	Huang, ZY; Liu, QY; Meng, HD; Liu, DP; Dobbs, D; Hyer, K; Conner, KO				Huang, Ziyue; Liu, Qingyue; Meng, Hongdao; Liu, Danping; Dobbs, Debra; Hyer, Kathryn; Conner, Kyaien O.			Factors associated with willingness to enter long-term care facilities among older adults in Chengdu, China	PLOS ONE			English	Article							ELDERLY CARE; MODEL	Objective To describe Chinese older adults' willingness to enter long-term care facilities and to examine individual factors associated with the willingness of using this growing model of long-term care in China. Methods A cross-sectional study involving a random sample of 670 adults aged 60+ in the Hezuo community in Chengdu, China in 2016. Respondents were interviewed by trained staff on socio-demographics, health status, quality of life, social support, and willingness to enter long-term care facilities. Results Only 11.9% of the respondents were willing to enter long-term care facilities for meeting their medical and social service needs. Multivariable logistic regression analysis showed that willingness to enter long-term care facilities was associated with higher household income (OR = 4.55, 95% CI: 1.72-12.00), insurance of Urban Resident Basic Medical Insurance (OR = 4.80, 95% CI: 1.17-19.67) and unemployment (OR = 0.48, 95% CI: 0.24-0.99). Among those who were willing to enter long-term care facilities, an overwhelming majority (81.2%) would prefer going to a facility within 30-minute walking distance from their current residence, 82.5% indicated the need of nursing care, and 90.0% expected a partnership between the long-term care facility and a large hospital. Conclusions A minority of older Chinese were willing to receive long-term care delivered at a facility within walking distance from their current residence. Recent policy aimed at increasing the supply of long-term care facilities may not be consistent with consumer preference for home and community-based care. Balancing investment between home and community-based care, and establishing long-term care insurance remain the top priorities for long-term care research and policy development in China.	[Huang, Ziyue; Liu, Qingyue; Liu, Danping] Sichuan Univ, West China Sch Publ Hlth, Dept Hlth Related Social & Behav Sci, Chengdu, Sichuan, Peoples R China; [Meng, Hongdao; Dobbs, Debra; Hyer, Kathryn] Univ S Florida, Sch Aging Studies, Coll Behav & Community Sci, Tampa, FL USA; [Conner, Kyaien O.] Univ S Florida, Dept Mental Hlth Law & Policy, Tampa, FL USA	Sichuan University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Liu, DP (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Dept Hlth Related Social & Behav Sci, Chengdu, Sichuan, Peoples R China.	liudanping03@163.com	Conner, Kyaien/HHS-3575-2022; Meng, Hongdao/AAF-1866-2020	Dobbs, Debra/0000-0002-9282-7624; Liu, Danping/0000-0002-8017-7134	Community Health Foundation of Chengdu	Community Health Foundation of Chengdu	This work was supported by the Community Health Foundation of Chengdu.	[Anonymous], 2018, OP STAT COUNC INT BA; [Anonymous], 2018, BED SUPPLY ELDERLY I; Banister J., 1994, 73 CIR US BUR CENS C; Bartlett H, 1997, HEALTH PLACE, V3, P149, DOI 10.1016/S1353-8292(97)00008-7; Butler RN, 1997, BRIT MED J, V315, P1082, DOI 10.1136/bmj.315.7115.1082; Byrd M R, 2005, BEHAV INTEGRATIVE CA, P1; Chen L, 2016, J AGING SOC POLICY, V28, P292, DOI 10.1080/08959420.2016.1151310; Chen S., 1996, SOCIAL POLICY EC STA; Cheng Q X, 2016, CHINESE HLTH SERVICE, V5, P334; Cheng Q X, 2016, CHINESE HLTH SERVICE, V5, P380; Du J, 2016, CHINA CIVIL AFFAIRS, V14, P49; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Eng C., 1996, CURR CONCEPTS GERIAT, V2, P4; Fang YY., 2016, J CHANGSHA SOC WORK, V23, P25; Feng ZL, 2011, J AM GERIATR SOC, V59, P738, DOI 10.1111/j.1532-5415.2011.03330.x; Goodwin Nick, 2015, Int J Integr Care, V15, pe037; Gu DN, 2007, SOC SCI MED, V64, P871, DOI 10.1016/j.socscimed.2006.10.026; Guo D., 2005, INT MED HLTH GUIDANC, V000, P43; [黄佳豪 Huang Jiahao], 2014, [中国卫生政策研究, Chinese Journal of Health Policy], V7, P63; Li R., 2016, UBLIC ADM LAW, V4, P42; Li T., 2015, PIONEER SCI TECHNOL, V28, P39; Lin WY, 2014, CHINA INT J, V12, P144; Liu DP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014510; Liu W J, 2016, CHINESE HLTH EC, V35, P35; MacAdam M, 2015, INT J INTEGR CARE, V15; Marek K D, 2000, Nurs Adm Q, V24, P1; Ministry of civil affairs of the people's repubic of China, 2013, OP STAT COUNC ACC DE; Mosqueda L, 2004, GERONTOLOGIST, V44, P703, DOI 10.1093/geront/44.5.703; Mui AC, 2002, J AGING SOC POLICY, V13, P53; National development and reform commission, 2013, OP STAT COUNC PROM D; Office of the national working committee on ageing, 2017, BBS INT IND PEAK AG; Office of the national working committee on aging, 2018, CHIN HAS 144 600 ELD; Ren L, 2017, CHINESE J GERONTOLOG, V37, P1782; Shen WW, 2015, CHINESE J GEN PRACTI, V6; Smith S M, 2007, COCHRANE DB SYST REV, V3, P10; Storch A, 2009, PARKINSONISM RELAT D, V15, pS41, DOI 10.1016/S1353-8020(09)70170-1; The state council of the people's repubic of China, 2015, GUID OP STAT COUNC P; Topp CW, 2015, PSYCHOTHER PSYCHOSOM, V84, DOI 10.1159/000376585; Tsutsui T, 2014, INT J INTEGR CARE, V14; van Bilsen PMA, 2008, HEALTH POLICY, V87, P285, DOI 10.1016/j.healthpol.2007.12.015; VICTOR CR, 1990, ARCH GERONTOL GERIAT, V10, P199, DOI 10.1016/0167-4943(90)90019-3; Wang D, 2018, HEALTH SOC CARE COMM, V26, pE164, DOI 10.1111/hsc.12490; Wang HF, 2011, HEALTH POLICY, V99, P37, DOI 10.1016/j.healthpol.2010.07.003; Wang LJ, 2016, INT J NURS PRACT, V22, P478, DOI 10.1111/ijn.12458; Wang Y., 2012, THESIS; Wang Y., 2016, STAT SCI PRACT, V8, P31; World Health Organization, 2003, WHO COLL LONG TERM C; Wu Bei, 2005, J Aging Soc Policy, V17, P37, DOI 10.1300/J031v17n04_03; Wu CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108548; Xiao SY., 1987, J CHINESE PSYCHIAT, V1, P184; Xiu-Ming L I, 2016, CHINESE GEN PRACTICE, V10, P1199; Xu QW, 2011, INT SOC WORK, V54, P374, DOI 10.1177/0020872810396260; Yan N, 2015, J HUAZHONG AGR U, V4, P22; ZANG Shaomin, 2015, SCI RES AGING, V12, P42; Zhan HJ, 2013, GENERATIONS, V37, P53; Zhang XF, 2017, CHINESE PRIMARY HLTH, V1, P1; Zhang ZY, 2014, CLIN INTERV AGING, V9, P771, DOI 10.2147/CIA.S58771; Zhao X F, 2014, LANZHOU ACAD J, V9, P129	58	10	11	3	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0202225	10.1371/journal.pone.0202225	http://dx.doi.org/10.1371/journal.pone.0202225			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GQ6RF	30114274	Green Published, Green Submitted, gold			2023-01-03	WOS:000441850400051
J	Salami, A; Bahmad, HF; Ghssein, G; Salloum, L; Fakih, H				Salami, Ali; Bahmad, Hisham F.; Ghssein, Ghassan; Salloum, Lamis; Fakih, Hadi			Prevalence of anemia among Lebanese hospitalized children: Risk and protective factors	PLOS ONE			English	Article							IRON-DEFICIENCY; INFANTS; SUPPLEMENTATION	Background Anemia is a global health problem associated with short- and long-term consequences especially in children. The incidence of anemia along with the factors associated with its increased or decreased risk is not yet well studied in Lebanon. Our study aims at determining the demographics of this health burden and identifying some of the important factors linked to it among the pediatric population. Methods A 4-months cross-sectional study was performed between August and November 2017 including 295 children aged 1 month to 12 years, who were hospitalized in a tertiary care hospital located in South Lebanon. We analyzed the different demographic data, age, gender, breast feeding duration, solid food introduction, iron supplementation and disease of diagnosis in association with multiple hematological parameters. Results The prevalence of both mild and moderate anemia was 71.8 and 25.4%, with only 2 cases of severe anemia encountered among children aged 6 months or above. Results showed that the risk of anemia increases by around 3.4 folds among malnourished children than in well-nourished children. This risk also decreased by almost 42% in children receiving iron supplement. Conclusion In consideration to the fact that anemia is a prevalent disease in the Lebanese childhood population, especially in infancy, simple preventive measures such as proper nutritional habits and supplementation of iron rich food to children are highly recommended and should be respected by public health providers.	[Salami, Ali] Lebanese Univ, Fac Sci 5, Dept Math, Nabatieh, Lebanon; [Bahmad, Hisham F.] Amer Univ Beirut, Fac Med, Dept Anat Cell Biol &Physiol Sci, Beirut, Lebanon; [Ghssein, Ghassan] Lebanese Univ, Fac Sci 5, Dept Biol, Nabatieh, Lebanon; [Salloum, Lamis; Fakih, Hadi] Ragheb Harb Hosp, Pediat Dept, Iranian Red Crescent, Toul, Lebanon; [Fakih, Hadi] Lebanese Univ, Fac Med Sci, Pediat Dept, Beirut, Lebanon	Lebanese University; American University of Beirut; Lebanese University; Lebanese University	Salami, A (corresponding author), Lebanese Univ, Fac Sci 5, Dept Math, Nabatieh, Lebanon.	salami.ali@hotmail.com	Bahmad, Hisham/A-5369-2019; Ghssein, Ghassan/GRJ-7050-2022; Salami, Ali/AAE-3988-2020	Bahmad, Hisham/0000-0003-3799-2595; Salami, Ali/0000-0003-3343-4035; Ghssein, Ghassan/0000-0002-9313-1418	RHH; LU	RHH; LU	We would like to express our gratitude thanks to the RHH and LU for their support in the conduction of this study.	[Anonymous], 2008, WORLDWIDE PREVALENCE; [Anonymous], 2001, IRON DEFICIENCY ANAE; [Anonymous], 2008, WORLDWIDE PREVALENCE; Assefa Selomon, 2014, BMC Hematol, V14, P3, DOI 10.1186/2052-1839-14-3; Berglund SK, 2015, J PEDIATR GASTR NUTR, V60, P390, DOI 10.1097/MPG.0000000000000633; Santos Rosemary Ferreira dos, 2011, Rev. Bras. Hematol. Hemoter., V33, P100, DOI 10.5581/1516-8484.20110028; Gallagher P.G., 2015, NATHAN OSKIS HEMATOL, P52; Garlo K, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000964; Levy A, 2005, EUR J EPIDEMIOL, V20, P277, DOI 10.1007/s10654-004-6515-6; Lima Ana C. V. M. S., 2006, J. Pediatr. (Rio J.), V82, P452, DOI [10.2223/JPED.1568, 10.1590/S0021-75572006000800010]; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Chulilla JAM, 2009, WORLD J GASTROENTERO, V15, P4627, DOI 10.3748/wjg.15.4627; Muncie HL, 2009, AM FAM PHYSICIAN, V80, P339; Muthusamy BG, 2017, INT J CONT PEDIAT, V4, P431, DOI 10.18203/2349-3291.IJCP20170683; Neves Márcia Bitar Portella, 2005, Cad. Saúde Pública, V21, P1911, DOI 10.1590/S0102-311X2005000600041; Righetti AA, 2012, AM J TROP MED HYG, V87, P425, DOI 10.4269/ajtmh.2012.11-0788; Rocha Daniela da Silva, 2012, Rev. bras. epidemiol., V15, P675, DOI 10.1590/S1415-790X2012000300020; Sachdev HPS, 2013, EUR J CLIN NUTR, V67, P475, DOI 10.1038/ejcn.2012.212; Sandoval C, 2018, APPROACH CHILD ANEMI; SILVA Danielle Góes da, 2002, Rev. Nutr., V15, P301; Simbauranga Rehema H, 2015, BMC Hematol, V15, P13, DOI 10.1186/s12878-015-0033-5; Travassos C, 1999, CIENC SAUDE COLET, V4, P367, DOI [10.1590/S1413-81231999000200011, DOI 10.1590/S1413-81231999000200011]; WALTER T, 1989, PEDIATRICS, V84, P7; Wang M, 2016, AM FAM PHYSICIAN, V93, P270; WHO Scientific Group on Nutritional Anaemias & World Health Organization, 1968, NUTR AN REP WHO SCI; World Health Organization, 1989, PREV CONTR AN PRIM H; World Health Organization, 2015, HAEM CONC DIAGN AN A	27	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2018	13	8							e0201806	10.1371/journal.pone.0201806	http://dx.doi.org/10.1371/journal.pone.0201806			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP7ZN	30086152	Green Submitted, gold, Green Published			2023-01-03	WOS:000441129300032
J	Budriesi, R; Vivarelli, F; Canistro, D; Aldini, R; Marquillas, CB; Corazza, I; Fato, R; Cirillo, S; Bergamini, C; D'Errico, A; Bolchi, C; Cevenini, M; Degiovanni, A; Frosini, M; Camarda, L; Chiarini, A; Micucci, M				Budriesi, Roberta; Vivarelli, Fabio; Canistro, Donatella; Aldini, Rita; Marquillas, Clara Babot; Corazza, Ivan; Fato, Romana; Cirillo, Silvia; Bergamini, Christian; D'Errico, Antonia; Bolchi, Cristiano; Cevenini, Monica; Degiovanni, Alessio; Frosini, Maria; Camarda, Luca; Chiarini, Alberto; Micucci, Matteo			Liver and intestinal protective effects of Castanea sativa Mill. bark extract in high-fat diet rats	PLOS ONE			English	Article							ELLAGIC ACID; INCREASED EXPRESSION; CYTOCHROME-P450 2E1; OXIDATIVE STRESS; NITRIC-OXIDE; GUINEA-PIG; OBESITY; CELLS; ANTIOXIDANT; STEATOHEPATITIS	The effects of Castanea sativa Mill. have been studied in high fat diet (HFD) overweight rats. Natural Extract of Chestnut bark (Castanea sativa Mill.) (ENC (R)), rich in ellagitannins, has been studied in 120 male Sprague-Dawley rats, divided in four groups. Two groups were controls: regular (RD) and HDF diet. Two groups received ENC (R) (20 mg/kg/day): RD + ENC (R) and HFD + ENC (R). At baseline and at 7, 14 and 21 days, weight gain, serum lipids, plasma cytokines, liver histology, microsomial enzymes and oxidation, intestinal oxidative stress and contractility were studied. HFD increased body weight, increased pro-inflammatory cytokines, induced hepatocytes microvescicular steatosis, altered microsomial, increased liver and intestinal oxidative stress, deranged intestinal contractility. In HFD-fed rats, ENC (R) exerted antiadipose and antioxidative activities and normalized intestinal contractility, suggesting a potential approach to overweight management associated diseases.	[Budriesi, Roberta; Vivarelli, Fabio; Canistro, Donatella; Aldini, Rita; Marquillas, Clara Babot; Fato, Romana; Cirillo, Silvia; Bergamini, Christian; Camarda, Luca; Chiarini, Alberto; Micucci, Matteo] Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy; [Corazza, Ivan] Alma Mater Studiorum Univ Bologna, S Orsola Hosp, Dept Specialist Expt & Diagnost Med, Bologna, Italy; [D'Errico, Antonia; Degiovanni, Alessio] Alma Mater Studiorum Univ Bologna, F Addari Inst Oncol & Transplant Pathol, Dept Specialist, Diagnost & Expt Med Dept, Bologna, Italy; [Bolchi, Cristiano] Univ Milan, Dept Pharmaceut Sci Pietro Pratesi, Milan, Italy; [Cevenini, Monica] Alma Mater Studiorum Univ Bologna, Dept Surg & Med Sci, Bologna, Italy; [Frosini, Maria] Univ Siena, Dept Life Sci, Siena, Italy; [Chiarini, Alberto] GVM Care & Res, Lugo, Ravenna, Italy	University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Milan; University of Bologna; University of Siena	Canistro, D; Micucci, M (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.	donatella.canistro@unibo.it; matteo.micucci2@unibo.it	bolchi, cristiano/G-5239-2015; Corazza, Ivan/AAY-8566-2021; Micucci, Matteo/AAM-6126-2020	bolchi, cristiano/0000-0002-6726-9501; Corazza, Ivan/0000-0003-2078-1978; Vivarelli, Fabio/0000-0002-8734-0985; CANISTRO, DONATELLA/0000-0002-6378-1698; MICUCCI, MATTEO/0000-0003-3525-1531; FROSINI, MARIA/0000-0002-4452-8128; Cirillo, Silvia/0000-0003-1533-6247	Alma Mater Studiorum-University of Bologna (Italy)	Alma Mater Studiorum-University of Bologna (Italy)	This work was supported by Alma Mater Studiorum-University of Bologna (Italy) in the form of research financial support awarded to RB, as an Associate Professor of the University of Bologna. GVM Care & Research provided support in the form of cultural contributions for AC. The specific role of this author is articulated in the 'author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors received no specific funding for this work and are grateful to Alma Mater Studiorum-University of Bologna (Italy) by research financial support (RFO-University of Bologna). The authors thank "GVM Care & Research" for cultural contribution and declare that it did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abdelmegeed MA, 2012, J HEPATOL, V57, P860, DOI 10.1016/j.jhep.2012.05.019; Abidov M, 2010, DIABETES OBES METAB, V12, P72, DOI 10.1111/j.1463-1326.2009.01132.x; Alexopoulos N, 2014, ATHEROSCLEROSIS, V233, P104, DOI 10.1016/j.atherosclerosis.2013.12.023; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Asayama K, 2001, FREE RADICAL RES, V34, P337, DOI 10.1080/10715760100300291; Aubert J, 2011, CLIN RES HEPATOL GAS, V35, P630, DOI 10.1016/j.clinre.2011.04.015; Basile A, 2000, FITOTERAPIA, V71, pS110, DOI 10.1016/S0367-326X(00)00185-4; Bhattarai Y, 2016, AM J PHYSIOL-GASTR L, V311, pG210, DOI 10.1152/ajpgi.00085.2016; Bowles DK, 2004, J APPL PHYSIOL, V96, P2240, DOI 10.1152/japplphysiol.01229.2003; Braunersreuther V, 2012, WORLD J GASTROENTERO, V18, P727, DOI 10.3748/wjg.v18.i8.727; Brizi C, 2016, J CELL BIOCHEM, V117, P510, DOI 10.1002/jcb.25302; Budriesi R, 2010, J MED FOOD, V13, P1104, DOI 10.1089/jmf.2009.0210; Calliste CA, 2005, J AGR FOOD CHEM, V53, P282, DOI 10.1021/jf049341c; Canistro D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02317-8; Chiarini A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/471790; Christou DD, 2012, AM J PHYSIOL-HEART C, V303, pH743, DOI 10.1152/ajpheart.00394.2012; Cimino F, 2013, GENES NUTR, V8, P391, DOI 10.1007/s12263-012-0324-4; Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003; El-Assal O, 2004, CELL MOL IMMUNOL, V1, P205; Frankic T, 2011, J SCI FOOD AGR, V91, P1432, DOI 10.1002/jsfa.4328; Girish C, 2008, FUND CLIN PHARMACOL, V22, P623, DOI 10.1111/j.1472-8206.2008.00618.x; Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88; Huang DW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010254; Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307; Jennings LJ, 1999, AM J PHYSL 1, V277; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Kang I, 2016, ADV NUTR, V7, P961, DOI 10.3945/an.116.012575; Lei F, 2007, INT J OBESITY, V31, P1023, DOI 10.1038/sj.ijo.0803502; Lemmers A, 2009, HEPATOLOGY, V49, P646, DOI 10.1002/hep.22680; Li ZP, 2015, ANAEROBE, V34, P164, DOI 10.1016/j.anaerobe.2015.05.012; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Matsuda M, 2014, REV ENDOCR METAB DIS, V15, P1, DOI 10.1007/s11154-013-9271-7; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Melega S, 2013, MUTAT RES-GEN TOX EN, V751, P45, DOI 10.1016/j.mrgentox.2012.10.013; Micucci M, 2017, J MED FOOD, V20, P592, DOI 10.1089/jmf.2016.0154; Micucci M, 2014, J MED FOOD, V17, P795, DOI 10.1089/jmf.2013.0090; Micucci M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080925; Phan MAT, 2018, CRIT REV FOOD SCI, V58, P1310, DOI 10.1080/10408398.2016.1254595; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Motulsky H., 2004, FITTING MODELS BIOL, P352, DOI 10.1002/pst.167; Nguyen JCD, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00375; Okla M, 2015, J NUTR BIOCHEM, V26, P82, DOI 10.1016/j.jnutbio.2014.09.010; Osabe M, 2008, DRUG METAB DISPOS, V36, P294, DOI 10.1124/dmd.107.017731; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Santini A, 2017, EUR J PHARM SCI, V96, P53, DOI 10.1016/j.ejps.2016.09.003; Santulli C, 2017, J CELL BIOCHEM, V118, P839, DOI 10.1002/jcb.25760; Sharma K, 2014, KIDNEY INT SUPPL, V4, P113, DOI 10.1038/kisup.2014.21; Soory Mena, 2009, Infectious Disorders - Drug Targets, V9, P400; Stepanova M, 2010, OBES SURG, V20, P640, DOI 10.1007/s11695-010-0078-2; Sun X, 2014, PHYSIOL BEHAV, V136, P63, DOI 10.1016/j.physbeh.2014.04.017; Sur Genel, 2014, Maedica (Bucur), V9, P15; Tallarida RJ, 1987, MANUAL PHARM CALCULA, Vx; Tomankova V, 2017, BIOMED PAP, V161, P144, DOI 10.5507/bp.2017.026; Vivarelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150913; Younossi ZM, 2005, HEPATOLOGY, V42, P665, DOI 10.1002/hep.20838; Yun JW, 2010, PHYTOCHEMISTRY, V71, P1625, DOI 10.1016/j.phytochem.2010.07.011	56	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2018	13	8							e0201540	10.1371/journal.pone.0201540	http://dx.doi.org/10.1371/journal.pone.0201540			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3UO	30080863	Green Published, gold, Green Submitted			2023-01-03	WOS:000440780000010
J	Sipila, JOT; Posti, JP; Ruuskanen, JO; Rautava, P; Kyto, V				Sipila, Jussi O. T.; Posti, Jussi P.; Ruuskanen, Jori O.; Rautava, Paivi; Kyto, Ville			Stroke hospitalization trends of the working-aged in Finland	PLOS ONE			English	Article							CARDIOVASCULAR RISK-FACTORS; SUBARACHNOID HEMORRHAGE; ISCHEMIC-STROKE; SECULAR TRENDS; GLOBAL BURDEN; SMOKING	Background The age-standardized incidence of stroke has decreased globally but, for reasons unknown, conflicting results have been observed regarding trend in incidence of major stroke subtypes in young adults. We studied these trends among people of working age in a population-based setting in Finland, where cardiovascular risk factor profiles have developed favorably. Methods All hospitalizations for stroke in 2004-2005 and 2013-2014 for persons 18-64 years of age were identified from a national register. The search included all hospitals that provide acute stroke care on mainland Finland. Results Hospitalizations for both intracerebral hemorrhage (ICH; -15.2%; p = 0.0008) and subarachnoid hemorrhage (SAH; -26.5%; p<0.0001) decreased overall and for both sexes separately. Concerning IS, hospitalizations decreased only for men (-6.3%; p = 0.0190) but not for women or overall. However, there was an increase in IS hospitalizations in men 35-44 years of age (+37.5%; p = 0.0019). The length of stay (LOS) of IS patients declined in nearly all subgroups (overall -20.8%, p<0.0001) whereas no change in LOS was observed for patients with ICH or SAH. In-hospital mortality decreased in patients with IS (-42.8%; p = 0.0092) but remained unchanged in patients with ICH or SAH. Conclusions Stroke hospitalizations of young people declined in Finland, except for men 35-44 years of age for whom IS hospitalizations increased. Declining LOS and in-hospital mortality of IS patients suggests admission of less severe cases, improved care or both.	[Sipila, Jussi O. T.] North Karelia Cent Hosp, Dept Neurol, Siun Sote, Joensuu, Finland; [Sipila, Jussi O. T.; Ruuskanen, Jori O.] Turku Univ Hosp, Dept Neurol, Div Clin Neurosci, Turku, Finland; [Sipila, Jussi O. T.; Posti, Jussi P.; Ruuskanen, Jori O.] Univ Turku, Dept Neurol, Turku, Finland; [Posti, Jussi P.] Turku Univ Hosp, Turku Brain Injury Ctr, Turku, Finland; [Posti, Jussi P.] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, Turku, Finland; [Rautava, Paivi] Univ Turku, Dept Publ Hlth, Turku, Finland; [Rautava, Paivi] Turku Univ Hosp, Turku Clin Res Ctr, Turku, Finland; [Kyto, Ville] Turku Univ Hosp, Heart Ctr, Turku, Finland; [Kyto, Ville] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku	Sipila, JOT (corresponding author), North Karelia Cent Hosp, Dept Neurol, Siun Sote, Joensuu, Finland.; Sipila, JOT (corresponding author), Turku Univ Hosp, Dept Neurol, Div Clin Neurosci, Turku, Finland.; Sipila, JOT (corresponding author), Univ Turku, Dept Neurol, Turku, Finland.	jussi.sipila@utu.fi	Sipilä, Jussi/C-8585-2015; Posti, Jussi/GQA-7745-2022; Posti, Jussi P./Y-2908-2019; Kytö, Ville/D-7971-2014	Sipilä, Jussi/0000-0003-0183-9054; Posti, Jussi/0000-0002-5925-5193; Posti, Jussi P./0000-0002-5925-5193; Kytö, Ville/0000-0002-4521-1093	Government's Special Financial Transfer tied to academic research in Health Sciences (Finland) of the hospital district of Southwestern Finland; Finnish Cardiac Society	Government's Special Financial Transfer tied to academic research in Health Sciences (Finland) of the hospital district of Southwestern Finland; Finnish Cardiac Society	This research was supported by the Government's Special Financial Transfer tied to academic research in Health Sciences (Finland) of the hospital district of Southwestern Finland (http://www.vsshp.fi/fi/tutkijoille/rahoitus/Sivut/default.aspx) and the Finnish Cardiac Society (https://www.fincardio.fi/in-english/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson CS, 2004, STROKE, V35, P633, DOI 10.1161/01.STR.0000115751.45473.48; Ay H, 2005, STROKE, V36, P2632, DOI 10.1161/01.STR.0000189991.23918.01; Bennett DA, 2014, GLOB HEART, V9, P107, DOI 10.1016/j.gheart.2014.01.001; Borodulin K, 2015, EUR J PUBLIC HEALTH, V25, P539, DOI 10.1093/eurpub/cku174; Burke JF, 2017, JAMA NEUROL, V74, P639, DOI 10.1001/jamaneurol.2017.0161; de los Rios F, 2012, STROKE, V43, P3179, DOI 10.1161/STROKEAHA.112.667808; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Finland, 2018, COUNTR DRUG REP 2018; Fromm A, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/183256; Furuta Y, 2018, ATHEROSCLEROSIS, V273, P84, DOI 10.1016/j.atherosclerosis.2018.04.010; George MG, 2017, JAMA NEUROL, V74, P695, DOI 10.1001/jamaneurol.2017.0020; Kim CK, 2012, J NEUROL NEUROSUR PS, V83, P1100, DOI 10.1136/jnnp-2012-302538; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Kleindorfer D, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0421-2; Korja M, 2016, NEUROLOGY, V87, P1118, DOI 10.1212/WNL.0000000000003091; Koton S, 2018, STROKE, V49, P1348, DOI 10.1161/STROKEAHA.117.019822; Krishnamurthi RV, 2014, GLOB HEART, V9, P101, DOI 10.1016/j.gheart.2014.01.003; Kugler C, 2003, J NEUROL, V250, P676, DOI 10.1007/s00415-003-1054-8; Kyto V, 2015, EUR J PREV CARDIOL, V22, P1003, DOI 10.1177/2047487314539434; Kyto V, 2014, EUR J CLIN INVEST, V44, P902, DOI 10.1111/eci.12321; Lecoffre C, 2017, STROKE, V48, P2939, DOI 10.1161/STROKEAHA.117.017640; Lindbohm JV, 2016, STROKE, V47, P1975, DOI 10.1161/STROKEAHA.116.012957; Madsen TE, 2016, ACAD EMERG MED, V23, P1128, DOI 10.1111/acem.13029; Meretoja A, 2011, THESIS; Meretoja A, 2011, ANN MED, V43, pS22, DOI 10.3109/07853890.2011.586361; Nuotio J, 2014, SCAND J PUBLIC HEALT, V42, P563, DOI 10.1177/1403494814541597; Putaala J, 2016, EUR STROKE J, V1, P28, DOI 10.1177/2396987316629860; Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052; Sipila JOT, 2017, ANN MED, V49, P310, DOI 10.1080/07853890.2016.1254350; Sivenius J, 2009, INT J STROKE, V4, P340, DOI 10.1111/j.1747-4949.2009.00330.x; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637	31	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2018	13	8							e0201633	10.1371/journal.pone.0201633	http://dx.doi.org/10.1371/journal.pone.0201633			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO9GY	30067825	Green Submitted, Green Published, gold			2023-01-03	WOS:000440415500105
J	Richins, RD; Rodriguez-Uribe, L; Lowe, K; Ferral, R; O'Connell, MA				Richins, Richard D.; Rodriguez-Uribe, Laura; Lowe, Kiah; Ferral, Rebekah; O'Connell, Mary A.			Accumulation of bioactive metabolites in cultivated medical Cannabis	PLOS ONE			English	Article							ACID-SYNTHASE; SATIVA L.; CHEMOTAXONOMIC ANALYSIS; CHEMICAL PHENOTYPE; GENES; PLANT; IDENTIFICATION; TRICHOMES; CYCLASE; FRUIT	There has been an increased use of medical Cannabis in the United States of America as more states legalize its use. Complete chemical analyses of this material can vary considerably between producers and is often not fully provided to consumers. As phytochemists in a state with legal medical Cannabis we sought to characterize the accumulation of phytochemicals in material grown by licensed commercial producers. We report the development of a simple extraction and analysis method, amenable to use by commercial laboratories for the detection and quantification of both cannabinoids and terpenoids. Through analysis of developing flowers on plants, we can identify sources of variability of floral metabolites due to flower maturity and position on the plant. The terpenoid composition varied by accession and was used to cluster cannabis strains into specific types. Inclusion of terpenoids with cannabinoids in the analysis of medical cannabis should be encouraged, as both of these classes of compounds could play a role in the beneficial medical effects of different cannabis strains.	[Richins, Richard D.; Rodriguez-Uribe, Laura; Lowe, Kiah; Ferral, Rebekah; O'Connell, Mary A.] New Mexico State Univ, Dept Plant & Environm Sci, Las Cruces, NM 88003 USA; [Richins, Richard D.] Rio Grande Analyt, Las Cruces, NM USA	New Mexico State University	O'Connell, MA (corresponding author), New Mexico State Univ, Dept Plant & Environm Sci, Las Cruces, NM 88003 USA.	moconnel@nmsu.edu		O'Connell, Mary/0000-0003-4430-6733	Agricultural Experiment Station at New Mexico State University	Agricultural Experiment Station at New Mexico State University	MOC, LRU, and RDR received support from the Agricultural Experiment Station at New Mexico State University. This funder provided support in the form of salaries for authors MOC, LRU, KL, RF, RDR, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, Rio Grande Analytics, a commercial licensed medical marijuana testing laboratory provided access to research space licensed for analysis of the plant material in this report. All material costs and salaries of staff working on this project were paid through the Agricultural Experiment Station at New Mexico State University. RDR is an owner of Rio Grande Analytics, in addition to his full-time position at NMSU, however, Rio Grande Analytics did not provide salary support or have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizpurua-Olaizola O, 2016, J NAT PROD, V79, P324, DOI 10.1021/acs.jnatprod.5b00949; Andre CM, 2016, FRONT PLANT SCI, V7, DOI [10.3389/fpls.2016.00463, 10.3389/fpls.2016.00019]; Atakan Z, 2012, THER ADV PSYCHOPHARM, V2, P241, DOI 10.1177/2045125312457586; Carvalho A, 2017, FEMS YEAST RES, V17, DOI 10.1093/femsyr/fox037; Chandra S, 2010, PLANTA MED, V76, P743, DOI 10.1055/s-0029-1240628; Curry J, 1999, PLANT SCI, V148, P47, DOI 10.1016/S0168-9452(99)00118-1; de Meijer EPM, 2003, GENETICS, V163, P335; Fischedick JT, 2017, CANNABIS CANNABINOID, V2, P34, DOI 10.1089/can.2016.0040; Fischedick JT, 2010, PHYTOCHEMISTRY, V71, P2058, DOI 10.1016/j.phytochem.2010.10.001; Friedman D, 2015, NEW ENGL J MED, V373, P1048, DOI 10.1056/NEJMra1407304; Gagne SJ, 2012, P NATL ACAD SCI USA, V109, P12811, DOI 10.1073/pnas.1200330109; Happyana N, 2016, PLANTA MED, V82, P1217, DOI 10.1055/s-0042-108058; Happyana N, 2013, PHYTOCHEMISTRY, V87, P51, DOI 10.1016/j.phytochem.2012.11.001; Hillig KW, 2004, BIOCHEM SYST ECOL, V32, P875, DOI 10.1016/j.bse.2004.04.004; Hillig KW, 2004, AM J BOT, V91, P966, DOI 10.3732/ajb.91.6.966; Ibrahim EA, 2018, PLANTA MED, V84, P250, DOI 10.1055/s-0043-124088; Jin D, 2017, J ANAL BIOANALYTICAL, V08; Keyhaninejad N, 2014, PLANT SCI, V215, P59, DOI 10.1016/j.plantsci.2013.10.013; Marks MD, 2009, J EXP BOT, V60, P3715, DOI 10.1093/jxb/erp210; Martin C, 2012, LAVENDER CULTIVAR TR; Mechoulam R, 2007, CHEM BIODIVERS, V4, P1678, DOI 10.1002/cbdv.200790147; Medina-Holguin AL, 2008, PHYTOCHEMISTRY, V69, P919, DOI 10.1016/j.phytochem.2007.11.006; Mudge EM, 2017, ANAL BIOANAL CHEM, V409, P3153, DOI 10.1007/s00216-017-0256-3; National Academies of Sciences. Engineering and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice, 2017, HLTH EFF CANN CANN C; Onofri C, 2015, PHYTOCHEMISTRY, V116, P57, DOI 10.1016/j.phytochem.2015.03.006; Pacifico D, 2008, EUPHYTICA, V160, P231, DOI 10.1007/s10681-007-9543-y; Page J.E., 2015, Patent No. [2015/196275 A1, 2015196275]; Page J.E., 2012, US patent, Patent No. [US20120144523A1, 20120144523]; Potter DJ, 2014, DRUG TEST ANAL, V6, P31, DOI 10.1002/dta.1531; Rodriguez-Uribe L, 2014, HORTSCIENCE, V49, P1370, DOI 10.21273/HORTSCI.49.11.1370; Rodriguez-Uribe L, 2012, J EXP BOT, V63, P517, DOI 10.1093/jxb/err302; Russo E., 2007, CHEM BIODIVER; Russo E., 2011, BRIT J PHARM, V163; Sawler J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133292; Sirikantaramas S, 2004, J BIOL CHEM, V279, P39767, DOI 10.1074/jbc.M403693200; SMALL E, 1973, LLOYDIA, V36, P144; Stewart C, 2007, J EXP BOT, V58, P979, DOI 10.1093/jxb/erl243; Taura F, 2007, FEBS LETT, V581, P2929, DOI 10.1016/j.febslet.2007.05.043; Thomas B, 2016, ANAL CHEM CANNABIS, P1; van Bakel H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r102; Weiblen GD, 2015, NEW PHYTOL, V208, P1241, DOI 10.1111/nph.13562; Welling MT, 2016, EUPHYTICA, V208, P463, DOI 10.1007/s10681-015-1585-y; Yang XM, 2016, FEBS J, V283, P1088, DOI 10.1111/febs.13654	43	42	42	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2018	13	7							e0201119	10.1371/journal.pone.0201119	http://dx.doi.org/10.1371/journal.pone.0201119			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN8PM	30036388	gold, Green Submitted, Green Published			2023-01-03	WOS:000439429200029
J	Ferreira, FMR; Chaves, MEA; Oliveira, VC; Van Petten, AMVN; Vimieiro, CBS				Rodrigues Martins Ferreira, Fernanda Marcia; Abreu Chaves, Maria Emilia; Oliveira, Vinicius Cunha; Valladao Novais Van Petten, Adriana Maria; Santos Vimieiro, Claysson Bruno			Effectiveness of robot therapy on body function and structure in people with limited upper limb function: A systematic review and meta-analysis	PLOS ONE			English	Review							ASSISTED THERAPY; CHRONIC STROKE; UPPER-EXTREMITY; MOTOR RECOVERY; RANDOMIZED-TRIAL; AIDED THERAPY; ARM ACTIVITY; POST STROKE; REHABILITATION; STIMULATION	Robot-Assisted Therapy (RT) is an innovative approach to neurological rehabilitation that uses intensive, repetitive, interactive, and individualized practice. This systematic review aimed to investigate the effectiveness of RT on the body function and structure of people with upper limb impairments (PROSPERO registration: CRD42017054982). A search strategy conducted on seven databases identified randomized controlled studies. Methodological quality was assessed using the PEDro scale. When possible, the data were pooled, the strength of evidence was assessed using the GRADE system, and the effect sizes were assessed using Cohen coefficient. Subgroup analyses investigated the impact on the estimated effects of the following parameters: methodological quality; portion of the assessed upper limb; duration of stroke; and intervention dose and duration. Thirty-eight studies involving 1174 participants were included. Pooled estimates revealed small effects of RT on motor control and medium effects on strength compared with other intervention (OI) at a short-term follow-up. Standardized differences in means were as follows: 0.3 (95% CI 0.1 to 0.4) and 0.5 (95% CI 0.2 to 0.8). Effects at other time points and on other investigated outcomes related to body function and structure were not found (p>0.05). The strength of the current evidence was usually low quality. Subgroup analyses suggested that the methodological quality, and duration and dose of RT may influence the estimated effects. In conclusion, RT has small effects on motor control and medium effects on strength in people with limited upper limb function. Poor methodological quality, and lower treatment dose and duration may impact negatively the estimated effects.	[Rodrigues Martins Ferreira, Fernanda Marcia] Univ Fed Minas Gerais, Programa Posgrad Engn Mecan, Bioengn Lab, Belo Horizonte, MG, Brazil; [Abreu Chaves, Maria Emilia] Univ Fed Minas Gerais, Bioengn Lab, Belo Horizonte, MG, Brazil; [Oliveira, Vinicius Cunha] Univ Fed Vales Jequitinhonha & Mucuri, Posgrad Reabil & Desempenho Func, Diamantina, MG, Brazil; [Valladao Novais Van Petten, Adriana Maria] Univ Fed Minas Gerais, Dept Occupat Therapy, Belo Horizonte, MG, Brazil; [Santos Vimieiro, Claysson Bruno] Univ Fed Minas Gerais, Grad Program Mech Engn, Belo Horizonte, MG, Brazil; [Santos Vimieiro, Claysson Bruno] Pontificia Univ Catolica Minas Gerais, Grad Program Mech Engn, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Pontificia Universidade Catolica de Minas Gerais	Vimieiro, CBS (corresponding author), Univ Fed Minas Gerais, Grad Program Mech Engn, Belo Horizonte, MG, Brazil.; Vimieiro, CBS (corresponding author), Pontificia Univ Catolica Minas Gerais, Grad Program Mech Engn, Belo Horizonte, MG, Brazil.	claysson@gmail.com	OLIVEIRA, VINICIUS CUNHA/E-1366-2014; Van Petten, Adriana Maria Valladão Novais/AAL-1545-2020; Vimieiro, Claysson B S/R-4765-2017	OLIVEIRA, VINICIUS CUNHA/0000-0002-8658-3774; Van Petten, Adriana Maria Valladão Novais/0000-0001-7979-2319; Vimieiro, Claysson B S/0000-0003-1916-0517; Ferreira, Fernanda/0000-0003-1031-7389				Abdullah HA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-50; Aisen ML, 1997, ARCH NEUROL-CHICAGO, V54, P443, DOI 10.1001/archneur.1997.00550160075019; Ang Kai Keng, 2014, Front Neuroeng, V7, P30, DOI 10.3389/fneng.2014.00030; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Basteris A, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-111; Bertani R, 2017, NEUROL SCI, V38, P1561, DOI 10.1007/s10072-017-2995-5; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Brokaw EB, 2014, NEUROREHAB NEURAL RE, V28, P367, DOI 10.1177/1545968313510974; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; Burgar CG, 2011, J REHABIL RES DEV, V48, P445, DOI 10.1682/JRRD.2010.04.0062; Byl NN, 2013, J HAND THER, V26, P343, DOI 10.1016/j.jht.2013.06.001; Cohen J., 1988, STAT POWER ANAL BEHA, P18, DOI [10.4324/9780203771587, DOI 10.1016/B978-0-12-179060-8.50006-2]; Conroy SS, 2011, ARCH PHYS MED REHAB, V92, P1754, DOI 10.1016/j.apmr.2011.06.016; Daly JJ, 2005, J REHABIL RES DEV, V42, P723, DOI 10.1682/JRRD.2005.02.0048; de Araujo RC, 2011, ARCH PHYS MED REHAB, V92, P1746, DOI 10.1016/j.apmr.2011.05.021; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Duret C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/482389; Fasoli SE, 2004, NEUROREHAB NEURAL RE, V18, P88, DOI 10.1177/0888439004267434; Hayward KS, 2015, CLIN REHABIL, V29, P1234, DOI 10.1177/0269215514565395; Henschke N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002014.pub3; Hesse S, 2005, STROKE, V36, P1960, DOI 10.1161/01.STR.0000177865.37334.ce; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; Hsieh Y, 2012, STROKE, V43, P1; Hsieh YW, 2011, NEUROREHAB NEURAL RE, V25, P503, DOI 10.1177/1545968310394871; Jarrasse N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00947; Kahn LE, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-12; Klamroth-Marganska V, 2014, LANCET NEUROL, V13, P159, DOI 10.1016/S1474-4422(13)70305-3; Kwakkel G., 2009, SCHWEIZ ARCH NEURO P, V160, P295, DOI [DOI 10.1080/09638280500534861, DOI 10.4414/SANP.2009.02103]; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Liao WW, 2012, CLIN REHABIL, V26, P111, DOI 10.1177/0269215511416383; Lin CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132589; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Lohse KR, 2014, STROKE, V45, P2053, DOI 10.1161/STROKEAHA.114.004695; Lum PS, 2006, J REHABIL RES DEV, V43, P631, DOI 10.1682/JRRD.2005.02.0044; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Maciejasz P, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-3; Masiero S, 2014, NEUROREHAB NEURAL RE, V28, P377, DOI 10.1177/1545968313513073; McCabe J, 2015, ARCH PHYS MED REHAB, V96, P981, DOI 10.1016/j.apmr.2014.10.022; Mehrholz J, 2015, COCHRANE DB SYST REV, V11, P1; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; Page SJ, 2013, CLIN REHABIL, V27, P494, DOI 10.1177/0269215512464795; Poli P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/153872; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Rabadi MH, 2008, CLIN REHABIL, V22, P1071, DOI 10.1177/0269215508095358; Ramos-Murguialday A, 2013, ANN NEUROL, V74, P100, DOI 10.1002/ana.23879; Reinkensmeyer David J, 2012, Am J Phys Med Rehabil, V91, pS232, DOI 10.1097/PHM.0b013e31826bce79; Sale P, 2014, INT J REHABIL RES, V37, P236, DOI 10.1097/MRR.0000000000000059; Sale P, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-104; Simkins M, 2013, IEEE INT C REH ROB, P1; Sivan M, 2011, J REHABIL MED, V43, P181, DOI 10.2340/16501977-0674; Susanto EA, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0033-5; Timmermans AAA, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-45; Veerbeek JM, 2016, NEUROREHAB NEURAL RE, P1; Volpe BT, 2008, NEUROREHAB NEURAL RE, V22, P305, DOI 10.1177/1545968307311102; Volpe BT, 1999, NEUROLOGY, V53, P1874, DOI 10.1212/WNL.53.8.1874; World Health Organization, 2001, ICF INT CLASFUNCT; Wu CY, 2012, PHYS THER, V92, P1006, DOI 10.2522/ptj.20110282; Xu GZ, 2014, ROBOTICA, V32, P1081, DOI 10.1017/S0263574713001264; Xu GZ, 2012, INT J ADV ROBOT SYST, V9, DOI 10.5772/51035; Yang CL, 2012, AM J OCCUP THER, V66, P198, DOI 10.5014/ajot.2012.003103; Yoo DH, 2013, J PHYS THER SCI, V25, P407, DOI 10.1589/jpts.25.407	62	25	25	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2018	13	7							e0200330	10.1371/journal.pone.0200330	http://dx.doi.org/10.1371/journal.pone.0200330			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GM8FT	30001417	Green Submitted, Green Published, gold			2023-01-03	WOS:000438457400045
J	Kim, JH; Beom, JH; You, JS; Cho, J; Min, IK; Chung, HS				Kim, Ji Hoon; Beom, Jin Ho; You, Je Sung; Cho, Junho; Min, In Kyung; Chung, Hyun Soo			Effect of flashlight guidance on manual ventilation performance in cardiopulmonary resuscitation: A randomized controlled simulation study	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; AUDIOVISUAL FEEDBACK; CHEST COMPRESSION; OLDER CHILDREN; TONE GUIDANCE; QUALITY; CPR; ASSOCIATION; ADOLESCENTS; PRESSURE	Several auditory-based feedback devices have been developed to improve the quality of ventilation performance during cardiopulmonary resuscitation (CPR), but their effectiveness has not been proven in actual CPR situations. In the present study, we investigated the effectiveness of visual flashlight guidance in maintaining high-quality ventilation performance. We conducted a simulation-based, randomized, parallel trial including 121 senior medical students. All participants were randomized to perform ventilation during 2 minutes of CPR with or without flashlight guidance. For each participant, we measured mean ventilation rate as a primary outcome and ventilation volume, inspiration velocity, and ventilation interval as secondary outcomes using a computerized device system. Mean ventilation rate did not significantly differ between flashlight guidance and control groups (P = 0.159), but participants in the flashlight guidance group exhibited significantly less variation in ventilation rate than participants in the control group (P<0.001). Ventilation interval was also more regular among participants in the flashlight guidance group. Our results demonstrate that flashlight guidance is effective in maintaining a constant ventilation rate and interval. If confirmed by further studies in clinical practice, flashlight guidance could be expected to improve the quality of ventilation performed during CPR.	[Kim, Ji Hoon; Beom, Jin Ho; You, Je Sung; Cho, Junho; Chung, Hyun Soo] Yonsei Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Min, In Kyung] Yonsei Univ, Coll Med, Dept Biostat, Collaborat Unit, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Chung, HS (corresponding author), Yonsei Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	HSC104@yush.ac.kr		Cho, Junho/0000-0003-2240-3989; You, Je Sung/0000-0002-2074-6745; Chung, Hyun Soo/0000-0001-6110-1495; Kim, Ji Hoon/0000-0002-0070-9568				Abella BS, 2007, RESUSCITATION, V73, P54, DOI 10.1016/j.resuscitation.2006.10.027; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Bohn A, 2011, RESUSCITATION, V82, P257, DOI 10.1016/j.resuscitation.2010.11.006; Cho YC, 2014, AM J EMERG MED, V32, P913, DOI 10.1016/j.ajem.2014.05.015; Cocucci C, 2015, ARCH DIS CHILD-FETAL, V100, pF47, DOI 10.1136/archdischild-2014-306407; Edelson DP, 2008, ARCH INTERN MED, V168, P1063, DOI 10.1001/archinte.168.10.1063; Edelson DP, 2010, RESUSCITATION, V81, P317, DOI 10.1016/j.resuscitation.2009.11.003; Kern KB, 2010, RESUSCITATION, V81, P206, DOI 10.1016/j.resuscitation.2009.10.015; Leturiondo M, 2018, RESUSCITATION, V124, P63, DOI 10.1016/j.resuscitation.2017.12.013; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Losert H, 2006, CRIT CARE MED, V34, P2399, DOI 10.1097/01.CCM.0000235666.40378.60; Maertens VL, 2013, RESUSCITATION, V84, P921, DOI 10.1016/j.resuscitation.2012.11.015; McInnes AD, 2012, RESUSCITATION, V83, P1462, DOI 10.1016/j.resuscitation.2012.05.010; McInnes AD, 2011, RESUSCITATION, V82, P1025, DOI 10.1016/j.resuscitation.2011.03.020; MILANDER MM, 1995, ACAD EMERG MED, V2, P708, DOI 10.1111/j.1553-2712.1995.tb03622.x; O'Neill JF, 2007, RESUSCITATION, V73, P82, DOI 10.1016/j.resuscitation.2006.09.012; Oh JH, 2008, RESUSCITATION, V79, P273, DOI 10.1016/j.resuscitation.2008.06.022; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Roberts K, 2010, RESUSCITATION, V81, P1544, DOI 10.1016/j.resuscitation.2010.07.010; Terndrup TE, 2006, RESUSCITATION, V71, P10, DOI 10.1016/j.resuscitation.2006.02.019; You JS, 2013, EMERG MED J, V30, P628, DOI 10.1136/emermed-2012-201605; You KM, 2017, AM J EMERG MED, V35, P292, DOI 10.1016/j.ajem.2016.10.085; Zapletal B, 2014, RESUSCITATION, V85, P560, DOI 10.1016/j.resuscitation.2013.10.028; Zhou XL, 2014, AM J EMERG MED, V32, P306, DOI 10.1016/j.ajem.2013.12.007	28	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2018	13	6							e0198907	10.1371/journal.pone.0198907	http://dx.doi.org/10.1371/journal.pone.0198907			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ2HI	29897951	Green Published, gold			2023-01-03	WOS:000435090700078
J	Marques, AP; Macedo, AF; Hernandez-Moreno, L; Ramos, PL; Butt, T; Rubin, G; Santana, R				Marques, Ana Patricia; Macedo, Antonio Filipe; Hernandez-Moreno, Laura; Ramos, Pedro Lima; Butt, Thomas; Rubin, Gary; Santana, Rui		Portuguese Visual Impairment Study	The use of informal care by people with vision impairment	PLOS ONE			English	Article							VISUAL DISABILITY VARIABLES; BLUE-MOUNTAINS-EYE; MACULAR DEGENERATION; ACTIVITY INVENTORY; UNITED-STATES; COSTS; SERVICES; HEALTH; QUESTIONNAIRE; INDIVIDUALS	Purpose To estimate and characterize the use of informal care by people with vision impairment in Portugal. Methods A total of 546 visually impaired individuals were recruited from Portuguese hospitals. Clinical information was obtained from medical records, socio-demographic details and informal care use were collected during face-to-face interviews. In addition, participants responded to a functional vision questionnaire (activity inventory) to assess their visual ability. Logistic regression was used to determine independent factors associated with informal care use and linear regression was used to determine independent predictors of intensity of informal care use. Results Informal care was reported by 39.6% of the participants. The probability of reporting informal care was higher in non-married, those with comorbidities, with lower visual ability and worse visual acuity. The median number of caregivers' hours per year was 390 (mean = 470; 95% CI = 488-407), which represent a median opportunity cost of 2,586. Visual ability was the only independent predictor of number of hours of informal care received. Conclusions Informal care was frequently used by individuals with impaired vision. Improving visual ability of people with impaired vision when performing valued activities may reduce the burden of visual loss at personal and societal level. This could be achieved with person-centred visual rehabilitation.	[Marques, Ana Patricia; Santana, Rui] NOVA Univ Lisbon, Natl Sch Publ Hlth, Lisbon, Portugal; [Marques, Ana Patricia; Santana, Rui] NOVA Univ Lisbon, Natl Sch Publ Hlth, Publ Hlth Res Ctr, Lisbon, Portugal; [Macedo, Antonio Filipe; Ramos, Pedro Lima] Linnaeus Univ Kalmar, Dept Med & Optometry, Kalmar, Sweden; [Macedo, Antonio Filipe; Hernandez-Moreno, Laura] Univ Minho Braga, Low Vis & Visual Rehabil Lab, Dept & Ctr Phys Optometry & Vis Sci, Braga, Portugal; [Butt, Thomas; Rubin, Gary] UCL, Inst Ophthalmol, London, England; [Butt, Thomas] Peking Univ, Natl Sch Dev, Beijing, Peoples R China	Universidade Nova de Lisboa; Universidade Nova de Lisboa; Linnaeus University; University of London; University College London; Peking University	Marques, AP (corresponding author), NOVA Univ Lisbon, Natl Sch Publ Hlth, Lisbon, Portugal.; Marques, AP (corresponding author), NOVA Univ Lisbon, Natl Sch Publ Hlth, Publ Hlth Res Ctr, Lisbon, Portugal.	ap.marques@ensp.unl.pt	Marques, Ana Patricia R S S/V-9571-2017; Macedo, Antonio/I-8108-2013; Marques, Ana Patricia/AAY-3342-2020; Butt, Thomas/AAH-7882-2019; Santana, Rui/I-3294-2017	Marques, Ana Patricia R S S/0000-0001-8242-7021; Macedo, Antonio/0000-0003-3436-2010; Marques, Ana Patricia/0000-0001-8242-7021; Butt, Thomas/0000-0002-0387-4550; Lima Ramos, Pedro/0000-0003-1280-9854; Santana, Rui/0000-0003-1370-3242	Fundacao para a Ciencia e a Tecnologia (COMPETE/QREN) [PTDC/DPT-EPI/0412/2012]; Fundação para a Ciência e a Tecnologia [PTDC/DTP-EPI/0412/2012] Funding Source: FCT	Fundacao para a Ciencia e a Tecnologia (COMPETE/QREN); Fundação para a Ciência e a Tecnologia	This study was supported by Fundacao para a Ciencia e a Tecnologia (COMPETE/QREN) grant reference PTDC/DPT-EPI/0412/2012 in the context of the Prevalence and Costs of Visual Impairment in Portugal: PCVIP-study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007; Bhandari A, 2006, MED CARE RES REV, V63, P217, DOI 10.1177/1077558705285298; Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003; Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030; Chisholm D, 2000, EPSILON STUDY, V177, ps28, DOI [10.1192/bjp.177.39.s28, DOI 10.1192/BJP.177.39.S28]; Chou SL, 2003, CLIN EXP OPHTHALMOL, V31, P336, DOI 10.1046/j.1442-9071.2003.00667.x; Costa N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/852368; Courtin E, 2014, HEALTH POLICY, V118, P84, DOI 10.1016/j.healthpol.2014.07.013; Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60; Frick KD, 2010, INVEST OPHTH VIS SCI, V51, P1801, DOI 10.1167/iovs.09-4469; Goldstein JE, 2014, JAMA OPHTHALMOL, V132, P1169, DOI 10.1001/jamaophthalmol.2014.1747; Goodrich K, 2012, VALUE HEALTH, V15, P975, DOI 10.1016/j.jval.2012.05.009; Hernandez-Moreno L, 2015, INVEST OPHTH VIS SCI, V56; Hong T, 2013, AM J OPHTHALMOL, V156, P393, DOI 10.1016/j.ajo.2013.04.002; Ke KM, 2007, BRIT J OPHTHALMOL, V91, P1279, DOI 10.1136/bjo.2006.113142; Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9; Keeffe JE, 2009, ARCH OPHTHALMOL-CHIC, V127, P1377, DOI 10.1001/archophthalmol.2009.242; Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471; Macedo AF, 2017, ACTA OPHTHALMOL, V95, pe783, DOI 10.1111/aos.13430; Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd; Massof RW, 2005, ARCH PHYS MED REHAB, V86, P946, DOI 10.1016/j.apmr.2004.09.016; Massof RW, 2005, ARCH PHYS MED REHAB, V86, P954, DOI 10.1016/j.apmr.2004.09.017; Oliva-Moreno J, 2017, PHARMACOECONOMICS, V35, P331, DOI 10.1007/s40273-016-0468-y; Pinto D, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-45; Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a; Schmier JK, 2009, DISABIL REHABIL, V31, P659, DOI 10.1080/09638280802239391; Severens JL, 2000, SOC SCI MED, V51, P243, DOI 10.1016/S0277-9536(99)00452-9; Thompson S, 2001, ANNOTATED COST QUEST; Triantafillou J., 2010, INFORMAL CARE LONG T; van Exel Job, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P557, DOI 10.1586/14737167.8.6.557; van Leeuwen LM, 2015, ACTA OPHTHALMOL, V93, P642, DOI 10.1111/aos.12782; Wang J.Y., 1999, J NW FOR COLL, V15, P9; Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773; Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644	34	11	11	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198631	10.1371/journal.pone.0198631	http://dx.doi.org/10.1371/journal.pone.0198631			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879193	gold, Green Published, Green Submitted			2023-01-03	WOS:000434384900063
J	McDermott, DF; Huseni, MA; Atkins, MB; Motzer, RJ; Rini, BI; Escudier, B; Fong, L; Joseph, RW; Pal, SK; Reeves, JA; Sznol, M; Hainsworth, J; Rathmell, WK; Stadler, WM; Hutson, T; Gore, ME; Ravaud, A; Bracarda, S; Suarez, C; Danielli, R; Gruenwald, V; Choueiri, TK; Nickles, D; Jhunjhunwala, S; Piault-Louis, E; Thobhani, A; Qiu, JH; Chen, DS; Hegde, PS; Schiff, C; Fine, GD; Powles, T				McDermott, David F.; Huseni, Mahrukh A.; Atkins, Michael B.; Motzer, Robert J.; Rini, Brian I.; Escudier, Bernard; Fong, Lawrence; Joseph, Richard W.; Pal, Sumanta K.; Reeves, James A.; Sznol, Mario; Hainsworth, John; Rathmell, W. Kimryn; Stadler, Walter M.; Hutson, Thomas; Gore, Martin E.; Ravaud, Alain; Bracarda, Sergio; Suarez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni K.; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel S.; Hegde, Priti S.; Schiff, Christina; Fine, Gregg D.; Powles, Thomas			Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SUPPRESSOR-CELLS; PD-L1 EXPRESSION; TUMOR-GROWTH; SINGLE-ARM; PHASE-III; CANCER; NIVOLUMAB; PATHWAY; MULTICENTER	We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-gamma response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.	[McDermott, David F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Huseni, Mahrukh A.; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Qiu, Jiaheng; Chen, Daniel S.; Hegde, Priti S.; Schiff, Christina; Fine, Gregg D.] Genentech Inc, San Francisco, CA 94080 USA; [Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA; [Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Escudier, Bernard] Gustave Roussy, Villejuif, France; [Fong, Lawrence] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA; [Joseph, Richard W.] Mayo Clin Hosp Florida, Jacksonville, FL USA; [Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Duarte, CA USA; [Reeves, James A.] Florida Canc Specialists, Ft Myers, FL USA; [Sznol, Mario] Yale Sch Med, New Haven, CT USA; [Hainsworth, John] Sarah Cannon Res Inst, Nashville, TN USA; [Rathmell, W. Kimryn] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Stadler, Walter M.] Univ Chicago Med, Chicago, IL USA; [Hutson, Thomas] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; [Gore, Martin E.] Royal Marsden Hosp, London, England; [Ravaud, Alain] CHU Hop Bordeaux, Hop St Andre, Bordeaux, France; [Bracarda, Sergio] Azienda USL Toscana Sudest, Osped San Donato, Arezzo, Italy; [Suarez, Cristina] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Danielli, Riccardo] Univ Senese, Azienda Osped, Ctr Immune Oncol, Siena, Italy; [Gruenwald, Viktor] Zentrum Innere Med, Med Hsch, Hannover, Germany; [Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Thobhani, Alpa] Roche Prod Ltd, Welwyn Garden City, Herts, England; [Powles, Thomas] Queen Mary Univ London, Barts Canc Inst, London, England; [Powles, Thomas] Queen Mary Univ London, Royal Free Hosp, London, England	Harvard University; Beth Israel Deaconess Medical Center; Roche Holding; Genentech; Memorial Sloan Kettering Cancer Center; Cleveland Clinic Foundation; UNICANCER; Gustave Roussy; University of California System; University of California San Francisco; City of Hope; Florida Cancer Specialists; Yale University; Sarah Cannon Research Institute; Vanderbilt University; Baylor University Medical Center; Royal Marsden NHS Foundation Trust; CHU Bordeaux; IRCCS Policlinico San Donato; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); University of Siena; University Hospital of Siena; Harvard University; Dana-Farber Cancer Institute; Roche Holding; University of London; Queen Mary University London; University of London; Queen Mary University London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	McDermott, DF (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	dmcdermo@bidmc.harvard.edu	Hutson, Thomas/AAS-9639-2020; Chen, Daniel Shin-Yu/AGD-8923-2022; Choueiri, Toni/K-5238-2019; Jhunjhunwala, Suchit/GNH-2256-2022; Miquel, Josep Maria/AAG-3508-2019	Hutson, Thomas/0000-0002-4529-4212; Chen, Daniel Shin-Yu/0000-0001-5085-3579; Choueiri, Toni/0000-0002-9201-3217; Jhunjhunwala, Suchit/0000-0003-3484-0588; Ravaud, Alain/0000-0001-9455-6744; Sznol, Mario/0000-0002-4359-8749; Suarez, Cristina/0000-0002-0502-5528; Bracarda, Sergio/0000-0002-0703-2959	P.S. Davies of Health Interactions, Inc. by F. Hoffmann-La Roche, AG; F. Hoffmann-La Roche, AG; NCI [P50 CA101942-13, P30 CA008748, P30 CA14599]; NATIONAL CANCER INSTITUTE [P30CA008748, P50CA101942, P30CA068485, P30CA014599] Funding Source: NIH RePORTER	P.S. Davies of Health Interactions, Inc. by F. Hoffmann-La Roche, AG; F. Hoffmann-La Roche, AG(Hoffmann-La Roche); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank A. Bailey for her contributions to development of the protocol and Z. Boyd for his contributions to the development of the PD-L1 IHC assay and its implementation in this study. Support for third-party writing assistance for this manuscript-by P.S. Davies of Health Interactions, Inc.-was provided by F. Hoffmann-La Roche, AG. This study was sponsored by F. Hoffmann-La Roche, AG. Authors were funded by NCI grants P50 CA101942-13 to D.F.M, M.B.A., and T.K.C.; P30 CA008748 to R.J.M.; and P30 CA14599 to W.M.S.	Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Brauer MJ, 2013, CLIN CANCER RES, V19, P3681, DOI 10.1158/1078-0432.CCR-12-3635; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Choueiri TK, 2014, ANN ONCOL, V25, P2178, DOI 10.1093/annonc/mdu445; Choueiri TK, 2017, P AM SOC CLIN ONCO S, V35, P4504, DOI DOI 10.1200/JC0.2017.35.15_; Clark JI, 2017, CLIN GENITOURIN CANC, V15, P31, DOI 10.1016/j.clgc.2016.10.008; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Draghiciu O, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.989764; Elamin YY, 2015, CANCER MICROENVIRON, V8, P15, DOI 10.1007/s12307-014-0160-8; Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; George DJ, 2003, NEW ENGL J MED, V349, P419, DOI 10.1056/NEJMp030061; Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053; Hsieh JJ, 2017, EUR UROL, V71, P405, DOI 10.1016/j.eururo.2016.10.007; Kaelin WG, 2003, J AM SOC NEPHROL, V14, P2703, DOI 10.1097/01.ASN.0000092803.69761.41; Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kusmartsev S, 2008, J IMMUNOL, V181, P346, DOI 10.4049/jimmunol.181.1.346; Latchman YE, 2004, P NATL ACAD SCI USA, V101, P10691, DOI 10.1073/pnas.0307252101; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Liu Q, 2016, CYTOKINE GROWTH F R, V31, P61, DOI 10.1016/j.cytogfr.2016.08.002; McDermott DF, 2016, J CLIN ONCOL, V34, P833, DOI 10.1200/JCO.2015.63.7421; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Motzer RJ, 2013, J CLIN ONCOL, V31, P3791, DOI 10.1200/JCO.2012.47.4940; Najjar YG, 2017, CLIN CANCER RES, V23, P2346, DOI 10.1158/1078-0432.CCR-15-1823; Osada T, 2008, CANCER IMMUNOL IMMUN, V57, P1115, DOI 10.1007/s00262-007-0441-x; Powles T, 2015, J IMMUNOTHER CANC S2, V3, P83; Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114; Reck M, 2017, ANN ONCOL, V28, DOI 10.1093/annonc/mdx760.002; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roland CL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007669; Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Russo RC, 2014, EXPERT REV CLIN IMMU, V10, P593, DOI 10.1586/1744666X.2014.894886; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Sumida K, 2012, EUR J IMMUNOL, V42, P2060, DOI 10.1002/eji.201142335; Thompson RH, 2007, CLIN CANCER RES, V13, P1757, DOI 10.1158/1078-0432.CCR-06-2599; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Voss MH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4523; Wallin JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12624; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; Wu TD, 2016, METHODS MOL BIOL, V1418, P283, DOI 10.1007/978-1-4939-3578-9_15; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Yang J, 2011, J IMMUNOL, V187, P1113, DOI 10.4049/jimmunol.1100056; Yuan M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6530410; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015	63	649	669	10	88	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2018	24	6					749	+		10.1038/s41591-018-0053-3	http://dx.doi.org/10.1038/s41591-018-0053-3			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GI3OQ	29867230	Green Accepted			2023-01-03	WOS:000434281300020
J	Schweizer, MT; Haugk, K; McKiernan, JS; Gulati, R; Cheng, HH; Maes, JL; Dumpit, RF; Nelson, PS; Montgomery, B; McCune, JS; Plymate, SR; Yu, EY				Schweizer, Michael T.; Haugk, Kathleen; McKiernan, Jozefa S.; Gulati, Roman; Cheng, Heather H.; Maes, Jessica L.; Dumpit, Ruth F.; Nelson, Peter S.; Montgomery, Bruce; McCune, Jeannine S.; Plymate, Stephen R.; Yu, Evan Y.			A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer	PLOS ONE			English	Article							RECEPTOR SPLICE VARIANTS; KAPPA-B PATHWAY; ANDROGEN-RECEPTOR; THERAPY RESISTANCE; INCREASED SURVIVAL; CLINICAL-TRIALS; ABIRATERONE; CELLS; PROGRESSION; INHIBITION	Background Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants (AR-Vs) or inhibiting other drug-resistance pathways (e. g., Wnt-signaling). Published pharmacokinetics data suggests that niclosamide has poor oral bioavailability, potentially limiting its use as a cancer drug. Therefore, we launched a Phase I study testing oral niclosamide in combination with enzalutamide, for longer and at higher doses than those used to treat helminthic infections. Methods We conducted a Phase I dose-escalation study testing oral niclosamide plus standard-dose enzalutamide in men with metastatic CRPC previously treated with abiraterone. Niclosamide was given three-times-daily (TID) at the following dose-levels: 500, 1000 or 1500mg. The primary objective was to assess safety. Secondary objectives, included measuring ARV expression from circulating tumor cells (CTCs) using the AdnaTest assay, evaluating PSA changes and determining niclosamide's pharmacokinetic profile. Results 20 patients screened and 5 enrolled after passing all screening procedures. 13(65%) patients had detectable CTCs, but only one was AR-V+. There were no dose-limiting toxicities (DLTs) in 3 patients on the 500mg TID cohort; however, both (N = 2) subjects on the 1000mg TID cohort experienced DLTs (prolonged grade 3 nausea, vomiting, diarrhea; and colitis). The maximum plasma concentration ranged from 35.7 +/- 82 ng/mL and was not consistently above the minimum effective concentration in preclinical studies. There were no PSA declines in any enrolled subject. Because plasma concentrations at the maximum tolerated dose (500mg TID) were not consistently above the expected therapeutic threshold, the Data Safety Monitoring Board closed the study for futility. Conclusions Oral niclosamide could not be escalated above 500mg TID, and plasma concentrations were not consistently above the threshold shown to inhibit growth in CRPC models. Oral niclosamide is not a viable compound for repurposing as a CRPC treatment.	[Schweizer, Michael T.; Cheng, Heather H.; Nelson, Peter S.; Montgomery, Bruce; Plymate, Stephen R.; Yu, Evan Y.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Schweizer, Michael T.; Cheng, Heather H.; Montgomery, Bruce; Yu, Evan Y.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Haugk, Kathleen; Plymate, Stephen R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA; [McKiernan, Jozefa S.; McCune, Jeannine S.] City Hope Comprehens Canc Ctr, Dept Populat Sci, Duarte, CA USA; [Gulati, Roman] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Maes, Jessica L.] Seattle Canc Care Alliance, Seattle, WA USA; [Dumpit, Ruth F.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; City of Hope; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance; Fred Hutchinson Cancer Center	Schweizer, MT (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Schweizer, MT (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.	schweize@uw.edu	Gulati, Roman/AAE-4298-2019; McCune, Jeannine/AAH-6704-2020	Gulati, Roman/0000-0002-7592-6567; McCune, Jeannine/0000-0002-0795-497X; Cheng, Heather/0000-0002-1365-0702	National Cancer Institute [P30 CA015704, P30 CA033572, R50 CA221836]; Pacific Northwest Prostate Cancer SPORE [CA097186]; Prostate Cancer Foundation; Department of Defense [W81XWH-16-1-0484]; NATIONAL CANCER INSTITUTE [P50CA097186, R50CA221836] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003324] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pacific Northwest Prostate Cancer SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate Cancer Foundation; Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge research support from National Cancer Institute grants P30 CA015704, P30 CA033572 and R50 CA221836; Pacific Northwest Prostate Cancer SPORE CA097186, The Prostate Cancer Foundation (including Young Investigator Awards to MTS and HHC); and Department of Defense Award W81XWH-16-1-0484.	ANDREWS P, 1982, PHARMACOL THERAPEUT, V19, P245, DOI 10.1016/0163-7258(82)90064-X; Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Circu ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146931; Craig P, 2007, CURR OPIN INFECT DIS, V20, P524, DOI 10.1097/QCO.0b013e3282ef579e; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Grunwald V, 2002, CANCER RES, V62, P6141; Hu R, 2010, EXPERT REV ENDOCRINO, V5, P753, DOI 10.1586/EEM.10.49; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huggins C, 1941, CANCER RES, V1, P293; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Jin RJ, 2014, CANCER RES, V74, P2763, DOI 10.1158/0008-5472.CAN-13-2543; Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008-5472.CAN-09-3950; Khanim FL, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.38; Liu CF, 2016, ONCOTARGET, V7, P32210, DOI 10.18632/oncotarget.8493; Liu CF, 2015, PROSTATE, V75, P1341, DOI 10.1002/pros.23015; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Marcelin-Jimenez G, 2012, BIOANALYSIS, V4, P909, DOI [10.4155/BIO.12.41, 10.4155/bio.12.41]; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; OQUIGLEY J, 1990, BIOMETRICS, V46, P33, DOI 10.2307/2531628; PEARSON RD, 1985, ANN INTERN MED, V102, P550, DOI 10.7326/0003-4819-102-4-550; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schweizer MT, 2016, EXPERT OPIN THER TAR, V20, P903, DOI 10.1517/14728222.2016.1159676; Schweizer MT, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0225-2; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Taplin ME, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5005; Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078-0432.CCR-12-2895; Wright JL, 2011, CANCER EPIDEM BIOMAR, V20, P619, DOI 10.1158/1055-9965.EPI-10-1023; Yang M, 2011, J CLIN ONCOL, V29, P2565, DOI 10.1200/JCO.2010.31.2405; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863	42	60	60	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0198389	10.1371/journal.pone.0198389	http://dx.doi.org/10.1371/journal.pone.0198389			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856824	Green Submitted, gold, Green Published			2023-01-03	WOS:000433900800111
J	Wang, C; Tallian, C; Su, J; Vielnascher, R; Silva, C; Cavaco-Paulo, A; Guebitz, GM; Fu, JJ				Wang, Cheng; Tallian, Claudia; Su, Jing; Vielnascher, Robert; Silva, Carla; Cavaco-Paulo, Artur; Guebitz, Georg M.; Fu, Jiajia			Ultrasound-assisted extraction of hemicellulose and phenolic compounds from bamboo bast fiber powder	PLOS ONE			English	Article							HOT-WATER EXTRACTION; LIGNIN; REACTORS; OIL; FRACTIONATION; POLYPHENOLS; BIOMASS; STRAW; WOOD	Ultrasound-assisted extraction of hemicellulose and phenolic compounds from bamboo bast fibre powder was investigated. The effect of ultrasonic probe depth and power input parameters on the type and amount of products extracted was assessed. The results of input energy and radical formation correlated with the calculated values for the anti-nodal point (lambda/4; 16.85 mm, maximum amplitude) of the ultrasonic wave in aqueous medium. Ultrasonic treatment at optimum probe depth of 15 mm improve 2.6-fold the extraction efficiencies of hemicellulose and phenolic lignin compounds from bamboo bast fibre powder. LC-Ms-Tof (liquid chromatography-mass spectrometry-time of flight) analysis indicated that ultrasound led to the extraction of coniferyl alcohol, sinapyl alcohol, vanillic acid, cellobiose, in contrast to boiling water extraction only. At optimized conditions, ultrasound caused the formation of radicals confirmed by the presence of (+)-pinoresinol which resulted from the radical coupling of coniferyl alcohol. Ultrasounds revealed to be an efficient methodology for the extraction of hemicellulosic and phenolic compounds from woody bamboo without the addition of harmful solvents.	[Wang, Cheng; Su, Jing; Cavaco-Paulo, Artur; Fu, Jiajia] Jiangnan Univ, Int Joint Res Lab Text & Fiber Bioproc, Wuxi, Peoples R China; [Tallian, Claudia; Vielnascher, Robert; Guebitz, Georg M.] Univ Nat Resources & Life Sci, Vienna BOKU, Dept Agrobiotechnol IFA Tulin, Inst Environm Biotechnol, Tulin An Der Donau, Austria; [Su, Jing; Silva, Carla; Cavaco-Paulo, Artur] Univ Minho, Ctr Biol Engn, Campus Gualtar, Braga, Portugal; [Vielnascher, Robert; Guebitz, Georg M.] Austrian Ctr Ind Biotechnol, Tulin An Der Donau, Austria; [Fu, Jiajia] Jiangnan Univ, Jiangsu Engn Technol Res Ctr Funct Text, Wuxi, Peoples R China	Jiangnan University; University of Natural Resources & Life Sciences, Vienna; Universidade do Minho; Austrian Centre of Industrial Biotechnology; Jiangnan University	Fu, JJ (corresponding author), Jiangnan Univ, Int Joint Res Lab Text & Fiber Bioproc, Wuxi, Peoples R China.; Fu, JJ (corresponding author), Jiangnan Univ, Jiangsu Engn Technol Res Ctr Funct Text, Wuxi, Peoples R China.	jiajiafu@jiangnan.edu.cn	Guebitz, Georg/AAW-1868-2021; da Silva, Carla Manuela Pereira Marinho/AAC-4547-2020; Su, Jing/B-9671-2017; Cavaco-Paulo, Artur/N-7898-2013	Guebitz, Georg/0000-0003-2262-487X; da Silva, Carla Manuela Pereira Marinho/0000-0001-6252-8693; Su, Jing/0000-0001-6176-2007; Vielnascher, Robert/0000-0002-5160-8070; Tallian, Claudia/0000-0002-0790-3881; Cavaco-Paulo, Artur/0000-0001-7204-2064	OeAD-GmbH; Austrian Federal Ministry of Science, Research and Economy Scientific and Technological Cooperation Programme [CN 03/2016]; Chinese Foundation Key projects of governmental cooperation in international scientific and technological innovation [2016 YFE0115700]; National Natural Science Foundation of China [31470509]; Portuguese Foundation for Science and Technology (FCT) [UID/BIO/04469/2013 unit]; COMPETE 2020 - European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte [POCI-01-0145-FEDER-006684]; BioTecNorte operation - European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte [NORTE-01-0145-FEDER-000004];  [B17021]	OeAD-GmbH; Austrian Federal Ministry of Science, Research and Economy Scientific and Technological Cooperation Programme; Chinese Foundation Key projects of governmental cooperation in international scientific and technological innovation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Portuguese Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and Technology); COMPETE 2020 - European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte; BioTecNorte operation - European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte; 	This work has received financial funding from the OeAD-GmbH and the Austrian Federal Ministry of Science, Research and Economy Scientific and Technological Cooperation Programme under the grant number CN 03/2016. The authors would like to thank to Chinese Foundation Key projects of governmental cooperation in international scientific and technological innovation (No. 2016 YFE0115700), the National Natural Science Foundation of China (Grant No. 31470509), and the project (No. B17021). The authors would like also to thank to Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2013 unit and COMPETE 2020 (POCI-01-0145-FEDER-006684) and BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando H, 2000, IND ENG CHEM RES, V39, P3688, DOI 10.1021/ie0000257; Asgharzadehahmadi S, 2016, RENEW SUST ENERG REV, V63, P302, DOI 10.1016/j.rser.2016.05.030; Bai YY, 2013, INT J MOL SCI, V14, P21394, DOI 10.3390/ijms141121394; BJORKMAN A, 1954, NATURE, V174, P1057, DOI 10.1038/1741057a0; Brauns, 1960, CHEM LIGNIN SUPPLEME; Camarero S, 2005, APPL ENVIRON MICROB, V71, P1775, DOI 10.1128/AEM.71.4.1775-1784.2005; Da Porto C, 2013, ULTRASON SONOCHEM, V20, P1076, DOI 10.1016/j.ultsonch.2012.12.002; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; Gogate PR, 2008, CHEM ENG PROCESS, V47, P515, DOI 10.1016/j.cep.2007.09.014; Goncalves I, 2014, ULTRASON SONOCHEM, V21, P774, DOI 10.1016/j.ultsonch.2013.08.006; Higuchi T., 1969, Wood Research, P1; Iskalieva A, 2012, ULTRASON SONOCHEM, V19, P984, DOI 10.1016/j.ultsonch.2012.02.007; Laine J. E., 1977, CELL CHEM TECHNOL, V11, P561; Li HZ, 2004, FOOD RES INT, V37, P731, DOI 10.1016/j.foodres.2004.02.016; Li MF, 2012, ULTRASON SONOCHEM, V19, P243, DOI 10.1016/j.ultsonch.2011.06.018; Li ZQ, 2013, BIORESOURCES, V8, P5690; Liese W., 1986, ANATOMY PROPERTIES B, P196; Little C, 2007, ULTRASON SONOCHEM, V14, P375, DOI 10.1016/j.ultsonch.2006.07.009; MAEKAWA E, 1975, AGR BIOL CHEM TOKYO, V39, P2281, DOI 10.1080/00021369.1975.10861959; Marczak W, 1997, J ACOUST SOC AM, V102, P2776, DOI 10.1121/1.420332; Monteil-Rivera F, 2012, BIORESOURCE TECHNOL, V104, P775, DOI 10.1016/j.biortech.2011.11.079; Peng H, 2012, BIORESOURCES, V7, P374; Pingret D, 2012, J FOOD ENG, V111, P73, DOI 10.1016/j.jfoodeng.2012.01.026; Silva R, 2010, ULTRASON SONOCHEM, V17, P628, DOI 10.1016/j.ultsonch.2009.10.010; Song T, 2012, BIORESOURCES, V7, P4214; Suparno O, 2005, RESOUR CONSERV RECY, V45, P114, DOI 10.1016/j.resconrec.2005.02.005; Vinatoru M, 2001, ULTRASON SONOCHEM, V8, P303, DOI 10.1016/S1350-4177(01)00071-2; Wen JL, 2011, CARBOHYD RES, V346, P111, DOI 10.1016/j.carres.2010.10.006; Xu F, 2013, APPL ENERG, V104, P801, DOI 10.1016/j.apenergy.2012.12.019; Zhang ZS, 2008, SEP PURIF TECHNOL, V62, P192, DOI 10.1016/j.seppur.2008.01.014	31	10	12	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0197537	10.1371/journal.pone.0197537	http://dx.doi.org/10.1371/journal.pone.0197537			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856764	Green Published, Green Submitted, gold			2023-01-03	WOS:000433900800029
J	Estrin, MA; Hussein, ITM; Puryear, WB; Kuan, AC; Artim, SC; Runstadler, JA				Estrin, Michael A.; Hussein, Islam T. M.; Puryear, Wendy B.; Kuan, Anne C.; Artim, Stephen C.; Runstadler, Jonathan A.			Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells	PLOS ONE			English	Article							WEST-NILE-VIRUS; MESSENGER-RNA; SEASONAL INFLUENZA; NEURAMINIDASE INHIBITORS; SCREEN REVEALS; NUCLEAR EXPORT; UNITED-STATES; IN-VIVO; REPLICATION; INFECTION	Influenza A virus infections are important causes of morbidity and mortality worldwide, and currently available prevention and treatment methods are suboptimal. In recent years, genome-wide investigations have revealed numerous host factors that are required for influenza to successfully complete its life cycle. However, only a select, small number of influenza strains were evaluated using this platform, and there was considerable variation in the genes identified across different investigations. In an effort to develop a universally efficacious therapeutic strategy with limited potential for the emergence of resistance, this study was performed to investigate the effect of combinatorial RNA interference (RNAi) on inhibiting the replication of diverse influenza A virus subtypes and strains. Candidate genes were selected for targeting based on the results of multiple previous independent genome-wide studies. The effect of single and combinatorial RNAi on the replication of 12 diverse influenza A viruses, including three strains isolated from birds and one strain isolated from seals, was then evaluated in primary normal human bronchial epithelial cells. After excluding overly toxic siRNA, two siRNA combinations were identified that reduced mean viral replication by greater than 79 percent in all mammalian strains, and greater than 68 percent in all avian strains. Host-directed combinatorial RNAi effectively prevents growth of a broad range of influenza virus strains in vitro, and is a potential therapeutic candidate for further development and future in vivo studies.	[Estrin, Michael A.; Hussein, Islam T. M.; Puryear, Wendy B.; Kuan, Anne C.; Artim, Stephen C.; Runstadler, Jonathan A.] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Runstadler, Jonathan A.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Hussein, Islam T. M.] Microbiotix, One Innovat Dr, Worcester, MA USA; [Puryear, Wendy B.; Runstadler, Jonathan A.] Tufts Univ, Cummings Sch Vet Med, Dept Infect Dis & Global Hlth, Grafton, MA 01536 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Tufts University	Runstadler, JA (corresponding author), MIT, Div Comparat Med, Cambridge, MA 02139 USA.; Runstadler, JA (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Runstadler, JA (corresponding author), Tufts Univ, Cummings Sch Vet Med, Dept Infect Dis & Global Hlth, Grafton, MA 01536 USA.	jonathan.runstadler@tufts.edu		/0000-0003-4503-9024; Runstadler, Jonathan/0000-0002-6747-7765	National Institute of Allergy and Infectious Diseases [CEIRS - HHSN272201400008C, HHSN266200700010C]; National Institutes of Health [T32-OD010978]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T32OD010978] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institute of Allergy and Infectious Diseases: CEIRS - HHSN272201400008C (current); and HHSN266200700010C (2007-2014). M. E. was supported in part by National Institutes of Health grant #T32-OD010978, which supported his postdoctoral training. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Cai HQ, 2007, DEV CELL, V12, P671, DOI 10.1016/j.devcel.2007.04.005; Chen HW, 2013, ANTIVIR RES, V99, P371, DOI 10.1016/j.antiviral.2013.06.014; Clarke DTW, 2014, CURRENT DRUG DELIVER; Cruz DJM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002471; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; de Francisco N, 2015, VACCINE, V33, P6537, DOI 10.1016/j.vaccine.2015.10.066; Ebina H, 2004, MICROBES INFECT, V6, P715, DOI 10.1016/j.micinf.2004.04.002; Flannery B, 2014, MMWR-MORBID MORTAL W, V63, P137; Fujita Y, 2015, INT J MOL SCI, V16, P5254, DOI 10.3390/ijms16035254; GAUSH CR, 1968, APPL MICROBIOL, V16, P588, DOI 10.1128/AEM.16.4.588-594.1968; Ge Q, 2003, P NATL ACAD SCI USA, V100, P2718, DOI 10.1073/pnas.0437841100; Govorkova EA, 2013, ANTIVIR RES, V98, P297, DOI 10.1016/j.antiviral.2013.02.013; GUINEA R, 1995, J VIROL, V69, P2306, DOI 10.1128/JVI.69.4.2306-2312.1995; GUINEA R, 1994, FEBS LETT, V349, P327, DOI 10.1016/0014-5793(94)00695-4; Hai R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3854; Hao LH, 2008, NATURE, V454, P890, DOI 10.1038/nature07151; Johnson LA, 2009, J VIROL, V83, P6335, DOI 10.1128/JVI.00375-09; Karlas A, 2010, NATURE, V463, P818, DOI 10.1038/nature08760; Keightley MC, 2013, FEBS LETT, V587, P2150, DOI 10.1016/j.febslet.2013.05.030; Kobayashi H, 2015, BIOCHEM BIOPH RES CO, V467, P121, DOI 10.1016/j.bbrc.2015.09.106; Konig R, 2010, NATURE, V463, P813, DOI 10.1038/nature08699; Konig R, 2008, CELL, V135, P49, DOI 10.1016/j.cell.2008.07.032; Krishnan MN, 2008, NATURE, V455, P242, DOI 10.1038/nature07207; Kurtovic-Kozaric A, 2015, LEUKEMIA, V29, P126, DOI 10.1038/leu.2014.144; Lam TTY, 2013, NATURE, V502, P241, DOI 10.1038/nature12515; Li TJ, 2014, NUCLEIC ACID THER, V24, P302, DOI 10.1089/nat.2014.0480; Liu Y, 2015, NUCLEIC ACIDS RES, V43, pD946, DOI 10.1093/nar/gku1086; Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845; Meliopoulos VA, 2012, FASEB J, V26, P1372, DOI 10.1096/fj.11-193466; Mercer J, 2012, CELL REP, V2, P1036, DOI 10.1016/j.celrep.2012.09.003; Merkel OM, 2014, ADV DRUG DELIVER REV, V75, P112, DOI 10.1016/j.addr.2014.05.018; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Momose F, 2002, J BIOL CHEM, V277, P45306, DOI 10.1074/jbc.M206822200; Murray James L., 2012, Antiviral Chemistry & Chemotherapy, V22, P205, DOI 10.3851/IMP2080; Nguyen HT, 2012, ANTIVIR THER, V17, P159, DOI 10.3851/IMP2067; Okomo-Adhiambo M, 2013, INFLUENZA OTHER RESP, V7, P44, DOI [10.1111/irv.12113, 10.1111/irv.12051]; Ooi YS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003835; Palese P., 2007, FIELDS VIROLOGY, P1647; Panda D, 2011, P NATL ACAD SCI USA, V108, P19036, DOI 10.1073/pnas.1113643108; Perwitasari O, 2014, J VIROL, V88, P10228, DOI 10.1128/JVI.01774-14; Perwitasari O, 2013, J VIROL, V87, P13775, DOI 10.1128/JVI.01509-13; Perwitasari O, 2013, ANTIMICROB AGENTS CH, V57, P475, DOI 10.1128/AAC.01532-12; Petrie JG, 2016, CLIN INFECT DIS, V62, P448, DOI 10.1093/cid/civ952; Prussia A, 2011, INT J MOL SCI, V12, P4027, DOI 10.3390/ijms12064027; Qi W, 2014, EUROPEAN COMMUNICABL, V19; Rajani KR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002929; Rappuoli R, 2012, SCIENCE, V336, P1531, DOI 10.1126/science.1221466; Read EKC, 2010, J GEN VIROL, V91, P1290, DOI 10.1099/vir.0.018564-0; Reed R, 2005, CURR OPIN CELL BIOL, V17, P269, DOI 10.1016/j.ceb.2005.04.011; Runstadler J, 2013, INFECT GENET EVOL, V17, P162, DOI 10.1016/j.meegid.2013.02.020; Samson M, 2013, ANTIVIR RES, V98, P174, DOI 10.1016/j.antiviral.2013.03.014; Scott LM, 2013, JNCI-J NATL CANCER I, V105, P1540, DOI 10.1093/jnci/djt257; Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018; Silva-Ayala D, 2013, P NATL ACAD SCI USA, V110, P10270, DOI 10.1073/pnas.1304932110; Sivan G, 2013, P NATL ACAD SCI USA, V110, P3519, DOI 10.1073/pnas.1300708110; Stertz S, 2011, MICROBES INFECT, V13, P516, DOI 10.1016/j.micinf.2011.01.012; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Su WC, 2013, P NATL ACAD SCI USA, V110, P17516, DOI 10.1073/pnas.1312374110; Tai AW, 2009, CELL HOST MICROBE, V5, P298, DOI 10.1016/j.chom.2009.02.001; Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009; Torner N, 2014, HUMAN VACCINES IMMUN, V11; Tran AT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.296; Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574; Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002; Ward SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039284; Watanabe T, 2014, CELL HOST MICROBE, V16, P795, DOI 10.1016/j.chom.2014.11.002; Watanabe T, 2013, NATURE, V501, P551, DOI 10.1038/nature12392; Watanabe T, 2010, CELL HOST MICROBE, V7, P427, DOI 10.1016/j.chom.2010.05.008; WHITNEY JA, 1995, CELL, V83, P703; Yang C, 2014, IEEE COMPUT SOC CONF, P9, DOI 10.1109/CVPRW.2014.7; Yang J, 2015, INFECT DIS POVERTY, V4, DOI 10.1186/s40249-015-0077-6; Yasunaga A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003914; Zhou X, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M112.445122	75	5	6	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2018	13	5							e0197246	10.1371/journal.pone.0197246	http://dx.doi.org/10.1371/journal.pone.0197246			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG2KJ	29775471	gold, Green Submitted, Green Published			2023-01-03	WOS:000432521100014
J	Giboin, LS; Amiri, E; Bertschinger, R; Gruber, M				Giboin, Louis-Solal; Amiri, Ehsan; Bertschinger, Raphael; Gruber, Markus			Active recovery affects the recovery of the corticospinal system but not of muscle contractile properties	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HUMAN KNEE EXTENSORS; VOLUNTARY ACTIVATION; FATIGUE; MECHANISMS; EXERCISE; TIME; DETERMINANTS; PERFORMANCE; METABOLISM	Purpose Active recovery is often used by athletes after strenuous exercise or competition but its underlying mechanisms are not well understood. We hypothesized that active recovery speeds-up recovery processes within the muscle and the central nervous system (CNS). Methods We assessed muscular and CNS recovery by measuring the voluntary activation (VA) in the vastus lateralis muscle with transcranial magnetic stimulation (VA(TMS)) and peripheral nerve stimulation (VA(PNS)) during maximal voluntary contractions (MVC) of the knee extensors in 11 subjects. Measurements were performed before and after a fatiguing cycling time-trial, after an active and a passive recovery treatment and after another fatiguing task (1 min MVC). The measurements were performed a second time 24 h after the time-trial. Results We observed a time x group interaction effect for VA(TMS) (p = 0.013). Post-hoc corrected T-tests demonstrated an increased VA(TMS) after active recovery when measured after the 1 min MVC performed 24 h after the time-trial (mean +/- SD; 95.2 +/- 4.1% vs. 89.2 +/- 6.6%, p = 0.026). No significant effects were observed for all other variables. Conclusions Active recovery increased aspects of central, rather than muscle recovery. However, no effect on MVC was seen, implying that even if active recovery speeds up CNS recovery, without affecting the recovery of muscle contractile properties, this doesn't translate into increases in overall performance.	[Giboin, Louis-Solal; Bertschinger, Raphael; Gruber, Markus] Univ Konstanz, Sensorimotor Performance Lab, Constance, Germany; [Amiri, Ehsan] Razi Univ, Fac Sport Sci, Kermanshah, Iran	University of Konstanz; Razi University	Giboin, LS (corresponding author), Univ Konstanz, Sensorimotor Performance Lab, Constance, Germany.	louis-solal.giboin@uni-konstanz.de	Amiri, Ehsan/AAA-1956-2021	Amiri, Ehsan/0000-0001-6120-9252; Gruber, Markus/0000-0002-0233-3912	Iranian Ministry of Science, Research and Technology	Iranian Ministry of Science, Research and Technology	EA was supported by the Iranian Ministry of Science, Research and Technology.	Ahmaidi S, 1996, MED SCI SPORT EXER, V28, P450, DOI 10.1097/00005768-199604000-00009; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; BANGSBO J, 1994, J APPL PHYSIOL, V77, P1890, DOI 10.1152/jappl.1994.77.4.1890; Barnett A, 2006, SPORTS MED, V36, P781, DOI 10.2165/00007256-200636090-00005; Carroll TJ, 2017, J APPL PHYSIOL, V122, P1068, DOI 10.1152/japplphysiol.00775.2016; Connolly Declan Aj, 2003, J Sports Sci Med, V2, P47; Dahmen T, 2011, SPORTS ENG, V14, P95, DOI 10.1007/s12283-011-0076-1; Finsterer J, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-218; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; Giboin LS, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00150; Goodall S, 2009, EXP PHYSIOL, V94, P995, DOI 10.1113/expphysiol.2009.047902; HENNEMAN E, 1965, J NEUROPHYSIOL, V28, P560, DOI 10.1152/jn.1965.28.3.560; Herbert RD, 1999, J NEUROPHYSIOL, V82, P2271, DOI 10.1152/jn.1999.82.5.2271; Husmann F, 2017, MED SCI SPORT EXER, V49, P440, DOI 10.1249/MSS.0000000000001133; Koizumi K, 2011, J SPORT SCI, V29, P919, DOI 10.1080/02640414.2011.572990; Meeusen R, 2013, MED SCI SPORT EXER, V45, P186, DOI 10.1249/MSS.0b013e318279a10a; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; Mika A, 2007, AM J PHYS MED REHAB, V86, P474, DOI 10.1097/PHM.0b013e31805b7c79; Mika A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164216; Minett GM, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00024; Nedelec M, 2012, SPORTS MED, V42, P997, DOI 10.2165/11635270-000000000-00000; Rattray B, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00079; Roelands B, 2013, SPORTS MED, V43, P301, DOI 10.1007/s40279-013-0030-4; Sargeant AJ, 2007, EXP PHYSIOL, V92, P323, DOI 10.1113/expphysiol.2006.034322; Sidhu SK, 2009, MUSCLE NERVE, V39, P186, DOI 10.1002/mus.21064; Simjanovic M, 2009, J SCI MED SPORT; SKINNER JS, 1980, RES Q EXERCISE SPORT, V51, P234, DOI 10.1080/02701367.1980.10609285; Taylor JL, 2006, CLIN EXP PHARMACOL P, V33, P400, DOI 10.1111/j.1440-1681.2006.04363.x; Thomas K, 2017, MED SCI SPORT EXER, V49, P955, DOI 10.1249/MSS.0000000000001196; Thomas K, 2015, MED SCI SPORT EXER, V47, P537, DOI 10.1249/MSS.0000000000000448; Todd G, 2003, J PHYSIOL-LONDON, V551, P661, DOI 10.1113/jphysiol.2003.044099; Todd G, 2016, J APPL PHYSIOL, V121, P678, DOI 10.1152/japplphysiol.00293.2016; Yang JZ, 2014, AM J SPORT MED, V42, P1456, DOI 10.1177/0363546514524699	33	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2018	13	5							e0197339	10.1371/journal.pone.0197339	http://dx.doi.org/10.1371/journal.pone.0197339			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF6MZ	29758055	Green Published, Green Submitted, gold			2023-01-03	WOS:000432082900041
J	Yang, CM; Hung, CL; Su, HC; Lin, HJ; Chen, CH; Lin, CC; Hu, HH; Lin, SH; Sung, PS				Yang, Chun-Ming; Hung, Chien-Ling; Su, Hui-Chen; Lin, Huey-Juan; Chen, Chih-Hung; Lin, Chou-Ching; Hu, Han-Hwa; Lin, Sheng-Hsiang; Sung, Pi-Shan			Leukoaraiosis and risk of intracranial hemorrhage and outcome after stroke thrombolysis	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; TISSUE-PLASMINOGEN ACTIVATOR; WHITE-MATTER LESIONS; INTRAVENOUS THROMBOLYSIS; GUIDELINES; ALTEPLASE; THERAPY; TAIWAN; SCALE	Background The impact of leukoaraiosis on the risk of symptomatic intracerebral hemorrhage (SICH) after stroke thrombolysis is conflicting, and the data on Asian populations are lacking. Therefore, in this study, we assessed the association between leukoaraiosis and SICH, and the association between leukoaraiosis and the 90-day functional outcome in the Asian population. Methods Data were collected from a two-center prospective registry of acute ischemic stroke patients given intravenous tissue plasminogen activator between 2006 and 2014. A total of 614 pretreatment brain CT and 455 posttreatment MRI were retrospectively assessed using two different rating scales for the presence of leukoaraiosis. Outcome measures were the occurrence of SICH with three definitions and any hemorrhage after thrombolysis and functional outcome at 3 months. Results Of the 614 patients assessed, 30.3% showed severe leukoaraiosis on the baseline brain CT. The SICH rate was 4.6% -7.2% based on different definitions, and overall, 24.9% of patients showed any post-tPA hemorrhage. No association was observed between the severity of leukoaraiosis and SICH, regardless of having used different leukoaraiosis rating scales or as assessment using different imaging modalities. However, severe leukoaraiosis was independently associated with poor functional outcome at 3 months (OR 1.96, 95% C1 1.24-3.11, P = 0.004) after adjustment for confounders. Conclusions Our results showed no association between leukoaraiosis and the risk of SICH. Although the presence of severe leukoaraiosis predicted a poor functional outcome after stroke, IV thrombolysis might not be withheld in acute ischemic stroke patients solely based on the presence of severe leukoaraiosis on pre-thrombolytic CT scans.	[Yang, Chun-Ming; Lin, Huey-Juan] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Hung, Chien-Ling] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan; [Hung, Chien-Ling; Lin, Sheng-Hsiang; Sung, Pi-Shan] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Su, Hui-Chen; Chen, Chih-Hung; Lin, Chou-Ching; Sung, Pi-Shan] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Neurol, Tainan, Taiwan; [Hu, Han-Hwa] Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan; [Hu, Han-Hwa] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, Taipei, Taiwan	Chi Mei Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Sung, PS (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.; Sung, PS (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Neurol, Tainan, Taiwan.	pishansung@gmail.com	Lin, Chou-Ching K/I-1451-2019	Lin, Chou-Ching K/0000-0002-3070-5787; Sung, Pi-shan/0000-0003-2505-7583	Chi Mei Hospital [CMNCKU10416]	Chi Mei Hospital	The funding of this study is from Chi Mei Hospital (grant number: CMNCKU10416), but the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed N, 2010, LANCET NEUROL, V9, P866, DOI 10.1016/S1474-4422(10)70165-4; Alvarez-Sabin J, 2013, LANCET NEUROL, V12, P689, DOI 10.1016/S1474-4422(13)70055-3; Aries MJH, 2010, EUR J NEUROL, V17, P866, DOI 10.1111/j.1468-1331.2010.02963.x; Chang Yeu-Jhy, 2008, Acta Neurol Taiwan, V17, P275; Chao AC, 2010, STROKE, V41, P885, DOI 10.1161/STROKEAHA.109.575605; Charidimou A, 2016, STROKE, V47, P2364, DOI 10.1161/STROKEAHA.116.014096; Choi JH, 2011, J KOREAN NEUROSURG S, V50, P75, DOI 10.3340/jkns.2011.50.2.75; Choi JC, 2015, J STROKE, V17, P7, DOI 10.5853/jos.2015.17.1.7; Costello CA, 2012, J CLIN NEUROSCI, V19, P360, DOI 10.1016/j.jocn.2011.08.014; Demchuk AM, 2008, CEREBROVASC DIS, V26, P120, DOI 10.1159/000139658; Derex L, 2008, J NEUROL NEUROSUR PS, V79, P1093, DOI 10.1136/jnnp.2007.133371; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Holmstedt CA, 2013, LANCET NEUROL, V12, P1106, DOI 10.1016/S1474-4422(13)70195-9; Hsieh FI, 2010, CIRCULATION, V122, P1116, DOI 10.1161/CIRCULATIONAHA.110.936526; INZITARI D, 1990, STROKE, V21, P1419, DOI 10.1161/01.STR.21.10.1419; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kongbunkiat K, 2017, NEUROLOGY, V88, P638, DOI 10.1212/WNL.0000000000003605; Lee SJ, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-31; Lin QQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153486; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mehta RH, 2014, STROKE, V45, P2263, DOI 10.1161/STROKEAHA.114.005019; Neumann-Haefelin T, 2006, STROKE, V37, P2463, DOI 10.1161/01.STR.0000239321.53203.ea; Nordahl CW, 2006, J COGNITIVE NEUROSCI, V18, P418, DOI 10.1162/jocn.2006.18.3.418; Ntaios G, 2015, NEUROLOGY, V84, P1213, DOI 10.1212/WNL.0000000000001402; O'Sullivan M, 2002, NEUROLOGY, V59, P321, DOI 10.1212/WNL.59.3.321; O'Sullivan Mike, 2008, Pract Neurol, V8, P26, DOI 10.1136/jnnp.2007.139428; Palumbo V, 2007, NEUROLOGY, V68, P1020, DOI 10.1212/01.wnl.0000257817.29883.48; SCHMIDT R, 1992, ARCH NEUROL-CHICAGO, V49, P825, DOI 10.1001/archneur.1992.00530320049011; Seet RCS, 2012, CEREBROVASC DIS, V34, P106, DOI 10.1159/000339675; SELEKLER K, 1989, STROKE, V20, P1016, DOI 10.1161/01.STR.20.8.1016; Smith EE, 2002, NEUROLOGY, V59, P193, DOI 10.1212/WNL.59.2.193; Sung SF, 2013, STROKE, V44, P1561, DOI 10.1161/STROKEAHA.111.000651; TSIVQOULIS G, 2008, LANCET, V372; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; Willer L, 2015, J STROKE CEREBROVASC, V24, P1126, DOI 10.1016/j.jstrokecerebrovasdis.2014.12.018; Xiong Yun Yun, 2011, J Aging Res, V2011, P617927, DOI 10.4061/2011/617927	40	13	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2018	13	5							e0196505	10.1371/journal.pone.0196505	http://dx.doi.org/10.1371/journal.pone.0196505			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE5RZ	29715283	Green Published, gold, Green Submitted			2023-01-03	WOS:000431281100027
J	Peikert, ML; Inhestern, L; Bergelt, C				Peikert, Mona Leandra; Inhestern, Laura; Bergelt, Corinna			Psychosocial interventions for rehabilitation and reintegration into daily life of pediatric cancer survivors and their families: A systematic review	PLOS ONE			English	Review							QUALITY-OF-LIFE; POSTTRAUMATIC STRESS SYMPTOMS; SOCIAL-SKILLS INTERVENTION; BRAIN-TUMOR SURVIVORS; CHILDHOOD-CANCER; ADOLESCENT SURVIVORS; TRAUMATIC STRESS; MENTAL-HEALTH; SUMMER CAMP; FOLLOW-UP	Background The survival rate of childhood cancer patients increased over the past decades. However, even after successful treatment the transition back to normalcy is often a major challenge for the whole family. Therefore, this study aims to provide an overview of psychosocial interventions for childhood cancer survivors and their families in the first years after the end of cancer treatment. Methods We conducted a systematic review following the PRISMA Checklist (Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO registration number: CRD42017059782). In November 2016 and September 2017, we searched the databases CINAHL, MEDLINE, PSYNDEX, and Web of Science. We included studies investigating psychosocial interventions for childhood cancer survivors diagnosed under the age of 21, their family members or the family as a whole. Further, we summarized the study characteristics and conducted a narrative synthesis of the results. Finally, we assessed the study quality with the Effective Public Health Practice Project Quality Assessment Tool. Results We identified a total of 8215 records based on our database searches and 17 additional records through hand searches. We included 33 articles in the qualitative synthesis. Most of the studies described interventions for the cancer survivor (n = 15). Nine studies investigated interventions for the whole family, and two studies interventions for siblings. The interventions mainly take place in an outpatient group setting (n = 15). Overall, most of the studies reported a significant psychosocial benefit of the interventions. However, the quality of the included studies was limited. Conclusion In summary, we identified a broad range of different interventions and thus could give a comprehensive overview of existing interventions for childhood cancer survivors and their families. However, there is a necessity for high quality studies. The results may help to optimize health care services that support families with the re-entry into daily life.	[Peikert, Mona Leandra; Inhestern, Laura; Bergelt, Corinna] Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Peikert, ML (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany.	m.peikert@uke.de		Bergelt, Corinna/0000-0003-1413-1872				Alderfer MA, 2003, J PEDIATR PSYCHOL, V28, P281, DOI 10.1093/jpepsy/jsg016; Alderfer MA, 2010, PSYCHO-ONCOLOGY, V19, P789, DOI 10.1002/pon.1638; Armijo-Olivo S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/j.1365-2753.2010.01516.x; Aslett H, 2007, EUR J CANCER, V43, P1781, DOI 10.1016/j.ejca.2007.04.009; Barakat LP, 2003, J PEDIATR PSYCHOL, V28, P299, DOI 10.1093/jpepsy/jsg019; Barnett M, 2016, J CANCER SURVIV, V10, P814, DOI 10.1007/s11764-016-0527-6; Barrera M, 2009, J PEDIATR PSYCHOL, V34, P1108, DOI 10.1093/jpepsy/jsp018; Barrera M, 2018, PSYCHO-ONCOLOGY, V27, P91, DOI 10.1002/pon.4385; Bender R, 2007, DEUT MED WOCHENSCHR, V132, P26; Braam KI, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008796.pub2; Bragadottir H, 2008, J NURS SCHOLARSHIP, V40, P32, DOI 10.1111/j.1547-5069.2007.00203.x; Brier MJ, 2015, HEALTH PSYCHOL, V34, P130, DOI 10.1037/hea0000119; Buchbinder D, 2011, PSYCHO-ONCOLOGY, V20, P1259, DOI 10.1002/pon.1848; Conrad AL, 2009, J PEDIATR ONCOL NURS, V26, P150, DOI 10.1177/1043454209334418; Daggelmann J, 2017, REHABILITATION, V56, P119, DOI 10.1055/s-0043-103064; Dawson S, 2012, THER RECREAT J, V46, P313; Devine KA, 2016, J DEV BEHAV PEDIATR, V37, P475, DOI 10.1097/DBP.0000000000000315; DieTrill M, 1996, J PSYCHOSOC ONCOL, V14, P23, DOI 10.1300/J077v14n02_02; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Effective Public Health Practice Project (EPHPP), QUAL ASS TOOL QUANT; Engelen V, 2011, PEDIATR BLOOD CANCER, V56, P646, DOI 10.1002/pbc.22795; Friedman DL, 2006, PEDIATR BLOOD CANCER, V46, P159, DOI 10.1002/pbc.20611; Gerhardt CA, 2015, PEDIATR BLOOD CANCER, V62, pS678, DOI 10.1002/pbc.25821; Gianinazzi ME, 2013, PSYCHO-ONCOLOGY, V22, P2051, DOI 10.1002/pon.3249; HABERLE H, 1991, KLIN PADIATR, V203, P206, DOI 10.1055/s-2007-1025431; Haberle H, 1997, PRAX KINDERPSYCHOL K, V46, P405; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hooke MC, 2016, J PEDIATR ONCOL NURS, V33, P64, DOI 10.1177/1043454214563936; Inhestern L, 2017, PRAX KINDERPSYCHOL K, V66, P179, DOI 10.13109/prkk.2017.66.3.179; Jorngarden A, 2007, EUR J CANCER, V43, P1952, DOI 10.1016/j.ejca.2007.05.031; Kaatsch P, 2010, CANCER TREAT REV, V36, P277, DOI 10.1016/j.ctrv.2010.02.003; Kaplan LM, 2013, FAM SYST HEALTH, V31, P205, DOI 10.1037/a0032550; Kazak AE, 1999, FAM PROCESS, V38, P175; Kazak AE, 2004, J FAM PSYCHOL, V18, P493, DOI 10.1037/0893-3200.18.3.493; Kazak AE, 2004, J PEDIATR PSYCHOL, V29, P211, DOI 10.1093/jpepsy/jsh022; Kazak AE, 2005, J PEDIATR PSYCHOL, V30, P29, DOI 10.1093/jpepsy/jsi013; Labay Larissa E, 2004, J Pediatr Oncol Nurs, V21, P165; Law EF, 2014, J PEDIATR PSYCHOL, V39, P866, DOI 10.1093/jpepsy/jsu032; Li HCW, 2013, PSYCHO-ONCOLOGY, V22, P2601, DOI 10.1002/pon.3326; Lim AN, 2010, FUTUR NEUROL, V5, P135, DOI 10.2217/FNL.09.65; Litzelman K, 2011, QUAL LIFE RES, V20, P1261, DOI 10.1007/s11136-011-9854-2; Long KA, 2011, CLIN CHILD FAM PSYCH, V14, P57, DOI 10.1007/s10567-010-0082-z; Martiniuk A, 2014, PEDIATR BLOOD CANCER, V61, P778, DOI 10.1002/pbc.24912; Maurice-Stam H, 2008, PEDIATR BLOOD CANCER, V50, P1047, DOI 10.1002/pbc.21374; Maurice-Stam H, 2014, J PSYCHOSOC ONCOL, V32, P310, DOI 10.1080/07347332.2014.897290; Maurice-Stam H, 2009, PSYCHO-ONCOLOGY, V18, P762, DOI 10.1002/pon.1470; McCubbin M, 2002, FAM RELAT, V51, P103, DOI 10.1111/j.1741-3729.2002.00103.x; Meltzer LJ, 2005, CHILD HEALTH CARE, V34, P305, DOI 10.1207/s15326888chc3404_5; Meyler E, 2010, J PEDIATR PSYCHOL, V35, P1116, DOI 10.1093/jpepsy/jsq032; Michel G, 2009, EUR J CANCER, V45, P1616, DOI 10.1016/j.ejca.2009.02.026; Mitchell W, 2006, PSYCHO-ONCOLOGY, V15, P805, DOI 10.1002/pon.1014; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Muglia-Wechsler A, 2014, AN PSICOL-SPAIN, V30, P94, DOI 10.6018/analesps.30.1.149161; Pai ALH, 2007, J FAM PSYCHOL, V21, P407, DOI 10.1037/0893-3200.21.3.407; Pai ALH, 2006, CURR OPIN PEDIATR, V18, P558, DOI 10.1097/01.mop.0000245358.06326.e9; Pai ALH, 2006, J PEDIATR PSYCHOL, V31, P978, DOI 10.1093/jpepsy/jsj109; Patel SK, 2009, J PEDIAT HEMATOL ONC, V31, P670, DOI 10.1097/MPH.0b013e3181b25a1d; Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013; Phipps S, 2005, PEDIATR BLOOD CANCER, V45, P952, DOI 10.1002/pbc.20373; Plante WA, 2001, J PEDIATR PSYCHOL, V26, P435, DOI 10.1093/jpepsy/26.7.435; Poggi G, 2009, DISABIL REHABIL, V31, P1066, DOI 10.1080/09638280802509546; Prchal A, 2009, PSYCHO-ONCOLOGY, V18, P1241, DOI 10.1002/pon.1565; Reinfjell T, 2009, EUR J CANCER CARE, V18, P364, DOI 10.1111/j.1365-2354.2008.00954.x; Richardson WS., 1995, ACP J CLUB, V3, pA12, DOI DOI 10.7326/ACPJC-1995-123-3-A12; Richter D, 2015, CRIT REV ONCOL HEMAT, V95, P370, DOI 10.1016/j.critrevonc.2015.04.003; Ryan R, 2016, DATA SYNTHESIS ANAL; Salavati B, 2014, CHILD HEALTH CARE, V43, P221, DOI 10.1080/02739615.2013.837820; Salem H, 2017, ACTA ONCOL, V56, P367, DOI 10.1080/0284186X.2016.1269194; Sawyer M, 2000, J PEDIAT HEMATOL ONC, V22, P214, DOI 10.1097/00043426-200005000-00006; Schrag NM, 2008, PEDIATR BLOOD CANCER, V50, P98, DOI 10.1002/pbc.21285; Schulte F, 2014, PSYCHO-ONCOLOGY, V23, P597, DOI 10.1002/pon.3472; Schulte F, 2014, PSYCHO-ONCOLOGY, V23, P183, DOI 10.1002/pon.3387; Seitz DCM, 2009, PSYCHO-ONCOLOGY, V18, P683, DOI 10.1002/pon.1473; Shekarabi-Ahari G, 2012, IRAN J CANCER PREV, V5, P183; Steele AC, 2015, PEDIATR BLOOD CANCER, V62, pS585, DOI 10.1002/pbc.25701; Thomas B H, 2004, Worldviews Evid Based Nurs, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x; van Buiren M, 1998, KLIN PADIATR, V210, P304, DOI 10.1055/s-2008-1043897; van Dijk-Lokkart EM, 2016, PSYCHO-ONCOLOGY, V25, P815, DOI 10.1002/pon.4016; van Dijk-Lokkart EM, 2015, SUPPORT CARE CANCER, V23, P2327, DOI 10.1007/s00520-014-2576-6; Van Schoors M, 2017, J PEDIATR PSYCHOL, V42, P6, DOI 10.1093/jpepsy/jsw070; Wakefield CE, 2016, SUPPORT CARE CANCER, V24, P2685, DOI 10.1007/s00520-016-3077-6; Wenninger K, 2013, PSYCHO-ONCOLOGY, V22, P854, DOI 10.1002/pon.3073; Wilkins Krista L, 2005, J Pediatr Oncol Nurs, V22, P305, DOI 10.1177/1043454205278035; Wu YP, 2011, CHILD YOUTH CARE FOR, V40, P121, DOI 10.1007/s10566-010-9123-5; Yeh CH, 2011, CANCER NURS, V34, P3, DOI 10.1097/NCC.0b013e3181e4553c; Zhu LY, 2015, INDIAN J PHARM EDUC, V49, P183, DOI 10.5530/ijper.49.3.3	87	17	17	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2018	13	4							e0196151	10.1371/journal.pone.0196151	http://dx.doi.org/10.1371/journal.pone.0196151			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD4BF	29672608	Green Published, gold, Green Submitted			2023-01-03	WOS:000430446800095
J	Philip, P; Bioulac, S; Altena, E; Morin, CM; Ghorayeb, I; Coste, O; Monteyrol, PJ; Micoulaud-Franchi, JA				Philip, Pierre; Bioulac, Stephanie; Altena, Elemarije; Morin, Charles M.; Ghorayeb, Imad; Coste, Olivier; Monteyrol, Pierre-Jean; Micoulaud-Franchi, Jean-Arthur			Specific insomnia symptoms and self-efficacy explain CPAP compliance in a sample of OSAS patients	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; LONG-TERM ADHERENCE; THERAPY; AGE; PREDICTORS; ASSOCIATION; VALIDATION; MEDICATION; VETERANS	This study explores the association between specific insomnia symptoms (sleep onset, sleep maintenance and early morning awakenings symptoms) and self-efficacy (perceived self-confidence in the ability to use CPAP) with CPAP compliance in French patients with obstructive sleep apnea syndrome (OSAS). We performed a retrospective, cross-sectional analysis of CPAP compliance in a cohort of 404 patients diagnosed with OSAS. Patients completed mailed questionnaires on sleepiness (ESS), insomnia (ISI) and self-efficacy in sleep apnea (SEMSA). Linear regression modeling analyses were performed to explore the impact of measured variables on the number of hours of CPAP use. Of the initial pool of 404 patients, 288 returned the questionnaires (71% response rate). Their mean age was 63.16 +/- 12.73 yrs, 31% were females, mean BMI was 30.39 6.31 kg/m(2), mean daily CPAP use was 6.19 +/- 2.03 h, mean number of years of use was 6.58 6.03 yrs, and mean initial AHI before CPAP use was 34.61 +/- 20.71 /h. Age (p<0.01), BMI (p<0.01), sleep onset insomnia symptoms (p<0.01), sleep maintenance insomnia symptoms (p<0.01) and self-efficacy (p<0.01) were significantly associated with mean daily CPAP use. We found that specific insomnia symptoms and self-efficacy were associated with CPAP compliance. Our findings underline the need to demonstrate that interventions that reduce insomnia symptoms and improve self-efficacy will increase CPAP compliance.	[Philip, Pierre; Bioulac, Stephanie; Ghorayeb, Imad; Coste, Olivier; Monteyrol, Pierre-Jean; Micoulaud-Franchi, Jean-Arthur] CHU Bordeaux, Clin Sommeil, Serv Explorat Fonct Syst Nerveux, Bordeaux, France; [Philip, Pierre; Bioulac, Stephanie; Altena, Elemarije; Micoulaud-Franchi, Jean-Arthur] Univ Bordeaux, SANPSY, Bordeaux, France; [Philip, Pierre; Bioulac, Stephanie; Altena, Elemarije; Micoulaud-Franchi, Jean-Arthur] SANPSY, CNRS, Bordeaux, France; [Morin, Charles M.] Univ Laval, 2325 Rue Univ, Quebec City, PQ G1V 0A6, Canada; [Morin, Charles M.] Inst Univ Sante Mentale Quebec, Ctr Rech CERVO, Quebec City, PQ, Canada; [Ghorayeb, Imad] Inst Neurosci Cognit & Integrat Aquitaine, CNRS, Bordeaux, France; [Ghorayeb, Imad] Univ Bordeaux, Inst Neurosci Cognit & Integrat Aquitaine, Bordeaux, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Laval University; Laval University; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Philip, P (corresponding author), CHU Bordeaux, Clin Sommeil, Serv Explorat Fonct Syst Nerveux, Bordeaux, France.; Philip, P (corresponding author), Univ Bordeaux, SANPSY, Bordeaux, France.; Philip, P (corresponding author), SANPSY, CNRS, Bordeaux, France.	pr.philip@free.com	Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895; PHILIP, Pierre/0000-0003-3267-634X; MICOULAUD-FRANCHI, Jean-Arthur/0000-0002-5203-8444; Altena, Ellemarije/0000-0002-8882-7963; bioulac, stephanie/0000-0003-2618-4234				[Adult Obstructive Sleep Apnea Task Force of SPLF Societe francaise de recherche et de medecine du sommeil Societe francaise d'ORL Societe francaise de medecine du travail Societe de physiologie Societe francaise de cardiologie], 2010, MED SOMMEIL, V7, P161; Aloia MS, 2008, ANN BEHAV MED, V36, P44, DOI 10.1007/s12160-008-9052-9; Altena E, 2008, J SLEEP RES, V17, P335, DOI 10.1111/j.1365-2869.2008.00671.x; Bailly S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157318; Bakker JP, 2011, SLEEP, V34, P1595, DOI 10.5665/sleep.1404; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beneto A, 2009, SLEEP MED REV, V13, P287, DOI 10.1016/j.smrv.2008.09.006; Billiard M, 2012, TROUBLES SOMMEIL; Bjornsdottir E, 2013, SLEEP, V36, P1901, DOI 10.5665/sleep.3226; Bradshaw DA, 2006, CHEST, V130, P1369, DOI 10.1378/chest.130.5.1369; Budhiraja R, 2016, J CLIN SLEEP MED, V12, P333, DOI 10.5664/jcsm.5578; Campos-Rodriguez F, 2016, SLEEP MED, V17, P1, DOI 10.1016/j.sleep.2015.07.038; Chai-Coetzer CL, 2013, SLEEP, V36, P1929, DOI 10.5665/sleep.3232; Dzierzewski JM, 2016, J CLIN SLEEP MED, V12, P169, DOI 10.5664/jcsm.5478; Gagnadoux F, 2016, CHEST, V149, P288, DOI 10.1016/j.chest.2015.09.032; Gagnadoux F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022503; Glidewell RN, 2014, SLEEP MED, V15, P899, DOI 10.1016/j.sleep.2014.05.001; GUILLEMINAULT C, 1973, SCIENCE, V181, P856, DOI 10.1126/science.181.4102.856; Jacobsen AR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189614; Jaehne A, 2012, SLEEP MED, V13, P1286, DOI 10.1016/j.sleep.2012.06.026; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Krakow B, 2001, CHEST, V120, P1923, DOI 10.1378/chest.120.6.1923; Lai AYK, 2013, SLEEP MED, V14, P1192, DOI 10.1016/j.sleep.2013.04.023; Luyster FS, 2010, J CLIN SLEEP MED, V6, P196; Markov D, 2006, PSYCHIAT CLIN N AM, V29, P841, DOI 10.1016/j.psc.2006.09.008; Micoulaud-Franchi JA, 2017, MED SOMMEIL, V14, P99; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Nguyen XL, 2013, EUR RESPIR J, V41, P593, DOI 10.1183/09031936.00080011; Nguyen XL, 2010, SLEEP MED, V11, P777, DOI 10.1016/j.sleep.2010.04.008; Olsen S, 2008, EUR RESPIR J, V32, P710, DOI 10.1183/09031936.00127507; Paine SJ, 2004, SLEEP, V27, P1163, DOI 10.1093/sleep/27.6.1163; Pieh C, 2013, SLEEP BREATH, V17, P99, DOI 10.1007/s11325-012-0655-9; Richards D, 2007, SLEEP, V30, P635, DOI 10.1093/sleep/30.5.635; Sawyer AM, 2011, SLEEP MED REV, V15, P343, DOI 10.1016/j.smrv.2011.01.003; Sawyer AM, 2011, PATIENT EDUC COUNS, V85, P85, DOI 10.1016/j.pec.2010.10.014; Smith SS, 2009, SLEEP BIOL RHYTHMS, V7, pA74; Steffen M, 2016, NEW ENGL J MED, V374, P401, DOI 10.1056/NEJMp1504547; STOOHS RA, 1993, SLEEP, V16, pS11; Suraiya S, 2006, SLEEP MED, V7, pS85, DOI DOI 10.1016/j.sleep.2006.07.203; Sweetman AM, 2017, SLEEP MED REV, V33, P28, DOI 10.1016/j.smrv.2016.04.004; Wallace DM, 2013, SLEEP BREATH, V17, P351, DOI 10.1007/s11325-012-0702-6; Wallace DM, 2013, J CLIN SLEEP MED, V9, P885, DOI 10.5664/jcsm.2988; Weaver TE, 2003, SLEEP, V26, P727, DOI 10.1093/sleep/26.6.727; Wickwire EM, 2008, CLIN CASE STUD, V7, P267; Wickwire EM, 2010, SLEEP MED, V11, P772, DOI 10.1016/j.sleep.2010.03.012; Woehrle H, 2011, SLEEP MED, V12, P1034, DOI 10.1016/j.sleep.2011.05.008; Wohlgemuth WK, 2015, SLEEP MED, V16, P336, DOI 10.1016/j.sleep.2014.08.013; Ye LC, 2012, J SLEEP RES, V21, P419, DOI 10.1111/j.1365-2869.2011.00969.x; Zhang L, 2006, AM J EPIDEMIOL, V164, P529, DOI 10.1093/aje/kwj231	49	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2018	13	4							e0195343	10.1371/journal.pone.0195343	http://dx.doi.org/10.1371/journal.pone.0195343			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB6SR	29617414	Green Submitted, Green Published, gold			2023-01-03	WOS:000429203800076
J	Qin, Y; Vasilatos, SN; Chen, L; Wu, H; Cao, ZS; Fu, YM; Huang, M; Vlad, AM; Lu, BF; Oesterreich, S; Davidson, NE; Huang, Y				Qin, Ye; Vasilatos, Shauna N.; Chen, Lin; Wu, Hao; Cao, Zhishen; Fu, Yumei; Huang, Min; Vlad, Anda M.; Lu, Binfeng; Oesterreich, Steffi; Davidson, Nancy E.; Huang, Yi			Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade	ONCOGENE			English	Article							INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; CANCER; LSD1; EXPRESSION; CHEMOKINES; MICROENVIRONMENT; PEMBROLIZUMAB; REEXPRESSION; MPDL3280A	Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed. In this study, we investigated whether epigenetic reprograming by modulating histone methylation could enhance effector T lymphocyte trafficking and improve therapeutic efficacy of immune checkpoint blockade in breast cancer with focus on triple-negative breast cancer (TNBC) subtype. In silico analysis of The Cancer Genome Atlas (TCGA) data shows that expression of histone lysine-specific demethylase 1 (LSD1) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemokine ligand 5 (CCL5), C-X-C motif chemokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens. Tiling chromatin immunoprecipitation study showed that re-expression of chemokines by LSD1 inhibition is associated with increased H3K4me2 levels at proximal promoter regions. Rescue experiments using concurrent treatment with small interfering RNA or inhibitor of chemokine receptors blocked LSD1 inhibitor-enhanced CD8+ T cell migration, indicating a critical role of key T cell chemokines in LSD1-mediated CD8+ lymphocyte trafficking to the tumor microenvironment. In mice bearing TNBC xenograft tumors, anti-PD-1 antibody alone failed to elicit obvious therapeutic effect. However, combining LSD1 inhibitors with PD-1 antibody significantly suppressed tumor growth and pulmonary metastasis, which was associated with reduced Ki-67 level and augmented CD8+ T cell infiltration in xenograft tumors. Overall, these results suggest that LSD1 inhibition may be an effective adjuvant treatment with immunotherapy as a novel management strategy for poorly immunogenic breast tumors.	[Qin, Ye; Vasilatos, Shauna N.; Chen, Lin; Wu, Hao; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15260 USA; [Qin, Ye; Huang, Min; Oesterreich, Steffi; Huang, Yi] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Cao, Zhishen; Vlad, Anda M.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Fu, Yumei] Allegheny Gen Hosp Pathol, Pittsburgh, PA USA; [Vlad, Anda M.; Lu, Binfeng] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Davidson, Nancy E.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA; [Davidson, Nancy E.] Univ Washington, Seattle, WA 98195 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle	Huang, Y (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15260 USA.; Huang, Y (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	yih26@pitt.edu	Huang, Yi/AAW-7892-2021	Huang, Yi/0000-0002-9982-117X; Chen, Lin/0000-0002-8126-3333	US Army Breast Cancer Research Program [W81XWH-14-1-0237, W81XWH-14-1-0238]; Breast Cancer Research Foundation; NIH/NCI [P30CA047904]; Natural Science Foundation of China [81502366]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER	US Army Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by US Army Breast Cancer Research Program (W81XWH-14-1-0237 to YH; W81XWH-14-1-0238 to NED/SO), Breast Cancer Research Foundation (to NED and SO), NIH/NCI P30CA047904 and Natural Science Foundation of China (81502366 to YQ).	Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Akahori T, 2006, TRANSPLANT P, V38, P3366, DOI 10.1016/j.transproceed.2006.10.115; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bhatti S, 2017, JCO PRECIS ONCOL, V1, P1; Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186; Cao CY, 2018, INT J CANCER, V143, P1388, DOI 10.1002/ijc.31419; Culhane JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI 10.1016/j.cbpa.2007.07.014; Cunnick GH, 2002, HISTOL HISTOPATHOL, V17, P863, DOI 10.14670/HH-17.863; Deken MA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238557; Dirix L, 2016, CANC RES S, V76, pS1; Dong HD, 1999, NAT MED, V5, P1365; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hopewell EL, 2013, J CLIN INVEST, V123, P2509, DOI 10.1172/JCI67250; Huang Y, 2012, ROYAL SOC CHEM DRUG, V17, P238; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Janzer A, 2012, J BIOL CHEM, V287, P30984, DOI 10.1074/jbc.M112.341040; Katz TA, 2014, ANN MED, V46, P397, DOI 10.3109/07853890.2014.923740; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Muthuswamy R, 2012, CANCER RES, V72, P3735, DOI 10.1158/0008-5472.CAN-11-4136; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Pasculli B, 2018, SEMIN CANCER BIOL, V51, P22, DOI 10.1016/j.semcancer.2018.01.007; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rugo HS, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-S5-07; Sandhu R, 2015, AM J PATHOL, V185, P282, DOI 10.1016/j.ajpath.2014.12.003; Shayan G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1261779; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Solinas C, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000255; Terranova-Barberio M, 2017, ONCOTARGET, V8; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033; Wang K, 2017, HUM PATHOL, V69, P110, DOI 10.1016/j.humpath.2017.09.012; Wimberly H, 2015, CANCER IMMUNOL RES, V3, P326, DOI 10.1158/2326-6066.CIR-14-0133; Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584	55	92	95	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					390	405		10.1038/s41388-018-0451-5	http://dx.doi.org/10.1038/s41388-018-0451-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30111819	Green Accepted			2023-01-03	WOS:000455851200007
J	Isidorov, V; Szoka, L; Nazaruk, J				Isidorov, Valery; Szoka, Lukasz; Nazaruk, Jolanta			Cytotoxicity of white birch bud extracts: Perspectives for therapy of tumours	PLOS ONE			English	Article							MEDICINAL-PLANTS; ANTICANCER; PRECURSORS; PROPOLIS	Birch buds (Gemmae Betulae) are widely used in Russian and Chinese traditional medicine mainly as a diuretic and diaphoretic agent but also as an antiseptic, anti-inflammatory and analgesic. Despite the long history of therapeutic use of birch buds in folk medicine, the existing information on their chemical composition and pharmacological effects is insufficient. This circumstance warrants further study of the chemistry and pharmacology of birch buds. The present study was designed to investigate (a) the chemical composition of buds from two species of white birch and (b) the in vitro cytotoxic effect of extracts from these sources on selected tumour cells. Extracts from Betula pubescens Ehrh. and Betula pendula Roth. buds were obtained using three different methods: carbon dioxide supercritical fluid extraction (SFE), washing of exudate covering whole buds, and extraction of milled buds with diethyl ether. The chemical composition of extracts was investigated by GC-MS. Cytotoxicity was determined by MTT assay, and cell proliferation was determined by [H-3]thymidine uptake in cancer cells and normal skin fibroblasts. The GC-MS investigation identified a total of 150 substances of different classes. The chemical composition of B. pubescens and B. pendula buds differed, with bud extracts from the former containing a relatively high quantity of sesquiterpenoids and flavonoids, while the main components of extracts from the latter were triterpenoids. The results of the biological assay indicated that birch bud extracts demonstrated time-and concentration-dependent and differential cytotoxicity. The highest cytotoxic activity demonstrated bud exudates and SFE extracts obtained from both Betula species. The rich chemical composition of birch buds suggests the possibility of a wider spectrum of biological activity than previously thought. Birch bud extracts could be a promising source of compounds with cytotoxic activity against various cancers.	[Isidorov, Valery] Bialystok Tech Univ, Forest Fac, Hajnowka, Poland; [Szoka, Lukasz] Med Univ Bialystok, Dept Med Chem, Bialystok, Poland; [Nazaruk, Jolanta] Med Univ Bialystok, Dept Pharmacognosy, Bialystok, Poland	Medical University of Bialystok; Medical University of Bialystok	Isidorov, V (corresponding author), Bialystok Tech Univ, Forest Fac, Hajnowka, Poland.	isidorov@uwb.edu.pl	Szoka, Lukasz/S-7336-2018; Isidorov, Valery/B-3698-2018	Szoka, Lukasz/0000-0003-2822-1588; Isidorov, Valery/0000-0001-8185-3301	National Science Centre (Poland) [2016/23/B/NZ7/03360]; Bialystok University of Technology Program [S/ZWL/1/2017]	National Science Centre (Poland); Bialystok University of Technology Program	This work was supported by grant of National Science Centre (Poland) 2016/23/B/NZ7/03360 to V.I., as well as by Bialystok University of Technology Program S/ZWL/1/2017 to V.I. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank Edward Roy and his staff (New Chemical Synthesis Institute, Pulawy) for SFE extraction of birch buds. This work was supported by grant of National Science Centre (Poland) 2016/23/B/NZ7/03360 and by Bialystok University of Technology Program S/ZWL/1/2017.	[Anonymous], 1990, STATE PHARMACOPOEIA, V2; Birch Raal A., 2010, RECENT PROGR MED PLA, V28, P123; Culpeper N., 1995, CULPEPERS COMPLETE H; Duric K., 2013, Journal of Plant Studies, V2, P61; Folkard C., 1995, ENCY HERBS THEIR USE; Galashkina N. G., 2004, Rastitel'nye Resursy, V40, P62; Goun EA, 2002, J ETHNOPHARMACOL, V81, P337, DOI 10.1016/S0378-8741(02)00116-2; HANSEL R., 1954, ARCH PHARM U BER DEUTSCH PHARM GES, V287, P117, DOI 10.1002/ardp.19542870303; Heywood VH, 1979, FLOWERING PLANTS WOR, P59; Isidorov V.A., 2015, 6 RUS KOR C CURR ISS, P189; Isidorov V.A., 2015, IDENTIFICATION BIOL, V1st ed.; Isidorov V, 2014, BIOCHEM SYST ECOL, V52, P41, DOI 10.1016/j.bse.2013.12.008; Isidorov VA, 2016, J CHEM ECOL, V42, P475, DOI 10.1007/s10886-016-0708-9; Isidorov VA, 2014, FOOD CHEM, V142, P101, DOI 10.1016/j.foodchem.2013.07.032; Isidorov VA, 2009, J CHROMATOGR A, V1216, P8998, DOI 10.1016/j.chroma.2009.10.079; Jayaprakasam B, 2006, J AGR FOOD CHEM, V54, P5375, DOI 10.1021/jf060899p; Kuznicka B, 1986, HIST NATURAL REMEDIE, P217; Laszczyk MN, 2009, PLANTA MED, V75, P1549, DOI 10.1055/s-0029-1186102; Lechner M, 2005, SEMIN CANCER BIOL, V15, P277, DOI 10.1016/j.semcancer.2005.04.004; Legault J, 2007, J PHARM PHARMACOL, V59, P1643, DOI 10.1211/jpp.59.12.0005; Mashentseva A. A., 2011, Journal of Phytology, V3, P18; National Institute of Standards and Technology-NIST, 2013, NIST CHEM WEBBOOK; NIKOLAEVA V G, 1981, Rastitel'nye Resursy, V17, P410; Plochmann K, 2007, ARCH BIOCHEM BIOPHYS, V460, P1, DOI 10.1016/j.abb.2007.02.003; PLUMB JA, 1989, CANCER RES, V49, P4435; Prokof'eva NG, 2007, CHEM NAT COMPD+, V43, P72, DOI 10.1007/s10600-007-0035-z; Raal A, 2008, EMEAHMPC2600182006; Shikov AN, 2014, J ETHNOPHARMACOL, V154, P481, DOI 10.1016/j.jep.2014.04.007; Spiridonov NA, 2005, PHYTOTHER RES, V19, P428, DOI 10.1002/ptr.1616; Tolmacheva AA, 2014, ACTA PHARMACEUT, V64, P173, DOI 10.2478/acph-2014-0019; Uwai K, 2008, BIOORGAN MED CHEM, V16, P7795, DOI 10.1016/j.bmc.2008.07.006; Wichtl M., 1994, HERBAL DRUGS PHYTOPH, P106; Yakovlev GP, 1999, ENCY DICT HERBS PROD; Zemlinsky SE, 1958, MED PLANTS SSSR, P84	34	12	12	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2018	13	8							e0201949	10.1371/journal.pone.0201949	http://dx.doi.org/10.1371/journal.pone.0201949			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ4SC	30106978	Green Published, Green Submitted, gold			2023-01-03	WOS:000441662800019
J	Daniels, B; Girosi, F; Tervonen, H; Kiely, BE; Lord, SJ; Houssami, N; Pearson, SA				Daniels, Benjamin; Girosi, Federico; Tervonen, Hanna; Kiely, Belinda E.; Lord, Sarah J.; Houssami, Nehmat; Pearson, Sallie-Anne			Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)	PLOS ONE			English	Article							TRASTUZUMAB PLUS TAXANE; PHASE-III; SURVIVAL ANALYSIS; PROGRESSION; LAPATINIB; WOMEN; CHEMOTHERAPY; PERTUZUMAB; EMTANSINE; THERAPY	Background Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines. As therapeutic options continue to expand, these restrictions may not be perceived to align with best practice and it is not known if their use in the real-world clinic adheres to these restrictions. We examined the treatment of women receiving trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) to determine the extent to which treatment adhered to national prescribing restrictions. Patients and methods Our population-based, retrospective cohort study used dispensing records for every Australian woman initiating publicly-subsidised trastuzumab for HER2+MBC between 2001-2013, followed through 2016. We used group-based trajectory models (GBTMs) to cluster patients, first on their patterns of trastuzumab exposure, and then on their patterns of lapatinib and chemotherapy exposure. We described the characteristics of patients within each cluster, and examined their treatments and combinations of treatments to determine restriction adherence. Results Of 5,052 patients initiating trastuzumab, 1,795 (36%) received at least one non-adherent HER2-targeted treatment. The most common non-adherent treatments were trastuzumab combinations involving vinorelbine (24% of non-adherent treatments); capecitabine (24%); and anthracyclines (10%). Non-adherent lapatinib use was observed in 4% of patients. GBTM identified three trastuzumab exposure clusters, each containing three further subclusters. The largest proportions of non-adherent treatments were in sub-clusters with longer trastuzumab exposure and more non-taxane chemotherapy. Patients in these sub-clusters were younger than those in sub-clusters with less non-adherent treatment. Conclusions Our study highlights that, even during the relatively simpler treatment era of our study period, a substantial amount of treatment did not adhere to prescribing restrictions. As more trials are conducted exploring pertuzumab and T-DM1 in combination with different chemotherapies and other HER2-targeted therapies, the regulation and funding of HER2-targeted treatment will become more challenging.	[Daniels, Benjamin; Tervonen, Hanna; Pearson, Sallie-Anne] UNSW, Ctr Big Data Res Hlth, Med Policy Res Unit, Sydney, NSW, Australia; [Girosi, Federico] Western Sydney Univ, Translat Hlth Res Inst, Penrith, NSW, Australia; [Girosi, Federico] Capital Markets CRC, Sydney, NSW, Australia; [Kiely, Belinda E.; Lord, Sarah J.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia; [Lord, Sarah J.] Univ Sydney, Sch Med, Univ Notre Dame Australia, NHMRC Clin Trials Ctr, Sydney, NSW, Australia; [Houssami, Nehmat] Univ Sydney, Sydney Sch Publ Hlth, Sydney Med Sch, Sydney, NSW, Australia	University of New South Wales Sydney; Western Sydney University; University of Sydney; University of Notre Dame Australia; University of Sydney; University of Sydney	Daniels, B (corresponding author), UNSW, Ctr Big Data Res Hlth, Med Policy Res Unit, Sydney, NSW, Australia.	b.daniels@unsw.edu.au	Lord, Sally/GZM-7796-2022; Houssami, Nehmat/ABC-1103-2020; Tervonen (nee Uosukainen), Hanna/B-9833-2015	Lord, Sally/0000-0003-2763-5949; Houssami, Nehmat/0000-0002-3641-952X; Girosi, Federico/0000-0003-3937-2285; Tervonen (nee Uosukainen), Hanna/0000-0002-1211-9709; Daniels, Benjamin/0000-0001-8617-6055	Cancer Australia Priority Driven Collaborative Support Scheme [1050648]; NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA) [1060407]; NHMRC [1094325]; Sydney Catalyst Translational Cancer Research Centre; CREMA; National Breast Cancer Foundation (Australia) Breast Cancer Research Leadership Fellowship	Cancer Australia Priority Driven Collaborative Support Scheme; NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Sydney Catalyst Translational Cancer Research Centre; CREMA; National Breast Cancer Foundation (Australia) Breast Cancer Research Leadership Fellowship	This work was supported by a Cancer Australia Priority Driven Collaborative Support Scheme (ID: 1050648) and the NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA; ID: 1060407). BD is supported by an NHMRC Postgraduate Research Scholarship (ID: 1094325), the Sydney Catalyst Translational Cancer Research Centre (no grant number), and a CREMA PhD scholarship top-up (no grant number). NH receives funding through a National Breast Cancer Foundation (Australia) Breast Cancer Research Leadership Fellowship (no grant number). FG is affiliated with the Capital Markets Cooperative Research Centre, Ltd. The listed funders provided support in the form of salary for NH and FG; and postgraduate research support for BD, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of NH, FG, and BD are articulated in the 'author contributions' section.	[Anonymous], R LANG ENV STAT COMP; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Bostock M, 2018, SUNBURSTR HTMLWIDGE; Burstein HJ, 2007, CANCER-AM CANCER SOC, V110, P965, DOI 10.1002/cncr.22885; Cameron D, 2010, ONCOLOGIST, V15, P924, DOI 10.1634/theoncologist.2009-0181; Cardoso F, 2017, ANN ONCOL; Chen T, 2011, CANCER TREAT REV, V37, P312, DOI 10.1016/j.ctrv.2010.09.001; Daniels B, 2018, BREAST, V38, P7, DOI 10.1016/j.breast.2017.11.007; Daniels B, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014439; Dawood S, 2010, J CLIN ONCOL, V28, P92, DOI 10.1200/JCO.2008.19.9844; Gelmon KA, 2015, J CLIN ONCOL, V33, P1574, DOI 10.1200/JCO.2014.56.9590; Gradishar WJ, 2012, NEW ENGL J MED, V366, P176, DOI 10.1056/NEJMe1113641; Haviland AM, 2011, SOCIOL METHOD RES, V40, P367, DOI 10.1177/0049124111400041; Jones BL, 2007, SOCIOL METHOD RES, V35, P542, DOI 10.1177/0049124106292364; Joshi V, 2017, ASIA-PAC J CLIN ONCO, V13, pE246, DOI 10.1111/ajco.12602; Masoud V, 2017, WORLD J CLIN ONCOL, V8, P120, DOI 10.5306/wjco.v8.i2.120; Mellish Leigh, 2015, BMC Res Notes, V8, P634, DOI 10.1186/s13104-015-1616-8; Nagin DS, STAT METHODS MED RES; Pearson SA, 2007, J CLIN ONCOL, V25, P3688, DOI 10.1200/JCO.2007.11.2516; Perez EA, 2017, J CLIN ONCOL, V35, P141, DOI 10.1200/JCO.2016.67.4887; Pharmaceutical Benefits Advisory Committee, 2014, PUBL SUMM DOC NOV 20; Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764; Santoro A, 2010, ANN ONCOL, V21, P2131, DOI 10.1093/annonc/mdq410; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; von Minckwitz G, 2011, EUR J CANCER, V47, P2273, DOI 10.1016/j.ejca.2011.06.021; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	28	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2018	13	7							e0198152	10.1371/journal.pone.0198152	http://dx.doi.org/10.1371/journal.pone.0198152			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4DQ	30048453	Green Published, gold, Green Submitted			2023-01-03	WOS:000439952400002
J	Holmgren, AJ; Adler-Milstein, J; Chen, LM				Holmgren, A. Jay; Adler-Milstein, Julia; Chen, Lena M.			Participation in a Voluntary Bundled Payment Program by Organizations Providing Care After an Acute Hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Holmgren, A. Jay] Harvard Sch Business, Wyss House,Soldiers Field Rd, Boston, MA 02163 USA; [Adler-Milstein, Julia] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Chen, Lena M.] Univ Michigan, Dept Internal Med, Div Gen Med, Ann Arbor, MI 48109 USA	Harvard University; University of California System; University of California San Francisco; University of Michigan System; University of Michigan	Holmgren, AJ (corresponding author), Harvard Sch Business, Wyss House,Soldiers Field Rd, Boston, MA 02163 USA.	aholmgren@hbs.edu			Agency for Healthcare Research and Quality (AHRQ) [R01HS024698]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS024698] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work was supported by R01HS024698 from the Agency for Healthcare Research and Quality (AHRQ).	Centers for Medicare & Medicaid Services, BPCI MOD 3 RETR POST; Centers for Medicare & Medicaid Services, NURS HOM CAR; Harris LJ, 2013, VERSITA DISCIPLIN, P1, DOI 10.2478/9788376560052; MedPac, 2017, DAT BOOK HLTH CAR SP; US Dept of Health and Human Services, PROP SUBM PHYS FOC P	5	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	2018	320	4					402	404		10.1001/jama.2018.8666	http://dx.doi.org/10.1001/jama.2018.8666			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GO0AX	29946694	Bronze, Green Published			2023-01-03	WOS:000439581200025
J	Gazibara, T; Milic, M; Parlic, M; Stevanovic, J; Lazic, D; Maric, G; Kisic-Tepavcevic, D; Pekmezovic, T				Gazibara, Tatjana; Milic, Marija; Parlic, Milan; Stevanovic, Jasmina; Lazic, Dragoslav; Maric, Gorica; Kisic-Tepavcevic, Darija; Pekmezovic, Tatjana			Illict drug use and academia in North Kosovo: Prevalence, patterns, predictors and health-related quality of life	PLOS ONE			English	Article							MALE COLLEGE-STUDENTS; UNIVERSITY-STUDENTS; GENDER-DIFFERENCES; SUBSTANCE-ABUSE; MARIJUANA USE; ALCOHOL; INITIATION; BEHAVIORS; COCAINE; MISUSE	Purpose The purpose of this study were to estimate the prevalence and patterns of illicit drug use in a sample of University students from North Kosovo, to assess factors associated with illicit drug use and to assess health-related quality of life (HRQoL) among students according to illicit drug use. Methods A cross-sectional study was conducted at the Student Public Health Center, where 514 University students were enrolled from April to June 2015 in North Kosovo. Participants completed the general socio-demographic and behavioral questionnaire, Beck Depression Inventory (BDI) and the SF-36 questionnaire for HRQoL assessment. Data on lifetime illicit drug use were self-reported. Results As much as 16.0% of students reported ever illicit drug use. The most frequently used drugs were marijuana (9.3%) and bromazepam (7.6%). Factors associated with ever illicit drug use were: being smoker and alcohol user, having chronic diseases and having higher depressive symptoms score. Ever illicit drug users reported all domains of HRQoL as worse. Conclusion These results could serve as a tool for implementation of preventive strategies and University policies to promote healthy lifestyles and behaviors. Measurement of HRQoL could also be used as indicator of the effect of interventions designed to reduce and/or prevent illicit drug use at institutions of higher education.	[Gazibara, Tatjana; Maric, Gorica; Kisic-Tepavcevic, Darija; Pekmezovic, Tatjana] Univ Belgrade, Inst Epidemiol, Fac Med, Belgrade, Serbia; [Milic, Marija; Parlic, Milan; Stevanovic, Jasmina] Univ Pristina, Fac Med, Dept Epidemiol, Kosovska Mitrovica, Kosovo, Kosovo; [Lazic, Dragoslav] Univ Pristina, Fac Dent, Kosovska Mitrovica, Kosovo, Kosovo	University of Belgrade	Pekmezovic, T (corresponding author), Univ Belgrade, Inst Epidemiol, Fac Med, Belgrade, Serbia.	pekmezovic@sezampro.rs		Gazibara, Tatjana/0000-0002-9621-8375; Milic, Marija/0000-0001-5575-0587; Maric, Gorica/0000-0003-2739-142X; Pekmezovic, Tatjana/0000-0001-7978-1409	Ministry of Education, Science and Technological Development of Republic of Serbia [175087]	Ministry of Education, Science and Technological Development of Republic of Serbia(Ministry of Education, Science & Technological Development, Serbia)	This work was supported by Ministry of Education, Science and Technological Development of Republic of Serbia (grant no. 175087). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansari El, 2015, GLOB J HLTH SCI, V7, P18; Atwoli L, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-34; Babor TF., 2010, DRUG POLICY PUBLIC G, V2nd ed., DOI [10.1093/oso/9780198818014.001.0001, DOI 10.1093/OSO/9780198818014.001.0001]; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Caldeira KM, 2012, DRUG ALCOHOL DEPEN, V125, P267, DOI 10.1016/j.drugalcdep.2012.02.022; Davies J, 2000, J AM COLL HEALTH, V48, P259, DOI 10.1080/07448480009596267; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; El Ansari W, 2013, INT J PREVENTIVE MED, V4, P293; Ford JA, 2008, ADDICT BEHAV, V33, P934, DOI 10.1016/j.addbeh.2008.02.016; Gupta S, 2013, J CLIN DIAGN RES, V7, P1632, DOI 10.7860/JCDR/2013/6441.3215; Institute of Public Health of Serbia, AN STUD 1997 2007; Jones SE, 2006, J ADOLESCENT HEALTH, V39, P291, DOI 10.1016/j.jadohealth.2005.12.003; Kasperski SJ, 2011, ADDICT BEHAV, V36, P408, DOI 10.1016/j.addbeh.2010.12.002; Kassa A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1044; Kisic-Tepavcevic D, 2013, AM J DRUG ALCOHOL AB, V39, P130, DOI 10.3109/00952990.2012.746348; Klemenc-Ketis Z, 2011, SRP ARK CELOK LEK, V139, P197, DOI 10.2298/SARH1104197K; Lev-Ran S, 2012, DRUG ALCOHOL DEPEN, V123, P190, DOI 10.1016/j.drugalcdep.2011.11.010; McCabe SE, 2009, DRUG ALCOHOL DEPEN, V102, P63, DOI 10.1016/j.drugalcdep.2009.01.007; Meisel MK, 2015, ADDICT BEHAV, V45, P110, DOI 10.1016/j.addbeh.2015.01.025; Mohammadpoorasl A, 2014, ASIAN J PSYCHIATR, V9, P41, DOI 10.1016/j.ajp.2013.12.015; Mohammadpoorasl A, 2013, AM J MENS HEALTH, V7, P475, DOI 10.1177/1557988313483540; Ott R, 2014, PHARMACOPSYCHIATRY, V47, P22, DOI 10.1055/s-0033-1358682; Palmer RS, 2012, J COLL STUDENT DEV, V53, P124, DOI 10.1353/csd.2012.0014; Pekmezovic T, 2011, QUAL LIFE RES, V20, P391, DOI 10.1007/s11136-010-9754-x; Pinchevsky GM, 2012, PREV SCI, V13, P43, DOI 10.1007/s11121-011-0243-4; Randolph ME, 2009, AM J DRUG ALCOHOL AB, V35, P80, DOI 10.1080/00952990802585422; Rimsza ME, 2005, PEDIATR CLIN N AM, V52, P307, DOI 10.1016/j.pcl.2004.10.008; Shamsipour M, 2014, SUBST USE MISUSE, V49, P1303, DOI 10.3109/10826084.2014.897730; Sim T, 2005, J AM COLL HEALTH, V54, P25, DOI 10.3200/JACH.54.1.25-29; Suerken CK, 2014, ADDICT BEHAV, V39, P302, DOI 10.1016/j.addbeh.2013.10.018; Topolski TD, 2001, J ADOLESCENT HEALTH, V29, P426, DOI 10.1016/S1054-139X(01)00305-6; Toprak S, 2010, J ADDICT MED, V4, P93, DOI 10.1097/ADM.0b013e3181b246c5; Unwin BK, 2013, AM FAM PHYSICIAN, V88, P596; Wagner GA, 2007, REV BRAS PSIQUIATR, V29, P123, DOI 10.1590/S1516-44462006005000033; Williams J, 2006, SUBST USE MISUSE, V41, P489, DOI 10.1080/10826080500521755	35	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2018	13	7							e0199921	10.1371/journal.pone.0199921	http://dx.doi.org/10.1371/journal.pone.0199921			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN2LQ	30011284	Green Submitted, Green Published, gold			2023-01-03	WOS:000438829800007
J	Ley, C; Sundaram, V; Sanchez, MD; Desai, M; Parsonnet, J				Ley, Catherine; Sundaram, Vandana; Sanchez, Maria de la Luz; Desai, Manisha; Parsonnet, Julie			Triclosan and triclocarban exposure, infectious disease symptoms and antibiotic prescription in infants-A community-based randomized intervention	PLOS ONE			English	Article							URINARY CONCENTRATIONS; US POPULATION; HEALTH	Background Triclosan and triclocarban (TCs) are broad-spectrum antimicrobials that, until recently, were found in a wide variety of household and personal wash products. Popular with consumers, TCs have not been shown to protect against infectious diseases. Objectives To determine whether use of TC-containing wash products reduces incidence of infection in children less than one year of age. Methods Starting in 2011, we nested a randomized intervention of wash products with and without TCs within a multiethnic birth cohort. Maternal reports of infectious disease symptoms and antibiotic use were collected weekly by automated survey; household visits occurred every four months. Antibiotic prescriptions were identified by medical chart review. Urinary triclosan levels were measured in a participant subset. Differences by intervention group in reported infectious disease (primary outcome) and antibiotic use (secondary outcome) were assessed using mixed effects logistic regression and Fisher's Exact tests, respectively. Results Infectious illness occurred in 6% of weeks, with upper respiratory illness the predominant syndrome. Among 60 (45%) TC-exposed and 73 (55%) non-TC-exposed babies, infectious disease reports did not differ in frequency between groups (likelihood ratio test: p = 0.88). Medical visits with antibiotic prescriptions were less common in the TC group than in the non-TC group (7.8% vs. 16.6%, respectively; p = 0.02). Conclusions Although randomization to TC-containing wash products was not associated with decreased infectious disease reports by mothers, TCs were associated with decreased antibiotic prescriptions, suggesting a benefit against bacterial infection. The recent removal of TCs from consumer wash products makes further elucidation of benefits and risks impracticable.	[Ley, Catherine; Sanchez, Maria de la Luz; Parsonnet, Julie] Stanford Sch Med, Dept Med, Div Infect Dis, Stanford, CA 94305 USA; [Sundaram, Vandana; Desai, Manisha] Stanford Sch Med, Dept Med, Quantitat Sci Unit, Stanford, CA USA; [Parsonnet, Julie] Stanford Sch Med, Dept Hlth Res & Policy, Div Epidemiol, Stanford, CA USA	Stanford University; Stanford University; Stanford University	Ley, C (corresponding author), Stanford Sch Med, Dept Med, Div Infect Dis, Stanford, CA 94305 USA.	cley@stanford.edu		Parsonnet, Julie/0000-0001-7342-5366	National Institutes of Health [5R01HD063142, 5R21ES023371]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health [grants 5R01HD063142 and 5R21ES023371], to Julie Parsonnet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello AE, 2007, CLIN INFECT DIS, V45, pS137, DOI 10.1086/519255; Anderson SE, 2016, J IMMUNOTOXICOL, V13, P165, DOI 10.3109/1547691X.2015.1029146; Bever CS, 2018, CHEMOSPHERE, V203, P467, DOI 10.1016/j.chemosphere.2018.03.186; Bondi CAM., 2007, AM J INFECT CONTROL, V35, pE34, DOI [10.1016/j.ajic.2007.04.027, DOI 10.1016/J.AJIC.2007.04.027]; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Chalew TEA, 2009, J AM WATER RESOUR AS, V45, P4, DOI 10.1111/j.1752-1688.2008.00284.x; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Dellanno C, 2009, AM J INFECT CONTROL, V37, P649, DOI 10.1016/j.ajic.2009.03.012; Gelman A, 2016, DATA ANAL USING REGR; Halden RU, 2014, ENVIRON SCI TECHNOL, V48, P3603, DOI 10.1021/es500495p; Halliday G, 2009, INT PSYCHOGERIATR, V21, P1041, DOI 10.1017/S1041610209990135; Han C, 2016, ENVIRON POLLUT, V208, P803, DOI 10.1016/j.envpol.2015.11.002; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hurd-Brown T, 2013, J APPL TOXICOL, V33, P495, DOI 10.1002/jat.2767; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Larson EL, 2004, ANN INTERN MED, V140, P321, DOI 10.7326/0003-4819-140-5-200403020-00007; Lassen TH, 2013, ENVIRON RES, V126, P164, DOI 10.1016/j.envres.2013.07.001; Ley C, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010810; Luby SP, 2005, LANCET, V366, P225, DOI 10.1016/S0140-6736(05)66912-7; Luby SP, 2004, JAMA-J AM MED ASSOC, V291, P2547, DOI 10.1001/jama.291.21.2547; McBain AJ, 2003, APPL ENVIRON MICROB, V69, P5433, DOI 10.1128/AEM.69.9.5433-5442.2003; Niederman Richard, 2005, Evid Based Dent, V6, P33, DOI 10.1038/sj.ebd.6400318; Palmer RK, 2012, TOXICOL APPL PHARM, V258, P99, DOI 10.1016/j.taap.2011.10.012; Park GW, 2010, J FOOD PROTECT, V73, P2232, DOI 10.4315/0362-028X-73.12.2232; Poole AC, 2016, MSPHERE, V1, P1; Sapkota A, 2007, ENVIRON RES, V103, P21, DOI 10.1016/j.envres.2006.03.006; Stam J, 2012, ACTA PAEDIATR, V101, P929, DOI 10.1111/j.1651-2227.2012.02728.x; US Department of Housing and Urban Development, 2007, MEAS OV HOUS; Vissing NH, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-160; Weatherly LM, 2017, J TOXICOL ENV HEAL B, V20, P447, DOI 10.1080/10937404.2017.1399306; Ye XY, 2016, ENVIRON SCI TECHNOL, V50, P13548, DOI 10.1021/acs.est.6b04668; Zoorob R, 2012, AM FAM PHYSICIAN, V86, P817	32	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							PII e0199298	10.1371/journal.pone.0199298	http://dx.doi.org/10.1371/journal.pone.0199298			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0GK	29953463	Green Published, Green Submitted, gold			2023-01-03	WOS:000436645400022
J	John, C; Diala, U; Adah, R; Lar, L; Envuladu, EA; Adedeji, I; Lasisi, K; Olusunde, O; James, F; Abdu, H				John, Collins; Diala, Udochukwu; Adah, Ruth; Lar, Luret; Envuladu, Esther Awazzi; Adedeji, Idris; Lasisi, Kazeem; Olusunde, Oluseyi; James, Femi; Abdu, Halima			Survival and nutritional status of children with severe acute malnutrition, six months post-discharge from outpatient treatment in Jigawa state, Nigeria	PLOS ONE			English	Article								Background The Outpatient Therapeutic Program (OTP) for treatment brings the management of Severe Acute Malnutrition (SAM) closer to the community. Many lives have been saved through this approach, but little data exists on the outcome of the children after discharge from such programmes. This study was aimed to determine the survival and nutritional status of children at six months after discharge from OTP for SAM. Methodology This was a prospective study of children with SAM admitted into 10 OTPs in two local government areas of Jigawa state from June 2016 to July 2016. Home visits at six months after discharge enabled the collection of data on survival and nutritional status. The primary outcome measures were survival and nutritional status (Mid upper arm circumference and weight-for-height z-score). Result Of 494 children with SAM, 410 were discharged and 379 were followed up. Of these, 354, (93.4%) were found alive while 25 (6.6%) died. Among the survivors 333 (94.1%) had MUAC >= 12.5cm and 64 (18.1%) had WHZ<-3. Mortality rates were higher 10 (8.4%) among the 6-11months old. Most deaths 16 (64%) occurred within the first 3months post-discharge. Those who died were significantly more stunted, p = 0.016 and had a smaller head circumference, p = 0.005 on entry to OTP programme. There was improvement from admission to six months follow up in the number of children with complete immunization (27.4% to 35.6%), and a decrease in the number of unimmunized children (34.8% vs 20.6%) at follow-up. Conclusion The study demonstrates good post discharge survival rate and improved nutritional status for SAM patients managed in OTPs. There were, however considerable post discharge mortality, especially in the first three months and lower immunization uptake post discharge. A follow-up programme will improve these indices further.	[John, Collins; Diala, Udochukwu; Adah, Ruth; Abdu, Halima] Jos Univ Teaching Hosp, Dept Paediat, Jos, Nigeria; [Lar, Luret; Envuladu, Esther Awazzi] Jos Univ Teaching Hosp, Dept Community Med, Jos, Nigeria; [Adedeji, Idris] Abubakar Tafawa Balewa Univ, Dept Paediat, Teaching Hosp Bauchi, Bauchi, Nigeria; [Lasisi, Kazeem] Abubakar Tafewa Balewa Univ Bauchi, Dept Math Sci, Bauchi, Nigeria; [Olusunde, Oluseyi] Natl Primary Hlth Care Dev Agcy, North Cent Zonal Off, Abuja, Nigeria; [James, Femi] Fed Minist Hlth, Maternal Newborn & Child Hlth Unit, Abuja, Nigeria		John, C (corresponding author), Jos Univ Teaching Hosp, Dept Paediat, Jos, Nigeria.	cchibunkem@yahoo.com		James, Femi/0000-0002-6623-4470; Lar, Luret/0000-0001-8002-443X; Diala, Udochukwu/0000-0002-8088-535X; , COLLINS/0000-0002-3408-8464	Department for International Development (UK) through Operation Research and Impact Evaluation (ORIE) [ORIE/RU-NRCB/UNIJOS/2016/01]	Department for International Development (UK) through Operation Research and Impact Evaluation (ORIE)	The research was funded by the Department for International Development (UK) through Operation Research and Impact Evaluation (ORIE) project grant no. ORIE/RU-NRCB/UNIJOS/2016/01 to HA. DFID/ORIE did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahwere P., 2012, Journal of Public Health and Epidemiology, V4, P215; Bashorun Adebobola, 2014, Pan Afr Med J, V18 Suppl 1, P3, DOI 10.11694/pamj.supp.2014.18.1.4608; Brugha RF, 1996, B WORLD HEALTH ORGAN, V74, P517; Chisti MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107663; Golden M., 2011, GUIDELINES INTEGRATE; Jani JV, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-161; Jekel JF, 2001, EPIDEMIOLOGY BIOSTAT; John C, 2017, S AFR J CLIN NUTR, V30, P55, DOI 10.1080/16070658.2016.1255486; Kalathia MB, 2014, INT ARCH INTEGR MED, V1, P9; Kerac M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096030; Minimum Standards in Food Security and Nutrition, HANDBOOK, P164; Minimum Standards in Food Security and Nutrition, SPHER HDB, P164; Moisi JC, 2011, B WORLD HEALTH ORGAN, V89, P725, DOI 10.2471/BLT.11.089235; National Population Commission, 2013, FED REP NIG FIN REP; United Nations Children's Fund, 2012, EV COMM MAN AC MALN; WHO, 2013, GUID UPD MAN SEV AC; Wiens MO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066698; Wilford R, 2012, HEALTH POLICY PLANN, V27, P127, DOI 10.1093/heapol/czr017; Yebyo HG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065840	19	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2018	13	6							e0196971	10.1371/journal.pone.0196971	http://dx.doi.org/10.1371/journal.pone.0196971			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ8QS	29924797	Green Submitted, gold, Green Published			2023-01-03	WOS:000435655600002
J	Caulley, L				Caulley, Lisa			Substitute Decision Making in End-of-Life Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESUSCITATION; FAMILY		[Caulley, Lisa] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA 02115 USA; [Caulley, Lisa] Harvard Med Sch, Boston, MA 02215 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Caulley, L (corresponding author), Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA 02115 USA.; Caulley, L (corresponding author), Harvard Med Sch, Boston, MA 02215 USA.			Caulley, Lisa/0000-0002-9661-4634				Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Bosslet GT, 2015, AM J RESP CRIT CARE, V191, P1318, DOI 10.1164/rccm.201505-0924ST; Brock DW, 1996, MILBANK Q, V74, P599, DOI 10.2307/3350394; Curtis J Randall, 2012, Virtual Mentor, V14, P545, DOI 10.1001/virtualmentor.2012.14.7.ecas3-1207; Dresser R, 2015, J MED ETHICS, V41, P731, DOI 10.1136/medethics-2014-102504; Kon AA, 2016, CRIT CARE MED, V44, P188, DOI 10.1097/CCM.0000000000001396; Mancini ME, 2015, CIRCULATION, V132, pS383, DOI 10.1161/CIR.0000000000000254; Puchalski CM, 2000, J AM GERIATR SOC, V48, pS84, DOI 10.1111/j.1532-5415.2000.tb03146.x; Wynn S., 2014, BIFOCAL, V36, P10; Yadav KN, 2017, HEALTH AFFAIR, V36, P1244, DOI 10.1377/hlthaff.2017.0175	10	3	3	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2018	378	24					2339	2341		10.1056/NEJMclde1800817	http://dx.doi.org/10.1056/NEJMclde1800817			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ2KR	29897848				2023-01-03	WOS:000435099900014
J	Richards, T				Richards, Tessa			Bring outpatients into the 21st century	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com						Bell SK, 2017, OPENNOTES POWER KNOW; Bloem BR, 2017, HEALTH AFFAIR, V36, P1987, DOI 10.1377/hlthaff.2017.0832; de Iongh A, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k430; Eliot TS, LOVE SONG JA PRUFROC; Guthrie B, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a867; Hagglund M, 2017, BMJ OPINION      JUN; Heida A, 2018, J CROHNS COLITIS, V12, P432, DOI 10.1093/ecco-jcc/jjx169; Laboi P, 2014, BMJ OPINION      NOV; Whear R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074774	9	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	2018	361								k2472	10.1136/bmj.k2472	http://dx.doi.org/10.1136/bmj.k2472			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ2BX	29875121	Bronze, Green Published			2023-01-03	WOS:000435073600006
J	Hales, CM; Kit, BK; Gu, QP; Ogden, CL				Hales, Craig M.; Kit, Brian K.; Gu, Qiuping; Ogden, Cynthia L.			Trends in Prescription Medication Use Among Children and Adolescents-United States, 1999-2014	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; NATIONAL TRENDS; ANTIBIOTIC USE; SLONE SURVEY; GUIDELINE; ADULTS; COUGH	IMPORTANCE Access to appropriate prescription medications, use of inappropriate or ineffective treatments, and adverse drug events are public health concerns among US children and adolescents. OBJECTIVE To evaluate trends in use of prescription medications among US children and adolescents. DESIGN, SETTING, AND PARTICIPANTS US children and adolescents aged 0 to 19 years in the 1999-2014 National Health and Nutrition Examination Survey (NHANES)serial cross-sectional, nationally representative surveys of the civilian noninstitutionalized population. EXPOSURES Sex, age, race and Hispanic origin, household income and education, insurance status, current health status. MAIN OUTCOMES AND MEASURES Use of any prescription medications or 2 or more prescription medications taken in the past 30 days; use of medications by therapeutic class; trends in medication use across 4-year periods from 1999-2002 to 2011-2014. Data were collected though in-home interview and direct observation of the prescription container. RESULTS Data on prescription medication use were available for 38 277 children and adolescents (mean age, 10 years; 49% girls). Overall, use of any prescription medication in the past 30 days decreased from 24.6%(95% CI, 22.6% to 26.6%) in 1999-2002 to 21.9% (95% CI, 20.3% to 23.6%) in 2011-2014 (beta = -0.41 percentage points every 2 years [95% CI, -0.79 to -0.03]; P =.04), but there was no linear trend in the use of 2 or more prescription medications (8.5%[95% CI, 7.6% to 9.4%] in 2011-2014). In 2011-2014, the most commonly used medication classes were asthma medications (6.1%[95% CI, 5.4% to 6.8%]), antibiotics (4.5%[95% CI, 3.7% to 5.5%]), attention-deficit/hyperactivity disorder (ADHD) medications (3.5%[95% CI, 2.9% to 4.2%]), topical agents (eg, dermatologic agents, nasal steroids) (3.5%[95% CI, 3.0% to 4.1%]), and antihistamines (2.0% [95% CI, 1.7% to 2.5%]). There were significant linear trends in 14 of 39 therapeutic classes or subclasses, or in individual medications, with 8 showing increases, including asthma and ADHD medications and contraceptives, and 6 showing decreases, including antibiotics, antihistamines, and upper respiratory combination medications. CONCLUSIONS AND RELEVANCE In this study of US children and adolescents based on a nationally representative survey, estimates of prescription medication use showed an overall decrease in use of any medication from 1999-2014. The prevalence of asthma medication, ADHD medication, and contraceptive use increased among certain age groups, whereas use of antibiotics, antihistamines, and upper respiratory combination medications decreased.	[Hales, Craig M.; Kit, Brian K.; Gu, Qiuping; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA; [Kit, Brian K.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hales, CM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.	chales@cdc.gov		Hales, Craig/0000-0002-2355-1177	National Center for Health Statistics (NCHS); Centers for Disease Control and Prevention (CDC)	National Center for Health Statistics (NCHS); Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The National Center for Health Statistics (NCHS) and the Centers for Disease Control and Prevention (CDC) had a role in the design and conduct of the National Health and Nutrition Examination Survey, in the collection and management of the data, and in the review and approval of the manuscript; however, the NCHS and the CDC had no role in the analysis and interpretation of the data; preparation of the manuscript; or the decision to submit the manuscript for publication.	Akinbami LJ, PEDIATRICS; [Anonymous], 2011, PEDIATRICS S5, V128, pS213; [Anonymous], 2017, SURV AN COMPL SURV S; CDC, 2017, ANT US US PROGR OPP; Centers for Disease Control and Prevention, 2016, CDC GUID PRESCR OP C; Centers for Disease Control and Prevention (CDC), BE ANT AW SMART US B; Chai G, 2012, PEDIATRICS, V130, P23, DOI 10.1542/peds.2011-2879; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Frenk SM, 2016, J ANTIMICROB CHEMOTH, V71, P251, DOI 10.1093/jac/dkv319; Johann-Liang R, 2009, PHARMACOEPIDEM DR S, V18, P24, DOI 10.1002/pds.1679; Johnson Clifford L, 2014, Vital Health Stat 2, P1; Jonas Bruce S, 2013, NCHS Data Brief, P1; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kit BK, 2012, PEDIATRICS, V129, P62, DOI 10.1542/peds.2011-1513; Korn E, 1998, SURV METHODOL, V24, P193; National Asthma Education and Prevention Program, 2007, EXPERT PANEL REPORT, P417; National Center for Health Statistics, NAT HLTH NUTR EX SUR; National Center for Health Statistics, 2017, HLTH US 2016; National Center for Health Statistics Centers for Disease Control and Prevention (CDC), NHANES RESP RAT; National Center for Health Statistics Centers for Disease Control and Prevention (CDC), NHANES 1988 2014 DAT; National Center for Health Statistics Centers for Disease Control and Prevention (CDC), NHANES DAT DOC COD F; Olfson M, 2015, JAMA PSYCHIAT, V72, P867, DOI 10.1001/jamapsychiatry.2015.0500; Olfson M, 2012, ARCH GEN PSYCHIAT, V69, P1247, DOI 10.1001/archgenpsychiatry.2012.647; Sharfstein JM, 2007, NEW ENGL J MED, V357, P2321, DOI 10.1056/NEJMp0707400; Shehab N, 2016, JAMA-J AM MED ASSOC, V316, P2115, DOI 10.1001/jama.2016.16201; The R Project for Statistical Computing (R Core Team), 2017, R LANG ENV STAT COMP; Tobias JD, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2396; Tran AR, 2012, PSYCHIAT SERV, V63, P1095, DOI 10.1176/appi.ps.201100547; Vaz LE, 2014, PEDIATRICS, V133, P375, DOI 10.1542/peds.2013-2903; Vernacchio L, 2008, PEDIATRICS, V122, pE323, DOI 10.1542/peds.2008-0498; Vernacchio L, 2009, PEDIATRICS, V124, P446, DOI 10.1542/peds.2008-2869; Visser SN, 2014, J AM ACAD CHILD PSY, V53, P34, DOI 10.1016/j.jaac.2013.09.001; Wolraich M, 2011, PEDIATRICS, V128, P1007, DOI 10.1542/peds.2011-2654; Youngster I, 2017, J PEDIATR-US, V182, P239, DOI 10.1016/j.jpeds.2016.11.027	34	81	81	3	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	2018	319	19					2009	2020		10.1001/jama.2018.5690	http://dx.doi.org/10.1001/jama.2018.5690			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF8QV	29800213	Green Published, Bronze			2023-01-03	WOS:000432238300018
J	O'Neill, TA; White, J; Delaloye, N; Gilfoyle, E				O'Neill, Thomas A.; White, Jesse; Delaloye, Nicole; Gilfoyle, Elaine			A taxonomy and rating system to measure situation awareness in resuscitation teams	PLOS ONE			English	Article							EMERGENCY CARDIOVASCULAR CARE; ASSOCIATION GUIDELINES UPDATE; CRISIS-RESOURCE-MANAGEMENT; OF-THE-LITERATURE; CARDIOPULMONARY-RESUSCITATION; NONTECHNICAL SKILLS; ASSESSMENT-TOOL; HEALTH-CARE; TEAMWORK; PERFORMANCE	Team SA involves a common perspective between two or more individuals regarding current environmental events, their meaning, and projected future status. Team SA has been theorized to be important for resuscitation team effectiveness. Accordingly, multidimensional frameworks of observable behaviors relevant to resuscitation teams are needed to understand more deeply the nature of team SA, its implications for team effectiveness, and whether it can be trained. A seven-dimension team resuscitation SA framework was developed following a literature review and consensus process using a modified Delphi approach with a group of content experts. We applied a pre-post design within a day-long team training program involving four video-recorded simulated resuscitation events and 42 teams across Canada. The first and fourth events represented "pre" and "post" training events, respectively. Teams were scored on SA five times within each 15-minute event. Distractions were introduced to investigate whether SA scores would be affected. The current study provides initial construct validity evidence for a new measure of SA and explicates SA's role in resuscitation teams.	[O'Neill, Thomas A.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [White, Jesse] Univ Toronto, Fac Law, Toronto, ON, Canada; [Delaloye, Nicole; Gilfoyle, Elaine] Univ Calgary, Dept Pediat, Calgary, AB, Canada	University of Calgary; University of Toronto; University of Calgary	O'Neill, TA (corresponding author), Univ Calgary, Dept Psychol, Calgary, AB, Canada.	toneill@ucalgary.ca		O'Neill, Thomas/0000-0002-8336-5763	 [PG-10-0482];  [OMF-110353]	; 	Two external research grants awarded to the last author supported this research: Grant # PG-10-0482 (http://www.heartandstroke.ca/) and Grant # OMF-110353 (http://www.cihr-irsc.gc.ca/e/193.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, the funders had no role in contracting individuals in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aamodt M.G., 2007, IND ORG PSYCHOL APPL; [Anonymous], 1998, HEALTH TECHNOL ASSES, DOI DOI 10.1186/s12888-014-0241-8; Baker D., 2003, MED TEAMWORK PATIENT; Bell HH, 2000, SITUATION AWARENESS ANALYSIS AND MEASUREMENT, P129; Bhanji F, 2015, CIRCULATION, V132, pS561, DOI 10.1161/CIR.0000000000000268; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Cooper S, 2014, OPEN ACCESS EMERG M, V6, P1, DOI 10.2147/OAEM.S53679; Cooper S, 2010, RESUSCITATION, V81, P446, DOI 10.1016/j.resuscitation.2009.11.027; Crozier MS, 2015, J SURG EDUC, V72, P156, DOI 10.1016/j.jsurg.2014.07.009; de Caen AR, 2015, CIRCULATION, V132, pS526, DOI 10.1161/CIR.0000000000000266; Durso F.T., 1995, EXPT ANAL MEASUREMEN, P295; Durso FT, 2008, HUM FACTORS, V50, P442, DOI 10.1518/001872008X288448; Endsley M.R., 2000, SITUATION AWARENESS; Endsley M.R., 2012, DESIGNING SITUATION, V2; ENDSLEY MR, 1995, HUM FACTORS, V37, P65, DOI 10.1518/001872095779049499; Endsley MR, 2001, NEW TRENDS COOPERATI, P47; Endsley MR., 2012, P NAT AER EL C 1988; Eppich WJ, 2008, CURR OPIN PEDIATR, V20, P255, DOI 10.1097/MOP.0b013e3282ffb3f3; Fernandez R, 2008, ACAD EMERG MED, V15, P1025, DOI 10.1111/j.1553-2712.2008.00232.x; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Fletcher G, 2003, BRIT J ANAESTH, V90, P580, DOI 10.1093/bja/aeg112; Flin R, 2004, QUAL SAF HEALTH CARE, V13, pI80, DOI 10.1136/qshc.2004.009993; Gaba DM, 1994, CRISIS MANAGEMENT AN; Gartenberg D, 2014, HUM FACTORS, V56, P710, DOI 10.1177/0018720813506223; Gilfoyle E, 2010, THESIS; Gilfoyle E, 2017, PEDIATR CRIT CARE ME, V18, pE62, DOI 10.1097/PCC.0000000000001025; Goldstein IL, 1993, PERSONNEL SELECTION, P3; Guise JM, 2008, SIMUL HEALTHC, V3, P217, DOI 10.1097/SIH.0b013e31816fdd0a; Hackman J.R., 1987, HDB ORG BEHAV, P315; Hansel M, 2012, MINERVA ANESTESIOL, V78, P901; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; JACKSON DN, 1971, PSYCHOL REV, V78, P229, DOI 10.1037/h0030852; Jones DG, 1996, AVIAT SPACE ENVIR MD, V67, P507; Kaber DB, 2005, P 11 INT C HCI 2005; Kim J, 2006, CRIT CARE MED, V34, P2167, DOI 10.1097/01.CCM.0000229877.45125.CC; King HB., 2008, ADV PATIENT SAFETY N, V3, P5; Lampton D. R., 2006, USE IMMERSIVE VIRTUA; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Manser T, 2009, ACTA ANAESTH SCAND, V53, P143, DOI 10.1111/j.1399-6576.2008.01717.x; Matthews M. D., 2000, P HUM PERF SIT AW AU; Messick S., 1995, ED MEASUREMENT ISSUE, V14, P5, DOI [10.1111/j.17453992.1995.tb00881.x, DOI 10.1111/J.1745-3992.1995.TB00881.X, 10.1111/j.1745-3992.1995.tb00881.x]; Muniz E, 1998, P S COLL CREW PERF C; Murray WB, 2000, J CLIN ANESTH, V12, P633, DOI 10.1016/S0952-8180(00)00223-3; Nemeth C. P., 2008, IMPROVING HEALTHCARE; Nunnally J, 1978, PSYCHOMETRIC METHODS; Rall M, 2009, MILLERS ANESTHESIA, P106; Reid J, 2012, RESUSCITATION, V83, P879, DOI 10.1016/j.resuscitation.2011.12.012; Rosen MA, 2008, ACAD EMERG MED, V15, P1190, DOI 10.1111/j.1553-2712.2008.00180.x; SALAS E, 1995, HUM FACTORS, V37, P123, DOI 10.1518/001872095779049525; Salas E, 2008, ACAD EMERG MED, V15, P1002, DOI 10.1111/j.1553-2712.2008.00254.x; Sarter NB, 1991, INT J AVIAT PSYCHOL, V1, P45, DOI DOI 10.1207/S15327108IJAP0101_4; Schulz CM, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0172-7; Schulz CM, 2013, ANESTHESIOLOGY, V118, P729, DOI 10.1097/ALN.0b013e318280a40f; Singh H, 2012, BMJ QUAL SAF, V21, P30, DOI 10.1136/bmjqs-2011-000310; Wallin CJ, 2007, MED EDUC, V41, P173, DOI 10.1111/j.1365-2929.2006.02670.x; Weinstock P, 2008, PEDIATR CLIN N AM, V55, P1011, DOI 10.1016/j.pcl.2008.04.001; Wright M.C., IMPROVING HEALTHCARE, P97; Wright MC, 2004, QUAL SAF HEALTH CARE, V13, pI65, DOI 10.1136/qshc.2004.009951; Yule S, 2006, SURGERY, V139, P140, DOI 10.1016/j.surg.2005.06.017	59	5	5	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2018	13	5							e0196825	10.1371/journal.pone.0196825	http://dx.doi.org/10.1371/journal.pone.0196825			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF6MZ	29758042	Green Submitted, Green Published, gold			2023-01-03	WOS:000432082900015
J	Gago-Arias, A; Sanchez-Nieto, B; Espinoza, I; Karger, CP; Pardo-Montero, J				Gago-Arias, Araceli; Sanchez-Nieto, Beatriz; Espinoza, Ignacio; Karger, Christian P.; Pardo-Montero, Juan			Impact of different biologically-adapted radiotherapy strategies on tumor control evaluated with a tumor response model	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; POSITRON-EMISSION-TOMOGRAPHY; ENDOTHELIAL-CELL-PROLIFERATION; PHASE-II TRIAL; NECK-CANCER; RADIATION-THERAPY; PROSTATE-CANCER; DOSE-ESCALATION; FRACTIONATED RADIOTHERAPY; HETEROGENEOUS TUMORS	Motivated by the capabilities of modern radiotherapy techniques and by the recent developments of functional imaging techniques, dose painting by numbers (DPBN) was proposed to treat tumors with heterogeneous biological characteristics. This work studies different DPBN optimization techniques for virtual head and neck tumors assessing tumor response in terms of cell survival and tumor control probability with a previously published tumor response model (TRM). Uniform doses of 2 Gy are redistributed according to the microscopic oxygen distribution and the density distribution of tumor cells in four virtual tumors with different biological characteristics. In addition, two different optimization objective functions are investigated, which: i) minimize tumor cell survival (OFsurv) or; ii) maximize the homogeneity of the density of surviving tumor cells (OFstd). Several adaptive schemes, ranging from single to daily dose optimization, are studied and the treatment response is compared to that of the uniform dose. The results show that the benefit of DPBN treatments depends on the tumor reoxygenation capability, which strongly differed among the set of virtual tumors investigated. The difference between daily (fraction by fraction) and three weekly optimizations (at the beginning of weeks 1, 3 and 4) was found to be small, and higher benefit was observed for the treatments optimized using OFsurv. This in silico study corroborates the hypothesis that DPBN may be beneficial for treatments of tumors which show reoxygenation during treatment, and that a few optimizations may be sufficient to achieve this therapeutic benefit.	[Gago-Arias, Araceli; Sanchez-Nieto, Beatriz; Espinoza, Ignacio] Pontificia Univ Catolica Chile, Inst Fis, Santiago, Chile; [Karger, Christian P.] HIRO, Natl Ctr Radiat Res Oncol NCRO, Heidelberg, Germany; [Pardo-Montero, Juan] Inst Invest Sanitaria IDIS, Grp Imaxe Mol, Santiago De Compostela, Spain; [Pardo-Montero, Juan] Univ Santiago de Compostela, Complexo Hosp, Serv Radiofis & Protecc Radiol, Santiago De Compostela, Spain	Pontificia Universidad Catolica de Chile; Universidade de Santiago de Compostela	Gago-Arias, A (corresponding author), Pontificia Univ Catolica Chile, Inst Fis, Santiago, Chile.	magagoa@uc.cl	nieto, Beatriz Sanchez/AAA-4310-2021; Gago-Arias, Araceli/ABE-7910-2020; Pardo-Montero, Juan/A-4459-2017	Gago-Arias, Maria Araceli/0000-0002-1999-2340; Sanchez-Nieto, Beatriz/0000-0003-0713-3108; Pardo-Montero, Juan/0000-0001-7990-3971	FONDECYT [3150333, 11170575, 111505601]; Institute de Salud Carlos III (Miguel Servet research grant) [CP12/03162, CPII17/00028]	FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Institute de Salud Carlos III (Miguel Servet research grant)	A.G-A., J.P-M and I.E. acknowledge the support of FONDECYT 2015 Postdoctoral 3150333 and FONDECYT 2017 Iniciacion 11170575, Institute de Salud Carlos III (Miguel Servet research grant CP12/03162 and CPII17/00028), and FONDECYT 2015 Iniciacion 111505601, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alber M, 2003, PHYS MED BIOL, V48, pN31, DOI 10.1088/0031-9155/48/2/404; Banerjee H., 2010, THESIS; Bentzen SM, 2005, LANCET ONCOL, V6, P112, DOI 10.1016/S1470-2045(05)01737-7; Bentzen SM, 2011, SEMIN RADIAT ONCOL, V21, P101, DOI 10.1016/j.semradonc.2010.10.001; Berwouts D, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0629-3; Berwouts D, 2015, RADIOTHER ONCOL, V115, P272, DOI 10.1016/j.radonc.2015.04.022; Berwouts D, 2013, RADIOTHER ONCOL, V107, P310, DOI 10.1016/j.radonc.2013.04.002; Bowen SR, 2009, PHYS MED BIOL, V54, P1483, DOI 10.1088/0031-9155/54/6/007; BRAHME A, 1987, ACTA ONCOL, V26, P377, DOI 10.3109/02841868709104364; Brahme A., 1996, IAEATECDOC896, P49; Bremer C, 2003, RADIOLOGY, V226, P214, DOI 10.1148/radiol.2261012140; Chang JH, 2013, ACTA ONCOL, V52, P1723, DOI 10.3109/0284186X.2012.759273; Chao KSC, 2001, INT J RADIAT ONCOL, V49, P1171, DOI 10.1016/S0360-3016(00)01433-4; Choi W, 2010, RADIOTHER ONCOL, V97, P176, DOI 10.1016/j.radonc.2010.04.012; Cox JD, 2012, INT J RADIAT ONCOL, V82, P1042, DOI 10.1016/j.ijrobp.2011.12.032; Czyzyk J, 1998, IEEE COMPUT SCI ENG, V5, P68, DOI 10.1109/99.714603; Das SK, 2011, SEMIN RADIAT ONCOL, V21, P111, DOI 10.1016/j.semradonc.2010.10.002; Das SK, 2004, MED PHYS, V31, P1452, DOI 10.1118/1.1750991; DENEKAMP J, 1982, BRIT J CANCER, V45, P136, DOI 10.1038/bjc.1982.16; DENEKAMP J, 1982, BRIT J CANCER, V46, P711, DOI 10.1038/bjc.1982.263; Dirscher T, 2012, Z MED PHYS, V22, P48, DOI 10.1016/j.zemedi.2011.09.006; Duprez F, 2011, INT J RADIAT ONCOL, V80, P1045, DOI 10.1016/j.ijrobp.2010.03.028; Ebert MA, 1996, PHYS MED BIOL, V41, P2125, DOI 10.1088/0031-9155/41/10/019; El Naqa I, 2006, INT J RADIAT ONCOL, V64, P1275, DOI 10.1016/j.ijrobp.2005.11.022; Espinoza I, 2015, MED PHYS, V42, P90, DOI 10.1118/1.4903298; Espinoza I, 2013, MED PHYS, V40, DOI 10.1118/1.4812431; Fleckenstein J, 2011, INT J RADIAT ONCOL, V81, pE283, DOI 10.1016/j.ijrobp.2011.01.020; Flynn R, 2007, MED PHYS, V34, P2522, DOI 10.1118/1.2761242; Fowler JF, 2008, CLIN ONCOL-UK, V20, P113, DOI 10.1016/j.clon.2007.11.003; FOWLER JF, 1989, BRIT J RADIOL, V62, P679, DOI 10.1259/0007-1285-62-740-679; Gago-Arias A, 2016, PHYS MED BIOL, V61, P1204, DOI 10.1088/0031-9155/61/3/1204; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; Gronlund E, 2017, RADIOTHER ONCOL, V122, P236, DOI 10.1016/j.radonc.2016.09.007; Gropp William., 1997, APPROXIMATION THEORY, P167; Harriss-Phillips WM, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/363564; Harting C, 2007, PHYS MED BIOL, V52, P4775, DOI 10.1088/0031-9155/52/16/005; Heukelom J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-84; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang ZB, 2010, CANCER RES, V70, P463, DOI 10.1158/0008-5472.CAN-09-2501; Jeraj R, 2015, J NUCL MED, V56, P1752, DOI 10.2967/jnumed.114.141424; Kachnic LA, 2013, INT J RADIAT ONCOL, V86, P27, DOI 10.1016/j.ijrobp.2012.09.023; Kong F, 2013, J CLIN ONCOL, V31, P7522; Kong FM, 2017, JAMA ONCOLOGY, DOI [10.1001/jameoneol.2017.0982, DOI 10.1001/JAMEONEOL.2017.0982]; Lee NY, 2008, INT J RADIAT ONCOL, V70, P2, DOI 10.1016/j.ijrobp.2007.06.039; Ling CC, 2000, INT J RADIAT ONCOL, V47, P551, DOI 10.1016/S0360-3016(00)00467-3; Madani I, 2007, INT J RADIAT ONCOL, V68, P126, DOI 10.1016/j.ijrobp.2006.12.070; Madani I, 2011, RADIOTHER ONCOL, V101, P351, DOI 10.1016/j.radonc.2011.06.020; Malinen E, 2006, PHYS MED BIOL, V51, P4903, DOI 10.1088/0031-9155/51/19/012; Marcu L, 2004, PHYS MED BIOL, V49, P3767, DOI 10.1088/0031-9155/49/16/021; Monnich D, 2011, PHYS MED BIOL, V56, P2045, DOI 10.1088/0031-9155/56/7/009; Moiseenko V, 2004, ACTA ONCOL, V43, P499, DOI 10.1080/02841860410032777; Movsas B, 2002, UROLOGY, V60, P634, DOI 10.1016/S0090-4295(02)01858-7; Nahum AE, 2003, INT J RADIAT ONCOL, V57, P391, DOI 10.1016/S0360-3016(03)00534-0; Nutting CM, 2002, BRIT J RADIOL, V75, P151, DOI 10.1259/bjr.75.890.750151; Onjukka E, 2017, CLIN ONCOL-UK, V29, P6, DOI 10.1016/j.clon.2016.09.009; Pedicini P, 2013, INT J RADIAT ONCOL, V85, pE231, DOI 10.1016/j.ijrobp.2012.11.033; Petit SF, 2009, PHYS MED BIOL, V54, P2179, DOI 10.1088/0031-9155/54/7/022; Sanchez-Nieto B, INT J RADIAT ONCOL, V44, P369, DOI [10.1016/60360-3016(99)000292, DOI 10.1016/60360-3016(99)000292]; SCHWACHOFER JHM, 1989, INT J RADIAT ONCOL, V17, P1015, DOI 10.1016/0360-3016(89)90149-1; Shi XR, 2014, CANCER LETT, V355, P169, DOI 10.1016/j.canlet.2014.07.042; Steel GG, 2002, BASIC CLIN RADIOBIOL; Thorwarth D, 2005, PHYS MED BIOL, V50, P2209, DOI 10.1088/0031-9155/50/10/002; Thorwarth D, 2007, INT J RADIAT ONCOL, V68, P291, DOI 10.1016/j.ijrobp.2006.11.061; Toma-Dasu I, 2009, ACTA ONCOL, V48, P1181, DOI 10.3109/02841860903188643; Trani D, 2015, CLIN CANCER RES, V21, P5511, DOI 10.1158/1078-0432.CCR-15-0290; Troost EGC, 2010, J NUCL MED, V51, P866, DOI 10.2967/jnumed.109.069310; Vanderstraeten B, 2006, RADIOTHER ONCOL, V79, P249, DOI 10.1016/j.radonc.2006.03.003; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; Wouters BG, 1997, RADIAT RES, V147, P541, DOI 10.2307/3579620; Yang Y, 2005, MED PHYS, V32, P1473, DOI 10.1118/1.1924312; Yaromina A, 2011, INT J RADIAT ONCOL, V80, P1205, DOI 10.1016/j.ijrobp.2011.02.015; ZAGARS GK, 1987, RADIOTHER ONCOL, V8, P353, DOI 10.1016/S0167-8140(87)80186-X; Zelefsky MJ, 2008, INT J RADIAT ONCOL, V70, P1124, DOI 10.1016/j.ijrobp.2007.11.044; Zhang C., 2014, QUANT BIOL, V2, P85, DOI [10.1007/s40484-014-0032-8, DOI 10.1007/S40484-014-0032-8]; Zhang QH, 2015, PHYS MEDICA, V31, P1060, DOI 10.1016/j.ejmp.2015.07.145	75	6	6	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2018	13	4							e0196310	10.1371/journal.pone.0196310	http://dx.doi.org/10.1371/journal.pone.0196310			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE1WN	29698534	gold, Green Submitted, Green Published			2023-01-03	WOS:000431007600061
J	Melguizo-Rodriguez, L; Ramos-Torrecillas, J; Manzano-Moreno, FJ; Illescas-Montes, R; Rivas, A; Ruiz, C; De Luna-Bertos, E; Garcia-Martinez, O				Melguizo-Rodriguez, Lucia; Ramos-Torrecillas, Javier; Javier Manzano-Moreno, Francisco; Illescas-Montes, Rebeca; Rivas, Ana; Ruiz, Concepcion; De Luna-Bertos, Elvira; Garcia-Martinez, Olga			Effect of phenolic extracts from different extra-virgin olive oil varieties on osteoblast-like cells	PLOS ONE			English	Article							ANTIGENIC PHENOTYPE; MEDITERRANEAN DIET; ARBEQUINA; QUALITY; GROWTH; CLASSIFICATION; HYDROXYTYROSOL; MODULATION; CANCER	The reported incidence of osteoporosis is lower in countries in which the Mediterranean diet predominates, and this apparent relationship may be mediated by the phenolic compounds present in olive oil. The objective of this study was to determine the effect of phenolic extracts from different varieties of extra-virgin olive oil (Picual, Arbequina, Picudo, and Hojiblanca) on the differentiation, antigenic expression, and phagocytic capacity of osteoblast-like MG-63 cells. At 24 h of treatment a significant increase in phosphatase alkaline activity and significant reductions in CD54, CD80, and HLA-DR expression and in phagocytic activity were observed in comparison to untreated controls. The in vitro study performed has demonstrated that phenolic compounds from different extra virgin olive oil varieties can modulate different parameters related to osteoblast differentiation and function.	[Melguizo-Rodriguez, Lucia; Ramos-Torrecillas, Javier; Ruiz, Concepcion; De Luna-Bertos, Elvira; Garcia-Martinez, Olga] Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada, Spain; [Melguizo-Rodriguez, Lucia; Ramos-Torrecillas, Javier; Javier Manzano-Moreno, Francisco; Illescas-Montes, Rebeca; Rivas, Ana; Ruiz, Concepcion; De Luna-Bertos, Elvira; Garcia-Martinez, Olga] Inst Invest Biosanitaria, Ibs Granada, Granada, Spain; [Javier Manzano-Moreno, Francisco] Univ Granada, Sch Dent, Dept Stomatol, Biomed Grp BIO277, Granada, Spain; [Illescas-Montes, Rebeca] Univ Granada, Fac Hlth Sci Melilla, Dept Nursing, Biomed Grp BIO277, Melilla, Spain; [Rivas, Ana] Univ Granada, Fac Pharm, Dept Nutr & Food Sci, AGR Grp 255, Granada, Spain; [Ruiz, Concepcion] Univ Granada, Inst Neurosci Federico Oloriz, Granada, Spain	University of Granada; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; University of Granada; University of Granada; University of Granada	De Luna-Bertos, E (corresponding author), Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada, Spain.; De Luna-Bertos, E (corresponding author), Inst Invest Biosanitaria, Ibs Granada, Granada, Spain.	elviradlb@ugr.es	Rivas, Ana/D-7841-2018; Ruiz, Concepcion/L-2808-2014; Ramos-Torrecillas, Javier/U-5789-2019; Illescas-Montes, Rebeca/F-8700-2016; Illescas-Montes, Rebeca/AAC-4437-2019; Ramos-Torrecillas, Javier/F-3746-2012; De Luna-Bertos, Elvira/F-8544-2016; Melguizo-Rodríguez, Lucía/F-4683-2018; Garcia-Martinez, Olga/L-2782-2014	Rivas, Ana/0000-0002-2143-0750; Ruiz, Concepcion/0000-0003-4332-6812; Ramos-Torrecillas, Javier/0000-0002-6631-7866; Illescas-Montes, Rebeca/0000-0001-9795-8159; Illescas-Montes, Rebeca/0000-0001-9795-8159; Ramos-Torrecillas, Javier/0000-0002-6631-7866; De Luna-Bertos, Elvira/0000-0002-4381-5942; Garcia-Martinez, Olga/0000-0003-1912-4639	research group (Junta de Andalucia) [BIO277]; Department of Nursing (University of Granada); Ministerio de Educacion, Cultura y Deporte [FPU15-05635]	research group (Junta de Andalucia)(Junta de Andalucia); Department of Nursing (University of Granada); Ministerio de Educacion, Cultura y Deporte	This study was supported by the research group BIO277 (Junta de Andalucia) and Department of Nursing (University of Granada).	Bakhouche A, 2013, FOOD RES INT, V50, P401, DOI 10.1016/j.foodres.2012.11.001; Caruso G, 2014, AGR WATER MANAGE, V134, P94, DOI 10.1016/j.agwat.2013.12.003; Cauley JA, 2017, CURR OPIN RHEUMATOL, V29, P150, DOI 10.1097/BOR.0000000000000365; Chin KY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13080755; Dabbou S, 2010, SCI HORTIC-AMSTERDAM, V124, P122, DOI 10.1016/j.scienta.2009.12.017; Diaz-Rodriguez L, 2009, ANN NY ACAD SCI, V1173, pE46, DOI 10.1111/j.1749-6632.2009.04950.x; Diaz-Rodriguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933; Farinelli D, 2015, SCI HORTIC-AMSTERDAM, V192, P97, DOI 10.1016/j.scienta.2015.04.035; Feng X, 2011, ANNU REV PATHOL-MECH, V6, P121, DOI 10.1146/annurev-pathol-011110-130203; Garcia JM, 2013, IRRIGATION SCI, V31, P359, DOI 10.1007/s00271-011-0315-z; Garcia-Martinez O, 2014, GRASAS ACEITES, V65, DOI 10.3989/gya.0111141; Garcia-Martinez O, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150045; Garcia-Martinez O, 2012, J ORAL MAXIL SURG, V70, P1558, DOI 10.1016/j.joms.2011.06.199; Hagiwara K, 2011, EUR J PHARMACOL, V662, P78, DOI 10.1016/j.ejphar.2011.04.023; *IOOC, 1984, 6 IOOC; Manzano-Moreno FJ, 2013, CLIN ORAL INVEST, V17, P1349, DOI 10.1007/s00784-012-0811-4; Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009-0024; Fernandez-Real JM, 2012, J CLIN ENDOCR METAB, V97, P3792, DOI 10.1210/jc.2012-2221; Martinez F, 1999, GRASAS ACEITES, V50, P122, DOI 10.3989/gya.1999.v50.i2.646; Martinez-Gonzalez MA, 2015, PROG CARDIOVASC DIS, V58, P50, DOI 10.1016/j.pcad.2015.04.003; McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134; Melguizo-Rodriguez L, 2018, EUR J CLIN IN PRESS; Perez E, 2006, BIOSCIENCE REP, V26, P281, DOI 10.1007/s10540-006-9022-z; Puel C, 2008, J AGR FOOD CHEM, V56, P9417, DOI 10.1021/jf801794q; Reyes-Botella C, 2002, CELL PHYSIOL BIOCHEM, V12, P359, DOI 10.1159/000067906; Rotelli MT, 2015, SURG ONCOL, V24, P145, DOI 10.1016/j.suronc.2015.08.001; Ruiz C, 2007, J BONE MINER METAB, V25, P286, DOI 10.1007/s00774-007-0767-7; Ruiz C, 2003, CELL PHYSIOL BIOCHEM, V13, P309, DOI 10.1159/000074546; Saleh NK, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-10; Sandrini E, 2005, J BIOMED MATER RES B, V73B, P392, DOI 10.1002/jbm.b.30241; Santiago-Mora R, 2011, OSTEOPOROSIS INT, V22, P675, DOI 10.1007/s00198-010-1270-x; Servili M, 2014, ANTIOXIDANTS-BASEL, V3, P1, DOI 10.3390/antiox3010001; Taamalli A, 2012, FOOD CHEM, V132, P561, DOI 10.1016/j.foodchem.2011.10.070; Taamalli A, 2010, EUR FOOD RES TECHNOL, V231, P965, DOI 10.1007/s00217-010-1350-3; Terzuoli E, 2016, MOL NUTR FOOD RES, V60, P519, DOI 10.1002/mnfr.201500498; Visioli F, 2011, CURR PHARM DESIGN, V17, P786, DOI 10.2174/138161211795428885	36	7	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2018	13	4							e0196530	10.1371/journal.pone.0196530	http://dx.doi.org/10.1371/journal.pone.0196530			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE1WN	29698527	Green Submitted, Green Published, gold			2023-01-03	WOS:000431007600094
J	Ponsonby, AL; Pezic, A; Cameron, FJ; Rodda, C; Kemp, AS; Carlin, JB; Hyoty, H; Sioofy-Khojine, A; Dwyer, T; Ellis, JA; Craig, ME				Ponsonby, Anne-Louise; Pezic, Angela; Cameron, Fergus J.; Rodda, Christine; Kemp, Andrew S.; Carlin, John B.; Hyoty, Heikki; Sioofy-Khojine, Amirbabak; Dwyer, Terence; Ellis, Justine A.; Craig, Maria E.			Higher parental occupational social contact is associated with a reduced risk of incident pediatric type 1 diabetes: Mediation through molecular enteroviral indices	PLOS ONE			English	Article							DIFFERENT EUROPEAN POPULATIONS; INFECTION; PLASMA; SERUM; EXPOSURE; RNA; VARICELLA; RESPONSES; CHILDREN; ZOSTER	We aimed to examine the association between parental occupational social contact and hygiene factors on type 1 diabetes (T1D) risk and possible mediation of these effects through child enteroviral infection. We interviewed 333 incident T1D cases and 660 controls from 2008-2011 in Melbourne, Australia. Enteroviral indices (ribonucleic acid by reverse transcription polymerase chain reaction and Coxsackie B virus antibody levels) in peripheral blood were measured in nested case control samples. Parent occupational social contact was assessed by the number of well or sick children, adults or animals contacted daily through work. Higher parental occupational social contact was strongly associated with reduced T1D risk with evidence of dose response (contact with the well or sick score, Adjusted odds ratio (AOR) per category: 0.73 (95% Confidence Interval (CI): 0.66, 0.81); P<0.001 or AOR 0.63 (95% CI: 0.53, 0.75); P<0.001) respectively). Nine of the ten parental social contact indices, were significant mediated through one or more enteroviral indices. The strength of association between enterovirus presence and T1D onset increased with child age (1.2 fold increase per year; P = 0.05). Lower child hand hygiene enhanced the adverse effect of low parental occupational contact with the sick; Synergy Index 5.16 (95% CI: 3.61, 7.36). The interaction between hand washing and parental occupational contact is more consistent with protection against parental enteroviral shedding than the sharing of a protective infectious agent or microbiome.	[Ponsonby, Anne-Louise; Pezic, Angela; Cameron, Fergus J.; Rodda, Christine; Kemp, Andrew S.; Carlin, John B.; Dwyer, Terence; Ellis, Justine A.] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Flemington Rd, Parkville, Vic, Australia; [Ponsonby, Anne-Louise] Australian Natl Univ, Natl Ctr Epidemiol, Canberra, ACT, Australia; [Rodda, Christine] Sunshine Hosp, Western Ctr Hlth Res & Educ, St Albans, Vic, Australia; [Hyoty, Heikki; Sioofy-Khojine, Amirbabak] Univ Tampere, Sch Med, Virol, Laakarinkatu, Finland; [Dwyer, Terence] Univ Oxford, George Inst Global Hlth, Oxford Martin Sch, Oxford, England; [Ellis, Justine A.] Deakin Univ, Fac Hlth, Ctr Social & Early Emot Dev, Burwood, Vic, Australia; [Craig, Maria E.] Univ New South Wales, Sch Womens & Childrens Hlth, Kensington, NSW, Australia; [Craig, Maria E.] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Australian National University; Tampere University; University of Oxford; Deakin University; University of New South Wales Sydney; University of Sydney	Ponsonby, AL (corresponding author), Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Flemington Rd, Parkville, Vic, Australia.; Ponsonby, AL (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol, Canberra, ACT, Australia.	anne-louise.ponsonby@mcri.edu.au	Sioofy-Khojine, Amir-Babak/M-6008-2019; Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020; Ponsonby, Anne-Louise/AAE-4351-2019	Sioofy-Khojine, Amir-Babak/0000-0001-5538-5153; Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Hyoty, Heikki/0000-0003-0370-4145; Ellis, Justine/0000-0003-4103-4445; Craig, Maria E/0000-0001-6004-576X; Ponsonby, Anne-Louise/0000-0002-6581-3657	National Health and Medical Research Council of Australia; Australian Research Council; Arthritis Australia; Diabetes Australia; Rebecca L Cooper Medical Research Foundation; L.E.W. Carty Charitable Fund; ANZ Medical Research and Technologies in Victoria Fund; Equity Trustees Lynne Quayle Charitable Trust Fund; Australian Academy of Science; Victorian State Government Operational Infrastructure Support Program; Murdoch Childrens Research Institute; National Health and Medical Research Council	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); Arthritis Australia; Diabetes Australia; Rebecca L Cooper Medical Research Foundation; L.E.W. Carty Charitable Fund; ANZ Medical Research and Technologies in Victoria Fund; Equity Trustees Lynne Quayle Charitable Trust Fund; Australian Academy of Science; Victorian State Government Operational Infrastructure Support Program; Murdoch Childrens Research Institute; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Funding was obtained from the National Health and Medical Research Council of Australia, the Australian Research Council, Arthritis Australia, Diabetes Australia, Rebecca L Cooper Medical Research Foundation, L.E.W. Carty Charitable Fund, ANZ Medical Research and Technologies in Victoria Fund, Equity Trustees Lynne Quayle Charitable Trust Fund, the Australian Academy of Science, The Victorian State Government Operational Infrastructure Support Program, and the Murdoch Childrens Research Institute Internal Grant Scheme. JAE was supported by an Australian Research Council Future Fellowship. ALP was supported by a National Health and Medical Research Council Senior Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alidjinou EK, 2014, DISCOV MED, V18, P273; Blacksell SD, 2012, AM J TROP MED HYG, V87, P573, DOI 10.4269/ajtmh.2012.12-0043; Boom R, 1999, J CLIN MICROBIOL, V37, P1489, DOI 10.1128/JCM.37.5.1489-1497.1999; Cairns CJS, 2002, INTENS CARE MED, V28, P1357, DOI 10.1007/s00134-002-1399-y; Carr EJ, 2016, NAT IMMUNOL, V17, P461, DOI 10.1038/ni.3371; Dink B., 2006, INTRO SOCIOECONMIC I; Ejemot-Nwadiaro RI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub3; Elfaitouri A, 2007, J MED VIROL, V79, P1861, DOI 10.1002/jmv.21008; Fear NT, 1999, DIABETIC MED, V16, P1025, DOI 10.1046/j.1464-5491.1999.00204.x; Fouchet D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002306; Gillespie KM, 2004, LANCET, V364, P1699, DOI 10.1016/S0140-6736(04)17357-1; Ginocchio CC, 1997, J CLIN MICROBIOL, V35, P2886, DOI 10.1128/JCM.35.11.2886-2893.1997; He XX, 2003, BIOMED ENVIRON SCI, V16, P40; Hicks R, 2011, STATA J, V11, P605, DOI 10.1177/1536867X1101100407; Juhela S, 2000, DIABETES, V49, P1308, DOI 10.2337/diabetes.49.8.1308; Kaila B, 2001, DIABETES CARE, V24, P1353, DOI 10.2337/diacare.24.8.1353; Kinlen LJ, 1997, BRIT J CANCER, V76, P1539, DOI 10.1038/bjc.1997.592; Krogvold L, 2015, DIABETES, V64, P1682, DOI 10.2337/db14-1370; Little R. J., 2019, STAT ANAL MISSING DA, V793; McIver CJ, 2005, J CLIN MICROBIOL, V43, P5102, DOI 10.1128/JCM.43.10.5102-5110.2005; Miller J, 2015, ARTHRITIS RHEUMATOL, V67, P1951, DOI 10.1002/art.39129; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Nair S, 2010, J MED VIROL, V82, P1950, DOI 10.1002/jmv.21900; Needell JC, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0781-z; Ogunjimi B, 2014, CLIN VACCINE IMMUNOL, V21, P417, DOI 10.1128/CVI.00818-13; Oikarinen M, 2012, DIABETES, V61, P687, DOI 10.2337/db11-1157; Oikarinen S, 2014, DIABETES, V63, P655, DOI 10.2337/db13-0620; Oikarinen S, 2011, DIABETES, V60, P276, DOI 10.2337/db10-0186; Parslow RC, 2001, INT J EPIDEMIOL, V30, P533, DOI 10.1093/ije/30.3.533; Parslow RC, 2001, INT J EPIDEMIOL, V30, P8; Ponsonby AL, 2014, NATURE, V507, P169, DOI 10.1038/507169b; Ponsonby Anne-Louise, 2012, Results Immunol, V2, P125, DOI 10.1016/j.rinim.2012.06.002; Rodriguez RJ, 1997, J ACQ IMMUN DEF SYND, V15, P49, DOI 10.1097/00042560-199705010-00008; Salvatoni A, 2013, PEDIATR DIABETES, V14, P407, DOI 10.1111/pedi.12056; Sherriff A, 2002, ARCH DIS CHILD, V87, P26, DOI 10.1136/adc.87.1.26; Siev M, 2011, CLIN VACCINE IMMUNOL, V18, P173, DOI 10.1128/CVI.00325-10; Skrondal A, 2003, AM J EPIDEMIOL, V158, P251, DOI 10.1093/aje/kwg113; STAGNO S, 1984, J MED VIROL, V13, P347, DOI 10.1002/jmv.1890130405; Stata Corp, 2015, STAT STAT SOFTW REL; Sun C, 2017, CANCER EPIDEM BIOMAR, V26, P1146, DOI [10.1158/1055-9965.EPI-16-0846, 10.1158/1055-9965.epi-16-0846]; Thomas SL, 2002, LANCET, V360, P678, DOI 10.1016/S0140-6736(02)09837-9; VanderWeele TJ, 2016, ANNU REV PUBL HEALTH, V37, P17, DOI 10.1146/annurev-publhealth-032315-021402; Viskari H, 2004, J MED VIROL, V72, P610, DOI 10.1002/jmv.20033; Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8; YEUNG WCG, 2011, BMJ-BRIT MED J, V342, DOI DOI 10.1136/BMJ.D35; Ziegler AG, 2011, J AUTOIMMUN, V37, P3, DOI 10.1016/j.jaut.2011.02.004	46	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2018	13	4							e0193992	10.1371/journal.pone.0193992	http://dx.doi.org/10.1371/journal.pone.0193992			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD1LV	29664909	Green Published, gold			2023-01-03	WOS:000430262300005
J	Takeda, Y; Akiyoshi, T; Matsueda, K; Fukuoka, H; Ogura, A; Miki, H; Hiyoshi, Y; Nagasaki, T; Konishi, T; Fujimoto, Y; Fukunaga, Y; Ueno, M				Takeda, Yasuhiro; Akiyoshi, Takashi; Matsueda, Kiyoshi; Fukuoka, Hironori; Ogura, Atsushi; Miki, Hisanori; Hiyoshi, Yukiharu; Nagasaki, Toshiya; Konishi, Tsuyoshi; Fujimoto, Yoshiya; Fukunaga, Yosuke; Ueno, Masashi			Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy	PLOS ONE			English	Article							LONG-TERM OUTCOMES; COLORECTAL-CANCER; PANCREATIC ADENOCARCINOMA; CLINICAL-IMPLICATIONS; CURATIVE RESECTION; SARCOPENIA; CACHEXIA; IMPACT; COMPLICATIONS; PREDICTOR	Background The impact of body composition on the short- or long-term outcomes of patients with surgically treated advanced rectal cancer after neoadjuvant chemoradiotherapy remains unclear. This study examined the correlation between low skeletal muscle mass and morbidity and survival in patients with advanced lower rectal cancer. Methods We enrolled 144 clinical stage II/III patients with advanced lower rectal cancer who underwent neoadjuvant chemoradiotherapy followed by curative resection between 2004 and 2011. The cross-sectional skeletal muscle area at the third lumbar vertebra (L3) level was evaluated by computed tomography before chemoradiotherapy, and this was normalized by the square of the height to obtain the skeletal muscle index. Low skeletal muscle mass was defined as the sex-specific lowest quartile of the L3 skeletal muscle index. The association between low skeletal muscle mass and morbidity, relapse-free survival, or overall survival was assessed. Results Low skeletal muscle mass was identified in 37 (25.7%) patients. Age and body mass index were associated with low skeletal muscle mass. By multivariate analysis, we found that low skeletal muscle mass was independently associated with poor overall survival (hazard ratio = 2.93; 95%CI: 1.11-7.71; p = 0.031) and relapse-free survival (hazard ratio = 2.15; 95%CI: 1.06-4.21; p = 0.035), but was not associated with the rate of postoperative complications. Conclusions Low skeletal muscle mass is an independent negative prognostic factor for relapse-free and overall survival in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy.	[Takeda, Yasuhiro; Akiyoshi, Takashi; Fukuoka, Hironori; Ogura, Atsushi; Miki, Hisanori; Hiyoshi, Yukiharu; Nagasaki, Toshiya; Konishi, Tsuyoshi; Fujimoto, Yoshiya; Fukunaga, Yosuke; Ueno, Masashi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Gastroenterol Ctr, Tokyo, Japan; [Matsueda, Kiyoshi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Diagnost Imaging, Tokyo, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Akiyoshi, T (corresponding author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Gastroenterol Ctr, Tokyo, Japan.	takashi.akiyoshi@jfcr.or.jp	Fukunaga, Yosuke/AAR-8933-2021; nagasaki, toshiya/AAE-6844-2020	Fukunaga, Yosuke/0000-0002-6397-0907; nagasaki, toshiya/0000-0001-5853-314X; Akiyoshi, Takashi/0000-0002-2321-1412	Japan Society for the Promotion of Science [15K10156]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was funded by Japan Society for the Promotion of Science grant 15K10156 to Dr. Takashi Akiyoshi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amini N, 2015, J GASTROINTEST SURG, V19, P1593, DOI 10.1007/s11605-015-2835-y; Aversa Z, 2017, THER ADV MED ONCOL, V9, P369, DOI 10.1177/1758834017698643; Barberan-Garcia A, 2018, ANN SURG, V267, P50, DOI 10.1097/SLA.0000000000002293; Chemama S, 2016, ANN SURG ONCOL, V23, P3891, DOI 10.1245/s10434-016-5360-7; Chen LK, 2014, J AM MED DIR ASSOC, V15, P95, DOI 10.1016/j.jamda.2013.11.025; Choi MH, 2018, J CACHEXIA SARCOPENI, V9, P53, DOI 10.1002/jcsm.12234; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Dello SAWG, 2013, HPB, V15, P165, DOI 10.1111/j.1477-2574.2012.00517.x; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Dodson S, 2011, ANNU REV MED, V62, P265, DOI 10.1146/annurev-med-061509-131248; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Guadagni M, 2009, CURR OPIN CLIN NUTR, V12, P617, DOI 10.1097/MCO.0b013e32833193bd; Harimoto N, 2013, BRIT J SURG, V100, P1523, DOI 10.1002/bjs.9258; Honda M, 2016, J SURG ONCOL, V114, P630, DOI 10.1002/jso.24376; Joglekar S, 2015, J SURG ONCOL, V112, P503, DOI 10.1002/jso.24025; Joglekar S, 2015, J SURG ONCOL, V111, P771, DOI 10.1002/jso.23862; Lieffers JR, 2012, BRIT J CANCER, V107, P931, DOI 10.1038/bjc.2012.350; Malietzis G, 2016, BRIT J SURG, V103, P572, DOI 10.1002/bjs.10075; Malietzis G, 2016, ANN SURG, V263, P320, DOI 10.1097/SLA.0000000000001113; Martin L, 2013, J CLIN ONCOL, V31, P1539, DOI 10.1200/JCO.2012.45.2722; Miyamoto Y, 2016, CLIN CANCER RES, V22, P3999, DOI 10.1158/1078-0432.CCR-16-0495; Miyamoto Y, 2015, ANN SURG ONCOL, V22, P2663, DOI 10.1245/s10434-014-4281-6; Miyamoto Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129742; Nagasaki T, 2015, DIGEST SURG, V32, P496, DOI 10.1159/000441396; Ogura A, 2018, EUR J CANCER, V91, P11, DOI 10.1016/j.ejca.2017.12.005; Peeters KCMJ, 2005, J CLIN ONCOL, V23, P6199, DOI 10.1200/JCO.2005.14.779; Peng P, 2012, J GASTROINTEST SURG, V16, P1478, DOI 10.1007/s11605-012-1923-5; Peng PD, 2011, HPB, V13, P439, DOI 10.1111/j.1477-2574.2011.00301.x; Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI 10.1016/S1470-2045(08)70153-0; Richards CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041883; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; Sabel MS, 2013, J SURG ONCOL, V108, P169, DOI 10.1002/jso.23366; Sabel MS, 2011, ANN SURG ONCOL, V18, P3579, DOI 10.1245/s10434-011-1976-9; Watanabe T, 2018, INT J CLIN ONCOL, V23, P1, DOI 10.1007/s10147-017-1101-6	36	34	35	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2018	13	4							e0195406	10.1371/journal.pone.0195406	http://dx.doi.org/10.1371/journal.pone.0195406			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC0YY	29630652	Green Submitted, gold, Green Published			2023-01-03	WOS:000429505000047
J	Bhatnagar, R; Keenan, EK; Keenan, EK; Morley, AJ; Kahan, BC; Stanton, AE; Haris, M; Harrison, RN; Mustafa, RA; Bishop, LJ; Ahmed, L; West, A; Holme, J; Evison, M; Munavvar, M; Sivasothy, P; Herre, J; Cooper, D; Roberts, M; Guhan, A; Hooper, C; Walters, J; Saba, TS; Chakrabarti, B; Gunatilake, S; Psallidas, I; Walker, SP; Bibby, AC; Smith, S; Stadon, LJ; Zahan-Evans, NJ; Lee, YCG; Harvey, JE; Rahman, NM; Miller, RF; Maskell, NA				Bhatnagar, R.; Keenan, E. K.; Keenan, E. K.; Morley, A. J.; Kahan, B. C.; Stanton, A. E.; Haris, M.; Harrison, R. N.; Mustafa, R. A.; Bishop, L. J.; Ahmed, L.; West, A.; Holme, J.; Evison, M.; Munavvar, M.; Sivasothy, P.; Herre, J.; Cooper, D.; Roberts, M.; Guhan, A.; Hooper, C.; Walters, J.; Saba, T. S.; Chakrabarti, B.; Gunatilake, S.; Psallidas, I.; Walker, S. P.; Bibby, A. C.; Smith, S.; Stadon, L. J.; Zahan-Evans, N. J.; Lee, Y. C. G.; Harvey, J. E.; Rahman, N. M.; Miller, R. F.; Maskell, N. A.			Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED-TRIAL; PLEURODESIS; EFFICACY; DRAINAGE; TUBE	BACKGROUND Malignant pleural effusion affects more than 750,000 persons each year across Europe and the United States. Pleurodesis with the administration of talc in hospitalized patients is the most common treatment, but indwelling pleural catheters placed for drainage offer an ambulatory alternative. We examined whether talc administered through an indwelling pleural catheter was more effective at inducing pleurodesis than the use of an indwelling pleural catheter alone. METHODS Over a period of 4 years, we recruited patients with malignant pleural effusion at 18 centers in the United Kingdom. After the insertion of an indwelling pleural catheter, patients underwent drainage regularly on an outpatient basis. If there was no evidence of substantial lung entrapment (nonexpandable lung, in which lung expansion and pleural apposition are not possible because of visceral fibrosis or bronchial obstruction) at 10 days, patients were randomly assigned to receive either 4 g of talc slurry or placebo through the indwelling pleural catheter on an outpatient basis. Talc or placebo was administered on a single-blind basis. Follow-up lasted for 70 days. The primary outcome was successful pleurodesis at day 35 after randomization. RESULTS The target of 154 patients undergoing randomization was reached after 584 patients were approached. At day 35, a total of 30 of 69 patients (43%) in the talc group had successful pleurodesis, as compared with 16 of 70 (23%) in the placebo group (hazard ratio, 2.20; 95% confidence interval, 1.23 to 3.92; P = 0.008). No significant between-group differences in effusion size and complexity, number of inpatient days, mortality, or number of adverse events were identified. No significant excess of blockages of the indwelling pleural catheter was noted in the talc group. CONCLUSIONS Among patients without substantial lung entrapment, the outpatient administration of talc through an indwelling pleural catheter for the treatment of malignant pleural effusion resulted in a significantly higher chance of pleurodesis at 35 days than an indwelling catheter alone, with no deleterious effects.	[Bhatnagar, R.; Walker, S. P.; Bibby, A. C.; Maskell, N. A.] Univ Bristol, Acad Resp Unit, Bristol, Avon, England; [Bhatnagar, R.; Keenan, E. K.; Morley, A. J.; Walker, S. P.; Bibby, A. C.; Smith, S.; Stadon, L. J.; Zahan-Evans, N. J.; Harvey, J. E.; Maskell, N. A.] North Bristol NHS Trust, Bristol, Avon, England; [Kahan, B. C.] Queen Mary Univ London, Pragmat Clin Trials Unit, London, England; [Ahmed, L.; West, A.] Guys & St Thomas NHS Fdn Trust, London, England; [Ahmed, L.] Kings Coll Univ, Kings Coll Sch Med, London, England; [Miller, R. F.] UCL, Inst Global Hlth, London, England; [Stanton, A. E.] Great Western Hosp NHS Fdn Trust, Swindon, Wilts, England; [Haris, M.] North Midlands NHS Trust, Univ Hosp, Stoke On Trent, Staffs, England; [Haris, M.] Keele Univ, Sch Med, Newcastle Under Lyme, England; [Harrison, R. N.] North Tees & Hartlepool NHS Fdn Trust, Stockton On Tees, England; [Mustafa, R. A.] South Tees Hosp NHS Fdn Trust, Middlesbrough, Cleveland, England; [Bishop, L. J.] Portsmouth Hosp NHS Trust, Portsmouth, Hants, England; [Holme, J.; Evison, M.] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Munavvar, M.] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England; [Sivasothy, P.; Herre, J.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England; [Cooper, D.] Northumbria Healthcare NHS Fdn Trust, North Shields, England; [Roberts, M.] Sherwood Forest Hosp NHS Fdn Trust, Sutton In Ashfield, England; [Guhan, A.] NHS Ayrshire & Arran, Ayr, Scotland; [Hooper, C.] Worcester Acute Hosp NHS Trust, Worcester, England; [Walters, J.] Royal United Hosp Bath NHS Fdn Trust, Bath, Avon, England; [Saba, T. S.] Blackpool Teaching Hosp NHS Fdn Trust, Blackpool, England; [Chakrabarti, B.] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Gunatilake, S.] Hampshire Hosp NHS Fdn Trust, Winchester, Hants, England; [Psallidas, I.; Rahman, N. M.] Univ Oxford, Oxford Resp Trials Unit, Oxford, England; [Psallidas, I.; Rahman, N. M.] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Rahman, N. M.] Oxford NIHR Biomed Res Ctr, Oxford, England; [Lee, Y. C. G.] Univ Western Australia, Inst Resp Hlth, Perth, WA, Australia; [Lee, Y. C. G.] Sir Charles Gairdner Hosp, Perth, WA, Australia	University of Bristol; North Bristol NHS Trust; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; Keele University; Portsmouth Hospitals NHS Trust; University of Cambridge; Aintree University Hospitals NHS Foundation Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Western Australia; University of Western Australia	Bhatnagar, R (corresponding author), Univ Bristol, Southmead Hosp, Acad Resp Unit, Learning & Res Bldg, Bristol BS10 5NB, Avon, England.	rahul.bhatnagar@bristol.ac.-uk	Lee, Y C Gary/H-5264-2014; Ahmed, Liju/I-6286-2018	Miller, Robert/0000-0003-2067-4291; Ahmed, Liju/0000-0001-7722-8829; Bibby, Anna/0000-0001-7386-7754; Rahman, Najib M/0000-0003-1195-1680; Bhatnagar, Rahul/0000-0003-3906-1997; maskell, nick/0000-0002-1276-6500	Becton Dickinson; Rocket Medical U.K.; GE Medical; Gilead Sciences; Janssen; Merck; ViiV Healthcare; Marie Curie [MCCC-RP-14-A17178] Funding Source: researchfish; Medical Research Council [G0600475] Funding Source: researchfish; National Institute for Health Research [CL-2014-25-502] Funding Source: researchfish; MRC [G0600475] Funding Source: UKRI	Becton Dickinson; Rocket Medical U.K.; GE Medical(General Electric); Gilead Sciences(Gilead Sciences); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); ViiV Healthcare; Marie Curie(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by an unrestricted research grant from Becton Dickinson.; Dr. Bishop reports receiving educational fees and donated medical equipment from Rocket Medical U.K. and educational fees and equipment from Becton Dickinson; Dr. Ahmed, receiving grant support from Becton Dickinson and GE Medical; Dr. Psallidas, being employed by AstraZeneca in addition to his affiliation with University of Oxford; Dr. Lee, receiving grant support and medical supplies from Rocket Medical U.K. and fees for serving on an advisory board from Becton Dickinson; Dr. Rahman, receiving consulting fees from Rocket Medical U.K.; Dr. Miller, receiving lecture fees and travel support from Gilead Sciences and lecture fees from Janssen, Merck, and ViiV Healthcare; and Dr. Maskell, receiving grant support and consulting fees from Becton Dickinson and grant support from Rocket Medical U.K. No other potential conflict of interest relevant to this article was reported.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ahmed L, 2014, CHEST, V146, pE190, DOI 10.1378/chest.14-0394; Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Antony VB, 2000, AM J RESP CRIT CARE, V162, P1987, DOI 10.1164/ajrccm.162.5.ats8-00; Clive AO, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010529.pub2; Clive AO, 2014, THORAX, V69, P1098, DOI 10.1136/thoraxjnl-2014-205285; Davies HE, 2012, JAMA-J AM MED ASSOC, V307, P2383, DOI 10.1001/jama.2012.5535; Demmy TL, 2012, J NATL COMPR CANC NE, V10, P975, DOI 10.6004/jnccn.2012.0102; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fysh ETH, 2013, CHEST, V144, P1597, DOI 10.1378/chest.12-3103; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; MAREL M, 1993, CHEST, V104, P1486, DOI 10.1378/chest.104.5.1486; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Olfert JAP, 2017, RESPIROLOGY, V22, P764, DOI 10.1111/resp.12962; Roberts ME, 2010, THORAX, V65, P32, DOI 10.1136/thx.2010.136994; Thomas R, 2017, JAMA-J AM MED ASSOC, V318, P1903, DOI 10.1001/jama.2017.17426; Tremblay A, 2006, CHEST, V129, P362, DOI 10.1378/chest.129.2.362; Van Meter MEM, 2011, J GEN INTERN MED, V26, P70, DOI 10.1007/s11606-010-1472-0; VILLANUEVA AG, 1994, THORAX, V49, P23, DOI 10.1136/thx.49.1.23; Wahidi MM, 2017, AM J RESP CRIT CARE, V195, P1050, DOI 10.1164/rccm.201607-1404OC; Warren WH, 2008, EUR J CARDIO-THORAC, V33, P89, DOI 10.1016/j.ejcts.2007.10.002; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; Zimmer PW, 1997, CHEST, V112, P430, DOI 10.1378/chest.112.2.430	25	121	127	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 5	2018	378	14					1313	1322		10.1056/NEJMoa1716883	http://dx.doi.org/10.1056/NEJMoa1716883			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB5LN	29617585	Green Published, Bronze			2023-01-03	WOS:000429105700007
J	Ribeiro, VP; Silva-Correia, J; Goncalves, C; Pina, S; Radhouani, H; Montonen, T; Hyttinen, J; Roy, A; Oliveira, AL; Reis, RL; Oliveira, JM				Ribeiro, Viviana P.; Silva-Correia, Joana; Goncalves, Cristiana; Pina, Sandra; Radhouani, Hajer; Montonen, Toni; Hyttinen, Jari; Roy, Anirban; Oliveira, Ana L.; Reis, Rui L.; Oliveira, Joaquim M.			Rapidly responsive silk fibroin hydrogels as an artificial matrix for the programmed tumor cells death	PLOS ONE			English	Article							OPTICAL PROJECTION TOMOGRAPHY; IN-VITRO; INJECTABLE HYDROGELS; FABRICATION; TRANSITION; SCAFFOLDS; PROTEINS; POLYMERS; GELATION; MODEL	Timely and spatially-regulated injectable hydrogels, able to suppress growing tumors in response to conformational transitions of proteins, are of great interest in cancer research and treatment. Herein, we report rapidly responsive silk fibroin (SF) hydrogels formed by a horseradish peroxidase (HRP) crosslinking reaction at physiological conditions, and demonstrate their use as an artificial biomimetic three-dimensional (3D) matrix. The proposed SF hydrogels presented a viscoelastic nature of injectable hydrogels and spontaneous conformational changes from random coil to beta-sheet conformation under physiological conditions. A human neuronal glioblastoma (U251) cell line was used for screening cell encapsulation and in vitro evaluation within the SF hydrogels. The transparent random coil SF hydrogels promoted cell viability and proliferation up to 10 days of culturing, while the crystalline SF hydrogels converted into beta-sheet structure induced the formation of TUNEL-positive apoptotic cells. Therefore, this work provides a powerful tool for the investigation of the microenvironment on the programed tumor cells death, by using rapidly responsive SF hydrogels as 3D in vitro tumor models.	[Ribeiro, Viviana P.; Silva-Correia, Joana; Goncalves, Cristiana; Pina, Sandra; Radhouani, Hajer; Reis, Rui L.; Oliveira, Joaquim M.] Univ Minho, Res Grp Biomat Biodegradables & Biomimet 3Bs, Headquarters European Inst Excellence Tissue Engn, Avepk Parque Ciencia & Tecnol,Zona Ind Gandra, Barco, Guimaraes, Portugal; [Ribeiro, Viviana P.; Silva-Correia, Joana; Goncalves, Cristiana; Pina, Sandra; Radhouani, Hajer; Reis, Rui L.; Oliveira, Joaquim M.] ICVS 3Bs PT Govt Associated Lab, Braga, Portugal; [Montonen, Toni; Hyttinen, Jari] Tampere Univ Technol, ELT Dept, Computat Biophys & Imaging Grp, Tampere, Finland; [Montonen, Toni; Hyttinen, Jari] BioMediTech Inst Biosci & Med Technol, Tampere, Finland; [Roy, Anirban] Anasys Instruments Corp Santa Barbara, Santa Barbara, CA USA; [Oliveira, Ana L.] Univ Catolica Portuguese, Escola Super Biotecnol, Lab Associado, CBQF Ctr Biotecnol & Quim Fina, Porto, Portugal; [Reis, Rui L.; Oliveira, Joaquim M.] Univ Minho, Discoveries Ctr Regenerat & Precis Med, Avepk Parque Ciencia & Tecnol,Zona Ind Gandra, Barco, Guimaraes, Portugal	Universidade do Minho; Tampere University; Universidade Catolica Portuguesa; Universidade do Minho	Ribeiro, VP (corresponding author), Univ Minho, Res Grp Biomat Biodegradables & Biomimet 3Bs, Headquarters European Inst Excellence Tissue Engn, Avepk Parque Ciencia & Tecnol,Zona Ind Gandra, Barco, Guimaraes, Portugal.; Ribeiro, VP (corresponding author), ICVS 3Bs PT Govt Associated Lab, Braga, Portugal.	viviana.riberiro@dep.uminho.pt	Oliveira, Ana L/J-3404-2013; Radhouani, Hajer Radhouani H/E-1837-2011; Ribeiro, Viviana/A-3670-2019; Oliveira, Joaquim Miguel/H-8636-2012; Pina, Sandra/U-8428-2019; Pina, Sandra/H-8133-2013; Reis, Rui L./A-8938-2008; Hyttinen, Jari A/G-4280-2014; Gonçalves, Cristiana/A-7131-2010; Silva-Correia, Joana/D-4980-2012	Oliveira, Ana L/0000-0001-8012-4203; Ribeiro, Viviana/0000-0002-3679-0759; Oliveira, Joaquim Miguel/0000-0001-7052-8837; Pina, Sandra/0000-0002-4361-1253; Pina, Sandra/0000-0002-4361-1253; Reis, Rui L./0000-0002-4295-6129; Hyttinen, Jari A/0000-0003-1850-3055; Gonçalves, Cristiana/0000-0002-3219-1310; Silva-Correia, Joana/0000-0003-1312-3109; Radhouani, Hajer/0000-0003-1007-4073; Montonen, Toni/0000-0003-3784-0890	Portuguese Foundation for Science and Technology (FCT) under POFC [PEst-C/SAU/ LA0026/2013]; FEDER programs; Investigator FCT program [IF/00423/2012, IF/01285/2015, IF/00411/2013, IF/00115/2015]; FCT/MCTES [PD/BD/113806/2015]; FSUPOCH [PD/59/2013]; R&D grant of Anasys Instruments Corp; Anasys Instruments Corp.;  [SFRH/BPD/94277/2013];  [SFRH/BPD/108763/2015];  [SFRH/BPD/100957/2014]; Fundação para a Ciência e a Tecnologia [PEst-C/SAU/LA0026/2013] Funding Source: FCT	Portuguese Foundation for Science and Technology (FCT) under POFC; FEDER programs; Investigator FCT program(Portuguese Foundation for Science and Technology); FCT/MCTES(Portuguese Foundation for Science and TechnologyEuropean Commission); FSUPOCH; R&D grant of Anasys Instruments Corp; Anasys Instruments Corp.; ; ; ; Fundação para a Ciência e a Tecnologia	This study was funded by the Portuguese Foundation for Science and Technology (FCT; http://www.fct.pt) project PEst (PEst-C/SAU/ LA0026/2013) under POFC and/or FEDER programs, attributed to RLR; Grants under the Investigator FCT program: IF/00423/2012 and IF/01285/2015 (JMO), IF/00411/2013 (ALO) and IF/00115/2015 (JSC); Postdoctoral fellows: SFRH/BPD/94277/2013 (CG), SFRH/BPD/108763/2015 (SP), SFRH/BPD/100957/2014 (HR); PhD scholarship PD/BD/113806/2015 attributed to VPR under the financial support from FCT/MCTES and FSUPOCH, PD/59/2013. An internal R&D grant of Anasys Instruments Corp provided support in the form of salary for author AR, but did not have any additional role in the study design, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the "author contributions" section. The remaining coauthors did not receive any funding from Anasys Instruments Corp.	Aho J, 2015, INT J PHARMACEUT, V494, P623, DOI 10.1016/j.ijpharm.2015.02.009; Bai S, 2013, ACTA BIOMATER, V9, P7806, DOI 10.1016/j.actbio.2013.04.033; Bastiancich C, 2016, J CONTROL RELEASE, V243, P29, DOI 10.1016/j.jconrel.2016.09.034; Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050; Cai YR, 2017, MAT SCI ENG C-MATER, V70, P148, DOI 10.1016/j.msec.2016.08.070; Chen X, 2007, PROTEINS, V68, P223, DOI 10.1002/prot.21414; Cho SY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8145; Davis NE, 2012, BIOMATERIALS, V33, P6691, DOI 10.1016/j.biomaterials.2012.06.015; de Moraes MA, 2010, POLYMERS-BASEL, V2, P719, DOI 10.3390/polym2040719; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; Du GY, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671-017-2316-1; Elisseeff J, 2008, NAT MATER, V7, P271, DOI 10.1038/nmat2147; Figueiras E, 2014, BIOMED OPT EXPRESS, V5, P3443, DOI 10.1364/BOE.5.003443; Fischbach C, 2007, BIOMATERIALS, V28, P2069, DOI 10.1016/j.biomaterials.2006.12.029; Ghosh S, 2008, ADV FUNCT MATER, V18, P1883, DOI 10.1002/adfm.200800040; Greish K, 2010, J GENE MED, V12, P572, DOI 10.1002/jgm.1469; Gutowska A, 2001, ANAT RECORD, V263, P342, DOI 10.1002/ar.1115; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hennink WE, 2002, ADV DRUG DELIVER REV, V54, P13, DOI 10.1016/j.addr.2012.09.009; Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]; Hutmacher DW, 2009, J CELL MOL MED, V13, P1417, DOI 10.1111/j.1582-4934.2009.00853.x; Jin R, 2010, BIOMATERIALS, V31, P3103, DOI 10.1016/j.biomaterials.2010.01.013; Kadowaki H, 2005, CELL DEATH DIFFER, V12, P19, DOI 10.1038/sj.cdd.4401528; Katt ME, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00012; Kim UJ, 2004, BIOMACROMOLECULES, V5, P786, DOI 10.1021/bm0345460; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Leisk GG, 2010, ADV MATER, V22, P711, DOI 10.1002/adma.200902643; Liu L, 2016, ASIAN J PHARM SCI, V11, P673, DOI 10.1016/j.ajps.2016.07.001; Loessner D, 2010, BIOMATERIALS, V31, P8494, DOI 10.1016/j.biomaterials.2010.07.064; Marcott C., 2012, MICROSCOPY TODAY, V20, P16; McGill M, 2017, ACTA BIOMATER, V63, P76, DOI 10.1016/j.actbio.2017.09.020; Mitropoulos AN, 2015, ACS BIOMATER SCI ENG, V1, P964, DOI 10.1021/acsbiomaterials.5b00215; Nogueira GM, 2011, MAT SCI ENG C-MATER, V31, P997, DOI 10.1016/j.msec.2011.02.019; Park KM, 2009, ACTA BIOMATER, V5, P1956, DOI 10.1016/j.actbio.2009.01.040; Partlow BP, 2014, ADV FUNCT MATER, V24, P4615, DOI 10.1002/adfm.201400526; Qin N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13079; Qiu PH, 2013, ADV MATER, V25, P2492, DOI 10.1002/adma.201204472; Reis RL, 2014, Portugal patent, Patent No. [107426, PT107426]; Ribeiro VP, 2017, BIOMATERIALS, V123, P92, DOI 10.1016/j.biomaterials.2017.01.027; Ryu S, 2016, J MATER CHEM B, V4, P4574, DOI 10.1039/c6tb00896h; Sah MK, 2011, AFR J BIOTECHNOL, V10, P7878; Sakai S, 2009, ACTA BIOMATER, V5, P554, DOI 10.1016/j.actbio.2008.10.010; Sakai S, 2009, BIOMATERIALS, V30, P3371, DOI 10.1016/j.biomaterials.2009.03.030; Seib FP, 2015, BIOMATERIALS, V51, P313, DOI 10.1016/j.biomaterials.2015.01.076; Shirmanova MV, 2017, ADV EXP MED BIOL, V1035, P143, DOI 10.1007/978-3-319-67358-5_10; Soto AM, 2016, LANGMUIR, V32, P5173, DOI 10.1021/acs.langmuir.6b00554; Sundarakrishnan A, 2016, ACTA BIOMATER, V42, P102, DOI 10.1016/j.actbio.2016.06.020; Szot CS, 2011, BIOMATERIALS, V32, P7905, DOI 10.1016/j.biomaterials.2011.07.001; Ta HT, 2008, J CONTROL RELEASE, V126, P205, DOI 10.1016/j.jconrel.2007.11.018; Teixeira LSM, 2012, BIOMATERIALS, V33, P1281, DOI 10.1016/j.biomaterials.2011.10.067; Tellado SF, 2017, TISSUE ENG PT A, V23, P859, DOI [10.1089/ten.tea.2016.0460, 10.1089/ten.TEA.2016.0460]; Wang XQ, 2008, BIOMATERIALS, V29, P1054, DOI 10.1016/j.biomaterials.2007.11.003; Wilson D, 2000, BIOPHYS J, V78, P2690, DOI 10.1016/S0006-3495(00)76813-5; Xia LW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3226; Xiong G., 2013, J BIOMATER NANOBIOTE, V4, P316, DOI DOI 10.4236/JBNB.2013.44040; Yan CQ, 2010, CHEM SOC REV, V39, P3528, DOI 10.1039/b919449p; Yan LP, 2017, J TISSUE ENG REGEN M, V11, P3168, DOI 10.1002/term.2226; Yan LP, 2016, SCI REP-UK, V6, DOI 10.1038/srep31037; Yang M, 2017, ADV FUNCTIONAL MAT; Yu E, 2016, INT POLYM PROC, V31, P638, DOI 10.3139/217.3247; Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k; Yucel T, 2009, BIOPHYS J, V97, P2044, DOI 10.1016/j.bpj.2009.07.028; Zainuddin, 2008, BIOMATERIALS, V29, P4268, DOI 10.1016/j.biomaterials.2008.07.041; Zheng R, 2004, PROTEIN SCI, V13, P1288, DOI 10.1110/ps.03550404; Zhou CZ, 2001, PROTEINS, V44, P119, DOI 10.1002/prot.1078	65	39	38	3	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2018	13	4							e0194441	10.1371/journal.pone.0194441	http://dx.doi.org/10.1371/journal.pone.0194441			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6SR	29617395	Green Submitted, Green Published, gold			2023-01-03	WOS:000429203800031
J	Psaty, BM; Dekkers, OM; Cooper, RS				Psaty, Bruce M.; Dekkers, Olaf M.; Cooper, Richard S.			Comparison of 2 Treatment Models Precision Medicine and Preventive Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; [Psaty, Bruce M.] Univ Washington, Dept Epidemiol & Hlth Serv, Seattle, WA 98195 USA; [Psaty, Bruce M.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA; [Dekkers, Olaf M.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; [Cooper, Richard S.] Loyola Univ, Sch Med, Dept Publ Hlth Sci, Maywood, IL 60153 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kaiser Permanente; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Loyola University Chicago	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Ste 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu			National Heart, Lung, and Blood Institute [HL105756, HL130114]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL105756, U01HL130114] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by grants HL105756 and HL130114 from the National Heart, Lung, and Blood Institute (Dr Psaty).	[Anonymous], 2018, WHAT IS PREC MED GEN; Chin Lauren, 2017, AMIA Jt Summits Transl Sci Proc, V2017, P30; George LA, 2017, NEW ENGL J MED, V377, P2215, DOI 10.1056/NEJMoa1708538; Khera AV, 2017, CIRCULATION, V135, P1005, DOI 10.1161/CIRCULATIONAHA.116.026479; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990; West KM, 2017, JAMA-J AM MED ASSOC, V317, P1831, DOI 10.1001/jama.2017.3096	7	32	35	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	2018	320	8					751	752		10.1001/jama.2018.8377	http://dx.doi.org/10.1001/jama.2018.8377			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR8HM	30054607				2023-01-03	WOS:000442958800014
J	Ehara, A				Ehara, Akira			Accessibility of pediatric inpatient services in japan	PLOS ONE			English	Article								In Japan, all citizens are covered by the national insurance system. Children's medical expenses are subsidized by local government co-payments. This removed most economic barriers to visiting medical facilities, geographical obstacles to pediatric medical services remain, including distance to medical facilities and transportation time. However, information on geographic accessibility of pediatric inpatient services is scarce. In this study, I calculated the proportion of children resident in areas accessible to pediatric inpatient service providers within 30 and 60 minutes by automobile. Calculations were based on addresses of hospitals that met criteria for high reimbursement for secondary and tertiary pediatric inpatient services, data for residential blocks, and data for the average velocity of an automobile. In total, 88.0% of children lived within 30 minutes of these hospitals and 95.2% of children lived within 60 minutes. The percentage of children with such access was higher in regions with high population density (e.g., Kanto and Kinki) compared with regions with low population density (e.g., Hokkaido, Tohoku, and Shikoku). Furthermore, regions with high population density also had high rates of children that lived within reach of hospitals with at least five full-time pediatricians.	[Ehara, Akira] Hiroshima Int Univ, Fac Hlth Serv Management, Hiroshima, Hiroshima, Japan		Ehara, A (corresponding author), Hiroshima Int Univ, Fac Hlth Serv Management, Hiroshima, Hiroshima, Japan.	a-ehara@hw.hirokoku-u.ac.jp	Ehara, Akira/AAA-2897-2021	Ehara, Akira/0000-0002-0616-8571	JSPS KAKENHI [15K01786]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The author received financial support from JSPS KAKENHI (Grant Number 15K01786 to AE) in designing the study, collecting and analyzing data, and writing this manuscript; http://www.jsps.go.jp/english/index.html.	Dijkstra E.W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]; Ehara A., 2013, J JPN PEDIAT SOC, V117, P1930; Ehara A., 2016, JPN J MED ASS, V145, P1660; Ehara A., 2017, J JPN MED ASS, V146, P90; Equal Employment Child and Family Policy Bureau Ministry of Health Labour and Welfare, 2015, RES SURV SUBS MED EX; Fire and Disaster Management Agency Ministry of Inner Affairs and Communication of Japan, 2016, CURR STAT EM RESC; Igakutushinsya, 2016, FEES MED PRACT REIMB; Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3; Ishikawa M., 2015, J JPN ASS HLTH CARE, V9, P5; Ministry of Health Labour and Welfare, 2014, SURV MED I; Ministry of Health Labour and Welfare, 2015, IND ACC CAUS BRAIN H; Ministry of Health Labour and Welfare, 2005, PUBL STUD SEC FOST Y; Ministry of Health Labour and Welfare in Japan, 2014, PAT SURV; Ministry of Health Labour and Welfare Japan, 2014, SURV PHYS DENT PHARM; Ministry of Land, 2012, ROAD TRAFF CENS; Obara S, 2008, JJAAM, V19, P201; Statistics Bureau Ministry of Inner Affairs and Communication of Japan, 2010 POP CENS; Statistics Bureau Ministry of Inner Affairs and Communication of Japan, 2016, SOC IND PREF	18	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2018	13	8							e0201443	10.1371/journal.pone.0201443	http://dx.doi.org/10.1371/journal.pone.0201443			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3QP	30074990	Green Submitted, Green Published, gold			2023-01-03	WOS:000440768100016
J	Heider, D; Matschinger, H; Meid, AD; Quinzler, R; Adler, JB; Gunster, C; Haefeli, WE; Konig, HH				Heider, Dirk; Matschinger, Herbert; Meid, Andreas D.; Quinzler, Renate; Adler, Juergen-Bernhard; Guenster, Christian; Haefeli, Walter E.; Koenig, Hans-Helmut			The impact of potentially inappropriate medication on the development of health care costs and its moderation by the number of prescribed substances. Results of a retrospective matched cohort study	PLOS ONE			English	Article							CONSENSUS PANEL; CRITERIA	Background In the growing population of the elderly, drug-related problems are considered an important health care safety issue. One aspect of this is the prescription of potentially inappropriate medication (PIM) which is considered to increase health care costs. Objective Using data from the Health Economics of Potentially Inappropriate Medication (HEPIME) study, we aimed to analyze how the number of prescribed substances moderates the association of PIM use as defined by the German PRISCUS list and health care costs applying a longitudinal perspective. Methods An initial number of 6,849,622 insurants aged 65+ of a large German health insurance company were included in a retrospective matched cohort study. Based on longitudinal claims data from the four separate quarters of a 12-month pre-period, 3,860,842 individuals with no exposure to PIM in 2011 were matched to 508,212 exposed individuals. Exposure effects of PIM use on health care costs and the number of prescribed substances were measured based on longitudinal claims data from the four separate quarters of the 12-month post-period. Results After successful balancing for the development of numerous matching variables during the four quarters of the pre-period, exposed individuals consumed 2.1 additional prescribed substances and had higher total health care costs of 1,237 (sic) when compared to nonexposed individuals in the 1st quarter of the post-period. Controlling for the number of prescribed substances, the difference in total health care costs between both study groups was 401 (sic). The average effect of one additionally prescribed substance (other than PIM) on total health care costs was increased by an amount of 137(sic) for those being exposed to a PIM. In quarters 2-4 of the post-period, the differences between both study groups tended to decrease sequentially. Conclusions PIM use has an increasing effect on the development of health care costs. This cost-increasing effect of PIM use is moderated by the number of prescribed substances.	[Heider, Dirk; Matschinger, Herbert; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Hamburg Ctr Hlth Econ, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany; [Meid, Andreas D.; Quinzler, Renate; Haefeli, Walter E.] Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Adler, Juergen-Bernhard; Guenster, Christian] AOK Res Inst WIdO, Berlin, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg	Heider, D (corresponding author), Univ Med Ctr Hamburg Eppendorf, Hamburg Ctr Hlth Econ, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany.	d.heider@uke.de	Haefeli, Walter Emil/AAJ-3024-2020; König, Hans-Helmut/P-1211-2018	Haefeli, Walter Emil/0000-0003-0672-6876; König, Hans-Helmut/0000-0001-5711-6862; Matschinger, Herbert/0000-0001-7146-6770	Federal Ministry of Education and Research (BMBF) [01GY1329A]	Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The HEPIME-study was funded by The Federal Ministry of Education and Research (BMBF) under project number 01GY1329A. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akazawa M, 2010, AM J GERIATR PHARMAC, V8, P146, DOI 10.1016/j.amjopharm.2010.03.005; Amann U, 2012, DTSCH ARZTEBL INT, V109, P69, DOI 10.3238/arztebl.2012.0069; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Cadogan CA, 2016, DRUG SAFETY, V39, P109, DOI 10.1007/s40264-015-0378-5; Chin MH, 1999, ACAD EMERG MED, V6, P1232, DOI 10.1111/j.1553-2712.1999.tb00139.x; Corsonello A, 2010, CURR MED CHEM, V17, P571, DOI 10.2174/092986710790416326; Eggers AC, 2015, AM J POLIT SCI, V59, P259, DOI 10.1111/ajps.12127; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Endres HG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146811; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fick DM, 2008, RES NURS HEALTH, V31, P42, DOI 10.1002/nur.20232; Fu AZ, 2007, MED CARE, V45, P472, DOI 10.1097/01.mlr.0000254571.05722.34; Gallagher PF, 2008, AGE AGEING, V37, P96, DOI 10.1093/ageing/afm116; Greene W.H.W.H., 2012, ECONOMETRIC ANAL, V7; Hainmueller J, 2013, J STAT SOFTW, V54; Hainmueller J, 2012, POLIT ANAL, V20, P25, DOI 10.1093/pan/mpr025; Heider D, 2017, DRUG AGING, V34, P289, DOI 10.1007/s40266-017-0441-2; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Hyttinen V, 2016, MED CARE, V54, P950, DOI 10.1097/MLR.0000000000000587; Laroche ML, 2007, EUR J CLIN PHARMACOL, V63, P725, DOI 10.1007/s00228-007-0324-2; Mansur N, 2009, ANN PHARMACOTHER, V43, P177, DOI 10.1345/aph.1L461; Montamat S C, 1992, Clin Geriatr Med, V8, P143; Nishtala PS, 2014, GERIATR GERONTOL INT, V14, P89, DOI 10.1111/ggi.12059; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quinzler R, 2007, PHARMACOEPIDEM DR S, V16, P1024, DOI 10.1002/pds.1406; Rognstad S, 2009, SCAND J PRIM HEALTH, V27, P153, DOI 10.1080/02813430902992215; Roy AD, 1951, OXFORD ECON PAP, V3, P135, DOI 10.1093/oxfordjournals.oep.a041827; RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350; Schaufler J, 2013, HERAUSGEBER; Schnee M, 2008, GESUNDHEITSMONITOR, P88; Schrijvers G., 2009, INT J INTEGR CARE, P9; StataCorp, 2013, STATA STAT SOFTW REL; Stockl KM, 2010, AM J MANAG CARE, V16, pE1; Stuart EA, 2014, HEALTH SERV OUTCOME, V14, P166, DOI 10.1007/s10742-014-0123-z; Wehling M., 2013, DRUG THERAPY ELDERLY, P21; WHO Collaborating Centre for Drug Statistics Methodology, 2016, GUID ATC CLASS DDD A	36	16	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2018	13	7							e0198004	10.1371/journal.pone.0198004	http://dx.doi.org/10.1371/journal.pone.0198004			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO7ZJ	30063697	Green Published, Green Submitted, gold			2023-01-03	WOS:000440300500004
J	Yang, YM; Lee, JJ; Jeong, E; Kim, SY; Han, MA; Choi, EJ				Yang, Young-Mo; Lee, Jae-Joon; Jeong, Eun; Kim, Sun Young; Han, Mi Ah; Choi, Eun Joo			A survey of perceptions and attitudes about direct-to-consumer advertising of prescription drugs among college students in South Korea	PLOS ONE			English	Article							HEALTH-CARE; PHARMACISTS; INFORMATION; KNOWLEDGE; BEHAVIOR; TRENDS; MEDIA; DTCA	Direct-to-consumer advertising (DTCA) of prescription drugs can be both beneficial and harmful to healthcare consumers. Therefore, DTCA for prescription drugs is a topic that should be considered crucially, at this point, when the interests of patients as well as pharmaceutical companies in DTCA of prescription drugs are growing in South Korea. The goals of this study were to investigate Korean college students' perceptions and attitudes about DTCA of prescription drugs through a survey as well as to analyze data according to their college majors in order to identify differences in their perceptions and attitudes about prescription drug DTCAs as future health care professionals and consumers, respectively. A descriptive, cross-sectional survey was conducted between September and November 2015. Participants were recruited from Chosun University in Gwangju, South Korea. Ethical approval for this study was obtained from the Chosun University Institutional Review Board. Of 1,040 questionnaires initially distributed, 774 were collected, and 742 were included in the analysis. The results of this study indicated that most students who had participated in the survey did not have sufficient knowledge of DTCA for prescription drugs. Approximately, 17% reported being cognizant of DTCA for prescription drugs. More healthcare students (24.6%) knew this term than non-healthcare students did (6.3%). In this study, most of the students were likely to feel that healthcare professionals (e.g., doctors and pharmacists) had the responsibility of delivering information about prescription drugs to patients, and that all prescription drugs DTCA, if it were permitted, had to be pre-approved by the Korean government. The results of this study indicated that DTCA for prescription drugs had to be permitted under the condition of pre-approval of the DTCA contents by the Korean government, and prescription drugs should not be advertised through the Internet. It is recommended that the Korean government cautiously examine whether DTCA of prescription drugs should be permitted, after considering the current marketing strategies of pharmaceutical companies on the Internet and the effects of online electronic-DTCA on Korean consumers.	[Yang, Young-Mo; Choi, Eun Joo] Chosun Univ, Coll Pharm, Dept Pharm, Gwangju, South Korea; [Lee, Jae-Joon; Jeong, Eun] Chosun Univ, Dept Food & Nutr, Gwangju, South Korea; [Kim, Sun Young] Chosun Univ, Dept Biol Educ, Gwangju, South Korea; [Han, Mi Ah] Chosun Univ, Coll Med, Dept Prevent Med, Gwangju, South Korea	Chosun University; Chosun University; Chosun University; Chosun University	Choi, EJ (corresponding author), Chosun Univ, Coll Pharm, Dept Pharm, Gwangju, South Korea.	ejchoi@chosun.ac.kr	Kim, Sun/GSN-4867-2022		National Research Foundation of Korea (NRF) - Korea government [2016R1C1B1015938]; National Research Foundation of Korea (NRF) - Korean government [2016R1C1B1015938]	National Research Foundation of Korea (NRF) - Korea government(National Research Foundation of Korea); National Research Foundation of Korea (NRF) - Korean government(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (No. 2016R1C1B1015938). -Grant recipient: EJC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (2016R1C1B1015938).	Abel GA, 2009, J CLIN ONCOL, V27, P4182, DOI 10.1200/JCO.2008.20.6599; Alperstein Neil M, 2014, Health Mark Q, V31, P231, DOI 10.1080/07359683.2014.936291; Chaar Betty, 2010, Int J Pharm Pract, V18, P43; Dens N, 2008, HEALTH COMMUN, V23, P45, DOI 10.1080/10410230701805190; Deshpande A, 2004, J HEALTH COMMUN, V9, P499, DOI 10.1080/10810730490523197; Frosch DL, 2007, ANN FAM MED, V5, P6, DOI 10.1370/afm.611; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Gibson S, 2014, LAWS, V3, P410, DOI [10.3390/laws3030410], DOI 10.3390/LAWS3030410]; Gilbody S, 2005, QUAL SAF HEALTH CARE, V14, P246, DOI 10.1136/qshc.2004.012781; Harrington AR, 2013, RES SOC ADMIN PHARM, V9, P458, DOI 10.1016/j.sapharm.2012.07.005; Herzenstein M, 2005, MARKET LETT, V15, P201, DOI 10.1007/s11002-005-0458-x; Humphreys G, 2009, B WORLD HEALTH ORGAN, V87, P576, DOI 10.2471/BLT.09.040809; Kannan S, 2015, Int J Risk Saf Med, V27, P77, DOI 10.3233/JRS-150644; Kim BK, 2005, DIRECT TO CONSUMER P, P20; Kim HJ, 2008, HEALTH AFFAIR, V27, pW260, DOI 10.1377/hlthaff.27.4.w260; 오지운, 2015, [Korean Journal of Clinical Pharmacy, 한국임상약학회지], V25, P42; Liang BA, 2011, JAMA-J AM MED ASSOC, V305, P824, DOI 10.1001/jama.2011.203; Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267; Mackey TK, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0885-1; Main K.J., 2004, INT J ADVERT, V23, P119, DOI [10.1080/02650487.2004.11072875, DOI 10.1080/02650487.2004.11072875], DOI 10.1080/02650487.2004.11072875]; Mintzes B, 2003, CAN MED ASSOC J, V169, P405; Murray E, 2004, J AM BOARD FAM PRACT, V17, P6, DOI 10.3122/jabfm.17.1.6; Naik RK, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj710586; Peyrot M, 1998, MARK HEALTH SERV, V18, P26; Singh T, 2005, J CONSUM MARK, V22, P369, DOI 10.1108/07363760510631101; Spake Deborah F, 2014, Health Mark Q, V31, P31, DOI 10.1080/07359683.2013.847344; Suh HS, 2011, HEALTH POLICY, V101, P260, DOI 10.1016/j.healthpol.2011.05.005; Tyrawski J, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4357; Viale PH, 2004, ONCOL NURS FORUM, V31, P777, DOI 10.1188/04.ONF.777-783; Williams PA, 2016, PATIENT EDUC COUNS, V99, P583, DOI 10.1016/j.pec.2015.10.019; Wu MH, 2016, CONTRACEPTION, V93, P398, DOI 10.1016/j.contraception.2016.01.010	31	1	1	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2018	13	7							e0201108	10.1371/journal.pone.0201108	http://dx.doi.org/10.1371/journal.pone.0201108			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO1WA	30040833	Green Submitted, Green Published, gold			2023-01-03	WOS:000439749200026
J	Vangoitsenhoven, R; van der Ende, M; Corbeels, K; Cunha, JPMCM; Lannoo, M; Bedossa, P; van der Merwe, S; Mertens, A; Gesquiere, I; Meulemans, A; Matthys, C; Mathieu, C; Overbergh, L; Van der Schueren, B				Vangoitsenhoven, Roman; van der Ende, Miranda; Corbeels, Katrien; Cunha, Joao Paulo Monteiro Carvalho Mori; Lannoo, Matthias; Bedossa, Pierre; van der Merwe, Schalk; Mertens, Ann; Gesquiere, Ina; Meulemans, Ann; Matthys, Christophe; Mathieu, Chantal; Overbergh, Lut; Van der Schueren, Bart			At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice	PLOS ONE			English	Article							FAT	Background Achieving weight loss is the cornerstone of the treatment of the metabolic consequences of obesity, in particular of glucose intolerance. Objective To determine whether improvement in glucose control depends on dietary macronutrient composition of the diet at identical weight loss. Materials and methods Twenty-two weeks old diet-induced obese C57BU6 mice lost weight through caloric restriction on normal chow (R-NC) or high fat diet (R-HF). Control mice were fed normal chow (LEAN) or high fat diet (OBESE) ad libitum. Body weight and composition were assessed after 8 weeks of dietary intervention. Glucose homeostasis was evaluated by intraperitoneal glucose tolerance tests (IPGTT). Epididymal white adipose (eWAT) and hepatic tissues were analyzed by immunohistochemistry and RT-qPCR. Results By 30 weeks of age, the body weight of the mice on R-NC (31.6 +/- 1.7g, mean +/- SEM) and RHF (32.3 +/- 0.9g) was similar to LEAN mice (31.9 +/- 1.4g), while OBESE mice weighed 51.7 +/- 2.4g. Glucose tolerance in R-NC was better than in LEAN mice (69% AUC IPGTT, P 0.0168) whereas R-HF mice remained significantly less glucose tolerant (125% AUC IPGTT, P 0.0279 vs LEAN), despite identical weight loss. The eWAT pads and adipocyte size were similar in LEAN and R-NC mice, while the eWAT pad size of R-HF was 180% of R-NC (P < 0.0001) and the average adipocyte size of R-HF mice was 134% of R-NC fed mice (P 0.0285). No LEAN or R-NC mice had hepatic steatosis, in contrast to 28.6% of R-HF mice. Compared to OBESE mice, inflammatory markers were lower in eWAT and liver tissue of R-NC, but not in R-HF mice. Measures of visceral adiposity correlated well with glucose tolerance parameters. Conclusions In mice, caloric restriction on a normal chow diet improved glucose tolerance significantly more when identical weight loss was achieved on a high fat diet.	[Vangoitsenhoven, Roman; van der Ende, Miranda; Corbeels, Katrien; Cunha, Joao Paulo Monteiro Carvalho Mori; Mertens, Ann; Gesquiere, Ina; Meulemans, Ann; Matthys, Christophe; Mathieu, Chantal; Overbergh, Lut; Van der Schueren, Bart] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium; [Vangoitsenhoven, Roman; Mertens, Ann; Meulemans, Ann; Matthys, Christophe; Mathieu, Chantal; Van der Schueren, Bart] Univ Hosp Leuven, Dept Endocrinol, Leuven, Belgium; [Lannoo, Matthias] Univ Hosp Leuven, Dept Abdominal Surg, Leuven, Belgium; [Bedossa, Pierre] Univ Paris Diderot, Dept Anat Pathol, INSERM U773, Paris, France; [van der Merwe, Schalk] Katholieke Univ Leuven, Lab Hepatol, Leuven, Belgium; [van der Merwe, Schalk] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; KU Leuven; KU Leuven; University Hospital Leuven	Vangoitsenhoven, R (corresponding author), Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium.; Vangoitsenhoven, R (corresponding author), Univ Hosp Leuven, Dept Endocrinol, Leuven, Belgium.	Roman.vangoitsenhoven@kuleuven.be	Vangoitsenhoven, Roman/B-3196-2018; mathieu, chantal/ABD-5505-2021; da Cunha, João Paulo Monteiro Carvalho Mori/M-3310-2017; Corbeels, Katrien/AAH-1232-2020; lannoo, matthias/AAB-1706-2020; Overbergh, Lut/AAC-3515-2020; Matthys, Christophe/I-4203-2016	Vangoitsenhoven, Roman/0000-0003-3523-669X; mathieu, chantal/0000-0002-4055-5233; da Cunha, João Paulo Monteiro Carvalho Mori/0000-0002-0749-6534; Corbeels, Katrien/0000-0001-9494-1650; Matthys, Christophe/0000-0003-1770-6862; Meulemans, Ann/0000-0003-3938-2408; Mertens, Ann/0000-0002-1649-4311; Lannoo, matthias/0000-0001-7815-1157; Van der Schueren, Bart/0000-0003-4754-784X; van der Ende, Miranda/0000-0001-9864-0505; Van der Merwe, Schalk/0000-0002-9891-2686	Flemish Research Foundation [G.0857.13]; clinical fellowship	Flemish Research Foundation(FWO); clinical fellowship	This work was supported by the Flemish Research Foundation (www.fwo.be): G.0857.13 and clinical fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Apovian CM, 2015, J CLIN ENDOCR METAB, V100, P342, DOI 10.1210/jc.2014-3415; Appel LJ, 2011, NEW ENGL J MED, V365, P1959, DOI 10.1056/NEJMoa1108660; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Bedossa P, 2012, HEPATOLOGY, V56, P1751, DOI 10.1002/hep.25889; Bray GA, 2012, INT J OBESITY, V36, P448, DOI 10.1038/ijo.2011.173; Brehm BJ, 2008, NAT CLIN PRACT ENDOC, V4, P140, DOI 10.1038/ncpendmet0730; Daniel S, 2013, CURR OPIN ENDOCRINOL, V20, P377, DOI 10.1097/01.med.0000433067.01671.f5; Deng QG, 2005, HEPATOLOGY, V42, P905, DOI 10.1002/hep.20877; du Plessis J, 2015, GASTROENTEROLOGY, V149, P635, DOI 10.1053/j.gastro.2015.05.044; Dubois V, 2016, ENDOCRINOLOGY, V157, P648, DOI 10.1210/en.2015-1713; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Goss AM, 2013, OBESITY, V21, P1133, DOI 10.1002/oby.20191; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Hall KD, 2015, CELL METAB, V22, P427, DOI 10.1016/j.cmet.2015.07.021; Heilbronn L, 2004, INT J OBESITY, V28, pS12, DOI 10.1038/sj.ijo.0802853; Heymsfield SB, 2007, AM J CLIN NUTR, V85, P346, DOI 10.1093/ajcn/85.2.346; Johnson AMF, 2013, CELL, V152, P673, DOI 10.1016/j.cell.2013.01.041; Kosinski C, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050517; Matsui Y, 2010, BIOL PHARM BULL, V33, P963, DOI 10.1248/bpb.33.963; Parlee SD, 2014, METHOD ENZYMOL, V537, P93, DOI 10.1016/B978-0-12-411619-1.00006-9; Poitout V, 2008, ENDOCR REV, V29, P351, DOI 10.1210/er.2007-0023; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Schwingshackl L, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0455-1; Swinburn BA, 2009, AM J CLIN NUTR, V89, P1723, DOI 10.3945/ajcn.2008.27061; Wei P, 2004, DIABETOLOGIA, V47, P1541, DOI 10.1007/s00125-004-1489-1; Williamson DA, 2010, J BEHAV MED, V33, P305, DOI 10.1007/s10865-010-9253-0	28	5	5	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2018	13	7							e0200779	10.1371/journal.pone.0200779	http://dx.doi.org/10.1371/journal.pone.0200779			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN8PM	30036374	Green Published, gold, Green Submitted			2023-01-03	WOS:000439429200016
J	Hershman, DL; Unger, JM; Greenlee, H; Capodice, JL; Lew, DL; Darke, AK; Kengla, AT; Melnik, MK; Jorgensen, C; Kreisle, WH; Minasian, LM; Fisch, MJ; Henry, NL; Crew, KD				Hershman, Dawn L.; Unger, Joseph M.; Greenlee, Heather; Capodice, Jillian L.; Lew, Danika L.; Darke, Amy K.; Kengla, Alice T.; Melnik, Marianne K.; Jorgensen, CarlaW.; Kreisle, William H.; Minasian, Lori M.; Fisch, Michael J.; Henry, N. Lynn; Crew, Katherine D.			Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	San Antonio Breast Cancer Symposium	DEC 05-09, 2017	San Antonio, TX				QUALITY-OF-LIFE; MUSCULOSKELETAL SYMPTOMS; IMMPACT RECOMMENDATIONS; HORMONAL-THERAPY; ARTHRALGIA; OUTCOMES; PLACEBO; DISCONTINUATION; MULTICENTER; VALIDATION	IMPORTANCE Musculoskeletal symptoms are the most common adverse effects of aromatase inhibitors and often result in therapy discontinuation. Small studies suggest that acupuncture may decrease aromatase inhibitor-related joint symptoms. OBJECTIVE To determine the effect of acupuncture in reducing aromatase inhibitor-related joint pain. DESIGN, SETTING, AND PATIENTS Randomized clinical trial conducted at 11 academic centers and clinical sites in the United States from March 2012 to February 2017 (final date of follow-up, September 5, 2017). Eligible patients were postmenopausal women with early-stage breast cancer who were taking an aromatase inhibitor and scored at least 3 on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range, 0-10; higher scores indicate greater pain). INTERVENTIONS Patients were randomized 2: 1: 1 to the true acupuncture (n = 110), sham acupuncture (n = 59), or waitlist control (n = 57) group. True acupuncture and sham acupuncture protocols consisted of 12 acupuncture sessions over 6 weeks (2 sessions per week), followed by 1 session per week for 6 weeks. The waitlist control group did not receive any intervention. All participants were offered 10 acupuncture sessions to be used between weeks 24 and 52. MAIN OUTCOMES AND MEASURES The primary end point was the 6-week BPI-WP score. Mean 6-week BPI-WP scores were compared by study group using linear regression, adjusted for baseline pain and stratification factors (clinically meaningful difference specified as 2 points). RESULTS Among 226 randomized patients (mean [SD] age, 60.7 [8.6] years; 88% white; mean [SD] baseline BPI-WP score, 6.6 [1.5]), 206 (91.1%) completed the trial. From baseline to 6 weeks, the mean observed BPI-WP score decreased by 2.05 points (reduced pain) in the true acupuncture group, by 1.07 points in the sham acupuncture group, and by 0.99 points in the waitlist control group. The adjusted difference for true acupuncture vs sham acupuncture was 0.92 points (95% CI, 0.20-1.65; P = .01) and for true acupuncture vs waitlist control was 0.96 points (95% CI, 0.24-1.67; P = .01). Patients in the true acupuncture group experienced more grade 1 bruising compared with patients in the sham acupuncture group (47% vs 25%; P = .01). CONCLUSIONS AND RELEVANCE Among postmenopausal women with early-stage breast cancer and aromatase inhibitor-related arthralgias, true acupuncture compared with sham acupuncture or with waitlist control resulted in a statistically significant reduction in joint pain at 6 weeks, although the observed improvement was of uncertain clinical importance.	[Hershman, Dawn L.] Columbia Univ, Med Ctr, New York, NY USA; [Unger, Joseph M.; Greenlee, Heather; Lew, Danika L.; Darke, Amy K.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Unger, Joseph M.; Lew, Danika L.; Darke, Amy K.] SWOG Stat & Data Management Ctr, Seattle, WA USA; [Capodice, Jillian L.] Mt Sinai Hosp, New York, NY 10029 USA; [Kengla, Alice T.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA; [Melnik, Marianne K.] Spectrum Hlth Med Grp, Grand Rapids, MI USA; [Jorgensen, CarlaW.] NCORP Carolinas Greenville Hlth Syst, Greenville, SC USA; [Kreisle, William H.] St Lukes Mt States Tumor Inst PCRC NCORP, Boise, ID USA; [Minasian, Lori M.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA; [Fisch, Michael J.] AIM Specialty Hlth, Chicago, IL USA; [Henry, N. Lynn] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA	Columbia University; Fred Hutchinson Cancer Center; Southwest Oncology Group; Icahn School of Medicine at Mount Sinai; Kaiser Permanente; Spectrum Health Medical Group; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Hershman, DL (corresponding author), Columbia Univ, 161 Ft Washington Ave,10-1068, New York, NY 10032 USA.	dlh23@columbia.edu	Unger, Joseph/O-7457-2019; Hershman, Dawn/AAG-2114-2020		National Institutes of Health (NIH) National Center for Complementary and Integrative Health; Office of Research on Women's Health [R01AT006376]; NIH/NCI/DCP (Division of Cancer Prevention) [UG1CA189974, U10CA37429]; NATIONAL CANCER INSTITUTE [U10CA037429, UG1CA189974] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT006376] Funding Source: NIH RePORTER	National Institutes of Health (NIH) National Center for Complementary and Integrative Health; Office of Research on Women's Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); NIH/NCI/DCP (Division of Cancer Prevention); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding was provided by the National Institutes of Health (NIH) National Center for Complementary and Integrative Health and the Office of Research on Women's Health R01AT006376; NIH/NCI/DCP (Division of Cancer Prevention) grant UG1CA189974 and legacy grant U10CA37429.	Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Burstein HJ, 2016, J CLIN ONCOL, V34, P1689, DOI 10.1200/JCO.2015.65.9573; Castel LD, 2013, CANCER-AM CANCER SOC, V119, P2375, DOI 10.1002/cncr.28016; Chirgwin JH, 2016, J CLIN ONCOL, V34, P2452, DOI 10.1200/JCO.2015.63.8619; Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573; Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019; Fallowfield LJ, 1999, BREAST CANCER RES TR, V55, P189; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Garcia SF, 2007, J CLIN ONCOL, V25, P5106, DOI 10.1200/JCO.2007.12.2341; Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700; Greenlee H, 2015, ACUPUNCT MERIDIAN ST, V8, P452; Helms JM., 1995, ACUPUNCTURE ENERGETI; Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651; Henry NL, 2015, J CLIN ONCOL, V33, P1870, DOI 10.1200/JCO.2015.61.1004; Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261; Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595; Hershman DL, 2010, J CLIN ONCOL, V28, P4120, DOI 10.1200/JCO.2009.25.9655; Hui Kathleen K S, 2007, BMC Complement Altern Med, V7, P33, DOI 10.1186/1472-6882-7-33; Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547; Kroenke K, 2010, JAMA-J AM MED ASSOC, V304, P163, DOI 10.1001/jama.2010.944; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893; MacPherson H., 2010, J EVID-BASED MED, V3, P140, DOI [10.1111/j.1756-5391.2010.01086.x, DOI 10.1111/J.1756-5391.2010.01086.X]; Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022; National Institutes of Health, 2015, RAC ETHN CAT DEF NIH; Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; SAS Institute Inc, 2016, SAS 9 4 SYST OPT; Sautner J, 2004, RHEUMATOLOGY, V43, P1409, DOI 10.1093/rheumatology/keh360; Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6; Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813; Tedesco D, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.2872; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	38	135	150	15	96	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2018	320	2					167	176		10.1001/jama.2018.8907	http://dx.doi.org/10.1001/jama.2018.8907			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	GM4MM	29998338	Bronze, Green Published			2023-01-03	WOS:000438094900017
J	Bielicki, JA; Sharland, M; Versporten, A; Goossens, H; Cromwell, DA				Bielicki, Julia A.; Sharland, Mike; Versporten, Ann; Goossens, Herman; Cromwell, David A.			Using risk adjustment to improve the interpretation of global inpatient pediatric antibiotic prescribing	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; CASE-MIX ADJUSTMENT; ANTIMICROBIAL STEWARDSHIP; EUROPEAN CHILDREN; UNITED-STATES; HOSPITALS; SURVEILLANCE; RESISTANCE; PREVALENCE; TRENDS	Objectives Assessment of regional pediatric last-resort antibiotic utilization patterns is hampered by potential confounding from population differences. We developed a risk-adjustment model from readily available, internationally used survey data and a simple patient classification to aid such comparisons. Design We investigated the association between pediatric conserve antibiotic (pCA) exposure and patient / treatment characteristics derived from global point prevalence surveys of antibiotic prescribing, and developed a risk-adjustment model using multivariable logistic regression. The performance of a simple patient classification of groups with different expected pCA exposure levels was compared to the risk model. Setting 226 centers in 41 countries across 5 continents. Participants Neonatal and pediatric inpatient antibiotic prescriptions for sepsis/bloodstream infection for 1281 patients. Results Overall pCA exposure was high (35%), strongly associated with each variable (patient age, ward, underlying disease, community acquisition or nosocomial infection and empiric or targeted treatment), and all were included in the final risk-adjustment model. The model demonstrated good discrimination (c-statistic = 0.83) and calibration (p = 0.38). The simple classification model demonstrated similar discrimination and calibration to the risk model. The crude regional pCA exposure rates ranged from 10.3% (Africa) to 67.4% (Latin America). Risk adjustment substantially reduced the regional variation, the adjusted rates ranging from 17.1% (Africa) to 42.8% (Latin America). Conclusions Greater comparability of pCA exposure rates can be achieved by using a few easily collected variables to produce risk-adjusted rates.	[Bielicki, Julia A.; Sharland, Mike] St Georges Univ London, Paediat Infect Dis Res Grp, Infect & Immun, London, England; [Bielicki, Julia A.; Cromwell, David A.] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England; [Bielicki, Julia A.] Univ Basel, Paediat Pharmacol Grp, Childrens Hosp, Basel, Switzerland; [Versporten, Ann; Goossens, Herman] Univ Antwerp, Lab Med Microbiol, Vaccine & Infect Dis Inst VAXINFECTIO, Fac Med & Hlth Sci, Antwerp, Belgium	St Georges University London; University of London; London School of Hygiene & Tropical Medicine; University of Basel; University of Antwerp	Bielicki, JA (corresponding author), St Georges Univ London, Paediat Infect Dis Res Grp, Infect & Immun, London, England.; Bielicki, JA (corresponding author), London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England.; Bielicki, JA (corresponding author), Univ Basel, Paediat Pharmacol Grp, Childrens Hosp, Basel, Switzerland.	jbielick@sgul.ac.uk	Cromwell, David/AAD-6519-2019	sharland, mike/0000-0001-8626-8291; Versporten, Ann/0000-0002-3551-6643	Directorate General for Health and Consumer Protection (DG SANCO) through the Executive Agency for Health and Consumers (ARPEC Project) [A 2009-11-01]	Directorate General for Health and Consumer Protection (DG SANCO) through the Executive Agency for Health and Consumers (ARPEC Project)	The ARPEC project was co-funded by the Directorate General for Health and Consumer Protection (DG SANCO) through the Executive Agency for Health and Consumers (grant number ARPEC Project A 2009-11-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amadeo B, 2010, CLIN MICROBIOL INFEC, V16, P735, DOI 10.1111/j.1469-0691.2009.02920.x; Bielicki JA, 2015, J ANTIMICROBIAL CHEM; Bielicki J, 2015, PEDIATR INFECT DIS J, V34, P311, DOI 10.1097/INF.0000000000000621; Bragg F, 2010, BMJ, V341; Downie L, 2012, ARCH DIS CHILD; Feudtner C, 2012, ARCH PEDIAT ADOL MED, V166, P9, DOI 10.1001/archpediatrics.2011.161; Harris AD, 2008, INFECT CONT HOSP EP, V29, P693, DOI 10.1086/590471; Haug JB, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/s13756-014-0040-5; Hebert C, 2012, INFECT CONT HOSP EP, V33, P381, DOI 10.1086/664768; Hersh AL, 2015, PEDIATRICS, V135, P33, DOI 10.1542/peds.2014-2579; Hyun DY, 2013, JAMA PEDIATR, V167, P859, DOI 10.1001/jamapediatrics.2013.2241; Kanerva M, 2011, J ANTIMICROB CHEMOTH, V66, P2651, DOI 10.1093/jac/dkr333; Kritsotakis EI, 2006, CLIN MICROBIOL INFEC, V12, P701, DOI 10.1111/j.1469-0691.2006.01415.x; Laupland KB, 2009, PEDIATR INFECT DIS J, V28, P114, DOI 10.1097/INF.0b013e318187ad5a; Le Doare K, 2015, J PEDIAT INF DIS SOC, V4, P11, DOI 10.1093/jpids/piu014; Llata E, 2009, CLIN INFECT DIS, V48, P1434, DOI 10.1086/598328; MacDougall C, 2008, INFECT CONT HOSP EP, V29, P203, DOI 10.1086/528810; Muller-Pebody B, 2011, ARCH DIS CHILD-FETAL, V96, pF4, DOI 10.1136/adc.2009.178483; Okeke IN, 2005, LANCET INFECT DIS, V5, P481, DOI 10.1016/S1473-3099(05)70189-4; Polk RE, 2011, CLIN INFECT DIS, V53, P1100, DOI 10.1093/cid/cir672; Raymond J, 2000, INFECT CONT HOSP EP, V21, P260, DOI 10.1086/501755; Robson MS., 2001, FETAL MAT MED REV, V12, P23, DOI [10.1017/S0965539501000122, DOI 10.1017/S0965539501000122]; Tokars JI, 2004, CLIN INFECT DIS, V39, P1347, DOI 10.1086/425000; Torloni MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014566; Versporten A, 2016, J ANTIMICROB CHEMOTH, V71, P1106, DOI 10.1093/jac/dkv418; Versporten A, 2013, PEDIATR INFECT DIS J, V32, pE242, DOI 10.1097/INF.0b013e318286c612; WHO Collaborating Centre for Drug Statistics Methodology, 2015, ATC DDD IND 2015; Wisplinghoff H, 2003, PEDIATR INFECT DIS J, V22, P686, DOI 10.1097/01.inf.0000078159.53132.40; World Health Organization, 2017, ESSE MED LIST; Zarb P, 2012, EURO SURVEILL, P17	30	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2018	13	7							e0199878	10.1371/journal.pone.0199878	http://dx.doi.org/10.1371/journal.pone.0199878			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM1FJ	29979795	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000437809500038
J	Conti, S; Vexler, A; Edry-Botzer, L; Kalich-Philosoph, L; Corn, BW; Shtraus, N; Meir, Y; Hagoel, L; Shtabsky, A; Marmor, S; Earon, G; Lev-Ari, S				Conti, Sefora; Vexler, Akiva; Edry-Botzer, Liat; Kalich-Philosoph, Lital; Corn, Benjamin W.; Shtraus, Natan; Meir, Yaron; Hagoel, Lior; Shtabsky, Alexander; Marmor, Sylvia; Earon, Gideon; Lev-Ari, Shahar			Combined acetyl-11-keto-beta-boswellic acid and radiation treatment inhibited glioblastoma tumor cells	PLOS ONE			English	Article							NF-KAPPA-B; BOSWELLIC ACIDS; IONIZING-RADIATION; MALIGNANT GLIOMA; TOPOISOMERASE-I; APOPTOSIS; ACTIVATION; CANCER; BCL-2; PATHWAY	Glioblastoma multiforme (GBM) is the most common and most aggressive subtype of malignant gliomas. The current standard of care for newly diagnosed GBM patients involves maximal surgical debulking, followed by radiation therapy and temozolomide chemotherapy. Despite the advances in GBM therapy, its outcome remains poor with a median survival of less than two years. This poor outcome is partly due to the ability of GBM tumors to acquire adaptive resistance to therapy and in particular to radiation. One of the mechanisms contributing to GBM tumor progression and resistance is an aberrant activation of NF-kappa B, a family of inducible transcription factors that play a pivotal role in regulation of many immune, inflammatory and carcinogenic responses. Acetyl-11-keto-beta-boswellic acid (AKBA) is a pentacyclic terpenoid extracted from the gum Ayurvedic therapeutic plant Boswellia serrata. AKBA is anti-inflammatory agent that exhibits potent cytotoxic activities against various types of tumors including GBM. One of the mechanisms underlying AKBA anti-tumor activity is its ability to modulate the NF-kappa B signaling pathway. The present study investigated in vitro and in vivo the effect of combining AKBA with ionizing radiation in the treatment of GBM and assessed AKBA anti-tumor activity and radio-enhancing potential. The effect of AKBA and/ or radiation on the survival of cultured glioblastoma cancer cells was evaluated by XTT assay. The mode of interaction of treatments tested was calculated using CalcuSyn software. Inducing of apoptosis following AKBA treatment was evaluated using flow cytometry. The effect of combined treatment on the expression of PARP protein was analysed by Western blot assay. Ectopic (subcutaneous) GBM model in nude mice was used for the evaluation of the effect of combined treatment on tumor growth. Immunohistochemical analysis of formalin-fixed paraffin-embedded tumor sections was used to assess treatment-related changes in Ki-67, CD31, rho 53, Bcl-2 and NF-kappa B-inhibitor I kappa B-alpha. AKBA treatment was found to inhibit the survival of all four tested cell lines in a dose dependent manner. The combined treatment resulted in a more significant inhibitory effect compared to the effect of treatment with radiation alone. A synergistic effect was detected in some of the tested cell lines. Flow Yytometric analysis with Annexin V-FITC/PI double staining of AKBA treated cells indicated induction of apoptosis. AKBA apoptotic activity was also confirmed by PARP cleavage detected by Western blot analysis. The combined treatment suppressed tumor growth in vivo compared to no treatment and each treatment alone. Immunohistochemical analysis showed anti-angiogenic and anti-proliferative activity of AKBA in vivo. It also demonstrated a decrease in p53 nuclear staining and in Bcl-2 staining and an increase in I kappa B-alpha staining following AKBA treatment both alone and in combination with radiotherapy. In this study, we demonstrated that AKBA exerts potent anti-proliferative and apoptotic activity, and significantly inhibits both the survival of glioblastoma cells in vitro and the growth of tumors generated by these cells. Combination of AKBA with radiotherapy was found to inhibit factors which involved in cell death regulation, tumor progression and radioresistence, therefore it may serve as a novel approach for GBM patients.	[Conti, Sefora; Vexler, Akiva; Edry-Botzer, Liat; Kalich-Philosoph, Lital; Hagoel, Lior; Earon, Gideon; Lev-Ari, Shahar] Tel Aviv Univ, Tel Aviv Med Ctr, Inst Oncol, Lab Herbal Med & Canc Res,Fac Med, Tel Aviv, Israel; [Corn, Benjamin W.; Shtraus, Natan; Meir, Yaron] Tel Aviv Univ, Tel Aviv Med Ctr, Inst Radiotherapy, Fac Med, Tel Aviv, Israel; [Shtabsky, Alexander; Marmor, Sylvia] Tel Aviv Univ, Tel Aviv Med Ctr, Pathol Dept, Fac Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Lev-Ari, S (corresponding author), Tel Aviv Univ, Tel Aviv Med Ctr, Inst Oncol, Lab Herbal Med & Canc Res,Fac Med, Tel Aviv, Israel.	Shaharl@tlvmc.gov.il		lev-ari, shahar/0000-0003-0187-9427	Chaya and Kadish Shermeister Endowment	Chaya and Kadish Shermeister Endowment	The study was supported by the Chaya and Kadish Shermeister Endowment.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed KM, 2008, FREE RADICAL BIO MED, V44, P1, DOI 10.1016/j.freeradbiomed.2007.09.022; Almasan A, 1997, INT J RADIAT ONCOL, V39, P178, DOI 10.1016/S0360-3016(97)80645-1; Ammon H P, 1996, Eur J Med Res, V1, P369; Barani IJ, 2015, CANCER TREAT RES, V163, P49, DOI 10.1007/978-3-319-12048-5_4; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Chashoo G, 2011, CHEM-BIOL INTERACT, V189, P60, DOI 10.1016/j.cbi.2010.10.017; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Feldman JP, 2009, J APPL QUANT METHODS, V4, P455, DOI DOI 10.1111/J.2042-3306.2010.TB05629.X; Friedman A, 2008, NATURE, V455, P1061, DOI DOI 10.1038/NATURE07385; Glaser T, 1999, BRIT J CANCER, V80, P756, DOI 10.1038/sj.bjc.6690419; Gupta I, 1997, Eur J Med Res, V2, P37; Hoernlein RF, 1999, J PHARMACOL EXP THER, V288, P613; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Kruger P, 2008, DRUG METAB DISPOS, V36, P1135, DOI 10.1124/dmd.107.018424; Li M, 2007, P NATL ACAD SCI USA, V104, P18636, DOI 10.1073/pnas.0709307104; Liu JJ, 2002, CARCINOGENESIS, V23, P2087, DOI 10.1093/carcin/23.12.2087; Liu JJ, 2002, INT J MOL MED, V10, P501; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Magne N, 2006, CANCER LETT, V231, P158, DOI 10.1016/j.canlet.2005.01.022; Mealey J, 1978, EVALUATION BCNU RADI, V49, P333; Pang XF, 2009, CANCER RES, V69, P5893, DOI 10.1158/0008-5472.CAN-09-0755; Park B, 2011, INT J CANCER, V129, P23, DOI 10.1002/ijc.25966; Park YS, 2002, PLANTA MED, V68, P397, DOI 10.1055/s-2002-32090; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; PAULL KD, 1988, J HETEROCYCLIC CHEM, V25, P911, DOI 10.1002/jhet.5570250340; Puliyappadamba VT, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963478; Puliyappadamba VT, 2013, CELL REP, V4, P764, DOI 10.1016/j.celrep.2013.07.025; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Suhail MM, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-129; Syrovets T, 2005, J BIOL CHEM, V280, P6170, DOI 10.1074/jbc.M409477200; Takada Y, 2015, ACETYL 11 KETO BETA; Toden S, 2015, CANCER PREV RES, V8, P431, DOI 10.1158/1940-6207.CAPR-14-0354; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Winking M, 2000, J NEURO-ONCOL, V46, P97, DOI 10.1023/A:1006387010528; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yamagishi JM N, 2009, INT J RADIAT BIOL, DOI [10.1080/095530097143374, DOI 10.1080/095530097143374]; Zhao WZ, 2003, CANCER DETECT PREV, V27, P67, DOI 10.1016/S0361-090X(02)00170-8	42	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2018	13	7							e0198627	10.1371/journal.pone.0198627	http://dx.doi.org/10.1371/journal.pone.0198627			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL5XD	29969452	Green Published, Green Submitted, gold			2023-01-03	WOS:000437246700004
J	Colby, DJ; Trautmann, L; Pinyakorn, S; Leyre, L; Pagliuzza, A; Kroon, E; Rolland, M; Takata, H; Buranapraditkun, S; Intasan, J; Chomchey, N; Muir, R; Haddad, EK; Tovanabutra, S; Ubolyam, S; Bolton, DL; Fullmer, BA; Gorelick, RJ; Fox, L; Crowell, TA; Trichavaroj, R; O'Connell, R; Chomont, N; Kim, JH; Michael, NL; Robb, ML; Phanuphak, N; Ananworanich, J				Colby, Donn J.; Trautmann, Lydie; Pinyakorn, Suteeraporn; Leyre, Louise; Pagliuzza, Amelie; Kroon, Eugene; Rolland, Morgane; Takata, Hiroshi; Buranapraditkun, Supranee; Intasan, Jintana; Chomchey, Nitiya; Muir, Roshell; Haddad, Elias K.; Tovanabutra, Sodsai; Ubolyam, Sasiwimol; Bolton, Diane L.; Fullmer, Brandie A.; Gorelick, Robert J.; Fox, Lawrence; Crowell, Trevor A.; Trichavaroj, Rapee; O'Connell, Robert; Chomont, Nicolas; Kim, Jerome H.; Michael, Nelson L.; Robb, Merlin L.; Phanuphak, Nittaya; Ananworanich, Jintanat		Rv411 Study Grp	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection	NATURE MEDICINE			English	Article							LATENT RESERVOIR; THERAPY; CELLS; PROLIFERATION; PERSISTENCE; MACAQUES; PLASMA	Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after analytical treatment interruption. We show that 8 participants, who initiated treatment during Fiebig I and were treated for a median of 2.8 years, all experienced rapid viral load rebound following analytical treatment interruption, indicating that additional strategies are required to control or eradicate HIV.	[Colby, Donn J.; Kroon, Eugene; Intasan, Jintana; Chomchey, Nitiya; Phanuphak, Nittaya; Ananworanich, Jintanat] Thai Red Cross AIDS Res Ctr, SEARCH, Bangkok, Thailand; [Trautmann, Lydie; Pinyakorn, Suteeraporn; Rolland, Morgane; Takata, Hiroshi; Buranapraditkun, Supranee; Tovanabutra, Sodsai; Bolton, Diane L.; Crowell, Trevor A.; Kim, Jerome H.; Michael, Nelson L.; Robb, Merlin L.; Ananworanich, Jintanat] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA; [Trautmann, Lydie; Pinyakorn, Suteeraporn; Rolland, Morgane; Takata, Hiroshi; Buranapraditkun, Supranee; Tovanabutra, Sodsai; Bolton, Diane L.; Crowell, Trevor A.; Robb, Merlin L.; Ananworanich, Jintanat] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA; [Leyre, Louise; Pagliuzza, Amelie; Chomont, Nicolas] Univ Montreal, Ctr Rech CHUM, Montreal, PQ, Canada; [Leyre, Louise; Pagliuzza, Amelie; Chomont, Nicolas] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Buranapraditkun, Supranee] Chulalongkorn Univ, Fac Med, Dept Med, Div Allergy & Clin Immunol, Bangkok, Thailand; [Buranapraditkun, Supranee] Chulalongkorn Univ, Fac Med, Chulalongkorn Vaccine Res Ctr, Bangkok, Thailand; [Muir, Roshell; Haddad, Elias K.] Drexel Univ, Coll Med, Dept Med, Div Infect Dis & HIV Med, Philadelphia, PA USA; [Ubolyam, Sasiwimol] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand; [Fullmer, Brandie A.; Gorelick, Robert J.] Leidos Biomed Res Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA; [Fox, Lawrence] NIAID, Div AIDS, Rockville, MD USA; [Trichavaroj, Rapee; O'Connell, Robert] Armed Forces Res Inst Med Sci United States Compo, Dept Retrovirol, Bangkok, Thailand; [Ananworanich, Jintanat] Univ Amsterdam, Dept Global Hlth, Amsterdam, Netherlands; [Kim, Jerome H.] Int Vaccine Inst, Seoul, South Korea; Yale Univ, Sch Med, Dept Neurol, New Haven, CT USA; Univ Calif San Francisco, San Francisco, CA USA; Natl Canc Ctr, NIH, CCR, Frederick, MD USA; NIAID, NIH, Bethesda, MD USA; Univ Missouri St Louis, Missouri Inst Mental Hlth, St Louis, MO USA; EMMES Corp, Rockville, MD USA	Thai Red Cross Society; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Universite de Montreal; Universite de Montreal; Chulalongkorn University; Chulalongkorn University; Drexel University; Thai Red Cross Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Amsterdam; International Vaccine Institute; Yale University; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Missouri System; University of Missouri Saint Louis; Emmes Corporation	Ananworanich, J (corresponding author), Thai Red Cross AIDS Res Ctr, SEARCH, Bangkok, Thailand.; Ananworanich, J (corresponding author), Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA.; Ananworanich, J (corresponding author), Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.; Ananworanich, J (corresponding author), Univ Amsterdam, Dept Global Hlth, Amsterdam, Netherlands.	jananworanich@hivresearch.org	Chomont, Nicolas/ABG-2545-2020; Crowell, Trevor A./W-3904-2019; Phanuphak, Nittaya/AAA-8579-2019; Ananworanich, Jintanat/AAC-6348-2021	Chomont, Nicolas/0000-0001-9747-5018; Crowell, Trevor A./0000-0001-5947-265X; Ananworanich, Jintanat/0000-0003-1369-3224; Subra, Caroline/0000-0001-5272-0972; Trautmann, Lydie/0000-0002-3012-0009; Takata, Hiroshi/0000-0003-1457-6919; colby, donn j./0000-0003-3931-5926	NIH [R01AI108433]; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]; U.S. Department of Defense (DoD) [W81XWH-07-2-0067]; Division of AIDS at the U.S. National Institute of Allergy and Infectious Diseases [W81XWH-07-2-0067]; Thai Red Cross AIDS Research Centre; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI108433] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.; U.S. Department of Defense (DoD)(United States Department of Defense); Division of AIDS at the U.S. National Institute of Allergy and Infectious Diseases; Thai Red Cross AIDS Research Centre; National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to the participants who have made this research possible. We thank T. Schacker for providing data on the lymph nodes from one participant. This work was supported by the NIH grant R01AI108433, a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the U.S. Department of Defense (DoD), the Division of AIDS at the U.S. National Institute of Allergy and Infectious Diseases, and by an intramural grant from the Thai Red Cross AIDS Research Centre. The US Army Medical Research Acquisition Activity (820 Chandler Street, Fort Detrick, MD 21702-5014, USA) is the awarding and administering acquisition office for the cooperative agreement. It is also supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. Antiretroviral therapy was supported by the Thai Government Pharmaceutical Organization, Gilead, Merck and ViiV Healthcare. The views expressed are those of the authors. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, the US Army, or the Department of Defense, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government, including the US National Institutes of Health.	Altman JD, 2011, J IMMUNOL, V187; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Bolton DL, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006445; Bruner KM, 2016, NAT MED, V22, P1043, DOI 10.1038/nm.4156; Byrareddy SN, 2016, SCIENCE, V354, P197, DOI 10.1126/science.aag1276; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Conway JM, 2015, P NATL ACAD SCI USA, V112, P5467, DOI 10.1073/pnas.1419162112; Cubas RA, 2013, NAT MED, V19, P494, DOI 10.1038/nm.3109; De Souza MS, 2015, AIDS, V29, P793, DOI 10.1097/QAD.0000000000000616; Deeks SG, 2016, NAT MED, V22, P839, DOI 10.1038/nm.4108; Deleage Claire, 2016, Pathog Immun, V1, P68; Dominguez MH, 2013, J IMMUNOL METHODS, V391, P133, DOI 10.1016/j.jim.2013.03.002; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Heipertz RA, 2013, AIDS RES HUM RETROV, V29, P1310, DOI [10.1089/AID.2013.0087, 10.1089/aid.2013.0087]; Hessell AJ, 2016, NAT MED, V22, P362, DOI 10.1038/nm.4063; Hill AL, 2014, P NATL ACAD SCI USA, V111, P13475, DOI 10.1073/pnas.1406663111; Hurst J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9495; Land S, 2009, J VIROL METHODS, V159, P185, DOI 10.1016/j.jviromet.2009.03.016; Muir R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005777; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Procopio F. A., EBIOMEDICINE, V2; Rhee SY, 2017, EBIOMEDICINE, V18, P225, DOI 10.1016/j.ebiom.2017.03.024; Rothenberger MK, 2015, P NATL ACAD SCI USA, V112, pE1126, DOI 10.1073/pnas.1414926112; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; Schuetz A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004543; Simonetti FR, 2016, P NATL ACAD SCI USA, V113, P1883, DOI 10.1073/pnas.1522675113; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848; Somsouk M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116306; Takata H, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1809; Vandergeeten C, 2014, J VIROL, V88, P12385, DOI 10.1128/JVI.00609-14; Wagner TA, 2014, SCIENCE, V345, P570, DOI 10.1126/science.1256304; Williams JP, 2014, ELIFE, V3, DOI 10.7554/eLife.03821	35	172	174	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2018	24	7					923	+		10.1038/s41591-018-0026-6	http://dx.doi.org/10.1038/s41591-018-0026-6			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GM5NV	29892063	Green Accepted			2023-01-03	WOS:000438187700018
J	Langerud, AK; Rustoen, T; Smastuen, MC; Kongsgaard, U; Stubhaug, A				Langerud, Anne Kathrine; Rustoen, Tone; Smastuen, Milada Cvancarova; Kongsgaard, Ulf; Stubhaug, Audun			Health-related quality of life in intensive care survivors: Associations with social support, comorbidity, and pain interference	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; SCORE SAPS-II; CRITICAL ILLNESS; LONG-TERM; PREEXISTING DISEASE; FOLLOW-UP; CANCER; UNIT; ICU; VALIDATION	Background Experiences during a stay in the intensive care unit (ICU), including pain, delirium, physical deterioration, and the critical illness itself, may all influence survivors' health-related quality of life (HRQOL). However, few studies have examined the influence of social support, comorbidity, and pain interference on ICU survivors' HRQOL. Objectives To investigate possible associations between social support, number of comorbidities, and pain interference on HRQOL in ICU survivors. Methods ICU survivors responded to a survey 3 months (n = 118) and 1 year (n = 89) after ICU discharge. HRQOL was measured using the Short Form Health Survey-12 (v1), social support using the revised Social Provision Scale, pain interference using the Brief Pain Inventory-Short Form, and comorbidities using the Self-Administered Comorbidity Questionnaire. Results Physical and mental HRQOL were reduced at both 3 months and 1 year in ICU survivors compared with the general population. This reduction was more pronounced at 3 months for physical HRQOL, while a small reduction in mental HRQOL was not clinically relevant. Social support was statistical significantly positively associated with mental HRQOL at 3 months, while number of comorbidities was statistical significantly associated with a reduction in physical HRQOL at 3 months and 1 year and mental HRQOL at 1 year. Lastly pain interference was significantly associated with a reduction in physical HRQOL at 3 months and 1 year. Conclusions ICU survivors primarily report reduced physical HRQOL. Social support was positively associated with mental HRQOL, while number of comorbidities, and pain interference were all significantly associated with a reduction in HRQOL. Pain interference was associated with the largest reduction in HRQOL.	[Langerud, Anne Kathrine; Rustoen, Tone] Oslo Univ Hosp, Dept Res & Dev, Div Emergencies & Crit Care, Oslo, Norway; [Langerud, Anne Kathrine] Oslo Univ Hosp, Rikshosp, Dept Postoperat & Crit Care, Div Emergencies & Crit Care, Oslo, Norway; [Langerud, Anne Kathrine; Kongsgaard, Ulf; Stubhaug, Audun] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Rustoen, Tone] Univ Oslo, Fac Med, Inst Hlth & Soc, Dept Nursing Sci, Oslo, Norway; [Smastuen, Milada Cvancarova] Oslo Metropolitan Univ, Fac Hlth Sci, Oslo, Norway; [Kongsgaard, Ulf] Oslo Univ Hosp, Radiumhospit, Dept Anesthesiol, Div Emergencies & Crit Care, Oslo, Norway; [Stubhaug, Audun] Oslo Univ Hosp, Dept Pain Management & Res, Div Emergencies & Crit Care, Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; Oslo Metropolitan University (OsloMet); University of Oslo; University of Oslo	Langerud, AK (corresponding author), Oslo Univ Hosp, Dept Res & Dev, Div Emergencies & Crit Care, Oslo, Norway.; Langerud, AK (corresponding author), Oslo Univ Hosp, Rikshosp, Dept Postoperat & Crit Care, Div Emergencies & Crit Care, Oslo, Norway.; Langerud, AK (corresponding author), Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway.	alangeru@ous-hf.no			Oslo University Hospital, Department of Research and Development, Division of Emergencies and Critical Care	Oslo University Hospital, Department of Research and Development, Division of Emergencies and Critical Care	The first author was funded by internal funding from Oslo University Hospital, Department of Research and Development, Division of Emergencies and Critical Care. The funder had no role in the study.	Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; Astrup GL, 2015, PAIN, V156, P967, DOI 10.1097/j.pain.0000000000000142; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Battle CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116304; Berntzen H, 2018, J CLIN NURS, V27, pE223, DOI 10.1111/jocn.13920; Bondevik M, 1997, LIFE OLDEST OLD STUD; Boyko Y, 2012, ACTA ANAESTH SCAND, V56, P950, DOI 10.1111/j.1399-6576.2012.02672.x; Boyle Martin, 2004, Aust Crit Care, V17, P104, DOI 10.1016/S1036-7314(04)80012-2; Brinkman S, 2013, INTENS CARE MED, V39, P1925, DOI 10.1007/s00134-013-3042-5; Cella D, 2002, MAYO CLIN PROC, V77, P384, DOI 10.4065/77.4.384; Chaboyer W, 2000, Intensive Crit Care Nurs, V16, P88, DOI 10.1054/iccn.1999.1582; Christensen VL, 2016, PAIN MANAG NURS, V17, P107, DOI 10.1016/j.pmn.2016.01.002; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; CONSTABLE JF, 1986, J HUM STRESS, V12, P20, DOI 10.1080/0097840X.1986.9936762; Cuthbertson BH, 2005, ANAESTHESIA, V60, P332, DOI 10.1111/j.1365-2044.2004.04109.x; CUTRONA CE, 1984, J ABNORM PSYCHOL, V93, P378, DOI 10.1037/0021-843X.93.4.378; CUTRONA CE, 1986, J PERS SOC PSYCHOL, V50, P349, DOI 10.1037/0022-3514.50.2.349; Cutrona CE, 1987, ADV PERSONAL RELATIO, P37; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Duggan MC, 2017, J CRIT CARE, V37, P72, DOI 10.1016/j.jcrc.2016.08.023; Elliott R, 2014, INTENS CRIT CARE NUR, V30, P246, DOI 10.1016/j.iccn.2014.04.003; Ferrans C E, 1992, Prog Cardiovasc Nurs, V7, P2; Ferrans C E, 1990, Semin Oncol Nurs, V6, P248, DOI 10.1016/0749-2081(90)90026-2; Flaatten H, 2001, INTENS CARE MED, V27, P1005, DOI 10.1007/s001340100960; Gandek B, 1998, J CLIN EPIDEMIOL; Granja C, 2005, CRIT CARE, V9, pR96, DOI 10.1186/cc3026; Griffiths RD, 1999, BRIT MED J, V319, P427, DOI 10.1136/bmj.319.7207.427; Griffiths RD, 2011, AM J RESP CRIT CARE, V183, P833, DOI 10.1164/rccm.201012-1988ED; Hermans G, 2014, INTERVENTIONS PREVEN, V2014, DOI [10.1002/14651858.CD006832.pub3, DOI 10.1002/14651858.CD006832.PUB3]; Hofhuis JGM, 2015, INTENS CARE MED, V41, P495, DOI 10.1007/s00134-015-3669-5; Hofhuis JGM, 2009, CURR OPIN CRIT CARE, V15, P425, DOI 10.1097/MCC.0b013e32833079e4; Hough CL, 2012, CURR OPIN CRIT CARE, V18, P8, DOI 10.1097/MCC.0b013e32834f186d; Hui DS, 2005, CHEST, V128, P2247, DOI 10.1378/chest.128.4.2247; Johansen C, 2007, ACTA ONCOL, V46, P441, DOI 10.1080/02841860701316057; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; Klepstad P, 2002, J PAIN SYMPTOM MANAG, V24, P517, DOI 10.1016/S0885-3924(02)00526-2; Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390; Kroenke K, 2012, J PAIN, V13, P764, DOI 10.1016/j.jpain.2012.05.004; Langerud AK, 2018, PAIN MANAG NURS, V19, P366, DOI 10.1016/j.pmn.2017.11.005; Langerud AK, 2018, NURS CRIT CARE, V23, P48, DOI 10.1111/nicc.12330; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Orwelius L, 2005, CRIT CARE MED, V33, P1557, DOI 10.1097/01.CCM.0000168208.32006.1C; Orwelius L, 2010, CRIT CARE, V14, DOI 10.1186/cc8967; Pisani MA, 2015, AM J RESP CRIT CARE, V191, P731, DOI 10.1164/rccm.201411-2099CI; Ratzer M, 2014, HEALTH PSYCHOL BEHAV, V2, P882, DOI 10.1080/21642850.2014.943760; RUSSELL D, 1984, J PERS SOC PSYCHOL, V46, P1313, DOI 10.1037/0022-3514.46.6.1313; RUSSELL DW, 1987, J APPL PSYCHOL, V72, P269, DOI 10.1037/0021-9010.72.2.269; Sangha O, 2003, ARTHRIT RHEUM-ARTHR, V49, P156, DOI 10.1002/art.10993; Schuster HP, 1997, INTENS CARE MED, V23, P1056, DOI 10.1007/s001340050456; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Shen B J, 2005, Eura Medicophys, V41, P75; Soliman IW, 2015, J CRIT CARE, V30, P181, DOI 10.1016/j.jcrc.2014.09.009; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Stricker KH, 2011, J CRIT CARE, V26, P379, DOI 10.1016/j.jcrc.2010.11.004; Svenningsen H, 2017, NURS CRIT CARE, V22, P212, DOI 10.1111/nicc.12165; Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005; Tilburgs B, 2015, INTENS CRIT CARE NUR, V31, P336, DOI 10.1016/j.iccn.2015.07.002; Timmers TK, 2011, ANN SURG, V253, P151, DOI 10.1097/SLA.0b013e3181ff45df; Varricchio Claudette G, 2010, Semin Oncol Nurs, V26, P12, DOI 10.1016/j.soncn.2009.11.003; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Ware J., 1998, SF 12 SCORE SF 12 PH; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Wu JSY, 2010, J PAIN SYMPTOM MANAG, V39, P230, DOI 10.1016/j.jpainsymman.2009.07.006	67	14	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2018	13	6							e0199656	10.1371/journal.pone.0199656	http://dx.doi.org/10.1371/journal.pone.0199656			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK3YY	29940026	Green Submitted, Green Published, gold			2023-01-03	WOS:000436088700032
J	Barrett, B; Hayney, MS; Muller, D; Rakel, D; Brown, R; Zgierska, AE; Barlow, S; Hayer, S; Barnet, JH; Torres, ER; Coe, CL				Barrett, Bruce; Hayney, Mary S.; Muller, Daniel; Rakel, David; Brown, Roger; Zgierska, Aleksandra E.; Barlow, Shari; Hayer, Supriya; Barnet, Jodi H.; Torres, Elisa R.; Coe, Christopher L.			Meditation or exercise for preventing acute respiratory infection (MEPARI-2): A randomized controlled trial	PLOS ONE			English	Article							SUFFICIENTLY IMPORTANT DIFFERENCE; MINDFULNESS-BASED INTERVENTIONS; COMMON COLD; PHYSICAL-ACTIVITY; INFLUENZA VACCINATION; COGNITIVE THERAPY; CARDIOVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; PSYCHOLOGICAL STRESS; DEPRESSIVE RELAPSE	Background Practice of meditation or exercise may enhance health to protect against acute infectious illness. Objective To assess preventive effects of meditation and exercise on acute respiratory infection (ARI) illness. Design Randomized controlled prevention trial with three parallel groups. Setting Madison, Wisconsin, USA. Participants Community-recruited adults who did not regularly exercise or meditate. Methods 1) 8-week behavioral training in mindfulness-based stress reduction (MBSR); 2) matched 8-week training in moderate intensity sustained exercise (EX); or 3) observational waitlist control. Training classes occurred in September and October, with weekly ARI surveillance through May. Incidence, duration, and area-under-curve ARI global severity were measured using daily reports on the WURSS-24 during ARI illness. Viruses were identified multiplex PCR. Absenteeism, health care utilization, and psychosocial health self-report assessments were also employed. Results Of 413 participants randomized, 390 completed the trial. In the MBSR group, 74 experienced 112 ARI episodes with 1045 days of ARI illness. Among exercisers, 84 had 120 episodes totaling 1010 illness days. Eighty-two of the controls had 134 episodes with 1210 days of ARI illness. Mean global severity was 315 for MBSR (95% confidence interval 244, 386), 256 (193, 318) for EX, and 336 (268, 403) for controls. A prespecified multivariate zero-inflated regression model suggested reduced incidence for MBSR (p = 0.036) and lower global severity for EX (p = 0.042), compared to control, not quite attaining the p<0.025 prespecified cut-off for null hypothesis rejection. There were 73 ARI-related missed-work days and 22 ARI-related health care visits in the MBSR group, 82 days and 21 visits for exercisers, and 105 days and 24 visits among controls. Viruses were identified in 63 ARI episodes in the MBSR group, compared to 64 for EX and 72 for control. Statistically significant (p<0.05) improvements in general mental health, self-efficacy, mindful attention, sleep quality, perceived stress, and depressive symptoms were observed in the MBSR and/or EX groups, compared to control. Conclusions Training in mindfulness meditation or exercise may help protect against ARI illness. Limitations This trial was likely underpowered.	[Barrett, Bruce; Zgierska, Aleksandra E.; Barlow, Shari; Hayer, Supriya; Barnet, Jodi H.] Univ Wisconsin, Dept Family Med & Community Hlth, Madison, WI 53706 USA; [Hayney, Mary S.] Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA; [Muller, Daniel] Univ Colorado, Dept Med, Rheumatol Div, Ft Collins, CO USA; [Rakel, David] Univ New Mexico, Dept Family & Community Hlth, Albuquerque, NM 87131 USA; [Brown, Roger] Univ Wisconsin, Sch Nursing, Design & Stat Unit, Madison, WI USA; [Barnet, Jodi H.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA; [Torres, Elisa R.] Univ Mississippi, Sch Nursing, Med Ctr, Madison, WI USA; [Coe, Christopher L.] Univ Wisconsin, Dept Psychol, Harlow Ctr Biol Psychol, 1202 W Johnson St, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of New Mexico; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Mississippi Medical Center; University of Wisconsin System; University of Wisconsin Madison	Barrett, B (corresponding author), Univ Wisconsin, Dept Family Med & Community Hlth, Madison, WI 53706 USA.	bruce.barrett@fammed.wisc.edu		Torres, Elisa/0000-0003-0064-2540; Zgierska, Aleksandra/0000-0002-7773-6003; Barrett, Bruce/0000-0002-3953-4718	National Center for Complementary and Integrative Health (NCCIH) at the U.S. National Institutes of Health [R01AT006970]; NCCIH [K24AT006543, T32AT006956]; Clinical and Translational Science Award (CTSA) through the National Center for Advancing Translational Sciences (NCATS) [UL1TR000427, KL2TR000428]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000428, UL1TR000427] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT006543, R01AT006970, T32AT006956] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health (NCCIH) at the U.S. National Institutes of Health; NCCIH; Clinical and Translational Science Award (CTSA) through the National Center for Advancing Translational Sciences (NCATS); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The data presented are from MEPARI-2 (Meditation or Exercise for Preventing Acute Respiratory Infection), a randomized controlled trial sponsored by the National Center for Complementary and Integrative Health (NCCIH) at the U.S. National Institutes of Health (R01AT006970) - nccih.nih.gov. During the trial and writing of this paper Bruce Barrett was supported by a mid-career research and mentoring grant from NCCIH (K24AT006543)- nccih.nih.gov; Supriya Hayer received support from a research training grant from NCCIH (T32AT006956) directed by Dr. Barrett. MEPARI-2 received some support from a Clinical and Translational Science Award (CTSA) through the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427, which also provided research career development support to Elisa Torres (KL2TR000428) - ncats.nih.gov. The funders of the study approved the study design, but had no role in data collection, analysis, interpretation, or writing of this report. The lead author was principal investigator and had full access to all the data in the study and had final responsibility for the decision to submit for publication.; The data presented are from MEPARI-2 (Meditation or Exercise for Preventing Acute Respiratory Infection), a randomized controlled trial sponsored by the National Center for Complementary and Integrative Health (NCCIH) at the U.S. National Institutes of Health (R01AT006970). The trial was registered at ClinicalTrials.gov (NCT01654289) on 19 July 2012, before the first participant was enrolled 1 August 2012. During the trial and writing of this paper Bruce Barrett was supported by a mid-career research and mentoring grant from NCCIH (K24AT006543); Supriya Hayer received support from a research training grant from NCCIH (T32AT006956) directed by Dr. Barrett. MEPARI-2 received some support from a Clinical and Translational Science Award (CTSA) through the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427, which also provided research career development support to Elisa Torres (KL2TR000428). We wish to thank Amber Schemmel and Joseph Chase for assisting with data collection, the UW Integrative Health MBSR instructors, the UW Sports Medicine exercise instructors, and the 413 research participants.	Abbott RA, 2014, J PSYCHOSOM RES, V76, P341, DOI 10.1016/j.jpsychores.2014.02.012; Adam Y, 2013, J PSYCHOSOM RES, V74, P69, DOI 10.1016/j.jpsychores.2012.08.013; [Anonymous], 2007, CIRCULATION, DOI DOI 10.1161/CIRCULATIONAHA.107.185649; Aquino-Russell C, 2014, CIRCULATION, V130; Arinaminpathy N, 2017, AM J EPIDEMIOL, V186, P92, DOI 10.1093/aje/kwx037; Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329; Barrett B, 2005, MED DECIS MAKING, V25, P250, DOI 10.1177/0272989X05276863; Barrett B, 2005, J CLIN EPIDEMIOL, V58, P609, DOI 10.1016/j.jclinepi.2004.11.019; Barrett B, 2005, MED DECIS MAKING, V25, P47, DOI 10.1177/0272989X04273147; Barrett B, 2007, ANN FAM MED, V5, P216, DOI 10.1370/afm.698; Barrett B, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-76; Barrett B, 2013, MED DECIS MAKING, V33, P869, DOI 10.1177/0272989X13476764; Barrett B, 2012, ANN FAM MED, V10, P337, DOI 10.1370/afm.1376; Barrett Bruce, 2007, WMJ, V106, P473; Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655; Brissette I, 2000, SOCIAL SUPPORT MEASU, P53, DOI DOI 10.1093/MED:PSYCH/9780195126709.003.0003; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Brown R. L., 2016, J LUNG PULMONARY RES, V3, P00076, DOI [10.15406/jlprr.2015.03.00076, DOI 10.15406/JLPRR.2015.03.00076]; Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790; Buysse D J, 1989, Psychiatry Res, V28, P193; Byington CL, 2015, CLIN INFECT DIS, V61, P1217, DOI 10.1093/cid/civ486; Cayoun B. A., 2004, MINDFULNESS BASED SE; Centers for Disease Control and Prevention and Department of Health and Human Services, 2005, BEH RISK FACT SURV S; Chubak J, 2006, AM J MED, V119, P937, DOI 10.1016/j.amjmed.2006.06.033; Cobb JMT, 1996, PSYCHOSOM MED, V58, P404, DOI 10.1097/00006842-199609000-00003; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; Cohen S, 2002, PSYCHOSOM MED, V64, P302, DOI 10.1097/00006842-200203000-00014; Cohen S, 2003, PSYCHOSOM MED, V65, P652, DOI 10.1097/01.PSY.0000077508.57784.DA; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 2012, J APPL SOC PSYCHOL, V42, P1320, DOI 10.1111/j.1559-1816.2012.00900.x; Cutrona CE, 1987, ADV PERSONAL RELATIO, P37; de Boer PT, 2017, EXPERT REV PHARM OUT, V17, P249, DOI 10.1080/14737167.2017.1343145; Doyle WJ, 2006, BRAIN BEHAV IMMUN, V20, P175, DOI 10.1016/j.bbi.2005.05.005; Everett B, 2009, INT J NURS STUD, V46, P824, DOI 10.1016/j.ijnurstu.2009.01.016; Fan VS, 2002, J CLIN EPIDEMIOL, V55, P371, DOI 10.1016/S0895-4356(01)00493-0; Ferreira ML, 2013, J CLIN EPIDEMIOL, V66, P1397, DOI 10.1016/j.jclinepi.2013.02.018; Fowlkes A, 2014, J INFECT DIS, V209, P1715, DOI 10.1093/infdis/jit806; Gandek B., USERS MANUAL SF 12V2; Gatwood J, 2012, DRUGS, V72, P35, DOI 10.2165/11597310-000000000-00000; Goyal M., 2014, COMP EFFECTIVENESS R, V124, P1; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; GRAHAM NMH, 1986, AM J EPIDEMIOL, V124, P389, DOI 10.1093/oxfordjournals.aje.a114409; Grande AJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010596.pub2; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Hayney MS, 2014, HUM VACC IMMUNOTHER, V10, P83, DOI 10.4161/hv.26661; Henriquez KM, 2016, VIRAL IMMUNOL, V29, P128, DOI 10.1089/vim.2015.0106; JACKSON GG, 1960, ANN INTERN MED, V53, P719, DOI 10.7326/0003-4819-53-4-719; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; John O. P., 2008, HDB PERSONALITY THEO, P114158, DOI DOI 10.1016/S0191-8869(97)81000-8; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; Kodama S, 2013, DIABETES CARE, V36, P471, DOI 10.2337/dc12-0783; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kuyken W, 2016, JAMA PSYCHIAT, V73, P565, DOI 10.1001/jamapsychiatry.2016.0076; Kuyken W, 2015, LANCET, V386, P63, DOI 10.1016/S0140-6736(14)62222-4; Kyu HH, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3857; Lavie CJ, 2016, CAN J CARDIOL, V32, pS365, DOI 10.1016/j.cjca.2016.07.508; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Loucks EB, 2016, AM J HEALTH BEHAV, V40, P258, DOI 10.5993/AJHB.40.2.11; Maxwell Lizzie, 2015, WMJ, V114, P100; Miller CK, 2014, HEALTH EDUC BEHAV, V41, P145, DOI 10.1177/1090198113493092; Mohren DCL, 2001, J PSYCHOSOM RES, V50, P21, DOI 10.1016/S0022-3999(00)00212-9; Nieman DC, 2011, AM J LIFESTYLE MED, V5, P338, DOI 10.1177/1559827610392876; Obasi CN, 2013, INFLUENZA OTHER RESP, V7, P938, DOI 10.1111/irv.12053; Postma MJ, 2000, DRUG AGING, V17, P217, DOI 10.2165/00002512-200017030-00005; Rakel D, 2013, FAM PRACT, V30, P390, DOI 10.1093/fampra/cmt008; Rebar AL, 2015, HEALTH PSYCHOL REV, V9, P366, DOI 10.1080/17437199.2015.1022901; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Shomaker LB, 2017, DEPRESS ANXIETY, V34, P866, DOI 10.1002/da.22617; Smith AP, 2013, PSYCHONEUROENDOCRINO, V38, P744, DOI 10.1016/j.psyneuen.2012.09.002; Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009; STONE AA, 1992, BEHAV MED, V18, P115, DOI 10.1080/08964289.1992.9936961; Takkouche B, 2001, EPIDEMIOLOGY, V12, P345, DOI 10.1097/00001648-200105000-00015; Teixeira RB, 2015, DIABETES VASC DIS RE, V12, P445, DOI 10.1177/1479164115602651; Turner D, 2010, J CLIN EPIDEMIOL, V63, P28, DOI 10.1016/j.jclinepi.2009.01.024; Umpierre D, 2011, JAMA-J AM MED ASSOC, V305, P1790, DOI 10.1001/jama.2011.576; Veehof MM, 2016, COGN BEHAV THERAPY, V45, P5, DOI 10.1080/16506073.2015.1098724; Violan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102149; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Yang Y, 2010, COMPUT STAT DATA AN, V54, P1525, DOI 10.1016/j.csda.2009.12.012; Zgierska A, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/952716; Zimmerman RK, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0806-2	83	32	32	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2018	13	6							e0197778	10.1371/journal.pone.0197778	http://dx.doi.org/10.1371/journal.pone.0197778			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK3VI	29933369	Green Submitted, Green Published, gold			2023-01-03	WOS:000436076600004
J	Tsai, WC; Kung, PT; Wang, YH; Kuo, WY; Li, YH				Tsai, Wen-Chen; Kung, Pei-Tseng; Wang, Yueh-Hsin; Kuo, Wei-Yin; Li, Ya-Hsin			Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer	PLOS ONE			English	Article							NATIONAL-HEALTH INSURANCE; PRIMARY BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CERVICAL-CANCER; SOCIOECONOMIC-STATUS; DELAYED DIAGNOSIS; UNITED-STATES; NECK-CANCER; TAIWAN; MORTALITY	Objectives Liver cancer is the fifth most common cancer in men and the ninth most common cancer in women, and the WHO expects that there will be 1,341,344 cases in 2034 worldwide. Liver cancer also has the second-highest cancer death rate, accounting for 7% of all cancers. The study is going to explore the relationship between time interval from diagnosis to treatment and survival status of early-stage liver cancer patients. Materials and methods This is a retrospective cohort study using the national database from Taiwan. The datasets include the Taiwan Cancer Registry Database (TCR), the National Health Insurance Research Database (NHIRD), and the National Registry of Deaths. The target population for the study was patients newly diagnosed with stage I and stage II liver cancer between the years 2004 and 2010. Total of 26,038 cases were included in the study. Except descriptive analysis, the relationship between patient characteristics and the time interval from diagnosis to treatment was examined by chi-square tests. In addition, modified Cox proportional hazard models were used to analyze the hazard ratio of patient death with various treatment delay durations. Results There were 20,430 patients (78.46%) who received treatment less than 30 days after diagnosis, while 2,674 patients (10.27%) received treatment between 31 and 60 days after diagnosis, and 2,068 patients (7.94%) received treatment between 61 and 180 days after diagnosis, and 866 patients (3.33%) who received treatment 181 days after diagnosis. Those treated more than 181 days and 61 +/- 180 days after diagnosis had a 1.68-fold increased risk of death (95% confidence interval: 1.50 +/- 1.88) and a 1.39-fold increased risk of death (95% confidence interval: 1.31 +/- 1.17), respectively. Being male, being elderly, having a higher CCI level, and being treated in a hospital with a low service volume were factors associated with a poorer prognosis. Conclusion Overall, this study utilized a national cohort to conclude that for early-stage liver cancer patients, a longer the time interval from diagnosis to treatment results in a lower survival rate.	[Tsai, Wen-Chen; Wang, Yueh-Hsin; Kuo, Wei-Yin] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Kung, Pei-Tseng] Asia Univ, Dept Healthcare Adm, Taichung, Taiwan; [Li, Ya-Hsin] Chung Shan Med Univ, Chung Shan Med Univ Hosp, Dept Hlth Policy & Management, Taichung, Taiwan	China Medical University Taiwan; Asia University Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Li, YH (corresponding author), Chung Shan Med Univ, Chung Shan Med Univ Hosp, Dept Hlth Policy & Management, Taichung, Taiwan.	yli@csmu.edu.tw	Tsai, Wen-Chen/O-3095-2015	Tsai, Wen-Chen/0000-0002-9684-0789; Wang, Yueh-Hsin/0000-0002-1282-5945	Ministry of Science and Technology, Taiwan [MOST 104-2410-H-039-002]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by Ministry of Science and Technology, Taiwan (MOST 104-2410-H-039-002), https://www.most.gov.tw/.	AFZELIUS P, 1994, ACTA ONCOL, V33, P345, DOI 10.3109/02841869409098427; Akram M, 2014, INT J PREVENTIVE MED, V5, P915; Artinyan A, 2010, CANCER-AM CANCER SOC, V116, P1367, DOI 10.1002/cncr.24817; Bilimoria KY, 2011, ANN SURG, V253, P779, DOI 10.1097/SLA.0b013e318211cc0f; Cance WG, 2000, CANCER, V88, P912, DOI 10.1002/(SICI)1097-0142(20000215)88:4<912::AID-CNCR23>3.0.CO;2-T; Caplan LS, 2000, AM J PUBLIC HEALTH, V90, P130, DOI 10.2105/AJPH.90.1.130; Chen Tzeng-Ji, 2007, J Chin Med Assoc, V70, P110; Chiang CJ, 2015, JPN J CLIN ONCOL, V45, P291, DOI 10.1093/jjco/hyu211; Chiang CJ, 2010, JPN J CLIN ONCOL, V40, P897, DOI 10.1093/jjco/hyq057; Chiou SJ, 2008, AM J MANAG CARE, V18, P488; Chu TB, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-60; Chuang YC, 2008, SOC SCI MED, V67, P1321, DOI 10.1016/j.socscimed.2008.06.033; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FISHER B, 1977, CANCER-AM CANCER SOC, V39, P2827, DOI 10.1002/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO;2-I; Gau CS, 2007, PHARMACOEPIDEM DR S, V16, P86, DOI 10.1002/pds.1324; Griffiths RI, 2014, INT J BREAST CANCER, V2014, DOI 10.1155/2014/970780; Gullatte Mary Magee, 2006, J Natl Black Nurses Assoc, V17, P45; Gyenwali D, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-29; Gyenwali D, 2013, ASIAN PAC J CANCER P, V14, P4373, DOI 10.7314/APJCP.2013.14.7.4373; Hsiao YY, 2013, INT J QUAL HEALTH C, V25, P232, DOI 10.1093/intqhc/mzt029; Hu R, 2003, SURGERY, V133, P251, DOI 10.1067/msy.2003.102; Huo TI, 2007, SCAND J GASTROENTERO, V42, P485, DOI 10.1080/00365520600931402; Joshi S, 2008, PUBLIC HEALTH, V122, P1144, DOI 10.1016/j.puhe.2008.04.003; Kiderlen M, 2013, ANN ONCOL, V24, P3011, DOI 10.1093/annonc/mdt367; KO YC, 1992, J ORAL PATHOL MED, V21, P261, DOI 10.1111/j.1600-0714.1992.tb01007.x; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; Liu CY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-446; Memon ZA, 2013, ASIAN PAC J CANCER P, V14, P7409, DOI 10.7314/APJCP.2013.14.12.7409; Montella M, 2001, EUR J CANCER PREV, V10, P53, DOI 10.1097/00008469-200102000-00006; Murphy CT, 2016, J CLIN ONCOL, V34, P169, DOI 10.1200/JCO.2015.61.5906; Noonan B, 2014, EUR J ONCOL NURS, V18, P118, DOI 10.1016/j.ejon.2013.07.005; Norsa'adah B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-141; Pack G. T., 1938, AM J CANCER, V33, P443, DOI DOI 10.1158/AJC.1938.443; Patnaik JL, 2011, JNCI-J NATL CANCER I, V103, P1101, DOI 10.1093/jnci/djr188; Poum A, 2014, J EPIDEMIOL, V24, P102, DOI 10.2188/jea.JE20130090; PRESSMAN PI, 1983, ARCH SURG-CHICAGO, V118, P992; ROSSI S, 1990, TUMORI, V76, P559, DOI 10.1177/030089169007600609; Singal AG, 2013, J NATL COMPR CANC NE, V11, P1101, DOI 10.6004/jnccn.2013.0131; Smith D, 1996, AUST NZ J PUBL HEAL, V20, P129, DOI 10.1111/j.1753-6405.1996.tb01806.x; Sogaard Mette, 2013, Clin Epidemiol, V5, P3, DOI 10.2147/CLEP.S47150; Tsai WC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175148; van Harten MC, 2015, ORAL ONCOL, V51, P272, DOI 10.1016/j.oraloncology.2014.12.003; World Health Organization Mortality Database, 2017, WHO STAT INF SYST; Yu T, 2008, J CAN DENT ASSOC, V74, P61	44	35	35	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2018	13	6							e0199532	10.1371/journal.pone.0199532	http://dx.doi.org/10.1371/journal.pone.0199532			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK3VI	29933395	gold, Green Published, Green Submitted			2023-01-03	WOS:000436076600029
J	da Rosa, CVD; de Campos, JM; Nakanishi, ABD; Comar, JF; Martine, IP; Mathias, PCD; Pedrosa, MMD; de Godoi, VAF; Natali, MRM				Dalto da Rosa, Carlos Vinicius; de Campos, Jessica Men; de Sa Nakanishi, Anacharis Babeto; Comar, Jurandir Fernando; Martine, Isabela Peixoto; de Freitas Mathias, Paulo Cezar; Diaz Pedrosa, Maria Montserrat; Ferreira de Godoi, Vilma Aparecida; Marcal Natali, Maria Raquel			Food restriction promotes damage reduction in rat models of type 2 diabetes mellitus	PLOS ONE			English	Article							BETA-CELL FUNCTION; CARDIOVASCULAR RISK-FACTORS; DIET-INDUCED OBESITY; LOW-CALORIE DIET; OXIDATIVE STRESS; GASTRIC BYPASS; ENERGY RESTRICTION; INSULIN-RESISTANCE; PHYSICAL-EXERCISE; SEVERELY OBESE	There are several animal models of type 2 diabetes mellitus induction but the comparison between models is scarce. Food restriction generates benefits, such as reducing oxidative stress, but there are few studies on its effects on diabetes. The objective of this study is to evaluate the differences in physiological and biochemical parameters between diabetes models and their responses to food restriction. For this, 30 male Wistar rats were distributed in 3 groups (n = 10/group): control (C); diabetes with streptozotocin and cafeteria-style diet (DE); and diabetes with streptozotocin and nicotinamide (DN), all treated for two months (pre-food restriction period). Then, the 3 groups were subdivided into 6, generating the groups CC (control), CCR (control+food restriction), DEC (diabetic+standard diet), DER (diabetic+food restriction), DNC (diabetic+standard diet) and DNR (diabetic+food restriction), treated for an additional two months (food restriction period). The food restriction (FR) used was 50% of the average daily dietary intake of group C. Throughout the treatment, physiological and biochemical parameters were evaluated. At the end of the treatment, serum biochemical parameters, oxidative stress and insulin were evaluated. Both diabetic models produced hyperglycemia, polyphagia, polydipsia, insulin resistance, high fructosamine, hepatic damage and reduced insulin, although only DE presented human diabeteslike alterations, such as dyslipidemia and neuropathy symptoms. Both DEC and DNC diabetic groups presented higher levels of protein carbonyl groups associated to lower antioxidant capacity in the plasma. FR promoted improvement of glycemia in DNR, lipid profile in DER, and insulin resistance and hepatic damage in both diabetes models. FR also reduced the protein carbonyl groups of both DER and DNR diabetic groups, but the antioxidant capacity was improved only in the plasma of DER group. It is concluded that FR is beneficial for diabetes but should be used in conjunction with other therapies.	[Dalto da Rosa, Carlos Vinicius; de Campos, Jessica Men; Marcal Natali, Maria Raquel] Univ Estadual Maringa, Dept Morphol Sci, Maringa, Parana, Brazil; [de Sa Nakanishi, Anacharis Babeto; Comar, Jurandir Fernando] Univ Estadual Maringa, Dept Biochem, Maringa, Parana, Brazil; [Martine, Isabela Peixoto; de Freitas Mathias, Paulo Cezar] Univ Estadual Maringa, Dept Biotechnol Cell Biol & Genet, Maringa, Parana, Brazil; [Diaz Pedrosa, Maria Montserrat; Ferreira de Godoi, Vilma Aparecida] Univ Estadual Maringa, Dept Physiol Sci, Maringa, Parana, Brazil	Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa	Natali, MRM (corresponding author), Univ Estadual Maringa, Dept Morphol Sci, Maringa, Parana, Brazil.	mrmnatali@uem.br	Comar, Jurandir Fernando/D-8160-2019; de Freitas Mathias, Paulo Cezar PCFM/O-6056-2015; DE FREITAS MATHIAS, PAULO CEZAR/AAQ-9682-2021; Comar, Jurandir F./I-7285-2013; Pedrosa, Maria Montserrat Diaz/AAW-6411-2020; Diaz Pedrosa, Maria Montserrat/R-9128-2017	Comar, Jurandir Fernando/0000-0002-9518-7589; de Freitas Mathias, Paulo Cezar PCFM/0000-0001-6994-4585; Rosa, Carlos Vinicius Dalto da/0000-0001-9428-630X; Diaz Pedrosa, Maria Montserrat/0000-0002-0596-3557; Natali, Maria Raquel Marcal/0000-0002-7486-2581	Coordenagao de Aperfeigoamento de Pessoa de Nivel Superior - CAPES [40004015001M9]; CVDR JMC ABSN JFC IPM PCFM MMDP VAFG MRMN	Coordenagao de Aperfeigoamento de Pessoa de Nivel Superior - CAPES; CVDR JMC ABSN JFC IPM PCFM MMDP VAFG MRMN	This work was supported by 40004015001M9, http://www.capes.gov.br/, Coordenagao de Aperfeigoamento de Pessoa de Nivel Superior - CAPES, CVDR JMC ABSN JFC IPM PCFM MMDP VAFG MRMN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badole SL, 2013, EUR J PHARMACOL, V698, P470, DOI 10.1016/j.ejphar.2012.10.002; Barbosa MMC, 2018, ENDOCR METAB IMMUNE, V18, P268, DOI 10.2174/1871530318666180215102029; Barnosky AR, 2014, TRANSL RES, V164, P302, DOI 10.1016/j.trsl.2014.05.013; Belem MD, 2015, EXP GERONTOL, V69, P85, DOI 10.1016/j.exger.2015.05.002; Biazon AC, 2016, J BIOSC MED, V4, P15, DOI DOI 10.4236/JBM.2016.42003; Blagosklonny MV, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.506; Bracht A, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1671-1; Branquinho NTD, 2017, J PHARM PHARMACOL, V5, DOI [10.17265/2328-2150/2017.07.003, DOI 10.17265/2328-2150/2017.07.003]; Brereton MF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5639; Ghizoni CVC, 2017, J CELL BIOCHEM, V118, P3409, DOI 10.1002/jcb.25998; Cirilo CP, 2013, NUTRITION, V29, P673, DOI 10.1016/j.nut.2012.09.004; Colombo M, 2006, METABOLISM, V55, P43, DOI 10.1016/j.metabol.2005.07.005; Correia-Santos AM., 2012, MEDICINA RIBEIRAO PR, V45, P436, DOI DOI 10.11606/ISSN.2176-7262.V45I4P436-444; Crisostomo J, 2010, BRIT J NUTR, V104, P76, DOI 10.1017/S0007114510000164; Deng XQ, 2010, ACTA DIABETOL, V47, pS177, DOI 10.1007/s00592-009-0159-7; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Fakhruddin S, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/8379327; Fanali G, 2012, MOL ASPECTS MED, V33, P209, DOI 10.1016/j.mam.2011.12.002; Schoffen JPF, 2014, EXP GERONTOL, V51, P54, DOI 10.1016/j.exger.2014.01.001; Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545; Goularte JF, 2012, BRIT J NUTR, V108, P1511, DOI 10.1017/S0007114511006933; Harvie MN, 2011, INT J OBESITY, V35, P714, DOI 10.1038/ijo.2010.171; Isbell JM, 2010, DIABETES CARE, V33, P1438, DOI 10.2337/dc09-2107; Islam Md Shahidul, 2012, Methods Mol Biol, V933, P161, DOI 10.1007/978-1-62703-068-7_10; Jazet IM, 2007, DIABETES RES CLIN PR, V77, P70, DOI 10.1016/j.diabres.2006.10.019; Kahleova H, 2014, DIABETOLOGIA, V57, P1552, DOI 10.1007/s00125-014-3253-5; Kanda Y, 2015, J NUTR BIOCHEM, V26, P219, DOI 10.1016/j.jnutbio.2014.10.007; Kapur Kavita, 2008, J Assoc Physicians India, V56, P27; Kashyap S. R., 2010, International Journal of Obesity, V34, P462, DOI 10.1038/ijo.2009.254; Kitada M, 2017, NEPHROLOGY, V22, P1030, DOI 10.1111/nep.13152; Kostolanska J, 2009, J PEDIATR ENDOCR MET, V22, P433; Kretschmer BD, 2005, LIFE SCI, V76, P1553, DOI 10.1016/j.lfs.2004.08.028; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lim EL, 2011, DIABETOLOGIA, V54, P2506, DOI 10.1007/s00125-011-2204-7; Lips MA, 2014, CLIN ENDOCRINOL, V80, P834, DOI 10.1111/cen.12254; Malandrucco I, 2012, AM J CLIN NUTR, V95, P609, DOI 10.3945/ajcn.111.023697; Mallipattu SK, 2014, AM J PHYSIOL-RENAL, V306, pF1008, DOI 10.1152/ajprenal.00597.2013; Masiello P, 1998, DIABETES, V47, P224, DOI 10.2337/diabetes.47.2.224; Meng Y, 2017, DIABETES RES CLIN PR, V131, P124, DOI 10.1016/j.diabres.2017.07.006; Minamiyama Y, 2007, J PHARMACOL EXP THER, V320, P535, DOI 10.1124/jpet.106.110460; Nankar RP, 2017, PHYTOMEDICINE, V37, P4, DOI 10.1016/j.phymed.2017.10.014; Okoduwa Stanley I R, 2017, Medicines (Basel), V4, DOI 10.3390/medicines4040073; Pandey KB, 2010, CLIN BIOCHEM, V43, P508, DOI 10.1016/j.clinbiochem.2009.11.011; Reed MJ, 2000, METABOLISM, V49, P1390, DOI 10.1053/meta.2000.17721; Rizvi AA, 2010, METAB SYNDR RELAT D, V8, P287, DOI 10.1089/met.2009.0116; Ross AP, 2015, J DIABETES COMPLICAT, V29, P329, DOI 10.1016/j.jdiacomp.2014.12.017; Sahin I, 2011, MOL CELL BIOCHEM, V355, P299, DOI 10.1007/s11010-011-0867-5; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; Sharma AK, 2012, J BIOMED RES, V26, P200, DOI 10.7555/JBR.26.20110054; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Srinivasan K, 2007, INDIAN J MED RES, V125, P451; Steinbrook R, 2004, NEW ENGL J MED, V350, P1075, DOI 10.1056/NEJMp048029; Stenkamp-Strahm CM, 2015, CELL TISSUE RES, V361, P411, DOI 10.1007/s00441-015-2132-9; Su HC, 2006, AM J PHYSIOL-ENDOC M, V290, pE1339, DOI 10.1152/ajpendo.00487.2005; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; Szkudelska K, 2014, INT J EXP PATHOL, V95, P86, DOI 10.1111/iep.12073; Tiwari Brahm Kumar, 2013, J Biomark, V2013, P378790, DOI 10.1155/2013/378790; Trammell SAJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26933; Troy S, 2008, CELL METAB, V8, P201, DOI 10.1016/j.cmet.2008.08.008; Ugochukwu NH, 2004, CLIN CHIM ACTA, V348, P121, DOI 10.1016/j.cccn.2004.05.005; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Weir GC, 2004, DIABETES, V53, pS16, DOI 10.2337/diabetes.53.suppl_3.S16; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Winiarska K, 2009, BIOCHIMIE, V91, P261, DOI 10.1016/j.biochi.2008.09.006; World Health Organization, 2016, GLOB REP PSOR; Zhou X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115148	66	6	6	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2018	13	6							e0199479	10.1371/journal.pone.0199479	http://dx.doi.org/10.1371/journal.pone.0199479			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ8QS	29924854	Green Submitted, Green Published, gold			2023-01-03	WOS:000435655600072
J	Carey, CM; Jena, AB; Barnett, ML				Carey, Colleen M.; Jena, Anupam B.; Barnett, Michael L.			Patterns of Potential Opioid Misuse and Subsequent Adverse Outcomes in Medicare, 2008 to 2012	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG-MONITORING PROGRAMS; SHOPPING BEHAVIOR; CHRONIC PAIN; OVERDOSE; DEATHS; COHORT	Background: Providers are increasingly being expected to examine their patients' opioid treatment histories before writing new opioid prescriptions. However, lithe evidence exists on how patterns of potential opioid misuse are associated with subsequent adverse outcomes nationally. Objective: To estimate how a range of patterns of potential opioid misuse relate to adverse outcomes during the subsequent year. Design: Observational study comparing outcomes for Medicare enrollees with potential opioid misuse patterns versus those for beneficiaries with no such patterns, adjusting for patient characteristics. Setting: Medicare, 2008 to 2012. Patients: A 5% sample of beneficiaries who had an opioid prescription without a cancer diagnosis. Measurements: Several measures for opioid misuse were defined on the basis of drug quantity, overlapping prescriptions, use of multiple prescribers or pharmacies, and use of out-ofstate prescribers or pharmacies. The primary outcome was a diagnosis of opioid overdose in the year after a 6-month index period. Secondary outcomes included subsequent opioid-related or overall mortality. Results: Overall, 0.6% to 8.5% of beneficiaries fulfilled a misuse measure. Subsequent opioid overdose was positively associated with successively greater numbers of prescribers or pharmacies or higher opioid quantities during the index period. For example, patients who obtained opioids from 2, 3, or 4 prescribers were increasingly more likely to have an opioid overdose (adjusted absolute risk per 1000 beneficiary-years [aAR], 3.5 [95% CI, 3.3 to 3.7]; 4.8 [CI, 4.5 to 5.2]; or 6.4 [CI, 5.8 to 6.9], respectively) than those with a single prescriber (aAR, 1.9 [CI, 1.8 to 2.0]). Subsequent overdose risk increased meaningfully with any deviation in the single prescriber-single pharmacy opioid use pattern. All misuse measures examined had a positive association with subsequent opioid overdose and death. Limitation: Risk estimates provide measures of association and may not generalize to non-Medicare populations. Conclusion: To fully assess patients' opioid overdose risk, clinicians should examine a wide range of misuse patterns.	[Carey, Colleen M.] Cornell Univ, 298 Martha van Rensselaer Hall, Ithaca, NY 14850 USA; [Jena, Anupam B.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Jena, Anupam B.] NBER, Cambridge, MA 02138 USA; [Barnett, Michael L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA	Cornell University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Bureau of Economic Research; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	colleen.carey@cornell.edu; mbarnett@hsph.harvard.edu	Barnett, Michael/AAF-4017-2019; Barnett, Michael/ABA-4159-2021	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609; carey, colleen/0000-0003-0069-9707	National Institutes of Health [1DP5OD 017897-01]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	By NIH Early Independence Award 1DP5OD 017897-01 (Dr. Jena).	Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2017, PRESCR DRUG AB POL S; [Anonymous], 2017, 1 5 MILLION ADULTS H; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Buchmueller TC, 2018, AM ECON J-ECON POLIC, V10, P77, DOI 10.1257/pol.20160094; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Centers for Medicare & Medicaid Services, 2017, AN PROP OP OV CRIT M; Cepeda MS, 2013, J CLIN PHARMACOL, V53, P112, DOI 10.1177/0091270012436561; Cepeda MS, 2012, DRUG SAFETY, V35, P325, DOI 10.2165/11596600-000000000-00000; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Gugelmann HM, 2011, JAMA-J AM MED ASSOC, V306, P2258, DOI 10.1001/jama.2011.1712; Haffajee RL, 2015, JAMA-J AM MED ASSOC, V313, P891, DOI 10.1001/jama.2014.18514; Irvine JM, 2014, J PAIN, V15, P747, DOI 10.1016/j.jpain.2014.04.003; Islam MM, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-46; Jena AB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1393; Krueger Alan, 2016, WORKING PAPER; Lipari R.N., 2016, PRESCRIPTION DRUG US; Meara E, 2016, NEW ENGL J MED, V375, P44, DOI 10.1056/NEJMsa1514387; Morden NE, 2014, MED CARE, V52, P852, DOI 10.1097/MLR.0000000000000183; National Institute on Drug Abuse, 2014, AM ADD OP HER PRESCR; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Pischke J.S., 2014, MASTERING METRICS PA; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Rowe C, 2017, ACAD EMERG MED, V24, P475, DOI 10.1111/acem.13121; Rutkow L, 2015, HEALTH AFFAIR, V34, P484, DOI 10.1377/hlthaff.2014.1085; Substance Abuse and Mental Health Services Administration, 2014, OP; U. S. Government Accountability Office, 2011, GAO11699	28	32	32	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2018	168	12					837	+		10.7326/M17-3065	http://dx.doi.org/10.7326/M17-3065			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK1TE	29800019				2023-01-03	WOS:000435903500013
J	Andersson, S; Belkic, K; Mints, M; Ostensson, E				Andersson, Sonia; Belkic, Karen; Mints, Miriam; Ostensson, Ellinor			Is self-sampling to test for high-risk papillomavirus an acceptable option among women who have been treated for high-grade cervical intraepithelial neoplasia?	PLOS ONE			English	Article							E6/E7 MESSENGER-RNA; MINORITY WOMEN; LOW-INCOME; FOLLOW-UP; CANCER; HPV; LATINAS; BREAST; COLLECTION; PREVENTION	Objective Self-sampling to test for high risk human papilloma virus (HPV) is becoming an increasingly important component of cervical cancer screening. The aim of this observational study is to examine how women treated for high-grade cervical intraepithelial neoplasia (CIN) view HPV self-sampling. Methods Invited to participate in the present study were patients who had undergone treatment of high-grade CIN (grade 2 or higher) and were followed-up at 6-months at the Karolinska University Hospital, Stockholm. The participants were instructed as to how to perform HPV self-sampling. Thereafter, the participants completed a questionnaire about HPV self-sampling and other cervical cancer screening methods, as well as about self-perceived risk of cervical cancer without regular gynecologic follow-up and about specific knowledge regarding HPV, CIN and cervical cancer. Results Altogether 479 women enrolled in this study. The participation rate was 96.6%. Nearly 75% of the participants stated they would consider performing the HPV self-sampling prior to their next gynecologic follow-up. Confidence in HPV self-sampling was a significant independent predictor of willingness to perform HPV self-sampling. However, confidence in HPV self-sampling was significantly lower than confidence in Papanicolaou smears and in HPV testing with samples collected by health professionals. Higher specific knowledge about HPV, CIN and cervical cancer was also a significant independent predictor of willingness to perform HPV self-sampling, as was having travelled longer distance to attend gynecologic follow-up. Participants with lower income and without completed university education expressed significantly higher confidence in HPV self-sampling and lower confidence in Papanicolaou smears than the other women. Conclusions To the best of our knowledge, this is the first study to examine the views of women treated for high-grade CIN vis-a-vis HPV self-sampling. The latter is an acceptable option for the vast majority of this cohort of women.	[Andersson, Sonia; Belkic, Karen; Mints, Miriam; Ostensson, Ellinor] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Belkic, Karen] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Belkic, Karen] Claremont Grad Univ, Sch Community & Global Hlth, Claremont, CA USA; [Belkic, Karen] Univ Southern Calif, Inst Prevent Res, Keck Sch Med, Alhambra, CA USA; [Ostensson, Ellinor] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Claremont Colleges; Claremont Graduate School; University of Southern California; Karolinska Institutet	Ostensson, E (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.; Ostensson, E (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.	ellinor.ostensson@ki.se		Ostensson, Ellinor/0000-0003-0668-088X	Swedish Cancer Foundation [11 0544, CAN 2011/471]; Karolinska Institutet Cancer Strategic Grants [5888/05-722]; Swedish Research Council [521-2008-2899]; Stockholm County Council [20130097, 20160155]; Gustaf V Jubilee Fund [154022]	Swedish Cancer Foundation; Karolinska Institutet Cancer Strategic Grants; Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council(Stockholm County Council); Gustaf V Jubilee Fund	This work was supported by The Swedish Cancer Foundation (11 0544, CAN 2011/471), www.cancerfonden.se, SA; Karolinska Institutet Cancer Strategic Grants (5888/05-722), www.ki.se, SA; The Swedish Research Council (521-2008-2899), www.vr.se, SA; Stockholm County Council (20130097, 20160155), www.skl.se, SA; The Gustaf V Jubilee Fund (154022), www.rahfo.se, SA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdoli G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093174; Altobelli E, 2015, INT J GYNECOL CANCER, V25, P474, DOI 10.1097/IGC.0000000000000374; Andersson S., 2017, ANN SCI M MAY CARD C; Andersson S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190156; Anhang R, 2005, J WOMENS HEALTH, V14, P721, DOI 10.1089/jwh.2005.14.721; Arbyn M, 2015, CLIN MICROBIOL INFEC, V21, P817, DOI 10.1016/j.cmi.2015.04.015; Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9; Arbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095; Arrossi S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3474-2; Asciutto KC, 2016, ACTA OBSTET GYN SCAN, V95, P1251, DOI 10.1111/aogs.12960; Azerkan F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0107624; Azerkan F, 2012, INT J CANCER, V130, P937, DOI 10.1002/ijc.26084; Baezconde-Garbanati L, 1999, HISPANIC J BEHAV SCI, V21, P302, DOI 10.1177/0739986399213007; Belinson JL, 2012, INT J CANCER, V130, P1855, DOI 10.1002/ijc.26202; Bloom Joan R, 2008, J Cancer Surviv, V2, P190, DOI 10.1007/s11764-008-0058-x; Brismar S, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.01.005; Brown DR, 2000, ANN EPIDEMIOL, V10, pS13, DOI 10.1016/S1047-2797(00)00197-6; Catarino R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143644; Chen Q, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027896; Chernesky M, 2014, SEX TRANSM DIS, V41, P365, DOI 10.1097/OLQ.0000000000000125; Cimprich B, 2005, PSYCHO-ONCOLOGY, V14, P704, DOI 10.1002/pon.891; Consedine NS, 2007, J HEALTH CARE POOR U, V18, P550, DOI 10.1353/hpu.2007.0057; Crofts V, 2015, INT J WOMENS HEALTH, V7, P149, DOI 10.2147/IJWH.S56307; Davis M, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0373-1; Ducancelle A, 2015, J INFECTION, V71, P377, DOI 10.1016/j.jinf.2015.05.001; Ebisch RMF, 2017, J CLIN ONCOL, V35, P2542, DOI 10.1200/JCO.2016.71.4543; Elfstrom KM, 2015, EUR J CANCER, V51, P950, DOI 10.1016/j.ejca.2015.03.008; Foster C, 2011, BRIT J CANCER, V105, pS21, DOI 10.1038/bjc.2011.419; Fouad MN, 2006, J CANCER EDUC, V21, pS91, DOI 10.1207/s15430154jce2101s_16; Galbraith KV, 2014, J COMMUN HEALTH, V39, P849, DOI 10.1007/s10900-014-9931-x; Garutti P, 2017, EUR J OBSTET GYN R B, V210, P236, DOI 10.1016/j.ejogrb.2016.12.018; Goel MS, 2003, J GEN INTERN MED, V18, P1028, DOI 10.1111/j.1525-1497.2003.20807.x; Harper DM, 2017, GYNECOL ONCOL, V146, P196, DOI 10.1016/j.ygyno.2017.04.004; Jentschke M, 2016, J CLIN VIROL, V82, P46, DOI 10.1016/j.jcv.2016.06.016; Kahn JA, 2005, J WOMENS HEALTH, V14, P650, DOI 10.1089/jwh.2005.14.650; Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS78, DOI 10.1097/LGT.0b013e31828543c5; Kocken M, 2012, GYNECOL ONCOL, V125, P500, DOI 10.1016/j.ygyno.2012.01.015; Kocken M, 2011, LANCET ONCOL, V12, P441, DOI 10.1016/S1470-2045(11)70078-X; Kuil LD, 2017, ACTA CYTOL, V61, P425, DOI 10.1159/000477331; Lim AWW, 2017, J MED SCREEN, V24, P43, DOI 10.1177/0969141316639346; Lindell M, 2012, BJOG-INT J OBSTET GY, V119, P245, DOI 10.1111/j.1471-0528.2011.03147.x; Luszczynska A, 2012, WOMEN HEALTH, V52, P162, DOI 10.1080/03630242.2012.656187; Ma'som M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-011022; Mao C, 2017, J WOMENS HEALTH, V26, P609, DOI 10.1089/jwh.2016.5965; Marlow LAV, 2015, BRIT J CANCER, V113, P833, DOI 10.1038/bjc.2015.248; Mousavi SM, 2012, INT J CANCER, V131, P497, DOI 10.1002/ijc.26395; Navarro AM, 1998, AM J PREV MED, V15, P32, DOI 10.1016/S0749-3797(98)00023-3; O'Connor M, 2014, BJOG-INT J OBSTET GY, V121, P1421, DOI 10.1111/1471-0528.12741; O'Connor M, 2015, WOMEN HEALTH ISS, V25, P528, DOI 10.1016/j.whi.2015.05.009; Ostensson E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128270; Ostensson E, 2013, ACTA OBSTET GYN SCAN, V92, P830, DOI 10.1111/aogs.12143; Otero-Sabogal R, 2003, HEALTH EDUC BEHAV, V30, P337, DOI 10.1177/1090198103030003008; Persson M, 2012, ONCOL REP, V28, P346, DOI 10.3892/or.2012.1755; Pimple S, 2016, CURR OPIN OBSTET GYN, V28, P4, DOI 10.1097/GCO.0000000000000241; Pruitt SL, 2009, CANCER EPIDEM BIOMAR, V18, P2579, DOI 10.1158/1055-9965.EPI-09-0135; Racey CS, 2016, J RURAL HEALTH, V32, P136, DOI 10.1111/jrh.12136; Remennick Larissa, 2003, J Immigr Health, V5, P153, DOI 10.1023/A:1026163008336; Singh GK, 2004, CANCER, V101, P1051, DOI 10.1002/cncr.20467; Smith RA, 2017, CA-CANCER J CLIN, V67, P100, DOI 10.3322/caac.21392; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Teran L, 2007, ANTICANCER RES, V27, P4325; Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858; Vahabi M, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3564-1; Wentzensen N, 2017, PREV MED, V98, P33, DOI 10.1016/j.ypmed.2016.12.040	64	8	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2018	13	6							e0199038	10.1371/journal.pone.0199038	http://dx.doi.org/10.1371/journal.pone.0199038			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GJ6XV	29912903	Green Published, Green Submitted, gold			2023-01-03	WOS:000435528600069
J	Martin, J; Cunliffe, J; Decary-Hetu, D; Aldridge, J				Martin, James; Cunliffe, Jack; Decary-Hetu, David; Aldridge, Judith			Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SILK ROAD; DRUG MARKETPLACE; UNITED-STATES; TRAFFICKING; CRYPTOMARKETS	Objective To examine the effect on the trade in opioids through online illicit markets ("cryptomarkets") of the US Drug Enforcement Administration's ruling in 2014 to reschedule hydrocodone combination products. Design Interrupted time series analysis. Setting 31 of the world's largest cryptomarkets operating from October 2013 to July 2016. Main outcome measures The proportion of total transactions, advertised and active listings for prescription opioids, prescription sedatives, prescription steroids, prescription stimulants, and illicit opioids, and the composition of the prescription opioid market between the US and elsewhere. Results The sale of prescription opioids through US cryptomarkets increased after the schedule change, with no statistically significant changes in sales of prescription sedatives, prescription steroids, prescription stimulants, or illicit opioids. In July 2016 sales of opioids through US cryptomarkets represented 13.7% of all drug sales (95% confidence interval 11.5% to 16.0%) compared with a modelled estimate of 6.7% of all sales (3.7% to 9.6%) had the new schedule not been introduced. This corresponds to a 4 percentage point yearly increase in the amount of trade that prescription opioids represent in the US market, set against no corresponding changes for comparable products or for prescription opioids sold outside the US. This change was first observed for sales, and later observed for product availability. There was also a change in the composition of the prescription opioid market: fentanyl was the least purchased product during July to September 2014, then the second most frequently purchased by July 2016. Conclusions The scheduling change in hydrocodone combination products coincided with a statistically significant, sustained increase in illicit trading of opioids through online US cryptomarkets. These changes were not observed for other drug groups or in other countries. A subsequent move was observed towards the purchase of more potent forms of prescription opioids, particularly oxycodone and fentanyl.	[Martin, James] Swinburne Univ, Dept Social Sci, Melbourne, Vic, Australia; [Cunliffe, Jack] Univ Kent, Sch Social Policy Sociol & Social Res, Canterbury CT2 7NF, Kent, England; [Decary-Hetu, David] Univ Montreal, Ecole Criminol, Montreal, PQ, Canada; [Aldridge, Judith] Univ Manchester, Sch Law, Manchester, Lancs, England	University of Kent; Universite de Montreal; University of Manchester	Cunliffe, J (corresponding author), Univ Kent, Sch Social Policy Sociol & Social Res, Canterbury CT2 7NF, Kent, England.	j.d.cunliffe@kent.ac.uk		Decary-Hetu, David/0000-0002-4360-140X; Cunliffe, Jack/0000-0001-9825-134X; Aldridge, Judith/0000-0002-9402-8682	Social Sciences and Humanities Research Council of Canada [430-2015-01089]; Macquarie University internal grants; Ministry of Justice and Security of the Netherlands	Social Sciences and Humanities Research Council of Canada(Social Sciences and Humanities Research Council of Canada (SSHRC)); Macquarie University internal grants; Ministry of Justice and Security of the Netherlands	The data collection was funded in parts by the Social Sciences and Humanities Research Council of Canada (#430-2015-01089), Macquarie University internal grants, and the Wetenschappelijk Onderzoek-en Documentatiecentrum (WODC) from the Ministry of Justice and Security of the Netherlands. The researchers remained independent from the funders at all time. The funders were not consulted before or during the work.	Aldridge J, 2017, ADDICTION; Aldridge J, 2016, INT J DRUG POLICY, V35, P7, DOI 10.1016/j.drugpo.2016.04.020; Bancroft A, 2016, INT J DRUG POLICY, V35, P42, DOI 10.1016/j.drugpo.2015.11.008; Barratt MJ, 2016, INT J DRUG POLICY, V35, P24, DOI 10.1016/j.drugpo.2016.04.019; Barratt MJ, 2016, INT J DRUG POLICY, V35, P1, DOI 10.1016/j.drugpo.2016.07.005; Barratt MJ, 2014, ADDICTION, V109, P774, DOI 10.1111/add.12470; Barratt MJ, 2012, ADDICTION, V107, P683, DOI 10.1111/j.1360-0443.2011.03709.x; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Bloom BS, 1999, ANN INTERN MED, V131, P830, DOI 10.7326/0003-4819-131-11-199912070-00005; Broseus J, 2017, FORENSIC SCI INT, V277, P88, DOI 10.1016/j.forsciint.2017.05.021; Christin N, 2013, WEB C, DOI DOI 10.1145/2488388.2488408; Cunliffe J, 2017, INT J DRUG POLICY, V50, P64, DOI 10.1016/j.drugpo.2017.09.005; Dcary-Htu D, 2014, SOCIAL SCI RES NETWO; Decary-Hetu D, 2017, CRIME LAW SOCIAL CH, V67, P55, DOI 10.1007/s10611-016-9644-4; Decary-Hetu D., 2015, EUR REV ORG CRIME, V2, P122; Decary-Hetu D, 2013, SOFTWARE PROGRAM; Decary-Hetu D, 2016, INT J DRUG POLICY, V35, P69, DOI 10.1016/j.drugpo.2016.06.003; Demant J, INT CRIM JUSTICE REV; Easton G, 2007, BRIT MED J, V334, P14, DOI 10.1136/bmj.39063.418391.68; Greenfield VA, 2017, INT J DRUG POLICY, V41, P162, DOI 10.1016/j.drugpo.2017.01.010; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Haynes A, 2016, CLIN TOXICOL, V54, P434, DOI 10.3109/15563650.2016.1148720; Jones CM, 2016, JAMA INTERN MED, V176, P399, DOI 10.1001/jamainternmed.2015.7799; Kontopantelis E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2750; Kruithof K, 2016, INTERNET FACILITATED, P21; LeQuang JA, 2017, J ANESTH CLIN RES, V5, P377; Littlejohn C, 2005, DRUG-EDUC PREV POLIC, V12, P75, DOI 10.1080/0968763042000275326; MacCoun Robert J., 2001, DRUG WAR HERESIES LE; Makary MA, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4792; Martin J., 2014, DRUGS DARK NET CRYPT; Martin J, 2014, CRIMINOL CRIM JUSTIC, V14, P351, DOI 10.1177/1748895813505234; Mireault C, 2016, CAN SOC FORENSIC SCI, V49, P161, DOI 10.1080/00085030.2016.1189229; Mort J, 2016, RES SOC ADMIN PHARM, V12, pE6, DOI 10.1016/j.sapharm.2016.05.017; Munksgaard R, 2016, INT J DRUG POLICY, V35, P92, DOI 10.1016/j.drugpo.2016.02.027; Nelson LS, 2015, JAMA-J AM MED ASSOC, V314, P1453, DOI 10.1001/jama.2015.12397; Norbutas L, 2018, INT J DRUG POLICY, V56, P92, DOI 10.1016/j.drugpo.2018.03.016; Oehler EC, 2016, AM J EMERG MED, V34, P2388, DOI 10.1016/j.ajem.2016.09.002; Orizio G, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1795; Paquet-Clouston M, 2018, INT J DRUG POLICY, V54, P87, DOI 10.1016/j.drugpo.2018.01.003; Raji MA, 2017, PHARMACOEPIDEM DR S, V27, P1; Roehr B, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4998; Roehr B, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4814; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Schultz Steven, 2016, J Opioid Manag, V12, P119, DOI 10.5055/jom.2016.0323; Seago Susan, 2016, Proc (Bayl Univ Med Cent), V29, P268; Soska K, 2015, PROCEEDINGS OF THE 24TH USENIX SECURITY SYMPOSIUM, P33; Thornton M., 1991, CATO I POLICY ANAL N; Van Buskirk J, 2016, INT J DRUG POLICY, V35, P32, DOI 10.1016/j.drugpo.2016.01.010; Van Hout MC, 2013, INT J DRUG POLICY, V24, P524, DOI 10.1016/j.drugpo.2013.08.011; Van Hout MC, 2013, INT J DRUG POLICY, V24, P385, DOI 10.1016/j.drugpo.2013.01.005; Volkow ND, 2014, AM ADDICTION OPIOIDS, P14; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010	52	45	45	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	2018	361								k2270	10.1136/bmj.k2270	http://dx.doi.org/10.1136/bmj.k2270			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ8JO	29899119	Green Published, Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000435635800010
J	Keravnou, A; Ioannides, M; Loizides, C; Tsangaras, K; Achilleos, A; Mina, P; Kypri, E; Hadjidaniel, MD; Neofytou, M; Kyriacou, S; Sismani, C; Koumbaris, G; Patsalis, PC				Keravnou, Anna; Ioannides, Marios; Loizides, Charalambos; Tsangaras, Kyriakos; Achilleos, Achilleas; Mina, Petros; Kypri, Elena; Hadjidaniel, Michael D.; Neofytou, Maria; Kyriacou, Skevi; Sismani, Carolina; Koumbaris, George; Patsalis, Philippos C.			MeDIP combined with in-solution targeted enrichment followed by NGS: Inter-individual methylation variability of fetal-specific biomarkers and their implementation in a proof of concept study for NIPT	PLOS ONE			English	Article							NONINVASIVE-PRENATAL-DIAGNOSIS; CELL-FREE DNA; MATERNAL PLASMA; PERIPHERAL-BLOOD; MARKERS; ANEUPLOIDY	DNA methylation is the most characterized epigenetic process exhibiting stochastic variation across different tissues and individuals. In non-invasive prenatal testing (NIPT) fetal specific methylated regions can potentially be used as biomarkers for the accurate detection of fetal aneuploidies. The aim of this study was the investigation of inter-individual methylation variability of previously reported fetal-specific markers and their implementation towards the development of a novel NIPT assay for the detection of trisomies 13, 18, and 21. Methylated DNA Immunoprecipitation (MeDIP) combined with in-solution targeted enrichment followed by NGS was performed in 29 CVS and 27 female plasma samples to assess inter-individual methylation variability of 331 fetal-specific differentially methylated regions (DMRs). The same approach was implemented for the NIPT of trisomies 13, 18 and 21 using spiked-in (n = 6) and pregnancy samples (n = 44), including one trisomy 13, one trisomy 18 and four trisomy 21. Despite the variability of DMRs, CVS samples showed statistically significant hypermethylation (p<2e-16) compared to plasma samples. Importantly, our assay correctly classified all euploid and aneuploid cases without any false positive results (n = 44). This work provides the starting point for the development of a NIPT assay based on a robust set of fetal specific biomarkers for the detection of fetal aneuploidies. Furthermore, the assay's targeted nature significantly reduces the analysis cost per sample while providing high read depth at regions of interest increasing significantly its accuracy.	[Keravnou, Anna; Hadjidaniel, Michael D.; Neofytou, Maria; Patsalis, Philippos C.] Cyprus Inst Neurol & Genet, Translat Genet Team, Nicosia, Cyprus; [Ioannides, Marios; Loizides, Charalambos; Tsangaras, Kyriakos; Achilleos, Achilleas; Mina, Petros; Kypri, Elena; Kyriacou, Skevi; Koumbaris, George; Patsalis, Philippos C.] NIPD Genet Ltd, Nicosia, Cyprus; [Sismani, Carolina] Cyprus Inst Neurol & Genet, Dept Cytogenet & Genom, Nicosia, Cyprus		Patsalis, PC (corresponding author), Cyprus Inst Neurol & Genet, Translat Genet Team, Nicosia, Cyprus.; Patsalis, PC (corresponding author), NIPD Genet Ltd, Nicosia, Cyprus.	p.patsalis@nipd.com			European Research Council (ERC) under 7th Framework Programme [322953];  [NEA YPiODeltaOMH/SigmaTPATH/0308/31]	European Research Council (ERC) under 7th Framework Programme; 	This work has received funding from the European Research Council (ERC) under 7th Framework Programme under grant agreement No 322953 for the project: A Novel Non-Invasive Prenatal Diagnosis of Genetic Disorders. Furthermore, the authors, Marios loannides, Charalambos Loizides, Kyriakos Tsangaras, Achilleas Achilleos, Petros Mina, Elena Kypri, Skevi Kyriacou, George Koumbaris and Philippos C Patsalis are employed by NIPD Genetics Ltd. NIPD Genetics Ltd., provided support in the form of salaries for authors MI, CL, KT, AA, PM, EK, SK, GK and PCP. Its role was mainly in the design of the study, data analysis, troubleshooting, editing of the manuscript and project supervision. The specific roles of these authors are articulated in the 'author contributions' section.; This project's computational processes were performed on the Cy-Tera High Performance computing facility for Cyprus (NEA Y Pi O Delta OMH/Sigma TPATH/0308/31).	Akolekar R, 2015, ULTRASOUND OBST GYN, V45, P16, DOI 10.1002/uog.14636; Avent ND, 2008, SEMIN FETAL NEONAT M, V13, P91, DOI 10.1016/j.siny.2007.12.011; Bock C, 2008, NUCLEIC ACIDS RES, V36, P2; Borgel Julie, 2012, Methods Mol Biol, V925, P149, DOI 10.1007/978-1-62703-011-3_9; Butcher LM, 2010, METHODS, V52, P223, DOI 10.1016/j.ymeth.2010.04.003; Chim SSC, 2008, CLIN CHEM, V54, P500, DOI 10.1373/clinchem.2007.098731; Chiu RWK, 2008, P NATL ACAD SCI USA, V105, P20458, DOI 10.1073/pnas.0810641105; Chu TJ, 2009, PRENATAL DIAG, V29, P1020, DOI 10.1002/pd.2335; Fan HC, 2008, P NATL ACAD SCI USA, V105, P16266, DOI 10.1073/pnas.0808319105; Gerundino F, 2016, J MATERN-FETAL NEO M, V30, P1; Hatt L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128918; Huang Dorothy J., 2008, V444, P203, DOI 10.1007/978-1-59745-066-9_15; Ioannides M, 2014, MOL CYTOGENET, V7, DOI 10.1186/s13039-014-0073-8; Keravnou A, 2016, GENET RES CAMB, V98, P1; Koumbaris G, 2016, CLIN CHEM, V62, P848, DOI 10.1373/clinchem.2015.252502; Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109; Lee DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078136; Lefkowitz RB, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.02.030; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liao GJW, 2011, CLIN CHEM, V57, P92, DOI 10.1373/clinchem.2010.154336; Lo YMD, 2007, NAT MED, V13, P218, DOI 10.1038/nm1530; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Maricic T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014004; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meyer Matthias, 2010, Cold Spring Harb Protoc, V2010, DOI 10.1101/pdb.prot5448; Motavaf M, 2014, NONINVASIVE PRENATAL, V5, P3; Neofytou MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171319; Ng EKO, 2003, P NATL ACAD SCI USA, V100, P4748, DOI 10.1073/pnas.0637450100; Old RW, 2007, REPROD BIOMED ONLINE, V15, P227, DOI 10.1016/S1472-6483(10)60713-4; Papageorgiou EA, 2011, NAT MED, V17, P510, DOI 10.1038/nm.2312; Papageorgiou EA, 2009, AM J PATHOL, V174, P1609, DOI 10.2353/ajpath.2009.081038; Schneider E, 2010, NUCLEIC ACIDS RES, V38, P3880, DOI 10.1093/nar/gkq126; Slieker RC, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005583; Sparks AB, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.01.030; Sparks AB, 2012, PRENATAL DIAG, V32, P3, DOI 10.1002/pd.2922; Tsaliki E, 2012, PRENATAL DIAG, V32, P996, DOI 10.1002/pd.3947; Tsangaras K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109101; Wong CCY, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12226; Xiang YQ, 2014, MOL HUM REPROD, V20, P875, DOI 10.1093/molehr/gau048; Xie HH, 2011, NUCLEIC ACIDS RES, V39, P4099, DOI 10.1093/nar/gkr017; Zimmermann B, 2005, CLIN CHEM, V51, P1598, DOI 10.1373/clinchem.2005.051235	42	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2018	13	6							e0199010	10.1371/journal.pone.0199010	http://dx.doi.org/10.1371/journal.pone.0199010			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI8PJ	29889893	gold, Green Published, Green Submitted			2023-01-03	WOS:000434786600071
J	Rassovsky, Y; Dunn, W; Wynn, JK; Wu, AD; Iacoboni, M; Hellemann, G; Green, MF				Rassovsky, Yuri; Dunn, Walter; Wynn, Jonathan K.; Wu, Allan D.; Iacoboni, Marco; Hellemann, Gerhard; Green, Michael F.			Single transcranial direct current stimulation in schizophrenia: Randomized, cross-over study of neurocognition, social cognition, ERPs, and side effects	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; IMPROVE COGNITION; AFFECTIVE PROSODY; HEALTHY-SUBJECTS; TDCS; MATRICS; DEFICITS; BATTERY; HALLUCINATIONS; RECOGNITION	Over the last decades, the treatment of schizophrenia has shifted fundamentally from a focus on symptom reduction to a focus on recovery and improving aspects of functioning. In this study, we examined the effect of transcranial direct current stimulation (tDCS) on social cognitive and nonsocial neurocognitive functions, as well as on electroencephalogram (EEG) measures, in individuals with schizophrenia. Thirty-seven individuals with schizophrenia were administered one of three different tDCS conditions (cathodal, anodal, and sham) per visit over the course of three visits, with approximately one week between each visit. Order of conditions was randomized and counterbalanced across subjects. For the active conditions, the electrode was placed over the left dorsolateral prefrontal cortex with the reference electrode over right supraorbital cortex. Current intensity was 2 mA and was maintained for two 20-minute sessions, with a one hour break between the sessions. Assessments were conducted immediately following each session, in a counterbalanced order of administration. No systematic effects were found across the social and nonsocial cognitive domains, and no significant effects were detected on event-related potentials (ERPs). The very small effect sizes, further validated by post-hoc power analyses (large Critical Ns), demonstrated that these findings were not due to lack of statistical power. Except for mild local discomfort, no significant side effects were reported. Findings demonstrate the safety and ease of administration of this procedure, but suggest that a single dose of tDCS over these areas does not yield a therapeutic effect on cognition in schizophrenia.	[Rassovsky, Yuri] Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; [Rassovsky, Yuri; Hellemann, Gerhard; Green, Michael F.] Bar Ilan Univ, Gonda Multidisciplinary Brain Res Ctr, Ramat Gan, Israel; [Rassovsky, Yuri; Dunn, Walter; Wynn, Jonathan K.; Green, Michael F.] UCLA Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Dunn, Walter; Wynn, Jonathan K.] VISN 22 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA; [Wu, Allan D.; Iacoboni, Marco] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Iacoboni, Marco] Univ Calif Los Angeles, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA USA	Bar Ilan University; Bar Ilan University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Rassovsky, Y (corresponding author), Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel.; Rassovsky, Y (corresponding author), Bar Ilan Univ, Gonda Multidisciplinary Brain Res Ctr, Ramat Gan, Israel.; Rassovsky, Y (corresponding author), UCLA Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.	yurir@biu.ac.il	Wynn, Jonathan/H-3749-2014	Wynn, Jonathan/0000-0002-1763-8540; Rassovsky, Yuri/0000-0002-6362-9944	NARSAD Independent Investigator Grant from the Brain & Behavior Research Foundation [22017]	NARSAD Independent Investigator Grant from the Brain & Behavior Research Foundation	This study was supported by a NARSAD Independent Investigator Grant from the Brain & Behavior Research Foundation (22017).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andreasen N., 1984, SCALE ASSESSMENT POS; Au J, 2016, J COGNITIVE NEUROSCI, V28, P1419, DOI 10.1162/jocn_a_00979; Brunelin J, 2012, BRAIN STIMUL, V5, P431, DOI 10.1016/j.brs.2011.03.010; Brunelin J, 2012, AM J PSYCHIAT, V169, P719, DOI 10.1176/appi.ajp.2012.11071091; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Buchanan RW, 2005, SCHIZOPHRENIA BULL, V31, P5, DOI 10.1093/schbul/sbi020; Dedoncker J, 2016, J NEURAL TRANSM, V123, P1159, DOI 10.1007/s00702-016-1558-x; Dresler M, 2013, NEUROPHARMACOLOGY, V64, P529, DOI 10.1016/j.neuropharm.2012.07.002; Dunn W, 2016, SCHIZOPHR RES, V174, P189, DOI 10.1016/j.schres.2016.04.021; Edwards J, 2002, CLIN PSYCHOL REV, V22, P789, DOI 10.1016/S0272-7358(02)00130-7; Ekman P., 2004, SUBTLE EXPRESSION TR; Ekman P, 1976, PICTURES FACIAL AFFE; First M.B., 1994, USERS GUIDE SCID 5 P; Fitzgerald PB, 2014, BRAIN STIMUL, V7, P813, DOI 10.1016/j.brs.2014.08.002; Gold J. M., 2004, COMPREHENSIVE TXB PS, P1436; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Green MF, 2004, BIOL PSYCHIAT, V56, P301, DOI 10.1016/j.biopsych.2004.06.023; Green MF, 2005, SCHIZOPHRENIA BULL, V31, P882, DOI 10.1093/schbul/sbi049; Green MF, 2004, SCHIZOPHR RES, V72, P41, DOI 10.1016/j.schres.2004.09.009; Green MF, 2000, SCHIZOPHRENIA BULL, V26, P119, DOI 10.1093/oxfordjournals.schbul.a033430; Green MF, 1996, AM J PSYCHIAT, V153, P321; Hasan A, 2016, SCHIZOPHRENIA BULL, V42, pS95, DOI 10.1093/schbul/sbv158; Hoy KE, 2014, SCHIZOPHR RES, V155, P96, DOI 10.1016/j.schres.2014.03.006; Jahshan C, 2013, SCHIZOPHR RES, V143, P348, DOI 10.1016/j.schres.2012.11.025; Kee KS, 2003, SCHIZOPHRENIA BULL, V29, P487, DOI 10.1093/oxfordjournals.schbul.a007021; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; Koenigs M, 2009, CLIN NEUROPHYSIOL, V120, P80, DOI 10.1016/j.clinph.2008.10.010; Lee J, 2011, PSYCHOL MED, V41, P2297, DOI 10.1017/S0033291711000614; Marder SR, 2004, SCHIZOPHR RES, V72, P5, DOI 10.1016/j.schres.2004.09.010; Mattai A, 2011, BRAIN STIMUL, V4, P275, DOI 10.1016/j.brs.2011.01.001; Mayer J. D., 2002, TECHNICAL MANUAL MSC; McDonald S, 2002, AWARENESS SOCIAL INF; Mondino M, 2015, SCHIZOPHR RES, V161, P515, DOI 10.1016/j.schres.2014.10.054; Nitsche MA, 2009, NEUROTHERAPEUTICS, V6, P244, DOI 10.1016/j.nurt.2009.01.003; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; Nuechterlein KH, 2004, SCHIZOPHR RES, V72, P29, DOI 10.1016/j.schres.2004.09.007; Oldrati V, 2018, BRAIN RES, V1678, P32, DOI 10.1016/j.brainres.2017.10.002; Pinkham AE, 2003, AM J PSYCHIAT, V160, P815, DOI 10.1176/appi.ajp.160.5.815; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Rassovsky Y, 2015, SCHIZOPHR RES, V165, P171, DOI 10.1016/j.schres.2015.04.016; Ruf SP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01055-1; Smith RC, 2015, SCHIZOPHR RES, V168, P260, DOI 10.1016/j.schres.2015.06.011; Stover EL, 2007, SCHIZOPHRENIA BULL, V33, P1093, DOI 10.1093/schbul/sbm085; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221; Vercammen A, 2011, SCHIZOPHR RES, V131, P198, DOI 10.1016/j.schres.2011.06.021; Wynn JK, 2013, PSYCHOL MED, V43, P109, DOI 10.1017/S0033291712001006; Wynn JK, 2008, SCHIZOPHRENIA BULL, V34, P679, DOI 10.1093/schbul/sbn047; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227	49	20	22	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2018	13	5							e0197023	10.1371/journal.pone.0197023	http://dx.doi.org/10.1371/journal.pone.0197023			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE8KX	29734347	Green Published, Green Submitted, gold			2023-01-03	WOS:000431481700041
J	Dumontet, C; Couray-Targe, S; Teisseire, M; Karlin, L; Maucort-Boulch, D				Dumontet, Charles; Couray-Targe, Sandrine; Teisseire, Marion; Karlin, Lionel; Maucort-Boulch, Delphine			Real life management of patients hospitalized with multiple myeloma in France	PLOS ONE			English	Article							VENOUS THROMBOEMBOLISM; POPULATION; BORTEZOMIB; PATTERNS; LENALIDOMIDE; SURVIVAL; AGE	Background Patients with multiple myeloma included in prospective clinical trials are highly selected and therefore are expected not to be representative of the entire patient population. Additionally recommendations based on literature data and randomized trials are not systematically implemented in all patients. We sought to determine how patients hospitalized with a diagnosis of multiple myeloma are currently treated in France. Methods and findings We performed a nation-wide search using the Programme de Medicalisation des Systemes d'Information (PMSI) database which includes anonymous data for all patients hospitalized in France. We identified newly diagnosed cases in 2012 and analyzed the number and duration of hospital stays, coexisting conditions and treatment modalities with data available until the end of 2015. A diagnosis of multiple myeloma was determined for the first time during a hospitalization in France in 2012 in 6,282 patients (3,234 males and 3,048 females). The median age at diagnosis was 74 years (72 in males and 76 in females). A majority (55.3%) of patients were diagnosed and treated in a single heath center, including 37% in a university hospital and 52% in a non-university public hospital. Comorbidities potentially impacting on myeloma treatment were present in 57.5% of patients at diagnosis, and 15% had an associated diagnosis of another neoplasia. Intensive therapies with stem cell transplants were performed in 1033 patients (16% of total), the majority of which were aged less than 65 (881 patients, 85.3%). Stem cell transplants were performed more frequently in males while the distance between the site of residence and the transplant center had no impact on likelihood of receiving a transplant. Only 60% of patients less than 65 years old who were treated for their disease underwent intensification with stem cell transplant within the 4-year follow-up period. Conclusions A large majority of patients hospitalized with a diagnosis of multiple myeloma are elderly, in particular females, and not eligible for transplants. Among the patients aged less than 65 and receiving therapy for their disease, 40% do not undergo transplants. These data emphasize the need for alternative therapies.	[Dumontet, Charles; Karlin, Lionel] Hosp Civils Lyon, Hematol Dept, Pierre Benite, France; [Dumontet, Charles; Maucort-Boulch, Delphine] Univ Lyon 1, Villeurbanne, France; [Couray-Targe, Sandrine; Teisseire, Marion] Hosp Civils Lyon, DIM, Lyon, France; [Maucort-Boulch, Delphine] Hosp Civils Lyon, Serv Biostat, Lyon, France; [Maucort-Boulch, Delphine] CNRS, UMR 5558, Equipe Biostat Sante, Pierre Benite, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); VetAgro Sup	Dumontet, C (corresponding author), Hosp Civils Lyon, Hematol Dept, Pierre Benite, France.; Dumontet, C (corresponding author), Univ Lyon 1, Villeurbanne, France.	charles.dumontet@chu-lyon.fr		Dumontet, Charles/0000-0003-1875-134X				Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; Blommestein HM, 2016, EUR J HAEMATOL, V96, P198, DOI 10.1111/ejh.12571; Fourrier-Reglat A, 2014, LEUKEMIA LYMPHOMA, V55, P848, DOI 10.3109/10428194.2013.806801; Grelaud A, 2016, LEUKEMIA LYMPHOMA, V57, P1349, DOI 10.3109/10428194.2015.1096354; Leleu X, 2013, THROMB HAEMOSTASIS, V110, P844, DOI 10.1160/TH13-02-0140; Mateos MV, 2015, BLOOD REV, V29, P387, DOI 10.1016/j.blre.2015.06.001; Mian M, 2016, ANTICANCER RES, V36, P1059; Moulis G, 2015, REV MED INTERNE, V36, P411, DOI 10.1016/j.revmed.2014.11.009; Offidani M, 2012, CL LYMPH MYELOM LEUK, V12, P423, DOI 10.1016/j.clml.2012.06.008; Palmaro A, 2017, PHARMACOEPIDEM DR S, V26, P578, DOI 10.1002/pds.4180; Palmaro A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006189; Quach H, 2009, INTERN MED J, V39, P290, DOI 10.1111/j.1445-5994.2008.01738.x; Rios-Tamayo R, 2016, AM J HEMATOL, V91, P700, DOI 10.1002/ajh.24389; Rios-Tamayo R, 2015, CANCER EPIDEMIOL, V39, P693, DOI 10.1016/j.canep.2015.08.002; Touzeau C, 2017, LEUKEMIA, V31, P1039, DOI 10.1038/leu.2017.60; Turesson I, 2010, MAYO CLIN PROC, V85, P225, DOI 10.4065/mcp.2009.0426; Velez R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009584; Waxman AJ, 2010, BLOOD, V116, P5501, DOI 10.1182/blood-2010-07-298760; Winn AN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv139	19	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2018	13	5							e0196596	10.1371/journal.pone.0196596	http://dx.doi.org/10.1371/journal.pone.0196596			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE5RZ	29715281	Green Submitted, Green Published, gold			2023-01-03	WOS:000431281100036
J	Teichman, J; Dodbiba, L; Thai, H; Fleet, A; Morey, T; Liu, L; McGregor, M; Cheng, DX; Chen, Z; Darling, G; Brhane, Y; Song, YY; Espin-Garcia, O; Xu, W; Girgis, H; Schwock, J; MacKay, H; Bristow, R; Ailles, L; Liu, G				Teichman, Jennifer; Dodbiba, Lorin; Thai, Henry; Fleet, Andrew; Morey, Trevor; Liu, Lucy; McGregor, Madison; Cheng, Dangxiao; Chen, Zhuo; Darling, Gail; Brhane, Yonathan; Song, Yuyao; Espin-Garcia, Osvaldo; Xu, Wei; Girgis, Hala; Schwock, Joerg; MacKay, Helen; Bristow, Robert; Ailles, Laurie; Liu, Geoffrey			Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma	PLOS ONE			English	Article							BARRETTS METAPLASIA; STEM-CELLS; GASTROESOPHAGEAL JUNCTION; GASTROINTESTINAL-TRACT; SMOOTHENED INHIBITOR; PANCREATIC-CANCER; IN-VIVO; PATHWAY; PROLIFERATION; ACTIVATION	Background The Hedgehog (Hh) signaling pathway is active in esophageal adenocarcinoma (EAC). We used a patient-derived murine xenograft (PDX) model of EAC to evaluate tumour response to conventional treatment with radiation/chemoradiation with or without Hh inhibition. Our goal was to determine the potential radioresistance effects of Hh signaling and radiosensitization by Hh inhibitors. Methods PDX models were treated with radiation, chemotherapy or combined chemoradiation. Tumour response was measured by growth delay. Hh transcript levels (qRT-PCR) were compared among frozen tumours from treated and control mice. 5E1, a monoclonal SHH antibody, or LDE225, a clinical SMO inhibitor (Novartis (R)) inhibited Hh signaling. Results Precision irradiation significantly delayed xenograft tumour growth in all 7 PDX models. Combined chemoradiation further delayed growth relative to either modality alone in three of six PDX models. Following irradiation, two of three PDX models demonstrated sustained up-regulation of Hh transcripts. Combined LDE225 and radiation, and 5E1 alone delayed growth relative to either treatment alone in a Hh-responsive PDX model, but not in a non-responsive model. Conclusion Hh signaling mediates the radiation response in some EAC PDX models, and inhibition of this pathway may augment the efficacy of radiation in tumours that are Hh dependent.	[Teichman, Jennifer; Morey, Trevor] Univ Toronto, Postgrad Med Educ, Toronto, ON, Canada; [Teichman, Jennifer; Dodbiba, Lorin; Liu, Lucy; Bristow, Robert; Ailles, Laurie; Liu, Geoffrey] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Thai, Henry; Fleet, Andrew; Liu, Lucy; McGregor, Madison; Cheng, Dangxiao; Chen, Zhuo; Xu, Wei; Bristow, Robert; Ailles, Laurie; Liu, Geoffrey] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Darling, Gail] Univ Hlth Network, Dept Thorac Surg, Toronto, ON, Canada; [Brhane, Yonathan; Song, Yuyao; Espin-Garcia, Osvaldo; Xu, Wei] Dalla Lana Sch Publ Hlth, Div Biostat, Toronto, ON, Canada; [Xu, Wei; Liu, Geoffrey] Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada; [Girgis, Hala; Schwock, Joerg] Dept Lab Med & Pathobiol, Toronto, ON, Canada; [MacKay, Helen] Sunnybrook Hlth Sci Ctr, Div Med Oncol, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Liu, G (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.; Liu, G (corresponding author), Princess Margaret Canc Ctr, Toronto, ON, Canada.; Liu, G (corresponding author), Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada.	Geoffrey.liu@uhn.ca	Teichman, Jennifer/AHE-5052-2022	Teichman, Jennifer/0000-0002-7538-5772; Bristow, Robert/0000-0002-8553-9544	Ontario Graduate Scholarship	Ontario Graduate Scholarship(Ontario Graduate Scholarship)	The work was supported by an Ontario Graduate Scholarship, and by institutional funding held by the principle investigator. LDE 225 was supplied by Novartis. Novartis had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Ahlgren SC, 1999, CURR BIOL, V9, P1304, DOI 10.1016/S0960-9822(00)80052-4; Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Bailey JM, 2008, CLIN CANCER RES, V14, P5995, DOI 10.1158/1078-0432.CCR-08-0291; Beachy PA, 2004, NATURE, V431, P402, DOI 10.1038/431402a; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Boonstra JJ, 2010, JNCI-J NATL CANCER I, V102, P271, DOI 10.1093/jnci/djp499; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chaudary N, 2012, CANCER-AM CANCER SOC, V118, P3105, DOI 10.1002/cncr.26635; Chen Y.F., 2011, INT J ROCK MECH MIN, V03, P1, DOI DOI 10.1016/J.IJR0BP.2011.01.003; Chung CH, 2011, J CLIN ONCOL, V29, P1326, DOI 10.1200/JCO.2010.32.3295; Clemons NJ, 2013, CANCER BIOL THER, V14, P782, DOI 10.4161/cbt.25362; Dallas VA Medical Center, 2000, FEAS ITR TARG THER I; Damhofer H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0469-1; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dodbiba L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121872; Dodbiba L, 2013, LAB INVEST, V93, P397, DOI 10.1038/labinvest.2013.8; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Gibson MK, 2013, ANN SURG, V258, P82, DOI 10.1097/SLA.0b013e318270500d; Kebenko M, 2015, CELL SIGNAL, V27, P373, DOI 10.1016/j.cellsig.2014.11.022; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Ma XL, 2006, INT J CANCER, V118, P139, DOI 10.1002/ijc.21295; Minsky BD, 2002, J CLIN ONCOL, V20, P1167, DOI 10.1200/JCO.20.5.1167; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; Polednak AP, 2003, INT J CANCER, V105, P98, DOI 10.1002/ijc.11029; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Shirai K, 2011, J RADIAT RES, V52, P264, DOI 10.1269/jrr.10166; Shridhar Ravi, 2013, J Gastrointest Cancer, V44, P375, DOI 10.1007/s12029-013-9511-9; Sidney Kimmel Comprehensive Cancer Center, 2000, PHAS 2 STUD GEMC NAB; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Souza RF, 2016, DIGEST DIS, V34, P483, DOI 10.1159/000445225; van den Brink GR, 2007, PHYSIOL REV, V87, P1343, DOI 10.1152/physrev.00054.2006; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Wadhwa R, 2017, BRIT J CANCER, V117, P648, DOI 10.1038/bjc.2017.225; Wang DH, 2014, J CLIN INVEST, V124, P3767, DOI 10.1172/JCI66603; Wang DH, 2010, GASTROENTEROLOGY, V138, P1810, DOI 10.1053/j.gastro.2010.01.048; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Yang Ling, 2012, Int J Biochem Mol Biol, V3, P46; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011; Yoshikawa R, 2008, BRIT J CANCER, V98, P1670, DOI 10.1038/sj.bjc.6604361; Zaidi AH, 2013, CANCER INVEST, V31, P480, DOI 10.3109/07357907.2013.820317; Zeng J, 2013, INT J RADIAT ONCOL, V86, P143, DOI 10.1016/j.ijrobp.2012.10.014; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	54	12	13	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2018	13	5							e0194809	10.1371/journal.pone.0194809	http://dx.doi.org/10.1371/journal.pone.0194809			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE5RZ	29715275	Green Submitted, Green Published, gold			2023-01-03	WOS:000431281100004
J	Oquendo, MA; Volkow, ND				Oquendo, Maria A.; Volkow, Nora D.			Suicide: A Silent Contributor to Opioid-Overdose Deaths	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Oquendo, Maria A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Volkow, Nora D.] NIDA, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Oquendo, MA (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.		Oquendo, Maria/AAC-6237-2019		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], 2017, AM J PUBLIC HEALTH, V107, P421; Bohnert KM, 2017, ADDICTION, V112, P1193, DOI 10.1111/add.13774; Johnson EM, 2013, J GEN INTERN MED, V28, P522, DOI 10.1007/s11606-012-2225-z; Mack Karin A, 2017, MMWR Surveill Summ, V66, P1, DOI 10.15585/mmwr.ss6619a1; Stone DM, 2017, AM J PUBLIC HEALTH, V107, P1233, DOI [10.2105/AJPH.2017.303863, 10.2105/ajph.2017.303863]	5	127	127	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2018	378	17					1567	1569		10.1056/NEJMp1801417	http://dx.doi.org/10.1056/NEJMp1801417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD8XP	29694805				2023-01-03	WOS:000430797900002
J	Tam, P; Nijjar, AP; Fok, M; Little, C; Shingina, A; Bittman, J; Raghavan, R; Khan, NA				Tam, Penny; Nijjar, Aman P.; Fok, Mark; Little, Chris; Shingina, Alexandra; Bittman, Jesse; Raghavan, Rashmi; Khan, Nadia A.			Structured patient handoff on an internal medicine ward: A cluster randomized control trial	PLOS ONE			English	Article							IMPLEMENTATION; CURRICULUM; PROGRAM; ERRORS; SYSTEM; CARE	Background The effect of a multi-faceted handoff strategy in a high volume internal medicine inpatient setting on process and patient outcomes has not been clearly established. We set out to determine if a multi-faceted handoff intervention consisting of education, standardized handoff procedures, including fixed time and location for face-to-face handoff would result in improved rates of handoff compared with usual practice. We also evaluated resident satisfaction, health resource utilization and clinical outcomes. Methods This was a cluster randomized controlled trial in a large academic tertiary care center with 18 inpatient internal medicine ward teams from January-April 2013. We randomized nine inpatient teams to an intervention where they received an education session standardizing who and how to handoff patients, with practice and feedback from facilitators. The control group of 9 teams continued usual non-standardized handoffs. The primary process outcome was the rate of patients handed over per 1000 patient nights. Other process outcomes included perceptions of inadequate handoff by overnight physicians, resource utilization overnight and hospital length of stay. Clinical outcomes included medical errors, frequency of patients requiring higher level of care overnight, and in-hospital mortality. Results The intervention group demonstrated a significant increase in the rate of patients handed over to the overnight physician (62.90/1000 person-nights vs. 46.86/1000 person-nights, p = 0.002). There was no significant difference in other process outcomes except resource utilization was increased in the intervention group (26.35/1000 person-days vs. 17.57/1000 person-days, p-value = 0.01). There was no significant difference between groups in medical errors (4.8% vs. 4.1%), need for higher level of care or in hospital mortality. Limitations include a dependence of accurate record keeping by the overnight physician, the possibility of cross-contamination in the handoff process, analysis at the cluster level and an overall low number of clinical events. Conclusions Implementation of a multi-faceted resident handoff intervention did not result in a significant improvement in patient safety although did improve number of patients handed off. Novel methods to improve handoff need to be explored.	[Tam, Penny; Nijjar, Aman P.; Little, Chris; Bittman, Jesse; Khan, Nadia A.] Univ British Columbia, Dept Med, Div Gen Internal Med, Vancouver, BC, Canada; [Fok, Mark] Univ British Columbia, Div Geriatr Med, Dept Med, Vancouver, BC, Canada; [Shingina, Alexandra] Univ Toronto, Dept Med, Toronto, ON, Canada; [Raghavan, Rashmi] Univ British Columbia, Div Family Practice, Dept Med, Vancouver, BC, Canada; [Khan, Nadia A.] Univ British Columbia, Ctr Hlth Evaluat & Outcomes Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of Toronto; University of British Columbia; University of British Columbia	Nijjar, AP (corresponding author), Univ British Columbia, Dept Med, Div Gen Internal Med, Vancouver, BC, Canada.	apnijjar@gmail.com			Canadian Medical Protective Agency [GRNT-2706]; Michael Smith Foundation for Health Research	Canadian Medical Protective Agency; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	This work was supported by the Canadian Medical Protective Agency GRNT-2706 to PT and the Michael Smith Foundation for Health Research to NAK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accreditation Council for Graduate Medical Education, COMM PROGR REQ; Allen S, 2014, ACAD MED, V89, P1366, DOI 10.1097/ACM.0000000000000462; [Anonymous], 2014, POL STAT HAND ED CAN; Bittman J, 2017, POSTGRAD MED J, V93, P313, DOI 10.1136/postgradmedj-2016-133999; Borowitz SM, 2008, QUAL SAF HEALTH CARE, V17, P6, DOI 10.1136/qshc.2006.019273; Chu ES, 2009, ACAD MED, V84, P347, DOI 10.1097/ACM.0b013e3181970829; Clanton J, 2017, AM J SURG, V213, P299, DOI 10.1016/j.amjsurg.2016.10.015; Colligan L, 2015, NEW ENGL J MED, V372, P490, DOI 10.1056/NEJMc1414788; Gakhar B, 2010, ACAD MED, V85, P1182, DOI 10.1097/ACM.0b013e3181da8370; Horwitz LI, 2007, J GEN INTERN MED, V22, P1470, DOI 10.1007/s11606-007-0331-0; Johnson David P, 2015, Hosp Pediatr, V5, P154, DOI 10.1542/hpeds.2014-0050; *JOINT COMM, 2009 HOSP NAT PAT SA; Pattani R, 2014, CAN MED ASSOC J, V186, P761, DOI 10.1503/cmaj.131053; Payne CE, 2012, BMJ QUAL SAF, V21, P925, DOI 10.1136/bmjqs-2011-000308; Rayar M, 2014, 2014 CAN C MED ED OT; Riebschleger M, ACGME ENHANCING QUAL; Riesenberg LA, 2009, ACAD MED, V84, P1775, DOI 10.1097/ACM.0b013e3181bf51a6; Schouten WM, 2015, J HOSP MED, V10, P137, DOI 10.1002/jhm.2293; Starmer AJ, 2014, NEW ENGL J MED, V371, P1803, DOI 10.1056/NEJMsa1405556; Starmer AJ, 2013, JAMA-J AM MED ASSOC, V310, P2262, DOI 10.1001/jama.2013.281961; Starmer AJ, 2012, PEDIATRICS, V129, P201, DOI 10.1542/peds.2011-2966; Van Eaton EG, 2005, J AM COLL SURGEONS, V200, P538, DOI 10.1016/j.jamcollsurg.2004.11.009; WHO, 2010, HIGH 5S PROJ ACT PAT	23	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2018	13	4							e0195216	10.1371/journal.pone.0195216	http://dx.doi.org/10.1371/journal.pone.0195216			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD4BF	29672526	Green Submitted, Green Published, gold			2023-01-03	WOS:000430446800023
J	Wronski, S; Dannenmaier, J; Schild, S; Macke, O; Muller, L; Burmeister, Y; Seilheimer, B; Muller, M				Wronski, Sabine; Dannenmaier, Julia; Schild, Sabine; Macke, Olaf; Mueller, Laura; Burmeister, Yvonne; Seilheimer, Bernd; Mueller, Meike			Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity	PLOS ONE			English	Article							ALVEOLAR MACROPHAGES; IN-VITRO; INFECTION; PATHOGENESIS; RECRUITMENT; IMMUNITY; GAMMA; CELLS; RSV; IFN	Background Respiratory viruses such as respiratory syncytial virus (RSV) or rhinovirus are one of the major causes for respiratory tract infections causing common cold disease. Respiratory viral infections range from mild symptoms in adults to serious illness especially in the very young or elderly as well as patients suffering from lung diseases or being immunocompromised due to other reasons. Engystol (EGY-2) is a multicomponent, multitarget preparation consisting of Vincetoxicum hirundinaria and Sulfur in various dilutions. The study objective was to test the effect of EGY-2 on the innate immune response during the early onset of respiratory viral infection in vivo as exemplified in a mouse model of RSV-induced respiratory inflammation. Methods Naive BALB/c mice were infected with 1x10(6) infectious units RSV A2 intranasally to cause a mild respiratory infection. EGY-2 was administered daily per oral gavage starting seven days prior to RSV infection at doses of 0.4 to 5.1 tablets/kg. Control groups received placebo treatment. Animals were sacrificed 1 to 3 days post infection (p.i.) to analyse the infection and induced immune response in the lung. Viral load in bronchoalveolar lavage fluid (BALF) and lung homogenate was determined by TCID50 assay as well as immunofluorescence staining of BALF cells using anti-RSV antibody and microscopic analysis. The RSV induced immune response was assessed by evaluation of BALF differential cell count, BALF cytokine secretion and analysis of the phagocytic capacity of alveolar macrophages. Results EGY-2 significantly reduced the RSV induced neutrophil and early lymphocyte influx on day 1 p.i. in BALF. EGY-2 treatment significantly diminished the RSV induced secretion of pro-inflammatory cytokines such as IFN-gamma, IL-1 beta, IL-6, KC and TNF-alpha at day 1. EGY-2 treatment was not protective for RSV infection per se, as no alteration in the viral load in lung and BALF was detected. Enhanced numbers of phagocytic-active macrophages were observed in EGY-2 treated animals on day 1 and this macrophage population showed strongly enhanced phagocytic activity on day 1 and day 3. Conclusion The data suggest a beneficial immunomodulatory effect of EGY-2 during early onset of respiratory viral infection in vivo, mediated by stimulation of macrophage phagocytosis, resulting in a reduced innate inflammatory response in terms of neutrophil and early lymphocyte infiltration as well as reduced inflammatory cytokine secretion.	[Wronski, Sabine; Schild, Sabine; Macke, Olaf; Mueller, Laura; Mueller, Meike] Fraunhofer Inst Toxicol & Expt Med, Dept Preclin Pharmacol & Immunol, Hannover, Germany; [Wronski, Sabine; Schild, Sabine; Macke, Olaf; Mueller, Laura; Mueller, Meike] German Ctr Lung Res, Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany; [Dannenmaier, Julia; Burmeister, Yvonne; Seilheimer, Bernd] Biol Heilmittel Heel GmbH, Baden, Switzerland	Fraunhofer Gesellschaft	Wronski, S (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Dept Preclin Pharmacol & Immunol, Hannover, Germany.; Wronski, S (corresponding author), German Ctr Lung Res, Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany.	sabine.wronski@item.fraunhofer.de			Biologische Heilmittel Heel GmbH, Baden-Baden, Germany	Biologische Heilmittel Heel GmbH, Baden-Baden, Germany	The study was funded by Biologische Heilmittel Heel GmbH, Baden-Baden, Germany, which employed authors JD, YB and BS at the time this work was generated and reviewed, and authorized the manuscript. The funder provided support in form of salaries for the authors JD, YB, and BS, and provided the test substance and placebo, but was not actively involved in practical implementation data collection, analysis and decision to publish. The specific roles of these authors are articulated in the 'authors contributions' section.	BECKER S, 1991, J IMMUNOL, V147, P4307; Caballero MT, 2018, PEDIAT PULMONOL, V65, P73; Divangahi M, 2015, TRENDS IMMUNOL, V36, P307, DOI 10.1016/j.it.2015.03.005; FRANKEULLMANN G, 1995, J IMMUNOL, V154, P268; Goritzka M, 2015, J EXP MED, V212, P699, DOI 10.1084/jem.20140825; Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9; Heilmann A., 1994, BIOMED THER, V12, P249; Herzberger G, 1997, BIOMEDICAL THERAPY, V15, P123; Hussell T, 1998, J GEN VIROL, V79, P2593, DOI 10.1099/0022-1317-79-11-2593; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Jafri HS, 2004, J INFECT DIS, V189, P1856, DOI 10.1086/386372; Kolli D, 2014, AM J RESP CELL MOL, V51, P502, DOI 10.1165/rcmb.2013-0414OC; Lay MK, 2013, MICROBES INFECT, V15, P230, DOI 10.1016/j.micinf.2012.11.012; Loebbermann J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032371; Makris S, 2016, J INNATE IMMUN, V8, P452, DOI 10.1159/000446824; Michel T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051230; Miller AL, 2004, J INFECT DIS, V189, P1419, DOI 10.1086/382958; Monto AS, 2002, AM J MED, V112, p4S; Oberbaum M, 2005, J ALTERN COMPLEM MED, V11, P855, DOI 10.1089/acm.2005.11.855; PANUSKA JR, 1995, J CLIN INVEST, V96, P2445, DOI 10.1172/JCI118302; Passioti M, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0413-5; Piedimonte G, 2015, CLEV CLIN J MED, V82, pS13, DOI 10.3949/ccjm.82.s1.03; Roeska Kerstin, 2010, J Immune Based Ther Vaccines, V8, P6, DOI 10.1186/1476-8518-8-6; Schmiedel V, 2006, EXPLORE-NY, V2, P109, DOI 10.1016/j.explore.2005.12.008; Tayyari F, 2012, EXPERT REV RESP MED, V6, P215, DOI [10.1586/ERS.12.8, 10.1586/ers.12.8]; Thompson TM, 2015, CLIN MICROBIOL, V4, DOI [10.4172/2327-5073.1000206, DOI 10.4172/2327-5073.1000206]; van Schaik SM, 2000, J MED VIROL, V62, P257, DOI 10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M	27	3	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2018	13	4							e0195822	10.1371/journal.pone.0195822	http://dx.doi.org/10.1371/journal.pone.0195822			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD4BF	29672626	Green Published, Green Submitted, gold			2023-01-03	WOS:000430446800047
J	Choi, SKY; Boyle, E; Cairney, J; Grootendorst, P; Gardner, S; Collins, EJ; Kendall, C; Rourke, SB				Choi, Stephanie K. Y.; Boyle, Eleanor; Cairney, John; Grootendorst, Paul; Gardner, Sandra; Collins, Evan J.; Kendall, Claire; Rourke, Sean B.		OHTN Cohort Study	Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study	PLOS ONE			English	Article							SUBSTANCE USE DISORDERS; LONG-TERM CONDITIONS; MENTAL-HEALTH; COLLABORATIVE CARE; INFECTED PATIENTS; UNSCHEDULED CARE; SERVICES; HIV/AIDS; OUTCOMES; ILLNESS	Introduction Nearly half of HIV-positive patients experience mental health and substance use problems, but many do not receive adequate or ongoing mental health or addiction care. This lack of ongoing care can result in the use of costly acute care services. Prospective evaluations of the relationship between psychiatric and substance use disorders and acute care services use are lacking, and this information is needed to understand unmet needs and improve access to appropriate services. Methods We conducted a secondary data analysis from a multicenter, longitudinal, prospective cohort study (n = 3,482 adults) between October 1, 2007 and March 31, 2013. We used explanatory extended Cox proportional hazard regression models to examine the impact of current depression and recreational drug use on acute care services use, and to explore whether current depression and recreational drug use were associated with potentially avoidable acute care services use. Results Over our 5.5 year study period, HIV-positive participants with current depression-only (aHR [95% CI]:1.2[1.1-1.4]), recreational drug use-only (1.3[1.1-1.6]), or co-occurring depression and recreational drug use (1.4[1.2-1.7]) were associated with elevated hazard of emergency department (ED) encounters compared to participants without these conditions. Over half of ED encounters were potentially avoidable. Participants with current depression-only (1.3[1.1-1.5];1.3[1.03-1.6]), recreational drug use-only (1.3[1.04-1.6];1.5[1.1-1.9]), or co-occurring depression and recreational drug use (1.3[1.04-1.7];1.4[1.06-1.9]) were associated with elevated hazard of low-acuity or repeated ED encounters respectively. Conclusions We found a significant increase in ED services use and potentially avoidable ED encounters (including low-acuity or repeated ED encounters), particularly among those with either current depression or recreational drug use. These findings emphasize the challenges in managing HIV and mental health/addiction co-morbidities in the current HIV care model. Future research should evaluate integrated and collaborative care programs for improving the coordination of care and effectively treat mental health and addiction problems among HIV-positive patients in Ontario.	[Choi, Stephanie K. Y.; Rourke, Sean B.] Ontario HIV Treatment Network, Toronto, ON, Canada; [Choi, Stephanie K. Y.] Univ New South Wales, Fac Med, Sydney, NSW, Australia; [Boyle, Eleanor; Cairney, John; Gardner, Sandra] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Boyle, Eleanor] Univ Southern Denmark, Inst Sports Sci & Clin Biomech, Odense, Denmark; [Cairney, John] McMaster Univ, Dept Family Med, Hamilton, ON, Canada; [Cairney, John; Kendall, Claire] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Cairney, John] McMaster Univ, Infant & Child Hlth Lab, Hamilton, ON, Canada; [Cairney, John] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Cairney, John] McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON, Canada; [Cairney, John] McMaster Univ, Offord Ctr Child Studies, Hamilton, ON, Canada; [Cairney, John] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Cairney, John] Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Cairney, John] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Grootendorst, Paul] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Grootendorst, Paul] Univ Toronto, Sch Publ Policy & Governance, Toronto, ON, Canada; [Grootendorst, Paul] McMaster Univ, Dept Econ, Hamilton, ON, Canada; [Gardner, Sandra] Baycrest Hosp, Rotman Res Inst, Toronto, ON, Canada; [Collins, Evan J.; Rourke, Sean B.] Univ Toronto, Dept Psychiat, Fac Med, Toronto, ON, Canada; [Collins, Evan J.] Univ Hlth Network, Toronto, ON, Canada; [Kendall, Claire] Bruyere Res Inst, Ottawa, ON, Canada; [Kendall, Claire] Univ Ottawa, Ottawa, ON, Canada; [Kendall, Claire] Ottawa Hosp, Ottawa, ON, Canada; [Rourke, Sean B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Urban Hlth Solut, Toronto, ON, Canada	University of New South Wales Sydney; University of Toronto; University of Southern Denmark; McMaster University; University of Toronto; McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of Toronto; McMaster University; University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Rourke, SB (corresponding author), Ontario HIV Treatment Network, Toronto, ON, Canada.; Rourke, SB (corresponding author), Univ Toronto, Dept Psychiat, Fac Med, Toronto, ON, Canada.; Rourke, SB (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Urban Hlth Solut, Toronto, ON, Canada.	sean.rocrke@utoronto.ca	Cairney, John/AAQ-9703-2020; Boyle, Eleanor/G-4567-2016	Cairney, John/0000-0003-2856-3967; Boyle, Eleanor/0000-0002-9012-9128; Choi, Stephanie Ka Yee/0000-0003-3019-5729; Kendall, Claire/0000-0003-2686-1135; Grootendorst, Paul/0000-0003-1978-2834	Ontario HIV Treatment Network (OHTN); Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care (MOHLTC)	Ontario HIV Treatment Network (OHTN); Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario)	The study was supported by the Ontario HIV Treatment Network (OHTN) and the Institute for Clinical Evaluative Sciences, which are funded by annual grants from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Atlantis E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004706; Bansil P, 2009, AIDS CARE, V21, P1432, DOI 10.1080/09540120902814387; Barua B, 2015, WAITING YOUR TURN; Bess KD, 2013, AIDS PATIENT CARE ST, V27, P171, DOI 10.1089/apc.2012.0406; Bing EG, 2001, ARCH GEN PSYCHIAT, V58, P721, DOI 10.1001/archpsyc.58.8.721; Brien S., 2015, TAKING STOCK REPORT; Bullard MJ, 2014, CAN J EMERG MED, V16, P485, DOI 10.2310/8000.2014.012014; Canadian Institute for Health Information [creator], 2015, DISCH ABSTR DAT; Chibanda D, 2014, JAIDS-J ACQ IMM DEF, V67, pS54, DOI 10.1097/QAI.0000000000000258; Choi BY, 2016, WEST J EMERG MED, V17, P153, DOI 10.5811/westjem.2016.1.28310; Choi SKY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165816; Choi SKY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156652; Choi SKY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142706; Christopoulos KA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001863; Chu C, 2011, J URBAN HEALTH, V88, P556, DOI 10.1007/s11524-011-9552-y; Cook JA, 2014, AIDS BEHAV, V18, P1094, DOI 10.1007/s10461-013-0679-6; Curran GM, 2011, AIDS CARE, V23, P1626, DOI 10.1080/09540121.2011.579943; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Dickens C, 2012, J PSYCHOSOM RES, V73, P334, DOI 10.1016/j.jpsychores.2012.08.018; Fairbairn N, 2012, J EMERG MED, V43, P236, DOI 10.1016/j.jemermed.2011.05.020; Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Himelhoch S, 2007, GEN HOSP PSYCHIAT, V29, P518, DOI 10.1016/j.genhosppsych.2007.03.008; Huang YF, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-260; Iron K., 2006, ICES REPORT HLTH DAT, V9, P24, DOI [10.12927/hcq, DOI 10.12927/HCQ]; Josephs JS, 2010, HIV MED, V11, P74, DOI 10.1111/j.1468-1293.2009.00748.x; Kaaya S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001447; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Katz MH, 1996, AIDS CARE, V8, P433, DOI 10.1080/09540129650125623; Krentz HB, 2006, HIV MED, V7, P457, DOI 10.1111/j.1468-1293.2006.00408.x; Kurdyak P, 2014, OPEN MED, V8, P99; Lam CN, 2016, WEST J EMERG MED, V17, P607, DOI 10.5811/westjem.2016.6.30690; Langer S, 2013, HEALTH SOC CARE COMM, V21, P339, DOI 10.1111/j.1365-2524.2012.01093.x; Mental Health Commission of Canada, 2012, CHANG DIR; Nanni MG, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-014-0530-4; Painter JT, 2015, JAIDS-J ACQ IMM DEF, V70, P377, DOI 10.1097/QAI.0000000000000732; Prina AM, 2015, J PSYCHOSOM RES, V78, P25, DOI 10.1016/j.jpsychores.2014.11.002; Ross LE, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0353-3; Rourke SB, 2013, INT J EPIDEMIOL, V42, P402, DOI 10.1093/ije/dyr230; Sharpe M, 2014, LANCET, V384, P1099, DOI 10.1016/S0140-6736(14)61231-9; Shmueli G, 2010, STAT SCI, V25, P289, DOI 10.1214/10-STS330; StataCorp, 2013, STAT STAT SOFTW REL; Taylor SL, 2004, RELATIONSHIP TYPE ME; The Canadian Institute for Health Information, 2015, NAT AMB CAR REP SYST; Tricco AC, 2014, CAN MED ASSOC J, V186, pE568, DOI 10.1503/cmaj.140289; Uthman OA, 2014, CURR HIV-AIDS REP, V11, P291, DOI 10.1007/s11904-014-0220-1; Vittinghoff E, 2012, REGRESSION METHODS B; Weaver MR, 2008, JAIDS-J ACQ IMM DEF, V47, P449, DOI 10.1097/QAI.0b013e3181642244; Woltmann E, 2012, AM J PSYCHIAT, V169, P790, DOI 10.1176/appi.ajp.2012.11111616	50	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2018	13	4							e0195185	10.1371/journal.pone.0195185	http://dx.doi.org/10.1371/journal.pone.0195185			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GC0YY	29630615	gold, Green Submitted, Green Published			2023-01-03	WOS:000429505000029
J	Kalzen, H; Larsson, B; Eksborg, S; Lindberg, L; Edberg, KE; Frostell, C				Kalzen, Hakan; Larsson, Bjorn; Eksborg, Staffan; Lindberg, Lars; Edberg, Karl Erik; Frostell, Claes			Survival after PICU admission: The impact of multiple admissions and complex chronic conditions	PLOS ONE			English	Article							PEDIATRIC INTENSIVE-CARE; RISK-FACTORS; CRITICAL ILLNESS; MORTALITY SCORE; OUTCOMES; CHILDREN; READMISSIONS; PREDICTION; INDEX; UNIT	Objective Factors predicting survival over time after pediatric intensive care unit (PICU) admissions are not fully understood. The primary aim of the current study was to investigate whether multiple admissions (MADM) compared to single PICU admissions (SADM) were associated with poor survival over time after being admitted to PICU facilities. Our secondary aim was to investigate if the presence of a complex chronic condition (CCC) would further impair prognosis. Design A closed cohort of all children up to 16 years of age admitted to the three PICUs in Sweden between 2008 and 2010 was prospectively collected and followed until 2012, providing survival data for at least one but up to four years of follow-up. Setting Three Swedish tertiary referral centers for pediatric intensive care and extracorporeal membrane oxygenation (ECMO) care were used. Patients In total, 3,688 Swedish children with 5,019 PICU admissions were included. Interventions No interventions were conducted. Measurements An extensive data set was recorded, including up to four-year survival information following first PICU admission. The patients were assigned to seven admission diagnostic groups, which were then divided into SADM or MADM groups. The difference in survival over time and mortality rates (MR) and mortality rate ratios (MRR) were calculated. SADM and MADM groups with and without an existing CCC were formed. The difference in survival over time between groups was calculated. Main results A highly significant difference in survival over time was noted between SADM and MADM patients (p<0.0001), which was intensified by the presence of a CCC. MADM patients with a CCC had the worst outcome, while SADM patients without a CCC had the best outcome. MADM patients with no CCC demonstrated decreased survival over time compared to SADM patients with a CCC. Survival over time was statistically worsened for patients with MADM compared to SADM for the following admission diagnostic groups: Cardiovascular, Gastrointestinal/Renal, Respiratory, Neurological, and Miscellaneous. The mortality rate (deaths/patient year of follow-up) during the time of follow-up was 0.023 for SADM and 0.062 for MADM patients. The mortality rate ratio (MRR) between these groups was 2.69. Conclusion Compared to single admissions, multiple admissions to PICU were associated with a significant decrease in survival over time in some but not all diagnostic groups. Regarding our secondary aim, we found that when the presence of a CCC is factored into the survival analysis, survival over time is further impaired.	[Kalzen, Hakan; Larsson, Bjorn] Karolinska Univ Hosp Solna, Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Paediat Anaesthesia Intens Care & ECMO Serv, Stockholm, Sweden; [Eksborg, Staffan] Karolinska Univ Hosp Solna, Astrid Lindgren Childrens Hosp, Karolinska Inst, Childhood Canc Res Unit Q6 05,Dept Womens & Child, Stockholm, Sweden; [Lindberg, Lars] Univ Hosp Lund, Paediat Intens Care Unit, Childrens Hosp, Dept Anaesthesia & Intens Care, Lund, Sweden; [Edberg, Karl Erik] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, Dept Paediat Intens Care, Gothenburg, Sweden; [Frostell, Claes] KIDS, Danderyd Hosp, Dept Anaesthesia & Intens Care, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Lund University; Skane University Hospital; Queen Silvia Children's Hospital; Sahlgrenska University Hospital; Danderyds Hospital	Kalzen, H (corresponding author), Karolinska Univ Hosp Solna, Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Paediat Anaesthesia Intens Care & ECMO Serv, Stockholm, Sweden.	hakan.kalzen@ki.se		Kalzen, Hakan/0000-0001-5859-070X; Eksborg, Staffan/0000-0001-7326-9471; Lindberg, Lars/0000-0002-2246-2826	Stockholm County Council [20130324, 20150224]; Karolinska Institutet [20130324, 20150224]; Stockholm County Council; Research and Consulting Inc.	Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Stockholm County Council(Stockholm County Council); Research and Consulting Inc.	Financial support from the regional agreement on medical training and clinical research (ALF), projects 20130324 and 20150224 between Stockholm County Council and Karolinska Institutet (Dr S Eksborg), additional financial support from Stockholm County Council (Hakan Kalzen 2+2 weeks of payed time for research) and C.F. Research and Consulting Inc. (computer resourse and covering costs for data extraction) are gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Czaja AS, 2013, PEDIATR CRIT CARE ME, V14, P571, DOI 10.1097/PCC.0b013e3182917a68; Costa GD, 2010, CLINICS, V65, P1087, DOI 10.1590/S1807-59322010001100005; Edwards JD, 2013, CRIT CARE MED, V41, P2773, DOI 10.1097/CCM.0b013e31829eb970; Edwards JD, 2012, CRIT CARE MED, V40, P2196, DOI 10.1097/CCM.0b013e31824e68cf; European Medicines Agency (EMA), MED CHINDR; Feudtner C, 2000, PEDIATRICS, V106, P205; Feudtner C, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-199; Feudtner C, 2009, J PALLIAT MED, V12, P160, DOI 10.1089/jpm.2008.0206; Gullberg N, 2008, ACTA ANAESTH SCAND, V52, P1086, DOI 10.1111/j.1399-6576.2008.01711.x; Namachivayam P, 2010, PEDIATR CRIT CARE ME, V11, P549, DOI 10.1097/PCC.0b013e3181ce7427; Namachivayam SP, 2015, CRIT CARE MED, V43, P1978, DOI 10.1097/CCM.0000000000001076; Nicholson Carol E, 2003, Pediatr Crit Care Med, V4, P196, DOI 10.1097/01.PCC.0000059728.63798.DA; O'Brien S, 2017, PEDIATR CRIT CARE ME, V18, P1, DOI 10.1097/PCC.0000000000000976; Odetola FO, 2007, PEDIATR CRIT CARE ME, V8, P343, DOI 10.1097/01.PCC.0000269400.67463.AC; Pinto NP, 2017, PEDIATR CRIT CARE ME, V18, pE122, DOI 10.1097/PCC.0000000000001070; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pollack MM, 2015, CRIT CARE MED, V43, P1699, DOI 10.1097/CCM.0000000000001081; Rhodes A, 2012, INTENS CARE MED, V38, P598, DOI 10.1007/s00134-011-2462-3; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Slater A, 2003, INTENS CARE MED, V29, P271, DOI 10.1007/s00134-002-1600-3; Socialstyrelsen. Dodsorsaker, 2013, DODS CAUS DEATH REG	22	17	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0193294	10.1371/journal.pone.0193294	http://dx.doi.org/10.1371/journal.pone.0193294			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6TQ	29621235	gold, Green Published, Green Submitted			2023-01-03	WOS:000429206800004
J	Olesen, SW; Barnett, ML; MacFadden, DR; Lipsitch, M; Grad, YH				Olesen, Scott W.; Barnett, Michael L.; MacFadden, Derek R.; Lipsitch, Marc; Grad, Yonatan H.			Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; ENGLISH PRIMARY-CARE; UNITED-STATES; PATIENT; CONSUMPTION; INFECTIONS; RESISTANCE; SETTINGS; PROVIDER	OBJECTIVE To identify temporal trends in outpatient antibiotic use and antibiotic prescribing practice among older adults in a high income country. DESIGN Observational study using United States Medicare administrative claims in 2011-15. SETTING Medicare, a US national healthcare program for which 98% of older adults are eligible. PARTICIPANTS 4.5 million fee-for-service Medicare beneficiaries aged 65 years old and older. MAIN OUTCOME MEASURES Overall rates of antibiotic prescription claims, rates of potentially appropriate and inappropriate prescribing, rates for each of the most frequently prescribed antibiotics, and rates of antibiotic claims associated with specific diagnoses. Trends in antibiotic use were estimated by multivariable regression adjusting for beneficiaries' demographic and clinical covariates. RESULTS The number of antibiotic claims fell from 1364.7 to 1309.3 claims per 1000 beneficiaries per year in 2011-14 (adjusted reduction of 2.1% (95% confidence interval 2.0% to 2.2%)), but then rose to 1364.3 claims per 1000 beneficiaries per year in 2015 (adjusted reduction of 0.20% over 201115 (0.09% to 0.30%)). Potentially inappropriate antibiotic claims fell from 552.7 to 522.1 per 1000 beneficiaries over 2011- 14, an adjusted reduction of 3.9% (3.7% to 4.1%). Individual antibiotics had heterogeneous changes in use. For example, azithromycin claims per beneficiary decreased by 18.5% (18.2% to 18.8%) while levofloxacin claims increased by 27.7% (27.2% to 28.3%). Azithromycin use associated with each of the potentially appropriate and inappropriate respiratory diagnoses decreased, while levofloxacin use associated with each of those diagnoses increased. CONCLUSIONS Among US Medicare beneficiaries, overall antibiotic use and potentially inappropriate use in 2011- 15 remained steady or fell modestly, but individual drugs had divergent changes in use. Trends in drug use across indications were stronger than trends in use for individual indications, suggesting that guidelines and concerns about antibiotic resistance were not major drivers of change in antibiotic use.	[Olesen, Scott W.; Lipsitch, Marc; Grad, Yonatan H.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Barnett, Michael L.] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Dept Med, Boston, MA USA; [MacFadden, Derek R.] Univ Toronto, Div Infect Dis, Dept Med, Toronto, ON, Canada; [MacFadden, Derek R.; Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Ctr Communicable Dis Dynam, Boston, MA USA; [Grad, Yonatan H.] Harvard Med Sch, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Grad, YH (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Grad, YH (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.	ygrad@hsph.harvard.edu	Barnett, Michael/ABA-4159-2021; Barnett, Michael/AAF-4017-2019	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609; Olesen, Scott/0000-0001-5400-4945	US National Institute of General Medical Sciences [U54GM088558]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM088558] Funding Source: NIH RePORTER	US National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	SWO and ML were supported by cooperative agreement U54GM088558 from the US National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.	Almalki ZS, 2016, PHARMACOEPIDEM DR S, V25, P1042, DOI 10.1002/pds.4021; Arizpe A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2091-0; Barnett ML, 2014, JAMA-J AM MED ASSOC, V311, P2020, DOI 10.1001/jama.2013.286141; Barnett ML, 2014, JAMA INTERN MED, V174, P138, DOI 10.1001/jamainternmed.2013.11673; Blue Cross Blue Shield, 2017, ANT PRESCR FILL RAT; Burke JP, 1998, JAMA-J AM MED ASSOC, V280, P1270, DOI 10.1001/jama.280.14.1270; Centers for Disease Control and Prevention, 2017, ANT PRESCR US US; Centers for Disease Control and Prevention, AMB HLTH CAR DAT; Department of Health and Human Services, 2012, OEI041000180 DEP HLT; Dolk FCK, 2018, J ANTIMICROB CHEMOTH, V73, P2, DOI 10.1093/jac/dkx504; Durkin MJ, 2018, INFECT CONT HOSP EP, V39, P584, DOI 10.1017/ice.2018.26; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Grijalva CG, 2009, JAMA-J AM MED ASSOC, V302, P758, DOI 10.1001/jama.2009.1163; Hicks LA, 2015, CLIN INFECT DIS, V60, P1308, DOI 10.1093/cid/civ076; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Lee GC, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-96; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Lynch JP, 2002, CLIN INFECT DIS, V34, pS27, DOI 10.1086/324527; MACKINNON JG, 1985, J ECONOMETRICS, V29, P305, DOI 10.1016/0304-4076(85)90158-7; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; McCaig LF, 2003, EMERG INFECT DIS, V9; Mues KE, 2017, CLIN EPIDEMIOL, V9, P267, DOI 10.2147/CLEP.S105613; Pichichero ME, 2002, JAMA-J AM MED ASSOC, V287, P3133, DOI 10.1001/jama.287.23.3133; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P19, DOI 10.1093/jac/dkx502; Price L, 2018, J ANTIMICROB CHEMOTH, V73, P1464, DOI 10.1093/jac/dky076; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Riedle BN, 2017, INFECT CONT HOSP EP, V38, P273, DOI 10.1017/ice.2016.269; Riley GF, 2009, HEALTH AFFAIR, V28, P1826, DOI 10.1377/hlthaff.28.6.1826; Roumie CL, 2005, J GEN INTERN MED, V20, P697, DOI 10.1111/j.1525-1497.2005.0148.x; Schmidt ML, 2018, INFECT CONT HOSP EP, V39, P307, DOI 10.1017/ice.2017.263; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Smieszek T, 2018, J ANTIMICROB CHEMOTH, V73, P36, DOI 10.1093/jac/dkx500; Smith DRM, 2018, J ANTIMICROB CHEMOTH, V73, P11, DOI 10.1093/jac/dkx503; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Suda KJ, 2018, CLIN INFECT DIS, V66, P185, DOI 10.1093/cid/cix773; United States Food and Drug Administration, 2016, FDA DRUG SAF COMM FD; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; Zhang YT, 2012, ARCH INTERN MED, V172, P1465, DOI 10.1001/archinternmed.2012.3717	41	47	48	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 27	2018	362								k3155	10.1136/bmj.k3155	http://dx.doi.org/10.1136/bmj.k3155			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GO9ED	30054353	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000440407100001
J	Haddad, F; Bourke, J; Wong, K; Leonard, H				Haddad, Fatma; Bourke, Jenny; Wong, Kingsley; Leonard, Helen			An investigation of the determinants of quality of life in adolescents and young adults with Down syndrome	PLOS ONE			English	Article							DEVELOPMENTAL BEHAVIOR CHECKLIST; ANXIETY STRESS SCALES; INTELLECTUAL DISABILITY; MENTAL-RETARDATION; WESTERN-AUSTRALIA; CHILDREN; PEOPLE; HEALTH; MOTHERS; PSYCHOPATHOLOGY	Background Young people with Down syndrome experience varying abilities in activities of daily living, cognitive functioning, behaviour and social skills. The aim of this research was to investigate, from a carer's perspective, the factors that influenced the quality of life of these young people. Methods Families of young people with Down syndrome (n = 197), aged 16-31 years, living in Western Australia, took part in a questionnaire study regarding young person daily functioning, family characteristics, medical background and quality of life measured by the Kidscreen 27-item scale. Kidscreen-10 total score was used as an outcome in the investigation of determinants with higher scores indicating better quality of life. Results After adjustment for confounders including carer's mental health measured by the Depression and Anxiety Scale (DASS), global impact of illness as well as impact of mental health and bowel conditions were all negatively associated with the young person's quality of life. Young people who had three or more friends had better quality of life than those with no friends. Scores were lower (reflecting poor quality of life) in individuals who had more behavioural problems but these relationships were attenuated after adjustment for confounders and DASS. Conclusions Overall, our findings revealed that quality of life of young people with Down syndrome was most negatively associated with burden of medical conditions, but also with lack of friendships. We were somewhat surprised to find the effect of medical problems on quality of life persisting into adolescence and adulthood where in general the burden of medical comorbidities is much less than in childhood.	[Haddad, Fatma; Leonard, Helen] Univ Western Australia, Perth, WA, Australia; [Bourke, Jenny; Wong, Kingsley; Leonard, Helen] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia	University of Western Australia; Telethon Kids Institute; University of Western Australia	Leonard, H (corresponding author), Univ Western Australia, Perth, WA, Australia.; Leonard, H (corresponding author), Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia.	helen.leonard@telethonkids.org.au	Wong, Kingsley/I-6935-2013; Leonard, Helen/A-1010-2013	Wong, Kingsley/0000-0001-5178-6080; Leonard, Helen/0000-0001-6405-5834	Australian Research Alliance for Children and Youth; Australian Research Council [LP0989847]; NHMRC [1117105]	Australian Research Alliance for Children and Youth; Australian Research Council(Australian Research Council); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We acknowledge the initial seed funding from Australian Research Alliance for Children and Youth and the ongoing funding provided by the Australian Research Council #LP0989847 for the project 'Leaving School: Maximising participation and life outcomes in youth with an intellectual disability transitioning from secondary school to adult life'. We acknowledge NHMRC Fellowship funding for Helen Leonard (#1117105).	Rodriguez VB, 2016, PSICOTHEMA, V28, P311, DOI 10.7334/psicothema2016.10; Bittles AH, 2007, EUR J PUBLIC HEALTH, V17, P221, DOI 10.1093/eurpub/ckl103; Bourke J, 2008, J PEDIATR-US, V153, P320, DOI 10.1016/j.jpeds.2008.02.047; Bower C, 2000, J PAEDIATR CHILD H, V36, P213, DOI 10.1046/j.1440-1754.2000.00480.x; Brown I, 2009, J POLICY PRACTICE IN, V6; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Clarke AR, 2003, J INTELL DISABIL RES, V47, P210, DOI 10.1046/j.1365-2788.2003.00470.x; Cuskelly M, 2003, AM J MENT RETARD, V108, P234, DOI 10.1352/0895-8017(2003)108<234:SROCWD>2.0.CO;2; Davis E, 2007, QUAL LIFE RES, V16, P863, DOI 10.1007/s11136-007-9187-3; de Winter CF, 2011, J INTELL DISABIL RES, V55, P675, DOI 10.1111/j.1365-2788.2011.01390.x; Dykens EM, 2007, MENT RETARD DEV D R, V13, P272, DOI 10.1002/mrdd.20159; EINFELD SL, 1995, J AUTISM DEV DISORD, V25, P81, DOI 10.1007/BF02178498; Einfeld SL, 1996, J INTELL DISABIL RES, V40, P99, DOI 10.1111/j.1365-2788.1996.tb00611.x; Einfeld SL, 2006, JAMA-J AM MED ASSOC, V296, P1981, DOI 10.1001/jama.296.16.1981; FELCE D, 1995, RES DEV DISABIL, V16, P51, DOI 10.1016/0891-4222(94)00028-8; Fidler Deborah J, 2006, Downs Syndr Res Pract, V10, P23, DOI 10.3104/reports.302; Finlay WML, 2002, MENT RETARD, V40, P14, DOI 10.1352/0047-6765(2002)040<0014:AIIWPW>2.0.CO;2; Fitzgerald P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070401; Foley KR, 2013, CHILD CARE HLTH DEV, V39, P789, DOI 10.1111/cch.12019; Foley KR, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000710; Foley KR, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0266-z; Foley KR, 2014, SOC PSYCH PSYCH EPID, V49, P1455, DOI 10.1007/s00127-013-0812-x; Graves RJ, 2016, AJIDD-AM J INTELLECT, V121, P312, DOI 10.1352/1944-7558-121.4.312; HEAL LW, 1995, J INTELL DISABIL RES, V39, P331, DOI 10.1111/j.1365-2788.1995.tb00525.x; Hodapp RM, 2001, PARENT-SCI PRACT, V1, P317, DOI 10.1207/S15327922PAR0104_3; Leonard S, 2002, J PAEDIATR CHILD H, V38, P160, DOI 10.1046/j.1440-1754.2002.00736.x; Mantry D, 2008, J INTELL DISABIL RES, V52, P141, DOI 10.1111/j.1365-2788.2007.00985.x; McCarthy J, 2008, J INTELL DISABIL RES, V52, P877, DOI 10.1111/j.1365-2788.2008.01104.x; McClintock K, 2003, J INTELL DISABIL RES, V47, P405, DOI 10.1046/j.1365-2788.2003.00517.x; MCCONKEY R, 1982, J MENT DEFIC RES, V26, P47; Mulroy S, 2008, J INTELL DISABIL RES, V52, P216, DOI 10.1111/j.1365-2788.2007.01005.x; Ng F, 2007, ACTA NEUROPSYCHIATR, V19, P304, DOI 10.1111/j.1601-5215.2007.00217.x; Oates A, 2011, DISABIL REHABIL, V33, P1880, DOI 10.3109/09638288.2011.553701; Olsson MB, 2001, J INTELL DISABIL RES, V45, P535, DOI 10.1046/j.1365-2788.2001.00372.x; Petterson B, 2005, ANN HUM BIOL, V32, P237, DOI 10.1080/03014460500075035; Phillips A, 2009, AUST J RURAL HEALTH, V17, P2, DOI 10.1111/j.1440-1584.2008.01029.x; Pikora TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096868; Pillay D, 2012, DISABIL REHABIL, V34, P1501, DOI 10.3109/09638288.2011.650313; RASCH G, 1966, BRIT J MATH STAT PSY, V19, P49, DOI 10.1111/j.2044-8317.1966.tb00354.x; Rofail D, 2017, ADV THERAPY; Roizen NJ, 2010, INT REV RES MENTAL R, V39; Thomas K, 2010, INT REV RES MENTAL R, V39; van Gameren-Oosterom HBM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021879; White-Koning M, 2005, DEV MED CHILD NEUROL, V47, P281, DOI 10.1017/S0012162205000526; World Health Organization, 2021, WHO GUID HLTH WORKF; Xanthopoulos MS, 2017, J PEDIAT SC, V189	46	19	19	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2018	13	6							e0197394	10.1371/journal.pone.0197394	http://dx.doi.org/10.1371/journal.pone.0197394			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GJ2HI	29897903	Green Published, Green Submitted, gold			2023-01-03	WOS:000435090700013
J	Verburg, IWM; de Jonge, E; Peek, N; de Keizer, NF				Verburg, Ilona W. M.; de Jonge, Evert; Peek, Niels; de Keizer, Nicolette F.			The association between outcome-based quality indicators for intensive care units	PLOS ONE			English	Article							IN-HOSPITAL MORTALITY; LENGTH-OF-STAY; CRITICALLY-ILL PATIENTS; RELIABILITY ADJUSTMENT; DISCHARGE PRACTICES; PREDICTION MODELS; READMISSION RATE; ACUTE PHYSIOLOGY; PERFORMANCE; ICU	Purpose To assess and improve the effectiveness of ICU care, in-hospital mortality rates are often used as principal quality indicator for benchmarking purposes. Two other often used, easily quantifiable, quality indicators to assess the efficiency of ICU care are based on readmission to the ICU and ICU length of stay. Our aim was to examine whether there is an association between case-mix adjusted outcome-based quality indicators in the general ICU population as well as within specific subgroups. Materials and methods We included patients admitted in 2015 of all Dutch ICUs. We derived the standardized in hospital mortality ratio (SMR); the standardized readmission ratio (SRR); and the standardized length of stay ratio (SLOSR). We expressed association through Pearson's correlation coefficients. Results The SMR ranged from 0.6 to 1.5; the SRR ranged from 0.7 to 2.1; and the SLOSR ranged from 0.7 to 1.3. For the total ICU population we found no significant associations. We found a positive, non-significant, association between SMR and SLOSR for admissions with low mortality risk, (r = 0.25; p = 0.024), and a negative association between these indicators for admissions with high-mortality risk (r =-0.49; p<0.001). Conclusion Overall, we found no association at ICU population level. Differential associations were found between performance on mortality and length of stay within different risk strata. We recommend users of quality information to take these three outcome indicators into account when benchmarking ICUs as they capture different aspects of ICU performance. Furthermore, we suggest to report quality indicators for patient subgroups.	[Verburg, Ilona W. M.; de Keizer, Nicolette F.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, Amsterdam Publ Hlth res inst, Amsterdam, Netherlands; [de Jonge, Evert] Leiden Univ, Med Ctr, Dept Intens Care, Leiden, Netherlands; [Peek, Niels] Univ Manchester, Div Informat Imaging & Data Sci, Manchester, Lancs, England	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Manchester	Verburg, IWM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, Amsterdam Publ Hlth res inst, Amsterdam, Netherlands.	i.w.verburg@amc.uva.nl	Peek, Niels/AAD-9334-2019	Peek, Niels/0000-0002-6393-9969	National Intensive Care Evaluation (NICE) Foundation	National Intensive Care Evaluation (NICE) Foundation	Drs. Verburg and De Keizer's institutions received grant support and support for participation in review activities from the National Intensive Care Evaluation (NICE) Foundation (The NICE Foundation pays the department of Medical Informatics for maintaining the national database, providing feedback reports, and doing analyses; Drs. Verburg and De Keizer are employees of the Department of Medical Informatics). Drs. de Keizer and De Jonge are members of the board of the NICE Foundation.	Bates D, PACKAGE IME4 1; Beck DH, 2002, INTENS CARE MED, V28, P1287, DOI 10.1007/s00134-002-1412-5; Benbassat J, 2000, ARCH INTERN MED, V160, P1074, DOI 10.1001/archinte.160.8.1074; Berenholtz SM, 2002, J CRIT CARE, V17, P1, DOI 10.1053/jcrc.2002.33035; Brinkman S, 2013, INTENS CARE MED, V39, P1925, DOI 10.1007/s00134-013-3042-5; Brinkman S, 2012, CRIT CARE MED, V40, P373, DOI 10.1097/CCM.0b013e318232d7b0; Brown SES, 2012, AM J RESP CRIT CARE, V185, P955, DOI 10.1164/rccm.201109-1720OC; Cooper GS, 1999, MED CARE, V37, P399, DOI 10.1097/00005650-199904000-00009; Dara SI, 2005, CHEST, V128, P567, DOI 10.1378/chest.128.2.567; Davies S., FITTING GEN LINEAR M; Development Core Team R, 2005, LANG ENV STAT COMP; Dimick JB, 2010, HEALTH SERV RES, V45, P1614, DOI 10.1111/j.1475-6773.2010.01158.x; Dutch National Intensive Care Evaluation (NICE) foundation, 2014, DAT IN BEELD; Engerstrom L, 2016, CRIT CARE MED, V44, pE1038, DOI 10.1097/CCM.0000000000001877; Flaatten H, 2012, ACTA ANAESTH SCAND, V56, P1078, DOI 10.1111/j.1399-6576.2012.02656.x; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; Harell FE, 2017, PACKAGE RMS 2017; Hashmi ZG, 2013, J TRAUMA ACUTE CARE, V75, P166, DOI 10.1097/TA.0b013e318298494f; Hofstede SN, 2018, BMJ QUAL SAF, V27, P474, DOI 10.1136/bmjqs-2017-006776; Kaboli PJ, 2012, ANN INTERN MED, V157, P837, DOI 10.7326/0003-4819-157-12-201212180-00003; Kahn JM, 2008, MED CARE, V46, P1226, DOI 10.1097/MLR.0b013e31817d9342; Koetsier A, 2013, METHOD INFORM MED, V52, P432, DOI 10.3414/ME12-02-0070; Kolfschoten NE, 2013, EJSO-EUR J SURG ONC, V39, P156, DOI 10.1016/j.ejso.2012.10.007; Kramer AA, 2013, CRIT CARE MED, V41, P24, DOI 10.1097/CCM.0b013e3182657b8a; Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081; Metnitz PGH, 2003, INTENS CARE MED, V29, P241, DOI 10.1007/s00134-002-1584-z; Moran JL, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-68; Mulvey GK, 2009, CIRC-CARDIOVASC QUAL, V2, P558, DOI 10.1161/CIRCOUTCOMES.108.826784; Pouw ME, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5913; Roos-Blom MJ, 2015, STUD HEALTH TECHNOL, V210, P429, DOI 10.3233/978-1-61499-512-8-429; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; Rosenberg AL, 2001, CRIT CARE MED, V29, P511, DOI 10.1097/00003246-200103000-00008; Russell S, 1999, HEART LUNG, V28, P365, DOI 10.1053/hl.1999.v28.a101055; Rydenfelt K, 2015, ACTA ANAESTH SCAND, V59, P846, DOI 10.1111/aas.12554; Savicky P., 2017, TEST ASS CORRELATION; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Strand K, 2010, CRIT CARE, V14, DOI 10.1186/cc9279; van de Klundert N, 2015, INT J EPIDEMIOL, V44, P1850, DOI 10.1093/ije/dyv291; van Sluisveld N, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2234-z; Vasilevskis EE, 2009, MED CARE, V47, P803, DOI 10.1097/MLR.0b013e3181a39454; Verburg IWM, 2018, STAT METHODS MED RES, V27, P3350, DOI 10.1177/0962280217700169; Verburg IWM, 2018, J CRIT CARE, V43, P114, DOI 10.1016/j.jcrc.2017.08.014; Verburg IWM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109684; Williams Teresa, 2004, Aust Health Rev, V28, P87; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	47	6	6	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2018	13	6							e0198522	10.1371/journal.pone.0198522	http://dx.doi.org/10.1371/journal.pone.0198522			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ2HI	29897994	Green Published, gold, Green Submitted			2023-01-03	WOS:000435090700057
J	Chan, AC; Burke, CA; Coffey, EM; Hilden, DR; Coira, DL; Warner-Cohen, J; Grady, M; Muskin, PR; Shinozaki, G				Chan, Aubrey C.; Burke, Christopher A.; Coffey, Ellen M.; Hilden, David R.; Coira, Diego L.; Warner-Cohen, Jessy; Grady, Margaret; Muskin, Philip R.; Shinozaki, Gen			Integrated Inpatient Medical and Psychiatric Care: Experiences of 5 Institutions	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DISORDERS		[Chan, Aubrey C.] Univ Iowa Hosp & Clin, Dept Psychiat & Internal Med, 200 Hawkins Dr, Iowa City, IA 52242 USA; [Shinozaki, Gen] Univ Iowa Hosp & Clin, Dept Psychiat, Med Labs B002F,25 South Grand Ave, Iowa City, IA 52242 USA; [Burke, Christopher A.] Long Isl Jewish Med Ctr, 270-05 76th Ave,Staff House Room 306, New Hyde Pk, NY 11040 USA; [Warner-Cohen, Jessy] Long Isl Jewish Med Ctr, Dept Psychiat, 270-05 76th Ave, New Hyde Pk, NY 11040 USA; [Coffey, Ellen M.] Hennepin Cty Med Ctr, Dept Internal Med, 701 Pk Ave, Minneapolis, MN 55415 USA; [Hilden, David R.] Hennepin Cty Med Ctr, Dept Med G5, 701 Pk Ave, Minneapolis, MN 55415 USA; [Coira, Diego L.; Grady, Margaret] Coira Inst, 851 Franklin Lake Rd,Suite 105, Franklin Lakes, NJ 07417 USA; [Muskin, Philip R.] Columbia Univ, Med Ctr, Dept Psychiat, 622 West 168th St,Mailbox 427, New York, NY 10032 USA	University of Iowa; University of Iowa; Northwell Health; Northwell Health; Hennepin County Medical Center; Hennepin County Medical Center; Columbia University	Shinozaki, G (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, Med Labs B002F,25 South Grand Ave, Iowa City, IA 52242 USA.	gen-shinozaki@uiowa.edu	Shinozaki, Gen/O-1281-2017	Shinozaki, Gen/0000-0001-6129-2789; Chan, Aubrey/0000-0002-9191-2173; Levin, Jessy/0000-0003-0928-8947				Baumeister H, 2015, BIOPSYCHOSOC MED, V9, DOI 10.1186/s13030-015-0039-z; Briskman I, 2012, INT J PSYCHIAT MED, V43, P339, DOI 10.2190/PM.43.4.d; Hussain M, 2014, PSYCHOSOMATICS, V55, P315, DOI 10.1016/j.psym.2013.08.003; Kathol RG, 2009, PSYCHOSOMATICS, V50, P93, DOI 10.1176/appi.psy.50.2.93; Mather B, 2014, ARCH PSYCHIAT NURS, V28, P80, DOI 10.1016/j.apnu.2013.10.009; Owens P, 2007, CARE ADULTS MENTAL H, V10	6	8	8	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 5	2018	168	11					815	+		10.7326/M17-3186	http://dx.doi.org/10.7326/M17-3186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GI3EK	29710091				2023-01-03	WOS:000434254100009
J	Kordbacheh, F; Carruthers, TJ; Bezos, A; Oakes, M; Du Fall, L; Hocart, CH; Parish, CR; Djordjevic, MA				Kordbacheh, Farzaneh; Carruthers, Thomas J.; Bezos, Anna; Oakes, Marie; Du Fall, Lauren; Hocart, Charles H.; Parish, Christopher R.; Djordjevic, Michael A.			Promotion of mammalian angiogenesis by neolignans derived from soybean extracellular fluids	PLOS ONE			English	Article							IN-VITRO ASSAYS; DRUG DISCOVERY; MASS-SPECTROMETRY; LIGNIN BIOSYNTHESIS; ANTITUMOR AGENTS; NATURAL-PRODUCTS; ISCHEMIC-STROKE; GROWTH-FACTOR; TUMOR-GROWTH; THERAPY	Excessive or insufficient angiogenesis is associated with major classes of chronic disease. Although less studied, small molecules which can promote angiogenesis are being sought as potential therapeutics for cardiovascular and peripheral arterial disease and stroke. Here we describe a bioassay-directed discovery approach utilising size exclusion and liquid chromatography to purify components of soybean xylem sap that have pro-angiogenic activity. Using high resolution accurate mass spectrometry and nuclear magnetic resonance spectroscopy, the structure of two pro-angiogenic molecules (FK1 and FK2) were identified as erythro-guaiacylglycerol-8-O-4'-(coniferyl alcohol) ether (eGGCE), and threo-guaiacylglycerol-8-O-4'-(coniferyl alcohol) ether (tGGCE). These two molecules, which are coniferyl neolignan stereoisomers, promoted in vitro angiogenesis in the mu M to nM range. Independently sourced samples of eGGCE and tGGCE exhibited comparable pro-angiogenic activity to the soybean derived molecules. The cellular mode of action of these molecules was investigated by studying their effect on endothelial cell proliferation, migration, tube formation and adhesion to the extracellular matrix (ECM) components, fibronectin and vitronectin. They were found to enhance endothelial cell proliferation and endothelial cell tube formation on Matrigel, but did not affect endothelial cell migration or adhesion to fibronectin and vitronectin. Thus, this study has identified two coniferyl neolignan stereoisomers, eGGCE and tGGCE, as pro-angiogenic molecules, with eGGCE being less active than tGGCE.	[Kordbacheh, Farzaneh; Oakes, Marie; Du Fall, Lauren; Hocart, Charles H.; Djordjevic, Michael A.] Australian Natl Univ, Res Sch Biol, Dept Plant Sci, Canberra, ACT, Australia; [Kordbacheh, Farzaneh; Bezos, Anna; Parish, Christopher R.] Australian Natl Univ, John Curtin Sch Med Res, ACRF Dept Canc Biol & Therapeut, Canberra, ACT, Australia; [Carruthers, Thomas J.] Australian Natl Univ, Res Sch Chem, Canberra, ACT, Australia	Australian National University; Australian National University; John Curtin School of Medical Research; Australian National University	Kordbacheh, F (corresponding author), Australian Natl Univ, Res Sch Biol, Dept Plant Sci, Canberra, ACT, Australia.; Kordbacheh, F (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, ACRF Dept Canc Biol & Therapeut, Canberra, ACT, Australia.	farzaneh.kordbacheh@anu.edu.au	Hocart, Charles H/F-2630-2011; Djordjevic, Michael/C-9945-2009	Hocart, Charles H/0000-0002-6167-2295; Parish, Christopher/0000-0001-7740-0430; Kordbacheh, Farzaneh/0000-0003-2208-1414; Djordjevic, Michael/0000-0002-9819-1372	ARC [DP1096299]; ARC Centre of Excellence [CEO348212]; NHMRC Program [455395]	ARC(Australian Research Council); ARC Centre of Excellence(Australian Research Council); NHMRC Program(National Health and Medical Research Council (NHMRC) of Australia)	MAD and CRP received research funding for this project, i.e., ARC Discovery Grant DP1096299 Dr MA Djordjevic; Prof LN Mander; Prof CR Parish "New functions for bioactive flavonoids in plants and mammals"; ARC Centre of Excellence Grant (CEO348212) and NHMRC Program Grant 455395 M. Berndt, C. Chesterman, B. Chong, P. Hogg, L. Khachigian, C. Parish and R. Stocker. Program entitled: "Vascular Biology". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhusban A, 2015, J HYPERTENS, V33, P170, DOI 10.1097/HJH.0000000000000364; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023; Baumgartner L, 2011, J NAT PROD, V74, P1779, DOI 10.1021/np200343t; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938; BROWN KJ, 1995, EXP CELL RES, V217, P132, DOI 10.1006/excr.1995.1072; Brown KJ, 1996, LAB INVEST, V75, P539; Buckler JN, 2017, ACS OMEGA, V2, P7375, DOI 10.1021/acsomega.7b01459; Butler MS, 2004, J NAT PROD, V67, P2141, DOI 10.1021/np040106y; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Costa F, 2009, LIFE SCI, V84, P785, DOI 10.1016/j.lfs.2009.03.002; Dembinska-Kiec A, 2004, EUR HEART J, V25, P471; Deshane J, 2007, J EXP MED, V204, P605, DOI 10.1084/jem.20061609; Djordjevic MA, 2007, J PROTEOME RES, V6, P3771, DOI 10.1021/pr0606833; Djordjevic MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112635; Folkman J, 2000, CLIN CANCER RES, V6; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Font MA, 2010, CURR CARDIOL REV, V6, P238, DOI 10.2174/157340310791658802; Goodwin AM, 2007, MICROVASC RES, V74, P172, DOI 10.1016/j.mvr.2007.05.006; Gupta R, 2009, CIRC RES, V105, P724, DOI 10.1161/CIRCRESAHA.109.200386; Hallund J, 2008, NUTR METAB CARDIOVAS, V18, P497, DOI 10.1016/j.numecd.2007.05.007; Herridge DF, 1997, CARBON NITROGEN NUTR; Hodges TW, 2004, J NAT PROD, V67, P767, DOI 10.1021/np030514m; Kancheva VD, 2012, BIOCHIMIE, V94, P403, DOI 10.1016/j.biochi.2011.08.008; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; Li QY, 2006, CURR MED CHEM, V13, P2021, DOI 10.2174/092986706777585004; Lin CM, 2010, J NUTR BIOCHEM, V21, P627, DOI 10.1016/j.jnutbio.2009.04.001; Liu CJ, 2009, J HEPATOL, V50, P958, DOI 10.1016/j.jhep.2008.12.023; Lourith N, 2005, J WOOD SCI, V51, P370, DOI 10.1007/s10086-004-0660-0; Mac Gabhann F, 2010, WIRES SYST BIOL MED, V2, P694, DOI 10.1002/wsbm.92; Morimoto N, 2008, J SURG RES, V145, P199, DOI 10.1016/j.jss.2007.05.031; Morreel K, 2010, ANAL CHEM, V82, P8095, DOI 10.1021/ac100968g; Morreel K, 2010, PLANT PHYSIOL, V153, P1464, DOI 10.1104/pp.110.156489; Mousa S, 2006, J CELL BIOCHEM, V97, P1370, DOI 10.1002/jcb.20741; Newman DJ, 2011, ABSTR PAP AM CHEM S, V241; NICOSIA RF, 1990, LAB INVEST, V63, P115; ONEILL HC, 1983, J IMMUNOL METHODS, V64, P257, DOI 10.1016/0022-1759(83)90433-7; Pandya NM, 2006, VASC PHARMACOL, V44, P265, DOI 10.1016/j.vph.2006.01.005; Parish CR, 1999, CANCER RES, V59, P3433; Patel N, 2018, MOL CELL PROTEOMICS, V17, P160, DOI [10.1074/mcp.RA117.000168, 10.1074/mcp.ra117.000168]; Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006-2952(96)00654-5; Qu HY, 2005, J NUTR, V135, P598, DOI 10.1093/jn/135.3.598; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; SCHAFER AI, 1995, J CLIN PHARMACOL, V35, P209, DOI 10.1002/j.1552-4604.1995.tb04050.x; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Silvestre JS, 2012, THROMB RES, V130, pS90, DOI 10.1016/j.thromres.2012.08.287; Staton CA, 2009, INT J EXP PATHOL, V90, P195, DOI 10.1111/j.1365-2613.2008.00633.x; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Tu Y, 2010, J NAT PROD, V73, P751, DOI 10.1021/np9007359; Vessecchi R, 2007, MINI-REV ORG CHEM, V4, P75, DOI 10.2174/157019307779815910; Wang JN, 2011, ARTERIOSCL THROM VAS, V31, pE19, DOI 10.1161/ATVBAHA.111.230706; Wang ZW, 2015, SEMIN CANCER BIOL, V35, pS224, DOI 10.1016/j.semcancer.2015.01.001; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; WHETTEN R, 1995, PLANT CELL, V7, P1001, DOI 10.2307/3870053; Zhou YJ, 2009, CLIN CANCER RES, V15, P5161, DOI 10.1158/1078-0432.CCR-09-0661	57	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2018	13	5							e0196843	10.1371/journal.pone.0196843	http://dx.doi.org/10.1371/journal.pone.0196843			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF1VY	29738532	Green Submitted, Green Published, gold			2023-01-03	WOS:000431724900023
J	Yoshida, T; Ri, M; Kinoshita, S; Narita, T; Totani, H; Ashour, R; Ito, A; Kusumoto, S; Ishida, T; Komatsu, H; Iida, S				Yoshida, Takashi; Ri, Masaki; Kinoshita, Shiori; Narita, Tomoko; Totani, Haruhito; Ashour, Reham; Ito, Asahi; Kusumoto, Shigeru; Ishida, Takashi; Komatsu, Hirokazu; Iida, Shinsuke			Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma	PLOS ONE			English	Article							MEDIATED DRUG-RESISTANCE; MARKER; NCAM; INHIBITOR; OVEREXPRESSION; TRANSLOCATION; CHEMOTHERAPY; SENSITIVITY; INDUCTION; APOPTOSIS	Bortezomib (Btz) is an active agent used to treat multiple myeloma (MM). Not all patients who receive Btz-containing therapy show a favorable response. Interaction of cellular adhesion molecules with MM and bone marrow stromal cells is crucial for the survival of MM cells. However, little is known about the role of these molecules in the sensitivity of MM to Btz-containing therapy. Thus, we evaluated the correlation between the level of cellular adhesion molecules in MM cells and the efficacy of Btz plus dexamethasone (Bd) therapy. The expression of the neural cell adhesion molecule gene (NCAM, also known as CD56), ITGA4, CXCR4, and other genes were analyzed in 74 samples of primary MM cells collected from patients before they received Bd therapy. Of the eight genes tested, expression of NCAM was lower among patients who responded poorly to Bd therapy. In vitro expression of NCAM induced by transfection of MM cells enhanced their sensitivity to Btz treatment by causing accumulation of polyubiquitinated proteins. Our results indicate that expression of NCAM is associated with better response to Btz treatment and is a promising candidate biomarker for predicting response to therapies involving Btz.	[Yoshida, Takashi; Ri, Masaki; Kinoshita, Shiori; Narita, Tomoko; Totani, Haruhito; Ashour, Reham; Ito, Asahi; Kusumoto, Shigeru; Ishida, Takashi; Komatsu, Hirokazu; Iida, Shinsuke] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan		Ri, M (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan.	rrmasaki@ybb.ne.jp	石田, 高司/GRS-3184-2022	石田, 高司/0000-0002-1060-0777; Yoshida, Takashi/0000-0002-1516-9613	Ministry of Education, Culture, Sports, Science and Technology [16K07179, 16K09855]; National Cancer Center Research and Development Fund [26-A-4]; Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED [15ck0106077h0002]	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED))	This work was supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (M.R: 16K07179, S.I: 16K09855); National Cancer Center Research and Development Fund (S.I.: 26-A-4); and Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED (S.I.: 15ck0106077h0002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Ms. Chiori Fukuyama for her skillful technical assistance. This study was partly supported by a Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (16K07179 & 16K09855), National Cancer Center Research and Development Fund (26-A-4), and by the Practical Research for Innovative Cancer Control project from Japan Agency for Medical Research and Development, AMED (15ck0106077h0002).	Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Bataille R, 2006, HAEMATOLOGICA, V91, P1234; Chang H, 2006, LEUKEMIA LYMPHOMA, V47, P43, DOI 10.1080/10428190500272549; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Durie BGM, 2017, LANCET, V389, P519, DOI 10.1016/S0140-6736(16)31594-X; Francavilla C, 2009, J CELL BIOL, V187, P1101, DOI 10.1083/jcb.200903030; Gambella M, 2014, HAEMATOLOGICA, V99, pE14, DOI 10.3324/haematol.2013.090142; Hundemer M, 2007, BONE MARROW TRANSPL, V40, P1033, DOI 10.1038/sj.bmt.1705857; Inagaki A, 2013, LEUKEMIA RES, V37, P1648, DOI 10.1016/j.leukres.2013.09.026; Jagannath S, 2006, HAEMATOL-HEMATOL J, V91, P929; Kaiser U, 1996, ANN HEMATOL, V73, P121, DOI 10.1007/s002770050212; Kaiser U, 1996, LEUKEMIA LYMPHOMA, V20, P389, DOI 10.3109/10428199609052420; Kremer M, 2005, J PATHOL, V205, P92, DOI 10.1002/path.1680; Kuhn DJ, 2012, BLOOD, V120, P3260, DOI 10.1182/blood-2011-10-386789; Leiba M, 2014, BRIT J HAEMATOL, V166, P702, DOI 10.1111/bjh.12946; Ling SCW, 2012, HAEMATOL-HEMATOL J, V97, P64, DOI 10.3324/haematol.2011.043331; Mateos MV, 2010, J CLIN ONCOL, V28, P2259, DOI 10.1200/JCO.2009.26.0638; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Miyazaki K.S., 2015, INT J MYELOM, V5, P30; Mizuno S, 2015, INT J HEMATOL, V102, P569, DOI 10.1007/s12185-015-1859-0; Narita T, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.98; Narita T, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.6; Noborio-Hatano K, 2009, ONCOGENE, V28, P231, DOI 10.1038/onc.2008.385; Paiva B, 2015, BLOOD, V125, P3059, DOI 10.1182/blood-2014-11-568907; Pan Y, 2016, LEUKEMIA RES, V40, P77, DOI 10.1016/j.leukres.2015.11.003; Pellat-Deceunynck C, 1998, LEUKEMIA, V12, P1977, DOI 10.1038/sj.leu.2401211; Rawstron AC, 2008, HAEMATOLOGICA, V93, P431, DOI 10.3324/haematol.11080; Ri M, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.26; Ri M, 2010, LEUKEMIA, V24, P1506, DOI 10.1038/leu.2010.137; Ri M, 2009, CANCER SCI, V100, P341, DOI 10.1111/j.1349-7006.2008.01038.x; Sahara N, 2004, LEUKEMIA LYMPHOMA, V45, P61, DOI 10.1080/1042819031000149377; Sahara N, 2002, BRIT J HAEMATOL, V117, P882, DOI 10.1046/j.1365-2141.2002.03513.x; Sonneveld P, 2012, J CLIN ONCOL, V30, P2946, DOI 10.1200/JCO.2011.39.6820; Yano H, 2008, CANCER SCI, V99, P2309, DOI 10.1111/j.1349-7006.2008.00936.x; Yin L, 2014, BLOOD, V123, P2997, DOI 10.1182/blood-2013-11-539395	35	13	17	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2018	13	5							e0196780	10.1371/journal.pone.0196780	http://dx.doi.org/10.1371/journal.pone.0196780			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF1VY	29738534	Green Published, Green Submitted, gold			2023-01-03	WOS:000431724900019
J	Weerahandi, H; Ziaeian, B; Fogerty, RL; Jenq, GY; Horwitz, LI				Weerahandi, Himali; Ziaeian, Boback; Fogerty, Robert L.; Jenq, Grace Y.; Horwitz, Leora I.			Predictors for patients understanding reason for hospitalization	PLOS ONE			English	Article							HEALTH LITERACY; DISCHARGE; CARE; COMMUNICATION; ASSOCIATION; OUTCOMES; QUALITY	Objective To examine predictors for understanding reason for hospitalization. Methods This was a retrospective analysis of a prospective, observational cohort study of patients 65 years or older admitted for acute coronary syndrome, heart failure, or pneumonia and discharged home. Primary outcome was complete understanding of diagnosis, based on post-discharge patient interview. Predictors assessed were the following: jargon on discharge instructions, type of medical team, whether outpatient provider knew if the patient was admitted, and whether the patient reported more than one day notice before discharge. Results Among 377 patients, 59.8% of patients completely understood their diagnosis. Bivariate analyses demonstrated that outpatient provider being aware of admission and having more than a day notice prior to discharge were not associated with patient understanding diagnosis. Presence of jargon was not associated with increased likelihood of understanding in a multivariable analysis. Patients on housestaff and cardiology teams were more likely to understand diagnosis compared to non-teaching teams (OR 2.45, 95% CI 1.30-4.61, p < 0.01 and OR 3.83, 95% CI 1.92-7.63, p < 0.01, respectively). Conclusions Non-teaching team patients were less likely to understand their diagnosis. Further investigation of how provider-patient interaction differs among teams may aid in development of tools to improve hospital to community transitions.	[Weerahandi, Himali; Horwitz, Leora I.] NYU, Sch Med, Dept Med, New York, NY 10003 USA; [Weerahandi, Himali; Horwitz, Leora I.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA; [Ziaeian, Boback] Univ Calif Los Angeles, Med Ctr, Div Cardiol, Los Angeles, CA 90024 USA; [Ziaeian, Boback] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA; [Fogerty, Robert L.] Yale Sch Med, Div Gen Internal Med, New Haven, CT USA; [Jenq, Grace Y.] Univ Michigan, Div Geriatr & Palliat Med, Ann Arbor, MI 48109 USA; [Horwitz, Leora I.] NYU, Langone Med Ctr, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA	New York University; New York University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Yale University; University of Michigan System; University of Michigan; New York University; NYU Langone Medical Center	Weerahandi, H (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10003 USA.; Weerahandi, H (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA.	Himali.Weerahandi@nyumc.org	Weerahandi, Himali/P-9560-2019; Ziaeian, Boback/A-3433-2016; Horwitz, Leora/ABD-1292-2020	Ziaeian, Boback/0000-0001-9787-3649; Weerahandi, Himali/0000-0001-9614-345X; Fogerty, Robert/0000-0001-9119-7707	CTSA grants from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 RR024139, KL2 RR024138]; National Institute on Aging [K08 AG038336]; American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine [P30AG021342 NIH/NIA]; NYU CTSA Grant [UL 1TR001445, KL2 TR001446]; NIH roadmap for Medical Research	CTSA grants from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine; NYU CTSA Grant; NIH roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	At the time this study was conducted, Dr. Horwitz was supported by the CTSA grants UL1 RR024139 and KL2 RR024138 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH roadmap for Medical Research, and was a Centers of Excellence Scholar in Geriatric Medicine by The John A. Hartford Foundation and the American Federation for Aging Research. Dr. Horwitz was also supported by the National Institute on Aging (K08 AG038336) and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. This work was also supported by a grant from the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (P30AG021342 NIH/NIA). Dr. Weerahandi is supported by the NYU CTSA Grant UL 1TR001445 and KL2 TR001446. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; At the time this study was conducted, Dr. Horwitz was supported by the CTSA Grant UL1 RR024139 and KL2 RR024138 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH roadmap for Medical Research, and was a Centers of Excellence Scholar in Geriatric Medicine by The John A. Hartford Foundation and the American Federation for Aging Research. Dr. Horwitz was also supported by the National Institute on Aging (K08 AG038336) and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. This work was also supported by a grant from the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (P30AG021342 NIH/NIA). Dr. Weerahandi is supported by the NYU CTSA Grant UL 1TR001445 and KL2 TR001446.	Chroinin DN, 2011, EUR GERIATR MED, V2, P74, DOI 10.1016/j.eurger.2011.01.004; Go JT, 2010, J HOSP MED, V5, P133, DOI 10.1002/jhm.612; Horwitz LI, 2013, JAMA INTERN MED, V173, P1715, DOI 10.1001/jamainternmed.2013.9318; Horwitz LI, 2013, J HOSP MED, V8, P436, DOI 10.1002/jhm.2021; Howrey BT, 2011, MED CARE, V49, P701, DOI 10.1097/MLR.0b013e3182166cb6; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Kripalani S, 2006, J GEN INTERN MED, V21, P888, DOI 10.1111/j.1525-1497.2006.00543.x; Kuo YF, 2011, ANN INTERN MED, V155, P152, DOI 10.7326/0003-4819-155-3-201108020-00005; Makaryus AN, 2005, MAYO CLIN PROC, V80, P991, DOI 10.4065/80.8.991; Pearson M. L., 2007, 282000005 RAND AG HE; Schillinger D, 2004, PATIENT EDUC COUNS, V52, P315, DOI 10.1016/S0738-3991(03)00107-1; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; Ziaeian B, 2012, J GEN INTERN MED, V27, P1513, DOI 10.1007/s11606-012-2168-4	14	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2018	13	4							e196479	10.1371/journal.pone.0196479	http://dx.doi.org/10.1371/journal.pone.0196479			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE1YS	29702676	gold, Green Published, Green Submitted			2023-01-03	WOS:000431013300035
J	Abbasi, J				Abbasi, Jennifer			Hurricane Maria and Puerto Rico: A Physician Looks Back at the Storm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	5	5	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2018	320	7					629	630		10.1001/jama.2018.8244	http://dx.doi.org/10.1001/jama.2018.8244			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR1XH	30073315				2023-01-03	WOS:000442348100001
J	Haffajee, RL; MacCoun, RJ; Mello, MM				Haffajee, Rebecca L.; MacCoun, Robert J.; Mello, Michelle M.			Behind Schedule - Reconciling Federal and State Marijuana Policy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Haffajee, Rebecca L.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [MacCoun, Robert J.; Mello, Michelle M.] Stanford Univ, Sch Med, Stanford Law Sch, Stanford, CA 94305 USA; [Mello, Michelle M.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University; Stanford University	Haffajee, RL (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.		MacCoun, Robert/N-1765-2019	MacCoun, Robert/0000-0003-0929-4423; Mello, Michelle/0000-0003-2877-4270				Boschma J., 2018, STATE MARIJUANA LAWS; Kreit Alex, 2015, CASE W RES L REV, V65, P689; MacCoun RJ, 2015, NEW ENGL J MED, V372, P989, DOI 10.1056/NEJMp1416014; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CONN CANN C	4	13	15	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 9	2018	379	6					501	504		10.1056/NEJMp1804408	http://dx.doi.org/10.1056/NEJMp1804408			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP7TB	29996065				2023-01-03	WOS:000441110600001
J	Emenyeonu, LC; Croxford, AE; Wilkinson, MJ				Emenyeonu, Lorretha C.; Croxford, Adam E.; Wilkinson, Mike J.			The potential of aerosol eDNA sampling for the characterisation of commercial seed lots	PLOS ONE			English	Article							RESOLUTION MELTING ANALYSIS; DNA EXTRACTION; UNITED-STATES; POLLEN; WHEAT; IDENTIFICATION; QUANTIFICATION; CONTAMINATION; DISPERSAL; AIRBORNE	Seed shipments, silos and storage houses often contain weed seeds or seeds of restricted crops such as undeclared genetically modified (GM) varieties. Random sub-sampling is the favoured approach to detect unwanted biological materials in seed lots but is prohibitively expensive or else ineffective for the huge volumes of seeds moved in commercial operations. This study uses maize and cowpea seed admixtures as an exemplar to evaluate the feasibility of using aerosol sampling of "seed dust" as an alternative to seed sub-sampling. In an initial calibration phase, qPCR of the rbcL barcode followed by high-resolution melting (HRM) of a DNA titration series revealed a strong linear relationship between mix composition and HRM profiles. However, the relationship became skewed when flour mixes were used to build the titration, implying a DNA extraction bias favouring cowpea. Aerosol samples of seed dust above a titration of mixed seed samples were then collected along vertical and lateral axes. Aerosols were characterised by light microscopy, qPCR-HRM and next-generation DNA sequencing (Illumina MiSeq). Both molecular approaches again showed bias but this time in a reverse direction to flour samples. Microscopic examination of the aerosol sample suggested this divergence could be attributed to differences in abundance of airborne starch particles. Despite the bias, it was nevertheless possible to estimate relative abundance of each species using the abundance of minibarcodes. In light of these results we explore the feasibility of aerosol sampling for commercial seed lot characterisation.	[Emenyeonu, Lorretha C.; Croxford, Adam E.] Univ Adelaide, Sch Agr Food & Wine, Waite Campus, Adelaide, SA, Australia; [Wilkinson, Mike J.] Aberystwyth Univ, Pwllpeiran Upland Res Ctr, Inst Biol Environm & Rural Sci, Aberystwyth, Ceredigion, Wales; [Emenyeonu, Lorretha C.] Natl Biotechnol Dev Agcy, Environm Biotechnol & Bioconservat Div, Bioresources Dev Ctr, Owode, Ogun State, Nigeria	University of Adelaide; Aberystwyth University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Institute of Biological, Environmental, Rural & Sciences (IBERS)	Wilkinson, MJ (corresponding author), Aberystwyth Univ, Pwllpeiran Upland Res Ctr, Inst Biol Environm & Rural Sci, Aberystwyth, Ceredigion, Wales.	mjw19@aber.ac.uk			International Centre for Genetic Engineering and Biotechnology (ICGEB); Biotechnology and Biological Sciences Research Council [BBS/E/0012843C]; University of Adelaide; BBSRC [BBS/E/W/0012843C] Funding Source: UKRI	International Centre for Genetic Engineering and Biotechnology (ICGEB); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); University of Adelaide; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funding for LCE time, for experimental materials received from the International Centre for Genetic Engineering and Biotechnology (ICGEB). The funder role funded for experimentation, aspects of data analysis and writing. Funding for AEC time, for some experimental materials and for MJW time (experimental planning) received from the University of Adelaide. The funder role funded for some experimentation and for aspects of data analysis and writing. Funding for most MJW time received from Biotechnology and Biological Sciences Research Council (BBS/E/0012843C) (https://bbsrc.ukri.org). The funder roles funded for conceptual aspects of data interpretation and analysis, and for writing.	Abd-Elsalam K, 2011, INT J MOL SCI, V12, P3459, DOI 10.3390/ijms12063459; Alderman Steve C., 2011, Seed Technology, V33, P7; Aohara T, 2009, PLANT CELL PHYSIOL, V50, P1886, DOI 10.1093/pcp/pcp133; Awano T, 2009, P NATL ACAD SCI USA, V106, P2794, DOI [10.1073/pnas.0905845106, 10.1073/pnas.0812297106]; Becklake MR, 2007, CAN RESPIR J, V14, P423, DOI 10.1155/2007/931094; Bell J., 2011, OVERVIEW TAILED AMPL; Bergmann GT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142409; Binns M.R., 2000, SAMPLING MONITORING; Botticella E, 2011, BMC PLANT BIOL, V11, DOI 10.1186/1471-2229-11-156; Burton RA, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00456; Carvalho E, 2008, AEROBIOLOGIA, V24, P191, DOI 10.1007/s10453-008-9098-y; Combes M.-C., 2018, FOOD CONTROL; Copeland LO, 2001, PRINCIPLES SEED SCI, P390; Craine JM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16738; Cui Lina, 2014, Australian Journal of Crop Science, V8, P1560; Dahinden I, 2001, EUR FOOD RES TECHNOL, V212, P228, DOI 10.1007/s002170000252; Despres VR, 2012, TELLUS B, V64, DOI 10.3402/tellusb.v64i0.15598; DONHAM KJ, 1986, AM J IND MED, V10, P205, DOI 10.1002/ajim.4700100305; Dugje I, 2008, GUIDE CERTIFIED SEED; Dundar E, 2009, INT J BIOL MACROMOL, V45, P206, DOI 10.1016/j.ijbiomac.2009.05.002; Elias S, 2012, SEED TESTING PRINCIP; EPA, 2008, STARL CORN REG INF; Esbensen KH, 2012, TRAC-TREND ANAL CHEM, V32, P154, DOI 10.1016/j.trac.2011.09.008; Flinn PW, 2003, PEST MANAG SCI, V59, P614, DOI 10.1002/ps.695; Ford CS, 2009, BOT J LINN SOC, V159, P1, DOI 10.1111/j.1095-8339.2008.00938.x; Ganopoulos I, 2012, FOOD CHEM, V133, P505, DOI 10.1016/j.foodchem.2012.01.015; Garcia-Robledo C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052967; Ghosh R, 2009, J VIROL METHODS, V159, P34, DOI 10.1016/j.jviromet.2009.02.020; Giraud E., 2013, PUTTING IT ALL TOGET; Gomez-Domenech M, 2010, AEROBIOLOGIA, V26, P149, DOI 10.1007/s10453-009-9152-4; Guarín Fernando Alzate, 2015, Hoehnea, V42, P9, DOI 10.1590/2236-8906-52/2013; Hernando A, 2008, EUR J GASTROEN HEPAT, V20, P545, DOI 10.1097/MEG.0b013e3282f46597; Holst-Jensen A, 2012, BIOTECHNOL ADV, V30, P1318, DOI 10.1016/j.biotechadv.2012.01.024; Hong E, 2017, J SCI FOOD AGR; Hornby C, 2009, EU REJECTS MORE US S; James C., 2011, GLOBAL STATUS COMMER; James D, 2003, J AGR FOOD CHEM, V51, P5829, DOI 10.1021/jf0341159; Kamal Sharma, 2013, African Journal of Biotechnology, V12, P1894; Kim JY, 2011, PLANT MOL BIOL, V76, P357, DOI 10.1007/s11103-010-9712-6; Kobilinsky A, 2005, CHEMOMETR INTELL LAB, V75, P189, DOI 10.1016/j.chemolab.2004.07.005; Koblentz GD, 2010, INT SECURITY, V34, P96, DOI 10.1162/isec.2010.34.4.96; Kress WJ, 2009, P NATL ACAD SCI USA, V106, P18621, DOI 10.1073/pnas.0909820106; Kulkarni Pramod., 2017, AEROSOL MEASUREMENT, VThird, DOI [DOI 10.1002/9781118001684, 10.1002/9781118001684]; Kuzmina M., 2013, PCR SEQUENCING PROTO; Levin RA, 2003, AM J BOT, V90, P107, DOI 10.3732/ajb.90.1.107; Lin CH, 2016, J FOOD DRUG ANAL, V24, P1, DOI 10.1016/j.jfda.2015.06.011; Lopez-Andreo M, 2005, ANAL BIOCHEM, V339, P73, DOI 10.1016/j.ab.2004.11.045; Mader E, 2011, ANAL BIOCHEM, V409, P153, DOI 10.1016/j.ab.2010.10.009; Madesis P, 2012, FOOD CONTROL, V25, P576, DOI 10.1016/j.foodcont.2011.11.034; Madsen AM, 2012, ANN OCCUP HYG, V56, P777, DOI 10.1093/annhyg/mes012; Malta-Vacas J, J TOXICOLOGY ENV H A; Maluszynska E., 2010, Biuletyn Instytutu Hodowli i Aklimatyzacji Roslin, P17; Muleo R, 2009, GENOME, V52, P252, DOI 10.1139/G09-002; Newmaster SG, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-222; Orlandi F, 2011, GRANA, V50, P73, DOI 10.1080/00173134.2011.563791; Paoletti C, 2006, EUR FOOD RES TECHNOL, V224, P129, DOI 10.1007/s00217-006-0299-8; Parker J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08461-5; Peel RG, 2014, ANN AGR ENV MED, V21, P745, DOI 10.5604/12321966.1129927; Pervaiz ZH, 2011, GENET MOL RES, V10, P1669, DOI 10.4238/vol10-3gmr1346; Prosser SWJ, 2017, FOOD CHEM, V214, P183, DOI 10.1016/j.foodchem.2016.07.077; Raclariu AC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00378; Ramessar K, 2008, NAT BIOTECHNOL, V26, P975, DOI 10.1038/nbt0908-975; Ranta H, 2008, GRANA, V47, P285, DOI 10.1080/00173130802457230; Ratnaningsih N, 2016, INT FOOD RES J, V23, P2041; Reed GH, 2007, PHARMACOGENOMICS, V8, P597, DOI 10.2217/14622416.8.6.597; Ripp F, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-639; Shaw MW, 2006, P R SOC B, V273, P1705, DOI 10.1098/rspb.2006.3491; Stein A. J., 2010, AgBioForum, V13, P173; USDA-GIPSA, 1995, GRAIN INSP HDB BOOK; Weller S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137343; WHO-FAO, 2000, 013 WHOFAO CXMAS; Wilkinson MJ, 2003, SCIENCE, V302, P457, DOI 10.1126/science.1088200; Wu SB, 2008, THEOR APPL GENET, V118, P1, DOI 10.1007/s00122-008-0870-8; Zhou X, 2013, GIGASCIENCE, V2, DOI 10.1186/2047-217X-2-4	74	2	2	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2018	13	8							e0201617	10.1371/journal.pone.0201617	http://dx.doi.org/10.1371/journal.pone.0201617			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO9GY	30067814	Green Submitted, Green Published, gold			2023-01-03	WOS:000440415500101
J	Szanto, K; Nyari, T; Balint, A; Bor, R; Milassin, A; Rutka, M; Fabian, A; Szepes, Z; Nagy, F; Molnar, T; Farkas, K				Szanto, Kata; Nyari, Tibor; Balint, Anita; Bor, Renate; Milassin, Agnes; Rutka, Mariann; Fabian, Anna; Szepes, Zoltan; Nagy, Ferenc; Molnar, Tamas; Farkas, Klaudia			Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center	PLOS ONE			English	Article							POPULATION-BASED COHORT; CROHNS-DISEASE; ULCERATIVE-COLITIS; CLINICAL-COURSE; DIAGNOSTIC DELAY; APPENDECTOMY; IBSEN; SEVERITY; SMOKING	Inflammatory bowel diseases (IBD) [Crohn's disease (CD) and ulcerative colitis (UC)], are chronic relapsing disorders of unknown etiology. The aim of this study was to determine demographic features, disease phenotypes, medical and surgical therapies in our IBD patients and to identify which parameters are in association with the need of surgery and/or biologic therapy. Data on demographic and clinical characteristics of the patients were analyzed from the IBD registry of the 1 st Department of Medicine, University of Szeged. The study period was between January 2007 and March 2015. Data of 911 IBD patients (428 CD, 483 UC) were analyzed. The median lag time between onset of symptoms and diagnosis proved to be significantly longer in UC than in CD (4.6 years vs. 2.1 years, p = 0.01). 40% of the patients received biological therapy, 301 patients underwent surgery required more frequently for CD than UC. Surgery was more common in CD patients with ileal location and penetrating behaviour. In UC, more severe disease onset predicted to unfavourable disease course. Higher proportion of surgery was shown in patient aged above 40 years in both CD and UC. Diagnostic delay of more than 1 year and appendectomy predicted to unfavourable disease outcome of both CD and UC. This analysis revealed that more than 1 year of diagnostic delay, disease activity at diagnosis in UC, CD, ileal location and penetrating behaviour are factors that may influence disease outcome. Use of thiopurines seemed to be protective in UC.	[Szanto, Kata; Balint, Anita; Bor, Renate; Milassin, Agnes; Rutka, Mariann; Fabian, Anna; Szepes, Zoltan; Nagy, Ferenc; Molnar, Tamas; Farkas, Klaudia] Univ Szeged, Dept Med 1, Szeged, Hungary; [Nyari, Tibor] Univ Szeged, Dept Med Phys & Informat, Szeged, Hungary	Szeged University; Szeged University	Farkas, K (corresponding author), Univ Szeged, Dept Med 1, Szeged, Hungary.	farkas.klaudia@gmail.com	Molnár, Tamás/GMX-4334-2022	Nyari, Tibor/0000-0001-8900-6641	National Research, Development and Innovation Office [119809, 125377]; UNKP-17-4 New National Excellence Program of the Ministry of Human Capacities;  [EFOP-3.6.2-16-2017-00006]	National Research, Development and Innovation Office(National Research, Development & Innovation Office (NRDIO) - Hungary); UNKP-17-4 New National Excellence Program of the Ministry of Human Capacities; 	This work was supported by the research grants of the National Research, Development and Innovation Office (Grant ID: 119809 and 125377), by the UNKP-17-4 New National Excellence Program of the Ministry of Human Capacities and by the EFOP-3.6.2-16-2017-00006 (URL: https://www.u-szeged.hu/fejlesztesiprojektek/efop-3-6-2-16-2017-00006/efop-3-6-2-16-2017-00006). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Ananthakrishnan AN, 2008, AM J GASTROENTEROL, V103, P154, DOI 10.1111/j.1572-0241.2007.01561.x; Andersson RE, 2003, GASTROENTEROLOGY, V124, P40, DOI 10.1053/gast.2003.50021; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Burisch J, 2013, CURR OPIN GASTROEN, V29, P357, DOI 10.1097/MOG.0b013e32836229fb; Burisch J, 2013, J CROHNS COLITIS, V7, P322, DOI 10.1016/j.crohns.2013.01.010; Cosnes J, 1999, ALIMENT PHARM THERAP, V13, P1403; Cosnes J, 2004, BEST PRACT RES CL GA, V18, P481, DOI 10.1016/j.bpg.2003.12.003; Dias CC, 2013, WORLD J GASTROENTERO, V19, P3866, DOI 10.3748/wjg.v19.i24.3866; Gardenbroek TJ, 2012, COLORECTAL DIS, V14, P545, DOI 10.1111/j.1463-1318.2011.02600.x; Gower-Rousseau C, 2009, AM J GASTROENTEROL, V104, P2080, DOI 10.1038/ajg.2009.177; Henriksen M, 2007, SCAND J GASTROENTERO, V42, P602, DOI 10.1080/00365520601076124; Henriksen M, 2006, INFLAMM BOWEL DIS, V12, P543, DOI 10.1097/01.MIB.0000225339.91484.fc; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Lakatos PL, 2007, WORLD J GASTROENTERO, V13, P6134, DOI 10.3748/wjg.13.6134; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Nahon S, 2014, J CROHNS COLITIS, V8, P964, DOI 10.1016/j.crohns.2014.01.023; Niewiadomski O, 2015, J GASTROEN HEPATOL, V30, P1346, DOI 10.1111/jgh.12967; Radford-Smith GL, 2002, GUT, V51, P808, DOI 10.1136/gut.51.6.808; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; Schoepfer AM, 2013, AM J GASTROENTEROL, V108, P1744, DOI 10.1038/ajg.2013.248; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Solberg IC, 2009, SCAND J GASTROENTERO, V44, P431, DOI 10.1080/00365520802600961	22	3	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2018	13	7							e0200824	10.1371/journal.pone.0200824	http://dx.doi.org/10.1371/journal.pone.0200824			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO7MT	30059523	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000440251600018
J	Kerkhof, M; Tran, TN; van den Berge, M; Brusselle, GG; Gopalan, G; Jones, RCM; Kocks, JWH; Menzies-Gow, A; Nuevo, J; Pavord, ID; Rastogi, S; Price, DB				Kerkhof, Marjan; Tran, Trung N.; van den Berge, Maarten; Brusselle, Guy G.; Gopalan, Gokul; Jones, Rupert C. M.; Kocks, Janwillem W. H.; Menzies-Gow, Andrew; Nuevo, Javier; Pavord, Ian D.; Rastogi, Sarang; Price, David B.			Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study	PLOS ONE			English	Article							HOSPITAL READMISSIONS; 30-DAY READMISSIONS; HEALTH-CARE; EXACERBATIONS; ADULTS; CORTICOSTEROIDS; PREDICTORS; INSIGHTS; DATABASE; OUTCOMES	Background Recent studies have demonstrated an association between high blood eosinophil counts and greater risk of asthma exacerbations. We sought to determine whether patients hospitalized for an asthma exacerbation were at greater risk of readmission if they had a high blood eosinophil count documented before the first hospitalization. Methods This historical cohort study drew on 2 years of medical record data (Clinical Practice Research Datalink with Hospital Episode Statistics linkage) of patients (aged >= 5 years) admitted to hospital in England for asthma, with recorded blood eosinophil count within 1 baseline year before admission. We analyzed the association between high blood eosinophil count (>= 0.35x10(9) cells/L) and readmission risk during 1 year of follow-up after hospital discharge, with adjustment for predefined, relevant confounders using forward selection. Results We identified 2,613 eligible patients with asthma-related admission, of median age 51 years (interquartile range, 36-69) and 76% women (1,997/2,613). Overall, 835/2,613 (32.0%) had a preadmission high blood eosinophil count. During the follow-up year, 130/2,613 patients (5.0%) were readmitted for asthma, including 55/835 (6.6%) with vs. 75/1,778 (4.2%) without high blood eosinophil count at baseline (adjusted hazard ratio [HR] 1.49; 95% CI 1.04-2.13, p = 0.029). The association was strongest in never-smokers (n = 1,296; HR 2.16, 95% CI 1.27-3.68, p = 0.005) and absent in current smokers (n = 547; HR 1.00, 95% CI 0.49-2.04, p = 0.997). Conclusions A high blood eosinophil count in the year before an asthma-related hospitalization is associated with increased risk of readmission within the following year. These findings suggest that patients with asthma and preadmission high blood eosinophil count require careful follow-up, with treatment optimization, after discharge.	[Kerkhof, Marjan; Kocks, Janwillem W. H.; Price, David B.] Observat & Pragmat Res Inst Pte Ltd, Singapore, Singapore; [Tran, Trung N.; Gopalan, Gokul; Rastogi, Sarang] AstraZeneca, Gaithersburg, MD USA; [van den Berge, Maarten; Kocks, Janwillem W. H.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Brusselle, Guy G.] Ghent Univ Hosp, Ghent, Belgium; [Jones, Rupert C. M.] Peninsula Coll Med & Dent, Plymouth, Devon, England; [Menzies-Gow, Andrew] Royal Brompton & Harefield NHS Fdn Trust, London, England; [Nuevo, Javier] AstraZeneca, Madrid, Spain; [Pavord, Ian D.] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford, England; [Pavord, Ian D.] Univ Oxford, Nuffield Dept Med, Oxford Resp NIHR BRC, Oxford, England; [Price, David B.] Univ Aberdeen, Acad Primary Care, Aberdeen, Scotland	AstraZeneca; University of Groningen; Ghent University; Ghent University Hospital; University of Plymouth; Royal Brompton & Harefield NHS Foundation Trust; University of Oxford; University of Oxford; University of Aberdeen	Price, DB (corresponding author), Observat & Pragmat Res Inst Pte Ltd, Singapore, Singapore.; Price, DB (corresponding author), Univ Aberdeen, Acad Primary Care, Aberdeen, Scotland.	dprice@opri.sg	Price, David/H-2837-2019	Price, David/0000-0002-9728-9992; van den Berge, Maarten/0000-0002-9336-7340; Brusselle, Guy/0000-0001-7021-8505	AstraZeneca; Observational and Pragmatic Research Institute Pte Ltd (OPRI)	AstraZeneca(AstraZeneca); Observational and Pragmatic Research Institute Pte Ltd (OPRI)	Data acquisition and analyses were funded by AstraZeneca. This was a collaborative study involving both employees of the sponsor and an independent steering committee. The funder of the study participated in the study design, decision to publish, and preparation of the manuscript. In addition, the funder provided support in the form of salaries for authors TNT, GG, JN, and SR. Employees of the sponsor were part of the study steering committee and participated in the study design. Writing and editorial support was funded by the Observational and Pragmatic Research Institute Pte Ltd (OPRI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], BOST COLL DRUG SURV; Beck AF, 2016, JAMA PEDIATR, V170, P695, DOI 10.1001/jamapediatrics.2016.0269; Buyantseva LV, 2016, J ASTHMA, V53, P684, DOI 10.3109/02770903.2016.1140773; Casciano J, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0263-8; Couillard S, 2017, CHEST, V151, P366, DOI 10.1016/j.chest.2016.10.003; Delmas M-C, 2011, Rev Mal Respir, V28, pe115, DOI 10.1016/j.rmr.2011.09.023; FitzGerald JM, 2018, LANCET RESP MED, V6, P51, DOI 10.1016/S2213-2600(17)30344-2; Fleishaker DL, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1135-3; Global Initiative for Asthma (GINA) NHLaBI National Institutes of Health, GINA REP GLOB STRAT; Gonzalez-Barcala FJ, 2018, IRISH J MED SCI, V187, P155, DOI 10.1007/s11845-017-1633-9; Gonzalez-Barcala FJ, 2018, EUR J INTERN MED, DOI [10.1016/j.ejim.2018.02.034, DOI 10.1016/J.EJIM.2018.02.034PMID:29514744]; Hasegawa K, 2016, CHEST, V149, P1021, DOI 10.1016/j.chest.2015.12.039; KELLGREN JH, 1951, BRIT MED J, V2, P1183, DOI 10.1136/bmj.2.4741.1183; Kerkhof M, 2018, THORAX, V73, P116, DOI 10.1136/thoraxjnl-2017-210531; Makela MJ, 2018, EUR CLIN RESPIR J, V5, DOI 10.1080/20018525.2018.1458560; Mukherjee M, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0657-8; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Petsky HL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005603.pub3; Pola-Bibian B, 2017, J INVEST ALLERG CLIN, V27, P238, DOI 10.18176/jiaci.0128; Polosa R, 2013, EUR RESPIR J, V41, P716, DOI 10.1183/09031936.00073312; Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Roche Nicolas, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS99, DOI 10.1513/AnnalsATS.201309-300RM; Sadatsafavi M, 2015, RESP MED, V109, P320, DOI 10.1016/j.rmed.2014.12.014; Salamzadeh J, 2003, J ASTHMA, V40, P645, DOI 10.1081/JAS-120019035; Sheikh A, 2016, BMC MED, V14, DOI 10.1186/s12916-015-0546-6; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; UK National Health Service, QUAL OUTC FRAM QOF; UK National Health Service, HOSP EP STAT HES; van den Berge M, 2016, J ASTHMA ALLERGY, V9, P27, DOI 10.2147/JAA.S78900; Veeranki SP, 2017, J ASTHMA, P1, DOI 10.1080/02770903.2017.1365888; Veeranki SP, 2016, CHEST, V150, P1162, DOI 10.1016/j.chest.2016.07.043; Westerhof GA, 2016, RESP MED, V118, P122, DOI 10.1016/j.rmed.2016.08.006; Yancey SW, 2017, J ALLERGY CLIN IMMUN, V139, P1167, DOI 10.1016/j.jaci.2016.08.008; Zeiger RS, 2017, J ALLER CL IMM-PRACT, V5, P144, DOI 10.1016/j.jaip.2016.07.015	36	24	25	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2018	13	7							e0201143	10.1371/journal.pone.0201143	http://dx.doi.org/10.1371/journal.pone.0201143			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4AN	30044863	Green Published, Green Submitted, gold			2023-01-03	WOS:000439942500083
J	Li, J; Qin, SK; Xu, RH; Shen, L; Xu, JM; Bai, YX; Yang, L; Deng, YH; Chen, ZD; Zhong, HJ; Pan, HM; Guo, WJ; Shu, YQ; Yuan, Y; Zhou, JF; Xu, N; Liu, TS; Ma, D; Wu, CP; Cheng, Y; Chen, DH; Li, W; Sun, SY; Yu, Z; Cao, PG; Chen, HH; Wang, JJ; Wang, SB; Wang, HB; Fan, SH; Hua, Y; Su, WG				Li, Jin; Qin, Shukui; Xu, Rui-Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Hua, Ye; Su, Weiguo			Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET	JUN 02-07, 2017	Chicago, IL	Amer Soc Clin Oncol			1ST-LINE TREATMENT; TYROSINE KINASES; DOUBLE-BLIND; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; BEVACIZUMAB; PLUS; MULTICENTER	IMPORTANCE Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. OBJECTIVE To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC. DESIGN, SETTING, AND PARTICIPANTS FRESCO (Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K-ras status. The final date of follow-up was January 17, 2017. INTERVENTIONS Patients were randomized in a 2: 1 ratio to receive either fruquintinib, 5 mg (n = 278) or placebo (n = 138) orally, once daily for 21 days, followed by 7 days off in 28-day cycles, until disease progression, intolerable toxicity, or study withdrawal. MAIN OUTCOMES AND MEASURES The primary end point was overall survival. Key secondary efficacy endpoints were progression-free survival (time from randomization to disease progression or death), objective response rate (confirmed complete or partial response), and disease control rate (complete or partial response, or stable disease recorded >= 8 weeks postrandomization). Duration of response was also assessed. Safety outcomes included treatment-emergent adverse events. RESULTS Of the 416 randomized patients (mean age, 54.6 years; 161 [38.7%] women), 404 (97.1%) completed the trial. Median overall survival was significantly prolonged with fruquintinib compared with placebo (9.3 months [95% CI, 8.2-10.5] vs 6.6 months [95% CI, 5.9-8.1]); hazard ratio (HR) for death, 0.65 (95% CI, 0.51-0.83; P < .001). Median progression-free survival was also significantly increased with fruquintinib (3.7 months [95% CI, 3.7-4.6] vs 1.8 months [95% CI, 1.8-1.8] months); HR for progression or death, 0.26 (95% CI, 0.21 to 0.34; P < .001). Grades 3 and 4 treatment-emergent adverse events occurred in 61.2%(170) of patients who received fruquintinib and 19.7%(27) who received placebo. Serious adverse events were reported by 15.5%(43) of patients in the fruquintinib group and 5.8% (8) in the placebo group, with 14.4%(40) of fruquintinib-treated and 5.1% (7) of placebo-treated patients requiring hospitalization. CONCLUSIONS AND RELEVANCE Among Chinese patients with metastatic CRC who had tumor progression following at least 2 prior chemotherapy regimens, oral fruquintinib compared with placebo resulted in a statistically significant increase in overall survival. Further research is needed to assess efficacy outside of China.	[Qin, Shukui] Nanjing Chinese Med Univ, Dept Med Oncol, Affiliated Bayi Hosp, 34,34 Biao, Nanjing 210001, Jiangsu, Peoples R China; [Li, Jin] Tongji Univ, Dept Med Oncol, Shanghai East Hosp, Shanghai, Peoples R China; [Li, Jin; Guo, Weijian] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai Med Coll, Shanghai, Peoples R China; [Xu, Rui-Hua] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Xu, Rui-Hua] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Shen, Lin] Beijing Univ, Dept Med Oncol, Canc Ctr, Beijing, Peoples R China; [Xu, Jianming] 307th Hosp Chinese Peoples Liberat Army, Affiliated Hosp Mil Med Sci, Dept Med Oncol, Beijing, Peoples R China; [Bai, Yuxian] Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China; [Yang, Lei] Nantong Canc Hosp, Dept Med Oncol, Nantong, Peoples R China; [Deng, Yanhong] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 6, Guangzhou, Guangdong, Peoples R China; [Chen, Zhen-dong] Anhui Med Univ, Hosp 2, Dept Med Oncol, Hefei, Anhui, Peoples R China; [Zhong, Haijun] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Pan, Hongming] Zhejiang Univ, Coll Med, Sir RunRun Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Shu, Yongqian] Jiangsu Prov Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China; [Yuan, Ying] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Zhou, Jianfeng] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China; [Xu, Nong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Liu, Tianshu] Fudan Univ, Zhongshan Hosp, Shanghai Med Coll, Dept Med Oncol, Shanghai, Peoples R China; [Ma, Dong] Guangdong Gen Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China; [Wu, Changping] First Peoples Hosp Changzhou, Dept Med Oncol, Changzhou, Peoples R China; [Cheng, Ying] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China; [Chen, Donghui] Shanghai Jiao Tong Univ, Dept Med Oncol, Affiliated Peoples Hosp 1, Shanghai, Peoples R China; [Li, Wei] Jilin Univ, Hosp 1, Dept Med Oncol, Changchun, Jilin, Peoples R China; [Sun, Sanyuan] Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China; [Yu, Zhuang] Qingdao Univ, Med Coll, Affiliated Hosp, Dept Med Oncol, Qingdao, Peoples R China; [Cao, Peiguo] Cent S Univ, Dept Med Oncol, Xiangya Hosp 3, Changsha, Hunan, Peoples R China; [Chen, Haihui] Liuzhou Workers Hosp, Dept Med Oncol, Liuzhou, Peoples R China; [Wang, Jiejun] Second Mil Med Univ, Dept Med Oncol, Shanghai Changzheng Hosp, Shanghai, Peoples R China; [Wang, Shubin] Beijing Univ, Peking Univ, Dept Med Oncol, Shenzhen Hosp, Shenzhen, Peoples R China; [Wang, Hongbing] Xuzhou Med Coll, Affiliated Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China; [Fan, Songhua; Hua, Ye; Su, Weiguo] Hutchison MediPharma Ltd, Shanghai, Peoples R China	Nanjing University of Chinese Medicine; Tongji University; Fudan University; State Key Lab Oncology South China; Sun Yat Sen University; Peking University; Sun Yat Sen University; Anhui Medical University; Zhejiang Cancer Hospital; Zhejiang University; Nanjing Medical University; Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Zhejiang University; Fudan University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Shanghai Jiao Tong University; Jilin University; Qingdao University; Central South University; Naval Medical University; Peking University; Xuzhou Medical University	Qin, SK (corresponding author), Nanjing Chinese Med Univ, Dept Med Oncol, Affiliated Bayi Hosp, 34,34 Biao, Nanjing 210001, Jiangsu, Peoples R China.	qinsk@csco.org.cn	Shu, Yongqian/ABD-5698-2021; xu, rui/GRX-5734-2022; Xu, Rui-Hua/AAW-4766-2021	Xu, Rui-Hua/0000-0001-9771-8534; liu, tianshu/0000-0002-2318-2869; Ying, Yuan/0000-0002-3922-9553	Hutchison MediPharma; Ministry of Science and Technology of the People's Republic of China [2013ZX09101105]; Science and Technology Development Fund of Pudong Shanghai China [PKJ2014-S01]	Hutchison MediPharma; Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); Science and Technology Development Fund of Pudong Shanghai China	This study was sponsored by Hutchison MediPharma, and was supported by grants from the Ministry of Science and Technology of the People's Republic of China (2013ZX09101105) and the Science and Technology Development Fund of Pudong Shanghai China (PKJ2014-S01).	Allison P.E., 2010, SURVIVAL ANAL USING, Vsecond; Borucka J., 2014, EKONOMETRIA, V45, P85, DOI DOI 10.15611/EKT.2014.3.07; Cao JN, 2016, CANCER CHEMOTH PHARM, V78, P259, DOI 10.1007/s00280-016-3069-8; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7; Luo HY, 2016, ANN ONCOL, V27, P1074, DOI 10.1093/annonc/mdw101; Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Sun QL, 2014, CANCER BIOL THER, V15, P1635, DOI 10.4161/15384047.2014.964087; Tampellini M, 2016, EXPERT OPIN INV DRUG, V25, P507, DOI 10.1517/13543784.2016.1161754; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201; Xu RH, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0384-9	22	118	141	5	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2018	319	24					2486	2496		10.1001/jama.2018.7855	http://dx.doi.org/10.1001/jama.2018.7855			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	GK6ZP	29946728	Green Published, Bronze			2023-01-03	WOS:000436342700019
J	Abt, D; Hechelhammer, L; Mullhaupt, G; Markart, S; Gusewell, S; Kessler, TM; Schmid, HP; Engeler, DS; Mordasini, L				Abt, Dominik; Hechelhammer, Lukas; Mullhaupt, Gautier; Markart, Stefan; Gusewell, Sabine; Kessler, Thomas M.; Schmid, Hans-Peter; Engeler, Daniel S.; Mordasini, Livio			Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FUNCTIONAL OUTCOMES; CLINICAL-TRIAL; FOLLOW-UP; SYMPTOMS; COMPLICATIONS; MULTICENTER; BPH; METAANALYSIS; EFFICACY; SOCIETY	Objective To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in terms of patient reported and functional outcomes. Design Randomised, open label, non-inferiority trial. Setting Urology and radiology departments of a Swiss tertiary care centre. Participants 103 patients aged >= 40 years with refractory lower urinary tract symptoms secondary to benign prostatic hyperplasia were randomised between 11 February 2014 and 24 May 2017; 48 and 51 patients reached the primary endpoint 12 weeks after PAE and TURP, respectively. Interventions PAE performed with 250-400 mu m microspheres under local anaesthesia versus monopolar TURP performed under spinal or general anaesthesia. Main outcomes and measures Primary outcome was change in international prostate symptoms score (IPSS) from baseline to 12 weeks after surgery; a difference of less than 3 points between treatments was defined as non-inferiority for PAE and tested with a one sided t test. Secondary outcomes included further questionnaires, functional measures, magnetic resonance imaging findings, and adverse events; changes from baseline to 12 weeks were compared between treatments with two sided tests for superiority. Results Mean reduction in IPSS from baseline to 12 weeks was -9.23 points after PAE and -10.77 points after TURP. Although the difference was less than 3 points (1.54 points in favour of TURP (95% confidence interval -1.45 to 4.52)), non-inferiority of PAE could not be shown (P=0.17). None of the patient reported secondary outcomes differed significantly between treatments when tested for superiority; IPSS also did not differ significantly (P=0.31). At 12 weeks, PAE was less effective than TURP regarding changes in maximum rate of urinary flow (5.19 v 15.34 mL/s; difference 10.15 (95% confidence interval -14.67 to -5.63); P<0.001), postvoid residual urine (-86.36 v -199.98 mL; 113.62 (39.25 to 187.98); P=0.003), prostate volume (-12.17 v -30.27 mL; 18.11 (10.11 to 26.10); P<0.001), and desobstructive effectiveness according to pressure flow studies (56% v 93% shift towards less obstructive category; P=0.003). Fewer adverse events occurred after PAE than after TURP (36 v 70 events; P=0.003). Conclusions The improvement in lower urinary tract symptoms secondary to benign prostatic hyperplasia seen 12 weeks after PAE is close to that after TURP. PAE is associated with fewer complications than TURP but has disadvantages regarding functional outcomes, which should be considered when selecting patients. Further comparative study findings, including longer follow-up, should be evaluated before PAE can be considered as a routine treatment.	[Abt, Dominik; Mullhaupt, Gautier; Schmid, Hans-Peter; Engeler, Daniel S.; Mordasini, Livio] St Gallen Cantonal Hosp, Dept Urol, CH-9007 St Gallen, Switzerland; [Hechelhammer, Lukas; Markart, Stefan] St Gallen Cantonal Hosp, Dept Radiol & Nucl Med, St Gallen, Switzerland; [Gusewell, Sabine] St Gallen Cantonal Hosp, Clin Trials Unit, St Gallen, Switzerland; [Kessler, Thomas M.] Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, Neurourol, Zurich, Switzerland; [Kessler, Thomas M.] Univ Zurich, Balgrist Univ Hosp, Res, Zurich, Switzerland	Kantonsspital St. Gallen; Kantonsspital St. Gallen; Kantonsspital St. Gallen; University of Zurich; University of Zurich	Abt, D (corresponding author), St Gallen Cantonal Hosp, Dept Urol, CH-9007 St Gallen, Switzerland.	dominik.abt@kssg.ch		Engeler, Daniel/0000-0003-1383-4701; Hechelhammer, Lukas/0000-0002-7849-3859; Abt, Dominik/0000-0002-1915-4726; , Livio/0000-0002-4087-6555; Mullhaupt, Gautier/0000-0002-5725-5608	research committee of St Gallen Cantonal Hospital [14/08]	research committee of St Gallen Cantonal Hospital	The trial was supported by a grant from the research committee of St Gallen Cantonal Hospital (14/08). The funder had no role in the conduct or analysis of the trial.	Abt D, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-94; Ahyai SA, 2010, EUR UROL, V58, P384, DOI 10.1016/j.eururo.2010.06.005; Andrade G, 2017, J VASC INTERV RADIOL, V28, P517, DOI 10.1016/j.jvir.2017.01.005; Bagla S, 2017, CARDIOVASC INTER RAD, V40, P1694, DOI 10.1007/s00270-017-1700-7; Bagla S, 2013, J VASC INTERV RADIOL, V24, P1603, DOI 10.1016/j.jvir.2013.06.024; BARRY MJ, 1993, J UROLOGY, V150, P351, DOI 10.1016/S0022-5347(17)35482-4; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Bilhim T, 2015, RADIOLOGY, V276, P310, DOI 10.1148/radiol.2015141853; Carnevale FC, 2016, CARDIOVASC INTER RAD, V39, P44, DOI 10.1007/s00270-015-1202-4; Carnevale FC, 2014, CARDIOVASC INTER RAD, V37, P1602, DOI 10.1007/s00270-014-0908-z; Carnevale FC, 2013, CARDIOVASC INTER RAD, V36, P1452, DOI 10.1007/s00270-013-0680-5; DeMeritt JS, 2000, J VASC INTERV RADIOL, V11, P767, DOI 10.1016/S1051-0443(07)61638-8; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Gao YA, 2014, RADIOLOGY, V270, P920, DOI 10.1148/radiol.13122803; Gravas S, 2018, EAU GUIDELINES MANAG; Hakenberg OW, 1997, J UROLOGY, V158, P94, DOI 10.1097/00005392-199707000-00025; Hill B, 2004, J UROLOGY, V171, P2336, DOI 10.1097/01.ju.0000127761.87421.a0; Lebdai S, 2016, WORLD J UROL, V34, P625, DOI 10.1007/s00345-015-1665-6; Lukacs B, 2013, EUR UROL, V64, P493, DOI 10.1016/j.eururo.2013.02.026; Malaeb BS, 2012, UROLOGY, V79, P1111, DOI 10.1016/j.urology.2011.11.084; Mattiasson A, 2007, UROLOGY, V69, P91, DOI 10.1016/j.urology.2006.08.1115; McVary KT, AM UROLOGICAL ASS GU; McWilliams JP, 2014, J VASC INTERV RADIOL, V25, P1349, DOI 10.1016/j.jvir.2014.05.005; Milam DF, 2012, HINMANS ATLAS UROLOG, DOI [10.1016/B978-1-4160-4210-5.00080-3, DOI 10.1016/B978-1-4160-4210-5.00080-3]; National Cancer Institute (NCI), COMMON TERMINOLOGY C; Neyer M, 2013, UROL INT, V90, P62, DOI 10.1159/000343688; Peters TJ, 1997, J UROLOGY, V157, P885, DOI 10.1016/S0022-5347(01)65075-4; Pisco JM, 2012, TECH VASC INTERV RAD, V15, P286, DOI 10.1053/j.tvir.2012.09.002; Reich O, 2008, J UROLOGY, V180, P246, DOI 10.1016/j.juro.2008.03.058; Russo GI, 2015, UROLOGY, V86, P343, DOI 10.1016/j.urology.2015.04.037; Schafer W, 2002, NEUROUROL URODYNAM, V21, P261, DOI 10.1002/nau.10066; Shim SR, 2017, J UROLOGY, V197, P465, DOI 10.1016/j.juro.2016.08.100; Swiss Federal Office of Public Health, WEGL R 06 05 DIAGN R; Taub David A, 2006, Curr Urol Rep, V7, P272, DOI 10.1007/s11934-996-0006-0; van Exel NA, 2006, EUR UROL, V49, P92, DOI 10.1016/j.eururo.2005.09.016; World Medical Association, 1964, DECL HELS ETH PRINC	37	139	139	4	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	2018	361								k2338	10.1136/bmj.k2338	http://dx.doi.org/10.1136/bmj.k2338			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK8SO	29921613	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000436498300001
J	Choi, IS; Choi, M; Lee, JH; Kim, JH; Suh, KJ; Lee, JY; Kang, B; Kim, JW; Kim, SH; Kim, JW; Lee, JO; Kim, YJ; Bang, SM; Lee, JS; Lee, KW				Choi, In Sil; Choi, Mihong; Lee, Ju Hyun; Kim, Jee Hyun; Suh, Koung Jin; Lee, Ji Yun; Kang, Beodeul; Kim, Ji-Won; Kim, Se-Hyun; Kim, Jin Won; Lee, Jeong-Ok; Kim, Yu Jung; Bang, Soo-Mee; Lee, Jong Seok; Lee, Keun-Wook			Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study	PLOS ONE			English	Article							PHASE-III TRIAL; SUPPORTIVE CARE; GASTROESOPHAGEAL ADENOCARCINOMA; DOUBLE-BLIND; PLUS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; 5-FLUOROURACIL	Purpose There is limited data on third-line chemotherapy in patients with metastatic gastric cancer (MGC). This study was conducted to assess third-line treatment patterns, outcomes, and clinical parameters related to survival outcomes in patients with MGC. Methods Using the Korean Health Insurance Review and Assessment Service (HIRA) database, a nationwide population-based outcomes study was conducted. From the HIRA database, patients newly diagnosed in 2010 with MGC were identified (N = 1,871), and of these, 229 patients who had received third-line chemotherapy were finally selected for this study. Results Prior to third-line chemotherapy, more than 90% of patients received fluoropyrimidine and platinum, and 43.7% and 40.6% received taxane and irinotecan, respectively. Various third line chemotherapy regimens containing taxane (docetaxel or paclitaxel), irinotecan, or oxaliplatin were prescribed. The median overall survival (OS) of all patients receiving third-line chemotherapy was 4.4 months. The median time from the start date of first-line chemotherapy to the start date of third-line chemotherapy (TF1T3) was 9.5 months, and a longer TF1T3 was the only factor that was significantly associated with an increased OS. The median OS of patients who had received fluoropyrimidine, platinum, and taxane followed by third-line irinotecan-based therapy was similar to that of patients who had received fluoropyrimidine, platinum, and irinotecan followed by third-line taxane-based therapy (p = 0.894). Conclusion In patients with MGC receiving third-line chemotherapy, TF1 T3 was the only significant factor associated with OS. The sequence of using taxane and irinotecan as subsequent therapy after first-line failure was not shown to impact survival outcome.	[Choi, In Sil] Seoul Natl Univ, Seoul Metropolitan Govt, Dept Internal Med, Coll Med,Boramae Med Ctr, Seoul, South Korea; [Choi, Mihong; Lee, Ju Hyun; Kim, Jee Hyun; Suh, Koung Jin; Lee, Ji Yun; Kang, Beodeul; Kim, Ji-Won; Kim, Se-Hyun; Kim, Jin Won; Lee, Jeong-Ok; Kim, Yu Jung; Bang, Soo-Mee; Lee, Jong Seok; Lee, Keun-Wook] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Lee, KW (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea.	hmodoctor@snubh.org		Kang, Beodeul/0000-0001-5177-8937; Kim, Jin Won/0000-0002-1357-7015	Seoul National University Bundang Hospital Research Fund [02-2016-044]	Seoul National University Bundang Hospital Research Fund	This study was partially supported by research grants from the Seoul National University Bundang Hospital Research Fund (02-2016-044) to KWL. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Ajani JA, 2010, J CLIN ONCOL, V28, P1547, DOI 10.1200/JCO.2009.25.4706; Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Ford HER, 2014, LANCET ONCOL, V15, P78, DOI 10.1016/S1470-2045(13)70549-7; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Glimelius B, 1997, ANN ONCOL, V8, P163, DOI 10.1023/A:1008243606668; Jung KW, 2017, CANCER RES TREAT, V49, P292, DOI 10.4143/crt.2017.118; Kang EJ, 2013, GASTRIC CANCER, V16, P581, DOI 10.1007/s10120-012-0227-5; Kang JH, 2012, J CLIN ONCOL, V30, P1513, DOI 10.1200/JCO.2011.39.4585; Kang YK, 2009, ANN ONCOL, V20, P666, DOI 10.1093/annonc/mdn717; Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5; Kim DY, 2003, ANN ONCOL, V14, P383, DOI 10.1093/annonc/mdg106; Kim YS, 2010, CANCER RES TREAT, V42, P24, DOI 10.4143/crt.2010.42.1.24; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI 10.1016/S1470-2045(08)70035-4; Lee JH, 2013, KOREAN J INTERN MED, V28, P314, DOI 10.3904/kjim.2013.28.3.314; Lee KW, 2016, J CANCER RES CLIN, V142, P687, DOI 10.1007/s00432-015-2075-2; Lee MJ, 2012, CANCER RES TREAT, V44, P235, DOI 10.4143/crt.2012.44.4.235; PYRHONEN S, 1995, BRIT J CANCER, V71, P587, DOI 10.1038/bjc.1995.114; Shim HJ, 2011, GASTRIC CANCER, V14, P249, DOI 10.1007/s10120-011-0032-6; Shimoyama R, 2009, GASTRIC CANCER, V12, P206, DOI 10.1007/s10120-009-0524-9; Thuss-Patience PC, 2014, EUR J CANCER, V47, P2306; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsuji K, 2012, JPN J CLIN ONCOL, V42, P686, DOI 10.1093/jjco/hys084; Wagner AD, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub4; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6	25	12	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198544	10.1371/journal.pone.0198544	http://dx.doi.org/10.1371/journal.pone.0198544			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879177	Green Published, gold, Green Submitted			2023-01-03	WOS:000434384900052
J	Egawa, Y; Saigo, C; Kito, Y; Moriki, T; Takeuchi, T				Egawa, Yuki; Saigo, Chiemi; Kito, Yusuke; Moriki, Toshiaki; Takeuchi, Tamotsu			Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma	PLOS ONE			English	Article							SENTINEL NODE BIOPSY; MALIGNANT-MELANOMA; CANCER; AGENT; TRANSLOCATION; ESTABLISHMENT; MOLECULE; GROWTH; MODEL; MICE	Clear cell sarcoma (CCS) is an aggressive type of soft tissue tumor that is associated with high rates of metastasis. In the present study, we found that CPI-613, which targets tumorous mitochondrial energy metabolism, induced autophagosome formation followed by lysosome fusion in HS-MM CCS cells in vitro. Interestingly, CPI-613 along with chloroquine, which inhibits the fusion of autophagosomes with lysosomes, significantly induced necrosis of HS-MM CCS cell growth in vitro. Subsequently, we established a murine orthotropic metastatic model of CCS and evaluated the putative suppressive effect of a combination of CPI-613 and chloroquine on CCS progression. Injection of HS-MM into the aponeuroses of the thigh, the most frequently affected site in CCS, resulted in massive metastasis in SCID-beige mice. By contrast, intraperitoneal administration of CPI-613 (25 mg/kg) and chloroquine (50 mg/kg), two days a week for two weeks, significantly decreased tumor growth at the injection site and abolished metastasis. The present results imply the inhibitory effects of a combination of CPI-613 and chloroquine on the progression of CCS.	[Egawa, Yuki; Saigo, Chiemi; Kito, Yusuke; Takeuchi, Tamotsu] Gifu Univ, Grad Sch Med, Dept Pathol & Translat Res, Gifu, Japan; [Egawa, Yuki; Moriki, Toshiaki] Shizuoka City Shizuoka Hosp, Div Pathol, Shizuoka, Japan	Gifu University	Takeuchi, T (corresponding author), Gifu Univ, Grad Sch Med, Dept Pathol & Translat Res, Gifu, Japan.	takeutit08@gmail.com		, Tamotsu/0000-0002-4264-3632	Ministry of Education of Japan [15K08361, 17K15642]	Ministry of Education of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by grants from the Ministry of Education of Japan (Grant nos. KAKEN 15K08361 to T.T. and 17K15642 to C.S.). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5; Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238-017-0451-1; Andreou D, 2013, ANN ONCOL, V24, P1400, DOI 10.1093/annonc/mds650; Andreou Dimosthenis, 2009, V179, P25; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; ENZINGER FM, 1965, CANCER, V18, P1163, DOI 10.1002/1097-0142(196509)18:9<1163::AID-CNCR2820180916>3.0.CO;2-0; Hong SH, 2015, ONCOTARGET, V6, P7151, DOI 10.18632/oncotarget.3345; Iwashita H, 2018, FEBS LETT, V592, P559, DOI 10.1002/1873-3468.12979; Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349; Kawarada Y, 1997, PANCREAS, V15, P251, DOI 10.1097/00006676-199710000-00006; Kundu N, 1996, JNCI-J NATL CANCER I, V88, P536, DOI 10.1093/jnci/88.8.536; MACDOUGALL JR, 1990, CELL IMMUNOL, V130, P106, DOI 10.1016/0008-8749(90)90165-N; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mavrogenis AF, 2013, HIPPOKRATIA, V17, P298; Pardee TS, 2014, CLIN CANCER RES, V20, P5255, DOI 10.1158/1078-0432.CCR-14-1019; Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168; Sonobe H, 1999, J PATHOL, V187, P594; SONOBE H, 1993, J PATHOL, V169, P317, DOI 10.1002/path.1711690307; Stuart SD, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-4; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; Takeuchi T, 2012, CARCINOGENESIS, V33, P548, DOI 10.1093/carcin/bgs001; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	24	17	17	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198940	10.1371/journal.pone.0198940	http://dx.doi.org/10.1371/journal.pone.0198940			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879220	Green Published, gold, Green Submitted			2023-01-03	WOS:000434384900098
J	Dequigiovanni, G; Ramos, SLF; Alves-Pereira, A; Fabri, EG; Picanco-Rodrigues, D; Clement, CR; Gepts, P; Veasey, EA				Dequigiovanni, Gabriel; Ferreyra Ramos, Santiago Linorio; Alves-Pereira, Alessandro; Fabri, Eliane Gomes; Picanco-Rodrigues, Doriane; Clement, Charles Roland; Gepts, Paul; Veasey, Elizabeth Ann			Highly structured genetic diversity of Bixa orellana var. urucurana, the wild ancestor of annatto, in Brazilian Amazonia	PLOS ONE			English	Article							POPULATION-STRUCTURE; R PACKAGE; DOMESTICATION; MODELS; ADAPTATION; PREDICTION; EVOLUTION; SOFTWARE; SYSTEMS; NICHE	Annatto (Bixa orellana L.) is a tropical American crop, commercially valuable due to its application in the food and cosmetics industries as a natural dye. The wild ancestor of cultivated annatto is B. orellana var. urucurana. Although never cultivated, this variety occurs in open forests and anthropogenic landscapes, and is always associated with riparian environments. In this study, we evaluated the genetic diversity and structure of B. orellana var. urucurana populations in Brazilian Amazonia using 16 microsatellite loci. We used Ecological Niche Modeling (ENM) to characterize the potential geographical range of this variety in northern South America. We analyzed 170 samples from 10 municipalities in the states of Rondonia, Para and Roraima. A total of 194 alleles was observed, with an average of 12.1 alleles per locus. Higher levels of expected (H-E) than observed (H-O) heterozygosities were found for all populations. Bayesian analysis, Neighbor-Joining dendrograms and PCAs suggest the existence of three strongly structured groups of populations. A strong and positive correlation between genetic and geographic distances was found, suggesting that genetic differentiation might be caused by geographic isolation. From species distribution modelling, we detected that South Rondonia, Madre di Dios River basin, Llanos de Mojos, Llanos de Orinoco and eastern Ecuador are highly suitable areas for wild annatto to occur, providing additional targets for future exploration and conservation. Climatic adaptation analyses revealed strong differentiation among populations, suggesting that precipitation plays a key role in wild annatto's current and potential distribution patterns.	[Dequigiovanni, Gabriel; Alves-Pereira, Alessandro; Veasey, Elizabeth Ann] Univ Sao Paulo, ESALQ, Dept Genet, Piracicaba, SP, Brazil; [Ferreyra Ramos, Santiago Linorio] Univ Fed Amazonas, Inst Ciencias Exatas & Tecnol Itacoatiara, Itacoatiara, Amazonas, Brazil; [Fabri, Eliane Gomes] Inst Agron Campinas, Ctr Hort, Campinas, SP, Brazil; [Picanco-Rodrigues, Doriane] Univ Fed Amazonas ICB UFAM, Inst Ciencias Biol, Manaus, Amazonas, Brazil; [Clement, Charles Roland] INPA, Manaus, Amazonas, Brazil; [Gepts, Paul] Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA	Universidade de Sao Paulo; Universidade Federal de Amazonas; Instituto Agronomico de Campinas (IAC); Institute Nacional de Pesquisas da Amazonia; University of California System; University of California Davis	Veasey, EA (corresponding author), Univ Sao Paulo, ESALQ, Dept Genet, Piracicaba, SP, Brazil.	eaveasey@usp.br	Alves-Pereira, Alessandro/I-6595-2012; Clement, Charles Roland/G-6081-2010; Gepts, Paul/O-8229-2019; Veasey, Elizabeth A/L-6843-2018; Ramos, Santiago Linorio Ferreyra/AAL-9978-2021; Veasey, Elizabeth/C-4511-2012	Alves-Pereira, Alessandro/0000-0002-3012-6355; Clement, Charles Roland/0000-0002-8421-1029; Gepts, Paul/0000-0002-1056-4665; Ramos, Santiago Linorio Ferreyra/0000-0003-0364-316X; Veasey, Elizabeth/0000-0002-7574-2020; Dequigiovanni, Gabriel/0000-0002-8093-8749	Sao Paulo Research Foundation (FAPESP) [2015/26837-0, 2012/08307-5]; National Council for Scientific and Technological Development (CNPq) CT Amazonia [575588/2008-0]; FAPESP [2013/08884-5, 2016/05912-6]; Coordination for the Improvement of Higher Education Personnel (CAPES); CNPq	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Council for Scientific and Technological Development (CNPq) CT Amazonia(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This project was financially supported by the Sao Paulo Research Foundation (FAPESP) (2015/26837-0; 2012/08307-5) and by the National Council for Scientific and Technological Development (CNPq) CT Amazonia (575588/2008-0). G.D. was supported by FAPESP with PhD scholarships (2013/08884-5; 2016/05912-6). A.A. P. thanks the Coordination for the Improvement of Higher Education Personnel (CAPES) for a postdoctoral scholarship. E.A.V. and C.R.C. were supported by CNPq research fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This project was financially supported by the Sao Paulo Research Foundation (FAPESP) (2011/10357-8; 2012/08307-5) and by the National Council for Scientific and Technological Development (CNPq) CT Amazonia (575588/2008-0). G. D. was supported by FAPESP with PhD scholarships (2013/08884-5; 2016/05912-6). A.A.P. thanks the Coordination for the Improvement of Higher Education Personnel (CAPES) for a post-doctoral scholarship. E.A.V. and C.R.C. were supported by CNPq research fellowships.	Akshatha V, 2011, J HORTIC SCI BIOTECH, V86, P319, DOI 10.1080/14620316.2011.11512767; Arce J., 1999, EARTH, P149; Baer D, 1976, THESIS; Barthem R., 2003, AQUATIC ECOLOGY RIO; Bonatelli IAS, 2014, MOL ECOL, V23, P3044, DOI 10.1111/mec.12780; Vieira MLC, 2016, GENET MOL BIOL, V39, P312, DOI 10.1590/1678-4685-GMB-2016-0027; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Clement C. R., 2010, Diversity, V2, P72; Clement Charles Roland, 2016, Bol. Mus. Para. Emílio Goeldi. Ciênc. hum., V11, P193, DOI 10.1590/1981.81222016000100010; Clement CR, 1999, ECON BOT, V53, P188, DOI 10.1007/BF02866498; d'Eeckenbrugge GC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107458; de Carvalho JFRP, 2005, PESQUI AGROPECU BRAS, V40, P653, DOI 10.1590/S0100-204X2005000700005; Dequigiovani G, 2017, GENET RESOUR CROP EV, V64, P1775, DOI 10.1007/s10722-017-0535-z; Dequigiovanni G, 2014, GENET MOL RES, V13, P9097, DOI 10.4238/2014.October.31.25; Dequigiovanni G, 2018, CROP BREED APPL BIOT; Dias F, 2008, U FEDERAL SANTA MARI, V38, P534, DOI [10.1590/S0103-84782008000200039, DOI 10.1590/S0103-84782008000200039]; Dick C. W., 2008, Tropical Plant Biology, V1, P20, DOI 10.1007/s12042-007-9006-6; Dieringer D, 2003, MOL ECOL NOTES, V3, P167, DOI 10.1046/j.1471-8286.2003.00351.x; Doyle J. L. ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; Dray S, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i04; Ducke A., 1946, B I AGRONOMICO NORTE, V8, P1; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; ElMousadik A, 1996, THEOR APPL GENET, V92, P832, DOI 10.1007/BF00221895; Erickson CL, 1995, ARCHAEOLOGY LOWLAND, P66; Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x; Felsenstein J., 1989, CLADISTICS, V5, P164; Fielding AH, 1997, ENVIRON CONSERV, V24, P38, DOI 10.1017/S0376892997000088; Gepts P., 2004, Plant Breeding Reviews, V24, P1, DOI 10.1002/9780470650288.ch1; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; *INPE, 2002, MON BRAZ AM FOR SAT; Jombart T, 2011, BIOINFORMATICS, V27, P3070, DOI 10.1093/bioinformatics/btr521; Jose AR, 1992, REV BRASILEIRA CORAN, V1, P101; Kamvar ZN, 2014, PEERJ, V2, DOI 10.7717/peerj.281; Keenan K, 2013, METHODS ECOL EVOL, V4, P782, DOI 10.1111/2041-210X.12067; Kuntze C., 1925, NATURL PFLANZ, P315; Leal F, 2010, REV UNELL CIENC TEC, V1, P78; Levis C, 2017, SCIENCE, V355, P925, DOI 10.1126/science.aal0157; LOVELESS MD, 1984, ANNU REV ECOL SYST, V15, P65, DOI 10.1146/annurev.es.15.110184.000433; Manel S, 2010, MOL ECOL, V19, P3824, DOI 10.1111/j.1365-294X.2010.04716.x; Medina Ada Maureen, 2001, Acta Cientifica Venezolana, V52, P14; Meyer RS, 2013, NAT REV GENET, V14, P840, DOI 10.1038/nrg3605; Meyer RS, 2012, NEW PHYTOL, V196, P29, DOI 10.1111/j.1469-8137.2012.04253.x; Moreira PA, 2015, ECON BOT, V69, P127, DOI 10.1007/s12231-015-9304-0; Nisar N, 2015, MOL PLANT, V8, P68, DOI 10.1016/j.molp.2014.12.007; Olsen KM, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00290; Osher LJ, 1998, GEODERMA, V83, P143, DOI 10.1016/S0016-7061(97)00133-X; Peakall R, 2012, BIOINFORMATICS, V28, P2537, DOI 10.1093/bioinformatics/bts460; Peres EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121543; Peterson AT, 2003, Q REV BIOL, V78, P419, DOI 10.1086/378926; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; de Menezes IPP, 2014, GENETICA, V142, P99, DOI 10.1007/s10709-014-9757-6; Piperno D.R., 1998, ORIGINS AGR LOWLAND; Pritchard JK, 2000, GENETICS, V155, P945; Reif JC, 2005, CROP SCI, V45, P1, DOI 10.2135/cropsci2005.0001; Reusch TBH, 2007, MOL ECOL, V16, P3973, DOI 10.1111/j.1365-294X.2007.03454.x; Ritland K, 2002, HEREDITY, V88, P221, DOI 10.1038/sj.hdy.6800029; Rivera-Madrid R, 2006, SCI HORTIC-AMSTERDAM, V109, P165, DOI 10.1016/j.scienta.2006.03.011; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandy-Cuen PM, 2003, BIODIVERSITAS, V7, P7; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; Schultes RE., 1984, PRECOLUMBIAN PLANT M, V76, P19; SLATKIN M, 1989, EVOLUTION, V43, P1349, DOI 10.1111/j.1558-5646.1989.tb02587.x; Stefano R, 2006, NEOTROPICAL SAVANNAS, P96; Team R. C, 2018, R LANG ENV STAT COMP; Valdez-Ojeda R, 2008, HORTSCIENCE, V43, P2013, DOI 10.21273/HORTSCI.43.7.2013; Valdez-Ojeda R, 2010, AGRON J, V102, P1340, DOI 10.2134/agronj2009.0510; VENCOVSKY R, 1994, REV BRAS GENET, V17, P349; Walker JH, 2008, HANDBOOK OF SOUTH AMERICAN ARCHAEOLOGY, P927, DOI 10.1007/978-0-387-74907-5_46; Wang T, 2016, SCI REP-UK, V6, DOI 10.1038/srep25031; Wiens JJ, 2011, PHILOS T R SOC B, V366, P2336, DOI 10.1098/rstb.2011.0059; WRIGHT S, 1965, EVOLUTION, V19, P395, DOI 10.2307/2406450; Wright S, 1931, GENETICS, V16, P0097	72	8	10	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2018	13	6							e0198593	10.1371/journal.pone.0198593	http://dx.doi.org/10.1371/journal.pone.0198593			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI4VN	29874280	Green Published, gold, Green Submitted			2023-01-03	WOS:000434369400052
J	Rao, DD; Luo, XQ; Wang, ZH; Jay, CM; Brunicardi, FC; Maltese, W; Manning, L; Senzer, N; Nemunaitis, J				Rao, Donald D.; Luo, Xiuquan; Wang, Zhaohui; Jay, Christopher M.; Brunicardi, Francis C.; Maltese, William; Manning, Luisa; Senzer, Neil; Nemunaitis, John			KRAS mutant allele -specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex	PLOS ONE			English	Article							K-RAS; FEEDBACK-REGULATION; PATHWAY INHIBITORS; ONCOGENIC KRAS; TUMOR-CELLS; GROWTH; COMBINATION; PROTEINS; SIRNA	The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeutics. This report presents the results of pre-clinical assessment of a lipoplex comprising a plasmid-encoded, modular bi-functional shRNA (bi-shRNA), which executes selective and multi-mutant allelic KRAS(G12mut) gene silencing, encased within a fusogenic liposome systemic delivery vehicle. Using both a dual luciferase reporter system and a Restriction Fragment Length Polymorphism (RFLP) assay, selective discrimination of KRAS(G12mut) from KRAS(wt) was confirmed in vitro in PANC1 cells. Subsequently, systemic administration of the bi-shRNA(KRAs) fusogenic lipoplex into female athymic Nu/Nu mice bearing PANC1 xenografts demonstrated intratumoral plasmid delivery, KRAS(G12mut) knockdown, and inhibition of tumor growth, without adverse effect. Clinical trials with the bishRNA lipoplex have been implemented.	[Rao, Donald D.; Luo, Xiuquan; Wang, Zhaohui; Jay, Christopher M.; Senzer, Neil; Nemunaitis, John] Strike Bio, Dallas, TX 75201 USA; [Brunicardi, Francis C.; Maltese, William; Nemunaitis, John] Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA; [Manning, Luisa; Senzer, Neil; Nemunaitis, John] Gradalis Inc, Dallas, TX 75201 USA	University System of Ohio; University of Toledo	Nemunaitis, J (corresponding author), Strike Bio, Dallas, TX 75201 USA.; Nemunaitis, J (corresponding author), Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.; Nemunaitis, J (corresponding author), Gradalis Inc, Dallas, TX 75201 USA.	johnnemunaits@gmail.com						Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bedard PL, 2015, CLIN CANCER RES, V21, P730, DOI 10.1158/1078-0432.CCR-14-1814; Bentley C, 2013, BIOCHEM J, V452, P313, DOI 10.1042/BJ20121578; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Castellano Esther, 2011, Genes Cancer, V2, P216, DOI 10.1177/1947601911408081; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Cicenas J, 2017, CANCERS, V9, DOI 10.3390/cancers9050042; Cirit M, 2010, J BIOL CHEM, V285, P36736, DOI 10.1074/jbc.M110.148759; Cleary JM, 2010, CURR ONCOL REP, V12, P87, DOI 10.1007/s11912-010-0091-6; Dahlgren C, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn190; Ebi H, 2014, CANCER SCI, V105, P499, DOI 10.1111/cas.12383; Fleming JB, 2005, MOL CANCER RES, V3, P413, DOI 10.1158/1541-7786.MCR-04-0206; Fritsche-Guenther R, 2016, ONCOTARGET, V7, P7960, DOI 10.18632/oncotarget.6959; Geng CM, 2011, CHINESE MED J-PEKING, V124, P106, DOI 10.3760/cma.j.issn.0366-6999.2011.01.020; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Golan T, 2015, ONCOTARGET, V6, P24560, DOI 10.18632/oncotarget.4183; Gradiz R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21648; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez-Valladares M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17307; Hetmanski JHR, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004909; Khvalevsky EZ, 2013, P NATL ACAD SCI USA, V110, P20723, DOI 10.1073/pnas.1314307110; Kulemann B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04601-z; Lake D, 2016, CELL MOL LIFE SCI, V73, P4397, DOI 10.1007/s00018-016-2297-8; Le Rolle AF, 2016, ONCOTARGET, V7, P2159, DOI 10.18632/oncotarget.6818; Lennerz Jochen K, 2015, Oncologist, V20, pe8, DOI 10.1634/theoncologist.2014-0408; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Long GV, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9011; Mann KM, 2016, PHARMACOL THERAPEUT, V168, P29, DOI 10.1016/j.pharmthera.2016.09.003; Markman B, 2010, ONCOTARGET, V1, P530, DOI 10.18632/oncotarget.188; McCormick F, 2016, J MOL MED, V94, P253, DOI 10.1007/s00109-016-1382-7; Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112; Ohnishi Yusuke, 2006, J RNAi Gene Silencing, V2, P154; Ohnishi Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002248; Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Rao DD, 2010, CANCER GENE THER, V17, P780, DOI 10.1038/cgt.2010.35; Rao Donald D, 2013, Methods Mol Biol, V942, P259, DOI 10.1007/978-1-62703-119-6_14; Riquelme E, 2016, CANCER RES, V76, P675, DOI 10.1158/0008-5472.CAN-15-1141; Ross SJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5253; Schwarz DS, 2006, PLOS GENET, V2, P1307, DOI 10.1371/journal.pgen.0020140; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tatarian T, 2016, SURG CLIN N AM, V96, P1207, DOI 10.1016/j.suc.2016.07.014; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Wang ZH, 2017, TOXICOL SCI, V155, P400, DOI 10.1093/toxsci/kfw223; Zhu H, 2006, CANCER BIOL THER, V5, P1693, DOI 10.4161/cbt.5.12.3466	47	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2018	13	5							e0193644	10.1371/journal.pone.0193644	http://dx.doi.org/10.1371/journal.pone.0193644			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8CD	29851957	Green Published, gold, Green Submitted			2023-01-03	WOS:000433893200001
J	Donohue, JM; Huskamp, HA				Donohue, Julie M.; Huskamp, Haiden A.			Doughnuts and Discounts - Changes to Medicare Part D under the Bipartisan Budget Act of 2018	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Donohue, Julie M.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Huskamp, Haiden A.] Harvard Med Sch, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School	Donohue, JM (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.							[Anonymous], 2012, MED D; Hsu J, 2008, JAMA-J AM MED ASSOC, V299, P1929, DOI 10.1001/jama.299.16.1929; Medicare Payment Advisory Commission, 2016, REP C MED HLTH CAR D; Medicare Payment Advisory Commission, 2018, REP C MED PAYM POL; Polinski JM, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001075	5	5	5	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 24	2018	378	21					1957	1960		10.1056/NEJMp1802159	http://dx.doi.org/10.1056/NEJMp1802159			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG6KK	29791823				2023-01-03	WOS:000432804900001
J	Chi, H; Chung, CH; Lin, YJ; Lin, CH				Chi, Hsin; Chung, Ching-Hu; Lin, Yuh-Jyh; Lin, Chyi-Her			Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan	PLOS ONE			English	Article							WEEKS GESTATION; YOUNG-CHILDREN; BRONCHOPULMONARY DYSPLASIA; BRONCHIOLITIS; PALIVIZUMAB; DURATION; BURDEN; BORN; CARE; AGE	Objectives To assess the nationwide seasonal peaks, risk factors, and utilization of medical resources of respiratory syncytial virus-associated hospitalization (RSVH) in preterm infants in Taiwan. Study design A Taiwan nationwide birth cohort was extracted from the Birth Certificate Application Database during 2007-2009 and prospectively linked to the National Health Insurance database. We evaluated the seasonal peaks and risk factors (gestational age [GA], chronologic age [CA], and bronchopulmonary dysplasia [BPD]) associated with the RSVH of preterm infants. The length of hospital stays (LOS), care in intensive care unit (ICU), and use of mechanical ventilation (MV) were also analyzed. Results There is a total duration of 9 months of RSVH season in Taiwan, three seasonal peaks and two seasonal peaks of RSVH in preterm infants with BPD and without BPD, respectively. Preterm infants had significantly higher RSVH rate than term infants (2.6% vs 0.9%, p<0.0001). Preterm infants born at 29-35 weeks of gestational age (wGA) with BPD had significantly higher RSVH rate than those without BPD (p<0.0001). Preterm infants without BPD born at < 32 wGA had higher RSVH rate than those born at 33-35 wGA (p<0.0001). Overall, 56.4% of RSVH occurred within 9 months of CA. Preterm infants with BPD had significantly higher ICU admission rate within 18 months of CA (p<0.0001), MV usage within 12 months of CA (p<0.0001) and LOS within 18 months of CA (p<0.001) than those without BPD. RSVH occurred within 6 months of CA was significantly associated with higher ICU admission rate (p<0.0001), MV usage (p = 0.0002) and longer LOS (p<0.001) in preterm infants without BPD. Conclusions There is a total duration of 9 months of RSVH season in Taiwan. Preterm < 32 wGA, BPD, and CA within 6 months were risk factors of RSVH which also contribute to higher utilization of medical resources.	[Chi, Hsin] Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan; [Chi, Hsin] Mackay Childrens Hosp, Taipei, Taiwan; [Chi, Hsin; Chung, Ching-Hu] Mackay Med Coll, Dept Med, New Taipei, Taiwan; [Lin, Yuh-Jyh; Lin, Chyi-Her] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Pediat, Tainan, Taiwan; [Lin, Yuh-Jyh; Lin, Chyi-Her] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan	Mackay Memorial Hospital; Mackay Medical College; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University	Lin, CH (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Pediat, Tainan, Taiwan.; Lin, CH (corresponding author), Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan.	neonate@mail.ncku.edu.tw	Lin, Yuh Jyh/AAK-4314-2020					Abraha HY, 2015, EXPERT REV RESP MED, V9, P779, DOI 10.1586/17476348.2015.1098536; Abramson JS, 2003, PEDIATRICS, V112, P1442; Anderson EJ, 2017, AM J PERINAT, V34, P51, DOI 10.1055/s-0036-1584147; Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]; Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Carbonell-Estrany X, 2000, PEDIATR INFECT DIS J, V19, P592, DOI 10.1097/00006454-200007000-00002; Chi H, 2011, J FORMOS MED ASSOC, V110, P388, DOI 10.1016/S0929-6646(11)60057-0; Cilla G, 2006, EPIDEMIOL INFECT, V134, P506, DOI 10.1017/S0950268805005571; Flaherman VJ, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-144; Gouyon JB, 2013, EPIDEMIOL INFECT, V141, P816, DOI 10.1017/S0950268812001069; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211; Helfrich AM, 2015, EARLY HUM DEV, V91, P541, DOI 10.1016/j.earlhumdev.2015.06.009; Hervas D, 2012, EUR J CLIN MICROBIOL, V31, P1975, DOI 10.1007/s10096-011-1529-y; Homaira N, 2016, EPIDEMIOL INFECT, V144, P1612, DOI 10.1017/S0950268815003015; Howard TS, 2000, J PEDIATR-US, V137, P227, DOI 10.1067/mpd.2000.107525; Hsu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110166; Kneyber MCJ, 2002, PEDIATR PULM, V33, P453, DOI 10.1002/ppul.10099; Landry JS, 2012, CHRON DIS INJ CAN, V33, P47; Lee Jian-Te, 2007, Journal of Microbiology Immunology and Infection, V40, P293; Mauskopf J, 2016, PEDIATR INFECT DIS J, V35, pE229, DOI 10.1097/INF.0000000000001163; Murray J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089186; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Panozzo CA, 2007, PEDIATR INFECT DIS J, V26, pS41, DOI 10.1097/INF.0b013e318157da82; Robbie GJ, 2012, ANTIMICROB AGENTS CH, V56, P4927, DOI 10.1128/AAC.06446-11; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144; Stensballe LG, 2003, PEDIATR INFECT DIS J, V22, pS21, DOI 10.1097/00006454-200302001-00004; Stevens TP, 2000, ARCH PEDIAT ADOL MED, V154, P55; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; Tang JLW, 2014, REV MED VIROL, V24, P15, DOI 10.1002/rmv.1771; Weisman LE, 2003, PEDIATR INFECT DIS J, V22, pS33, DOI 10.1097/00006454-200302001-00005; Winterstein AG, 2013, JAMA PEDIATR, V167, P1118, DOI 10.1001/jamapediatrics.2013.2636; Yusuf S, 2007, EPIDEMIOL INFECT, V135, P1077, DOI 10.1017/S095026880600776X	37	4	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0197410	10.1371/journal.pone.0197410	http://dx.doi.org/10.1371/journal.pone.0197410			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF3JM	29746578	Green Submitted, gold, Green Published			2023-01-03	WOS:000431851700110
J	McEvoy, JW				McEvoy, John W.			Excess oxygen in acute illness: adding fuel to the fire	LANCET			English	Editorial Material							HYPEROXIA		[McEvoy, John W.] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21287 USA	Johns Hopkins University	McEvoy, JW (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21287 USA.	jmcevoy1@jhmi.edu						Aggarwal NR, 2018, CRIT CARE MED, V46, P517, DOI 10.1097/CCM.0000000000002886; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Damiani E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0711-x; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; Hafner S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0084-6; Helmerhorst HJF, 2015, CRIT CARE MED, V43, P1508, DOI 10.1097/CCM.0000000000000998; JAMIESON D, 1986, ANNU REV PHYSIOL, V48, P703, DOI 10.1146/annurev.ph.48.030186.003415; McCarthy CP, 2017, TRENDS CARDIOVAS MED, V27, P483, DOI 10.1016/j.tcm.2017.05.001; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Packer M, 2017, CIRCULATION, V136, P2097, DOI 10.1161/CIRCULATIONAHA.117.030209; Singer M, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1913-9	11	7	7	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	2018	391	10131					1640	1642		10.1016/S0140-6736(18)30546-4	http://dx.doi.org/10.1016/S0140-6736(18)30546-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE7NC	29726326				2023-01-03	WOS:000431419100006
J	Moore, KL; Patel, K; Boscardin, WJ; Steinman, MA; Ritchie, C; Schwartz, JB				Moore, Kelly L.; Patel, Kanan; Boscardin, W. John; Steinman, Michael A.; Ritchie, Christine; Schwartz, Janice B.			Medication burden attributable to chronic co-morbid conditions in the very old and vulnerable	PLOS ONE			English	Article							ADVERSE DRUG EVENTS; NURSING-HOME; UNITED-STATES; POLYPHARMACY; RESIDENTS; QUALITY; ADULTS; CARE; MULTIMORBIDITY; PREVALENCE	Objective & para;& para;Polypharmacy is common in older patients but relationships between polypharmacy and common co-morbid conditions have not been elucidated. Our goal was to determine relationships between daily oral medication use and common co-morbid disease dyads and triads using comprehensive medication and diagnostic data from a national sample of nursing homes (NH).& para;& para;Design & para;& para;Retrospective, cross-sectional study.& para;& para;Setting & para;& para;Nationally representative sample of U.S. Nursing Homes.& para;& para;Participants & para;& para;Nationally representative sample of long-term stay residents (n = 11734, 75% women) aged 65 years or older.& para;& para;Measurements & para;& para;Diagnosis and medication data were analyzed. Proportion of daily oral medication intake attributed to treatment of common two-(dyads) and three-disease (triad) combinations and "health maintenance" agents (vitamins, dietary supplements, stool softeners without related diagnoses) was determined.& para;& para;Results & para;& para;Older NH residents received slightly >8 oral medications/day with the number related to number of medical diagnoses (p < .0001). One third of chronic oral medication intake/day (excluding health maintenance agents) could be attributed to dyad combinations and about half to triad combinations despite an average of 5 other diagnoses. Triads were comprised of hypertension +/- arthritis +/- vascular disease, +/-depression, +/- osteoporosis +/- gastroesophageal reflux disease and +/- diabetes. Health maintenance agents accounted for 15-17% of daily oral medication intake (1.4 medications) such that almost two-thirds of daily oral medications were attributable to disease triads plus health maintenance. Fewer medications were prescribed for NH residents over age 85 (decreased ACE inhibitor and HMG CoA reductase inhibitor USE (p < .001)) while use of Alzheimer medications was higher (p < .01).& para;& para;Conclusions & para;& para;A large fraction of daily oral medications were attributed to management of common co-morbid disease dyads and triads. Efforts to reduce polypharmacy and unwanted medication interactions could focus on regimens for common co-morbid dyads and triads in varying populations.	[Moore, Kelly L.; Patel, Kanan; Ritchie, Christine; Schwartz, Janice B.] Ctr Res Aging Jewish Home, San Francisco, CA 94112 USA; [Patel, Kanan; Boscardin, W. John; Steinman, Michael A.; Ritchie, Christine; Schwartz, Janice B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA; [Schwartz, Janice B.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Schwartz, JB (corresponding author), Ctr Res Aging Jewish Home, San Francisco, CA 94112 USA.; Schwartz, JB (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Schwartz, JB (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.	Janice.schwartz@ucsf.edu	Schwartz, Janice/K-6354-2019		National Institute for Aging [RC1 AG 036377, K24AG049057]; Jewish Home of San Francisco; NIA [RC1 AG 036377, K24AG049057]	National Institute for Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Jewish Home of San Francisco; NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded in part by National Institute for Aging (https://www.nia.nih.gov) grants RC1 AG 036377 (JBS, MS) and K24AG049057 (MS), and with funds from the Jewish Home of San Francisco (JBS, CR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was funded in part by NIA grants RC1 AG 036377 and K24AG049057, and with funds from the Jewish Home of San Francisco. The authors report no conflicts of interest in relation to this work.	[Anonymous], 2009, NAT NURS HOM SURV 20; Arnett DK, 2014, J AM COLL CARDIOL, V64, P1851, DOI 10.1016/j.jacc.2014.07.012; Aronow WS, 2011, J AM SOC HYPERTENS, V5, P259, DOI 10.1016/j.jash.2011.06.001; Bach PB, 2006, NEW ENGL J MED, V354, P2312, DOI 10.1056/NEJMp068108; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Boyd CM, 2010, PUBLIC HEALTH REV, V32, P451, DOI 10.1007/BF03391611; Budnitz DS, 2007, ANN INTERN MED, V147, P755, DOI 10.7326/0003-4819-147-11-200712040-00006; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Calderon-Larranaga A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084967; Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295; CARBONIN P, 1991, J AM GERIATR SOC, V39, P1093, DOI 10.1111/j.1532-5415.1991.tb02875.x; CMS, 2017, MED FEE SERV PROV UT; Cms.gov, NURS HOM DAT COMP 20; Dwyer Lisa L, 2009, Vital Health Stat 1, P1; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Field TS, 2001, ARCH INTERN MED, V161, P1629, DOI 10.1001/archinte.161.13.1629; Gurwitz JH, 2005, AM J MED, V118, P251, DOI 10.1016/j.amjmed.2004.09.018; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HELLING DK, 1987, J AM GERIATR SOC, V35, P4, DOI 10.1111/j.1532-5415.1987.tb01312.x; Ickowicz E, 2012, J AM GERIATR SOC, V60, pE1, DOI 10.1111/j.1532-5415.2012.04188.x; Jokanovic N, 2015, J AM MED DIR ASSOC, V16, DOI 10.1016/j.jamda.2015.03.003; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Karkare SU, 2011, AM J GERIATR PHARMAC, V9, P109, DOI 10.1016/j.amjopharm.2011.03.001; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Moore KL, 2014, J NUTR HEALTH AGING, V18, P429, DOI 10.1007/s12603-014-0001-y; Moore KL, 2012, J AM GERIATR SOC, V60, P756, DOI 10.1111/j.1532-5415.2012.03909.x; National Action Plan for Adverse Drug Event Prevention, 2014, OFF DIS PREV HLTH PR; National Nursing Home Survey Data, DRUG EST CHAR P FIL; NOLAN L, 1989, AGE AGEING, V18, P52, DOI 10.1093/ageing/18.1.52; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; Onder G, 2012, J GERONTOL A-BIOL, V67, P698, DOI 10.1093/gerona/glr233; Schwartz JB, 2016, J AM GERIATR SOC, V64, P1996, DOI 10.1111/jgs.14288; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Sharma M, 2015, CIRCULATION, V132, P194, DOI 10.1161/CIRCULATIONAHA.114.013267; Steinman MA, 2014, J GEN INTERN MED, V29, P1379, DOI 10.1007/s11606-014-2924-8	39	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2018	13	4							e0196109	10.1371/journal.pone.0196109	http://dx.doi.org/10.1371/journal.pone.0196109			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD7AK	29684077	Green Published, gold, Green Submitted			2023-01-03	WOS:000430660600038
J	Komenda, P; Tangri, N; Klajncar, E; Eng, A; Di Nella, M; Hiebert, B; Strome, T; de Faria, RL; Zacharias, JM; Verrelli, M; Sood, MM; Rigatto, C				Komenda, Paul; Tangri, Navdeep; Klajncar, Evan; Eng, Amanda; Di Nella, Michelle; Hiebert, Brett; Strome, Trevor; de Faria, Ricardo Lobato; Zacharias, James M.; Verrelli, Mauro; Sood, Manish M.; Rigatto, Claudio			Patterns of emergency department utilization by patients on chronic dialysis: A population-based study	PLOS ONE			English	Article							PATIENTS RECEIVING HEMODIALYSIS; STAGE RENAL-DISEASE; HEART-FAILURE; FREQUENT USERS; HOSPITAL READMISSION; RANDOMIZED-TRIAL; OUTCOMES; MANAGEMENT; MORTALITY; HEALTH	Importance Patients on dialysis are often elderly and frail, with multiple comorbid conditions, and are heavy users of Emergency Department (ED) services. However, objective data on the frequency and pattern of ED utilization by dialysis patients are sparse. Such data could identify periods of highest risk for ED visits and inform health systems interventions to mitigate these risks and improve outcomes Objective To describe the pattern and frequency of presentation to ER by dialysis patients Design Retrospective cohort study using administrative data collected over ten years (2000-2009) in the Province of Manitoba, Canada. Setting Patients presenting to any of 9 ED's in Winnipeg and Brandon Manitoba. These departments serve >90% of the population of Manitoba, Canada (population 1.2 million). Participants All patients presenting to an ED in any of 9 emergency departments in Manitoba, Canada. Exposure Dialysis status Main outcomes Presentation to the ED Results Over 2.1 million ED visits by more than 1.2 million non-dialysis patients and 17,782 ED visits by 3257 dialysis patients were included. Dialysis patients presented 8.5 times more frequently to the ED than the general population (age and sex adjusted, p<0.001). For dialysis patients, ED utilization was significantly higher following the long interdialytic interval (33.6% higher Mondays and 19.5% higher Tuesdays vs. other days of the week, p<0.001) and was 10-fold higher in the 7 days before and after the initiation of dialysis. Conclusion and relevance The heavy use of ED services by dialysis patients spikes upward following the long interdialytic interval and also in the week before and after dialysis initiation. The relative risks associated with these vulnerable periods were much higher than those reported for clinical patient characteristics. We propose that intrinsic gaps in the structure of care delivery (e.g. 3 times a week dialysis, imperfect surveillance and clinical monitoring of patients with low GFR) may be the fundamental drivers of this periodicity. Strategies to mitigate this excess health risk are needed.	[Komenda, Paul; Tangri, Navdeep; Klajncar, Evan; Eng, Amanda; Zacharias, James M.; Verrelli, Mauro; Rigatto, Claudio] Univ Manitoba, Fac Med, Winnipeg, MB, Canada; [Komenda, Paul; Tangri, Navdeep; Zacharias, James M.; Verrelli, Mauro; Rigatto, Claudio] Manitoba Renal Program, Winnipeg, MB, Canada; [Komenda, Paul; Tangri, Navdeep; Di Nella, Michelle; Zacharias, James M.; Sood, Manish M.; Rigatto, Claudio] Seven Oaks Gen Hosp, Chron Dis Innovat Ctr, Winnipeg, MB, Canada; [Hiebert, Brett] St Boniface Gen Hosp, Cardiac Sci Program, Winnipeg, MB, Canada; [Strome, Trevor; de Faria, Ricardo Lobato] Winnipeg Reg Hlth Author, Emergency Dept Program, Winnipeg, MB, Canada; [Sood, Manish M.] Univ Ottawa, Ottawa, ON, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Ottawa	Rigatto, C (corresponding author), Univ Manitoba, Fac Med, Winnipeg, MB, Canada.; Rigatto, C (corresponding author), Manitoba Renal Program, Winnipeg, MB, Canada.; Rigatto, C (corresponding author), Seven Oaks Gen Hosp, Chron Dis Innovat Ctr, Winnipeg, MB, Canada.	crigatto@sbgh.mb.ca	Sood, Manish M/H-3134-2019	Sood, Manish M/0000-0002-9146-2344	University of Manitoba Rady Faculty of Medicine BSc Medicine Studentships	University of Manitoba Rady Faculty of Medicine BSc Medicine Studentships	This work was supported by the University of Manitoba Rady Faculty of Medicine BSc Medicine Studentships (EK, AE).	Antonicelli R, 2008, J TELEMED TELECARE, V14, P300, DOI 10.1258/jtt.2008.071213; Breton M, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0117-9; Canadian Institute for Health Information, 2006, CORR REP DIAL REN TR; Castillo EM, 2014, J EMERG MED, V47, P343, DOI 10.1016/j.jemermed.2014.03.014; Clermont G, 2002, KIDNEY INT, V62, P986, DOI 10.1046/j.1523-1755.2002.00509.x; Dendale P, 2012, EUR J HEART FAIL, V14, P333, DOI 10.1093/eurjhf/hfr144; Doupe M, 2008, INITIAL ANAL EMERGEN, V1, DOI [10.1681/ASN.2013080879, DOI 10.1681/ASN.2013080879]; Doupe MB, 2012, ANN EMERG MED, V60, P24, DOI 10.1016/j.annemergmed.2011.11.036; Erickson KF, 2014, J AM SOC NEPHROL, V25, P2079, DOI 10.1681/ASN.2013080879; Foley RN, 2011, NEW ENGL J MED, V365, P1099, DOI 10.1056/NEJMoa1103313; Giordano A, 2009, INT J CARDIOL, V131, P192, DOI 10.1016/j.ijcard.2007.10.027; Gordon JA, 2001, J URBAN HEALTH, V78, P104, DOI 10.1093/jurban/78.1.104; Hutchison CA, 2007, CRIT CARE, V11, DOI 10.1186/cc5785; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; Kitsiou S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4174; Leventhal ME, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13171; Lovasik BP, 2016, JAMA INTERN MED, V176, P1563, DOI 10.1001/jamainternmed.2016.4975; Mandelberg JH, 2000, ACAD EMERG MED, V7, P637, DOI 10.1111/j.1553-2712.2000.tb02037.x; Miller JB, 2013, AM J EMERG MED, V31, P16, DOI 10.1016/j.ajem.2012.05.001; Niska Richard, 2010, Natl Health Stat Report, P1; Ondler C, 2014, AM J EMERG MED, V32, P1215, DOI 10.1016/j.ajem.2014.07.013; Ostermann M, 2008, CRIT CARE, V12, DOI 10.1186/cc7085; Pines Jesse M, 2011, Acad Emerg Med, V18, pe64, DOI 10.1111/j.1553-2712.2011.01086.x; Sood MM, 2011, NEPHROL DIAL TRANSPL, V26, P2965, DOI 10.1093/ndt/gfq835; Sood MM, 2010, CAN MED ASSOC J, V182, P1433, DOI 10.1503/cmaj.100105; Strijack B, 2009, J AM SOC NEPHROL, V20, P2441, DOI 10.1681/ASN.2009040366; Sun BC, 2003, ACAD EMERG MED, V10, P320, DOI 10.1111/j.1553-2712.2003.tb01344.x; U. S. Renal Data System, 2008, ATL CHRON KIDN END S	28	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2018	13	4							e0195323	10.1371/journal.pone.0195323	http://dx.doi.org/10.1371/journal.pone.0195323			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD1LV	29664922	gold, Green Submitted, Green Published			2023-01-03	WOS:000430262300017
J	Desai, RJ; Sarpatwari, A; Dejene, S; Khan, NF; Lii, J; Rogers, JR; Dutcher, SK; Raofi, S; Bohn, J; Connolly, J; Fischer, MA; Kesselheim, AS; Gagne, JJ				Desai, Rishi J.; Sarpatwari, Ameet; Dejene, Sara; Khan, Nazleen F.; Lii, Joyce; Rogers, James R.; Dutcher, Sarah K.; Raofi, Saeid; Bohn, Justin; Connolly, John; Fischer, Michael A.; Kesselheim, Aaron S.; Gagne, Joshua J.			Differences in rates of switchbacks after switching from - branded to authorized generic and branded to generic drug products: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ANTIEPILEPTIC DRUGS; PILL APPEARANCE; NAME STATINS; MEDICATIONS; SUBSTITUTION; LAMOTRIGINE; EPILEPSY; CONSEQUENCES; NONADHERENCE	OBJECTIVES To compare rates of switchbacks to branded drug products for patients switched from branded to authorized generic drug products, which have the same active ingredients, appearance, and excipients as the branded product, with patients switched from branded to generic drug products, which have the same active ingredients as the branded product but may differ in appearance and excipients. DESIGN Observational cohort study. SETTING Private (a large commercial health plan) and public (Medicaid) insurance programs in the US. PARTICIPANTS Beneficiaries of a large US commercial health insurer between 2004 and 2013 (primary cohort) and Medicaid beneficiaries between 2000 and 2010 (replication cohort). MAIN OUTCOME MEASURES Patients taking branded products for one of the study drugs (alendronate tablets, amlodipine tablets, amlodipine-benazepril capsules, calcitonin salmon nasal spray, escitalopram tablets, glipizide extended release tablets, quinapril tablets, and sertraline tablets) were identified when they switched to an authorized generic or a generic drug product after the date of market entry of generic drug products. These patients were followed for switchbacks to the branded drug product in the year after their switch to an authorized generic or a generic drug product. Cox proportional hazard models were used to estimate hazard ratios and 95% confidence intervals after adjusting for demographics, including age, sex, and calendar year. Inverse variance meta-analysis was used to pool adjusted hazard ratios across all drug products. RESULTS A total of 94 909 patients switched from branded to authorized generic drug products and 116 017 patients switched from branded to generic drug products and contributed to the switchback analysis. Unadjusted incidence rates of switchback varied across drug products, ranging from a low of 3.8 per 100 person years (for alendronate tablets) to a high of 17.8 per 100 person years (for amlodipinebenazepril capsules), with an overall rate of 8.2 per 100 person years across all drug products. Adjusted switchback rates were consistently lower for patients who switched from branded to authorized generic drug products compared with branded to generic drug products in the primary cohort (pooled hazard ratio 0.72, 95% confidence interval 0.64 to 0.81). Similar results (0.75, 0.62 to 0.91) were observed in the replication cohort. CONCLUSION Switching from branded to authorized generic drug products was associated with lower switchback rates compared with switching from branded to generic drug products.	[Desai, Rishi J.; Sarpatwari, Ameet; Dejene, Sara; Khan, Nazleen F.; Lii, Joyce; Rogers, James R.; Fischer, Michael A.; Kesselheim, Aaron S.; Gagne, Joshua J.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; [Desai, Rishi J.; Sarpatwari, Ameet; Dejene, Sara; Khan, Nazleen F.; Lii, Joyce; Rogers, James R.; Fischer, Michael A.; Kesselheim, Aaron S.; Gagne, Joshua J.] Harvard Med Sch, Boston, MA 02120 USA; [Dutcher, Sarah K.; Raofi, Saeid] US FDA, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA; [Bohn, Justin; Connolly, John] Harvard Sch Publ Hlth, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Food & Drug Administration (FDA); Harvard University; Harvard T.H. Chan School of Public Health	Desai, RJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA.; Desai, RJ (corresponding author), Harvard Med Sch, Boston, MA 02120 USA.	rdesai@bwh.harvard.edu	Desai, Rishi/AAH-8988-2021	Bohn, Justin/0000-0003-4430-798X	US Food and Drug Administration, Office of Generic Drugs [U01FD005279]	US Food and Drug Administration, Office of Generic Drugs	This study was supported by the US Food and Drug Administration, Office of Generic Drugs (U01FD005279). Views expressed in this publication do not necessarily reflect the official policies of the Department of Health and Human Services, nor does any mention of trade names, commercial practices, or organization imply endorsement by the US Government.	Andermann F, 2007, EPILEPSIA, V48, P464, DOI 10.1111/j.1528-1167.2007.01007.x; Bingel U, 2014, JAMA-J AM MED ASSOC, V312, P693, DOI 10.1001/jama.2014.8342; Brennan TA, 2004, ANN INTERN MED, V141, P126, DOI 10.7326/0003-4819-141-2-200407200-00011; Colloca L, 2017, SCIENCE, V358, P44, DOI 10.1126/science.aap8488; Corrao G, 2014, EUR J INTERN MED, V25, P745, DOI 10.1016/j.ejim.2014.08.002; Corrao G, 2014, EUR J CLIN INVEST, V44, P933, DOI 10.1111/eci.12326; Desai R, 2016, SUBST GEN DRUGS PERC; Duerden MG, 2010, BRIT J CLIN PHARMACO, V70, P335, DOI 10.1111/j.1365-2125.2010.03718.x; Faasse K, 2013, PSYCHOSOM MED, V75, P90, DOI 10.1097/PSY.0b013e3182738826; Figueiras MJ, 2009, PSYCHOL HEALTH MED, V14, P311, DOI 10.1080/13548500802613043; Gagne JJ, 2015, EPILEPSY BEHAV, V52, P14, DOI 10.1016/j.yebeh.2015.08.014; Gagne JJ, 2014, ANN INTERN MED, V161, P400, DOI 10.7326/M13-2942; Generic Pharmaceutical Association. Washington DC, 2016, GEN DRUG SAV ACC US; Greene JA, 2011, NEW ENGL J MED, V365, P83, DOI 10.1056/NEJMhle1101722; Hansen RA, 2018, CLIN PHARMACOL THER, V103, P310, DOI 10.1002/cpt.591; Hansen RA, 2017, PHARMACOTHERAPY, V37, P429, DOI 10.1002/phar.1908; Jackevicius CA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003350; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kesselheim AS, 2014, ANN INTERN MED, V161, P96, DOI 10.7326/M13-2381; Kesselheim AS, 2013, JAMA INTERN MED, V173, P202, DOI 10.1001/2013.jamainternmed.997; LeLorier J, 2008, NEUROLOGY, V70, P2179, DOI 10.1212/01.wnl.0000313154.55518.25; Molinier A, 2017, EUR J CLIN PHARMACOL, V73, P471, DOI 10.1007/s00228-016-2185-z; Pasina L, 2016, EUR J CLIN PHARMACOL, DOI [10.1007/s00228-016-2069-2, DOI 10.1007/S00228-016-2069-2]; Privitera MD, 2016, LANCET NEUROL, V15, P365, DOI 10.1016/S1474-4422(16)00014-4; Sarpatwari A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001802; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Shrank WH, 2011, ANN PHARMACOTHER, V45, P31, DOI 10.1345/aph.1P389; Shrank WH, 2009, HEALTH AFFAIR, V28, P546, DOI 10.1377/hlthaff.28.2.546; Ting TY, 2015, EPILEPSIA, V56, P1415, DOI 10.1111/epi.13095; United States Food & Drug Administration, LIST AUTH GEN DRUGS; United States Food & Drug Administration, WHAT AR GEN DRUGS; Weissenfeld J, 2010, PHARMAZIE, V65, P451, DOI 10.1691/ph.2010.9749	32	18	18	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2018	361								k1180	10.1136/bmj.k1180	http://dx.doi.org/10.1136/bmj.k1180			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC3AG	29615391	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000429655300001
J	Barry, KC; Hsu, J; Broz, ML; Cueto, FJ; Binnewies, M; Combes, AJ; Nelson, AE; Loo, K; Kumar, R; Rosenblum, MD; Alvarado, MD; Wolf, DM; Bogunovic, D; Bhardwaj, N; Daud, AI; Ha, PK; Ryan, WR; Pollack, JL; Samad, B; Asthana, S; Chan, V; Krummel, MF				Barry, Kevin C.; Hsu, Joy; Broz, Miranda L.; Cueto, Francisco J.; Binnewies, Mikhail; Combes, Alexis J.; Nelson, Amanda E.; Loo, Kimberly; Kumar, Raj; Rosenblum, Michael D.; Alvarado, Michael D.; Wolf, Denise M.; Bogunovic, Dusan; Bhardwaj, Nina; Daud, Adil, I; Ha, Patrick K.; Ryan, William R.; Pollack, Joshua L.; Samad, Bushra; Asthana, Saurabh; Chan, Vincent; Krummel, Matthew F.			A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments	NATURE MEDICINE			English	Article							T-CELL; CANCER-IMMUNOTHERAPY; IN-VIVO; READ ALIGNMENT; MELANOMA; RECEPTOR; IMMUNITY; EXPRESSION; BLOCKADE; MICE	Intratumoral stimulatory dendritic cells (SDCs) play an important role in stimulating cytotoxic T cells and driving immune responses against cancer. Understanding the mechanisms that regulate their abundance in the tumor microenvironment (TME) could unveil new therapeutic opportunities. We find that in human melanoma, SDC abundance is associated with intratumoral expression of the gene encoding the cytokine FLT3LG. FLT3LG is predominantly produced by lymphocytes, notably natural killer (NK) cells in mouse and human tumors. NK cells stably form conjugates with SDCs in the mouse TME, and genetic and cellular ablation of NK cells in mice demonstrates their importance in positively regulating SDC abundance in tumor through production of FLT3L. Although anti-PD-1 'checkpoint' immunotherapy for cancer largely targets T cells, we find that NK cell frequency correlates with protective SDCs in human cancers, with patient responsiveness to anti-PD-1 immunotherapy, and with increased overall survival. Our studies reveal that innate immune SDCs and NK cells cluster together as an excellent prognostic tool for T cell-directed immunotherapy and that these innate cells are necessary for enhanced T cell tumor responses, suggesting this axis as a target for new therapies.	[Barry, Kevin C.; Hsu, Joy; Broz, Miranda L.; Cueto, Francisco J.; Binnewies, Mikhail; Combes, Alexis J.; Nelson, Amanda E.; Kumar, Raj; Samad, Bushra; Chan, Vincent; Krummel, Matthew F.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Barry, Kevin C.; Hsu, Joy; Broz, Miranda L.; Combes, Alexis J.; Nelson, Amanda E.; Loo, Kimberly; Kumar, Raj; Samad, Bushra; Asthana, Saurabh; Chan, Vincent; Krummel, Matthew F.] Univ Calif San Francisco, UCSF Immunoprofiler Initiat, San Francisco, CA 94143 USA; [Cueto, Francisco J.] Ctr Nacl Invest Cardiovasc Carlos III CNIC, Madrid, Spain; [Cueto, Francisco J.] Univ Autonoma Madrid, Fac Med, Dept Biochem, Madrid, Spain; [Loo, Kimberly] Univ Calif San Francisco, Melanoma Clin Res Unit, San Francisco, CA 94143 USA; [Loo, Kimberly; Rosenblum, Michael D.; Alvarado, Michael D.; Daud, Adil, I] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Wolf, Denise M.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Bogunovic, Dusan] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Bhardwaj, Nina] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Ha, Patrick K.; Ryan, William R.] Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA; [Pollack, Joshua L.] Pionyr Immunotherapeut, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Francisco	Krummel, MF (corresponding author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.; Krummel, MF (corresponding author), Univ Calif San Francisco, UCSF Immunoprofiler Initiat, San Francisco, CA 94143 USA.	matthew.krummel@ucsf.edu	Cueto, Francisco J/AGN-4489-2022; Daud, Adil/T-3079-2019	Cueto, Francisco J/0000-0002-7457-9583; Daud, Adil/0000-0002-6617-8421; Barry, Kevin/0000-0003-1064-5964; Hsu, Joy/0000-0001-6571-9276; Combes, Alexis/0000-0002-9110-6542; Samad, Bushra/0000-0002-2893-0897; Bhardwaj, Nina/0000-0003-1865-4187	National Institutes of Health (NIH) [R01CA197363]; AbbVie of the Immunoprofiler Consortium; Amgen of the Immunoprofiler Consortium; Bristol-Myers Squibb of the Immunoprofiler Consortium; NIH [5P30CA082103]; Genentech Predoctoral Research Fellowship; Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award; Achievement Reward for College Scientists Scholarship; Cancer Research Institute; Fibrolamellar Cancer Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA197363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114787, T32AI007334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [DP2AR068130] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AbbVie of the Immunoprofiler Consortium(AbbVie); Amgen of the Immunoprofiler Consortium(Amgen); Bristol-Myers Squibb of the Immunoprofiler Consortium(Bristol-Myers Squibb); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech Predoctoral Research Fellowship; Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award; Achievement Reward for College Scientists Scholarship; Cancer Research Institute; Fibrolamellar Cancer Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank L. Lanier, J. Roose and L. Fong for advice, and we thank M. Spasic and N. Khurana for support with response data. This work was supported by National Institutes of Health (NIH) grant R01CA197363, awarded to M.F.K. Acquisition and processing of human melanoma samples in cohort A described in this study was funded in part by contributions from AbbVie, Amgen, and Bristol-Myers Squibb as members of the Immunoprofiler Consortium. Further support came from NIH grant 5P30CA082103, awarded to the University of California, San Francisco (UCSF) Hellen Diller Family Comprehensive Cancer Center. M.B. was supported by the Genentech Predoctoral Research Fellowship, the Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award, and the Achievement Reward for College Scientists Scholarship. K.C.B. was supported by a postdoctoral fellowship from the Cancer Research Institute and Fibrolamellar Cancer Foundation.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bezman NA, 2012, NAT IMMUNOL, V13, P1000, DOI 10.1038/ni.2395; Blake SJ, 2016, CANCER DISCOV, V6, P446, DOI 10.1158/2159-8290.CD-15-0944; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cheng PF, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14183; CORBETT TH, 1975, CANCER RES, V35, P2434; Dougall WC, 2017, IMMUNOL REV, V276, P112, DOI 10.1111/imr.12518; Du XL, 2006, GENOMICS, V87, P693, DOI 10.1016/j.ygeno.2006.02.003; Engelhardt JJ, 2012, CANCER CELL, V21, P402, DOI 10.1016/j.ccr.2012.01.008; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; FIDLER IJ, 1975, CANCER RES, V35, P218; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Goding SR, 2017, CLIN IMMUNOL, V177, P76, DOI 10.1016/j.clim.2016.06.013; GRAF LH, 1984, SOMAT CELL MOLEC GEN, V10, P139, DOI 10.1007/BF01534903; Hadjantonakis Anna-Katerina, 2002, BMC Biotechnol, V2, P11, DOI 10.1186/1472-6750-2-11; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Khanna KM, 2010, J IMMUNOL, V185, P239, DOI 10.4049/jimmunol.0901047; Krieg C, 2018, NAT MED, V24, P144, DOI 10.1038/nm.4466; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu K, 2010, IMMUNOL REV, V234, P45, DOI 10.1111/j.0105-2896.2009.00879.x; Loo K, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93433; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; Miloud T, 2012, J IMMUNOL, V188, P1125, DOI 10.4049/jimmunol.1003920; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pinkard H, 2016, NAT METHODS, V13, P807, DOI 10.1038/nmeth.3991; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Ruffell B, 2012, P NATL ACAD SCI USA, V109, P2796, DOI 10.1073/pnas.1104303108; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Sanchez-Paulete AR, 2016, CANCER DISCOV, V6, P71, DOI 10.1158/2159-8290.CD-15-0510; Solanilla A, 2000, LEUKEMIA, V14, P153, DOI 10.1038/sj.leu.2401635; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wu C., 2016, NUCLEIC ACIDS RES, V44, pD1; Wu CL, 2016, NUCLEIC ACIDS RES, V44, pD313, DOI 10.1093/nar/gkv1104; Yamazaki C, 2013, J IMMUNOL, V190, P6071, DOI 10.4049/jimmunol.1202798; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040	46	451	464	10	116	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2018	24	8					1178	1191		10.1038/s41591-018-0085-8	http://dx.doi.org/10.1038/s41591-018-0085-8			14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GP5ZF	29942093	Green Accepted			2023-01-03	WOS:000440955500024
J	Tai, YH; Chang, WK; Wu, HL; Chan, MY; Chen, HH; Chang, KY				Tai, Ying-Hsuan; Chang, Wen-Kuei; Wu, Hsiang-Ling; Chan, Min-Ya; Chen, Hsiu-Hsi; Chang, Kuang-Yi			The effect of epidural analgesia on cancer progression in patients with stage IV colorectal cancer after primary tumor resection: A retrospective cohort study	PLOS ONE			English	Article							PERIOPERATIVE BLOOD-TRANSFUSIONS; LONG-TERM OUTCOMES; MU-OPIOID RECEPTOR; COLON-CANCER; CLINICAL-OUTCOMES; CELL TRANSFUSIONS; LIVER METASTASES; SURGERY; RECURRENCE; SURVIVAL	Retrospective clinical studies showed perioperative epidural analgesia (EA) was associated with better postoperative oncologic outcomes in patients with specific types of non-metastatic cancers. This study aimed to investigate the effects of EA on cancer prognosis after surgical intervention for stage IV colorectal cancer. In this retrospective study, patients with stage IV colorectal cancer undergoing primary tumor resection and metastasectomy between January 2005 and December 2014 were classified into two groups based on their use of perioperative EA or not and evaluated through August 2016. Primary and secondary endpoints were postoperative progression-free survival (PFS) and overall survival (OS), respectively. A total of 999 patients were included and 165 (16.5%) of them received EA. The median follow-up interval was 17.5 months and no significant difference in PFS or OS was noted between the EA and non-EA groups in the univariate analysis. Multivariable Cox proportional hazards model identified four independent risk factors both for disease progression and mortality, including American Society of Anesthesiologists (ASA) physical status >= 3, higher pretreatment carcinoembryonic antigen (CEA), multiple distant metastases, and pathologic lymphovascular invasion. After adjustment for the selected risk factors, the effects of EA on PFS and OS remained non-significant (hazard ratio: 1.06, 95% CI: 0.87 to 1.29, for PFS and 0.90, 95% CI: 0.68 to 1.20 for OS). Similar findings were demonstrated by propensity score analysis. Our results did not support the association between perioperative epidural analgesia and better progression-free or overall survival in patients following stage IV colorectal cancer surgery.	[Tai, Ying-Hsuan; Chang, Wen-Kuei; Wu, Hsiang-Ling; Chan, Min-Ya; Chang, Kuang-Yi] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Tai, Ying-Hsuan] Taipei Med Univ, Shuang Ho Hosp, Dept Anesthesiol, New Taipei, Taiwan; [Tai, Ying-Hsuan; Chang, Wen-Kuei; Wu, Hsiang-Ling; Chang, Kuang-Yi] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Tai, Ying-Hsuan] Taipei Med Univ, Coll Med, Sch Med, Dept Anesthesiol, Taipei, Taiwan; [Wu, Hsiang-Ling] Taipei Vet Gen Hosp, Dept Surg, Yuli Branch, Hualien, Taiwan; [Chan, Min-Ya] Natl Taiwan Normal Univ, Dept Technol Applicat & Human Resource Dev, Taipei, Taiwan; [Chen, Hsiu-Hsi] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol & Prevent Med, Div Biostat, Taipei, Taiwan	Taipei Veterans General Hospital; Taipei Medical University; Shuang Ho Hospital; National Yang Ming Chiao Tung University; Taipei Medical University; Taipei Veterans General Hospital; National Taiwan Normal University; National Taiwan University	Chang, KY (corresponding author), Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.; Chang, KY (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.	kychang@vghtpe.gov.tw	tai, yh/GRR-4574-2022	Chen, Hsiu-Hsi/0000-0002-5799-6705	Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C [V104C-096]; Ministry of Science and Technology, Taipei, Taiwan, R.O.C [MOST 104-2314-B-075-015]; Anesthesiology Research and Development Foundation, Taipei, Taiwan [ARDF10501]	Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C(Taipei Veterans General Hospital); Ministry of Science and Technology, Taipei, Taiwan, R.O.C; Anesthesiology Research and Development Foundation, Taipei, Taiwan	This study was supported by the grants from Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C (V104C-096; https://www.vghtpe.gov.tw), Ministry of Science and Technology, Taipei, Taiwan, R.O.C (MOST 104-2314-B-075-015; https://www.most.gov.tw) and Anesthesiology Research and Development Foundation, Taipei, Taiwan (ARDF10501). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acheson AG, 2012, ANN SURG, V256, P235, DOI 10.1097/SLA.0b013e31825b35d5; Aggarwal C, 2013, ANN ONCOL, V24, P420, DOI 10.1093/annonc/mds336; Amato A, 2006, COCHRANE DB SYST REV, DOI 10.1002/1465158.CD005033.pub2; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Betge J, 2012, CANCER-AM CANCER SOC, V118, P628, DOI 10.1002/cncr.26310; Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848; Buggy DJ, 1999, BMJ-BRIT MED J, V319, P530, DOI 10.1136/bmj.319.7209.530; Cata JP, 2013, BRIT J ANAESTH, V110, P690, DOI 10.1093/bja/aet068; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Hallet J, 2015, ANN SURG ONCOL, V22, P4038, DOI 10.1245/s10434-015-4477-4; Hiller JG, 2018, NAT REV CLIN ONCOL, V15, P205, DOI 10.1038/nrclinonc.2017.194; Hogan J, 2015, DIS COLON RECTUM, V58, P547, DOI 10.1097/DCR.0000000000000361; Hutchins G, 2011, J CLIN ONCOL, V29, P1261, DOI 10.1200/JCO.2010.30.1366; Kawaraguchi Y, 2011, ANESTHESIOLOGY, V115, P499, DOI 10.1097/ALN.0b013e3182276d42; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Lennon FE, 2012, ANESTHESIOLOGY, V116, P940, DOI 10.1097/ALN.0b013e31824b9512; Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949; Loop T, 2005, ANESTHESIOLOGY, V102, P1147, DOI 10.1097/00000542-200506000-00014; Loupakis F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju427; Nitsche U, 2013, ANN SURG, V258, P775, DOI 10.1097/SLA.0b013e3182a69f7e; Nylund G, 2008, DIGEST DIS SCI, V53, P461, DOI 10.1007/s10620-007-9897-y; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Singleton PA, 2015, CANCER-AM CANCER SOC, V121, P2681, DOI 10.1002/cncr.29460; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Sun YX, 2015, REGION ANESTH PAIN M, V40, P589, DOI 10.1097/AAP.0000000000000273; Thirunavukarasu P, 2015, JAMA SURG, V150, P747, DOI 10.1001/jamasurg.2015.0871; Thirunavukarasu P, 2011, JNCI-J NATL CANCER I, V103, P689, DOI 10.1093/jnci/djr078; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Van Osdol AD, 2015, AM J SURG, V210, P990, DOI 10.1016/j.amjsurg.2015.06.026; Venderbosch S, 2011, ANN SURG ONCOL, V18, P3252, DOI 10.1245/s10434-011-1951-5; Wada H, 2007, ANESTHESIOLOGY, V106, P499, DOI 10.1097/00000542-200703000-00014; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Zimmitti G, 2016, ANN SURG ONCOL, V23, P1003, DOI 10.1245/s10434-015-4933-1; Zylla D, 2013, CANCER-AM CANCER SOC, V119, P4103, DOI 10.1002/cncr.28345	40	15	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2018	13	7							e0200893	10.1371/journal.pone.0200893	http://dx.doi.org/10.1371/journal.pone.0200893			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN8GG	30028851	Green Published, gold			2023-01-03	WOS:000439396900023
J	Maddox, KEJ; Orav, EJ; Zheng, J; Epstein, AM				Maddox, Karen E. Joynt; Orav, E. John; Zheng, Jie; Epstein, Arnold M.			Evaluation of Medicare's Bundled Payments Initiative for Medical Conditions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPISODE; CARE; READMISSIONS; ASSOCIATION; IMPROVEMENT	BACKGROUND The Center for Medicare and Medicaid Innovation (CMMI) launched the Bundled Payments for Care Improvement (BPCI) initiative in 2013. A subsequent study showed that the initiative was associated with reductions in Medicare payments for total joint replacement, but little is known about the effect of BPCI on medical conditions. METHODS We used Medicare claims from 2013 through 2015 to identify admissions for the Five most commonly selected medical conditions in BPCI: congestive heart failure (CHF), pneumonia, chronic obstructive pulmonary disease (COPD), sepsis, and acute myocardial infarction (AMI). We used difference-in-differences analyses to assess changes in standardized Medicare payments per episode of care (defined as the hospitalization plus 90 days after discharge) for these conditions at BPCI hospitals and matched control hospitals. RESULTS A total of 125 hospitals participated in BPCI for CHF, 105 hospitals for pneumonia, 101 hospitals for COPD, 88 hospitals for sepsis, and 73 hospitals for AMI. At baseline, the average Medicare payment per episode of care across the five conditions at BPCI hospitals was $24,280, which decreased to $23,993 during the intervention period (difference, -$286; P=0.41). Control hospitals had an average payment for all episodes of $23,901, which decreased to $23,503 during the intervention period (difference, -$398; P=0.08; difference in differences, $112; P=0.79). Changes from baseline to the intervention period in clinical complexity, length of stay, emergency department use or readmission within 30 or 90 days after hospital discharge, or death within 30 or 90 days after admission did not differ significantly between the intervention and control hospitals. CONCLUSIONS Hospital participation in five common medical bundles under BPCI was not associated with significant changes in Medicare payments, clinical complexity, length of stay, emergency department use, hospital readmission, or mortality.	[Maddox, Karen E. Joynt] Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63130 USA; [Orav, E. John; Epstein, Arnold M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Orav, E. John; Zheng, Jie; Epstein, Arnold M.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Maddox, KEJ (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63130 USA.	kjoyntmaddox@wustl.edu			Commonwealth Fund	Commonwealth Fund	Supported by the Commonwealth Fund.	Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Bhatt SP, 2017, ANN AM THORAC SOC, V14, P643, DOI 10.1513/AnnalsATS.201610-775BC; Centers for Medicare and Medicaid Services, 2017, BUNDL PAYM CAR IMPR; Centers for Medicare & Medicaid Services, 2013, EV MED AC CAR EP ACE; Das A, 2016, JAMA INTERN MED, V176, P117, DOI 10.1001/jamainternmed.2015.6261; Department of Justice, 2015, HERF HIRSCHM IND; Dummit, 2017, CMS BUNDLED PAYMENTS; Dummit L, 2016, CMS BUNDLED PAYMENTS; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Dundon JM, 2016, J BONE JOINT SURG AM, V98, P1949, DOI 10.2106/JBJS.16.00523; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Iorio R, 2016, J ARTHROPLASTY, V31, P343, DOI 10.1016/j.arth.2015.09.004; Kasper J, 2010, CHRONIC DIS CO MORBI; Korea Health Promotion Institute, 2020, 04202000301; McHugh JP, 2017, HEALTH AFFAIR, V36, P1591, DOI 10.1377/hlthaff.2017.0211; Mechanic RW, 2016, MEDICARES BUNDLED PA; Navathe AS, 2017, JAMA INTERN MED, V177, P214, DOI 10.1001/jamainternmed.2016.8263; Samson LW, 2018, HEALTH AFFAIR, V37, P86, DOI 10.1377/hlthaff.2017.0914; Tsai TC, 2015, HEALTH AFFAIR, V34, P371, DOI 10.1377/hlthaff.2014.0900	19	89	89	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2018	379	3					260	269		10.1056/NEJMsa1801369	http://dx.doi.org/10.1056/NEJMsa1801369			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN5CX	30021090				2023-01-03	WOS:000439063900009
J	Samet, JH; Botticelli, M; Bharel, M				Samet, Jeffrey H.; Botticelli, Michael; Bharel, Monica			Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MAINTENANCE; TRIAL		[Samet, Jeffrey H.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Samet, Jeffrey H.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA; [Samet, Jeffrey H.] Boston Med Ctr, Boston, MA 02118 USA; [Samet, Jeffrey H.; Botticelli, Michael] Boston Med Ctr, Grayken Ctr Addict, Boston, MA 02118 USA; [Bharel, Monica] Massachusetts Dept Publ Hlth, Boston, MA USA	Boston University; Boston University; Boston Medical Center; Boston Medical Center; Massachusetts Department of Public Health	Samet, JH (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.; Samet, JH (corresponding author), Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.; Samet, JH (corresponding author), Boston Med Ctr, Boston, MA 02118 USA.; Samet, JH (corresponding author), Boston Med Ctr, Grayken Ctr Addict, Boston, MA 02118 USA.							DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002; Fiellin DA, 2001, JAMA-J AM MED ASSOC, V286, P1724, DOI 10.1001/jama.286.14.1724; Merrill JO, 2005, J GEN INTERN MED, V20, P344, DOI 10.1111/j.1525-1497.2005.04028.x; Saloner B, 2015, JAMA-J AM MED ASSOC, V314, P1515, DOI 10.1001/jama.2015.10345; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550	5	69	69	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2018	379	1					7	8		10.1056/NEJMp1803982	http://dx.doi.org/10.1056/NEJMp1803982			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GL5ZG	29972744	Bronze			2023-01-03	WOS:000437254200003
J	Oursler, KK; Sorkin, JD; Ryan, AS; Katzel, LI				Oursler, Krisann K.; Sorkin, John D.; Ryan, Alice S.; Katzel, Leslie I.			A pilot randomized aerobic exercise trial in older HIV-infected men: Insights into strategies for successful aging with HIV	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CARDIORESPIRATORY FITNESS; SEROPOSITIVE INDIVIDUALS; RESISTANCE EXERCISE; ADULTS; METAANALYSIS; INTENSITY; LIPODYSTROPHY; MORTALITY; MODERATE	Background HIV-infected adults have increased risk for age-related diseases and low cardiorespiratory fitness that can be prevented and improved with exercise. Yet, exercise strategies have not been well studied in older adults with HIV and may require substantial adaptation to this special population. Objective To determine the safety and efficacy of aerobic exercise in older HIV-infected men in a randomized trial comparing different levels of exercise intensity. Methods We conducted a pilot exercise trial in 22 HIV-infected men >= 50 years of age receiving entiretroviral therapy who were randomized 1:1 to moderate-intensity aerobic exercise (Mod-AEX) or high-intensity aerobic exercise (High-AEX) that was performed three times weekly for 16 weeks in a supervised setting. Primary outcome was cardiorespiratory fitness (VO(2)peak) measured by treadmill testing. Secondary outcomes were exercise endurance, six-minute walk distance (6-MWD), body composition measured by Dual-energy X-ray absorptiometry (DXA), and fasting plasma levels of lipids and glucose. Results VO(2)peak increased in the High-AEX group (3.6 +/- 1.2 mL/kg/min, p = 0.02) but not in the Mod-AEX group (0.4 +/- 1.4 mL/kg/min, p = 0.7) with a significant between group difference (p<0.01). Exercise endurance increased in both the High-AEX group (27 +/- 11%, p = 0.02) and the Mod-AEX group (11 +/- 4%, p = 0.04). The 6-MWD increased in both the High-AEX (62 +/- 18m, p = 0.01) and the Mod-AEX group (54 +/- 14m, p = 0.01). Changes in VO(2)peak and 6-MWD were clinically relevant. There were no serious exercise-related adverse events. Dropouts were similar between group (27% overall) and were related to joint pain. Conclusions This pilot exercise trial demonstrates that moderate to high-intensity aerobic exercise in older HIV-infected men increases endurance and ambulatory function. However, increased cardiorespiratory fitness was observed only with high-intensity aerobic exercise despite substantial baseline impairment. Future research is needed to determine exercise strategies in older HIV-infected adults that address advanced aging and comorbidity yet are durable and feasible.	[Oursler, Krisann K.; Sorkin, John D.; Ryan, Alice S.; Katzel, Leslie I.] Vet Affairs Maryland Hlth Care Syst, Baltimore Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Baltimore, MD 21201 USA; [Oursler, Krisann K.; Sorkin, John D.; Ryan, Alice S.; Katzel, Leslie I.] Univ Maryland, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Baltimore, MD 21201 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore	Oursler, KK (corresponding author), Vet Affairs Maryland Hlth Care Syst, Baltimore Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Baltimore, MD 21201 USA.; Oursler, KK (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Baltimore, MD 21201 USA.	Krisann.Oursler@va.gov			National Institute on Aging [AG024896]; Claude D. Pepper Older Americans Independence Center [P30-AG-028747]; National Institute of Diabetes and Digestive and Kidney Diseases under grant Mid-Atlantic Nutrition Obesity Research Center [P30-DK-072488]; Veterans Affairs under award RR&D Senior Research Career Scientist; Veterans Affairs under the Baltimore VA Medical Center Geriatrics Research Education and Clinical Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028747] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Claude D. Pepper Older Americans Independence Center; National Institute of Diabetes and Digestive and Kidney Diseases under grant Mid-Atlantic Nutrition Obesity Research Center; Veterans Affairs under award RR&D Senior Research Career Scientist; Veterans Affairs under the Baltimore VA Medical Center Geriatrics Research Education and Clinical Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by The National Institute on Aging under grant AG024896 (KO) and Claude D. Pepper Older Americans Independence Center under grant P30-AG-028747 (AR, JS, LK); The National Institute of Diabetes and Digestive and Kidney Diseases under grant Mid-Atlantic Nutrition Obesity Research Center P30-DK-072488 (AR, JS); The Veterans Affairs under award RR&D Senior Research Career Scientist (AR) and under the Baltimore VA Medical Center Geriatrics Research Education and Clinical Center (KO,JS,AR, LK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Sports Medicine, 2010, ACSMS GUIDELINES EXE; Balducci S, 2010, NUTR METAB CARDIOVAS, V20, P608, DOI 10.1016/j.numecd.2009.04.015; Beraldo RA, 2015, EUR J CLIN NUTR, V69, P274, DOI 10.1038/ejcn.2014.149; Byrne H, 2017, SPORTS MED, V47, P717, DOI 10.1007/s40279-016-0593-y; Centers for Disease Control and Prevention, 2016, HIV SURV SUPPL REP 2; Currie KD, 2015, J SCI MED SPORT, V18, P637, DOI 10.1016/j.jsams.2014.09.013; Cutrono SE, 2016, AIDS BEHAV, V20, P1123, DOI 10.1007/s10461-015-1245-1; d'Ettorre G, 2014, AIDS RES HUM RETROV, V30, P936, DOI [10.1089/aid.2014.0069, 10.1089/AID.2014.0069]; Dolan SE, 2006, ARCH INTERN MED, V166, P1225, DOI 10.1001/archinte.166.11.1225; Eckel RH, 2014, CIRCULATION, V129, pS76, DOI 10.1161/01.cir.0000437740.48606.d1; Edwards MK, 2018, CLIN PHYSIOL FUNCT I, V38, P93, DOI 10.1111/cpf.12388; Enright PL, 2003, CHEST, V123, P387, DOI 10.1378/chest.123.2.387; Fillipas S, 2006, AUST J PHYSIOTHER, V52, P185, DOI 10.1016/S0004-9514(06)70027-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Gomes M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138066; Gomes-Neto M, 2013, CLINICS, V68, P1157, DOI 10.6061/clinics/2013(08)16; Greene M, 2013, JAMA-J AM MED ASSOC, V309, P1397, DOI 10.1001/jama.2013.2963; Hand GA, 2008, AIDS CARE, V20, P1066, DOI 10.1080/09540120701796900; Hand GA, 2009, AM J LIFESTYLE MED, V3, P489, DOI 10.1177/1559827609342198; Harris CD, 2013, MMWR-MORBID MORTAL W, V62, P326; Hawkins SA, 2003, SPORTS MED, V33, P877, DOI 10.2165/00007256-200333120-00002; High KP, 2012, JAIDS-J ACQ IMM DEF, V60, pS1, DOI 10.1097/QAI.0b013e31825a3668; Lee DC, 2011, CIRCULATION, V124, P2483, DOI 10.1161/CIRCULATIONAHA.111.038422; Legarth RA, 2016, JAIDS-J ACQ IMM DEF, V71, P213, DOI 10.1097/QAI.0000000000000825; Lindegaard B, 2008, J CLIN ENDOCR METAB, V93, P3860, DOI 10.1210/jc.2007-2733; de Souza PML, 2011, CLINICS, V66, P261, DOI 10.1590/S1807-59322011000200014; Morris NR, 2016, RESPIROLOGY, V21, P1185, DOI 10.1111/resp.12864; Mutimura E, 2008, AIDS RES HUM RETROV, V24, P15, DOI 10.1089/aid.2007.0023; O'Brien KK, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1478-2; Ortmeyer HK, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12794; Oursler KK, 2006, AIDS RES HUM RETROV, V22, P1113, DOI 10.1089/aid.2006.22.1113; Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168; Sandercock G, 2013, INT J CARDIOL, V167, P894, DOI 10.1016/j.ijcard.2011.11.068; Schafer J, 2017, AIDS CARE, V29, P1056, DOI 10.1080/09540121.2016.1274016; Starr KNP, 2014, J AM MED DIR ASSOC, V15, P240, DOI 10.1016/j.jamda.2013.11.008; Sui XM, 2007, JAMA-J AM MED ASSOC, V298, P2507, DOI 10.1001/jama.298.21.2507; Swain David P, 2005, Prev Cardiol, V8, P55, DOI 10.1111/j.1520-037X.2005.02791.x; Terry L, 1999, INT J SPORTS MED, V20, P142, DOI 10.1055/s-2007-971108; Terry L, 2006, MED SCI SPORT EXER, V38, P411, DOI 10.1249/01.mss.0000191347.73848.80; Vancampfort D, 2017, AIDS CARE, V29, P636, DOI 10.1080/09540121.2016.1248347; Vancampfort D, 2016, PREV MED, V93, P106, DOI 10.1016/j.ypmed.2016.10.001; Zanetti HR, 2016, EUR J SPORT SCI, V16, P1232, DOI 10.1080/17461391.2016.1167962	43	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2018	13	6							e0198855	10.1371/journal.pone.0198855	http://dx.doi.org/10.1371/journal.pone.0198855			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GJ1PQ	29894513	Green Submitted, Green Published, gold			2023-01-03	WOS:000435030900031
J	Bekelman, JE; Joffe, S				Bekelman, Justin E.; Joffe, Steven			Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bekelman, Justin E.] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Abramson Canc Ctr,Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Joffe, Steven] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Bekelman, JE (corresponding author), Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd,4W, Philadelphia, PA 19104 USA.	bekelman@upenn.edu	Joffe, Steven/H-3941-2019	Joffe, Steven/0000-0002-0667-7384	NATIONAL CANCER INSTITUTE [K07CA163616] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; INIS Institute for Healthcare Informatics, 2016, GLOB ONC TREND REP; MS Institute for Healthcare Informatics, 2017, MED US SPEND US; US Department of Health and Human Services, 2017, HIGH PRIC DRUGS AR I; *US FDA, CANC DRUG APPR ENDP; US Food and Drug Administration, 2017, FDA APPR NER EXT ADJ	6	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	2018	319	21					2167	2168		10.1001/jama.2018.3414	http://dx.doi.org/10.1001/jama.2018.3414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI1MA	29710240				2023-01-03	WOS:000434133400010
J	Lemaire, JB; Ewashina, D; Polachek, AJ; Dixit, J; Yiu, V				Lemaire, Jane B.; Ewashina, Darby; Polachek, Alicia J.; Dixit, Jaya; Yiu, Verna			Understanding how patients perceive physician wellness and its links to patient care: A qualitative study	PLOS ONE			English	Article							WORK-LIFE BALANCE; JOB-SATISFACTION; BURNOUT; HEALTH; PRACTITIONERS; INTERVENTIONS; OUTCOMES; COMMUNICATION; METAANALYSIS; POPULATION	Despite increased interest in physician wellness, little is known about patients' views on the topic. We explore patients' perceptions of physician wellness and how it links to patient care. This exploratory, qualitative study employed semi-structured interviews with a convenience sample of 20 patients from outpatient care settings in a western Canadian city. Using inductive thematic analysis, interview transcripts were independently coded by two authors and then discussed to ensure consensus and to abstract into higher-level themes. Three overarching premises were identified. First, patients notice cues that they interpret as signs of physician wellness. These include overt indicators, such as a physician's demeanor or physical appearance, along with a general impression about a physician's wellness. Second, patients form judgments based on what they notice, and these judgments affect patients' views about their care; feelings, such as trust, in their interactions with physicians; and actions, such as following care plans. Third, participants perceive a bi-directional link between physician wellness and patient care. Physician wellness impacts patient care, but physician wellness is also impacted by the care they provide and the challenges they face within the healthcare system. Patients' judgments regarding physician wellness may have important impacts on the doctor-patient relationship. Furthermore, patients appear to have a nuanced understanding about how physicians' work may put physicians at risk for being unwell. Patients may be powerful allies in supporting physician wellness initiatives focused on the shared responsibility of individual physicians, the medical profession, and healthcare organizations.	[Lemaire, Jane B.] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada; [Lemaire, Jane B.; Polachek, Alicia J.] Univ Calgary, Res & Innovat Ctr W21C, Cumming Sch Med, Calgary, AB, Canada; [Ewashina, Darby] Univ Calgary, Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada; [Dixit, Jaya] Univ Calgary, Calgary, AB, Canada; [Yiu, Verna] Alberta Hlth Serv, Edmonton, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Alberta Health Services (AHS)	Lemaire, JB (corresponding author), Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada.; Lemaire, JB (corresponding author), Univ Calgary, Res & Innovat Ctr W21C, Cumming Sch Med, Calgary, AB, Canada.	lemaire@ucalgary.ca			Alberta Health Services	Alberta Health Services	Alberta Health Services (https://www.albertahealthservices.ca) provided funding for this research to the corresponding author. A member of Alberta Health Services (VY) was involved in the study by providing feedback on the study design and interpretation of the data. She was not involved in recruitment, data collection, or analysis of the raw data, but did review the paper and contribute to the decision to approve publication of the finished manuscript. The W21C Research and Innovation Center (www.w21c.org), University of Calgary provided in-kind support in the form of salaries, space, and administrative oversight for research staff involved in the project. The W21C had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.	Baldisseri MR, 2007, CRIT CARE MED, V35, pS106, DOI 10.1097/01.CCM.0000252918.87746.96; Berg B.L., 2012, QUALITATIVE RES METH, V8th; Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Center C, 2003, JAMA-J AM MED ASSOC, V289, P3161, DOI 10.1001/jama.289.23.3161; Cornuz J, 2000, FAM PRACT, V17, P535, DOI 10.1093/fampra/17.6.535; Cruess RL, 2008, PERSPECT BIOL MED, V51, P579, DOI 10.1353/pbm.0.0045; De Vries AMM, 2014, PSYCHO-ONCOLOGY, V23, P375, DOI 10.1002/pon.3445; DIMATTEO MR, 1993, HEALTH PSYCHOL, V12, P93, DOI 10.1037/0278-6133.12.2.93; Fahrenkopf AM, 2008, BRIT MED J, V336, P488, DOI 10.1136/bmj.39469.763218.BE; Frank E, 2000, ARCH FAM MED, V9, P287, DOI 10.1001/archfami.9.3.287; Frank E, 2009, CAN FAM PHYSICIAN, V55; Frank E, 2013, CAN MED ASSOC J, V185, P649, DOI 10.1503/cmaj.121028; Goehring C, 2005, SWISS MED WKLY, V135, P101; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Halbesleben JRB, 2008, HEALTH CARE MANAGE R, V33, P29, DOI 10.1097/01.HMR.0000304493.87898.72; Hawton K, 2001, J EPIDEMIOL COMMUN H, V55, P296, DOI 10.1136/jech.55.5.296; Howe LC, 2017, J PERS SOC PSYCHOL, V112, P718, DOI 10.1037/pspi0000085; Lafreniere JP, 2016, J GEN INTERN MED, V31, P203, DOI 10.1007/s11606-015-3503-3; Lemaire JB, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3360; Lemaire JB, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-18; Linzer M, 2015, J GEN INTERN MED, V30, P1105, DOI 10.1007/s11606-015-3235-4; Panagioti M, 2017, JAMA INTERN MED, V177, P195, DOI 10.1001/jamainternmed.2016.7674; Perez HR, 2017, J HEALTHC QUAL, V39, P43, DOI 10.1097/JHQ.0000000000000016; Puhl RM, 2013, INT J OBESITY, V37, P1415, DOI 10.1038/ijo.2013.33; Ratanawongsa N, 2008, J GEN INTERN MED, V23, P1581, DOI 10.1007/s11606-008-0702-1; Sandelowski M, 1995, RES NURSING HLTH, V18; Shanafelt TD, 2015, MAYO CLIN PROC, V90, P1600, DOI 10.1016/j.mayocp.2015.08.023; Shanafelt TD, 2012, ARCH INTERN MED, V172, P1377, DOI 10.1001/archinternmed.2012.3199; Shanafelt TD, 2011, ARCH SURG-CHICAGO, V146, P54, DOI 10.1001/archsurg.2010.292; Tavakol M, 2014, MED TEACH, V36, P838, DOI 10.3109/0142159X.2014.915297; Thommasen HV, 2001, CAN FAM PHYSICIAN, V47, P737; Thompson WT, 2001, BRIT MED J, V323, P728, DOI 10.1136/bmj.323.7315.728; UALLACHAIN GN, 2008, IRISH MED J, V100, P489; Wallace JE, 2009, LANCET, V374, P1714, DOI 10.1016/S0140-6736(09)61424-0; West CP, 2016, LANCET, V388, P2272, DOI 10.1016/S0140-6736(16)31279-X; Williams ES, 2007, HEALTH CARE MANAGE R, V32, P203, DOI 10.1097/01.HMR.0000281626.28363.59; Williams ES, 2003, HEALTH CARE MANAGE R, V28, P119, DOI 10.1097/00004010-200304000-00004	38	15	15	2	78	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2018	13	5							e0196888	10.1371/journal.pone.0196888	http://dx.doi.org/10.1371/journal.pone.0196888			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF7AA	29763443	gold, Green Published, Green Submitted			2023-01-03	WOS:000432118800017
J	Li, RR; Kowalski, PS; Morselt, HWM; Schepel, I; Jongman, RM; Aslan, A; Ruiters, MHJ; Zijlstra, JG; Molema, G; van Meurs, M; Kamps, JAAM				Li, Ranran; Kowalski, Piotr S.; Morselt, Henriette W. M.; Schepel, Ilona; Jongman, Rianne M.; Aslan, Adnan; Ruiters, Marcel H. J.; Zijlstra, Jan G.; Molema, Grietje; van Meurs, Matijs; Kamps, Jan A. A. M.			Endothelium-targeted delivery of dexamethasone by anti-VCAM-1 SAINT-O-Somes in mouse endotoxemia	PLOS ONE			English	Article							NF-KAPPA-B; SEPTIC SHOCK; SEPSIS; CELLS; SIRNA; GLUCOCORTICOSTEROIDS; HYDROCORTISONE; INFLAMMATION; MORTALITY; LIPOSOMES	Microvascular endothelial cells play a pivotal role in the pathogenesis of sepsis-induced inflammatory responses and multiple organ failure. Therefore, they represent an important target for pharmacological intervention in the treatment of sepsis. Glucocorticosteroids were widely used in the treatment of sepsis but vast evidence to support their systemic use is lacking. The limited effects of glucocorticoids in the treatment of sepsis may be explained by differential effects of drug initiated NF-kappa B inhibition in different cell types and insufficient drug delivery in target cells. The current study aimed therefore to investigate the effects of an endothelial targeted delivery of dexamethasone in a mouse model of endotoxemia induced by two consecutive i.p. injections of lipopolysaccharide (LPS). To achieve endothelial cell specific delivery of dexamethasone, we modified SAINT-O-Somes, a new generation of liposomes that contain the cationic amphiphile SAINT-C18 (1-methyl-4-(cis-9-dioleyl) methyl-pyridinium chloride, with antibodies against vascular cell adhesion molecule-1 (VCAM-1). In LPS challenged mice, the systemic administration of free dexamethasone had negligible effects on the microvascular inflammatory endothelial responses. Dexamethasone-loaded anti-VCAM-1 SAINT-O-Somes specifically localized at VCAM-1 expressing endothelial cells in the microvasculature of inflamed organs. This was associated with a marginal attenuation of the expression of a few pro-inflammatory genes in kidney and liver, while no effects in the lung were observed. This study reveals that, although local accumulation of the targeted drug was achieved, endothelial targeted dexamethasone containing anti-VCAM-1 SAINT-O-Somes exhibited marginal effects on inflammatory endothelial cell activation in a model of endotoxemia. Studies with more potent drugs encapsulated into anti-VCAM-1 SAINT-O-Somes will in the future reveal whether this delivery system can be further developed for efficacious endothelial directed delivery of drugs in the treatment of sepsis.	[Li, Ranran; Kowalski, Piotr S.; Morselt, Henriette W. M.; Schepel, Ilona; Jongman, Rianne M.; Aslan, Adnan; Ruiters, Marcel H. J.; Molema, Grietje; van Meurs, Matijs; Kamps, Jan A. A. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Med Biol Sect,Lab Endothelial Biomed & Vasc Drug, Groningen, Netherlands; [Jongman, Rianne M.; Aslan, Adnan; Zijlstra, Jan G.; van Meurs, Matijs] Univ Groningen, Univ Med Ctr Groningen, Dept Crit Care, Groningen, Netherlands; [Jongman, Rianne M.] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kamps, JAAM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Med Biol Sect,Lab Endothelial Biomed & Vasc Drug, Groningen, Netherlands.	j.a.a.m.kamps@umcg.nl	Kowalski, Piotr/AAF-7450-2021; Li, Ranran/N-1948-2015; Zijlstra, Jan/E-6782-2011	Kowalski, Piotr/0000-0001-8607-0189; Zijlstra, Jan/0000-0001-9079-0795; Molema, Grietje/0000-0002-4147-6676	Top Institute Pharma (TI Pharma project, The Netherlands) [D5-301]; University Medical Center Groningen, The Netherlands	Top Institute Pharma (TI Pharma project, The Netherlands); University Medical Center Groningen, The Netherlands(Netherlands Government)	This work was funded by the Top Institute Pharma (TI Pharma project D5-301, The Netherlands) and the University Medical Center Groningen, The Netherlands.	Adrian JE, 2010, J CONTROL RELEASE, V144, P341, DOI 10.1016/j.jconrel.2010.03.003; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Annane D, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-7; Asgeirdottir SA, 2008, AM J PHYSIOL-RENAL, V294, pF554, DOI 10.1152/ajprenal.00391.2007; Asgeirsdottir SA, 2012, AM J PHYSIOL-RENAL, V302, pF1630, DOI 10.1152/ajprenal.00400.2011; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Choi M, 2017, J AM SOC NEPHROL, V28, P3190, DOI 10.1681/ASN.2016060690; Howard MD, 2014, ANNU REV PHARMACOL, V54, P205, DOI 10.1146/annurev-pharmtox-011613-140002; KAMPS JAA, 2007, LIPOSOME TECHNOLOGY, V3, P127; Kamps JAAM, 1997, P NATL ACAD SCI USA, V94, P11681, DOI 10.1073/pnas.94.21.11681; Kowalski PS, 2014, J CONTROL RELEASE, V176, P64, DOI 10.1016/j.jconrel.2013.12.029; Kowalski PS, 2013, MOL PHARMACEUT, V10, P3033, DOI 10.1021/mp4001124; Kowalski PS, 2011, IUBMB LIFE, V63, P648, DOI 10.1002/iub.487; Marik PE, 2009, CHEST, V135, P181, DOI 10.1378/chest.08-1149; Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; van Meurs M, 2008, SHOCK, V29, P291, DOI 10.1097/shk.0b013e318145a7c1; van Meurs M, 2011, ANESTHESIOLOGY, V115, P474, DOI 10.1097/ALN.0b013e318229a640; Volbeda M, 2015, INTENS CARE MED, V41, P1220, DOI 10.1007/s00134-015-3899-6; Xu C, 2014, KIDNEY INT, V85, P72, DOI 10.1038/ki.2013.286; Yano K, 2006, J EXP MED, V203, P1447, DOI 10.1084/jem.20060375; Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393	24	15	15	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2018	13	5							e0196976	10.1371/journal.pone.0196976	http://dx.doi.org/10.1371/journal.pone.0196976			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF7AA	29763440	Green Published, Green Submitted, gold			2023-01-03	WOS:000432118800021
J	Landier, J; Parker, DM; Thu, AM; Lwin, KM; Delmas, G; Nosten, FH				Landier, Jordi; Parker, Daniel M.; Thu, Aung Myint; Lwin, Khin Maung; Delmas, Gilles; Nosten, Francois H.		Malaria Elimination Task Force Grp	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme	LANCET			English	Article							SPREAD; EPIDEMIOLOGY; RESISTANCE; AREA	Background Potentially untreatable Plasmodium falciparum malaria threatens the Greater Mekong subregion. A previous series of pilot projects in Myanmar, Laos, Cambodia, and Vietnam suggested that mass drug administration was safe, and when added to provision of early diagnosis and treatment, could reduce the reservoir of P falciparum and interrupts transmission. We examined the effects of a scaled-up programme of this strategy in four townships of eastern Myanmar on the incidence of P falciparum malaria. Methods The programme was implemented in the four townships of Myawaddy, Kawkareik, Hlaingbwe, and Hpapun in Kayin state, Myanmar. Increased access to early diagnosis and treatment of malaria was provided to all villages through community-based malaria posts equipped with rapid diagnostic tests, and treatment with artemether-lumefantrine plus single low-dose primaquine. Villages were identified as malarial hotspots (operationally defined as > 40% malaria, of which 20% was P falciparum) with surveys using ultrasensitive quantitative PCR either randomly or targeted at villages where the incidence of clinical cases of P falciparum malaria remained high (ie, > 100 cases per 1000 individuals per year) despite a functioning malaria post. During each survey, a 2 mL sample of venous blood was obtained from randomly selected adults. Hotspots received targeted mass drug administration with dihydroartemisinin-piperaquine plus single-dose primaquine once per month for 3 consecutive months in addition to the malaria posts. The main outcome was the change in village incidence of clinical P falciparum malaria, quantified using a multivariate, generalised, additive multilevel model. Malaria prevalence was measured in the hotspots 12 months after mass drug administration. Findings Between May 1, 2014, and April 30, 2017, 1222 malarial posts were opened, providing early diagnosis and treatment to an estimated 365 000 individuals. Incidence of P falciparum malaria decreased by 60 to 98% in the four townships. 272 prevalence surveys were undertaken and 69 hotspot villages were identified. By April 2017, 50 hotspots were treated with mass drug administration. Hotspot villages had a three times higher incidence of P falciparum at malarial posts than neighbouring villages (adjusted incidence rate ratio [IRR] 2.7, 95% CI 1.8-4.4). Early diagnosis and treatment was associated with a significant decrease in P falciparum incidence in hotspots (IRR 0.82, 95% CI 0.76-0.88 per quarter) and in other villages (0.75, 0.73-0.78 per quarter). Mass drug administration was associated with a five-times decrease in P falciparum incidence within hotspot villages (IRR 0.19, 95% CI 0.13-0.26). By April, 2017, 965 villages (79%) of 1222 corresponding to 104 village tracts were free from P falciparum malaria for at least 6 months. The prevalence of wild-type genotype for K13 molecular markers of artemisinin resistance was stable over the three years (39%; 249/631). Interpretation Providing early diagnosis and effective treatment substantially decreased village-level incidence of artemisinin-resistant P falciparum malaria in hard-to-reach, politically sensitive regions of eastern Myanmar. Targeted mass drug administration significantly reduced malaria incidence in hotspots. If these activities could proceed in all contiguous endemic areas in addition to standard control programmes already implemented, there is a possibility of subnational elimination of P falciparum.	[Landier, Jordi; Parker, Daniel M.; Thu, Aung Myint; Lwin, Khin Maung; Delmas, Gilles; Nosten, Francois H.] Mahidol Univ, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Fac Trop Med, POB 46, Mae Sot 63110, Thailand; [Landier, Jordi] Aix Marseille Univ, Inst Rech Dev, INSERM, SESSTIM, Marseille, France; [Parker, Daniel M.] Univ Calif Irvine, Dept Populat Hlth & Dis Prevent, Irvine, CA USA; [Delmas, Gilles; Nosten, Francois H.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England	Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of California System; University of California Irvine; University of Oxford	Landier, J (corresponding author), Mahidol Univ, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Fac Trop Med, POB 46, Mae Sot 63110, Thailand.	jordi.landier@gmail.com	White, Lisa/AAC-9396-2020; Chaumeau, Victor/AAZ-5422-2021; Nosten, Francois/AAC-5509-2019; gaudart, jean/D-9071-2013; Phyo, Aung Pyae/K-2413-2019; Parker, Daniel M./B-5471-2013	White, Lisa/0000-0002-6523-185X; Chaumeau, Victor/0000-0003-0171-2176; Nosten, Francois/0000-0002-7951-0745; gaudart, jean/0000-0001-9006-5729; Phyo, Aung Pyae/0000-0002-0383-9624; Parker, Daniel M./0000-0002-5352-7338; Bonnington, Craig A./0000-0003-3133-9384; Landier, Jordi/0000-0001-8619-9775; corbel, vincent/0000-0003-0995-3257; White, Nicholas/0000-0002-1897-1978; Tangseefa, Decha/0000-0002-0329-6471	Bill & Melinda Gates Foundation; Regional Artemisinin Initiative (Global Fund against AIDS, Tuberculosis and Malaria); Wellcome Trust	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Regional Artemisinin Initiative (Global Fund against AIDS, Tuberculosis and Malaria); Wellcome Trust(Wellcome TrustEuropean Commission)	The Bill & Melinda Gates Foundation, the Regional Artemisinin Initiative (Global Fund against AIDS, Tuberculosis and Malaria), and the Wellcome Trust.	Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981; Thu AM, 2017, FEBS J, V284, P2569, DOI 10.1111/febs.14127; Das S, 2017, AM J TROP MED HYG, V97, P1540, DOI 10.4269/ajtmh.17-0245; Eisele TP, 2016, J INFECT DIS, V214, P1831, DOI 10.1093/infdis/jiw416; Goncalves BP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01270-4; Imwong M, 2015, J INFECT DIS, V213; Imwong M, 2017, LANCET INFECT DIS, V17, P1022, DOI 10.1016/S1473-3099(17)30524-8; Imwong M, 2017, LANCET INFECT DIS, V17, P491, DOI [10.1016/S1473-3099(17)30048-8, 10.1016/s1473-3099(17)30048-8]; Imwong M, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0906-x; Imwong M, 2014, J CLIN MICROBIOL, V52, P3303, DOI 10.1128/JCM.01057-14; Kajeechiwa Ladda, 2017, Wellcome Open Res, V2, P59, DOI 10.12688/wellcomeopenres.12051.1; Konig A., 2018, Wellcome Open Research, V3, P22, DOI 10.12688/wellcomeopenres.13965.1; Landier J, 2017, WELLCOME OPEN RES, V2, P1; Landier J, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1399-y; Luxemburger C, 1997, T ROY SOC TROP MED H, V91, P256, DOI 10.1016/S0035-9203(97)90066-3; Lwin KM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0838-5; Maude RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037166; Mu TT, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1567-0; Nguitragool W, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2407-y; Parker DM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0712-5; Parker DM, 2017, MYANMAR WELLCOME OPE, V2, P98; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; Phyo AP, 2016, CLIN INFECT DIS, V63, P784, DOI 10.1093/cid/ciw388; Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876; Smithuis FM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-363; Stigler S M, 1997, Stat Methods Med Res, V6, P103; Tadesse FG, 2018, CLIN INFECT DIS, V66, P1883, DOI 10.1093/cid/cix1123; Tripura R, 2017, MALARIA J, V16, P1; Tun KM, 2015, LANCET INFECT DIS, V3099, P21; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WHO, 2017, MASS DRUG ADM FALC M; World Health Organization, 2016, EL MAL GREAT MEK SUB	32	82	82	3	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 12	2018	391	10133					1916	1926		10.1016/S0140-6736(18)30792-X	http://dx.doi.org/10.1016/S0140-6736(18)30792-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF3NC	29703425	Green Published, hybrid			2023-01-03	WOS:000431861800027
J	Hong, JC; Ayala-Peacock, DN; Lee, J; Blackstock, AW; Okunieff, P; Sung, MW; Weichselbaum, RR; Kao, J; Urbanic, JJ; Milano, MT; Chmura, SJ; Salama, JK				Hong, Julian C.; Ayala-Peacock, Diandra N.; Lee, Jason; Blackstock, A. William; Okunieff, Paul; Sung, Max W.; Weichselbaum, Ralph R.; Kao, Johnny; Urbanic, James J.; Milano, Michael T.; Chmura, Steven J.; Salama, Joseph K.			Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis	PLOS ONE			English	Article							STEREOTACTIC BODY RADIOTHERAPY; CELL LUNG-CANCER; DOSE-ESCALATION TRIAL; PHASE I/II TRIAL; RADIATION-THERAPY; PROGNOSTIC-FACTORS; EXTRACRANIAL OLIGOMETASTASES; COLORECTAL METASTASES; CONCURRENT SUNITINIB; SUGGEST IMPLICATIONS	Background Radiotherapy is increasingly used to treat oligometastatic patients. We sought to identify prognostic criteria in oligometastatic patients undergoing definitive hypofractionated image guided radiotherapy (HIGRT). Methods Exclusively extracranial oligometastatic patients treated with HIGRT were pooled. Characteristics including age, sex, primary tumor type, interval to metastatic diagnosis, number of treated metastases and organs, metastatic site, prior systemic therapy for primary tumor treatment, prior definitive metastasis-directed therapy, and systemic therapy for metastasis associated with overall survival (OS), progression-free survival (PFS), and treated metastasis control (TMC) were assessed by the Cox proportional hazards method. Recursive partitioning analysis (RPA) identified prognostic risk strata for OS and PFS based on pretreatment factors. Results 361 patients were included. Primary tumors included non-small cell lung (17%), colorectal (19%), and breast cancer (16%). Three-year OS was 56%, PFS was 24%, and TMC was 72%. On multivariate analysis, primary tumor, interval to metastases, treated metastases number, and mediastinal/hilar lymph node, liver, or adrenal metastases were associated with OS. Primary tumor site, involved organ number, liver metastasis, and prior primary disease chemotherapy were associated with PFS. OS RPA identified five classes: class 1: all breast, kidney, or prostate cancer patients (BKP) (3-year OS 75%, 95% CI 66-85%); class 2: patients without BKP with disease-free interval of 75+ months (3-year OS 85%, 95% CI 67-100%); class 3: patients without BKP, shorter disease-free interval, <= two metastases, and age < 62 (3-year OS 55%, 95% CI 48-64%); class 4: patients without BKP, shorter disease-free interval, >= three metastases, and age < 62 (3-year OS 38%, 95% CI 24-60%); class 5: all others (3-year OS 13%, 95% CI 5-35%). Higher biologically effective dose (BED) (p < 0.01) was associated with OS. Conclusions We identified clinical factors defining oligometastatic patients with favorable outcomes, who we hypothesize are most likely to benefit from metastasis-directed therapy.	[Hong, Julian C.; Salama, Joseph K.] Duke Univ, Dept Radiat Oncol, Durham, NC 27708 USA; [Ayala-Peacock, Diandra N.] Vanderbilt Univ, Dept Radiat Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Lee, Jason] Mem & St Elizabeths Canc Treatment Ctr, Swansea, IL USA; [Blackstock, A. William] Wake Forest Univ, Dept Radiat Oncol, Winston Salem, NC 27109 USA; [Okunieff, Paul] Univ Florida, Dept Radiat Oncol, Gainesville, FL USA; [Sung, Max W.] Mt Sinai Sch Med, Div Hematol & Med Oncol, New York, NY USA; [Weichselbaum, Ralph R.; Chmura, Steven J.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Kao, Johnny] Good Samaritan Hosp Med Ctr, Dept Radiat Oncol, West Islip, NY USA; [Urbanic, James J.] Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA; [Milano, Michael T.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA	Duke University; Vanderbilt University; Wake Forest University; State University System of Florida; University of Florida; Icahn School of Medicine at Mount Sinai; University of Chicago; University of California System; University of California San Diego; University of Rochester	Salama, JK (corresponding author), Duke Univ, Dept Radiat Oncol, Durham, NC 27708 USA.	joseph.salama@duke.edu	Chmura, Steven Joseph/ACU-8438-2022; Hong, Julian/X-6397-2018	Hong, Julian/0000-0001-5172-6889	Pfizer; Brain-Lab AG; Ludwig Center for Metastasis Research, University of Chicago Research Center [5-30,073]; Chicago Tumor Institute Center for Radiation Therapy; University of Chicago Comprehensive Cancer Center [P30 CM14599]	Pfizer(Pfizer); Brain-Lab AG; Ludwig Center for Metastasis Research, University of Chicago Research Center; Chicago Tumor Institute Center for Radiation Therapy; University of Chicago Comprehensive Cancer Center	The Mount Sinai study was funded in part by Pfizer (www.pfizer.com). The University of Rochester study was funded in part by Brain-Lab AG (www.brainlab.com). This work was also supported by Ludwig Center for Metastasis Research, University of Chicago Research Center. Grant Number: 5-30,073; The Chicago Tumor Institute Center for Radiation Therapy; University of Chicago Comprehensive Cancer Center. Grant Number: P30 CM14599. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed KA, 2016, INT J RADIAT ONCOL, V95, P1399, DOI 10.1016/j.ijrobp.2016.03.050; Ahmed KA, 2015, INT J RADIAT ONCOL, V92, P837, DOI 10.1016/j.ijrobp.2015.01.036; Al-Hallaq HA, 2016, PRACT RADIAT ONCOL, V6, pE291, DOI 10.1016/j.prro.2016.05.004; Albain KS, 2008, J CLIN ONCOL, V26, P3950, DOI 10.1200/JCO.2007.11.9362; Ashworth AB, 2014, CLIN LUNG CANCER, V15, P346, DOI 10.1016/j.cllc.2014.04.003; Breiman L., 1984, CLASSIFICATION REGRE, DOI 10.1201/9781315139470; Bujold A, 2012, J CLIN ONCOL, V44, P1659, DOI DOI 10.1200/JC0.2012.44.1659; Chang JY, 2015, LANCET ONCOL, V16, P630, DOI 10.1016/S1470-2045(15)70168-3; Collen C, 2014, ANN ONCOL, V25, P1954, DOI 10.1093/annonc/mdu370; Dagan R, 2016, ACTA ONCOL, V55, P633, DOI 10.3109/0284186X.2015.1118659; de Vin T, 2014, ANN ONCOL, V25, P467, DOI 10.1093/annonc/mdt537; Fode MM, 2015, RADIOTHER ONCOL, V114, P155, DOI 10.1016/j.radonc.2014.12.003; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; Gomez DR, 2016, LANCET ONCOL, V17, P1672, DOI 10.1016/S1470-2045(16)30532-0; Griffioen GHMJ, 2013, LUNG CANCER, V82, P95, DOI 10.1016/j.lungcan.2013.07.023; Guckenberger M, 2016, J THORAC ONCOL, V11, pS143, DOI 10.1016/S1556-0864(16)30307-0; HELLMAN S, 1995, J CLIN ONCOL, V13, P8, DOI 10.1200/JCO.1995.13.1.8; HELLMAN S, 1994, J CLIN ONCOL, V12, P2229, DOI 10.1200/JCO.1994.12.10.2229; Herman JM, 2015, CANCER-AM CANCER SOC, V121, P1128, DOI 10.1002/cncr.29161; Hoyer M, 2006, ACTA ONCOL, V45, P823, DOI 10.1080/02841860600904854; Iyengar P, 2014, J CLIN ONCOL, V32, P3824, DOI 10.1200/JCO.2014.56.7412; Kao J, 2014, TARGET ONCOL, V9, P145, DOI 10.1007/s11523-013-0280-y; Kao J, 2009, CANCER-AM CANCER SOC, V115, P3571, DOI 10.1002/cncr.24412; King CR, 2013, RADIOTHER ONCOL, V109, P217, DOI 10.1016/j.radonc.2013.08.030; Klement RJ, 2017, RADIOTHER ONCOL, V123, P227, DOI 10.1016/j.radonc.2017.01.013; Kress MAS, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-148; Lester-Coll NH, 2016, INT J RADIAT ONCOL, V95, P663, DOI 10.1016/j.ijrobp.2016.01.020; Lewis SL, 2017, AM J CLIN ONCOL-CANC, V40, P418, DOI 10.1097/COC.0000000000000169; Milano MT, 2008, CANCER-AM CANCER SOC, V112, P650, DOI 10.1002/cncr.23209; Milano MT, 2012, INT J RADIAT ONCOL, V83, P878, DOI 10.1016/j.ijrobp.2011.08.036; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Palma DA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-305; Pastorino U, 1997, J THORAC CARDIOV SUR, V113, P37, DOI 10.1016/S0022-5223(97)70397-0; Rieber J, 2017, INT J RADIAT ONCOL, V98, P511, DOI 10.1016/j.ijrobp.2016.09.026; Rieber J, 2016, LUNG CANCER, V97, P51, DOI 10.1016/j.lungcan.2016.04.012; Ruers T, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3501; Rusthoven KE, 2009, J CLIN ONCOL, V27, P1572, DOI 10.1200/JCO.2008.19.6329; Rusthoven KE, 2009, J CLIN ONCOL, V27, P1579, DOI 10.1200/JCO.2008.19.6386; Salama JK, 2008, CLIN CANCER RES, V14, P5255, DOI 10.1158/1078-0432.CCR-08-0358; Salama Joseph K, 2015, Am Soc Clin Oncol Educ Book, pe8, DOI 10.14694/EdBook_AM.2015.35.e8; Salama JK, 2014, J CLIN ONCOL, V32, P2902, DOI 10.1200/JCO.2014.55.9567; Salama JK, 2012, CANCER-AM CANCER SOC, V118, P2962, DOI 10.1002/cncr.26611; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tong CCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036979; Wahl DR, 2016, J CLIN ONCOL, V34, P452, DOI 10.1200/JCO.2015.61.4925; Wong AC, 2016, CANCER-AM CANCER SOC, V122, P2242, DOI 10.1002/cncr.30058	47	75	76	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2018	13	4							e0195149	10.1371/journal.pone.0195149	http://dx.doi.org/10.1371/journal.pone.0195149			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4YG	29649281	Green Published, Green Submitted, gold			2023-01-03	WOS:000429791900028
J	Okugn, A; Woldeyohannes, D				Okugn, Akoma; Woldeyohannes, Demelash			Food hygiene practices and its associated factors among model and non model households in Abobo district, southwestern Ethiopia: Comparative cross-sectional study	PLOS ONE			English	Article								Background In developing country most of human infectious diseases are caused by eating contaminated food. Estimated nine out ten of the diarrheal disease is attributable to the environment and associated with risk factors of poor food hygiene practice. Understanding the risk of eating unsafe food is the major concern to prevent and control food borne diseases. The main goal of this study was to assessing food hygiene practices and its associated factors among model and non model households at Abobo district. Methods This study was conducted from 18 October 2013 to 13 June 2014. A community-based comparative cross-sectional study design was used. Pretested structured questionnaire was used to collect data. A total of 1247 households (417 model and 830 non model households) were included in the study from Abobo district. Bivariate and multivariate logistic regression analysis was used to identify factors associated with outcome variable. Results The study revealed that good food hygiene practice was 51%, of which 79% were model and 36.70% were non model households. Type of household [AOR: 2.07, 95% CI: (1.32-3.39)], sex of household head [AOR: 1.63, 95% CI: (1.06-2.48)], Availability of liquid wastes disposal pit [AOR: 2.23, 95% CI: (1.39,3.63)], Knowledge of liquid waste to cause diseases [AOR: 1.95, 95% (1.23,3.08)], and availability of functional hand washing facility [AOR: 3.61, 95% CI: (1.86-7.02)] were the factors associated with food handling practices. Conclusion This study revealed that good food handling practice is low among model and non model households. While type of household (model versus non model households), sex, knowledge of solid waste to cause diseases, availability of functional hand washing facility, and availability of liquid wastes disposal pit were the factors associated with outcome variable. Health extension workers should play a great role in educating households regarding food hygiene practices to improve their knowledge and practices of the food hygiene.	[Okugn, Akoma] Gambella Coll Hlth Sci, Dept Nursing, Gambella, Ethiopia; [Woldeyohannes, Demelash] Madda Walabu Univ, Coll Med & Hlth Sci, Dept Nursing, Bale Goba, Ethiopia	University of Gondar	Woldeyohannes, D (corresponding author), Madda Walabu Univ, Coll Med & Hlth Sci, Dept Nursing, Bale Goba, Ethiopia.	woldemel@gmail.com		Handiso, Demelash Woldeyohannes/0000-0002-4071-795X				Abobo district a Health Office, 2013, AB DISTR HLTH OFF RE; Abobo district Office of Finance and Economic Development, 2010, ANN REPORT; [Anonymous], 2001, GLOBAL SURVEILLANCE; Central Statistical Agency [Ethiopia] and ORC Macro [USA], 2011, ETH DEM HLTH SURV; Gambella People National Regional State, 2011, GAMB PEOPL NAT REG S; Gambella Regional Health Bureau, 2011, ENV SAN HYG REP; Korma S, 2011, THESIS; Ministry of Health, 2007, EST BURD WAT BORN DI; MOH, 2004, FOOD HYG SAF MEAS EX; MOH, 2005, NAT HYG SAN STRAT; MOH, 2004, IMPR ACC COV RUR POO; Tadesse D, RAPID ASSESSMENT DRI; WHO, 2006, REV DIS HLTH ENV EST	13	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0194391	10.1371/journal.pone.0194391	http://dx.doi.org/10.1371/journal.pone.0194391			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6TQ	29621267	Green Published, gold, Green Submitted			2023-01-03	WOS:000429206800017
J	Moore, HB; Moore, EE; Chapman, MP; McVaney, K; Bryskiewicz, G; Blechar, R; Chin, T; Burlew, CC; Pieracci, F; West, FB; Fleming, CD; Ghasabyan, A; Chandler, J; Silliman, CC; Banerjee, A; Sauaia, A				Moore, Hunter B.; Moore, Ernest E.; Chapman, Michael P.; McVaney, Kevin; Bryskiewicz, Gary; Blechar, Robert; Chin, Theresa; Burlew, Clay Cothren; Pieracci, Fredric; West, F. Bernadette; Fleming, Courtney D.; Ghasabyan, Arsen; Chandler, James; Silliman, Christopher C.; Banerjee, Anirban; Sauaia, Angela			Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial	LANCET			English	Article							FRESH-FROZEN PLASMA; SEVERE TRAUMA; TRANSFUSION; RATIO; MORTALITY; MULTICENTER; SEVERITY; INJURY; MODEL; FIELD	Background Plasma is integral to haemostatic resuscitation after injury, but the timing of administration remains controversial. Anticipating approval of lyophilised plasma by the US Food and Drug Administration, the US Department of Defense funded trials of prehospital plasma resuscitation. We investigated use of prehospital plasma during rapid ground rescue of patients with haemorrhagic shock before arrival at an urban level 1 trauma centre. Methods The Control of Major Bleeding After Trauma Trial was a pragmatic, randomised, single-centre trial done at the Denver Health Medical Center (DHMC), which houses the paramedic division for Denver city. Consecutive trauma patients in haemorrhagic shock (defined as systolic blood pressure [SBP] <= 70 mm Hg or 71-90 mm Hg plus heart rate >= 108 beats per min) were assessed for eligibility at the scene of the injury by trained paramedics. Eligible patients were randomly assigned to receive plasma or normal saline (control). Randomisation was achieved by preloading all ambulances with sealed coolers at the start of each shift. Coolers were randomly assigned to groups 1:1 in blocks of 20 according to a schedule generated by the research coordinators. If the coolers contained two units of frozen plasma, they were defrosted in the ambulance and the infusion started. If the coolers contained a dummy load of frozen water, this indicated allocation to the control group and saline was infused. The primary endpoint was mortality within 28 days of injury. Analyses were done in the as-treated population and by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01838863. Findings From April 1, 2014, to March 31, 2017, paramedics randomly assigned 144 patients to study groups. The astreated analysis included 125 eligible patients, 65 received plasma and 60 received saline. Median age was 33 years (IQR 25-47) and median New Injury Severity Score was 27 (10-38). 70 (56%) patients required blood transfusions within 6 h of injury. The groups were similar at baseline and had similar transport times (plasma group median 19 min [IQR 16-23] vs control 16 min [14-22]). The groups did not dilfer in mortality at 28 days (15% in the plasma group vs 10% in the control group, p=0.37). In the intention-to-treat analysis, we saw no significant dilferences between the groups in safety outcomes and adverse events. Due to the consistent lack of deferences in the analyses, the study was stopped for futility after 144 of 150 planned enrolments. Interpretation During rapid ground rescue to an urban level 1 trauma centre, use of prehospital plasma was not associated with survival benefit. Blood products might be beneficial in settings with longer transport times, but the financial burden would not be justified in an urban environment with short distances to mature trauma centres. Funding US Department of Defense. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Moore, Hunter B.; Moore, Ernest E.] Univ Colorado Denver, Sch Med, Dept Surg, Aurora, CO 80045 USA; [Chapman, Michael P.] Univ Colorado Denver, Sch Med, Dept Radiol, Aurora, CO 80045 USA; [Silliman, Christopher C.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO 80045 USA; [Silliman, Christopher C.] Bonfils Blood Ctr, Denver, CO USA; [Moore, Ernest E.; Burlew, Clay Cothren; Pieracci, Fredric; Fleming, Courtney D.; Ghasabyan, Arsen; Chandler, James; Banerjee, Anirban] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; [McVaney, Kevin] Denver Hlth Med Ctr, Emergency Dept, Denver, CO USA; [Bryskiewicz, Gary; Blechar, Robert] Denver Hlth Med Ctr, Paramed Div, Denver, CO USA; [Chin, Theresa] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA; [West, F. Bernadette] Amer Red Cross Connecticut Midatlantic & Appalach, Hartford, CA USA; [Sauaia, Angela] Univ Colorado Denver, Sch Publ Hlth, Hlth Syst Management & Policy, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Denver Health Medical Center; Denver Health Medical Center; Denver Health Medical Center; University of California System; University of California Irvine; Children's Hospital Colorado; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus	Chapman, MP (corresponding author), Univ Colorado Denver, Sch Med, Dept Radiol, Aurora, CO 80045 USA.	michael.chapman@ucdenver.edu			US Department of Defense; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008315, P50GM049222] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	US Department of Defense.	American Association of Blood Banks, 2014, STANDARDS BLOOD BANK, P7; Ban KC, 2015, SHOCK, V44, P452, DOI 10.1097/SHK.0000000000000452; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brown LM, 2011, J TRAUMA, V71, pS358, DOI 10.1097/TA.0b013e318227f152; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Chapman MP, 2015, SHOCK, V44, P63, DOI 10.1097/SHK.0000000000000376; Chin TL, 2015, SURGERY, V157, P10, DOI 10.1016/j.surg.2014.05.021; D'Alessandro A, 2016, SHOCK, V46, P173, DOI 10.1097/SHK.0000000000000588; ELERDING SC, 1979, AM J SURG, V138, P883, DOI 10.1016/0002-9610(79)90316-7; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Holcomb JB, 2017, J TRAUMA ACUTE CARE, V83, pS83, DOI 10.1097/TA.0000000000001484; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2015, PREHOSP EMERG CARE, V19, P1, DOI 10.3109/10903127.2014.923077; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holland LL, 2005, TRANSFUSION, V45, P1234, DOI 10.1111/j.1537-2995.2005.00184.x; KASHUK JL, 1982, J TRAUMA, V22, P672, DOI 10.1097/00005373-198208000-00004; Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Moore EE, 2014, SHOCK, V41, P35, DOI 10.1097/SHK.0000000000000110; Moore HB, 2015, J TRAUMA ACUTE CARE, V79, P897, DOI 10.1097/TA.0000000000000792; Nascimento B, 2013, CAN MED ASSOC J, V185, pE583, DOI 10.1503/cmaj.121986; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; Smith IM, 2016, SHOCK, V46, P3, DOI 10.1097/SHK.0000000000000569; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f	30	150	153	3	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2018	392	10144					283	291		10.1016/S0140-6736(18)31553-8	http://dx.doi.org/10.1016/S0140-6736(18)31553-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GO3WD	30032977	Green Accepted			2023-01-03	WOS:000439928300024
J	Cousins, S				Cousins, Sophie			Proposed regulation of oxytocin in India causes concern	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2018	392	10142					108	108		10.1016/S0140-6736(18)31605-2	http://dx.doi.org/10.1016/S0140-6736(18)31605-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM8RQ	30017119				2023-01-03	WOS:000438501300012
J	Wang, X; Zheng, BB; Lu, XL; Bai, RH; Feng, LL; Wang, Q; Zhao, Y; He, SX				Wang, Xin; Zheng, Bobo; Lu, Xinlan; Bai, Ruhai; Feng, Linlin; Wang, Quan; Zhao, Yan; He, Shuixiang			Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer: Meta-analysis with trial sequential analysis of long-term survival data	PLOS ONE			English	Article							RANDOMIZED-TRIAL; STAGE-II; DELAYED SURGERY; ADJUVANT CHEMOTHERAPY; COURSE CHEMORADIATION; CHEMORADIOTHERAPY; QUALITY; RADIATION; RECURRENCE; OUTCOMES	Background and purpose The role of preoperative short-course radiotherapy (SCRT) in rectal cancer treatment, when compared to long-course radiochemotherapy (LCRT), is still controversial. Thus the meta-analysis with trial sequential analysis (TSA) was performed to evaluate the long-term survival of SCRT and LCRT as therapeutic regimens for locally advanced rectal cancer. Material and methods PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched up to August 2017 for eligible studies. Hazard ratios (HRs) or odds ratios (ORs) of overall survival (OS), disease free survival (DFS) and local recurrence (LR) with the corresponding 95% confidence intervals (Cis) were calculated and TSA was applied. Results 11 studies with 1984 patients were included. There was no significant difference in OS (HR = 0.92, 95% CI: 0.75-1.13, p = 0.44), DFS (HR = 0.94, 95% CI: 0.79-1.12, p = 0.50) and LR (OR = 0.73, 95% CI: 0.49-1.08, p = 0.11) between SCRT and LCRT groups. TSA suggested firm evidence for lacking on average a -10% relative risk reduction (RRR) in 4-year OS but no statistical significance in 4-year DFS. Conclusions Preoperative SCRT is as effective as LCRT for locally advanced colorectal cancer in longterm survival. SCRT could be preferential while facing long waiting lists or lacking medical resource.	[Wang, Xin; Lu, Xinlan; Zhao, Yan; He, Shuixiang] Xi An Jiao Tong Univ, Dept Gastroenterol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Zheng, Bobo] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China; [Bai, Ruhai] Xi An Jiao Tong Univ, Global Hlth Inst, Hlth Sci Ctr, Xian, Shaanxi, Peoples R China; [Feng, Linlin] Northwest Womens & Childrens Hosp, Med Imaging Ctr, Xian, Shaanxi, Peoples R China; [Wang, Quan] Fourth Mil Med Univ, Digest Dis Hosp, Xijing Hosp, Xian, Shaanxi, Peoples R China; [Wang, Xin] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA	Xi'an Jiaotong University; Sichuan University; Xi'an Jiaotong University; Air Force Military Medical University; University of Pennsylvania; Pennsylvania Medicine	Lu, XL; He, SX (corresponding author), Xi An Jiao Tong Univ, Dept Gastroenterol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.	luneworchid@126.com; heshuixiang2017@yeah.net	Bai, Ruhai/AAV-2762-2020	ruhai, bai/0000-0001-5426-6291; Wang, Xin/0000-0001-5585-073X				Abdel-Rahman O, 2017, CLIN COLORECTAL CANC; Beppu N, 2015, SURGERY, V158, P225, DOI 10.1016/j.surg.2015.03.014; Bisschop C, 2017, ANN SURG ONCOL, V24, P2632, DOI 10.1245/s10434-017-5897-0; Bosset JF, 2004, EUR J CANCER, V40, P219, DOI 10.1016/j.ejca.2003.09.032; Brok J, 2009, INT J EPIDEMIOL, V38, P287, DOI 10.1093/ije/dyn188; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Bujko K, 2006, BRIT J SURG, V93, P1215, DOI 10.1002/bjs.5506; Bujko K, 2004, RADIOTHER ONCOL, V72, P15, DOI 10.1016/j.radonc.2003.12.006; Camma C, 2000, JAMA-J AM MED ASSOC, V284, P1008, DOI 10.1001/jama.284.8.1008; Ceelen W, 2009, INT J CANCER, V124, P2966, DOI 10.1002/ijc.24247; De Caluwe L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006041.pub3; Eitta Mahfouz A, 2010, J Egypt Natl Canc Inst, V22, P155; Folkesson J, 2005, J CLIN ONCOL, V23, P5644, DOI 10.1200/JCO.2005.08.144; Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629; Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI 10.1093/annonc/mdx224; Gray R, 2001, LANCET, V358, P1291; Greenhalgh T, 1997, BRIT MED J, V315, P305, DOI 10.1136/bmj.315.7103.305; Guckenberger M, 2012, STRAHLENTHER ONKOL, V188, P551, DOI 10.1007/s00066-012-0131-2; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Inoue Y, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e14093; Kairevice L, 2017, MEDICINA-LITHUANIA, V53, P150, DOI 10.1016/j.medici.2017.05.006; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Klenova A, 2007, J BUON, V12, P227; Krajcovicova I, 2012, Klin Onkol, V25, P364; Latkauskas T, 2010, COLORECTAL DIS, V12, P1075, DOI 10.1111/j.1463-1318.2009.02015.x; Latkauskas T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2959-9; Liu Shi-Xin, 2015, Asian Pac J Cancer Prev, V16, P5755; Loree JM, 2016, CLIN COLORECTAL CANC, V15, P352, DOI 10.1016/j.clcc.2016.04.003; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Ngan SY, 2012, J CLIN ONCOL, V30, P3827, DOI 10.1200/JCO.2012.42.9597; Olivo SA, 2008, PHYS THER, V88, P156, DOI 10.2522/ptj.20070147; Oremus M, 2001, DEMENT GERIATR COGN, V12, P232, DOI 10.1159/000051263; Pahlman L, 1997, NEW ENGL J MED, V336, P980; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Quan Wang, 2013, ANTERIOR APPROACH VE; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Thorlund K, 2009, INT J EPIDEMIOL, V38, P276, DOI 10.1093/ije/dyn179; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Valentini V, 2009, RADIOTHER ONCOL, V92, P148, DOI 10.1016/j.radonc.2009.06.027; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Yeh CH, 2012, INT J CLIN ONCOL, V17, P482, DOI 10.1007/s10147-011-0317-0; Zhou ZR, 2014, SURG ONCOL, V23, P211, DOI 10.1016/j.suronc.2014.10.003	43	16	16	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2018	13	7							e0200142	10.1371/journal.pone.0200142	http://dx.doi.org/10.1371/journal.pone.0200142			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM8FT	30001375	Green Submitted, Green Published, gold			2023-01-03	WOS:000438457400027
J	Alcantar-Fernandez, J; Navarro, RE; Salazar-Martinez, AM; Perez-Andrade, ME; Miranda-Rios, J				Alcantar-Fernandez, Jonathan; Navarro, Rosa E.; Maria Salazar-Martinez, Ana; Elva Perez-Andrade, Martha; Miranda-Rios, Juan			Caenorhabditis elegans respond to high-glucose diets through a network of stress-responsive transcription factors	PLOS ONE			English	Article							LIFE-SPAN; C. ELEGANS; OXIDATIVE STRESS; MODEL; GENETICS; INSULIN; PROTEIN; QUANTIFICATION; DAF-16/FOXO; LONGEVITY	High-glycemic-index diets, as well as a sedentary lifestyle are considered as determinant factors for the development of obesity, type 2 diabetes, and cardiovascular diseases in humans. These diets have been shown to shorten the life span of C. elegans in a manner that is dependent on insulin signaling, but the participation of other signaling pathways have not been addressed. In this study, we have determined that worms fed with high-glucose diets show alterations in glucose content and uptake, triglyceride content, body size, number of eggs laid, egg-laying defects, and signs of oxidative stress and accelerated aging. Additionally, we analyzed the participation of different key regulators of carbohydrate and lipid metabolism, oxidative stress and longevity such as SKN-1/NRF2, HIF-1/HIF1 alpha, SBP-1/SREBP, CRH-1/CREB, CEP-1/p53, and DAF-16/FOXO, in the reduction of lifespan in glucose-fed worms.	[Alcantar-Fernandez, Jonathan] Univ Nacl Autonoma Mexico, Programa Doctorado Ciencias Biomed, Mexico City, DF, Mexico; [Alcantar-Fernandez, Jonathan; Elva Perez-Andrade, Martha; Miranda-Rios, Juan] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Unidad Genet Nutr, Mexico City, DF, Mexico; [Alcantar-Fernandez, Jonathan; Elva Perez-Andrade, Martha; Miranda-Rios, Juan] Inst Nacl Pediat, Mexico City, DF, Mexico; [Navarro, Rosa E.] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular & Desarrollo, Mexico City, DF, Mexico; [Maria Salazar-Martinez, Ana] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Med Genom & Toxicol Ambiental, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Miranda-Rios, J (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Unidad Genet Nutr, Mexico City, DF, Mexico.; Miranda-Rios, J (corresponding author), Inst Nacl Pediat, Mexico City, DF, Mexico.	riosjuanm@biomedicas.unam.mx	Miranda Ríos, Juan/ABB-7767-2021; Fernández, Jonathan Alcántar/AAP-9407-2020	Fernández, Jonathan Alcántar/0000-0001-5302-4223; Navarro, Rosa/0000-0003-4992-4450	Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT), Direccion General de Asuntos del Personal Academico UNAM [IN205818]; Fondos Federales Secretaria de Salud, Instituto Nacional de Pediatria [036/2015]; CONACyT; PAPIIT-UNAM; NIH Office of Research Infra-structure Programs [P40 OD010440]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER	Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT), Direccion General de Asuntos del Personal Academico UNAM; Fondos Federales Secretaria de Salud, Instituto Nacional de Pediatria; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); PAPIIT-UNAM(Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico); NIH Office of Research Infra-structure Programs; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT), Direccion General de Asuntos del Personal Academico UNAM (IN205818) and Fondos Federales Secretaria de Salud, Instituto Nacional de Pediatria (036/2015) to J.M-R. J. A-F. is a doctoral student from Programa de Doctorado en Ciencias Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM) and received fellowships from CONACyT and PAPIIT-UNAM. Some strains were provided by CGC, which is funded by NIH Office of Research Infra-structure Programs (P40 OD010440). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altintas O, 2016, BMB REP, V49, P81, DOI 10.5483/BMBRep.2016.49.2.261; Bonomini F, 2015, AGING DIS, V6, P109, DOI 10.14336/AD.2014.0305; BRENNER S, 1974, GENETICS, V77, P71; Burmeister C, 2008, FASEB J, V22, P343, DOI 10.1096/fj.06-7426com; Chang HW, 2017, AGING CELL, V16, P814, DOI 10.1111/acel.12619; Chen JJ, 2004, J NEMATOL, V36, P107; Choi SS, 2011, NUTR RES PRACT, V5, P214, DOI 10.4162/nrp.2011.5.3.214; Cox-Paulson EA, 2012, CBE-LIFE SCI EDUC, V11, P165, DOI 10.1187/cbe-11-06-0045; Davies SK, 2012, MECH AGEING DEV, V133, P46, DOI 10.1016/j.mad.2011.11.002; Depuydt G, 2014, J PROTEOME RES, V13, P1938, DOI 10.1021/pr401081b; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Feldman N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085964; Garcia-Segura L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142262; Garigan D, 2002, GENETICS, V161, P1101; GOTH L, 1991, CLIN CHIM ACTA, V196, P143, DOI 10.1016/0009-8981(91)90067-M; Gusarov I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15868; Hoogewijs D, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-9; Huelgas-Morales G, 2016, G3-GENES GENOM GENET, V6, P1031, DOI 10.1534/g3.115.026815; Hunter T, 1997, J BIOL CHEM, V272, P28652, DOI 10.1074/jbc.272.45.28652; Inoue H, 2005, GENE DEV, V19, P2278, DOI 10.1101/gad.1324805; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kaletta T, 2006, NAT REV DRUG DISCOV, V5, P387, DOI 10.1038/nrd2031; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; Kitaoka S, 2016, FEBS OPEN BIO, V6, P576, DOI 10.1002/2211-5463.12068; Kubagawa HM, 2006, NAT CELL BIOL, V8, P1143, DOI 10.1038/ncb1476; Labuschagne CF, 2013, AGING CELL, V12, P214, DOI 10.1111/acel.12043; Lee D, 2015, GENE DEV, V29, P2490, DOI 10.1101/gad.266304.115; Lee SJ, 2009, CELL METAB, V10, P379, DOI 10.1016/j.cmet.2009.10.003; Lempradl A, 2015, NAT REV GENET, V16, P665, DOI 10.1038/nrg3941; Leung MCK, 2008, TOXICOL SCI, V106, P5, DOI 10.1093/toxsci/kfn121; Li J, 2009, PROTEOMICS, V9, P4539, DOI 10.1002/pmic.200900101; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Luersen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060731; Mair W, 2011, NATURE, V470, P404, DOI 10.1038/nature09706; Markaki M, 2010, BIOTECHNOL J, V5, P1261, DOI 10.1002/biot.201000183; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Mendler M, 2012, EXP CLIN ENDOCR DIAB, V120, P182, DOI 10.1055/s-0032-1304570; Mendler M, 2015, DIABETOLOGIA, V58, P393, DOI 10.1007/s00125-014-3415-5; Mondoux MA, 2011, GENETICS, V188, P369, DOI 10.1534/genetics.111.126490; Petrascheck Michael, 2017, Front Genet, V8, P92, DOI 10.3389/fgene.2017.00092; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Przybysz AJ, 2009, MECH AGEING DEV, V130, P357, DOI 10.1016/j.mad.2009.02.004; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Reisner K, 2011, J BIOCHEM MOL TOXIC, V25, P269, DOI 10.1002/jbt.20386; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Saito K, 2011, ANAL BIOCHEM, V412, P9, DOI 10.1016/j.ab.2011.01.022; Schlotterer A, 2009, DIABETES, V58, P2450, DOI 10.2337/db09-0567; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; So Shuhei, 2012, Worm, V1, P93, DOI 10.4161/worm.20175; Svensk E, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005982; Tain LS, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-28; Tauffenberger A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004346; Tauffenberger A, 2012, AGING CELL, V11, P856, DOI 10.1111/j.1474-9726.2012.00855.x; Teshiba E, 2016, BIOSCI BIOTECH BIOCH, V80, P1436, DOI 10.1080/09168451.2016.1158634; TRUSWELL AS, 1994, AM J CLIN NUTR, V59, p710S, DOI 10.1093/ajcn/59.3.710S; Tullet JMA, 2017, AGING CELL, V16, P1191, DOI 10.1111/acel.12627; Van Raamsdonk JM, 2011, MECH AGEING DEV, V132, P519, DOI 10.1016/j.mad.2011.08.006; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; Vanfleteren JR, 1998, J GERONTOL A-BIOL, V53, pB380, DOI 10.1093/gerona/53A.5.B380; Villanueva-Chimal E, 2017, GENESIS, V55, DOI 10.1002/dvg.23072; Wood W, 1998, NEMATODE CAENORHABDI, V17, P667; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103	66	29	29	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2018	13	7							e0199888	10.1371/journal.pone.0199888	http://dx.doi.org/10.1371/journal.pone.0199888			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM5IS	29990370	Green Published, gold, Green Submitted			2023-01-03	WOS:000438170300019
J	Juul, FE; Garborg, K; Bretthauer, M; Skudal, H; Oines, MN; Wiig, H; Rose, O; Seip, B; Lamont, JT; Midtvedt, T; Valeur, J; Kalager, M; Holme, O; Helsingen, L; Loberg, M; Adami, HO				Juul, Frederik E.; Garborg, Kjetil; Bretthauer, Michael; Skudal, Hilde; Oines, Mari N.; Wiig, Havard; Rose, Oystein; Seip, Birgitte; Lamont, J. Thomas; Midtvedt, Tore; Valeur, Jorgen; Kalager, Mette; Holme, Oyvind; Helsingen, Lise; Loberg, Magnus; Adami, Hans-Olov			Fecal Microbiota Transplantation for Primary Clostridium difficile Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Juul, Frederik E.; Garborg, Kjetil; Helsingen, Lise; Adami, Hans-Olov] Oslo Univ Hosp, Oslo, Norway; [Bretthauer, Michael; Kalager, Mette; Holme, Oyvind; Loberg, Magnus] Univ Oslo, Oslo, Norway; [Skudal, Hilde] Telemark Hosp, Skien, Norway; [Oines, Mari N.] Rigshosp, Copenhagen, Denmark; [Wiig, Havard] Sorlandet Hosp, Kristiansand, Norway; [Rose, Oystein] Vestre Viken Baerum Hosp, Gjettum, Norway; [Seip, Birgitte] Vestfold Hosp, Tonsberg, Norway; [Lamont, J. Thomas] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Midtvedt, Tore] Karolinska Inst, Stockholm, Sweden; [Valeur, Jorgen] Lovisenberg Diaconal Hosp, Oslo, Norway	University of Oslo; University of Oslo; Telemark Hospital Trust; Rigshospitalet; University of Copenhagen; Harvard University; Beth Israel Deaconess Medical Center; Karolinska Institutet	Bretthauer, M (corresponding author), Univ Oslo, Oslo, Norway.	michael.bretthauer@medisin.uio.no	Helsingen, Lise/AAU-2290-2021; Valeur, Jorgen/AEO-0359-2022; Valeur, Jørgen/AGF-5332-2022; Juul, Frederik Emil/AAH-3294-2020; Helsingen, Lise/ABD-6025-2021; Valeur, Jørgen/AFU-6716-2022	Valeur, Jørgen/0000-0001-7193-7069; Helsingen, Lise/0000-0002-2055-3978; Valeur, Jørgen/0000-0001-7193-7069; Juul, Frederik Emil/0000-0003-3317-6988; Garborg, Kjetil/0000-0002-5484-5995	Southeastern Norway Regional Health Authority	Southeastern Norway Regional Health Authority	Supported by the Toppforsk program of the Research Council of Norway, a network grant from the Southeastern Norway Regional Health Authority, and a Ph.D. scholarship grant (to Dr. Juul) from the Southeastern Norway Regional Health Authority.	[Anonymous], 2013, NAT GUID ANT US HOSP; Gustafsson A, 1999, SCAND J GASTROENTERO, V34, P580, DOI 10.1080/003655299750026038; Jorup-Ronstrom C, 2012, SCAND J GASTROENTERO, V47, P548, DOI 10.3109/00365521.2012.672587; Leffler DA, 2015, NEW ENGL J MED, V372, P1539, DOI 10.1056/NEJMra1403772; McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]	5	122	131	2	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2018	378	26					2535	+		10.1056/NEJMc1803103	http://dx.doi.org/10.1056/NEJMc1803103			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK8UC	29860912	Green Published, Bronze			2023-01-03	WOS:000436503300015
J	Nayak, S; Bhatt, MLB; Goel, MM; Gupta, S; Mandi, AA; Mishra, A; Mehrotra, D				Nayak, Seema; Bhatt, M. L. B.; Goel, Madhu Mati; Gupta, Seema; Mandi, Abbas Ali; Mishra, Anupam; Mehrotra, Divya			Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemoradiotherapy	PLOS ONE			English	Article							RADIATION-RESISTANCE; TRANSGLUTAMINASE 3; CANCER; HEAD; RADIOTHERAPY	Radioresistance is one of the main determinants of treatment outcome in oral squamous cell carcinoma (OSCC), but its prediction is difficult. Several authors aimed to establish radioresistant OSCC cell lines to identify genes with altered expression in response to radioresistance. The development of OSCC is a multistep carcinogenic process that includes activation of several oncogenes and inactivation of tumour suppressor genes. TGM-3 is a tumour suppressor gene and contributes to carcinogenesis process. The aim of this study was to estimate serum and tissue expression of TGM-3 and its correlation with clinico-pathological factors and overall survival in patients of OSCC undergoing chemo-radiotherapy. Tissue expression was observed in formalin fixed tissue biopsies of 96 cases of OSCC and 32 healthy controls were subjected to immunohistochemistry (IHC) by using antibody against TGM-3 and serum level was estimated by ELISA method. mRNA expression was determined by using Real-Time PCR. Patients were followed for 2 year for chemo radiotherapy response. In OSCC, 76.70% cases and in controls 90.62% were positive for TGM-3 IHC expression. TGM-3 expression was cytoplasmic and nuclear staining expressed in keratinized layer, stratum granulosum and stratum spinosum in controls and tumour cells. Mean serum TGM-3 in pre chemo-radiotherapy OSCC cases were 1304.83 +/- 573.55, post chemo-radiotherapy samples were 1530.64 +/- 669.33 and controls were 1869.16 +/- 1377.36, but difference was significant in pre chemo-radiotherapy samples as compared to controls (p<0.018). This finding was also confirmed by real-time PCR analysis in which down regulation (-7.92 fold change) of TGM-3 in OSCC as compared to controls. TGM-3 expression was significantly associated with response to chemo-radiotherapy treatment (p<0.007) and overall survival (p<0.015). Patents having higher level of TGM-3 expression have good response to chemo-radiotherapy and also have better overall survival. TGM-3 may serve as a candidate biomarker for responsiveness to chemo-radiotherapy treatment in OSCC patients.	[Nayak, Seema; Bhatt, M. L. B.; Gupta, Seema] King Georges Med Univ Lucknow, Dept Radiotherapy, Lucknow, Uttar Pradesh, India; [Goel, Madhu Mati] King Georges Med Univ Lucknow, Dept Pathol, Lucknow, Uttar Pradesh, India; [Mandi, Abbas Ali] King Georges Med Univ Lucknow, Dept Biochem, Lucknow, Uttar Pradesh, India; [Mishra, Anupam] King Georges Med Univ Lucknow, Dept Otorhinolaryngol, Lucknow, Uttar Pradesh, India; [Mehrotra, Divya] King Georges Med Univ Lucknow, Dept Oral & Maxillofacial Surg, Lucknow, Uttar Pradesh, India	King George's Medical University; King George's Medical University; King George's Medical University; King George's Medical University; King George's Medical University	Nayak, S (corresponding author), King Georges Med Univ Lucknow, Dept Radiotherapy, Lucknow, Uttar Pradesh, India.	seemagkp@gmail.com	Mehrotra, Divya/AAN-1469-2020	Mehrotra, Divya/0000-0003-3504-8680; Mishra, Anupam/0000-0002-2289-9104; Nayak, Dr. Seema/0000-0002-3670-6553; Mahdi, Abbas Ali/0000-0002-8580-9911	ICMR, HRD, DHR, New Delhi [DHR/HRD/Women Scientist/Type-V/4/2014-15]	ICMR, HRD, DHR, New Delhi	This work was supported by a Women Scientist fellowship to Dr. Seema Nayak from ICMR, HRD, DHR, Grant no. DHR/HRD/Women Scientist/Type-V/4/2014-15, New Delhi.	Al-Sarraf Muhyi, 2002, Cancer Control, V9, P387; Belbin TJ, 2005, ARCH OTOLARYNGOL, V131, P10, DOI 10.1001/archotol.131.1.10; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608; Dinshaw KA, 2006, CLIN ONCOL-UK, V18, P383, DOI 10.1016/j.clon.2006.02.009; Eckert RL, 2005, J INVEST DERMATOL, V124, P481, DOI 10.1111/j.0022-202X.2005.23627.x; Eze Nnamdi, 2017, Cancers Head Neck, V2, P6, DOI 10.1186/s41199-017-0025-1; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He Guang, 2002, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V19, P120; Hitomi K, 2005, EUR J DERMATOL, V15, P313; Hitomi K, 2003, J DERMATOL SCI, V32, P95, DOI 10.1016/S0923-1811(03)00091-4; Hitomi K, 2001, INT J BIOCHEM CELL B, V33, P491, DOI 10.1016/S1357-2725(01)00033-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Lee SY, 2013, INT J ORAL MAX SURG, V42, P169, DOI 10.1016/j.ijom.2012.10.022; Li W, 2016, ONCOL REP, V36, P1723, DOI 10.3892/or.2016.4921; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mendez E, 2007, HEAD NECK-J SCI SPEC, V29, P803, DOI 10.1002/hed.20598; Mignogna MD, 2004, EUR J CANCER PREV, V13, P139, DOI 10.1097/00008469-200404000-00008; Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0; Mohr S, 2002, J CLIN ONCOL, V20, P3165, DOI 10.1200/JCO.2002.12.073; Nayak S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138801; Negishi A, 2009, CANCER SCI, V100, P1605, DOI 10.1111/j.1349-7006.2009.01227.x; Sahu N, 2011, ANTI-CANCER DRUG, V22, P656, DOI 10.1097/CAD.0b013e32834249ba; Sano D, 2007, CANCER METAST REV, V26, P645, DOI 10.1007/s10555-007-9082-y; Shintani S, 2003, CANCER SCI, V94, P894, DOI 10.1111/j.1349-7006.2003.tb01372.x; Silva P, 2007, CLIN OTOLARYNGOL, V32, P337, DOI 10.1111/j.1749-4486.2007.01544.x; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Uemura N, 2009, INT J CANCER, V124, P2106, DOI 10.1002/ijc.24194; Wu XB, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-151	31	5	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0199665	10.1371/journal.pone.0199665	http://dx.doi.org/10.1371/journal.pone.0199665			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0GK	29953521	Green Published, Green Submitted, gold			2023-01-03	WOS:000436645400049
J	Badejo, OA; Menson, WNA; Sam-Agudu, NA; Pharr, J; Erekaha, S; Bruno, T; Nwanne, G; Ogunsola, O; Llozumba, J; Busari, O; Ezeanolue, EE				Badejo, Okikiolu A.; Menson, William N. A.; Sam-Agudu, Nadia A.; Pharr, Jennifer; Erekaha, Salome; Bruno, Tamara; Nwanne, Gift; Ogunsola, Olabanjo; Llozumba, Jude; Busari, Olusegun; Ezeanolue, Echezona E.			Pediatric to adult healthcare transitioning for adolescents living with HIV in Nigeria: A national survey	PLOS ONE			English	Article							YOUNG-ADULTS; ANTIRETROVIRAL THERAPY; INFECTED ADOLESCENTS; OUTCOMES; STRATEGIES; PEOPLE	Introduction The period of transition from pediatric to adult care has been associated with poor health outcomes among 10-19 year old adolescents living with HIV (ALHIV). This has prompted a focus on the quality of transition services, especially in high ALHIV-burden countries. Due to lack of guidelines, there are no healthcare transition standards for Nigeria's estimated 240,000 ALHIV. We conducted a nationwide survey to characterize routine transition procedures for Nigerian ALHIV. Materials and methods This cross-sectional survey was conducted at public healthcare facilities supported by five local HIV service implementing partners. Comprehensive HIV treatment facilities with >1 year of HIV service provision and >20 ALHIVs enrolled were selected. A structured questionnaire assessed availability of treatment, care and transition services for ALHIV. Transition was defined as a preparatory process catering to the medical, psychosocial, and educational needs of adolescents moving from pediatric to adult care. Comprehensive transition services were defined by 6 core elements: policy, tracking and monitoring, readiness evaluation, planning, transfer of care, and follow-up. Results All 152 eligible facilities were surveyed and comprised 106 (69.7%) secondary and 46 (30.3%) tertiary centers at which 17,662 ALHIV were enrolled. The majority (73, 48.3%) of the 151 facilities responding to the "clinic type" question were family-centered and saw all clients together regardless of age. Only 42 (27.8%) facilities had an adolescent-specific HIV clinic; 53 (35.1%) had separate pediatric/adolescent and adult HIV clinics, of which 39 (73.6%) reported having a transfer/transition policy. Only 6 (15.4%) of these 39 facilities reported having a written protocol. There was a bimodal peak at 15 and 18 years for age of ALHIV transfer to adult care. No surveyed facility met the study definition for comprehensive transition services. Conclusions Facilities surveyed were more likely to have non-specialized HIV treatment services and had loosely-defined, abrupt transfer versus transition practices, which lacked the core transition elements. Evidence-based standards of transitional care tailored to non-specialized HIV treatment programs need to be established to optimize transition outcomes among ALHIV in Nigeria and in similar settings.	[Badejo, Okikiolu A.] FHI360, Abuja, Nigeria; [Menson, William N. A.; Pharr, Jennifer; Bruno, Tamara] Univ Nevada, Global Hlth Initiat, Sch Community Hlth Sci, Las Vegas, NV 89154 USA; [Sam-Agudu, Nadia A.; Erekaha, Salome; Nwanne, Gift] Inst Human Virol Nigeria, Int Res Ctr Excellence, Abuja, Nigeria; [Sam-Agudu, Nadia A.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; [Ogunsola, Olabanjo] APIN Publ Hlth Initiat, Abuja, Nigeria; [Llozumba, Jude] Ctr Clin Care & Clin Res Nigeria, Abuja, Nigeria; [Busari, Olusegun] Ctr Integrated Hlth Programs, Abuja, Nigeria; [Ezeanolue, Echezona E.] HealthySunrise Fdn, Las Vegas, NV USA; [Ezeanolue, Echezona E.] Univ Nigeria Nsukka, Dept Paediat & Child Hlth, Enugu, Nigeria	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; University System of Maryland; University of Maryland Baltimore; University of Nigeria	Sam-Agudu, NA (corresponding author), Inst Human Virol Nigeria, Int Res Ctr Excellence, Abuja, Nigeria.; Sam-Agudu, NA (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.	nsamagudu@ihvnigeria.org	Pharr, Jennifer/AAZ-1368-2020	Pharr, Jennifer/0000-0002-0383-2641; Badejo, Okikiolu/0000-0002-8124-7018; Busari, Olusegun/0000-0003-3468-2364; Erekaha, Salome/0000-0002-6304-4209	Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health [R01HD089871]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD089871] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (https://grants.nih.gov/grants/oer.htm) under award number R01HD089871, awarded to EEE and NASA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agwu AL, 2015, J ADOLESCENT HEALTH, V56, P345, DOI 10.1016/j.jadohealth.2014.11.009; [Anonymous], 2014, 6 CORE ELEMENTS HLTH; [Anonymous], 2017, UNAIDS DAT 2017; Auld AF, 2014, MMWR-MORBID MORTAL W, V63, P1097; Boudreau ME, 2012, J ASSOC NURSE AIDS C, V23, P318, DOI 10.1016/j.jana.2011.06.003; Callahan T, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21858; Chu PY, 2015, J PEDIATR NURS, V30, pE19, DOI 10.1016/j.pedn.2015.05.022; Crowley R, 2011, ARCH DIS CHILD, V96, P548, DOI 10.1136/adc.2010.202473; Dahourou DL, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21528; Davies MA, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21668; Davis AM, 2014, PEDIATRICS, V134, P900, DOI 10.1542/peds.2014-1909; Ekouevi DK, 2010, TROP MED INT HEALTH, V15, P34, DOI 10.1111/j.1365-3156.2010.02505.x; Ezeanolue EE, 2016, JAIDS-J ACQ IMM DEF, V72, pS161, DOI 10.1097/QAI.0000000000001066; Federal Government of Nigeria National AIDS Spending Assessment (NASA), 2013, 2014 LEV FLOW RES EX; Federal Ministry of Health Nigeria, 2010, NAT GUID HIV AIDS TR; Federal Ministry of Health Nigeria, 2011, CLIN PROT HLTH DEV A; Federal Ministry of Health Nigeria/ UNFPA, 2010, ACT PLAN ADV YOUNG P; Fish R, 2014, HIV MED, V15, P239, DOI 10.1111/hiv.12091; Folayan MO, 2017, AIDS BEHAV, V21, P2736, DOI 10.1007/s10461-016-1534-3; Hussen SA, 2014, FUTURE VIROL, V9, P921, DOI 10.2217/FVL.14.73; IBM Corp, 2012, SOFTW WIND REL 21 0; Kasedde S, 2013, CURR HIV-AIDS REP, V10, P159, DOI 10.1007/s11904-013-0159-7; Katusiime C, 2013, S AFR J HIV MED, V14, P20, DOI 10.7196/SAJHIVMED.885; Kennedy A, 2008, CURR OPIN PEDIATR, V20, P403, DOI 10.1097/MOP.0b013e328305e128; Kung T H, 2016, SAMJ, S. Afr. med. j., V106, P804, DOI [10.7196/SAMJ.2016.v106i8.10496, 10.7196/samj.2016.v106i8.10496]; Lam PK, 2017, JIAS S3, V20, P91; Mark D, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21591; Maturo D, 2007, J PEDIATR HEALTH CAR, V25, p16 ; Okoboi S, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.5.20841; Olakunde BO, 2015, ANN GLOB HEALTH, V81, P684, DOI 10.1016/j.aogh.2015.10.005; Peter NG, 2009, PEDIATRICS, V123, P417, DOI 10.1542/peds.2008-0740; Pettitt ED, 2013, AFR J REPROD HLTH, V17; Ridgeway K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189770; Ryscavage PA, 2011, JAIDS-J ACQ IMM DEF, V58, P193, DOI [10.1097/QAI.0B013E31822D7564, 10.1097/QAI.0b013e31822d7564]; Sainz T, 2015, C RETR OPP INF CROI, P918; Sam-Agudu NA, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2347-z; Slogrove AL, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21520; Sohn AH, 2017, J INT AIDS SOC, V20, p19 ; UNAIDS, 2013, GLOBAL REPORT UNAIDS; UNAIDS, 2017, AIDSINFO 2016 DAT; UNICEF, 2019, TANZ MOST VULN AD BE; UNICEF, 2016, GLOB REG TRENDS UNIC; UNICEF, 2014, AD AND AIDS; United States President's Emergency Plan for AIDS Relief, NIG COUNTR OP PLAN C; Vreeman RC, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18466; Weijsenfeld AM, 2016, CLIN INFECT DIS, V63, P1105, DOI 10.1093/cid/ciw487; World Health Organization, HIV AD GUID ACT	47	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2018	13	6							e0198802	10.1371/journal.pone.0198802	http://dx.doi.org/10.1371/journal.pone.0198802			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ1PQ	29894519	Green Published, gold			2023-01-03	WOS:000435030900028
J	Sangineto, M; Graziano, G; D'Amore, S; Salvia, R; Palasciano, G; Sabba, C; Vacca, M; Cariello, M				Sangineto, Moris; Graziano, Giusi; D'Amore, Simona; Salvia, Roberto; Palasciano, Giuseppe; Sabba, Carlo; Vacca, Michele; Cariello, Marica			Identification of peculiar gene expression profile in peripheral blood mononuclear cells (PBMC) of celiac patients on gluten free diet	PLOS ONE			English	Article							HEAT-SHOCK PROTEINS; MAP KINASES; DISEASE; CANCER; RECEPTORS; RISK; ATHEROSCLEROSIS; ASSOCIATION; MORTALITY; RESPONSES	Celiac disease (CD) is a systemic disorder characterized by an immune-mediated reaction to gluten and a wide spectrum of clinical manifestations. Currently, the main treatment of CD is represented by adherence to a gluten-free diet (GFD) which determines the resolution of symptoms, and the normalization of the serology and of the duodenal villous atrophy. In the present study, we aimed to identify changes in gene expression in peripheral blood mononuclear cells (PBMCs) of celiac patients on GFD for at least 2 years, in order to identify novel disease biomarkers and candidate targets for putative therapeutic approaches. Microarray analysis was performed on PBMCs from 17 celiac patients on long-term GFD and 20 healthy controls. We identified 517 annotated genes that were significantly modulated between celiac patients and controls. Significant biological pathways were functionally clustered using the Core Function of Ingenuity System Pathway Analysis (IPA). Intriguingly, despite being on a GFD, celiac patients exhibited a peculiar PBMC profile characterized by an aberrant expression of genes involved in the regulation of immunity, inflammatory response, metabolism, and cell proliferation. Random forest algorithm was then used to validate the prediction ability of core genes as classifiers of the "celiac status". In conclusion, our study identified a characteristic PBMCs signature profile in clinically asymptomatic celiac patient.	[Sangineto, Moris; D'Amore, Simona; Salvia, Roberto; Sabba, Carlo; Vacca, Michele; Cariello, Marica] Aldo Moro Univ Bari, Dept Interdisciplinary Med, Bari, Italy; [Graziano, Giusi] IRCCS Oncol Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy; [Palasciano, Giuseppe] Aldo Moro Univ Bari, Clin Med A Murri, Dept Biomed Sci & Human Oncol, Bari, Italy; [Cariello, Marica] INBB, Rome, Italy	Universita degli Studi di Bari Aldo Moro; IRCCS Istituto Tumori Bari Giovanni Paolo II; Universita degli Studi di Bari Aldo Moro	Cariello, M (corresponding author), Aldo Moro Univ Bari, Dept Interdisciplinary Med, Bari, Italy.; Cariello, M (corresponding author), INBB, Rome, Italy.	maricacariello@gmail.com	Vacca, Michele/B-4736-2013; Salvia, Roberto/J-1773-2018; Cariello, Marica/K-4064-2018; Sangineto, Moris/AAJ-8889-2021	Vacca, Michele/0000-0002-1973-224X; Sangineto, Moris/0000-0002-0936-8843; D'Amore, Simona/0000-0002-5432-8808				Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749; Arts RJW, 2013, J LEUKOCYTE BIOL, V93, P209, DOI 10.1189/jlb.0312145; Bai JC, 2013, J CLIN GASTROENTEROL, V47, P121, DOI 10.1097/MCG.0b013e31827a6f83; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bidmon-Fliegenschnee B, 2015, PEDIATR RES, V78, P358, DOI 10.1038/pr.2015.112; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Broide E, 2009, DIGEST DIS SCI, V54, P1270, DOI 10.1007/s10620-008-0480-y; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Cariello M, 2012, ANTIOXID REDOX SIGN, V16, P428, DOI 10.1089/ars.2011.4062; Chowers Y, 1997, CLIN EXP IMMUNOL, V107, P141, DOI 10.1046/j.1365-2249.1997.d01-892.x; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; D'Amore S, 2013, BBA-MOL BASIS DIS, V1832, P2289, DOI 10.1016/j.bbadis.2013.09.006; Di Sabatino A, 2009, LANCET, V373, P1480, DOI 10.1016/S0140-6736(09)60254-3; Diaz-Uriarte R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-3; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014; Dumpe ML, 1998, NURS ECON, V16, P170; Fan DP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040498; Fasano A, 2012, NEW ENGL J MED, V367, P2419, DOI 10.1056/NEJMcp1113994; Fernandez-Jimenez N, 2014, HUM MOL GENET, V23, P1298, DOI 10.1093/hmg/ddt520; Green PHR, 2015, J ALLERGY CLIN IMMUN, V135, P1099, DOI 10.1016/j.jaci.2015.01.044; Harris KM, 2010, CLIN IMMUNOL, V135, P430, DOI 10.1016/j.clim.2010.01.003; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Kalliomaki M, 2012, J PEDIATR GASTR NUTR, V54, P727, DOI 10.1097/MPG.0b013e318241cfa8; Kurien M, 2016, DIABETES CARE, V39, P371, DOI 10.2337/dc15-2117; Lazaris AC, 1997, BREAST CANCER RES TR, V43, P43, DOI 10.1023/A:1005706110275; Lebwohl B, 2013, ALIMENT PHARM THER, V37, P332, DOI 10.1111/apt.12164; Liu QZ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-S5-S1; Ludvigsson JF, 2009, JAMA-J AM MED ASSOC, V302, P1171, DOI 10.1001/jama.2009.1320; Manavalan JS, 2010, HUM IMMUNOL, V71, P50, DOI 10.1016/j.humimm.2009.09.351; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Mesko B, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-15; Miao EA, 2007, SEMIN IMMUNOPATHOL, V29, P275, DOI 10.1007/s00281-007-0078-z; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; Palova-Jelinkova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062426; PARTANEN J, 1993, TISSUE ANTIGENS, V41, P15, DOI 10.1111/j.1399-0039.1993.tb01971.x; Ramos-Arroyo MA, 2001, HUM IMMUNOL, V62, P821, DOI 10.1016/S0198-8859(01)00277-4; Rueda B, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-29; Rybak A, 2014, NUTRIENTS, V6, P2718, DOI 10.3390/nu6072718; See Jacalyn, 2006, Nutr Clin Pract, V21, P1, DOI 10.1177/011542650602100101; Setty M, 2015, GASTROENTEROLOGY, V149, P681, DOI 10.1053/j.gastro.2015.05.013; Silvester JA, 2016, NUTRITION, V32, P777, DOI 10.1016/j.nut.2016.01.021; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; Vacca M, 2016, CARDIOVASC RES, V109, P228, DOI 10.1093/cvr/cvv266; Zhang YL, 2005, CELL MOL IMMUNOL, V2, P20	45	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197915	10.1371/journal.pone.0197915	http://dx.doi.org/10.1371/journal.pone.0197915			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH0HY	29795662	Green Published, Green Submitted, gold			2023-01-03	WOS:000433084300094
J	Bin Gwag, H; Chun, KJ; Hwang, JK; Park, SJ; Kim, JS; Park, KM; On, YK				Bin Gwag, Hye; Chun, Kwang Jin; Hwang, Jin Kyung; Park, Seung-Jung; Kim, June Soo; Park, Kyoung-Min; On, Young Keun			Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients	PLOS ONE			English	Article							SINUS RHYTHM; RANDOMIZED-TRIAL; MAINTENANCE; MANAGEMENT; EFFICACY; PROPAFENONE; THERAPIES; SOTALOL	The relative efficacy of antiarrhythmic drugs (AADs) after electrical cardioversion are not well established. This study aimed to investigate the efficacies of different AADs for maintaining sinus rhythm (SR) after electrical cardioversion for atrial fibrillation (AF). We selected patients from a retrospective registry including patients admitted for cardioversion between January 2012 and June 2016. The primary outcome was time to AF recurrence during the first year after cardioversion. The secondary outcomes included AF recurrence within 1 month, and first readmission due to heart failure, stroke, or additional non-pharmacological rhythm control. A total of 265 patients were divided into the 4 groups according to AAD type: flecainide (n = 33), propafenone (n = 64), amiodarone (n = 128), and dronedarone (n = 40). During the first year after cardioversion, the AF recurrence-free survival was similar between all AAD groups (69.7% vs. 67.2% vs. 71.9% vs. 80.0%, p = 0.439). About half of all recurrences occurred during the first month. There was no difference in any of the secondary outcomes, although the amiodarone group showed a trend toward more non-pharmacological rhythm control. AAD type was not associated with recurrence in multivariate analysis. In this study, half of all patients received amiodarone after electrical cardioversion. Flecainide, propafenone, amiodarone, and dronedarone showed similar efficacies for maintaining SR after electrical cardioversion. Thus, it might be reasonable to reconsider amiodarone use after cardioversion, since it did not show superior efficacy to the other drugs considered and is associated with potential side effects.	[Bin Gwag, Hye; Hwang, Jin Kyung; Park, Seung-Jung; Kim, June Soo; Park, Kyoung-Min; On, Young Keun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Cardiol,Dept Internal Med,Heart Vasc Stroke I, Seoul, South Korea; [Chun, Kwang Jin] Hallym Univ, Med Ctr, Kangnam Sacred Heart Hosp, Div Cardiol,Dept Med, Seoul, South Korea; [Chun, Kwang Jin] Kangwon Natl Univ, Div Cardiol, Dept Med, Coll Med, Chunchon, South Korea; [Hwang, Jin Kyung] VHS Med Ctr, Div Cardiol, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Hallym University; Kangwon National University; Veterans Health Service Medical Center	On, YK (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Cardiol,Dept Internal Med,Heart Vasc Stroke I, Seoul, South Korea.	yk.on@samsung.com						Abed HS, 2013, JAMA-J AM MED ASSOC, V310, P2050, DOI 10.1001/jama.2013.280521; Bellandi F, 2001, AM J CARDIOL, V88, P640, DOI 10.1016/S0002-9149(01)01806-9; Chun KJ, 2014, CLIN THER, V36, P1169, DOI 10.1016/j.clinthera.2014.07.013; Fetsch T, 2004, EUR HEART J, V25, P1385, DOI 10.1016/j.ehj.2004.04.015; Hagens VE, 2004, EUR HEART J, V25, P1542, DOI 10.1016/j.ehj.2004.06.020; Hohnloser SH, 2001, EUR HEART J, V22, P801, DOI 10.1053/euhj.2001.2596; January CT, 2014, CIRCULATION, V130, pE199, DOI [10.1161/CIR.0000000000000041, 10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.021, 10.1016/j.jacc.2014.03.022]; Kim SK, 2009, EUROPACE, V11, P1632, DOI 10.1093/europace/eup321; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Kuhn EW, 2014, EUR J CARDIO-THORAC, V45, P17, DOI 10.1093/ejcts/ezt181; Lafuente-Lafuente C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005049.pub2; Lindholm CJA, 2004, HEART, V90, P534, DOI 10.1136/hrt.2003.017707; Macchia A, 2013, J AM COLL CARDIOL, V61, P463, DOI 10.1016/j.jacc.2012.11.021; Alegret JM, 2008, REV ESP CARDIOL, V61, P1274, DOI 10.1016/S1885-5857(09)60055-4; Nergardh AK, 2007, EUR HEART J, V28, P1351, DOI 10.1093/eurheartj/ehl544; Overvad TF, 2013, HEART, V99, P1093, DOI 10.1136/heartjnl-2013-304036; Plewan A, 2001, EUR HEART J, V22, P1504, DOI 10.1053/euhj.2000.2546; Qin DX, 2016, J CARDIOL, V67, P471, DOI 10.1016/j.jjcc.2015.07.001; Saksena S, 2011, J AM COLL CARDIOL, V58, P1975, DOI 10.1016/j.jacc.2011.07.036; Savelieva I, 2011, EUROPACE, V13, P610, DOI 10.1093/europace/eur023; Schilling RJ, 2010, HEART, V96, P333, DOI 10.1136/hrt.2008.155812; Shin DG, 2015, YONSEI MED J, V56, P1552, DOI 10.3349/ymj.2015.56.6.1552	22	8	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2018	13	5							e0197352	10.1371/journal.pone.0197352	http://dx.doi.org/10.1371/journal.pone.0197352			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG6DG	29787592	Green Submitted, gold, Green Published			2023-01-03	WOS:000432785700023
J	McIntosh, J; Alonso, A; MacLure, K; Stewart, D; Kempen, T; Mair, A; Castel-Branco, M; Codina, C; Fernandez-Llimos, F; Fleming, G; Gennimata, D; Gillespie, U; Harrison, C; Illario, M; Junius-Walker, U; Kampolis, CF; Kardas, P; Lewek, P; Malva, J; Menditto, E; Scullin, C; Wiese, B				McIntosh, Jennifer; Alonso, Albert; MacLure, Katie; Stewart, Derek; Kempen, Thomas; Mair, Alpana; Castel-Branco, Margarida; Codina, Carles; Fernandez-Llimos, Fernando; Fleming, Glenda; Gennimata, Dimitra; Gillespie, Ulrika; Harrison, Cathy; Illario, Maddalena; Junius-Walker, Ulrike; Kampolis, Christos F.; Kardas, Przemyslaw; Lewek, Pawel; Malva, Joao; Menditto, Enrica; Scullin, Claire; Wiese, Birgitt		SIMPATHY Consortium	A case study of polypharmacy management in nine European countries: Implications for change management and implementation	PLOS ONE			English	Article							ADVERSE DRUG EVENTS; CARE MANAGEMENT; RISK-FACTORS; HEALTH-CARE; PREVALENCE; MULTIMORBIDITY; DISEASE; BURDEN	Background Multimorbidity and its associated polypharmacy contribute to an increase in adverse drug events, hospitalizations, and healthcare spending. This study aimed to address: what exists regarding polypharmacy management in the European Union (EU); why programs were, or were not, developed; and, how identified initiatives were developed, implemented, and sustained. Methods Change management principles (Kotter) and normalization process theory (NPT) informed data collection and analysis. Nine case studies were conducted in eight EU countries: Germany (Lower Saxony), Greece, Italy (Campania), Poland, Portugal, Spain (Catalonia), Sweden (Uppsala), and the United Kingdom (Northern Ireland and Scotland). The workflow included a review of country/region specific polypharmacy policies, key informant interviews with stakeholders involved in policy development and implementation and, focus groups of clinicians and managers. Data were analyzed using thematic analysis of individual cases and framework analysis across cases. Results Polypharmacy initiatives were identified in five regions (Catalonia, Lower Saxony, Northern Ireland, Scotland, and Uppsala) and included all care settings. There was agreement, even in cases without initiatives, that polypharmacy is a significant issue to address. Common themes regarding the development and implementation of polypharmacy management initiatives were: locally adapted solutions, organizational culture supporting innovation and teamwork, adequate workforce training, multidisciplinary teams, changes in workflow, redefinition of roles and responsibilities of professionals, policies and legislation supporting the initiative, and data management and information and communication systems to assist development and implementation. Depending on the setting, these were considered either facilitators or barriers to implementation. Conclusion Within the studied EU countries, polypharmacy management was not widely addressed. These results highlight the importance of change management and theory-based implementation strategies, and provide examples of polypharmacy management initiatives that can assist managers and policymakers in developing new programs or scaling up existing ones, particularly in places currently lacking such initiatives.	[McIntosh, Jennifer; Alonso, Albert] Fundacio Clin Recerca Biorned, Dept Recerca & Innovacio, Barcelona, Spain; [MacLure, Katie; Stewart, Derek] Robert Gordon Univ, Sch Pharm & Life Sci, Aberdeen, Scotland; [Kempen, Thomas; Gillespie, Ulrika] Uppsala Univ Hosp, Pharm Dept, Uppsala, Sweden; [Mair, Alpana] Scottish Govt, Effect Prescribing & Therapeut, Hlth & Social Care Directorate, Edinburgh, Midlothian, Scotland; [Castel-Branco, Margarida] Univ Coimbra, Lab Pharmacol & Pharmaceut Care, Fac Pharm, Coimbra, Portugal; [Codina, Carles] Hosp Clin Barcelona, Serv Farm, Barcelona, Spain; [Fernandez-Llimos, Fernando] Univ Lisbon, Inst Med Res, Dept Social Pharm, Fac Pharm, Lisbon, Portugal; [Fleming, Glenda] Northern Hlth & Social Care Trust, Pharm Dept, Belfast, Antrim, North Ireland; [Fleming, Glenda] Northern Hlth & Social Care Trust, Reg Med Optimisat Innovat Ctr MOIC, Belfast, Antrim, North Ireland; [Gennimata, Dimitra; Kampolis, Christos F.] Univ Peloponnese, Dept Social & Educ Policy, Korinthos, Greece; [Gennimata, Dimitra; Kampolis, Christos F.] Ist Reg Hlth Author Attica, eHlth Innovat Unit, Athens, Greece; [Harrison, Cathy] Dept Hlth, Belfast, Antrim, North Ireland; [Illario, Maddalena] Federico II Univ Hosp, Naples, Italy; [Junius-Walker, Ulrike; Wiese, Birgitt] Hannover Med Sch, Inst Gen Practice, Hannover, Germany; [Kardas, Przemyslaw; Lewek, Pawel] Med Univ Lodz, Dept Family Med, Lodz, Poland; [Malva, Joao] Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci, Coimbra, Portugal; [Malva, Joao] Univ Coimbra, Fac Med, Inst Pharmacol & Expt Therapeut, Coimbra, Portugal; [Menditto, Enrica] Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy; [Scullin, Claire] Queens Univ, Sch Pharm, Clin & Practice Res Grp, Belfast, Antrim, North Ireland	Robert Gordon University; Uppsala University; Uppsala University Hospital; Universidade de Coimbra; University of Barcelona; Hospital Clinic de Barcelona; Universidade de Lisboa; University of Peloponnese; University of Naples Federico II; Hannover Medical School; Medical University Lodz; Universidade de Coimbra; Universidade de Coimbra; University of Naples Federico II; Queens University Belfast	McIntosh, J (corresponding author), Fundacio Clin Recerca Biorned, Dept Recerca & Innovacio, Barcelona, Spain.	mcintosh@clinic.cat	Fernandez-Llimos, Fernando/B-8931-2008; Castel-Branco, Maria Margarida/A-2093-2017; iMed.ULisboa, PEPSocPh/B-4101-2014; MacLure, Katie/GRJ-8912-2022; Malva, Joao/L-3557-2014	Fernandez-Llimos, Fernando/0000-0002-8529-9595; Castel-Branco, Maria Margarida/0000-0002-6533-9932; Kempen, Thomas/0000-0001-5173-5005; Alonso, Albert/0000-0003-0921-8033; Malva, Joao/0000-0002-5438-4447; Lewek, Pawel/0000-0003-3690-7096; McIntosh, Jenifer/0000-0002-8140-9304; Kardas, Przemyslaw/0000-0002-6078-2628; orlando, valentina/0000-0002-8209-8878; fleming, glenda/0000-0001-7321-8092; MacLure, Katie/0000-0003-0686-948X; menditto, enrica/0000-0001-8633-5650	SIMPATHY project [663082]; European Commission CHAFEA Health Program	SIMPATHY project; European Commission CHAFEA Health Program	This work has been supported by the SIMPATHY project, grant agreement number 663082 to AM, co-funded by the European Commission CHAFEA Health Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Benziger CP, 2016, GLOB HEART, V11, P393, DOI 10.1016/j.gheart.2016.10.024; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Canadian Electronic Library (Firm), BETT HLTH BETT CAR B; Cooper JA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009235; Craig P, 2006, DEV EVALUATING COMPL; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Field TS, 2001, ARCH INTERN MED, V161, P1629, DOI 10.1001/archinte.161.13.1629; Fortin M, 2006, ANN FAM MED, V4, P104, DOI 10.1370/afm.516; Fortin Martin, 2004, Health Qual Life Outcomes, V2, P51, DOI 10.1186/1477-7525-2-51; Foster M, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1270-4; Fu S, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140205; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gallacher K, 2011, ANN FAM MED, V9, P235, DOI 10.1370/afm.1249; Guiding principles for the care of older adults with multimorbidity: an approach for clinicians, 2012, J Am Geriatr Soc, V60, pE1, DOI 10.1111/j.1532-5415.2012.04188.x; Holtrop JS, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1613-1; Iles V, 2001, NATL COORDINATING CT; Institute of Medicine (U. S.), 2001, COMM QUAL HLTH CAR A, pxx; Jager C, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-016-0535-y; Kojima G, 2012, JAMDA, V13, pe11; Kotter J., 2012, LEADING CHANGE; Lee JK, 2013, J AM GERIATR SOC, V61, P1119, DOI 10.1111/jgs.12323; Loffler C, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0151-7; Mair AF-LF, 2017, SIMPATHY CONSORTIUM; Marcum ZA, 2012, J AM GERIATR SOC, V60, P34, DOI 10.1111/j.1532-5415.2011.03772.x; May CR, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-29; Menotti A, 2001, J CLIN EPIDEMIOL, V54, P680, DOI 10.1016/S0895-4356(00)00368-1; Molokhia M, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0642-0; OECD/EU, 2016, 2016 STAT HLTH EU CY; Patterson SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008165.pub3, 10.1002/14651858.CD008165.pub4]; Payne RA, 2011, BRIT J GEN PRACT, V61, P83, DOI 10.3399/bjgp11X556146; Petrovic M, 2016, DRUG AGING, V33, P179, DOI 10.1007/s40266-016-0352-7; Rollason V, 2003, DRUG AGING, V20, P817, DOI 10.2165/00002512-200320110-00003; Stewart D, 2017, PLOS ONE; Stewart D, 2017, EXPERT OPIN DRUG SAF, V16, P203, DOI 10.1080/14740338.2017.1265503; Stewart D, 2016, INT J CLIN PHARM-NET, V38, P615, DOI 10.1007/s11096-015-0216-y; Stoehr GP, 2008, AM J GERIATR PHARMAC, V6, P255, DOI 10.1016/j.amjopharm.2008.11.001; Taylor AW, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-718; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Valentijn PP, 2013, INT J INTEGR CARE, V13; Valentijn PP, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0278-x; van den Bussche H, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-54; van Oostrom SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160264; Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1; World Health Organization, 2017, MED HARM GLOB PAT SA; World Health Organization, 2016, MULT TECHN SER SAF P; Yin R., 2014, APPL CASE STUDY RES; Yuksel I., 2012, IJBM, V7, P14; Zulman DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007771	50	25	25	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2018	13	4							e0195232	10.1371/journal.pone.0195232	http://dx.doi.org/10.1371/journal.pone.0195232			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD1VU	29668763	Green Published, gold			2023-01-03	WOS:000430290200034
J	Kuntz, AB; Chopp-Hurley, JN; Brenneman, EC; Karampatos, S; Wiebenga, EG; Adachi, JD; Noseworthy, MD; Maly, MR				Kuntz, Alexander B.; Chopp-Hurley, Jaclyn N.; Brenneman, Elora C.; Karampatos, Sarah; Wiebenga, Emily G.; Adachi, Jonathan D.; Noseworthy, Michael D.; Maly, Monica R.			Efficacy of a biomechanically-based yoga exercise program in knee osteoarthritis: A randomized controlled trial	PLOS ONE			English	Article							CLINICALLY IMPORTANT IMPROVEMENT; ASSESS PHYSICAL FUNCTION; QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; PERFORMANCE-MEASURES; DISEASE PROGRESSION; MUSCLE STRENGTH; FLEXION MOMENTS; SELF-REPORT; PAIN	Objective Certain exercises could overload the osteoarthritic knee. We developed an exercise program from yoga postures with a minimal knee adduction moment for knee osteoarthritis. The purpose was to compare the effectiveness of this biomechanically-based yoga exercise (YE), with traditional exercise (TE), and a no-exercise attention-equivalent control (NE) for improving pain, self-reported physical function and mobility performance in women with knee osteoarthritis. Design Single-blind, three-arm randomized controlled trial. Setting Community in Southwestern Ontario, Canada. Participants A convenience sample of 31 women with symptomatic knee osteoarthritis was recruited through rheumatology, orthopaedic and physiotherapy clinics, newspapers and word-of-mouth. Interventions Participants were stratified by disease severity and randomly allocated to one of three 12-week, supervised interventions. YE included biomechanically-based yoga exercises; TE included traditional leg strengthening on machines; and NE included meditation with no exercise. Participants were asked to attend three 1-hour group classes/sessions each week. Measurements Primary outcomes were pain, self-reported physical function and mobility performance. Secondary outcomes were knee strength, depression, and health-related quality of life. All were assessed by a blinded assessor at baseline and immediately following the intervention. Results The YE group demonstrated greater improvements in KOOS pain (mean difference of 22.9 [95% CI, 6.9 to 38.8; p = 0.003]), intermittent pain (mean difference of -19.6 [95% CI, -34.8 to -4.4; p = 0.009]) and self-reported physical function (mean difference of 17.2 [95% CI, 5.2 to 29.2; p = 0.003]) compared to NE. Improvements in these outcomes were similar between YE and TE. However, TE demonstrated a greater improvement in knee flexor strength compared to YE (mean difference of 0.1 [95% CI, 0.1 to 0.2]. Improvements from baseline to follow-up were present in quality of life score for YE and knee flexor strength for TE, while both also demonstrated improvements in mobility. No improvement in any outcome was present in NE. Conclusions The biomechanically-based yoga exercise program produced clinically meaningful improvements in pain, self-reported physical function and mobility in women with clinical knee OA compared to no exercise. While not statistically significant, improvements in these outcomes were larger than those elicited from the traditional exercise-based program. Though this may suggest that the yoga program may be more efficacious for knee OA, future research studying a larger sample is required.	[Kuntz, Alexander B.; Brenneman, Elora C.; Maly, Monica R.] McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada; [Chopp-Hurley, Jaclyn N.; Karampatos, Sarah; Wiebenga, Emily G.; Maly, Monica R.] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [Adachi, Jonathan D.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Noseworthy, Michael D.] McMaster Univ, Dept Elect & Comp Engn, Hamilton, ON, Canada; [Maly, Monica R.] Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada	McMaster University; McMaster University; McMaster University; McMaster University; University of Waterloo	Maly, MR (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada.; Maly, MR (corresponding author), McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada.; Maly, MR (corresponding author), Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada.	mrmaly@uwaterloo.ca			Canadian Institutes for Health Research (CIHR) [137147]; Canada Foundation for Innovation; Ontario Research Fund; Joint Motion Program (A CIHR training initiative); Ontario Graduate Scholarship; Michael G. DeGroote Fellowship Award in Clinical Research at McMaster University; CIHR fellowship award; CIHR New Investigator Award	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Ontario Research Fund; Joint Motion Program (A CIHR training initiative)(Canadian Institutes of Health Research (CIHR)); Ontario Graduate Scholarship(Ontario Graduate Scholarship); Michael G. DeGroote Fellowship Award in Clinical Research at McMaster University; CIHR fellowship award(Canadian Institutes of Health Research (CIHR)); CIHR New Investigator Award(Canadian Institutes of Health Research (CIHR))	Project funding was received through a Canadian Institutes for Health Research (CIHR) Bridge Grant #137147 (MRM). Funding for certain equipment used in this research was received through the Canada Foundation for Innovation and the Ontario Research Fund. Alexander Kuntz was supported by the Joint Motion Program (A CIHR training initiative) and the Ontario Graduate Scholarship. Jaclyn Chopp-Hurley was supported through the Michael G. DeGroote Fellowship Award in Clinical Research at McMaster University and a CIHR fellowship award. Elora Brenneman was supported by an Ontario Graduate Scholarship. Monica Maly was supported by a CIHR New Investigator Award.	ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Bennell KL, 2013, RHEUM DIS CLIN N AM, V39, P145, DOI 10.1016/j.rdc.2012.11.003; Bennell KL, 2011, ANN RHEUM DIS, V70, P1770, DOI 10.1136/ard.2010.147082; Binkley JM, 1999, PHYS THER, V79, P371; BLALOCK SJ, 1989, ARTHRITIS RHEUM, V32, P991, DOI 10.1002/anr.1780320808; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brenneman EC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136854; Cahalin LP, 1996, CHEST, V110, P325, DOI 10.1378/chest.110.2.325; Chang AH, 2015, OSTEOARTHR CARTILAGE, V23, P1099, DOI 10.1016/j.joca.2015.02.005; Chehab EF, 2014, OSTEOARTHR CARTILAGE, V22, P1833, DOI 10.1016/j.joca.2014.08.009; Colak TK, 2017, RHEUMATOL INT, V37, P399, DOI 10.1007/s00296-016-3646-5; Collins NJ, 2011, ARTHRITIS CARE RES; Dobson F, 2013, OSTEOARTHR CARTILAGE, V21, P1042, DOI 10.1016/j.joca.2013.05.002; Dobson F, 2012, OSTEOARTHR CARTILAGE, V20, P1548, DOI 10.1016/j.joca.2012.08.015; Ferreira AH, 2015, REV BRAS REUMATOL, V55, P434, DOI 10.1016/j.rbr.2015.03.001; Field A, 2009, DISCOVERING STAT SPS, V2da; Fogarty FA, 2015, ANN RHEUM DIS, V74, P472, DOI 10.1136/annrheumdis-2014-205946; Fransen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004376.pub3; GOLDSMITH CH, 1993, J RHEUMATOL, V20, P561; Haaz S, 2011, RHEUM DIS CLIN N AM, V37, P33, DOI 10.1016/j.rdc.2010.11.001; Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P409, DOI 10.1016/j.joca.2007.12.015; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Hoogeboom TJ, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-117; Juhl C, 2014, ARTHRITIS RHEUMATOL, V66, P622, DOI 10.1002/art.38290; Kabat-Zinn J., 1990, FULLCATASTROPHE LIVI; Kennedy DM, 2011, J ORTHOP SPORT PHYS, V41, P232, DOI 10.2519/jospt.2011.3516; Kennedy DM, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-3; Liu Anna, 2012, ARTHRITIS RHEUMA S10, V24, P244; Longpre HS, 2015, CLIN BIOMECH, V30, P820, DOI 10.1016/j.clinbiomech.2015.06.007; Losina E, 2013, OSTEOARTHR CARTILAGE, V21, P1264, DOI 10.1016/j.joca.2013.04.013; Lun V, 2015, CLIN J SPORT MED, V25, P509, DOI 10.1097/JSM.0000000000000170; Maly MR, 2007, DISABIL REHABIL, V29, P1423, DOI 10.1080/09638280601029985; McCall MC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/945895; McCarthy EK, 2004, J GERONTOL A-BIOL, V59, P1207, DOI 10.1093/gerona/59.11.1207; Miyazaki T, 2002, ANN RHEUM DIS, V61, P617, DOI 10.1136/ard.61.7.617; Pua YH, 2009, J CLIN EPIDEMIOL, V62, P1103, DOI 10.1016/j.jclinepi.2008.11.011; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Robbins SM, 2011, ARTHRIT CARE RES, V63, P991, DOI 10.1002/acr.20476; Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P64, DOI 10.1186/1477-7525-1-64; Rosemann T, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-48; Rosenzweig S, 2010, J PSYCHOSOM RES, V68, P29, DOI 10.1016/j.jpsychores.2009.03.010; Sharma M, 2014, J EVID-BASED INTEGR, V19, P51, DOI 10.1177/2156587213499918; Singh JA, 2014, J RHEUMATOL, V41, P509, DOI 10.3899/jrheum.130609; Stratford PW, 2010, PHYS THER, V90, P1288, DOI 10.2522/ptj.20100058; Stratford PW, 2006, J CLIN EPIDEMIOL, V59, P160, DOI 10.1016/j.jclinepi.2005.07.012; Stratford PW, 2003, ARTHRIT RHEUM-ARTHR, V49, P535, DOI 10.1002/art.11196; Tubach F, 2012, ARTHRIT CARE RES, V64, P1699, DOI 10.1002/acr.21747; Zacharias A, 2014, OSTEOARTHR CARTILAGE, V22, P1752, DOI 10.1016/j.joca.2014.07.005; Zambon S, 2015, ARTHRITIS CARE RES; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013	51	21	22	5	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2018	13	4							e0195653	10.1371/journal.pone.0195653	http://dx.doi.org/10.1371/journal.pone.0195653			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD1LV	29664955	Green Submitted, Green Published, gold			2023-01-03	WOS:000430262300024
J	Zhao, Q; Yang, MM; Huang, YY; Chen, WL				Zhao, Qian; Yang, Miles M.; Huang, Yu-Ying; Chen, Wenlin			How to make hand hygiene interventions more attractive to nurses: A discrete choice experiment	PLOS ONE			English	Article							HEALTH-CARE WORKERS; BEHAVIOR-CHANGE; IMPROVEMENT; GUIDELINES; PROGRAM; MODELS; IMPACT; SAFETY	Background Better understanding of the characteristics of interventions which are attractive to nurses is required in order to implement effective hand hygiene interventions. Methods The intervention characteristics were derived from diffusion of innovation theory (DIT): relative advantage, compatibility, simplicity, trialability, and observability. To identify nurses' preferences for the five characteristics, a discrete choice experiment (DCE) was conducted. Participants were nurses working at Taiwanese tertiary care hospitals selected through stratified sampling. In addition, the hand hygiene moment (before or after patient contact) was taken into consideration in the DCE to investigate whether nurses' preferences for the intervention characteristics were the same at different hand hygiene moments. Results This survey was conducted between 1 October and 31 December 2014. Among 200 nurses from three Taiwanese tertiary care hospitals, significant preferences for the five intervention characteristics were observed. That is, when an intervention makes the hand hygiene activity more convenient (p<0.001), when nurses participate in the design of the intervention (p<0.001), when an intervention is explained well to nurses before implementing it (p<0.001), when the evidence of hand hygiene is provided at a trial stage to show its effectiveness (p<0.001), and when nurses' hand hygiene performance is observable to their peers (p<0.001), nurses are more willing to wash their hands with high compliance. In addition, nurses preferred for providing evidence at a trial stage most, and well explanation about the intervention to increase simplicity was least. The rankings of the preference for the five intervention characteristics were the same at different hand hygiene moments (p = 0.453) Conclusions The findings suggest policy directions for decision makers aiming to improve overall hand hygiene compliance in healthcare facilities.	[Zhao, Qian] Chengdu Univ, Sch Informat Sci & Engn, Chengdu, Sichuan, Peoples R China; [Yang, Miles M.] Macquarie Univ, Sydney, NSW, Australia; [Huang, Yu-Ying] Commerce Dev Res Inst, Healthcare Serv Dept, Taipei, Taiwan; [Chen, Wenlin] Univ New South Wales, Business Sch, Sydney, NSW, Australia	Chengdu University; Macquarie University; University of New South Wales Sydney	Chen, WL (corresponding author), Univ New South Wales, Business Sch, Sydney, NSW, Australia.	wenlincd@126.com		Yang, Miles/0000-0002-0911-6179				Armellino D, 2012, CLIN INFECT DIS, V54, P1, DOI 10.1093/cid/cir773; Barrett R, 2008, J CLIN NURS, V17, P1851, DOI 10.1111/j.1365-2702.2007.02215.x; Boscart VM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-77; BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301; Bryce EA, 2007, AM J INFECT CONTROL, V35, P271, DOI 10.1016/j.ajic.2006.05.293; Burgers JS, 2003, BRIT J GEN PRACT, V53, P15; Chen JK, 2016, AM J INFECT CONTROL, V44, P222, DOI 10.1016/j.ajic.2015.10.004; de Bekker-Grob EW, 2010, VALUE HEALTH, V13, P315, DOI 10.1111/j.1524-4733.2009.00670.x; Erasmus V, 2009, INFECT CONT HOSP EP, V30, P415, DOI 10.1086/596773; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Gould D., 2013, Journal of Infection Prevention, V14, P88, DOI 10.1177/1757177413482608; Gould DJ, 2008, J HOSP INFECT, V68, P193, DOI 10.1016/j.jhin.2007.11.013; Grol RPTM, 2007, MILBANK Q, V85, P93, DOI 10.1111/j.1468-0009.2007.00478.x; Hjelmgren J, 2007, HEALTH POLICY, V83, P314, DOI 10.1016/j.healthpol.2007.02.006; Huang TT, 2008, J HOSP INFECT, V68, P164, DOI 10.1016/j.jhin.2007.11.020; Huicho L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050315; Huis A, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-92; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Jang JH, 2010, INFECT CONT HOSP EP, V31, P144, DOI 10.1086/649792; Kingston L, 2016, J HOSP INFECT, V92, P309, DOI 10.1016/j.jhin.2015.11.012; Lancsar E, 2007, SOC SCI MED, V64, P1738, DOI 10.1016/j.socscimed.2006.12.007; Liu WI, 2014, INT J NURS PRACT, V20, P46, DOI 10.1111/ijn.12120; MANSKI CF, 1977, THEOR DECIS, V8, P229, DOI 10.1007/BF00133443; McFadden D., 1973, CONDITIONAL LOGIT AN; McLaws ML, 2012, AM J INFECT CONTROL, V40, P336, DOI 10.1016/j.ajic.2011.04.004; Pan SC, 2014, AM J INFECT CONTROL, V42, P231, DOI 10.1016/j.ajic.2013.09.032; Pessoa-Silva CL, 2005, INFECT CONTROL HOSP, V26; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Rogers EM, 2010, DIFFUSION INNOVATION; Rogers EM, 1983, DIFFUSION INOOVATION; Rogers EM, 2003, DIFFUSION INNOVATION; Salmon S, 2015, AM J INFECT CONTROL, V43, P1086, DOI 10.1016/j.ajic.2015.05.039; Sax H, 2007, INFECT CONT HOSP EP, V28, P1267, DOI 10.1086/521663; Sharma M, 2021, THEORETICAL FDN HLTH; Smitz MF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165940; Srigley JA, 2015, J HOSP INFECT, V91, P202, DOI 10.1016/j.jhin.2015.06.019; Stevens S., 2013, Healthcare Infection, V18, P86, DOI 10.1071/HI12056; TRIANDIS HC, 1976, INT J PSYCHOL, V11, P155, DOI 10.1080/00207597608247355; Vincent C, 2014, BMJ QUAL SAF, V23, P670, DOI 10.1136/bmjqs-2013-002757; Viney Rosalie, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P319, DOI 10.1586/14737167.2.4.319; Whitby M, 2007, J HOSP INFECT, V65, P1, DOI 10.1016/j.jhin.2006.09.026; Wilson S, 2011, CRIT PUBLIC HEALTH, V21, P119, DOI 10.1080/09581591003786122; Wisdom JP, 2014, ADM POLICY MENT HLTH, V41, P480, DOI 10.1007/s10488-013-0486-4	43	11	13	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0202014	10.1371/journal.pone.0202014	http://dx.doi.org/10.1371/journal.pone.0202014			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP9JF	30092024	gold, Green Submitted, Green Published			2023-01-03	WOS:000441232600077
J	Vuong, TT; Ronning, SB; Ahmed, TAE; Brathagen, K; Host, V; Hincke, MT; Suso, HP; Pedersen, ME				Vuong, Tram T.; Ronning, Sissel B.; Ahmed, Tamer A. E.; Brathagen, Kristiane; Host, Vibeke; Hincke, Maxwell T.; Suso, Henri-Pierre; Pedersen, Mona E.			Processed eggshell membrane powder regulates cellular functions and increase MMP-activity important in early wound healing processes	PLOS ONE			English	Article							TISSUE-DERIVED INHIBITORS; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; DIFFERENTIAL EXPRESSION; FIBROBLAST MIGRATION; DERMAL FIBROBLASTS; CLEAVAGE SITES; IV COLLAGENASE; SYNDECAN-4; ADHESION	Avian eggshell membrane (ESM) is a natural biomaterial that has been used as an alternative natural bandage to cure wounds, and is available in large quantities from egg industries. We have previously demonstrated that processed eggshell membrane powder (PEP), aiming to be used in a low cost wound healing product, possesses anti-inflammatory properties. In this study, we further investigated effects of PEP on MMP activities in vitro (a dermal fibroblast cell culture system) and in vivo (a mouse skin wound healing model). Three days incubation with PEP in cell culture led to rearrangement of the actin-cytoskeleton and vinculin in focal adhesions and increased syndecan-4 shedding. In addition, we observed increased matrix metalloproteinase type 2 (MMP-2) enzyme activation, without effects on protein levels of MMP-2 or its regulators (membrane type 1 (MT1)-MMP and tissue inhibitor of matrix metalloproteinase type 2 (TIMP-2). Longer incubation (10 days) led to increased protein levels of MMP-2 and its regulators. We also observed an increased alpha-smooth muscle actin (alpha-SMA) production, suggesting an effect of PEP on myofibroblast differentiation. In vivo, using the mouse skin wound healing model, PEP treatment (3 days) increased MMP activity at the wound edges, along with increased MMP-2 and MMP-9 protein levels, and increased keratinocyte cell proliferation. Altogether, our data suggest PEP stimulates MMP activity, and with a positive effect on early cellular events during wound healing.	[Vuong, Tram T.; Ronning, Sissel B.; Brathagen, Kristiane; Host, Vibeke; Pedersen, Mona E.] Nofima AS, As, Norway; [Ahmed, Tamer A. E.; Hincke, Maxwell T.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Ahmed, Tamer A. E.] City Sci Res & Technol Applicat SRTA City, Genet Engn & Biotechnol Res Inst, Med Biotechnol Dept, Alexandria, Egypt; [Hincke, Maxwell T.] Univ Ottawa, Fac Med, Dept Innovat Med Educ, Ottawa, ON, Canada; [Suso, Henri-Pierre] Biovotec AS, Oslo, Norway	Nofima; University of Ottawa; Egyptian Knowledge Bank (EKB); City of Scientific Research & Technological Applications (SRTA-City); University of Ottawa	Pedersen, ME (corresponding author), Nofima AS, As, Norway.	mona.pedersen@nofima.no		Ronning, Sissel Beate/0000-0002-2255-0172; Pedersen, Mona Elisabeth/0000-0002-1081-3238; Ahmed, Tamer/0000-0002-6922-6193	Norwegian Research Council [NFR 235545]; Nofima; Biovotec AS	Norwegian Research Council(Research Council of NorwayEuropean Commission); Nofima(Nofima); Biovotec AS	This work was supported by grants from Norwegian Research Council (NFR 235545) (HPS). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors TTV, SBR, MEP are employed by Nofima AS, which is a public Research Institute in Norway. Nofima provided support in the form of salaries for these authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. HPS is employed by Biovotec AS. Biovotec AS contributed with salary for HPS and provided the PEP material used but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.	Acharya PS, 2008, J CELL SCI, V121, P1393, DOI 10.1242/jcs.021683; AGREN MS, 1994, BRIT J DERMATOL, V131, P634, DOI 10.1111/j.1365-2133.1994.tb04974.x; Ahmed TAE, 2017, J PROTEOMICS, V155, P49, DOI 10.1016/j.jprot.2017.01.002; AILENBERG M, 1991, BIOCHEM J, V279, P75, DOI 10.1042/bj2790075; Bahar MA, 2004, WOUND REPAIR REGEN, V12, P175, DOI 10.1111/j.1067-1927.2004.012110.x; Bass MD, 2007, J CELL BIOL, V177, P527, DOI 10.1083/jcb.200610076; Bellin RM, 2009, P NATL ACAD SCI USA, V106, P22102, DOI 10.1073/pnas.0902639106; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brooks Rebecca, 2012, Small GTPases, V3, P73, DOI 10.4161/sgtp.19301; Burley R., 1989, AVIAN EGG CHEM BIOL; Rodriguez-Manzaneque JC, 2009, INT J BIOCHEM CELL B, V41, P800, DOI 10.1016/j.biocel.2008.08.014; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chang WYC, 2010, AM J PHYSIOL-LUNG C, V299, pL393, DOI 10.1152/ajplung.00437.2009; Chen W, 2007, INT J BIOCHEM CELL B, V39, P997, DOI 10.1016/j.biocel.2007.01.023; Cook H, 2000, J INVEST DERMATOL, V115, P225, DOI 10.1046/j.1523-1747.2000.00044.x; Cordeiro CMM, 2016, J PROTEOMICS, V130, P11, DOI 10.1016/j.jprot.2015.08.014; Dugina V, 2001, J CELL SCI, V114, P3285; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Fusenig N E, 1994, J Dermatol Sci, V7 Suppl, pS142, DOI 10.1016/0923-1811(94)90045-0; Gabbott CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020388; Gautron J, 2001, CONNECT TISSUE RES, V42, P255, DOI 10.3109/03008200109016840; Gillard JA, 2004, WOUND REPAIR REGEN, V12, P295, DOI 10.1111/j.1067-1927.2004.012314.x; Greiling D, 1997, J CELL SCI, V110, P861; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Guarderas F, 2016, ADV SKIN WOUND CARE, V29, P131, DOI 10.1097/01.ASW.0000480359.58866.e9; Hadler-Olsen E, 2010, J HISTOCHEM CYTOCHEM, V58, P29, DOI 10.1369/jhc.2009.954354; Hattori N, 2009, AM J PATHOL, V175, P533, DOI 10.2353/ajpath.2009.081080; Hincke MT, 2012, FRONT BIOSCI-LANDMRK, V17, P1266, DOI 10.2741/3985; Hincke MT, 2000, MATRIX BIOL, V19, P443, DOI 10.1016/S0945-053X(00)00095-0; Hinz B, 2003, THROMB HAEMOSTASIS, V90, P993, DOI 10.1160/TH03-05-0328; Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02-11-0729; Hinz B, 2007, J INVEST DERMATOL, V127; Horzum U, 2014, METHODSX, V1, P56, DOI 10.1016/j.mex.2014.06.004; Humphries JD, 2007, J CELL BIOL, V179, P1043, DOI 10.1083/jcb.200703036; KOOP S, 1994, CANCER RES, V54, P4791; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Lin FB, 2005, J INVEST DERMATOL, V124, P906, DOI 10.1111/j.0022-202X.2005.23740.x; Lindner D, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/875742; Liu ZG, 2014, GLYCOCONJUGATE J, V31, P593, DOI 10.1007/s10719-014-9557-3; Makkar S, 2015, J AGR FOOD CHEM, V63, P9888, DOI 10.1021/acs.jafc.5b04266; Manon-Jensen T, 2013, FEBS J, V280, P2320, DOI 10.1111/febs.12174; Martins VL, 2013, CELL TISSUE RES, V351, P255, DOI 10.1007/s00441-012-1410-z; Mirastschijski U, 2010, WOUND REPAIR REGEN, V18, P223, DOI 10.1111/j.1524-475X.2010.00574.x; Moses MA, 1996, J CELL BIOCHEM, V60, P379, DOI 10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.0.CO;2-T; Mulholland B, 2005, EYE, V19, P584, DOI 10.1038/sj.eye.6701557; Nagase H, 1998, Cell Res, V8, P179; Oh ES, 2004, MOL CELLS, V17, P181; Ohto-Fujita E, 2011, CELL TISSUE RES, V345, P177, DOI 10.1007/s00441-011-1172-z; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Pereda MP, 2000, J CLIN ENDOCR METAB, V85, P263, DOI 10.1210/jc.85.1.263; Ravanti L, 2000, INT J MOL MED, V6, P391; Rietz A, 2012, BRIT J PHARMACOL, V166, P1225, DOI 10.1111/j.1476-5381.2012.01917.x; Rittie L, 2016, J CELL COMMUN SIGNAL, V10, P103, DOI 10.1007/s12079-016-0330-1; Sariahmetoglu M, 2007, FASEB J, V21, P2486, DOI 10.1096/fj.06-7938com; Sawicki G, 2005, MOL CELL BIOCHEM, V269, P209, DOI 10.1007/s11010-005-3178-x; Schmidt A, 2005, J BIOL CHEM, V280, P34441, DOI 10.1074/jbc.M501903200; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Soo C, 2000, PLAST RECONSTR SURG, V105, P638, DOI 10.1097/00006534-200002000-00024; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; Theocharis AD, 2015, ADV DRUG DELIVERY RE; Tomasek JJ, 2002, NATURE REV MOLL CELL, V3; Verma RP, 2007, BIOORGAN MED CHEM, V15, P2223, DOI 10.1016/j.bmc.2007.01.011; Vuong TT, 2017, J INFLAMM RES, V10, P83, DOI 10.2147/JIR.S130974; Wall SJ, 2002, J INVEST DERMATOL, V119, P91, DOI 10.1046/j.1523-1747.2002.01779.x; Wang XS, 2013, NAT PROTOC, V8, P302, DOI 10.1038/nprot.2013.002; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; Wise LM, 2012, CELL MICROBIOL, V14, P1376, DOI 10.1111/j.1462-5822.2012.01802.x; WONG M, 1984, DEV BIOL, V104, P28, DOI 10.1016/0012-1606(84)90033-2; Xie YQ, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.36; Yang L, 2017, J MOL HISTOLOGY; Zigrino P, 2016, J INVEST DERMATOL, V136, P1575, DOI 10.1016/j.jid.2016.03.036; Zigrino P, 2012, EUR J CELL BIOL, V91, P748, DOI 10.1016/j.ejcb.2012.05.003	74	21	23	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2018	13	8							e0201975	10.1371/journal.pone.0201975	http://dx.doi.org/10.1371/journal.pone.0201975			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3UO	30080894	Green Submitted, Green Published, gold			2023-01-03	WOS:000440780000031
J	Fisher, CB; Fried, AL; Puri, LI; Macapagal, K; Mustanski, B				Fisher, Celia B.; Fried, Adam L.; Puri, Leah Ibrahim; Macapagal, Kathryn; Mustanski, Brian			"Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men	PLOS ONE			English	Article							PREVENTIVE MISCONCEPTION; HEALTH-CARE; PREEXPOSURE PROPHYLAXIS; HIV; BARRIERS; GAY; TRANSGENDER; EXPERIENCES; DISPARITIES; CONSENT	Background Adolescent men who have sex with men (AMSM) account for disproportionately high numbers of new HIV diagnoses. Non-adherence to daily use limiting the effectiveness of oral PrEP (Truvada) has led to current trials with adult MSM testing Cabotegravir, a long-term injectable medication. Once comparative studies with young adult MSM have established relative safety and efficacy of these medications, there will be a need for such comparative trials involving adolescents. Trends in state laws and IRB protocol review indicate that many of these studies will permit youth to provide independent consent for participation. Understanding the motivations of AMSM to participate in HIV biomedical prevention studies is important to ensure their agreement is voluntary without misunderstanding and undue influence. This study examined AMSM attitudes toward participation in oral/injectable PrEP RCTs to inform protections of youth's rights and welfare in future studies. Methods We administered to 198 ethnically diverse U.S. AMSM, 14-17 years, a web-based survey including demographic and sexual health questions, description of a year-long oral versus injectable PrEP RCT and 26 Likert-type and one open-ended item assessing motivations for and against participation including: perceived benefits and risks of PrEP; free HIV/STI testing and counseling; confidentiality concerns; random assignment; and benefit to others. Results Sixty-two percent indicated they were likely to participate in the study. The majority endorsed daily HIV protection, free HIV/STI testing, sexual health counseling, not having to rely on partner's condom use, and altruism as reasons to participate. Reasons against participation included medication side effects, concern taking the pill daily and clinic visits would reveal their sexual orientation and behaviors to parents. Over half erroneously assumed they would be assigned to the condition best for them and 39% indicated free access to services would lead them to participate even if they did not want to. Multiple regression indicated these factors accounted for 55% of the variance in participation choice. Nether age or ethnicity yielded significance. Conclusions Results suggest future biomedical HIV prevention research will need to develop procedures to address AMSM's confidentiality concerns, enhance youth's understanding of random assignment, the continued importance of medication adherence and partner condom use during trial participation, and availability of alternative sexual health services to avoid the potentially undue influence of access to free sexual health services.	[Fisher, Celia B.; Puri, Leah Ibrahim] Fordham Univ, Ctr Eth Educ, New York, NY 10023 USA; [Fried, Adam L.] Midwestern Univ, Clin Psychol Dept, Glendale, AZ USA; [Macapagal, Kathryn; Mustanski, Brian] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Fordham University; Midwestern University; Northwestern University; Feinberg School of Medicine	Fisher, CB (corresponding author), Fordham Univ, Ctr Eth Educ, New York, NY 10023 USA.	fisher@fordham.edu		Fisher, Celia/0000-0002-3849-7281	NIMHD [R01MD009561]; National Institute on Minority Health and Health Disparities [R01MD009561] Funding Source: NIH RePORTER	NIMHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	The research was funded by NIMHD #R01MD009561 to Celia B. Fisher and Brian Mustanski. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Administration USFaD, 2012, FDA APPR 1 DRUG RED; Bauermeister JA, 2012, FIELD METHOD, V24, P272, DOI 10.1177/1525822X12443097; CDC, 2019, HIV GAY BIS MEN; Chin LJ, 2016, J EMPIRICAL RES HUMA, V11; Cohen S., 2015, J INT AIDS SOC S3, V18; Coker TR, 2010, ANNU REV PUBL HEALTH, V31, P457, DOI 10.1146/annurev.publhealth.012809.103636; Corneli A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125458; D'Amico E, 2012, J GLBT FAM STUD, V8, P215, DOI 10.1080/1550428X.2012.677232; Dellar RC, 2014, AIDS BEHAV, V18, P1746, DOI 10.1007/s10461-014-0771-6; DiClemente RJ, 2010, JAIDS-J ACQ IMM DEF, V54, pS12, DOI 10.1097/QAI.0b013e3181e1e2c0; Emanuel E, 2004, JAMA-J AM MED ASSOC, V283, P2701; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2005, AM J BIOETHICS, V5, P9, DOI 10.1080/15265160500244959; Fisher CB, 2017, AIDS EDUC PREV, V29, P205, DOI 10.1521/aeap.2017.29.3.205; Fisher CB, 2016, J EMPIR RES HUM RES, V11, P3, DOI 10.1177/1556264616633963; Fisher CB, 2014, HASTINGS CENT REP, V44, pS28, DOI 10.1002/hast.367; Gilbert AL, 2015, J ADOLESCENT HEALTH, V57, P113, DOI 10.1016/j.jadohealth.2015.03.017; Gilead Sciences, 2018, US FOOD DRUG ADM APP; Grady Christine, 2016, AJOB Empir Bioeth, V7, P1; Grant RW, 2004, J MED PHILOS, V29, P717, DOI 10.1080/03605310490883046; Health NIo, 2015, NIH SUPP CLIN TRAILS; Heerman William J, 2016, IRB, V38, P8; Henderson GP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000749; Herrick AL, 2011, J ADOLESCENT HEALTH, V48, P306, DOI 10.1016/j.jadohealth.2010.07.008; Hill B. J., 2012, J HEALTH CARE L PORV, V15, P37; HIV Prevention Trials Network, 2017, LONG ACT INJ CAB PRE; Hoffman LF, 2016, J ADOLESCENT HEALTH, V58, P576, DOI 10.1016/j.jadohealth.2016.01.007; Hosek SG, 2017, JAMA PEDIATR, V171, P1063, DOI 10.1001/jamapediatrics.2017.2007; Hurst SA, 2008, BIOETHICS, V22, P191, DOI 10.1111/j.1467-8519.2008.00631.x; Institute of Medicine Committee on Lesbian, 2011, BIS TRANSG HLTH ISS; Jackson CL, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3467-1; Kann L, 2016, MORBIDITY MORTALITY, V65, P1, DOI DOI 10.15585/MMWR.SS6509A1; Kim Scott Y H, 2013, IRB, V35, P1; King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x; Kokolo MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022497; Konstan JA, 2005, J COMPUT-MEDIAT COMM, V10; Levy ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183521; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; Macapagal K, 2016, LGBT HEALTH, V3, P434, DOI 10.1089/lgbt.2015.0124; Macapagal K, 2016, ARCH SEX BEHAV, V45, P1513, DOI 10.1007/s10508-016-0698-2; Machado DM, 2017, ADOLESC HEALTH MED T, V8, P137, DOI 10.2147/AHMT.S112757; Meyers K, 2018, AIDS BEHAV, V22, P1209, DOI 10.1007/s10461-017-1871-x; Milhausen RR, 2013, CAN J HUM SEX, V22, P142, DOI DOI 10.3138/CJHS.2316; Miller Victoria A, 2016, IRB, V38, P1; Montgomery MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157742; Mustanski B, 2017, PERSPECT SEX REPRO H, V49, P111, DOI 10.1363/psrh.12027; Mustanski B, 2016, AM J PREV MED, V51, P249, DOI 10.1016/j.amepre.2016.02.026; Mustanski BS, 2011, J SEX RES, V48, P218, DOI 10.1080/00224499.2011.558645; Napper LE, 2012, AIDS BEHAV, V16, P1075, DOI 10.1007/s10461-011-0003-2; NYS, 2016, GOV CUOM ANN PROP IN; Ott MA, 2013, J MED ETHICS, V39, P765, DOI 10.1136/medethics-2012-100821; Pace C, 2003, CRIT CARE MED, V31, pS121, DOI 10.1097/01.CCM.0000054907.33928.48; Pettifor A, 2015, J INT AIDS SOC, V18, P8, DOI 10.7448/IAS.18.2.19434; Philbin MM, 2014, AIDS BEHAV, V18, P1501, DOI 10.1007/s10461-013-0650-6; Phillips G, 2015, J ADOLESCENT HEALTH, V57, P407, DOI 10.1016/j.jadohealth.2015.06.014; Services DoHH, 2017, FED REGISTER, V83, P7149; Simon AE, 2007, AM J PREV MED, V32, P370, DOI 10.1016/j.amepre.2007.01.007; Smalley KB, 2016, HEALTH PSYCHOL, V35, P103, DOI 10.1037/hea0000231; Strutz KL, 2015, AM J PREV MED, V48, P76, DOI 10.1016/j.amepre.2014.07.038; Uusitalo S, 2017, AM J BIOETHICS, V17, P44, DOI 10.1080/15265161.2017.1388882; Vasgird D R, 2000, J Public Health Manag Pract, V6, P37; Wertheimer A, 2008, J MED ETHICS, V34, P389, DOI 10.1136/jme.2007.021857; Woodsong C, 2012, AIDS BEHAV, V16, P785, DOI 10.1007/s10461-011-0027-7	63	18	18	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2018	13	7							e0200560	10.1371/journal.pone.0200560	http://dx.doi.org/10.1371/journal.pone.0200560			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO4AN	30044845	gold, Green Published, Green Submitted			2023-01-03	WOS:000439942500060
J	Zhang, RM; Xi, XY; Wang, CY; Pan, Y; Ge, CH; Zhang, LY; Zhang, S; Liu, HM				Zhang, Ruimei; Xi, Xiangyu; Wang, Chunying; Pan, Yong; Ge, Changhua; Zhang, Liying; Zhang, Shuo; Liu, Huimei			Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis	PLOS ONE			English	Review							MULTIDRUG-RESISTANT TUBERCULOSIS; SPUTUM CULTURE CONVERSION; MYCOBACTERIUM-AVIUM COMPLEX; TUMOR-NECROSIS-FACTOR; CD8 T-CELLS; PULMONARY TUBERCULOSIS; IFN-GAMMA; MEDIATED PROTECTION; INFECTION; MICE	Background Interleukin 2 (IL-2) is a cytokine secreted by activated T cells. Studies exploring recombinant human interleukin 2 (rhuIL-2) as an adjunctive immunotherapeutic agent to treat tuberculosis (TB) have shown variable results; however, the true therapeutic efficacy of rhuIL-2 administration in TB patients has not been determined. Methods A systematic review to identify publications exploring the association between rhuIL-2-based immunotherapy for TB and outcomes (sputum culture conversion, sputum smear conversion, radiographic changes, and leukocyte phenotype changes) in patients with pulmonary TB published before June 8, 2018 was performed. Data were extracted and analyzed by two investigators independently. Results A total of 2,272 records were screened. Four randomized controlled trials (RCTs) comprising 656 pulmonary TB patients were finally included. The rhuIL-2 treatment could significantly improve the sputum culture conversion of TB (RR, 1.18; 95% CI: 1.03-1.36; I-2 < 0.01; P = 0.019) after at least 3 months of anti-TB therapy and the sputum smear conversion of TB during anti-TB therapy. Treating multidrug-resistant tuberculosis (MDR-TB) with rhuIL-2 could improve the sputum culture conversion (RR, 1.28; 95% CI: 1.05-1.57; I-2 < 0.01; P = 0.016) and smear conversion (RR, 1.28; 95% CI: 1.09-1.51; I-2 < 0.01; P = 0.003) at the end of anti-TB treatment. Meanwhile, rhuIL-2-based adjunctive immunotherapy could expand the proliferation and conversion of CD4(+) and natural killer (NK) cells. Three of the included studies suggested that radiographic changes could not be improved by the use of rhuIL-2 as adjunctive immunotherapy. Publication bias did not exist. Conclusions Based on this first meta-analysis, rhuIL-2-based adjunctive immunotherapy appears to expand the proliferation and conversion of CD4(+) and NK cells, as well as improve the sputum culture (at 3 months and later) and smear conversion of TB patients.	[Zhang, Ruimei; Xi, Xiangyu; Wang, Chunying; Pan, Yong; Ge, Changhua; Zhang, Liying; Zhang, Shuo; Liu, Huimei] Xuzhou Infect Dis Hosp, Dept TB, Xuzhou, Jiangsu, Peoples R China		Liu, HM (corresponding author), Xuzhou Infect Dis Hosp, Dept TB, Xuzhou, Jiangsu, Peoples R China.	doctorliu1979@163.com						AKUFFO H, 1990, J INFECT DIS, V161, P775, DOI 10.1093/infdis/161.4.775; BERMUDEZ LEM, 1989, J IMMUNOL, V143, P2996; BERMUDEZ LEM, 1988, J IMMUNOL, V140, P3006; Billeskov R, 2007, J IMMUNOL, V179, P3973, DOI 10.4049/jimmunol.179.6.3973; Caccamo N, 2010, EUR J IMMUNOL, V40, P2211, DOI 10.1002/eji.201040455; Chen CY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000392; Chu Nai-hui, 2003, Zhonghua Jiehe He Huxi Zazhi, V26, P548; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Dheda K, 2010, RESPIROLOGY, V15, P433, DOI 10.1111/j.1440-1843.2010.01739.x; Dobbs TE, 2017, MICROBIOL SPECTR, V5; Dominguez-Castellano A, 2003, INT J TUBERC LUNG D, V7, P432; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Feng CG, 2006, J IMMUNOL, V177, P7086, DOI 10.4049/jimmunol.177.10.7086; Gaffen SL, 2004, CYTOKINE, V28, P109, DOI 10.1016/j.cyto.2004.06.010; Granucci F, 2004, J EXP MED, V200, P287, DOI 10.1084/jem.20040370; Green AM, 2013, J IMMUNOL, V190, P270, DOI 10.4049/jimmunol.1200061; Guler M, 2007, INT J CLIN PRACT, V61, P231, DOI 10.1111/j.1742-1241.2006.01131.x; Higgins J.P.T, 2011, BMJ, V343; Hoffner S., 2016, INT J MYCOBACTERIOL, V5, P59; Bini EI, 2014, CURR RESPIR MED REV, V10, P74, DOI 10.2174/1573398X10666140807232241; JEEVAN A, 1988, INFECT IMMUN, V56, P660, DOI 10.1128/IAI.56.3.660-664.1988; Johnson BJ, 1997, TUBERCLE LUNG DIS, V78, P195, DOI 10.1016/S0962-8479(97)90026-5; JOHNSON BJ, 1995, CYTOKINES MOL THER, V1, P185; Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Junqueira-Kipnis AP, 2003, J IMMUNOL, V171, P6039, DOI 10.4049/jimmunol.171.11.6039; KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993; KELSO A, 1984, J IMMUNOL, V132, P2932; KIM TC, 1984, AM REV RESPIR DIS, V129, P264; Kurbatova EV, 2012, INT J TUBERC LUNG D, V16, P1335, DOI 10.5588/ijtld.11.0811; Kurbatova EV, 2015, LANCET RESP MED, V3, P201, DOI 10.1016/S2213-2600(15)00036-3; Lee S. K., 1995, Annals Academy of Medicine Singapore, V24, P442; LEVETON C, 1989, INFECT IMMUN, V57, P390, DOI 10.1128/IAI.57.2.390-395.1989; Lin CH, 2003, EUR J IMMUNOL, V33, P626, DOI 10.1002/eji.200323570; Liu ZY, 1999, ARCH INTERN MED, V159, P1110, DOI 10.1001/archinte.159.10.1110; Mattila JT, 2011, J IMMUNOL, V186, P3527, DOI 10.4049/jimmunol.1003773; Mdluli K, 2015, COLD SPRING HARB PER, V5; Neelam R, 2012, INT RES J PHARM, V3, P46; Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744; Prezzemolo T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00180; Rao Nisar Ahmed, 2007, J Pak Med Assoc, V57, P252; Ryu YJ, 2015, TUBERC RESPIR DIS, V78, P64, DOI 10.4046/trd.2015.78.2.64; Shen H, 2015, ARCH MED SCI, V11, P584, DOI 10.5114/aoms.2015.52362; Tan Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18200-5; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; Urdahl KB, 2003, J IMMUNOL, V170, P1987, DOI 10.4049/jimmunol.170.4.1987; van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.3.CO;2-W; Vashishtha VM, 2009, INDIAN PEDIATR, V46, P401; Villemagne B, 2012, EUR J MED CHEM, V51, P1, DOI 10.1016/j.ejmech.2012.02.033; Yew WW, 2008, RESPIROLOGY, V13, P21, DOI 10.1111/j.1440-1843.2007.01180.x; YONEDA T, 1983, BRIT J DIS CHEST, V77, P185, DOI 10.1016/0007-0971(83)90026-8; Zumla A, 2015, LANCET GLOB HEALTH, V3, pE10, DOI 10.1016/S2214-109X(14)70361-4	52	15	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2018	13	7							e0201025	10.1371/journal.pone.0201025	http://dx.doi.org/10.1371/journal.pone.0201025			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN5RC	30024982	Green Submitted, Green Published, gold			2023-01-03	WOS:000439120000079
J	Raba, DN; Chambre, DR; Copolovici, DM; Moldovan, C; Copolovici, LO				Raba, Diana Nicoleta; Chambre, Dorina Rodica; Copolovici, Dana-Maria; Moldovan, Camelia; Copolovici, Lucian Octav			The influence of high-temperature heating on composition and thermo-oxidative stability of the oil extracted from Arabica coffee beans	PLOS ONE			English	Article							FATTY-ACID-COMPOSITION; GREEN COFFEE; LIPID FRACTION; ROASTED COFFEE; VEGETABLE-OILS; THERMAL-DECOMPOSITION; COSMETIC FORMULATIONS; ANTIOXIDANT ACTIVITY; OXIDATIVE STABILITY; SUNFLOWER OIL	The aim of the present study was to establish the influence of high-temperature heating on the composition and thermal behavior of coffee oils obtained from Arabica green and roasted coffee beans, respectively. Morphological studies performed using scanning electron microscopy revealed the oil bodies uniformly distributed within the cells in both types of coffee beans analyzed. The obtained oils have a fatty acid composition rich in linoleic acid, palmitic acid, oleic acid, stearic acid, arachidic acid and linolenic acid. The total content of saturated fatty acids of investigated oils was 49.38 and 46.55%, the others being unsaturated fatty acids. The thermal behavior and thermo-oxidative stability of coffee oils extracted from green coffee beans and roasted coffee beans, the coffee oil high-temperature heated up to 200 degrees C, were investigated using simultaneous thermal analysis TG/DTG/DTA, in an oxidizing atmosphere. The data obtained for the analyzed samples depend mainly on the nature and compositions of fatty acids, and to a lesser extent on the roasting process of the coffee beans and the high-temperature heating process of the extracted oil. The chromatographic and TG/DTG/DTA data suggest that Arabica coffee oil has great potential for use in technological processes which require high-temperature heating (e.g. food industry or pastries).	[Raba, Diana Nicoleta] Banats Univ Agr Sci & Vet Med King Michael I Roma, Dept Food Technol, Timisoara, Romania; [Chambre, Dorina Rodica; Copolovici, Dana-Maria; Copolovici, Lucian Octav] Aurel Vlaicu Univ Arad, Dept Tech & Nat Sci, Arad, Romania; [Chambre, Dorina Rodica; Copolovici, Dana-Maria; Copolovici, Lucian Octav] Aurel Vlaicu Univ Arad, Inst Res Dev Innovat Tech & Nat Sci, Arad, Romania; [Moldovan, Camelia] Banats Univ Agr Sci & Vet Med King Michael I Roma, Dept Food Control, Timisoara, Romania	Banat University of Agricultural Sciences & Veterinary Medicine; Aurel Vlaicu University of Arad; Aurel Vlaicu University of Arad; Banat University of Agricultural Sciences & Veterinary Medicine	Chambre, DR; Copolovici, DM (corresponding author), Aurel Vlaicu Univ Arad, Dept Tech & Nat Sci, Arad, Romania.; Chambre, DR; Copolovici, DM (corresponding author), Aurel Vlaicu Univ Arad, Inst Res Dev Innovat Tech & Nat Sci, Arad, Romania.	dorina.chambre@uav.ro; dana.copolovici@uav.ro	Moldovan, Camelia/ADV-8991-2022; Copolovici, Dana Maria/C-5207-2012; Copolovici, Lucian/B-6552-2011	Moldovan, Camelia/0000-0003-0051-8582; Copolovici, Dana Maria/0000-0002-1491-0473; Copolovici, Lucian/0000-0002-4454-200X	European Commission; Romanian Government [POSCCE 621/2014]	European Commission(European CommissionEuropean Commission Joint Research Centre); Romanian Government(Romanian Government)	This work was supported by The European Commission and The Romanian Government (project POSCCE 621/2014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AlKanhal MA, 1997, INT J FOOD SCI NUTR, V48, P135, DOI 10.3109/09637489709006973; Alvarez AMR, 2000, GRASAS ACEITES, V51, P74; Alves MR, 2003, J AM OIL CHEM SOC, V80, P511, DOI 10.1007/s11746-003-0730-0; Amarowicz R, 2009, EUR J LIPID SCI TECH, V111, P109, DOI 10.1002/ejlt.200900011; Anese M, 2000, ITAL J FOOD SCI, V12, P457; Arora S, 2010, J THERM ANAL CALORIM, V102, P375, DOI 10.1007/s10973-009-0460-2; Bohn SK, 2014, MOL NUTR FOOD RES, V58, P915, DOI 10.1002/mnfr.201300526; Budryn G, 2013, J FOOD PROCESS PRES, V37, P835, DOI 10.1111/j.1745-4549.2012.00710.x; Budryn G, 2013, EUR FOOD RES TECHNOL, V236, P969, DOI 10.1007/s00217-013-1956-3; Budryn G, 2012, EUR J LIPID SCI TECH, V114, P1052, DOI 10.1002/ejlt.201100324; Budryn G, 2011, GRASAS ACEITES, V62, P155, DOI 10.3989/gya.067210; Calligaris S, 2009, EUR J LIPID SCI TECH, V111, P1270, DOI 10.1002/ejlt.200900042; Campos-Vega R, 2015, TRENDS FOOD SCI TECH, V45, P24, DOI 10.1016/j.tifs.2015.04.012; Carvalho AGS, 2014, FOOD RES INT, V61, P236, DOI 10.1016/j.foodres.2013.08.012; Copolovici D, 2017, REV CHIM-BUCHAREST, V68, P507; Couto RM, 2009, J SUPERCRIT FLUID, V51, P159, DOI 10.1016/j.supflu.2009.09.009; de Souza AG, 2004, BRAZ J CHEM ENG, V21, P265, DOI 10.1590/S0104-66322004000200017; Dennis EA, 2009, EAT BEHAV, V10, P237, DOI 10.1016/j.eatbeh.2009.07.006; Dong WJ, 2015, MOLECULES, V20, P16687, DOI 10.3390/molecules200916687; Dweck J, 2004, J THERM ANAL CALORIM, V75, P385, DOI 10.1023/B:JTAN.0000027124.96546.0f; Ferrari M, 2010, COLLOID SURFACE A, V365, P79, DOI 10.1016/j.colsurfa.2010.02.002; Garcia CC, 2007, J THERM ANAL CALORIM, V87, P645, DOI 10.1007/s10973-006-7769-x; Gennaro L, 1998, J AGR FOOD CHEM, V46, P4465, DOI 10.1021/jf980562q; Getachew AT, 2016, LWT-FOOD SCI TECHNOL, V70, P126, DOI 10.1016/j.lwt.2016.02.025; Hurtado-Benavides A, 2016, J SUPERCRIT FLUID, V113, P44, DOI 10.1016/j.supflu.2016.03.008; Kim JH, 2016, ANTIOXIDANTS-BASEL, V5, DOI 10.3390/antiox5030021; Kim MK, 2014, J I BREWING, V120, P537, DOI 10.1002/jib.180; Kobelnilk M, 2014, J THERM ANAL CALORIM, V115, P2045, DOI 10.1007/s10973-013-3150-z; Lercker G, 1996, IND ALIMENT-ITALY, V35, P1186; Wagemaker TAL, 2011, IND CROP PROD, V33, P469, DOI 10.1016/j.indcrop.2010.10.026; Marto J, 2016, J PHOTOCH PHOTOBIO B, V162, P56, DOI 10.1016/j.jphotobiol.2016.06.026; Marto J, 2016, DRUG DELIV, V23, P1594, DOI 10.3109/10717544.2015.1128496; Moustafa H, 2017, ACS SUSTAIN CHEM ENG, V5, P1906, DOI 10.1021/acssuschemeng.6b02633; Naidu MM, 2008, FOOD CHEM, V107, P377, DOI 10.1016/j.foodchem.2007.08.056; Phimsen S, 2016, ENERG CONVERS MANAGE, V126, P1028, DOI 10.1016/j.enconman.2016.08.085; Raba DN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138080; Santos JCO, 2004, J THERM ANAL CALORIM, V75, P419, DOI 10.1023/B:JTAN.0000027128.62480.db; Santos JCO, 2002, J FOOD SCI, V67, P1393, DOI 10.1111/j.1365-2621.2002.tb10296.x; Santos JCO, 2007, J FOOD TECHNOL, V5, P79; Speer Karl, 2006, Braz. J. Plant Physiol., V18, P201, DOI 10.1590/S1677-04202006000100014; Sulieman AERM, 2006, J FOOD LIPIDS, V13, P259, DOI 10.1111/j.1745-4522.2006.00050.x; Tsukui A, 2014, FOOD CHEM, V164, P266, DOI 10.1016/j.foodchem.2014.05.039; Vecchio S, 2008, J THERM ANAL CALORIM, V91, P51, DOI 10.1007/s10973-007-8373-4; Vila MA, 2005, J AM OIL CHEM SOC, V82, P639, DOI 10.1007/s11746-005-1122-1; Wagemaker TAL, 2015, INT J COSMETIC SCI, V37, P506, DOI 10.1111/ics.12225; Wagemaker TAL, 2016, DRUG DEV IND PHARM, V42, P1695, DOI 10.3109/03639045.2016.1165692; Wagemaker TAL, 2015, IND CROP PROD, V63, P34, DOI 10.1016/j.indcrop.2014.09.045; Wagemaker TAL, 2013, TOXICOL LETT, V221, pS231, DOI 10.1016/j.toxlet.2013.05.561; Zhang ZS, 2013, ASIAN J CHEM, V25, P10082, DOI 10.14233/ajchem.2013.15159; Zyzelewicz D, 2014, FOOD RES INT, V63, P328, DOI 10.1016/j.foodres.2014.04.053	52	16	16	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2018	13	7							e0200314	10.1371/journal.pone.0200314	http://dx.doi.org/10.1371/journal.pone.0200314			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM7QQ	29995918	gold, Green Submitted, Green Published			2023-01-03	WOS:000438388800052
J	Rubio, MC; Soriano, JB; Lopez-Campos, JL; Soler-Cataluna, JJ; Navarrete, BA; Gonzalez-Moro, JMR; Miravitiles, M; Barrecheguren, M; Ferrer, MEF; Hermosa, JLR				Calle Rubio, Myriam; Soriano, Joan B.; Luis Lopez-Campos, Jose; Soler-Cataluna, Juan J.; Alcazar Navarrete, Bernardino; Rodriguez Gonzalez-Moro, Jose Miguel; Miravitiles, Marc; Barrecheguren, Miriam; Fuentes Ferrer, Manuel E.; Rodriguez Hermosa, Juan Luis		EPOCONSUL Study	Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study	PLOS ONE			English	Article							ALPHA(1)-ANTITRYPSIN DEFICIENCY; ANTITRYPSIN DEFICIENCY; DIAGNOSIS; PREVALENCE; GUIDELINES; MANAGEMENT; KNOWLEDGE; PROGRAM; NUMBERS	Background Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults, but is under-recognized. In Spain, the number of patients diagnosed with AATD is much lower than expected according to epidemiologic studies. The objectives of this study were to assess the frequency and determinants of testing serum alpha 1-antitrypsin (AAT) levels in COPD patients, and to describe factors associated with testing. Methods EPOCONSUL is a cross-sectional clinical audit, recruiting consecutive COPD cases over one year. The study evaluated serum AAT level determination in COPD patients and associations between individual, disease-related, and hospital characteristics. Results A total of 4,405 clinical records for COPD patients from 57 Spanish hospitals were evaluated. Only 995 (22.5%) patients had serum AAT tested on some occasion. A number of patient characteristics (being male [OR 0.5, p < 0.001], <= 55 years old [OR 2.38, p<0.001], BMI <= 21 kg/m(2) [OR 1.71, p<0.001], FEV1(%)< 50% [OR 1.35, p<0.001], chronic bronchitis [OR 0.79, p < 0.001], Charlson index >= 3 [OR 0.66, p < 0.001], or history or symptoms of asthma [OR 1.32, p<0.001]), and management at a specialized COPD outpatient clinic [OR 2.73, p<0.001] were identified as factors independently associated with ever testing COPD patients for AATD. Overall, 114 COPD patients (11.5% of those tested) had AATD. Of them, 26 (22.8%) patients had severe deficiency. Patients with AATD were younger, with a low pack-year index, and were more likely to have emphysema (p<0.05). Conclusion Testing of AAT blood levels in COPD patients treated at outpatient respiratory clinics in Spain is infrequent. However, when tested, AATD (based on the serum AAT levels <= 100 mg/dL) is detected in one in five COPD patients. Efforts to optimize AATD case detection in COPD are needed.	[Calle Rubio, Myriam; Rodriguez Hermosa, Juan Luis] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Pulm Dept, Madrid, Spain; [Calle Rubio, Myriam; Fuentes Ferrer, Manuel E.; Rodriguez Hermosa, Juan Luis] Univ Complutense Madrid, Fac Med, Dept Med, Madrid, Spain; [Soriano, Joan B.] Univ Autonoma Madrid, Consultant Methodol & Res SEPAR, Inst Invest Hosp Univ Princesa IISP, Madrid, Spain; [Luis Lopez-Campos, Jose] Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla IBiS, Unidad Med Quirurg Enfermedades Resp, Seville, Spain; [Luis Lopez-Campos, Jose; Alcazar Navarrete, Bernardino] Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Soler-Cataluna, Juan J.] H Arnau de Vilanova, Pulm Dept, Valencia, Spain; [Alcazar Navarrete, Bernardino] Hosp Alta Resoluc Loja, Pulm Dept, Granada, Spain; [Rodriguez Gonzalez-Moro, Jose Miguel] H Univ Principe Asturias, Pulm Dept, Madrid, Spain; [Miravitiles, Marc; Barrecheguren, Miriam] Hosp Univ Vall Hebron, Pulm Dept, Barcelona, Spain; [Miravitiles, Marc] CIBER Enfermedades Resp CIBERES, Barcelona, Spain; [Fuentes Ferrer, Manuel E.] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, UGC Med Prevent, Madrid, Spain	Hospital Clinico San Carlos; Complutense University of Madrid; Autonomous University of Madrid; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Hospital Universitari Vall d'Hebron; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Clinico San Carlos	Rubio, MC (corresponding author), Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Pulm Dept, Madrid, Spain.; Rubio, MC (corresponding author), Univ Complutense Madrid, Fac Med, Dept Med, Madrid, Spain.	mcallerubio@gmail.com	Andújar-Espinosa, Rubén/ABD-6716-2020; Ferrer, Manuel Enrique Fuentes Ferrer ME Fuentes/L-1086-2017; Rodriguez Hermosa, Juan Luis/H-2377-2017; Alcázar-Navarrete, Bernardino/X-8947-2018; Miravitlles, Marc/AAH-5284-2019; Calle Rubio, Myriam/B-9780-2017; Soriano, Joan B/O-1215-2017; Lopez-Campos Bodineau, Jose Luis/Q-1637-2018	Andújar-Espinosa, Rubén/0000-0002-6714-9438; Ferrer, Manuel Enrique Fuentes Ferrer ME Fuentes/0000-0002-5177-1441; Rodriguez Hermosa, Juan Luis/0000-0003-0552-2484; Alcázar-Navarrete, Bernardino/0000-0003-2356-9366; Miravitlles, Marc/0000-0002-9850-9520; Calle Rubio, Myriam/0000-0002-3890-2742; Puente-Maestu, Luis/0000-0001-8501-0117; Soriano, Joan B/0000-0001-9740-2994; Lopez-Campos Bodineau, Jose Luis/0000-0003-1703-1367; Soler-Cataluna, Juan Jose/0000-0003-1134-0783; Barrecheguren, Miriam/0000-0002-6041-1499; Aburto, Myriam/0000-0001-8644-1015; Rodriguez Gonzalez-Moro, Jose Miguel/0000-0002-8446-3373	SEPAR; Boehringer Ingelheim	SEPAR; Boehringer Ingelheim(Boehringer Ingelheim)	This study has been promoted and sponsored by the SEPAR. We thank Boehringer Ingelheim for its financial support to carry out the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amer Thoracic Soc European Respir, 2003, AM J RESP CRIT CARE, V168, P818, DOI 10.1164/rccm.168.7.818; [Anonymous], 1997, B WORLD HEALTH ORGAN, V75, P397; Barrecheguren M, 2016, INT J CHRONIC OBSTR, V11, P999, DOI 10.2147/COPD.S108505; Blanco I, 2006, EUR RESPIR J, V27, P77, DOI 10.1183/09031936.06.00062305; Blanco I, 2017, INT J CHRONIC OBSTR, V12, P1683, DOI 10.2147/COPD.S137852; Blanco I, 2017, INT J CHRONIC OBSTR, V12, DOI 10.2147/COPD.S125389; Rubio MC, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0685-8; Rubio MC, 2017, INT J CHRONIC OBSTR, V12, P417, DOI 10.2147/COPD.S124482; de la Roza C, 2005, EUR RESPIR J, V26, P616, DOI 10.1183/09031936.05.00007305; Esquinas C, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0222-4; Greulich T, 2013, RESP MED, V107, P1400, DOI 10.1016/j.rmed.2013.04.023; Ingebrigtsen TS, 2015, THORAX, V70, P1014, DOI 10.1136/thoraxjnl-2015-207561; Lara B, 2017, ARCH BRONCONEUMOL, V53, P13, DOI 10.1016/j.arbres.2016.05.003; Lara B, 2011, ARCH BRONCONEUMOL, V47, P389, DOI 10.1016/j.arbres.2011.04.002; Luisetti M, 1999, RESP MED, V93, P169, DOI 10.1016/S0954-6111(99)90003-3; Miravitlles M, 2004, MED CLIN-BARCELONA, V123, P778, DOI 10.1157/13069812; Miravitlles M, 2010, EUR RESPIR J, V35, P960, DOI 10.1183/09031936.00069709; Miravitlles M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00610-2017; Miravitlles M, 2017, ARCH BRONCONEUMOL, V53, P324, DOI 10.1016/j.arbres.2017.03.018; Molina Jesus, 2011, Ther Adv Respir Dis, V5, P237, DOI 10.1177/1753465811404919; Stoller JK, 2013, COPD, V10, P26, DOI 10.3109/15412555.2013.763782; Stoller JK, 1997, CHEST, V111, pS123, DOI 10.1378/chest.111.6_Supplement.123S; Taliercio RM, 2010, RESP CARE, V55, P322; Vidal R, 2006, ARCH BRONCONEUMOL, V42, P645, DOI 10.1016/S1579-2129(07)60007-X	24	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0198777	10.1371/journal.pone.0198777	http://dx.doi.org/10.1371/journal.pone.0198777			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0GK	29953442	Green Published, gold, Green Submitted			2023-01-03	WOS:000436645400008
J	Sanguigno, L; Casamassa, A; Funel, N; Minale, M; Riccio, R; Riccio, S; Boscia, F; Brancaccio, P; Pollina, LE; Anzilotti, S; Di Renzo, G; Cuomo, O				Sanguigno, Luca; Casamassa, Antonella; Funel, Niccola; Minale, Massimiliano; Riccio, Rodolfo; Riccio, Salvatore; Boscia, Francesca; Brancaccio, Paola; Pollina, Luca Emanuele; Anzilotti, Serenella; Di Renzo, Gianfranco; Cuomo, Ornella			Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells	PLOS ONE			English	Article							DENDRITIC CELLS; TISSUE-REPAIR; WOUND REPAIR; IN-VITRO; MACROPHAGES; FIBROSIS; RESPONSES; EFFICACY; PROTEIN; IBA1	Triticum vulgare has been extensively used in traditional medicine thanks to its properties of accelerating tissue repair. The specific extract of Triticum vulgare manufactured by Farma-ceutici Damor (TVE-DAMOR) is already present in some pharmaceutical formulations used in the treatment of decubitus ulcers, skin lesions and burns. It has been recently suggested that this Triticum vulgare extract may possess potential anti-inflammatory properties. In the light of these premises the aim of the present paper was to verify the anti-inflammatory role of TVE, using the LPS-stimulated microglia model of inflammation. In particular the effect of different concentrations of TVE on the release of several mediators of inflammation such as nitric oxide, IL-6, PGE2 and TNF alpha was evaluated. More important, the anti-inflammatory effect of TVE was confirmed also in primary rat microglia cultures. The results of the present study show that TVE exerts anti-inflammatory properties since it reduces the release of all the evaluated markers of inflammation, such as NO, IL6, TNF alpha and PGE2 in LPS-activated BV2 microglial cells. Intriguingly, TVE reduced microglia activation and NO release also in primary microglia. Indeed, to verify the pathway of modulation of the inflammatory markers reported above, we found that TVE restores the cytoplasmic expression of p65 protein, kwown as specific marker associated with activation of inflammatory response. The evidence for an inhibitory activity on inflammation of this specific extract of Triticum vulgare may open the way to the possibility of a therapeutical use of the Triticum vulgare extract as an anti-inflammatory compound in certain pathological states such as burns, decubitus ulcers, folliculitis and inflammation of peripheral nerve.	[Sanguigno, Luca] Federico II Univ Naples, Sch Med, Dept Mol Med & Med Biotechnol, Naples, Italy; [Casamassa, Antonella; Boscia, Francesca; Brancaccio, Paola; Di Renzo, Gianfranco; Cuomo, Ornella] Federico II Univ Naples, Sch Med, Dept Neurosci Reprod & Dent Sci, Div Pharmacol, Naples, Italy; [Funel, Niccola] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy; [Minale, Massimiliano; Riccio, Rodolfo; Riccio, Salvatore] Farmaceut Damor SpA, Naples, Italy; [Pollina, Luca Emanuele] Hosp Pisa, Div Surg Pathol 2, Pisa, Italy; [Anzilotti, Serenella] IRCSS SDN, Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Pisa; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN)	Cuomo, O (corresponding author), Federico II Univ Naples, Sch Med, Dept Neurosci Reprod & Dent Sci, Div Pharmacol, Naples, Italy.	orcuomo@yahoo.it	anzilotti, Serenella/I-8686-2018; Brancaccio, Paola/GZL-0449-2022	sanguigno, luca/0000-0002-1375-6304; Funel, Niccola/0000-0002-5028-2363; anzilotti, serenella/0000-0002-8729-0009	Ministero Istruzione e Ricerca (MIUR), Italy [DM285772006]; Fondazione Italiana Sclerosi Multipla FISM [2012/R/1]	Ministero Istruzione e Ricerca (MIUR), Italy(Ministry of Education, Universities and Research (MIUR)); Fondazione Italiana Sclerosi Multipla FISM(Fondazione Italiana Sclerosi Multipla (FISM))	Financial support from Ministero Istruzione e Ricerca (MIUR), Italy, under Grant DM285772006 and from Fondazione Italiana Sclerosi Multipla FISM 2012/R/1 to F.B is gratefully acknowledged. Damor Farmaceutici provided support in the form of salaries for authors ((MM and RR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ariel A, 2013, J PATHOL, V229, P250, DOI 10.1002/path.4108; Boscia F, 2016, MOL NEUROBIOL, V53, P1365, DOI 10.1007/s12035-015-9095-4; Boscia F, 2013, J NEUROCHEM, V126, P428, DOI 10.1111/jnc.12209; Boscia F, 2009, STROKE, V40, P3608, DOI 10.1161/STROKEAHA.109.557439; Chaturvedi A., 2010, J PLASTIC DERMATOLOG, V6, P3; da Silva L, 2011, BBA-MOL CELL RES, V1813, P1863, DOI 10.1016/j.bbamcr.2011.06.018; Delavary BM, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/j.imbio.2011.01.001; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; El Kharrassi Y, 2014, BIOCHEM BIOPH RES CO, V446, P798, DOI 10.1016/j.bbrc.2014.02.074; FARINELLA Z, 1986, INT J TISSUE REACT, V8, P337; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Katholnig K, 2013, BIOCHEM SOC T, V41, P927, DOI 10.1042/BST20130032; Komarcevic A, 2000, Med Pregl, V53, P363; Lech M, 2013, BBA-MOL BASIS DIS, V1832, P989, DOI 10.1016/j.bbadis.2012.12.001; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Martini P, 2011, DERMAT RES PRACT, V2011, DOI 10.1155/2011/978291; Mollica G., 2008, Gazzetta Medica Italiana Archivio per le Scienze Mediche, V167, P87; Portou MJ, 2015, VASC PHARMACOL, V71, P31, DOI 10.1016/j.vph.2015.02.007; Rodero MP, 2010, INT J CLIN EXP PATHO, V3, P643; Romanelli M, 2015, DRUG DES DEV THER, V9, P2787, DOI 10.2147/DDDT.S82712; Saih FE, 2017, MOLECULES, V22, DOI 10.3390/molecules22010102; Sanguigno L, 2015, J ETHNOPHARMACOL, V159, P198, DOI 10.1016/j.jep.2014.10.051; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schafer M, 2008, PHARMACOL RES, V58, P165, DOI 10.1016/j.phrs.2008.06.004; Serafini G, 2012, DENT CLIN, V3, P35; Soliman ML, 2012, J NEUROCHEM, V123, P555, DOI 10.1111/j.1471-4159.2012.07955.x; Steiling H, 1999, EXP CELL RES, V247, P484, DOI 10.1006/excr.1998.4366; Sugama S, 2009, MED HYPOTHESES, V73, P1031, DOI 10.1016/j.mehy.2009.02.047; Wang YP, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-95; Weiclenbusch M, 2012, J INNATE IMMUN, V4, P463, DOI 10.1159/000336717; Wilson K, 1997, Nurs Crit Care, V2, P291; Xue Liang, 2013, Zhonghua Shao Shang Za Zhi, V29, P62	34	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2018	13	6							e0197493	10.1371/journal.pone.0197493	http://dx.doi.org/10.1371/journal.pone.0197493			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ5MF	29902182	gold, Green Submitted, Green Published			2023-01-03	WOS:000435424900004
J	Robinson, JC; Howell, S; Pearson, SD				Robinson, James C.; Howell, Scott; Pearson, Steven D.			Value-Based Pricing and Patient Access for Specialty Drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Robinson, James C.] Univ Calif Berkeley, 247 Univ Hall, Berkeley, CA 94720 USA; [Howell, Scott] Novartis Pharmaceut, E Hanover, NJ USA; [Pearson, Steven D.] Inst Clin & Econ Review, Boston, MA USA	University of California System; University of California Berkeley; Novartis	Robinson, JC (corresponding author), Univ Calif Berkeley, 247 Univ Hall, Berkeley, CA 94720 USA.	James.Robinson@Berkeley.edu		Robinson, James/0000-0003-0056-3017	Blue Shield of California Foundation; California Health Care Foundation; Laura and John Arnold Foundation; Aetna; America's Health Insurance Plans; Anthem; Blue Shield of California; CVS Caremark; Express Scripts; Harvard Pilgrim Health Care; OmedaRx; United Healthcare; Kaiser Permanente; Prernera; AstraZeneca; Genentech; GlaxoSmithKline; Johnson Johnson; Merck; National Pharmaceutical Council; Prime Therapeutics; Sanofi; Novartis; Spark Therapeutics; Health Care Service Corp; Editas; Alnylam	Blue Shield of California Foundation; California Health Care Foundation; Laura and John Arnold Foundation; Aetna; America's Health Insurance Plans; Anthem; Blue Shield of California; CVS Caremark; Express Scripts; Harvard Pilgrim Health Care; OmedaRx; United Healthcare; Kaiser Permanente; Prernera; AstraZeneca(AstraZeneca); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Merck(Merck & Company); National Pharmaceutical Council; Prime Therapeutics; Sanofi; Novartis(Novartis); Spark Therapeutics; Health Care Service Corp; Editas; Alnylam	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest Dr Howell reported being previously employed by Jazz Pharmaceuticals and Cardinal Health; being currently employed by Novartis Pharmaceuticals Corp; and owning a number of health care-related stocks, including pharmaceutical manufacturers, pharmacy benefit managers, and insurance companies. Dr Pearson is president of the Institute for Clinical and Economic Review, which receives funding from Blue Shield of California Foundation, California Health Care Foundation, and Laura and John Arnold Foundation; other funding from Aetna, America's Health Insurance Plans, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, OmedaRx, United Healthcare, Kaiser Permanente, Prernera, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Novartis, Spark Therapeutics, Prime Therapeutics, Health Care Service Corp, Editas, and Alnylam. No other disclosures were reported.	American Medical Association, 2017, 2016 AMA PRIOR AUTH; Claxton G, EMPLOYER HLTH BENEFI; Hoadley J, 2006, MEDICARE D; Howard DH, 2015, J ECON PERSPECT, V29, P139, DOI 10.1257/jep.29.1.139; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Langreth R, BLOOMBERG	6	20	20	3	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	2018	319	21					2169	2170		10.1001/jama.2018.5367	http://dx.doi.org/10.1001/jama.2018.5367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI1MA	29801023				2023-01-03	WOS:000434133400011
J	Maita, H; Kobayashi, T; Osawa, H; Kato, H				Maita, Hiroki; Kobayashi, Tadashi; Osawa, Hiroshi; Kato, Hiroyuki			Self-diagnosis of seasonal influenza in a rural primary care setting in Japan: A cross sectional observational study	PLOS ONE			English	Article							INFECTION; PHYSICIAN; SYMPTOMS; TESTS; METAANALYSIS; ACCURACY; MALARIA; IMPACT	Objective To elucidate the accuracy and optimal cut-off point of self-diagnosis and clinical symptoms of seasonal influenza compared with rapid influenza diagnostic tests as the reference standard, we conducted a cross sectional observational study at a rural clinic in Japan. Methods Data during three influenza seasons (December 2013 to April 2016) were retrospectively collected from the medical records and pre-examination sheets of 111 patients aged >11 years (mean age 48.1 years, men 53.2%) who were suspected of influenza infection and underwent rapid influenza diagnostic testing. Patients' characteristics (age, sex, and past medical history of influenza infection), clinical signs (axillary temperature, pulse rate, cough, joint and muscle pain, and history of fever [acute or sudden, gradual, and absence of fever]), duration from the onset of symptoms, severity of feeling sick compared with a common cold (severe, similar, and mild), self-reported likelihood of influenza (%), and results of rapid influenza diagnostic tests. Results At the optimal cut-off point (30%) for estimation of self-diagnosis of seasonal influenza, the positive likelihood ratio (LR+) was 1.46 (95% confidence interval 1.07 to 2.00) and negative likelihood ratio (LR-) was 0.57 (0.35 to 0.93). At a 10% cut-off point, LR-was 0.33 (0.12 to 0.96). At an 80% cut-off point, LR+ was 2.75 (0.75 to 10.07). As for clinical signs, the combination of acute or sudden onset fever and cough had LR+ of 3.27 (1.68 to 6.35). Absence of cough showed LR-of 0.15 (0.04 to 0.61). Conclusions Self-diagnosis of influenza using the optimal cut-off point (30%) was not found useful for ruling in or ruling out an influenza diagnosis. However, it could be useful when patients self-report extremely high (80%) or low (10%) probability of having influenza. Clinically useful signs were the combination of history of fever and cough, and absence of cough.	[Maita, Hiroki; Kato, Hiroyuki] Hirosaki Univ, Grad Sch Med, Dev Community Healthcare, Hirosaki, Aomori, Japan; [Maita, Hiroki; Kato, Hiroyuki] Hirosaki Univ, Grad Sch Med, Gen Med, Hirosaki, Aomori, Japan; [Kobayashi, Tadashi; Osawa, Hiroshi; Kato, Hiroyuki] Hirosaki Univ, Sch Med & Hosp, Dept Gen Med, Hirosaki, Aomori, Japan	Hirosaki University; Hirosaki University; Hirosaki University	Maita, H (corresponding author), Hirosaki Univ, Grad Sch Med, Dev Community Healthcare, Hirosaki, Aomori, Japan.; Maita, H (corresponding author), Hirosaki Univ, Grad Sch Med, Gen Med, Hirosaki, Aomori, Japan.	maita@hirosaki-u.ac.jp	Kobayashi, Tadashi/I-7237-2019	Kobayashi, Tadashi/0000-0002-2001-4464				ABBOTT J, 1995, ANN EMERG MED, V25, P587, DOI 10.1016/S0196-0644(95)70168-0; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Bastian LA, 1998, ARCH FAM MED, V7, P465, DOI 10.1001/archfami.7.5.465; Chartrand C, 2012, ANN INTERN MED, V156, P500, DOI 10.7326/0003-4819-156-7-201204030-00403; Copeland DL, 2013, CLIN INFECT DIS, V56, P509, DOI 10.1093/cid/cis890; Donofrio JC, 2013, J EMERG MED, V45, P969, DOI 10.1016/j.jemermed.2013.07.019; Gupta K, 2001, ANN INTERN MED, V135, P9, DOI 10.7326/0003-4819-135-1-200107030-00004; Hesse BW, 2005, ARCH INTERN MED, V165, P2618, DOI 10.1001/archinte.165.22.2618; Hynes V, 2013, CAN MED ASSOC J, V185, pE149, DOI 10.1503/cmaj.109-4383; Infectious Disease Surveillance Center, 2004, INF AG SURV REP IASR; Infectious Disease Surveillance Center, 2004, INF AG SURV REP IASR; Jelinek T, 1999, LANCET, V354, P1609, DOI 10.1016/S0140-6736(99)01969-8; Jelinek Tomas, 2004, Travel Med Infect Dis, V2, P143, DOI 10.1016/j.tmaid.2004.03.003; Jutel A, 2013, SOC SCI MED, V99, P49, DOI 10.1016/j.socscimed.2013.10.011; Jutel A, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000234; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Klepser ME, 2014, DRUGS, V74, P1467, DOI 10.1007/s40265-014-0245-1; Lupton D, 2015, SOC SCI MED, V133, P128, DOI 10.1016/j.socscimed.2015.04.004; Mitamura Keiko, 2006, Virus (Nagoya), V56, P109; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; Pilger D, 2008, REV INST MED TROP SP, V50, P121, DOI 10.1590/S0036-46652008000200011; Semigran HL, 2016, JAMA INTERN MED, V176, P1860, DOI 10.1001/jamainternmed.2016.6001; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Tormo MJ, 2000, J EPIDEMIOL COMMUN H, V54, P221, DOI 10.1136/jech.54.3.221; US Centers for Disease Control and Prevention, GUID CLIN US RAP INF; Whitty CJM, 2000, AM J TROP MED HYG, V63, P295, DOI 10.4269/ajtmh.2000.63.295	26	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0197163	10.1371/journal.pone.0197163	http://dx.doi.org/10.1371/journal.pone.0197163			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF3JM	29746573	gold, Green Published, Green Submitted			2023-01-03	WOS:000431851700077
J	Matho, A; Mulqueen, M; Tanino, M; Quidort, A; Cheung, J; Pollard, J; Rodriguez, J; Swamy, S; Tayler, B; Garrison, G; Ata, A; Sorum, P				Matho, Andrea; Mulqueen, Mary; Tanino, Miyuki; Quidort, Aaron; Cheung, Jesse; Pollard, Jennifer; Rodriguez, Julieta; Swamy, Supraja; Tayler, Brittany; Garrison, Gina; Ata, Ashar; Sorum, Paul			High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial	PLOS ONE			English	Article							ENHANCED AMOXICILLIN-CLAVULANATE; COMMUNITY-ACQUIRED PNEUMONIA; ACUTE MAXILLARY SINUSITIS; QUALITY-OF-LIFE; DOUBLE-BLIND; 3 TIMES; ACUTE RHINOSINUSITIS; 2,000/125 MILLIGRAMS; CO-AMOXICLAV; 2000/125 MG	Background The recommended treatment for acute bacterial sinusitis in adults, amoxicillin with clavulanate, provides only modest benefit. Objective To see if a higher dose of amoxicillin will lead to more rapid improvement. Design, setting, and participants Double-blind randomized trial in which, from November 2014 through February 2017, we enrolled 315 adult outpatients diagnosed with acute sinusitis in accordance with Infectious Disease Society of America guidelines. Interventions Standard-dose (SD) immediate-release (IR) amoxicillin/clavulanate 875 /125 mg (n = 159) vs. high-dose (HD) (n = 156). The original HD formulation, 2000 mg of extended-release (ER) amoxicillin with 125 mg of IR clavulanate twice a day, became unavailable half way through the study. The IRB then approved a revised protocol after patient 180 to provide 1750 mg of IR amoxicillin twice a day in the HD formulation and to compare Time Period 1 (ER) with Time Period 2 (IR). Main measure The primary outcome was the percentage in each group reporting a major improvement- defined as a global assessment of sinusitis symptoms as "a lot better" or "no symptoms"- after 3 days of treatment. Key results Major improvement after 3 days was reported during Period 1 by 38.8% of ER HD versus 37.9% of SD patients (P = 0.91) and during Period 2 by 52.4% of IR HD versus 34.4% of SD patients, an effect size of 18% (95% Cl 0.75 to 35%, P = 0.04). No significant differences in efficacy were seen at Day 10. The major side effect, severe diarrhea at Day 3, was reported during Period 1 by 7.4% of HD and 5.7% of SD patients (P = 0.66) and during Period 2 by 15.8% of HD and 4.8% of SD patients (P = 0.048). Conclusions Adults with clinically diagnosed acute bacterial sinusitis were more likely to improve rapidly when treated with IR HD than with SD but not when treated with ER HD. They were also more likely to suffer severe diarrhea. Further study is needed to confirm these findings.	[Matho, Andrea; Mulqueen, Mary; Tanino, Miyuki; Quidort, Aaron] Albany Med Ctr Hosp, Albany, NY 12208 USA; [Cheung, Jesse; Pollard, Jennifer; Rodriguez, Julieta; Swamy, Supraja; Tayler, Brittany] Albany Med Coll, Albany, NY 12208 USA; [Garrison, Gina] Albany Coll Pharm & Hlth Sci, Albany, NY USA; [Ata, Ashar] Albany Med Coll, Dept Surg, Albany, NY 12208 USA; [Sorum, Paul] Albany Med Coll, Dept Med, Albany, NY 12208 USA; [Sorum, Paul] Albany Med Coll, Dept Pediat, Albany, NY 12208 USA	Albany Medical College; Albany Medical College; Albany College of Pharmacy & Health Sciences; Albany Medical College; Albany Medical College; Albany Medical College	Sorum, P (corresponding author), Albany Med Coll, Dept Med, Albany, NY 12208 USA.; Sorum, P (corresponding author), Albany Med Coll, Dept Pediat, Albany, NY 12208 USA.	sourmp@mail.amc.edu						Brook I, 2005, INT J ANTIMICROB AG, V26, P416, DOI 10.1016/j.ijantimicag.2005.08.012; Bucher HC, 2003, ARCH INTERN MED, V163, P1793, DOI 10.1001/archinte.163.15.1793; Canafax DM, 1998, PEDIATR INFECT DIS J, V17, P149, DOI 10.1097/00006454-199802000-00014; CARENFELT C, 1976, SCAND J INFECT DIS, P78; Chow AW, 2012, CLIN INFECT DIS, V54, pE72, DOI [10.1093/cid/cis370, 10.1093/cid/cir1043]; Conrad R, 2017, J PALLIAT MED, V20, P604, DOI 10.1089/jpm.2016.0218; Dinis PB, 2000, LARYNGOSCOPE, V110, P1050; Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1; Falagas ME, 2008, LANCET INFECT DIS, V8, P543, DOI 10.1016/S1473-3099(08)70202-0; File TA, 2004, ANTIMICROB AGENTS CH, V48, P3323, DOI 10.1128/AAC.48.9.3323-3331.2004; Fischer D, 1999, JAMA-J AM MED ASSOC, V282, P1157, DOI 10.1001/jama.282.12.1157; Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059; Garau J, 2003, J ANTIMICROB CHEMOTH, V52, P826, DOI 10.1093/jac/dkg458; Garbutt J, 2011, ARCH OTOLARYNGOL, V137, P792, DOI 10.1001/archoto.2011.120; Garbutt JM, 2012, JAMA-J AM MED ASSOC, V307, P685, DOI 10.1001/jama.2012.138; Gehanno P, 2002, J ANTIMICROB CHEMOTH, V49, P821, DOI 10.1093/jac/dkf014; Godil SS, 2013, SPINE J, V13, P1006, DOI 10.1016/j.spinee.2013.04.008; Guyatt GH, 2002, J CLIN EPIDEMIOL, V55, P900, DOI 10.1016/S0895-4356(02)00435-3; Hoffman A, 1998, J CONTROL RELEASE, V54, P29, DOI 10.1016/S0168-3659(97)00165-X; Jehl F, 2002, PRESSE MED, V31, P1596; Kaye CM, 2001, CLIN THER, V23, P578, DOI 10.1016/S0149-2918(01)80061-8; King D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006821.pub3; KMENT G, 1995, EUR ARCH OTO-RHINO-L, V252, P236; KROBER MS, 1985, JAMA-J AM MED ASSOC, V253, P1271, DOI 10.1001/jama.253.9.1271; Kronzer VL, 2017, QUAL LIFE RES, V26, P2093, DOI 10.1007/s11136-017-1560-2; Lemiengre MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006089.pub4; Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; Mayo Clinic, CHRON SIN; Merenstein D, 2005, J FAM PRACTICE, V54, P144; Metz SM, 2007, QUAL LIFE RES, V16, P1193, DOI 10.1007/s11136-007-9225-1; Passali D, 2001, Acta Otorhinolaryngol Belg, V55, P259; Petitpretz P, 2002, INT J ANTIMICROB AG, V20, P119, DOI 10.1016/S0924-8579(02)00126-7; Piglansky L, 2003, PEDIATR INFECT DIS J, V22, P405, DOI 10.1097/00006454-200305000-00003; Quadri N, 2013, OTOLARYNG HEAD NECK, V149, P161, DOI 10.1177/0194599813482872; REVICKI DA, 1993, QUAL LIFE RES, V2, P477, DOI 10.1007/BF00422222; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sealed Envelope, POW SAMPL SIZ CALC; Seikel K, 1997, PEDIATR INFECT DIS J, V16, P710, DOI 10.1097/00006454-199707000-00014; Sethi S, 2005, ANTIMICROB AGENTS CH, V49, P153, DOI 10.1128/AAC.49.1.153-160.2005; Stiel S, 2011, J PALLIAT MED, V14, P599, DOI 10.1089/jpm.2010.0473; Vree TB, 2003, J ANTIMICROB CHEMOTH, V51, P373, DOI 10.1093/jac/dkg082; Wald ER, 2009, PEDIATRICS, V124, P9, DOI 10.1542/peds.2008-2902; WALD ER, 1986, PEDIATRICS, V77, P795; Williamson IG, 2007, JAMA-J AM MED ASSOC, V298, P2487, DOI 10.1001/jama.298.21.2487; Zalmanovici Trestioreanu A, 2013, COCHRANE DB SYST REV, V2, DOI 10.1002/14651858.CD005149.pub4	46	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2018	13	5							e0196734	10.1371/journal.pone.0196734	http://dx.doi.org/10.1371/journal.pone.0196734			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF1VY	29738561	gold, Green Submitted, Green Published			2023-01-03	WOS:000431724900014
J	Paiatto, LN; Silva, FGD; Yamada, AT; Tamashiro, WMSC; Simioni, PU				Paiatto, Lisiery N.; Silva, Fernanda G. D.; Yamada, Aureo T.; Tamashiro, Wirla M. S. C.; Simioni, Patricia U.			Adoptive transfer of dendritic cells expressing CD11c reduces the immunological response associated with experimental colitis in BALB/c mice	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; ORAL TOLERANCE; T-CELLS; BYSTANDER SUPPRESSION; ULCERATIVE-COLITIS; TH17 CELLS; INDUCTION; MODELS; PATHOGENESIS; ANTIBODIES	Introduction In addition to conventional therapies, several new strategies have been proposed for modulating autoimmune diseases, including the adoptive transfer of immunological cells. In this context, dendritic cells (DCs) appear to be one of the most promising treatments for autoimmune disorders. The present study aimed to evaluate the effects of adoptive transfer of DCs obtained from both naive and ovalbumin (OVA)-tolerant mice on the severity of TNBS induced colitis and analyze the eventual protective mechanisms. Methods and results To induce oral tolerance, BALB/c mice were fed 4mg/mL OVA solution for seven consecutive days. Spleen DCs were isolated from tolerant (tDC) and naive (nDC) mice, and then adoptively transferred to syngeneic mice. Three days later, colitis was induced in DC treated mice by intrarectal instillation of 100 mu g2,4,6-trinitrobenzenesulfonic acid (TNBS) dissolved in 50% ethanol. Control subjects received only intrarectal instillation of either TNBS solution or a vehicle. Five days later, mice from all groups were euthanized and examined for physiological and immunological parameters. Regarding the phenotype, we observed that the frequencies of CD11(+) MHC II+ and CD11(+) MHCII+ CD86(+) cells were significantly lower in DCs isolated from tolerant mice than in those from naive mice. However, pretreatment with both types of DCs was able to significantly reduce clinical signs of colitis such as diarrhea, rectal prolapse, bleeding, and cachexia, although only treatment with tDCs was able to prevent weight loss from instillation of TNBS. In vitro proliferation of spleen cells from mice treated with either type of DCs was significantly lower than that observed in splenic cell cultures of naive mice. Although no significant difference was observed in the frequencies of Treg cells in the experimental groups, the frequency of Th17(+)CD4(+) cellsand the secretion of IL-17 were more reduced in the cultures of spleen cells from mice treated with either type of DCs. The levels of that no competing interests exist. IL-9 and IFN-gamma were lower in supernatants of cells from mice treated with nDCs. Conclusion The results allow us to conclude that the adoptive transfer of cells expressing CD11c is able to reduce the clinical and immunological signs of drug-induced colitis. Adoptive transfer of CD11c(+)DC isolated from both naive and tolerant mice altered the proliferative and T cell responses. To the best of our knowledge, there is no previously published data showing the protective effects of DCs from naive or tolerant mice in the treatment of colitis.	[Paiatto, Lisiery N.; Simioni, Patricia U.] Univ Estadual Paulista, UNESP, Inst Biosci, Rio Claro, SP, Brazil; [Silva, Fernanda G. D.] Univ Estadual Campinas, UNICAMP, Fac Food Engn, Campinas, SP, Brazil; [Silva, Fernanda G. D.] Univ Fed Ouro Preto, Sch Nutr, Dept Food, Ouro Preto, MG, Brazil; [Yamada, Aureo T.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP, Brazil; [Tamashiro, Wirla M. S. C.; Simioni, Patricia U.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil; [Simioni, Patricia U.] Fac Amer, FAM, Dept Biomed Sci, Americana, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual de Campinas; Universidade Federal de Ouro Preto; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas	Simioni, PU (corresponding author), Univ Estadual Paulista, UNESP, Inst Biosci, Rio Claro, SP, Brazil.; Simioni, PU (corresponding author), Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil.; Simioni, PU (corresponding author), Fac Amer, FAM, Dept Biomed Sci, Americana, SP, Brazil.	psimioni@gmail.com	Silva, Fernanda/O-6177-2019; Simioni, Patricia/A-3169-2009; Silva, Fernanda G.D./M-2564-2017	Silva, Fernanda/0000-0002-9615-5415; Simioni, Patricia/0000-0002-6951-5040; Silva, Fernanda G.D./0000-0002-9615-5415	Sao Paulo Research Foundation (FAPESP), Brazil [2013/20258-2, 2014/086192, 2015/09326-1, 2014/167010, 2014/08591-0]; Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES)	Sao Paulo Research Foundation (FAPESP), Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work has been supported by Sao Paulo Research Foundation (FAPESP, http://tapesp.br/), Brazil (Grant No. 2013/20258-2) and fellowships (#2014/086192, #2015/09326-1 #2014/167010 and #2014/08591-0) and by Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES, http://www.capes.gov.br) (LNP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrade MC, 2003, BRAZ J MED BIOL RES, V36, P1227, DOI 10.1590/S0100-879X2003000900013; Arijs I, 2011, AM J GASTROENTEROL, V106, P748, DOI 10.1038/ajg.2011.27; Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245; Defendenti C, 2015, INT J IMMUNOPATH PH, V28, P569, DOI 10.1177/0394632015600535; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; Elyaman W, 2009, P NATL ACAD SCI USA, V106, P12885, DOI 10.1073/pnas.0812530106; Engel MA, 2010, J GASTROENTEROL, V45, P571, DOI 10.1007/s00535-010-0219-3; Eri R, 2008, INFLAMM BOWEL DIS, V14, P458, DOI 10.1002/ibd.20344; Feng T, 2010, J EXP MED, V207, P1321, DOI 10.1084/jem.20092253; Fukaya T, 2011, METHODS MOL BIOL, V677, P113, DOI 10.1007/978-1-60761-869-0_8; Gerlach K, 2014, NAT IMMUNOL, V15, P676, DOI 10.1038/ni.2920; Girard-Madoux MJH, 2016, ONCOTARGET, V7, P32015, DOI 10.18632/oncotarget.8337; Glocker EO, 2011, ANN NY ACAD SCI, V1246, P102, DOI 10.1111/j.1749-6632.2011.06339.x; Gordon JR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00007; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Guo BC, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00242; Kalantari T, 2011, IMMUNOL RES, V51, P153, DOI 10.1007/s12026-011-8255-5; Kobayashi T, 2008, GUT, V57, P1682, DOI 10.1136/gut.2007.135053; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Li HM, 2008, J IMMUNOL, V181, P2483, DOI 10.4049/jimmunol.181.4.2483; Lindsay J, 2002, GENE THER, V9, P1715, DOI 10.1038/sj.gt.3301841; Liu ZJ, 2009, WORLD J GASTROENTERO, V15, P5784, DOI 10.3748/wjg.15.5784; Lutz MB, 2002, J IMMUNOL, V169, P3574, DOI 10.4049/jimmunol.169.7.3574; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Matricon J, 2010, M S-MED SCI, V26, P405, DOI 10.1051/medsci/2010264405; Matteoli G, 2010, GUT, V59, P595, DOI 10.1136/gut.2009.185108; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; Millington OR, 2004, J IMMUNOL, V173, P6059, DOI 10.4049/jimmunol.173.10.6059; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Muller G, 2002, J INVEST DERMATOL, V119, P836, DOI 10.1046/j.1523-1747.2002.00496.x; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; Niess JH, 2006, CURR OPIN GASTROEN, V22, P354, DOI 10.1097/01.mog.0000231807.03149.54; Ohnmacht C, 2009, J EXP MED, V206, P549, DOI 10.1084/jem.20082394; Owczarek D, 2009, POL ARCH MED WEWN, V119, P84, DOI 10.20452/pamw.614; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Paiatto LN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170205; Pedersen AE, 2007, IMMUNOLOGY, V121, P526, DOI 10.1111/j.1365-2567.2007.02600.x; Perrier C, 2011, IMMUNOTHERAPY-UK, V3, P1341, DOI [10.2217/imt.11.122, 10.2217/IMT.11.122]; de Mattos BRR, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/493012; Randhawa PK, 2014, KOREAN J PHYSIOL PHA, V18, P279, DOI 10.4196/kjpp.2014.18.4.279; Rutella S, 2011, WORLD J GASTROENTERO, V17, P3761, DOI 10.3748/wjg.v17.i33.3761; Shen W, 2010, NEUROCHEM RES, V35, P940, DOI 10.1007/s11064-009-0091-9; Simioni PU, 2017, INT J IMMUNOPATH PH, V30, P44, DOI 10.1177/0394632016678873; Simioni PU, 2004, SCAND J IMMUNOL, V60, P257, DOI 10.1111/j.0300-9475.2004.01454.x; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Takamatsu M, 2013, J IMMUNOL, V191, P3057, DOI 10.4049/jimmunol.1203306; Thome R, 2012, CELL IMMUNOL, V280, P113, DOI 10.1016/j.cellimm.2012.11.017; Tontini GE, 2015, WORLD J GASTROENTERO, V21, P21, DOI 10.3748/wjg.v21.i1.21; Wang LM, 2016, EUR J IMMUNOL, V46, P2454, DOI 10.1002/eji.201546274; Whittem C.G., 2010, JOVE-J VIS EXP, V35, DOI [10.3791/1652, DOI 10.3791/1652]; WILDNER G, 1995, EUR J IMMUNOL, V25, P1292, DOI 10.1002/eji.1830250524; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Wu XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083013; Yamazaki S, 2009, J DERMATOL SCI, V54, P69, DOI 10.1016/j.jdermsci.2009.02.001; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774; Zonneveld-Huijssoon E, 2011, ANN RHEUM DIS, V70, P2199, DOI 10.1136/ard.2010.136994	57	5	5	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2018	13	5							e0196994	10.1371/journal.pone.0196994	http://dx.doi.org/10.1371/journal.pone.0196994			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF1VY	29738575	gold, Green Submitted, Green Published			2023-01-03	WOS:000431724900039
J	Lip, GYH; Pan, XY; Kamble, S; Kawabata, H; Mardekian, J; Masseria, C; Phatak, H				Lip, Gregory Y. H.; Pan, Xianying; Kamble, Shital; Kawabata, Hugh; Mardekian, Jack; Masseria, Cristina; Phatak, Hemant			Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban	PLOS ONE			English	Article							ORAL ANTICOAGULANTS; STROKE; THERAPY; OUTCOMES; PREVENTION; TRIAL	Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) patients to an increased risk of stroke. This study describes the real-world discontinuation rates and compared the risk of drug discontinuation among NVAF patients initiating apixaban, warfarin, dabigatran, or rivaroxaban. This retrospective cohort study evaluated newly-anticoagulated NVAF patients in the MarketScan((R)) data population from 01/01/2012 through 12/31/2014. Discontinuation was defined as a lack of subsequent prescription of the index drug within 30 days after the last supply day of the last prescription. A Cox model was used to estimate the hazard ratio (HR) of discontinuation, adjusted for age, sex, and comorbidities. Among 45,361 eligible NVAF patients, 15,461 (34.1%) initiated warfarin; 7,438 (16.4%) apixaban; 4,661 (10.3%) dabigatran; and 17,801 (39.2%) initiated rivaroxaban treatment. Compared to warfarin, patients who initiated dabigatran (adjusted HR [aHR]: 0.84, 95% confidence interval [Cl]: 0.80-0.87, P<0.001), rivaroxaban (aHR: 0.70, 95% Cl: 0.68-0.73, P<0.001), or apixaban (aHR: 0.57, 95% Cl: 0.55-0.60, P<0.001) were 16%, 30%, and 43% less likely to discontinue treatment, respectively. When compared to apixaban, patients who initiated dabigatran (aHR: 1.46, 95% Cl: 1.38-1.54, P<0.001) or rivaroxaban (aHR: 1.23, 95% Cl: 1.17-1.28, P<0.001) were more likely to discontinue treatment. Among newly-anticoagulated NVAF patients in the real-world setting, initiation on rivaroxaban, dabigatran, or apixaban was associated with a significantly lower risk of discontinuation compared to warfarin. When compared to apixaban, patients who initiated treatment with warfarin, dabigatran, or rivaroxaban were more likely to discontinue treatment.	[Lip, Gregory Y. H.] Univ Birmingham, Inst Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England; [Lip, Gregory Y. H.] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark; [Pan, Xianying; Kawabata, Hugh] Bristol Myers Squibb Co BMS, Ctr Observat Res & Data Sci, Princeton, NJ USA; [Kamble, Shital; Phatak, Hemant] Bristol Myers Squibb Co BMS, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA; [Mardekian, Jack; Masseria, Cristina] Pfizer Inc, Outcomes & Evidence Patient & Hlth Impact, New York, NY USA	University of Birmingham; Aalborg University; Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer	Lip, GYH (corresponding author), Univ Birmingham, Inst Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England.; Lip, GYH (corresponding author), Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark.	g.y.h.lip@bham.ac.uk			Bristol-Myers Squibb Company, Princeton, NJ, USA; Pfizer Inc., New York, New York, USA	Bristol-Myers Squibb Company, Princeton, NJ, USA(Bristol-Myers Squibb); Pfizer Inc., New York, New York, USA(Pfizer)	This study was sponsored by Bristol-Myers Squibb Company, Princeton, NJ, USA and Pfizer Inc., New York, New York, USA. The funder provided support in the form of salaries for authors XP, SK, HK, JM, CM, HM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson D, 2008, HLTH RES DATA REAL W; Al-Khalili F, 2015, EUR SOC CARD ESC C A; Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Deitelzweig SB, 2013, CLIN THER, V35, P1201, DOI 10.1016/j.clinthera.2013.06.005; Ewen E, 2012, VASC HEALTH RISK MAN, V8, P587, DOI 10.2147/VHRM.S34280; Forslund T, 2016, EUR J CLIN PHARMACOL, V72, P329, DOI 10.1007/s00228-015-1983-z; Gadkari AS, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-98; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hansen ML, 2010, ARCH INTERN MED, V170, P1433, DOI 10.1001/archinternmed.2010.271; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Heidbuchel H, 2015, EUROPACE, V17, P1467, DOI 10.1093/europace/euv309; Ho JCS, 2012, CLIN CARDIOL, V35, pE40, DOI 10.1002/clc.22069; Jacobs Ashley, 2014, Hosp Pharm, V49, P115, DOI 10.1310/hpj4902-115; Jensen PN, 2012, PHARMACOEPIDEM DR S, V21, P141, DOI 10.1002/pds.2317; Lopes RD, 2010, AM HEART J, V159, P331, DOI 10.1016/j.ahj.2009.07.035; Mitchell SA, 2013, CLIN APPL THROMB-HEM, V19, P619, DOI 10.1177/1076029613486539; Ogilvie IM, 2010, AM J MED, V123, P638, DOI 10.1016/j.amjmed.2009.11.025; Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Phatak HM, 2006, ANN PHARMACOTHER, V40, P1737, DOI 10.1345/aph.1H153; Shore S, 2014, AM HEART J, V167, P810, DOI 10.1016/j.ahj.2014.03.023; Spivey CA, 2015, CURR MED RES OPIN, V31, P2021, DOI 10.1185/03007995.2015.1082995; Zalesak M, 2013, CIRC-CARDIOVASC QUAL, V6, P567, DOI 10.1161/CIRCOUTCOMES.113.000192	25	40	40	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0195950	10.1371/journal.pone.0195950	http://dx.doi.org/10.1371/journal.pone.0195950			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE3RI	29709012	Green Published, gold, Green Submitted			2023-01-03	WOS:000431130100011
J	Peeples, L				Peeples, Lynne			TIME TRIALS	NATURE			English	News Item							CHRONOTHERAPY; FLUOROURACIL; CHEMOTHERAPY; OXALIPLATIN; CANCER											Chan S, 2017, CLIN ONCOL-UK, V29, P231, DOI 10.1016/j.clon.2016.12.005; Chen CY, 2016, P NATL ACAD SCI USA, V113, P206, DOI 10.1073/pnas.1508249112; Fischer D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178782; Giacchetti S., 2017, CANC RES, V77; Giacchetti S, 2006, J CLIN ONCOL, V24, P3562, DOI 10.1200/JCO.2006.06.1440; Hermida RC, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12909; Kobayashi M, 2002, CHRONOBIOL INT, V19, P237, DOI 10.1081/CBI-120002600; Leder K, 2014, CELL, V156, P603, DOI 10.1016/j.cell.2013.12.029; Levi F, 1997, LANCET, V350, P681, DOI 10.1016/S0140-6736(97)03358-8; Li J, 2015, CANCER CHEMOTH PHARM, V76, P651, DOI 10.1007/s00280-015-2804-x; Montaigne D, 2018, LANCET, V391, P59, DOI 10.1016/S0140-6736(17)32132-3; Pitter KL, 2016, BRAIN, V139, P1458, DOI 10.1093/brain/aww046; Selfridge JM, 2016, DRUGS, V76, P1507, DOI 10.1007/s40265-016-0646-4; Slat EA, 2017, J BIOL RHYTHM, V32, P121, DOI 10.1177/0748730417696788	14	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 19	2018	556	7701					290	292		10.1038/d41586-018-04600-8	http://dx.doi.org/10.1038/d41586-018-04600-8			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD1TW	29666501	Bronze			2023-01-03	WOS:000430285200021
J	Weidenauer, D; Hamp, T; Schriefl, C; Holaubek, C; Gattinger, M; Krammel, M; Winnisch, M; Weidenauer, A; Mundigler, G; Lang, I; Schreiber, W; Sterz, F; Herkner, H; Domanovits, H				Weidenauer, David; Hamp, Thomas; Schriefl, Christoph; Holaubek, Caroline; Gattinger, Markus; Krammel, Mario; Winnisch, Markus; Weidenauer, Ana; Mundigler, Gerald; Lang, Irene; Schreiber, Wolfgang; Sterz, Fritz; Herkner, Harald; Domanovits, Hans			The impact of cardiopulmonary resuscitation (CPR) manikin chest stiffness on motivation and CPR performance measures in children undergoing CPR training-A prospective, randomized, single-blind, controlled trial	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; EMERGENCY CARDIOVASCULAR CARE; ASSOCIATION GUIDELINES UPDATE; BASIC LIFE-SUPPORT; EUROPEAN RESUSCITATION; COUNCIL GUIDELINES; BYSTANDER CPR; QUALITY; SCHOOLCHILDREN; RECOMMENDATIONS	Background Cardio-pulmonary-resuscitation (CPR) training starting at the age of 12 years is recommended internationally. Training younger children is not recommended because young children lack the physical ability to perform adequate CPR and discouragement to perform CPR later is apprehended. The aim of this study was to answer the following questions: Are younger children discouraged after CPR training? Is discouragement caused by their lack in physical ability to perform adequate chest compressions on a standard manikin and would the use of manikins with a reduced resistance affect their motivation or performance? Methods We investigated the motivation and CPR performance of children aged 8-13 years after CPR training on manikins of different chest stiffness in a prospective, randomized, single-blind, controlled trial. 322 children underwent randomization and received 30 minutes CPR training in small groups at school. We used two optically identical resuscitation manikins with different compression resistances of 45kg and 30kg. Motivation was assessed with a self-administered questionnaire. Performance was measured with the Resusci (R) AnneSkillReporter (TM). Findings Motivation after the training was generally high and there was no difference between the two groups in any of the questionnaire items on motivation: Children had fun (98 vs. 99%; P = 0.32), were interested in the training (99 vs. 98%; P = 0.65), and were glad to train resuscitation again in the future (89 vs. 91%; P = 0.89). CPR performance was generally poor (median compression score (8, IQR 1-45 and 29, IQR 11-54; P<0.001) and the mean compression depth was lower in the 45kg-resistance than in the 30kg-resistance group (33 +/- 10mm vs. 41 +/- 9; P<0.001). Conclusions Compression resistances of manikins, though influencing CPR performance, did not discourage 8 to 13 year old children after CPR training. The findings refute the view that young children are discouraged when receiving CPR training even though they are physically not able to perform adequate CPR.	[Weidenauer, David; Mundigler, Gerald; Lang, Irene] Med Univ Vienna, Dept Internal Med 2, Vienna, Austria; [Hamp, Thomas] Med Univ Vienna, Prehosp Emergency Med Res Grp, Dept Gen Anesthesia & Intens Care, Vienna, Austria; [Schriefl, Christoph; Schreiber, Wolfgang; Sterz, Fritz; Herkner, Harald; Domanovits, Hans] Med Univ Vienna, Dept Emergency Med, Vienna, Austria; [Holaubek, Caroline] Med Univ Vienna, Dept Cardiothorac & Vasc Anesthesia, Vienna, Austria; [Gattinger, Markus] Med Univ Vienna, Vienna, Austria; [Krammel, Mario] Municipal Ambulance Serv Vienna, Vienna, Austria; [Winnisch, Markus] Med Univ Vienna, Dept Trauma Surg, Vienna, Austria; [Weidenauer, Ana] Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Hamp, T (corresponding author), Med Univ Vienna, Prehosp Emergency Med Res Grp, Dept Gen Anesthesia & Intens Care, Vienna, Austria.	thomas.hamp@meduniwien.ac.at		Hamp, Thomas/0000-0001-7294-9168; Schriefl, Christoph/0000-0003-4390-1362; Herkner, Harald/0000-0003-1329-6149; Holaubek, Caroline/0000-0002-6896-7854				Abelairas-Gomez C, 2014, RESUSCITATION; [Anonymous], 2015, RESUSCITATION, V94, pA5, DOI 10.1016/j.resuscitation.2015.07.005; Baldi E, 2017, CAN J EMERG MED, V19, P480, DOI 10.1017/cem.2016.410; Bottiger BW, 2015, LANCET, V385, P2353, DOI 10.1016/S0140-6736(15)61099-6; Bollig G, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-13; Bollig G, 2009, RESUSCITATION, V80, P689, DOI 10.1016/j.resuscitation.2009.03.012; Bottiger BW, 1999, HEART, V82, P674, DOI 10.1136/hrt.82.6.674; Brown GTL, 2015, ASSESS EDUC, V22, P444, DOI 10.1080/0969594X.2014.996523; BURGHOFER K, 2005, NOTFALL RETTUNGSMED, V8, P408; Cave DM, 2011, CIRCULATION, V123, P691, DOI 10.1161/CIR.0b013e31820b5328; Cortegiani A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169591; Eisenburger P, 1999, RESUSCITATION, V41, P3, DOI 10.1016/S0300-9572(99)00034-9; Fleischhackl R, 2009, CRIT CARE, V13, DOI 10.1186/cc7984; Greif R, 2015, RESUSCITATION, V95, P288, DOI 10.1016/j.resuscitation.2015.07.032; Holmberg M, 2000, RESUSCITATION, V47, P59, DOI 10.1016/S0300-9572(00)00199-4; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jones I, 2007, BMJ-BRIT MED J, V334, P1201, DOI 10.1136/bmj.39167.459028.DE; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Lee MJ, 2013, RESUSCITATION, V84, P889, DOI 10.1016/j.resuscitation.2013.01.009; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Nolan JP, 2015, RESUSCITATION, V95, pE1, DOI 10.1016/j.resuscitation.2015.07.039; Plant N, 2013, RESUSCITATION, V84, P415, DOI 10.1016/j.resuscitation.2012.12.008; Sasson C, 2010, ANN INTERN MED, V153, P19, DOI 10.7326/0003-4819-153-1-201007060-00255; Stroobants J, 2014, RESUSCITATION, V85, P1769, DOI 10.1016/j.resuscitation.2014.10.013; Taniguchi D, 2012, EMERG MED CLIN N AM, V30, P1, DOI 10.1016/j.emc.2011.09.003; Uray T, 2003, RESUSCITATION, V59, P211, DOI 10.1016/S0300-9572(03)00233-8; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483	30	4	5	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0202430	10.1371/journal.pone.0202430	http://dx.doi.org/10.1371/journal.pone.0202430			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ6RF	30114240	gold, Green Submitted, Green Published			2023-01-03	WOS:000441850400071
J	Dallimore, DJ; Neukirchinger, B; Noyes, J				Dallimore, David J.; Neukirchinger, Barbara; Noyes, Jane			Why is transition between child and adult services a dangerous time for young people with chronic kidney disease? A mixed-method systematic review	PLOS ONE			English	Review							QUALITY-OF-LIFE; TRANSPLANT RECIPIENTS; HEALTH-CARE; ADOLESCENTS; ADHERENCE; SURVIVAL; FAILURE; IMPACT; AGE; PERSPECTIVES	Young people age 14-25 years with chronic kidney disease have been identified as generally having poor health outcomes and are a high-risk group for kidney transplant loss due in part to poor self-management. This raises a key question as to what happens during transition from child to adult services? This paper presents a mixed-method systematic review of health and social care evidence concerning young people with chronic kidney disease transitioning from child to adult health and social care services. Quantitative and qualitative evidence were synthesised in streams followed by an overarching synthesis. Literature searches (2000 to March 2017) were conducted using Pubmed, BioMed Central and Cochrane Library, grey literature sources ZETOC,. gov.uk, third sector organisations, NHS Evidence, SCIE, TRIP, Opengrey. Snowball searching was conducted in the databases Ovid, CINAHL, ISI Web of Science, Scopus and Google Scholar. Of 3,125 records screened, 60 texts were included. We found that while strategies to support transition contained consistent messages, they supported the principle of a health-dominated pathway. Well-being is mainly defined and measured in clinical terms and the transition process is often presented as a linear, one-dimensional conduit. Individual characteristics, along with social, familial and societal relationships are rarely considered. Evidence from young people and their families highlights transition as a zone of conflict between independence and dependency with young people feeling powerless on one hand and overwhelmed on the other. We found few novel interventions and fewer that had been evaluated. Studies were rarely conducted by allied health and social care professionals (e.g. renal social workers and psychologists) as part of multi-disciplinary renal teams. We conclude that there is a lack of good evidence to inform providers of health and social care services about how best to meet the needs of this small but vulnerable cohort.	[Dallimore, David J.; Neukirchinger, Barbara; Noyes, Jane] Bangor Univ, Sch Social Sci, Bangor, Gwynedd, Wales	Bangor University	Dallimore, DJ (corresponding author), Bangor Univ, Sch Social Sci, Bangor, Gwynedd, Wales.	d.j.dallimore@bangor.ac.uk		Dallimore, David/0000-0002-4557-8186	Health and Care Research Wales	Health and Care Research Wales	This work was undertaken by the Wales Kidney Research Unit, funded by Health and Care Research Wales (https://www.healthandcareresearch.gov.wales). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aasebo W, 2009, NEPHROL DIAL TRANSPL, V24, P304, DOI 10.1093/ndt/gfn537; Akchurin OM, 2014, PEDIATR TRANSPLANT, V18, P538, DOI 10.1111/petr.12289; Andreoni KA, 2013, JAMA INTERN MED, V173, P1524, DOI 10.1001/jamainternmed.2013.8495; Bell Hayley, 2012, Nurs Times, V108, P12; Bell L, 2007, NEPHROL DIAL TRANSPL, V22, P988, DOI 10.1093/ndt/gfl770; Bobanga ID, 2015, J PEDIATR SURG, V50, P996, DOI 10.1016/j.jpedsurg.2015.03.021; Bronfenbrenner, 1994, ECOLOGICAL MODELS HU, V3; Caplan B, 2015, RES DEV DISABIL, V37, P143, DOI 10.1016/j.ridd.2014.10.045; Carroll C, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-29; Chaturvedi S, 2009, PEDIATR NEPHROL, V24, P1055, DOI 10.1007/s00467-009-1124-y; de Ferris MEDG, 2011, BLOOD PURIFICAT, V31, P203, DOI 10.1159/000321854; Department of Health, 2006, NAT SERV FRAM REN SE; Dobbels F, 2010, PEDIATR TRANSPLANT, V14, P603, DOI 10.1111/j.1399-3046.2010.01299.x; East Midlands Renal Network, 2012, SUPP YOUNG AD CHRON; England NHS, 2007, REN ACT LEARN SETS P; EPOC, 2017, COCHRANE EFF PRACT O; Ferris ME, 2015, BLOOD PURIFICAT, V39, P99, DOI 10.1159/000368978; Forbes TA, 2014, PEDIATR NEPHROL, V29, P1617, DOI 10.1007/s00467-014-2809-4; Foster BJ, 2011, PEDIATR TRANSPLANT, V15, P750, DOI 10.1111/j.1399-3046.2011.01567.x; Foster BJ, 2014, OPEN UROL NEPHROL J, V7, P133, DOI DOI 10.2174/1874303X014070100133; Garbarino J., 1980, ECOLOGY HUMAN DEV EX, V2, DOI [10.1016/0190-7409(80)90036-5, DOI 10.1016/0190-7409(80)90036-5]; Gilleland J, 2012, J PEDIATR PSYCHOL, V37, P85, DOI 10.1093/jpepsy/jsr049; Gillen DL, 2008, AM J TRANSPLANT, V8, P2600, DOI 10.1111/j.1600-6143.2008.02410.x; Hamilton AJ, 2016, NEPHROL DIAL TRANSPL, V31, P40; Hannigan KL, 2011, BR J REN MED, V16, P12; Harden P, 2010, TRANSPLANTATION, V90, P107; Harden PN, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3718; Harden Paul N, 2006, Prog Transplant, V16, P324; Iitaka K, 2008, CLIN EXP NEPHROL, V12, P28, DOI 10.1007/s10157-007-0014-5; Iredale R, 2006, HEALTH EXPECT, V9, P207, DOI 10.1111/j.1369-7625.2006.00387.x; Javalk K, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140072; Joly E, 2016, J ADV NURS, V72, P1251, DOI 10.1111/jan.12939; Jorge S, 2007, POR J NEPHROL HYPERT, V21, P211; Kiberd JA, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-54; Kreuzer M, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-505; LaRosa C, 2011, PEDIATRICS, V127, P742, DOI 10.1542/peds.2010-1232; Lewin S, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001895; Lewis H., 2012, EXPERIENCES BIOGRAPH; Lewis H, 2015, CHRONIC ILLN, V11, P184, DOI 10.1177/1742395314566823; Lewis H, 2015, HEALTH-LONDON, V19, P67, DOI 10.1177/1363459314539773; Lewis H, 2014, PEDIATR NEPHROL, V29, P2379, DOI 10.1007/s00467-014-2864-x; Marchak JG, 2015, PEDIATR TRANSPLANT, V19, P849, DOI 10.1111/petr.12615; McDonagh JE, 2010, PEDIATR TRANSPLANT, V14, P688, DOI 10.1111/j.1399-3046.2010.01343.x; McQuillan Rory F, 2015, Can J Kidney Health Dis, V2, P45, DOI 10.1186/s40697-015-0081-6; Mekahli D, 2014, PEDIATR NEPHROL, V29, P1387, DOI 10.1007/s00467-014-2785-8; Meleis AI, 2000, ADV NURS SCI, V23, P12, DOI 10.1097/00012272-200009000-00006; Miles M., 1994, QUALITATIVE ANAL EXP; Mori Ipsos / NHS Kidney Care, 2012, WALK THEIR SHOES UND; Mori Ipsos/NHS Kidney Care, 2012, WALK THEIR SHOES UND; Mori Ipsos/NHS Kidney Care, 2013, PAR VIEW KIDN CAR ET; Murray PD, 2014, J ADOLESCENT HEALTH, V55, P505, DOI 10.1016/j.jadohealth.2014.03.017; Myers Pamela S, 2002, Nephrol Nurs J, V29, P375; Nagra A, 2015, ARCH DIS CHILDHOOD-E, V100, P313, DOI 10.1136/archdischild-2014-307423; National Institute for Clinical Excellence (NICE), 2015, TRANSITION; Noyes J., 2014, HEALTH SERV DELIVERY, V2, DOI [10.3310/HSDR02080, DOI 10.3310/HSDR02080]; Noyes J., 2015, COCHRANE HDB SYSTEMA, P571, DOI DOI 10.1002/9780470712184.CH20; Oliver S, 2005, EVALUATION, V11, P428, DOI DOI 10.1177/1356389005059383; Pape L, 2013, PEDIATR TRANSPLANT, V17, P518, DOI 10.1111/petr.12102; Remorino Rowena, 2006, Prog Transplant, V16, P303; Ritchie AG, 2012, NEPHROLOGY, V17, P539, DOI 10.1111/j.1440-1797.2012.01610.x; Ritchie J., 2002, QUALITATIVE DATA ANA; Samuel S, 2011, GRAFT FAILURE ADAPTA; Samuel SM, 2014, PEDIATRICS, V133, pE993, DOI 10.1542/peds.2013-2345; Samuel SM, 2012, PEDIATR TRANSPLANT, V16, P735, DOI 10.1111/j.1399-3046.2012.01694.x; Sattoe JNT, 2014, J RENAL CARE, V40, P131, DOI 10.1002/jorc.12046; Sattoe JNT, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-279; Schwartz L, 2011, CHILD CARE HEAL; Shaw RJ, 2003, PEDIATR TRANSPLANT, V7, P489, DOI 10.1046/j.1397-3142.2003.00117.x; Shemilt I, 2008, COCHRANE HDB SYSTEMA, P449, DOI DOI 10.1002/14651858.CD004741.PUB2; Tong A, 2015, NEPHROLOGY, V20, P352, DOI 10.1111/nep.12396; Tong A, 2013, EUR J PEDIATR, V172, P293, DOI 10.1007/s00431-012-1725-5; Tong A, 2011, PEDIATR TRANSPLANT, V15, P285, DOI 10.1111/j.1399-3046.2010.01470.x; van den Heuvel MEN, 2010, NEPHROL DIAL TRANSPL, V25, P1662, DOI 10.1093/ndt/gfp684; Wang G, 2010, J PEDIATR NURS, V25, P505, DOI 10.1016/j.pedn.2009.07.003; Watson AR, 2011, PEDIATR NEPHROL, V26, P1753, DOI 10.1007/s00467-011-1981-z; Watson AR, 2000, PEDIATR NEPHROL, V14, P469, DOI 10.1007/s004670050794; Watson AR, 2011, BR J REN MED, V16, P15; Webb N, 2010, ARCH DIS CHILD, V95, P606, DOI 10.1136/adc.2009.176255; Wells F, 2013, CHILD CARE HLTH DEV, V39, P602, DOI 10.1111/j.1365-2214.2012.01399.x; Woodland J., 2013, YOUNG PEOPLE SHAPING; Zheng Kai, 2010, AMIA Annu Symp Proc, V2010, P942	81	12	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2018	13	8							e0201098	10.1371/journal.pone.0201098	http://dx.doi.org/10.1371/journal.pone.0201098			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP3UD	30071028	Green Published, Green Submitted, gold			2023-01-03	WOS:000440778600025
J	Bungartz, KD; Lalowski, K; Elkin, SK				Bungartz, Kathryn D.; Lalowski, Kristen; Elkin, Sheryl K.			Making the right calls in precision oncology	NATURE BIOTECHNOLOGY			English	Editorial Material							CANCER; VARIANTS; PARADIGM; MEDICINE		[Bungartz, Kathryn D.; Lalowski, Kristen; Elkin, Sheryl K.] N Of One Inc, Concord, MA 01742 USA		Lalowski, K (corresponding author), N Of One Inc, Concord, MA 01742 USA.	kristen.lalowski@n-of-one.com		Bungartz, Kathryn/0000-0003-3373-7837				Alper BS, 2004, J MED LIBR ASSOC, V92, P429; Blay JY, 2017, EUR J CANCER, V70, P83, DOI 10.1016/j.ejca.2016.07.028; Bohannon J, 2015, SCIENCE, V349, P252, DOI 10.1126/science.349.6245.252; Burger JD, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau094; Butler Taylor, 2015, P T, V40, P191; Cabitza F, 2017, JAMA-J AM MED ASSOC, V318, P517, DOI 10.1001/jama.2017.7797; Castillo M, 2011, TIME; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Dewdney SB, 2017, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00268; Freedman D. H, 2017, MIT TECHNOL REV; Griffith M, 2017, NAT GENET, V49, P170, DOI 10.1038/ng.3774; Guizzo E, 2011, IEEE SPECTRUM, V48, P16, DOI 10.1109/MSPEC.2011.5719709; Heymach J, 2018, J CLIN ONCOL, V36, P1020, DOI 10.1200/JCO.2017.77.0446; Hirschman L, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw115; Hyman DM, 2017, CELL, V168, P584, DOI 10.1016/j.cell.2016.12.015; Jensen MA, 2017, BLOOD, V130, P453, DOI 10.1182/blood-2017-03-735654; Johnston C., 2011, ARS TECHNICA; Jorgensen JT, 2018, CLIN PHARMACOL THER, V103, P999, DOI 10.1002/cpt.955; Kerr ID, 2017, J COMMUN GENET, V8, P87, DOI 10.1007/s12687-016-0289-x; Khare R, 2016, BRIEF BIOINFORM, V17, P23, DOI 10.1093/bib/bbv021; Kourou K, 2015, COMPUT STRUCT BIOTEC, V13, P8, DOI 10.1016/j.csbj.2014.11.005; Koyama T, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.e12549; Kumar S, 2017, GLOBAL ONCOLOGY TREN; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694; Maley CC, 2017, NAT REV CANCER, V17, P605, DOI 10.1038/nrc.2017.69; Moore TJ, 2014, JAMA INTERN MED, V174, P90, DOI 10.1001/jamainternmed.2013.11813; Moran S, 2017, NAT REV CLIN ONCOL, V14, P682, DOI 10.1038/nrclinonc.2017.97; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nebot-Bral L, 2017, EUR J CANCER, V84, P290, DOI 10.1016/j.ejca.2017.07.026; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Ross C., 2017, STAT NEWS       0905; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Singhal A, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw161; Somashekhar SP, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.8527; Somashekhar SP, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.SABCS16-S6-07; Stover DG, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-015-0438-0; Voosen P, 2017, SCIENCE, V357, P22, DOI 10.1126/science.357.6346.22; Widschwendter M, 2018, NAT REV CLIN ONCOL, V15, P292, DOI 10.1038/nrclinonc.2018.30; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Wrzeszczynski KO, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000164	42	1	1	3	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2018	36	8					692	696		10.1038/nbt.4214	http://dx.doi.org/10.1038/nbt.4214			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	GQ1AH	30080824				2023-01-03	WOS:000441353500013
J	Dalvi, PS; Yang, S; Swain, N; Kim, J; Saha, S; Bourdon, C; Zhang, L; Chami, R; Bandsma, RHJ				Dalvi, Prasad S.; Yang, Steven; Swain, Nathan; Kim, Junsoo; Saha, Senjuti; Bourdon, Celine; Zhang, Ling; Chami, Rose; Bandsma, Robert H. J.			Long-term metabolic effects of malnutrition: Liver steatosis and insulin resistance following early-life protein restriction	PLOS ONE			English	Article							HIGH-FAT DIET; NONALCOHOLIC STEATOHEPATITIS; GLUCOSE-TOLERANCE; MALNOURISHED CHILDREN; HEPATIC STEATOSIS; CHRONIC DISEASE; HIGH-FRUCTOSE; ADULT HEALTH; MURINE MODEL; SAO-PAULO	Early postnatal-life malnutrition remains prevalent globally, and about 45% of all child deaths are linked to malnutrition. It is not clear whether survivors of childhood malnutrition suffer from long-term metabolic effects, especially when they are later in life exposed to a fat and carbohydrate rich obesogenic diet. The lack of knowledge around this dietary "double burden" warrants studies to understand the long-term consequences of children previously exposed to malnutrition. We hypothesized that an early-life nutritional insult of low protein consumption in mice would lead to long-term metabolic disturbances that would exacerbate the development of diet-induced insulin resistance and non-alcoholic fatty liver disease (NAFLD). We investigated the effects of feeding a low protein diet (4% wt/wt) immediately after weaning for four weeks and subsequent feeding of a high carbohydrate high fat feeding for 16 weeks on metabolic function and development of NAFLD. Mice exposed to early-life protein restriction demonstrated a transient glucose intolerance upon recovery by regular chow diet feeding. However, protein restriction after weaning in mice did not exacerbate an obesogenic diet-induced insulin resistance or progression to NAFLD. These data suggest that transient protein restriction in early-life does not exacerbate an obesogenic diet-induced NAFLD and insulin resistance.	[Dalvi, Prasad S.; Yang, Steven; Swain, Nathan; Kim, Junsoo; Saha, Senjuti; Bourdon, Celine; Zhang, Ling; Bandsma, Robert H. J.] Hosp Sick Children, Translat Med Res Program, Toronto, ON, Canada; [Dalvi, Prasad S.] Gannon Univ, Morosky Coll Hlth Profess & Sci, Erie, PA USA; [Chami, Rose] Univ Toronto, Fac Med, Dept Lab Med & Pathol, Toronto, ON, Canada; [Chami, Rose] Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON, Canada; [Bandsma, Robert H. J.] Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Bandsma, RHJ (corresponding author), Hosp Sick Children, Translat Med Res Program, Toronto, ON, Canada.; Bandsma, RHJ (corresponding author), Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON, Canada.	robert.bandsma@sickkids.ca		Saha, Senjuti/0000-0001-6087-6766; Chami, Rose/0000-0002-1242-9352	Hospital for Sick Children	Hospital for Sick Children(University of Toronto)	This work was supported through an internal grant from the Hospital for Sick Children.	Aguila M, 2003, LIVER INT, V23, P363, DOI 10.1034/j.1478-3231.2003.00858.x; ALLEYNE GAO, 1972, BRIT J NUTR, V27, P585, DOI 10.1079/BJN19720128; Bandsma RHJ, 2015, AM J PHYSIOL-ENDOC M, V309, pE466, DOI 10.1152/ajpendo.00090.2015; Bandsma RHJ, 2010, PEDIATR RES, V68, P423, DOI 10.1203/PDR.0b013e3181f2b959; Barker DJP, 2012, PUBLIC HEALTH, V126, P185, DOI 10.1016/j.puhe.2011.11.014; BARKER DJP, 1986, LANCET, V1, P1077; Bartz S, 2014, J CLIN ENDOCR METAB, V99, P2128, DOI 10.1210/jc.2013-4018; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; Brown EM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8806; Catta-Preta M, 2011, VIRCHOWS ARCH, V459, P477, DOI 10.1007/s00428-011-1147-1; De Bruyne RML, 2010, HEPATOL INT, V4, P375, DOI 10.1007/s12072-009-9160-z; Dewey KG, 2011, MATERN CHILD NUTR, V7, P5, DOI 10.1111/j.1740-8709.2011.00349.x; Di Giovanni V, 2016, J NUTR, V146, P2436, DOI 10.3945/jn.116.239145; Eriksson JG, 2002, DIABETOLOGIA, V45, P342, DOI 10.1007/s00125-001-0757-6; Franco VHM, 1999, J TROP PEDIATRICS, V45, P71, DOI 10.1093/tropej/45.2.71; Gonzalez-Barranco J, 2003, METABOLISM, V52, P1005, DOI 10.1016/S0026-0495(03)00151-3; Guerrant RL, 2008, NUTR REV, V66, P487, DOI 10.1111/j.1753-4887.2008.00082.x; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hoffman DJ, 2000, AM J CLIN NUTR, V72, P702; Ishimoto T, 2012, P NATL ACAD SCI USA, V109, P4320, DOI 10.1073/pnas.1119908109; Kawasaki T, 2009, J NUTR, V139, P2067, DOI 10.3945/jn.109.105858; Kohli R, 2010, HEPATOLOGY, V52, P934, DOI 10.1002/hep.23797; Kong LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109434; Kus V, 2008, AM J PHYSIOL-ENDOC M, V295, pE356, DOI 10.1152/ajpendo.90256.2008; Lelijveld N, 2016, LANCET GLOB HEALTH, V4, pE654, DOI 10.1016/S2214-109X(16)30133-4; Li ML, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/437107; Lieber CS, 2004, AM J CLIN NUTR, V79, P502; Liyanage Vichithra R B, 2014, Biology (Basel), V3, P670, DOI 10.3390/biology3040670; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McCullough Arthur J, 2004, Clin Liver Dis, V8, P521, DOI 10.1016/j.cld.2004.04.004; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382; Owczarzy R, 2008, NUCLEIC ACIDS RES, V36, pW163, DOI 10.1093/nar/gkn198; Petronis A, 2010, NATURE, V465, P721, DOI 10.1038/nature09230; Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Rising R, 2010, J NUTR METAB, V2010, DOI 10.1155/2010/171490; Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001; Sahai A, 2004, AM J PHYSIOL-GASTR L, V287, pG1035, DOI 10.1152/ajpgi.00199.2004; Sargent G, 2016, J CELL BIOL, V214, P677, DOI 10.1083/jcb.201511034; Sawaya AL, 1998, J NUTR, V128, p415S, DOI 10.1093/jn/128.2.415S; Spoelstra MN, 2012, METABOLISM, V61, P1224, DOI 10.1016/j.metabol.2012.01.019; Tetri LH, 2008, AM J PHYSIOL-GASTR L, V295, pG987, DOI 10.1152/ajpgi.90272.2008; van Zutphen T, 2016, J HEPATOL, V65, P1198, DOI 10.1016/j.jhep.2016.05.046; Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4; Wang NJ, 2016, J CLIN ENDOCR METAB, V101, P2218, DOI 10.1210/jc.2016-1076; Wang YH, 2010, OBESITY, V18, P588, DOI 10.1038/oby.2009.296; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x; Zauner C, 2000, AM J CLIN NUTR, V71, P1511	50	21	21	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2018	13	7							e0199916	10.1371/journal.pone.0199916	http://dx.doi.org/10.1371/journal.pone.0199916			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL5QR	29965973	Green Published, gold, Green Submitted			2023-01-03	WOS:000437224100028
J	Knight, JM; Mandal, P; Morlacchi, P; Mak, G; Li, E; Madison, M; Landers, C; Saxton, B; Felix, E; Gilbert, B; Sederstrom, J; Varadhachary, A; Singh, MM; Chatterjee, D; Corry, DB; McMurray, JS				Knight, J. Morgan; Mandal, Pijus; Morlacchi, Pietro; Mak, Garbo; Li, Evan; Madison, Matthew; Landers, Cameron; Saxton, Brandon; Felix, Ed; Gilbert, Brian; Sederstrom, Joel; Varadhachary, Atul; Singh, Melissa M.; Chatterjee, Dev; Corry, David B.; McMurray, John S.			Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						asthma; STAT transcription factor; allergen; fungi; cytokine; peptidomimetic; SH2 domain; STAT5; STAT6	DOSE INHALED FLUTICASONE; INNATE LYMPHOID-CELLS; SIGNAL-TRANSDUCTION; CARNITINE HOMEOSTASIS; PHOSPHATASE SHP-1; INFLUENZA-VIRUS; ASTHMA; THERAPY; IL-4; INFLAMMATION	Asthma is a chronic inflammatory disease of the lungs and airways and one of the most burdensome of all chronic maladies. Previous studies have established that expression of experimental and human asthma requires the IL-4/IL-13/IL-4 receptor (IL-4R) signaling pathway, which activates the transcription factor STAT6. However, no small molecules targeting this important pathway are currently in clinical development. To this end, using a preclinical asthma model, we sought to develop and test a small-molecule inhibitor of the Src homology 2 domains in mouse and human STAT6. We previously developed multiple peptidomimetic compounds on the basis of blocking the docking site of STAT6 to IL-4R and phosphorylation of Tyr(641) in STAT6. Here, we expanded the scope of our initial in vitro structure-activity relationship studies to include central and C-terminal analogs of these peptides to develop a lead compound, PM-43I. Conducting initial dose range, toxicity, and pharmacokinetic experiments with PM-43I, we found that it potently inhibits both STAT5- and STAT6-dependent allergic airway disease in mice. Moreover, PM-43I reversed preexisting allergic airway disease in mice with a minimum ED50 of 0.25 g/kg. Of note, PM-43I was efficiently cleared through the kidneys with no long-term toxicity. We conclude that PM-43I represents the first of a class of small molecules that may be suitable for further clinical development against asthma.	[Knight, J. Morgan; Mak, Garbo; Li, Evan; Corry, David B.] Baylor Coll Med, Dept Med, 1 Baylor Plaza,BCM285, Houston, TX 77030 USA; [Knight, J. Morgan; Corry, David B.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Saxton, Brandon; Gilbert, Brian] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Madison, Matthew; Landers, Cameron; Corry, David B.] Baylor Coll Med, Translat Biol & Mol Med Program, Houston, TX 77030 USA; [Li, Evan; Corry, David B.] Baylor Coll Med, Biol Inflammat Ctr, Houston, TX 77030 USA; [Mandal, Pijus; Morlacchi, Pietro; Felix, Ed; McMurray, John S.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX USA; [Sederstrom, Joel] Baylor Coll Med, Flow Cytometry Core Facil, Houston, TX USA; [Corry, David B.] Michael E Debakey Vet Affairs Ctr Translat Res In, Houston, TX 77030 USA; [Varadhachary, Atul; Singh, Melissa M.; Chatterjee, Dev] Fannin Innovat Studio & Atrapos Therapeut LLC, Houston, TX 77027 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Knight, JM; Corry, DB (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,BCM285, Houston, TX 77030 USA.	JMK@bcm.edu; dcorry@bcm.edu		Madison, Matthew/0000-0001-8143-7471; Landers, Cameron/0000-0002-1507-282X	National Institutes of Health [R41AI25007, R01 HL117181]; Veterans Affairs Office of Research and Development [I01BX002221, I01 CX001673]; American Asthma Foundation; Biology of Inflammation Center, Baylor College of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI125007] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002221] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Office of Research and Development; American Asthma Foundation; Biology of Inflammation Center, Baylor College of Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	This study was funded by National Institutes of Health Grants R41AI25007 and R01 HL117181, Veterans Affairs Office of Research and Development Grants I01BX002221 and I01 CX001673, the American Asthma Foundation, and the Biology of Inflammation Center, Baylor College of Medicine. J.M.K., P. Mandal, P. Morlacchi, D.B.C., and Atrapos Therapeutics, LLC hold intellectual property rights in compound PM-43I. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ahmed CMI, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00183; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Bhattacharjee A, 2013, FREE RADICAL BIO MED, V54, P1, DOI 10.1016/j.freeradbiomed.2012.10.553; Board on Environmental Studies and Toxicology Division on Earth and Life Sciences National Research Council, 2014, REV FORM ASS NAT TOX; Brass EP, 2002, PHARMACOL REV, V54, P589, DOI 10.1124/pr.54.4.589; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; Cates C. J., 2012, COCHRANE DATABASE SY; Chang GH, 2013, AM J OTOLARYNG, V34, P743, DOI 10.1016/j.amjoto.2013.07.016; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; Duerr CU, 2016, CYTOKINE, V87, P1, DOI 10.1016/j.cyto.2016.01.018; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fairfax AJ, 1999, THORAX, V54, P860, DOI 10.1136/thx.54.9.860; Gavino AC, 2016, ALLERGY, V71, P1684, DOI 10.1111/all.12937; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HALLER O, 1979, J EXP MED, V149, P601, DOI 10.1084/jem.149.3.601; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hao YH, 2014, INFECT IMMUN, V82, P5246, DOI 10.1128/IAI.01989-14; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Hoffmann F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00107; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Iwasaki A, 2017, NAT REV IMMUNOL, V17, P7, DOI 10.1038/nri.2016.117; Jia YY, 2013, BASIC CLIN PHARMACOL, V113, P431, DOI 10.1111/bcpt.12112; Kabata H, 2015, ALLERGOL INT, V64, P227, DOI 10.1016/j.alit.2015.03.004; Knight JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142212; Knight JM, 2014, J ALLERGY CLIN IMMUN, V133, P189, DOI 10.1016/j.jaci.2013.03.049; KNIGHT V, 1988, EUR J CLIN MICROBIOL, V7, P721, DOI 10.1007/BF01975037; Knight V, 1987, Infect Dis Clin North Am, V1, P441; Knosp CA, 2011, J EXP MED, V208, P1523, DOI 10.1084/jem.20101167; LAVROV SV, 1968, NATURE, V217, P856, DOI 10.1038/217856a0; Leav BA, 2000, NEW ENGL J MED, V343, P586, DOI 10.1056/NEJM200008243430818; Lee SH, 2008, J IMMUNOL, V180, P4656, DOI 10.4049/jimmunol.180.7.4656; Losman JA, 1999, J IMMUNOL, V162, P3770; Mandal PK, 2015, J MED CHEM, V58, P8970, DOI 10.1021/acs.jmedchem.5b01321; Mandal PK, 2011, J MED CHEM, V54, P3549, DOI 10.1021/jm2000882; Mandal PK, 2009, ORG LETT, V11, P3394, DOI 10.1021/ol9012662; McDonald VM, 2017, RESPIROLOGY, V22, P53, DOI 10.1111/resp.12957; McMurray John S, 2012, JAKSTAT, V1, P263, DOI 10.4161/jkst.22682; Mitkus RJ, 2013, VACCINE, V31, P2738, DOI 10.1016/j.vaccine.2013.03.071; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; Morlacchi P, 2014, ACS MED CHEM LETT, V5, P69, DOI 10.1021/ml4003919; Patnaik A, 2002, CLIN CANCER RES, V8, P2142; Peter E, 2002, CLIN INFECT DIS, V35, pE54, DOI 10.1086/341971; Peters MC, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0651-4; PHALEN RF, 1984, INHALATION STUDIES F, P211; Porter P, 2009, MUCOSAL IMMUNOL, V2, P504, DOI 10.1038/mi.2009.102; Porter PC, 2014, J ALLERGY CLIN IMMUN, V134, P325, DOI 10.1016/j.jaci.2014.04.028; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Reich Nancy C, 2013, JAKSTAT, V2, pe27080, DOI 10.4161/jkst.27080; SCHLESINGER RB, 1985, J TOXICOL ENV HEALTH, V15, P197, DOI 10.1080/15287398509530647; Simeone-Penney MC, 2007, J IMMUNOL, V178, P6191, DOI 10.4049/jimmunol.178.10.6191; Tan HTT, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0650-5; Uehara Y, 2015, CIRC J, V79, P2523, DOI 10.1253/circj.CJ-15-0960; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wu JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077795; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Yang XXO, 2013, NAT IMMUNOL, V14, P732, DOI 10.1038/ni.2633; Zhu JF, 2010, IMMUNOL CELL BIOL, V88, P244, DOI 10.1038/icb.2009.114	63	11	11	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2018	293	26					10026	10040		10.1074/jbc.RA117.000567	http://dx.doi.org/10.1074/jbc.RA117.000567			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GL4DA	29739850	hybrid, Green Published			2023-01-03	WOS:000437096700008
J	Austad, K; Shah, P; Rohloff, P				Austad, Kirsten; Shah, Pooja; Rohloff, Peter			Correlates of long-acting reversible contraception uptake among rural women in Guatemala	PLOS ONE			English	Article								Objective In many low-resource settings around the world utilization of long-acting reversible contraception (LARC) is low, in part due to access barriers. We sought to explore LARC utilization patterns as well as factors associated with LARC initiation by women seeking contraception in rural Guatemala from a program working to reduce contraception access barriers. Study design We analyzed data from a program that provides family planning in six remote, primarily indigenous, villages in Guatemala with limited access to alternative health services. Methods are free and delivered directly within villages by culturally competent providers. We conducted a retrospective chart review of all 288 women who initiated a contraceptive method over a 16-month period and conducted a logistic regression to obtain adjusted odds ratios (OR) for predictors of LARC uptake. Results Overall 79.2% of women elected a LARC method. More than half of women (49.8%) switched to LARC from short-acting hormonal methods. In the univariate analysis prior use of short-acting method (p = 0.014), number of prior methods (p = 0.049), and current contraceptive use (p<0.01) were significantly associated with choosing a LARC. In the logistic regression model current use of contraception remained significant (OR 3.29, 95% CI 1.678.04). Report of abnormal bleeding or other side effects from prior short-acting method use did not predict LARC uptake (p = 0.82 and p = 0.079). Conclusions Most women in this marginalized population opted for a LARC method.	[Austad, Kirsten] Brigham & Womens Hosp, Dept Med, Div Womens Hlth, 75 Francis St, Boston, MA 02115 USA; [Austad, Kirsten; Shah, Pooja; Rohloff, Peter] Wuqu Kawoq Maya Hlth Alliance, Santiago Sacatepequez, Guatemala; [Shah, Pooja] UCSF Sch Med, San Francisco, CA USA; [Rohloff, Peter] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital	Rohloff, P (corresponding author), Wuqu Kawoq Maya Hlth Alliance, Santiago Sacatepequez, Guatemala.; Rohloff, P (corresponding author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.	peter@wuqukawoq.org	Austad, Kirsten/ABC-7684-2021; Rohloff, Peter/P-8722-2017	Rohloff, Peter/0000-0001-7274-8315; Shah, Pooja/0000-0003-2183-9641; Austad, Kirsten/0000-0001-5237-2955	Brigham and Women's Hospital Global Women's Health Fellowship	Brigham and Women's Hospital Global Women's Health Fellowship	Dr. Kirsten Austad received funding from Brigham and Women's Hospital Global Women's Health Fellowship. The funder had no role in study design, data collection and analysis, or preparation of the manuscript.	Adetunji J.A., 2011, ETUDE POPUL AFR, V25, P587, DOI DOI 10.11564/25-2-247; Alemayehu M, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-6; Ali M, 2011, WORLD HLTH; Asnake Mengistu, 2013, Int J Gynaecol Obstet, V123 Suppl 1, pe29, DOI 10.1016/j.ijgo.2013.07.003; Belaid L, 2016, TROP MED INT HEALTH, V21, P1240, DOI 10.1111/tmi.12758; Bertrand JT, 2014, INT PERSPECT SEX R H, V40, P144, DOI 10.1363/4014414; Brown K, 2016, MATERN CHILD NUTR, V12, P262, DOI 10.1111/mcn.12141; Chary A, 2013, HUM ORGAN, V72, P87, DOI 10.17730/humo.72.2.f2014210742702r2; Curtis KM, 2017, NEW ENGL J MED, V376, P461, DOI 10.1056/NEJMcp1608736; Darroch JE, 2013, LANCET, V381, P1756, DOI 10.1016/S0140-6736(13)60597-8; Dassah ET, 2013, EUR J CONTRACEP REPR, V18, P293, DOI 10.3109/13625187.2013.790951; Dempsey AR, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.014; Farmer DB, 2015, GLOB HEALTH, V3, P242, DOI 10.9745/GHSP-D-14-00198; Goldstone P, 2014, MED J AUSTRALIA, V201, P412, DOI 10.5694/mja14.00011; Harper CC, 2015, LANCET, V386, P562, DOI 10.1016/S0140-6736(14)62460-0; Hosmer DW, 2013, WILEY SER PROBAB ST, P269; Hubacher D, 2011, CONTRACEPTION, V84, P413, DOI 10.1016/j.contraception.2011.02.007; Instituto Nacional de Estadistica (INE), 2012, CAR EST REP GUAT 201; Ministerio de Salud Publica y Asistencia Social (MSPAS), 2017, ENC NAC SAL MAT INF; Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089; O'Shea M, 2014, CONTRACEPTION, V90, P312, DOI 10.1016/j.contraception.2014.05.070; Powers BJ, 2015, WORLD HEAL ORG, V87, P276, DOI DOI 10.2165/00128413-200112870-00010; Prata N, 2009, PHILOS T R SOC B, V364, P3093, DOI 10.1098/rstb.2009.0172; Raine T, 2003, CONTRACEPTION, V68, P19, DOI 10.1016/S0010-7824(03)00107-0; Rees H, 2017, SAMJ S AFR MED J, V107, P939, DOI [10.7196/SAMJ.2017.v107i11.12903, 10.7196/samj.2017.v107i11.12903]; Reproductive Health Access Project, 2016, QUICK START ALG; Rios-Zertuche D, 2017, CONTRACEPTION, V95, P549, DOI 10.1016/j.contraception.2017.01.005; Secura GM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.017; Seiber EE, 2002, HEALTH POLICY PLANN, V17, P167, DOI 10.1093/heapol/17.2.167; Snow R, 1997, ACCEPTABILITY USERS; Speizer IS, 2009, REPROD HLTH, V6, P19, DOI [10.1186/1742-4755-6-19, DOI 10.1186/1742-4755-6-19]; Staveteig S, 2015, UPTAKE DISCONTINUATI, P1; Tibaijuka L, 2017, BMC WOMENS HEALTH, V17, P1, DOI [10.1186/s12905-016-0358-7, DOI 10.1186/S12905-016-0358-7]; Tilahun Y, 2017, GLOB HEALTH-SCI PRAC, V5, P592, DOI 10.9745/GHSP-D-17-00215; U.S. Agency for International Development (USAID, 2010, EXP CONTR CHOIC UND; [United Nation Department of Economic and Social Affairs PD], 2015, TRENDS CONTR US WORL, DOI [10.1016/j.contraception.2012.08.029, DOI 10.1016/J.CONTRACEPTION.2012.08.029]; USAID, 2015, TEST SERV DEL MOD OF; Whitaker AK, 2016, PATIENT EDUC COUNS, V99, P1663, DOI 10.1016/j.pec.2016.05.011; Whitaker AK, 2010, CONTRACEPTION, V81, P299, DOI 10.1016/j.contraception.2009.11.008	39	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2018	13	6							e0199536	10.1371/journal.pone.0199536	http://dx.doi.org/10.1371/journal.pone.0199536			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK9FZ	29949633	Green Submitted, Green Published, gold			2023-01-03	WOS:000436549200055
J	Jean, G; Lafage-Proust, MH; Souberbielle, JC; Lechevallier, S; Deleaval, P; Lorriaux, C; Hurot, JM; Mayor, B; Mehdi, M; Chazot, C				Jean, Guillaume; Lafage-Proust, Marie Helene; Souberbielle, Jean Claude; Lechevallier, Sylvain; Deleaval, Patrik; Lorriaux, Christie; Hurot, Jean Marc; Mayor, Brice; Mehdi, Manolie; Chazot, Charles			Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; MINERAL METABOLISM; BONE BIOMARKERS; CALCIUM; PROGRESSION; OUTCOMES; CARE; CALCIFICATION; PHOSPHORUS; MORTALITY	Background Secondary hyperparathyroidism (SHPT) is a frequent complication of renal disease and most commonly occurs in patients on haemodialysis (HD) with metabolic, vascular, endocrine, and bone complications. The aim of this study was to analyze the evolution of mineral metabolism parameters during the first 36 months of HD treatment and identify the initial factors associated with severe SHPT. Methods Serum parathyroid hormone (PTH), calcium and phosphate levels were measured monthly; bone-specific alkaline phosphatase (b-ALP) and beta-CrossLaps (CTX) were measured biannually. Severe SHPT was defined as the need for cinacalcet treatment. Patients with less than 24 months of follow-up were excluded. Results One hundred thirty-three incident HD patients were included. Baseline mean PTH was 275 +/- 210 pg/mL. After an initial drop at the third month (172 +/- 133 pg/mL), the serum PTH level progressively increased to the maximum at 36 months (367 +/- 254 pg/mL). This initial drop was associated with the initial correction of both hypocalcaemia and hyperphosphataemia. Serum CTX and b-ALP revealed no significant changes over time. Severe SHPT was observed in 18% of patients and was associated with higher mean calcaemia and phosphataemia. In logistic regression, the initial factors associated with the risk of severe SHPT were: female sex, higher baseline PTH and CTX values. A receiver operation characteristic curve analysis identified a cut-off value of >374 pg/mL for baseline PTH and >1.2 pg/L for CTX for increased risk of developing severe SHPT. The relative risk of developing severe SHPT was 3.7 (1.8-7.5, p = 0.002) for high baseline CTX, 4.9 (2.4-9.7, p = 0.001) for high baseline PTH, and 7.7 (3.6-16, p<0.0001) when both criteria were present. Conclusion After an initial drop, a progressive increase in the serum PTH level during the first 3 years of HD treatment was observed despite aggressive therapy. High baseline levels of PTH and CTX increased the risk of developing severe SHPT.	[Jean, Guillaume; Deleaval, Patrik; Lorriaux, Christie; Hurot, Jean Marc; Mayor, Brice; Mehdi, Manolie; Chazot, Charles] NEPHROCARE Tassin Charcot, Haemodialysis, Sainte Foy Les Lyon, France; [Lafage-Proust, Marie Helene; Chazot, Charles] CHU St Etienne, INSERM 890, St Etienne, France; [Souberbielle, Jean Claude; Chazot, Charles] Univ Paris 05, INSERM, U845, Paris, France; [Souberbielle, Jean Claude; Chazot, Charles] Hop Necker Enfants Malad, Serv Explorat Fonct, Paris, France; [Lechevallier, Sylvain; Chazot, Charles] CERBALLIANCE, Lab Biol Med Grand Vallon, Sainte Foy Les Lyon, France; [Chazot, Charles] F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France	CHU de St Etienne; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Jean, G (corresponding author), NEPHROCARE Tassin Charcot, Haemodialysis, Sainte Foy Les Lyon, France.	guillaume-jean-crat@wanadoo.fr		Lafage-Proust, Marie-Helene/0000-0002-2091-3961; Jean, guillaume/0000-0003-4757-9956	NEPHROCARE (Fresenius Medical Care France); CERBALLIANCE	NEPHROCARE (Fresenius Medical Care France); CERBALLIANCE	NEPHROCARE (Fresenius Medical Care France) and CERBALLIANCE provided support in the form of salaries for authors GJ, PD, CL, JMH, BM, MM, CC and SL but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aparicio M, 2012, J RENAL NUTR, V22, pS22, DOI 10.1053/j.jrn.2011.09.006; Basile C, 2012, AM J KIDNEY DIS, V59, P92, DOI 10.1053/j.ajkd.2011.08.033; Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523-1755.2002.00434.x; Delanaye P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12808-3; Delanaye P, 2014, NEPHROL DIAL TRANSPL, V29, P997, DOI 10.1093/ndt/gft275; Felsenfeld AJ, 2015, SEMIN DIALYSIS, V28, P564, DOI 10.1111/sdi.12411; Figurek A, 2017, ROM J INTERN MED, V55, P222, DOI 10.1515/rjim-2017-0021; Fouque D, 2013, NEPHROL DIAL TRANSPL, V28, P360, DOI 10.1093/ndt/gfs404; Hansen D, 2011, KIDNEY INT, V80, P841, DOI 10.1038/ki.2011.226; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Jean G, 2007, CLIN NEPHROL, V68, P63; Jean G, 2017, NEPHROL THER, V13, P470, DOI 10.1016/j.nephro.2017.02.009; Jean G, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0365-9; Jean G, 2013, NEPHROL THER, V9, P154, DOI 10.1016/j.nephro.2013.02.006; Jean G, 2013, NEPHROL DIAL TRANSPL, V28, P176, DOI 10.1093/ndt/gfs119; Jean G, 2012, NEPHRON CLIN PRACT, V120, pC132, DOI 10.1159/000334424; Kandula P, 2011, CLIN J AM SOC NEPHRO, V6, P50, DOI 10.2215/CJN.03940510; KDIGO C-M, 2009, KIDNEY INT S113, V76, pS1, DOI DOI 10.1038/KI.2009.188; Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006; Kovesdy CP, 2008, KIDNEY INT, V73, P1296, DOI 10.1038/ki.2008.64; Liabeuf S, 2017, NEPHROL DIAL TRANSPL, V32, P1737, DOI 10.1093/ndt/gfw409; Lishmanov A, 2012, INT UROL NEPHROL, V44, P541, DOI 10.1007/s11255-010-9897-2; LLACH F, 1990, KIDNEY INT, V38, pS62; Moranne O, 2009, J AM SOC NEPHROL, V20, P164, DOI 10.1681/ASN.2008020159; QI QL, 1995, AM J KIDNEY DIS, V26, P622, DOI 10.1016/0272-6386(95)90599-5; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; Reichel H, 2004, NEPHRON CLIN PRACT, V98, pC112, DOI 10.1159/000081552; Rodriguez M, 2005, CALCIUM SENSING RECE, V288, pF253, DOI [10.1152/ajprenal.00302.2004, DOI 10.1152/AJPRENAL.00302.2004]; Schumock GT, 2008, CURR MED RES OPIN, V24, P3037, DOI 10.1185/03007990802437943 ; Souberbielle JC, 2006, KIDNEY INT, V70, P345, DOI 10.1038/sj.ki.5001606; Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213; Wolf M, 2010, J AM SOC NEPHROL, V21, P1427, DOI 10.1681/ASN.2009121293; Yan JF, 2015, INT UROL NEPHROL, V47, P701, DOI 10.1007/s11255-015-0917-0; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x	34	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2018	13	6							e0199140	10.1371/journal.pone.0199140	http://dx.doi.org/10.1371/journal.pone.0199140			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ6XV	29912988	gold, Green Published, Green Submitted			2023-01-03	WOS:000435528600080
J	Adderley, NJ; Nirantharakumar, K; Marshall, T				Adderley, Nicola J.; Nirantharakumar, Krishnarajah; Marshall, Tom			Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CATHETER ABLATION; MANAGEMENT; ANTICOAGULANTS; GUIDELINES; CARDIOVERSION; WARFARIN; OUTCOMES; THERAPY	OBJECTIVES To determine rates of stroke or transient ischaemic attack (TIA) and all cause mortality in patients with a diagnosis of "resolved" atrial fibrillation compared to patients with unresolved atrial fibrillation and without atrial fibrillation. DESIGN Two retrospective cohort studies. SETTING General practices contributing to The Health Improvement Network, 1 January 2000 to 15 May 2016. PARTICIPANTS Adults aged 18 years or more with no previous stroke or TIA: 11 159 with resolved atrial fibrillation, 15 059 controls with atrial fibrillation, and 22 266 controls without atrial fibrillation. MAIN OUTCOME MEASURES Primary outcome was incidence of stroke or TIA. Secondary outcome was all cause mortality. RESULTS Adjusted incidence rate ratios for stroke or TIA in patients with resolved atrial fibrillation were 0.76 (95% confidence interval 0.67 to 0.85, P<0.001) versus controls with atrial fibrillation and 1.63 (1.46 to 1.83, P<0.001) versus controls without atrial fibrillation. Adjusted incidence rate ratios for mortality in patients with resolved atrial fibrillation were 0.60 (0.56 to 0.65, P<0.001) versus controls with atrial fibrillation and 1.13 (1.06 to 1.21, P<0.001) versus controls without atrial fibrillation. When patients with resolved atrial fibrillation and documented recurrent atrial fibrillation were excluded the adjusted incidence rate ratio for stroke or TIA was 1.45 (1.26 to 1.67, P<0.001) versus controls without atrial fibrillation. CONCLUSION Patients with resolved atrial fibrillation remain at higher risk of stroke or TIA than patients without atrial fibrillation. The risk is increased even in those in whom recurrent atrial fibrillation is riot documented. Guidelines should be updated to advocate continued use of anticoagulants in patients with resolved atrial fibrillation.	[Adderley, Nicola J.; Nirantharakumar, Krishnarajah; Marshall, Tom] Univ Birmingham, Inst Appl Hlth Res, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Nirantharakumar, K (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham B15 2TT, W Midlands, England.	K.Nirantharan@bham.ac.uk	Adderley, Nicola J/ABD-7501-2021	Adderley, Nicola/0000-0003-0543-3254; Marshall, Tom/0000-0001-9277-5214	NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands initiative; MRC [MR/S003878/1, MC_PC_15079] Funding Source: UKRI	NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands initiative; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	NA and TM are funded by the NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands initiative. This paper presents independent research and the views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adderley N, 2017, BRIT J GEN PRACT, V67, pE588, DOI 10.3399/bjgp17X691685; Aguilar MI, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006186.pub2; Aguilar MI, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001927.pub2; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bjorck S, 2013, STROKE, V44, P3103, DOI 10.1161/STROKEAHA.113.002329; Bunch TJ, 2013, HEART RHYTHM, V10, P1272, DOI 10.1016/j.hrthm.2013.07.002; Camm AJ, 2012, EUR HEART J, V33; Chao TF, 2015, J THORAC DIS, V7, P172, DOI 10.3978/j.issn.2072-1439.2015.01.18; Chao TF, 2012, CIRC-ARRHYTHMIA ELEC, V5, P514, DOI 10.1161/CIRCEP.111.968032; Christiansen CB, 2016, EUROPACE, V18, P1689, DOI 10.1093/europace/euv401; Cowan C, 2013, HEART, V99, P1166, DOI 10.1136/heartjnl-2012-303472; DeWilde S, 2006, HEART, V92, P1064, DOI 10.1136/hrt.2005.069492; Friberg L, 2016, EUR HEART J, V37, P2478, DOI 10.1093/eurheartj/ehw087; Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d; General Practitioners Committee NHS Employers and NHS England, 2016, NHS EMPL NHS ENGL 20; Isaew A, 2017, HEART, V103, P1502, DOI 10.1136/heartjnl-2016-310927; January CT, 2014, CIRCULATION, V130, pE199, DOI [10.1161/CIR.0000000000000041, 10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.021, 10.1016/j.jacc.2014.03.022]; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Lane DA, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005155; Link MS, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.116.004267; Maguire A, 2009, PHARMACOEPIDEM DR S, V18, P76, DOI 10.1002/pds.1688; Marston L, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004958; National Clinical Guideline Centre (UK), 2014, ATR FIBR MAN ATR FIB; National Institute for Health and Care Excellence, 2014, 180 NICE; National Institute for Health and Clinical Excellence, 2006, 36 NICE; NHS England, 2016, NEW GMS CONTR QOF IM; Noseworthy PA, 2015, HEART RHYTHM, V12, P1154, DOI 10.1016/j.hrthm.2015.02.020; Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025; The National Collaborating Centre for Chronic Conditions, 2006, ATR FIBR NAT CLIN GU; Tilz RR, 2012, J AM COLL CARDIOL, V60, P1921, DOI 10.1016/j.jacc.2012.04.060; Vanassche T, 2015, EUR HEART J, V36, P281, DOI 10.1093/eurheartj/ehu307; Verma A, 2014, CAN J CARDIOL, V30, P1114, DOI 10.1016/j.cjca.2014.08.001; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Zimetbaum P, 2012, CIRCULATION, V125, P381, DOI 10.1161/CIRCULATIONAHA.111.019927	34	32	32	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 9	2018	361								k1717	10.1136/bmj.k1717	http://dx.doi.org/10.1136/bmj.k1717			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF4ZZ	29743285				2023-01-03	WOS:000431975300005
J	Siegler, JC; Marshall, PWM; Finn, H; Cross, R; Mudie, K				Siegler, Jason C.; Marshall, Paul W. M.; Finn, Harrison; Cross, Rebecca; Mudie, Kurt			Acute attenuation of fatigue after sodium bicarbonate supplementation does not manifest into greater training adaptations after 10-weeks of resistance training exercise	PLOS ONE			English	Article							FORCE DEVELOPMENT; METABOLIC ALKALOSIS; INTENSITY; INGESTION; STRENGTH; PERFORMANCE; POWER; MECHANISMS; CAFFEINE; NAHCO3	Purpose In two concurrent studies, we aimed to a) confirm the acute effect of 0.3 g.kg(-1) body weight (BW) sodium bicarbonate (NaHCO3) supplementation on central and peripheral mechanisms associated with explosive power (Study 1) and b) determine whether chronic NaHCO3 supplementation would improve the adaptive response of the neuromuscular system during a 10-week resistance training program (Study 2). Methods Eight resistance trained participants volunteered after providing written consent. The experimental design consisted of a week of baseline testing, followed by ten weeks of training with progress measures performed in Week 5. Study 1 involved neuromuscular measurements before and after the leg extension portion of a power based training session performed in Week 1. Changes in maximal torque (MVT) and rates of torque development (RTD), along with other variables derived from femoral nerve stimulation (e.g. voluntary activation, neural recruitment) were analysed to determine the extent of fatigue under NaHCO3 or placebo conditions. Changes in these same variables, coupled with functional 1-repetition maximum leg extension strength, were measured in Study 2 from baseline (Week 0) to Week 5, and again at Week 10. Results and conclusion In Study 1, we observed a decline after the leg extension task in both MVT (similar to 30%) and rates of torque production (RTD) irrespective of acid-base status, however the decline in maximal RTD (RTDMAX) was nearly 20% less in the NaHCO3 condition when compared to placebo (mean difference of 294.8 +/- 133.4 Nm.s(-1) (95% CI -583.1 to -6.5 Nm, p < 0.05)). The primary finding in Study 2, however, suggests that introducing NaHCO3 repeatedly during a 10-week RT program does not confer any additional benefit to the mechanisms (and subsequent adaptive processes) related to explosive power production.	[Siegler, Jason C.; Marshall, Paul W. M.; Finn, Harrison; Cross, Rebecca; Mudie, Kurt] Western Sydney Univ, Sch Sci & Hlth, Sport & Exercise Sci, Sydney, NSW, Australia; [Finn, Harrison] Neurosci Res Australia, Sydney, NSW, Australia; [Mudie, Kurt] Victoria Univ, ISEAL, Melbourne, Vic, Australia	Western Sydney University; Neuroscience Research Australia; Victoria University	Siegler, JC (corresponding author), Western Sydney Univ, Sch Sci & Hlth, Sport & Exercise Sci, Sydney, NSW, Australia.	j.siegler@westernsydney.edu.au	Finn, Harrison/AGI-9875-2022	Mudie, Kurt/0000-0001-9328-4759; Cross, Rebecca/0000-0002-3966-9313; Siegler, Jason/0000-0003-1346-4982	University of Western Sydney: School of Science and Health's Seed Grant scheme; Western Sydney University's School of Science and Health's Seed Grant scheme	University of Western Sydney: School of Science and Health's Seed Grant scheme; Western Sydney University's School of Science and Health's Seed Grant scheme	This work was supported by the University of Western Sydney: School of Science and Health's Seed Grant scheme (Dr. Jason C Siegler). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to acknowledge Bulk Nutrients (TM) for supplying the carbohydrate and protein powders for the standardized pre-exercise meal replacement shake. Additional support was also provided by the Western Sydney University's School of Science and Health's Seed Grant scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; Broch-Lips M, 2007, J APPL PHYSIOL, V103, P494, DOI 10.1152/japplphysiol.00049.2007; Carr AJ, 2011, SPORTS MED, V41, P801, DOI 10.2165/11591440-000000000-00000; Carr BM, 2013, EUR J APPL PHYSIOL, V113, P743, DOI 10.1007/s00421-012-2484-8; Coombes J., 1993, J STRENGTH COND RES, V7, P241, DOI DOI 10.1519/1533-4287(1993)007<0241; Davis JK, 2009, SPORTS MED, V39, P813, DOI 10.2165/11317770-000000000-00000; Douroudos II, 2006, MED SCI SPORT EXER, V38, P1746, DOI 10.1249/01.mss.0000230210.60957.67; Duncan MJ, 2014, J STRENGTH COND RES, V28, P1358, DOI 10.1519/JSC.0000000000000277; Fyfe JJ, 2014, SPORTS MED, V44, P743, DOI 10.1007/s40279-014-0162-1; Gough LA, 2017, SPORTS MED, P1; Higgins MF, 2013, EUR J APPL PHYSIOL, V113, P1331, DOI 10.1007/s00421-012-2557-8; Hodges PW, 1996, ELECTROMYOGR MOTOR C, V101, P511, DOI 10.1016/S0921-884X(96)95190-5; Jones RL, 2016, INT J SPORT NUTR EXE, V26, P445, DOI 10.1123/ijsnem.2015-0286; Kreider RB, 2017, J INT SOC SPORT NUTR, V14, DOI 10.1186/s12970-017-0173-z; Mangine GT, 2016, EUR J APPL PHYSIOL, V116, P2367, DOI 10.1007/s00421-016-3488-6; Marshall PWM, 2011, EUR J APPL PHYSIOL, V111, P3007, DOI 10.1007/s00421-011-1944-x; McMaster DT, 2013, SPORTS MED, V43, P367, DOI 10.1007/s40279-013-0031-3; McNaughton L, 1999, EUR J APPL PHYSIOL O, V80, P333, DOI 10.1007/s004210050600; McNaughton LR, 2008, CURR SPORT MED REP, V7, P230, DOI 10.1249/JSR.0b013e31817ef530; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; Mitchell CJ, 2012, J APPL PHYSIOL, V113, P71, DOI 10.1152/japplphysiol.00307.2012; Peart DJ, 2012, J STRENGTH COND RES, V26, P1975, DOI 10.1519/JSC.0b013e3182576f3d; Portington KJ, 1998, MED SCI SPORT EXER, V30, P523, DOI 10.1097/00005768-199804000-00009; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Rhea MR, 2002, J STRENGTH COND RES, V16, P525; Siegler JC, 2016, EXP PHYSIOL, V101, P1383, DOI 10.1113/EP085933; Siegler JC, 2015, EXP PHYSIOL, V100, P519, DOI 10.1113/EP085054; Siegler JC, 2015, EUR J APPL PHYSIOL, V115, P565, DOI 10.1007/s00421-014-3027-2; Siegler JC, 2013, J APPL PHYSIOL, V115, P1634, DOI 10.1152/japplphysiol.00688.2013; Siegler JC, 2016, SPORTS MED OPEN, P1; Strojnik V, 1998, J APPL PHYSIOL, V84, P344, DOI 10.1152/jappl.1998.84.1.344; Tarnopolsky MA, 2010, ANN NUTR METAB, V57, P1, DOI 10.1159/000322696; Volek JS, 2004, MED SCI SPORT EXER, V36, P689, DOI 10.1249/01.MSS.0000121944.19275.C4; WEBSTER MJ, 1993, MED SCI SPORT EXER, V25, P960; Zhang SJ, 2006, J PHYSIOL-LONDON, V572, P551, DOI 10.1113/jphysiol.2005.104521	35	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2018	13	5							e0196677	10.1371/journal.pone.0196677	http://dx.doi.org/10.1371/journal.pone.0196677			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE5SH	29718968	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000431281900068
J	Jones, CM; Einstein, EB; Compton, WM				Jones, Christopher M.; Einstein, Emily B.; Compton, Wilson M.			Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Jones, Christopher M.] Substance Abuse & Mental Hlth Serv Adm, 5600 Fishers Ln,Ste 18E63, Rockville, MD 20857 USA; [Einstein, Emily B.; Compton, Wilson M.] Natl Inst Drug Abuse, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Jones, CM (corresponding author), Substance Abuse & Mental Hlth Serv Adm, 5600 Fishers Ln,Ste 18E63, Rockville, MD 20857 USA.	christopher.jones@samhsa.hhs.gov						Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Centers for Disease Control and Prevention, 2017, NAT VIT STAT SYST 20; Drug Enforcement Administration, 2017, NAT DRUG THREAT ASS; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Tomassoni AJ, 2017, MMWR-MORBID MORTAL W, V66, P107, DOI 10.15585/mm6604a4	5	201	201	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2018	319	17					1819	1821		10.1001/jama.2018.2844	http://dx.doi.org/10.1001/jama.2018.2844			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE3UQ	29715347	Green Published, Bronze			2023-01-03	WOS:000431138800021
J	Park, JY; Cho, JH; Jang, HM; Kim, YS; Kang, SW; Yang, CW; Kim, NH; Choi, JY; Park, SH; Kim, CD; Kim, YL				Park, Ja-Yong; Cho, Jang-Hee; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim			Survival predictors in anuric patients on peritoneal dialysis: A prospective, multicenter, propensity score-matched cohort study	PLOS ONE			English	Article							RESIDUAL RENAL-FUNCTION; C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; NUTRITIONAL-STATUS; TRANSPORT RATE; SERUM-ALBUMIN; CAPD PATIENTS; BODY-SIZE; MORTALITY; SOLUTE	Prevalent anuric peritoneal dialysis (PD) patients usually have higher mortality than PD patients with residual urine volume. We aimed to evaluate the predictors of survival in anuric PD patients. Anuric PD patients (n = 505, <100 mL of daily urine) enrolled in Korean nationwide prospective cohort were analyzed. Survived and non-survived anuric PD patients were compared by propensity score matching analysis with a ratio of two to one. The propensity method was used to adjust for patient age, dialysis duration, and presence of diabetes. Among the total anuric PD patients, non-survived patients showed a significantly older age, higher incidence of diabetes, coronary artery disease, and arrhythmia, and lower serum creatinine and albumin. After propensity score matching, multivariate Cox regression analysis for patient survival showed a decreasing risk as serum albumin increased (HR = 0.347, p = 0.0094). Analysis using the receiver-operating-characteristic (ROC) curve showed that survival could be predicted with a sensitivity of 59.4% and a specificity of 63.2% using a cutoff value of 3.6 g/dL of serum albumin in unmatched total PD patients. The beneficial impact of high albumin level on death was significantly greater for patients with older age (>= 50 years), no diabetes, low ultrafiltration (UF) volume (<1000 mL/day), and low levels of serum creatinine (<10 mg/dL), total cholesterol (<177.5 mg/dL), ferritin (<100 ng/mL), and high-sensitivity C-reactive protein (hs-CRP) (<0.1 mg/dL). Survival in anuric PD patients was associated with age, comorbidities, and nutritional factors such as creatinine and albumin. After adjustment by propensity score matching, serum albumin level was an independent predictor for survival in anuric PD patients.	[Park, Ja-Yong; Cho, Jang-Hee; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] CRC ESRD Korea, Daegu, South Korea; [Park, Ja-Yong; Cho, Jang-Hee; Jang, Hye Min; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Daegu, South Korea; [Kim, Yon Su] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Coll Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Gwangju, South Korea	Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University	Kim, CD; Kim, YL (corresponding author), CRC ESRD Korea, Daegu, South Korea.; Kim, CD; Kim, YL (corresponding author), Kyungpook Natl Univ, Sch Med, Daegu, South Korea.	drcdkim@knu.ac.kr; ylkim@knu.ac.kr	Park, Sun/GSD-9620-2022; Cho, Jang-hee/ABD-3534-2020	Cho, Jang-hee/0000-0002-7031-5214	Korean Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea (Korea National Institute of Health) [HI15C0001, HC15C1129]	Korean Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea (Korea National Institute of Health)	This research was supported by a grant of the Korean Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI, URL: http.//www.khidi.or.kr/kps, recipient: YLK), funded by the Ministry of Health and Welfare, Republic of Korea (URL: http://www.moliw.go.kr, recipient: YLK) (Korea National Institute of Health HI15C0001 and HC15C1129).	[Anonymous], 2005, NEPHROL DIAL TRANSPL, V20; Apple FS, 2002, CIRCULATION, V106, P2941, DOI 10.1161/01.CIR.0000041254.30637.34; AVRAM MM, 1994, AM J KIDNEY DIS, V23, P91, DOI 10.1016/S0272-6386(12)80817-1; Avram Morrell M, 2005, Adv Perit Dial, V21, P154; Avram Morrell M, 2012, Adv Perit Dial, V28, P144; Bhaskaran S, 2000, PERITON DIALYSIS INT, V20, P181; BLAKE PG, 1993, J AM SOC NEPHROL, V3, P1501; Chung SH, 2001, NEPHROL DIAL TRANSPL, V16, P2240, DOI 10.1093/ndt/16.11.2240; Davies SJ, 1998, NEPHROL DIAL TRANSPL, V13, P962, DOI 10.1093/ndt/13.4.962; Diaz-Buxo JA, 1999, AM J KIDNEY DIS, V33, P523, DOI 10.1016/S0272-6386(99)70190-3; Dong J, 2008, KIDNEY INT, V73, P334, DOI 10.1038/sj.ki.5002644; Ducloux D, 2002, KIDNEY INT, V62, P1417, DOI 10.1111/j.1523-1755.2002.kid562.x; GENESTIER S, 1995, NEPHROL DIAL TRANSPL, V10, P1905; Herzig KA, 2001, J AM SOC NEPHROL, V12, P814, DOI 10.1681/ASN.V124814; Jansen MAM, 2005, KIDNEY INT, V68, P1199, DOI 10.1111/j.1523-1755.2005.00512.x; Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x; Johansen KL, 2004, AM J CLIN NUTR, V80, P324, DOI 10.1093/ajcn/80.2.324; Jones CH, 1998, NEPHROL DIAL TRANSPL, V13, P393, DOI 10.1093/oxfordjournals.ndt.a027836; Kendrick J, 2010, CLIN J AM SOC NEPHRO, V5, P1123, DOI 10.2215/CJN.04300709; Kim HW, 2015, PERITON DIALYSIS INT, V35, P703, DOI 10.3747/pdi.2013.00328; Lin XH, 2010, NEPHROL DIAL TRANSPL, V25, P2322, DOI 10.1093/ndt/gfq001; Lo WK, 2006, PERITON DIALYSIS INT, V26, P520; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Noori N, 2011, AM J NEPHROL, V33, P157, DOI 10.1159/000323972; Oh KH, 2008, NEPHROL DIAL TRANSPL, V23, P2356, DOI 10.1093/ndt/gfm921; Park J, 2013, NEPHROL DIAL TRANSPL, V28, P2146, DOI 10.1093/ndt/gft213; Ramkumar N, 2005, PERITON DIALYSIS INT, V25, P461; Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C; Sezer S, 2001, Adv Perit Dial, V17, P210; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; Szeto CC, 2001, J AM SOC NEPHROL, V12, P355, DOI 10.1681/ASN.V122355; VALDERRABANO F, 1995, NEPHROL DIAL TRANSPL, V10, P1; Walther CP, 2012, NEPHROL DIAL TRANSPL, V27, P771, DOI 10.1093/ndt/gfr389; Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P396, DOI 10.1093/ndt/gfh331; Wang AYM, 2003, J AM SOC NEPHROL, V14, P1871, DOI 10.1097/01.ASN.0000070071.57901.B3	35	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2018	13	4							e0196294	10.1371/journal.pone.0196294	http://dx.doi.org/10.1371/journal.pone.0196294			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD8ZI	29694445	Green Submitted, Green Published, gold			2023-01-03	WOS:000430802400080
J	Goldstein, JN; Dudzinski, DM; Erickson, TB; Linder, G				Goldstein, Joshua N.; Dudzinski, David M.; Erickson, Timothy B.; Linder, Grace			Case 12-2018: A 30-Year-Old Woman with Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS LIPID EMULSION; TRICYCLIC ANTIDEPRESSANT INGESTION; EMERGENCY-DEPARTMENT; PREDICTING SEIZURES; OVERDOSE; TOXICITY; CARDIOTOXICITY; AMITRIPTYLINE; THERAPY; PHYSOSTIGMINE		[Goldstein, Joshua N.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Dudzinski, David M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA; [Linder, Grace] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; [Erickson, Timothy B.] Harvard Med Sch, Brigham & Womens Hosp, Dept Emergency Med, Boston, MA USA; [Goldstein, Joshua N.; Erickson, Timothy B.] Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA; [Dudzinski, David M.] Harvard Med Sch, Dept Med, Boston, MA USA; [Linder, Grace] Harvard Med Sch, Dept Pathol, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Goldstein, JN (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA.; Goldstein, JN (corresponding author), Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA.		Goldstein, Joshua N/H-8953-2016; Erickson, Timothy/ABB-7761-2021					Abeyaratne Dayakshi D K, 2016, BMC Res Notes, V9, P167, DOI 10.1186/s13104-016-1963-0; Agarwala R, 2014, J MED TOXICOL, V10, P210, DOI 10.1007/s13181-013-0353-4; Am Acad Clin Toxicol, 2005, CLIN TOXICOL, V43, P61, DOI 10.1081/CLT-200051867; Amer Coll Med Toxicology, 2017, J MED TOXICOL, V13, P124, DOI 10.1007/s13181-016-0550-z; Amiri H, 2016, JRSM CARDIOVASC DIS, V5, DOI 10.1177/2048004016682178; Barrueto F, 2006, J MED TOXICOL, V2, P147, DOI 10.1007/BF03161182; Bebarta VS, 2007, AM J CARDIOL, V100, P656, DOI 10.1016/j.amjcard.2007.03.077; Blaber MS, 2012, J EMERG MED, V43, P465, DOI 10.1016/j.jemermed.2011.09.010; BOEHNERT MT, 1985, NEW ENGL J MED, V313, P474, DOI 10.1056/NEJM198508223130804; Bruccoleri RE, 2016, J MED TOXICOL, V12, P121, DOI 10.1007/s13181-015-0483-y; Burns MJ, 2000, ANN EMERG MED, V35, P374, DOI 10.1016/S0196-0644(00)70057-6; CALLAHAM M, 1985, ANN EMERG MED, V14, P1, DOI 10.1016/S0196-0644(85)80725-3; Cao DZ, 2015, J EMERG MED, V48, P387, DOI 10.1016/j.jemermed.2014.10.009; Chia MYC, 2017, RESUSCITATION, V111, P34, DOI 10.1016/j.resuscitation.2016.11.019; EREN CS, 2014, AM J EMERG MED, V32, P1103, DOI DOI 10.1016/J.AJEM.2014.05.019; Fettiplace MR, 2015, ANN EMERG MED, V66, P185, DOI 10.1016/j.annemergmed.2015.01.020; Foianini A, 2010, CLIN TOXICOL, V48, P325, DOI 10.3109/15563650.2010.487050; Garg U, 2012, THERAPEUTIC DRUG MONITORING: NEWER DRUGS AND BIOMARKERS, P269, DOI 10.1016/B978-0-12-385467-4.00013-0; GOODWIN DA, 1993, CRIT CARE MED, V21, P625, DOI 10.1097/00003246-199304000-00025; Gosselin S, 2016, CLIN TOXICOL, V54, P899, DOI 10.1080/15563650.2016.1214275; Harrigan RA, 1999, AM J EMERG MED, V17, P387, DOI 10.1016/S0735-6757(99)90094-3; Heinonen JA, 2013, BASIC CLIN PHARMACOL, V113, P193, DOI 10.1111/bcpt.12082; Khalid MM., 2017, STATPEARLS; Kontio T, 2015, THER HYPOTHERMIA TEM, V5, P104, DOI 10.1089/ther.2014.0030; LAVOIE FW, 1990, ANN EMERG MED, V19, P696, DOI 10.1016/S0196-0644(05)82482-5; Le Fevre P, 2017, BMJ CASE REP; Levine MD, 2018, ROSENS EMERGENCY MED, P1868; Levine M, 2016, CLIN TOXICOL, V54, P194, DOI 10.3109/15563650.2015.1126286; Levine M, 2014, J MED TOXICOL, V10, P10, DOI 10.1007/s13181-013-0356-1; LIEBELT EL, 1995, ANN EMERG MED, V26, P195, DOI 10.1016/S0196-0644(95)70151-6; Liebelt EL, 1997, CRIT CARE MED, V25, P1721, DOI 10.1097/00003246-199710000-00024; Melanson SEF, 2007, J ANAL TOXICOL, V31, P270, DOI 10.1093/jat/31.5.270; Milone MC, 2012, THERAPEUTIC DRUG MONITORING: NEWER DRUGS AND BIOMARKERS, P49, DOI 10.1016/B978-0-12-385467-4.00003-8; NIEMANN JT, 1986, AM J CARDIOL, V57, P1154, DOI 10.1016/0002-9149(86)90691-0; Odigwe Chibuzo Clement, 2016, Proc (Bayl Univ Med Cent), V29, P284; Olson KR, 2010, J MED TOXICOL, V6, P190, DOI 10.1007/s13181-010-0046-1; PENTEL P, 1980, ANN EMERG MED, V9, P588, DOI 10.1016/S0196-0644(80)80232-0; Phillips MA, 2014, J MED TOXICOL, V10, P205, DOI 10.1007/s13181-013-0330-y; Ramasubbu BM, 2016, TOXICOL LETT, V258, pS100, DOI 10.1016/j.toxlet.2016.06.1429; Shanon M, 1998, PEDIATR EMERG CARE, V14, P293, DOI 10.1097/00006565-199808000-00015; Varney SM, 2014, ACAD EMERG MED, V21, P1212, DOI 10.1111/acem.12513; Watkins JW, 2015, J MED TOXICOL, V11, P179, DOI 10.1007/s13181-014-0452-x	42	4	4	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2018	378	16					1538	1549		10.1056/NEJMcpc1800322	http://dx.doi.org/10.1056/NEJMcpc1800322			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD2EI	29669228				2023-01-03	WOS:000430312500011
J	Ryu, DH; Jung, YH; Jeung, KW; Lee, BK; Jeong, YW; Geun Yun, J; Lee, DH; Lee, SM; Heo, T; Min, YI				Ryu, Dong Hyun; Jung, Yong Hun; Jeung, Kyung Woon; Lee, Byung Kook; Jeong, Young Won; Geun Yun, Jong; Lee, Dong Hun; Lee, Sung Min; Heo, Tag; Min, Yong Il			Effect of one-lung ventilation on end-tidal carbon dioxide during cardiopulmonary resuscitation in a pig model of cardiac arrest	PLOS ONE			English	Article							HEART-ASSOCIATION GUIDELINES; LIFE-SUPPORT; INDICATOR; PRESSURE	Unrecognized endobronchial intubation frequently occurs after emergency intubation. However, no study has evaluated the effect of one-lung ventilation on end-tidal carbon dioxide (ETCO2) during cardiopulmonary resuscitation (CPR). We compared the hemodynamic parameters, blood gases, and ETCO2 during one-lung ventilation with those during conventional two-lung ventilation in a pig model of CPR, to determine the effect of the former on ETCO2. A randomized crossover study was conducted in 12 pigs intubated with double lumen endobronchial tube to achieve lung separation. During CPR, the animals underwent three 5-min ventilation trials based on a randomized crossover design: left-lung, right-lung, or two-lung ventilation. Arterial blood gases were measured at the end of each ventilation trial. Ventilation was provided using the same tidal volume throughout the ventilation trials. Comparison using generalized linear mixed model revealed no significant group effects with respect to aortic pressure, coronary perfusion pressure, and carotid blood flow; however, significant group effect in terms of ETCO2 was found (P < 0.001). In the post hoc analyses, ETCO2 was lower during the right-lung ventilation than during the two-lung (P = 0.006) or left-lung ventilation (P < 0.001). However, no difference in ETCO2 was detected between the left-lung and two-lung ventilations. The partial pressure of arterial carbon dioxide (PaCO2), partial pressure of arterial oxygen (PaO2), and oxygen saturation (SaO(2)) differed among the three types of ventilation (P = 0.003, P = 0.001, and P = 0.001, respectively). The post hoc analyses revealed a higher PaCO2, lower PaO2, and lower SaO(2) during right-lung ventilation than during two-lung or left-lung ventilation. However, the levels of these blood gases did not differ between the left-lung and two-lung ventilations. In a pig model of CPR, ETCO2 was significantly lower during right-lung ventilation than during two-lung ventilation. However, interestingly, ETCO2 during left-lung ventilation was comparable to that during two-lung ventilation.	[Ryu, Dong Hyun; Jung, Yong Hun; Jeung, Kyung Woon; Lee, Byung Kook; Jeong, Young Won; Lee, Dong Hun; Lee, Sung Min; Heo, Tag; Min, Yong Il] Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea; [Geun Yun, Jong] Honam Univ, Dept Emergency Med Serv, Gwangju, South Korea	Chonnam National University; Chonnam National University Hospital; Honam University	Jeung, KW (corresponding author), Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea.	neoneti@hanmail.net	Lee, Byung Kook/M-2236-2018	Lee, Byung Kook/0000-0003-3571-9448	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2015R1D1A1A09057248]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2015R1D1A1A09057248). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BISSINGER U, 1989, ANN EMERG MED, V18, P853, DOI 10.1016/S0196-0644(89)80211-2; BRUNEL W, 1989, CHEST, V96, P1043, DOI 10.1378/chest.96.5.1043; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; Cheng Christopher P, 2006, Congenit Heart Dis, V1, P210, DOI 10.1111/j.1747-0803.2006.00037.x; Cho YC, 2011, EMERG MED J, V28, P40, DOI 10.1136/emj.2010.099911; DRONEN S, 1982, ANN EMERG MED, V11, P116, DOI 10.1016/S0196-0644(82)80328-4; GANDHI SK, 1991, J CLIN MONITOR, V7, P35, DOI 10.1007/BF01617896; Hamrick JL, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000450; Jin XH, 2000, CRIT CARE MED, V28, P2415, DOI 10.1097/00003246-200007000-00037; JOHNSON DH, 1992, CAN J ANAESTH, V39, P184, DOI 10.1007/BF03008654; Kolar M, 2008, CRIT CARE, V12, DOI 10.1186/cc7009; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Markstaller K, 2002, RESUSCITATION, V53, P307, DOI 10.1016/S0300-9572(02)00031-X; Markstaller K, 2008, RESUSCITATION, V79, P125, DOI 10.1016/j.resuscitation.2008.03.228; Neumar RW, 2010, CIRCULATION, V122, pS729, DOI 10.1161/CIRCULATIONAHA.110.970988; ORNATO JP, 1983, CRIT CARE MED, V11, P79, DOI 10.1097/00003246-198302000-00004; Rubertsson S, 1998, ACTA ANAESTH SCAND, V42, P32, DOI 10.1111/j.1399-6576.1998.tb05077.x; Ryu SJ, 2016, ACTA ANAESTH SCAND, V60, P1012, DOI 10.1111/aas.12728; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; Sheak KR, 2015, RESUSCITATION, V89, P149, DOI 10.1016/j.resuscitation.2015.01.026; Sitzwohl C, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5943; Spindelboeck W, 2013, RESUSCITATION, V84, P770, DOI 10.1016/j.resuscitation.2013.01.012; Timmermann A, 2007, ANESTH ANALG, V104, P619, DOI 10.1213/01.ane.0000253523.80050.e9; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011	24	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2018	13	4							e0195826	10.1371/journal.pone.0195826	http://dx.doi.org/10.1371/journal.pone.0195826			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4YG	29649316	Green Published, Green Submitted, gold			2023-01-03	WOS:000429791900094
J	Smedegaard, L; Kragholm, K; Nume, AK; Charlot, MG; Gislason, GH; Hansen, PR				Smedegaard, Laerke; Kragholm, Kristian; Nume, Anna-Karin; Charlot, Mette Gitz; Gislason, Gunnar Hilmar; Hansen, Peter Riis			Nursing home admission after myocardial infarction in the elderly: A nationwide cohort study	PLOS ONE			English	Article							OUTCOMES; DISABILITY; MORTALITY; TRENDS; RISK; HOSPITALIZATION; INDEPENDENCE; REGISTERS; DISEASE; HEALTH	Background Data on nursing home admission after myocardial infarction (MI) in the elderly are scarce. We investigated nursing home admission within 6 months and 2 years after MI including predictors for nursing home admission in a nationwide cohort of elderly patients. Methods Using Danish nationwide registries, we identified all subjects 65 years or older residing at home who were discharged following first-time MI in the period 2008-2015. We determined sex- and age-stratified incidence rates per 1000 person years (IRs) and incidence rate ratios (IRRs) of nursing home admissions using Poisson regression models compared to the Danish population 65 years or older with no prior MI. Poisson regression models were also applied to identify predictors of nursing home admission. Results The 26,539 patients who were discharged after MI had a median age of 76 (quartile 1-quartile 3: 70-83) years. The IRs of nursing home admission after MI increased with increasing age and for 80-84-year-old women IRs after 6 months and 2 years were 113.9 and 62.9, respectively, compared to 29.4 for women of the same age with no prior MI. The IRs for 8084-year-old men after MI were 56.0 and 36.2, respectively, compared to 24.3 for men of the same age with no prior MI. In adjusted analyses the 6 months and 2 years IRRs for 80-84-year-old subjects were 2.56 (95% CI 2.11-3.10) and 1.41 (95% CI 1.22-1.65) for women and 1.74 (95% CI 1.34-2.25) and 1.05 (95% CI 0.88-1.26) for men, respectively. Predictors were advanced age, dementia, home care, Parkinson's disease, cerebrovascular disease, living alone, depression, and arrhythmia. Conclusion In elderly patients discharged following first-time MI, the risk of subsequent nursing home admission within 6 months was 2-fold higher compared to an age-stratified population with no prior MI. After 2 years this risk remained higher in women.	[Smedegaard, Laerke; Nume, Anna-Karin; Charlot, Mette Gitz; Gislason, Gunnar Hilmar; Hansen, Peter Riis] Herlev & Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; [Kragholm, Kristian] Aalborg Univ Hosp, Dept Clin Epidemiol & Biostat, Aalborg, Denmark; [Gislason, Gunnar Hilmar] Univ Southern Denmark, Inst Publ Hlth, Copenhagen, Denmark; [Gislason, Gunnar Hilmar; Hansen, Peter Riis] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark; [Gislason, Gunnar Hilmar] Danish Heart Fdn, Copenhagen, Denmark; [Smedegaard, Laerke] Herlev & Gentofte Univ Hosp, Dept Cardiol, Kildegaardsvej 28,Entrance 8, Hellerup, Denmark	Aalborg University; Aalborg University Hospital; University of Southern Denmark; University of Copenhagen	Smedegaard, L (corresponding author), Herlev & Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark.; Smedegaard, L (corresponding author), Herlev & Gentofte Univ Hosp, Dept Cardiol, Kildegaardsvej 28,Entrance 8, Hellerup, Denmark.	LaerkeSmedegaard@gmail.com	Gislason, Gunnar/B-7561-2009; Hansen, Peter Riis/AAR-7659-2020	Gislason, Gunnar/0000-0002-0548-402X; Hansen, Peter Riis/0000-0002-9056-535X; Smedegaard, Laerke/0000-0003-0493-4671; Kragholm, Kristian/0000-0001-9629-8670	Danish Agency for Science, Technology and Innovation; Danish Council for Strategic Research (EDITORS: Eastern Denmark Initiative to Improve Revascularisation Strategies) [09-066994]	Danish Agency for Science, Technology and Innovation; Danish Council for Strategic Research (EDITORS: Eastern Denmark Initiative to Improve Revascularisation Strategies)	This work was supported by the Danish Agency for Science, Technology and Innovation and by the Danish Council for Strategic Research (EDITORS: Eastern Denmark Initiative to Improve Revascularisation Strategies, grant 09-066994). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed A, 2007, AM J GERIATR CARDIOL, V16, P76, DOI 10.1111/j.1076-7460.2007.05519.x; Andersen PK, 2012, INT J EPIDEMIOL, V41, P861, DOI 10.1093/ije/dyr213; Arnold SV, 2009, J AM GERIATR SOC, V57, P209, DOI 10.1111/j.1532-5415.2008.02106.x; Baadsgaard M, 2011, SCAND J PUBLIC HEALT, V39, P103, DOI 10.1177/1403494811405098; Banaszak-Holl J, 2004, ALZ DIS ASSOC DIS, V18, P83, DOI 10.1097/01.wad.0000126619.80941.91; Carstensen B, 2007, STAT MED, V26, P3018, DOI 10.1002/sim.2764; Danmarks Statistik, AFV PLEJ FORTS; Danmarks Statistik, AELDR IMP PLEJ; Danmarks Statistik, 2012, PLEJ AELDR 2012; de Leon CFM, 2005, ARCH INTERN MED, V165, P763, DOI 10.1001/archinte.165.7.763; de Meijer CAM, 2009, MED CARE, V47, P1156, DOI 10.1097/MLR.0b013e3181b69fa8; Dodson JA, 2012, AM HEART J, V163, P790, DOI 10.1016/j.ahj.2012.02.024; Floyd KC, 2009, CIRC-CARDIOVASC QUAL, V2, P88, DOI 10.1161/CIRCOUTCOMES.108.811828; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Goodwin JE, 2011, J HYPERTENS, V29, P1347, DOI [10.1093/gerona/glr171, 10.1097/HJH.0b013e328347da54]; Guzman-Castillo M, 2017, LANCET PUBLIC HEALTH, V2, pE307, DOI 10.1016/S2468-2667(17)30091-9; Khera S, 2014, J AM MED DIR ASSOC, V15, P593, DOI 10.1016/j.jamda.2014.04.017; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kucharska-Newton A, 2017, J AM HEART ASS, V6; Luppa M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-186; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Miller EA, 2000, MED CARE RES REV, V57, P259, DOI 10.1177/107755870005700301; Motivala AA, 2011, J AM COLL CARDIOL, V58, P1760, DOI 10.1016/j.jacc.2011.06.050; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nichols M, 2013, EUR HEART J, V34, P3028, DOI 10.1093/eurheartj/eht356; Olesen Jonas Bjerring, 2011, BMJ, V342, pd124, DOI 10.1136/bmj.d124; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7; Quan Hude, 2004, Home Health Care Serv Q, V23, P43, DOI 10.1300/J027v23n01_03; Quine S, 2007, HEALTH SOC CARE COMM, V15, P212, DOI 10.1111/j.1365-2524.2006.00675.x; Quinones Philip Andrew, 2014, BMC Geriatr, V14, P34, DOI 10.1186/1471-2318-14-34; Rapp K, 2015, J AM MED DIR ASSOC, V16, DOI 10.1016/j.jamda.2015.05.013; Schoenenberger AW, 2016, EUR HEART J, V37, P1304, DOI 10.1093/eurheartj/ehv698; Smedegaard L, 2017, EUR HEART J CARDIOVA; Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956; Van Rensbergen G, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-46; Windecker S, 2014, EUR HEART J, V35, P2541, DOI [10.5603/KP.2014.0224, 10.1093/eurheartj/ehu278, 10.1093/ejcts/ezu366]; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610	39	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2018	13	8							e0202177	10.1371/journal.pone.0202177	http://dx.doi.org/10.1371/journal.pone.0202177			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GQ5PD	30110366	Green Published, gold, Green Submitted			2023-01-03	WOS:000441738000054
J	Ng, JKC; Kwan, BCH; Chow, KM; Pang, WF; Cheng, PMS; Leung, CB; Li, PKT; Szeto, CC				Ng, Jack Kit-Chung; Kwan, Bonnie Ching-Ha; Chow, Kai-Ming; Pang, Wing-Fai; Cheng, Phyllis Mei-Shan; Leung, Chi-Bon; Li, Philip Kam-To; Szeto, Cheuk-Chun			Asymptomatic fluid overload predicts survival and cardiovascular event in incident Chinese peritoneal dialysis patients	PLOS ONE			English	Article							BIOIMPEDANCE SPECTROSCOPY; BODY-COMPOSITION; HYDRATION STATUS; RISK; OVERHYDRATION; OUTCOMES	Background Fluid overload is common among asymptomatic peritoneal dialysis (PD) patients. We aim to determine the prevalence and prognostic significance of fluid overload, as measured by bioimpedance spectroscopy, in asymptomatic incident PD patients. Methods We performed a single-center study on 311 incident PD patients. Volume status was represented by the volume of overhydration (OH), OH/extracellular water (ECW) ratio, ECW/total body water (TBW) ratio, and ECW to intracellular water (ICW) ratio (E:1 ratio). Patient survival, technique survival and cardiovascular event-free survival were determined. Results The median period of follow up was 27.3 months. Fluid overload was present in 272 patients (87.5%) when defined as OH volume over 1.1L. All hydration parameters significantly correlated with Charlson Comorbidity Index, and inversely with total Kt/V and serum albumin. Multivariate cause-specific Cox analysis showed that volume status independently predicted patient survival; every 0.1 unit increase in E:1 ratio was associated with 24.5% increase in allcause mortality (adjusted cause-specific hazard ratio [ACSHR] 1.245, p = 0.002). Hydration status was also an independent predictor of cardiovascular event-free survival after excluding hospital admission for congestive heart failure; each 0.1 unit increase in E:1 ratio was associated with 18.7% decrease in cardiovascular event-free survival (ACSHR 1.187, p = 0.011). In contrast, hydration parameters were not associated with technique survival. Conclusions Fluid overload is common in asymptomatic incident PD patients and is a strong predictor of patient survival and cardiovascular event. The impact of bioimpedance spectroscopy-guided fluid management on the outcome of PD patients deserves further study.	[Ng, Jack Kit-Chung; Kwan, Bonnie Ching-Ha; Chow, Kai-Ming; Pang, Wing-Fai; Cheng, Phyllis Mei-Shan; Leung, Chi-Bon; Li, Philip Kam-To; Szeto, Cheuk-Chun] Chinese Univ Hong Kong, Prince Wales Hosp, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Szeto, CC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	ccszeto@cuhk.edu.hk	Ming, Chow Kai/Y-5568-2019; Szeto, Cheuk Chun/N-4954-2015; Ng, Jack KC/L-6473-2019; Li, Philip K. T./D-4051-2017; Kwan, Bonnie/N-3463-2015	Ming, Chow Kai/0000-0001-5310-5197; Szeto, Cheuk Chun/0000-0002-8898-8505; Ng, Jack KC/0000-0002-9549-9611; Kwan, Bonnie/0000-0001-6742-8480	Chinese University of Hong Kong (CUHK) [6901031, 7101215]; Baxter Healthcare	Chinese University of Hong Kong (CUHK)(Chinese University of Hong Kong); Baxter Healthcare	This study was supported by the Chinese University of Hong Kong (CUHK) research accounts 6901031 and 7101215. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. CC Szeto receives research grant and consultancy from Baxter Healthcare.	Beddhu S, 2002, AM J MED, V112, P696, DOI 10.1016/S0002-9343(02)01097-5; Bergstrom J, 1998, PERITON DIALYSIS INT, V18, P467; Chamney PW, 2007, AM J CLIN NUTR, V85, P80, DOI 10.1093/ajcn/85.1.80; Cooper BA, 2000, KIDNEY INT, V58, P408, DOI 10.1046/j.1523-1755.2000.00180.x; Davies SJ, 2014, KIDNEY INT, V86, P489, DOI 10.1038/ki.2014.207; Demirci MS, 2011, NEPHROL DIAL TRANSPL, V26, P1708, DOI 10.1093/ndt/gfq588; Guo QY, 2015, PERITON DIALYSIS INT, V35, P691, DOI 10.3747/pdi.2014.00008; Kang SWS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165638; Kim YL, 2017, SEMIN NEPHROL, V37, P43, DOI 10.1016/j.semnephrol.2016.10.006; Konings CJAM, 2003, KIDNEY INT, V63, P1556, DOI 10.1046/j.1523-1755.2003.00887.x; Krediet RT, 2010, NAT REV NEPHROL, V6, P451, DOI 10.1038/nrneph.2010.68; Kwan BCH, 2014, PERITON DIALYSIS INT, V34, P409, DOI 10.3747/pdi.2013.00066; Moissl UM, 2006, PHYSIOL MEAS, V27, P921, DOI 10.1088/0967-3334/27/9/012; O'Lone EL, 2014, NEPHROL DIAL TRANSPL, V29, P1430, DOI 10.1093/ndt/gfu049; Parmentier SP, 2013, INT UROL NEPHROL, V45, P229, DOI 10.1007/s11255-012-0216-y; Ronco C, 2015, NEPHROL DIAL TRANSPL, V30, P849, DOI 10.1093/ndt/gfv013; Santhakumaran T, 2016, NEPHROLOGY, V21, P404, DOI 10.1111/nep.12622; Tian N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153115; Van Biesen W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017148; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Wong FKY, 2010, INT J NURS STUD, V47, P268, DOI 10.1016/j.ijnurstu.2009.07.001; Yoon HE, 2016, INT J MED SCI, V13, P686, DOI 10.7150/ijms.16372	22	17	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2018	13	8							e0202203	10.1371/journal.pone.0202203	http://dx.doi.org/10.1371/journal.pone.0202203			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ2CL	30102739	Green Published, Green Submitted, gold			2023-01-03	WOS:000441452200035
J	Rodelo-Haad, C; Rodriguez-Ortiz, ME; Martin-Malo, A; de Mier, MVPR; Aguera, ML; Munoz-Castaneda, JR; Soriano, S; Caravaca, F; Alvarez-Lara, MA; Felsenfeld, A; Aljama, P; Rodrigue, M				Rodelo-Haad, Cristian; Rodriguez-Ortiz, Maria E.; Martin-Malo, Alejandro; Victoria Pendon-Ruiz de Mier, M.; Luisa Aguera, M.; Munoz-Castaneda, Juan R.; Soriano, Sagrario; Caravaca, Francisco; Antonia Alvarez-Lara, M.; Felsenfeld, Arnold; Aljama, Pedro; Rodrigue, Mariano			Phosphate control in reducing FGF23 levels in hemodialysis patients	PLOS ONE			English	Article							GROWTH-FACTOR 23; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; CKD-MBD; SECONDARY HYPERPARATHYROIDISM; CARDIOVASCULAR-DISEASE; MINERAL METABOLISM; DIALYSIS PATIENTS; LANTHANUM CARBONATE; PARATHYROID-HORMONE	Background In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. Material and methods The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. Results During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate <4.5 mg/dl. In these 12 patients, iFGF23 decreased to less than half whereas cFGF23 did not reduce significantly. In patients with serum phosphate >4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. Conclusions The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation.	[Rodelo-Haad, Cristian; Rodriguez-Ortiz, Maria E.; Martin-Malo, Alejandro; Victoria Pendon-Ruiz de Mier, M.; Luisa Aguera, M.; Munoz-Castaneda, Juan R.; Soriano, Sagrario; Antonia Alvarez-Lara, M.; Aljama, Pedro; Rodrigue, Mariano] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Reina Sofia Univ Hosp, Cordoba, Spain; [Rodelo-Haad, Cristian; Martin-Malo, Alejandro; Victoria Pendon-Ruiz de Mier, M.; Luisa Aguera, M.; Munoz-Castaneda, Juan R.; Soriano, Sagrario; Antonia Alvarez-Lara, M.; Aljama, Pedro; Rodrigue, Mariano] Reina Sofia Univ Hosp, Nephrol Serv, Cordoba, Spain; [Rodelo-Haad, Cristian; Rodriguez-Ortiz, Maria E.; Martin-Malo, Alejandro; Victoria Pendon-Ruiz de Mier, M.; Luisa Aguera, M.; Munoz-Castaneda, Juan R.; Soriano, Sagrario; Antonia Alvarez-Lara, M.; Aljama, Pedro; Rodrigue, Mariano] RETICs REDinREN Natl Inst Hlth Carlos III, Madrid, Spain; [Caravaca, Francisco] Infanta Cristina Hosp, Nephrol Serv, Badajoz, Spain; [Felsenfeld, Arnold] UCLA, Wadsworth VA, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Felsenfeld, Arnold] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	Universidad de Cordoba; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Martin-Malo, A (corresponding author), Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Reina Sofia Univ Hosp, Cordoba, Spain.; Martin-Malo, A (corresponding author), Reina Sofia Univ Hosp, Nephrol Serv, Cordoba, Spain.; Martin-Malo, A (corresponding author), RETICs REDinREN Natl Inst Hlth Carlos III, Madrid, Spain.	amartinma@senefro.org	Muñoz-Castañeda, Juan R./AFQ-3443-2022	Rodriguez, Mariano/0000-0002-9380-6614; Rodelo-Haad, Cristian/0000-0002-8139-3840; Caravaca Sanchez, Francisco/0000-0002-1209-2657; Aguera Morales, Maria Luisa/0000-0002-7736-908X	National Institute of Health Carlos III [FIS 14/00638, FIS 17/01785, FIS 17-01010]; Consejeria de Salud of Junta de Andalucia [PI-0311-2014, PI-0136-2016]; REDinREN from the National Institute of Health Carlos III; EUTox Work group; Nicolas Monardes Programme from Consejeria de Salud-SAS (Junta de Andalucia)	National Institute of Health Carlos III; Consejeria de Salud of Junta de Andalucia(Junta de Andalucia); REDinREN from the National Institute of Health Carlos III; EUTox Work group; Nicolas Monardes Programme from Consejeria de Salud-SAS (Junta de Andalucia)	This study was supported by grants from the National Institute of Health Carlos III (FIS 14/00638, FIS 17/01785, and FIS 17-01010), the Consejeria de Salud of Junta de Andalucia (PI-0311-2014 and PI-0136-2016), the REDinREN from the National Institute of Health Carlos III and the EUTox Work group. JR Munoz-Castaneda is a senior researcher supported by the Nicolas Monardes Programme from Consejeria de Salud-SAS (Junta de Andalucia). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almaden Y, 1996, J BONE MINER RES, V11, P970; Belsley DA, 1980, KE REGRESSION DIAGNO; Bielesz BO, 2014, CLIN BIOCHEM, V47, P1316, DOI 10.1016/j.clinbiochem.2014.06.009; Block GA, 2019, NEPHROL DIAL TRANSPL, V34, P339, DOI 10.1093/ndt/gfy061; Brandenburg VM, 2010, NEPHROL DIAL TRANSPL, V25, P2672, DOI 10.1093/ndt/gfq053; Canalejo R, 2010, J AM SOC NEPHROL, V21, P1125, DOI 10.1681/ASN.2009040427; Cancela ALE, 2011, NEPHRON CLIN PRACT, V117, pC74, DOI 10.1159/000319650; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; David V, 2016, KIDNEY INT, V89, P135, DOI 10.1038/ki.2015.290; David V, 2013, ENDOCRINOLOGY, V154, P4469, DOI 10.1210/en.2013-1627; di Giuseppe R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133580; Evenepoel P, 2014, SEMIN NEPHROL, V34, P151, DOI 10.1016/j.semnephrol.2014.02.007; Galitzer H, 2010, KIDNEY INT, V77, P211, DOI 10.1038/ki.2009.464; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Gutierrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506; Honda H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176984; Imanishi Y, 2004, KIDNEY INT, V65, P1943, DOI 10.1111/j.1523-1755.2004.00604.x; Isakova T, 2013, CLIN J AM SOC NEPHRO, V8, P1009, DOI 10.2215/CJN.09250912; Isakova T, 2011, CLIN J AM SOC NEPHRO, V6, P2688, DOI 10.2215/CJN.04290511; Johnson JW, 2000, MULTIVAR BEHAV RES, V35, P1, DOI 10.1207/S15327906MBR3501_1; Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006; Koizumi M, 2012, NEPHROL DIAL TRANSPL, V27, P784, DOI 10.1093/ndt/gfr384; Kovesdy CP, 2013, NEPHROL DIAL TRANSPL, V28, P2228, DOI 10.1093/ndt/gft065; Kuro-o M, 2013, KIDNEY INT SUPPL, V3, P420, DOI 10.1038/kisup.2013.88; Lavi-Moshayoff V, 2010, AM J PHYSIOL-RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010; Leifheit-Nestler M, 2016, NEPHROL DIAL TRANSPL, V31, P1088, DOI 10.1093/ndt/gfv421; Lin HH, 2014, NEPHROLOGY, V19, P672, DOI 10.1111/nep.12319; Lopez I, 2011, KIDNEY INT, V80, P475, DOI 10.1038/ki.2011.107; Lorenzo-Seva U, 2011, BEHAV RES METHODS, V43, P1, DOI 10.3758/s13428-010-0043-y; Meir T, 2014, KIDNEY INT, V86, P1106, DOI 10.1038/ki.2014.215; Mendoza FA, 2012, CLIN J AM SOC NEPHRO, V7, P1155, DOI 10.2215/CJN.13281211; Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876; Navarro-Gonzalez JF, 2011, CLIN J AM SOC NEPHRO, V6, P2272, DOI 10.2215/CJN.01650211; Navarro-Gonzalez JF, 2009, CLIN J AM SOC NEPHRO, V4, P1646, DOI 10.2215/CJN.02420409; Ohta H, 2016, J MED INVESTIG, V63, P58, DOI 10.2152/jmi.63.58; Olauson H, 2010, NEPHROL DIAL TRANSPL, V25, P3033, DOI 10.1093/ndt/gfq191; Oliveira RB, 2010, CLIN J AM SOC NEPHRO, V5, P286, DOI 10.2215/CJN.05420709; Quinn SJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE310, DOI 10.1152/ajpendo.00460.2012; Razzaque MS, 2011, CLIN SCI, V120, P91, DOI 10.1042/CS20100377; Rodriguez M, 2012, NEFROLOGIA, V32, P275, DOI 10.3265/Nefrologia.pre2012.Mar.11415; Rodriguez-Ortiz Maria E, 2015, F1000Res, V4, DOI 10.12688/f1000research.7189.1; Rodriguez-Ortiz ME, 2012, J AM SOC NEPHROL, V23, P1190, DOI 10.1681/ASN.2011101006; Rossaint J, 2017, NEPHROL DIAL TRANSPL, V32, P1448, DOI 10.1093/ndt/gfw331; Shigematsu T, 2012, NEPHROL DIAL TRANSPL, V27, P1050, DOI 10.1093/ndt/gfr388; Silver J, 2012, NEPHROL DIAL TRANSPL, V27, P1715, DOI 10.1093/ndt/gfs050; Singh S, 2016, KIDNEY INT, V90, P985, DOI 10.1016/j.kint.2016.05.019; Soriano S, 2013, CLIN NEPHROL, V80, P17, DOI 10.5414/CN107764; Sprague SM, 2015, CLIN J AM SOC NEPHRO, V10, P1021, DOI 10.2215/CJN.03270314; Tonidandel S, 2009, PSYCHOL METHODS, V14, P387, DOI 10.1037/a0017735; Torregrosa JV, 2011, NEFROLOGIA, V31, P3, DOI 10.3265/Nefrologia.pre2011.Jan.10816; Van Buren PN, 2015, AM J KIDNEY DIS, V66, P479, DOI 10.1053/j.ajkd.2015.03.013; Wetmore JB, 2011, J CLIN ENDOCR METAB, V96, pE57, DOI 10.1210/jc.2010-1277; Witasp A, 2017, CLIN SCI, V131, P1649, DOI 10.1042/CS20160596; Wolf M, 2014, CURR OPIN NEPHROL HY, V23, P411, DOI 10.1097/01.mnh.0000447020.74593.6f; Wolf M, 2010, J AM SOC NEPHROL, V21, P1427, DOI 10.1681/ASN.2009121293; Yamada S, 2014, AM J PHYSIOL-RENAL, V306, pF1418, DOI 10.1152/ajprenal.00633.2013	56	21	22	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2018	13	8							e0201537	10.1371/journal.pone.0201537	http://dx.doi.org/10.1371/journal.pone.0201537			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP7ZN	30086150	Green Published, Green Submitted, gold			2023-01-03	WOS:000441129300020
J	Naumann, DN; Doughty, H; Cotton, BA				Naumann, David N.; Doughty, Heidi; Cotton, Bryan A.			No gains with plasma-first resuscitation in urban settings?	LANCET			English	Editorial Material							TRANSFUSION; TRIAL		[Naumann, David N.] Queen Elizabeth Hosp Birmingham, Acad Dept Mil Surg & Trauma, Royal Ctr Def Med, Birmingham, W Midlands, England; [Doughty, Heidi] NHS Blood & Transplant, Birmingham, W Midlands, England; [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Ctr Translat Injury Res, Dept Surg, Houston, TX 77030 USA	Royal Centre for Defence Medicine; University of Birmingham; University of Texas System; University of Texas Health Science Center Houston	Naumann, DN (corresponding author), Queen Elizabeth Hosp Birmingham, Acad Dept Mil Surg & Trauma, Royal Ctr Def Med, Birmingham, W Midlands, England.	david.naumann@nhs.net	Naumann, David/S-9917-2019	Naumann, David/0000-0003-2243-2325				Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0; Brown JB, 2015, PREHOSP EMERG CARE, V19, P343, DOI 10.3109/10903127.2014.995851; Fox EE, 2017, SHOCK, V47, P567, DOI 10.1097/SHK.0000000000000788; Glen J, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3051; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Moore HB, 2018, LANCET, DOI DOI 10.1016/S0140-6736(18)31565-4; Smith IM, 2016, SHOCK, V46, P3, DOI 10.1097/SHK.0000000000000569; Smith IM, 2017, TRANSFUSION MED, DOI [10.1111/tme.1248, DOI 10.1111/TME.1248]; Tolles J, 2018, J TRAUMA ACUTE CARE, V84, pS28, DOI 10.1097/TA.0000000000001904; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Woolley T, 2018, J TRAUMA ACUTE CARE, V84, pS3, DOI 10.1097/TA.0000000000001856	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2018	392	10144					255	+		10.1016/S0140-6736(18)31565-4	http://dx.doi.org/10.1016/S0140-6736(18)31565-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GO3WD	30032982				2023-01-03	WOS:000439928300004
J	Vijay, A; Becker, JE; Ross, JS				Vijay, Aishwarya; Becker, Jessica E.; Ross, Joseph S.			Patterns and predictors of off-label prescription of psychiatric drugs	PLOS ONE			English	Article							ANTIPSYCHOTIC MEDICATIONS; PRIMARY-CARE; ANTIDEPRESSANTS; ASSOCIATION; GABAPENTIN; PHYSICIANS; TRAZODONE; MEDICAID; INSOMNIA; SYSTEM	Off-label prescribing of psychiatric drugs is common, despite lacking strong scientific evidence of efficacy and potentially increasing risk for adverse events. The goal of this study was to characterize prevalence of off-label prescriptions of psychiatric drugs and examine patient and clinician predictors of off-label use. This manuscript presents a retrospective, cross-sectional study using data from the 2012 and 2013 National Ambulatory Medical Care Surveys (NAMCS). The study examined all adult outpatient visits to psychiatric practices for chronic care management with a single listed visit diagnosis in which at least one psychiatric drug was prescribed. The main outcome measure was off-label prescribing of at least one psychiatric drug, defined as prescription for a condition for which it has not been approved for use by the FDA. Among our sample representative of 1.85 billion outpatient visits, 18.5 million (1.3%) visits were to psychiatrists for chronic care management in which at least one psychiatric drug was prescribed. Overall, the rate of off-label use was 12.9% (95% CI: 12.215.7). The most common off-label uses were for manic-depressive psychosis treated with citalopram and primary insomnia treated with trazodone. Several patient and clinician characteristics were positively associated with off-label prescribing, including seeing a psychiatrist (OR: 1.06, 95% CI, 1.01-1.12; p = 0.03) instead of another type of clinician, the office visit taking place in the Western region of the country (OR: 1.09, 95% CI, 1.01-1.17; p = 0.02), and the patient having 3 or more chronic conditions (OR: 1.12, 95% CI, 1.02-1.14; p = 0.003). In contrast, having Medicare coverage (OR: 0.93, 95% CI, 0.84-0.97; p = 0.04) and receiving payment assistance from a medical charity (OR: 0.91, 95% CI, 0.88-0.96; p = 0.03) instead of private insurance were negatively associated with off-label prescribing. These results suggest that certain classes of psychiatric medications are being commonly prescribed to treat conditions for which they have not been determined by the FDA to be clinically efficacious and/or safe.	[Vijay, Aishwarya] Yale Univ, Sch Med, New Haven, CT USA; [Becker, Jessica E.] Massachusetts Gen Hosp, MGH McLean Psychiat Residency Program, Boston, MA 02114 USA; [Becker, Jessica E.] Harvard Med Sch, Boston, MA USA; [Ross, Joseph S.] Yale Sch Med, Sect Gen Internal Med, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Sch Med, Natl Clinician Scholars Program, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA	Yale University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Yale University; Yale University; Yale University	Ross, JS (corresponding author), Yale Sch Med, Sect Gen Internal Med, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale Sch Med, Natl Clinician Scholars Program, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06510 USA.; Ross, JS (corresponding author), Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA.	joseph.ross@yale.edu		Becker, Jessica/0000-0003-0522-2836; Ross, Joseph/0000-0002-9218-3320	NIMH NIH HHS [R25 MH094612] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH094612] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams C, 2003, NEWSPAPER ARTICLE SE; Alexander GC, 2011, PHARMACOEPIDEM DR S, V20, P177, DOI 10.1002/pds.2082; [Anonymous], 2013, LEXICON PLUS; [Anonymous], 2016, ABILIFY ARIPIPRAZOLE; Anxiety Disorders Association America, 2009, ANX DIS MED; Canada H., 2013, GOOD PHARMACOVIGILAN; Chen H, 2006, J CLIN PSYCHIAT, V67, P972, DOI 10.4088/JCP.v67n0615; CMS, 2013, ANT MED US FOOD DRUG; Eguale T, 2016, JAMA INTERN MED, V176, P55, DOI 10.1001/jamainternmed.2015.6058; Eguale T, 2012, ARCH INTERN MED, V172, P781, DOI 10.1001/archinternmed.2012.340; FDA, 2015, PED EXP ADV PAN GUID; FLEISCHMAN W, 2016, BMJ-BRIT MED J, V354, DOI DOI 10.1136/BMJ.I4189; Fukada Christine, 2012, Can Pharm J (Ott), V145, P280, DOI 10.3821/145.6.cpj280; Gazarian M, 2006, MED J AUSTRALIA, V185, P544, DOI 10.5694/j.1326-5377.2006.tb00689.x; Grundy Q, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001561; Horen B, 2002, BRIT J CLIN PHARMACO, V54, P665, DOI 10.1046/j.1365-2125.2002.t01-3-01689.x; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Jaffer KY, 2017, INNOVATIONS CLIN NEU, V14; James SP, 2004, J CLIN PSYCHIAT, V65, P752; Kamble P, 2010, PSYCHIAT SERV, V61, P130, DOI 10.1176/ps.2010.61.2.130; Kapczynski A, 2016, JAMA INTERN MED, V176, P295, DOI 10.1001/jamainternmed.2015.8155; King M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f264; Lai LL, 2011, DRUG HEALTHC PATIENT, V3, P27, DOI 10.2147/DHPS.S21079; Lamy FX, 2017, CURR MED RES OPIN, V33, P891, DOI 10.1080/03007995.2017.1294055; Leslie DL, 2009, PSYCHIAT SERV, V60, P1174, DOI 10.1176/ps.2009.60.9.1175; Leslie DL, 2012, AM J MANAG CARE, V18, pE109; McInerney SJ, 2014, PRIMARY CARE COMPANI, V16; Neubert A, 2004, DRUG SAFETY, V27, P1059, DOI 10.2165/00002018-200427130-00006; Patwardhan AR, 2016, PHYS PHARM SALES REP; Pena E., 2003, PHARMAVOICE; R-Core-Team, 2016, LANG ENV STAT COMP; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; RICKELS K, 1993, ARCH GEN PSYCHIAT, V50, P884; Schappert SM, 2008, AMBULATORY MED CARE; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107; Turner S, 1999, ACTA PAEDIATR, V88, P965, DOI 10.1080/08035259950168469; Wallach JD, 2018, JAMA-J AM MED ASSOC, V319, P776, DOI 10.1001/jama.2017.21897; Walton SN, 2008, PHARMACOTHERAPY, V28, P1443, DOI 10.1592/phco.28.12.1443; Wiegand MH, 2008, DRUGS, V68, P2411, DOI 10.2165/0003495-200868170-00001; Wijkstra J, 2017, BJPSYCH ADV, V23, P2; Wiktorowicz M, 2012, SOC SCI MED, V75, P165, DOI 10.1016/j.socscimed.2011.11.046; Wong J, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j603; Zuur AF, 2010, METHODS ECOL EVOL, V1, P3, DOI 10.1111/j.2041-210X.2009.00001.x	43	20	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2018	13	7							e0198363	10.1371/journal.pone.0198363	http://dx.doi.org/10.1371/journal.pone.0198363			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN5RC	30024873	Green Submitted, gold, Green Published			2023-01-03	WOS:000439120000003
J	Justin, C; Samrot, AV; Sruthi, PD; Sahithya, CS; Bhavya, KS; Saipriya, C				Justin, C.; Samrot, Antony V.; Sruthi, Durga P.; Sahithya, Chamarthy Sai; Bhavya, Karanam Sai; Saipriya, C.			Preparation, characterization and utilization of coreshell super paramagnetic iron oxide nanoparticles for curcumin delivery	PLOS ONE			English	Article							ANTICANCER ACTIVITY; CHITOSAN; SPIONS; TUMOR	In this study, super paramagnetic iron oxide nanoparticles (SPIONs) were produced by chemical co-precipitation method, then it was constructed to be a core shell nanoparticle by functionalizing with SDS, loading with curcumin and coating with a biopolymer i.e. chitosan. Each step was analyzed microscopically and spectroscopically. The produced coreshell particles were between 40 and 45nm and these coreshell particles were utilized for drug delivery studies against cervical cancer cell line-HeLa cells. The coreshell SPIONs were found to be releasing curcumin in between 6 and 12 h, which was evidenced by increased apoptotic cells and increased caspase 3 expression in HeLa cells.	[Justin, C.; Samrot, Antony V.; Sruthi, Durga P.; Sahithya, Chamarthy Sai; Bhavya, Karanam Sai; Saipriya, C.] Sathyabama Inst Sci & Technol, Dept Biotechnol, Chennai, Tamil Nadu, India	Sathyabama Institute of Science & Technology	Samrot, AV (corresponding author), Sathyabama Inst Sci & Technol, Dept Biotechnol, Chennai, Tamil Nadu, India.	antonysamrot@gmail.com	samrot, antony Vincent/C-1509-2011	samrot, antony Vincent/0000-0001-9536-0567				Allegra A, 2017, CANCER INVEST, V35, P1, DOI 10.1080/07357907.2016.1247166; Biosciences B. D., 2011, DETECTION APOPTOSIS; Bolden NW, 2008, NSTI NANOTECH 2008, VOL 2, TECHNICAL PROCEEDINGS, P390; Cortajarena Aitziber L, 2014, Nanobiomedicine (Rij), V1, P2, DOI 10.5772/58841; Disch S, 2012, NEW J PHYS, V14, DOI 10.1088/1367-2630/14/1/013025; Griffiths D, 2011, NANOTECHNOLOGY 2011: ADVANCED MATERIALS, CNTS, PARTICLES, FILMS AND COMPOSITES, NSTI-NANOTECH 2011, VOL 1, P4; Gupta AK, 2007, NANOMEDICINE-UK, V2, P23, DOI 10.2217/17435889.2.1.23; Hamley IW, 2003, ANGEW CHEM INT EDIT, V42, P1692, DOI 10.1002/anie.200200546; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hazra K., 2015, INT J PHARMACOL, V2, P127, DOI DOI 10.13040/IJPSR.0975-8232.IJP.2(3).127-30; Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2; Hong SC, 2011, INT J NANOMED, V6, P3219, DOI 10.2147/IJN.S26355; Justin C, 2017, APPL NANOSCI, V7, P463, DOI 10.1007/s13204-017-0583-x; Kievit FM, 2011, ACCOUNTS CHEM RES, V44, P853, DOI 10.1021/ar2000277; Klein S, 2014, J PHYS CHEM B, V118, P6159, DOI 10.1021/jp5026224; Kolev TM, 2005, INT J QUANTUM CHEM, V102, P1069, DOI 10.1002/qua.20469; Laurent S, 2014, EXPERT OPIN DRUG DEL, V11, P1449, DOI 10.1517/17425247.2014.924501; Layek S., 2010, INT J ENG SCI TECHNO, V2; Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Magro M, 2014, CHEM-EUR J, V20, P11913, DOI 10.1002/chem.201402820; Martinez-Boubeta C, 2013, SCI REP-UK, V3, DOI 10.1038/srep01652; Mitchell E, 2015, POWDER TECHNOL, V272, P295, DOI 10.1016/j.powtec.2014.12.021; Mohammad F, 2010, J PHYS CHEM C, V114, P19194, DOI 10.1021/jp105807r; Mohan PRK, 2012, VIB SPECTROSC, V62, P77, DOI 10.1016/j.vibspec.2012.05.002; Morsy S.M.I., 2014, INT J CURR MICROBIOL, V3, P237, DOI DOI 10.1007/978-3-319-13596-0_10; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Narang AS, 2007, INT J PHARM, V345, P9, DOI 10.1016/j.ijpharm.2007.08.057; Onyishi V. I., 2013, African Journal of Pharmacy and Pharmacology, V7, P809; PICQUART M, 1986, J PHYS CHEM-US, V90, P243, DOI 10.1021/j100274a008; Priyadarsini KI, 2014, MOLECULES, V19, P20091, DOI 10.3390/molecules191220091; Qin CQ, 2006, CARBOHYD POLYM, V63, P367, DOI 10.1016/j.carbpol.2005.09.023; Rajan M, 2017, RSC ADV, V7, P46271, DOI 10.1039/c7ra06615e; Rieger AM, 2011, JOVE-J VIS EXP, DOI 10.3791/2597; Rudakovskaya PG, 2010, MENDELEEV COMMUN, V20, P158, DOI 10.1016/j.mencom.2010.05.012; Sakai S, 2009, J MATER CHEM, V19, P230, DOI 10.1039/b812086b; Scialabba C, 2014, EUR J PHARM BIOPHARM, V88, P695, DOI 10.1016/j.ejpb.2014.09.008; Shang HS, 2016, ONCOL REP, V36, P2207, DOI 10.3892/or.2016.5002; Sweetman SC, 2011, COMPLETE DRUG REFERE; Tombacz E, 2013, COLLOID SURFACE A, V435, P91, DOI 10.1016/j.colsurfa.2013.01.023; van der Zee J, 2002, ANN ONCOL, V13, P1173, DOI 10.1093/annonc/mdf280; VandeVord PJ, 2002, J BIOMED MATER RES, V59, P585, DOI 10.1002/jbm.1270; VILLA S, 2016, MATERIALS, V9; Wang LY, 2005, J PHYS CHEM B, V109, P21593, DOI 10.1021/jp0543429; Wright JS, 2002, J MOL STRUC-THEOCHEM, V591, P207, DOI 10.1016/S0166-1280(02)00242-7; Yallapu MM, 2014, BIOMATERIALS, V35, P8635, DOI 10.1016/j.biomaterials.2014.06.040; Zhang Jin, 2006, Cancer Genomics & Proteomics, V3, P147	47	33	33	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0200440	10.1371/journal.pone.0200440	http://dx.doi.org/10.1371/journal.pone.0200440			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN4SJ	30021002	Green Submitted, Green Published, gold			2023-01-03	WOS:000439022400049
J	Cressman, ENK; Guo, CX; Karbasian, N				Cressman, Erik N. K.; Guo, Chunxiao; Karbasian, Niloofar			Image-guided chemistry altering biology: An in vivo study of thermoembolization	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; ADVANCED HEPATOCELLULAR-CARCINOMA; THERMOCHEMICAL ABLATION; RADIOFREQUENCY ABLATION; MICROWAVE ABLATION; THERAPY; SORAFENIB; EMBOLIZATION; HYPERTHERMIA; CANCER	Rationale Advances in image-guided drug delivery for liver cancer have shown a significant survival benefit. However, incomplete treatment is common and residual disease is often found in explanted liver specimens. In addition, the need to treat a malignancy from multiple mechanisms at the same time for optimal outcomes is becoming more widely appreciated. To address this, we hypothesized that an exothermic chemical reaction could be performed in situ. Such a strategy could in principle combine several angles of attack, including ischemia, hyperthermia, acidic protein denaturation, and metabolic modulation of the local environment. Methods The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee approved this study. Outbred swine (25-35 kg, 5 control and 5 experimental) were treated under general anesthesia. Embolization was performed with coaxial microcatheter technique in a segmental hepatic arterial branch using either ethiodized oil as control or with thermoembolic solutionBlood samples were obtained before, immediately after, and the day following the procedure just before CT scans and euthanasia. Livers were explanted and samples were obtained for histologic analysis. Results All animals survived the procedure and laboratory values of the control and experimental groups remained within normal limits. The control group had a diffuse or cloudy pattern of attenuation on follow-up CT scan the day after, consistent with gradual antegrade sinusoidal transit of the embolic material. The experimental group had clearly defined vascular casts with some degree of peripheral involvement. At histology, the control group samples had the appearance of normal liver, whereas the experimental group had coagulative necrosis in small pale, punctate areas extending several hundred microns away from the treated vessels and a brisk inflammatory response just outside the margins. Conclusion In situ chemistry via thermoembolization shows early promise as a fundamentally new tactic for image-guided therapy of solid tumors.	[Cressman, Erik N. K.; Guo, Chunxiao; Karbasian, Niloofar] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Cressman, ENK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX 77030 USA.	ecressman@mdanderson.org		Cressman, Erik/0000-0002-8671-9862	Institutional Research Grant from the University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [R01CA201127] Funding Source: NIH RePORTER	Institutional Research Grant from the University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study was funded by an Institutional Research Grant from the University of Texas MD Anderson Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argyrou C, 2017, J BUON, V22, P6; BODDIE AW, 1985, INVEST RADIOL, V20, P159, DOI 10.1097/00004424-198503000-00012; Bouattour M, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1675-8; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Cao W, 2010, EUR J RADIOL, V73, P412, DOI 10.1016/j.ejrad.2008.11.001; Chen XZ, 2015, FREE RADICAL BIO MED, V79, P253, DOI 10.1016/j.freeradbiomed.2014.08.027; Cressman ENK, 2009, IEEE ENG MED BIO, P4291, DOI 10.1109/IEMBS.2009.5333503; Cressman ENK, 2013, INT J HYPERTHER, V29, P71, DOI 10.3109/02656736.2012.756124; Cressman ENK, 2012, INT J HYPERTHER, V28, P113, DOI 10.3109/02656736.2011.644621; Cressman ENK, 2012, INT J HYPERTHER, V28, P105, DOI 10.3109/02656736.2011.644620; Cressman ENK, 2010, INT J HYPERTHER, V26, P327, DOI 10.3109/02656731003614516; Deng ZS, 2013, J HEALTHC ENG, V4, P409, DOI 10.1260/2040-2295.4.3.409; DEVORE JA, 1969, J PHYS CHEM-US, V73, P2644, DOI 10.1021/j100842a031; DOYON D, 1981, B CANCER, V68, P295; Georgiades CS, 2006, J VASC INTERV RADIOL, V17, P1619, DOI 10.1097/01.RVI.0000236608.91960.34; Guo Z. X., 2015, J ELECT ENG, V10, P10, DOI DOI 10.1371/J0URNAL.P0NE.0138619; HARADA M, 1995, ACAD RADIOL, V2, P475, DOI 10.1016/S1076-6332(05)80403-9; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Keating GM, 2017, TARGET ONCOL, V12, P243, DOI 10.1007/s11523-017-0484-7; Lee HJ, 2017, J VASC INTERV RADIOL, V28, P1240, DOI 10.1016/j.jvir.2017.05.015; Liu Y, 2013, CLIN RADIOL, V68, P21, DOI 10.1016/j.crad.2012.05.007; Lu LC, 2017, ANTICANCER RES, V37, P2593, DOI 10.21873/anticanres.11604; Margini C, 2016, LIVER INT, V36, P317, DOI 10.1111/liv.13031; Marin HL, 2009, J GASTROINTEST LIVER, V18, P169; Massarweh NN, 2017, CANCER CONTROL, V24, DOI 10.1177/1073274817729245; Meloni MF, 2017, INT J HYPERTHER, V33, P15, DOI 10.1080/02656736.2016.1209694; Mitchell J, 2016, ONCOLOGY-BASEL, V91, P90, DOI 10.1159/000446074; Molvar C, 2015, RADIOL CLIN N AM, V53, P973, DOI 10.1016/j.rcl.2015.05.011; Moroz P, 2002, PHYS MED BIOL, V47, P1591, DOI 10.1088/0031-9155/47/9/312; N'Kontchou G, 2009, HEPATOLOGY, V50, P1475, DOI 10.1002/hep.23181; Rao W, 2008, MINIM INVASIV THER, V17, P43, DOI 10.1080/13645700701803826; Rao W, 2009, MINIM INVASIV THER, V18, P30, DOI 10.1080/13645700802384023; Rhim H, 2008, J GASTROEN HEPATOL, V23, P1492, DOI 10.1111/j.1440-1746.2008.05550.x; Richani M, 2016, ANN HEPATOL, V15, P82, DOI 10.5604/16652681.1184233; Rimassa L, 2009, EXPERT REV ANTICANC, V9, P739, DOI 10.1586/ERA.09.41; Ryan TP, 2017, INT J HYPERTHER, V33, P3, DOI 10.1080/02656736.2016.1214884; Salamon S, 2017, NUTR CANCER, V69, P177, DOI 10.1080/01635581.2017.1263751; Seki T, 2000, CANCER, V89, P1245, DOI 10.1002/1097-0142(20000915)89:6<1245::AID-CNCR8>3.0.CO;2-F; Villanueva A, 2010, CLIN CANCER RES, V16, P4688, DOI 10.1158/1078-0432.CCR-09-1811; Wallace MC, 2017, DIGEST DIS SCI, V62, P2182, DOI 10.1007/s10620-017-4622-y; Yopp AC, 2015, DIGEST DIS, V33, P642, DOI 10.1159/000438473	41	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2018	13	7							e0200471	10.1371/journal.pone.0200471	http://dx.doi.org/10.1371/journal.pone.0200471			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2LQ	30011300	Green Submitted, Green Published, gold			2023-01-03	WOS:000438829800020
J	Resurreccion, DM; Motrico, E; Rubio-Valera, M; Mora-Pardo, JA; Moreno-Peral, P				Resurreccion, Davinia Maria; Motrico, Emma; Rubio-Valera, Maria; Antonio Mora-Pardo, Jose; Moreno-Peral, Patricia			Reasons for dropout from cardiac rehabilitation programs in women: A qualitative study	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; AMERICAN-ASSOCIATION; SCIENTIFIC STATEMENT; CLINICAL CARDIOLOGY; PHYSICAL-ACTIVITY; HEART-DISEASE; PARTICIPATION; PREVENTION; METABOLISM; NUTRITION	Background Empirical evidence has shown that cardiac rehabilitation programs are effective in reducing morbidity and mortality, improving quality of life in patients with cardiovascular disease. Despite the benefits, women have a high cardiac rehabilitation dropout rate. Our aim was to explore women's perceptions about the reasons they faced for dropout from these programs. Methods Semi-structured interviews were conducted with women (n = 10) after dropping out from three different cardiac rehabilitation centers in Spain. In addition, a focus group and a semistructured interview with cardiovascular professionals were conducted. From a grounded theory perspective, thematic analysis was used to derive themes from interview transcripts. Results The women were between 41 and 70 years. We identified five general themes that illustrated reasons for cardiac rehabilitation dropout: intrapersonal reasons (self-reported health, self-reported mental health, health beliefs); interpersonal reasons (family caregiver role, work conflicts); logistical reasons (transport, distance); cardiac rehabilitation program characteristics (perception of the objective of cardiac rehabilitation, exercise component, inconvenient timing, cardiac rehabilitation equipment); and health system reasons (financial assistance for transport, long waiting list). The cardiovascular professionals found barriers to cardiac rehabilitation completion similar to those found by the women. Conclusions In order to prevent cardiac rehabilitation dropout in women, modular and flexible programs are needed. In addition, the inclusion of primary care centers or community resources could improve cardiac rehabilitation completion in women. Psychological assessment and counseling during cardiac rehabilitation should be included as an essential part of the programs and recommended for those women with depressive symptoms. Finally, improved financial assistance for transport from the health system is essential.	[Resurreccion, Davinia Maria; Motrico, Emma] Univ Loyola Andalucia, Dept Psychol, Seville, Spain; [Motrico, Emma; Moreno-Peral, Patricia] Primary Care Prevent & Hlth Promot Res Network Re, Malaga, Spain; [Rubio-Valera, Maria] Inst Recerca St Joan de Deu, Res & Dev Unit, Barcelona, Spain; [Rubio-Valera, Maria] Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Barcelona, Spain; [Antonio Mora-Pardo, Jose] Hosp Nuestra Senora de Valme, Seville, Spain; [Moreno-Peral, Patricia] Inst Invest Biomed Malaga IBIMA, Malaga, Spain	Universidad Loyola Andalucia; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universidad de Malaga	Motrico, E (corresponding author), Univ Loyola Andalucia, Dept Psychol, Seville, Spain.; Motrico, E (corresponding author), Primary Care Prevent & Hlth Promot Res Network Re, Malaga, Spain.	emotrico@uloyola.es	MOTRICO, EMMA/D-2016-2019; Moreno-Peral, Patricia/I-3594-2012; PRISMA, Grupo/AAI-6753-2021; Rubio-Valera, Maria/H-4840-2012; Resurreccion, Davinia Maria/J-5537-2016	MOTRICO, EMMA/0000-0002-0720-567X; Moreno-Peral, Patricia/0000-0003-4130-9090; Rubio-Valera, Maria/0000-0003-2856-1697; Resurreccion, Davinia Maria/0000-0002-0046-8020				Ades PA, 2017, MAYO CLIN PROC, V92, P234, DOI 10.1016/j.mayocp.2016.10.014; [Anonymous], 2017, Circulation, V136, pe196, DOI 10.1161/CIR.0000000000000530; Arena R, 2012, CIRCULATION, V125, P1321, DOI 10.1161/CIR.0b013e318246b1e5; Balady GJ, 2007, CIRCULATION, V115, P2675, DOI 10.1161/CIRCULATIONAHA.106.180945; Chamosa S, 2015, J CARDIOPULM REHABIL, V35, P255, DOI 10.1097/HCR.0000000000000126; Chauhan U, 2010, EUR J CARDIOVASC NUR, V9, P68, DOI 10.1016/j.ejcnurse.2009.10.003; Clark AM, 2013, CLIN REHABIL, V27, P948, DOI 10.1177/0269215513481046; Garcia P, 2014, ENFERMERIA CARDIOLOG, VXXI, P76; Kotseva K, 2016, EUR J PREV CARDIOL, V23, P636, DOI 10.1177/2047487315569401; Leon AS, 2005, CIRCULATION, V111, P369, DOI 10.1161/01.CIR.0000151788.08740.5C; McCarthy MM, 2011, J CARDIOVASC NURS, V26, pE1, DOI 10.1097/JCN.0b013e3181f877e9; McSweeney J C, 2001, Rehabil Nurs, V26, P132; Mosca L, 2011, CIRCULATION, V124, P2145, DOI 10.1161/CIRCULATIONAHA.110.968792; Mosca L, 2011, J AM COLL CARDIOL, V57, P1404, DOI [10.1016/j.jacc.2011.02.005, 10.1161/CIR.0b013e31820faaf8]; Nichols M, 2014, EUR HEART J, V35, P2950, DOI 10.1093/eurheartj/ehu299; Raeisi-Giglou P, 2018, J WOMENS HEALTH, V27, P128, DOI 10.1089/jwh.2016.6316; Resurreccion DM, 2017, J WOMENS HEALTH, V26, P849, DOI 10.1089/jwh.2016.6249; Roger Veronique L, 2011, Circulation, V123, pe18, DOI 10.1161/CIR.0b013e3182009701; Ruano-Ravina A, 2016, INT J CARDIOL, V223, P436, DOI 10.1016/j.ijcard.2016.08.120; Sherwood SA, 2011, INT J THER REHABIL, V18, P266, DOI 10.12968/ijtr.2011.18.5.266; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Suaya JA, 2007, CIRCULATION, V116, P1653, DOI 10.1161/CIRCULATIONAHA.107.701466; Supervia M, 2017, MAYO CLIN PROC, V92, P565, DOI 10.1016/j.mayocp.2017.01.002; Taylor RS, 2015, HEART, V101, P1256, DOI 10.1136/heartjnl-2015-307778; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Turk-Adawi KI, 2015, HEART LUNG CIRC, V24, P510, DOI 10.1016/j.hlc.2014.11.013	26	18	20	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2018	13	7							e0200636	10.1371/journal.pone.0200636	http://dx.doi.org/10.1371/journal.pone.0200636			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN2LQ	30011341	Green Submitted, Green Published, gold			2023-01-03	WOS:000438829800037
J	Chen, CK; Tsai, TH; Lin, YC; Lin, CC; Hsu, SC; Chung, CY; Pei, YC; Wong, AMK				Chen, Chih-Kuang; Tsai, Tsai-Hsuan; Lin, Yin-Chou; Lin, Chung-Chih; Hsu, Su-Chu; Chung, Chia-Ying; Pei, Yu-Cheng; Wong, Alice M. K.			Acceptance of different design exergames in elders	PLOS ONE			English	Article							USER ACCEPTANCE; OLDER-ADULTS; INFORMATION-TECHNOLOGY; MODEL; BALANCE; ONLINE; USABILITY; QUALITY; FITNESS	For promoting the successful aging of elderly residents of Chang Gung Silver Village in Taiwan, five interactive exergames were developed to promote the well-being of the elderly. The exergames included both physical games and cognitive games, and were implemented using various computer-based technologies in the Chang Gung Silver Village. The exergames were trialed by 39 elderly residents (15 male, 24 female; mean age 79.5 +/- 17.5 years) of Chang Gung Silver Village. Following the trials, the participants were requested to complete a Technology Acceptance Model 2 (TAM2) questionnaire. The results showed that the perceived playfulness and perceived usefulness of the exergames were significantly related to the users' usage behavior and intention to use for both the physical games and the cognitive games. However, a relationship between the output quality of the game and the usage behavior was apparent only in the case of the cognitive exergames. Finally, the impact of social influence on the intention to use and the usage behavior was more pronounced for the physical exergames. Overall, the results revealed that the acceptance of exergames by the elderly depends not so much on the awareness of fun in using the game, but the perceived usefulness of the related physical and cognitive abilities.	[Chen, Chih-Kuang; Lin, Yin-Chou; Chung, Chia-Ying; Pei, Yu-Cheng; Wong, Alice M. K.] Chang Gung Mem Hosp, Dept Phys Med & Rehabil, Taoyuan, Taiwan; [Chen, Chih-Kuang; Lin, Yin-Chou; Lin, Chung-Chih; Chung, Chia-Ying; Pei, Yu-Cheng; Wong, Alice M. K.] Chang Gung Univ, Hlth Aging Res Ctr, Taoyuan, Taiwan; [Tsai, Tsai-Hsuan] Chang Gung Univ, Dept Ind Design, Taoyuan, Taiwan; [Lin, Chung-Chih] Chang Gung Univ, Dept Comp Sci & Informat Engn, Taoyuan, Taiwan; [Hsu, Su-Chu] Taipei Natl Univ Arts, Dept New Media Art, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung University	Wong, AMK (corresponding author), Chang Gung Mem Hosp, Dept Phys Med & Rehabil, Taoyuan, Taiwan.; Wong, AMK (corresponding author), Chang Gung Univ, Hlth Aging Res Ctr, Taoyuan, Taiwan.	walice@cgmh.org.tw		Lin, Yin-Chou/0000-0002-1058-2329; Pei, Yu-Cheng/0000-0001-5986-0046	Chang Gung Medical Foundation [CMRPG5B0051-53, CMPRD3B0031-33, CMRPG5B0061-63]	Chang Gung Medical Foundation	This research was supported by the Chang Gung Medical Foundation, https://www.cgmh.org.tw/eng2002/center_main.htm, grants: CMRPG5B0051-53 (Alice M K Wong), CMPRD3B0031-33 (Chung-Chih Lin), and CMRPG5B0061-63 (Chia-Ying Chung). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn T, 2007, INFORM MANAGE-AMSTER, V44, P263, DOI 10.1016/j.im.2006.12.008; Anderson-Hanley C, 2012, AM J PREV MED, V42, P109, DOI 10.1016/j.amepre.2011.10.016; [Anonymous], 2000, BOREDOM ANXIETY; Bagozzi R. P., 1988, J ACAD MARKETING SCI, V16, P74, DOI 10.1177/009207038801600107; Ben-Sadoun G, 2016, J ALZHEIMERS DIS, V53, P1299, DOI 10.3233/JAD-160268; Bentler PM, 1980, SIGNIFICANCE TESTS G, P588; Bieryla KA, 2013, CLIN INTERV AGING, V8, P775, DOI 10.2147/CIA.S46164; Carlson J, 2010, J SERV MARK, V24, P112, DOI 10.1108/08876041011031091; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cook N, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.5423; Crespo AH, 2008, INTERACT COMPUT, V20, P212, DOI 10.1016/j.intcom.2007.11.005; DAVIS FD, 1989, MANAGE SCI, V35, P982, DOI 10.1287/mnsc.35.8.982; DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008; ENGEL GL, 1982, NEW ENGL J MED, V307, P760; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Fishbein M., 1975, BELIEF ATTITUDE INTE; Fox KR, 2007, OBES REV, V8, P115, DOI 10.1111/j.1467-789X.2007.00329.x; Fu AS, 2015, ARCH PHYS MED REHAB, V96, P2096, DOI 10.1016/j.apmr.2015.08.427; Gao Y, 2012, P SIGCHI C HUM FACT, P1863, DOI DOI 10.1145/2207676.2208323; Gerling KM, 2011, PROCEEDINGS OF THE 8TH INTERNATIONAL CONFERENCE ON ADVANCES IN COMPUTER ENTERTAINMENT TECHNOLOGY (ACE 2011); Hair J.F., 1998, MULTIVARIATE DATA AN, V5th; Harris Dale M, 2015, Front Aging Neurosci, V7, P167, DOI 10.3389/fnagi.2015.00167; Joseph F, 1986, MULTIVARIATE DATA AN; Kim HB, 2009, TOURISM MANAGE, V30, P266, DOI 10.1016/j.tourman.2008.07.001; Klompstra LV, 2014, EUR J CARDIOVASC NUR, V13, P388, DOI 10.1177/1474515113512203; Koufaris M, 2002, INFORM SYST RES, V13, P205, DOI 10.1287/isre.13.2.205.83; Lin HF, 2007, ELECTRON COMMER R A, V6, P433, DOI 10.1016/j.elerap.2007.02.002; Moon JW, 2001, INFORM MANAGE, V38, P217, DOI 10.1016/S0378-7206(00)00061-6; Moore GC, 1991, INFORM SYST RES, V2, P192, DOI 10.1287/isre.2.3.192; Myint Y.-L, 2009, P 3 INT CONV REH ENG, P1, DOI [https://doi.org/10.1145/1592700.1592712, DOI 10.1145/1592700.1592712]; O'Cass A., 2004, J PROD BRAND MANAG, V13, P257, DOI DOI 10.1108/10610420410546961; Ramon-Jeronimo MA, 2013, SOC SCI COMPUT REV, V31, P389, DOI 10.1177/0894439312473421; Schutzer KA, 2004, PREV MED, V39, P1056, DOI 10.1016/j.ypmed.2004.04.003; Scott J., 1995, ACM SIGNS DATABASE, V26, P43, DOI DOI 10.1145/206476.206484; Seyal A, 2002, DETERMINANTS ACAD US, P71; Triandis, 1971, ATTITUDE ATTITUDE CH; Tsai T-H, 2011, INT C UN ACC HUM COM; van Diest M, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-101; Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926; Venkatesh V, 2003, MIS QUART, V27, P425, DOI 10.2307/30036540; Venkatesh V, 2008, DECISION SCI, V39, P273, DOI 10.1111/j.1540-5915.2008.00192.x; Whitlock L. A., 2011, P HUMAN FACTORS ERGO, V55, P187; Wong AMK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040591; Wuest S, 2014, GAMES HEALTH J, V3, P106, DOI 10.1089/g4h.2013.0093; Xue LS, 2012, INT J MED INFORM, V81, P637, DOI 10.1016/j.ijmedinf.2012.04.008	45	33	33	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2018	13	7							e0200185	10.1371/journal.pone.0200185	http://dx.doi.org/10.1371/journal.pone.0200185			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL7YG	29975755	Green Published, Green Submitted, gold			2023-01-03	WOS:000437424500074
J	Walsh, TJ; Shores, MM; Krakauer, CA; Forsberg, CW; Fox, AE; Moore, KP; Korpak, A; Heckbert, SR; Zeliadt, SB; Kinsey, CE; Thompson, ML; Smith, NL; Matsumoto, AM				Walsh, Thomas J.; Shores, Molly M.; Krakauer, Chloe A.; Forsberg, Christopher W.; Fox, Alexandra E.; Moore, Kathryn P.; Korpak, Anna; Heckbert, Susan R.; Zeliadt, Steven B.; Kinsey, Chloe E.; Thompson, Mary Lou; Smith, Nicholas L.; Matsumoto, Alvin M.			Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels	PLOS ONE			English	Article							REPLACEMENT THERAPY; HYPOGONADAL MEN; ANDROGEN DEFICIENCY; OLDER MEN; PREVALENCE; METAANALYSIS; OUTCOMES; ANTIGEN; TRENDS; SAFETY	Purpose Testosterone treatment of men with low testosterone is common and, although relatively short-term, has raised concern regarding an increased risk of prostate cancer (CaP). We investigated the association between modest-duration testosterone treatment and incident aggressive CaP. Materials and methods Retrospective inception cohort study of male Veterans aged 40 to 89 years with a laboratory-defined low testosterone measurement from 2002 to 2011 and recent prostate specific antigen (PSA) testing; excluding those with recent testosterone treatment, prostate or breast cancer, high PSA or prior prostate biopsy. Histologically-confirmed incident aggressive prostate cancer or any prostate cancer were the primary and secondary outcomes, respectively. Results Of the 147,593 men included, 58,617 were treated with testosterone. 313 aggressive CaPs were diagnosed, 190 among untreated men (incidence rate (IR) 0.57 per 1000 person years, 95% CI 0.49-0.65) and 123 among treated men (IR 0.58 per 1000 person years; 95% CI 0.48-0.69). After adjusting for age, race, hospitalization during year prior to cohort entry, geography, BMI, medical comorbidities, repeated testosterone and PSA testing, testosterone treatment was not associated with incident aggressive CaP (HR 0.89; 95% CI 0.70-1.13) or any CaP (HR 0.90; 95% CI 0.81-1.01). No association between cumulative testosterone dose or formulation and CaP was observed. Conclusions Among men with low testosterone levels and normal PSA, testosterone treatment was not associated with an increased risk of aggressive or any CaP. The clinical risks and benefits of testosterone treatment can only be fully addressed by large, longer-term randomized controlled trials.	[Walsh, Thomas J.; Shores, Molly M.; Heckbert, Susan R.; Thompson, Mary Lou; Smith, Nicholas L.] Univ Washington, Seattle, WA 98195 USA; [Walsh, Thomas J.; Shores, Molly M.; Krakauer, Chloe A.; Forsberg, Christopher W.; Fox, Alexandra E.; Moore, Kathryn P.; Korpak, Anna; Zeliadt, Steven B.; Kinsey, Chloe E.; Thompson, Mary Lou; Smith, Nicholas L.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA; [Heckbert, Susan R.; Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA; [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA; [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Group Health Cooperative; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Walsh, TJ (corresponding author), Univ Washington, Seattle, WA 98195 USA.; Walsh, TJ (corresponding author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.	walsht@uw.edu	Matsumoto, Alvin/AAH-6096-2020		National Institutes of Health National Institute on Aging [R01 AG042934-01]; Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center; Seattle Epidemiologic Research and Information Center of the Cooperative Studies Program within the VA Office of Research and Development, Seattle, Washington [SDR 02-237, 98-004]; NATIONAL INSTITUTE ON AGING [R01AG042934] Funding Source: NIH RePORTER	National Institutes of Health National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center; Seattle Epidemiologic Research and Information Center of the Cooperative Studies Program within the VA Office of Research and Development, Seattle, Washington; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research is supported by grant R01 AG042934-01, National Institutes of Health National Institute on Aging to T.W.; Supported by grant R01 AG042934-01, National Institutes of Health National Institute on Aging. Support for VA/CMS data provided by the Department of Veterans Affairs, VA Health Services Research and Development Service, VA Information Resource Center and by the Seattle Epidemiologic Research and Information Center of the Cooperative Studies Program within the VA Office of Research and Development, Seattle, Washington (Project Numbers SDR 02-237 and 98-004). The authors have no conflicts of interest to declare. This work was supported with resources and the use of facilities at the VA Puget Sound Health Care System. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.	Albertsen PC, 2005, JAMA-J AM MED ASSOC, V293, P2095, DOI 10.1001/jama.293.17.2095; Araujo AB, 2004, J CLIN ENDOCR METAB, V89, P5920, DOI 10.1210/jc.2003-031719; Araujo AB, 2007, J CLIN ENDOCR METAB, V92, P4241, DOI 10.1210/jc.2007-1245; Baillargeon J, 2015, J UROLOGY, V194, P1612, DOI 10.1016/j.juro.2015.05.099; BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; Bostwick DG, 2004, CANCER-AM CANCER SOC, V101, P2371, DOI 10.1002/cncr.20408; Calof OM, 2005, J GERONTOL A-BIOL, V60, P1451, DOI 10.1093/gerona/60.11.1451; Cui Y, 2014, PROSTATE CANCER P D, V17, P132, DOI 10.1038/pcan.2013.60; Feneley MR, 2012, J SEX MED, V9, P2138, DOI 10.1111/j.1743-6109.2012.02808.x; FOWLER JE, 1981, J UROLOGY, V126, P372, DOI 10.1016/S0022-5347(17)54531-0; Gould DC, 2006, BJU INT, V98, P1, DOI 10.1111/j.1464-410X.2006.06191.x; Haider A, 2015, J UROLOGY, V193, P80, DOI 10.1016/j.juro.2014.06.071; Handelsman DJ, 2013, MED J AUSTRALIA, V199, P548, DOI 10.5694/mja13.10111; Kaplan AL, 2013, UROLOGY, V82, P321, DOI 10.1016/j.urology.2013.03.049; Khera M, 2011, J UROLOGY, V186, P1005, DOI 10.1016/j.juro.2011.04.065; Layton JB, 2014, J CLIN ENDOCR METAB, V99, P835, DOI 10.1210/jc.2013-3570; Loeb S, 2017, J CLIN ONCOL, V35, P1430, DOI 10.1200/JCO.2016.69.5304; Fernandez-Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210/jc.2009-2575; Mulligan T, 2006, INT J CLIN PRACT, V60, P762, DOI 10.1111/j.1742-1241.2006.00992.x; Schneider HJ, 2009, CLIN ENDOCRINOL, V70, P446, DOI 10.1111/j.1365-2265.2008.03370.x; Shabsigh R, 2009, INT J IMPOT RES, V21, P9, DOI 10.1038/ijir.2008.31; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; Sharifi N, 2010, ENDOCR-RELAT CANCER, V17, pR305, DOI 10.1677/ERC-10-0187; Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661; Wallis CJD, 2016, LANCET DIABETES ENDO, V4, P498, DOI 10.1016/S2213-8587(16)00112-1; Walsh TJ, 2015, ANDROLOGY-US, V3, P287, DOI 10.1111/andr.12014; Wu FCW, 2010, NEW ENGL J MED, V363, P123, DOI 10.1056/NEJMoa0911101	28	20	20	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2018	13	6							e0199194	10.1371/journal.pone.0199194	http://dx.doi.org/10.1371/journal.pone.0199194			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK3VI	29933385	Green Published, gold, Green Submitted			2023-01-03	WOS:000436076600016
J	Korhonen, K; Einio, E; Leinonen, T; Tarkiainen, L; Martikainen, P				Korhonen, Kaarina; Einio, Elina; Leinonen, Taina; Tarkiainen, Lasse; Martikainen, Pekka			Time-varying effects of socio-demographic and economic factors on the use of institutional long-term care before dementia-related death: A Finnish register-based study	PLOS ONE			English	Article							NURSING-HOME PLACEMENT; OLDER-PEOPLE; LIVING ARRANGEMENTS; ALZHEIMERS-DISEASE; INCIDENT DEMENTIA; RISK-FACTORS; FOLLOW-UP; PREDICTORS; PROXIMITY; FINLAND	Objectives The effects of socio-demographic and economic factors on institutional long-term care (LTC) among people with dementia remain unclear. Inconsistent findings may relate to time varying effects of these factors as dementia progresses. To clarify the question, we estimated institutional LTC trajectories by age, marital status and household income in the eight years preceding dementia-related and non-dementia-related deaths. Methods We assessed a population-representative sample of Finnish men and women for institutional LTC over an eight-year period before death. Deaths related to dementia and all other causes at the age of 70+ in 2001-2007 were identified from the Death Register. Dates in institutional LTC were obtained from national care registers. We calculated the average and time-varying marginal effects of age, marital status and household income on the estimated probability of institutional LTC use, employing repeated-measures logistic regression models with generalised estimating equations (GEE). Results The effects of age, marital status and household income on institutional LTC varied across the time before death, and the patterns differed between dementia-related and non-dementia-related deaths. Among people who died of dementia, being of older age, non-married and having a lower income predicted a higher probability of institutional LTC only until three to four years before death, after which the differences diminished or disappeared. Among women in particular, the probability of institutional LTC was nearly equal across age, marital status and income groups in the last year before dementia-related death. Among those who died from non-dementia-related causes, in contrast, the differences widened until death. Conclusions We show that individuals with dementia require intensive professional care at the end of life, regardless of their socio-demographic or economic resources. The results imply that the potential for extending community living for people with dementia is likely to be difficult through modification of their socio-demographic and economic environments.	[Korhonen, Kaarina; Einio, Elina; Tarkiainen, Lasse; Martikainen, Pekka] Univ Helsinki, Fac Social Sci, Populat Res Unit, Helsinki, Finland; [Einio, Elina] London Sch Econ & Polit Sci, Dept Social Policy, London, England; [Einio, Elina; Martikainen, Pekka] Max Planck Inst Demog Res, Rostock, Germany; [Leinonen, Taina] Finnish Inst Occupat Hlth, Helsinki, Finland; [Martikainen, Pekka] Stockholm Univ, Dept Publ Hlth Sci, Stockholm, Sweden	University of Helsinki; University of London; London School Economics & Political Science; Max Planck Society; Finnish Institute of Occupational Health; Stockholm University	Korhonen, K (corresponding author), Univ Helsinki, Fac Social Sci, Populat Res Unit, Helsinki, Finland.	karina.korhonen@helsinki.fi		Korhonen, Kaarina/0000-0001-8499-2008	Eino Jutikkala Fund; Academy of Finland; Strategic Research Council PROMEQ project [303615]; European Union Horizon2020 Programme [667661]	Eino Jutikkala Fund; Academy of Finland(Academy of Finland); Strategic Research Council PROMEQ project; European Union Horizon2020 Programme	This work was funded by the Eino Jutikkala Fund (KK) and Academy of Finland (PM). KK & PM were also funded by the Strategic Research Council PROMEQ project (#303615). PM was also supported by the European Union Horizon2020 Programme under grant agreement n 667661 (Promoting mental wellbeing in the ageing population-MINDMAP). The study does not necessarily reflect the Commission's views and in no way anticipates the Commission's future policy in this area. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguero-Torres H, 2001, J CLIN EPIDEMIOL, V54, P795, DOI 10.1016/S0895-4356(00)00371-1; Andel R, 2007, J AGING HEALTH, V19, P213, DOI 10.1177/0898264307299359; [Anonymous], 2013, OECD FRAMEWORK STAT, DOI [10.1787/9789264194830-en, DOI 10.1787/9789264194830-EN]; Brayne C, 2006, PLOS MED, V3, P1922, DOI 10.1371/journal.pmed.0030397; Eska K, 2013, DEMENT GER COGN D EX, V3, P426, DOI 10.1159/000355079; Garcia-Ptacek S, 2016, J AM GERIATR SOC, V64, pE137, DOI 10.1111/jgs.14421; Gaugler JE, 2005, J AM GERIATR SOC, V53, P2098, DOI 10.1111/j.1532-5415.2005.00495.x; Gaugler JE, 2003, GERONTOLOGIST, V43, P219, DOI 10.1093/geront/43.2.219; Gaugler JE, 2009, MED CARE, V47, P191, DOI 10.1097/MLR.0b013e31818457ce; Hakkinen U, 2008, HEALTH ECON POLICY L, V3, P165, DOI 10.1017/S174413310800443X; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; Huang S-W, 2015, MEDICINE, P94, DOI [10.1097/114D.0000000000002155, DOI 10.1097/114D.0000000000002155]; Johansson, 2010, 76 ENEPRI; Jones DS, 2016, NEW ENGL J MED, V374, P507, DOI 10.1056/NEJMp1514434; Knapp M., 2007, DEMENTIA UK FULL REP; Luppa M, 2012, DEMENT GERIATR COGN, V33, P282, DOI 10.1159/000339729; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Martikainen P, 2012, J EPIDEMIOL COMMUN H, V66, P1152, DOI 10.1136/jech-2011-200756; Martikainen P, 2009, GERONTOLOGIST, V49, P34, DOI 10.1093/geront/gnp013; McCann M, 2011, AGE AGEING, V40, P358, DOI 10.1093/ageing/afr031; Mittelman MS, 2006, NEUROLOGY, V67, P1592, DOI 10.1212/01.wnl.0000242727.81172.91; Murphy M, 2013, SOC SCI MED, V88, P39, DOI 10.1016/j.socscimed.2013.03.042; Nihtila E, 2007, POP STUD-J DEMOG, V61, P299, DOI 10.1080/00324720701524193; Nihtila EK, 2008, EUR J PUBLIC HEALTH, V18, P77, DOI 10.1093/eurpub/ckm025; Norton MC, 2009, J GERONTOL B-PSYCHOL, V64, P560, DOI 10.1093/geronb/gbp052; Peeters JM, 2010, BMC NURS, V9, DOI 10.1186/1472-6955-9-9; Prince M, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0188-8; Schulze J, 2015, SOC PSYCH PSYCH EPID, V50, P143, DOI 10.1007/s00127-014-0911-3; Smith GE, 2000, J AM GERIATR SOC, V48, P519, DOI 10.1111/j.1532-5415.2000.tb04998.x; Solomon A, 2014, ALZHEIMERS DEMENT, V10, P303, DOI 10.1016/j.jalz.2013.03.004; StataCorp, 2015, STAT STAT SOFTW REL; Tarricone R, 2008, HOME CARE EUROPE SOL; Todd S, 2013, INT J GERIATR PSYCH, V28, P1109, DOI 10.1002/gps.3946; Twisk JWR, 2003, APPL LONGITUDINAL DA; van de Vorst IE, 2016, AM J EPIDEMIOL, V184, P219, DOI 10.1093/aje/kwv319; Wattmo C, 2011, GERONTOLOGIST, V51, P17, DOI 10.1093/geront/gnq050; Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209	37	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2018	13	6							e0199551	10.1371/journal.pone.0199551	http://dx.doi.org/10.1371/journal.pone.0199551			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK0LV	29928067	gold, Green Published, Green Submitted			2023-01-03	WOS:000435802500108
J	Ramsingh, AI; Gray, SJ; Reilly, A; Koday, M; Bratt, D; Koday, MT; Murnane, R; Smedley, J; Hu, YH; Messer, A; Fuller, DH				Ramsingh, Arlene I.; Gray, Steven J.; Reilly, Andrew; Koday, Michael; Bratt, Debbie; Koday, Merika Treants; Murnane, Robert; Smedley, Jeremy; Hu, Yuhui; Messer, Anne; Fuller, Deborah Heydenburg			Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation	PLOS ONE			English	Article							GIANT AXONAL NEUROPATHY; CENTRAL-NERVOUS-SYSTEM; IMMUNE TOLERANCE; GENE DELIVERY; POMPE DISEASE; GIGAXONIN; PATHOGENESIS; RESTORATION; RECEPTOR; VECTORS	A critical issue in transgene delivery studies is immune reactivity to the transgene- encoded protein and its impact on sustained gene expression. Here, we test the hypothesis that immunomodulation by rapamycin can decrease immune reactivity after intrathecal AAV9 delivery of a transgene (GFP) in non-human primates, resulting in sustained GFP expression in the CNS. We show that rapamycin treatment clearly reduced the overall immunogenicity of the AAV9/GFP vector by lowering GFP- and AAV9-specific antibody responses, and decreasing T cell responses including cytokine and cytolytic effector responses. Spinal cord GFP protein expression was sustained for twelve weeks, with no toxicity. Immune correlates of robust transgene expression include negligible GFP-specific CD4 and CD8 T cell responses, absence of GFP-specific IFN-gamma producing T cells, and absence of GFP-specific cytotoxic T cells, which support the hypothesis that decreased T cell reactivity results in sustained transgene expression. These data strongly support the use of modest doses of rapamycin to modulate immune responses for intrathecal gene therapies, and potentially a much wider range of viral vector-based therapeutics.	[Ramsingh, Arlene I.] NYVAX Inc, Miami, FL USA; [Gray, Steven J.; Hu, Yuhui] Univ North Carolina Chapel Hill, Gene Therapy Ctr, Chapel Hill, NC USA; [Gray, Steven J.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Reilly, Andrew] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; [Koday, Michael; Bratt, Debbie; Murnane, Robert; Smedley, Jeremy; Fuller, Deborah Heydenburg] Washington Natl Primate Res Ctr, Seattle, WA 98195 USA; [Koday, Merika Treants; Fuller, Deborah Heydenburg] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Messer, Anne] Neural Stem Cell Inst, Rensselaer, NY USA; [Reilly, Andrew] Delmar, New York, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; Wadsworth Center; University of Washington; University of Washington Seattle	Fuller, DH (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	fullerdh@wanprc.org	Bratt, Debra/B-1106-2019; Core, Vector/CAF-4832-2022; , Pathology Services Core/CEZ-2246-2022	Fuller, Deborah/0000-0001-7315-2441; Smedley, Jeremy/0000-0003-3369-4662	Hannah's Hope Fund; National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01 NS087175]; National Institutes of Health [P51-0D010425]; National Cancer Institute [3P30CA016086]; UNC University Cancer Research Fund (UCRF); NCI Center Core Support [CA16086]; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087175] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD010425] Funding Source: NIH RePORTER	Hannah's Hope Fund; National Institutes of Health/National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UNC University Cancer Research Fund (UCRF); NCI Center Core Support; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors wish to acknowledge financial support from Hannah's Hope Fund, along with National Institutes of Health/National Institute of Neurological Disorders and Stroke R01 NS087175 (to S.G.) and National Institutes of Health/P51-0D010425 (to WaNPRC via D.H.F. allocation). Indirect administrative support for S.G. was provided by Research to Prevent Blindness to the UNC-CH Department of Ophthalmology. We acknowledge the use of resources at the UNC Translational Pathology Laboratory, which is supported, in part, by grants from the National Cancer Institute (3P30CA016086) and the UNC University Cancer Research Fund (UCRF). Arlene I. Ramsingh is affiliated to NYVAX Inc. but is not a paid employee of NYVAX Inc. which is in the early stage of a start-up. NYVAX Inc. did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.; We thank Rachel Bailey, Mary Keener, Clifford Heindel, and Violeta Zaric (UNC) for technical support. We also thank the Department of Primate Resources and Research Services Group at the Washington National Primate Research Center for excellent veterinary support for the procedures and animal care. We acknowledge the use of resources at the UNC Translational Pathology Laboratory which is supported, in part, by an NCI Center Core Support Grant (CA16086) to the UNC Lineberger Comprehensive Cancer Center.	Araki K, 2011, CURR OPIN CELL BIOL, V23, P707, DOI 10.1016/j.ceb.2011.08.006; Demir E, 2005, J NEUROL NEUROSUR PS, V76, P825, DOI 10.1136/jnnp.2003.035162; Doerfler PA, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2015.53; Doerfler PA, 2016, HUM GENE THER, V27, P43, DOI 10.1089/hum.2015.103; Garcia JM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00244; Gray SJ, 2013, GENE THER, V20, P450, DOI 10.1038/gt.2012.101; Grieger JC, 2016, MOL THER, V24, P287, DOI 10.1038/mt.2015.187; Hinderer C, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.51; Jabri B, 2015, NAT REV IMMUNOL, V15, P771, DOI 10.1038/nri3919; Johnson-Kerner BL, 2015, HUM MOL GENET, V24, P1420, DOI 10.1093/hmg/ddu556; Johnson-Kerner BL, 2014, MUSCLE NERVE, V50, P467, DOI 10.1002/mus.24321; Kang JJ, 2016, HUM GENET, V135, P675, DOI 10.1007/s00439-016-1659-5; Kantor B, 2014, ADV GENET, V87, P125, DOI 10.1016/B978-0-12-800149-3.00003-2; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Mingozzi F, 2017, ANNU REV VIROL, V4, P511, DOI 10.1146/annurev-virology-101416-041936; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mussche S, 2013, HUM GENE THER, V24, P209, DOI 10.1089/hum.2012.107; PENA SDJ, 1983, EUR J CELL BIOL, V31, P227; Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024; Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014; Samaranch L, 2014, MOL THER, V22, P329, DOI 10.1038/mt.2013.266; Schlom J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22546; Sochocka M, 2017, MOL NEUROBIOL, V54, P8071, DOI 10.1007/s12035-016-0297-1; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10; Spulber S, 2009, BRAIN BEHAV IMMUN, V23, P573, DOI 10.1016/j.bbi.2009.02.015; Sun L, 2015, CYTOKINE, V75, P249, DOI 10.1016/j.cyto.2015.01.030; Takatsu K, 2011, P JPN ACAD B-PHYS, V87, P463, DOI 10.2183/pjab.87.463; Tardieu M, 2017, LANCET NEUROL, V16, P712, DOI 10.1016/S1474-4422(17)30169-2; Tornoe J, 2002, GENE, V297, P21, DOI 10.1016/S0378-1119(02)00878-8; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	31	12	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2018	13	6							e0198154	10.1371/journal.pone.0198154	http://dx.doi.org/10.1371/journal.pone.0198154			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI4VN	29874260	Green Published, Green Submitted, gold			2023-01-03	WOS:000434369400042
J	Guglielmi, G				Guglielmi, Giorgia			GUT MICROBES JOIN THE FIGHT AGAINST CANCER	NATURE			English	News Item							IMMUNOTHERAPY; EFFICACY							Guglielmi, Giorgia/0000-0003-0649-3232				Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537	9	16	20	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 24	2018	557	7706					482	484		10.1038/d41586-018-05208-8	http://dx.doi.org/10.1038/d41586-018-05208-8			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG6GP	29795257				2023-01-03	WOS:000432794900020
J	McMahon, G; Morse, CI; Winwood, K; Burden, A; Onambele, GL				McMahon, Gerard; Morse, Christopher I.; Winwood, Keith; Burden, Adrian; Onambele, Gladys L.			Gender associated muscle-tendon adaptations to resistance training	PLOS ONE			English	Article							HUMAN PATELLAR TENDON; GROWTH-FACTOR-I; EXERCISE-INDUCED CHANGES; MECHANICAL-PROPERTIES; SKELETAL-MUSCLE; COLLAGEN-SYNTHESIS; PROTEIN-SYNTHESIS; TRANSFORMING GROWTH-FACTOR-BETA-1; SEX; STIFFNESS	Purpose To compare the relative changes in muscle-tendon complex (MTC) properties following high load resistance training (RT) in young males and females, and determine any link with circulating TGF beta-1 and IGF-I levels. Methods Twenty-eight participants were assigned to a training group and subdivided by sex (T males [TM] aged 20 +/- 1 year, n = 8, T females [TF] aged 19 +/- 3 year, n = 8), whilst age-matched 6 males and 6 females were assigned to control groups (ConM/F). The training groups completed 8 weeks of resistance training (RT). MTC properties (Vastus Lateralis, VL) physiological cross-sectional area (pCSA), quadriceps torque, patella tendon stiffness [K], Young's modulus, volume, cross-sectional area, and length, circulating levels of TGF beta-1 and IGF-I were assessed at baseline and post RT. Results Post RT, there was a significant increase in the mechanical and morphological properties of the MTC in both training groups, compared to ConM/F (p<0.001). However, there were no significant sex-specific changes in most MTC variables. There were however significant sex differences in changes in K, with females exhibiting greater changes than males at lower MVC (Maximal Voluntary Contraction) force levels (10% p = 0.030 & 20% MVC p = 0.032) and the opposite effect seen at higher force levels (90% p = 0.040 & 100% MVC p = 0.044). There were significant increases (p<0.05) in IGF-I in both TF and TM following training, with no change in TGF beta-1. There were no gender differences (p>0.05) in IGF-I or TGF beta-1. Interestingly, pooled population data showed that TGF beta-1 correlated with K at baseline, with no correlations identified between IGF-I and MTC properties. Conclusions Greater resting TGF6-1 levels are associated with superior tendon mechanical properties. RT can impact opposite ends of the patella tendon force-elongation relationship in each sex.	[McMahon, Gerard] Ulster Univ, Sch Sport, Belfast, Antrim, North Ireland; [McMahon, Gerard; Morse, Christopher I.; Winwood, Keith; Burden, Adrian; Onambele, Gladys L.] Manchester Metropolitan Univ, Hlth Exercise & Act Living HEAL Res Ctr, Crewe, Cheshire, England	Ulster University; Manchester Metropolitan University	McMahon, G (corresponding author), Ulster Univ, Sch Sport, Belfast, Antrim, North Ireland.; McMahon, G (corresponding author), Manchester Metropolitan Univ, Hlth Exercise & Act Living HEAL Res Ctr, Crewe, Cheshire, England.	g.mcmahon@ulster.ac.uk	Onambélé-Pearson, Gladys Leopoldine/F-1679-2013; Morse, Christopher/AAE-7913-2022	Onambélé-Pearson, Gladys Leopoldine/0000-0002-1466-3265; Morse, Christopher/0000-0002-5261-2637; McMahon, Gerard/0000-0002-4852-9988; Winwood, Keith/0000-0002-8696-9976				Albracht K, 2013, EUR J APPL PHYSIOL, V113, P1605, DOI 10.1007/s00421-012-2585-4; Astill BD, 2017, J APPL PHYSIOL, V122, P361, DOI 10.1152/japplphysiol.00878.2016; BELL DG, 1986, MED SCI SPORT EXER, V18, P31; Bryant AL, 2008, J APPL PHYSIOL, V105, P1035, DOI 10.1152/japplphysiol.01281.2007; Doessing S, 2010, J PHYSIOL-LONDON, V588, P341, DOI 10.1113/jphysiol.2009.179325; Esformes JI, 2002, EUR J APPL PHYSIOL, V87, P90, DOI 10.1007/s00421-002-0592-6; Goodier HCJ, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0947-8; Grainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133, DOI 10.1016/S1359-6101(99)00037-4; Hansen M, 2014, EXERC SPORT SCI REV, V42, P183, DOI 10.1249/JES.0000000000000026; Heinemeier K, 2003, J APPL PHYSIOL, V95, P2390, DOI 10.1152/japplphysiol.00403.2003; Heinemeier K, 2003, EUR J APPL PHYSIOL, V90, P171, DOI 10.1007/s00421-003-0881-8; Hicks KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150848; Hicks KM, 2013, ACTA PHYSIOL, V209, P235, DOI 10.1111/apha.12159; Knobloch K, 2010, KNEE SURG SPORT TR A, V18, P648, DOI 10.1007/s00167-009-1006-7; Kubo K, 2003, EUR J APPL PHYSIOL, V88, P520, DOI 10.1007/s00421-002-0744-8; LeMoine JK, 2009, AM J PHYSIOL-REG I, V296, pR119, DOI 10.1152/ajpregu.90607.2008; Little D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096526; Lyras DN, 2010, ACTA ORTHOP BELG, V76, P380; Maffulli N, 2003, CLIN SPORT MED, V22, P675, DOI 10.1016/S0278-5919(03)00004-8; McMahon G, 2014, MUSCLE NERVE, V49, P108, DOI 10.1002/mus.23884; McMahon GE, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.91; Miller BF, 2007, J APPL PHYSIOL, V102, P541, DOI 10.1152/japplphysiol.00797.2006; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Molloy T, 2003, SPORTS MED, V33, P381, DOI 10.2165/00007256-200333050-00004; Nielsen RH, 2014, J APPL PHYSIOL, V116, P42, DOI 10.1152/japplphysiol.01084.2013; Onambele GNL, 2007, J ORTHOP RES, V25, P1635, DOI 10.1002/jor.20404; Onambele-Pearson GL, 2012, AGE, V34, P427, DOI 10.1007/s11357-011-9248-y; Pearson SJ, 2005, CHRONOBIOL INT, V22, P1013, DOI 10.1080/07420520500397900; Pearson SJ, 2006, MUSCLE NERVE, V33, P792, DOI 10.1002/mus.20529; Reeves ND, 2004, EUR J APPL PHYSIOL, V91, P116, DOI 10.1007/s00421-003-0961-9; Reeves ND, 2004, J APPL PHYSIOL, V96, P885, DOI 10.1152/japplphysiol.00688.2003; Seynnes OR, 2011, SCAND J MED SCI SPOR, V21, P39, DOI 10.1111/j.1600-0838.2011.01340.x; Sipila S, 2013, BIOGERONTOLOGY, V14, P231, DOI 10.1007/s10522-013-9425-8; Smith FW, 2002, SPORTS MED ARTHROSC, V10, P98, DOI 10.1097/00132585-200210010-00014; Sullivan BE, 2009, J APPL PHYSIOL, V106, P468, DOI 10.1152/japplphysiol.91341.2008; WAKEFIELD LM, 1995, CLIN CANCER RES, V1, P129; Westh E, 2008, SCAND J MED SCI SPOR, V18, P23, DOI 10.1111/j.1600-0838.2007.00638.x; Yang GG, 2004, J BIOMECH, V37, P1543, DOI 10.1016/j.jbiomech.2004.01.005	38	15	16	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2018	13	5							e0197852	10.1371/journal.pone.0197852	http://dx.doi.org/10.1371/journal.pone.0197852			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG6DG	29787583	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000432785700053
J	Chang, CC; Chen, TL; Lin, CS; Chung, CL; Yeh, CC; Hu, CJ; Lane, HL; Liao, CC; Shih, CC				Chang, Chuen-Chau; Chen, Ta-Liang; Lin, Chao-Shun; Chung, Chi-Li; Yeh, Chun-Chieh; Hu, Chaur-Jong; Lane, Hsin-Long; Liao, Chien-Chang; Shih, Chun-Chuan			Decreased risk of pneumonia in stroke patients receiving acupuncture: A nationwide matched-pair retrospective cohort study	PLOS ONE			English	Article							CEREBRAL-BLOOD-FLOW; POSTSTROKE PAIN; ELECTROACUPUNCTURE; OUTCOMES; INJURY	Background Acupuncture treatment is common among stroke patients, but there is limited information available on whether acupuncture effectively prevents post-stroke pneumonia. The aim of this study was to analyze the differential risk of pneumonia after stroke between patients who did and did not receive acupuncture after discharge. Methods We used the Taiwan National Health Insurance Research Database to conduct a retrospective cohort study using propensity score matched-pairs of new stroke patients in 2000-2004 who did and did not receive acupuncture post-stroke. Both cohorts were followed up until the end of 2009 for new-onset pneumonia. After correcting for immortal time bias, the incidence and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of pneumonia associated with acupuncture use were calculated using multivariate Cox proportional hazard models. Results Overall, 12557 stroke patients with 12557 paired controls were included in the analysis; pneumonia was diagnosed in 6796 (27.1%). Stroke patients receiving acupuncture had a lower incidence of pneumonia than those without acupuncture (53.4 vs. 58.9 per 1000 person-years), with an adjusted HR of 0.86 (95% CI 0.82-0.90). The association between pneumonia risk and acupuncture use was significant in men (HR 0.92, 95% CI 0.86-0.98) and women (HR 0.79, 95% 0.70-0.82) and was also observed in every age group from 2079 years. Conclusion Stroke patients receiving acupuncture had a lower risk of pneumonia than those who did not. Further randomized control studies are needed to validate the protective effect of acupuncture on the risk of pneumonia among stroke patients.	[Chang, Chuen-Chau; Chen, Ta-Liang; Lin, Chao-Shun; Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Chang, Chuen-Chau; Chen, Ta-Liang; Lin, Chao-Shun; Liao, Chien-Chang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei, Taiwan; [Chang, Chuen-Chau; Chen, Ta-Liang; Lin, Chao-Shun; Liao, Chien-Chang] Taipei Med Univ, Coll Med, Sch Med, Dept Anesthesiol, Taipei, Taiwan; [Chung, Chi-Li] Taipei Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taipei, Taiwan; [Yeh, Chun-Chieh] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Yeh, Chun-Chieh] Univ Illinois, Dept Surg, Chicago, IL 60680 USA; [Hu, Chaur-Jong] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, New Taipei City, Taiwan; [Lane, Hsin-Long] I Shou Univ, Coll Med, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan; [Liao, Chien-Chang] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung, Taiwan; [Liao, Chien-Chang] Taipei Med Univ, Shuan Ho Hosp, Dept Anesthesiol, Taipei, Taiwan; [Shih, Chun-Chuan] Taipei Med Univ, PhD Program Clin Drug Discovery Bot Herbs, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Taipei Medical University; I Shou University; China Medical University Taiwan; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University	Shih, CC (corresponding author), Taipei Med Univ, PhD Program Clin Drug Discovery Bot Herbs, Taipei, Taiwan.	hwathai@seed.net.tw	Yeh, Chun Chieh/I-4893-2019	Yeh, Chun Chieh/0000-0001-6753-7564	Taiwan's National Union of Chinese Medical Doctors' Association [UNCMA104-H-001]; Taiwan's Ministry of Science and Technology [MOST106-2320-B-214-003, MOST105-2629-B-038-001, MOST103-2320-B-214-010-MY2]	Taiwan's National Union of Chinese Medical Doctors' Association; Taiwan's Ministry of Science and Technology	This research was supported in part by Taiwans National Union of Chinese Medical Doctors Association (UNCMA104-H-001), Taiwans Ministry of Science and Technology (MOST106-2320-B-214-003; MOST105-2629-B-038-001; MOST103-2320-B-214-010-MY2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida OP, 2010, ANN NEUROL, V68, P503, DOI 10.1002/ana.22189; Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B; Burton CAC, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008860.pub2; Byeon HS, 2011, J ALTERN COMPLEM MED, V17, P219, DOI 10.1089/acm.2010.0232; Cai HY, 2015, INT J CLIN EXP MED, V8, P14090; Chang CC, 2016, J ETHNOPHARMACOL, V177, P46, DOI 10.1016/j.jep.2015.11.028; Chau JPC, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00030; Chen C, 2013, NEUROLOGY, V80, pS27, DOI 10.1212/WNL.0b013e3182762569; Chuang SF, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0828-8; Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196; Du YH, 2011, NEUROL RES, V33, P101, DOI 10.1179/016164110X12714125204317; Feng R, 2014, AFR J TRADIT COMPLEM, V11, P25, DOI 10.4314/ajtcam.v11i3.5; Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1; Geeganage C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000323.pub2; Hannawi Y, 2013, CEREBROVASC DIS, V35, P430, DOI 10.1159/000350199; Hinchey JA, 2005, STROKE, V36, P1972, DOI 10.1161/01.STR.0000177529.86868.8d; Hsiu H, 2011, MICROVASC RES, V81, P289, DOI 10.1016/j.mvr.2011.03.001; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056736; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Lee GJ, 2010, NEUROL RES, V32, pS79, DOI 10.1179/016164109X12537002794200; Lee S, 2015, CLIN EXP PHARMACOL P, V42, P822, DOI 10.1111/1440-1681.12413; Li J, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-441; Liu YM, 2010, J NEUROIMMUNOL, V220, P25, DOI 10.1016/j.jneuroim.2009.12.005; MacPherson H, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001518; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Murthy SB, 2016, NEUROCRIT CARE, V25, P178, DOI 10.1007/s12028-016-0282-6; Neumann S, 2015, INT J MOL SCI, V16, P29029, DOI 10.3390/ijms161226141; Paolucci S, 2016, PAIN MED, V17, P924, DOI 10.1093/pm/pnv019; Shih CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089208; Shim R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010064; Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478; Wang Li-ping, 2006, Zhongguo Zhen Jiu, V26, P141; Weng SW, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010539; Weng SW, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1272-0; Wijeysundera DN, 2008, LANCET, V372, P562, DOI 10.1016/S0140-6736(08)61121-6; Wolfe CDA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001033; Xie Y, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006076.pub2; Zhang SH, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003317.pub2; Zhang XZ, 2014, NEUROCHEM INT, V65, P23, DOI 10.1016/j.neuint.2013.12.004	40	6	8	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2018	13	5							e0196094	10.1371/journal.pone.0196094	http://dx.doi.org/10.1371/journal.pone.0196094			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG2QJ	29782526	Green Published, Green Submitted, gold			2023-01-03	WOS:000432537100003
J	Park, H; Jeong, D; Nguyen, P; Henry, L; Hoang, J; Kim, Y; Sheen, E; Nguyen, MH				Park, Haesuk; Jeong, Donghak; Nguyen, Pauline; Henry, Linda; Hoang, Joseph; Kim, Yoona; Sheen, Edward; Nguyen, Mindie H.			Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis	PLOS ONE			English	Article							NATURAL-HISTORY; HCV INFECTION; HEPATOCELLULAR-CARCINOMA; ASIAN PATIENTS; HBV INFECTION; UNITED-STATES; C INFECTION; DEATH; MORTALITY; COHORT	Background Economic burden of HBV and HCV infection are trending upwards. Aims Compare hepatitis B virus (HBV) and hepatitis C virus (HCV) related hospital admission rates, charges, mortality rates, causes of death in a US population-based study. Methods Retrospective cohort analysis of HBV and HCV patients from the California Office of Statewide Health Planning and Development (2006-2013) database. Results A total of 23,891 HBV and 148,229 HCV patients were identified. Across the 8-year period, the mean increase for all-cause ($1,863 vs $1,388) and liver-related hospitalization charges ($1,175 vs $675) were significantly higher for the HBV cohort compared to the HCV cohort. HBV patients had significantly higher liver-related hospital charges per person per year than HCV patients after controlling for covariates ($123,239 vs $111,837; p = 0.002). Compared to HCV patients, adjusted mortality hazard ratio was slightly lower in HBV patients (relative risk = 0.96; 95% CI 0.94-0.99). The major causes and places of death were different. The three major causes of death for HBV were: other malignant neoplasms (35%), cardiovascular disease/other circulatory disorders (17%), and liver-related disease (15%) whereas for HCV patients were: liver-related disease (22%), other malignant neoplasms (20%), and cardiovascular disease (16%). Regarding the place of death, 53% of HBV patients and 44% of HCV patients died in hospital inpatient, respectively. Conclusions HBV patients incurred higher liver-related hospital charges and higher mean increase for all-cause and liver-related hospitalization charges over the 8-year period compared to HCV patients. HBV patients had slightly lower mortality rate and their major causes and places of death were noticeably different from HCV patients.	[Park, Haesuk; Henry, Linda] Univ Florida, Coll Pharm, Pharmaceut Outcomes & Policy, Gainesville, FL 32611 USA; [Jeong, Donghak; Nguyen, Pauline; Hoang, Joseph; Kim, Yoona; Sheen, Edward; Nguyen, Mindie H.] Stanford Univ, Med Ctr, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA	State University System of Florida; University of Florida; Stanford University	Nguyen, MH (corresponding author), Stanford Univ, Med Ctr, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA.	mindiehn@stanford.edu						Amin J, 2006, LANCET, V368, P938, DOI 10.1016/S0140-6736(06)69374-4; California Department of Public Health (COPH), 2016, CHRON HEP B INF CAL; California Department of Public Health (COPH), 2016, CHRON HEP C INF CAL; Chen CJ, 2011, J GASTROEN HEPATOL, V26, P628, DOI 10.1111/j.1440-1746.2011.06695.x; Chen G, 2005, INT J EPIDEMIOL, V34, P132, DOI 10.1093/ije/dyh339; Cholankeril G, 2016, DIGEST DIS SCI, V61, P2505, DOI 10.1007/s10620-016-4160-z; Devaki P, 2014, CANCER-AM CANCER SOC, V120, P1725, DOI 10.1002/cncr.28639; Duberg AS, 2008, J VIRAL HEPATITIS, V15, P538, DOI 10.1111/j.1365-2893.2008.00982.x; Gidding HF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-52; Hajarizadeh B, 2013, NAT REV GASTRO HEPAT, V10, P553, DOI 10.1038/nrgastro.2013.107; Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infection, 2010, HEPATITIS LIVER CANC, DOI DOI 10.17226/12793; Kim N, 2018, CANCER IN PRESS, DOI [10.1002/cncr.31373, DOI 10.1002/CNCR.31373]; Kowdley KV, 2012, HEPATOLOGY, V56, P422, DOI 10.1002/hep.24804; Lin SY, 2007, HEPATOLOGY, V46, P1034, DOI 10.1002/hep.21784; Mitchell Tarissa, 2013, PLoS One, V8, DOI 10.1371/annotation/7f73ed17-709e-4d7f-9aae-aab1f4a34985; Montuclard C, 2015, J HEPATOL, V62, P1265, DOI 10.1016/j.jhep.2015.01.020; Nguyen LH, 2013, ALIMENT PHARM THER, V37, P921, DOI 10.1111/apt.12300; Office of Statewide Health Planning and Development, 2017, CAL INP DAT REP MAN; Rajbhandari R, 2015, ALIMENT PHARM THER, V41, P928, DOI 10.1111/apt.13162; Sie L, 2013, J VIRAL HEPATITIS, V20, P628, DOI 10.1111/jvh.12086; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Szpakowski JL, 2013, HEPATOLOGY, V58, P21, DOI 10.1002/hep.26110; Tran SA, 2018, BMJ OPEN GASTROENTER, V5, DOI 10.1136/bmjgast-2017-000192; Walter SR, 2011, J HEPATOL, V54, P879, DOI 10.1016/j.jhep.2010.08.035; WHO, 2016, HEP C; World Health Organization, 2016, HEP B; Yip B, 2014, DIGEST DIS SCI, V59, P192, DOI 10.1007/s10620-013-2948-7; Zingmond DS, 2004, J CLIN EPIDEMIOL, V57, P21, DOI 10.1016/S0895-4356(03)00250-6	28	8	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196452	10.1371/journal.pone.0196452	http://dx.doi.org/10.1371/journal.pone.0196452			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE3RI	29708985	Green Submitted, Green Published, gold			2023-01-03	WOS:000431130100027
J	Belchev, Z; Bodner, GE; Fawcett, JM				Belchev, Zorry; Bodner, Glen E.; Fawcett, Jonathan M.			Inducing preference reversals in aesthetic choices for paintings: Introducing the contrast paradigm	PLOS ONE			English	Article							DECISION-MAKING; COGNITIVE-DISSONANCE; MUSIC PREFERENCES; CONTEXT; ASSIMILATION; ATTRACTIVENESS; APPRECIATION; ALTERNATIVES; PSYCHOLOGY; JUDGMENTS	Understanding what leads people to reverse their choices is important in many domains. We introduce a contrast paradigm for studying reversals in choices-here between pairs of abstract paintings-implemented in both within-subject (Experiment 1; N = 320) and between-subject (Experiment 2; N = 384) designs. On each trial, participants chose between a pair of paintings. A critical pair of average-beauty paintings was presented before and after either a reversal or control block. In the reversal block, we made efforts to bias preference away from the chosen average-beauty painting (by pairing it with more-beautiful paintings) and toward the non-chosen average-beauty painting (by pairing it with less-beautiful paintings). Meta-analysis revealed more reversals after reversal blocks than after control blocks, though only when the biasing manipulations succeeded. A second meta-analysis revealed that reversals were generally more likely for participants who later misidentified their initial choice, demonstrating that memory for initial choices influences later choices. Thus, the contrast paradigm has utility both for inducing choice reversals and identifying their causes.	[Belchev, Zorry; Bodner, Glen E.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Fawcett, Jonathan M.] Mem Univ Newfoundland, Dept Psychol, St John, NF, Canada; [Belchev, Zorry] Univ Toronto, Dept Psychol, Toronto, ON, Canada; [Bodner, Glen E.] Flinders Univ S Australia, Psychol, Adelaide, SA, Australia	University of Calgary; Memorial University Newfoundland; University of Toronto; Flinders University South Australia	Bodner, GE (corresponding author), Univ Calgary, Dept Psychol, Calgary, AB, Canada.; Bodner, GE (corresponding author), Flinders Univ S Australia, Psychol, Adelaide, SA, Australia.	glen.bodner@flinders.edu.au		Belchev, Zorry/0000-0002-9361-0865; Bodner, Glen/0000-0001-7837-4879	Natural Sciences and Engineering Research Council of Canada [RGPIN 238599-2015]	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This research was supported by the Natural Sciences and Engineering Research Council of Canada through Discovery Grant RGPIN 238599-2015 to GEB. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arielli E, 2012, EMPIR STUD ARTS, V30, P59, DOI 10.2190/EM.30.1.f; Belchev Z., 2015, THESIS; BOSTIC R, 1990, J ECON BEHAV ORGAN, V13, P193, DOI 10.1016/0167-2681(90)90086-S; BREHM JW, 1956, J ABNORM SOC PSYCH, V52, P384, DOI 10.1037/h0041006; Burkley E, 2008, PERS SOC PSYCHOL B, V34, P419, DOI 10.1177/0146167207310458; Busemeyer JR., 2007, MARKETING THEOR, V7, P39, DOI [10.1177/1470593107073844, DOI 10.1177/1470593107073844]; Chammat M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41320; Chen MK, 2010, J PERS SOC PSYCHOL, V99, P573, DOI 10.1037/a0020217; Dolese M., 2005, B PSYCHOL ARTS, V5, P21; Engelmann JB, 2013, PROG BRAIN RES, V202, P215, DOI 10.1016/B978-0-444-62604-2.00013-7; Fechner G.T., 1876, PRESCHOOL AESTHETICS; Festinger L., 1957, COGNITIVE DISSONANCE; FOX WS, 1974, PUBLIC OPIN QUART, V38, P352, DOI 10.1086/268171; GEISELMAN RE, 1984, J EXP SOC PSYCHOL, V20, P409, DOI 10.1016/0022-1031(84)90035-0; Gelman A., 2007, DATA ANAL USING REGR; GIRGUS JS, 1982, PERCEPT PSYCHOPHYS, V32, P555, DOI 10.3758/BF03204210; Graf LKM, 2015, PERS SOC PSYCHOL REV, V19, P395, DOI 10.1177/1088868315574978; HOVLAND CI, 1957, J ABNORM SOC PSYCH, V55, P244, DOI 10.1037/h0048480; Ito T, 2014, SOC COGN AFFECT NEUR, V9, P1546, DOI 10.1093/scan/nst147; Izuma K, 2010, P NATL ACAD SCI USA, V107, P22014, DOI 10.1073/pnas.1011879108; Jacobsen T, 2006, LEONARDO, V39, P155, DOI 10.1162/leon.2006.39.2.155; Kahneman D., 2011, THINKING FAST SLOW; Leder H, 2004, BRIT J PSYCHOL, V95, P489, DOI 10.1348/0007126042369811; LICHTENSTEIN S, 1971, J EXP PSYCHOL, V89, P46, DOI 10.1037/h0031207; Lindell AK, 2011, J COGN PSYCHOL, V23, P453, DOI 10.1080/20445911.2011.539556; Mallon B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00161; Parker S., 2008, PSYCHOL AESTHET CREA, V2, P171, DOI DOI 10.1037/1931-3896.2.3.171; Pine A, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01051; R-Core-Team, 2016, LANG ENV STAT COMP; Redies C, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00218; Rentfrow PJ, 2003, J PERS SOC PSYCHOL, V84, P1236, DOI 10.1037/0022-3514.84.6.1236; Rhodes G, 2006, ANNU REV PSYCHOL, V57, P199, DOI 10.1146/annurev.psych.57.102904.190208; Salti M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108579; Scherer KR, 2005, SOC SCI INFORM, V44, P695, DOI 10.1177/0539018405058216; Shimojo S, 2003, NAT NEUROSCI, V6, P1317, DOI 10.1038/nn1150; Sidhu DM, PLOS ONE REV; SIMONSON I, 1989, J CONSUM RES, V16, P158, DOI 10.1086/209205; Stan Development Team, 2016, RSTAN BAYES APPL REG; Stern HS, 2014, BAYESIAN DATA ANAL, V3rd; SVENSON O, 1992, ACTA PSYCHOL, V80, P143, DOI 10.1016/0001-6918(92)90044-E; SVENSON O, 1992, J ECON PSYCHOL, V13, P315, DOI 10.1016/0167-4870(92)90036-7; Tousignant C, 2017, PSYCHOL AES IN PRESS, DOI [10.1037/aca0000146, DOI 10.1037/ACA0000146]; Tousignant C, 2014, PSYCHOL AESTHET CREA, V8, P81, DOI 10.1037/a0034942; Trueblood J., 2015, DECISION, V2, P13, DOI [DOI 10.1037/DEC0000015, 10.1037/dec0000015]; Trueblood JS, 2013, PSYCHOL SCI, V24, P901, DOI 10.1177/0956797612464241; Trueblood JS, 2012, PSYCHON B REV, V19, P962, DOI 10.3758/s13423-012-0288-9; Tsetsos K, 2010, PSYCHOL REV, V117, P1275, DOI 10.1037/a0020580; TVERSKY A, 1986, J BUS, V59, pS251, DOI 10.1086/296365; TVERSKY A, 1993, MANAGE SCI, V39, P1179, DOI 10.1287/mnsc.39.10.1179; Vessel EA, 2010, J VISION, V10, DOI 10.1167/10.2.18; Voigt K, 2017, J EXP PSYCHOL LEARN, V43, P1872, DOI 10.1037/xlm0000415; WEDELL DH, 1991, J EXP PSYCHOL LEARN, V17, P767, DOI 10.1037/0278-7393.17.4.767; ZAJONC RB, 1982, J CONSUM RES, V9, P123, DOI 10.1086/208905; ZAJONC RB, 1968, J PERS SOC PSYCHOL, V9, P1, DOI 10.1037/h0025848; ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151; Zellner DA, 2006, PSYCHON B REV, V13, P235, DOI 10.3758/BF03193836; Zellner DA, 2014, ATTEN PERCEPT PSYCHO, V76, P2189, DOI 10.3758/s13414-014-0768-2; Zellner DA, 2010, ATTEN PERCEPT PSYCHO, V72, P1261, DOI 10.3758/APP.72.5.1261; Zellner DA, 2009, ATTEN PERCEPT PSYCHO, V71, P1228, DOI 10.3758/APP.71.6.1228	59	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2018	13	4							e0196246	10.1371/journal.pone.0196246	http://dx.doi.org/10.1371/journal.pone.0196246			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD4BF	29672641	Green Published, Green Submitted, gold			2023-01-03	WOS:000430446800103
J	Broadfoot, M				Broadfoot, Marla			A DELICATE BALANCE Routinely giving antibiotics to premature babies may do more harm than good	SCIENCE			English	Editorial Material																			0	2	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 6	2018	360	6384					18	20		10.1126/science.360.6384.18	http://dx.doi.org/10.1126/science.360.6384.18			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB7OE	29622636				2023-01-03	WOS:000429263100015
J	Sarwar, M; Khaja, ASS; Aleskandarany, M; Karlsson, R; Althobiti, M; Odum, N; Mongan, NP; Dizeyi, N; Johnson, H; Green, AR; Ellis, IO; Rakha, EA; Persson, JL				Sarwar, Martuza; Khaja, Azharuddin Sajid Syed; Aleskandarany, Mohammed; Karlsson, Richard; Althobiti, Maryam; Odum, Niels; Mongan, Nigel P.; Dizeyi, Nisthman; Johnson, Heather; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.; Persson, Jenny L.			The role of PIP5K1 alpha/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 alpha inhibitor	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; ESTROGEN-RECEPTOR; METASTASIS; EXPRESSION; PREVENTION; RESISTANCE; PATHWAY; PROTEIN; ALPHA; BONE	Despite recent improvement in adjuvant therapies, triple-negative, and ER+ subtypes of breast cancer (BC) with metastatic potentials remain the leading cause of BC-related deaths. We investigated the role of phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5K alpha), a key upstream factor of PI3K/AKT, and the therapeutic effect of PIP5K alpha inhibitor on subtypes of BC. The clinical importance of PIP5K1 alpha and its association with survivals were analyzed using three BC cohorts from Nottingham (n = 913), KM plotter (n = 112) and TCGA (n = 817). Targeted overexpression or knockdown of PIP5K1 alpha were introduced into BC cell lines. The effects of PIP5K1 alpha and its inhibitor on growth and invasion of BC were confirmed by using in vitro assays including proliferation, migration, apoptosis and luciferase reporter assays and in vivo xenograft mouse models. All statistical tests were two-sided. PIP5K1 alpha was associated with poor patient outcome in triple-negative BC (for PIP5K1 alpha protein, p = 0.011 and for mRNA expression, p = 0.028, log-rank test). 29% of triple-negative BC had PIP5K1A gene amplification. Elevated level of PIP5K1 alpha increased expression of pSer-473 AKT (p < 0.001) and invasiveness of triple-negative MDA-MB-231 cells (p < 0.001). Conversely, inhibition of PIP5K1 alpha using its inhibitor ISA-2011B, or via knockdown suppressed growth and invasiveness of MDA-MB-231 xenografts (mean vehicle-treated controls = 2160 mm(3), and mean ISA-2011B-treated = 600 mm(3), p < 0.001). ISA-2011B-treatment reduced expression of pSer-473 AKT (p < 0.001) and its downstream effectors including cyclin D1, VEGF and its receptors, VEGFR1 and VEGFR2 (p < 0.001) in xenograft tumors. In ER+ cancer cells, PIP5K1 alpha acted on pSer-473 AKT, and was in complexes with VEGFR2, serving as co-factor of ER-alpha to regulate activities of target genes including cyclin D1 and CDK1. Our study suggests that our developed PIP5K1 alpha inhibitor has a great potential on refining targeted therapeutics for treatment of triple-negative and ER+ BC with abnormal PI3K/AKT pathways.	[Sarwar, Martuza; Persson, Jenny L.] Lund Univ, Clin Res Ctr, Dept Translat Med, Div Expt Canc Res, Malmo, Sweden; [Khaja, Azharuddin Sajid Syed; Karlsson, Richard; Persson, Jenny L.] Umea Univ, Dept Mol Biol, Div Basal Tumor Biol, Umea, Sweden; [Aleskandarany, Mohammed; Althobiti, Maryam; Green, Andrew R.; Ellis, Ian O.; Rakha, Emad A.] Univ Nottingham, Acad Pathol, Sch Med, Div Canc & Stem Cells, Nottingham, England; [Odum, Niels] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Mongan, Nigel P.] Univ Nottingham, Fac Med & Hlth Sci, Sch Vet Med & Sci, Nottingham, England; [Mongan, Nigel P.] Weill Cornell Med, Dept Pharmacol, New York, NY 10065 USA; [Dizeyi, Nisthman] Lund Univ, Clin Res Ctr, Dept Translat Med, Div Reprod Res, Malmo, Sweden; [Johnson, Heather] Beijing Inst Basic Med Sci, Dept Biodiag, Beijing, Peoples R China	Lund University; Umea University; University of Nottingham; University of Copenhagen; University of Nottingham; Cornell University; Lund University; Academy of Military Medical Sciences - China	Persson, JL (corresponding author), Lund Univ, Clin Res Ctr, Dept Translat Med, Div Expt Canc Res, Malmo, Sweden.; Persson, JL (corresponding author), Umea Univ, Dept Mol Biol, Div Basal Tumor Biol, Umea, Sweden.	jenny_l.persson@med.lu.se	Green, Andrew/AAF-1991-2020; Aleskandarany, Mohammed/X-8585-2019; Rakha, Emad/Q-5554-2019; Syed Khaja, Azharuddin Sajid/AAF-2693-2021; Aleskandarany, Mohammed/D-9162-2018	Syed Khaja, Azharuddin Sajid/0000-0003-1594-1826; Aleskandarany, Mohammed/0000-0001-5538-5946; Rakha, Emad/0000-0002-5009-5525; Mongan, Nigel/0000-0001-5438-1126; Ellis, Ian/0000-0001-5292-8474; JOHNSON, HEATHER/0000-0001-7468-0705; Green, Andrew/0000-0002-0488-5913; Karlsson, Richard Torbjorn Gustav/0000-0003-0448-6135; Persson, Jenny/0000-0001-7682-7678	Swedish Cancer Society; Swedish National Research Council; Swedish Children Foundation; Malmo Cancer Foundation; Government Health Innovation Grant; Kempe STF; Umea University; Medical Faculty Grants; Royal Physiographical Foundation; University of Nottingham; Weill Cornell Medicine	Swedish Cancer Society(Swedish Cancer Society); Swedish National Research Council; Swedish Children Foundation; Malmo Cancer Foundation; Government Health Innovation Grant; Kempe STF; Umea University; Medical Faculty Grants; Royal Physiographical Foundation; University of Nottingham; Weill Cornell Medicine	This work was supported by grants from the Swedish Cancer Society, The Swedish National Research Council, The Swedish Children Foundation, Malmo Cancer Foundation, Malmo Cancer Foundation, the Government Health Innovation Grant, Kempe STF, Umea University, Medical Faculty Grants to JLP. The Royal Physiographical Foundation to MS. We acknowledge the support of the University of Nottingham and Weill Cornell Medicine (NPM). The authors sincerely thank Teresa Frisan (Umea University, Umea and Karolinska Institute, Stockholm), Pirkko Harkonen (University of Turku, Turku), Yafang Mei (Umea University, Umea) and Yvonne Lundberg Giwercman (Lund University, Lund) for providing reagents for this study. We also thank Per-Anders Bertilsson, Kristina Ekstrom-Holka and Elise Nilsson for technical help, and the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank for the provision of tissue samples.	Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Aesoy R, 2008, MOL CANCER RES, V6, P1630, DOI 10.1158/1541-7786.MCR-07-2172; Aleskandarany MA, 2016, BREAST CANCER RES TR, V156, P9, DOI 10.1007/s10549-016-3709-z; Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P407, DOI 10.1007/s10549-010-1012-y; Andruska N, 2012, J BIOMOL SCREEN, V17, P921, DOI 10.1177/1087057112442960; Applanat MP, 2008, ADV EXP MED BIOL, V617, P437, DOI 10.1007/978-0-387-69080-3_42; Auld DS, 2009, P NATL ACAD SCI USA, V106, P3585, DOI 10.1073/pnas.0813345106; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Coleman RE, 2002, AM J CLIN ONCOL-CANC, V25, pS32, DOI 10.1097/00000421-200212001-00006; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Khaja ASS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072210; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lim E, 2012, ONCOLOGY-NY, V26, P688; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Marino N, 2013, AM J PATHOL, V183, P1084, DOI 10.1016/j.ajpath.2013.06.012; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sarwar M, 2016, ONCOTARGET, V7, P63065, DOI 10.18632/oncotarget.11757; Semenas J, 2014, P NATL ACAD SCI USA, V111, pE3689, DOI 10.1073/pnas.1405801111; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Solzak JP, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0016-8; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Yamaguchi H, 2010, CANCER SCI, V101, P1632, DOI 10.1111/j.1349-7006.2010.01574.x; Yang ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep07758; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838	36	18	18	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					375	389		10.1038/s41388-018-0438-2	http://dx.doi.org/10.1038/s41388-018-0438-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30104711	Green Published, hybrid			2023-01-03	WOS:000455851200006
J	Tufail, S; Sherwani, MA; Shoaib, S; Azmi, S; Owais, M; Islam, N				Tufail, Saba; Sherwani, Mohd. Asif; Shoaib, Shoaib; Azmi, Sarfuddin; Owais, Mohammad; Islam, Najmul			Ovalbumin self-assembles into amyloid nanosheets that elicit immune responses and facilitate sustained drug release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						amyloid; albumin; nanotechnology; drug delivery; drug delivery system; antigen; antigen delivery; nanosheet; ovalbumin	PEPTIDE NANOFIBERS; SECRETORY GRANULES; ENDOTHELIAL-CELLS; THIOFLAVIN T; DELIVERY; FIBRILS; AGGREGATION; NANOTUBES; PROTEINS; GRAPHENE	Amyloids are associated with many neurodegenerative diseases, motivating investigations into their structure and function. Although not linked to a specific disease, albumins have been reported to form many structural aggregates. We were interested in investigating host immune responses to amyloid fibrils assembled from the model protein ovalbumin. Surprisingly, upon subjecting ovalbumin to standard denaturing conditions, we encountered giant protein nanosheets harboring amyloid-like features and hypothesized that these nanosheets might have potential in clinical or therapeutic applications. We found that the nanosheets, without the administration of any additional adjuvant, evoked a strong antibody response in mice that was higher than that observed for native ovalbumin. This suggests that amyloid nanosheets have a self-adjuvanting property. The nanosheet-induced immune response was helper T cell 2 (Th2) biased and negligibly inflammatory. While testing whether the nanosheets might form depots for the sustained release of precursor proteins, we did observe release of ovalbumin that mimicked the conformation of native protein. Moreover, the nanosheets could load the anticancer drug doxorubicin and release it in a slow and sustained manner. Taken together, our results suggest that amyloid nanosheets should be further investigated as either an antigen delivery vehicle or a multifunctional antigen and drug co-delivery system, with potential applications in simultaneous immunotherapy and chemotherapy.	[Tufail, Saba; Shoaib, Shoaib; Azmi, Sarfuddin; Islam, Najmul] Aligarh Muslim Univ, Jawaharlal Nehru Med Coll, Fac Med, Dept Biochem, Aligarh 202002, Uttar Pradesh, India; [Owais, Mohammad] Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Aligarh 202002, Uttar Pradesh, India; [Tufail, Saba] Aligarh Muslim Univ, Biochem Sect, Womens Coll, Aligarh 202002, Uttar Pradesh, India; [Sherwani, Mohd. Asif] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA	Aligarh Muslim University; Aligarh Muslim University; Aligarh Muslim University; University of Alabama System; University of Alabama Birmingham	Tufail, S; Islam, N (corresponding author), Aligarh Muslim Univ, Jawaharlal Nehru Med Coll, Fac Med, Dept Biochem, Aligarh 202002, Uttar Pradesh, India.	sabatufail12@gmail.com; nxi7@hotmail.com	Sherwani, Mohammad Asif/AAQ-2949-2021; Sherwani, Mohammad/AAR-6089-2021; Azmi, Sarfuddin/AAE-7602-2022	Sherwani, Mohammad Asif/0000-0001-5317-1557; Azmi, Sarfuddin/0000-0002-1868-3458; Mohammad, Owais/0000-0001-7377-7388	University Grants Commission, Government of India	University Grants Commission, Government of India(University Grants Commission, India)	Recipient of a postdoctoral fellowship from the University Grants Commission, Government of India.	An J, 2013, MAT SCI ENG C-MATER, V33, P2827, DOI 10.1016/j.msec.2013.03.008; Ansari Mairaj Ahmed, 2012, Int J Nanomedicine, V7, P2433, DOI 10.2147/IJN.S25875; Azmi S, 2013, J MED CHEM, V56, P924, DOI 10.1021/jm301407k; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; Banoczi Z, 2008, J PEPT SCI, V14, P610, DOI 10.1002/psc.950; Bemporad F, 2006, PROTEIN SCI, V15, P862, DOI 10.1110/ps.051915806; Bolisetty S, 2012, ADV FUNCT MATER, V22, P3424, DOI 10.1002/adfm.201103054; Buttstedt A, 2013, AMYLOID, V20, P86, DOI 10.3109/13506129.2013.784962; Chen WS, 2017, ADV MATER, V29, DOI 10.1002/adma.201603864; Childers WS, 2010, ANGEW CHEM INT EDIT, V49, P4104, DOI 10.1002/anie.201000212; Dai B, 2015, P NATL ACAD SCI USA, V112, P2996, DOI 10.1073/pnas.1416690112; Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80; Dogra P, 2017, J PHYS CHEM B, V121, P412, DOI 10.1021/acs.jpcb.6b11281; Greenwald J, 2010, STRUCTURE, V18, P1244, DOI 10.1016/j.str.2010.08.009; Gulseren G, 2016, J MATER CHEM B, V4, P4605, DOI 10.1039/c6tb00795c; Guo C, 2012, ACS NANO, V6, P3907, DOI 10.1021/nn300015g; Gupta S, 2010, P NATL ACAD SCI USA, V107, P13246, DOI 10.1073/pnas.1005704107; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Hsieh PCH, 2006, J CLIN INVEST, V116, P237, DOI 10.1172/JCI25878; Hu Y, 2016, ACS NANO, V10, P880, DOI 10.1021/acsnano.5b06011; Humblet-Hua NPK, 2012, J AGR FOOD CHEM, V60, P9502, DOI 10.1021/jf3024529; Jacob RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23370; Jung JP, 2009, BIOMATERIALS, V30, P2400, DOI 10.1016/j.biomaterials.2009.01.033; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Knowles TPJ, 2011, NAT NANOTECHNOL, V6, P469, DOI [10.1038/NNANO.2011.102, 10.1038/nnano.2011.102]; Knowles TPJ, 2010, NAT NANOTECHNOL, V5, P204, DOI [10.1038/nnano.2010.26, 10.1038/NNANO.2010.26]; Koutsopoulos S, 2009, P NATL ACAD SCI USA, V106, P4623, DOI 10.1073/pnas.0807506106; Lakshmanan A, 2012, TRENDS BIOTECHNOL, V30, P155, DOI 10.1016/j.tibtech.2011.11.001; Lara C, 2012, BIOMACROMOLECULES, V13, P4213, DOI 10.1021/bm301481v; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li CX, 2013, NANOSCALE, V5, P6207, DOI 10.1039/c3nr01644g; Li CX, 2012, NAT NANOTECHNOL, V7, P421, DOI [10.1038/nnano.2012.62, 10.1038/NNANO.2012.62]; Li H, 2016, ACS APPL MATER INTER, V8, P1147, DOI 10.1021/acsami.5b08963; Lin YY, 2017, J AM CHEM SOC, V139, P13592, DOI 10.1021/jacs.7b06591; Liu T, 2014, ADV MATER, V26, P3433, DOI 10.1002/adma.201305256; Lu K, 2003, J AM CHEM SOC, V125, P6391, DOI 10.1021/ja0341642; Maji SK, 2008, PLOS BIOL, V6, P240, DOI 10.1371/journal.pbio.0060017; Maji SK, 2009, SCIENCE, V325, P328, DOI 10.1126/science.1173155; Mesquida P, 2007, J MATER SCI-MATER M, V18, P1325, DOI 10.1007/s10856-006-0075-0; Min KI, 2016, ANGEW CHEM INT EDIT, V55, P6925, DOI 10.1002/anie.201601675; MINE Y, 1995, TRENDS FOOD SCI TECH, V6, P225, DOI 10.1016/S0924-2244(00)89083-4; Mitra S, 2017, J AM CHEM SOC, V139, P4513, DOI 10.1021/jacs.7b00925; Monsellier E, 2007, EMBO REP, V8, P737, DOI 10.1038/sj.embor.7401034; O'Nuallain B, 2005, BIOCHEMISTRY-US, V44, P12709, DOI 10.1021/bi050927h; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; Reches M, 2006, NAT NANOTECHNOL, V1, P195, DOI 10.1038/nnano.2006.139; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107; Rufo CM, 2014, NAT CHEM, V6, P303, DOI [10.1038/NCHEM.1894, 10.1038/nchem.1894]; Sanii B, 2011, J AM CHEM SOC, V133, P20808, DOI 10.1021/ja206199d; Sasahara K, 2008, BIOCHEMISTRY-US, V47, P2650, DOI 10.1021/bi701968g; Schladitz C, 1999, BIOPHYS J, V77, P3305, DOI 10.1016/S0006-3495(99)77161-4; Sengupta U, 2016, EBIOMEDICINE, V6, P42, DOI 10.1016/j.ebiom.2016.03.035; Shojaee M, 2015, MAT SCI ENG C-MATER, V48, P158, DOI 10.1016/j.msec.2014.11.063; Shorter J, 2005, NAT REV GENET, V6, P435, DOI 10.1038/nrg1616; Steward A, 2002, J MOL BIOL, V318, P935, DOI 10.1016/S0022-2836(02)00184-5; Taboada P, 2006, J PHYS CHEM B, V110, P20733, DOI 10.1021/jp064861r; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; Tufail S, 2015, J BIOL CHEM, V290, P4131, DOI 10.1074/jbc.M113.540989; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Udomprasert A, 2014, NAT NANOTECHNOL, V9, P537, DOI [10.1038/nnano.2014.102, 10.1038/NNANO.2014.102]; Vigneron Nathalie, 2013, Cancer Immun, V13, P15; Wang DH, 2016, ADV MATER, V28, P7414, DOI 10.1002/adma.201506476; White JA, 2005, NEUROBIOL DIS, V18, P459, DOI 10.1016/j.nbd.2004.12.013; You J, 2017, ADV MATER, V29, DOI 10.1002/adma.201606895; Zhao XB, 2010, CHEM SOC REV, V39, P3480, DOI 10.1039/b915923c	67	11	12	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2018	293	29					11310	11324		10.1074/jbc.RA118.002550	http://dx.doi.org/10.1074/jbc.RA118.002550			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN8UL	29853634	hybrid, Green Published			2023-01-03	WOS:000439449700005
J	Lipska, KJ; Parker, MM; Moffet, HH; Huang, ES; Karter, AJ				Lipska, Kasia J.; Parker, Melissa M.; Moffet, Howard H.; Huang, Elbert S.; Karter, Andrew J.			Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEIGHBORHOOD DEPRIVATION; PHARMACY RECORDS; AFRICAN-AMERICAN; REAL-WORLD; RISK; GLARGINE; MELLITUS; EFFICACY; RATES; NPH	IMPORTANCE In clinical trials of patients with type 2 diabetes, long-acting insulin analogs modestly reduced the risk of nocturnal hypoglycemia compared with human neutral protamine Hagedorn (NPH) insulin, but cost 2 to 10 times more. Outcomes in clinical practice may differ from trial results. OBJECTIVE To compare the rates of hypoglycemia-related emergency department (ED) visits or hospital admissions associated with initiation of long-acting insulin analogs vs human NPH insulin in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS A retrospective observational study using data from Kaiser Permanente of Northern California from January 1, 2006, through September 30, 2015. Patients with type 2 diabetes who initiated a long-acting insulin analog or NPH insulin were included and censored at death, loss of health plan coverage, change in insulin treatment, or study end on September 30, 2015. EXPOSURE Initiation of basal insulin analogs (glargine or detemir) vs NPH insulin. MAIN OUTCOMES AND MEASURES The primary outcome was the time to a hypoglycemia-related ED visit or hospital admission and the secondary outcome was the change in hemoglobin A(1c) level within 1 year of insulin initiation. RESULTS There were 25 489 patients with type 2 diabetes who initiated basal insulin therapy (mean age, 60.2 [SD, 11.8] years; 51.9% white; 46.8% female). During a mean follow-up of 1.7 years, there were 39 hypoglycemia-related ED visits or hospital admissions among 1928 patients who initiated insulin analogs (11.9 events [95% CI, 8.1 to 15.6] per 1000 person-years) compared with 354 hypoglycemia-related ED visits or hospital admissions among 23 561 patients who initiated NPH insulin (8.8 events [95% CI, 7.9 to 9.8] per 1000 person-years) (between-group difference, 3.1 events [95% CI,-1.5 to 7.7] per 1000 person-years; P =.07). Among 4428 patients matched by propensity score, the adjusted hazard ratio was 1.16 (95% CI, 0.71 to 1.78) for hypoglycemia-related ED visits or hospital admissions associated with insulin analog use. Within 1 year of insulin initiation, hemoglobin A1c level decreased from 9.4%(95% CI, 9.3% to 9.5%) to 8.2%(95% CI, 8.1% to 8.2%) after initiation of insulin analogs and from 9.4%(95% CI, 9.3% to 9.5%) to 7.9%(95% CI, 7.9% to 8.0%) after initiation of NPH insulin (adjusted difference-in-differences for glycemic control,-0.22%[95% CI,-0.09% to-0.37%]). CONCLUSIONS AND RELEVANCE Among patients with type 2 diabetes, initiation of a basal insulin analog compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions or with improved glycemic control. These findings suggest that the use of basal insulin analogs in usual practice settings may not be associated with clinical advantages for these outcomes.	[Lipska, Kasia J.] Yale Univ, Sch Med, Dept Internal Med, Sect Endocrinol, New Haven, CT 06510 USA; [Parker, Melissa M.; Moffet, Howard H.; Karter, Andrew J.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA; [Huang, Elbert S.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Karter, Andrew J.] Univ Calif San Francisco, Dept Gen Internal Med, San Francisco, CA 94143 USA; [Karter, Andrew J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Karter, Andrew J.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	Yale University; Kaiser Permanente; University of Chicago; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lipska, KJ (corresponding author), Yale Sch Med, POB 208020, New Haven, CT 06520 USA.	kasia.lipska@yale.edu			National Institutes of Health [R01DK103721, R01DK081796]; National Institute on Aging; American Federation of Aging Research through Paul Beeson Career Development award from the Yale Claude D. Pepper Older Americans Independence Center [K23AG048359, P30AG021342]; Centers for Diabetes Translational Research within the National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK092924, P30 DK092949]; National Institute of Diabetes and Digestive and Kidney Diseases [K24 DK105340]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092949, R01DK103721, P30DK092924, R01DK081796, K24DK105340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG051683, K23AG048359, P30AG021342] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation of Aging Research through Paul Beeson Career Development award from the Yale Claude D. Pepper Older Americans Independence Center; Centers for Diabetes Translational Research within the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This project was supported by grants R01DK103721 and R01DK081796 from the National Institutes of Health. Dr Lipska receives support from the National Institute on Aging and the American Federation of Aging Research through Paul Beeson Career Development award K23AG048359 and award P30AG021342 from the Yale Claude D. Pepper Older Americans Independence Center. Drs Huang and Karter are supported by awards P30 DK092924 and P30 DK092949, respectively, from the Centers for Diabetes Translational Research within the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Huang was also supported by grant K24 DK105340 from the National Institute of Diabetes and Digestive and Kidney Diseases.	Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Best JD, 2012, DIABETES CARE, V35, P1165, DOI 10.2337/dc11-1307; Cefalu WT, 2018, DIABETES CARE, V41, P1299, DOI 10.2337/dci18-0019; Cheung YB, 2007, AM J EPIDEMIOL, V166, P1337, DOI 10.1093/aje/kwm223; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Edelman SV, 2017, DIABETES CARE, V40, P1425, DOI 10.2337/dc16-1974; Freemantle N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009421; Ginde Adit A, 2008, BMC Endocr Disord, V8, P4, DOI 10.1186/1472-6823-8-4; Haukka J, 2013, PHARMACOEPIDEM DR S, V22, P1326, DOI 10.1002/pds.3534; Horvath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005613.pub3; Hua XY, 2016, JAMA-J AM MED ASSOC, V315, P1400, DOI 10.1001/jama.2016.0126; Huang ES, 2011, DIABETES CARE, V34, P1329, DOI 10.2337/dc10-2377; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Karter AJ, 2018, HEALTH SERV RES, V53, P1227, DOI 10.1111/1475-6773.12700; Karter AJ, 2017, J DIABETES COMPLICAT, V31, P869, DOI 10.1016/j.jdiacomp.2017.02.009; Karter AJ, 2013, DIABETES CARE, V36, P574, DOI 10.2337/dc12-0722; Kirk JK, 2006, DIABETES CARE, V29, P2130, DOI 10.2337/dc05-1973; Landon BE, 2018, J GEN INTERN MED, V33, P471, DOI 10.1007/s11606-018-4310-4; Laraia BA, 2012, SOC SCI MED, V74, P1082, DOI 10.1016/j.socscimed.2011.11.036; Lipska KJ, 2017, JAMA-J AM MED ASSOC, V318, P23, DOI 10.1001/jama.2017.6939; Lipska KJ, 2017, DIABETES CARE, V40, P468, DOI 10.2337/dc16-0985; Lipska KJ, 2014, JAMA-J AM MED ASSOC, V311, P2331, DOI 10.1001/jama.2014.6316; Little RR, 2011, CLIN CHEM, V57, P205, DOI 10.1373/clinchem.2010.148841; Luo J, 2015, JAMA INTERN MED, V175, P1681, DOI 10.1001/jamainternmed.2015.4338; Messer LC, 2006, J URBAN HEALTH, V83, P1041, DOI 10.1007/s11524-006-9094-x; MEYER BD, 1995, J BUS ECON STAT, V13, P151, DOI 10.2307/1392369; Owens DR, 2017, DIABETES RES CLIN PR, V124, P57, DOI 10.1016/j.diabres.2016.10.022; Piette JD, 2004, DIABETES CARE, V27, P384, DOI 10.2337/diacare.27.2.384; Prentice JC, 2015, AM J MANAG CARE, V21, pE235; Randall L, 2011, DIABETES CARE, V34, P1891, DOI 10.2337/dc11-0701; Rys P, 2015, ACTA DIABETOL, V52, P649, DOI 10.1007/s00592-014-0698-4; Singh SR, 2009, CAN MED ASSOC J, V180, P385, DOI 10.1503/cmaj.081041; Sinisi SE, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1069; Spain CV, 2016, CLIN THER, V38, P1653, DOI 10.1016/j.clinthera.2016.05.009; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Strandberg AY, 2017, ANN MED, V49, P357, DOI 10.1080/07853890.2016.1278302; Strandberg AY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151910; Turner LW, 2014, DIABETES CARE, V37, P985, DOI 10.2337/dc13-2097; Zhang TT, 2017, DIABETES TECHNOL THE, V19, P675, DOI 10.1089/dia.2017.0111	40	52	54	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2018	320	1					53	62		10.1001/jama.2018.7993	http://dx.doi.org/10.1001/jama.2018.7993			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL5PC	29936529	Green Published, Bronze			2023-01-03	WOS:000437219400017
J	Hao, JY; Wan, Y; Yao, XH; Zhao, WG; Hu, RZ; Chen, C; Li, L; Zhang, DY; Wu, GH				Hao, Jing-Yi; Wan, Yi; Yao, Xiao-Hui; Zhao, Wei-Guo; Hu, Run-Ze; Chen, Cong; Li, Long; Zhang, Dong-Yang; Wu, Guo-Hua			Effect of different planting areas on the chemical compositions and hypoglycemic and antioxidant activities of mulberry leaf extracts in Southern China	PLOS ONE			English	Article							MORUS-ALBA L.; BLOOD-GLUCOSE; ALPHA-GLUCOSIDASE; 1-DEOXYNOJIRIMYCIN; LEAVES; ATHEROSCLEROSIS; FAGOMINE	Guangdong, Guangxi and Chongqing are emerging sericulture areas in China where the production of mulberry leaves is huge. In order to identity high quality mulberry leaves that are suitable for healthy products to expand planting, 24 samples from three regions (Guangdong, Guangxi, Chongqing) in the south of China were quantified for two alkaloids (1-deoxynojirimycin and fagomine) and five phenols (chlorogenic acid, rutin, isoquercitrin, etc.) using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). Additionally, the total phenolic and total flavonoid contents, antioxidant and glycosidase inhibitory activities (hypoglycemic activity) were tested using different assays (DPPH, ABTS, FRAP) to comprehensively evaluate the quality of the mulberry leaves. The contents of DNJ and fagomine ranged from 0.401 +/- 0.003 to 5.309 +/- 0.036 mg/g and from 0.279 +/- 0.031 to 2.300 +/- 0.060 mg/g, respectively. The main phenolic constituents were chlorogenic acid, rutin and isoquercitrin, with chlorogenic acid present in the highest concentrations, ranging from 3.104 +/- 0.191 to 10.050 +/- 0.143 mg/g. The antioxidant activity exhibited a tendency as follows: Guangxi > Guangdong > Chongqing, except for two samples from Chongqing, which showed the highest antioxidant activity. Based on our study, mulberry leaves from Guangdong and Guangxi could be future sources of natural hypoglycemic and antioxidant products.	[Hao, Jing-Yi; Wan, Yi; Yao, Xiao-Hui; Zhao, Wei-Guo; Hu, Run-Ze; Chen, Cong; Li, Long; Zhang, Dong-Yang; Wu, Guo-Hua] Jiangsu Univ Sci & Technol, Coll Biotechnol, Zhenjiang, Peoples R China; [Hao, Jing-Yi; Wan, Yi; Yao, Xiao-Hui; Zhao, Wei-Guo; Hu, Run-Ze; Chen, Cong; Li, Long; Zhang, Dong-Yang; Wu, Guo-Hua] Jiangsu Univ Sci & Technol, Sericulture Res Inst, Zhenjiang, Peoples R China; [Hao, Jing-Yi; Wan, Yi; Yao, Xiao-Hui; Zhao, Wei-Guo; Hu, Run-Ze; Chen, Cong; Li, Long; Zhang, Dong-Yang; Wu, Guo-Hua] Minist Agr, Lab Qual & Safty Risk Assessment Sericulture Prod, Zhenjiang, Peoples R China; [Hao, Jing-Yi; Wan, Yi; Yao, Xiao-Hui; Zhao, Wei-Guo; Hu, Run-Ze; Chen, Cong; Li, Long; Zhang, Dong-Yang; Wu, Guo-Hua] Minist Agr, Qual Inspect Ctr Sericultutal Prod, Zhenjiang, Peoples R China	Jiangsu University of Science & Technology; Jiangsu University of Science & Technology; Ministry of Agriculture & Rural Affairs; Ministry of Agriculture & Rural Affairs	Li, L; Zhang, DY (corresponding author), Jiangsu Univ Sci & Technol, Coll Biotechnol, Zhenjiang, Peoples R China.; Li, L; Zhang, DY (corresponding author), Jiangsu Univ Sci & Technol, Sericulture Res Inst, Zhenjiang, Peoples R China.; Li, L; Zhang, DY (corresponding author), Minist Agr, Lab Qual & Safty Risk Assessment Sericulture Prod, Zhenjiang, Peoples R China.; Li, L; Zhang, DY (corresponding author), Minist Agr, Qual Inspect Ctr Sericultutal Prod, Zhenjiang, Peoples R China.	lilong10029@126.com; zhangdongyang1987@126.com	wu, george/HHC-8454-2022		Sericulture Industry Technology in China Agriculture Research System [CARS-22-ZJ0308]; Project of National Agricultural Product Quality Safety Risk Assessment [GJFP201801003]; Natural Science Foundation of Jiangsu Province [BK201605553]; National Natural Science Foundation of China [31600461]; Scientific Research Start-up Funding of New Teacher at Jiangsu University of Science and Technology [1732931607, 1732921407]; Graduate Education Teaching Reform Research and Practice of Jiangsu University of Science [1102151504]	Sericulture Industry Technology in China Agriculture Research System; Project of National Agricultural Product Quality Safety Risk Assessment; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Start-up Funding of New Teacher at Jiangsu University of Science and Technology; Graduate Education Teaching Reform Research and Practice of Jiangsu University of Science	This work was supported by the Sericulture Industry Technology in China Agriculture Research System (project no. CARS-22-ZJ0308), Project of National Agricultural Product Quality Safety Risk Assessment (GJFP201801003), Natural Science Foundation of Jiangsu Province (BK201605553), National Natural Science Foundation of China (31600461), Scientific Research Start-up Funding of New Teacher at Jiangsu University of Science and Technology (1732931607), Scientific Research Start-up Funding of New Teacher at Jiangsu University of Science and Technology (1732921407), and Graduate Education Teaching Reform Research and Practice of Jiangsu University of Science (1102151504). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad A, 2013, LIFE SCI, V92, P202, DOI 10.1016/j.lfs.2012.11.020; Amezqueta S, 2012, ANAL BIOANAL CHEM, V402, P1953, DOI 10.1007/s00216-011-5639-2; Andallu B, 2003, CLIN CHIM ACTA, V338, P3, DOI 10.1016/S0009-8981(03)00322-X; Andallu B, 2014, J HERB MED, V4, P10, DOI 10.1016/j.hermed.2013.10.002; Asano N, 2001, J AGR FOOD CHEM, V49, P4208, DOI 10.1021/jf010567e; Bae SH, 2007, LWT-FOOD SCI TECHNOL, V40, P955, DOI 10.1016/j.lwt.2006.06.007; Chan KC, 2013, J AGR FOOD CHEM, V61, P2780, DOI 10.1021/jf305328d; Chang YC, 2016, J FUNCT FOODS, V21, P249, DOI 10.1016/j.jff.2015.11.033; Chen CC, 2005, FOOD CHEM, V91, P601, DOI 10.1016/j.foodchem.2004.06.039; Chen PN, 2006, CANCER LETT, V235, P248, DOI 10.1016/j.canlet.2005.04.033; Chen XW, 2005, CHIN J PHARMACOEPIDE, V14, P70; [韩世玉 HAN Shiyu], 2006, [贵州农业科学, Guizhou Agricultural Sciences], V34, P118; Hu XQ, 2013, IND CROP PROD, V49, P782, DOI 10.1016/j.indcrop.2013.06.030; Jia FQ, 2007, QILU PHARM AFFAIR, V1; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kim JW, 2003, J CHROMATOGR A, V1002, P93, DOI 10.1016/S0021-9673(03)00728-3; Kimura T, 2007, J AGR FOOD CHEM, V55, P5869, DOI 10.1021/jf062680g; Liu C, 2015, IND CROP PROD, V70, P309, DOI 10.1016/j.indcrop.2015.02.046; Liu L, 2008, CHIN ARG SCI B, V24, P488; Mart?nez, 2017, J FOOD NUTR RES, V5, P253, DOI [10.12691/jfnr-5-4-7, DOI 10.12691/jfnr-5-4-7]; Masoodsadiq B, 2008, TRENDS FOOD SCI TECH, V19, P505; Mudra M, 2007, DIABETES CARE, V30, P1272, DOI 10.2337/dc06-2120; Ou-yang Z, 2013, REV BRAS FARMACOGN, V23, P776, DOI 10.1590/S0102-695X2013000500009; Riche DM, 2017, COMPLEMENT THER MED, V32, P105, DOI 10.1016/j.ctim.2017.04.006; Sato Y, 2011, INT J PHARMACEUT, V403, P136, DOI 10.1016/j.ijpharm.2010.09.035; Shin SO, 2016, EUR J INTEGR MED, V8, P602, DOI 10.1016/j.eujim.2016.06.008; Shivanna Yogisha, 2009, Journal of Natural Products (India), V2, P64; Sugiyama M, 2016, J SCI FOOD AGR, V96, P3915, DOI 10.1002/jsfa.7614; Taniguchi S, 1998, HORM METAB RES, V30, P679, DOI 10.1055/s-2007-978957; Wang F, 2010, J FOOD PROCESS ENG, V33, P39, DOI 10.1111/j.1745-4530.2008.00258.x; Yang NC, 2012, FOOD CHEM, V132, P1796, DOI 10.1016/j.foodchem.2011.11.143; Yang ZZ, 2012, FOOD CHEM, V131, P617, DOI 10.1016/j.foodchem.2011.09.040; Yu XF, FOOD SCI; Zhang DY, 2013, FOOD CHEM, V141, P2213, DOI 10.1016/j.foodchem.2013.05.045; 杨兵, 2012, [中药材, Journal of Chinese Medicinal Materials], V35, P876	35	23	29	5	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2018	13	6							e0198072	10.1371/journal.pone.0198072	http://dx.doi.org/10.1371/journal.pone.0198072			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK7JR	29944667	Green Published, Green Submitted, gold			2023-01-03	WOS:000436377800004
J	Sinha, MS; Curfman, GD; Carrier, MA				Sinha, Michael S.; Curfman, Gregory D.; Carrier, Michael A.			Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sinha, Michael S.; Curfman, Gregory D.] Brigham & Womens Hosp, Dept Med, Program Regulat Therapeut & Law, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Sinha, Michael S.; Curfman, Gregory D.] Harvard Med Sch, Boston, MA USA; [Curfman, Gregory D.] Northeastern Univ, Ctr Hlth Policy & Law, Sch Law, Boston, MA 02115 USA; [Carrier, Michael A.] Rutgers State Univ, Rutgers Law Sch, Camden, NJ USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Northeastern University; Rutgers State University Camden; Rutgers State University New Brunswick	Carrier, MA (corresponding author), Rutgers Law Sch, JD,217 N Fifth St, Camden, NJ 08102 USA.	mcarrier@law.rutgers.edu			Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science	Drs Sinha and Curfman are members of the Program On Regulation Therapeutics, And Law, which receives funding from the Laura and John Arnold Foundation, with additional support from the Engelberg Foundation and the Harvard Program in Therapeutic Science.	[Anonymous], 2017, REGENERIC PHARM PRIC; Carrier Michael A., 2017, BERKELEY TECH LJ, V31, P1379; Kan D, 2017, REEPIPEN EPINEPHRINE	3	6	6	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2018	319	22					2271	2272		10.1001/jama.2018.3478	http://dx.doi.org/10.1001/jama.2018.3478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ2UP	29801104				2023-01-03	WOS:000435129300010
J	Santana, CP; Medeiros, FD; Correia, LP; Diniz, PHGD; Veras, G; Medeiros, ACD				Santana, Cleildo P.; Medeiros, Francinalva D.; Correia, Lidiane P.; Diniz, Paulo Henrique G. D.; Veras, Germano; Medeiros, Ana Claudia D.			Dissolution and uniformity of content of tablets developed with extract of Ximenia americana L.	PLOS ONE			English	Article								Herbal medicines currently represent an important part of the world pharmaceutical market, which shows growing interest in the use of herbal medicines. However, the production of such medicines involves a complex series of steps, which determine the production viability and the quality of the final product. Ximenia americana L. is a plant occurring in several regions of the world, with well-known and applied medicinal properties. Thus, the aim of this work was to develop and evaluate the physical and physical-chemical quality of tablets produced with X americana L. extract. The extract was spray-dried from a hydroethanolic extractive solution and characterized as to its phytochemical composition. The chemical marker was determined and quantified using validated chromatographic methods. These methods indicated the presence of gallic acid at a concentration of 1.61 mg g(-1). Formulations were proposed and analyzed for their flow and compaction properties. The best formulation was used to obtain a batch of tablets, which was evaluated for its quality characteristics and showed to be within the pharmacopoeial specifications for average weight, hardness, friability, and disintegration time. The dissolution profile of the tablets produced was obtained, showing the release of about 70% of the vegetable extract content within 30 minutes. Results showed that it was possible to obtain herbal tablets containing a high content of vegetal extract by direct compression, developing a rapid process of formulation and production and guaranteeing the quality characteristics of the final product.	[Santana, Cleildo P.; Medeiros, Francinalva D.; Medeiros, Ana Claudia D.] Univ Estadual Paraiba, Ctr Ciencias Biol & Saude, Lab Desenvolvimento & Ensaios Medicamentos, Campina Grande, Paraiba, Brazil; [Correia, Lidiane P.; Medeiros, Ana Claudia D.] Univ Estadual Paraiba, Ctr Ciencias Biol & Saude, Dept Farm, Campina Grande, Paraiba, Brazil; [Diniz, Paulo Henrique G. D.; Veras, Germano] Univ Estadual Paraiba, Lab Quim Analit & Quimiometria, Campina Grande, Paraiba, Brazil	Universidade Estadual da Paraiba; Universidade Estadual da Paraiba; Universidade Estadual da Paraiba	Medeiros, ACD (corresponding author), Univ Estadual Paraiba, Ctr Ciencias Biol & Saude, Lab Desenvolvimento & Ensaios Medicamentos, Campina Grande, Paraiba, Brazil.; Medeiros, ACD (corresponding author), Univ Estadual Paraiba, Ctr Ciencias Biol & Saude, Dept Farm, Campina Grande, Paraiba, Brazil.	anaclaudia@uepb.edu.br	Diniz, Paulo/F-2724-2012; Neto, Jose Germano Veras/E-3751-2013; de Medeiros, Ana Cláudia Dantas/E-3387-2013; Veras, Germano/AAN-7721-2020	Diniz, Paulo/0000-0002-8652-5478; Neto, Jose Germano Veras/0000-0003-0173-3778; de Medeiros, Ana Cláudia Dantas/0000-0002-8682-0178; Veras, Germano/0000-0003-0173-3778; Santana, Cleildo/0000-0002-8097-7633				Abu-Diak OA, 2011, MOL PHARMACEUT, V8, P1362, DOI 10.1021/mp200157b; Afifi SA, 2012, LIFE SCI J, V9, P4260; Bernatoniene J, 2010, J MED PLANTS RES, V4, P925; Cartaxo SL, 2010, J ETHNOPHARMACOL, V131, P326, DOI 10.1016/j.jep.2010.07.003; Chaves TP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155532; da Silva KMA, 2015, B LATINOAM CARIBE PL, V14, P92; Fereja TH, 2015, J PHARM PHARMACOL, V2, P1; Fernandes FHA, 2016, J THERM ANAL CALORIM, V123, P2531, DOI 10.1007/s10973-016-5241-0; Fernandes HA, 2017, J THERM ANAL CALORIM, DOI 10.1007/s10973-017-6437-7; Gallo L., 2013, INT J RES PHARM BIOM, V4, P1360; Gupta R, 2013, INDO AM J PHARM RES, V3, P4366; ICH, 2005, INT C HARM TECHN REQ; Kartini K. A., 2012, ASIAN J PHARM CLIN R, V5, P191; Kumar N, 2011, AFR J PHARM PHARMACO, V5, P2335, DOI 10.5897/AJPP11.694; MAKKAR HPS, 1993, J CHEM ECOL, V19, P613, DOI 10.1007/BF00984996; Medeiros ACD, 2007, J THERM ANAL CALORIM, V88, P311, DOI 10.1007/s10973-006-8005-4; Qian F, 2012, PHARM RES-DORDR, V29, P2766, DOI 10.1007/s11095-012-0695-7; Rasheed NMA, 2012, ANN PHYTOMEDICINE, V1, P1; Santana CP, 2018, J THERM ANAL CALORIM, V133, P603, DOI 10.1007/s10973-017-6764-8; Silva MSP, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/681207; The United States Pharmacopeia, 2013, NAT FORM 25; van Drooge DJ, 2004, J CONTROL RELEASE, V97, P441, DOI 10.1016/j.jconrel.2004.03.018	22	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197323	10.1371/journal.pone.0197323	http://dx.doi.org/10.1371/journal.pone.0197323			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH0HY	29795592	Green Published, gold, Green Submitted			2023-01-03	WOS:000433084300037
J	Naz, R; Nosheen, A; Yasmin, H; Bano, A; Keyani, R				Naz, Rabia; Nosheen, Asia; Yasmin, Humaira; Bano, Asghari; Keyani, Rumana			Botanical-chemical formulations enhanced yield and protection against Bipolaris sorokiniana in wheat by inducing the expression of pathogenesis-related proteins	PLOS ONE			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; ESSENTIAL OILS; LEAF EXTRACT; RICE; PEROXIDASE; INDUCTION; BLIGHT; PLANT	Two experiments (pot and field experiments) were conducted in two consecutive years to evaluate the protective effects of botanical-chemical formulations on physiological, biochemical performance and grain yield of wheat inoculated with Bipolaris sorokiniana. We compared different formulations comprising Calotropis procera, Jacaranda mimosifolia, Thevetia peruviana extracts, chemical fungicide (mefenoxam) and salicylic acid to modulate the defense system of wheat host plants. Among the selected plant species J. mimosifolia aqueous and methanolic leaf extracts (1.2% w/v) resulted in 96 to 97% inhibition against B. sorokiniana. Both in pot and field experiments, among all the formulations of selected plant extracts the combined formulation of JAF2 (J. mimosifolia 0.6%)+MFF2 (mefenoxam 0.1%) lowered the dose of chemical fungicide required to reduce the leaf spot blotch disease. The same formulation induced resistance in wheat apparently through the accumulation of peroxidase, polyphenol oxidase, protease, acid invertase, chitinase and phenylalanine ammonia lyase. This formulation also stimulated the defense-related gene expression of PR-proteins. The same treatment gave even more increase (48%, 12% and 22%) in no. of grains/spike, grains weight and grain yield, than the MFF1 (mefenoxam 0.2%). We conclude that foliar application of J. mimosifolia leaf extract with very low dose of chemical fungicide (J. mimosifolia 0.6%+mefenoxam 0.1%) is a promising approach for the management of leaf blight and spot blotch in wheat.	[Naz, Rabia; Nosheen, Asia; Yasmin, Humaira; Keyani, Rumana] COMSATS Inst Informat Technol CIIT, Dept Biosci, Islamabad, Pakistan; [Bano, Asghari] Univ Wah, Dept Biosci, Wah Gantt, Pakistan	COMSATS University Islamabad (CUI)	Naz, R (corresponding author), COMSATS Inst Informat Technol CIIT, Dept Biosci, Islamabad, Pakistan.	rabia.naz@comsats.edu.pk	Naz, Rabia/AAI-8801-2020; Keyani, Rumana/AAN-2321-2020; Yasmin, Humaira/ABB-1384-2021; Yasmin, Humaira/AAS-9944-2020; Yasmin, Humaira/AAO-6630-2020	Yasmin, Humaira/0000-0002-4220-4808; Yasmin, Humaira/0000-0002-8738-4216; Naz, Rabia/0000-0002-2716-2267	Higher Education Commission of Pakistan; HEC [074-0998-Av4-036]	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); HEC	The authors express their deep sense of gratitude to the Higher Education Commission of Pakistan for financial support for this research work. The personal identification number (PIN) for this financial support/scholarship from HEC is 074-0998-Av4-036. http://hec.gov.pk/english/pages/home.aspx.	AFTABUDDIN A, 1991, P 1 INT WORKSH COMM, P45; [Anonymous], 1996, STAND EV SYST RIC, V4th; Ashry N. A., 2011, World Journal of Agricultural Sciences, V7, P78; Barkai-Golan R., 2001, POSTHARVEST DIS FRUI, DOI DOI 10.1016/B978-044450584-2/50008-3; Bdliya BS, 2008, ARCH PHYTOPATHOLOGY, P1; Biswas SK., 2012, J PLANT PATHOL MICRO, V3, P1, DOI [10.4172/2157-7471.1000128, DOI 10.4172/2157-7471.1000128]; Catinot J, 2008, FEBS LETT, V582, P473, DOI 10.1016/j.febslet.2007.12.039; El-Mougy N. S., 2004, Egyptian Journal of Phytopathology, V32, P23; Gomez K.A., 1984, STAT PROCEDURE AGR R, V2nd; Gong YP, 2001, BOT BULL ACAD SINICA, V42, P259; Gozzo F, 2013, J AGR FOOD CHEM, V61, P12473, DOI 10.1021/jf404156x; Hadi M. R., 2010, American-Eurasian Journal of Agricultural and Environmental Science, V7, P492; Hossain M. M., 2016, Bulletin of the Institute of Tropical Agriculture Kyushu University, V39, P43; Hsu CL, 2003, FOOD CHEM, V83, P85, DOI 10.1016/S0308-8146(03)00053-0; HWANG BK, 1986, PHYTOPATHOLOGY, V76, P365, DOI 10.1094/Phyto-76-365; Iftikhar S, 2006, PAK J BOT, V38, P205; Iram S, 2004, PAKISTAN J BOT, V36, P439; Joseph B., 2008, GLOB J BIOTECH BIOCH, V3, P56; Joshi AK, 2007, FIELD CROP RES, V103, P53, DOI 10.1016/j.fcr.2007.04.010; Kagale S, 2004, PHYSIOL MOL PLANT P, V65, P91, DOI 10.1016/j.pmpp.2004.11.008; Kagale S, 2011, PLANT SIGNAL BEHAV, V6, P919, DOI 10.4161/psb.6.7.15304; Kamalakannan A., 2001, Indian Phytopathology, V54, P490; KAR M, 1976, PLANT PHYSIOL, V57, P315, DOI 10.1104/pp.57.2.315; Kishwar A, 1992, SARHAD J AGR, V8, P541; Koike ST, 2011, USITC PUBL, V7252; Kumar J, 2002, MOL PLANT PATHOL, V3, P185, DOI 10.1046/j.1364-3703.2002.00120.x; Lee SO, 2007, PLANT PATHOLOGY J, V23, P97, DOI 10.25231/pee.2017.23.4.97; Lopes MA, 2008, MYCOL RES, V112, P399, DOI 10.1016/j.mycres.2007.10.017; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinez J.A., 2012, FUNGICIDES PLANT ANI, V13, P12; MCDONALD CE, 1965, ANAL BIOCHEM, V10, P175, DOI 10.1016/0003-2697(65)90255-1; Nashwa SMA, 2012, PLANT PROTECT SCI, V48, P74, DOI 10.17221/14/2011-PPS; Naz R, 2014, PHYTOPATHOLOGY, V104, P933, DOI 10.1094/PHYTO-11-13-0317-R; Nduagu C., 2008, Journal of Applied Biosciences, V6, P184; Nguefack J, 2004, INT J FOOD MICROBIOL, V94, P329, DOI 10.1016/j.ijfoodmicro.2004.02.017; Paul PK, 2002, PHYSIOL MOL PLANT P, V61, P3, DOI 10.1006/pmpp.2002.0412; Ramirez MG, 2004, J MICROBIOL METH, V56, P213, DOI 10.1016/j.mimet.2003.10.011; Rosyara UR, 2009, J PLANT PATHOL, V91, P113; Saravanakumar D, 2007, CROP PROT, V26, P556, DOI 10.1016/j.cropro.2006.05.007; SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49; Soylu S., 2008, BIOCH RESPONSES PLAN, p33 ; Stangarlin Jose R., 2000, Summa Phytopathologica, V26, P34; Suzuki LS, 2003, PHYTON-ANN REI BOT A, V43, P179; Vallad GE, 2004, CROP SCI, V44, P1920, DOI 10.2135/cropsci2004.1920; VETTER JL, 1958, J AGR FOOD CHEM, V6, P39, DOI 10.1021/jf60083a006; Vimala R., 2009, Journal of Biopesticides, V2, P111; Washington JA, 1980, MANUAL CLIN MICROBIO, V56, P279; Xue L, 1998, PHYTOPATHOLOGY, V88, P359, DOI 10.1094/PHYTO.1998.88.4.359; Yang VW, 2007, INT BIODETER BIODEGR, V59, P302, DOI 10.1016/j.ibiod.2006.09.004	49	14	16	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196194	10.1371/journal.pone.0196194	http://dx.doi.org/10.1371/journal.pone.0196194			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE3RI	29708983	Green Published, gold, Green Submitted			2023-01-03	WOS:000431130100020
J	Fryzek, JP; Reichert, H; Summers, N; Townes, L; Deuson, R; Alexander, DD; Vanderpuye-Orgle, J				Fryzek, Jon P.; Reichert, Heidi; Summers, Nicholas; Townes, Lindsay; Deuson, Robert; Alexander, Dominik D.; Vanderpuye-Orgle, Jackie			Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen	PLOS ONE			English	Article							ABIRATERONE ACETATE; ENZALUTAMIDE; SURVIVAL; INTERVENTIONS; CHEMOTHERAPY	Background The objective of this study was to conduct an indirect treatment comparison between cabazitaxel, abiraterone and enzalutamide to determine the clinical efficacy and safety of cabazitaxel relative to comparators in the treatment of patients with metastatic castrate-resistant prostate cancer who progress on docetaxel-based therapies. Methods A systematic literature review was conducted to inform the network meta-analysis of cabazitaxel, abiraterone and enzalutamide. Due to a lack of head-to-head trials, studies with a comparator arm of best supportive care were included in the analysis. Overall survival, progression-free survival, and adverse events were compared within both Bayesian and Frequentist frameworks. The ratios for survival outcomes were estimated using hazard ratios (HR), and the ratios for adverse events between groups were estimated using odds ratios (ORs); uncertainty was reported as 95% confidence (Frequentist) and credible (Baysesian) Intervals. Results Three of thirteen trials identified for abstraction were relevant for analyses. Median overall survival was not statistically significantly different for abiraterone (HR = 1.04; 95% CI = 0.83-1.28) or enzalutamide (HR = 0.88; 95% CI = 0.69-1.11) when compared to cabazitaxel in the Bayesian analysis. Anaemia (OR = 3.71; 95% CI = 1.01-10.44), diarrhoea (OR = 16.60; 95% CI = 1.41-75.31) and haematuria (OR = 3.88; 95% CI = 1.03-10.09) were more likely to occur in the cabazitaxel group than the abiraterone group, while pyrexia risk was higher in cabazitaxel compared to enzalutamide (OR = 36.23; 95% CI = 1.14-206.40). Frequentist analyses produced similar results. Conclusions The scarcity of clinical studies and lack of a common comparator limited analyses. The adverse event results must be interpreted with caution as many were based on small numbers. The results from this analysis indicate comparable survival outcomes and adverse event profiles. As these pivotal studies may not reflect the contemporary treatment landscape and patient profiles, additional research, including head-to-head clinical trials and real world observational studies, should be conducted to further elucidate the beneficial effects of these therapies.	[Fryzek, Jon P.; Reichert, Heidi; Townes, Lindsay] EpidStat Inst, Ann Arbor, MI 48105 USA; [Summers, Nicholas; Alexander, Dominik D.; Vanderpuye-Orgle, Jackie] Precis Hlth Econ, Los Angeles, CA 90025 USA; [Deuson, Robert] Medenomics LLC, Moorpark, CA USA		Fryzek, JP (corresponding author), EpidStat Inst, Ann Arbor, MI 48105 USA.; Summers, N (corresponding author), Precis Hlth Econ, Los Angeles, CA 90025 USA.	jon@epidstat.com; nick.summers@pheconomics.com			Sanofi	Sanofi(Sanofi-Aventis)	This research was funded by Sanofi to NS. Sanofi contributed to the study design and reviewed the final version of the manuscript to ensure that the descriptions of Sanofi products are medically accurate, but did not take part in the writing of the manuscript.	American Cancer Society, 2016, KEY STAT PROST CANC; Brodszky Valentin, 2014, Magy Onkol, V58, P189; Cancer Research UK, 2016, PROST CANC STAT; de Bono J. S., 2001, NEW ENGL J MED, V364, P1995, DOI DOI 10.1056/; Dearden L, 2014, VALUE HEALTH, V17, pA616, DOI 10.1016/j.jval.2014.08.2170; Dias S, 2011, 2 NICE DSU; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Green AK, 2015, ONCOLOGIST, V20, P516, DOI 10.1634/theoncologist.2014-0432; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Joulain F., 201001 SAN; Mills EJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2914; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Stata Corp, 2015, STAT STAT SOFTW REL; Summers N, 2017, CURR MED RES OPIN, V33, P1995, DOI 10.1080/03007995.2017.1341869; Systematic Reviews, 2009, SYSTEMATIC REV CRDS; Tan PS, 2014, CLIN MED INSIGHTS-ON, V8, P29, DOI 10.4137/CMO.S13671; Woods BS, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-54; Zhang W, 2016, ASIAN J ANDROL	20	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2018	13	4							e0195790	10.1371/journal.pone.0195790	http://dx.doi.org/10.1371/journal.pone.0195790			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4GL	29641566	Green Published, gold, Green Submitted			2023-01-03	WOS:000429742900093
J	Kisler, LB; Gurion, I; Granovsky, Y; Sinai, A; Sprecher, E; Shamay-Tsoory, S; Weissman-Fogel, I				Kisler, Lee-Bareket; Gurion, Ilan; Granovsky, Yelena; Sinai, Alon; Sprecher, Elliot; Shamay-Tsoory, Simone; Weissman-Fogel, Irit			Can a single pulse transcranial magnetic stimulation targeted to the motor cortex interrupt pain processing?	PLOS ONE			English	Article							EVOKED-POTENTIALS; NEUROPATHIC PAIN; SENSORIMOTOR CORTEX; BRAIN; TMS; PERCEPTION; SUPPRESSION; ACTIVATION; RTMS; REPRESENTATIONS	The modulatory role of the primary motor cortex (M1), reflected by an inhibitory effect of Ml-stimulation on clinical pain, motivated us to deepen our understanding of M1's role in pain modulation. We used Transcranial Magnetic Stimulation (TMS)-induced virtual lesion (VL) to interrupt with M1 activity during noxious heat pain. We hypothesized that TMS-VL will effect experimental pain ratings. Three VL protocols were applied consisting of single-pulse TMS to transiently interfere with right M1 activity: (1) VLM1-TMS applied to 11 subjects, 20 msec before the individual's first pain-related M1 peak activation, as determined by source analysis (sLORETA), (2) VL-50 (N = 16; TMS applied 50 ms prior to noxious stimulus onset), and (3) VL+150 (N = 16; TMS applied 150 ms after noxious stimulus onset). Each protocol included 3 conditions ('pain -alone', ' TMS-VL', and `SHAM-VL'), each consisted of 30 noxious heat stimuli. Pain ratings were compared, in each protocol, for TMS-VL vs. SHAM-VL and vs. pain-alone conditions. Repeated measures analysis of variance, corrected for multiple comparisons revealed no significant differences in the pain ratings between the different conditions within each protocol. Therefore, our results from this exploratory study suggest that a single pulse TMS-induced VL that is targeted to M1 failed to interrupt experimental pain processing in the specific three stimulation timing examined here.	[Kisler, Lee-Bareket; Gurion, Ilan; Shamay-Tsoory, Simone] Univ Haifa, Dept Psychol, Haifa, Israel; [Kisler, Lee-Bareket; Granovsky, Yelena] Technion Fac Med, Lab Clin Neurophysiol, Haifa, Israel; [Granovsky, Yelena; Sinai, Alon; Sprecher, Elliot] Rambam Hlth Care Campus, Dept Neurol, Haifa, Israel; [Sinai, Alon] Rambam Hlth Care Campus, Dept Neurosurg, Haifa, Israel; [Weissman-Fogel, Irit] Univ Haifa, Fac Social Welf & Hlth Sci, Haifa, Israel	University of Haifa; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Rambam Health Care Campus; University of Haifa	Weissman-Fogel, I (corresponding author), Univ Haifa, Fac Social Welf & Hlth Sci, Haifa, Israel.	ifogel@univ.haifa.ac.il			Israel Science Foundation [518/12]; IWF	Israel Science Foundation(Israel Science Foundation); IWF	This work was supported by the Israel Science Foundation grant #518/12 (https://www.isf.org.il/#/) to AS, YG and IWF. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; BECKERS G, 1995, BRAIN, V118, P49, DOI 10.1093/brain/118.1.49; Bestmann S, 2004, EUR J NEUROSCI, V19, P1950, DOI 10.1111/j.1460-9568.2004.03277.x; Bingel U, 2002, PAIN, V99, P313, DOI 10.1016/S0304-3959(02)00157-4; Borckardt JJ, 2011, CLIN J PAIN, V27, P486, DOI 10.1097/AJP.0b013e31820d2733; Bradley C, 2016, BRAIN STIMUL, V9, P48, DOI 10.1016/j.brs.2015.08.015; BRASILNETO JP, 1992, ELECTROEN CLIN NEURO, V85, P9, DOI 10.1016/0168-5597(92)90095-S; Burns E, 2016, EUR J PAIN, V20, P1203, DOI 10.1002/ejp.859; Cohen NR, 2009, EXP BRAIN RES, V196, P303, DOI 10.1007/s00221-009-1838-x; Cohen NR, 2009, NEUROPSYCHOLOGIA, V47, P1553, DOI 10.1016/j.neuropsychologia.2008.12.034; Dambeck N, 2006, BRAIN RES, V1072, P194, DOI 10.1016/j.brainres.2005.05.075; Di Lazzaro V, 2004, CLIN NEUROPHYSIOL, V115, P255, DOI 10.1016/j.clinph.2003.10.009; DosSantos MF, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00018; Epstein CM, 1999, CLIN NEUROPHYSIOL, V110, P1073, DOI 10.1016/S1388-2457(99)00047-4; Franca NRM, 2013, BEHAV BRAIN RES, V250, P211, DOI 10.1016/j.bbr.2013.05.019; Frot M, 2013, HUM BRAIN MAPP, V34, P2655, DOI 10.1002/hbm.22097; Garcia-Larrea L, 2003, NEUROPHYSIOL CLIN, V33, P279, DOI 10.1016/j.neucli.2003.10.008; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 1997, STEREOT FUNCT NEUROS, V68, P141, DOI 10.1159/000099915; Garcia-Larrea L, 2007, NEUROIMAGE, V37, pS71, DOI 10.1016/j.neuroimage.2007.05.062; Gelnar PA, 1999, NEUROIMAGE, V10, P460, DOI 10.1006/nimg.1999.0482; Gerloff C, 1997, BRAIN, V120, P1587, DOI 10.1093/brain/120.9.1587; Granovsky Y, 2005, PAIN, V115, P238, DOI 10.1016/j.pain.2005.02.017; Granovsky Y, 2016, EUR J PAIN, V20, P241, DOI 10.1002/ejp.715; Granovsky Y, 2008, J PAIN, V9, P53, DOI 10.1016/j.jpain.2007.08.010; Hamilton RH, 1998, TRENDS COGN SCI, V2, P168, DOI 10.1016/S1364-6613(98)01172-3; Harris JA, 2008, J COGNITIVE NEUROSCI, V20, P734, DOI 10.1162/jocn.2008.20048; Jahanshahi M, 2000, EXP BRAIN RES, V131, P1, DOI 10.1007/s002219900224; Kanda M, 2003, CLIN NEUROPHYSIOL, V114, P860, DOI 10.1016/S1388-2457(03)00034-8; Kisler LB, 2017, BEHAV BRAIN RES, V328, P209, DOI 10.1016/j.bbr.2017.04.006; Kisler LB, 2016, EXP BRAIN RES, V234, P3119, DOI 10.1007/s00221-016-4710-9; Kramer JLK, 2012, CLIN NEUROPHYSIOL, V123, P582, DOI 10.1016/j.clinph.2011.08.013; Kramer JLK, 2013, PAIN, V154, P235, DOI 10.1016/j.pain.2012.10.027; Lee MC, 2009, J NEUROSCI, V29, P7909, DOI 10.1523/JNEUROSCI.0014-09.2009; Lefaucheur JP, 2006, NEUROLOGY, V67, P1568, DOI 10.1212/01.wnl.0000242731.10074.3c; Lin KP, 2012, CHINESE J PHYSIOL, V55, P163, DOI 10.4077/CJP.2012.AMM117; Lisanby SH, 2001, BIOL PSYCHIAT, V49, P460, DOI 10.1016/S0006-3223(00)01110-0; Lockwood PL, 2013, CORTEX, V49, P2201, DOI 10.1016/j.cortex.2012.10.006; Loo CK, 2000, BIOL PSYCHIAT, V47, P325, DOI 10.1016/S0006-3223(99)00285-1; Meister IG, 2006, NEUROSCIENCE, V142, P119, DOI 10.1016/j.neuroscience.2006.06.023; Moont R, 2011, PAIN, V152, P1469, DOI 10.1016/j.pain.2011.01.036; Mull BR, 2001, CLIN NEUROPHYSIOL, V112, P1672, DOI 10.1016/S1388-2457(01)00606-X; Mylius V, 2007, NEUROSCI LETT, V415, P49, DOI 10.1016/j.neulet.2006.12.042; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; Nizard J, 2012, DISCOV MED, V14, P237; Ohara PT, 2005, CELL MOL LIFE SCI, V62, P44, DOI 10.1007/s00018-004-4283-9; Osaka N, 2007, NEUROSCI LETT, V418, P232, DOI 10.1016/j.neulet.2007.01.087; Pagano RL, 2012, PAIN, V153, P2359, DOI 10.1016/j.pain.2012.08.002; Pascual-Leone A, 1999, PHILOS T R SOC B, V354, P1229, DOI 10.1098/rstb.1999.0476; Pascual-Marqui R.D., 2007, ARXIV07103341; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Peyron R, 2007, NEUROIMAGE, V34, P310, DOI 10.1016/j.neuroimage.2006.08.037; Pleger B, 2004, NEUROSCI LETT, V356, P87, DOI 10.1016/j.neulet.2003.11.037; Porro CA, 2007, BEHAV BRAIN RES, V178, P183, DOI 10.1016/j.bbr.2006.11.011; PRICE DD, 1977, PAIN, V3, P57, DOI 10.1016/0304-3959(77)90035-5; Reichenbach A, 2011, NEUROIMAGE, V54, P1375, DOI 10.1016/j.neuroimage.2010.08.047; Rice NJ, 2006, J NEUROSCI, V26, P8176, DOI 10.1523/JNEUROSCI.1641-06.2006; ROTHWELL JC, 1987, BRAIN, V110, P1173, DOI 10.1093/brain/110.5.1173; Schieber MH, 2001, J NEUROPHYSIOL, V86, P2125, DOI 10.1152/jn.2001.86.5.2125; Shitara H, 2011, NEUROIMAGE, V56, P1469, DOI 10.1016/j.neuroimage.2011.03.011; Siebner HR, 2009, CORTEX, V45, P1035, DOI 10.1016/j.cortex.2009.02.007; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Siebner HR, 2001, HUM BRAIN MAPP, V12, P157, DOI 10.1002/1097-0193(200103)12:3<157::AID-HBM1012>3.0.CO;2-V; Soto D, 2009, NEUROSCI LETT, V451, P261, DOI 10.1016/j.neulet.2008.12.052; Thut G, 2003, CLIN NEUROPHYSIOL, V114, P2071, DOI 10.1016/S1388-2457(03)00205-0; TSUBOKAWA T, 1991, PACE, V14, P131, DOI 10.1111/j.1540-8159.1991.tb04058.x; Tunik E, 2005, NAT NEUROSCI, V8, P505, DOI 10.1038/nn1430; Valeriani M, 2007, CLIN NEUROPHYSIOL, V118, P1097, DOI 10.1016/j.clinph.2007.01.015; Walsh V, 1998, P ROY SOC B-BIOL SCI, V265, P537, DOI 10.1098/rspb.1998.0328; Walsh V, 1999, NEUROPSYCHOLOGIA, V37, P125; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; Ziemann U, 2010, CORTEX, V46, P124, DOI 10.1016/j.cortex.2009.02.020	73	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2018	13	4							e0195739	10.1371/journal.pone.0195739	http://dx.doi.org/10.1371/journal.pone.0195739			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC0YY	29630681	gold, Green Published, Green Submitted			2023-01-03	WOS:000429505000069
J	Fieldhouse, JK; Toh, TH; Lima, WH; Ting, J; Ha, SJ; Hii, KC; Kong, CI; Wong, TM; Wong, SC; Warkentien, TE; Gray, GC				Fieldhouse, Jane K.; Toh, Teck-Hock; Lima, Wei-Honn; Ting, Jakie; Ha, Siaw-Jing; Hii, King-Ching; Kong, Cheng-Ing; Wong, Toh-Mee; Wong, See-Chang; Warkentien, Tyler E.; Gray, Gregory C.			Surveillance for respiratory syncytial virus and parainfluenza virus among patients hospitalized with pneumonia in Sarawak, Malaysia	PLOS ONE			English	Article							REAL-TIME PCR; REQUIRING HOSPITALIZATION; INFECTION; EPIDEMIOLOGY; CHILDREN; PATHOGENS; GAPS	Background Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are frequent causes of pneumonia and death among children at Sibu and Kapit Hospitals in Sarawak, Malaysia. Objectives To determine the prevalence and risk factors for RSV subtypes A and B and PIV types 1-4 among patients hospitalized with pneumonia. Methods In a cross-sectional, pilot study nasopharyngeal swabs were studied with real-time reverse transcription polymerase chain reaction assays. Concurrently, we helped Sibu and Kapit Hospitals adapt their first molecular diagnostics for RSV and PIV. Results Of 129 specimens collected (June to July 2017), 39 tested positive for RSV-A (30.2%), two were positive for RSV B (1.6%), one was positive for PIV-3 (0.8%) and one was positive for PIV-4 (0.8%). No samples were positive for PIV-1 or PIV-2. Of the 39 RSV-A positive specimens, 46.2% were collected from children under one year of age and only 5.1% were from patients over the age of 18. A multivariable analysis found the odds of children <1 year of age testing positive for RSV-A were 32.7 (95% CI: 3.9, 276.2) times larger than >18 years of age, and the odds of patients hospitalized at Kapit Hospital testing positive for RSV-A were 3.2 (95% CI: 1.3, 7.8) times larger than patients hospitalized at Sibu Hospital. Conclusion This study found an unusually high prevalence of RSV-A among pneumonia patients admitted to the two hospitals. Subsequently, Sibu Hospital adapted the molecular assays with the goal of providing more directed care for such pneumonia patients.	[Fieldhouse, Jane K.; Gray, Gregory C.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA; [Fieldhouse, Jane K.; Gray, Gregory C.] Duke Univ, Sch Med, Div Infect Dis, Durham, NC 27708 USA; [Toh, Teck-Hock; Lima, Wei-Honn; Ting, Jakie; Ha, Siaw-Jing] Sibu Hosp, Clin Res Ctr, Sibu, Sarawak, Malaysia; [Toh, Teck-Hock; Ha, Siaw-Jing; Wong, See-Chang] Sibu Hosp, Dept Paediat, Sibu, Sarawak, Malaysia; [Toh, Teck-Hock; Wong, See-Chang] SEGi Univ, Dept Paediat, Sibu Hosp, Fac Med, Sibu Clin Campus, Sibu, Sarawak, Malaysia; [Hii, King-Ching; Kong, Cheng-Ing] Kapit Hosp, Kapit, Sarawak, Malaysia; [Wong, Toh-Mee] Sibu Hosp, Dept Med, Sibu, Sarawak, Malaysia; [Warkentien, Tyler E.] United States Naval Med Res Ctr Asia, Singapore, Singapore; [Gray, Gregory C.] Duke NUS Med Sch, Emerging Infect Dis Program, Singapore, Singapore	Duke University; Duke University; SEGi University; National University of Singapore	Fieldhouse, JK (corresponding author), Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA.; Fieldhouse, JK (corresponding author), Duke Univ, Sch Med, Div Infect Dis, Durham, NC 27708 USA.	jane.fieldhouse@duke.edu	Toh, Teck-Hock/AAW-7715-2021; Gray, Gregory C./ABF-1298-2020; Lim, Wei Honn/N-4108-2017	Toh, Teck-Hock/0000-0001-5909-4855; Lim, Wei Honn/0000-0002-6408-4747; Fieldhouse, Jane/0000-0002-5450-0970	US Naval Medical Research Center-Asia; Vysnova Partners [SC-2016-SABER-003-002]; Duke Global Health Institute; Duke University's Global Health Institute; US Naval Medical Research Center, Asia via Vysnova Partners Inc.	US Naval Medical Research Center-Asia; Vysnova Partners; Duke Global Health Institute; Duke University's Global Health Institute; US Naval Medical Research Center, Asia via Vysnova Partners Inc.	This work was funded in part by the US Naval Medical Research Center-Asia (http://www.med.navy.mil/sites/nmrca/SitePages/Home.aspx) and Vysnova Partners subcontract SC-2016-SABER-003-002 (http://www.vysnova.com/), received by CGC and THT. Research conducted by JKF was supported in part by funding from the Duke Global Health Institute (https://globalhealth.duke.edu/) and by discretionary funds from Dr. Gregory Gray with Duke University's Global Health Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the Director General of Health, Malaysia for his permission to publish this paper. We thank the Medical Officers of Sibu and Kapit Hospitals (namely Chuet-Zou Lau, Nga-Hung Ngu, Khai-Fatt Chao, Sing-Ling Kong, Zhen-Hao Ching, Edmund Kwang-Yuen Wong, Tiana Ti, and Hilary Hon-Yun Kueh) for enrolling patients. This work was sponsored by the US Naval Medical Research Center, Asia via Vysnova Partners Inc., and conducted in partnership with Duke University, the Duke Global Health Institute, Sibu Hospital Clinical Research Center, Kapit Hospital and SEGi University Sibu Clinical Campus.	Borchers AT, 2013, CLIN REV ALLERG IMMU, V45, P331, DOI 10.1007/s12016-013-8368-9; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Bredius RGM, 2004, PEDIAT INFECT DIS J, V23; Chan PWK, 2002, PEDIATR PULM, V34, P47, DOI 10.1002/ppul.10095; Department of Statistics Malaysia, 2016, POP ETHN GROUP; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI [10.1056/NEJMoa1500245, 10.1056/NEJMc1511751]; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Jalilian FA, 2015, J BIOL REG HOMEOS AG, V29, P7; Kaplan NM, 2008, J MED VIROL, V80, P168, DOI 10.1002/jmv.21067; Khor CS, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-32; Kim L, 2017, CLIN INFECT DIS, V65, P1020, DOI 10.1093/cid/cix432; Langley JM, 2016, J INFECT DIS; Mazur N, 2015, LANCET RESP MED, V3, P888, DOI 10.1016/S2213-2600(15)00255-6; Obando-Pacheco P, 2018, J INFECT DIS, V217, P1356, DOI 10.1093/infdis/jiy056; Pangesti KNA, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1968; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Slinger R, 2012, CLIN MICROBIOL INFEC, V18, pE286, DOI 10.1111/j.1469-0691.2012.03896.x; Tang JW, 2017, LANCET INFECT DIS, V17, pE320, DOI 10.1016/S1473-3099(17)30238-4; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; van de Pol AC, 2007, J CLIN MICROBIOL, V45, P2260, DOI 10.1128/JCM.00848-07; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wishaupt JO, 2017, J CLIN VIROL, V90, P1, DOI 10.1016/j.jcv.2017.02.010	24	5	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2018	13	8							e0202147	10.1371/journal.pone.0202147	http://dx.doi.org/10.1371/journal.pone.0202147			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ5PD	30110367	gold, Green Submitted, Green Published			2023-01-03	WOS:000441738000053
J	Iorgulescu, JB; Reardon, DA; Chiocca, EA; Wu, CJ				Iorgulescu, J. Bryan; Reardon, David A.; Chiocca, E. Antonio; Wu, Catherine J.			Immunotherapy for glioblastoma: going viral	NATURE MEDICINE			English	Editorial Material							GENE		[Iorgulescu, J. Bryan; Reardon, David A.; Wu, Catherine J.] Dana Farber Canc Ctr, Dept Med Oncol, Boston, MA 02215 USA; [Iorgulescu, J. Bryan; Reardon, David A.; Chiocca, E. Antonio; Wu, Catherine J.] Harvard Med Sch, Boston, MA 02115 USA; [Iorgulescu, J. Bryan] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Reardon, David A.; Wu, Catherine J.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Chiocca, E. Antonio] Brigham & Womens Hosp, Dana Farber Canc Ctr, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Wu, CJ (corresponding author), Dana Farber Canc Ctr, Dept Med Oncol, Boston, MA 02215 USA.; Wu, CJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Wu, CJ (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	cwu@partners.org		Iorgulescu, J. Bryan/0000-0003-1405-3667	Abbvie; Agenus; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Taiho Oncology, Inc.; Advantagene; Dnatrix; NATIONAL CANCER INSTITUTE [P01CA163205] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER	Abbvie(AbbVie); Agenus; Bristol-Myers Squibb(Bristol-Myers Squibb); Celldex; EMD Serono; Genentech/Roche(Roche HoldingGenentech); Inovio; Merck(Merck & Company); Merck KGaA; Monteris; Novocure(Novocure Limited); Oncorus; Oxigene; Regeneron(Regeneron); Stemline; Taiho Oncology, Inc.; Advantagene; Dnatrix; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	D.A.R. reports receiving honoraria, advisory, and consultant fees from Abbvie; Agenus; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; and Taiho Oncology, Inc. E.A.C. reports receiving consultant and advisory fees from Advantagene and Dnatrix. C.J.W. is cofounder of Neon Therapeutics and a member of its scientific advisory board. All other authors declare that they have no competing interests.	Brown MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan4220; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Grob JJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9534; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; Keskin D. B, 2018, CANC RES, V78; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Reardon D. A, 2017, NEUROONCOL, V19; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Trask TW, 2000, MOL THER, V1, P195, DOI 10.1006/mthe.2000.0030; Wheeler LA, 2016, NEURO-ONCOLOGY, V18, P1137, DOI 10.1093/neuonc/now002	12	17	18	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2018	24	8					1094	1096		10.1038/s41591-018-0142-3	http://dx.doi.org/10.1038/s41591-018-0142-3			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GP5ZF	30082860	Green Accepted			2023-01-03	WOS:000440955500012
J	Plotkin, M; Bishanga, D; Kidanto, H; Jennings, MC; Ricca, J; Mwanamsangu, A; Tibaijuka, G; Lemwayi, R; Ngereza, B; Drake, M; Zougrana, J; Khadka, N; Litch, JA; Rawlins, B				Plotkin, Marya; Bishanga, Dunstan; Kidanto, Hussein; Jennings, Mary Carol; Ricca, Jim; Mwanamsangu, Amasha; Tibaijuka, Gaudiosa; Lemwayi, Ruth; Ngereza, Benny; Drake, Mary; Zougrana, Jeremie; Khadka, Neena; Litch, James A.; Rawlins, Barbara			Tracking facility-based perinatal deaths in Tanzania: Results from an indicator validation assessment	PLOS ONE			English	Article							INCOME COUNTRIES; STILLBIRTHS; MORTALITY; SETTINGS; NEWBORN; COST	Background Globally, an estimated 2.7 million babies die in the neonatal period annually, and of these, about 0.7 million die from intrapartum-related events. In Tanzania 51,000 newborn deaths and 43,000 stillbirths occur every year. Approximately two-thirds of these deaths could be potentially prevented with improvements in intrapartum and neonatal care. Routine measurement of fetal intrapartum deaths and newborn deaths that occur in health facilities can help to evaluate efforts to improve the quality of intrapartum care to save lives. However, few examples exist of indicators on perinatal mortality in the facility setting that are readily available through health management information systems (HMIS). Methods From November 2016 to April 2017, health providers at 10 government health facilities in Kagera region, Tanzania, underwent refresher training on perinatal death classification and training on the use of handheld Doppler devices to assess fetal heart rate upon admission to maternity services. Doppler devices were provided to maternity services at the study facilities. We assessed the validity of an indicator to measure facility-based pre-discharge perinatal mortality by comparing perinatal outcomes extracted from the HMIS maternity registers to a gold standard perinatal death audit. Results Sensitivity and specificity of the HMIS neonatal outcomes to predict gold standard audit outcomes were both over 98% based on analysis of 128 HMIS-gold standard audit pairs. After this validation, we calculated facility perinatal mortality indicator from HMIS data using fresh stillbirths and pre-discharge newborn death as the numerator and women admitted labour with positive fetal heart tones as the denominator. Further emphasizing the validity of the indicator, FPM values aligned with expected mortality by facility level, with lowest rates in health centers (range 0.3%-0.5%), compared to district hospitals (1.5%-2.9%) and the regional hospital (4.2%). Conclusion This facility perinatal mortality indicator provides an important health outcome measure that facilities can use to monitor levels of perinatal deaths occurring in the facility and evaluate impact of quality of care improvement activities.	[Plotkin, Marya; Ricca, Jim; Rawlins, Barbara] Jhpiego Baltimore, Baltimore, MD 21231 USA; [Bishanga, Dunstan; Mwanamsangu, Amasha; Tibaijuka, Gaudiosa; Lemwayi, Ruth; Ngereza, Benny; Drake, Mary; Zougrana, Jeremie] Jhpiego Tanzania, Dar Es Salaam, Tanzania; [Kidanto, Hussein] Minist Hlth Community Dev Gender Elderly & Childr, Dar Es Salaam, Tanzania; [Jennings, Mary Carol] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Khadka, Neena] Save Children, Washington, DC USA; [Litch, James A.] Global Alliance Prevent Prematur & Stillbirth, Lynnwood, WA USA	Jhpiego; Jhpiego; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Save the Children	Plotkin, M (corresponding author), Jhpiego Baltimore, Baltimore, MD 21231 USA.	Marya.plotkin@jhpiego.org		Jennings, Mary Carol/0000-0003-1050-7035; Mwanamsangu, Amasha/0000-0003-0702-3304; Litch, James/0000-0003-0570-0308; Kidanto, Hussein Lesio/0000-0001-9167-8068	United States Agency for International Development (USAID) [AID-OAA-A-14-00028]	United States Agency for International Development (USAID)(United States Agency for International Development (USAID))	This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID), under the terms of the Cooperative Agreement AID-OAA-A-14-00028. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afnan-Holmes H, 2015, LANCET GLOB HEALTH, V3, pE396, DOI 10.1016/S2214-109X(15)00059-5; Armstrong CE, 2014, TROP MED INT HEALTH, V19, P1087, DOI 10.1111/tmi.12353; Baqui AH, 2016, B WORLD HEALTH ORGAN, V94, P752, DOI 10.2471/BLT.15.160945; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bhutto ZA, 2011, LANCET, V377, P1523, DOI 10.1016/S0140-6736(10)62269-6; Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2; Chuwa FS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182250; Gold KJ, 2014, INT J GYNECOL OBSTET, V125, P223, DOI 10.1016/j.ijgo.2013.12.006; Goldenberg RL, 2013, INT J GYNECOL OBSTET, V122, P230, DOI 10.1016/j.ijgo.2013.04.008; Karuri J., 2014, Journal of Health Informatics in Developing Countries, V8, P38; Kidanto HL, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-45; Koblinsky M, 2017, GLOB HEALTH-SCI PRAC, V5, P333, DOI 10.9745/GHSP-D-17-00308; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Manji K., 2009, SITUATION ANAL NEWBO; Ministry of Health Zanzibar National Bureau of Statistics Dar es Salaam Office of Chief Government Statitician Zanzibar ICF USAID UNICEF, 2016, TANZ DEM HLTH SURV M; Msemo G, 2013, PEDIATRICS, V131, pE353, DOI 10.1542/peds.2012-1795; Northern Regional Alliance Northern Youth Health Network, 2017, STAND QUAL CAR AD YO; Reproductive and Child Health Section Ministry of Health and Social Welfare, 2015, TANZ UR MAT PER DEAT; UNICEF WHO & World Bank Group., 2021, LEVELS TRENDS CHILD; WHO, 2016, MAK EV BAB COUNT AUD; WHO, 2018, MON FRAM QUAL EQ DIG; WHO, 2009, MON EM OBST CAR; World Health Organization, 2006, NEON PER MORT COUNTR; World Health Organization, 2016, WHO TREATM GUID DRUG; World Health Organization, 2016, MAT PER HLTH	26	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2018	13	7							e0201238	10.1371/journal.pone.0201238	http://dx.doi.org/10.1371/journal.pone.0201238			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4SZ	30052662	Green Published, gold, Green Submitted			2023-01-03	WOS:000440006600032
J	Dumont, L; Larochelle-Brunet, F; Theoret, H; Riedl, R; Senecal, S; Leger, PM				Dumont, Laurence; Larochelle-Brunet, Felix; Theoret, Hugo; Riedl, Rene; Senecal, Sylvain; Leger, Pierre-Majorique			Non-invasive brain stimulation in information systems research: A proof-of-concept study	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; COGNITIVE NEUROSCIENCE; RISK-TAKING; TDCS; HEALTHY; NEUROIS; ACCEPTANCE; PERCEPTION; ACTIVATION; INCREASES	One of the founding experiments in the field of Neuro-Information-Systems (NeuroIS), which aims at exploring the neural correlates of the technology acceptance model, suggests that perceived ease of use (PEoU) is associated with activity in the dorsolateral prefrontal cortex (DLPFC) while perceived usefulness is associated with activity in the insula, caudate nucleus and anterior cingulate cortex. To further assess the link between DLPFC and PEoU, transcranial direct current stimulation (tDCS) was applied over bilateral DLPFC (F3 and F4) immediately before an online shopping task. Forty-two participants were divided in three stimulation groups: left anodal/right cathodal, left cathodal/right anodal and sham. No change in PEoU was observed post stimulation but participants in the left anodal/right cathodal stimulation group took longer to make a purchase compared to sham stimulation and had different visual fixation patterns over the buy buttons. This is, to our knowledge, the first use of non-invasive brain stimulation in the field of NeuroIS. Although the involvement of DLPFC in PEoU could not be confirmed, the present study suggests that non-invasive brain stimulation may be a useful research tool in NeuroIS.	[Dumont, Laurence; Larochelle-Brunet, Felix; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Dumont, Laurence; Senecal, Sylvain; Leger, Pierre-Majorique] HEC Montreal, Tech3Lab, Montreal, PQ, Canada; [Riedl, Rene] Univ Linz, Dept Business Informat Informat Engn, Linz, Austria; [Riedl, Rene] Univ Appl Sci Upper Austria, Sch Management, Digital Business, Steyr, Austria	Universite de Montreal; Universite de Montreal; HEC Montreal; Johannes Kepler University Linz	Dumont, L (corresponding author), Univ Montreal, Dept Psychol, Montreal, PQ, Canada.; Dumont, L (corresponding author), HEC Montreal, Tech3Lab, Montreal, PQ, Canada.	laurence.dumont@hec.ca		Theoret, Hugo/0000-0002-7458-8797; Dumont, Laurence/0000-0002-8081-7525	Social Sciences and Humanities Research Council [435-2012-1232]	Social Sciences and Humanities Research Council(Social Sciences and Humanities Research Council of Canada (SSHRC))	This work was supported by a grant from the Social Sciences and Humanities Research Council (http://www.sshrc-crsh.gc.ca/) (435-2012-1232). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali ASB, 2008, PROJ MANAG J, V39, P5, DOI 10.1002/pmj.20041; Barbey AK, 2013, CORTEX, V49, P1195, DOI 10.1016/j.cortex.2012.05.022; Benwell CSY, 2015, CORTEX, V69, P152, DOI 10.1016/j.cortex.2015.05.007; Berryhill ME, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00800; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Boggio PS, 2010, DRUG ALCOHOL DEPEN, V112, P220, DOI 10.1016/j.drugalcdep.2010.06.019; Boonstra TW, 2016, FRONT HUM NEUROSCI, V10, P1; BORNSTEIN RF, 1989, PSYCHOL BULL, V106, P265, DOI 10.1037/0033-2909.106.2.265; Buhusi CV, 2005, NAT REV NEUROSCI, V6, P755, DOI 10.1038/nrn1764; Cieslik EC, 2013, CEREB CORTEX, V23, P2677, DOI 10.1093/cercor/bhs256; Clarke PJF, 2014, BIOL PSYCHIAT, V76, P946, DOI 10.1016/j.biopsych.2014.03.003; DAVIS FD, 1993, INT J MAN MACH STUD, V38, P475, DOI 10.1006/imms.1993.1022; Dedoncker J, 2016, BRAIN STIMUL, V9, P501, DOI 10.1016/j.brs.2016.04.006; Dimoka A, 2011, INFORM SYST RES, V22, P687, DOI 10.1287/isre.1100.0284; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Fecteau S, 2007, J NEUROSCI, V27, P6212, DOI 10.1523/JNEUROSCI.0314-07.2007; Fecteau Shirley, 2012, Front Psychiatry, V3, P97, DOI 10.3389/fpsyt.2012.00097; Fregni F, 2008, APPETITE, V51, P34, DOI 10.1016/j.appet.2007.09.016; Hecht D, 2010, J NEUROSCI, V30, P4241, DOI 10.1523/JNEUROSCI.2924-09.2010; Hornbak Kasper, 2017, ACM Transactions on Computer-Human Interaction, V24, DOI 10.1145/3127358; Hortensius R, 2012, SOC COGN AFFECT NEUR, V7, P342, DOI 10.1093/scan/nsr012; Horvath JC, 2015, BRAIN STIMUL, V8, P535, DOI 10.1016/j.brs.2015.01.400; Hoshi E, 2006, NEUROSCI RES, V54, P73, DOI 10.1016/j.neures.2005.10.013; Iuculano T, 2013, J NEUROSCI, V33, P4482, DOI 10.1523/JNEUROSCI.4927-12.2013; Kable Joseph W, 2011, J Neurosci Psychol Econ, V4, P63; Keinanen H, 2015, J BUS IND MARK, V30, P711, DOI 10.1108/JBIM-04-2013-0095; Kuo M-F, 2016, PHYSL TRANSCRANIAL D, P29, DOI [10.1007/978-3-319-33967-2_3, DOI 10.1007/978-3-319-33967-2_3]; Lauro LJR, 2014, CORTEX, V58, P99, DOI 10.1016/j.cortex.2014.05.003; Leite J, 2013, BRAIN STIMUL, V6, P660, DOI 10.1016/j.brs.2012.10.006; Loiacono ET, 2007, INT J ELECTRON COMM, V11, P51, DOI 10.2753/JEC1086-4415110302; Loos P, 2010, BUS INFORM SYST ENG+, V2, P395, DOI 10.1007/s12599-010-0130-8; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mancuso LE, 2016, J COGNITIVE NEUROSCI, V28, P1063, DOI 10.1162/jocn_a_00956; Minati L, 2012, COGN NEUROSCI-UK, V3, P80, DOI 10.1080/17588928.2011.628382; Mylius V, 2013, NEUROIMAGE, V78, P224, DOI 10.1016/j.neuroimage.2013.03.061; Mylius V, 2012, EUR J PAIN, V16, P974, DOI 10.1002/j.1532-2149.2011.00105.x; Nelson JT, 2014, NEUROIMAGE, V85, P909, DOI 10.1016/j.neuroimage.2012.11.061; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nozari N, 2013, NEUROPSYCHOLOGIA, V51, P2770, DOI 10.1016/j.neuropsychologia.2013.08.019; Parkin BL, 2015, NEURON, V87, P932, DOI 10.1016/j.neuron.2015.07.032; Pechmann C, 1988, J CURRENT ISSUES RES, V11, P285, DOI DOI 10.1080/01633392.1988.10504936; Pena-Gomez C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022812; Priori A, 2008, CEREB CORTEX, V18, P451, DOI 10.1093/cercor/bhm088; Riedl R, 2017, P INT C INF SYST; Riedl R., 2016, FUNDAMENTALS NEUROIS, DOI [10.1007/978-3-662-450 91-8, DOI 10.1007/978-3-662-45091-8, 10.1007/978-3-662-45091-8]; Riedl R, 2010, COMMUN ASSOC INF SYS, V27, P243; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Schestatsky P, 2013, JOVE-J VIS EXP, DOI 10.3791/50426; Sela T, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00022; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Tremblay S, 2014, BRAIN STIMUL, V7, P773, DOI 10.1016/j.brs.2014.10.003; Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926; Weierich MR, 2010, NEUROIMAGE, V49, P2871, DOI 10.1016/j.neuroimage.2009.09.047; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; Wrobel A, 2000, ACTA NEUROBIOL EXP, V60, P247	57	5	6	3	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2018	13	7							e0201128	10.1371/journal.pone.0201128	http://dx.doi.org/10.1371/journal.pone.0201128			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO4DQ	30048490	gold, Green Published, Green Submitted			2023-01-03	WOS:000439952400052
J	Kim, YR; Lee, B; Byun, MR; Lee, JK; Choi, JW				Kim, Yi Rang; Lee, Bada; Byun, Mi Ran; Lee, Jong Kil; Choi, Jin Woo			Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; NECK CANCERS; PLUS GEMCITABINE; METASTATIC HEAD; CLINICAL-TRIAL; MESSENGER-RNA; PHASE-II; RECURRENT; CISPLATIN; CETUXIMAB	Although human papillomavirus (HPV) positive oral and oropharyngeal cancers have distinct epidemiologic and molecular characteristics compared to HPV-negative cancers, all patients with oral and oropharyngeal cancers received same standard regimen regardless of HPV status. For these reasons, specific regimens for patients with HPV-positive oral and oropharyngeal cancer are needed. Differentially expressed genes (DEG) between HPV-positive and HPV-negative oropharyngeal cancers were re-analyzed and categorized from public database. Then, druggable targets to HPV-positive oral and oropharyngeal cancer were identified and were validated with E6/E7, which is oncogene of HPV, transfected oral and oropharyngeal cancer cell lines and HPV infected cell lines. In DEG analysis, HPV-positive oral and oropharyngeal cancer showed distinct disease entity from HPV-negative cancers. Unlike HPV-negative oral and oropharyngeal cancer, thymidylate synthase (TS) and topoisomerase II (Topo II) were overexpressed in HPV-positive cancers. Transfection of Lenti-virus containing E6/E7 to HPV-negative oral and oropharyngeal cancer cells induced upregulation of TS and Topo II in those cells. Although cisplatin, which is standard regimen in head and neck cancers, showed more effectiveness in HPV-negative cells, 5-FU and pemetrexed, which are TS inhibitors, or etoposide, which is Topo II inhibitors, worked more effectively in HPV-positive cells. In addition, cisplatin/etoposide and cisplatin/pemetrexed combination regimens showed synergic effects in HPV-positive cells. Pemetrexed or etoposide alone, or in combination with other chemotherapeutic agents such as cisplatin, can be used as novel substitutes in a regimen of concurrent chemoradiotherapy or a palliative regimen for HPV-positive oral and oropharyngeal cancer patients. However, a well-designed clinical trial is needed.	[Kim, Yi Rang] Yuseong Sun Hosp, Dept Hematooncol, Daejeon, South Korea; [Lee, Bada; Byun, Mi Ran; Lee, Jong Kil; Choi, Jin Woo] Kyung Hee Univ, Coll Pharm, Dept Pharmacol, Seoul, South Korea; [Lee, Bada; Byun, Mi Ran; Choi, Jin Woo] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea	Kyung Hee University; Kyung Hee University	Choi, JW (corresponding author), Kyung Hee Univ, Coll Pharm, Dept Pharmacol, Seoul, South Korea.; Choi, JW (corresponding author), Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea.	jinwoo.ch@khu.ac.kr	Lee, Jong Kil/AAK-8231-2020	Choi, Jin Woo/0000-0003-1177-598X	National Research Foundation of Korea [2014R1A1A1002431, NRF-2014R1A1A1002431, NRF-2016R1D1A1B03930490]	National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by grants from National Research Foundation of Korea (2014R1A1A1002431, NRF-2014R1A1A1002431, and NRF-2016R1D1A1B03930490). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelstein D, 2017, J NATL COMPR CANC NE, V15, P761, DOI 10.6004/jnccn.2017.0101; Argiris A, 2011, J CLIN ONCOL, V29, P1140, DOI 10.1200/JCO.2010.33.3591; Baldwin E. L., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P363, DOI 10.2174/1568011054222364; Broglie MA, 2017, IMPACT HUMAN PAPILLO; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chi AC, 2015, CA-CANCER J CLIN, V65, P401, DOI 10.3322/caac.21293; Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9; Dayyani F, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-15; DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Fury MG, 2011, CANCER-AM CANCER SOC, V117, P795, DOI 10.1002/cncr.25464; Gedlicka C, 2006, CANCER INVEST, V24, P252, DOI 10.1080/07357900600633734; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gondivkar SM, 2012, ORAL ONCOL, V48, P195, DOI 10.1016/j.oraloncology.2011.10.007; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Ijuin T, 2007, ACTA OTO-LARYNGOL, V127, P305, DOI 10.1080/00016480600801381; KISH J, 1982, CANCER TREAT REP, V66, P471; Malhotra B, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00362; Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001; Marur S, 2017, J CLIN ONCOL, V35, P490, DOI 10.1200/JCO.2016.68.3300; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1; O'Sullivan B, 2016, LANCET ONCOL, V17, P440, DOI 10.1016/S1470-2045(15)00560-4; Osoba D, 1992, SEMINARS ONCOLOGY; Pivot X, 2001, BRIT J CANCER, V85, P649, DOI 10.1054/bjoc.2001.2010; Pytynia KB, 2014, ORAL ONCOL, V50, P380, DOI 10.1016/j.oraloncology.2013.12.019; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sturgis EM, 2011, J NATL COMPR CANC NE, V9, P665, DOI 10.6004/jnccn.2011.0055; Tao YG, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-40; Urba S, 2012, CANCER-AM CANCER SOC, V118, P4694, DOI 10.1002/cncr.27449; Vermorken JB, 2013, EUR J CANCER, V49, P2877, DOI 10.1016/j.ejca.2013.05.002; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Wiest T, 2002, ONCOGENE, V21, P1510, DOI 10.1038/sj.onc.1205214; Wyss A, 2013, AM J EPIDEMIOL, V178, P679, DOI 10.1093/aje/kwt029	39	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2018	13	7							e0200509	10.1371/journal.pone.0200509	http://dx.doi.org/10.1371/journal.pone.0200509			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM7QQ	29995943	Green Published, Green Submitted, gold			2023-01-03	WOS:000438388800077
J	Cavalcante, DDB; Brizon, VSC; Probst, LF; Meneghim, MD; Pereira, AC; Ambrosano, GMB				Barros Cavalcante, Denise De Fatima; Candido Brizon, Valeria Silva; Probst, Livia Fernandes; Meneghim, Marcelo de Castro; Pereira, Antonio Carlos; Bovi Ambrosano, Glaucia Maria			Did the Family Health Strategy have an impact on indicators of hospitalizations for stroke and heart failure? Longitudinal study in Brazil: 1998-2013	PLOS ONE			English	Article							CARE-SENSITIVE HOSPITALIZATIONS; AVOIDABLE HOSPITALIZATION; CARDIOVASCULAR-DISEASE; MORTALITY; INEQUALITIES; BURDEN; TRENDS; RATES	Introduction The objective was to analyze whether socioeconomic factors related to the context and those related to the model of care - specifically the coverage of primary care by the Family Health Strategy (ESF) - had an impact on hospitalizations due to heart failure (HF) and stroke, in the State of Sao Paulo/Brazil between 1998 and 2013. Methods A longitudinal ecological study involving 645 municipalities was conducted in the state of Sao Paulo/Brazil from 1998 to 2013, using the Hospital Information System (SIH - DataSUS database). The hospitalizations for primary care sensitive conditions: Stroke and heart failure (HF) that correspond to the International Classification of Diseases (ICD 10): I50, I63 to I67; I69, G45 to G46 were analyzed longitudinally during the period indicated regarding the percentage of people covered by the Family Health Program (PSF) adjusted for confounders (population size, gross domestic product -GDP and human development index-HDI). Results There was a significant decrease in the number of hospitalizations for heart failure and stroke per 10000 (inhabitants) in the period (p < 0.0001), with a significant relationship with increased proportion of ESF (p < 0.0001), and this remained significant even when possible confounders (population size, GDP and HDI) were included in the model (p < 0.0001). Conclusions GDP per capita was close to or higher than that if many European countries, which shows the relevance of the study. The health care model based on the Family Health Strategy positively impacted hospitalization indicators for heart failure and stroke, indicating that this model is effective in the prevention of primary care sensitive conditions.	[Barros Cavalcante, Denise De Fatima; Candido Brizon, Valeria Silva; Probst, Livia Fernandes; Meneghim, Marcelo de Castro; Pereira, Antonio Carlos; Bovi Ambrosano, Glaucia Maria] Univ Estadual Campinas, UNICAMP, Piracicaba Dent Sch, Dept Community Dent, Piracicaba, SP, Brazil	Universidade Estadual de Campinas	Brizon, VSC (corresponding author), Univ Estadual Campinas, UNICAMP, Piracicaba Dent Sch, Dept Community Dent, Piracicaba, SP, Brazil.	dradenisecavalcante@gmail.com	Probst, Livia Fernandes/B-3475-2016	Probst, Livia Fernandes/0000-0002-4696-0862; Ambrosano, Glaucia Maria Bovi/0000-0001-5950-6370; Pereira, Antonio Carlos/0000-0003-1703-8171; Barros Cavalcante, Denise de Fatima/0000-0002-9166-0367				Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Alfradique ME, 2009, CAD SAUDE PUBLICA, V25, P1337, DOI 10.1590/S0102-311X2009000600016; Asaria P, 2012, INT J EPIDEMIOL, V41, P1737, DOI 10.1093/ije/dys151; Batista SRR, REV SAUDE PUBLICA, V46, P34; Boing AF, 2012, REV SAUDE PUBL, V46, P359, DOI 10.1590/S0034-89102012005000011; Bonita R., 2006, BASIC EPIDEMIOLOGY, V2nd ed.; BRASIL. Ministerio da SaUde, 2011, PLAN AC ESTR ENTR DO; Cabral Norberto L, 2012, Am J Public Health, V102, pe90, DOI 10.2105/AJPH.2012.301024; Caminal J, 2004, EUROPEAN J PUBLIC HL, V14; Chaix B, 2012, INT J EPIDEMIOL, V41, P1283, DOI 10.1093/ije/dyr107; Galil AGD, 2016, INT J CARDIOL, V221, P1004, DOI 10.1016/j.ijcard.2016.07.041; Freund T, 2014, Z EVIDENZ FORTBILD Q, V108, P251, DOI 10.1016/j.zefq.2014.05.001; Gaziano TA, 2007, HEALTH AFFAIR, V26, P13, DOI 10.1377/hlthaff.26.1.13; Gibson OR, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-336; Hogerzeil H, 2011, WORLD MED SITUATION, V3; Hone T, 2017, HEALTH AFFAIR, V36, P149, DOI 10.1377/hlthaff.2016.0966; Lentsck Maicon Henrique, 2015, Rev. bras. epidemiol., V18, P372, DOI 10.1590/1980-5497201500020007; Macinko J, 2006, J EPIDEMIOL COMMUN H, V60, P13, DOI 10.1136/jech.2005.038323; Macinko J, 2011, AM J PUBLIC HEALTH, V101, P1963, DOI 10.2105/AJPH.2010.198887; Malta DC, 2014, EPIDEMIOL SERV SAUDE, V23, P753, DOI [10.5123/S1679-49742014000300002, 10.5123/S1679-49742014000400017, 10.5123/S1679-49742014000400002]; Malta DC, 2013, EPIDEMIOL SERV SAUDE, V22, P151, DOI 10.5123/S1679-49742013000100016; Ministe A rio da SauAde, 1998, PORT GM 3 916 30 OUT; Ministe A rio da SauAde, DAD COB PROGR SAUD F; Ministerio da Saude, 2014, POL NAC CONTR TAB RE; Niti M, 2003, J EPIDEMIOL COMMUN H, V57, P17, DOI 10.1136/jech.57.1.17; Organizacai Mundial de Saude, CALSS EST INT DOENC; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Portes LH, 2015, REV PANAM SALUD PUBL, V38, P370; Purdy S, 2009, PUBLIC HEALTH, V123, P169, DOI 10.1016/j.puhe.2008.11.001; Rasella D, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4014; Rosano A, 2013, EUR J PUBLIC HEALTH, V23, P356, DOI 10.1093/eurpub/cks053; SAS, 1999, SAS SOFTW VERS 9 1; Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; Schmittdiel JA, 2006, ANN FAMILY MED, V4; Schramm Joyce Mendes de Andrade, 2004, Ciênc. saúde coletiva, V9, P897, DOI 10.1590/S1413-81232004000400011; Paniz VMV, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00009915; WHO, 2008, PREV CHRON DIS VIT I	37	11	12	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2018	13	6							e0198428	10.1371/journal.pone.0198428	http://dx.doi.org/10.1371/journal.pone.0198428			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK7JR	29944665	gold, Green Published, Green Submitted			2023-01-03	WOS:000436377800008
J	Finato, AC; Frage-Silva, TF; Prati, AUC; de Souza, AA; Mazzeu, BF; Felippe, LG; Pinto, RA; Golim, MD; Arruda, MSP; Furlan, M; Venturini, J				Finato, Angela Carolina; Frage-Silva, Thais Fernanda; Carvalho Prati, Amanda Uliana; de Souza Junior, Amauri Alves; Mazzeu, Bruna Fonseca; Felippe, Lidiane Gaspareto; Pinto, Rute Alves; Golim, Marjorie de Assis; Parreira Arruda, Maria Sueli; Furlan, Maysa; Venturini, James			Crude leaf extracts of Piperaceae species downmodulate inflammatory responses by human monocytes	PLOS ONE			English	Article							NF-KAPPA-B; TRYPANOCIDAL TETRAHYDROFURAN LIGNANS; ABSOLUTE-CONFIGURATION; IN-VITRO; NEONATAL SEPSIS; TUBERCULATUM; ARBOREUM; DERIVATIVES; ACTIVATION; BIOMARKERS	In this study, we aimed to evaluate the immunomodulatory effects of crude leaf extracts from Piper gaudichaudianum Kunth, P. arboreum Aub., P. umbellata L., P. fuligineum Kunth, and Peperomia obtusifolia A. Dietr. on an in vitro model of inflammatory response. The crude extracts were previously obtained by maceration of the leaves. The half-maximal inhibitory concentration was determined by the MTT assay using human peripheral blood mononuclear cells. Human monocytes were simultaneously challenged with each crude extract and lipopolysaccharide (LPS), the major component of the outer membrane of Gram-negative bacteria, to induce a strong inflammatory response. After 24 h of incubation, cell-free supernatants were used for evaluating the mediators involved in inflammation: H2O2, TNF-alpha, IL-8, IL-6, IL-1 beta, IL-10, IL-12, FGF-b, and TGF-beta 1. We also compared the results with the effects of ketoprofen, a well-known anti-inflammatory drug. The P. gaudichaudianum crude extract downmodulated the production of H2O2, IL-1 beta, IL-6, IL-8, and TGF-beta 1 by LPS-stimulated monocytes; P. arboreum, IL-1 beta, IL-6, IL-8, and TNF-alpha; P. umbellata and P. fuligineum, H2O2, IL-1 beta, IL-6, IL-8, IL-10, and TNF-alpha; and P. obtusifolia, H2O2, IL-6, IL-8, IL-10, and TNF-alpha. In general, the crude leaf extracts amplified the anti-inflammatory response when compared with ketoprofen, particularly reducing the production of IL-8, a mediator involved in neutrophil recruitment during tissue damage. Thus, the crude leaf extracts of P. gaudichaudianum, P. arboreum, P. umbellata, P. fuligineum, and Peperomia obtusifolia elicited an anti-inflammatory response against LPS-challenged monocytes. These findings show the anti-inflammatory properties of these crude leaf extracts and offer new perspectives for their use in the treatment of inflammatory diseases.	[Finato, Angela Carolina; Frage-Silva, Thais Fernanda; Parreira Arruda, Maria Sueli; Venturini, James] Univ Estadual Paulista Unesp, Fac Ciencias, Bauru, SP, Brazil; [Frage-Silva, Thais Fernanda] Univ Estadual Paulista Unesp, Inst Biociencias, Bauru, SP, Brazil; [Carvalho Prati, Amanda Uliana; de Souza Junior, Amauri Alves; Mazzeu, Bruna Fonseca; Felippe, Lidiane Gaspareto; Pinto, Rute Alves; Furlan, Maysa] Univ Estadual Paulista Unesp, Inst Quim, Araraquara, SP, Brazil; [Golim, Marjorie de Assis] Univ Estadual Paulista Unesp, Fac Med, Botucatu, SP, Brazil; [Venturini, James] Univ Fed Mato Grosso Sul UFMS, Fac Med, Campo Grande, MS, Brazil	Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Federal de Mato Grosso do Sul	Venturini, J (corresponding author), Univ Estadual Paulista Unesp, Fac Ciencias, Bauru, SP, Brazil.; Venturini, J (corresponding author), Univ Fed Mato Grosso Sul UFMS, Fac Med, Campo Grande, MS, Brazil.	james.venturini@ufms.br	Furlan, Maysa/H-9798-2013; Felippe, Lidiane/ABH-2812-2021; Fraga-Silva, Thais Fernanda de Campos/D-3962-2016; Venturini, James/AAM-4486-2021; Fapesp, Biota/F-8655-2017	Furlan, Maysa/0000-0002-8434-5238; Fraga-Silva, Thais Fernanda de Campos/0000-0002-2053-8938; Fapesp, Biota/0000-0002-9887-8449; Felippe, Lidiane Gaspareto/0000-0003-3797-3677; de Assis Golim, Marjorie/0000-0002-4824-9441	Fundacao de Apoio a Pesquisa do Estado de Sao Paulo - FAPESP [2016/17627-4]	Fundacao de Apoio a Pesquisa do Estado de Sao Paulo - FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by the Fundacao de Apoio a Pesquisa do Estado de Sao Paulo - FAPESP provided financial support, Grant 2016/17627-4 (http://www.bv.fapesp.br/pt/auxilios/95690/potencial-imunomodulador-de-substancias-bioativas-vegetais-na-ativacao-do-inflamassoma-e-na-polariza/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas A.K., 2014, CELLULAR MOL IMMUNOL; Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; Anstead GM, 2003, J LEUKOCYTE BIOL, V74, P982, DOI 10.1189/jlb.0203064; Arrigoni-Blank MD, 2004, J ETHNOPHARMACOL, V91, P215, DOI 10.1016/j.jep.2003.12.030; Astiz M, 1996, J LAB CLIN MED, V128, P594, DOI 10.1016/S0022-2143(96)90132-8; Batista JM, 2012, TETRAHEDRON LETT, V53, P6051, DOI 10.1016/j.tetlet.2012.08.113; Batista JM, 2011, J NAT PROD, V74, P1154, DOI 10.1021/np200085h; Batista JM, 2011, J ORG CHEM, V76, P2603, DOI 10.1021/jo1025089; Batista JM, 2008, BIOL PHARM BULL, V31, P538, DOI 10.1248/bpb.31.538; Benevides PJC, 1999, PHYTOCHEMISTRY, V52, P339, DOI 10.1016/S0031-9422(99)00177-6; Brennan FM, 1998, SPRINGER SEMIN IMMUN, V20, P133, DOI 10.1007/BF00832003; Campos DP, 2010, J PEDIAT-BRAZIL, V86, P509, DOI [10.1590/S0021-75572010000600011, 10.2223/JPED.2043]; Carleo A, 2016, CURR OPIN PULM MED, V22, P509, DOI 10.1097/MCP.0000000000000306; Chen YL, 2017, IMMUNOL LETT, V186, P52, DOI 10.1016/j.imlet.2017.04.003; da Silva RV, 2002, PHYTOCHEMISTRY, V59, P521, DOI 10.1016/S0031-9422(01)00431-9; De Figueiredo RA, 2000, ANN BOT-LONDON, V85, P455, DOI 10.1006/anbo.1999.1087; Navickiene HMD, 2006, QUIM NOVA, V29, P467, DOI 10.1590/S0100-40422006000300012; Di Stasi L.C., 2002, PLANTAS MED AMAZONIA; Ee GCL, 2009, NAT PROD RES, V23, P1416, DOI 10.1080/14786410902757998; Felipe FCB, 2007, PHYTOMEDICINE, V14, P605, DOI 10.1016/j.phymed.2006.12.015; Felippe LG, 2012, ORG BIOMOL CHEM, V10, P4208, DOI 10.1039/c2ob25109d; Felippe LG, 2011, PHYTOCHEM LETT, V4, P245, DOI 10.1016/j.phytol.2011.04.007; Felippe LG, 2008, PHYTOCHEMISTRY, V69, P445, DOI 10.1016/j.phytochem.2007.08.012; Ganguly S, 2007, J PHARM PHARMACOL, V59, P711, DOI 10.1211/jpp.59.5.0012; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hamdani D. A., 2014, African Journal of Pharmacy and Pharmacology, V8, P386; Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003; Holanda BBC, 2017, THERMOCHIM ACTA, V647, P47, DOI 10.1016/j.tca.2016.11.007; Jaramillo MA, 2004, INT J PLANT SCI, V165, P403, DOI 10.1086/382803; Jardim ACG, 2015, ANTIVIR RES, V115, P39, DOI 10.1016/j.antiviral.2014.12.018; Kato MJ, 2007, PURE APPL CHEM, V79, P529, DOI 10.1351/pac200779040529; KIJJOA A, 1980, PLANTA MED, V39, P85, DOI 10.1055/s-2008-1074908; Lago JHG, 2004, J NAT PROD, V67, P1783, DOI 10.1021/np030530j; Ley B, 2014, AM J PHYSIOL-LUNG C, V307, pL681, DOI 10.1152/ajplung.00014.2014; Lopera D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001232; Martins RCC, 2003, PHYTOCHEMISTRY, V64, P667, DOI 10.1016/S0031-9422(03)00356-X; Marques LMM, 2014, J PHARMACEUT BIOMED, V95, P113, DOI 10.1016/j.jpba.2014.02.020; MEADOW W, 1995, CLIN PERINATOL, V22, P519; Meng XM, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00082; Miranda JE, 2003, APIDOLOGIE, V34, P409, DOI 10.1051/apido:2003036; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mota JD, 2009, PLANTA MED, V75, P620, DOI 10.1055/s-0029-1185364; Muroi M, 2002, INFECT IMMUN, V70, P6043, DOI 10.1128/IAI.70.11.6043-6047.2002; Navickiene HMD, 2007, PEST MANAG SCI, V63, P399, DOI 10.1002/ps.1340; Neovius M, 2015, ANN RHEUM DIS, V74, P354, DOI 10.1136/annrheumdis-2013-204128; Pejin B, 2014, NAT PROD RES, V28, P2053, DOI 10.1080/14786419.2014.921686; Perazzo FF, 2005, J ETHNOPHARMACOL, V99, P215, DOI 10.1016/j.jep.2005.02.023; Quijano-Abril MA, 2006, J BIOGEOGR, V33, P1266, DOI 10.1111/j.1365-2699.2006.01501.x; Regasini LO, 2008, LAT AM J PHARM, V27, P900; Regasini LO, 2009, REV BRAS FARMACOGN, V19, P199, DOI 10.1590/S0102-695X2009000200003; Regasini LO, 2009, AFR J BIOTECHNOL, V8, P2866; RUSSO M, 1989, BRAZ J MED BIOL RES, V22, P1271; Samain MS, 2010, ANN BOT-LONDON, V105, P677, DOI 10.1093/aob/mcq031; Schildberger A, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/697972; SHIMIZU M, 1994, BIOL PHARM BULL, V17, P665; Silveira RC, 1999, ACTA PAEDIATR, V88, P647, DOI 10.1080/08035259950169314; Srirangan S, 2010, THER ADV MUSCULOSKEL, V2, P247, DOI 10.1177/1759720X10378372; Stidham RW, 2014, ALIMENT PHARM THER, V39, P1349, DOI 10.1111/apt.12749; Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052; Vukovac EL, 2014, MED SCI MONITOR, V20, P255, DOI 10.12659/MSM.889800; Wanke S, 2006, PLANT BIOLOGY, V8, P93, DOI 10.1055/s-2005-873060; Wei Lee Seong, 2011, Acta Med Iran, V49, P670; Wu D, 2002, PHYTOMEDICINE, V9, P41, DOI 10.1078/0944-7113-00068; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yuncker T. G., 1973, PIPERACEAE BRAZIL; Yuncker TG, 1972, PIPERACEAE BRAZIL; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	69	5	5	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2018	13	6							e0198682	10.1371/journal.pone.0198682	http://dx.doi.org/10.1371/journal.pone.0198682			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ8QS	29924840	Green Published, gold, Green Submitted			2023-01-03	WOS:000435655600032
J	Lindtjorn, B; Mitike, D; Zidda, Z; Yaya, Y				Lindtjorn, Bernt; Mitike, Demissew; Zidda, Zillo; Yaya, Yaliso			Reducing stillbirths in Ethiopia: Results of an intervention programme	PLOS ONE			English	Article							SERVICE DELIVERY; RURAL ETHIOPIA; CHILD HEALTH; CARE; NEWBORN; TRENDS; MORTALITY; COVERAGE	Previous studies from South Ethiopia have shown that interventions that focus on intrapartum care substantially reduce maternal mortality and there is a need to operationalize health packages that could reduce stillbirths. The aim of this paper is to evaluate if a programme that aimed to improve maternal health, and mainly focusing on strengthening intrapartum care, also would reduce the number of stillbirths, and to estimate if there are other indicators that explains high stillbirth rates. Our study used a "continuum of care" approach and focussed on providing essential antenatal and obstetric services in communities through health extension workers, at antenatal and health facility services. In this follow up study, which includes the same 38.312 births registered by community health workers, shows that interventions focusing on improved intrapartum care can also reduce stillbirths (by 46%; from 14.5 to 7.8 per 1000 births). Other risk factors for stillbirths are mainly related to complications during delivery and illnesses during pregnancy. We show that focusing on Comprehensive Emergency Obstetric Care and antenatal services reduces stillbirths. However, the study also underlines that illnesses during pregnancy and complications during delivery still represent the main risk factors for stillbirths. This indicates that obstetric care need still to be strengthened, should include the continuum of care from home to the health facility, make care accessible to all, and reduce delays.	[Lindtjorn, Bernt; Yaya, Yaliso] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Mitike, Demissew] Gidole Hosp, Gidole, Ethiopia; [Zidda, Zillo] Arba Minch Hosp, Arba Minch, Ethiopia	University of Bergen	Lindtjorn, B (corresponding author), Univ Bergen, Ctr Int Hlth, Bergen, Norway.	bernt.lindtjorn@uib.no	Lindtjorn, Bernt/K-9465-2018	Lindtjorn, Bernt/0000-0002-6267-6984	Regional office of the Ministry of Health; Zonal office of the Ministry of Health; University of Bergen in Norway; Norwegian Lutheran Mission in Norway	Regional office of the Ministry of Health; Zonal office of the Ministry of Health; University of Bergen in Norway; Norwegian Lutheran Mission in Norway	We would like to thank the staff at each of the health institution, as well as the health extension workers, for taking part in this work. The authorities in the districts are also thanked. We are also grateful to for the support from the Regional and Zonal offices of the Ministry of Health.; The main funding came through the University of Bergen in Norway, and through the Norwegian Lutheran Mission in Norway. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2003, SURG CAR DISTR HOSP; Atnafu H, 2016, INT J WOMENS HEALTH, V8, P421, DOI 10.2147/IJWH.S104160; Ballard K, 2016, INT J GYNECOL OBSTET, V133, P164, DOI 10.1016/j.ijgo.2015.09.027; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P29, DOI 10.4314/ejhs.v24i0.4S; Berhie Kidanemariam Alem, 2016, Matern Health Neonatol Perinatol, V2, P10, DOI 10.1186/s40748-016-0038-5; Bhutta ZA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002364; Boerma JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; Campbell OMR, 2016, LANCET, V388, P2193, DOI 10.1016/S0140-6736(16)31528-8; Cousens S, 2011, LANCET, V377, P1319, DOI 10.1016/S0140-6736(10)62310-0; Engmann C, 2012, J PERINATOL, V32, P585, DOI 10.1038/jp.2011.154; Flenady V, 2017, SEMIN FETAL NEONAT M, V22, P176, DOI 10.1016/j.siny.2017.02.009; Freedman LP, 2007, LANCET, V370, P1383, DOI 10.1016/S0140-6736(07)61581-5; Gaym Asheber, 2012, Ethiop Med J, V50, P209; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Lindtjorn B. Project, 2008, RMM PROJ DOC RED MAT; Lindtjorn B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169304; Liu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168743; Otolorin E, 2015, INT J GYNECOL OBSTET, V130, pS46, DOI 10.1016/j.ijgo.2015.03.007; Reinebrant HE, 2018, BJOG-INT J OBSTET GY, V125, P212, DOI 10.1111/1471-0528.14971; Sisay MM, 2014, J MIDWIFERY WOM HEAL, V59, pS110, DOI 10.1111/jmwh.12156; UNICEF, 2013, ETH FAR REACH HLTH W; Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; WHO, 2022, WHO RECOMMENDATIONS; World Health Organization, 2017, STILLB; World Health Organization (WHO); UNFPA; UNICEF; Columbia University. Mailman School of Public Health, 2009, MON EM OBST CAR HDB; Yaya Y., 2015, MATERNAL NEONATAL MO; Yaya Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119321; Yaya Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096294	29	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2018	13	5							e0197708	10.1371/journal.pone.0197708	http://dx.doi.org/10.1371/journal.pone.0197708			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH7NG	29847607	Green Published, Green Submitted, gold			2023-01-03	WOS:000433634800039
J	Bagenal, J; Roche, N; Ross, G; Kirby, A; Dodwell, D				Bagenal, Jessamy; Roche, Nicola; Ross, Gill; Kirby, Anna; Dodwell, David			Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bagenal, Jessamy; Roche, Nicola; Ross, Gill; Kirby, Anna] Royal Marsden Hosp, London, England; [Dodwell, David] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England	Royal Marsden NHS Foundation Trust; University of Oxford	Bagenal, J (corresponding author), Royal Marsden Hosp, London, England.	jessamy.bagenal@googlemail.com							0	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2018	361								k1410	10.1136/bmj.k1410	http://dx.doi.org/10.1136/bmj.k1410			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG6IZ	29773535	Green Submitted			2023-01-03	WOS:000432801100002
J	Berg, L; Brannstrom, L				Berg, Lisa; Brannstrom, Lars			Evicted children and subsequent placement in out-of-home care: A cohort study	PLOS ONE			English	Article							FAMILY STRESS MODEL; FOSTER-CARE; FINANCIAL CRISIS; PUBLIC CARE; HEALTH; RISK; MALTREATMENT; FORECLOSURE; INVOLVEMENT; EVICTIONS	Background Evictions may have serious consequences for individuals' health and wellbeing. Even though an eviction may be experienced as a significant crisis for the family, there is little previous knowledge on consequences for evicted children. This study represents the first attempt to examine to what extent children from evicted households were separated from their parents and placed in out-of-home care (foster family or residential care) using population-based data, net of observed confounding factors related to the socioeconomic and psychosocial circumstances of their parents. Methods This study takes advantage of information from a Swedish national database, consisting of about 8 000 evicted individuals and a random sample of 770 000 individuals from the national population, linked to individual-level, longitudinal data from Swedish national registers. Our analytical sample consists of information for more than 250 000 children born in 1995-2008, including 2 224 children from evicted households. We used binary logistic regression based on the Karlson/Holm/Breen method to account for observed imbalances at baseline between evicted and non-evicted children. Results Compared to non-evicted children, the crude odds ratio for placement in out-of-home care in evicted children was 12.10 (95% CI 8.54-17.14). Net of observed confounding factors related to the socioeconomic and psychosocial circumstances of the parents, evicted children had a twofold elevated risk of being placed in out-of-home care (odds ratio 2.26, 95% CI 1.55-3.27). Crude OR for evicted children in comparison with children under threat of eviction (eviction not formally executed) was 1.71 (95% CI 1.17-2.49) and adjusted OR 1.58 (95% CI 1.06-2.35). Conclusion Children who experience eviction constitute a disadvantaged group and are at significant risk of being separated from their parents and placed in out-of-home care. These results demonstrate the importance of providing support for these children and their parents. Strategies to prevent households with children from being evicted seem to be an important and viable intervention path.	[Berg, Lisa] Stockholm Univ, Dept Publ Hlth Sci, Ctr Hlth Equ Studies, Stockholm, Sweden; [Berg, Lisa] Stockholm Univ, Swedish Inst Social Res, Stockholm, Sweden; [Brannstrom, Lars] Stockholm Univ, Dept Social Work, Stockholm, Sweden	Stockholm University; Stockholm University; Stockholm University	Berg, L (corresponding author), Stockholm Univ, Dept Publ Hlth Sci, Ctr Hlth Equ Studies, Stockholm, Sweden.; Berg, L (corresponding author), Stockholm Univ, Swedish Inst Social Res, Stockholm, Sweden.	lisa.berg@su.se		Berg, Lisa/0000-0002-8707-180X	Swedish Research Council for Health, Working Life and Welfare [2013-0452]	Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte))	This work was supported by the Swedish Research Council for Health, Working Life and Welfare, grant number 2013-0452, http://forte.se/en/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen SH, 2014, SOC FORCES, V93, P269, DOI 10.1093/sf/sou027; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2014, THESIS; Berger LM, 2015, PEDIATRICS, V136, P299, DOI 10.1542/peds.2014-2832; Bergstrom M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-868; Brannstrom L, 2017, CHILD MALTREATMENT, V22, P205, DOI 10.1177/1077559517701855; Caliendo M, 2017, LABOUR ECON, V46, P14, DOI 10.1016/j.labeco.2017.02.001; Cameron CA, 2011, HDB EMPIRICAL EC FIN, P1; Conger RD, 2010, J MARRIAGE FAM, V72, P685, DOI 10.1111/j.1741-3737.2010.00725.x; Coulton CJ, 1999, CHILD ABUSE NEGLECT, V23, P1019, DOI 10.1016/S0145-2134(99)00076-9; Coulton CJ, 2007, CHILD ABUSE NEGLECT, V31, P1117, DOI 10.1016/j.chiabu.2007.03.023; Cowal K, 2002, AM J COMMUN PSYCHOL, V30, P711, DOI 10.1023/A:1016325332527; Crane M, 2000, HOUSING STUD, V15, P757, DOI 10.1080/02673030050134592; Culhane JF, 2003, J SOCIOLOGY SOCIAL W, V30; Cummings P, 2009, ARCH PEDIAT ADOL MED, V163, P438, DOI 10.1001/archpediatrics.2009.31; Desmond M, 2016, URBAN AFF REV, V52, P421, DOI 10.1177/1078087415589192; Desmond M, 2016, SOC PROBL, V63, P46, DOI 10.1093/socpro/spv025; Desmond M, 2015, SOC FORCES, V94, P295, DOI 10.1093/sf/sov044; Desmond M, 2012, AM J SOCIOL, V118, P88, DOI 10.1086/666082; Eisenstein Qvarfordt, 2016, THESIS; Fernandez E., 2010, DOES FOSTER CARE WOR; Fowler KA, 2015, AM J PUBLIC HEALTH, V105, P311, DOI 10.2105/AJPH.2014.301945; Fowler PJ, 2013, AM J COMMUN PSYCHOL, V52, P106, DOI 10.1007/s10464-013-9580-8; Fox O'Mahony L., 2006, CONCEPTUALISING HOME; Fransson E, 2016, SCAND J PUBLIC HEALT, V44, P177, DOI 10.1177/1403494815614463; Franzen E, 2008, BRIT J SOC WORK, V38, P1043, DOI 10.1093/bjsw/bcl380; Hartman C, 2003, HOUS POLICY DEBATE, V14, P461; Hertzman C., 2010, CHAOS ITS INFLUENCE; Kaariala A, 2017, CHILD YOUTH SERV REV, V79, P107, DOI 10.1016/j.childyouth.2017.05.030; Karlson KB, 2012, SOCIOL METHODOL, V42, P286, DOI 10.1177/0081175012444861; Kenna P, 2016, PILOT PROJECT PROMOT; Kling S, 2016, ACTA PAEDIATR, V105, P416, DOI 10.1111/apa.13304; Kohler M, 2015, ACTA PAEDIATR, V104, P508, DOI 10.1111/apa.12901; Kohler U, 2011, STATA J, V11, P420, DOI 10.1177/1536867X1101100306; Kronofogdemyndigheten [Swedish Enforment Agency], 2015, AVHYSN 1982 2015; McLaughlin KA, 2012, PSYCHOL MED, V42, P1441, DOI 10.1017/S0033291711002613; Molnar BE, 2016, CHILD ABUSE NEGLECT, V51, P41, DOI 10.1016/j.chiabu.2015.11.007; Neppl TK, 2016, J FAM PSYCHOL, V30, P12, DOI 10.1037/fam0000168; Nilsson A, 2004, EKONOMISKT UTSATTA B, V2004, P41; Nilsson A, 2004, MARGINALISERINGSPROC, V1, P14; Park JM, 2004, CHILD WELFARE, V83, P423; Pollack CE, 2009, AM J PUBLIC HEALTH, V99, P1833, DOI 10.2105/AJPH.2009.161380; Rodriguez JM, 2016, CHILD ABUSE NEGLECT, V57, P41, DOI 10.1016/j.chiabu.2016.06.004; Rojas Y, 2016, J EPIDEMIOL COMMUN H, V70, P409, DOI 10.1136/jech-2015-206419; Rosenberg R, 2018, J PUBLIC CHILD WELF, V12, P99, DOI 10.1080/15548732.2017.1347551; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; Shuey EA, 2017, CHILD YOUTH SERV REV, V72, P52, DOI 10.1016/j.childyouth.2016.09.031; Simkiss DE, 2013, CHILD CARE HLTH DEV, V39, P628, DOI 10.1111/cch.12010; Stenberg S, 2011, VARFOR VRAKS BARN FO; Swann CA, 2006, DEMOGRAPHY, V43, P309, DOI 10.1353/dem.2006.0019; Tsai AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123182; Turney K, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1118; van Laere IR, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-3; Vasquez-Vera H, 2017, SOC SCI MED, V175, P199, DOI 10.1016/j.socscimed.2017.01.010; Viner RM, 2005, PEDIATRICS, V115, P894, DOI 10.1542/peds.2004-1311; von Otter C., 2017, EUROPEAN J HOMELESSN, V11, P1; Wallgren A, 2007, ADM DATA STAT PURPOS; Warren EJ, 2015, SOC SERV REV, V89, P9, DOI 10.1086/680043; Zlotnick C, 1998, AM J PUBLIC HEALTH, V88, P1368, DOI 10.2105/AJPH.88.9.1368; Zlotnick C, 2003, ADDICT BEHAV, V28, P1373, DOI 10.1016/S0306-4603(02)00261-7	60	6	6	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2018	13	4							e0195295	10.1371/journal.pone.0195295	http://dx.doi.org/10.1371/journal.pone.0195295			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD1VU	29668737	gold, Green Submitted, Green Published			2023-01-03	WOS:000430290200038
J	Fenske, W; Refardt, J; Chifu, I; Schnyder, I; Winzeler, B; Drummond, J; Ribeiro-Oliveira, A; Drescher, T; Bilz, S; Vogt, DR; Malzahn, U; Kroiss, M; Christ, E; Henzen, C; Fischli, S; Tonjes, A; Mueller, B; Schopohl, J; Flitsch, J; Brabant, G; Fassnacht, M; Christ-Crain, M				Fenske, W.; Refardt, J.; Chifu, I.; Schnyder, I.; Winzeler, B.; Drummond, J.; Ribeiro-Oliveira, A., Jr.; Drescher, T.; Bilz, S.; Vogt, D. R.; Malzahn, U.; Kroiss, M.; Christ, E.; Henzen, C.; Fischli, S.; Toenjes, A.; Mueller, B.; Schopohl, J.; Flitsch, J.; Brabant, G.; Fassnacht, M.; Christ-Crain, M.			A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFERENTIAL-DIAGNOSIS; POLYURIA-POLYDIPSIA; VASOPRESSIN; WATER; PLASMA; DISORDERS; HYPONATREMIA; HOMEOSTASIS; SECRETION; URINE	BACKGROUND The indirect water-deprivation test is the current reference standard for the diagnosis of diabetes insipidus. However, it is technically cumbersome to administer, and the results are often inaccurate. The current study compared the indirect water-deprivation test with direct detection of plasma copeptin, a precursor-derived surrogate of arginine vasopressin. METHODS From 2013 to 2017, we recruited 156 patients with hypotonic polyuria at 11 medical centers to undergo both water-deprivation and hypertonic saline infusion tests. In the latter test, plasma copeptin was measured when the plasma sodium level had increased to at least 150 mmol per liter after infusion of hypertonic saline. The primary outcome was the overall diagnostic accuracy of each test as compared with the final reference diagnosis, which was determined on the basis of medical history, test results, and treatment response, with copeptin levels masked. RESULTS A total of 144 patients underwent both tests. The final diagnosis was primary polydipsia in 82 patients (57%), central diabetes insipidus in 59 (41%), and nephrogenic diabetes insipidus in 3 (2%). Overall, among the 141 patients included in the analysis, the indirect water-deprivation test determined the correct diagnosis in 108 patients (diagnostic accuracy, 76.6%; 95% confidence interval [CI], 68.9 to 83.2), and the hypertonic saline infusion test (with a copeptin cutoff level of >4.9 pmol per liter) determined the correct diagnosis in 136 patients (96.5%; 95% CI, 92.1 to 98.6; P<0.001). The indirect water-deprivation test correctly distinguished primary polydipsia from partial central diabetes insipidus in 77 of 105 patients (73.3%; 95% CI, 63.9 to 81.2), and the hypertonic saline infusion test distinguished between the two conditions in 99 of 104 patients (95.2%; 95% CI, 89.4 to 98.1; adjusted P<0.001). One serious adverse event (desmopressin-induced hyponatremia that resulted in hospitalization) occurred during the water-deprivation test. CONCLUSIONS The direct measurement of hypertonic saline-stimulated plasma copeptin had greater diagnostic accuracy than the water-deprivation test in patients with hypotonic polyuria. (Funded by the Swiss National Foundation and others; ClinicalTrials.gov number, NCT01940614.)	[Fenske, W.; Toenjes, A.] Univ Leipzig, Dept Endocrinol & Nephrol, Liebigstr 21, D-04103 Leipzig, Germany; [Fenske, W.] Univ Leipzig, Med Ctr, Integrated Res & Treatment Ctr Adipos Dis, Leipzig, Germany; [Chifu, I.; Kroiss, M.; Fassnacht, M.] Univ Wurzburg, Univ Hosp, Div Endocrinol & Diabet, Dept Internal Med 1, Wurzburg, Germany; [Malzahn, U.] Univ Hosp Wurzburg, Clin Trial Ctr, Wurzburg, Germany; [Fassnacht, M.] Univ Hosp Wurzburg, Cent Lab, Wurzburg, Germany; [Schopohl, J.] Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 4, Munich, Germany; [Flitsch, J.] Univ Hosp Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany; [Brabant, G.] Univ Hosp Lubeck, Expt & Clin Endocrinol, Lubeck, Germany; [Refardt, J.; Schnyder, I.; Winzeler, B.; Christ, E.; Christ-Crain, M.] Univ Basel, Clin Endocrinol Diabetol & Metab, Dept Clin Res, Basel, Switzerland; [Vogt, D. R.] Univ Basel, Clin Trial Unit, Dept Clin Res, Basel, Switzerland; Univ Hosp Basel, Basel, Switzerland; [Drescher, T.; Bilz, S.] Kantonsspital St Gallen, Dept Endocrinol, St Gallen, Switzerland; [Christ, E.] Inselspital Bern, Dept Endocrinol, Bern, Switzerland; [Henzen, C.; Fischli, S.] Luzerner Kantonsspital, Dept Endocrinol, Luzern, Switzerland; [Mueller, B.] Kantonsspital Aarau, Med Univ Clin, Div Endocrinol Diabetol & Metab, Aarau, Switzerland; [Drummond, J.; Ribeiro-Oliveira, A., Jr.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil; [Drummond, J.] Hermes Pardini Inst, Belo Horizonte, MG, Brazil	Leipzig University; Leipzig University; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Basel; University of Basel; University of Basel; Kantonsspital St. Gallen; University of Bern; University Hospital of Bern; Lucerne Cantonal Hospital; Kantonsspital Aarau AG (KSA); Universidade Federal de Minas Gerais	Christ-Crain, M (corresponding author), Univ Hosp Basel, Dept Endocrinol Diabet & Metab, Petersgraben 4, CH-4031 Basel, Switzerland.; Fenske, W (corresponding author), Univ Leipzig, Dept Endocrinol & Nephrol, Liebigstr 21, D-04103 Leipzig, Germany.	wiebkekristin.fenske@medizin.unileipzig.de; mirjam.christcrain@unibas.ch	Kroiss, Matthias/B-4785-2014; Kroiss, Matthias/AAF-1624-2019; Refardt, Julie/AAH-1889-2019; Vogt, Deborah/AAA-6583-2020; Fassnacht, Martin/N-9614-2019; Schopohl, Jochen/AAD-6184-2021; Mueller, Beat/G-2662-2012	Kroiss, Matthias/0000-0002-7628-3161; Kroiss, Matthias/0000-0002-7628-3161; Refardt, Julie/0000-0002-3040-4685; Vogt, Deborah/0000-0002-0668-5675; Fassnacht, Martin/0000-0001-6170-6398; Schopohl, Jochen/0000-0003-3591-3101; Christ-Crain, Mirjam/0000-0002-6336-0965	Swiss National Foundation [SNF-162608]; University Hospital Basel, Switzerland [SNF-162608]; Federal Ministry of Education and Research, Germany [01EO1501]; Deutsche Forschungsgemeinschaft, Germany [AOBJ: 624808]; Thermo Fisher Scientific	Swiss National Foundation(Swiss National Science Foundation (SNSF)); University Hospital Basel, Switzerland; Federal Ministry of Education and Research, Germany(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft, Germany(German Research Foundation (DFG)); Thermo Fisher Scientific	Supported by a grant (SNF-162608, to Dr. Christ-Crain) from the Swiss National Foundation and the University Hospital Basel, Switzerland, a grant (FKZ: 01EO1501, to Dr. Fenske) from the Federal Ministry of Education and Research, Germany, and a grant (AOBJ: 624808, to Dr. Fenske) from Deutsche Forschungsgemeinschaft, Germany. Laboratory measurement of copeptin was funded by Thermo Fisher Scientific.	ALEXANDER CS, 1959, J LAB CLIN MED, V54, P566; Balanescu S, 2011, J CLIN ENDOCR METAB, V96, P1046, DOI 10.1210/jc.2010-2499; BAYLIS PH, 1981, Q J MED, V50, P345; BLOCK LH, 1981, KLIN WOCHENSCHR, V59, P831, DOI 10.1007/BF01721052; Christ-Crain M, 2016, BEST PRACT RES CL EN, V30, P235, DOI 10.1016/j.beem.2016.02.003; Christ-Crain M, 2016, NAT REV ENDOCRINOL, V12, P168, DOI 10.1038/nrendo.2015.224; DASHE AM, 1963, JAMA-J AM MED ASSOC, V185, P699, DOI 10.1001/jama.1963.03060090031011; DEWARDENER HE, 1957, J PHYSIOL-LONDON, V139, P42, DOI 10.1113/jphysiol.1957.sp005873; EPSTEIN FH, 1957, J CLIN INVEST, V36, P629, DOI 10.1172/JCI103462; Fenske W, 2012, J CLIN ENDOCR METAB, V97, P3426, DOI 10.1210/jc.2012-1981; Fenske W, 2011, J CLIN ENDOCR METAB, V96, P1506, DOI 10.1210/jc.2010-2345; Fenske WK, 2018, J CLIN ENDOCR METAB, V103, P505, DOI 10.1210/jc.2017-01891; Fujisawa I, 2004, J NEUROENDOCRINOL, V16, P297, DOI 10.1111/j.0953-8194.2004.01183.x; HARRINGTON AR, 1968, J CLIN INVEST, V47, P502, DOI 10.1172/JCI105746; Hickey RC, 1944, J CLIN INVEST, V23, P768, DOI 10.1172/JCI101549; Kluge M, 1999, CLIN CHEM, V45, P98; Kurokawa H, 1998, RADIOLOGY, V207, P79, DOI 10.1148/radiology.207.1.9530302; Loh JA, 2008, ENDOCRIN METAB CLIN, V37, P213, DOI 10.1016/j.ecl.2007.10.008; MILLER M, 1970, ANN INTERN MED, V73, P721, DOI 10.7326/0003-4819-73-5-721; MILLES JJ, 1983, ACTA ENDOCRINOL-COP, V104, P410, DOI 10.1530/acta.0.1040410; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; MOSES AM, 1967, AM J MED, V42, P368, DOI 10.1016/0002-9343(67)90265-3; PREIBISZ JJ, 1983, HYPERTENSION, V5, pI129, DOI 10.1161/01.HYP.5.2_Pt_2.I129; Qureshi S, 2014, ENDOCRINOLOGY, V155, P4605, DOI 10.1210/en.2014-1385; Robertson G L, 1976, Recent Prog Horm Res, V33, P333; Robertson GL, 2016, BEST PRACT RES CL EN, V30, P205, DOI 10.1016/j.beem.2016.02.007; ROBERTSON GL, 1995, ENDOCRIN METAB CLIN, V24, P549, DOI 10.1016/S0889-8529(18)30031-8; ROBERTSON GL, 1976, KIDNEY INT, V10, P25, DOI 10.1038/ki.1976.76; ROBERTSON GL, 1973, J CLIN INVEST, V52, P2340, DOI 10.1172/JCI107423; Rose BD, 2001, CLIN PHYSL ACID BASE, P748; Sailer CO, 2017, CLIN ENDOCRINOL, V87, P492, DOI 10.1111/cen.13384; Timper K, 2015, J CLIN ENDOCR METAB, V100, P2268, DOI 10.1210/jc.2014-4507; Verbalis JG, 2003, BEST PRACT RES CL EN, V17, P471, DOI 10.1016/S1521-690X(03)00049-6; Vergier J, 2018, ARCH PEDIATRIE, V25, P45, DOI 10.1016/j.arcped.2017.11.010; Winzeler B, 2015, J CLIN ENDOCR METAB, V100, P2275, DOI 10.1210/jc.2014-4527; Wun T, 1997, PLATELETS, V8, P15, DOI 10.1080/09537109777492; ZERBE RL, 1981, NEW ENGL J MED, V305, P1539, DOI 10.1056/NEJM198112243052601	37	103	102	2	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2018	379	5					428	439		10.1056/NEJMoa1803760	http://dx.doi.org/10.1056/NEJMoa1803760			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GO9HB	30067922	Bronze			2023-01-03	WOS:000440415800006
J	Iancu-Rubin, C; Hoffman, R; Migliaccio, AR				Iancu-Rubin, Camelia; Hoffman, Ronald; Migliaccio, Anna Rita			Whirling Platelets Away for Transfusion	CELL			English	Editorial Material							STEM-CELLS	With a growing demand for platelet transfusions, large-scale ex vivo platelet production would alleviate the reliance on donors. Now, Ito et al. report that turbulence is an important physical regulator of platelet generation in vivo and can be exploited in a bioreactor to enable clinical scale production of functional platelets starting from human iPSCs.	[Iancu-Rubin, Camelia; Hoffman, Ronald] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Migliaccio, Anna Rita] Alma Mater Univ, Dept Biomed & Neuromotorial Sci, Bologna, Italy	Icahn School of Medicine at Mount Sinai; University of Bologna	Migliaccio, AR (corresponding author), Alma Mater Univ, Dept Biomed & Neuromotorial Sci, Bologna, Italy.	annarita.migliaccio@unibo.it	Migliaccio, Anna Rita/GWZ-9323-2022	FRANCO MIGLIACCIO, ANNA RITA/0000-0003-1800-271X	NHLBI NIH HHS [R01 HL134684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL134684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2011, 2011 NATL BLOOD COLL; Avanzi MP, 2014, BRIT J HAEMATOL, V165, P237, DOI 10.1111/bjh.12764; FONG H, 2016, BLOOD, V128; Kato Y, 2018, CELL, V174, P636; Kumar A, 2015, TRANSFUSION, V55, P1116, DOI 10.1111/trf.12943; Lambert MP, 2013, BLOOD, V121, P3319, DOI 10.1182/blood-2012-09-455428; Nakamura S, 2014, CELL STEM CELL, V14, P535, DOI 10.1016/j.stem.2014.01.011; Thon JN, 2017, PLATELETS, V28, P472, DOI 10.1080/09537104.2016.1265922; Xi JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054941	9	3	3	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	2018	174	3					503	504		10.1016/j.cell.2018.07.018	http://dx.doi.org/10.1016/j.cell.2018.07.018			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GO3EH	30053423	Green Accepted, Bronze			2023-01-03	WOS:000439870500003
J	Figueiredo, PHS; Lima, MMO; Costa, HS; Martins, JB; Flecha, OD; Goncalves, PF; Alves, FL; Rodrigues, VGB; Maciel, EHB; Mendonca, VA; Lacerda, ACR; Vieira, ELM; Teixeira, AL; de Paula, F; Balthazar, CH				Scheidt Figueiredo, Pedro Henrique; Oliveira Lima, Marcia Maria; Costa, Henrique Silveira; Martins, Jeanne Brenda; Flecha, Olga Dumont; Goncalves, Patricia Furtado; Alves, Frederico Lopes; Brandao Rodrigues, Vanessa Gomes; Barroso Maciel, Emilio Henrique; Mendonca, Vanessa Amaral; Rodrigues Lacerda, Ana Cristina; Marciano Vieira, Erica Leandro; Teixeira, Antonio Lucio; de Paula, Fabricio; Balthazar, Claudio Heitor			Effects of the inspiratory muscle training and aerobic training on respiratory and functional parameters, inflammatory biomarkers, redox status and quality of life in hemodialysis patients: A randomized clinical trial	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; SHUTTLE WALK TEST; OXIDATIVE STRESS; REFERENCE VALUES; PHYSICAL FUNCTION; FAILURE PATIENTS; SERUM RESISTIN; ADIPONECTIN; STRENGTH; EXERCISE	Objective Evaluate and compare the isolated and combined effects of Inspiratory Muscle Training (IMT) and Aerobic Training (AT) on respiratory and functional parameters, inflamatory biomarkers, redox status and health-related quality of life (HRQoL) in hemodialysis patients. Methods A randomised controlled trial with factorial allocation and intention-to-treat analysis was performed in hemodialysis patients. Volunteers were randomly assigned to performe 8-weeks of IMT at 50% of maximal inspiratory pressure (MIP), low intensity AT or combined training (CT). Before the interventions, all the volunteers went 8-weeks through a control period (without training). Measures are taken at baseline, 8-week (after control period) and 16week (after the interventions). Primary outcomes were functional capacity (incremental shuttle walk test), MIP and lower limbs strength (Sit-to-Stand test of 30 seconds). Plasma levels of interleukin-6 (IL-6), soluble tumor necrosis factor receptor 1 (sTNFR1) and 2 (sTNFR2), adiponectin, resistin and leptin, redox status parameters and HRQoL (KDQOL-SF questionnaire) were the scondary outcomes. Data analyses were performed by two-way repeated measurements ANOVA. Results 37 hemodialysis patients aged 48.2 years old (IC95% 43.2-54.7) were randomized. Increase of MIP, functional capacity, lower limbs strength and resistin levels, and reduction of sTNFR2 levels in 16-week, compared to baseline and 8-week, were observed in all the groups (p< 0.001). IMT improved functional capacity, MIP and lower limbs strength in 96.7m (IC95% 5.6-189.9), 34.5cmH(2)O (IC95% 22.4-46.7) and 2.2repetitions (IC95% 1.1-3.2) respectively. Increase in resistin leves and reduction in sTNFR2 leves after IMT was 0.8ng/dL (IC95% 0.5-1.1) and 0.8ng/dL (IC95% 0.3-1.3), respectively, without between-group differences. Compared to baseline and 8-week, adiponectin levels (p< 0.001) and fatigue domain of the HRQoL (p< 0.05) increased in 16-week only in CT. Conclusion IMT, AT and CT improved functional parameters and modulated inflammatory biomarkers, in addition, IMT provoked a similar response to low intensity AT in hemodialysis patients.	[Scheidt Figueiredo, Pedro Henrique; Martins, Jeanne Brenda; Mendonca, Vanessa Amaral; Rodrigues Lacerda, Ana Cristina; Balthazar, Claudio Heitor] Univ Fed Vales Jequitinhonha & Mucuri, PMPGCF, Diamantina, MG, Brazil; [Scheidt Figueiredo, Pedro Henrique; Oliveira Lima, Marcia Maria; Mendonca, Vanessa Amaral; Rodrigues Lacerda, Ana Cristina; Balthazar, Claudio Heitor] Univ Fed Vales Jequitinhonha & Mucuri, Phys Therapy Sch, Diamantina, MG, Brazil; [Costa, Henrique Silveira; Marciano Vieira, Erica Leandro; Teixeira, Antonio Lucio] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil; [Flecha, Olga Dumont; Goncalves, Patricia Furtado] Univ Fed Vales Jequitinhonha & Mucuri, Sch Dent, Diamantina, MG, Brazil; [Alves, Frederico Lopes; Brandao Rodrigues, Vanessa Gomes; Barroso Maciel, Emilio Henrique; de Paula, Fabricio] Santa Casa Caridade Diamantina Hosp, Hemodialysis Unit, Diamantina, MG, Brazil; [Alves, Frederico Lopes; Brandao Rodrigues, Vanessa Gomes; Barroso Maciel, Emilio Henrique] Univ Fed Vales Jequitinhonha & Mucuri, Sch Med, Diamantina, MG, Brazil	Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal de Minas Gerais; Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM); Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM)	Figueiredo, PHS (corresponding author), Univ Fed Vales Jequitinhonha & Mucuri, PMPGCF, Diamantina, MG, Brazil.; Figueiredo, PHS (corresponding author), Univ Fed Vales Jequitinhonha & Mucuri, Phys Therapy Sch, Diamantina, MG, Brazil.	phsfig@yahoo.com.br	Vieira, Erica L M/A-1976-2013; Teixeira, Antonio L/N-3315-2014; Mendonça, Vanessa Amaral/T-7958-2019; Costa, Henrique Silveira/H-8286-2014; Figueiredo, Pedro Henrique/AAP-2158-2020; Lacerda, Ana Cristina/J-2181-2012	Vieira, Erica L M/0000-0002-4147-5614; Teixeira, Antonio L/0000-0002-9621-5422; Mendonça, Vanessa Amaral/0000-0002-1696-6091; Costa, Henrique Silveira/0000-0002-1426-7246; Lacerda, Ana Cristina/0000-0001-5366-3754	Fundacao de Amparo a Pesquisa do Estado de Minas gerais [APQ-03093-15]	Fundacao de Amparo a Pesquisa do Estado de Minas gerais(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Minas gerais, APQ-03093-15; Authors who received the funding: MMOL; http://www.fapemig.br/arquivos/site/chamadas/analise/20151215114952-2015-01-universal-aprovados.pdf.	Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; Alves R, 2016, EUR J PHYS REHAB MED, V52, P20; Beetham KS, 2015, REDOX REP, V20, P126, DOI 10.1179/1351000214Y.0000000114; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Bo S, 2005, INT J OBESITY, V29, P1315, DOI 10.1038/sj.ijo.0803037; Bostrom EA, 2011, ARTHRITIS RHEUM-US, V63, P2894, DOI 10.1002/art.30527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; de Medeiros AIC, 2017, J PHYSIOTHER, V63, P76, DOI 10.1016/j.jphys.2017.02.016; Chen CT, 2013, THESCIENTIFICWORLDJO, V5, P2; Chung W, 2012, J KOREAN MED SCI, V27, P377, DOI 10.3346/jkms.2012.27.4.377; Chung YC, 2017, J CLIN NURS, V26, P1801, DOI 10.1111/jocn.13514; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; da Cunha IT, 2007, AM J PHYS MED REHAB, V86, P574, DOI 10.1097/PHM.0b013e31806de721; den Hoedt CH, 2014, CLIN J AM SOC NEPHRO, V9, P318, DOI 10.2215/CJN.04470413; Dourado VZ, 2013, J BRAS PNEUMOL, V39, P190, DOI 10.1590/S1806-37132013000200010; Duarte PS, 2005, BRAZ J MED BIOL RES, V38, P261, DOI 10.1590/S0100-879X2005000200015; Figueiredo RR, 2012, CLIN REHABIL, V26, P724, DOI 10.1177/0269215511431088; GLASS GA, 1981, BIOCHEM BIOPH RES CO, V103, P1245, DOI 10.1016/0006-291X(81)90256-4; Gosselink R, 2011, EUR RESPIR J, V37, P416, DOI 10.1183/09031936.00031810; Houchen-Wolloff L, 2015, EUR J PREV CARDIOL, V22, P972, DOI 10.1177/2047487314540840; Jackson MJ, 2015, J APPL PHYSIOL, V119, P163, DOI 10.1152/japplphysiol.00760.2014; Jakel J, 2005, EPIDEMIOLOGIA BIOEST; Johansen KL, 2003, KIDNEY INT, V63, P291, DOI 10.1046/j.1523-1755.2003.00704.x; Kato A, 2001, NEPHROL DIAL TRANSPL, V16, P1838, DOI 10.1093/ndt/16.9.1838; Mandoorah QM, 2014, SAUDI J KIDNEY DIS T, V25, P432, DOI 10.4103/1319-2442.128613; Montemezzo D, 2014, ARCH PHYS MED REHAB, V95, P1398, DOI 10.1016/j.apmr.2014.02.022; Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007; Neirynck N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122073; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Ohashi N, 2008, INTERNAL MED, V47, P485, DOI 10.2169/internalmedicine.47.0614; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Painter P, 2013, CLIN J AM SOC NEPHRO, V8, P861, DOI 10.2215/CJN.06590712; Pellizzaro CO, 2013, RENAL FAILURE, V35, P189, DOI 10.3109/0886022X.2012.745727; Perseghin G, 2006, DIABETOLOGIA, V49, P1893, DOI 10.1007/s00125-006-0267-7; Probst VS, 2012, RESP MED, V106, P243, DOI 10.1016/j.rmed.2011.07.023; Rashidlamir A, 2012, SCI SPORT, V27, P351, DOI 10.1016/j.scispo.2011.11.004; Rusu Crina Claudia, 2016, Clujul Med, V89, P250, DOI 10.15386/cjmed-537; Sallam N, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7239639; Figueiredo PHS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173159; Silva Vanessa Giendruczak da, 2011, Braz. J. Nephrol., V33, P62; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Siri W., 1961, TECHNIQUES MEASURING, P223; Smart NA, 2013, J SCI MED SPORT, V16, P406, DOI 10.1016/j.jsams.2013.01.005; Song WJ, 2012, J KOREAN ACAD NURS, V42, P947, DOI 10.4040/jkan.2012.42.7.947; Spoto B, 2013, NEPHROL DIAL TRANSPL, V28, P181, DOI 10.1093/ndt/gft365; Srivastava S, 2007, CARDIOVASC RES, V74, P445, DOI 10.1016/j.cardiores.2007.02.016; Thompson S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012085; Viana JL, 2014, J AM SOC NEPHROL, V25, P2121, DOI 10.1681/ASN.2013070702; Wang AYM, 2004, J AM SOC NEPHROL, V15, P3134, DOI 10.1097/01.ASN.0000144206.29951.B2; Wang ZV, 2016, J MOL CELL BIOL, V8, P93, DOI 10.1093/jmcb/mjw011; Weiner Palteil, 1996, Harefuah, V130, P73; Wilkinson TJ, 2019, PHYSIOTHER THEOR PR, V35, P565, DOI 10.1080/09593985.2018.1455249; Wilund KR, 2010, NEPHROL DIAL TRANSPL, V25, P2695, DOI 10.1093/ndt/gfq106	53	15	17	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2018	13	7							e0200727	10.1371/journal.pone.0200727	http://dx.doi.org/10.1371/journal.pone.0200727			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4DQ	30048473	Green Published, gold, Green Submitted			2023-01-03	WOS:000439952400016
J	Gudina, EK; Tesfaye, M; Wieser, A; Pfister, HW; Klein, M				Gudina, Esayas Kebede; Tesfaye, Markos; Wieser, Andreas; Pfister, Hans-Walter; Klein, Matthias			Outcome of patients with acute bacterial meningitis in a teaching hospital in Ethiopia: A prospective study	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; MENINGOCOCCAL MENINGITIS; TUBERCULOUS MENINGITIS; ADDIS-ABABA; ADULTS; DEXAMETHASONE; EPIDEMIOLOGY; ADOLESCENTS; MANAGEMENT; PREDICTORS	Background The mortality and neurologic sequelae associated with acute bacterial meningitis (ABM) remain high despite advances in medical care. The main aim of this study was to evaluate short-term outcome in patients treated as bacterial meningitis at a teaching hospital in Ethiopia to identify factors that could be focused on to improve outcome in this setting. Methods A hospital based longitudinal study was conducted at Jimma University Hospital in southwest Ethiopia from March 1, 2013 to December 31, 2015. Participants of this study were patients of age 18 years and older who were treated as confirmed or possible cases of ABM. Patients were followed throughout their hospital stay for change in their clinical course and predefined end points. A multivariable analysis was done to identify factors associated with unfavorable outcomes. Result 90 patients admitted with diagnosis of acute bacterial meningitis were included in the study; cerebrospinal fluid was analysed for 85 (94.4%) of them. Causative bacteria were isolated in 26 (28.9%) patients only; most of these isolates (84.6%) were either Streptococcus pneumoniae or Neisseria meningitidis. Patients managed as cases of ABM at the hospital suffered from a high rate of unfavorable outcome (36.7%) and an overall mortality rate of 22.2%. Impaired level of consciousness (AOR = 0.766, 95% CI = 0.589-0.995), dexamethasone therapy (AOR = 4.676, 95% CI = 1.12-19.50) and fever persisting after two days of admission (AOR = 24.226, 95% CI = 5.24-111.96) were found to be independently associated with unfavorable outcome. Conclusion Outcome in patients treated for ABM at the hospital was found to be poor. Impaired mentation, treatment with adjunctive dexamethasone and persistent fever were found to be associated with poor outcome. Thus, development of clinical guidelines for treatment of ABM that suit the local context is essential to improve patient management and outcome.	[Gudina, Esayas Kebede] Jimma Univ, Dept Internal Med, Jimma, Ethiopia; [Gudina, Esayas Kebede; Tesfaye, Markos] Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, Germany; [Tesfaye, Markos] St Pauls Hosp, Millennium Med Coll, Dept Psychiat, Addis Ababa, Ethiopia; [Wieser, Andreas] Ludwig Maximilians Univ Munchen, Max von Pettenkofer Inst, Dept Bacteriol, Munich, Germany; [Wieser, Andreas] Univ Munich, Ludwig Maximilians Univ, Med Ctr, Div Infect Dis & Trop Med, Munich, Germany; [Wieser, Andreas] Partner Site Munich, German Ctr Infect Res DZIF, Munich, Germany; [Pfister, Hans-Walter; Klein, Matthias] Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Dept Neurol, Munich, Germany	Jimma University; University of Munich; University of Munich; University of Munich; German Center for Infection Research; University of Munich	Gudina, EK (corresponding author), Jimma Univ, Dept Internal Med, Jimma, Ethiopia.; Gudina, EK (corresponding author), Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, Germany.	esayas.kebede@ju.edu.et	Tesfaye, Markos/H-9297-2019; Klein, Matthias/F-4118-2017; Gudina, Esayas Kebede/U-9370-2019; Gudina, Esayas Kebede/AAX-2374-2020	Klein, Matthias/0000-0001-9064-6865; Gudina, Esayas Kebede/0000-0002-6264-9695; Gudina, Esayas Kebede/0000-0002-6264-9695; Tesfaye, Markos/0000-0002-3351-701X	Else Kroner-Fresenius-Stiftung, Bad Homburg, Germany;  [2013_HA77]	Else Kroner-Fresenius-Stiftung, Bad Homburg, Germany; 	This research was funded by Else Kroner-Fresenius-Stiftung, Bad Homburg, Germany (https://www.ekfs.de/). MK received the grant (grant number - 2013_HA77). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkali NH, 2013, ANN AFR MED, V12, P1, DOI 10.4103/1596-3519.108242; Assiri AM, 2009, MAYO CLIN PROC, V84, P403, DOI [10.1016/S0025-6196(11)60558-2, 10.4065/84.5.403]; Beardsley J, 2016, NEW ENGL J MED, V374, P542, DOI 10.1056/NEJMoa1509024; Bijlsma MW, 2016, LANCET INFECT DIS, V16, P339, DOI 10.1016/S1473-3099(15)00430-2; Borchorst S, 2012, ACTA ANAESTH SCAND, V56, P1210, DOI 10.1111/j.1399-6576.2012.02698.x; Brouwer MC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub4; Brouwer MC, 2010, CLIN MICROBIOL REV, V23, P467, DOI 10.1128/CMR.00070-09; Buchholz G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1498-8; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; Desmond NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068163; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Durski KN, 2013, JAIDS-J ACQ IMM DEF, V63, pE101, DOI 10.1097/QAI.0b013e31828e1e56; Dzupova O, 2009, SCAND J INFECT DIS, V41, P348, DOI 10.1080/00365540902849391; Ethiopian Health and Nutrition Research Institute, 2013, NAT GUID MEN MEN SUR; FEKADE D, 1992, ETHIOPIAN MED J, V30, P135; [FMHACA Ethiopia FMaHAaCAo], 2014, STAND TREAT GUID GEN; Ghana National Drug Policy (GNDP), 2010, MEN STAND TREATM GUI, P356; Gituro C, 2017, PAN AFRICAN MED J S1, V28; Glimaker M, 2015, CLIN INFECT DIS, V60, P1162, DOI 10.1093/cid/civ011; Global_ Health_ Observatory_(GHO) data, 2015, EP MEN MEN WHO; Gordon SB, 2000, CLIN INFECT DIS, V31, P53, DOI 10.1086/313910; Gudina EK, 2016, CHALLENGES BACTERIAL; Hailu M, 2001, ETHIOPIAN MED J, V39, P29; Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17; Jarvis JN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-67; JENNETT B, 1975, LANCET, V1, P480; Karstaedt AS, 1998, QJM-INT J MED, V91, P743, DOI 10.1093/qjmed/91.11.743; Klein M, 2009, EXPERT OPIN PHARMACO, V10, P2609, DOI 10.1517/14656560903277210; Mai NTH, 2007, NEW ENGL J MED, V357, P2431, DOI 10.1056/NEJMoa070852; Mengistu G, 2003, ETHIOPIAN MED J, V41, P319; Mihret W, 2016, EMERG INFECT DIS, V22, P75, DOI 10.3201/eid2201.150432; Mihret Wude, 2014, Ethiop Med J, VSuppl 1, P43; Molyneux EM, 2002, LANCET, V360, P211, DOI 10.1016/S0140-6736(02)09458-8; Mulu A, 2005, NW ETHIOPIA ETHIOPJH, V19, P160; Rajasingham R, 2015, AM J TROP MED HYG, V92, P274, DOI 10.4269/ajtmh.14-0452; Sanya E, 2006, INTERNET J INFECT DI, V6; Scarborough M, 2008, LANCET NEUROL, V7, P637, DOI 10.1016/S1474-4422(08)70139-X; Sheu JJ, 2009, AM J MED SCI, V338, P134, DOI 10.1097/MAJ.0b013e3181a590f1; Short William R., 2001, Curr Infect Dis Rep, V3, P360, DOI 10.1007/s11908-001-0076-6; Thinyane KH, 2015, J TROP MED-US, V2015, DOI 10.1155/2015/423161; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; van de Beek D, 2004, LANCET INFECT DIS, V4, P139, DOI 10.1016/S1473-3099(04)00937-5; van de Beek D, 2010, LANCET NEUROL, V9, P254, DOI 10.1016/S1474-4422(10)70023-5; Veltman Jennifer A, 2014, J Int AIDS Soc, V17, P19184, DOI 10.7448/IAS.17.1.19184; Wall EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069783; WHO, 2014, MEN OUTBR RESP SUBS; WHO, 2001, WKLY EPIDEMIOL REC, V76, P282; WHO, 1998, CONTR EP MEN DIS	51	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0200067	10.1371/journal.pone.0200067	http://dx.doi.org/10.1371/journal.pone.0200067			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN4SJ	30020952	Green Published, Green Submitted, gold			2023-01-03	WOS:000439022400039
J	Chu, DC; Yen, YF; Hu, HY; Lai, YJ; Sun, WJ; Ko, MC; Huang, LY; Chen, CC; Curtis, JR; Lee, YL; Huang, SJ				Chu, Dachen; Yen, Yung-Feng; Hu, Hsiao-Yun; Lai, Yun-Ju; Sun, Wen-Jung; Ko, Ming-Chung; Huang, Li-Ying; Chen, Chu-Chieh; Curtis, J. Randall; Lee, Ya-Ling; Huang, Sheng-Jean			Factors associated with advance directives completion among patients with advance care planning communication in Taipei, Taiwan	PLOS ONE			English	Article							HEALTH-CARE; PREFERENCES; DISPARITY	Background Although advance directives (AD) have been implemented for years in western countries, the concept of AD is not promoted extensively in eastern countries. In this study we evaluate a program to systematically conduct advance care planning (ACP) communication for hospitalized patients in Taiwan and identify the factors associated with AD completion. Methods In this retrospective evaluation of a clinical ACP program, we identified adult patients with chronic life-limiting illness admitted to Taipei City Hospital between April 2015 and January 2016. Trained healthcare providers held an ACP meeting to discuss patients' preference regarding end-of-life care and AD completion. A multiple logistic regression was performed to determine the factors associated with the AD completion. Results A total of 2878 patients were determined to be eligible for ACP during the study, among which 1798 (62.5%) completed ACP and data was available for 1411 patients (49.1%). Of the 1411 patients who received ACP communication with complete data, the rate of AD completion was 82.6%. The overall mean (SD) age was 78.2 (14.4) years. Adjusting for other variables, AD completion was associated with patients aged >= 85 years [adjusted odds ratio (AOR) = 1.80, 95% CI 1.21-2.67], critical illness (AOR = 1.17, 95% CI 1.06-1.30), and social workers participating in ACP meetings (AOR = 1.74, 95% CI 1.24-2.45). Conclusion The majority of inpatients with chronic life-limiting illness had ACP communication as part of this ACP program and over 80% completed an AD. Our study demonstrates the feasibility of implementing ACP discussion in East Asia and suggests that social workers may be an important component of ACP communication with patients.	[Chu, Dachen; Huang, Sheng-Jean] Taipei City Hosp, Dept Neurosurg, Taipei, Taiwan; [Chu, Dachen; Yen, Yung-Feng; Hu, Hsiao-Yun] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan; [Chu, Dachen; Yen, Yung-Feng; Hu, Hsiao-Yun] Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan; [Chu, Dachen; Yen, Yung-Feng; Lai, Yun-Ju] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Chu, Dachen; Yen, Yung-Feng; Ko, Ming-Chung; Chen, Chu-Chieh] Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan; [Yen, Yung-Feng] Taipei City Hosp, Infect Dis Sect, Taipei, Taiwan; [Hu, Hsiao-Yun] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan; [Lai, Yun-Ju] Taichung Vet Gen Hosp, Div Endocrinol & Metab, Dept Internal Med, Puli Branch, Nantou, Taiwan; [Lai, Yun-Ju] Natl Taiwan Univ Sport, Dept Exercise Hlth Sci, Taichung, Taiwan; [Sun, Wen-Jung] Taipei City Hosp, Dept Community Med, Zhongxing Branch, Taipei, Taiwan; [Sun, Wen-Jung] Taipei City Hosp, Family Med Div, Zhongxing Branch, Taipei, Taiwan; [Ko, Ming-Chung] Taipei City Hosp, Dept Urol, Taipei, Taiwan; [Huang, Li-Ying] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei, Taiwan; [Huang, Li-Ying] Fu Jen Catholic Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, New Taipei, Taiwan; [Curtis, J. Randall] Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, 325 9th Ave, Seattle, WA 98104 USA; [Lee, Ya-Ling] Taipei City Hosp, Dept Dent, Taipei, Taiwan; [Lee, Ya-Ling] Natl Yang Ming Univ, Sch Dent, Dept Dent, Taipei, Taiwan; [Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Dept Surg, Coll Med, Taipei, Taiwan	Taipei City Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taipei University of Nursing & Health Science (NTUNHS); Taipei City Hospital; Taipei City Hospital; Taichung Veterans General Hospital; National Taiwan University of Sport; Taipei City Hospital; Taipei City Hospital; Taipei City Hospital; Fu Jen Catholic University; Fu Jen Catholic University; Fu Jen Catholic University Hospital; Harborview Medical Center; University of Washington; University of Washington Seattle; Taipei City Hospital; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Chu, DC (corresponding author), Taipei City Hosp, Dept Neurosurg, Taipei, Taiwan.; Chu, DC (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.; Chu, DC (corresponding author), Natl Yang Ming Univ, Community Med Res Ctr, Taipei, Taiwan.; Chu, DC (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Chu, DC (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Dept Hlth Care Management, Taipei, Taiwan.	DAD57@tpech.gov.tw	Lai, Yun-Ju/AAX-4990-2020	Curtis, J. Randall/0000-0001-9529-845X				Bays AM, 2014, J PALLIAT MED, V17, P159, DOI 10.1089/jpm.2013.0318; Bradley EH, 1998, ARCH FAM MED, V7, P417, DOI 10.1001/archfami.7.5.417; Braun KL, 2001, J AM GERIATR SOC, V49, P1708, DOI 10.1046/j.1532-5415.2001.49284.x; Bravo G, 2003, ALZ DIS ASSOC DIS, V17, P215, DOI 10.1097/00002093-200310000-00004; Brown Barbara A, 2003, J Gerontol Nurs, V29, P4; Chu LW, 2011, J AM MED DIR ASSOC, V12, P143, DOI 10.1016/j.jamda.2010.08.015; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Francoeur RB, 2016, SOC WORK PUBLIC HLTH, P1; Lin WY, 2014, SUPPORT CARE CANCER, V22, P1907, DOI 10.1007/s00520-014-2168-5; Lynn J, 2003, LIVING WELL END LIFE; Modrykamien Ariel M, 2015, Proc (Bayl Univ Med Cent), V28, P163; National Association of Social Workers, 1996, COD ETH NAT ASS SOC; Nicholas LH, 2011, JAMA-J AM MED ASSOC, V306, P1447, DOI 10.1001/jama.2011.1410; Rich SE, 2009, J AM GERIATR SOC, V57, P146, DOI 10.1111/j.1532-5415.2008.02090.x; Rosnick CB, 2003, J AGING HEALTH, V15, P409, DOI 10.1177/0898264303015002005; Rurup ML, 2006, SOC SCI MED, V62, P1552, DOI 10.1016/j.socscimed.2005.08.010; Seymour Jane, 2010, BMC Palliat Care, V9, P4, DOI 10.1186/1472-684X-9-4; Sharma RK, 2014, J GEN INTERN MED, V29, P750, DOI 10.1007/s11606-014-2791-3; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Ting Fion H., 2011, Hong Kong Medical Journal, V17, P105; Trarieux-Signol S, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-57; Vaughn G, 2000, J AM GERIATR SOC, V48, P554, DOI 10.1111/j.1532-5415.2000.tb05003.x; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056; Wong SY, 2012, HONG KONG MED J, V18, P178	25	31	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2018	13	7							e0197552	10.1371/journal.pone.0197552	http://dx.doi.org/10.1371/journal.pone.0197552			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GM1FJ	29979678	Green Published, Green Submitted, gold			2023-01-03	WOS:000437809500004
J	Shen, L; Assanangkornchai, S; Liu, W; Cai, L; Li, F; Tang, SY; Shen, JC; McNeil, EB; Chongsuvivatwong, V				Shen, Ling; Assanangkornchai, Sawitri; Liu, Wei; Cai, Le; Li, Fei; Tang, Songyuan; Shen, Jiucheng; McNeil, Edward B.; Chongsuvivatwong, Virasakdi			Influence of social network on drug use among clients of methadone maintenance treatment centers in Kunming, China	PLOS ONE			English	Article							HIV RISK BEHAVIOR; SUBSTANCE USE; SUPPORT; YUNNAN; NORMS; METHAMPHETAMINE; ASSOCIATION; PREDICTORS; RETENTION; BALTIMORE	Aims To examine drug use behavior of clients attending Methadone Maintenance Treatment (MMT) programs and its relationship with the clients' social network characteristics. Design Cross-sectional study. Setting Four MMT clinics in Kunming, Yunnan province, China. Participants 324 consecutive MMT clients. Measurements A structured, self-completed questionnaire on background characteristics and existing social network. Current drug use was assessed by urine test for opiate metabolites. Analysis The association between client's social network characteristics and their own current drug use behavior is analysed using multiple logistic regression adjusting forsocio-demographic characteristics. Adjusted odds ratios (AOR) with 95% confidence intervals (CI) are obtained to give the strength of the associations. Findings MMT clients were more likely to concurrently use heroin while attending MMT if their social network had any of the following characteristics: more than half of the members were older than them (AOR = 1.03, 95% CI = 1.00,1.06), any member had a high level of influence on them (AOR = 6.47, 95% CI = 2.86,14.65) and any member joined them in using drugs (AOR = 1.94, 95% CI = 1.04,3.63). Having a social network member who could provide emotional support (AOR = 0.11, 95% CI = 0.03,0.35), having a spouse and/or child in their social network (AOR = 0.44, 95% CI = 0.24,0.81) and having a social network member with a high level of closeness (AOR = 0.28, 95% CI = 0.09,0.90) were associated with a decreased odds of heroin use. Conclusion Social networks who could provide MMT clients with emotional support and a close relationship were significant factors for reducing the risk of concurrent drug use among clients attending MMT clinics in Kunming, China. Behavioral interventions should address the role of family and social network members in providing support to these clients.	[Shen, Ling; Assanangkornchai, Sawitri; McNeil, Edward B.; Chongsuvivatwong, Virasakdi] Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Thailand; [Shen, Ling; Liu, Wei; Cai, Le; Tang, Songyuan] Kunming Med Univ, Sch Publ Hlth, Kunming, Yunnan, Peoples R China; [Li, Fei] Kunming Med Univ, Sch Basic Med Sci, Kunming, Yunnan, Peoples R China; [Shen, Jiucheng] Yunnan Inst Drug Abuse, Kunming, Yunnan, Peoples R China	Prince of Songkla University; Kunming Medical University; Kunming Medical University	Assanangkornchai, S (corresponding author), Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Thailand.	savitree.a@psu.ac.th		Assanangkornchai, Sawitri/0000-0003-2174-3287; McNeil, Edward Braddon/0000-0002-9492-1040				Tran BX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051569; Barati M, 2014, J RES HEALTH SCI, V14, P221; Cao Xiao-bin, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P269; Chang YP, 2014, PUBLIC HEALTH ACTION, V4, P28, DOI 10.5588/pha.13.0101; Chen W, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-23; Cheng Xiao-Qing, 2013, Zhonghua Liu Xing Bing Xue Za Zhi, V34, P792; *CHIN NHAFPCOTPSRO, 2015, 2015 CHIN AIDS RESP; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; De P, 2007, ADDICTION, V102, P1730, DOI 10.1111/j.1360-0443.2007.01936.x; El-Bassel N, 1998, AIDS CARE, V10, P735, DOI 10.1080/09540129848352; El-Bassel N, 2006, J URBAN HEALTH, V83, P602, DOI 10.1007/s11524-006-9075-0; Friedman SR, 2007, AIDS BEHAV, V11, P641, DOI 10.1007/s10461-006-9166-7; Friedman SR, 2001, J URBAN HEALTH, V78, P411, DOI 10.1093/jurban/78.3.411; GOEHL L, 1993, AM J DRUG ALCOHOL AB, V19, P251, DOI 10.3109/00952999309001617; Gyarmathy V Anna, 2006, Connect (Tor), V27, P25; Hall A, 1985, SOCIAL NETWORKS SOCI; Havens JR, 2009, J SUBST ABUSE TREAT, V36, P306, DOI 10.1016/j.jsat.2008.07.002; HOUSE JS, 1988, ANNU REV SOCIOL, V14, P293, DOI 10.1146/annurev.so.14.080188.001453; HURD GS, 1981, INT J FAM THER, V3, P246, DOI 10.1007/BF00924352; Janulis P, 2016, INT J DRUG POLICY, V27, P56, DOI 10.1016/j.drugpo.2015.09.006; Kamal F, 2007, Ir Med J, V100, P393; Knowlton AR, 2005, AIDS CARE, V17, P479, DOI 10.1080/0954012051233131314349; Koram N, 2011, AIDS BEHAV, V15, P1579, DOI 10.1007/s10461-011-9930-1; Latkin C, 1996, J ACQ IMMUN DEF SYND, V13, P273, DOI 10.1097/00042560-199611010-00010; LATKIN C, 1994, SEX TRANSM DIS, V21, P161, DOI 10.1097/00007435-199405000-00006; Latkin CA, 2010, AIDS BEHAV, V14, P1159, DOI 10.1007/s10461-009-9576-4; Latkin CA, 2005, AIDS CARE, V17, pS102, DOI 10.1080/09540120500121185; Latkin CA, 2003, SOC SCI MED, V56, P465, DOI 10.1016/S0277-9536(02)00047-3; Latkin C, 2009, HEALTH PSYCHOL, V28, P323, DOI 10.1037/a0014707; Latkin Carl M a W, 1995, DRUG ALCOHOL DEPEN; Li J, 2015, PUBLIC HEALTH, V129, P1237, DOI 10.1016/j.puhe.2015.07.020; Li L, 2011, DRUG ALCOHOL DEPEN, V116, P246, DOI 10.1016/j.drugalcdep.2010.12.007; Li L, 2012, ADDICT BEHAV, V37, P264, DOI 10.1016/j.addbeh.2011.11.004; Liao MZ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-172; Lin C, 2011, PUBLIC HEALTH, V125, P269, DOI 10.1016/j.puhe.2011.01.009; Lin CQ, 2011, SUBST USE MISUSE, V46, P1190, DOI 10.3109/10826084.2011.561905; Lin CQ, 2010, J SUBST ABUSE TREAT, V38, P119, DOI 10.1016/j.jsat.2009.09.002; Liu HJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-563; Luo XF, 2016, INT J ENV RES PUB HE, V13; MATTICK RP, 2003, COCHRANE DATABASE SY, V2; NEAIGUS A, 1994, SOC SCI MED, V38, P67, DOI 10.1016/0277-9536(94)90301-8; Neaigus A, 1995, NIDA Res Monogr, V151, P20; Shariatirad S, 2013, INT J DRUG POLICY, V24, P636, DOI [10.1016/j.drugpo.2013.04.003, 10.1016/j.drugpo.2013.05.003]; Strain EC, 1999, JAMA-J AM MED ASSOC, V281, P1000, DOI 10.1001/jama.281.11.1000; Suh Tongwoo M W, 1997, DRUG ALCOHOL DEPEN; Sullivan SG, 2007, INT J DRUG POLICY, V18, P118, DOI 10.1016/j.drugpo.2006.11.014; Sullivan SG, 2014, J SUBST ABUSE TREAT, V47, P86, DOI 10.1016/j.jsat.2013.12.004; Sun HM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-005997; Trujillo KA, 2011, PHARMACOL BIOCHEM BE, V99, P451, DOI 10.1016/j.pbb.2011.04.014; Valente T., 2003, CONNECTIONS CONNECT, V25, P11; Valente TW, 2001, AM J PUBLIC HEALTH, V91, P406, DOI 10.2105/AJPH.91.3.406; VLAHOV D, 1990, AM J EPIDEMIOL, V132, P847, DOI 10.1093/oxfordjournals.aje.a115727; Wang L, 2015, ADDICTION, V110, P20, DOI 10.1111/add.12779; Wang M, 2017, J SUBST ABUSE TREAT, V77, P89, DOI 10.1016/j.jsat.2017.03.004; Wang RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133431; Yin WY, 2010, INT J EPIDEMIOL, V39, pII29, DOI 10.1093/ije/dyq210; Zapka JG, 1993, AIDS ED PREVENTION	57	12	12	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2018	13	7							e0200105	10.1371/journal.pone.0200105	http://dx.doi.org/10.1371/journal.pone.0200105			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL5XD	29969481	Green Published, gold, Green Submitted			2023-01-03	WOS:000437246700045
J	Staud, R				Staud, Roland			Tai chi reduced severity of fibromyalgia symptoms at 24 weeks compared with aerobic exercise	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Staud, Roland] Univ Florida, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Staud, R (corresponding author), Univ Florida, Gainesville, FL 32611 USA.		Staud, Roland/A-8442-2008					Hauser W, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3002; Langhorst J, 2013, RHEUMATOL INT, V33, P193, DOI 10.1007/s00296-012-2360-1	2	1	1	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2018	168	12					JC70	JC70		10.7326/ACPJC-2018-168-12-070	http://dx.doi.org/10.7326/ACPJC-2018-168-12-070			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK1TE	29913495				2023-01-03	WOS:000435903500011
J	Zapata, CB				Zapata, Carly Benner			Survival Techniques	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Zapata, Carly Benner] Univ Calif San Francisco, Dept Med, Div Hosp Med, 533 Parnassus Ave,POB 1031, San Francisco, CA 94134 USA	University of California System; University of California San Francisco	Zapata, CB (corresponding author), Univ Calif San Francisco, Dept Med, Div Hosp Med, 533 Parnassus Ave,POB 1031, San Francisco, CA 94134 USA.	carly.zapata@ucsf.edu							0	1	1	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	2018	319	21					2171	2172		10.1001/jama.2018.6069	http://dx.doi.org/10.1001/jama.2018.6069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI1MA	29872862				2023-01-03	WOS:000434133400012
J	Falk, M; Donaldsson, S; Drevhammar, T				Falk, Markus; Donaldsson, Snorri; Drevhammar, Thomas			Infant CPAP for low-income countries: An experimental comparison of standard bubble CPAP and the Pumani system	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; RESISTANCE; WORK	Introduction Access to inexpensive respiratory support to newborn infants improves survival in low-income countries. Standard bubble continuous positive airway pressure (CPAP) has been extensively used worldwide for more than 30 years. One project aimed at providing affordable CPAP is the Pumani system developed by Rice 360 degrees. Compared to standard bubble CPAP the system has an unconventional design. The aim was to compare the Pumani system with two traditional bubble CPAP systems, focusing on in-vitro performance and safety. Methods The Pumani system was compared to traditional bubble CPAP from Fisher & Paykel (Auckland, New Zealand) and Diamedica (Devon, United Kingdom). The systems were tested using static flow resistance and simulated breathing for a range of fresh gas flows and submersion levels. Results There were large differences between the Pumani CPAP and the conventional bubble CPAP systems. The Pumani system was not pressure stable, had high resistance and high imposed work of breathing. It was not possible to use submersion depth to adjust CPAP without accounting for fresh gas flow. Discussion The Pumani design is novel and not similar to any previously described CPAP system. The main mechanism for CPAP generation was resistance, not submersion depth. The system should therefore not be referred to as bubble CPAP. The clinical consequences of its pressure instability and high imposed work of breathing are not known and trials on outcome and safety are needed.	[Falk, Markus; Donaldsson, Snorri; Drevhammar, Thomas] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Falk, Markus; Drevhammar, Thomas] Ostersund Hosp, Dept Anaesthesiol, Ostersund, Sweden; [Donaldsson, Snorri] Karolinska Univ Hosp, Dept Neonatol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Drevhammar, T (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.; Drevhammar, T (corresponding author), Ostersund Hosp, Dept Anaesthesiol, Ostersund, Sweden.	thomas.drevhammar@regionjh.se	Drevhammar, Thomas/ABA-6177-2020; Donaldsson, Snorri/K-6410-2019	Drevhammar, Thomas/0000-0002-4038-2221; Njafloo, Zahra/0000-0003-3151-9625; Falk, Markus/0000-0002-4318-5039	FoU-enheten Region Jamtland Harjedalen; Stockholm lans landsting	FoU-enheten Region Jamtland Harjedalen; Stockholm lans landsting	This work was supported by FoU-enheten Region Jamtland Harjedalen (http://www.researchweb.org/is/sverige/unit/531) to MF, TD and Stockholm lans landsting (https://forskningsstod.vmi.se/Ansokan/start.asp) to SD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banner MJ, 1996, CHEST, V109, P1141, DOI 10.1378/chest.109.5.1141; Brown J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053622; Chisti MJ, 2015, LANCET, V386, P1057, DOI 10.1016/S0140-6736(15)60249-5; Donaldsson S, 2016, ARCH DIS CHILD FETAL; Drevhammar T, 2013, PEDIATR CRIT CARE ME, V14, pE196, DOI 10.1097/PCC.0b013e31827212e4; Drevhammar T, 2012, PEDIATR CRIT CARE ME, V13, pE113, DOI 10.1097/PCC.0b013e31822f1b79; Duke T, 2014, PAEDIATR INT CHILD H, V34, P3, DOI 10.1179/2046905513Y.0000000102; Falk M, 2017, ACTA PAEDIATR, V106, P1760, DOI 10.1111/apa.13994; Fischer HS, 2013, PEDIATRICS, V132, pE1351, DOI 10.1542/peds.2013-1880; GOLDMAN SL, 1979, PEDIATRICS, V64, P160; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; Ho JJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002271.pub2; Huckstadt T, 2003, INTENS CARE MED, V29, P1134, DOI 10.1007/s00134-003-1785-0; Kawaza K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086327; Mahmoud RA, 2011, PAEDIATR RESPIR REV, V12, P196, DOI 10.1016/j.prrv.2010.12.001; MAPLESON W W, 1954, Br J Anaesth, V26, P323, DOI 10.1093/bja/26.5.323; mbey RGP, 2015, INT J PEDIAT RES PRA, V1, P3; Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Wald M, 2011, ARTIF ORGANS, V35, P22, DOI 10.1111/j.1525-1594.2010.01020.x; WHO, 2017, GLOB STRAT ACT PLAN; World Health Organization, 2017, WHO REC NEWB HLTH GU	23	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0196683	10.1371/journal.pone.0196683	http://dx.doi.org/10.1371/journal.pone.0196683			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF9WG	29768512	gold, Green Submitted, Green Published			2023-01-03	WOS:000432329200040
J	Stephenson, J; Heslehurst, N; Hall, J; Schoenaker, DAJM; Hutchinson, J; Cade, JE; Poston, L; Barrett, G; Crozier, SR; Barker, M; Kumaran, K; Yajnik, CS; Baird, J; Mishra, GD				Stephenson, Judith; Heslehurst, Nicola; Hall, Jennifer; Schoenaker, Danielle A. J. M.; Hutchinson, Jayne; Cade, Janet E.; Poston, Lucilla; Barrett, Geraldine; Crozier, Sarah R.; Barker, Mary; Kumaran, Kalyanaraman; Yajnik, Chittaranjan S.; Baird, Janis; Mishra, Gita D.			Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health	LANCET			English	Article							GESTATIONAL DIABETES-MELLITUS; OBESE PREGNANT-WOMEN; BODY-MASS INDEX; PREPREGNANCY DIETARY PATTERNS; FOLIC-ACID SUPPLEMENTATION; LONG-TERM HEALTH; PHYSICAL-ACTIVITY; UNPLANNED PREGNANCY; MATERNAL OBESITY; LONDON MEASURE	A woman who is healthy at the time of conception is more likely to have a successful pregnancy and a healthy child. We reviewed published evidence and present new data from low-income, middle-income, and high-income countries on the timing and importance of preconception health for subsequent maternal and child health. We describe the extent to which pregnancy is planned, and whether planning is linked to preconception health behaviours. Observational studies show strong links between health before pregnancy and maternal and child health outcomes, with consequences that can extend across generations, but awareness of these links is not widespread. Poor nutrition and obesity are rife among women of reproductive age, and differences between high-income and low-income countries have become less distinct, with typical diets falling far short of nutritional recommendations in both settings and especially among adolescents. Several studies show that micronutrient supplementation starting in pregnancy can correct important maternal nutrient deficiencies, but effects on child health outcomes are disappointing. Other interventions to improve diet during pregnancy have had little effect on maternal and newborn health outcomes. Comparatively few interventions have been made for preconception diet and lifestyle. Improvements in the measurement of pregnancy planning have quantified the degree of pregnancy planning and suggest that it is more common than previously recognised. Planning for pregnancy is associated with a mixed pattern of health behaviours before conception. We propose novel definitions of the preconception period relating to embryo development and actions at individual or population level. A sharper focus on intervention before conception is needed to improve maternal and child health and reduce the growing burden of non-communicable diseases. Alongside continued efforts to reduce smoking, alcohol consumption, and obesity in the population, we call for heightened awareness of preconception health, particularly regarding diet and nutrition. Importantly, health professionals should be alerted to ways of identifying women who are planning a pregnancy.	[Stephenson, Judith; Hall, Jennifer; Barrett, Geraldine] UCL, Inst Womens Hlth, London WC1E 6AU, England; [Heslehurst, Nicola] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Schoenaker, Danielle A. J. M.; Mishra, Gita D.] Univ Queensland, Sch Publ Hlth, Herston, Qld, Australia; [Hutchinson, Jayne; Cade, Janet E.] Univ Leeds, Sch Food Sci & Nutr, Nutrit Epidemiol Grp, Leeds, W Yorkshire, England; [Poston, Lucilla] St Thomas Hosp, Kings Coll London, Dept Women & Childrens Hlth, London, England; [Crozier, Sarah R.; Barker, Mary; Kumaran, Kalyanaraman; Baird, Janis] Univ Southampton, Southampton Gen Hosp, Med Res Council, Lifecourse Epidemiol Unit, Southampton, Hants, England; [Barker, Mary; Baird, Janis] Southampton Gen Hosp, Natl Inst Hlth Res, Southampton Biomed Res Ctr, Southampton, Hants, England; [Kumaran, Kalyanaraman] CSI Holdsworth Mem Hosp, Epidemiol Res Unit, Mysore, Karnataka, India; [Yajnik, Chittaranjan S.] King Edward Mem Hosp & Res Ctr, Diabet Unit, Pune, Maharashtra, India	University of London; University College London; Newcastle University - UK; University of Queensland; University of Leeds; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Southampton; University of Southampton	Stephenson, J (corresponding author), UCL, Inst Womens Hlth, London WC1E 6AU, England.	judith.stephenson@ucl.ac.uk	Schoenaker, Danielle/H-5397-2011; Cade, Janet/G-4250-2016; Mishra, Gita/F-8052-2011	Schoenaker, Danielle/0000-0002-7652-990X; Crozier, Sarah/0000-0002-9524-1127; Barrett, Geraldine/0000-0002-9738-1051; Barker, Mary/0000-0003-2976-0217; Baird, Janis/0000-0002-4039-4361; Poston, Lucilla/0000-0003-1100-2821; Heslehurst, Nicola/0000-0001-8656-2319; Cade, Janet/0000-0003-3421-0121; Mishra, Gita/0000-0001-9610-5904	Rank Prize Funds, on Developmental Programming for Human Disease: Preconception Nutrition and Lifelong Health in Grasmere, UK; Australian Government Department of Health; Tommy's Charity, London, UK; National Institute for Health Research Biomedical Research Centre at King's College London; Guys and St Thomas' National Health Service (NHS) Foundation Trust, London, UK; Central and North West London NHS Foundation Trust, London, UK; MRC [MC_UP_A620_1016, MC_UP_A620_1017, MR/M026361/1, MC_UU_12011/3, MC_UU_12011/4, MR/N011848/1] Funding Source: UKRI	Rank Prize Funds, on Developmental Programming for Human Disease: Preconception Nutrition and Lifelong Health in Grasmere, UK; Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Tommy's Charity, London, UK; National Institute for Health Research Biomedical Research Centre at King's College London; Guys and St Thomas' National Health Service (NHS) Foundation Trust, London, UK; Central and North West London NHS Foundation Trust, London, UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The idea for this Series was conceived by JS and developed during a 4-day symposium, led by MB and JS and funded by The Rank Prize Funds, on Developmental Programming for Human Disease: Preconception Nutrition and Lifelong Health in Grasmere, UK, in February, 2016. We thank the Australian Government Department of Health for funding the Australian Longitudinal Study on Women's Health, Kate Best for producing the Forest plots, and Andrew Copp for advice on folate concentrations and the developing fetus. LP is supported by Tommy's Charity, London, UK, and the National Institute for Health Research Biomedical Research Centre at King's College London, and Guys and St Thomas' National Health Service (NHS) Foundation Trust, London, UK. JS is supported by Central and North West London NHS Foundation Trust, London, UK.	Almaghaslah E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185433; [Anonymous], 2013, FP2020 PARTNERSHIP A; [Anonymous], 2016, ALC PREGN PREV MAN F; Aune D, 2014, EPIDEMIOLOGY, V25, P331, DOI 10.1097/EDE.0000000000000036; Baird J, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1603-y; Baker PN, 2009, AM J CLIN NUTR, V89, P1114, DOI 10.3945/ajcn.2008.27097; Bankole A, 1998, J BIOSOC SCI, V30, P439, DOI 10.1017/S0021932098004398; Bao W, 2014, AM J CLIN NUTR, V99, P1378, DOI 10.3945/ajcn.113.082966; Barrett G, 2004, J EPIDEMIOL COMMUN H, V58, P426, DOI 10.1136/jech.2003.014787; Barrett G, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0672-3; Bates B., 2014, NATL DIET NUTR SURVE; Bath SC, 2013, LANCET, V382, P331, DOI 10.1016/S0140-6736(13)60436-5; Been JV, 2014, LANCET, V383, P1549, DOI 10.1016/S0140-6736(14)60082-9; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Boylan S, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2332; Brackenridge L, CLIN OBES IN PRESS; Campbell F, 2010, SYSTEMATIC REV DIETA; Centers for Disease Control and Prevention, PREC HLTH REPR LIF P; Chiswick C, 2015, LANCET DIABETES ENDO, V3, P778, DOI 10.1016/S2213-8587(15)00219-3; Cooper C, 2016, LANCET DIABETES ENDO, V4, P393, DOI 10.1016/S2213-8587(16)00044-9; Cordain L, 2005, AM J CLIN NUTR, V81, P341, DOI 10.1093/ajcn.81.2.341; Crozier SR, 2009, PAEDIATR PERINAT EP, V23, P446, DOI 10.1111/j.1365-3016.2009.01036.x; Cuskelly GJ, 1996, LANCET, V347, P657, DOI 10.1016/S0140-6736(96)91205-2; Davies SC, 2014, ANN REPORT CHIEF MED, P167; De-Regil Luz Maria, 2015, Cochrane Database Syst Rev, pCD007950, DOI 10.1002/14651858.CD007950.pub3; De-Regil LM, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008873.pub3, 10.1590/1516-3180.20161343T2]; Dean S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001508; Dean SV, 2014, REPROD HEALTH, V11, DOI [10.1186/1742-4755-11-S3-S3, 10.1186/1742-4755-11-S3-S1]; Devakumar D, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0633-3; Dodd JM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0161-y; Flynn AC, 2016, INT J BEHAV NUTR PHY, V13, DOI 10.1186/s12966-016-0450-2; Galazis N, 2014, EUR J OBSTET GYN R B, V181, P45, DOI 10.1016/j.ejogrb.2014.07.015; Gao YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165626; Gardner B, 2011, OBES REV, V12, pE602, DOI 10.1111/j.1467-789X.2011.00884.x; Gnoth C, 2003, HUM REPROD, V18, P1959, DOI 10.1093/humrep/deg366; Godfrey KM, 2017, LANCET DIABETES ENDO, V5, P53, DOI 10.1016/S2213-8587(16)30107-3; Goossens J, 2016, HUM REPROD, V31, P2821, DOI 10.1093/humrep/dew266; Graham W, 2016, LANCET, V388, P2164, DOI 10.1016/S0140-6736(16)31533-1; Gresham E, 2016, PUBLIC HEALTH NUTR, V19, P2975, DOI 10.1017/S1368980016001245; Grieger JA, 2014, J NUTR, V144, P1075, DOI 10.3945/jn.114.190686; Habib MA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1339-z; Haider BA, 2015, COCHRANE DB SYST REV; Hall J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-200; Hall JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165621; Hanson M, 2017, LANCET DIABETES ENDO, V5, P65, DOI 10.1016/S2213-8587(16)30108-5; Hanson MA, 2015, INT J GYNECOL OBSTET, V131, pS213, DOI 10.1016/S0020-7292(15)30034-5; Harding KB, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011761.pub2; He Y, 2016, LANCET, V388, P91; Hodgetts VA, 2015, BJOG-INT J OBSTET GY, V122, P478, DOI 10.1111/1471-0528.13202; Inskip HM, 2006, INT J EPIDEMIOL, V35, P42, DOI 10.1093/ije/dyi202; International Weight Management in Pregnancy (i-WIP) Collaborative Group, 2017, BMJ, V358, pj3119, DOI 10.1136/bmj.j3119; Johansson K, 2015, NEW ENGL J MED, V372, P814, DOI 10.1056/NEJMoa1405789; Johnson KA, 2012, ACOUSTIC AUDITORY PH, P1; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Kort HI, 2006, J ANDROL, V27, P450, DOI 10.2164/jandrol.05124; Kumaran Kalyanaraman, 2017, BMC Nutr, V3, P41, DOI 10.1186/s40795-017-0143-5; Law DCG, 2007, HUM REPROD, V22, P414, DOI 10.1093/humrep/de1400; Lee C, 2005, INT J EPIDEMIOL, V34, P987, DOI 10.1093/ije/dyi098; Marchi J, 2015, OBES REV, V16, P621, DOI 10.1111/obr.12288; Mastroiacovo P, 2011, BIOFACTORS, V37, P272, DOI 10.1002/biof.172; Mitchell EW, 2012, MATERN CHILD HLTH J, V16, P31, DOI 10.1007/s10995-010-0663-y; Morof D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035381; Mosher William D, 2012, Natl Health Stat Report, P1; Muktabhant B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007145.pub3; National Center for Chronic Disease Prevention and Health Promo- tion (U.S.) Office on Smoking and Health, 2014, HLTH CONSMOK 50 YE; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Patel N, 2017, INT J OBESITY, V41, P1018, DOI 10.1038/ijo.2017.44; Pena-Rosas JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub4; Phelan S, 2017, JAMA-J AM MED ASSOC, V317, P2381, DOI 10.1001/jama.2017.7119; Poston L, 2016, LANCET DIABETES ENDO, V4, P1025, DOI 10.1016/S2213-8587(16)30217-0; Potdar RD, 2014, AM J CLIN NUTR, V100, P1257, DOI 10.3945/ajcn.114.084921; POTTER RG, 1964, POP STUD-J DEMOG, V18, P99, DOI 10.2307/2172634; Public Health England, 2016, GOV DIET REC GOV REC; Ramakrishnan U, 2012, PAEDIATR PERINAT EP, V26, P285, DOI 10.1111/j.1365-3016.2012.01281.x; Rao R, 2003, J NUTR, V133, P3215, DOI 10.1093/jn/133.10.3215; Reeves Shane, 2008, Expert Rev Obstet Gynecol, V3, P719, DOI 10.1586/17474108.3.6.719; Rocca C, 2016, CONTRACEPTION, V94, P423, DOI 10.1016/j.contraception.2016.07.148; Rocca CH, 2010, DEMOGR RES, V23, P293, DOI 10.4054/DemRes.2010.23.11; Roshanaei S, 2015, E MEDITERR HEALTH J, V21, P572, DOI 10.26719/2015.21.8.572; Sahariah SA, 2016, J NUTR, V146, p1453S, DOI 10.3945/jn.115.223461; Schoenaker DAJM, 2016, AM J CLIN NUTR, V104, P638, DOI 10.3945/ajcn.116.133884; Schoenaker DAJM, 2015, DIABETOLOGIA, V58, P2726, DOI 10.1007/s00125-015-3742-1; Schoenaker DAJM, 2015, AM J CLIN NUTR, V102, P94, DOI 10.3945/ajcn.114.102475; Schummers L, 2015, OBSTET GYNECOL, V125, P133, DOI 10.1097/AOG.0000000000000591; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Stephenson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103085; Stoltzfus RJ, 2001, J NUTR, V131, p565S, DOI 10.1093/jn/131.2.565S; Syngelaki A, 2016, NEW ENGL J MED, V374, P434, DOI 10.1056/NEJMoa1509819; The Demographic and Health Surveys Programme, MOD WOM QUEST; Tian X, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.113910; Tobias DK, 2012, AM J CLIN NUTR, V96, P289, DOI 10.3945/ajcn.111.028266; Tobias DK, 2011, DIABETES CARE, V34, P223, DOI 10.2337/dc10-1368; Turcksin R, 2014, MATERN CHILD NUTR, V10, P166, DOI 10.1111/j.1740-8709.2012.00439.x; US AID Strengthening Partnerships Results and Innovations in Nutrition Globally (SPRING), 2015, NUTR AD GIRLS WOM RE; Borges ALV, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1037-2; Wellings K, 2013, LANCET, V382, P1807, DOI 10.1016/S0140-6736(13)62071-1; WHO Food and Agricultural Organization of the United Nations, 2006, GUIDELINES FOOD FORT; Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8; Yi XY, 2015, INT J GYNECOL OBSTET, V130, P3, DOI 10.1016/j.ijgo.2015.01.011; Zhang C, 2006, DIABETOLOGIA, V49, P2604, DOI 10.1007/s00125-006-0422-1; Zhang CL, 2006, ARCH INTERN MED, V166, P543, DOI 10.1001/archinte.166.5.543; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	103	453	460	22	214	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2018	391	10132					1830	1841		10.1016/S0140-6736(18)30311-8	http://dx.doi.org/10.1016/S0140-6736(18)30311-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE7NY	29673873	Green Accepted, Green Submitted			2023-01-03	WOS:000431421300028
J	Uhlich, GA; Andreozzi, E; Cottrell, BJ; Reichenberger, ER; Zhang, XM; Paoli, GC				Uhlich, Gaylen A.; Andreozzi, Elise; Cottrell, Bryan J.; Reichenberger, Erin R.; Zhang, Xinmin; Paoli, George C.			Sulfamethoxazole-Trimethoprim represses csgD but maintains virulence genes at 30 degrees C in a clinical Escherichia coli O157:H7 isolate	PLOS ONE			English	Article							HEMOLYTIC-UREMIC SYNDROME; ENTEROCYTE EFFACEMENT GENES; BIOFILM FORMATION; CONTROLS EXPRESSION; LOCUS; O157-H7; REGULATOR; PROMOTER; TRANSCRIPTION; ANTIBIOTICS	The high frequency of prophage insertions in the mlrA gene of clinical serotype O157: H7 isolates renders such strains deficient in csgD-dependent biofilm formation but prophage induction may restore certain mlrA properties. In this study we used transcriptomics to study the effect of high and low sulfamethoxazole-trimethoprim (SMX-TM) concentrations on prophage induction, biofilm regulation, and virulence gene expression in strain PA20 under environmental conditions following 5-hour and 12-hour exposures in broth or on agar. SMXTM at a sub-lethal concentration induced strong RecA expression resulting in concentrationand time-dependent major transcriptional shifts with emphasis on up-regulation of genes within horizontally-transferred chromosomal regions (HTR). Neither high or low levels of SMX-TM stimulated csgD expression at either time point, but both levels resulted in slight repression. Full expression of Ler-dependent genes paralleled expression of group 1 pch homologues in the presence of high glrA. Finally, stx(2) expression, which is strongly dependent on prophage induction, was enhanced at 12 hours but repressed at five hours, in spite of early SOS initiation by the high SMX-TM concentration. Our findings indicate that, similar to host conditions, exposure to environmental conditions increased the expression of virulence genes in a clinical isolate but genes involved in the protective biofilm response were repressed.	[Uhlich, Gaylen A.; Andreozzi, Elise; Cottrell, Bryan J.; Reichenberger, Erin R.; Paoli, George C.] ARS, USDA, Mol Characterizat Foodborne Pathogens Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA 19038 USA; [Zhang, Xinmin] BioInfoRx Inc, Madison, WI USA	United States Department of Agriculture (USDA)	Uhlich, GA (corresponding author), ARS, USDA, Mol Characterizat Foodborne Pathogens Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA 19038 USA.	gaylen.uhlich@ars.usda.gov			United States Department of Agriculture, Agricultural Research Service, National Program 108 Food Safety [8072-42000-076]; BioInfoRx Inc.	United States Department of Agriculture, Agricultural Research Service, National Program 108 Food Safety; BioInfoRx Inc.	This work was supported by United States Department of Agriculture, Agricultural Research Service, National Program 108 Food Safety [Project # 8072-42000-076] (GAU). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Neither Dr. Xinmin Zhang or BioInfoRx Inc. provided financial support in any form. The specific roles of this author are detailed in the 'Author Contributions' section. Dr. Xinmin Zhang's affiliation with BioInfoRx, Inc.	[Anonymous], R LANG ENV STAT COMP; Asadulghani M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000408; Barba J, 2005, J BACTERIOL, V187, P7918, DOI 10.1128/JB.187.23.7918-7930.2005; Bingle LEH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0080160; Boerlin P, 1999, J CLIN MICROBIOL, V37, P497, DOI 10.1128/JCM.37.3.497-503.1999; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; Boyd E Fidelma, 2012, Bacteriophage, V2, P139; Brown PK, 2001, MOL MICROBIOL, V41, P349, DOI 10.1046/j.1365-2958.2001.02529.x; Chen CJ, 2016, PHYS PLASMAS, V23, DOI 10.1063/1.4968841; COLLINSON SK, 1991, J BACTERIOL, V173, P4773, DOI 10.1128/jb.173.15.4773-4781.1991; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Elliott SJ, 2000, INFECT IMMUN, V68, P6115, DOI 10.1128/IAI.68.11.6115-6126.2000; Elliott SJ, 1998, MOL MICROBIOL, V28, P1, DOI 10.1046/j.1365-2958.1998.00783.x; Ethelberg S, 2004, EMERG INFECT DIS, V10, P842, DOI 10.3201/eid1005.030576; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; Freedman SB, 2016, CLIN INFECT DIS, V62, P1251, DOI 10.1093/cid/ciw099; Frye JG, 2005, J BACTERIOL, V187, P1485, DOI 10.1128/JB.187.4.1485-1492.2005; Garcia A, 2010, ILAR J, V51, P221, DOI 10.1093/ilar.51.3.221; Gerstel U, 2003, RES MICROBIOL, V154, P659, DOI 10.1016/j.resmic.2003.08.005; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Herold S, 2005, ANTIMICROB AGENTS CH, V49, P931, DOI 10.1128/AAC.49.3.931-944.2005; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Iyoda S, 2004, MICROBIOL-SGM, V150, P2357, DOI 10.1099/mic.0.27100-0; Jorgensen MG, 2012, MOL MICROBIOL, V84, P36, DOI 10.1111/j.1365-2958.2012.07976.x; Kimmitt PT, 2000, EMERG INFECT DIS, V6, P458, DOI 10.3201/eid0605.000503; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Landstorfer R, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-353; Lara-Ochoa C, 2010, CURRENT RES TECHNOLO, V1, P635; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lim JY, 2010, J MICROBIOL BIOTECHN, V20, P5, DOI 10.4014/jmb.0908.08007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McGannon CM, 2010, ANTIMICROB AGENTS CH, V54, P3790, DOI 10.1128/AAC.01783-09; Mellies JL, 2007, INFECT IMMUN, V75, P4199, DOI 10.1128/IAI.01927-06; Mellies JL, 1999, MOL MICROBIOL, V33, P296, DOI 10.1046/j.1365-2958.1999.01473.x; Miyashita A, 2012, FEMS MICROBIOL LETT, V333, P59, DOI 10.1111/j.1574-6968.2012.02599.x; Ogasawara H, 2010, FEMS MICROBIOL LETT, V312, P160, DOI 10.1111/j.1574-6968.2010.02112.x; Ogasawara H, 2010, MICROBIOL-SGM, V156, P2470, DOI 10.1099/mic.0.039131-0; Pennington H, 2010, LANCET, V376, P1428, DOI 10.1016/S0140-6736(10)60963-4; Porter ME, 2005, J BACTERIOL, V187, P458, DOI 10.1128/JB.187.2.458-472.2005; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Russell RM, 2007, J BACTERIOL, V189, P5387, DOI 10.1128/JB.00553-07; Sangurdekar DP, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-583; Scheiring J, 2008, PEDIATR NEPHROL, V23, P1749, DOI 10.1007/s00467-008-0935-6; Shaikh N, 2003, J BACTERIOL, V185, P3596, DOI 10.1128/JB.185.12.3596-3605.2003; Sharp FC, 2007, INFECT IMMUN, V75, P2432, DOI 10.1128/IAI.02003-06; Snedecor G.W., 1983, AMES IOWA STATE U PR, V6th; Sommerfeldt N, 2009, MICROBIOL-SGM, V155, P1318, DOI 10.1099/mic.0.024257-0; Sperandio V, 2000, MOL MICROBIOL, V38, P781, DOI 10.1046/j.1365-2958.2000.02168.x; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Thomason MK, 2010, ANNU REV GENET, V44, P167, DOI 10.1146/annurev-genet-102209-163523; Tobe T, 2006, P NATL ACAD SCI USA, V103, P14941, DOI 10.1073/pnas.0604891103; Tree JJ, 2009, TRENDS MICROBIOL, V17, P361, DOI 10.1016/j.tim.2009.06.001; Uhlich GA, 2017, GENOME ANNOUNCEMENTS, V5, DOI 10.1128/genomeA.01460-16; Uhlich GA, 2017, MICROBIOL-SGM, V163, P611, DOI 10.1099/mic.0.000448; Uhlich GA, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw123; Uhlich GA, 2013, MICROBIOL-SGM, V159, P1586, DOI 10.1099/mic.0.066118-0; Uhlich GA, 2012, PLASMID, V67, P259, DOI 10.1016/j.plasmid.2011.12.003; Uhlich GA, 2009, MICROBIOL-SGM, V155, P3589, DOI 10.1099/mic.0.031435-0; Wagner PL, 2001, J BACTERIOL, V183, P2081, DOI 10.1128/JB.183.6.2081-2085.2001; Wang GQ, 2010, FEBS LETT, V584, P194, DOI 10.1016/j.febslet.2009.11.067; Wang X, 2005, MOL MICROBIOL, V56, P1648, DOI 10.1111/j.1365-2958.2005.04648.x; Williams AP, 2006, FEMS MICROBIOL ECOL, V58, P54, DOI 10.1111/j.1574-6941.2006.00142.x; Zhang LH, 2004, INFECT IMMUN, V72, P7282, DOI 10.1128/IAI.72.12.7282-7293.2004	64	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2018	13	5							e0196271	10.1371/journal.pone.0196271	http://dx.doi.org/10.1371/journal.pone.0196271			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE5SH	29718957	Green Published, Green Submitted, gold			2023-01-03	WOS:000431281900049
J	Dutta, S; Chakraborty, AK; Dey, P; Kar, P; Guha, P; Sen, S; Kumar, A; Sen, A; Chaudhuri, TK				Dutta, Somit; Chakraborty, Arnab Kumar; Dey, Priyankar; Kar, Pallab; Guha, Pokhraj; Sen, Subhajit; Kumar, Anoop; Sen, Arnab; Chaudhuri, Tapas Kumar			Amelioration of CCl4 induced liver injury in swiss albino mice by antioxidant rich leaf extract of Croton bonplandianus Baill	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; CARBON-TETRACHLORIDE; OXIDATIVE STRESS; NITRIC-OXIDE; GLUTATHIONE DEPLETION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; HEPATOTOXICITY; HEPATOCYTES; SENSITIZATION	The progress in industrialization has blessed mankind with a technologically superior lifestyle but poor management of industrial waste has in turn poisoned nature. One such chemical is carbon tetra chloride (CCl4), which is a potent environmental toxin emitted from chemical industries and its presence in the atmosphere is increasing at an alarming rate. Presence of CCl4 in human body is reported to cause liver damage through free radical mediated inflammatory processes. Kupffer cells present in the liver are potentially more sensitive to oxidative stress than hepatocytes. Kuffer cells produced tumor necrosis factor-alpha (TNF-alpha) in response to reactive oxygen species (ROS), that might further cause inflammation or apoptosis. In this study hepatoprotective capacity of antioxidant rich extract of Croton bonplandianus Baill. (CBL) was evaluated on CCl4 induced acute hepatotoxicity in murine model. Hydro-methanolic extract of C. bonplandianus leaf was used for evaluation of free radical scavenging activity. Liver cells of experimental mice were damaged using CCl4 and subsequently hepatoprotective potential of the plant extract was evaluated using series of in-vivo and in-vitro studies. In the hepatoprotective study, silymarin was used as a positive control. Antioxidant enzymes, pro-inflammatory markers, liver enzymatic and biochemical parameters were studied to evaluate hepatoprotective activity of Croton bonplandianus leaf extract. Free radical scavenging activity of CBL extract was also observed in WRL-68 cell line. The phytochemicals identified by GCMS analysis were scrutinized using in-silico molecular docking procedure. The results showed that CBL extract have potent free radical scavenging capacity. The biochemical parameters were over expressed due to CCl4 administration, which were significantly normalized by CBL extract treatment. This finding was also supported by histopathological evidences showing less hepatocellularnecrosis, inflammation and fibrosis in CBL and silymarin treated group, compared to CCl4 group. ROS generated due to H2O2 in WRL-68 cell line were normalize in the highest group (200 mu g/ml) when compared with control and negative control (CCl4) group. After molecular docking analysis, it was observed that the compound alpha-amyrin present in the leaf extract of C. bonplandianus has better potentiality to protect hepatocellular damages than the standard drug Silymarin. The present study provided supportive evidence that CBL extract possesses potent hepatoprotective capacity by ameliorating haloalkane induced liver injury in the murine model. The antioxidant and anti-inflammatory activities also affirm the same. The synergistic effects of the phytochemicals present in CBL are to be credited for all the hepatoprotective activity claimed above.	[Dutta, Somit; Dey, Priyankar; Guha, Pokhraj; Chaudhuri, Tapas Kumar] Univ North Bengal, Dept Zool, Cellular Immunol Lab, Siliguri, W Bengal, India; [Chakraborty, Arnab Kumar; Kar, Pallab; Sen, Arnab] Univ North Bengal, Dept Bot, Mol Genet Lab, Siliguri, W Bengal, India; [Sen, Subhajit] Univ N Bengal, Dept Biotechnol, OMICS Lab, Siliguri, W Bengal, India; [Kumar, Anoop] Univ North Bengal, Dept Biotechnol, ANMOL Lab, Siliguri, W Bengal, India; [Chaudhuri, Tapas Kumar] Bodoland Univ, Dept Zool, Kokrajhar, Assam, India	University of North Bengal; University of North Bengal; University of North Bengal; University of North Bengal	Chaudhuri, TK (corresponding author), Univ North Bengal, Dept Zool, Cellular Immunol Lab, Siliguri, W Bengal, India.; Chaudhuri, TK (corresponding author), Bodoland Univ, Dept Zool, Kokrajhar, Assam, India.	dr_tkc_nbu@rediffmail.com	Dey, Priyankar/AAG-5125-2022; Dey, Priyankar/AFE-4921-2022; Kumar, Anoop/ABB-7336-2020; KAR, PALLAB/AAZ-4222-2021	Dey, Priyankar/0000-0002-9513-425X; Dey, Priyankar/0000-0002-9513-425X; Guha, Dr. Pokhraj/0000-0003-0952-8111				Al-Shabanah OA, 1999, LIFE SCI, V66, P265; Amacher DE, 2002, HUM EXP TOXICOL, V21, P253, DOI 10.1191/0960327102ht247oa; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Aruoma O. I., 2003, MUTAT RES, V532, P9; Barzegar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026012; Bhakat R. K., 2008, TRIBES TRIBALS, V2, P55; Branda M, 2006, HEPATOLOGY, V43, P891, DOI 10.1002/hep.21196; Cederbaum AI, 2009, ARCH TOXICOL, V83, P519, DOI 10.1007/s00204-009-0432-0; Chaudhuri A.B., 2007, ENDANGERED MED PLANT, P226; Chia R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010627; Cichoz-Lach H, 2014, WORLD J GASTROENTERO, V20, P8082, DOI 10.3748/wjg.v20.i25.8082; De Iuliis GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006446; DEGROOT H, 1988, ARCH BIOCHEM BIOPHYS, V264, P591, DOI 10.1016/0003-9861(88)90325-6; Dey P, 2013, J PHARM SCI INNOV, V2, P1; Dey P, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1260-4; Dey P, 2015, CHEM-BIOL INTERACT, V235, P37, DOI 10.1016/j.cbi.2015.03.025; Di Meo S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1245049; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Feng YB, 2011, J ETHNOPHARMACOL, V138, P683, DOI 10.1016/j.jep.2011.09.032; Flora SJS, 2008, INDIAN J MED RES, V128, P501; Freshney R.I., 2005, CULTURE ANIMAL CELLS, DOI [10.1002/0471747599.CAC022, DOI 10.1002/0471747599.CAC022]; Gabele E, 2009, BIOCHEM BIOPH RES CO, V378, P348, DOI 10.1016/j.bbrc.2008.10.155; Hazra B, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-20; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Hoffman A, 2008, FREE RADICAL BIO MED, V45, P265, DOI 10.1016/j.freeradbiomed.2008.03.025; Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c; Islam M. S., 2010, International Journal of Agricultural Technology, V6, P79; KIECZKA H, 1980, TOXICOL LETT, V5, P191, DOI 10.1016/0378-4274(80)90058-2; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Luck H., 1971, CATALASE METHODS ENZ; Mahakunakorn P, 2004, BIOL PHARM BULL, V27, P38, DOI 10.1248/bpb.27.38; Marvibaigi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158942; MASUDA Y, 1990, BIOCHEM PHARMACOL, V40, P1865; Matsumaru K, 2003, HEPATOLOGY, V37, P1425, DOI 10.1053/jhep.2003.50230; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Mishra S, 2011, INDIAN J NAT PROD RE, V2, P515; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Morio LA, 2001, TOXICOL APPL PHARM, V172, P44, DOI 10.1006/taap.2000.9133; Nagai H, 2002, HEPATOLOGY, V36, P55, DOI 10.1053/jhep.2002.33995; Nishanta R, 2012, PHARM BIOL, V40, P235; OHNO Y, 1985, J BIOL CHEM, V260, P8438; RUPRAH M, 1985, LANCET, V1, P1027, DOI 10.1016/S0140-6736(85)91624-1; RUWART MJ, 1989, HEPATOLOGY, V10, P801, DOI 10.1002/hep.1840100509; Sadasivam S., 2008, BIOCH METHODS, V3rd; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Torres MCM, 2008, CHEM BIODIVERS, V5, P2724, DOI 10.1002/cbdv.200890227; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Tsai CF, 2009, FOOD CHEM TOXICOL, V47, P2031, DOI 10.1016/j.fct.2009.05.021; U.S. Environmental Protection Agency, 2010, TOX REV CARB TETR; Vadlapudi V, 2010, PHARMACOPHORE, V1, P214; Valko M, 2004, MOL CELL BIOCHEM, V266, P37, DOI 10.1023/B:MCBI.0000049134.69131.89; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Zhang DY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021397; Zhang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046574; Zimmerman H J, 2000, Clin Liver Dis, V4, P73, DOI 10.1016/S1089-3261(05)70097-0; Zimmerman HJ., 1998, TOXICOLOGY LIVER, P3	56	58	61	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196411	10.1371/journal.pone.0196411	http://dx.doi.org/10.1371/journal.pone.0196411			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE3RI	29709010	Green Published, gold, Green Submitted			2023-01-03	WOS:000431130100025
J	Graham-Clarke, E; Rushton, A; Noblet, T; Marriott, J				Graham-Clarke, Emma; Rushton, Alison; Noblet, Timothy; Marriott, John			Facilitators and barriers to non-medical prescribing - A systematic review and thematic synthesis	PLOS ONE			English	Review							STAKEHOLDER VIEWS; NURSE	Introduction Non-medical prescribing has the potential to deliver innovative healthcare within limited finances. However, uptake has been slow, and a proportion of non-medical prescribers do not use the qualification. This systematic review aimed to describe the facilitators and barriers to non-medical prescribing in the United Kingdom. Methods The systematic review and thematic analysis included qualitative and mixed methods papers reporting facilitators and barriers to independent non-medical prescribing in the United Kingdom. The following databases were searched to identify relevant papers: AMED, ASSIA, BNI, CINAHL, EMBASE, ERIC, MEDLINE, Open Grey, Open access theses and dissertations, and Web of Science. Papers published between 2006 and March 2017 were included. Studies were quality assessed using a validated tool (QATSDD), then underwent thematic analysis. The protocol was registered with PROSPERO (CRD42015019786). Results Of 3991 potentially relevant identified studies, 42 were eligible for inclusion. The studies were generally of moderate quality (83%), and most (71%) were published 2007-2012. The nursing profession dominated the studies (30/42). Thematic analysis identified three overarching themes: non-medical prescriber, human factors, and organisational aspects. Each theme consisted of several sub-themes; the four most highly mentioned were 'medical professionals', 'area of competence', 'impact on time' and 'service'. Sub-themes were frequently interdependent on each other, having the potential to act as a barrier or facilitator depending on circumstances. Discussion Addressing the identified themes and subthemes enables strategies to be developed to support and optimise non-medical prescribing. Further research is required to identify if similar themes are encountered by other non-medical prescribing groups than nurses and pharmacists.	[Graham-Clarke, Emma; Marriott, John] Univ Birmingham, Inst Clin Sci, Sch Pharm, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Rushton, Alison; Noblet, Timothy] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Coll Life & Environm Sci, Ctr Precis Rehabil Spinal Pain, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Graham-Clarke, E (corresponding author), Univ Birmingham, Inst Clin Sci, Sch Pharm, Coll Med & Dent Sci, Birmingham, W Midlands, England.	EMG315@bham.ac.uk	Noblet, Tim/AAK-9611-2021; Graham-Clarke, Emma/GZG-8429-2022; Graham-Clarke, Emma/U-1559-2019; Rushton, Alison/V-1260-2017	Graham-Clarke, Emma/0000-0001-5657-778X; Rushton, Alison/0000-0001-8114-7669				Adigwe O.P., 2012, THESIS U LEEDS; [Anonymous], 2016, COMP FRAM ALL PRESCR; [Anonymous], 2006, STAND PROF NURS MIDW; [Anonymous], 2016, PRESCR SURV REP, P54; Armstrong A., 2015, NURSE PRESCRIBING, V13, P614, DOI [10.12968/npre.2015.13.12.614, DOI 10.12968/NPRE.2015.13.12.614]; Bennett J, 2008, HIV NURSING, V8, P12; Bewley Toni, 2007, Paediatr Nurs, V19, P23; Bowskill D., 2009, INTEGRATION NURSE PR; Bowskill D, 2013, J CLIN NURS, V22, P2077, DOI 10.1111/j.1365-2702.2012.04338.x; Brodie L., 2014, NURSE PRESCRIBING, V12, P353, DOI [DOI 10.12968/NPRE.2014.12.7.353, 10.12968/npre.2014.12.7.353]; Carey N, 2009, NURSE PRESCRIBING, V7, P205, DOI DOI 10.12968/NPRE.2009.7.5.42356; Carey N, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-27; Carey Nicola, 2009, Paediatr Nurs, V21, P25; Carey N, 2010, J CLIN NURS, V19, P498, DOI 10.1111/j.1365-2702.2009.02874.x; Cooper RJ, 2008, HEALTH POLICY, V85, P277, DOI 10.1016/j.healthpol.2007.07.016; Courtenay M, 2008, J ADV NURS, V61, P291, DOI 10.1111/j.1365-2648.2007.04512.x; Courtenay M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-138; Courtenay M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-142; Courtenay M, 2009, J CLIN NURS, V18, P2668, DOI 10.1111/j.1365-2702.2009.02799.x; Courtenay M, 2009, J ADV NURS, V65, P1207, DOI 10.1111/j.1365-2648.2009.04974.x; Cousins R, 2012, FAM PRACT, V29, P223, DOI 10.1093/fampra/cmr077; Dapar MP, 2012, THESIS; Daughtry J., 2010, PRACTICE NURSING, V21, P310, DOI [DOI 10.12968/PNUR.2010.21.6.48329, 10.12968/pnur.2010.21.6.48329]; Department of Health, 2001, PAT GET QUICK ACC ME; Dobel-Ober D, 2010, J PSYCHIATR MENT HLT, V17, P487, DOI 10.1111/j.1365-2850.2009.01541.x; Dorer, 2010, EVALUATION NURSE PHA; Downer Frances, 2010, Br J Community Nurs, V15, P348; EPPI, 2007, EPPI CTR METH COND S; Green B., 2008, MENTAL HLTH PRACTICE, V12, P28; Hannes K., 2011, SUPPLEMENTARY GUIDAN; Hannes K, 2010, QUAL HEALTH RES, V20, P1736, DOI 10.1177/1049732310378656; Herklots Annie, 2015, Br J Community Nurs, V20, P217, DOI 10.12968/bjcn.2015.20.5.217; Hill DR, 2014, J SUBST USE, V19, P56, DOI 10.3109/14659891.2012.734540; Kelly Amber, 2010, Community Pract, V83, P21; Lewin S, 2011, SUPPLEMENTARY GUIDAN, Vfirst; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Loughran I, 2015, NURSE PRESCRIBING, V13, P94, DOI [10.12968/npre.2015.13.2.94, DOI 10.12968/NPRE.2015.13.2.94]; MacLure K, 2013, INT J CLIN PHARM-NET, V35, P704, DOI 10.1007/s11096-013-9792-x; Maddox C, 2016, RES SOC ADMIN PHARM, V12, P41, DOI 10.1016/j.sapharm.2015.04.001; Maddox C, 2011, THESIS; McCann L, 2012, J INTERPROF CARE, V26, P127, DOI 10.3109/13561820.2011.642425; McCann L, 2011, INT J CLIN PHARM-NET, V33, P824, DOI 10.1007/s11096-011-9545-7; McCann LM, 2015, HEALTH EXPECT, V18, P58, DOI 10.1111/hex.12008; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mulholland PJ, 2014, EUR J HOSP PHARM-S P, V21, P335, DOI 10.1136/ejhpharm-2013-000401; Mundt-Leach R, 2012, MENTAL HLTH PRACTICE, V16, P28; NHS England, 2015, NHS ENGL SETS OUT PR; NHS England, 2017, NEXT STEPS NHS 5 YEA; Nursing and Midwifery Council, 2017, NURS MIDW COUNC ANN; Oldknow H, 2013, MENTAL HLTH NURSING, V33, P10; Oldknow H., 2010, NURSE PRESCRIBING, V8, P66, DOI DOI 10.12968/NPRE.2010.8.2.46527; Phelps A, 2014, GPHC REGISTRANT SURV; Ross JD, 2015, J PSYCHIATR MENT HLT, V22, P529, DOI 10.1111/jpm.12207; Ross JD, 2012, J PSYCHIATR MENT HLT, V19, P916, DOI 10.1111/j.1365-2850.2011.01872.x; Sandelowski Margarete, 2006, Res Sch, V13, P29; Shannon E., 2011, BRIT J CARDIAC NURSI, V6, P450, DOI [10.12968/bjca.2011.6.9.450, DOI 10.12968/BJCA.2011.6.9.450]; Shaw R. L., 2004, BMC MED RES METHODOL, V4, P1, DOI DOI 10.1186/1471-2288-4-5; Sirriyeh R, 2012, J EVAL CLIN PRACT, V18, P746, DOI 10.1111/j.1365-2753.2011.01662.x; Stenner K., 2007, NURSE PRESCRIBING, V5, P257, DOI DOI 10.12968/NPRE.2007.5.6.24292; Stenner K, 2008, J ADV NURS, V63, P276, DOI 10.1111/j.1365-2648.2008.04707.x; Stenner K, 2008, J ADV NURS, V63, P27, DOI 10.1111/j.1365-2648.2008.04644.x; Stenner K, 2010, J ADV NURS, V66, P522, DOI 10.1111/j.1365-2648.2009.05212.x; Stenner KL, 2011, INT J NURS STUD, V48, P37, DOI 10.1016/j.ijnurstu.2010.06.006; The Health Foundation, 2016, STAFF MATT FUND COUN; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Tong A, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-181	67	30	30	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196471	10.1371/journal.pone.0196471	http://dx.doi.org/10.1371/journal.pone.0196471			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE3RI	29709006	Green Published, gold			2023-01-03	WOS:000431130100030
J	Regolisti, G; Maggiore, U; Sabatino, A; Gandolfini, I; Pioli, S; Torino, C; Aucella, F; Cupisti, A; Pistolesi, V; Capitanini, A; Caloro, G; Gregorini, M; Battaglia, Y; Mandreoli, M; Dani, L; Mosconi, G; Bellizzi, V; Di Iorio, BR; Conti, P; Fiaccadori, E				Regolisti, Giuseppe; Maggiore, Umberto; Sabatino, Alice; Gandolfini, Ilaria; Pioli, Sarah; Torino, Claudia; Aucella, Filippo; Cupisti, Adamasco; Pistolesi, Valentina; Capitanini, Alessandro; Caloro, Giorgia; Gregorini, Mariacristina; Battaglia, Yuri; Mandreoli, Marcora; Dani, Lucia; Mosconi, Giovanni; Bellizzi, Vincenzo; Di Iorio, Biagio Raffaele; Conti, Paolo; Fiaccadori, Enrico		Soc Italiana Nefrologia	Interaction of healthcare staff's attitude with barriers to physical activity in hemodialysis patients: A quantitative assessment	PLOS ONE			English	Article							STAGE RENAL-DISEASE; QUALITY-OF-LIFE; EXERCISE PARTICIPATION; AMBULATORY PATIENTS; DIALYSIS; NEPHROLOGISTS; ADULTS; ASSOCIATION; DEPRESSION; MORTALITY	Background and aim of the study In hemodialysis patients, sedentarism is a potentially modifiable mortality risk factor. We explored whether healthcare staff's attitude towards exercise interacts with patient-perceived barriers in modifying the level of physical activity in this population. Methods In this prospective, cross-sectional, multicenter study we recruited 608 adult patients and 330 members of the healthcare staff in 16 hemodialysis units in Italy. We assessed patient-perceived barriers to, and healthcare staff's attitude towards, exercise by specific questionnaires. We fitted multilevel linear models to analyze the relationships of either barriers or staff's attitude, and their interaction, with a measure of patient self-reported physical activity (the Human Activity Profile-Adjusted Activity Score [HAP-AAS]), adjusting for multiple confounders. We also employed latent class analysis to dichotomize patients into those endorsing or not endorsing barriers. Results Most barriers were negatively associated with the HAP-AAS (adjusted change attributable to a given barrier ranging between -5.1 ["Feeling too old", 95% Confidence Interval: -9.4 to -0.8] and -15.6 ["Ulcers on legs and feet", 95%CI: -24.8 to -6.5]. We found a significant interaction between staff's attitude and barriers (adjusted P values ranging between 0.03 ["I do not believe that it is physician's or nurse's role providing advice on exercise to patients on dialysis"] and 0.001 ["I do not often ask patients about exercise"]). A beneficial effect of a proactive staff's attitude was evident only in patients not endorsing barriers. Conclusions Barriers and non-proactive staff's attitude reduce physical activity in hemodialysis patients. Patients not endorsing barriers benefit the most from a proactive staff's attitude.	[Regolisti, Giuseppe; Maggiore, Umberto; Sabatino, Alice; Gandolfini, Ilaria; Fiaccadori, Enrico] Univ Parma, Unita Fisiopatol Insufficienza Renale, Parma, Italy; [Regolisti, Giuseppe; Maggiore, Umberto; Sabatino, Alice; Gandolfini, Ilaria; Fiaccadori, Enrico] Univ Parma, Scuola Specializzaz Nefrol, Parma, Italy; [Maggiore, Umberto; Gandolfini, Ilaria; Fiaccadori, Enrico] Univ Parma, Ctr Trapianti Rene Pancreas, Azienda Osped, Parma, Italy; [Pioli, Sarah] Nefrol ASL Parma, Parma, Italy; [Torino, Claudia] Nefrol Dialisi & Trapianto, Reggio Di Calabria, Italy; [Aucella, Filippo] IRCCS Casa Sollievo Sofferenza, Nefrol & Dialisi, Foggia, Italy; [Cupisti, Adamasco] Univ Pisa, Dipartimento Med Clin & Sperimentale, Pisa, Italy; [Pistolesi, Valentina] Policlin, SSD Dialisi, Rome, Italy; [Capitanini, Alessandro] Nefrologia, Pistoia, Italy; [Caloro, Giorgia] Nefrol Dialisi & Trapianto, Bari, Italy; [Gregorini, Mariacristina] Nefrol & Dialisi ASMN, Reggio Emilia, Italy; [Battaglia, Yuri] Nefrologia, Ferrara, Italy; [Mandreoli, Marcora] Nefrol & Dialisi, Imola, Italy; [Dani, Lucia] Nefrol & Dialisi, San Miniato, Empoli, Italy; [Mosconi, Giovanni] Nefrol & Dialisi, Forli, Italy; [Bellizzi, Vincenzo] Nefrol & Dialisi, Salerno, Italy; [Di Iorio, Biagio Raffaele] AOSG Moscati, Nefrol & Dialisi, Avellino, Italy; [Conti, Paolo] Azienda USL Toscana Sud Est, Nefrol & Dialisi, Grosseto, Italy	University of Parma; University of Parma; University of Parma; University Hospital of Parma; IRCCS Casa Sollievo Della Sofferenza; University of Pisa; San Giuseppe Moscati Hospital	Regolisti, G (corresponding author), Univ Parma, Unita Fisiopatol Insufficienza Renale, Parma, Italy.; Regolisti, G (corresponding author), Univ Parma, Scuola Specializzaz Nefrol, Parma, Italy.	giuregolisti@gmail.com	Sabatino, Alice/L-2846-2019; Battaglia, Yuri/AAN-4982-2020; Pistolesi, Valentina/J-9975-2016; Regolisti, Giuseppe/AAH-4766-2021; Torino, Claudia/AAF-3693-2019	Sabatino, Alice/0000-0003-2098-7597; Battaglia, Yuri/0000-0003-3947-1814; Pistolesi, Valentina/0000-0002-9720-9462; Regolisti, Giuseppe/0000-0002-9976-5681; Torino, Claudia/0000-0002-4967-0916; Maggiore, Umberto/0000-0002-7468-9600; CUPISTI, ADAMASCO/0000-0002-8995-936X; Aucella, Filippo/0000-0003-1027-7049				Abdulnassir L, 2017, CLIN KIDNEY J, V10, P516, DOI 10.1093/ckj/sfw142; [Anonymous], 2017, STATA STRUCTURAL EQU, P483; Bennett PN, 2010, SEMIN DIALYSIS, V23, P62, DOI 10.1111/j.1525-139X.2009.00652.x; Bossola M, 2014, BLOOD PURIFICAT, V38, P24, DOI 10.1159/000363599; Bulckaen M, 2011, J NEPHROL, V24, P790, DOI 10.5301/JN.2011.6386; Capitanini A, 2014, KIDNEY BLOOD PRESS R, V39, P129, DOI 10.1159/000355787; CARNEY RM, 1987, NEPHRON, V47, P194, DOI 10.1159/000184490; Chan DW, 2016, HEMODIAL INT, V20, P650, DOI 10.1111/hdi.12432; Chang YM, 2010, INT J NURS STUD, V47, P1383, DOI 10.1016/j.ijnurstu.2010.05.002; Davidson M, 2007, CLIN REHABIL, V21, P151, DOI 10.1177/0269215506069475; Delgado C, 2012, NEPHROL DIAL TRANSPL, V27, P1152, DOI 10.1093/ndt/gfr404; Delgado C, 2010, NEPHRON CLIN PRACT, V116, pC330, DOI 10.1159/000319593; Fiaccadori E, 2014, KIDNEY BLOOD PRESS R, V39, P169, DOI 10.1159/000355793; Hagenaars J.A., 2002, APPL LATENT CLASS AN, DOI DOI 10.1017/CBO9780511499531; Heiwe S, 2014, AM J KIDNEY DIS, V64, P383, DOI 10.1053/j.ajkd.2014.03.020; Jhamb M, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0399-z; Johansen KL, 2013, SEMIN DIALYSIS, V26, P690, DOI 10.1111/sdi.12126; Johansen KL, 2013, CLIN J AM SOC NEPHRO, V8, P248, DOI 10.2215/CJN.08560812; Johansen KL, 2010, KIDNEY INT, V78, P1164, DOI 10.1038/ki.2010.312; Johansen KL, 2003, AM J KIDNEY DIS, V41, P171, DOI 10.1053/ajkd.2003.50001; Johansen KL, 2001, KIDNEY INT, V59, P1121, DOI 10.1046/j.1523-1755.2001.00597.x; Jung Tae-Du, 2011, Chonnam Med J, V47, P61, DOI 10.4068/cmj.2011.47.2.61; Kontos PC, 2007, INT UROL NEPHROL, V39, P1303, DOI 10.1007/s11255-007-9265-z; Kutner NG, 2010, SEMIN NEPHROL, V30, P59, DOI 10.1016/j.semnephrol.2009.10.013; Lopes AA, 2014, CLIN J AM SOC NEPHRO, V9, P1702, DOI 10.2215/CJN.12371213; Manfredini F, 2017, J AM SOC NEPHROL, V28, P1259, DOI 10.1681/ASN.2016030378; O'Hare AM, 2003, AM J KIDNEY DIS, V41, P447, DOI 10.1053/ajkd.2003.50055; Painter P, 2000, AM J KIDNEY DIS, V35, P482, DOI 10.1016/S0272-6386(00)70202-2; Painter Patricia, 2004, Nephrol Nurs J, V31, P67; Painter P, 2014, AM J KIDNEY DIS, V64, P425, DOI 10.1053/j.ajkd.2014.01.433; Painter P, 2013, CURR OPIN NEPHROL HY, V22, P615, DOI 10.1097/MNH.0b013e328365b43a; Roshanravan B, 2012, AM J KIDNEY DIS, V60, P912, DOI 10.1053/j.ajkd.2012.05.017; Silva LC, 2015, J PHYS THER SCI, V27, P2991, DOI 10.1589/jpts.27.2991; Tentori F, 2010, NEPHROL DIAL TRANSPL, V25, P3050, DOI 10.1093/ndt/gfq138; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Young HML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128995; Zheng J, 2010, INT J NURS STUD, V47, P166, DOI 10.1016/j.ijnurstu.2009.05.023	37	35	36	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2018	13	4							e0196313	10.1371/journal.pone.0196313	http://dx.doi.org/10.1371/journal.pone.0196313			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE1YS	29702702	Green Submitted, gold, Green Published			2023-01-03	WOS:000431013300026
J	Cross, MR; Lahti, J; Brown, SR; Chedati, M; Jimenez-Reyes, P; Samozino, P; Eriksrud, O; Morin, JB				Cross, Matt R.; Lahti, Johan; Brown, Scott R.; Chedati, Mehdi; Jimenez-Reyes, Pedro; Samozino, Pierre; Eriksrud, Ola; Morin, Jean-Benoit			Training at maximal power in resisted sprinting: Optimal load determination methodology and pilot results in team sport athletes	PLOS ONE			English	Article							FORCE-VELOCITY PROFILE; MECHANICAL-PROPERTIES; SOCCER PLAYERS; RUGBY UNION; PERFORMANCE; KINEMATICS; INJURY	Aims In the current study we investigated the effects of resisted sprint training on sprinting performance and underlying mechanical parameters (force-velocity-power profile) based on two different training protocols: (i) loads that represented maximum power output (L-opt) and a 50% decrease in maximum unresisted sprinting velocity and (ii) lighter loads that represented a 10% decrease in maximum unresisted sprinting velocity, as drawn from previous research (L-10). Methods Soccer [n = 15 male] and rugby [n = 21; 9 male and 12 female] club-level athletes were individually assessed for horizontal force-velocity and load-velocity profiles using a battery of resisted sprints, sled or robotic resistance respectively. Athletes then performed a 12-session resisted (10 x 20-m; and pre-post-profiling) sprint training intervention following the L-10 or Lopt protocol. Results Both L-10 and L-opt training protocols had minor effects on sprinting performance (average of-1.4 to-2.3% split-times respectively), and provided trivial, small and unclear changes in mechanical sprinting parameters. Unexpectedly, L-opt impacted velocity dominant variables to a greater degree than L-10 (trivial benefit in maximum velocity; small increase in slope of the force-velocity relationship), while L-10 improved force and power dominant metrics (trivial benefit in maximal power; small benefit in maximal effectiveness of ground force orientation). Conclusions Both resisted-sprint training protocols were likely to improve performance after a short training intervention in already sprint trained athletes. However, widely varied individualised results indicated that adaptations may be dependent on pre-training force-velocity characteristics.	[Cross, Matt R.; Samozino, Pierre] Univ Savoie Mt Blanc, Lab Interuniv Biol Motricite, EA, Chambery, France; [Cross, Matt R.] Federat Francaise Ski, Dept Sci & Sportif, Annecy, France; [Cross, Matt R.; Brown, Scott R.; Morin, Jean-Benoit] Auckland Univ Technol, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Lahti, Johan; Chedati, Mehdi; Morin, Jean-Benoit] Univ Cote Azur, LAMHESS, Nice, France; [Lahti, Johan] Univ Jyvaskyla, Fac Sports & Hlth Sci, Jyvaskyla, Finland; [Brown, Scott R.] Univ Michigan, Med Sch, Dept Phys Med & Rehabil, Neuromuscular & Rehabil Robot Lab NeuRRo Lab, Ann Arbor, MI 48109 USA; [Jimenez-Reyes, Pedro] Catholic Univ San Antonio, Fac Phys Sci & Sport, Murcia, Spain; [Eriksrud, Ola] Norwegian Sch Sports Sci, Dept Phys Performance, Oslo, Norway	Auckland University of Technology; UDICE-French Research Universities; Universite Cote d'Azur; University of Jyvaskyla; University of Michigan System; University of Michigan; Universidad Catolica de Murcia; Norwegian School of Sport Sciences	Morin, JB (corresponding author), Auckland Univ Technol, Sports Performance Res Inst New Zealand, Auckland, New Zealand.; Morin, JB (corresponding author), Univ Cote Azur, LAMHESS, Nice, France.	jean-benoit.morin@unice.fr	Samozino, Pierre/R-1927-2019; Eriksrud, Ola/AAK-1328-2020; Cross, Matthew/AAP-8022-2021; Jimenez-Reyes, Pedro/P-1075-2016	Eriksrud, Ola/0000-0003-4971-6723; Cross, Matthew/0000-0003-1579-3720; Jimenez-Reyes, Pedro/0000-0002-8156-243X; Morin, Jean-Benoit/0000-0003-3808-6762	1080 Motion AB	1080 Motion AB	From the onset of the study to present, co-author Ola Eriksrud holds a position with 1080 Motion AB. 1080 Motion AB provided support for this project via shipping costs and use of the 1080 Sprint machine for data collection, and monetary support to the Universite Cote d'Azur via a collaboration contract. None of the authors received any commercial funding or salary in any form that would influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcaraz PE, 2009, J STRENGTH COND RES, V23, P480, DOI 10.1519/JSC.0b013e318198f92c; Chelly SM, 2001, MED SCI SPORT EXER, V33, P326; Cormie P, 2011, SPORTS MED, V41, P125, DOI 10.2165/11538500-000000000-00000; Cormie P, 2011, SPORTS MED, V41, P17, DOI 10.2165/11537690-000000000-00000; Cronin JB, 2005, J STRENGTH COND RES, V19, P349; Cross MR, 2018, EUR J APPL PHYSIOL, V118, P563, DOI 10.1007/s00421-017-3796-5; Cross MR, 2017, INT J SPORT PHYSIOL, V12, P1069, DOI 10.1123/ijspp.2016-0362; Cross MR, 2017, J SPORT SCI, V35, P2198, DOI 10.1080/02640414.2016.1261178; Cross MR, 2017, SPORTS MED, V47, P1255, DOI 10.1007/s40279-016-0653-3; Cross MR, 2015, INT J SPORT PHYSIOL, V10, P695, DOI 10.1123/ijspp.2014-0151; Dorel S, 2012, MED SCI SPORT EXER, V44, P2154, DOI 10.1249/MSS.0b013e3182625423; Dorel S, 2010, MED SCI SPORT EXER, V42, P1174, DOI 10.1249/MSS.0b013e3181c91f35; Giroux C, 2016, J APPL BIOMECH, V32, P59, DOI 10.1123/jab.2015-0070; Haugen T, 2018, INT J SPORT PHYSIOL, V13, P678, DOI 10.1123/ijspp.2017-0441; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Jimenez-Reyes P, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00677; Kawamori N, 2014, J SPORT SCI, V32, P1139, DOI 10.1080/02640414.2014.886129; Lockie RG, 2003, J STRENGTH COND RES, V17, P760; Mangine GT, 2018, J STRENGTH COND RES, V32, P1531, DOI 10.1519/JSC.0000000000002030; Marrier B, 2017, INT J SPORT PHYSIOL, V12, P1163, DOI 10.1123/ijspp.2016-0607; Mendiguchia J, 2016, J SPORT SCI, V34, P535, DOI 10.1080/02640414.2015.1122207; Mendiguchia J, 2014, INT J SPORTS MED, V35, P690, DOI 10.1055/s-0033-1363192; Morin JB, 2017, INT J SPORT PHYSIOL, V12, P840, DOI 10.1123/ijspp.2016-0444; Morin JB, 2016, INT J SPORT PHYSIOL, V11, P267, DOI 10.1123/ijspp.2015-0638; Morin JB, 2011, MED SCI SPORT EXER, V43, P1680, DOI 10.1249/MSS.0b013e318216ea37; Petrakos G, 2016, SPORTS MED, V46, P381, DOI 10.1007/s40279-015-0422-8; Samozino P, 2016, SCAND J MED SCI SPOR, V26, P648, DOI 10.1111/sms.12490; Samozino P, 2014, INT J SPORTS MED, V35, P505, DOI 10.1055/s-0033-1354382; Samozino P, 2012, MED SCI SPORT EXER, V44, P313, DOI 10.1249/MSS.0b013e31822d757a; Spinks CD, 2007, J STRENGTH COND RES, V21, P77, DOI 10.1519/00124278-200702000-00015	30	46	46	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2018	13	4							e0195477	10.1371/journal.pone.0195477	http://dx.doi.org/10.1371/journal.pone.0195477			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4GL	29641589	gold, Green Published, Green Submitted			2023-01-03	WOS:000429742900071
J	Chow, M; Gao, LN; MacManiman, JD; Bicocca, VT; Chang, BH; Alumkal, JJ; Tyner, JW				Chow, Marilynn; Gao, Lina; MacManiman, Jason D.; Bicocca, Vincent T.; Chang, Bill H.; Alumkal, Joshi J.; Tyner, Jeffrey W.			Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMI-METHYLATED DNA; CELL RECEPTOR; ANTIGEN ROR1; SRA DOMAIN; CANCER; EXPRESSION; NAPHTHAZARIN	Expression of the transmembrane pseudokinase ROR1 is required for survival of t(1;19)-pre-B-cell acute lymphoblastic leukemia (t(1;19) pre-B-ALL), chronic lymphocytic leukemia, and many solid tumors. However, targeting ROR1 with small-molecules has been challenging due to the absence of ROR1 kinase activity. To identify genes that regulate ROR1 expression and may, therefore, serve as surrogate drug targets, we employed an siRNA screening approach and determined that the epigenetic regulator and E3 ubiquitin ligase, UHRF1, is required for t(1;19) pre-B-ALL cell viability in a ROR1-dependent manner. Upon UHRF1 silencing, ROR1 protein is reduced without altering ROR1 mRNA, and ectopically expressed UHRF1 is sufficient to increase ROR1 levels. Additionally, proteasome inhibition rescues loss of ROR1 protein after UHRF1 silencing, suggesting a role for the proteasome in the UHRF1-ROR1 axis. Finally, we show that ROR1-positive cells are twice as sensitive to the UHRF1-targeting drug, naphthazarin, and undergo increased apoptosis compared to ROR1-negative cells. Naphthazarin elicits reduced expression of UHRF1 and ROR1, and combination of naphthazarin with inhibitors of pre-B cell receptor signaling results in further reduction of cell survival compared with either inhibitor alone. Therefore, our work reveals a mechanism by which UHRF1 stabilizes ROR1, suggesting a potential targeting strategy to inhibit ROR1 in t(1;19) pre-B-ALL and other malignancies.	[Chow, Marilynn; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Gao, Lina; MacManiman, Jason D.; Bicocca, Vincent T.; Chang, Bill H.; Alumkal, Joshi J.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Gao, Lina; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; [MacManiman, Jason D.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Chang, Bill H.] Oregon Hlth & Sci Univ, Div Pediat Hematol & Oncol, Doernbecher Childrens Hosp, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA.	tynerj@ohsu.edu		Chow-Castro, Marilynn/0000-0001-8819-4441; Bicocca, Vincent/0000-0002-5702-4586	Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) [TL1TR000129]; Hyundai Hope on Wheels; Leukemia and Lymphoma Society; V Foundation for Cancer Research; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute [5R00CA151457-04, 1R01CA183947-01]; NATIONAL CANCER INSTITUTE [R00CA151457, K99CA151457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000129] Funding Source: NIH RePORTER	Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Hyundai Hope on Wheels; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); V Foundation for Cancer Research; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The pCS2-6XMYC vector was a generous gift from Dr. Monika Davare. The authors would like to thank David K. Edwards V, Samantha L. Savage, Anna M. Reister Schultz, Dr. Haijiao Zhang, and Janet Pittsenbarger for their technical expertise and Dr. Kevin M. Watanabe-Smith for editing the manuscript. MC was supported in part by the Oregon Clinical and Translational Research Institute (OCTRI) (TL1TR000129) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). BHC is supported by the Hyundai Hope on Wheels. JWT is supported by The Leukemia and Lymphoma Society, the V Foundation for Cancer Research, Gabrielle's Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01).	Abu-Alainin W, 2016, J PATHOL, V238, P423, DOI 10.1002/path.4665; Acharya BR, 2011, APOPTOSIS, V16, P924, DOI 10.1007/s10495-011-0613-1; Alhosin M, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0453-5; Alhosin M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08996; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Baskar S, 2012, MABS-AUSTIN, V4, P349, DOI 10.4161/mabs.19870; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238-014-0059-7; Fernandez NB, 2016, MOL CARCINOGEN, V55, P1772, DOI 10.1002/mc.22426; Broome HE, 2011, LEUKEMIA RES, V35, P1390, DOI 10.1016/j.leukres.2011.06.021; Chen DF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162638; Choi MY, 2015, CL LYMPH MYELOM LEUK, V15, pS167, DOI 10.1016/j.clml.2015.02.010; DaneshManesh AH, 2008, INT J CANCER, V123, P1190, DOI 10.1002/ijc.23587; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Foa R, 2003, BRIT J HAEMATOL, V120, P484, DOI 10.1046/j.1365-2141.2003.04113.x; Fukuda T, 2008, P NATL ACAD SCI USA, V105, P3047, DOI 10.1073/pnas.0712148105; Gentile A, 2011, CANCER RES, V71, P3132, DOI 10.1158/0008-5472.CAN-10-2662; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; Jia YH, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.7; Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07; Kaucka M, 2011, ACTA PHYSIOL, V203, P351, DOI 10.1111/j.1748-1716.2011.02306.x; Kim JA, 2012, INT J ONCOL, V40, P157, DOI 10.3892/ijo.2011.1195; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Kim MY, 2015, INT J ONCOL, V46, P1659, DOI 10.3892/ijo.2015.2857; Kueh AJ, 2011, MOL CELL BIOL, V31, P845, DOI 10.1128/MCB.00159-10; Li P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011859; Loh ML, 2012, CLIN CANCER RES, V18, P2754, DOI 10.1158/1078-0432.CCR-11-1936; Ma J, 2015, BIOCHEM BIOPH RES CO, V464, P147, DOI 10.1016/j.bbrc.2015.06.104; Mani R, 2015, LEUKEMIA, V29, P346, DOI 10.1038/leu.2014.199; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Moorman AV, 2010, BLOOD, V115, P206, DOI 10.1182/blood-2009-07-232124; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Myrianthopoulos V, 2016, EUR J MED CHEM, V114, P390, DOI 10.1016/j.ejmech.2016.02.043; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nygren MK, 2009, EXP HEMATOL, V37, P225, DOI 10.1016/j.exphem.2008.10.007; Qu XY, 2015, EPIGENETICS-US, V10, P526, DOI 10.1080/15592294.2015.1048060; Rajakumara E, 2011, MOL CELL, V43, P275, DOI 10.1016/j.molcel.2011.07.006; Rau R, 2009, HEMATOL ONCOL, V27, P171, DOI 10.1002/hon.904; Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152; Sanchez-Aguilera A, 2010, LEUKEMIA, V24, P97, DOI 10.1038/leu.2009.217; Sanda T, 2013, CANCER DISCOV, V3, P564, DOI 10.1158/2159-8290.CD-12-0504; Shabani M, 2008, LEUKEMIA LYMPHOMA, V49, P1360, DOI 10.1080/10428190802124000; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Tasian SK, 2017, BRIT J HAEMATOL, V176, P867, DOI 10.1111/bjh.14474; Troeger A, 2012, BLOOD, V119, P4708, DOI 10.1182/blood-2011-12-395939; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1; Widhopf GF, 2014, P NATL ACAD SCI USA, V111, P793, DOI 10.1073/pnas.1308374111; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Zhang SP, 2012, AM J PATHOL, V181, P1903, DOI 10.1016/j.ajpath.2012.08.024; Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]	60	6	6	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5221	5232		10.1038/s41388-018-0299-8	http://dx.doi.org/10.1038/s41388-018-0299-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849118	Green Accepted			2023-01-03	WOS:000445093100006
J	Chen, SL; Lu, XL; Bai, GY; Zhang, YQ; Li, BJ; Wang, W; Liang, L; Ma, L; Li, Y; Wang, XF; Wang, YY; Zhao, CY; Zhao, HR				Chen, Suliang; Lu, Xinli; Bai, Guangyi; Zhang, Yuqi; Li, Baojun; Wang, Wei; Liang, Liang; Ma, Lin; Li, Yan; Wang, Xiaofeng; Wang, Yingying; Zhao, Cuiying; Zhao, Hongru			Twenty-seven year surveillance of blood transfusion recipients infected with HIV-1 in Hebei Province, China	PLOS ONE			English	Article								We conducted an investigation of blood management in which blood transfusion recipients underwent molecular biological analysis, to trace the possible source of HIV infection. Epidemiological investigation was carried out among HIV-infected individuals. Blood transfusion recipients infected with HIV were tracked for the date of transfusion, reason for transfusion, hospital where transfusion was received, source of blood, components of transfusion, number of transfusions, and transfusion volume. A total of 285 blood transfusion recipients infected with HIV-1 were detected in Hebei over the study period, with 42.81% (122/285) detected through clinical diagnostic testing. These cases showed a concentrated distribution in southern Hebei, with local outbreak characteristics. A census of the population in Shahe County, which had a high concentration of cases, revealed that recipients of blood transfusions had an HIV infection rate of 15.54% (92/592). Post-transfusion infection frequently occurred among blood transfusion recipients at township medical institutions, with a peak in 1995. Owing to late detection of HIV infection among blood transfusion recipients, the rates of spousal transmission and mother-to-child transmission reached 20.87% and 28.05%, respectively. Around 1995, community medical institutions did not screen for HIV antibodies among paid blood donors, which was an important cause of the outbreak of HIV1 infection among blood transfusion recipients. Our findings indicate that cases of blood transfusion-related infection decreased rapidly with gradual improvement in the HIV screening system for blood donors that began in 1995, particularly after full implementation of HIV nucleic acid testing of volunteer blood donors was begun in 2015.	[Chen, Suliang; Lu, Xinli; Bai, Guangyi; Zhang, Yuqi; Li, Baojun; Wang, Wei; Liang, Liang; Ma, Lin; Li, Yan; Wang, Xiaofeng; Wang, Yingying; Zhao, Cuiying; Zhao, Hongru] Hebei Prov Ctr Dis Control & Prevent, Shijiazhuang, Hebei, Peoples R China		Lu, XL (corresponding author), Hebei Prov Ctr Dis Control & Prevent, Shijiazhuang, Hebei, Peoples R China.	hebeicdc2013@sina.com	wang, yan/GSE-6489-2022; wang, yingying/GRS-3058-2022; wang, yi/GVT-8516-2022	lu, xinli/0000-0003-4613-2028	natural science fund of Hebei province [H2016303006]	natural science fund of Hebei province	This study was supported by the natural science fund of Hebei province (H2016303006). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen SL, 2010, CHIN J DIS CONTROL P, V14, P848; Chen Su-Liang, 1994, Zhonghua Yufang Yixue Zazhi, V28, P350; Chen SL, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1073-y; Liu ShuJun, 2010, Modern Preventive Medicine, V37, P3153; Lu XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171481; Shao Y, 2008, DIAGNOSTIC CRITERIA; Shao Y, 1994, CHINESE J VIROL, V12, P291; Yan J, 2004, S CHINAJ PREV MED, V30, P1; ZHANG WH, 1990, LANCET, V335, P353, DOI 10.1016/0140-6736(90)90637-K; Zhao CY, 2010, CHIN J HLTH LAB TECH, V20, P3136; Zheng X, 2000, CHIN J EPIDEMIOL, V21, P352	11	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2018	13	8							e0202265	10.1371/journal.pone.0202265	http://dx.doi.org/10.1371/journal.pone.0202265			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ5PD	30110373	Green Published, Green Submitted, gold			2023-01-03	WOS:000441738000059
J	Hussain, MA; Katzenellenbogen, JM; Sanfilippo, FM; Murray, K; Thompson, SC				Hussain, Mohammad Akhtar; Katzenellenbogen, Judith M.; Sanfilippo, Frank M.; Murray, Kevin; Thompson, Sandra C.			Complexity in disease management: A linked data analysis of multimorbidity in Aboriginal and non-Aboriginal patients hospitalised with atherothrombotic disease in Western Australia	PLOS ONE			English	Article							HEALTH-CARE; SOCIOECONOMIC-STATUS; PREVALENCE; PATTERNS; COMORBIDITY; DISPARITIES; MORBIDITY; QUALITY; LINKAGE; STROKE	Background Hospitalisation for atherothrombotic disease (ATD) is expected to rise in coming decades. However, increasingly, associated comorbidities impose challenges in managing patients and deciding appropriate secondary prevention. We investigated the prevalence and pattern of multimorbidity (presence of two or more chronic conditions) in Aboriginal and non-Aboriginal Western Australian residents with ATDs. Methods and findings We used population-based de-identified linked administrative health data from 1 January 2000 to 30 June 2014 to identify a cohort of patients aged 25 +/- 59 years admitted to Western Australian hospitals with a discharge diagnosis of ATD. The prevalence of common chronic diseases in these patients was estimated and the patterns of comorbidities and multimorbidities empirically explored using two different approaches: identification of the most commonly occurring pairs and triplets of comorbid diseases, and through latent class analysis (LCA). Half of the cohort had multimorbidity, although this was much higher in Aboriginal people (Aboriginal: 79.2% vs. non-Aboriginal: 39.3%). Only a quarter were without any documented comorbidities. Hypertension, diabetes, alcohol abuse disorders and acid peptic diseases were the leading comorbidities in the major comorbid combinations across both Aboriginal and non-Aboriginal cohorts. The LCA identified four and six distinct clinically meaningful classes of multimorbidity for Aboriginal and non-Aboriginal patients, respectively. Out of the six groups in non-Aboriginal patients, four were similar to the groups identified in Aboriginal patients. The largest proportion of patients (33% in Aboriginal and 66% in non-Aboriginal) was assigned to the "minimally diseased" (or relatively healthy) group, with most patients having less than two conditions. Other groups showed variability in degree and pattern of multimorbidity. Conclusion Multimorbidity is common in ATD patients and the comorbidities tend to interact and cluster together. Physicians need to consider these in their clinical practice. Different treatment and secondary prevention strategies are likely to be useful for management in these cluster groups.	[Hussain, Mohammad Akhtar; Thompson, Sandra C.] Univ Western Australia, Western Australian Ctr Rural Hlth, Geraldton, WA, Australia; [Katzenellenbogen, Judith M.; Sanfilippo, Frank M.; Murray, Kevin] Univ Western Australia, Sch Populat & Global Hlth, Perth, WA, Australia	University of Western Australia; University of Western Australia	Hussain, MA (corresponding author), Univ Western Australia, Western Australian Ctr Rural Hlth, Geraldton, WA, Australia.	akhtar.hussain@uwa.edu.au	Hussain, Mohammad Akhtar/G-8446-2012; Thompson, Sandra/H-5955-2014; Murray, Kevin/H-5503-2014; Sanfilippo, Frank/H-9334-2013	Hussain, Mohammad Akhtar/0000-0002-6012-3702; Thompson, Sandra/0000-0003-0327-7155; Murray, Kevin/0000-0002-8856-6046; Sanfilippo, Frank/0000-0003-3639-0787; Katzenellenbogen, Judith/0000-0001-5287-5819	Australian Department of Health; National Health and Medical Research Council of Australia [1031057]; Heart Foundation of Australia Future Leader Fellowship	Australian Department of Health(Australian GovernmentDepartment of Health & Ageing); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Heart Foundation of Australia Future Leader Fellowship	The Western Australian Centre for Rural Health receives funding from the Australian Department of Health. This work was partly supported by the National Health and Medical Research Council of Australia (Grant Number 1031057). JMK is supported by a Heart Foundation of Australia Future Leader Fellowship.	Adhikari P, 2006, SOC EC IND AR INTR U; AIHW Tong B, 2007, CARD DIS SER, V28; AIo Health, 2017, MED CARD DIS; Aspin C, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-143; Atkins ER, 2013, AUST HEALTH REV, V37, P488, DOI 10.1071/AH13083; Australian Bureau of Statistics, 2016, W AUSTR 2016 CENS AL; Australian Institute of Health and Welfare, 2017, BULLETIN, V141; Australian Institute of Health and Welfare, 2016, AUSTR BURD DIS STUD, V6; Australian Institute of Health and Welfare, 2015, CARD DIAB CHRON KIDN, V5; Australian Institute of Health and Welfare, 2014, CARD DIAB CHRON KIND, V3; Australian Institute of Health and Welfare, 2004, RURAL HLTH SERIES; Australian Institute of Health and Welfare, 2016, AUSTR HLTH 2016 AUST, V15; Australian Institute of Health and Welfare. Cardiovascular Health Compendium, 2017, CARD HLTH COMP; Australian Institute of Health & Welfare, 2016, AUSTR BURD DIS STUD, V3; Azais Boris, 2016, J Comorb, V6, P1, DOI 10.15256/joc.2016.6.71; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Brameld KJ, 2003, INT J EPIDEMIOL, V32, P617, DOI 10.1093/ije/dyg191; Briffa TG, 2013, INT J CARDIOL, V164, P185, DOI 10.1016/j.ijcard.2011.06.122; Briffa TG, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-111; Britt HC, 2008, MED J AUSTRALIA, V189, P72, DOI 10.5694/j.1326-5377.2008.tb01919.x; Byles JE, 2005, J CLIN EPIDEMIOL, V58, P997, DOI 10.1016/j.jclinepi.2005.02.025; Chandraratne NK, 2018, AUST J GEN PRACT, V47, P15, DOI 10.31128/AFP-09-17-4346; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christensen D, 2014, AUST J SOC ISSUES, V49, P423, DOI 10.1002/j.1839-4655.2014.tb00322.x; Crocetti E, 2013, BRIT J CANCER, V109, P219, DOI 10.1038/bjc.2013.311; Fortin Martin, 2004, Health Qual Life Outcomes, V2, P51, DOI 10.1186/1477-7525-2-51; Gray C., 2012, REV CARDIOVASCULAR H; Harrison C, 2016, AUST NZ J PUBL HEAL, V40, P239, DOI 10.1111/1753-6405.12509; Harrison C, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004694; Health Care Homes, 2018, HDB GEN PRACT AB COM; Holden L, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-15; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Hussain MA, 2015, BMJ OPEN, V5; Islam MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083783; Katzenellenbogen JM, 2015, HEART, V101, P712, DOI 10.1136/heartjnl-2014-306678; Katzenellenbogen JM, 2014, INT J STROKE, V9, P61, DOI 10.1111/ijs.12278; Katzenellenbogen JM, 2012, EUR J PREV CARDIOL, V19, P983, DOI 10.1177/1741826711417925; Katzenellenbogen JM, 2011, STROKE, V42, P1515, DOI 10.1161/STROKEAHA.110.601799; Katzenellenbogen JM, 2010, HEART LUNG CIRC, V19, P717, DOI 10.1016/j.hlc.2010.08.009; Kendir C, 2017, EUR J GEN PRACT, V24, P45, DOI 10.1080/13814788.2017.1398318; Lanza ST, 2007, STRUCT EQU MODELING, V14, P671, DOI 10.1080/10705510701575602; Lehnert T, 2011, MED CARE RES REV, V68, P387, DOI 10.1177/1077558711399580; Marengoni A, 2009, J AM GERIATR SOC, V57, P225, DOI 10.1111/j.1532-5415.2008.02109.x; Mather T, 2014, AUST NZ J PUBL HEAL, V38, P436, DOI 10.1111/1753-6405.12239; McPhail SM, 2016, RISK MANAG HEALTHC P, V9, P143, DOI 10.2147/RMHP.S97248; Millar E, 2018, J PRIM HEALTH CARE, V10, P44, DOI 10.1071/HC17074; Morgan VA, 2010, BRIT J PSYCHIAT, V197, P8, DOI 10.1192/bjp.bp.109.076588; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Palmer K, 2018, HEALTH POLICY, V122, P4, DOI 10.1016/j.healthpol.2017.09.006; Pathirana TI, 2018, AUST NZ J PUBL HEAL, V42, P186, DOI 10.1111/1753-6405.12762; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Prados-Torres A, 2014, J CLIN EPIDEMIOL, V67, P254, DOI 10.1016/j.jclinepi.2013.09.021; Randall DA, 2018, MED J AUSTRALIA, V209, P19, DOI 10.5694/mja17.00878; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Sarfati D, 2010, NEW ZEAL MED J, V123, P50; Sarink D, 2016, EUR J PREV CARDIOL, V23, P23, DOI 10.1177/2047487314554865; Smith SM, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-6; Taylor AW, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-718; Teng THK, 2014, INT J CARDIOL, V173, P110, DOI 10.1016/j.ijcard.2014.02.020; Thompson SC, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-133; Violan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102149; Wallace C, 1998, BRIT J PSYCHIAT, V172, P477, DOI 10.1192/bjp.172.6.477; Wallace E, 2015, BMJ-BRIT MED J, V350; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Whitson HE, 2016, J AM GERIATR SOC, V64, P1668, DOI 10.1111/jgs.14201; Wilber ST, 2010, ACAD EMERG MED, V17, P649, DOI 10.1111/j.1553-2712.2010.00773.x	68	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2018	13	8							e0201496	10.1371/journal.pone.0201496	http://dx.doi.org/10.1371/journal.pone.0201496			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GQ4SC	30106971	gold, Green Submitted, Green Published			2023-01-03	WOS:000441662800010
J	Klemenc-Ketis, Z; Makivic, I; Susic, AP				Klemenc-Ketis, Zalika; Makivic, Irena; Susic, Antonija Poplas			The development and validation of a new interprofessional team approach evaluation scale	PLOS ONE			English	Article							QUALITY-OF-CARE; FAMILY MEDICINE; PATIENT-EVALUATION; MODEL PRACTICES; SLOVENIA; QUESTIONNAIRE; SATISFACTION; INSTRUMENTS; IMPROVEMENT; SETTINGS	A team approach in health care involves an interprofessional approach to patient care. We wanted to develop and validate a tool that would evaluate the interprofessional team approach to patients of a family medicine team. We performed a descriptive study in three consecutive phases: a literature review, consensus development panels, and a cross-sectional validation study. Three rounds of consensus development panels were carried out in order to evaluate and adapt the initial scale. The cross-sectional study was carried out in all Slovenian family medicine practices, each invited 10 consecutive patients. In the quantitative study, 3,292 patients participated (a 50.7% response rate), of which 1,810 (55.0%) were women. The mean age of the sample was 53.1 +/- 1.2 years. The final Cronbach's alpha was 0.901. A factor analysis of the 9-item scale put forward two factors (Team Approach and Person-Centred approach) which explained 68.6% of the variance. This study provided a new scale for the evaluation of patient satisfaction with the interprofessional family medicine team from the patients' point of view. It opened the question of family medicine team competencies and pointed towards the need to develop a family medicine interprofessional team competency framework and a comprehensive tool for its assessment.	[Klemenc-Ketis, Zalika; Makivic, Irena; Susic, Antonija Poplas] Community Hlth Ctr Ljubljana, Ljubljana, Slovenia; [Klemenc-Ketis, Zalika] Univ Ljubljana, Dept Family Med, Fac Med, Ljubljana, Slovenia; [Klemenc-Ketis, Zalika] Univ Maribor, Dept Family Med, Fac Med, Maribor, Slovenia	University of Ljubljana; University of Maribor	Klemenc-Ketis, Z (corresponding author), Community Hlth Ctr Ljubljana, Ljubljana, Slovenia.; Klemenc-Ketis, Z (corresponding author), Univ Ljubljana, Dept Family Med, Fac Med, Ljubljana, Slovenia.; Klemenc-Ketis, Z (corresponding author), Univ Maribor, Dept Family Med, Fac Med, Maribor, Slovenia.	zalika.klemenc@um.si	Klemenc-Ketis, Zalika/V-6251-2019	Klemenc-Ketis, Zalika/0000-0002-0270-1754; Makivic, Irena/0000-0003-2748-5522	Slovenian Research Agency [P3-0339]; Ljubljana Community Health Centre	Slovenian Research Agency(Slovenian Research Agency - Slovenia); Ljubljana Community Health Centre	ZKK's work on this project was partly supported by the Slovenian Research Agency [Research core funding research in The Field of Public Health No. P3-0339]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors were internally supported by their employer Ljubljana Community Health Centre. There was no additional external funding received for this study.	Agosta LJ, 2009, J NURS MEAS, V17, P114, DOI 10.1891/1061-3749.17.2.114; Allen J., 2011, EUROPEAN DEFINITION; [Anonymous], 2005, EURACT ED AGENDA; Baker R, 1996, METHOD SURVEYING PAT; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Czabanowska K, 2012, J CONTIN EDUC HEALTH, V32, P174, DOI 10.1002/chp.21142; de Wet C, 2010, QUAL SAF HEALTH CARE, V19, P578, DOI 10.1136/qshc.2008.031062; Deilkas ET, 2010, PATIENT SAFETY CULTU; FERKETICH S, 1991, RES NURS HEALTH, V14, P165, DOI 10.1002/nur.4770140211; Frank JR., 2005, CANMEDS 2005 PHYS CO; Grol R, 2000, BRIT J GEN PRACT, V50, P882; Halcomb EJ, 2011, J NURS SCHOLARSHIP, V43, P318, DOI 10.1111/j.1547-5069.2011.01408.x; Henry BW, 2016, HEALTH EXPECT, V19, P702, DOI 10.1111/hex.12148; Institute of Medicine, 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Institute of Medicine, 2003, HLTH PROFESSIONS ED; Katerndabl DA, 2010, ANN FAM MED, V8, P341, DOI [10.1370/afm.1108, 10.1370/afm.1157]; Kersnik J, 2000, INT J QUAL HEALTH C, V12, P143, DOI 10.1093/intqhc/12.2.143; Klemenc-Ketis Z, 2017, J CLIN NURS, V26, P5025, DOI 10.1111/jocn.14002; Klemenc-Ketis Z, 2017, ZDRAV VARST, V56, P211, DOI 10.1515/sjph-2017-0029; Klemenc-Ketis Z, 2017, ZDRAV VARST, V56, P203, DOI 10.1515/sjph-2017-0028; Klemenc-Ketis Z, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-016-1972-7; Klemenc-Ketis Z, 2014, J CLIN NURS, V23, P1323, DOI 10.1111/jocn.12377; Klemenc-Ketis Z, 2012, HEALTH POLICY, V106, P269, DOI 10.1016/j.healthpol.2012.04.009; Makivic I, 2016, ZDRAV VARST, V55, P86, DOI 10.1515/sjph-2016-0004; Mead N, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-13; Mitchell P, 2012, NAM PERSPECT, DOI DOI 10.31478/201210C; Nancarrow SA, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-19; Ohman-Strickland PA, 2007, HEALTH SERV RES, V42, P1257, DOI 10.1111/j.1475-6773.2006.00644.x; Petek D, 2016, ZDRAV VARST, V55, P179, DOI 10.1515/sjph-2016-0023; Poplas-Susic T, 2015, ZDRAV VARST, V54, P161, DOI 10.1515/sjph-2015-0023; Poulton BC, 1996, BRIT J GEN PRACT, V46, P26; Ramsay J, 2000, FAM PRACT, V17, P372, DOI 10.1093/fampra/17.5.372; Rattray J, 2007, J CLIN NURS, V16, P234, DOI 10.1111/j.1365-2702.2006.01573.x; Sexton JB, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-44; Shi LY, 2001, J FAM PRACTICE, V50, P161; Shoemaker SJ, 2016, J INTERPROF CARE, V30, P423, DOI 10.3109/13561820.2016.1154023; Susic TP, 2013, ZDR VESTN, V82, P635; Valentine MA, 2015, MED CARE, V53, pE16, DOI 10.1097/MLR.0b013e31827feef6; Zhao JQ, 2016, Int J Nurs Sci, V3, P398, DOI 10.1016/j.ijnss.2016.08.009	39	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0201385	10.1371/journal.pone.0201385	http://dx.doi.org/10.1371/journal.pone.0201385			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP9JF	30092005	Green Published, Green Submitted, gold			2023-01-03	WOS:000441232600025
J	Garcia-Lacarte, M; Martinez, JA; Zulet, MA; Milagro, FI				Garcia-Lacarte, Marcos; Alfredo Martinez, J.; Angeles Zulet, M.; Milagro, Fermin I.			Implication of miR-612 and miR-1976 in the regulation of TP53 and CD40 and their relationship in the response to specific weight-loss diets	PLOS ONE			English	Article							CIRCULATING MICRORNAS; ADIPOSE-TISSUE; P53; ADIPOCYTES; ATHEROSCLEROSIS; ADIPOGENESIS; METHYLATION; ACTIVATION; MECHANISMS; OVERWEIGHT	Background Non-coding RNAs (i.e., miRNAs) play a role in the development of obesity and related comorbidities and the regulation of body weight. Objective To identify candidate miRNA biomarkers throughout omics approaches in order to predict the response to specific weight-loss dietary treatments. Design Genomic DNA and cDNA isolated from white blood cells of a subset from the RESMENA nutritional intervention study (Low-responders (LR) vs High-responders (HR)) was hybridized in Infinium Human Methylation450 BeadChip and in Illumina Human HT-12 v4 gene expression BeadChips arrays respectively. A bioinformatic prediction of putative target sites of selected miRNAs was performed by applying miRBase algorithms. HEK-293T cells were co-transfected with expression vectors containing the 3'-UTR of candidate genes to validate the binding of miRNAs to its target sites. Results 134 miRNAs were differentially methylated between HR and LR in the methylation array, whereas 44 miRNAs were differentially expressed between both groups in the expression array. Specifically, miR-1237, miR-1976, miR-642, miR-636, miR-612 and miR-193B were simultaneously hypomethylated and overexpressed in HR. miR-612 and miR-1976 showed greatest differences in methylation and expression levels, respectively. The bioinformatic prediction revealed that TP53 was a putative target gene of miR-612 and CD40 of miR-1976. Moreover, TP53 was downregulated in the expression array when comparing HR vs LR expression levels adjusted by sex, diet, age and baseline weight, and CD40 showed a statistical trend. Furthermore, gene expression levels of TP53 and CD40 in white blood cells, when measured by qPCR, were also downregulated in HR. Finally, miR-612 and miR-1976 potently repressed TP53 and CD40 respectively by targeting its 3'-UTR regions. Conclusion miR-612 and miR-1976 levels could be prospective biomarkers of response to specific weight-loss diets and might regulate the gene expression of TP53 and CD40.	[Garcia-Lacarte, Marcos; Alfredo Martinez, J.; Angeles Zulet, M.; Milagro, Fermin I.] Univ Navarra, Dept Nutr Food Sci & Physiol, Pamplona, Spain; [Garcia-Lacarte, Marcos; Alfredo Martinez, J.; Angeles Zulet, M.; Milagro, Fermin I.] Univ Navarra, Ctr Nutr Res, Pamplona, Spain; [Alfredo Martinez, J.; Angeles Zulet, M.; Milagro, Fermin I.] ISCIII Madrid, Ctr Biomed Res Network, Physiopathol Obes & Nutr, CIBERobn, Madrid, Spain; [Alfredo Martinez, J.; Angeles Zulet, M.; Milagro, Fermin I.] Navarras Hlth Res Inst, IdiSNA, Pamplona, Spain	University of Navarra; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN	Martinez, JA (corresponding author), Univ Navarra, Dept Nutr Food Sci & Physiol, Pamplona, Spain.; Martinez, JA (corresponding author), Univ Navarra, Ctr Nutr Res, Pamplona, Spain.; Martinez, JA (corresponding author), ISCIII Madrid, Ctr Biomed Res Network, Physiopathol Obes & Nutr, CIBERobn, Madrid, Spain.; Martinez, JA (corresponding author), Navarras Hlth Res Inst, IdiSNA, Pamplona, Spain.	jalfmtz@unav.es	Milagro, Fermin/F-2315-2015; Garcia-Lacarte, Marcos/B-2730-2017; Martinez Hernandez, J Alfredo/K-8709-2014	Milagro, Fermin/0000-0002-3228-9916; Garcia-Lacarte, Marcos/0000-0003-0614-8682; Martinez Hernandez, J Alfredo/0000-0001-5218-6941	MINECO, Spanish Government of Economy and Competitiveness [AGL2013-45554-R]; CIBERobn; Instituto de Salud Carlos III; Center for Nutrition Research of the University of Navarra	MINECO, Spanish Government of Economy and Competitiveness; CIBERobn; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Center for Nutrition Research of the University of Navarra	This work was supported by MINECO, Spanish Government of Economy and Competitiveness (Nutrigenio project: AGL2013-45554-R), CIBERobn, and Instituto de Salud Carlos III. MGL holds a grant from Center for Nutrition Research of the University of Navarra. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362; Arner P, 2015, NAT REV ENDOCRINOL, V11, P276, DOI 10.1038/nrendo.2015.25; Berisha SZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016729; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Campion J, 2009, OBESITY, V17, P1293, DOI 10.1038/oby.2008.679; Chatzigeorgiou A, 2013, HORM METAB RES, V45, P741, DOI 10.1055/s-0033-1348221; Cordero P, 2011, J PHYSIOL BIOCHEM, V67, P463, DOI 10.1007/s13105-011-0084-4; Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452; Etheridge A, 2011, MUTAT RES-FUND MOL M, V717, P85, DOI 10.1016/j.mrfmmm.2011.03.004; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Garcia-Lacarte M, 2016, REDOX REP, V21, P67, DOI 10.1179/1351000215Y.0000000029; Ge Q, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/987285; Goni L, 2016, J NUTR, V146, p905S, DOI 10.3945/jn.115.218354; Guo X, 2016, SCI REP-UK, V6, DOI 10.1038/srep35302; Hanke Merle, 2010, Urol Oncol, V28, P655, DOI 10.1016/j.urolonc.2009.01.027; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Luo SY, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0063-7; Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mansego ML, 2017, PEDIATR OBES, V12, P19, DOI 10.1111/ijpo.12101; Marques-Rocha JL, 2015, FASEB J, V29, P3595, DOI 10.1096/fj.14-260323; Mayeux Richard, 2004, NeuroRx, V1, P182, DOI 10.1007/BF03206601; McClelland AD, 2014, CLIN SCI, V126, P95, DOI 10.1042/CS20130079; Milagro FI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054319; Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Molchadsky A, 2013, CELL DEATH DIFFER, V20, P774, DOI 10.1038/cdd.2013.9; Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736; Peng YD, 2014, CELL SIGNAL, V26, P1888, DOI 10.1016/j.cellsig.2014.05.006; Poggi M, 2009, DIABETOLOGIA, V52, P1152, DOI 10.1007/s00125-009-1267-1; Ramos-Lopez O, 2017, J NUTRIGENET NUTRIGE, V10, P43, DOI 10.1159/000477729; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Tian S, 2010, BIOCHEM BIOPH RES CO, V396, P435, DOI 10.1016/j.bbrc.2010.04.112; Unek IT, 2010, CLIN MED RES, V8, P89, DOI 10.3121/cmr.2010.889; Unek IT, 2010, METABOLISM, V59, P305, DOI 10.1016/j.metabol.2009.04.034; Vijayakumaran R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00284; Xie HM, 2009, DIABETES, V58, P1050, DOI 10.2337/db08-1299; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Zhang XM, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0512-5; Zulet MA, 2011, NUTR HOSP, V26, P16, DOI 10.3305/nh.2011.26.1.5050	42	11	11	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2018	13	8							e0201217	10.1371/journal.pone.0201217	http://dx.doi.org/10.1371/journal.pone.0201217			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP7NS	30089130	Green Published, Green Submitted, gold			2023-01-03	WOS:000441090300034
J	Larochelle, MR; Bernson, D; Land, T; Stopka, TJ; Wang, N; Xuan, Z; Bagley, SM; Liebschutz, JM; Walley, AY				Larochelle, M. R.; Bernson, D.; Land, T.; Stopka, T. J.; Wang, N.; Xuan, Z.; Bagley, S. M.; Liebschutz, J. M.; Walley, A. Y.		Cohort Study	Medicines for Patients After an Opioid Overdose	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													Stopka, Thomas/GSN-6831-2022						0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2018	169	3					I16	I16		10.7326/P18-0009	http://dx.doi.org/10.7326/P18-0009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ0AJ	29913484				2023-01-03	WOS:000441277700022
J	Larochelle, MR; Bernson, D; Land, T; Stopka, TJ; Wang, N; Xuan, ZM; Bagley, SM; Liebschutz, JM; Walley, AY				Larochelle, Marc R.; Bernson, Dana; Land, Thomas; Stopka, Thomas J.; Wang, Na; Xuan, Ziming; Bagley, Sarah M.; Liebschutz, Jane M.; Walley, Alexander Y.			Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							EXTENDED-RELEASE NALTREXONE; RANDOMIZED CLINICAL-TRIAL; INJECTION-DRUG USERS; UNITED-STATES; IMPLANT-NALTREXONE; ORAL NALTREXONE; HEROIN OVERDOSE; FATAL OVERDOSE; DEPENDENCE; BUPRENORPHINE	Background: Opioid overdose survivors have an increased risk for death. Whether use of medications for opioid use disorder (MOUD) after overdose is associated with mortality is not known. Objective: To identify MOUD use after opioid overdose and its association with all-cause and opioid-related mortality. Design: Retrospective cohort study. Setting: 7 individually linked data sets from Massachusetts government agencies. Participants: 17 568 Massachusetts adults without cancer who survived an opioid overdose between 2012 and 2014. Measurements: Three types of MOUD were examined: methadone maintenance treatment (MMT), buprenorphine, and naltrexone. Exposure to MOUD was identified at monthly intervals, and persons were considered exposed through the month after last receipt. A multivariable Cox proportional hazards model was used to examine MOUD as a monthly time-varying exposure variable to predict time to all-cause and opioid-related mortality. Results: In the 12 months after a nonfatal overdose, 2040 persons (11%) enrolled in MMT for a median of 5 months (interquartile range, 2 to 9 months), 3022 persons (17%) received buprenorphine for a median of 4 months (interquartile range, 2 to 8 months), and 1099 persons (6%) received naltrexone for a me dian of 1 month (interquartile range, 1 to 2 months). Among the entire cohort, all-cause mortality was 4.7 deaths (95% CI, 4.4 to 5.0 deaths) per 100 person years and opioid related mortality was 2.1 deaths (CI, 1.9 to 2.4 deaths) per 100 person-years. Compared with no MOUD, MMT was associated with decreased all-cause mortality (adjusted hazard ratio [AHR], 0.47 [CI, 0.32 to 0.71]) and opioid-related mortality (AHR, 0.41 [CI, 0.24 to 0.70]). Buprenorphine was associated with decreased all-cause mortality (AHR, 0.63 [CI, 0.46 to 0.87]) and opioid-related mortality (AHR, 0.62 [CI, 0.41 to 0.92]). No associations between naltrexone and all-cause mortality (AHR, 1.44 [CI, 0.84 to 2.46]) or opioid-related mortality (AHR, 1.42 [CI, 0.73 to 2.79]) were identified. Limitation: Few events among naltrexone recipients preclude confident conclusions. Conclusion: A minority of opioid overdose survivors received MOUD. Buprenorphine and MMT were associated with reduced all-cause and opioid-related mortality. Primary Funding Source: National Center for Advancing Translational Sciences of the National Institutes of Health.	[Larochelle, Marc R.; Bagley, Sarah M.; Liebschutz, Jane M.; Walley, Alexander Y.] Boston Univ, Clin Addict Res & Educ Unit, Sch Med, Boston, MA 02215 USA; [Larochelle, Marc R.; Bagley, Sarah M.; Liebschutz, Jane M.; Walley, Alexander Y.] Boston Med Ctr, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA; [Bernson, Dana; Land, Thomas] Massachusetts Dept Publ Hlth, Off Special Analyt Projects, Off Populat Hlth, Boston, MA USA; [Stopka, Thomas J.] Tufts Univ, Sch Med, 136 Harrison Ave,MV244, Boston, MA 02111 USA; [Wang, Na; Xuan, Ziming] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Ctr, Boston, MA USA; [Liebschutz, Jane M.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, 200 Lothrop St,Suite 933W, Pittsburgh, PA 15213 USA; [Walley, Alexander Y.] Massachusetts Dept Publ Hlth, Bur Subst Addict Serv, Boston, MA USA; [Bernson, Dana; Land, Thomas] Massachusetts Dept Publ Hlth, 250 Washington St,6th Floor, Boston, MA 02108 USA; [Wang, Na; Xuan, Ziming] Boston Univ, Sch Publ Hlth, 801 Massachusetts Ave,3rd Floor, Boston, MA 02118 USA	Boston University; Boston Medical Center; Massachusetts Department of Public Health; Tufts University; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Massachusetts Department of Public Health; Massachusetts Department of Public Health; Boston University	Larochelle, MR (corresponding author), Boston Med Ctr, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA.	marc.larochelle@bmc.org	Bagley, Sarah/AAC-1458-2021; Stopka, Thomas/GSN-6831-2022; Bagley, Sarah/AAI-5334-2021	Bagley, Sarah/0000-0002-7524-0178; Bernson, Dana/0000-0003-1510-4489	National Center for Advancing Translational Sciences of the National Institutes of Health; National Center for Advancing Translational Sciences of the National Institutes of Health [1UL1TR001430]; National Institute on Drug Abuse [K23 DA042168]; Boston University School of Medicine Department of Medicine Career Investment Award; GE Foundation [33924399]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K23DA042168] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Boston University School of Medicine Department of Medicine Career Investment Award; GE Foundation(General Electric); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	National Center for Advancing Translational Sciences of the National Institutes of Health.; By grant 1UL1TR001430 from the National Center for Advancing Translational Sciences of the National Institutes of Health. Dr. Larochelle was supported by award K23 DA042168 from the National Institute on Drug Abuse and a Boston University School of Medicine Department of Medicine Career Investment Award. Dr. Stopka was supported by award 33924399 from the GE Foundation.	Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI [10.1197/j.aem.2007.04.005, 10.1111/j.1553-2712.2007.tb01846.x]; Cousins SJ, 2016, J SUBST ABUSE TREAT, V63, P66, DOI 10.1016/j.jsat.2015.12.004; D'Onofrio G, 2017, J GEN INTERN MED, V32, P660, DOI 10.1007/s11606-017-3993-2; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Darke S, 2007, J URBAN HEALTH, V84, P283, DOI 10.1007/s11524-006-9156-0; Darke S, 2011, DRUG ALCOHOL DEPEN, V115, P190, DOI 10.1016/j.drugalcdep.2010.10.021; Davoli M, 2007, ADDICTION, V102, P1954, DOI 10.1111/j.1360-0443.2007.02025.x; Digiusto E, 2004, ADDICTION, V99, P450, DOI 10.1111/j.1360-0443.2004.00654.x; Frazier W, 2017, JAMA-J AM MED ASSOC, V318, P750, DOI 10.1001/jama.2017.7818; Gibson AE, 2007, DRUG ALCOHOL REV, V26, P405, DOI 10.1080/09595230701373834; Green CA, 2017, PHARMACOEPIDEM DR S, V26, P509, DOI 10.1002/pds.4157; Hulse GK, 2009, ARCH GEN PSYCHIAT, V66, P1108, DOI 10.1001/archgenpsychiatry.2009.130; Kelty E, 2012, ADDICTION, V107, P1817, DOI 10.1111/j.1360-0443.2012.03910.x; Krupitsky E, 2012, ARCH GEN PSYCHIAT, V69, P973, DOI 10.1001/archgenpsychiatry.2012.1a; Krupitsky E, 2011, LANCET, V377, P1506, DOI 10.1016/S0140-6736(11)60358-9; Larochelle MR, 2016, ANN INTERN MED, V164, P1, DOI 10.7326/M15-0038; Lee JD, 2018, LANCET, V391, P309, DOI 10.1016/S0140-6736(17)32812-X; Lee JD, 2016, NEW ENGL J MED, V374, P1232, DOI 10.1056/NEJMoa1505409; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Lincoln T, 2018, J SUBST ABUSE TREAT, V85, P97, DOI 10.1016/j.jsat.2017.04.002; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Morgan JR, 2018, J SUBST ABUSE TREAT, V85, P90, DOI 10.1016/j.jsat.2017.07.001; Pollini RA, 2006, DRUG ALCOHOL DEPEN, V83, P104, DOI 10.1016/j.drugalcdep.2005.10.015; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Snapinn SM, 2005, AM STAT, V59, P301, DOI 10.1198/000313005X70371; SORDO L, 2017, BMJ-BRIT MED J, V357, DOI DOI 10.1136/BMJ.J1550; Stoove MA, 2009, DRUG ALCOHOL REV, V28, P347, DOI 10.1111/j.1465-3362.2009.00057.x; The Commonwealth of Massachusetts, 2018, DAT BRIEF OP REL OV; The Commonwealth of Massachusetts, 2017, ASS FAT NONF OP OV M; The Commonwealth of Massachusetts, 2016, ASS OP REL DEATHS MA; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Wu LT, 2016, DRUG ALCOHOL DEPEN, V165, P181, DOI 10.1016/j.drugalcdep.2016.06.002	35	450	450	2	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2018	169	3					137	+		10.7326/M17-3107	http://dx.doi.org/10.7326/M17-3107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ0AJ	29913516	Green Accepted			2023-01-03	WOS:000441277700002
J	Beyle, A; Glonnegger, H; Cerff, B; Graber, S; Berg, D; Liepelt-Scarfone, I				Beyle, Aline; Glonnegger, Hannah; Cerff, Bernhard; Graeber, Susanne; Berg, Daniela; Liepelt-Scarfone, Inga			The Multiple Object Test as a performance- based tool to assess the decline of ADL function in Parkinson's disease	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; INSTRUMENTAL ACTIVITIES; DIAGNOSTIC-CRITERIA; PILL QUESTIONNAIRE; DEMENTIA; DEFICITS; ASSOCIATION; PROGRESSION; PREDICTORS; DISABILITY	Introduction As cognitive-driven worsening of activities of the daily living (ADL) in Parkinson's disease (PD) is the core feature of PD dementia (PDD), there is great need for sensitive quantitative assessment. Aim of our study was the evaluation of cognitive-driven worsening of ADL by the performance-based Multiple Object Test (MOT), offering an essential clinical advantage as it is quick and easy to apply in a clinical context even on severely impaired patients. Methods 73 PD patients were assessed longitudinally over a period of 37 (6-49) months. According to their neuropsychological profile the sample was divided into two groups: PD patients with (n = 34, PD-CI) and without cognitive impairment (n = 39, PD-noCl). The MOT comprises five routine tasks (e.g. to make coffee) quick and easy to apply. Quantitative (total error number, processing time) and qualitative parameters (error type) were analyzed using non-parametric test statistic (e.g.Wilcoxon signed-rank test, binary logistic regression). Results Median number of total errors (p = 0.001), processing time (p<0.001), perplexity (p = 0.035), and omission errors (p<0.001) increased significantly from baseline to follow-up in the total sample. Worsening of MOT performance was correlated to cognitive decline in the attention/executive function and visuo-constructive domain. PD-CI showed an increase in omission errors (p = 0.027) compared to PD-noCl over time. This increase in omission errors between visits was further identified as a risk marker for PDD conversion. Conclusion The MOT, especially frequency of omission errors, is a promising tool to rate PD patients objectively and might help to identify patients with a high risk for having mild cognitive impairment or dementia.	[Beyle, Aline; Glonnegger, Hannah; Cerff, Bernhard; Graeber, Susanne; Berg, Daniela; Liepelt-Scarfone, Inga] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany; [Beyle, Aline; Glonnegger, Hannah; Cerff, Bernhard; Graeber, Susanne; Liepelt-Scarfone, Inga] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany; [Beyle, Aline] Univ Hosp Bonn, Dept Neurol, Bonn, Germany; [Berg, Daniela] Univ Kiel, Dept Neurol, Kiel, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Bonn; University of Kiel	Liepelt-Scarfone, I (corresponding author), German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany.; Liepelt-Scarfone, I (corresponding author), Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany.	inga.liepelt@uni-tuebingen.de	Berg, Daniela/A-8728-2019	Berg, Daniela/0000-0001-5796-5442	Deutsche Forschungsgemeinschaft; University of Tubingen	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Tubingen	We acknowledge financial support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tubingen for open publication of the manuscript.	Bouwens SFM, 2009, INT J GERIATR PSYCH, V24, P764, DOI 10.1002/gps.2193; Brennan L, 2016, MOVEMENT DISORD, V31, P126, DOI 10.1002/mds.26339; Bronnick K, 2006, J NEUROL NEUROSUR PS, V77, P1136, DOI 10.1136/jnnp.2006.093146; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; Giovannetti T, 2012, J INT NEUROPSYCH SOC, V18, P787, DOI 10.1017/S135561771200046X; Glonnegger H, 2016, J ALZHEIMERS DIS, V53, P1475, DOI 10.3233/JAD-160173; Goetz CG, 2004, MOVEMENT DISORD, V19, P1020, DOI 10.1002/mds.20213; Goetz CG, 2003, MOVEMENT DISORD, V18, P738, DOI 10.1002/mds.10473; H?rting, 2000, WECHSLER GEDACHTNIST; Harrison MB, 2009, MOVEMENT DISORD, V24, P224, DOI 10.1002/mds.22335; HAUTZINGER M, 1991, NERVENARZT, V62, P689; Holroyd S, 2005, NEUROLOGY, V64, P2134, DOI 10.1212/01.WNL.0000165958.12724.0D; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Janvin CC, 2006, MOVEMENT DISORD, V21, P1343, DOI 10.1002/mds.20974; Janvin CC, 2005, J GERIATR PSYCH NEUR, V18, P149, DOI 10.1177/0891988705277540; Kalbe E, 2008, PARKINSONISM RELAT D, V14, P93, DOI 10.1016/j.parkreldis.2007.06.008; Kulisevsky J, 2013, PARKINSONISM RELAT D, V19, P812, DOI 10.1016/j.parkreldis.2013.05.007; Lawson RA, 2017, J NEUROL NEUROSUR PS, V88, P648, DOI 10.1136/jnnp-2016-315099; Leritz E, 2004, CLIN NEUROPSYCHOL, V18, P352, DOI 10.1080/1385404049052412; Leroi I, 2012, J GERIATR PSYCH NEUR, V25, P208, DOI 10.1177/0891988712464823; Litvan I, 2012, MOVEMENT DISORD, V27, P349, DOI 10.1002/mds.24893; Manning KJ, 2012, CLIN NEUROPSYCHOL, V26, P45, DOI 10.1080/13854046.2011.639312; Martinez-Martin P, 2013, MOVEMENT DISORD, V28, P1832, DOI 10.1002/mds.25649; Oswald W.D., 1999, NURNBERGER ALTERS IN, V4th; Pfeiffer HCV, 2014, ACTA NEUROL SCAND, V129, P307, DOI 10.1111/ane.12189; Pirogovsky E, 2014, NEUROPSYCHOLOGY, V28, P229, DOI 10.1037/neu0000045; Pirogovsky E, 2013, J CLIN EXP NEUROPSYC, V35, P926, DOI 10.1080/13803395.2013.838940; Pirogovsky E, 2012, J INT NEUROPSYCH SOC, V18, P986, DOI 10.1017/S1355617712000781; Rasovska H, 2011, J NEUROL SCI, V310, P279, DOI 10.1016/j.jns.2011.07.048; Reginold W, 2012, MOVEMENT DISORD, V27, P1308, DOI 10.1002/mds.25124; Rosenthal E, 2010, MOVEMENT DISORD, V25, P1170, DOI 10.1002/mds.23073; Schmid NS, 2014, DEMENT GER COGN D EX, V4, P322, DOI 10.1159/000357774; Shulman LM, 2006, MOVEMENT DISORD, V21, P794, DOI 10.1002/mds.20803; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Warrington E., 1992, VOSP TESTBATTERIE VI; Williams-Gray CH, 2007, BRAIN, V130, P1787, DOI 10.1093/brain/awm111	37	7	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2018	13	8							e0200990	10.1371/journal.pone.0200990	http://dx.doi.org/10.1371/journal.pone.0200990			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO9GY	30067788	Green Published, gold, Green Submitted			2023-01-03	WOS:000440415500064
J	Niihara, Y; Miller, ST; Kanter, J; Lanzkron, S; Smith, WR; Hsu, LL; Gordeuk, VR; Viswanathan, K; Sarnaik, S; Osunkwo, I; Guillaume, E; Sadanandan, S; Sieger, L; Lasky, JL; Panosyan, EH; Blake, OA; New, TN; Bellevue, R; Tran, LT; Razon, RL; Stark, CW; Neumayr, LD; Vichinsky, EP				Niihara, Yutaka; Miller, Scott T.; Kanter, Julie; Lanzkron, Sophie; Smith, Wally R.; Hsu, Lewis L.; Gordeuk, Victor R.; Viswanathan, Kusum; Sarnaik, Sharada; Osunkwo, Ifeyinwa; Guillaume, Edouard; Sadanandan, Swayam; Sieger, Lance; Lasky, Joseph L.; Panosyan, Eduard H.; Blake, Osbourne A.; New, Tamara N.; Bellevue, Rita; Tran, Lan T.; Razon, Rafael L.; Stark, Charles W.; Neumayr, Lynne D.; Vichinsky, Elliott P.		Investigators Phase 3 Trial L-Glut	A Phase 3 Trial of L-Glutamine in Sickle Cell Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CHEST SYNDROME; PULMONARY-HYPERTENSION; ANEMIA; HYDROXYUREA; REGRESSION; CRISES	BACKGROUND Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical-grade L-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which probably reduces oxidative stress and could result in fewer episodes of sickle cell-related pain. METHODS In a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial, we tested the efficacy of pharmaceutical-grade L-glutamine (0.3 g per kilogram of body weight per dose) administered twice daily by mouth, as compared with placebo, in reducing the incidence of pain crises among patients with sickle cell anemia or sickle jr-thalassemia and a history of two or more pain crises during the previous year. Patients who were receiving hydroxyurea at a dose that had been stable for at least 3 months before screening continued that therapy through the 48-week treatment period. RESULTS A total of 230 patients (age range, 5 to 58 years; 53.9% female) were randomly assigned, in a 2:1 ratio, to receive L-glutamine (152 patients) or placebo (78 patients). The patients in the L-glutamine group had significantly fewer pain crises than those in the placebo group (P=0.005), with a median of 3.0 in the L-glutamine group and 4.0 in the placebo group. Fewer hospitalizations occurred in the L-glutamine group than in the placebo group (P=0.005), with a median of 2.0 in the L-glutamine group and 3.0 in the placebo group. Two thirds of the patients in both trial groups received concomitant hydroxyurea. Low-grade nausea, noncardiac chest pain, fatigue, and musculoskeletal pain occurred more frequently in the L-glutamine group than in the placebo group. CONCLUSIONS Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with L-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea.	[Niihara, Yutaka; Tran, Lan T.; Razon, Rafael L.; Stark, Charles W.] Emmaus Med, Torrance, CA USA; [Niihara, Yutaka] Univ Calif Los Angeles, Los Angeles, CA USA; [Lasky, Joseph L.; Panosyan, Eduard H.] Harbor UCLA, Los Angeles, CA USA; [Lasky, Joseph L.; Panosyan, Eduard H.] Los Angeles BioMed Res Inst, Los Angeles, CA USA; [Stark, Charles W.] Univ Southern Calif, Los Angeles, CA USA; [Sieger, Lance; Blake, Osbourne A.] Los Angeles Kaiser Permanente Med Ctr, Inglewood, CA USA; [Neumayr, Lynne D.; Vichinsky, Elliott P.] UCSF Benioff Childrens Hosp & Res Ctr, Oakland, CA USA; [Miller, Scott T.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Viswanathan, Kusum] Brookdale Univ Hosp & Med Ctr, Brooklyn, NY USA; [Guillaume, Edouard] Interfaith Med Ctr, Brooklyn, NY USA; [Sadanandan, Swayam] Brooklyn Hosp Ctr, Brooklyn, NY USA; [Bellevue, Rita] New York Presbyterian Brooklyn Methodist Hosp, Brooklyn, NY USA; [Kanter, Julie] Med Univ South Carolina, Charleston, SC 29425 USA; [Lanzkron, Sophie] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; [Smith, Wally R.] Virginia Commonwealth Univ Healthcare Syst, Richmond, VA USA; [Hsu, Lewis L.; Gordeuk, Victor R.] Univ Illinois, Chicago, IL USA; [Sarnaik, Sharada] Childrens Hosp Michigan, Detroit, MI 48201 USA; [Osunkwo, Ifeyinwa] Carolinas HealthCare Syst, Charlotte, NC USA; [New, Tamara N.] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Brooklyn Hospital Center; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; Medical University of South Carolina; Johns Hopkins University; Johns Hopkins Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Children's Hospital of Michigan; Carolinas HealthCare System; Children's Healthcare of Atlanta (CHOA); Emory University	Stark, CW (corresponding author), Emmaus Med, 21250 Hawthorne Blvd,Suite 800, Torrance, CA 90503 USA.	cstark@emmausmedical.com	Osunkwo, Ifeyinwa/AAT-9315-2020; Vichinsky, Elliott P/F-8541-2011; Lanzkron, Sophie/AAD-7584-2022; Gordeuk, Victor/AAG-6577-2019; Lanzkron, Sophie/AFU-9516-2022	Vichinsky, Elliott P/0000-0002-0500-9579; Lanzkron, Sophie/0000-0002-2878-0251; Lanzkron, Sophie/0000-0002-2878-0251	Emmaus Medical	Emmaus Medical	Supported by Emmaus Medical.	Al-Ali AK, 2002, ACTA HAEMATOL-BASEL, V108, P19, DOI 10.1159/000063062; Ataga KI, 2017, NEW ENGL J MED, V376, P429, DOI 10.1056/NEJMoa1611770; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Chirico EN, 2012, IUBMB LIFE, V64, P72, DOI 10.1002/iub.584; Dessap AM, 2008, AM J RESP CRIT CARE, V177, P646, DOI 10.1164/rccm.200710-1606OC; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Holecek M, 2013, JPEN-PARENTER ENTER, V37, P607, DOI 10.1177/0148607112460682; Hsu L, FEATURED CLIN TOPIC; Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259; Mok E, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/617597; Morris CR, 2008, BLOOD, V111, P402, DOI 10.1182/blood-2007-04-081703; Morris CR, 2010, BLOOD, V116, P687, DOI 10.1182/blood.V116.21.1636.1636; Niihara Y., 1995, Journal of Investigative Medicine, V43, p131A; Niihara Y, 1998, AM J HEMATOL, V58, P117, DOI 10.1002/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V; Niihara YMH, 2014, CLIN PHARM BIOPHARM, V3, P116, DOI DOI 10.4172/2167-065X.1000116; Niihara Yutaka, 2005, BMC Blood Disord, V5, P4, DOI 10.1186/1471-2326-5-4; Niihara Y, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.86.86; Nur E, 2011, AM J HEMATOL, V86, P484, DOI 10.1002/ajh.22012; Paul R, 2013, EUR J HAEMATOL, V91, P62, DOI 10.1111/ejh.12118; Peters-Lawrence MH, 2012, CONTEMP CLIN TRIALS, V33, P291, DOI 10.1016/j.cct.2011.11.018; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Strouse JJ, 2016, SOUTH MED J, V109, P535, DOI 10.14423/SMJ.0000000000000515; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; Ward E, 2009, EUR J CLIN NUTR, V63, P134, DOI 10.1038/sj.ejcn.1602894; ZEREZ CR, 1994, BLOOD, V84, pA411; ZEREZ CR, 1988, BLOOD, V71, P512; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	27	237	239	3	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2018	379	3					226	235		10.1056/NEJMoa1715971	http://dx.doi.org/10.1056/NEJMoa1715971			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN5CX	30021096	Bronze			2023-01-03	WOS:000439063900006
J	Daukantaite, D; Tellhed, U; Maddux, RE; Svensson, T; Melander, O				Daukantaite, Daiva; Tellhed, Una; Maddux, Rachel E.; Svensson, Thomas; Melander, Olle			Five-week yin yoga-based interventions decreased plasma adrenomedullin and increased psychological health in stressed adults: A randomized controlled trial	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE RISK; ACUTE MYOCARDIAL-INFARCTION; HOSPITAL ANXIETY; POPULATION; PEPTIDES; EXERCISE; INSOMNIA; PROGRAM	Background Non-communicable diseases (NCDs, e.g. cardiovascular disease) are responsible for high rates of morbidity and the majority of premature deaths worldwide. It is necessary to develop preventative interventions that can reduce the associated risk factors of NCDs. Researchers have found that the biomarker adrenomedullin (ADM) becomes elevated years before the onset of NCDs and might play an important role in their development. ADM has also been linked to psychological problems such as stress, anxiety, and depression, which are known risk factors of NCDs. In this randomized controlled trial, we examined whether participating in a five-week yoga intervention reduces ADM and increases psychological health in middle-aged adults who self-report as moderately to highly stressed, but who otherwise exhibit no physical complaints. Methods One hundred and five adults (78% women; mean age = 53.5, SD = 6.7) were randomly assigned to (1) a five-week Yin yoga intervention, (2) a five-week intervention combining Yin yoga with psychoeducation and mindfulness practice (called the YOMI program), or (3) a control group who did not practice yoga or mindfulness for five weeks. Results Compared to the control group, we observed significantly greater pre-post reductions in plasma ADM levels (p < .001), anxiety (p <= .002), and sleep problems (p <= .003) in both intervention groups. Furthermore, the YOMI group exclusively showed significantly greater pre-post reductions in stress (p = .012) and depression (p = .021) compared to the control group. Significant correlations (p < .05) were found between pre-post reductions in ADM and anxiety symptoms (p = .02) and depression (p = .04) in the entire sample. Conclusion The five-week Yin yoga-based interventions appeared to reduce both the physiological and psychological risk factors known to be associated with NCDs. The study suggests that incorporating Yin yoga could be an easy and low-cost method of limiting the negative health effects associated with high stress.	[Daukantaite, Daiva; Tellhed, Una; Maddux, Rachel E.] Lund Univ, Dept Psychol, Lund, Sweden; [Svensson, Thomas; Melander, Olle] Lund Univ, Dept Clin Sci, Lund, Sweden; [Svensson, Thomas] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Clin Biotechnol, Tokyo, Japan; [Melander, Olle] Skane Univ Hosp, Dept Internal Med, Malmo, Sweden	Lund University; Lund University; University of Tokyo; Lund University; Skane University Hospital	Melander, O (corresponding author), Lund Univ, Dept Clin Sci, Lund, Sweden.; Melander, O (corresponding author), Skane Univ Hosp, Dept Internal Med, Malmo, Sweden.	Olle.Melander@med.lu.se	Svensson, Thomas/AAJ-4578-2020	Svensson, Thomas/0000-0003-1283-358X; Daukantaite, Daiva/0000-0002-1994-041X; Tellhed, Una/0000-0002-7283-6021; Melander, Olle/0000-0002-2581-484X	Knut and Alice Wallenberg Foundation; Goran Gustafsson Foundation; Swedish Heart- and Lung Foundation; Swedish Research Council; Novo Nordisk Foundation; Ernhold Lundstroms Stiftelse	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Goran Gustafsson Foundation; Swedish Heart- and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Ernhold Lundstroms Stiftelse	The study was supported by Knut and Alice Wallenberg Foundation, Goran Gustafsson Foundation, the Swedish Heart- and Lung Foundation, the Swedish Research Council, the Novo Nordisk Foundation, and Ernhold Lundstroms Stiftelse. None of them had any role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.	Akpinar A, 2013, PROG NEURO-PSYCHOPH, V46, P120, DOI 10.1016/j.pnpbp.2013.07.003; Al-Ayadhi LY, 2005, ANN SAUDI MED, V25, P36, DOI 10.5144/0256-4947.2005.36; American Psychological Association, STRESS AM OUR HLTH R; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Batelaan NM, 2016, BRIT J PSYCHIAT, V208, P223, DOI 10.1192/bjp.bp.114.156554; Belting M, 2012, CANCER EPIDEM BIOMAR, V21, P513, DOI 10.1158/1055-9965.EPI-11-0840; BJELLAND I, 2002, J PSYCHOSOM RES, V0052; Booth J, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0456-4; Bussing A, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI [10.1155/2012/219402, 10.1155/2012/165410]; Chu P, 2016, EUR J PREV CARDIOL, V23, P291, DOI 10.1177/2047487314562741; Cohen J., 2013, STAT POWER ANAL BEHA; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cramer H, 2014, INT J CARDIOL, V173, P170, DOI 10.1016/j.ijcard.2014.02.017; European Agency for Safety and Health at Work, 2009, OSH FIG STRESS WORK; Ezzati M, 2013, NEW ENGL J MED, V369, P954, DOI 10.1056/NEJMra1203528; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Grilley P., 2002, YIN YOGA OUTLINE QUI; HARTLEY HO, 1971, BIOMETRICS, V27, P783, DOI 10.2307/2528820; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hughes MF, 2016, PSYCHOSOM MED, V78, P401, DOI 10.1097/PSY.0000000000000289; Hylander F, 2017, ANXIETY STRESS COPIN, V30, P365, DOI 10.1080/10615806.2017.1301189; Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1; Innes KE, 2007, ALTERN THER HEALTH M, V13, P44; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Kato J, 2002, HYPERTENS RES, V25, P887; Khan S, 1999, NEUROREPORT, V10, P2829, DOI 10.1097/00001756-199909090-00024; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kong DG, 2014, CLIN EXP HYPERTENS, V36, P27, DOI 10.3109/10641963.2013.783049; Laugsand LE, 2011, CIRCULATION, V124, P2073, DOI 10.1161/CIRCULATIONAHA.111.025858; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424; Maddux RE, 2018, ANXIETY STRESS COPIN, V31, P121, DOI 10.1080/10615806.2017.1405261; Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49, DOI 10.1001/jama.2009.943; Meyer T, 2015, PSYCHONEUROENDOCRINO, V62, P227, DOI 10.1016/j.psyneuen.2015.08.007; Mithoefer B., 2006, YIN YOGA KIT PRACTIC; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Muktibodhananda S., 2012, HATHA YOGA PRADIPIKA; Nomura I, 2009, REGUL PEPTIDES, V158, P127, DOI 10.1016/j.regpep.2009.08.003; Nordin M, 2013, SCAND J PSYCHOL, V54, P502, DOI 10.1111/sjop.12071; Purdy RA, 2013, CAN J NEUROL SCI, V40, P139, DOI 10.1017/S0317167100013640; Riley KE, 2015, HEALTH PSYCHOL REV, V9, P224, DOI 10.1080/17437199.2014.895928; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; Ross A, 2010, J ALTERN COMPLEM MED, V16, P3, DOI 10.1089/acm.2009.0044; Rossler A, 1999, HYPERTENSION, V34, P1147, DOI 10.1161/01.HYP.34.5.1147; Saoji AA, 2016, N AM J MED SCI, V8, P200, DOI 10.4103/1947-2714.179962; Sengupta P, 2012, INT J PREVENTIVE MED, V3, P444; TANAKA M, 1995, INTERNAL MED, V34, P728, DOI 10.2169/internalmedicine.34.728; Urbaniak G.C., 2015, RES RANDOMIZER VERSI; Valenzuela-Sanchez F, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.65; World Health Organization, 2015, NONCOMMUNICABLE DIS; Yuyun MF, 2015, AM J CARDIOL, V115, P986, DOI 10.1016/j.amjcard.2015.01.027; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	11	11	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0200518	10.1371/journal.pone.0200518	http://dx.doi.org/10.1371/journal.pone.0200518			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN4SJ	30020987	gold, Green Published, Green Submitted			2023-01-03	WOS:000439022400052
J	Palmer, R; Witts, H; Chater, T				Palmer, Rebecca; Witts, Helen; Chater, Timothy			What speech and language therapy do community dwelling stroke survivors with aphasia receive in the UK?	PLOS ONE			English	Article							SERVICES; POSTSTROKE; PEOPLE; CARE	Background Speech and language therapy provision for aphasia (a language disorder) post stroke has been studied over time through surveys completed by speech and language therapists. This paper revisits provision based on what was received by 278 patients in 21 UK speech and language therapy departments in 2014-2016. Aims To explore the speech and language therapy received by community dwelling people with post stroke aphasia in the UK. Methods and procedures A quantitative content analysis was conducted by two speech and language therapist researchers. Therapy goals recorded were coded into categories and subcategories. Descriptive statistics were used to identify the frequency with which goal categories were targeted, average therapy time received, length and frequency of therapy sessions, personnel involved and mode of delivery. Outcomes and results Forty-five percent of participants were in receipt of therapy in the three month window observed. Six goal categories were identified. Rehabilitation was the most frequent (60%) followed by enabling (17.2%), review (4.3%), assessment (3.6%), supportive (3.5%) and activity to support therapy (2.8%). The median amount of therapy received in three months was 6.3 hours at an average of one 60-minute session every two weeks. Seventy-seven percent of therapy sessions were delivered by qualified speech and language therapists and 23% by assistants. Ninety percent of sessions were one to one, face to face sessions whilst 9.5% were group sessions. Discussion In line with previous reports, speech and language therapy for community dwelling stroke survivors with aphasia is restricted. Rehabilitation is a large focus of therapy but the intensity and dose with which it is provided is substantially lower than that required for an effective outcome. Despite this, one to one face to face therapy is favoured. More efficient methods to support more therapeutic doses of therapy are not commonly used in routine clinical services.	[Palmer, Rebecca; Chater, Timothy] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Witts, Helen] Derbyshire Community Hlth Serv NHS Fdn Trust, Speech & Language Therapy, Chesterfield, England	University of Sheffield	Palmer, R (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England.	r.l.palmer@sheffield.ac.uk	Chater, Tim/Q-4355-2016	Chater, Tim/0000-0002-1138-0147; Witts, Helen/0000-0001-5177-7117; Palmer, Rebecca/0000-0002-2335-7104	National Institute for Health Research Health Technology Assessment Programme [12/21/01]; Tavistock Trust for Aphasia	National Institute for Health Research Health Technology Assessment Programme(National Institute for Health Research (NIHR)); Tavistock Trust for Aphasia	This project was funded by the National Institute for Health Research Health Technology Assessment Programme (12/21/01). Additional funding support was provided by the Tavistock Trust for Aphasia. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Health Technology Assessment Programme, the National Institute for Health Research, the National Health Service or the Department of Health and Social Care. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen L, 2012, TOP STROKE REHABIL, V19, P523, DOI 10.1310/tsr1906-523; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Bowen A, 2012, BMJ-BRIT MED J, P345; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Breitenstein C, 2017, LANCET, V389, P1528, DOI 10.1016/S0140-6736(17)30067-3; Code C, 2003, DISABIL REHABIL, V25, P1231, DOI 10.1080/09638280310001599961; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; Katz RC, 2000, INT J LANG COMM DIS, V35, P303; Lavoie M, 2017, J COMMUN DISORD, V65, P43, DOI 10.1016/j.jcomdis.2017.01.001; List D., 2007, KNOW YOUR AUDIENCE P; MACKENZIE C, 1993, EUR J DISORDER COMM, V28, P43; Malcomess K, 2005, SPEECH LANGUAGE THER; Palmer R., 2016, CONSENT SUPPORT TOOL; Palmer R, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0527-7; Palmer R, 2012, STROKE, V43, P1904, DOI 10.1161/STROKEAHA.112.650671; Rose M, 2014, INT J SPEECH-LANG PA, V16, P169, DOI 10.3109/17549507.2013.794474; Royal College of Physicians, 2016, NAT CLIN GUID STROK; Steps Consultancy Ltd, STEPBYSTEP SOFTW; Stroke Association, 2016, STAT NAT STROK STAT; Swinburn K., 2004, COMPREHENSIVE APHASI; Verna A, 2009, INT J SPEECH-LANG PA, V11, P191, DOI 10.1080/17549500902726059; World Health Organisation, 2001, ICF INT CLASFUNCT; Worrall L, 2011, APHASIOLOGY, V25, P309, DOI 10.1080/02687038.2010.508530	23	33	33	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2018	13	7							e0200096	10.1371/journal.pone.0200096	http://dx.doi.org/10.1371/journal.pone.0200096			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM5IS	29990345	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000438170300029
J	Benson, MD; Waddington-Cruz, M; Berk, JL; Polydefkis, M; Dyck, PJ; Wang, AK; Plante-Bordeneuve, V; Barroso, FA; Merlini, G; Obici, L; Scheinberg, M; Brannagan, TH; Litchy, WJ; Whelan, C; Drachman, BM; Adams, D; Heitner, SB; Conceicao, I; Schmidt, HH; Vita, G; Campistol, JM; Gamez, J; Gorevic, PD; Gane, E; Shah, AM; Solomon, SD; Monia, BP; Hughes, SG; Kwoh, TJ; McEvoy, BW; Jung, SW; Baker, BF; Ackermann, EJ; Gertz, MA; Coelho, T				Benson, M. D.; Waddington-Cruz, M.; Berk, J. L.; Polydefkis, M.; Dyck, P. J.; Wang, A. K.; Plante-Bordeneuve, V.; Barroso, F. A.; Merlini, G.; Obici, L.; Scheinberg, M.; Brannagan, T. H., III; Litchy, W. J.; Whelan, C.; Drachman, B. M.; Adams, D.; Heitner, S. B.; Conceicao, I.; Schmidt, H. H.; Vita, G.; Campistol, J. M.; Gamez, J.; Gorevic, P. D.; Gane, E.; Shah, A. M.; Solomon, S. D.; Monia, B. P.; Hughes, S. G.; Kwoh, T. J.; McEvoy, B. W.; Jung, S. W.; Baker, B. F.; Ackermann, E. J.; Gertz, M. A.; Coelho, T.			Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTISENSE OLIGONUCLEOTIDES; ATTR AMYLOIDOSIS; POLYNEUROPATHY; 2'-O-METHOXYETHYL; DIFLUNISAL; NEUROPATHY; TAFAMIDIS; DISEASE; SAFETY	BACKGROUND Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and systemic deposition of amyloid. Progressive amyloid accumulation leads to multi-organ dysfunction and death. Inotersen, a 2'-O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic production of transthyretin. METHODS We conducted an international, randomized, double-blind, placebo-controlled, 15-month, phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 (patient is ambulatory with assistance) hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomly assigned, in a 2:1 ratio, to receive weekly subcutaneous injections of inotersen (300 mg) or placebo. The primary end points were the change in the modified Neuropathy Impairment Score+7 (mNIS+7; range, -22.3 to 346.3, with higher scores indicating poorer function; minimal clinically meaningful change, 2 points) and the change in the score on the patient-reported Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating poorer quality of life). A decrease in scores indicated improvement. RESULTS A total of 172 patients (112 in the inotersen group and 60 in the placebo group) received at least one dose of a trial regimen, and 139 (81%) completed the intervention period. Both primary efficacy assessments favored inotersen: the difference in the least-squares mean change from baseline to week 66 between the two groups (inotersen minus placebo) was -19.7 points (95% confidence interval [CI], -26.4 to -13.0; P<0.001) for the mNIS+7 and -11.7 points (95% CI, -18.3 to -5.1; P<0.001) for the Norfolk QOL-DN score. These improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy. There were five deaths in the inotersen group and none in the placebo group. The most frequent serious adverse events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and thrombocytopenia (in 3 patients [3%]), with one death associated with one of the cases of grade 4 thrombocytopenia. Thereafter, all patients received enhanced monitoring. CONCLUSIONS Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring.	[Benson, M. D.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Waddington-Cruz, M.] Fed Univ Rio Janeiro, Univ Hosp, Ctr Estudos Paramiloidose Antonio Rodrigues de Me, Natl Amyloidosis Referral Ctr, Rio De Janeiro, Brazil; [Berk, J. L.] Boston Univ, Sch Med, Amyloidosis Ctr, Boston, MA USA; [Shah, A. M.; Solomon, S. D.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Polydefkis, M.] Johns Hopkins Univ, Baltimore, MD USA; [Dyck, P. J.; Litchy, W. J.; Gertz, M. A.] Mayo Clin, Rochester, MN USA; [Wang, A. K.] Univ Calif Irvine, Irvine, CA USA; [Plante-Bordeneuve, V.] Univ Paris Est, Hosp Henri Mondor, AP HP, Amyloid Network, Creteil, France; [Barroso, F. A.] Inst Neurol Res Raul Carrea, FLENI, Buenos Aires, DF, Argentina; [Merlini, G.; Obici, L.] Univ Pavia, Amyloidosis Res & Treatment Ctr, Fdn IRCCS Policlin San Matteo, Pavia, Italy; [Vita, G.] Univ Hosp, Unit Neurol, Messina, Italy; [Scheinberg, M.] Hosp AACD, Associacao Assistencia Crianca Deficiente, Sao Paulo, Brazil; [Brannagan, T. H., III] Columbia Univ, Med Ctr, New York, NY USA; [Gorevic, P. D.] Mt Sinai Med Ctr, New York, NY 10029 USA; [Whelan, C.] UCL, Natl Amyloidosis Ctr, London, England; [Drachman, B. M.] Univ Penn Hlth Syst, Penn Presbyterian Med Ctr, Philadelphia, PA USA; [Adams, D.] Univ Paris Sud, AP HP, Unite 1195, CHU Bicetre, Paris, France; [Heitner, S. B.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Conceicao, I.] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Lisbon, Portugal; [Coelho, T.] Ctr Hos Porto, Porto, Portugal; [Schmidt, H. H.] Univ Klinikum Munster, Munster, Germany; [Campistol, J. M.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Hosp Clin, Barcelona, Spain; [Gamez, J.] Hosp Univ Vall dHebron, Barcelona, Spain; [Gane, E.] Auckland City Hosp, Auckland, New Zealand; [Monia, B. P.; Hughes, S. G.; Kwoh, T. J.; McEvoy, B. W.; Jung, S. W.; Baker, B. F.; Ackermann, E. J.] Ionis Pharmaceut, Carlsbad, CA USA	Indiana University System; Indiana University Bloomington; Universidade Federal do Rio de Janeiro; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; Mayo Clinic; University of California System; University of California Irvine; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; IRCCS Fondazione San Matteo; University of Pavia; AOU Policlinico Gaetano Martino; Columbia University; Icahn School of Medicine at Mount Sinai; University of London; University College London; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Presbyterian Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Oregon Health & Science University; Universidade de Lisboa; Hospital Santa Maria; University of Munster; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitari Vall d'Hebron; Auckland City Hospital; Ionis Pharmaceuticals, Inc.	Coelho, T (corresponding author), Hosp Santo Antonio, Ctr Hosp Porto, P-4099001 Porto, Portugal.	tcoelho@netcabo.pt	Gertz, Morie/K-2873-2019; Scheinberg, Morton/AAU-8142-2020; Conceicao, Isabel/AAC-6075-2022; Merlini, Giampaolo/A-3817-2008; Obici, Laura/AAC-3060-2019	Conceicao, Isabel/0000-0003-0934-9631; Merlini, Giampaolo/0000-0001-7680-3254; Obici, Laura/0000-0001-7468-700X; Brannagan, Thomas/0000-0002-1812-8331; Barroso, Fabio/0000-0002-3647-1803; Gamez, Josep/0000-0003-3127-7486; Baker, Brenda/0000-0001-8586-768X; Plante Bordeneuve, Violaine/0000-0002-7880-2316	Ionis Pharmaceuticals	Ionis Pharmaceuticals	Funded by Ionis Pharmaceuticals; NEURO-TTR ClinicalTrials.gov number, NCT01737398.	Ackermann EJ, 2016, AMYLOID, V23, P148, DOI 10.1080/13506129.2016.1191458; Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153; ALBERS JW, 1995, ANN NEUROL, V38, P478; Alexander KM, 2017, PHARMACOL THERAPEUT, V180, P129, DOI 10.1016/j.pharmthera.2017.06.011; Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; Barroso FA, 2017, AMYLOID, V24, P194, DOI 10.1080/13506129.2017.1357545; Berk JL, 2013, JAMA-J AM MED ASSOC, V310, P2658, DOI 10.1001/jama.2013.283815; Coelho T., 2008, PHYS  GUIDE TRANSTHY, P1; Coelho T, 2012, NEUROLOGY, V79, P785, DOI 10.1212/WNL.0b013e3182661eb1; Crooke ST, 2018, NUCLEIC ACID THER, V28, P10, DOI 10.1089/nat.2017.0693; Crooke ST, 2017, NUCLEIC ACID THER, V27, P121, DOI 10.1089/nat.2016.0650; Crooke ST, 2016, MOL THER, V24, P1771, DOI 10.1038/mt.2016.136; Dyck PJ, 2017, MUSCLE NERVE, V56, P901, DOI 10.1002/mus.25563; Dyck PJ, 2012, ARCH NEUROL-CHICAGO, V69, P1609, DOI 10.1001/archneurol.2012.1481; DYCK PJ, 1991, NEUROLOGY, V41, P799, DOI 10.1212/WNL.41.6.799; Ericzon BG, 2015, TRANSPLANTATION, V99, P1847, DOI 10.1097/TP.0000000000000574; Gertz MA, 2017, AM J MANAG CARE, V23, pA107; Liepnieks JJ, 2010, NEUROLOGY, V75, P324, DOI 10.1212/WNL.0b013e3181ea15d4; Lobato L, 2003, NEPHROL DIAL TRANSPL, V18, P532, DOI 10.1093/ndt/18.3.532; Lobato L, 2012, CLIN J AM SOC NEPHRO, V7, P1337, DOI 10.2215/CJN.08720811; Maurer MS, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.116.003815; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Plante-Bordeneuve V, 2011, LANCET NEUROL, V10, P1086, DOI 10.1016/S1474-4422(11)70246-0; Rapezzi C, 2010, NAT REV CARDIOL, V7, P398, DOI 10.1038/nrcardio.2010.67; Sekijima Y, 2006, AMYLOID, V13, P236, DOI 10.1080/13506120600960882; Sekijima Y, 2015, J NEUROL NEUROSUR PS, V86, P1036, DOI 10.1136/jnnp-2014-308724; Suanprasert N, 2014, J NEUROL SCI, V344, P121, DOI 10.1016/j.jns.2014.06.041; Vinik Etta J, 2005, Diabetes Technol Ther, V7, P497, DOI 10.1089/dia.2005.7.497; Vinik EJ, 2014, J PERIPHER NERV SYST, V19, P104, DOI 10.1111/jns5.12059	29	677	694	6	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2018	379	1					22	31		10.1056/NEJMoa1716793	http://dx.doi.org/10.1056/NEJMoa1716793			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL5ZG	29972757	Bronze, Green Published			2023-01-03	WOS:000437254200006
J	Alessandra-Perini, J; Rodrigues-Baptista, KC; Machado, DE; Nasciutti, LE; Perini, JA				Alessandra-Perini, Jessica; Rodrigues-Baptista, Karina Cristina; Machado, Daniel Escorsim; Nasciutti, Luiz Eurico; Perini, Jamila Alessandra			Anticancer potential, molecular mechanisms and toxicity of Euterpe oleracea extract (acai): A systematic review	PLOS ONE			English	Review							MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; AMAZONIAN PALM BERRY; ORAL CONTRAST AGENT; MART. ACAI; JUICE BLEND; IN-VITRO; HEALTHY-VOLUNTEERS; MICRONUCLEUS TEST; OXIDATIVE STRESS; NATURAL-PRODUCTS	Cancer is an increasingly frequent malignancy worldwide, and despite the advances in drug development, it is still necessary to develop new plant-derived medicines. Euterpe oleracea (acai) is abundant in South and Central America and has health benefits due to its high levels of phytochemicals, including lignans and polyphenols. The aim of this review was to systematically describe the safety and antitumor effects of acai in preclinical models using rodents to provide a more comprehensive assessment of acai for both therapeutic uses and the development of future clinical studies in cancer. Eligible studies were identified using four international databases (PubMed, Medline, Lilacs and SciELO) from their inception date through December 2017. The included studies were analyzed with methodological rigor (QATRS) to enable better quality control for these experimental studies. Sixty publications were identified in the databases, but only 9 articles were eligible: 6 evaluated the pharmacological effects of acai in animal models of cancer (1 model each of esophageal cancer, urothelial cancer, melanoma and Walker-256 tumor and 2 models of colon cancer), and 3 were toxicological assays using preclinical models with rodents. Overall, 747 animals were analyzed. On a QATRS score scale of 0-20, the quality of the studies ranged from 16 to 20 points. Pulp was the main fraction of acai administered, and an oral administration route was most common. The acai dosage administered by gavage ranged from 30 mg/ kg to 40,000 mg/kg, and acai fed in the diet accounted for 2.5% to 5% of the diet. The anticarcinogenic and chemopreventive activities of acai were observed in all experimental models of cancer and reduced the incidence, tumor cell proliferation, multiplicity and size of the tumors due to the antiinflammatory, antiproliferative and proapoptotic properties of acai. No genotoxic effects were observed after acai administration. The results of this review suggest that acai is safe and can be used as a chemoprotective agent against cancer development. acai therapy may be a novel strategy for treating cancer.	[Alessandra-Perini, Jessica; Machado, Daniel Escorsim; Nasciutti, Luiz Eurico] Univ Fed Rio de Janeiro, Morphol Sci Program PCM, Biomed Sci Inst, Rio De Janeiro, RJ, Brazil; [Alessandra-Perini, Jessica; Rodrigues-Baptista, Karina Cristina; Machado, Daniel Escorsim; Perini, Jamila Alessandra] West Zone State Univ, Res Lab Pharmaceut Sci LAPESF, Rio De Janeiro, RJ, Brazil; [Rodrigues-Baptista, Karina Cristina; Perini, Jamila Alessandra] Fundacao Oswaldo Cruz, Program Postgrad Publ Hlth & Environm ENSP, Natl Sch Publ Hlth, Rio De Janeiro, RJ, Brazil; [Machado, Daniel Escorsim] Laureate Univ, Univ Ctr IBMR, Rio De Janeiro, RJ, Brazil; [Perini, Jamila Alessandra] Natl Inst Traumatol & Orthoped INTO, Res Div, Rio De Janeiro, RJ, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Alessandra-Perini, J (corresponding author), Univ Fed Rio de Janeiro, Morphol Sci Program PCM, Biomed Sci Inst, Rio De Janeiro, RJ, Brazil.; Alessandra-Perini, J (corresponding author), West Zone State Univ, Res Lab Pharmaceut Sci LAPESF, Rio De Janeiro, RJ, Brazil.	jessicaperini@yahoo.com.br			Brazilian agency Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ; Fundacao Ary Frauzino - Oncobiologia; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES	Brazilian agency Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Fundacao Ary Frauzino - Oncobiologia; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was supported by the Brazilian agency Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJ (JAP and DEM), Fundacao Ary Frauzino - Oncobiologia (DEM) and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES (JA-P and KCRB).	Alqurashi RM, 2016, AM J CLIN NUTR, V104, P1227, DOI 10.3945/ajcn.115.128728; Barbosa PO, 2016, NUTRITION, V32, P674, DOI 10.1016/j.nut.2015.12.030; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Bittman ME, 2014, PEDIATR RADIOL, V44, P883, DOI 10.1007/s00247-014-2884-5; Brasil A, 2017, NUTR NEUROSCI, V20, P265, DOI [10.1080/1028415x.2015.1119378, 10.1080/1028415X.2015.1119378]; Brito C, 2016, ARCH ORAL BIOL, V68, P29, DOI 10.1016/j.archoralbio.2016.03.016; Brito C, 2017, ARCH ORAL BIOL, V83, P348, DOI 10.1016/j.archoralbio.2017.09.001; Caiado RR, 2017, CURR EYE RES, V42, P1185, DOI 10.1080/02713683.2017.1297995; Cardoso AL, 2018, PLANTA MED, V84, P487, DOI 10.1055/s-0044-101624; Carvalho-Peixoto J, 2015, APPL PHYSIOL NUTR ME, V40, P725, DOI 10.1139/apnm-2014-0518; Choi YJ, 2017, GUT LIVER, V11, P243, DOI 10.5009/gnl16068; Cordova-Fraga T, 2004, MAGN RESON IMAGING, V22, P389, DOI 10.1016/j.mri.2004.01.018; da Costa CA, 2017, J MED FOOD, V20, P1002, DOI 10.1089/jmf.2017.0011; Yamaguchi KKD, 2015, FOOD CHEM, V179, P137, DOI 10.1016/j.foodchem.2015.01.055; de Moura RS, 2016, J CARDIOVASC PHARM, V68, P19, DOI 10.1097/FJC.0000000000000347; de Moura RS, 2012, PHYTOMEDICINE, V19, P262, DOI 10.1016/j.phymed.2011.11.004; de Moura RS, 2011, FOOD CHEM TOXICOL, V49, P855, DOI 10.1016/j.fct.2010.12.007; de Oliveira PRB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143721; de Souza MO, 2012, NUTR RES, V32, P976, DOI 10.1016/j.nutres.2012.10.001; Del Pozo-Insfran D, 2006, J AGR FOOD CHEM, V54, P1222, DOI 10.1021/jf052132n; Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n; Dias MMD, 2014, NUTR CANCER, V66, P1394, DOI 10.1080/01635581.2014.956252; dos Santos RA, 2008, FOOD CHEM TOXICOL, V46, P671, DOI 10.1016/j.fct.2007.09.090; Dutra Rafael C, 2016, Pharmacol Res, V112, P4, DOI 10.1016/j.phrs.2016.01.021; El Morsy EM, 2015, LIFE SCI, V123, P35, DOI 10.1016/j.lfs.2014.11.013; Ellinger S, 2012, J AGR FOOD CHEM, V60, P11292, DOI 10.1021/jf300719t; Souza BSFE, 2017, BIOMED PHARMACOTHER, V90, P542, DOI 10.1016/j.biopha.2017.04.005; Felzenszwalb I, 2013, FOOD CHEM TOXICOL, V58, P536, DOI 10.1016/j.fct.2013.05.029; Forester SC, 2012, MOL NUTR FOOD RES, V56, P1647, DOI 10.1002/mnfr.201200206; Fragoso MF, 2012, PLANT FOOD HUM NUTR, V67, P235, DOI 10.1007/s11130-012-0308-y; Fragoso MF, 2013, FOOD CHEM TOXICOL, V58, P68, DOI 10.1016/j.fct.2013.04.011; Freitas DD, 2017, J PHARM PHARMACOL, V69, P714, DOI 10.1111/jphp.12679; Freitas RD, 2017, NUTR HOSP, V34, P186, DOI 10.20960/nh.996; Gale AM, 2014, INT J CARDIOL, V174, P421, DOI 10.1016/j.ijcard.2014.04.036; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Guzinska-Ustymowicz K, 2009, ANTICANCER RES, V29, P3049; Heinrich M, 2011, PHYTOCHEM LETT, V4, P10, DOI 10.1016/j.phytol.2010.11.005; Hogan S, 2010, FOOD CHEM, V118, P208, DOI 10.1016/j.foodchem.2009.04.099; Jensen GS, 2008, J AGR FOOD CHEM, V56, P8326, DOI 10.1021/jf8016157; Jensen GS, 2011, J MED FOOD, V14, P702, DOI 10.1089/jmf.2010.0150; Kim YS, 2013, MOL MED REP, V7, P881, DOI 10.3892/mmr.2013.1259; Kinghorn AD, 2011, FITOTERAPIA, V82, P71, DOI 10.1016/j.fitote.2010.08.015; Kowar M, 2015, DEUT MED WOCHENSCHR, V140, P1759, DOI 10.1055/s-0041-105987; Leba LJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071014; Machado AK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8940850; Machado DE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166059; Machado DE, 2014, HISTOL HISTOPATHOL, V29, P903, DOI 10.14670/HH-29.903; Machado FD, 2016, METAB BRAIN DIS, V31, P1427, DOI 10.1007/s11011-016-9873-3; Marques ES, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16039700; Marques ES, 2016, FOOD CHEM TOXICOL, V93, P13, DOI 10.1016/j.fct.2016.04.018; Matheus ME, 2006, J ETHNOPHARMACOL, V107, P291, DOI 10.1016/j.jep.2006.03.010; Mertens-Talcott SU, 2008, J AGR FOOD CHEM, V56, P7796, DOI 10.1021/jf8007037; Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057; Monge-Fuentes V, 2017, J PHOTOCH PHOTOBIO B, V166, P301, DOI 10.1016/j.jphotobiol.2016.12.002; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; do Nascimento VHN, 2016, ACTA CIR BRAS, V31, P597, DOI 10.1590/S0102-865020160090000004; Pala D, 2018, CLIN NUTR, V37, P618, DOI 10.1016/j.clnu.2017.02.001; Pereira ID, 2015, NUTR HOSP, V32, P931, DOI 10.3305/nh.2015.32.2.9135; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Poulose SM, 2012, J AGR FOOD CHEM, V60, P1084, DOI 10.1021/jf203989k; Qiu XM, 2017, ONCOL LETT, V14, P2912, DOI 10.3892/ol.2017.6516; Ribeiro JC, 2010, MUTAT RES-GEN TOX EN, V695, P22, DOI 10.1016/j.mrgentox.2009.10.009; Rim KT, 2015, SAF HEALTH WORK, V6, P184, DOI 10.1016/j.shaw.2015.05.005; Rodrigues RB, 2006, J AGR FOOD CHEM, V54, P4162, DOI 10.1021/jf058169p; Roy AM, 2005, MOL CANCER THER, V4, P81; Sadowska-Krepa E, 2015, BIOL SPORT, V32, P161, DOI 10.5604/20831862.1144419; Sanchez TA, 2009, J COMPUT ASSIST TOMO, V33, P666, DOI 10.1097/RCT.0b013e31819012a0; Schauss AG, 2006, J AGR FOOD CHEM, V54, P8604, DOI 10.1021/jf0609779; Schauss AG, 2006, J AGR FOOD CHEM, V54, P8598, DOI 10.1021/jf060976g; Schauss AG, 2010, TOXICOLOGY, V278, P46, DOI 10.1016/j.tox.2010.04.017; Schreckinger ME, 2010, J MED FOOD, V13, P233, DOI 10.1089/jmf.2009.0233; Silva DCVR, 2013, THESIS; Silva DF, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-175; Spada PDS, 2008, J MED FOOD, V11, P144, DOI 10.1089/jmf.2007.598; Stoner GD, 2010, PHARM RES-DORDR, V27, P1138, DOI 10.1007/s11095-010-0102-1; Sudo RT, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0724-2; Tajali SB, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-1; Udani JK, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-45; Ulbricht Catherine, 2012, Journal of Dietary Supplements, V9, P128, DOI 10.3109/19390211.2012.686347; Valli M, 2013, J NAT PROD, V76, P439, DOI 10.1021/np3006875; Vrailas-Mortimer A, 2012, EXP GERONTOL, V47, P712, DOI 10.1016/j.exger.2012.06.016; Wong DYS, 2013, NEUROSCI LETT, V556, P221, DOI 10.1016/j.neulet.2013.10.027; Xie CH, 2012, J NUTR BIOCHEM, V23, P1184, DOI 10.1016/j.jnutbio.2011.06.013	84	12	12	3	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2018	13	7							e0200101	10.1371/journal.pone.0200101	http://dx.doi.org/10.1371/journal.pone.0200101			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL5QR	29966007	Green Published, gold, Green Submitted			2023-01-03	WOS:000437224100049
J	Venot, Q; Blanc, T; Rabia, SH; Berteloot, L; Ladraa, S; Duong, JP; Blanc, E; Johnson, SC; Hoguin, C; Boccara, O; Sarnacki, S; Boddaert, N; Pannier, S; Martinez, F; Magassa, S; Yamaguchi, J; Knebelmann, B; Merville, P; Grenier, N; Joly, D; Cormier-Daire, V; Michot, C; Bole-Feysot, C; Picard, A; Soupre, V; Lyonnet, S; Sadoine, J; Slimani, L; Chaussain, C; Laroche-Raynaud, C; Guibaud, L; Broissand, C; Amiel, J; Legendre, C; Terzi, F; Canaud, G				Venot, Quitterie; Blanc, Thomas; Rabia, Smail Hadj; Berteloot, Laureline; Ladraa, Sophia; Duong, Jean-Paul; Blanc, Estelle; Johnson, Simon C.; Hoguin, Clement; Boccara, Olivia; Sarnacki, Sabine; Boddaert, Nathalie; Pannier, Stephanie; Martinez, Frank; Magassa, Sato; Yamaguchi, Junna; Knebelmann, Bertrand; Merville, Pierre; Grenier, Nicolas; Joly, Dominique; Cormier-Daire, Valerie; Michot, Caroline; Bole-Feysot, Christine; Picard, Arnaud; Soupre, Veronique; Lyonnet, Stanislas; Sadoine, Jeremy; Slimani, Lotfi; Chaussain, Catherine; Laroche-Raynaud, Cecile; Guibaud, Laurent; Broissand, Christine; Amiel, Jeanne; Legendre, Christophe; Terzi, Fabiola; Canaud, Guillaume			Targeted therapy in patients with PIK3CA-related overgrowth syndrome	NATURE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PIK3CA(H1047R) MUTATION; EXPRESSION; INHIBITION; NVP-BYL719; DISCOVERY; SPECTRUM; CRITERIA	CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome) is a genetic disorder that results from somatic, mosaic gain-of-function mutations of the PIK3CA gene, and belongs to the spectrum of PIK3CA-related overgrowth syndromes (PROS). This rare condition has no specific treatment and a poor survival rate. Here, we describe a postnatal mouse model of PROS/CLOVES that partially recapitulates the human disease, and demonstrate the efficacy of BYL719, an inhibitor of PIK3CA, in preventing and improving organ dysfunction. On the basis of these results, we used BYL719 to treat nineteen patients with PROS. The drug improved the disease symptoms in all patients. Previously intractable vascular tumours became smaller, congestive heart failure was improved, hemihypertrophy was reduced, and scoliosis was attenuated. The treatment was not associated with any substantial side effects. In conclusion, this study provides the first direct evidence supporting PIK3CA inhibition as a promising therapeutic strategy in patients with PROS.	[Venot, Quitterie; Blanc, Thomas; Ladraa, Sophia; Hoguin, Clement; Magassa, Sato; Yamaguchi, Junna; Knebelmann, Bertrand; Joly, Dominique; Legendre, Christophe; Terzi, Fabiola; Canaud, Guillaume] Inst Necker Enfants Malad, INSERM, U1151, Paris, France; [Blanc, Thomas; Rabia, Smail Hadj; Duong, Jean-Paul; Sarnacki, Sabine; Boddaert, Nathalie; Pannier, Stephanie; Knebelmann, Bertrand; Joly, Dominique; Cormier-Daire, Valerie; Michot, Caroline; Picard, Arnaud; Lyonnet, Stanislas; Chaussain, Catherine; Amiel, Jeanne; Legendre, Christophe; Terzi, Fabiola; Canaud, Guillaume] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Blanc, Thomas; Sarnacki, Sabine] Hop Necker Enfants Malad, AP HP, Serv Chirurg Viscerale Pediat, Paris, France; [Rabia, Smail Hadj; Boccara, Olivia] Hop Necker Enfants Malad, AP HP, Serv Dermatol Pediat, Paris, France; [Rabia, Smail Hadj; Berteloot, Laureline; Boddaert, Nathalie; Cormier-Daire, Valerie; Michot, Caroline; Bole-Feysot, Christine; Lyonnet, Stanislas; Amiel, Jeanne] Hop Necker Enfants Malad, AP HP, Inst Imagine, UMR 1163, Paris, France; [Berteloot, Laureline; Boddaert, Nathalie] Hop Necker Enfants Malad, AP HP, Dept Radiol Pediat, Paris, France; [Duong, Jean-Paul] Hop Necker Enfants Malad, AP HP, Dept Anatomopathol, Paris, France; [Blanc, Estelle] Hop Marie Lannelongue, Dept Nucl Med, Le Plessis Robinsson, France; [Johnson, Simon C.] Seattle Childrens Res Inst, Dept Integrat Brain Res, Seattle, WA USA; [Pannier, Stephanie] Hop Necker Enfants Malad, AP HP, Serv Orthoped Pediat, Paris, France; [Martinez, Frank; Knebelmann, Bertrand; Joly, Dominique; Canaud, Guillaume] Hop Necker Enfants Malad, AP HP, Serv Nephrol Transplantat Adultes, Paris, France; [Merville, Pierre] CHU Pellegrin, Serv Nephrol, Transplantat, Dialyse,Aphereses, Bordeaux, France; [Merville, Pierre] CNRS, Immuno ConcEpT, UMR 5164, Bordeaux, France; [Grenier, Nicolas] CHU Pellegrin, Serv Imagerie Diagnost & Intervent Adulte, Bordeaux, France; [Cormier-Daire, Valerie; Michot, Caroline; Lyonnet, Stanislas; Amiel, Jeanne] Hop Necker Enfants Malad, AP HP, Serv Genet Med, Paris, France; [Picard, Arnaud; Soupre, Veronique] Hop Necker Enfants Malad, AP HP, Serv Chirurg Maxillofaciale & Chirurg Plast, Paris, France; [Sadoine, Jeremy; Slimani, Lotfi; Chaussain, Catherine] Lab EA 2496 Orofacial Pathol Imaging & Biotherapi, Montrouge, France; [Laroche-Raynaud, Cecile] Hop Mere & Enfant, Serv Neuropediat, Limoges, France; [Guibaud, Laurent] Hop Femme Mere Enfant, Serv Imagerie Pediat, Bron, France; [Broissand, Christine] Hop Necker Enfants Malad, AP HP, Pharm, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Marie Lannelongue; Seattle Children's Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Limoges; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Canaud, G (corresponding author), Inst Necker Enfants Malad, INSERM, U1151, Paris, France.; Canaud, G (corresponding author), Univ Paris 05, Sorbonne Paris Cite, Paris, France.; Canaud, G (corresponding author), Hop Necker Enfants Malad, AP HP, Serv Nephrol Transplantat Adultes, Paris, France.	guillaume.canaud@inserm.fr	amiel, jeanne/AGX-1124-2022; boddaert, nathalie/GWV-2865-2022; Slimani, Lotfi/AAC-4038-2019; Terzi, Fabiola/N-5482-2018; Sarnacki, Sabine/I-2692-2017	Chaussain, Catherine/0000-0002-3463-3936; Johnson, Simon/0000-0002-1942-3674; Sarnacki, Sabine/0000-0003-4304-5578; Pannier, Stephanie/0000-0002-5581-4699; Slimani, Lotfi/0000-0003-1806-0514; Venot, Quitterie/0000-0001-5964-5370; Sadoine, Jeremy/0000-0003-4809-3018	European Research Council under the European Union's Horizon 2020 research and innovation program grants [679254, 737546]; Emmanuel BOUSSARD Foundation; DAY SOLVAY Foundation; Fondation TOURRE; Fondation Simone et Cino Del Duca; INSERM; Assistance Publique-Hopitaux de Paris; University of Paris, Descartes	European Research Council under the European Union's Horizon 2020 research and innovation program grants; Emmanuel BOUSSARD Foundation; DAY SOLVAY Foundation(Solvay SA); Fondation TOURRE; Fondation Simone et Cino Del Duca; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Assistance Publique-Hopitaux de Paris; University of Paris, Descartes	This project received funding from the European Research Council under the European Union's Horizon 2020 research and innovation program grants, (STG-2015) 679254 and (PoC-2016) 737546 (both awarded to G.C.). This work was also supported by the Emmanuel BOUSSARD Foundation, the DAY SOLVAY Foundation, Fondation TOURRE, Fondation Simone et Cino Del Duca, INSERM, Assistance Publique-Hopitaux de Paris and the University of Paris, Descartes. We would like to thank the two patients and their families. We also thank C. Semaille from the ANSM for help and advice; S. Bisot-Locard (Novartis) for the BYL719; G. Autret for performing the mouse MRIs; S. Berissi and colleagues at the Plateforme d'histologie et morphologie du petit animal, INEM, Paris; S. Principe for administrative management; A. Klippel for advice and for providing plasmids encoding Myr-p110*-myc and Myr-p110* KR-myc constructs; K. Rajewsky for advice; and the radiological team from the Centre d'Imagerie de Franconville and in particular M. Canaud and A. Scemama for their help.	Canaud G, 2014, NEW ENGL J MED, V371, P303, DOI 10.1056/NEJMoa1312890; Canaud G, 2013, NAT MED, V19, P1288, DOI 10.1038/nm.3313; Castillo SD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9982; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865; Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007; Hammill AM, 2011, PEDIATR BLOOD CANCER, V57, P1018, DOI 10.1002/pbc.23124; Hare LM, 2015, DEV BIOL, V404, P14, DOI 10.1016/j.ydbio.2015.04.022; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Keppler-Noreuil KM, 2015, AM J MED GENET A, V167, P287, DOI 10.1002/ajmg.a.36836; Keppler-Noreuil KM, 2014, AM J MED GENET A, V164, P1713, DOI 10.1002/ajmg.a.36552; Kinross KM, 2015, FASEB J, V29, P1426, DOI 10.1096/fj.14-262782; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kurek KC, 2012, AM J HUM GENET, V90, P1108, DOI 10.1016/j.ajhg.2012.05.006; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mayer IA, 2017, CLIN CANCER RES, V23, P26, DOI 10.1158/1078-0432.CCR-16-0134; Mirzaa G, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87623; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Seluanov Andrei, 2010, J Vis Exp, DOI 10.3791/2033; Srinivasan L, 2009, CELL, V139, P573, DOI 10.1016/j.cell.2009.08.041; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Velarde-Jurado E, 2002, SALUD PUBLICA MEXICO, V44, P349, DOI 10.1590/S0036-36342002000400009	27	240	245	5	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2018	558	7711					540	+		10.1038/s41586-018-0217-9	http://dx.doi.org/10.1038/s41586-018-0217-9			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK9SN	29899452	Green Accepted			2023-01-03	WOS:000436594300051
J	Dimopoulos, MA; Tedeschi, A; Trotman, J; Garcia-Sanz, R; Macdonald, D; Leblond, V; Mahe, B; Herbaux, C; Tam, C; Orsucci, L; Palomba, ML; Matous, JV; Shustik, C; Kastritis, E; Treon, SP; Li, J; Salman, Z; Graef, T; Buske, C				Dimopoulos, M. A.; Tedeschi, A.; Trotman, J.; Garcia-Sanz, R.; Macdonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C.; Orsucci, L.; Palomba, M. L.; Matous, J. V.; Shustik, C.; Kastritis, E.; Treon, S. P.; Li, J.; Salman, Z.; Graef, T.; Buske, C.		INNOVATE Study Grp European Consor	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSENSUS PANEL RECOMMENDATIONS; PREVIOUSLY TREATED PATIENTS; 2ND INTERNATIONAL WORKSHOP; TERM-FOLLOW-UP; OPEN-LABEL; THERAPY; DEXAMETHASONE; MULTICENTER; GUIDELINES; MANAGEMENT	BACKGROUND Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenstrom's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab in patients with this disease, both in those who had not received previous treatment and in those with disease recurrence. METHODS We randomly assigned 150 symptomatic patients to receive ibrutinib plus rituximab or placebo plus rituximab. The primary end point was progression-free survival, as assessed by an independent review committee. Key secondary end points were response rates, sustained hematologic improvement from baseline, and safety. The mutational status of MYD88 and CXCR4 was assessed in bone marrow samples. RESULTS At 30 months, the progression-free survival rate was 82% with ibrutinib-rituximab versus 28% with placebo-rituximab (hazard ratio for progression or death, 0.20; P<0.001). The benefit in the ibrutinib-rituximab group over that in the placebo-rituximab group was independent of the MYD88 or CXCR4 genotype. The rate of major response was higher with ibrutinib-rituximab than with placebo-rituximab (72% vs. 32%, P<0.001). More patients had sustained increases in hemoglobin level with ibrutinib-rituximab than with placebo-rituximab (73% vs. 41%, P<0.001). The most common adverse events of any grade with ibrutinib-rituximab included infusion-related reactions, diarrhea, arthralgia, and nausea. Events of grade 3 or higher that occurred more frequently with ibrutinib-rituximab than with placebo-rituximab included atrial fibrillation (12% vs. 1%) and hypertension (13% vs. 4%); those that occurred less frequently included infusion reactions (1% vs. 16%) and any grade of IgM flare (8% vs. 47%). The major hemorrhage rate was the same in the two trial groups (4%). CONCLUSIONS Among patients with Waldenstrom's macroglobulinemia, the use of ibrutinib-rituximab resulted in significantly higher rates of progression-free survival than the use of placebo-rituximab, both among those who had received no previous treatment and among those with disease recurrence. Atrial fibrillation and hypertension were more common with ibrutinib-rituximab, whereas infusion reactions and IgM flare were more common with placebo-rituximab.	[Dimopoulos, M. A.; Kastritis, E.] Univ Athens, Sch Med, Athens, Greece; [Tedeschi, A.] ASST Grande Osped Metropolitano Niguarda, Milan, Italy; [Orsucci, L.] Citta Salute Hosp & Univ, Turin, Italy; [Trotman, J.] Univ Sydney, Concord Hosp, Concord, NSW, Australia; [Tam, C.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Tam, C.] St Vincents Hosp, Melbourne, Vic, Australia; [Garcia-Sanz, R.] Hosp Univ Salamanca, Salamanca, Spain; [Macdonald, D.] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada; [Shustik, C.] McGill Univ, Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada; [Leblond, V.] Univ Paris 06, AP HP, Hop Pitie Salpetriere, Dept Hematol, Paris, France; [Mahe, B.] CHU Nantes, Nantes, France; [Herbaux, C.] Ctr Hosp Reg Univ Lille, Inst Hematol Tranfus, Lille, France; [Palomba, M. L.] Mem Sloan Kettering Canc Ctr, New York, NY USA; [Matous, J. V.] Colorado Blood Canc Inst, Denver, CO USA; [Treon, S. P.] Dana Farber Canc Inst, Boston, MA USA; [Li, J.; Salman, Z.; Graef, T.] Pharmacyclics, Sunnyvale, CA USA; [Buske, C.] Univ Hosp Ulm, Dept Internal Med 3, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany	Athens Medical School; National & Kapodistrian University of Athens; A.O.U. Citta della Salute e della Scienza di Torino; Concord Repatriation General Hospital; University of Sydney; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Salamanca; University of Ottawa; Ottawa Hospital Research Institute; McGill University; Royal Victoria Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; CHU Lille; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Pharmacyclics; Ulm University	Dimopoulos, MA (corresponding author), Univ Athens, Alexandra Hosp, Sch Med, Dept Clini Therapeut, Athens 11528, Greece.	mdimop@med.uoa.gr	Kastritis, Efstathios/AAD-3656-2019; Dimopoulos, Meletios Athanasios/AAD-4130-2019; Symeonidis, Argiris/K-2287-2019; Kastritis, Efstathios/AAE-4483-2020; Hernandez-Rivas, Jose-Angel/ADF-6441-2022; Trappe, Ralf Ulrich/W-5801-2019; Hatjiharissi, Evdoxia/AAG-7425-2020; Garcia-Sanz, Ramon/B-7986-2017	Kastritis, Efstathios/0000-0001-8191-5832; Symeonidis, Argiris/0000-0002-3685-3473; Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; Trappe, Ralf Ulrich/0000-0001-7565-7160; Talaulikar, Dipti/0000-0001-6766-8345; Trotman, Judith/0000-0001-8009-4593; Garcia-Sanz, Ramon/0000-0003-4120-2787	Pharmacyclics; Janssen Research and Development	Pharmacyclics; Janssen Research and Development	Funded by Pharmacyclics and Janssen Research and Development; ClinicalTrials.gov number, NCT02165397.	Buske C, 2013, ANN ONCOL, V24, P155, DOI 10.1093/annonc/mdt298; Buske C, 2015, BLOOD, V126, P2096; Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038; Castillo JJ, 2016, BRIT J HAEMATOL, V172, P709, DOI 10.1111/bjh.13883; Cella D, 1997, SEMIN HEMATOL, V34, P13; Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400; Dimopoulos MA, 2002, J CLIN ONCOL, V20, P2327, DOI 10.1200/JCO.2002.09.039; Dimopoulos MA, 2017, LANCET ONCOL, V18, P241, DOI 10.1016/S1470-2045(16)30632-5; Dimopoulos MA, 2014, BLOOD, V124, P1404, DOI 10.1182/blood-2014-03-565135; Dimopoulos MA, 2013, BLOOD, V122, P3276, DOI 10.1182/blood-2013-05-503862; Dimopoulos MA, 2007, J CLIN ONCOL, V25, P3344, DOI 10.1200/JCO.2007.10.9926; Ghobrial IM, 2013, J CLIN ONCOL, V31, P291, DOI 10.1200/JCO.2012.46.6177; Kyle RA, 2003, SEMIN ONCOL, V30, P116, DOI 10.1053/sonc.2003.50038; Leblond V, 2016, BLOOD, V128, P1321, DOI 10.1182/blood-2016-04-711234; Leblond V, 2013, J CLIN ONCOL, V31, P301, DOI 10.1200/JCO.2012.44.7920; Morel P, 2009, BLOOD, V113, P4163, DOI 10.1182/blood-2008-08-174961; Olszewski AJ, 2016, ONCOLOGIST, V21, P1377, DOI 10.1634/theoncologist.2016-0126; Owen RG, 2003, SEMIN ONCOL, V30, P110, DOI 10.1053/sonc.2003.50082; Owen RG, 2014, BRIT J HAEMATOL, V165, P316, DOI 10.1111/bjh.12760; Rourke M, 2010, LEUKEMIA LYMPHOMA, V51, P1779, DOI 10.3109/10428194.2010.499977; Ruella M, 2017, LEUKEMIA, V31, P246, DOI 10.1038/leu.2016.262; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; Treon SP, 2005, ANN ONCOL, V16, P132, DOI 10.1093/annonc/mdi022; Treon SP, 2017, BLOOD, V130; Treon SP, 2015, BLOOD, V126, P721, DOI 10.1182/blood-2015-01-553974; Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Wang ML, 2015, BLOOD, V126, P739, DOI 10.1182/blood-2015-03-635326; Zhang L, 2014, BLOOD, V124, P1774	29	205	211	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2018	378	25					2399	2410		10.1056/NEJMoa1802917	http://dx.doi.org/10.1056/NEJMoa1802917			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ8SS	29856685	Bronze			2023-01-03	WOS:000435661600008
J	Canini, F; Qin, BL; Arvy, N; Poulet, L; Batandier, C; Roussei, AM; Anderson, RA				Canini, Frederic; Qin, Bolin; Arvy, Nathalie; Poulet, Laurent; Batandier, Cecile; Roussei, Anne-Marie; Anderson, Richard A.			Stress exposure alters brain mRNA expression of the genes involved in insulin signalling, an effect modified by a high fat/high fructose diet and cinnamon supplement	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; HIGH-FAT DIET; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; RESTRAINT STRESS; PSYCHOLOGICAL STRESS; METABOLIC SYNDROME; MAJOR DEPRESSION; CEREBRAL-CORTEX; RISK-FACTOR	In occidental societies, high fat and high sugar diets often coincide with episodes of stress. The association is likely to modify brain energy control. Brain insulin signalling is rarely studied in stressed individuals consuming high fat diets. Furthermore the effects of cinnamon supplement are not known in these conditions. Therefore, we exposed rats, over a 12-week period, to a control (C) or a high fat/high fructose (HF/HFr) diet that induces peripheral insulin resistance. A cinnamon supplement (C+CN and HF/HFr+CN) was added or not. After diet exposure, one group of rats was exposed to a 30-min restraint followed by a 10-min open-field test, their combination featuring a moderate stressor, the other rats staying unstressed in their home cages. The insulin signalling in hippocampus and frontal cortex was studied through the mRNA expression of the following genes: insulin receptor (Ir), insulin receptor substrate (Irs1), glucose transporters (Glut1 and Glut3), glycogen synthase (Gys1) and their modulators, Akt1 and Pten. In C rats, stress enhanced the expression of Ir, Irs1, Glut1, Gys1 and Akt1 mRNA. In C+CN rats, stress induced an increase in Pten but a decrease in Gys1 mRNA expression. In HF/HFr rats, stress was associated with an increase in Pten mRNA expression. In HF/HFr+CN rats, stress increased Pten mRNA expression but also decreased Gys1 mRNA expression. This suggests that a single moderate stress favours energy refilling mechanisms, an effect blunted by a previous HF/HFr diet and cinnamon supplement.	[Canini, Frederic] IRBA, Dept Neurosci & Contraintes Operat, Bretigny Sur Orge, France; [Canini, Frederic] Ecole Val Grace, 1 Pl Laveran, Paris, France; [Qin, Bolin] In Ingredients Com, Columbia, TN USA; [Qin, Bolin; Anderson, Richard A.] ARS, Diet Genom & Immunol Lab, Beltsville Human Nutr Res Ctr, USDA, Beltsville, MD USA; [Arvy, Nathalie] INRA, Lab Nutr & Integrat Neurobiol, UMR 1286, Bordeaux, France; [Arvy, Nathalie] Univ Bordeaux, Lab Nutr & Integrat Neurobiol, UMR 1286, Bordeaux, France; [Poulet, Laurent; Batandier, Cecile; Roussei, Anne-Marie] Grenoble Alpes Univ, INSERM, LBFA 1055, Grenoble, France; [Anderson, Richard A.] PolyChrom Technol LLC, Edgewater, MD USA	United States Department of Agriculture (USDA); INRAE; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Canini, F (corresponding author), IRBA, Dept Neurosci & Contraintes Operat, Bretigny Sur Orge, France.; Canini, F (corresponding author), Ecole Val Grace, 1 Pl Laveran, Paris, France.	fredericcanini@gmail.com	Marissal-Arvy, Nathalie/AAL-6103-2021	Marissal-Arvy, Nathalie/0000-0002-3147-5741; Poulet, Laurent/0000-0003-2795-4122	USDA/ARS/USA CRADA [58-3K95-7-1184]; French National Agency for Research [PNRA 007]	USDA/ARS/USA CRADA; French National Agency for Research(French National Research Agency (ANR))	The work was funded by USDA/ARS/USA CRADA: 58-3K95-7-1184 and French National Agency for Research (PNRA 007). The funders provided support in the form of salary for one of the authors [BQ], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Ali S, 2006, DIABETIC MED, V23, P1165, DOI 10.1111/j.1464-5491.2006.01943.x; Anderson RA, 2004, J AGR FOOD CHEM, V52, P65, DOI 10.1021/jf034916b; Anderson RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083243; Andreoulakis E, 2012, HIPPOKRATIA, V16, P205; Archuleta TL, 2009, FREE RADICAL BIO MED, V47, P1486, DOI 10.1016/j.freeradbiomed.2009.08.014; Arnold SE, 2014, NEUROBIOL DIS, V67, P79, DOI 10.1016/j.nbd.2014.03.011; Atif F, 2008, EUR J PHARMACOL, V600, P59, DOI 10.1016/j.ejphar.2008.09.029; Bhat NR, 2013, J ALZHEIMERS DIS, V36, P781, DOI 10.3233/JAD-2012-121030; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown RC, 2016, J PEDIATR HEALTH CAR, V30, P558, DOI 10.1016/j.pedhc.2015.11.015; Buynitsky T, 2009, NEUROSCI BIOBEHAV R, V33, P1089, DOI 10.1016/j.neubiorev.2009.05.004; Calvo-Ochoa E, 2014, J CEREBR BLOOD F MET, V34, P1001, DOI 10.1038/jcbfm.2014.48; Clegg DJ, 2011, PHYSIOL BEHAV, V103, P10, DOI 10.1016/j.physbeh.2011.01.010; Couturier K, 2010, ARCH BIOCHEM BIOPHYS, V501, P158, DOI 10.1016/j.abb.2010.05.032; Couturier K, 2011, METABOLISM, V60, P1590, DOI 10.1016/j.metabol.2011.03.016; CULLINAN WE, 1995, NEUROSCIENCE, V64, P477, DOI 10.1016/0306-4522(94)00355-9; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; Depke M, 2008, ENDOCRINOLOGY, V149, P2714, DOI 10.1210/en.2008-0038; Detka J, 2013, PHARMACOL REP, V65, P1591, DOI 10.1016/S1734-1140(13)71520-2; Devaney JM, 2011, HUM GENET, V129, P129, DOI 10.1007/s00439-010-0910-8; Drouet JB, 2015, NEUROSCIENCE, V285, P155, DOI 10.1016/j.neuroscience.2014.10.058; Duarte AI, 2008, BBA-MOL CELL RES, V1783, P994, DOI 10.1016/j.bbamcr.2008.02.016; Fachinetto R, 2005, PHARMACOL BIOCHEM BE, V81, P585, DOI 10.1016/j.pbb.2005.05.001; Falkowska A, 2015, INT J MOL SCI, V16, P25959, DOI 10.3390/ijms161125939; Fernandez AM, 2017, NEUROPHARMACOLOGY, P1; Fukunaga K, 2003, J PHARMACOL SCI, V92, P317; Ghasemi R, 2013, MOL NEUROBIOL, V47, P145, DOI 10.1007/s12035-012-8339-9; Gruetter R, 2003, J NEUROSCI RES, V74, P179, DOI 10.1002/jnr.10785; Hagen RM, 2010, FEBS LETT, V584, P2689, DOI 10.1016/j.febslet.2010.04.004; Harmon BT, 2010, HUM GENET, V128, P635, DOI 10.1007/s00439-010-0891-7; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; Henriksen EJ, 2013, METHOD ENZYMOL, V528, P269, DOI 10.1016/B978-0-12-405881-1.00016-1; Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837; Killday KB, 2011, J NAT PROD, V74, P1833, DOI 10.1021/np1007944; Knol MJ, 2006, DIABETOLOGIA, V49, P837, DOI 10.1007/s00125-006-0159-x; Kokoszka A, 2009, EUR PSYCHIAT, V24, P425, DOI 10.1016/j.eurpsy.2009.04.002; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lee YJ, 2006, NEUROSCI LETT, V392, P27, DOI 10.1016/j.neulet.2005.08.065; Li L, 2013, J ENDOCRINOL, V217, P175, DOI 10.1530/JOE-12-0559; Lu JM, 2010, CARCINOGENESIS, V31, P481, DOI 10.1093/carcin/bgp292; Marissal-Arvy N, 2014, BRIT J NUTR, V111, P1190, DOI 10.1017/S0007114513003577; McEwen BS, 2004, EUR J PHARMACOL, V490, P13, DOI 10.1016/j.ejphar.2004.02.041; MCGOWAN KM, 1995, PHARMACOL THERAPEUT, V66, P465, DOI 10.1016/0163-7258(95)00007-4; McIntyre Roger S, 2007, Ann Clin Psychiatry, V19, P257, DOI 10.1080/10401230701653377; McNay EC, 2010, NEUROBIOL LEARN MEM, V93, P546, DOI 10.1016/j.nlm.2010.02.002; Mezuk B, 2008, DIABETES CARE, V31, P2383, DOI 10.2337/dc08-0985; Moroz N, 2008, J ALZHEIMERS DIS, V15, P29; Munhoz CD, 2008, BRAZ J MED BIOL RES, V41, P1037, DOI 10.1590/S0100-879X2008001200001; Niraula K, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-309; Nouwen A, 2010, DIABETOLOGIA, V53, P2480, DOI 10.1007/s00125-010-1874-x; Okamoto K, 2006, BRAIN RES, V1081, P19, DOI 10.1016/j.brainres.2006.01.081; Park HR, 2010, NEUROSCI LETT, V482, P235, DOI 10.1016/j.neulet.2010.07.046; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Ribeiro MCP, 2009, CELL BIOCHEM FUNCT, V27, P473, DOI 10.1002/cbf.1599; Pratchayasakul W, 2011, LIFE SCI, V88, P619, DOI 10.1016/j.lfs.2011.02.003; Preuss HG, 2006, J AM COLL NUTR, V25, P144, DOI 10.1080/07315724.2006.10719525; Ramalingam M, 2015, J RECEPT SIG TRANSD, V35, P1, DOI 10.3109/10799893.2014.922576; Reagan LP, 1999, ANN NY ACAD SCI, V893, P126, DOI 10.1111/j.1749-6632.1999.tb07822.x; Reagan LP, 2000, BRAIN RES, V862, P292, DOI 10.1016/S0006-8993(00)02212-5; Rustad JK, 2011, PSYCHONEUROENDOCRINO, V36, P1276, DOI 10.1016/j.psyneuen.2011.03.005; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sartorius T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092358; SORG O, 1992, J NEUROSCI, V12, P4923; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; Tamashiro KL, 2011, STRESS, V14, P468, DOI 10.3109/10253890.2011.606341; WINOKUR A, 1988, AM J PSYCHIAT, V145, P325; Yan JQ, 2012, FREE RADICAL BIO MED, V52, P1648, DOI 10.1016/j.freeradbiomed.2012.01.033; Zhang XC, 2005, EXP NEUROL, V191, P318, DOI 10.1016/j.expneurol.2004.10.011	70	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2018	13	5							e0197094	10.1371/journal.pone.0197094	http://dx.doi.org/10.1371/journal.pone.0197094			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH6AR	29813096	Green Published, Green Submitted, gold			2023-01-03	WOS:000433521800011
J	Schulz, A; Ajayi, T; Specchio, N; de Los Reyes, E; Gissen, P; Ballon, D; Dyke, JP; Cahan, H; Slasor, P; Jacoby, D; Kohlschutter, A				Schulz, Angela; Ajayi, Temitayo; Specchio, Nicola; de Los Reyes, Emily; Gissen, Paul; Ballon, Douglas; Dyke, Jonathan P.; Cahan, Heather; Slasor, Peter; Jacoby, David; Kohlschutter, Alfried		CLN2 Study Grp	Study of Intraventricular Cerliponase Alfa for CLN2 Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; ENZYME REPLACEMENT; LYSOSOMAL STORAGE; CANINE MODEL; PERSPECTIVES; MUTATIONS; DISORDER	BACKGROUND Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children. METHODS In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years. Treatment was initiated at a dose of 30 mg, 100 mg, or 300 mg; all the patients then received the 300-mg dose for at least 96 weeks. The primary outcome was the time until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale (which ranges from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains), which was compared with the time until a 2-point decline in 42 historical controls. We also compared the rate of decline in the motor-language score between the two groups, using data from baseline to the last assessment with a score of more than 0, divided by the length of follow-up (in units of 48 weeks). RESULTS Twenty-four patients were enrolled, 23 of whom constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (+/- SD) unadjusted rate of decline in the motor-language score per 48-week period was 0.27 +/- 0.35 points in treated patients and 2.12 +/- 0.98 points in 42 historical controls (mean difference, 1.85; P<0.001). Common adverse events included convulsions, pyrexia, vomiting, hypersensitivity reactions, and failure of the intraventricular device. In 2 patients, infections developed in the intraventricular device that was used to administer the infusion, which required antibiotic treatment and device replacement. CONCLUSIONS Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls. Serious adverse events included failure of the intraventricular device and device-related infections.	[Schulz, Angela; Kohlschutter, Alfried] Univ Med Ctr Hamburg Eppendorf, Dept Pediat, Martinistr 52, D-20246 Hamburg, Germany; [Ajayi, Temitayo; Cahan, Heather; Slasor, Peter; Jacoby, David] BioMarin Pharmaceut, Novato, CA USA; [Specchio, Nicola] Bambino Gesu Pediat Hosp, IRCCS, Dept Neurosci, Rome, Italy; [de Los Reyes, Emily] Nationwide Childrens Hosp, Columbus, OH USA; [de Los Reyes, Emily] Ohio State Univ, Columbus, OH 43210 USA; [Gissen, Paul] UCL Great Ormond St Inst Child Hlth, London, England; [Ballon, Douglas; Dyke, Jonathan P.] Weill Cornell Med Coll, Citigrp Biomed Imaging Ctr, Dept Radiol, New York, NY USA; [Ballon, Douglas; Dyke, Jonathan P.] Weill Cornell Med Coll, Citigrp Biomed Imaging Ctr, Dept Med Genet, New York, NY USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; BioMarin Pharmaceutical Inc.; IRCCS Bambino Gesu; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University of London; University College London; Cornell University; Cornell University	Schulz, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat, Martinistr 52, D-20246 Hamburg, Germany.	an.schulz@uke.de	Specchio, Nicola/K-9461-2016; de los Reyes, Emily C/AAP-3836-2020; Kohlschütter, Alfried/ABE-3495-2021; Dyke, Jonathan/AAX-4362-2020; Kohlschütter, Alfried/ABH-5710-2020	Kohlschütter, Alfried/0000-0002-2700-0401; Dyke, Jonathan/0000-0001-7170-488X; Nickel, Miriam/0000-0002-1870-1142; Gissen, Paul/0000-0002-9712-6122; SPECCHIO, NICOLA/0000-0002-8120-0287	BioMarin Pharmaceutical; German Federal Ministry of Education and Research [NCL2Treat]; European Union [66691, 281234]; National Institute for Health Research; UCL Institute of Child Health Biomedical Research Centre	BioMarin Pharmaceutical(Johnson & Johnson); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); UCL Institute of Child Health Biomedical Research Centre	Supported by BioMarin Pharmaceutical, by a grant (NCL2Treat, to Dr. Schulz) from the German Federal Ministry of Education and Research, by a grant (66691, to Dr. Schulz) from the European Union's Horizon 2020 Research and Innovation Program, and by a grant from the National Institute for Health Research to Great Ormond Street Hospital and UCL Institute of Child Health Biomedical Research Centre, which provided core funding for the clinical research facility. The Dementia in Childhood consortium, which provided data for the historical cohort, is supported by a grant (281234, to Dr. Schulz) from the European Union Seventh Framework Program.	Bigger BW, 2015, BEST PRACT RES CL EN, V29, P183, DOI 10.1016/j.beem.2015.01.006; Hunt SV, 2009, INT J CLIN PHARM TH, V47, pS86; Johannsen J, 2016, NEUROPEDIATRICS, V47, P194, DOI 10.1055/s-0036-1579784; Katz ML, 2014, J NEUROSCI RES, V92, P1591, DOI 10.1002/jnr.23423; Kishnani PS, 2016, MOL GENET METAB, V117, P66, DOI 10.1016/j.ymgme.2015.11.001; Kohlschutter A, 2016, PEDIATR ENDOCR REV P, V13, P682; Mole S., 2011, NEURONAL CEROID LIPO, DOI DOI 10.1093/MED/9780199590018.003.0018; Mole SE, 2004, BRAIN PATHOL, V14, P70, DOI 10.1111/j.1750-3639.2004.tb00500.x; Schulz A, 2015, EUR J PAEDIAT NEU S1, V19, pS16; Schulz A, 2013, BBA-MOL BASIS DIS, V1832, P1801, DOI 10.1016/j.bbadis.2013.04.008; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Steinfeld R, 2002, AM J MED GENET, V112, P347, DOI 10.1002/ajmg.10660; Vuillemenot BR, 2015, MOL GENET METAB, V114, P281, DOI 10.1016/j.ymgme.2014.09.004; Vuillemenot BR, 2011, MOL GENET METAB, V104, P325, DOI 10.1016/j.ymgme.2011.06.018; Whiting REH, 2014, EXP EYE RES, V125, P164, DOI 10.1016/j.exer.2014.06.008; Worgall S, 2007, NEUROLOGY, V69, P521, DOI 10.1212/01.wnl.0000267885.47092.40	17	231	243	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 17	2018	378	20					1898	1907		10.1056/NEJMoa1712649	http://dx.doi.org/10.1056/NEJMoa1712649			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF9LR	29688815	Bronze, Green Published			2023-01-03	WOS:000432299600007
J	Sun, X; Guo, SY; Wang, W; Cao, ZY; Dan, JH; Cheng, JL; Cao, W; Tian, F; Cao, WW; Tian, Y				Sun, Xin; Guo, Shuyuan; Wang, Wei; Cao, Zhengyu; Dan, Juhua; Cheng, Jiali; Cao, Wei; Tian, Fang; Cao, Wenwu; Tian, Ye			Potential involvement of the 18 kDa translocator protein and reactive oxygen species in apoptosis of TH P-1 macrophages induced by sonodynamic therapy	PLOS ONE			English	Article							MITOCHONDRIAL BENZODIAZEPINE-RECEPTORS; PROTOPORPHYRIN-IX; CYTOCHROME-C; CELLS; PORPHYRINS; INTENSITY; VDAC	Sonodynamic therapy (SDT) with exogenous protoporphyrin IX (PpIX) or endogenous PpIX derived from 5-aminolevulinic acid (ALA) has been carried out to produce apoptotic effects on macrophages, indicating a potential treatment methodology for atherosclerosis. Our previous studies have found that mitochondria damage by reactive oxygen species (ROS) plays a major role in the SDT-induced apoptosis. This study aimed at investigating the potential involvement of the mitochondrial 18 kDa translocator protein (TSPO) and ROS in the pro-apoptotic effects of SDT on THP-1 macrophages. THP-1 macrophages were divided into control and SDT groups, and went through pretreatment of the specific TSPO ligand PK11195 and ROS scavengers N-Acetyl Cysteine (NAC), then compared with groups without pretreatment. Application of PK11195 reduced intracellular accumulation of endogenous PpIX. PK11195 and NAC reduced the generation of intracellular ROS and oxidation of cardiolipin induced by SDT, respectively. PK11195 and NAC also reduced SDT-induced mitochondrial membrane potential (Delta Psi(m)) loss, the translocation of cytochrome c and cell apoptosis. PpIX accumulation, ROS generation and cell apoptosis were also attenuated by siTSPO. Our findings indicate the pivotal role of TSPO and ROS in SDT-induced cardiolipin oxidation, Delta Psi(m) collapse, cytochrome c translocation and apoptosis in THP-1 macrophages.	[Sun, Xin; Cao, Wenwu] Harbin Inst Technol, Lab Photo & Sonotheranost Technol, Harbin, Heilongjiang, Peoples R China; [Sun, Xin; Guo, Shuyuan; Wang, Wei; Cao, Zhengyu; Cheng, Jiali; Cao, Wei; Tian, Fang; Tian, Ye] Harbin Med Univ, Affiliated Hosp 1, Cardiovasc Inst, Dept Cardiol, Harbin, Heilongjiang, Peoples R China; [Sun, Xin; Guo, Shuyuan; Wang, Wei; Dan, Juhua; Tian, Fang; Tian, Ye] Minist Educ, Key Lab Cardiovasc Res, Dept Pathophysiol, State Prov Key Labs Biomed Pharmaceut China, Harbin, Heilongjiang, Peoples R China; [Cao, Wenwu] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA	Harbin Institute of Technology; Harbin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cao, WW (corresponding author), Harbin Inst Technol, Lab Photo & Sonotheranost Technol, Harbin, Heilongjiang, Peoples R China.; Tian, Y (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Cardiovasc Inst, Dept Cardiol, Harbin, Heilongjiang, Peoples R China.; Tian, Y (corresponding author), Minist Educ, Key Lab Cardiovasc Res, Dept Pathophysiol, State Prov Key Labs Biomed Pharmaceut China, Harbin, Heilongjiang, Peoples R China.; Cao, WW (corresponding author), Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA.	dzk@psu.edu; yetian@ems.hrbmu.edu.cn	Cao, Wenwu/F-6091-2012	Cao, Wenwu/0000-0002-2447-1486; Tian, Ye/0000-0003-3726-7270	National Natural Science Foundation of China (NSFC) [81400339, 81701848]; State Key Program of NSFC [81530052]; Natural Science Foundation of Heilongjiang Province [QC2016121]; Medical Scientific Research Foundation of Harbin Medical University [2016LCZX57]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); State Key Program of NSFC; Natural Science Foundation of Heilongjiang Province(Natural Science Foundation of Heilongjiang Province); Medical Scientific Research Foundation of Harbin Medical University	This study was supported by the National Natural Science Foundation of China (NSFC) (81400339 and 81701848), the State Key Program of NSFC (81530052), Natural Science Foundation of Heilongjiang Province (QC2016121), and Medical Scientific Research Foundation of Harbin Medical University (2016LCZX57). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abourbeh G, 2012, J NEUROSCI, V32, P5728, DOI 10.1523/JNEUROSCI.2900-11.2012; Bisland SK, 2007, LASER SURG MED, V39, P678, DOI 10.1002/lsm.20544; Busch AWU, 2017, BIOCHEMISTRY-US, V56, P73, DOI 10.1021/acs.biochem.6b01019; Cheng JL, 2013, INT J NANOMED, V8, P669, DOI 10.2147/IJN.S39844; Ghorai A, 2015, APOPTOSIS, V20, P562, DOI 10.1007/s10495-015-1107-3; Goncalves RP, 2007, J MOL BIOL, V369, P413, DOI 10.1016/j.jmb.2007.03.063; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Gupta R, 2017, BIOCHEM BIOPH RES CO, V490, P1221, DOI 10.1016/j.bbrc.2017.06.194; Kanter JE, 2017, CIRC RES, V121, P1109, DOI 10.1161/CIRCRESAHA.117.311973; Kavurma MM, 2017, CURR OPIN LIPIDOL, V28, P91, DOI 10.1097/MOL.0000000000000394; KRAMMER B, 2008, PHOTOCH PHOTOBIO SCI, V7, P283, DOI DOI 10.1039/B712847A; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li ZT, 2015, THROMB HAEMOSTASIS, V114, P793, DOI [10.1160/TH114-12-1030, 10.1160/TH14-12-1030]; Liang BX, 2017, EUR J PHARMACOL, V796, P139, DOI 10.1016/j.ejphar.2016.12.030; Lv YH, 2012, CELL PHYSIOL BIOCHEM, V30, P321, DOI 10.1159/000339067; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Marginedas-Freixa I, 2016, SCI REP-UK, V6, DOI 10.1038/srep33516; McHale AP, 2016, ADV EXP MED BIOL, V880, P429, DOI 10.1007/978-3-319-22536-4_22; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Nahum R, 2017, EXP CLIN ENDOCRINOL; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Ozaki H, 2010, SYNAPSE, V64, P649, DOI 10.1002/syn.20779; Peng CH, 2011, J PHOTOCH PHOTOBIO B, V102, P26, DOI 10.1016/j.jphotobiol.2010.09.001; Quintanilla RA, 2017, BIOCHEM BIOPH RES CO, V483, P1078, DOI 10.1016/j.bbrc.2016.09.054; Serpe L, 2011, TECHNOL CANCER RES T, V10, P85, DOI 10.7785/tcrt.2012.500182; Song W, 2011, ANTICANCER RES, V31, P39; Verma A, 1998, MOL MED, V4, P40, DOI 10.1007/BF03401728; VERMA A, 1987, P NATL ACAD SCI USA, V84, P2256, DOI 10.1073/pnas.84.8.2256; Wan GY, 2016, CANCER BIOL MED, V13, P325, DOI 10.20892/j.issn.2095-3941.2016.0068; Zhang JL, 2017, BIOENGINEERED, V8, P424, DOI 10.1080/21655979.2016.1230572	30	5	7	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0196541	10.1371/journal.pone.0196541	http://dx.doi.org/10.1371/journal.pone.0196541			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF3JM	29746502	gold, Green Published, Green Submitted			2023-01-03	WOS:000431851700022
J	Donoyama, N; Satoh, T; Hamano, T; Ohkoshi, N; Onuki, M				Donoyama, Nozomi; Satoh, Toyomi; Hamano, Tetsutaro; Ohkoshi, Norio; Onuki, Mamiko			Effects of Anma therapy (Japanese massage) on health-related quality of life in gynecologic cancer survivors: A randomized controlled trial	PLOS ONE			English	Article							OVARIAN-CANCER; BREAST-CANCER; INTEGRATIVE MEDICINE; CLINICAL-TRIALS; SYMPTOM BURDEN; COMPLEMENTARY; DEPRESSION; ONCOLOGY; STRESS; SCALE	Objectives Anma therapy (Japanese massage therapy, AMT) significantly reduces the severity of physical complaints in survivors of gynecologic cancer. However, whether this reduction of severity is accompanied by improvement in health-related quality of life is unknown. Methods Forty survivors of gynecologic cancer were randomly allocated to either an AMT group that received one 40-min AMT session per week for 8 weeks or a no-AMT group. We prospectively measured quality of life by using the Japanese version of the European Organization for Research and Treatment of Cancer QLQ-C30 version 3.0 (EORTC QLQ-C30) at baseline and at 8-week follow-up. The QLQ-C30 response rate was 100%. Hospital Anxiety Depression Scale (HADS), Profile of Mood States (POMS), and Measure of Adjustment to Cancer were also prespecified and prospectively evaluated. Results The QLQ-C30 Global Health Status and Quality of Life showed significant improvement at 8 weeks (P = 0.042) in the AMT group compared with the no-AMT group, and the estimated mean difference reached a minimal clinically important difference of 10 points (10.4 points, 95% CI = 1.2 to 19.6). Scores on fatigue and insomnia showed significant improvement in the AMT group compared with the no-AMT group (P= 0.047 and 0.003, respectively). There were no significant between-group improvements in HADS anxiety and depression scales; however, POMS-assessed anger-hostility showed significant improvement in the AMT group compared with the no-AMT group (p = 0.028). Conclusions AMT improved health-related quality of life in gynecologic cancer survivors. AMT can be of potential benefit for applications in oncology.	[Donoyama, Nozomi; Ohkoshi, Norio] Tsukuba Univ Technol, Dept Hlth, Fac Hlth Sci, Tsukuba, Ibaraki, Japan; [Satoh, Toyomi; Onuki, Mamiko] Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki, Japan; [Hamano, Tetsutaro] P4 Stat Co Ltd, Setagaya Ku, Tokyo, Japan	Tsukuba University of Technology; University of Tsukuba	Donoyama, N (corresponding author), Tsukuba Univ Technol, Dept Hlth, Fac Hlth Sci, Tsukuba, Ibaraki, Japan.	donoyama@k.tsukuba-tech.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [22531058]	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a Grant-in-Aid (No. 22531058) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, 2010-2014 (PI: Nozomi Donoyama). The funder provided support in the form of research expenses, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section. One of the authors (TH) runs a commercial company P4 Statistics Co. Ltd., Tokyo, Japan. However, this organization has nothing to do with our research. TH privately took part in our present trial as one of our research colleagues, who was assigned statistical analysis without charge. TH provided his statistical ability with our study as one of our research colleagues, as opposed to financial support and research materials for this research. Thus, the organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Akechi T, 2001, BREAST CANCER RES TR, V65, P195, DOI 10.1023/A:1010661530585; Akechi T, 1997, JPN J PSYCHIAT TREAT, V12, P1065; Burles M, 2013, CANCER NURS, V36, P436, DOI 10.1097/NCC.0b013e318277b57e; Cantarero-Villanueva I, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/620619; Cassileth BR, 2014, INT REV PSYCHIATR, V26, P114, DOI 10.3109/09540261.2013.838153; Cutshall SM, 2015, SUPPORT CARE CANCER, V23, P2989, DOI 10.1007/s00520-015-2666-0; Donoyama N, 2016, GYNECOL ONCOL, V142, P531, DOI 10.1016/j.ygyno.2016.06.022; Donoyama N, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-233; Donoyama Nozomi, 2011, Journal of  the Japanese Society of Balneology Climatology and Physical Medicine, V74, P155; Edman JS, 2014, INTEGR CANCER THER, V13, P405, DOI 10.1177/1534735414537876; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Fernandez-Lao C, 2012, EUR J CANCER CARE, V21, P233, DOI 10.1111/j.1365-2354.2011.01306.x; Ferrell B, 2005, ONCOL NURS FORUM, V32, P1143, DOI 10.1188/05.ONF.1143-1149; Gross AH, 2013, CANCER NURS, V36, P256, DOI 10.1097/NCC.0b013e31826f3bc4; Hernandez-Reif M, 2005, INT J NEUROSCI, V115, P495, DOI 10.1080/00207450590523080; Hodgson NA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/456897; Jacobs S, 2016, PEDIATR BLOOD CANCER, V63, P880, DOI 10.1002/pbc.25902; Kashani Fahimeh, 2014, Iran J Nurs Midwifery Res, V19, P113; Kimura A, 2003, JAPANESE ANMA; Kobayakawa M, 2011, JPN J CLIN ONCOL, V41, P1233, DOI 10.1093/jjco/hyr119; Koh MJ, 2014, J PSYCHOSOM RES, V77, P76, DOI 10.1016/j.jpsychores.2014.04.008; Kugaya A, 1998, JPN J CLIN ONCOL, V28, P333, DOI 10.1093/jjco/28.5.333; Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003; Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508; McNair D. M, 1992, PROFILE MOOD STATES; Miladinia M, 2017, CANCER NURS, V40, P31, DOI 10.1097/NCC.0000000000000353; Osoba D, 2005, EUR J CANCER, V41, P280, DOI 10.1016/j.ejca.2004.10.017; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5; Pennebaker JW., 1989, ADV EXPT SOCIAL PSYC, P211, DOI DOI 10.1016/S0065-2601(08)60309-3; Roland KB, 2013, PSYCHO-ONCOLOGY, V22, P2408, DOI 10.1002/pon.3322; Samuel CA, 2014, EUR J CANCER CARE, V23, P180, DOI 10.1111/ecc.12099; Serfaty M, 2012, PSYCHO-ONCOLOGY, V21, P563, DOI 10.1002/pon.1921; Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; Wenzel LB, 2002, PSYCHO-ONCOLOGY, V11, P142, DOI 10.1002/pon.567; Wu HS, 2015, CANCER NURS, V38, pE29, DOI 10.1097/NCC.0000000000000135; Yokoyama K, 2005, POMS TANSHUKUBAN TEB; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	40	9	11	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2018	13	5							e0196638	10.1371/journal.pone.0196638	http://dx.doi.org/10.1371/journal.pone.0196638			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE6AF	29723235	gold, Green Published, Green Submitted			2023-01-03	WOS:000431305100046
J	Werner, RM; Konetzka, RT				Werner, Rachel M.; Konetzka, R. Tamara			Trends in Post-Acute Care Use Among Medicare Beneficiaries: 2000 to 2015	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Werner, Rachel M.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, 423 Guardian Dr,Blockley Hall,Room 1314, Philadelphia, PA 19104 USA; [Konetzka, R. Tamara] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA	University of Pennsylvania; Pennsylvania Medicine; University of Chicago	Werner, RM (corresponding author), Univ Penn, Perelman Sch Med, Div Gen Internal Med, 423 Guardian Dr,Blockley Hall,Room 1314, Philadelphia, PA 19104 USA.	rwerner@upenn.edu		Konetzka, R Tamara/0000-0003-3016-1318; Werner, Rachel/0000-0003-3435-4221	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS024266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG047908] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS024266] Funding Source: Medline; NIA NIH HHS [K24 AG047908] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Burke RE, 2015, JAMA INTERN MED, V175, P295, DOI 10.1001/jamainternmed.2014.6383; Centers for Medicare & Medicaid Services, MEDPAR RIF; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Mechanic R, 2014, NEW ENGL J MED, V370, P692, DOI 10.1056/NEJMp1315607; MedPac, 2017, DAT BOOK HLTH CAR SP	5	64	64	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2018	319	15					1616	1617		10.1001/jama.2018.2408	http://dx.doi.org/10.1001/jama.2018.2408			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD0UT	29677292	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000430217100022
J	Wang, CH; Li, NN; Wang, H; Yin, HY; Zhao, YW				Wang, Cunhui; Li, Niannian; Wang, Heng; Yin, Hongyan; Zhao, Yunwu			Study on essential drug use status and its influencing factors among cerebral infarction inpatients in county level hospitals of Anhui Province, China	PLOS ONE			English	Article							ESSENTIAL MEDICINES POLICY; LENGTH-OF-STAY; CARE FACILITIES; COST; MORTALITY; STROKE; IMPACT	Background and purpose Drug costs is one of the main components of hospitalization expenditure for cerebral infarction inpatients. In China, the National Essential Medicine System (NEMS) was created to relieve the heavy drug-cost burden for patients. The objective of this study was to investigate essential drug-use status and its influencing factors among cerebral infarction inpatients in county-level hospitals of Anhui province, China. Methods Three county-level hospitals were selected through a multi-stage cluster random sampling method. The hospitalization cost data of cerebral infarction inpatients in the three hospitals were extracted from the Anhui provincial information platform of the New Rural Cooperative Insurance System (NCMS), and whether the proportion of essential drug cost in the total drug cost reached the median value of 33.05% which was set as the evaluation index for essential drug-use status. Questionnaires for hospitals and physicians were designed and given to them to assess influencing factors. Results We retrieved the cost data of 2,189 inpatients from the NCMS platform and investigated 51 corresponding physicians in total. The drug costs accounted for 52.6% of the total hospitalization cost, and essential drug costs alone accounted for 37.0% of the total drug costs. The essential drug-cost proportion was high among physicians with a higher recognition degree on NEMS, older age, lower final academic degree, longer work experience and lower professional title. Married physicians and those with tight organizational affiliation also prescribed more essential drugs. Conclusions Increasing the proportion of essential drugs was an effective way to reduce the disease burden for cerebral infarction patients. Perfecting the NEMS, increasing government investment, reinforcing education and propaganda, and formulating relevant incentive and restrictive mechanisms were all effective ways to promote and increase the number of essential drug prescriptions written by physicians.	[Wang, Cunhui; Wang, Heng; Yin, Hongyan] Anhui Med Univ, Social Sci & Hlth Management Sch, Hefei, Anhui, Peoples R China; [Li, Niannian] Anhui Med Univ, Affiliated Hosp 1, Dept Res Adm, Hefei, Anhui, Peoples R China; [Wang, Heng] Anhui Med Univ, Affiliated Hosp 1, Dept Deams Off, Hefei, Anhui, Peoples R China; [Zhao, Yunwu] Anhui Med Univ, Affiliated Hosp 1, Dept Human Resources, Hefei, Anhui, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Wang, H (corresponding author), Anhui Med Univ, Social Sci & Hlth Management Sch, Hefei, Anhui, Peoples R China.; Wang, H (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Deams Off, Hefei, Anhui, Peoples R China.	wanghengteam@163.com	Yin, Hong/AAC-5784-2020		National Science Foundation of China [71473003, 71774001]; Young's Culture Plan of the First Affiliated Hospital of Anhui Medical University [2015kj10]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young's Culture Plan of the First Affiliated Hospital of Anhui Medical University	This research was supported by grants from the National Science Foundation of China (No. 71473003; No. 71774001 Received by HW) and Young's Culture Plan of the First Affiliated Hospital of Anhui Medical University (No. 2015kj10; Received by NL). The URL of the National Science Foundation of China is http://www.nsfc.gov.cni The URL of the latter funder is http://www.ayfy.com/menhuweb/show.php?itemid=7555. Neither of the above two funders had role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anhui Provincial Statistics Bureau, 2016, STAT B NAT EC SOC DE; [Anonymous], 2017, AV AG STROK CHIN IS; Bian C, PLOSONE, V10; Chen W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-211; Eriksen J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014345; Fang Y, 2013, LANCET GLOB HEALTH, V1, pE227, DOI 10.1016/S2214-109X(13)70072-X; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Guan XD, 2011, J PUBLIC HEALTH POL, V32, P305, DOI 10.1057/jphp.2011.34; Gustafsson LL, 2011, BASIC CLIN PHARMACOL, V108, P224, DOI 10.1111/j.1742-7843.2011.00682.x; Kitagawa KT, 2009, STROKE DATA BANK 200, P23; Lee H, 2015, PREV MED, V70, P19, DOI 10.1016/j.ypmed.2014.11.007; Li L, 2008, CHINESE HLTH EC, V27, P79; [李林蔚 Li Linwei], 2015, [中国全科医学, Chinese General Practice], V18, P4239; Ma C., 2015, MOL CELL PROBE, V29, P1; Ma Y, 2010, EUR J NEUROL, V17, P1270, DOI 10.1111/j.1468-1331.2010.03007.x; National Health and Family Planning Commission of China, 2015, CHIN STAT YB HLTH FA; Norman C, 2009, INT J CLIN PRACT, V63, P1320, DOI 10.1111/j.1742-1241.2009.02129.x; Orzella L, 2010, HEALTH POLICY, V95, P236, DOI 10.1016/j.healthpol.2009.12.005; Peltola M, 2015, HEALTH ECON, V24, P38, DOI 10.1002/hec.3264; Rao ML, 2007, GUIDELINES PREVENTIO; Research group of the development research center of the State Council, 2005, CHINA DEV REV CHIN A, VA01, P1; Samsa GP, 1999, STROKE, V30, P338, DOI 10.1161/01.STR.30.2.338; Sekimoto M, 2008, HEALTH POLICY, V88, P100, DOI 10.1016/j.healthpol.2008.01.013; Song Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0507-3; Tu F, 2002, HEALTH POLICY, V59, P243, DOI 10.1016/S0168-8510(01)00182-8; Turk AS, 2014, J NEUROINTERV SURG, P1; Wang H, 2012, CHINESE J HLTH POLIC, V5, P30; Wang H, 2012, CHIN J HOSP ADM, V2012, P544; Wang H. Y., 2013, J CONTROL SCI ENG, V2013, P8, DOI DOI 10.1371/J0URNAL.P0NE.0056800; Wang LD., 2016, STROKE PREVENTION CO; Wettermark Bjorn, 2009, Qual Prim Care, V17, P179; WHO, 2002, WHO POL PERSP MED 4, V4; WHO. World Health Organization, 1992, INT STAT CLASS DIS R; Xi XY, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1008-8; Xu SM, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1073-z; Yang L, 2013, B WORLD HEALTH ORGAN, V91, P184, DOI 10.2471/BLT.11.097998; Yang LP, 2013, HEALTH POLICY PLANN, V28, P750, DOI 10.1093/heapol/czs116; Yoneda Y, 2003, STROKE, V34, P718, DOI 10.1161/01.STR.0000056171.55342.FF; [于倩倩 Yu Qianqian], 2014, [中国全科医学, Chinese General Practice], V17, P2277; Zhang QY, 2011, PRACTICAL PREVENTIVE, V18, P1593; Zhao YW, 2015, CHINESE MED J-PEKING, V128, P2887, DOI 10.4103/0366-6999.168046; Zou SN, 2015, CHINESE HLTH EC, V34, P72; Zu XL, 2014, CHINESE J HLTH STAT, V26, p[515, 518]; 胡丹, 2014, [中国卫生统计, Chinese Journal of Health Statistics], V31, P707	44	3	3	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0193513	10.1371/journal.pone.0193513	http://dx.doi.org/10.1371/journal.pone.0193513			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB6TQ	29621245	gold, Green Submitted, Green Published			2023-01-03	WOS:000429206800006
J	Wang, YH; Wu, JY; Kong, SC; Chiang, MH; Ho, ML; Yeh, ML; Chen, CH				Wang, Yan-Hsiung; Wu, Jyun-Yi; Kong, Su Chii; Chiang, Min-Hsuan; Ho, Mei-Ling; Yeh, Ming-Long; Chen, Chia-Hsin			Low power laser irradiation and human adipose-derived stem cell treatments promote bone regeneration in critical-sized calvarial defects in rats	PLOS ONE			English	Article							ENERGY DIODE-LASER; IN-VITRO; THERAPY; TISSUE; PROLIFERATION; REPAIR; DIFFERENTIATION; VIVO	Both stem cell therapy and physical treatments have been shown to be beneficial in accelerating bone healing. However, the efficacy of combined treatment with stem cells and physical stimuli for large bone defects remains uncertain. The aim of this study was to evaluate the bone regeneration effects of low-power laser irradiation (LPLI) and human adipose derived stem cell (ADSC) treatments during fracture repair using a comparative rat calvarial defect model. We evaluated the viability of human ADSCs, which were cultured on a porous PLGA scaffold using an MTS assay. The critical-sized calvarial bone defect rats were divided into 4 groups: control group, LPLI group, ADSC group, and ADSC+LPLI group. Bone formation was evaluated using micro-CT. New bone formation areas and osteogenic factor expression levels were then examined by histomorphological analysis and immunohistochemical staining. Our data showed that PLGA had no cytotoxic effect on human ADSCs. Micro-CT analyses revealed that both the LPLI and ADSC groups showed improved calvarial bone defect healing compared to the control group. In addition, the ADSC+LPLI group showed significantly increased bone volume at 16 weeks after surgery. The area of new bone formation ranked as follows: control group < LPLI group < ADSC group < ADSC+LPLI group. There were significant differences between the groups. In addition, both ADSC and ADSC+LPLI groups showed strong signals of vWF expression. ADSC and LPLI treatments improved fracture repair in critical-sized calvarial defects in rats. Importantly, the combined treatment of ADSCs and LPLI further enhances the bone healing process.	[Wang, Yan-Hsiung; Chiang, Min-Hsuan] Kaohsiung Med Univ, Sch Dent, Coll Dent Med, Kaohsiung, Taiwan; [Wang, Yan-Hsiung; Wu, Jyun-Yi; Kong, Su Chii; Chiang, Min-Hsuan; Ho, Mei-Ling; Chen, Chia-Hsin] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan; [Wang, Yan-Hsiung; Ho, Mei-Ling] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Wu, Jyun-Yi] Fresenius Kabi Taiwan Ltd, Taipei, Taiwan; [Ho, Mei-Ling] Kaohsiung Med Univ, Dept Physiol, Coll Med, Kaohsiung, Taiwan; [Ho, Mei-Ling] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan; [Yeh, Ming-Long] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan; [Yeh, Ming-Long] Natl Cheng Kung Univ, Med Device Innovat Ctr, Tainan, Taiwan; [Chen, Chia-Hsin] Kaohsiung Med Univ, Coll Med, Dept Phys Med & Rehabil, Sch Med, Kaohsiung, Taiwan; [Chen, Chia-Hsin] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Sun Yat Sen University; National Cheng Kung University; National Cheng Kung University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Chen, CH (corresponding author), Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan.; Chen, CH (corresponding author), Kaohsiung Med Univ, Coll Med, Dept Phys Med & Rehabil, Sch Med, Kaohsiung, Taiwan.; Chen, CH (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Phys Med & Rehabil, Kaohsiung, Taiwan.	chchen@kmu.edu.tw	Wang, Yan-Hsiung/ABD-4004-2020	Wang, Yan-Hsiung/0000-0001-8161-7472; Ho, Mei-Ling/0000-0001-8064-8488	Ministry of Economic Affairs, Ministry of Science and Technology [102-EC-17-A-19-S1-176]; ITRI Southern Taiwan Industry Joint Service Center [MOST-104-2314-6-037-059, MOST -105-2314-B-037-012]; Kaohsiung Medical University [KMUTP103808, KMU-TP104811, KMU-TP105611]	Ministry of Economic Affairs, Ministry of Science and Technology; ITRI Southern Taiwan Industry Joint Service Center; Kaohsiung Medical University	We gratefully acknowledge support for this research provided by the Ministry of Economic Affairs, Ministry of Science and Technology, ITRI Southern Taiwan Industry Joint Service Center and Kaohsiung Medical University Aim for the Top Universities Grant under grant numbers 102-EC-17-A-19-S1-176, MOST-104-2314-6-037-059, MOST -105-2314-B-037-012, ST105007, KMUTP103808, KMU-TP104811 and KMU-TP105611, respectively. The funder, Fresenius Kabi Taiwan Ltd., provided support in the form of salaries for J Y Wu, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Ahn TY, 2016, INT J BIOL MACROMOL, V93, P1488, DOI 10.1016/j.ijbiomac.2016.07.027; Amid R, 2014, J LASERS MED SCI, V5, P163; Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623-200310000-00010; Asumda FZ, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-44; Barba M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/416391; Barbosa D, 2013, LASER MED SCI, V28, P651, DOI 10.1007/s10103-012-1125-0; Barboza CAG, 2017, INT J EXP PATHOL; Beane OS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115963; Behr B, 2011, STEM CELLS, V29, P286, DOI 10.1002/stem.581; Burastero G, 2010, BONE, V47, P117, DOI 10.1016/j.bone.2010.03.023; Chen HT, 2012, J CELL MOL MED, V16, DOI 10.1111/j.1582-4934.2011.01335.x; Colnot C, 2005, J CELL BIOCHEM, V95, P688, DOI 10.1002/jcb.20449; Costa-Almeida R, 2014, EUR CELLS MATER, V28, P51, DOI 10.22203/eCM.v028a05; David R, 1996, LASER SURG MED, V19, P458, DOI 10.1002/(SICI)1096-9101(1996)19:4<458::AID-LSM12>3.0.CO;2-Z; De Francesco F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006537; de Oliveira FA, 2017, J PHOTOCH PHOTOBIO B, V169, P35, DOI 10.1016/j.jphotobiol.2017.02.020; Desiderio V, 2013, J CELL PHYSIOL, V228, P1762, DOI 10.1002/jcp.24336; Dmitrieva RI, 2012, CELL CYCLE, V11, P377, DOI 10.4161/cc.11.2.18858; Ducy P, 2011, DIABETOLOGIA, V54, P1291, DOI 10.1007/s00125-011-2155-z; El-Maghraby EMF, 2013, ARCH ORAL BIOL, V58, P796, DOI 10.1016/j.archoralbio.2012.10.003; Fujihara NA, 2006, LASER SURG MED, V38, P332, DOI 10.1002/lsm.20298; Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-4; Geuze RE, 2012, TISSUE ENG PT A, V18, P2052, DOI [10.1089/ten.tea.2011.0560, 10.1089/ten.TEA.2011.0560]; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Kazancioglu HO, 2013, J CRANIOFAC SURG, V24, P2141, DOI 10.1097/SCS.0b013e3182a244ae; Khadra M, 2004, CLIN ORAL IMPLAN RES, V15, P325, DOI 10.1111/j.1600-0501.2004.00994.x; Kim H, 2012, J DERMATOL SCI, V68, P149, DOI 10.1016/j.jdermsci.2012.09.013; Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420; Liu YC, 2015, J TISSUE ENG REGEN M, V9, P85, DOI 10.1002/term.1617; Huertas RM, 2014, BIOL RES NURS, V16, P191, DOI 10.1177/1099800413482695; Renno ACM, 2010, PHOTOMED LASER SURG, V28, P131, DOI 10.1089/pho.2009.2487; Nakao N, 2010, AM J PATHOL, V177, P547, DOI 10.2353/ajpath.2010.091042; Nascimento SB, 2010, PHOTOMED LASER SURG, V28, P45, DOI 10.1089/pho.2008.2396; Nauth A, 2012, INDIAN J ORTHOP, V46, P19, DOI 10.4103/0019-5413.91630; Ninomiya T, 2003, J BONE MINER METAB, V21, P67, DOI 10.1007/s007740300011; Nurkovic J, 2017, LASER MED SCI, V32, P151, DOI 10.1007/s10103-016-2097-2; Paino F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.308; Pretel H, 2007, LASER SURG MED, V39, P788, DOI 10.1002/lsm.20585; Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198-007-0492-z; Rosland GV, 2009, CANCER RES, V69, P5331, DOI 10.1158/0008-5472.CAN-08-4630; Schindl A, 1999, DERMATOLOGY, V198, P314, DOI 10.1159/000018140; SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299, DOI 10.1097/00003086-198604000-00036; Shao J, 2015, BIOL RES, V48, DOI [10.1186/S40659-015-0053-4, 10.1186/s40659-015-0053-4]; Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161; Taniguchi D, 2009, LASER SURG MED, V41, P232, DOI 10.1002/lsm.20750; Torricelli P, 2001, BIOMED PHARMACOTHER, V55, P117, DOI 10.1016/S0753-3322(00)00025-1; Wu J., 2013, ADV MATER SCI ENG, V2013, P10, DOI [DOI 10.1016/J.DYEPIG.2013.12.023, DOI 10.1016/J.CARBP0L.2013.10.093]; Wu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054067, 10.1371/journal.pone.0067644]; Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0046393, 10.1371/journal.pone.0044027]; Wu SC, 2010, BIOMATERIALS, V31, P631, DOI 10.1016/j.biomaterials.2009.09.089; Yamada K, 1991, Nihon Seikeigeka Gakkai Zasshi, V65, P787; Zuk, 2013, ISRN STEM CELLS, DOI [10.1155/2013/713959, DOI 10.1155/2013/713959]; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	53	27	27	4	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0195337	10.1371/journal.pone.0195337	http://dx.doi.org/10.1371/journal.pone.0195337			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6TQ	29621288	Green Published, gold, Green Submitted			2023-01-03	WOS:000429206800066
J	Ludecke, D; Bien, B; McKee, K; Krevers, B; Mestheneos, E; Di Rose, M; von dem Knesebeckl, O; Kofahl, C				Luedecke, Daniel; Bien, Barbara; McKee, Kevin; Krevers, Barbro; Mestheneos, Elizabeth; Di Rose, Mirko; von dem Knesebeckl, Olaf; Kofahl, Christopher			For better or worse: Factors predicting outcomes of family care of older people over a one-year period. A six-country European study	PLOS ONE			English	Article							CAREGIVER BURDEN; INFORMAL CAREGIVERS; SUPPORT SERVICES; ELDERLY PARENTS; HOME-CARE; DEMENTIA; QUALITY	Objectives Demographic change has led to an increase of older people in need of long-term care in nearly all European countries. Informal carers primarily provide the care and support needed by dependent people. The supply and willingness of individuals to act as carers are critical to sustain informal care resources as part of the home health care provision. This paper describes a longitudinal study of informal care in six European countries and reports analyses that determine those factors predicting the outcomes of family care over a one-year period. Methods Analyses are based on data from the EUROFAMCARE project, a longitudinal survey study of family carers of older people with baseline data collection in 2004 and follow-up data collection a year later in six European countries (Germany, Greece, Italy, Poland, Sweden, and the United Kingdom), N = 3,348. Descriptive statistics of the sample characteristics are reported. Binary logistic random-intercept regressions were computed, predicting the outcome of change of the care dyad's status at follow-up. Results Where care is provided by a more distant family member or by a friend or neighbour, the care-recipient is significantly more likely to be cared for by someone else (OR 1.62) or to be in residential care (OR 3.37) after one year. The same holds true if the care-recipient has memory problems with a dementia diagnosis (OR 1.79/OR 1.84). Higher dependency (OR 1.22) and behavioural problems (OR 1.76) in the care-recipient also lead to a change of care dyad status. Country of residence explained a relatively small amount of variance (8%) in whether a care-recipient was cared for by someone else after one year, but explained a substantial amount of variance (52%) in whether a care-recipient was in residential care. Particularly in Sweden, care-recipients are much more likely to be cared for by another family or professional carer or to be in residential care, whereas in Greece the status of the care dyad is much less likely to change. Discussion The majority of family carers continued to provide care to their respective older relatives over a one-year period, despite often high levels of functional, cognitive and behavioural problems in the care-recipient. Those family carers could benefit most from appropriate support. The carer/care-recipient relationship plays an important role in whether or not a family care dyad remains intact over a one-year period. The support of health and social care services should be particularly targeted toward those care dyads where there is no partner or spouse acting as carer, or no extended family network that might absorb the caring role when required. Distant relatives, friends or acquaintances who are acting as carers might need substantial intervention if their caregiving role is to be maintained.	[Luedecke, Daniel; von dem Knesebeckl, Olaf; Kofahl, Christopher] Univ Med Ctr Hamburg Eppendorf, Dept Med Sociol, Martinistr, Hamburg, Germany; [Bien, Barbara] Med Univ Bialystok, Dept Geriatr, Bialystok, Poland; [McKee, Kevin] Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden; [Krevers, Barbro] Linkoping Univ, Div Hlth Care Anal, Dept Med & Hlth Sci, Linkoping, Sweden; [Mestheneos, Elizabeth] 50 Hellas, Ammohostou 6, Halandri Attiki, Greece; [Di Rose, Mirko] Natl Inst Hlth & Sci Aging, Ancona, Italy	University of Hamburg; University Medical Center Hamburg-Eppendorf; Medical University of Bialystok; Dalarna University; Linkoping University	Ludecke, D (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med Sociol, Martinistr, Hamburg, Germany.	d.luedecke@uke.de	Kofahl, Christopher/AGZ-7071-2022; Di Rosa, Mirko/J-5974-2016	Di Rosa, Mirko/0000-0002-1862-4159; Bien, Barbara/0000-0002-2953-989X; Kofahl, Christopher/0000-0002-0503-3077; von dem Knesebeck, Olaf/0000-0001-6310-5879; Ludecke, Daniel/0000-0002-8895-3206	EU [QLK6-CT-2002-02647]	EU(European Commission)	The EUROFAMCARE project was funded by the EU (contract no.: QLK6-CT-2002-02647), FP5. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramsson M, 2016, HOUS THEORY SOC, V33, P217, DOI 10.1080/14036096.2015.1104385; Alber J, 2004, HLTH CARE ENLARGED E; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bien B, 2008, FAMILY CARERS OLDER, P233; Bien B, 2013, EUR J PUBLIC HEALTH, V23, P1032, DOI 10.1093/eurpub/cks190; Bonsang E, 2009, J HEALTH ECON, V28, P143, DOI 10.1016/j.jhealeco.2008.09.002; Bouget D, 2016, WORK LIFE BALANCE ME, P74; Brodaty H, 2014, J ALZHEIMERS DIS, V40, P221, DOI 10.3233/JAD-131850; Carretero S, 2009, ARCH GERONTOL GERIAT, V49, P74, DOI 10.1016/j.archger.2008.05.004; Chen QX, 2015, STAT MED, V34, P3637, DOI 10.1002/sim.6618; Chiao CY, 2015, INT NURS REV, V62, P340, DOI 10.1111/inr.12194; Crespo L, 2014, REV ECON STAT, V96, P693, DOI 10.1162/REST_a_00426; Delalibera M, 2015, CIENC SAUDE COLETIVA, V20, P2731, DOI 10.1590/1413-81232015209.09562014; Dilworth-Anderson P, 2007, J APPL GERONTOL, V26, P355, DOI 10.1177/0733464807302669; Epps F, 2015, J RELIG SPIRITUAL A, V27, P166, DOI 10.1080/15528030.2014.971141; Farre M, 2016, INT J NURS STUD, V55, P39, DOI 10.1016/j.ijnurstu.2015.10.012; Frericks P, 2014, J AGING STUD, V29, P66, DOI 10.1016/j.jaging.2013.12.002; Fulmer T, 2005, GERONTOLOGIST, V45, P525, DOI 10.1093/geront/45.4.525; Genet N, 2013, HEALTH POLICY, V110, P84, DOI 10.1016/j.healthpol.2013.01.009; Genet N, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-207; Hajek A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148916; Hajek A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144203; Hochgraeber I, 2015, DEMENTIA; Hodge DR, 2012, AGING MENT HEALTH, V16, P689, DOI 10.1080/13607863.2012.678481; Jeong YG, 2015, J PHYS THER SCI, V27, P1543, DOI 10.1589/jpts.27.1543; Kalwij A, 2014, REV ECON HOUSEHOLD, V12, P379, DOI 10.1007/s11150-012-9159-4; Keady J, 1996, J Psychiatr Ment Health Nurs, V3, P163, DOI 10.1111/j.1365-2850.1996.tb00083.x; Keating NC, 2014, J ECON AGEING, V3, P11, DOI 10.1016/j.jeoa.2014.03.002; Kehusmaa S, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-317; Kofahl C, 2009, PFLEGE GESELLSCHAFT, V3, P236; Kofahl C., 2008, EUROPAISCHE PERSPEKT, P130; Kohler S, 2012, QUALITATIVE UNTERSUC, p293 ; Kommission Europaische, 2007, LIV COND EUR DAT 200; Lamura G, 2006, Z GERONTOL GERIATR, V39, P429, DOI 10.1007/s00391-006-0416-0; Lamura G, 2008, GERONTOLOGIST, V48, P752, DOI 10.1093/geront/48.6.752; Lamura Giovanni, 2008, FAMILY CARERS OLDER; Ldecke D., 2014, HLTH CARE UTILIZATIO, P171, DOI [10.1007/978-1-4614-9191-0_10, DOI 10.1007/978-1-4614-9191-0_10]; Conde-Sala JL, 2010, INT J NURS STUD, V47, P1262, DOI 10.1016/j.ijnurstu.2010.03.001; Ludecke D., 2018, SJPLOT DATA VISUALIZ; McKee K, 2008, FAMILY CARERS OLDER, P49; McKee KJ, 2003, AGING MENT HEALTH, V7, P39, DOI 10.1080/1360786021000006956; Mestheneos E, 2005, SUPPORTING FAMILY CA, V1; Mortazavi Hamed, 2015, Int J Community Based Nurs Midwifery, V3, P187; Oberg B, 2008, FAMILY CARERS OLDER, P75; Park M, 2015, INT PSYCHOGERIATR, V27, P1355, DOI 10.1017/S1041610215000460; R Core Team, 2021, R LANG ENV STAT COMP; Romero-Moreno R, 2011, INT PSYCHOGERIATR, V23, P573, DOI 10.1017/S1041610210001821; Shahly V., 2012, PSYCHOL MED, V9, P1; Stones D, 2016, AGEING SOC, V36, P449, DOI 10.1017/S0144686X14001214; Sutcliffe CL, 2015, INT J GERIATR PSYCHI; Wang YN, 2011, J ADV NURS, V67, P829, DOI 10.1111/j.1365-2648.2010.05505.x; Wu S, 2012, CONTEMP CLIN TRIALS, V33, P869, DOI 10.1016/j.cct.2012.05.004; Wun LM, 2007, STAT MED, V26, P1875, DOI 10.1002/sim.2809	53	17	17	3	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2018	13	4							e0195294	10.1371/journal.pone.0195294	http://dx.doi.org/10.1371/journal.pone.0195294			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB5DC	29614108	Green Submitted, gold, Green Published			2023-01-03	WOS:000429081600041
J	Sheng, ZL; Zhao, JH; Muhammad, I; Zhang, Y				Sheng, Zunlai; Zhao, Jiahong; Muhammad, Ishfaq; Zhang, Ying			Optimization of total phenolic content from Terminalia chebula Retz. fruits using response surface methodology and evaluation of their antioxidant activities	PLOS ONE			English	Article							ULTRASONIC-ASSISTED EXTRACTION; IN-VITRO; POLYPHENOLIC COMPOUNDS; OXIDATIVE STRESS; GALLIC ACID; POLYSACCHARIDES; IDENTIFICATION; GREEN; OIL; L.	Ultrasonic-assisted extraction (UAE), using aqueous ethanol as the solvent, was firstly applied to extract phenolic compounds from Terminalia chebula Retz. fruits (T. chebula fruits). In this study, ethanol concentration (%), ultrasonic intensity (W/cm(2)), particle diameter (mm), extraction temperature (degrees C), ultrasonic time (min), liquid-solid ratio (mL/g) and extraction cycle were investigated by single-factor experiment and then optimized using a Box-Behnken design. The optimized result for UAE was 68% ethanol concentration, ultrasonic intensity of 3.6 W/cm(2), solid-liquid ratio of 23 mg/mL, particle size of 0.18 mm and ultrasonic time of 20 min for 2 times at 70 degrees C. The yield of total phenolic was 448.7 +/- 2.15 mg GAE/g DW under the above optimum conditions, which agreed with the predicted value (447.8 mg GAE/g DW). Compared to conventional solvent extraction (CSE), UAE extracts showed excellent DPPH radical, DPPH, ABTS scavenging activities and reducing power in a dose-dependent manner, and better than that of CSE extracts. Additionally, the extract of the T. chebula fruits was analyzed by HPLC-ESI/MS. In summary, UAE could effectively extract phenolic compounds from T. chebula fruits. In addition, the extract could be used as a potential source of natural antioxidants.	[Sheng, Zunlai; Zhao, Jiahong; Muhammad, Ishfaq; Zhang, Ying] Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China	Northeast Agricultural University - China	Sheng, ZL (corresponding author), Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China.	shengzunlai@neau.edu.cn	Ishfaq, Muhammad/U-9965-2019; Ishfaq, Muhammad/HGD-1422-2022	Ishfaq, Muhammad/0000-0003-1376-8986; zunlai, sheng/0000-0002-3059-022X	National Natural Science Foundation of China [31572559]; Academic Backbone Project of Northeast Agricultural University [16XG16]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Academic Backbone Project of Northeast Agricultural University	This research was supported by the National Natural Science Foundation of China (grant number 31572559); and Academic Backbone Project of Northeast Agricultural University (grant number 16XG16).	Al-Farsi MA, 2008, FOOD CHEM, V108, P977, DOI 10.1016/j.foodchem.2007.12.009; Altemimi A, 2015, MOLECULES, V20, P6611, DOI 10.3390/molecules20046611; Altemimi A, 2015, CHEM CENT J, V9, DOI 10.1186/s13065-015-0113-4; Altemimi A, 2015, ULTRASON SONOCHEM, V24, P247, DOI 10.1016/j.ultsonch.2014.10.023; Avula B, 2009, CHROMATOGRAPHIA, V69, P307, DOI 10.1365/s10337-008-0884-z; Avula B, 2013, PLANTA MED, V79, P181, DOI 10.1055/s-0032-1328089; Bag Anwesa, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P244, DOI 10.1016/S2221-1691(13)60059-3; Bedner M, 2011, ANAL CHEM, V83, P6169, DOI 10.1021/ac200372d; Boukroufa M, 2015, ULTRASON SONOCHEM, V24, P72, DOI 10.1016/j.ultsonch.2014.11.015; Chemat F, 2011, ULTRASON SONOCHEM, V18, P813, DOI 10.1016/j.ultsonch.2010.11.023; Entezari MH, 2004, ULTRASON SONOCHEM, V11, P379, DOI 10.1016/j.ultsonch.2003.10.005; Hassan M, 2016, INT J BIOL MACROMOL, V82, P573, DOI 10.1016/j.ijbiomac.2015.09.057; Huang B, 2011, FOOD CHEM TOXICOL, V49, P185, DOI 10.1016/j.fct.2010.10.015; Jambrak AR, 2007, CZECH J FOOD SCI, V25, P90, DOI 10.17221/757-CJFS; Konyalioglu S, 2005, PHARM BIOL, V43, P683, DOI 10.1080/13880200500383538; Lee JH, 2005, J AGR FOOD CHEM, V53, P6003, DOI 10.1021/jf050468r; Liu J, 2013, FOOD CHEM TOXICOL, V51, P310, DOI 10.1016/j.fct.2012.10.014; Lv LZ, 2015, J APPL BOT FOOD QUAL, V88, P152, DOI 10.5073/JABFQ.2015.088.022; Manna K, 2014, J ETHNOPHARMACOL, V155, P132, DOI 10.1016/j.jep.2014.04.046; Naik GH, 2002, XI BIENNIAL MEETING OF THE SOCIETY FOR FREE RADICAL RESEARCH INTERNATIONAL, P551; Pawlowska AM, 2006, J AGR FOOD CHEM, V54, P10234, DOI 10.1021/jf062230o; Pfundstein B, 2010, PHYTOCHEMISTRY, V71, P1132, DOI 10.1016/j.phytochem.2010.03.018; Prado P, 2008, SCI MAR, V72, P645, DOI 10.3989/scimar.2008.72n4645; Rangsiriwong P, 2009, SEP PURIF TECHNOL, V66, P51, DOI 10.1016/j.seppur.2008.11.023; Roslan J, 2014, SAINS MALAYS, V43, P1715; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Skotti E, 2014, IND CROP PROD, V53, P46, DOI 10.1016/j.indcrop.2013.12.013; Soria AC, 2010, TRENDS FOOD SCI TECH, V21, P323, DOI 10.1016/j.tifs.2010.04.003; Sun YS, 2013, ULTRASON SONOCHEM, V20, P180, DOI 10.1016/j.ultsonch.2012.07.002; Sun YJ, 2011, ULTRASON SONOCHEM, V18, P243, DOI 10.1016/j.ultsonch.2010.05.014; Suzek H, 2016, PHARM BIOL, V54, P451, DOI 10.3109/13880209.2015.1045086; Tubtimdee C, 2011, SEP PURIF TECHNOL, V77, P339, DOI 10.1016/j.seppur.2011.01.002; Tung YT, 2009, FOOD CHEM TOXICOL, V47, P1385, DOI 10.1016/j.fct.2009.03.021; Wang BC, 2007, COLLOID SURFACE B, V57, P17, DOI 10.1016/j.colsurfb.2006.12.003; Wang CX, 2014, J KOREAN SOC APPL BI, V57, P647, DOI 10.1007/s13765-014-4058-4; Wang L, 2008, ULTRASON SONOCHEM, V15, P738, DOI 10.1016/j.ultsonch.2007.12.008; Wu MY, 2007, J AQUAT PLANT MANAGE, V45, P76; Wu T, 2013, FOOD CHEM, V138, P1333, DOI 10.1016/j.foodchem.2012.10.086; Ye CL, 2011, INT J BIOL MACROMOL, V49, P466, DOI 10.1016/j.ijbiomac.2011.05.026; Zhang GW, 2011, INNOV FOOD SCI EMERG, V12, P18, DOI 10.1016/j.ifset.2010.12.003; Zhang ZG, 2010, BIOL TRACE ELEM RES, V138, P8, DOI 10.1007/s12011-009-8606-4; Zhang ZJ, 2009, FOOD CHEM, V113, P160, DOI 10.1016/j.foodchem.2008.07.061; Zheng Y, 2014, CARBOHYD POLYM, V111, P315, DOI 10.1016/j.carbpol.2014.04.034	43	14	15	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2018	13	8							e0202368	10.1371/journal.pone.0202368	http://dx.doi.org/10.1371/journal.pone.0202368			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ4SC	30106980	gold, Green Published, Green Submitted			2023-01-03	WOS:000441662800043
J	Hsieh, CH; Lu, CH; Kuo, YY; Chen, WT; Chao, CY				Hsieh, Chih-Hsiung; Lu, Chueh-Hsuan; Kuo, Yu-Yi; Chen, Wei-Ting; Chao, Chih-Yu			Studies on the non-invasive anticancer remedy of the triple combination of epigallocatechin gallate, pulsed electric field, and ultrasound	PLOS ONE			English	Article							INTENSITY FOCUSED ULTRASOUND; GROWTH-FACTOR RECEPTOR; OXIDATIVE STRESS; CANCER; APOPTOSIS; (-)-EPIGALLOCATECHIN-3-GALLATE; MICROBUBBLES; AUTOPHAGY; THERAPY; ACTIVATION	Cancer is one of the most troublesome diseases and a leading cause of death worldwide. Recently, novel treatments have been continuously developed to improve the disadvantages of conventional therapies, such as prodigious expenses, unwanted side effects, and tumor recurrence. Here, we provide the first non-invasive treatment that has combined epigallocatechin gallate (EGCG), the most abundant catechin in green tea, with a low strength pulsed electric field (PEF) and a low energy ultrasound (US). It has been observed that the cell viability of human pancreatic cancer PANC-1 was decreased approximately to 20% of the control after this combination treatment for 72 h. Besides, the combined triple treatment significantly reduced the high tolerance of HepG2 cells to the EGCG-induced cytotoxicity and similarly exhibited compelling proliferation-inhibitory effects. We also found the combined triple treatment increased the intracellular reactive oxygen species (ROS) and acidic vesicles, and the EGCG-induced inhibition of Akt phosphorylation was dramatically intensified. In this study, the apoptosis inhibitor Z-VAD-FMK and the autophagy inhibitor 3-MA were, respectively, shown to attenuate the anticancer effects of the triple treatment. This indicates that the triple treatment-induced autophagy was switched from cytoprotective to cytotoxic, and hence, cooperatively caused cell death with the apoptosis. Since the EGCG is easily accessible from the green tea and mild for a long-term treatment, and the non-invasive physical stimulations could be modified to focus on a specific location, this combined triple treatment may serve as a promising strategy for anticancer therapy.	[Hsieh, Chih-Hsiung; Lu, Chueh-Hsuan; Kuo, Yu-Yi; Chen, Wei-Ting; Chao, Chih-Yu] Natl Taiwan Univ, Lab Med Phys & Biomed Engn, Dept Phys, Taipei, Taiwan; [Hsieh, Chih-Hsiung; Lu, Chueh-Hsuan; Kuo, Yu-Yi; Chen, Wei-Ting; Chao, Chih-Yu] Natl Taiwan Univ, Coll Med, Biomed & Mol Imaging Ctr, Taipei, Taiwan; [Chao, Chih-Yu] Natl Taiwan Univ, Inst Appl Phys, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Chao, CY (corresponding author), Natl Taiwan Univ, Lab Med Phys & Biomed Engn, Dept Phys, Taipei, Taiwan.; Chao, CY (corresponding author), Natl Taiwan Univ, Coll Med, Biomed & Mol Imaging Ctr, Taipei, Taiwan.; Chao, CY (corresponding author), Natl Taiwan Univ, Inst Appl Phys, Taipei, Taiwan.	cychao@phys.ntu.edu.tw	Hsieh, Chih-Hsiung/GMX-1452-2022; Hsieh, Chih-Hsiung/AFI-4085-2022		Ministry of Science and Technology of the Republic of China [MOST 105-2112-M-002-006-MY3]; Ministry of Education of the Republic of China [MOE 106R880708]	Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan); Ministry of Education of the Republic of China(Ministry of Education, Taiwan)	This work was supported by grants from Ministry of Science and Technology (MOST 105-2112-M-002-006-MY3 to Chih-Yu Chao) and Ministry of Education (MOE 106R880708 to Chih-Yu Chao) of the Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi S, 2007, CANCER RES, V67, P6493, DOI 10.1158/0008-5472.CAN-07-0411; Bains OS, 2013, J PHARMACOL EXP THER, V347, P375, DOI 10.1124/jpet.113.206805; Basta G, 2003, CARDIOVASC RES, V58, P156, DOI 10.1016/S0008-6363(02)00665-X; Bazou D, 2017, APPL SCI-BASEL, V7, DOI 10.3390/app7121275; Bhat R, 2011, ULTRASON SONOCHEM, V18, P1295, DOI 10.1016/j.ultsonch.2011.04.002; Carlsson SR, 2015, J CELL SCI, V128, P193, DOI 10.1242/jcs.141036; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Dimcevski G, 2016, J CONTROL RELEASE, V243, P172, DOI 10.1016/j.jconrel.2016.10.007; Ding J, 2015, ACS APPL MATER INTER, V7, P18145, DOI 10.1021/acsami.5b05618; Dubinsky TJ, 2008, AM J ROENTGENOL, V190, P191, DOI 10.2214/AJR.07.2671; Farooqui AA, 2012, PHYTOCHEMICALS SIGNA; Ferrara K, 2007, ANNU REV BIOMED ENG, V9, P415, DOI 10.1146/annurev.bioeng.8.061505.095852; FREI E, 1965, BLOOD-J HEMATOL, V26, P642, DOI 10.1182/blood.V26.5.642.642; Gewirtz DA, 2013, AUTOPHAGY, V9, P1263, DOI 10.4161/auto.25233; Honda H, 2004, ULTRASOUND MED BIOL, V30, P683, DOI 10.1016/j.ultrasmedbio.2004.02.008; Hong J, 2002, CANCER RES, V62, P7241; Hou Z, 2005, CANCER RES, V65, P8049, DOI 10.1158/0008-5472.CAN-05-0480; Hsieh CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188885; Jiang YQ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8519169; Johns LD, 2002, J ATHL TRAINING, V37, P293; Jung SE, 2011, ABDOM IMAGING, V36, P185, DOI 10.1007/s00261-010-9628-2; Kiessling F, 2012, J NUCL MED, V53, P345, DOI 10.2967/jnumed.111.099754; Krasovitski B, 2011, P NATL ACAD SCI USA, V108, P3258, DOI 10.1073/pnas.1015771108; Lang BHH, 2017, J THER ULTRASOUND, V5, DOI 10.1186/s40349-017-0091-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liu S, 2013, AM J CHINESE MED, V41, P629, DOI 10.1142/S0192415X13500444; LOVE LA, 1980, J ACOUST SOC AM, V67, P1045, DOI 10.1121/1.384072; Minero C, 2005, ENVIRON SCI TECHNOL, V39, P8936, DOI 10.1021/es050314s; Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723; Morgan KE, 2000, IEEE T ULTRASON FERR, V47, P1494, DOI 10.1109/58.883539; Nadeem M, 2018, ULTRASON SONOCHEM, V45, P1, DOI 10.1016/j.ultsonch.2018.02.034; Nahirnyak V, 2007, ULTRASOUND MED BIOL, V33, P1285, DOI 10.1016/j.ultrasmedbio.2007.02.005; Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x; Pan MH, 2000, J AGR FOOD CHEM, V48, P6337, DOI 10.1021/jf000777b; Rwei P, 2017, BIOCHEM BIOPH RES CO, V482, P954, DOI 10.1016/j.bbrc.2016.11.139; Schroeder A, 2009, CHEM PHYS LIPIDS, V162, P1, DOI 10.1016/j.chemphyslip.2009.08.003; Sevgi EB, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.001735; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Terrault NA, 2009, HEPATOLOGY, V49, pS122, DOI 10.1002/hep.22921; van den Bijgaart RJE, 2017, CANCER IMMUNOL IMMUN, V66, P247, DOI 10.1007/s00262-016-1891-9; Vancraeynest D, 2009, ULTRASOUND MED BIOL, V35, P672, DOI 10.1016/j.ultrasmedbio.2008.10.005; Wang JK, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0047127, 10.1371/journal.pone.0037647, 10.1371/journal.pone.0030209, 10.1371/journal.pone.0051808]; Wang PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010202; Wang TY, 2013, CURR PHARM BIOTECHNO, V14, P743; Wei YQ, 2016, FOOD CHEM, V204, P218, DOI 10.1016/j.foodchem.2016.02.134; Wong YH, 2015, BMC MED GENOMICS, V8, DOI 10.1186/1755-8794-8-S4-S4; Yap TA, 2013, J CLIN ONCOL, V31, P1592, DOI 10.1200/JCO.2011.37.6418; Yasuda J, 2016, JAPANESE J APPL PHYS, V55; Yasui K, 2005, ULTRASON SONOCHEM, V12, P43, DOI 10.1016/j.ultsonch.2004.06.003; Zhang B, 2014, MOL MED REP, V10, P3282, DOI 10.3892/mmr.2014.2654; Zhou YF, 2011, WORLD J CLIN ONCOL, V2, P8, DOI 10.5306/wjco.v2.i1.8	51	11	11	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2018	13	8							e0201920	10.1371/journal.pone.0201920	http://dx.doi.org/10.1371/journal.pone.0201920			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3UO	30080905	gold, Green Submitted, Green Published			2023-01-03	WOS:000440780000028
J	Tan, PJ; Khoo, EM; Chinna, K; Saedon, NI; Zakaria, MI; Zahedi, AZA; Ramli, N; Khalidin, N; Mazlan, M; Chee, KH; Abidin, IZ; Nalathamby, N; Mat, S; Jaafar, MH; Khor, HM; Khannas, NM; Majid, LA; Tan, KM; Chin, AV; Kamaruzzaman, SB; Poi, P; Morgan, K; Hill, KD; MacKenzie, L; Tan, MP				Tan, Pey June; Khoo, Ee Ming; Chinna, Karuthan; Saedon, Nor I'zzati; Zakaria, Mohd Idzwan; Zahedi, Ahmad Zulkarnain Ahmad; Ramli, Norlina; Khalidin, Nurliza; Mazlan, Mazlina; Chee, Kok Han; Abidin, Imran Zainal; Nalathamby, Nemala; Mat, Sumaiyah; Jaafar, Mohamad Hasif; Khor, Hui Min; Khannas, Norfazilah Mohamad; Majid, Lokman Abdul; Tan, Kit Mun; Chin, Ai-Vyrn; Kamaruzzaman, Shahrul Bahyah; Poi, Philip; Morgan, Karen; Hill, Keith D.; MacKenzie, Lynette; Tan, Maw Pin			Individually-tailored multifactorial intervention to reduce falls in the Malaysian Falls Assessment and Intervention Trial (MyFAIT): A randomized controlled trial	PLOS ONE			English	Article							IDENTIFYING OLDER-PEOPLE; PREVENTION INTERVENTION; RISK-FACTORS; ADULTS; FEAR; CONSEQUENCES; EMERGENCY; ACCIDENT	Objective To determine the effectiveness of an individually-tailored multifactorial intervention in reducing falls among at risk older adult fallers in a multi-ethnic, middle-income nation in South-East Asia. Design Pragmatic, randomized-controlled trial. Setting Emergency room, medical outpatient and primary care clinic in a teaching hospital in Kuala Lumpur, Malaysia. Participants Individuals aged 65 years and above with two or more falls or one injurious fall in the past 12 months. Intervention Individually-tailored interventions, included a modified Otago exercise programme, HOME-FAST home hazards modification, visual intervention, cardiovascular intervention, medication review and falls education, was compared against a control group involving conventional treatment. Primary and secondary outcome measures The primary outcome was any fall recurrence at 12-month follow-up. Secondary outcomes were rate of fall and time to first fall. Results Two hundred and sixty-eight participants (mean age 75.3 +/- 7.2 SD years, 67% women) were randomized to multifactorial intervention (n = 134) or convention treatment (n = 134). All participants in the intervention group received medication review and falls education, 92 (68%) were prescribed Otago exercises, 86 (64%) visual intervention, 64 (47%) home hazards modification and 51 (38%) cardiovascular intervention. Fall recurrence did not differ between intervention and control groups at 12-months [Risk Ratio, RR = 1.037 (95% CI 0.613-1.753)]. Rate of fall [RR = 1.155 (95% CI 0.846-1.576], time to first fall [Hazard Ratio, HR = 0.948 (95% CI 0.782-1.522)] and mortality rate [RR = 0.896 (95% CI 0.335-2.400)] did not differ between groups. Conclusion Individually-tailored multifactorial intervention was ineffective as a strategy to reduce falls. Future research efforts are now required to develop culturally-appropriate and affordable methods of addressing this increasingly prominent public health issue in middle-income nations.	[Tan, Pey June; Saedon, Nor I'zzati; Nalathamby, Nemala; Mat, Sumaiyah; Jaafar, Mohamad Hasif; Khor, Hui Min; Tan, Kit Mun; Chin, Ai-Vyrn; Kamaruzzaman, Shahrul Bahyah; Poi, Philip; Tan, Maw Pin] Univ Malaya, Ageing & Age Associated Disorders Res Grp, Kuala Lumpur, Malaysia; [Tan, Pey June] Geriatr Educ & Res Inst, Singapore, Singapore; [Khoo, Ee Ming] Univ Malaya, Dept Primary Care Med, Fac Med, Kuala Lumpur, Malaysia; [Chinna, Karuthan] Univ Malaya, Dept Social & Prevent Med, Fac Med, Kuala Lumpur, Malaysia; [Saedon, Nor I'zzati; Khor, Hui Min; Tan, Kit Mun; Chin, Ai-Vyrn; Kamaruzzaman, Shahrul Bahyah; Poi, Philip; Tan, Maw Pin] Univ Malaya, Div Geriatr Med, Dept Med, Fac Med, Kuala Lumpur, Malaysia; [Zakaria, Mohd Idzwan; Zahedi, Ahmad Zulkarnain Ahmad] Univ Malaya, Dept Trauma & Emergency Med, Fac Med, Kuala Lumpur, Malaysia; [Ramli, Norlina; Khalidin, Nurliza] Univ Malaya, Dept Ophthalmol, Fac Med, Kuala Lumpur, Malaysia; [Mazlan, Mazlina] Univ Malaya, Dept Rehabil Med, Fac Med, Kuala Limpur, Malaysia; [Chee, Kok Han; Abidin, Imran Zainal] Univ Malaya, Div Cardiol, Dept Med, Fac Med, Kuala Lumpur, Malaysia; [Khannas, Norfazilah Mohamad; Majid, Lokman Abdul] Univ Malaya, Dept Rehabil Med, Med Ctr, Kuala Lumpur, Malaysia; [Morgan, Karen] Perdana Univ, Dept Psychol & Behav Sci, RCSI Sch Med, Serdang, Selangor, Malaysia; [Hill, Keith D.] Curtin Univ, Sch Physiotherapy & Exercise Sci, Fac Hlth Sci, Perth, WA, Australia; [MacKenzie, Lynette] Univ Sydney, Dept Occupat Therapy, Fac Hlth Sci, Sydney, NSW, Australia	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Perdana University; Curtin University; University of Sydney	Tan, MP (corresponding author), Univ Malaya, Ageing & Age Associated Disorders Res Grp, Kuala Lumpur, Malaysia.; Tan, MP (corresponding author), Univ Malaya, Div Geriatr Med, Dept Med, Fac Med, Kuala Lumpur, Malaysia.	mptan@ummc.edu.my	Tan, Kit Mun/D-5301-2013; Ahmad Zahedi, Ahmad Zulkarnain/AAB-5602-2022; Zakaria, Mohd Idzwan/E-3167-2010; RAMLI, NORLINA MOHD/B-9386-2010; Ramli, Norlina/GSD-7939-2022; KHALIDDIN, NURLIZA/AHE-2379-2022; Kamaruzzaman, Shahrul Bahyah/B-9728-2010; MAZLAN, MAZLINA/Y-9327-2019; Tan, Maw Pin/G-6917-2011; Jaafar, Mohamad Hasif Hasif/AAX-3318-2021; Saedon, Nor Izzati/B-9295-2010; morgan, karen/C-3846-2012; Ai-Vyrn, Chin/E-4237-2013; Chee, Kok Han/I-2138-2013; KHOO, EE MING/B-8785-2010; Mazlan, Mazlina/A-1015-2011; Khor, Hui Min/H-6832-2017; Mat, Sumaiyah/AFY-9404-2022; Zakaria, Mohd Idzwan/AAH-8525-2019; Kamaruzzaman, Shahrul Bahyah/Q-3189-2019; Mat, Sumaiyah/O-5610-2017; Tan, Pey June/W-7301-2019; Hill, Keith/L-6398-2017; Ramli, NORLISAH/G-5209-2010	Tan, Kit Mun/0000-0003-1611-3109; Ahmad Zahedi, Ahmad Zulkarnain/0000-0001-7511-0296; Zakaria, Mohd Idzwan/0000-0003-0793-8504; RAMLI, NORLINA MOHD/0000-0002-1484-949X; KHALIDDIN, NURLIZA/0000-0003-1167-5313; Tan, Maw Pin/0000-0002-3400-8540; Jaafar, Mohamad Hasif Hasif/0000-0002-8420-7580; Saedon, Nor Izzati/0000-0002-6634-7934; morgan, karen/0000-0001-6193-1747; Ai-Vyrn, Chin/0000-0002-0332-0048; Chee, Kok Han/0000-0002-4485-0504; KHOO, EE MING/0000-0003-3191-1264; Mazlan, Mazlina/0000-0002-4012-1873; Mat, Sumaiyah/0000-0003-4973-6986; Hill, Keith/0000-0002-2191-0308; Ramli, NORLISAH/0000-0001-7497-8093	University Malaya Research Grant [UMRG-RP-010-2012]; University of Malaya Postgraduate Research Fund [PPP-2015B-4805]; Ministry of Science and Technology Science Fund [SF017-2013]; University of Malaya Grand Challenge fund [GC002-14HTM]	University Malaya Research Grant; University of Malaya Postgraduate Research Fund(Universiti Malaya); Ministry of Science and Technology Science Fund; University of Malaya Grand Challenge fund	This work was supported by the University Malaya Research Grant (grant number UMRG-RP-010-2012 to MPT, URL: https://www.um.edu.my/research-and-community/information-for-researchers/research-funding), the University of Malaya Postgraduate Research Fund (grant number PPP-2015B-4805 to PJT, URL: https://www.um.edu.my/research-and-community/information-for-researchers/research-funding), Ministry of Science and Technology Science Fund (grant number SF017-2013 to MPT, http://www.mosti.gov.my/en/), and the University of Malaya Grand Challenge fund (grant number GC002-14HTM to MPT, https://www.um.edu.my/research-and-community/information-for-researchers/research-funding). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Campbell AJ, 2007, AGE AGEING, V36, P656, DOI 10.1093/ageing/afm122; Campbell AJ, 1999, AGE AGEING, V28, P513, DOI 10.1093/ageing/28.6.513; Choi M, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.04.022; Davison J, 2005, AGE AGEING, V34, P162, DOI 10.1093/ageing/afi053; Day L, 2002, BRIT MED J, V325, P128, DOI 10.1136/bmj.325.7356.128; de Boer MR, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0162-z; Delbaere K, 2010, AGE AGEING, V39, P210, DOI 10.1093/ageing/afp225; Denkinger MD, 2015, AM J GERIAT PSYCHIAT, V23, P72, DOI 10.1016/j.jagp.2014.03.002; Dong YR, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-222; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; El-Khoury F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6234; Freeman R, 2011, CLIN AUTON RES, V21, P69, DOI 10.1007/s10286-011-0119-5; Gaughan AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055882; Gill Sudeep S, 2004, Can J Clin Pharmacol, V11, pe274; Gillespie LD, 2012, COCHRANE DATABASE SY, V9; Gillespie LD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007146.pub3; Hairi NN, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-492; Halil M, 2006, ARCH GERONTOL GERIAT, V43, P351, DOI 10.1016/j.archger.2005.12.005; Hartholt KA, 2011, J TRAUMA, V71, P748, DOI 10.1097/TA.0b013e3181f6f5e5; Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478; Hauer K, 2006, AGE AGEING, V35, P5, DOI 10.1093/ageing/afi218; Jones GW, 2013, POPULATION SE ASIA; Kempen GIJM, 2008, AGE AGEING, V37, P45, DOI 10.1093/ageing/afm157; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Kruse RL, 2010, J HOUS ELDER, V24, P110, DOI 10.1080/02763891003757031; Kwan MMS, 2011, J AM GERIATR SOC, V59, P536, DOI 10.1111/j.1532-5415.2010.03286.x; Lau B., 2016, MIMS TODAY      0510; Lee HC, 2013, ARCH PHYS MED REHAB, V94, P606, DOI 10.1016/j.apmr.2012.11.037; Liew LK, 2019, J GERIATR PHYS THER, V42, P123, DOI 10.1519/JPT.0000000000000155; Loganathan A, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0274-6; Loganathan A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008460; Lovibond S.H., 1995, MANUAL DEPRESSION AN, V2; Mackenzie L, 2002, DISABIL REHABIL, V24, P266, DOI 10.1080/09638280110087089; Mahoney JE, 2007, J AM GERIATR SOC, V55, P489, DOI 10.1111/j.1532-5415.2007.01144.x; Mahoney JE, 2010, ARCH INTERN MED, V170, P1117, DOI 10.1001/archinternmed.2010.193; Malaysia DoS, 2017, ABR LIF TABL MAL 201; Mat S, 2018, PM&R, V10, P254, DOI 10.1016/j.pmrj.2017.08.405; Moore M, 2010, J AM GERIATR SOC, V58, P357, DOI 10.1111/j.1532-5415.2009.02683.x; Musa R, 2007, ASEAN J PSYCHIATR, V8, P82; Parry SW, 2009, HEART, V95, P416, DOI 10.1136/hrt.2007.136457; PETERS H B, 1961, Am J Optom Arch Am Acad Optom, V38, P487; Romli MH, 2017, PUBLIC HEALTH, V145, P96, DOI 10.1016/j.puhe.2016.12.035; Schoene D, 2013, J AM GERIATR SOC, V61, P202, DOI 10.1111/jgs.12106; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Shumway-Cook A, 2007, J GERONTOL A-BIOL, V62, P1420, DOI 10.1093/gerona/62.12.1420; Tan MP, 2016, GERIATR GERONTOL INT, V16, P111, DOI 10.1111/ggi.12446; Tan MP, 2006, CLIN INTERV AGING, V1, P57, DOI 10.2147/ciia.2006.1.1.57; Tan PJ, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-78; Tey NP, 2016, GERONTOLOGIST, V56, P603, DOI 10.1093/geront/gnv153; Van der Velde N, 2007, BRIT J CLIN PHARMACO, V63, P232, DOI 10.1111/j.1365-2125.2006.02736.x; Vind AB, 2009, J AM GERIATR SOC, V57, P971, DOI 10.1111/j.1532-5415.2009.02270.x; World Health Organization, 2015, WORLD POP AG 2015	52	16	16	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2018	13	8							e0199219	10.1371/journal.pone.0199219	http://dx.doi.org/10.1371/journal.pone.0199219			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP3QP	30074996	Green Published, Green Submitted, gold			2023-01-03	WOS:000440768100002
J	Xiao, XL; Wang, J; Gu, YM; Cai, YF; Ma, LX				Xiao, Xiangli; Wang, Jian; Gu, Yanmei; Cai, Yanfang; Ma, Lixin			Effect of community based practice of Baduanjin on self-efficacy of adults with cardiovascular diseases	PLOS ONE			English	Article							MANAGING CHRONIC DISEASE; OLDER-ADULTS; MANAGEMENT; EXERCISE; PROGRAM; QIGONG	Background Low self-efficacy in chronic disease patients is one of the main disturbances which require physical and mental rehabilitation, calling for the development of a home accessible way to improve self-management. Objectives The purpose of this study was to explore the effectiveness of a community based Baduanjin exercise on self-efficacy in adults with cardiovascular disease. Design A randomized controlled trial, longitudinal research design was employed. Participants After screening by health documents in Community Health Service Station, a total of 134 patients with records of cardiovascular diseases were had been enrolled according to the following inclusion criteria: (1) Community dwelling adults in Xili Community; (2) Patients diagnosed with cardiovascular diseases by community doctors, or other clinicians in health records in the past 3 years (2013 +/- 2015); (3) independent walking. Participants were excluded if they: (1) had impaired mobility and limited extremities functionality; (2) had not been in stable health condition and could not adhere to the exercise regime; (3) had communication difficulties and limited ability to follow instructions. Methods Participants were randomly assigned to the Baduanjin group or the control group. Those in the Baduanjin group received 16 weeks of Baduanjin exercise training, while those in the control group kept the original exercise mode unchanged. The Self-Efficacy for Managing Chronic Disease 6-item Scale (SEMCD6) was administered to subjects before and after intervention. Results Demographic data showed that 65.12% of the enrolled 129 participants were aged 65 or older, 92.25% received less than 12 years of education, and 68.21% participants' monthly income was less than 1999 RMB. Before intervention, SEMCD6 scores of 86.36% participants in Baduanjin group were below 7 points, while 85.71% in control group; after 16 weeks of Baduanjin exercise, SEMCD6 scores lower than 7 points in Baduanjin group (21.21%) were significantly lower than that of the control group (84.13%). The increase of SEMCD6 scores in Baduanjin group was statistically significant in the confidence to keep the fatigue, to keep the physical discomfort or pain, to keep the emotional distress and do the different tasks and activities (P<0.01). Conclusions Adults with cardiovascular diseases in community have lower level of education, most of whom have a low monthly income; thus, community dwelling cardiovascular disease patients are more suitable for an economic program to persist their long term management of the disease. Baduanjin is a traditional Chinese medicine regimen with less physical and cognitive demand; community based exercise of Baduanjin could help to increase self-efficacy in patients with cardiovascular diseases, thus better self-management of rehabilitation process.	[Xiao, Xiangli] Hebei Prov Childrens Hosp, Nursing Dept, Shijiazhuang, Hebei, Peoples R China; [Wang, Jian; Gu, Yanmei; Cai, Yanfang] HeBei Univ Chinese Med, Sch Nursing, Shijiazhuang, Hebei, Peoples R China; [Ma, Lixin] Hlth Serv Ctr XiLi Community, Shijiazhuang, Hebei, Peoples R China	Hebei University of Chinese Medicine	Gu, YM (corresponding author), HeBei Univ Chinese Med, Sch Nursing, Shijiazhuang, Hebei, Peoples R China.	1410879908@qq.com	, Jaaing/ABA-4467-2020					Azizan Azliyana, 2013, Curr Gerontol Geriatr Res, V2013, P282315, DOI 10.1155/2013/282315; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bossy D, 2017, HEALTH EXPECT, V20, P159, DOI 10.1111/hex.12448; Chan SCC, 2011, REHABIL PSYCHOL, V56, P191, DOI 10.1037/a0024584; Chen MC, 2012, INT J NURS STUD, V49, P265, DOI 10.1016/j.ijnurstu.2011.09.009; Chen MD, 2016, J PSYCHIATR PRACT, V22, P241, DOI 10.1097/PRA.0000000000000158; Chen TT, 2017, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.02015; Chen W.W., 2017, CHINA J CIRCULATION, V32, P521, DOI [10.3969/j.issn.1000-3614.2017.06.001, DOI 10.3969/J.ISSN.1000-3614.2017.06.001]; Chrisman JA, 2009, J HUMANIST PSYCHOL, V49, P236, DOI 10.1177/0022167808327750; Dalal HM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5631; Fan XZ, 2016, EUR J CARDIOVASC NUR, V15, P255, DOI 10.1177/1474515114566157; Farrell K, 2016, CLIN NURS RES, V13, P289; Franks P, 2009, BRIT J HEALTH PSYCH, V14, P473, DOI 10.1348/135910708X360700; Freund T, 2013, J EVAL CLIN PRACT, V19, P39, DOI 10.1111/j.1365-2753.2011.01764.x; Huanhuan Hu, 2013, ISRN PUBLIC HLTH, V2013, P1, DOI DOI 10.1155/2013/298986; Imayama I, 2013, J PHYS ACT HEALTH, V10, P676, DOI 10.1123/jpah.10.5.676; Jiang Yun-Han, 2017, Behav Sleep Med, P1, DOI 10.1080/15402002.2017.1363042; KOH TC, 1982, AM J CHINESE MED, V10, P14, DOI 10.1142/S0192415X8200004X; Li M, 2015, PLOS ONE, V10; Marks R, 2016, A REVIEW AND SYNTHES, P37; McAuley E, 2011, AM J PREV MED, V41, P284, DOI 10.1016/j.amepre.2011.04.014; Mersal FA., 2015, CHINESE GEN PRACT, V4, P244; Prabhakaran D, 2016, CIRCULATION, V133, P1605, DOI 10.1161/CIRCULATIONAHA.114.008729; Scholz U, 2005, J SPORT EXERCISE PSY, V27, P135, DOI 10.1123/jsep.27.2.135; SCHWARZER R, 2008, APPL PSYCHOL INT REV, V57, P1; Schwarzer R, 2016, ACTUAL PSICOL, V30, P119, DOI 10.15517/ap.v30i121.23458; Tao J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41581; Willis E, 2016, HEALTH COMMUN, V31, P299, DOI 10.1080/10410236.2014.950019; Xiao CM, 2016, GERIATR GERONTOL INT, V16, P911, DOI 10.1111/ggi.12571; Xiao CM, 2016, J AM GERIATR SOC, V64, pE227, DOI 10.1111/jgs.14438	31	13	14	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2018	13	7							e0200246	10.1371/journal.pone.0200246	http://dx.doi.org/10.1371/journal.pone.0200246			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO7MT	30059552	Green Published, gold, Green Submitted			2023-01-03	WOS:000440251600009
J	Lee, TF; Sung, KC; Chao, PJ; Huang, YJ; Lan, JH; Wu, HY; Chang, LY; Ting, HM				Lee, Tsair-Fwu; Sung, Kuo-Chiang; Chao, Pei-Ju; Huang, Yu-Jie; Lan, Jen-Hong; Wu, Horng-Yuan; Chang, Liyun; Ting, Hui-Min			Relationships among patient characteristics, irradiation treatment planning parameters, and treatment toxicity of acute radiation dermatitis after breast hybrid intensity modulation radiation therapy	PLOS ONE			English	Article							ARC RADIOTHERAPY VMAT; CLINIC QUANTEC; CANCER; IMRT; HEAD; XEROSTOMIA; SURFACE; BEAMS; PLANS; SKIN	To evaluate the relationships among patient characteristics, irradiation treatment planning parameters, and treatment toxicity of acute radiation dermatitis (RD) after breast hybrid intensity modulation radiation therapy (IMRT). The study cohort consisted of 95 breast cancer patients treated with hybrid IMRT. RD grade >= 2 (2(+)) toxicity was defined as clinically significant. Patient characteristics and the irradiation treatment planning parameters were used as the initial candidate factors. Prognostic factors were identified using the least absolute shrinkage and selection operator (LASSO)-based normal tissue complication probability (NTCP) model. A univariate cut-off dose NTCP model was developed to find the dose-volume limitation. Fifty-two (54.7%) of ninety-five patients experienced acute RD grade 2(+) toxicity. The volume of skin receiving a dose >35 Gy (V-35) was the most significant dosimetric predictor associated with RD grade 2(+) toxicity. The NTCP model parameters for V-35Gy were TV50 = 85.7 mL and y(50) = 0.77, where TV50 was defined as the volume corresponding to a 50% incidence of complications, and y(50) was the normalized slope of the volume-response curve. Additional potential predictive patient characteristics were energy and surgery, but the results were not statistically significant. To ensure a better quality of life and compliance for breast hybrid IMRT patients, the skin volume receiving a dose >35 Gy should be limited to <85.7 mL to keep the incidence of RD grade 2(+) toxicities below 50%. To avoid RD toxicity, the volume of skin receiving a dose >35 Gy should follow sparing tolerance and the inherent patient characteristics should be considered.	[Lee, Tsair-Fwu; Chao, Pei-Ju; Lan, Jen-Hong; Ting, Hui-Min] Natl Kaohsiung Univ Sci & Technol, Med Phys & Informat Lab Elect Engn, Kaohsiung, Taiwan; [Lee, Tsair-Fwu] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan; [Lee, Tsair-Fwu; Sung, Kuo-Chiang; Chao, Pei-Ju; Huang, Yu-Jie; Lan, Jen-Hong; Ting, Hui-Min] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Lee, Tsair-Fwu; Sung, Kuo-Chiang; Chao, Pei-Ju; Huang, Yu-Jie; Lan, Jen-Hong; Ting, Hui-Min] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Sung, Kuo-Chiang; Wu, Horng-Yuan] Natl Kaohsiung Univ Sci & Technol, Dept Elect Engn, Kaohsiung, Taiwan; [Chang, Liyun] I Shou Univ, Dept Med Imaging & Radiol Sci, Kaohsiung, Taiwan	National Kaohsiung University of Science & Technology; Kaohsiung Medical University; Chang Gung Memorial Hospital; Chang Gung University; National Kaohsiung University of Science & Technology; I Shou University	Ting, HM (corresponding author), Natl Kaohsiung Univ Sci & Technol, Med Phys & Informat Lab Elect Engn, Kaohsiung, Taiwan.; Ting, HM (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan.; Ting, HM (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Chang, LY (corresponding author), I Shou Univ, Dept Med Imaging & Radiol Sci, Kaohsiung, Taiwan.	cliyun2000@gmail.com; hmting618@gmail.com	chao, P/GSD-8001-2022		Ministry of Science and Technology (MOST) of the Executive Yuan of the Republic of China [MOST-106-2221-E-151-010, MOST 106-2221-E-992-328]; CMRPG [8F1521]	Ministry of Science and Technology (MOST) of the Executive Yuan of the Republic of China; CMRPG	This study was supported financially, in part, by grants from the Ministry of Science and Technology (MOST) of the Executive Yuan of the Republic of China, (MOST-106-2221-E-151-010 and MOST 106-2221-E-992-328) and CMRPG 8F1521. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Shih-Sian Guo and Cheng-Shian Hsu for statistical technical supports. This study was supported financially, in part, by grants from MOST-106-2221-E-151-010, MOST 106-2221-E-992-328 and CMRPG 8F1521.	BENTZEN SM, 1994, ADV RADIAT BIOL, V18, P25; Bentzen SM, 2010, INT J RADIAT ONCOL, V76, pS3, DOI 10.1016/j.ijrobp.2009.09.040; CHEN MF, 2010, BMC CANCER, V10, DOI DOI 10.1186/1471-2407-10-1120/JACMPV12I4.3587; Chung HT, 2005, MED PHYS, V32, P2682, DOI 10.1118/1.1992067; Cox JD, 2009, RAD ONCOLOGY RATIONA; Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8; Farhood B, 2014, IRAN J MED PHYS, V11, P316; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P1717, DOI 10.1002/1097-0142(19860501)57:9<1717::AID-CNCR2820570902>3.0.CO;2-H; Freedman GM, 2009, INT J RADIAT ONCOL, V74, P689, DOI 10.1016/j.ijrobp.2008.08.071; Halg RA, 2012, MED PHYS, V39, P7662, DOI 10.1118/1.4767773; Hall EJ, RADIOBIOLOGY RADIOLO, V7th; Halperin E C, 2008, PEREZ BRADYS PRINCIP; Kelly A, 2011, PHYS MED BIOL, V56, P1001, DOI 10.1088/0031-9155/56/4/008; Kong C, 2016, SCI REP-UK, V6, DOI 10.1038/srep26378; Kraus-Tiefenbacher U, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-217; Kry Stephen F, 2012, J Appl Clin Med Phys, V13, P3734, DOI 10.1120/jacmp.v13i3.3734; Lee N, 2002, INT J RADIAT ONCOL, V53, P630, DOI 10.1016/S0360-3016(02)02756-6; Lee TF, 2012, CLIN ONCOL-UK, V24, P196, DOI 10.1016/j.clon.2011.06.006; Lee T-F, 2015, RADIAT ONCOL, V10, P1; Lee TF, 2008, RADIOTHER ONCOL, V89, P89, DOI 10.1016/j.radonc.2008.05.010; Lee TF, 2015, SCI REP-UK, V5, DOI 10.1038/srep13165; Lee TF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06217; Lee TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089700; Lee TF, 2013, RADIOTHER ONCOL, V106, P352, DOI 10.1016/j.radonc.2012.11.013; Lee TF, 2011, J APPL CLIN MED PHYS, V12, P158, DOI 10.1120/jacmp.v12i4.3587; Ma CM, 2003, PHYS MED BIOL, V48, P909, DOI 10.1088/0031-9155/48/7/308; Mansouri S, 2014, ASIAN PAC J CANCER P, V15, P4727, DOI 10.7314/APJCP.2014.15.11.4727; Mayo CS, 2005, INT J RADIAT ONCOL, V61, P922, DOI 10.1016/j.ijrobp.2004.10.033; Michalski A, 2014, MED DOSIM, V39, P163, DOI 10.1016/j.meddos.2013.12.003; NORMAN A, 1992, RADIOTHER ONCOL, V23, P196, DOI 10.1016/0167-8140(92)90331-N; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Pignol JP, 2008, J CLIN ONCOL, V26, P2085, DOI 10.1200/JCO.2007.15.2488; ROSE MA, 1989, ARCH SURG-CHICAGO, V124, P153; Ryan JL, 2012, J INVEST DERMATOL, V132, P985, DOI 10.1038/jid.2011.411; Sun LM, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-50; Tejwani A, 2009, CANCER-AM CANCER SOC, V115, P1286, DOI 10.1002/cncr.24120; Trott KR, 2012, RADIOTHER ONCOL, V105, P79, DOI 10.1016/j.radonc.2012.05.008; VANLIMBERGEN E, 1990, INT J RADIAT ONCOL, V18, P1239, DOI 10.1016/0360-3016(90)90464-U; Vicini FA, 2002, INT J RADIAT ONCOL, V54, P1336, DOI 10.1016/S0360-3016(02)03746-X; Washington CM, 2015, PRINCIPLES PRACTICE	40	10	10	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2018	13	7							e0200192	10.1371/journal.pone.0200192	http://dx.doi.org/10.1371/journal.pone.0200192			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2LQ	30011291	Green Published, Green Submitted, gold			2023-01-03	WOS:000438829800013
J	Adams, D; Gonzalez-Duarte, A; O'Riordan, WD; Yang, CC; Ueda, M; Kristen, AV; Tournev, I; Schmidt, HH; Coelho, T; Berk, JL; Lin, KP; Vita, G; Attarian, S; Plante-Bordeneuve, V; Mezei, MM; Campistol, JM; Buades, J; Brannagan, TH; Kim, BJ; Oh, J; Parman, Y; Sekijima, Y; Hawkins, PN; Solomon, SD; Polydefkis, M; Dyck, PJ; Gandhi, PJ; Goyal, S; Chen, J; Strahs, AL; Nochur, SV; Sweetser, MT; Garg, PP; Vaishnaw, AK; Gollob, JA; Suhr, OB				Adams, D.; Gonzalez-Duarte, A.; O'Riordan, W. D.; Yang, C. -C.; Ueda, M.; Kristen, A. V.; Tournev, I.; Schmidt, H. H.; Coelho, T.; Berk, J. L.; Lin, K. -P.; Vita, G.; Attarian, S.; Plante-Bordeneuve, V.; Mezei, M. M.; Campistol, J. M.; Buades, J.; Brannagan, T. H., III; Kim, B. J.; Oh, J.; Parman, Y.; Sekijima, Y.; Hawkins, P. N.; Solomon, S. D.; Polydefkis, M.; Dyck, P. J.; Gandhi, P. J.; Goyal, S.; Chen, J.; Strahs, A. L.; Nochur, S. V.; Sweetser, M. T.; Garg, P. P.; Vaishnaw, A. K.; Gollob, J. A.; Suhr, O. B.			Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; LATE-ONSET; POLYNEUROPATHY; TAFAMIDIS; SAFETY; PROGRESSION; EFFICACY	BACKGROUND Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks. The primary end point was the change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment) at 18 months. Other assessments included the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating worse quality of life), 10-m walk test (with gait speed measured in meters per second), and modified body-mass index (modified BMI, defined as [weight in kilograms divided by square of height in meters] x albumin level in grams per liter; lower values indicated worse nutritional status). RESULTS A total of 225 patients underwent randomization (148 to the patisiran group and 77 to the placebo group). The mean (+/- SD) mNIS+7 at baseline was 80.9 +/- 41.5 in the patisiran group and 74.6 +/- 37.0 in the placebo group; the least-squares mean (+/- SE) change from baseline was -6.0 +/- 1.7 versus 28.0 +/- 2.6 (difference, -34.0 points; P<0.001) at 18 months. The mean (+/- SD) baseline Norfolk QOL-DN score was 59.6 +/- 28.2 in the patisiran group and 55.5 +/- 24.3 in the placebo group; the least-squares mean (+/- SE) change from baseline was -6.7 +/- 1.8 versus 14.4 +/- 2.7 (difference, -21.1 points; P<0.001) at 18 months. Patisiran also showed an effect on gait speed and modified BMI. At 18 months, the least-squares mean change from baseline in gait speed was 0.08 +/- 0.02 m per second with patisiran versus -0.24 +/- 0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was -3.7 +/- 9.6 versus -119.4 +/- 14.5 (difference, 115.7; P<0.001). Approximately 20% of the patients who received patisiran and 10% of those who received placebo had mild or moderate infusion-related reactions; the overall incidence and types of adverse events were similar in the two groups. CONCLUSIONS In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis.	[Adams, D.] Univ Paris Sud, CHU Bicetre, AP HP, INSERM Unite 1195,Natl Reference Ctr Familial Amy, Le Kremlin Bicetre, France; [Attarian, S.] Hop La Timone, Dept Neuromuscular Disorders & ALS, Marseille, France; [Plante-Bordeneuve, V.] CHU Henri Mondor, AP HP, Amyloid Network, Dept Neurol, Creteil, France; [Gonzalez-Duarte, A.] Natl Inst Med Sci & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [O'Riordan, W. D.] eStudySite, Dept Clin Res, San Diego, CA USA; [Yang, C. -C.] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Lin, K. -P.] Taipei Vet Gen Hosp, Dept Neurol, Taipei, Taiwan; Kumamoto Univ Hosp, Kumamoto, Japan; [Sekijima, Y.] Shinshu Univ, Dept Med Neurol & Rheumatol, Matsumoto, Nagano, Japan; [Kristen, A. V.] Heidelberg Univ, Dept Cardiol, Heidelberg, Germany; [Schmidt, H. H.] Univ Klinikum Munster, Med Klin B Gastroenterol & Hepatol, Munster, Germany; [Tournev, I.] Univ Multiprofile Hosp Act Treatment, Sofia, Bulgaria; [Coelho, T.] Hosp Santo Antonio, Ctr Hosp Porto, Porto, Portugal; [Berk, J. L.] Boston Med Ctr, Dept Med, Amyloidosis Ctr, Boston, MA USA; [Solomon, S. D.] Harvard Med Sch, Boston, MA USA; [Vita, G.] Univ Hosp Messina, Dept Clin & Expt Med, Messina, Italy; [Mezei, M. M.] Vancouver Gen Hosp, Dept Neurol, Vancouver, BC, Canada; [Mezei, M. M.] Vancouver Gen Hosp, Dept Med, Vancouver, BC, Canada; [Campistol, J. M.] Hosp Clin Barcelona, Dept Nephrol, Barcelona, Spain; [Buades, J.] Balear Isl Hlth Res Inst, Palma de Mallorca, Spain; [Buades, J.] Hosp Son Llatzer, Palma de Mallorca, Spain; [Brannagan, T. H., III] Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY USA; [Kim, B. J.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Oh, J.] Konkuk Univ, Med Ctr, Dept Neurol, Seoul, South Korea; [Parman, Y.] Istanbul Univ, Dept Neurol, Istanbul, Turkey; [Hawkins, P. N.] UCL, Div Med, London, England; [Polydefkis, M.] Johns Hopkins Bayview Med Ctr Baltimore, Baltimore, MD USA; [Dyck, P. J.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Gandhi, P. J.; Goyal, S.; Chen, J.; Strahs, A. L.; Nochur, S. V.; Sweetser, M. T.; Garg, P. P.; Vaishnaw, A. K.; Gollob, J. A.] Alnylam Pharmaceut, Cambridge, MA USA; [Suhr, O. B.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Taiwan University; National Taiwan University Hospital; Taipei Veterans General Hospital; Kumamoto University; Shinshu University; Ruprecht Karls University Heidelberg; University of Munster; Medical University Sofia; Boston Medical Center; Harvard University; Harvard Medical School; AOU Policlinico Gaetano Martino; University of British Columbia; University of British Columbia; University of Barcelona; Hospital Clinic de Barcelona; Institut Investigacio Sanitaria Illes Balears (IdISBa); Hospital Universitari Son Llatzer; Columbia University; Sungkyunkwan University (SKKU); Samsung Medical Center; Konkuk University; Konkuk University Medical Center; Istanbul University; University of London; University College London; Johns Hopkins University; Mayo Clinic; Umea University	Adams, D (corresponding author), CHU Bicetre, Dept Neurol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	david.adams@aphp.fr	Attarian, Shahram/AAE-6214-2021	Plante Bordeneuve, Violaine/0000-0002-7880-2316; Brannagan, Thomas/0000-0002-1812-8331; adams, david/0000-0002-8722-4108	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	Funded by Alnylam Pharmaceuticals	Adams D, 2015, ORPHANET J RARE D S1, V10; Adams D, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0948-5; Adams D, 2015, NEUROLOGY, V85, P675, DOI 10.1212/WNL.0000000000001870; Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793; Berk JL, 2013, JAMA-J AM MED ASSOC, V310, P2658, DOI 10.1001/jama.2013.283815; Castano A, 2015, HEART FAIL REV, V20, P163, DOI 10.1007/s10741-014-9462-7; Coelho T, 2013, J NEUROL, V260, P2802, DOI 10.1007/s00415-013-7051-7; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Coelho T, 2012, NEUROLOGY, V79, P785, DOI 10.1212/WNL.0b013e3182661eb1; Conceicao I, 2016, J PERIPHER NERV SYST, V21, P5, DOI 10.1111/jns.12153; Cortese A, 2016, J NEUROL, V263, P916, DOI 10.1007/s00415-016-8064-9; Dungu JN, 2012, HEART, V98, P1546, DOI 10.1136/heartjnl-2012-301924; Dyck PJ, 2017, MUSCLE NERVE, V56, P901, DOI 10.1002/mus.25563; Hawkins PN, 2015, ANN MED, V47, P625, DOI 10.3109/07853890.2015.1068949; Koike H, 2012, J NEUROL NEUROSUR PS, V83, P152, DOI 10.1136/jnnp-2011-301299; Liepnieks JJ, 2010, NEUROLOGY, V75, P324, DOI 10.1212/WNL.0b013e3181ea15d4; Lozeron P, 2013, EUR J NEUROL, V20, P1539, DOI 10.1111/ene.12225; Mariani LL, 2015, ANN NEUROL, V78, P901, DOI 10.1002/ana.24519; Partisano A, 2017, ORPHANET J RARE D S1, V12, P165; Plante-Bordeneuve V, 2017, J NEUROL, V264, P268, DOI 10.1007/s00415-016-8337-3; Ruberg FL, 2012, CIRCULATION, V126, P1286, DOI 10.1161/CIRCULATIONAHA.111.078915; Ruberg FL, 2012, AM HEART J, V164, P222, DOI 10.1016/j.ahj.2012.04.015; Sepp-Lorenzino L, 2008, CLIN PHARMACOL THER, V84, P628, DOI 10.1038/clpt.2008.174; Suanprasert N, 2014, J NEUROL SCI, V344, P121, DOI 10.1016/j.jns.2014.06.041; Suhr OB, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0326-6	26	1265	1297	31	245	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2018	379	1					11	21		10.1056/NEJMoa1716153	http://dx.doi.org/10.1056/NEJMoa1716153			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL5ZG	29972753	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000437254200005
J	Nijboer, TCW; Winters, C; Kollen, BJ; Kwakkel, G				Nijboer, Tanja C. W.; Winters, Caroline; Kollen, Boudewijn J.; Kwakkel, Gert			Impact of clinical severity of stroke on the severity and recovery of visuospatial neglect	PLOS ONE			English	Article							RIGHT-HEMISPHERE; RANDOMIZED-TRIAL; NATURAL-HISTORY; SPATIAL NEGLECT; VISUAL NEGLECT; UPPER-LIMB; REHABILITATION; DIASCHISIS; GENERALIZABILITY; IMPROVEMENT	Background and purpose There is growing evidence that visuospatial neglect (VSN) is associated with lower functional performance in other modalities and is not restricted to the lesioned hemisphere alone, and may also affect the non-lesioned hemisphere in severe first-ever strokes. We aimed to investigate the longitudinal association between the severity of VSN, as reflected by the extent of ipsilesional and contralesional spatial attention deficit, and clinical severity of stroke. Methods This is a secondary data analysis with merged data from two prospective cohort studies. Resulting in 90 patients and 8 longitudinal measurements at 1, 2, 3, 4, 5, 8, 12, and 26 weeks post-stroke onset. A letter cancellation test (LCT) was used as the primary outcome measure to demonstrate presence and severity of VSN. The clinical severity of stroke was classified using the Bamford Classification. Results No significant association between clinical severity and the number of ipsilesional, as well as contralesional, omissions on the LCT was observed. Recovery of VSN at the contralesional hemiplegic, as well as ipsilesional non-hemiplegic side, was only dependent on 'time' as a reflection of spontaneous neurobiological recovery post-stroke. The recovery of the ipsilesional extension of VSN was significantly slower for the total anterior circulation infarct (TACI) group compared to the non-TACI group. Conclusions Larger strokes have a significant negative impact on recovery of visual attention at the non-hemiplegic side. No clinical determinants that regulate spontaneous time-dependent recovery of VSN were found. While early 'stroke severity' has been regarded as a strong predictor of functional outcome at a group level, other prognostic factors (demographic, stroke related) need to be determined.	[Nijboer, Tanja C. W.] Univ Utrecht, Expt Psychol, Utrecht, Netherlands; [Nijboer, Tanja C. W.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Nijboer, Tanja C. W.] Univ Med Ctr Utrecht, Ctr Excellence Rehabil Med, Utrecht, Netherlands; [Nijboer, Tanja C. W.] Hoogstr Rehabil Ctr, Utrecht, Netherlands; [Winters, Caroline; Kwakkel, Gert] Vrije Univ Amsterdam, Med Ctr, Dept Rehabil Med, Amsterdam Movement Sci, Amsterdam, Netherlands; [Winters, Caroline; Kwakkel, Gert] Vrije Univ Amsterdam, Amsterdam Neurosci Campus, Amsterdam, Netherlands; [Winters, Caroline] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands; [Kwakkel, Gert] Ctr Rehabil & Rheumatol READE, Dept Neurorehabil, Amsterdam, Netherlands; [Kwakkel, Gert] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA	Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Groningen; Northwestern University	Nijboer, TCW (corresponding author), Univ Utrecht, Expt Psychol, Utrecht, Netherlands.; Nijboer, TCW (corresponding author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.; Nijboer, TCW (corresponding author), Univ Med Ctr Utrecht, Ctr Excellence Rehabil Med, Utrecht, Netherlands.; Nijboer, TCW (corresponding author), Hoogstr Rehabil Ctr, Utrecht, Netherlands.	t.c.w.nijboer@uu.nl		Nijboer, Tanja/0000-0001-6683-0267; Kwakkel, Gert/0000-0002-4041-4043	NWO (Netherlands Organization for Scientific Research) [451-10-013]; EXPLICIT-stroke grant of ZonMw [89000001]; 4D-EEG (ERC) [291339-4D-EEG]	NWO (Netherlands Organization for Scientific Research)(Netherlands Organization for Scientific Research (NWO)); EXPLICIT-stroke grant of ZonMw; 4D-EEG (ERC)	Supported by a grant from NWO (Netherlands Organization for Scientific Research; grant 451-10-013 to TCWN, and by the EXPLICIT-stroke grant of ZonMw (grant 89000001) and 4D-EEG (ERC advanced grant 291339-4D-EEG) to GK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Bernhardt J, 2017, NEUROREHAB NEURAL RE, V31, P793, DOI 10.1177/1545968317732668; Boyd LA, 2017, INT J STROKE, V12, P480, DOI 10.1177/1747493017714176; Carrera E, 2014, BRAIN, V137, P2408, DOI 10.1093/brain/awu101; Collin C, 1988, Int Disabil Stud, V10, P61; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Corbett D, 2017, INT J STROKE, V12, P462, DOI 10.1177/1747493017711814; Corbetta M, 2005, NAT NEUROSCI, V8, P1603, DOI 10.1038/nn1574; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Halligan P.W., 1993, UNILATERAL NEGLECT C; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Katz N, 1999, ARCH PHYS MED REHAB, V80, P379, DOI 10.1016/S0003-9993(99)90273-3; Kinsbourne M., 1987, ADV PSYCHOL, V45, P69, DOI DOI 10.1016/S0166-4115(08)61709-4; Kinsbourne M., 1993, UNILATERAL NEGLECT C, P63, DOI DOI 10.4324/9780203765258; Koch G, 2008, BRAIN, V131, P3147, DOI 10.1093/brain/awn273; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Kwakkel G, 2017, INT J STROKE, V12, P451, DOI 10.1177/1747493017711813; Kwakkel G, 2016, NEUROREHAB NEURAL RE, V30, P804, DOI 10.1177/1545968315624784; Kwakkel G, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-49; Lazar RM, 2010, STROKE, V41, P1485, DOI 10.1161/STROKEAHA.109.577338; Lunven M, 2015, BRAIN, V138, P746, DOI 10.1093/brain/awu389; Nijboer TCW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100584; Nijboer TCW, 2013, CORTEX, V49, P2021, DOI 10.1016/j.cortex.2012.11.006; Rasquin S, 2009, TIJDSCHRIFT NEUROPSY, V3, P44; Smith C J, 2001, J Stroke Cerebrovasc Dis, V10, P205, DOI 10.1053/jscd.2001.29825; Ten Brink AF, 2016, BEHAV BRAIN RES, V304, P71, DOI 10.1016/j.bbr.2016.02.004; Veerbeek JM, 2017, NEUROREHAB NEURAL RE, V31, P107, DOI 10.1177/1545968316666957; Von Monakow C., 1969, DIASCHISIS; Winters C, 2017, NEUROREHAB NEURAL RE, V31, P334, DOI 10.1177/1545968316680492; Winters C, 2015, NEUROREHAB NEURAL RE, V29, P614, DOI 10.1177/1545968314562115	40	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2018	13	7							e0198755	10.1371/journal.pone.0198755	http://dx.doi.org/10.1371/journal.pone.0198755			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL5QR	29966012	Green Published, gold			2023-01-03	WOS:000437224100008
J	Veroniki, AA; Antony, J; Straus, SE; Ashoor, HM; Finkelstein, Y; Khan, PA; Ghassemi, M; Blondal, E; Ivory, JD; Hutton, B; Gough, K; Hemmelgarn, BR; Lillie, E; Vafaei, A; Tricco, AC				Veroniki, Areti Angeliki; Antony, Jesmin; Straus, Sharon E.; Ashoor, Huda M.; Finkelstein, Yaron; Khan, Paul A.; Ghassemi, Marco; Blondal, Erik; Ivory, John D.; Hutton, Brian; Gough, Kevin; Hemmelgarn, Brenda R.; Lillie, Erin; Vafaei, Afshin; Tricco, Andrea C.			Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs	PLOS ONE			English	Review							PRETERM BIRTH; PREGNANT-WOMEN; 1ST TRIMESTER; EXPOSURE; RISK; INCONSISTENCY; COHORT; INTERVENTIONS; CONSISTENCY; EFFICACY	Background Nearly all newly infected children acquire Human Immunodeficiency virus (HIV) via mother-to-child transmission (MTCT) during pregnancy, labour or breastfeeding from untreated HIV-positive mothers. Antiretroviral therapy (ART) is the standard care for pregnant women with HIV. However, evidence of ART effectiveness and harms in infants and children of HIV-positive pregnant women exposed to ART has been largely inconclusive. The aim of our systematic review and network meta-analysis (NMA) was to evaluate the comparative safety and effectiveness of ART drugs in children exposed to maternal HIV and ART (or no ART/placebo) across different study designs. Methods We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (inception until December 7, 2015). Primary outcomes were any congenital malformations (CMs; safety), including overall major and minor CMs, and mother-to-child transmission (MTCT; effectiveness). Random-effects Bayesian pairwise meta-analyses and NMAs were conducted. After screening 6,468 citations and 1,373 full-text articles, 90 studies of various study designs and 90,563 patients were included. Results The NMA on CMs (20 studies, 7,503 children, 16 drugs) found that none of the ART drugs examined here were associated with a significant increase in CMs. However, zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight. A NMA on MTCT (11 studies, 10,786 patients, 6 drugs) found that zidovudine administered once (odds ratio [OR] = 0.39, 95% credible interval [Crl]: 0.19-0.83) or twice (OR = 0.43, 95% CrI: 0.21 -0.68) was associated with significantly reduced risk of MTCT. Conclusions Our findings suggest that ART drugs are not associated with an increased risk of CMs, yet some may increase adverse birth events. Some ART drugs (e.g., zidovudine) effectively reduce MTCT.	[Veroniki, Areti Angeliki; Antony, Jesmin; Straus, Sharon E.; Ashoor, Huda M.; Khan, Paul A.; Ghassemi, Marco; Blondal, Erik; Ivory, John D.; Gough, Kevin; Lillie, Erin; Vafaei, Afshin; Tricco, Andrea C.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Straus, Sharon E.; Gough, Kevin] Univ Toronto, Dept Med, Toronto, ON, Canada; [Finkelstein, Yaron] Hosp Sick Children, Toronto, ON, Canada; [Finkelstein, Yaron] Univ Toronto, Dept Paediat, Toronto, ON, Canada; [Finkelstein, Yaron] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada; [Hutton, Brian] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Fac Med, Ottawa, ON, Canada; [Hutton, Brian] Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa Hosp Gen Campus, Ottawa, ON, Canada; [Hemmelgarn, Brenda R.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Hemmelgarn, Brenda R.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Tricco, Andrea C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Calgary; University of Calgary; University of Toronto	Tricco, AC (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.; Tricco, AC (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada.	TriccoA@smh.ca	Tricco, Andrea/B-9920-2011; Ivory, John Damien/AAG-8036-2020	Tricco, Andrea/0000-0002-4114-8971; Ivory, John Damien/0000-0002-8445-4602; /0000-0001-6388-4825; Khan, Paul/0000-0003-2863-0496	Tier 1 Canada Research Chair in Knowledge Translation [Tier 1 - 2010-05-01]; CIHR/DSEN New Investigator Award in Knowledge Synthesis [201209]; Banting Postdoctoral Fellowship Program from the Canadian Institutes of Health Research (CIHR) [139157]; Tier 2 Canada Research Chair in Knowledge Synthesis [Tier 2 - 2016-07-01]	Tier 1 Canada Research Chair in Knowledge Translation; CIHR/DSEN New Investigator Award in Knowledge Synthesis; Banting Postdoctoral Fellowship Program from the Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Tier 2 Canada Research Chair in Knowledge Synthesis	We were commissioned to conduct this research for policy-makers from Health Canada through the Canadian Institutes of Health Research Drug Safety and Effectiveness Network Grant. SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation, Grant: Tier 1 - 2010-05-01 (http://www.chairs-chaires.gc.calchairholders-titulaires/profile-eng.aspx?profileld=2699). BH is supported by a CIHR/DSEN New Investigator Award in Knowledge Synthesis, Grant: New Investigator Salary Award - PA: Drug Safety and Effectiveness 201209. AAV is funded by the Banting Postdoctoral Fellowship Program from the Canadian Institutes of Health Research (CIHR), Grant: 139157 (htp://banting.fellowshps-bourses.gc.ca/en/2014-2015-eng.html). ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis, Grant: Tier 2 - 2016-07-01 (http://www.chairs-chaires.gc.cathairholders-titulares/profile-eng.aspx?profileld=3706). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, GLOB UPD HLTH SECT R; [Anonymous], 2012, EVIDENCE SYNTHESIS D; Beckerman K AJ, 2009, AIDS 2010 18 INT AID; Boer K, 2007, BJOG-INT J OBSTET GY, V114, P148, DOI 10.1111/j.1471-0528.2006.01183.x; Cameron C, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0133-0; Canadian Agency for Drugs and Technologies in Health (CADTH), 2015, GREY MATT PRACT TOOL; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; de Lemos LMD, 2012, REV SOC BRAS MED TRO, V45, P682, DOI 10.1590/S0037-86822012000600005; Efthimiou O, 2017, STAT MED; European AIDS Clinical Society, 2011, TREATM HIV PREGN WOM, V6; European AIDS Clinical Society, 2016, EUR AIDS CLIN SOC GU; Floridia M, 2013, BJOG-INT J OBSTET GY, V120, P1466, DOI 10.1111/1471-0528.12285; Ford N, 2014, AIDS, V28, pS123, DOI 10.1097/QAD.0000000000000231; Ford N, 2010, AIDS, V24, P2645, DOI 10.1097/QAD.0b013e32833ec5b2; Hempel S, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-107; Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jansen JP, 2014, VALUE HEALTH, V17, P157, DOI 10.1016/j.jval.2014.01.004; Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159; Jao J, 2014, PEDIATR INFECT DIS J, V33, P734, DOI 10.1097/INF.0000000000000224; Kanters S, 2016, LANCET HIV, V3, pE510, DOI 10.1016/S2352-3018(16)30091-1; Kirkham JJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009810; Loutfy MR, 2012, INT J GYNECOL OBSTET, V119, P89, DOI 10.1016/j.ijgo.2012.06.004; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lunn D, 2009, STAT MED, V28, P3049, DOI 10.1002/sim.3680; Marczynska M, 2000, SCAND J INFECT DIS, V32, P165, DOI 10.1080/003655400750045277; Mesfin YM, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0149-5; Money D vSJ, 2007, CAN J INFECT DIS SB, V18, p31B; Palmer T.M., 2016, METAANALYSIS STATA U; Panel on Treatment of HIV Infected Pregnant Women and Prevention of Perinatal Transmission, 2016, REC US ANT DRUGS PRE; Patel K, 2010, J INFECT DIS, V201, P1035, DOI 10.1086/651232; Phiri K, 2014, PEDIATR INFECT DIS J, V33, P741, DOI 10.1097/INF.0000000000000251; Registry Antiretroviral Pregnancy, 2014, PER HIV GUID WORK GR; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Rosenblad A., 2009, INT STAT REV, V77, P478, DOI DOI 10.1111/J.1751-5823.2009.00095_15.X; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Salanti G, 2009, J CLIN EPIDEMIOL, V62, P857, DOI 10.1016/j.jclinepi.2008.10.001; Sampson M, 2009, J CLIN EPIDEMIOL, V62, P944, DOI 10.1016/j.jclinepi.2008.10.012; Schmitz S, 2013, STAT MED, V32, P2935, DOI 10.1002/sim.5764; Schulte J, 2007, PEDIATRICS, V119, pE900, DOI 10.1542/peds.2006-1123; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; Siegfried N, 1996, COCHRANE DATABASE SY; Siegfried N vdML, 2011, ANTIRETROVIRALS REDU; Simon T, 2002, Zentralbl Gynakol, V124, P413, DOI 10.1055/s-2002-38125; Soler-Palacin P, 2012, AIDS RES HUM RETROV, V28, P752, DOI [10.1089/aid.2011.0198, 10.1089/AID.2011.0198]; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Sturt AS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008440; Torpey K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042859; Tricco AC, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-51; Vannappagari V, 2013, PHARMACOEPIDEMIOLOGY; Veroniki A, 2018, OPEN SCI FRAMEWORK; Veroniki AA, 2016, J CLIN EPIDEMIOL, V76, P193, DOI 10.1016/j.jclinepi.2016.02.016; Veroniki AA, 2013, INT J EPIDEMIOL, V42, P332, DOI 10.1093/ije/dys222; Wang LM, 2013, CLIN INFECT DIS, V57, P1773, DOI 10.1093/cid/cit601; White A, 1997, ACTA PAEDIATR, V86, P86; White IR, 2012, RES SYNTH METHODS, V3, P111, DOI 10.1002/jrsm.1045; Williams PL, 2015, JAMA PEDIATR, V169, P48, DOI 10.1001/jamapediatrics.2014.1889; World Health Organization, 2014, GLOB SUMM HIV AIDS E; Zuccotti GV, 1999, ACTA PAEDIATR, V88, P1298, DOI 10.1080/080352599750030491	62	14	14	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2018	13	6							e0198447	10.1371/journal.pone.0198447	http://dx.doi.org/10.1371/journal.pone.0198447			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ6XV	29912896	Green Submitted, Green Published, gold			2023-01-03	WOS:000435528600029
J	Park, J; Soh, DH; Singh, D; Lee, S; Lee, JS; Lee, CH				Park, Jinyong; Soh, Dong Ho; Singh, Digar; Lee, Sarah; Lee, Jong Seok; Lee, Choong Hwan			Systematic metabolic profiling and bioactivity assays for bioconversion of Aceraceae family	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; ANTIOXIDANT ACTIVITY; ASPERGILLUS-ORYZAE; SECONDARY METABOLITES; FERMENTATION; MS/MS; BIOTRANSFORMATION; IDENTIFICATION; EXTRACTION; COMPONENTS	Plants are an important and inexhaustible source of bioactive molecules in food, medicine, agriculture, and industry. In this study, we performed systematic liquid chromatography mass spectrometry (LC-MS)-based metabolic profiling coupled with antioxidant assays for indigenous plant family extracts. Partial least-squares discriminant analysis of LC-MS data sets for the extracts of 34 plant species belonging to the families Aceraceae, Asteraceae, and Rosaceae showed that these species were clustered according to their respective phylogenies. In particular, seven Aceraceae species were clearly demarcated with higher average antioxidant activities, rationalizing their application for bioconversion studies. On the basis of further evaluation of the interspecies variability of metabolic profiles and antioxidant activities among Aceraceae family plants, we found that Acer tataricum (TA) extracts were clearly distinguished from those of other species, with a higher relative abundance of tannin derivatives. Further, we detected a strong positive correlation between most tannin derivatives and the observed higher antioxidant activities. Following Aspergillus oryzae-mediated fermentative bioconversion of Acerplant extracts, we observed a time-correlated (0-8 days) linear increase in antioxidant phenotypes for all species, with TA having the highest activity. Temporal analysis of the MS data revealed tannin bioconversion mechanisms with a relatively higher abundance of gallic acid (m/z 169) accumulated at the end of 8 days, particularly in TA. Similarly, quercetin precursor (glycoside) metabolites were also transformed to quercetin aglycones (m/z 301) in most Acerplant extracts. The present study underscores the efficacy of fermentative bioconversion strategies aimed at enhancing the quality and availability of bioactive metabolites from plant extracts.	[Park, Jinyong; Soh, Dong Ho; Singh, Digar; Lee, Choong Hwan] Konkuk Univ, Dept Biosci & Biotechnol, Seoul, South Korea; [Lee, Sarah; Lee, Jong Seok] Natl Inst Biol Resources, Environm Res Complex, Incheon, South Korea	Konkuk University; National Institute of Biological Resources	Lee, CH (corresponding author), Konkuk Univ, Dept Biosci & Biotechnol, Seoul, South Korea.	chlee123@konkuk.ac.kr			Konkuk University	Konkuk University	This paper was supported by Konkuk University in 2016.	Abdel-Nabey M. A., 2011, Biotechnology, V10, P149; Abu-Reidah IM, 2015, FOOD CHEM, V166, P179, DOI 10.1016/j.foodchem.2014.06.011; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Bessada SMP, 2015, IND CROP PROD, V76, P604, DOI 10.1016/j.indcrop.2015.07.073; Bi W, 2016, J ETHNOPHARMACOL, V189, P31, DOI 10.1016/j.jep.2016.04.021; Chan EWL, 2014, PHYTOCHEMISTRY, V107, P148, DOI 10.1016/j.phytochem.2014.07.028; Cheng L, 2009, J CHROMATOGR A, V1216, P4859, DOI 10.1016/j.chroma.2009.04.031; Choudhary RK, 2011, NAT PROD RES, V25, P1101, DOI 10.1080/14786419.2010.498372; Dall'Asta M, 2012, NUTRITION, V28, P197, DOI 10.1016/j.nut.2011.06.005; de Brito ES, 2007, FOOD CHEM, V105, P1112, DOI 10.1016/j.foodchem.2007.02.009; De Jong P., 1994, MAPLES OF THE WORLD; Dietz BM, 2005, CHEM RES TOXICOL, V18, P1296, DOI 10.1021/tx050058x; Duenas M, 2005, J SCI FOOD AGR, V85, P297, DOI 10.1002/jsfa.1924; Farag MA, 2015, PHYTOCHEMISTRY, V119, P41, DOI 10.1016/j.phytochem.2015.09.004; Gallage NJ, 2015, MOL PLANT, V8, P40, DOI 10.1016/j.molp.2014.11.008; Gruz J, 2008, FOOD CHEM, V111, P789, DOI 10.1016/j.foodchem.2008.05.014; Gu DY, 2013, PHYTOCHEM ANALYSIS, V24, P661, DOI 10.1002/pca.2451; Hasani-Ranjbar S, 2009, WORLD J GASTROENTERO, V15, P3073, DOI 10.3748/wjg.15.3073; He Z, 2007, FOOD CHEM, V105, P1307, DOI 10.1016/j.foodchem.2007.04.049; Hossain MK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040569; Hur SJ, 2014, FOOD CHEM, V160, P346, DOI 10.1016/j.foodchem.2014.03.112; John KMM, 2013, FOOD RES INT, V54, P487, DOI 10.1016/j.foodres.2013.07.045; Kim MJ, 2013, FOOD RES INT, V53, P670, DOI 10.1016/j.foodres.2012.12.053; Lee M, 2015, J AGR FOOD CHEM, V63, P6102, DOI 10.1021/acs.jafc.5b01730; Lee S, 2014, BIOSCI BIOTECH BIOCH, V78, P167, DOI 10.1080/09168451.2014.877827; Li H, 2017, PEERJ, V5, DOI 10.7717/peerj.3264; Martins S, 2011, BIOTECHNOL ADV, V29, P365, DOI 10.1016/j.biotechadv.2011.01.008; Meyers KJ, 2006, J AGR FOOD CHEM, V54, P7686, DOI 10.1021/jf061264t; Huynh NT, 2016, BIOCHEM ENG J, V116, P27, DOI 10.1016/j.bej.2015.12.005; Rajak RC, 2017, BIOCATAL BIOTRANSFOR, V35, P27, DOI 10.1080/10242422.2016.1278210; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Schaab MR, 2006, BIOCHEMISTRY-US, V45, P1009, DOI 10.1021/bi051571c; Singh HB, 2010, BIORESOURCE TECHNOL, V101, P6444, DOI 10.1016/j.biortech.2010.03.057; Son SY, 2016, PLANT CELL REP, V35, P1917, DOI 10.1007/s00299-016-2006-y; Suh DH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149022; Tohma H, 2016, ANTIOXIDANTS-BASEL, V5, DOI 10.3390/antiox5040038; Tomas-Barberan FA, 2001, J AGR FOOD CHEM, V49, P4748, DOI 10.1021/jf0104681; Truchado P, 2011, J CHROMATOGR A, V1218, P7601, DOI 10.1016/j.chroma.2011.07.049; Wu QX, 2006, NAT PROD REP, V23, P699, DOI 10.1039/b606168k; Zhang CZ, 2007, PROCESS BIOCHEM, V42, P83, DOI 10.1016/j.procbio.2006.07.019; Zheng ZX, 2000, J AGR FOOD CHEM, V48, P895, DOI 10.1021/jf990972u; Zhou JW, 2014, CURR OPIN BIOTECH, V25, P17, DOI 10.1016/j.copbio.2013.08.009	42	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198739	10.1371/journal.pone.0198739	http://dx.doi.org/10.1371/journal.pone.0198739			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879203	Green Submitted, Green Published, gold			2023-01-03	WOS:000434384900078
J	Lo, B				Lo, Bernard			Beyond Legalization - Dilemmas Physicians Confront Regarding Aid in Dying	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ASSISTED SUICIDE; OREGON DEATH; DIGNITY ACT; EXPERIENCES; ATTITUDES; EUTHANASIA; LIFE; END		[Lo, Bernard] Greenwall Fdn, New York, NY 10119 USA		Lo, B (corresponding author), Greenwall Fdn, New York, NY 10119 USA.							Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Quill TE, 2016, JAMA-J AM MED ASSOC, V315, P245, DOI 10.1001/jama.2015.16210	5	16	16	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2018	378	22					2060	2062		10.1056/NEJMp1802218	http://dx.doi.org/10.1056/NEJMp1802218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH5AL	29847753				2023-01-03	WOS:000433428000002
J	Hahn-Goldberg, S; Jeffs, L; Troup, A; Kubba, R; Okrainec, K				Hahn-Goldberg, Shoshana; Jeffs, Lianne; Troup, Amy; Kubba, Rasha; Okrainec, Karen			"We are doing it together"; The integral role of caregivers in a patients' transition home from the medicine unit	PLOS ONE			English	Article							QUALITATIVE DATA-ANALYSIS; DISCHARGE INSTRUCTIONS; CARE TRANSITIONS; FAMILY-MEMBERS; HEART-FAILURE; PERSPECTIVES; EXPERIENCES; DISEASE; COMPREHENSION; INFORMATION	Background An admission to hospital for acute illness can be difficult for patients and lead to high levels of anxiety. Patients are given a lot of information throughout their hospital stay and instructions at discharge to follow when they get home. For complex medical patients, the ability to retain, understand, and adhere to these instructions is a critical marker of a successful transition. This study was undertaken to explore factors impacting the ability of patients to understand and adhere to instructions. Methods A qualitative design of interviews with patients and caregivers was used. Participants were adult patients and caregivers with congestive heart failure, chronic obstructive pulmonary disease, or community-acquired pneumonia being discharged home from three academic acute care hospitals in Ontario, Canada. Semi structured interviews were conducted with participants within one week following their discharge from hospital. Interviews were audio-taped and transcribed. Five independent researchers participated in an iterative process of coding, reviewing, and analyzing the interviews using direct content analysis. Results In total, 27 participants completed qualitative interviews. Analysis revealed the role of the caregiver to be critical in its relation to the ability of patients to understand and adhere to discharge instructions. Within the topic of caregiving, we draw on three areas of insight: The first clarified how caregivers support patients after they are discharged home from the hospital. The second highlighted how caregiver involvement impacts patient understanding and adherence to discharge instructions. The third revealed system factors that influence a caregiver's involvement when receiving discharge instructions. Conclusion Caregivers play an important role in the transition of a complex medical patient by impacting a patient's ability to understand and adhere to their discharge instructions. The themes identified in this paper highlight opportunities for healthcare providers and institutions to effectively involve caregivers during transitions from acute care hospitals to home.	[Hahn-Goldberg, Shoshana; Troup, Amy; Kubba, Rasha] Univ Hlth Network, OpenLab, Toronto, ON, Canada; [Hahn-Goldberg, Shoshana] Yok Univ, Sch Hlth Policy & Management, Toronto, ON, Canada; [Jeffs, Lianne] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Okrainec, Karen] Univ Hlth Network, Toronto, ON, Canada; [Okrainec, Karen] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Hahn-Goldberg, S (corresponding author), Univ Hlth Network, OpenLab, Toronto, ON, Canada.; Hahn-Goldberg, S (corresponding author), Yok Univ, Sch Hlth Policy & Management, Toronto, ON, Canada.	Shoshana.Hahn-Goldberg@uhn.ca	Okrainec, Karen/ABB-1447-2020; Jeffs, Lianne P/U-9147-2018	, Shoshana/0000-0002-7016-5295; Okrainec, Karen/0000-0003-0754-1830	Toronto General Hospital Foundation	Toronto General Hospital Foundation	The Donald J Mathews Fund from Toronto General Hospital Foundation provided some financial support for this work. The funding group had no role in design, conduct, or implementation of the study or manuscript.	Albrecht JS, 2014, J GEN INTERN MED, V29, P1491, DOI 10.1007/s11606-014-2956-0; ANDERSON JL, 1979, RHEUMATOL REHABIL, V18, P18, DOI 10.1093/rheumatology/18.1.18; Basit TN, 2003, EDUC RES-UK, V45, P143, DOI 10.1080/0013188032000133548; Blair J, 2014, J CARDIOVASC NURS, V29, P29, DOI 10.1097/JCN.0b013e3182784123; Bragstad LK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-331; Bull MJ, 2000, APPL NURS RES, V13, P76, DOI 10.1016/S0897-1897(00)80004-X; Chapin RK, 2014, SOC WORK HEALTH CARE, V53, P311, DOI 10.1080/00981389.2014.884037; CHPCA, 2004, VOIC HLTH POL ROL IN, P9; Coleman EA, 2004, J AM GERIATR SOC, V52, P1817, DOI 10.1111/j.1532-5415.2004.52504.x; Connolly M, 2009, J CLIN NURS, V18, P549, DOI 10.1111/j.1365-2702.2008.02551.x; Cowie MR, 2014, ESC HEART FAIL, V1, P110, DOI 10.1002/ehf2.12021; Dossa A, 2012, REHABIL NURS, V37, P277, DOI 10.1002/rnj.047; Dyrstad DN, 2015, J CLIN NURS, V24, P1693, DOI 10.1111/jocn.12773; Farmer SA, 2016, MAYO CLIN PROC, V91, P1056, DOI 10.1016/j.mayocp.2016.05.016; Farrell M, 2016, HSFR UPDATE FUTURE D; Ford BK, 2016, HEALTH SOC WORK, V41, P129, DOI 10.1093/hsw/hlw009; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Foust JB, 2012, WESTERN J NURS RES, V34, P194, DOI 10.1177/0193945911400448; Hahn-Goldberg S, 2016, HEALTHCARE Q, V19; Hahn-Goldberg S, 2015, J HOSP MED, V10, P804, DOI 10.1002/jhm.2444; Heng K. W. J., 2007, SMJ Singapore Medical Journal, V48, P1107; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hwang Stephen W, 2005, BMC Fam Pract, V6, P26, DOI 10.1186/1471-2296-6-26; Jack B, 2013, REENGINEERED DISCHAR; Jeffs L, 2017, WOLDVIEWS EVIDENCE B, V00, P1; Jeffs L, 2014, J INTERPROF CARE, V28, P507, DOI 10.3109/13561820.2014.923988; Jeffs L, 2012, PATIENT PREFER ADHER, V6, P711, DOI 10.2147/PPA.S36797; Kessels RPC, 2003, J ROY SOC MED, V96, P219, DOI 10.1258/jrsm.96.5.219; Kwan JL, 2015, J HOSP MED, V10, P799, DOI 10.1002/jhm.2442; Leech NL, 2007, SCHOOL PSYCHOL QUART, V22, P557, DOI 10.1037/1045-3830.22.4.557; Mosca L, 2011, J CARDIOVASC NURS, V26, P305, DOI 10.1097/JCN.0b013e3181f34bb3; Okrainec K, 2016, IMPACT PATIENT CTR D; Okrainec K, 2017, J HOSP MED, V12, P110, DOI 10.12788/jhm.2692; Ontario Ministry of Health and Long Term Care, HLTH SYST FUND REF; Powers BJ, 2010, JAMA-J AM MED ASSOC, V304, P76, DOI 10.1001/jama.2010.896; Priest Helena, 2002, Nurse Res, V10, P30; Sharma A, 2017, INTERN EMERG MED, V12, P789, DOI 10.1007/s11739-017-1654-4; Shyu YIL, 2008, J CLIN NURS, V17, P2497, DOI 10.1111/j.1365-2702.2008.02450.x; SPANDORFER JM, 1995, ANN EMERG MED, V25, P71, DOI 10.1016/S0196-0644(95)70358-6; Takemura M, 2011, INT J CHRONIC OBSTR, V6, P97, DOI 10.2147/COPD.S16173	40	31	32	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197831	10.1371/journal.pone.0197831	http://dx.doi.org/10.1371/journal.pone.0197831			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GH0HY	29795623	Green Published, Green Submitted, gold			2023-01-03	WOS:000433084300075
J	Adewuyi, EO; Auta, A; Khanal, V; Bamidele, OD; Akuoko, CP; Adefemi, K; Tapshak, SJ; Zhao, Y				Adewuyi, Emmanuel Olorunleke; Auta, Asa; Khanal, Vishnu; Bamidele, Olasunkanmi David; Akuoko, Cynthia Pomaa; Adefemi, Kazeem; Tapshak, Samson Joseph; Zhao, Yun			Prevalence and factors associated with underutilization of antenatal care services in Nigeria: A comparative study of rural and urban residences based on the 2013 Nigeria demographic and health survey	PLOS ONE			English	Article							MATERNAL MORTALITY; NEONATAL-MORTALITY; RISK-FACTORS; FACILITY; MODEL	Introduction Antenatal care (ANC) is a major public health intervention aimed at ensuring safe pregnancy outcomes. In Nigeria, the recommended minimum of four times ANC attendance is underutilized. This study investigates the prevalence and factors associated with underutilization of ANC services with a focus on the differences between rural and urban residences in Nigeria. Methods We analyzed the 2013 Nigeria Demographic and Health Survey dataset with adjustment for the sampling weight and the cluster design of the survey. The prevalence of underutilization of ANC was assessed using frequency tabulation while associated factors were examined using Chi-Square test and multivariable logistic regression analysis. Results The prevalence of underutilization of ANC was 46.5% in Nigeria, 61.1% in rural residence and 22.4% in urban residence. The North-West region had the highest prevalence of ANC underuse in Nigeria at 69.3%, 76.6% and 44.8% for the overall, rural and urban residences respectively. Factors associated with greater odds of ANC underuse in rural residence were maternal non-working status, birth interval < 24 months, single birth type, not listening to radio at all, lack of companionship to health facility and not getting money for health services. In urban residence, mothers professing Islam, those who did not read newspaper at all, and those who lacked health insurance, had greater odds of ANC underuse. In both rural and urban residence, maternal and husband's education level, region of residence, wealth index, maternal age, frequency of watching television, distance to- and permission to visit health facility were significantly associated with ANC underuse. Conclusions Rural-urban differences exist in the use of ANC services, and to varying degrees, factors associated with underuse of ANC in Nigeria. Interventions aimed at addressing factors identified in this study may help to improve the utilization of ANC services both in rural and urban Nigeria. Such interventions need to focus more on reducing socioeconomic, geographic and regional disparities in access to ANC in Nigeria.	[Adewuyi, Emmanuel Olorunleke] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Stat & Genom Epidemiol Lab, Brisbane, Qld, Australia; [Auta, Asa] Univ Cent Lancashire, Sch Pharm & Biomed Sci, Preston, Lancs, England; [Khanal, Vishnu] Nepal Dev Soc, Butwal, Nepal; [Bamidele, Olasunkanmi David] Obafemi Awolowo Univ, Fac Pharm, Drug Res & Prod Unit, Ife, Osun State, Nigeria; [Akuoko, Cynthia Pomaa] Queensland Univ Technol, Fac Hlth, Sch Nursing, Brisbane, Qld, Australia; [Adefemi, Kazeem] Hlth & Social Relief Initiat, Ilorin, Kwara State, Nigeria; [Tapshak, Samson Joseph] Chivar Specialist Hosp, Dept Obstet & Gynaecol, Abuja, Nigeria; [Tapshak, Samson Joseph] Urol Ctr LTD, Abuja, Nigeria; [Zhao, Yun] Curtin Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bentley Campus, Perth, WA, Australia	Queensland University of Technology (QUT); University of Central Lancashire; Obafemi Awolowo University; Queensland University of Technology (QUT); Curtin University	Adewuyi, EO (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Stat & Genom Epidemiol Lab, Brisbane, Qld, Australia.	Emmanuel.adewuyi@qut.edu.au	Akuoko, Cynthia/W-1519-2019; Adewuyi, Emmanuel O/H-9568-2019; Khanal, Vishnu/AAE-5948-2020	Akuoko, Cynthia/0000-0002-3661-8625; Adewuyi, Emmanuel O/0000-0002-4533-0340; Khanal, Vishnu/0000-0002-3863-9913; Auta, Asa/0000-0001-6515-5802	Queensland University of Technology	Queensland University of Technology	The Queensland University of Technology supported this paper financially by providing article publication charge sponsorship. The fund for publication has no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Abegunde D, 2015, INT J GYNECOL OBSTET, V128, P251, DOI 10.1016/j.ijgo.2014.09.029; Acharya Dilaram, 2015, BMC Res Notes, V8, P345, DOI 10.1186/s13104-015-1312-8; Adewuyi EO, 2017, SCAND J PUBLIC HEALT, V45, P675, DOI 10.1177/1403494817705562; Adewuyi EO, 2017, PEDIATR INT, V59, P190, DOI 10.1111/ped.13086; Adewuyi EO, 2017, SCAND J PUBLIC HEALT, V45, P543, DOI 10.1177/1403494817696599; Adewuyi EO, 2016, INT J COMMUN HLTH, V9, P109; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Babalola BI, 2014, AFRICAN POPULATION S, V28; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P93, DOI 10.4314/ejhs.v24i0.9S; Chen XK, 2007, AUST NZ J OBSTET GYN, V47, P122, DOI 10.1111/j.1479-828X.2007.00697.x; Dahiru T, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.321.6527; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dowswell T, 2010, COCHRANE DATABASE SY, P10; Eweje Gabriel, 2007, Managerial Law, V49, P218, DOI 10.1108/03090550710841340; Fagbamigbe AF, 2017, HEALTH CARE WOMEN IN, V38, P17, DOI 10.1080/07399332.2016.1225743; Fagbamigbe AF, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0527-y; Federal Ministry of Health, 2011, SAV NEWB LIV NIG NEW, V2; Ghana Statistical Service (GSS) GHSG and ICF International, 2015, GHAN DEM HLTH SURV 2; Gupta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101893; Hosseinpoor AR, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001727; Ijadunola KT, 2007, J HEALTH POPUL NUTR, V25, P94; Khanal V, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0646-5; Maine D, 1999, AM J PUBLIC HEALTH, V89, P480, DOI 10.2105/AJPH.89.4.480; Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5; Mugo NS, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0491-6; National Collaborating Centre for Women's and Children's Health, 2008, ANT CAR ROUT CAR HLT; National Population Commission (NPC) [Nigeria] and ICF International, 2014, NIG DEM HLTH SURV 20; Raatikainen K, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-268; Saad-Haddad G, 2016, J GLOB HEALTH, V6, DOI [10.7189/Jogh.06.010404, 10.7189/jogh.06.010404]; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Sinai I, 2017, AFR J REPROD HEALTH, V21, P96, DOI 10.29063/ajrh2017/v21i2.11; Solanke BL, 2015, AFRICAN POPULATION S, V29, P1868; Titaley CR, BMC PUBLIC; UNICEF, 2014, COMM CHILD SURV PROM; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; West BT, 2008, J TRAUMA STRESS, V21, P440, DOI 10.1002/jts.20356; World Health Organization, 2005, WORLD HLTH REPORT 20; World Health Organization, 2011, WHO STAT ANT CAR; World Health Organization, 2014, MON PROGR UN HLTH CO	41	76	76	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2018	13	5							e0197324	10.1371/journal.pone.0197324	http://dx.doi.org/10.1371/journal.pone.0197324			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GG2QJ	29782511	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000432537100019
J	Shepherd, ES; DeLoache, WC; Pruss, KM; Whitaker, WR; Sonnenburg, JL				Shepherd, Elizabeth Stanley; DeLoache, William C.; Pruss, Kali M.; Whitaker, Weston R.; Sonnenburg, Justin L.			An exclusive metabolic niche enables strain engraftment in the gut microbiota	NATURE			English	Article							BACTERIAL SYMBIONT; FECAL MICROBIOTA; COLONIZATION; SPECIFICITY; INTESTINE	The dense microbial ecosystem in the gut is intimately connected to numerous facets of human biology, and manipulation of the gut microbiota has broad implications for human health. In the absence of profound perturbation, the bacterial strains that reside within an individual are mostly stable over time(1). By contrast, the fate of exogenous commensal and probiotic strains applied to an established microbiota is variable, generally unpredictable and greatly influenced by the background microbiota(2,3). Therefore, analysis of the factors that govern strain engraftment and abundance is of critical importance to the emerging field of microbiome reprogramming. Here we generate an exclusive metabolic niche in mice via administration of a marine polysaccharide, porphyran, and an exogenous Bacteroides strain harbouring a rare gene cluster for porphyran utilization. Privileged nutrient access enables reliable engraftment of the exogenous strain at predictable abundances in mice harbouring diverse communities of gut microbes. This targeted dietary support is sufficient to overcome priority exclusion by an isogenic strain(4), and enables strain replacement. We demonstrate transfer of the 60-kb porphyran utilization locus into a naive strain of Bacteroides, and show finely tuned control of strain abundance in the mouse gut across multiple orders of magnitude by varying porphyran dosage. Finally, we show that this system enables the introduction of a new strain into the colonic crypt ecosystem. These data highlight the influence of nutrient availability in shaping microbiota membership, expand the ability to perform a broad spectrum of investigations in the context of a complex microbiota, and have implications for cell-based therapeutic strategies in the gut.	[Shepherd, Elizabeth Stanley; Pruss, Kali M.; Sonnenburg, Justin L.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; [Shepherd, Elizabeth Stanley; DeLoache, William C.; Whitaker, Weston R.] Novome Biotechnol, San Francisco, CA USA	Stanford University	Sonnenburg, JL (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA.	jsonnenburg@stanford.edu			National Science Foundation [1648230]; NIDDK [R01-DK085025]; NSF [DGE-114747]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085025] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank N. Ratnayeke for early experimental assistance, S. Higginbottom for gnotobiotic assistance, and K. Ng, Z. Russ and W. Van Treuren for analytical assistance; the Amieva and Huang laboratories for use of their microscopy resources, and D. Shepherd for valuable discussions; N. Pudlo and E. Martens for the protocol on porphyran extraction, and E. Sonnenburg, T. Fukami and M. Fischbach for commenting on this manuscript. This material is based upon work supported by the National Science Foundation under grant number 1648230, the NIDDK (R01-DK085025 to J.L.S.) and an NSF Graduate Fellowship (DGE-114747 to E.S.S.).	Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chandran S, 2017, METHODS MOL BIOL, V1472, P187, DOI 10.1007/978-1-4939-6343-0_14; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; DRAKE JA, 1991, AM NAT, V137, P1, DOI 10.1086/285143; Ericsson AC, 2017, FRONT MICROBIOL, V8, P1, DOI 10.3389/fmicb.2017.00196; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Frese S.A., 2012, ADV MICROBIOL-IRVINE, V02, P399, DOI DOI 10.4236/AIM.2012.23051; Fukami T, 2015, ANNU REV ECOL EVOL S, V46, P1, DOI 10.1146/annurev-ecolsys-110411-160340; Hehemann JH, 2012, P NATL ACAD SCI USA, V109, P19786, DOI 10.1073/pnas.1211002109; Hehemann JH, 2010, NATURE, V464, P908, DOI 10.1038/nature08937; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Landy J, 2015, SCI REP-UK, V5, DOI 10.1038/srep12955; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Lee SM, 2013, NATURE, V501, P426, DOI 10.1038/nature12447; Maldonado-Gomez MX, 2016, CELL HOST MICROBE, V20, P515, DOI 10.1016/j.chom.2016.09.001; Martens EC, 2008, CELL HOST MICROBE, V4, P447, DOI 10.1016/j.chom.2008.09.007; Ostrov N, 2016, SCIENCE, V353, P819, DOI 10.1126/science.aaf3639; Ratner M, 2016, NAT BIOTECHNOL, V34, P1004, DOI 10.1038/nbt1016-1004b; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Sonnenburg ED, 2016, NATURE, V529, P212, DOI 10.1038/nature16504; Sonnenburg ED, 2010, CELL, V141, P1241, DOI 10.1016/j.cell.2010.05.005; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Stecher B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000711; Whitaker WR, 2017, CELL, V169, P538, DOI 10.1016/j.cell.2017.03.041; Xu J, 2007, PLOS BIOL, V5, P1574, DOI 10.1371/journal.pbio.0050156	27	155	159	16	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 17	2018	557	7705					434	+		10.1038/s41586-018-0092-4	http://dx.doi.org/10.1038/s41586-018-0092-4			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF8SB	29743671	Green Accepted			2023-01-03	WOS:000432242000062
J	Rozenberg, K; Rosenzweig, T				Rozenberg, Konstantin; Rosenzweig, Tovit			Sarcopoterium spinosum extract improved insulin sensitivity in mice models of glucose intolerance and diabetes	PLOS ONE			English	Article							HIGH-FAT-DIET; MEDICINAL-PLANTS; NONALCOHOLIC STEATOHEPATITIS; ETHNOBOTANICAL SURVEY; GENETIC ARCHITECTURE; SKELETAL-MUSCLE; OBESITY; RESISTANCE; MECHANISMS; COMPLICATIONS	Background The glucose lowering properties of Sarcopoterium spinosum, a traditional medicinal plant, were previously validated by us using KK-Ay mice as a genetic model for type 2 diabetes (T2D). Objective To clarify the effects of Sarcopoterium spinosum extract (SSE) on diet-induced glucose intolerance and to investigate SSE effects on carbohydrate and lipid metabolism in target tissues of both high-fat-diet (HFD)-fed and KK-Ay mice. Results Mice were given SSE (70 mg/day) for 6 weeks. SSE improved glucose tolerance and insulin sensitivity in HFD-fed mice as was demonstrated previously in KK-Ay mice. Higher insulin sensitivity was validated by lower serum insulin and activation of the insulin signaling cascade in skeletal muscle and liver of SSE-treated mice in both models. H&E staining of the livers demonstrated lower severity of steatosis in SSE-treated mice. Several model-specific effects of SSE were observed-mRNA expression of proinflammatory genes and CD36 was reduced in SSE-treated KK-Ay mice. Hepatic mRNA expression of PEPCK was also reduced in SSE-treated KK-Ay mice, while other genes involved in carbohydrates and lipid metabolism were not affected. HFD-fed mice treated by SSE had elevated hepatic glycogen stores. Gluconeogenic gene expression was not affected, while GCK expression was increased. HFD-induced hepatic steatosis was not affected by SSE. However, while genes involved in lipid metabolism were downregulated by HFD, this was not found in HFD-fed mice given SSE, demonstrating an expression profile which is similar to that of standard diet-fed mice. Conclusion Our study supports the insulin sensitizing activity of SSE and suggests that this extract might improve other manifestations of the metabolic syndrome.	[Rosenzweig, Tovit] Ariel Univ, Dept Mol Biol, Ariel, Israel; Ariel Univ, Dept Nutr Studies, Ariel, Israel	Ariel University; Ariel University	Rosenzweig, T (corresponding author), Ariel Univ, Dept Mol Biol, Ariel, Israel.	tovitro@ariel.ac.il	Rosenzweig, Tovit/AAG-4216-2019	Rosenzweig, Tovit/0000-0002-1706-0136	Israeli Ministry of Agriculture and Rural Development; Diabest botanical Drug Ltd.	Israeli Ministry of Agriculture and Rural Development; Diabest botanical Drug Ltd.	This work was supported by the Israeli Ministry of Agriculture and Rural Development and Diabest botanical Drug Ltd. which provided research materials in addition to financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Qura'n S, 2009, J ETHNOPHARMACOL, V123, P45, DOI 10.1016/j.jep.2009.02.031; Ali-Shtayeh MS, 2000, J ETHNOPHARMACOL, V73, P221, DOI 10.1016/S0378-8741(00)00316-0; Bachrach ZY, 2007, ISR J PLANT SCI, V55, P111, DOI 10.1560/IJPS.55.1.111; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; Bhupathiraju SN, 2016, CIRC RES, V118, P1723, DOI 10.1161/CIRCRESAHA.115.306825; Buechler C, 2011, WORLD J GASTROENTERO, V17, P2801, DOI 10.3748/wjg.v17.i23.2801; Centers for Disease C Prevention, 2004, MMWR MORB MORTAL WKL, V53, P1066; Chamorro-Garcia R, 2014, CURR OPIN PHARMACOL, V19, P153, DOI 10.1016/j.coph.2014.10.010; Chaturvedi N, 2007, DIABETES RES CLIN PR, V76, pS3, DOI 10.1016/j.diabres.2007.01.019; Claeson P, 2014, J ETHNOPHARMACOL, V158, P463, DOI 10.1016/j.jep.2014.07.017; DAFNI A, 1984, J ETHNOPHARMACOL, V10, P295, DOI 10.1016/0378-8741(84)90017-5; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Elyasiyan U, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1860-7; Franks PW, 2016, SCIENCE, V354, P69, DOI 10.1126/science.aaf5094; Guo SD, 2014, J ENDOCRINOL, V220, pT1, DOI 10.1530/JOE-13-0327; Heo HS, 2013, MOL CELLS, V36, P25, DOI 10.1007/s10059-013-2336-3; Huang MA, 2005, AM J GASTROENTEROL, V100, P1072, DOI 10.1111/j.1572-0241.2005.41334.x; Hung HY, 2012, NAT PROD REP, V29, P580, DOI 10.1039/c2np00074a; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kaser S, 2005, GUT, V54, P117, DOI 10.1136/gut.2003.037010; Khunti K, 2010, DIABETES OBES METAB, V12, P474, DOI 10.1111/j.1463-1326.2009.01186.x; Labaronne E, 2017, J NUTR BIOCHEM, V45, P83, DOI 10.1016/j.jnutbio.2017.04.001; Lake A, 2006, J R SOC PROMO HEALTH, V126, P262, DOI 10.1177/1466424006070487; Lam DW, 2012, CURR OPIN ENDOCRINOL, V19, P93, DOI 10.1097/MED.0b013e328350583a; Lu BB, 2014, DIABETES, V63, P2935, DOI 10.2337/db13-1531; Mahajan A, 2014, NAT GENET, V46, P234, DOI 10.1038/ng.2897; Marles RJ, 1995, PHYTOMEDICINE, V2, P137, DOI 10.1016/S0944-7113(11)80059-0; Mishra A, 2012, J CLIN EXP HEPATOL, V2, P135, DOI 10.1016/S0973-6883(12)60102-9; Mohlke KL, 2015, HUM MOL GENET, V24, pR85, DOI 10.1093/hmg/ddv264; Montgomery MK, 2013, DIABETOLOGIA, V56, P1129, DOI 10.1007/s00125-013-2846-8; Muoio DM, 2008, NAT REV MOL CELL BIO, V9, P193, DOI 10.1038/nrm2327; Nascimento EBM, 2006, DIABETES, V55, P3221, DOI 10.2337/db05-1390; Osei-Assibey G, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001538; Prabhakar PK, 2008, CURR DIABETES REV, V4, P291, DOI 10.2174/157339908786241124; Qi Lu, 2012, Curr Nutr Rep, V1, P222; Ravussin E, 2000, EUR J PHARMACOL, V410, P131, DOI 10.1016/S0014-2999(00)00811-6; Rozenberg K, 2014, J ETHNOPHARMACOL; Samad A, 2009, CURR DIABETES REV, V5, P102, DOI 10.2174/157339909788166837; Sampson SR, 2010, APOPTOSIS, V15, P1165, DOI 10.1007/s10495-010-0517-5; Shanik MH, 2008, DIABETES CARE, V31, pS262, DOI 10.2337/dc08-s264; Smirin P, 2010, J ETHNOPHARMACOL, V129, P10, DOI 10.1016/j.jep.2010.02.021; Sonntag D, 2015, NUTRIENTS, V7, P8565, DOI 10.3390/nu7105414; Tumova J, 2016, PHYSIOL RES, V65, P193, DOI 10.33549/physiolres.932993; Vida M, 2015, DIS MODEL MECH, V8, P721, DOI 10.1242/dmm.019166; Ye Jianping, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P65	46	13	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0196736	10.1371/journal.pone.0196736	http://dx.doi.org/10.1371/journal.pone.0196736			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF9WG	29768504	gold, Green Published, Green Submitted			2023-01-03	WOS:000432329200044
J	Binnewies, M; Roberts, EW; Kersten, K; Chan, V; Fearon, DF; Merad, M; Coussens, LM; Gabrilovich, DI; Ostrand-Rosenberg, S; Hedrick, CC; Vonderheide, RH; Pittet, MJ; Jain, RK; Zou, WP; Howcroft, TK; Woodhouse, EC; Weinberg, RA; Krummel, MF				Binnewies, Mikhail; Roberts, Edward W.; Kersten, Kelly; Chan, Vincent; Fearon, Douglas F.; Merad, Miriam; Coussens, Lisa M.; Gabrilovich, Dmitry I.; Ostrand-Rosenberg, Suzanne; Hedrick, Catherine C.; Vonderheide, Robert H.; Pittet, Mikael J.; Jain, Rakesh K.; Zou, Weiping; Howcroft, T. Kevin; Woodhouse, Elisa C.; Weinberg, Robert A.; Krummel, Matthew F.			Understanding the tumor immune microenvironment (TIME) for effective therapy	NATURE MEDICINE			English	Review							TERTIARY LYMPHOID STRUCTURES; T-CELL DYSFUNCTION; BREAST-CANCER; DENDRITIC CELLS; COLORECTAL-CANCER; MACROPHAGE ACTIVATION; MOLECULAR SUBTYPES; PANCREATIC-CANCER; LABORATORY MICE; PROMOTES	The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen pronounced clinical response with immunotherapeutic intervention; however, many more patients have experienced minimal or no clinical benefit when provided the same treatment. As technology has advanced, so has the understanding of the complexity and diversity of the immune context of the tumor microenvironment and its influence on response to therapy. It has been possible to identify different subclasses of immune environment that have an influence on tumor initiation and response and therapy; by parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient's tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.	[Binnewies, Mikhail; Roberts, Edward W.; Kersten, Kelly; Krummel, Matthew F.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Chan, Vincent; Krummel, Matthew F.] Univ Calif San Francisco, UCSF Immunoprofiler Initiat, San Francisco, CA 94143 USA; [Fearon, Douglas F.] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA; [Merad, Miriam] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Coussens, Lisa M.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Gabrilovich, Dmitry I.] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA; [Ostrand-Rosenberg, Suzanne] Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21228 USA; [Ostrand-Rosenberg, Suzanne] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Ostrand-Rosenberg, Suzanne] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Hedrick, Catherine C.] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA USA; [Vonderheide, Robert H.] Univ Penn, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Pittet, Mikael J.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA; [Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs Tumor Biol, Boston, MA 02114 USA; [Jain, Rakesh K.] Harvard Med Sch, Boston, MA USA; [Zou, Weiping] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI USA; [Howcroft, T. Kevin; Woodhouse, Elisa C.] NCI, Div Canc Biol, NIH, Bethesda, MD 20892 USA; [Weinberg, Robert A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory; Icahn School of Medicine at Mount Sinai; Oregon Health & Science University; The Wistar Institute; University System of Maryland; University of Maryland Baltimore County; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; La Jolla Institute for Immunology; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Massachusetts Institute of Technology (MIT); Whitehead Institute	Krummel, MF (corresponding author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.; Krummel, MF (corresponding author), Univ Calif San Francisco, UCSF Immunoprofiler Initiat, San Francisco, CA 94143 USA.; Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu; matthew.krummel@ucsf.edu	Gabrilovich, Dmitry/ABE-7122-2020; Jain, Rakesh K/I-1384-2017; Coussens, Lisa/ABH-9834-2020; Pittet, Mikael/ABD-6300-2021	Jain, Rakesh K/0000-0001-7571-3548; Ostrand-Rosenberg, Suzanne/0000-0002-2095-9732; Roberts, Edward/0000-0002-8229-1715	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA190400, R01CA206890, R01CA173861, R01CA202987, R35CA197743, P01CA080124, R01CA211016, P30CA010815, R01CA208205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114787] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA211016, R01 CA208205, R01 CA190400, R01 CA202987, R35 CA197743, P30 CA010815, P01 CA080124, R01 CA173861, R01 CA206890] Funding Source: Medline; NIAID NIH HHS [R01 AI114787] Funding Source: Medline; NICHD NIH HHS [T32 HD007470] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21; Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010; Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Boland PM, 2017, CANCERS, V9, DOI 10.3390/cancers9050050; Bonavita E, 2015, CELL, V160, P700, DOI 10.1016/j.cell.2015.01.004; Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Casbon AJ, 2015, P NATL ACAD SCI USA, V112, pE566, DOI 10.1073/pnas.1424927112; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47; Cortez-Retamozo V, 2013, IMMUNITY, V38, P296, DOI 10.1016/j.immuni.2012.10.015; Daley D, 2017, NAT MED, V23, P556, DOI 10.1038/nm.4314; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Di Biase S, 2016, CANCER CELL, V30, P136, DOI 10.1016/j.ccell.2016.06.005; DuPage M, 2011, CANCER CELL, V19, P72, DOI 10.1016/j.ccr.2010.11.011; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Engblom C, 2017, SCIENCE, V358, DOI 10.1126/science.aal5081; Evans RA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88328; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Flint TR, 2016, CELL METAB, V24, P672, DOI 10.1016/j.cmet.2016.10.010; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Garbe AI, 2006, CANCER RES, V66, P508, DOI 10.1158/0008-5472.CAN-05-2383; Gatalica Z, 2014, CANCER EPIDEM BIOMAR, V23, P2965, DOI 10.1158/1055-9965.EPI-14-0654; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Hale M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118784; Hanna RN, 2015, SCIENCE, V350, P985, DOI 10.1126/science.aac9407; Headley MB, 2016, NATURE, V531, P513, DOI 10.1038/nature16985; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067; Julia V, 2015, NAT REV IMMUNOL, V15, P308, DOI 10.1038/nri3830; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Khalili JS, 2012, CLIN CANCER RES, V18, P5329, DOI 10.1158/1078-0432.CCR-12-1632; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Koelwyn GJ, 2017, NAT REV CANCER, V17, P620, DOI 10.1038/nrc.2017.78; Kokolus KM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00023; Kokolus KM, 2013, P NATL ACAD SCI USA, V110, P20176, DOI 10.1073/pnas.1304291110; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kumar V, 2017, CANCER CELL, V32, P654, DOI 10.1016/j.ccell.2017.10.005; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Lee HJ, 2016, J CLIN PATHOL, V69, P422, DOI 10.1136/jclinpath-2015-203089; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Lutz ER, 2014, CANCER IMMUNOL RES, V2, P616, DOI 10.1158/2326-6066.CIR-14-0027; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Neyt K, 2012, TRENDS IMMUNOL, V33, P297, DOI 10.1016/j.it.2012.04.006; Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pucci F, 2016, CELL REP, V17, P1764, DOI 10.1016/j.celrep.2016.10.031; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Ruhland MK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11762; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Sanchez-Paulete AR, 2016, CANCER DISCOV, V6, P71, DOI 10.1158/2159-8290.CD-15-0510; Sautes-Fridman C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00407; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2016, INT IMMUNOL, V28, P383, DOI 10.1093/intimm/dxw014; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Svoronos N, 2017, CANCER DISCOV, V7, P72, DOI 10.1158/2159-8290.CD-16-0502; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Thompson MG, 2017, CANCER IMMUNOL IMMUN, V66, P615, DOI 10.1007/s00262-017-1972-4; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Verschoor CP, 2013, J LEUKOCYTE BIOL, V93, P633, DOI 10.1189/jlb.0912461; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Waight JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027690; Wang A, 2016, CELL, V166, P1512, DOI 10.1016/j.cell.2016.07.026; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014	111	2047	2091	159	1204	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2018	24	5					541	550		10.1038/s41591-018-0014-x	http://dx.doi.org/10.1038/s41591-018-0014-x			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GF7CY	29686425	Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000432126800009
J	Dittrich, N; Agostino, D; Philippe, RA; Guglielmo, LGA; Place, N				Dittrich, Naiandra; Agostino, Daniel; Philippe, Roberta Antonini; Guglielmo, Luiz Guilherme A.; Place, Nicolas			Effect of hypnotic suggestion on knee extensor neuromuscular properties in resting and fatigued states	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; INTERVAL INTRACORTICAL INHIBITION; CORTICOCORTICAL INHIBITION; HYPNOSIS; PERFORMANCE; EXCITABILITY; CONTRACTIONS; EXERCISE; MUSCLE; SUSCEPTIBILITY	Purpose The aim of this study was to investigate whether hypnotic suggestions can alter knee extensor neuromuscular function at rest and during exercise. Methods Thirteen healthy volunteers (8 men and 5 women, 27 +/- 3 years old) took part in this counterbalanced, crossover study including two experimental (hypnosis and control) sessions. Knee extensor neuromuscular function was tested before and after hypnosis suggestion by using a combination of voluntary contraction, transcutaneous femoral nerve electrical stimulation and transcranial magnetic stimulation (TMS). A fatiguing exercise (sustained submaximal contraction at 20% maximal voluntary contraction (MVC) force) was also performed to evaluate the potential influence of hypnosis on the extent and origin of neuromuscular adjustments. Results Hypnosis did not (p>0.05) alter MVC force or knee extensor neural properties. Corticospinal excitability, assessed with the amplitude of knee extensor motor evoked potentials, was also unchanged (p>0.05), as was the level of intracortical inhibition assessed with paired pulse TMS (short-interval intracortical inhibition, SICI). Time to task failure (similar to 300 s) was not different (p>0.05) between the two sessions; accordingly, hypnosis did not influence neuromuscular adjustments measured during exercise and at task failure (p>0.05). Conclusion Hypnotic suggestions did not alter neuromuscular properties of the knee extensor muscles under resting condition or during/after exercise, suggesting that hypnosis-induced improvement in exercise performance and enhanced corticospinal excitability might be limited to highly susceptible participants.	[Dittrich, Naiandra; Guglielmo, Luiz Guilherme A.] Univ Fed Santa Catarina, Sports Ctr, Phys Effort Lab, Florianopolis, SC, Brazil; [Dittrich, Naiandra; Agostino, Daniel; Place, Nicolas] Univ Lausanne, Fac Biol & Med, Inst Sport Sci, Lausanne, Switzerland; [Philippe, Roberta Antonini] Univ Lausanne, Fac Social & Polit Sci, Inst Sport Sci, Lausanne, Switzerland	Universidade Federal de Santa Catarina (UFSC); University of Lausanne; University of Lausanne	Place, N (corresponding author), Univ Lausanne, Fac Biol & Med, Inst Sport Sci, Lausanne, Switzerland.	nicolas.place@unil.ch	Guglielmo, Luiz Guilherme GA Antonacci/I-1160-2015; Place, Nicolas/B-3416-2018	Guglielmo, Luiz Guilherme GA Antonacci/0000-0001-6757-5050; Place, Nicolas/0000-0001-9044-0621; Antonini Philippe, Roberta/0000-0001-9650-5174	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), Brazil [99999.006368/2015-08]; PDSE (Programa de Doutorado Sanduiche) program	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); PDSE (Programa de Doutorado Sanduiche) program	This study was supported by grants and fellowship from CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; process N. 99999.006368/2015-08), Brazil. Part of this study was supported by the PDSE (Programa de Doutorado Sanduiche) program.	Bioy A, 2010, EUR J CLIN HYPN, V10, P2; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Chen R, 1998, J NEUROPHYSIOL, V80, P2870, DOI 10.1152/jn.1998.80.6.2870; Crawford HJ., 1991, 5 INT C PSYCH BUD; Facco E, 2013, ANAESTHESIA, V68, P961, DOI 10.1111/anae.12251; Gandevia SC, 2001, PHYSIOL REV, V81, P1725, DOI 10.1152/physrev.2001.81.4.1725; Green JP, 2005, INT J CLIN EXP HYP, V53, P259, DOI 10.1080/00207140590961321; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; HILGARD ER, 1961, PSYCHOL MONOGR, V75, P1; Hoeft F, 2012, ARCH GEN PSYCHIAT, V69, P1064, DOI 10.1001/archgenpsychiatry.2011.2190; Hunter SK, 2016, EXP BRAIN RES, V234, P2541, DOI 10.1007/s00221-016-4658-9; Iglesias A, 2011, AM J CLIN HYPN, V53, P183, DOI 10.1080/00029157.2011.10401756; IKAI M, 1961, J APPL PHYSIOL, V16, P157, DOI 10.1152/jappl.1961.16.1.157; Kihlstrom JF, 2013, CORTEX, V49, P365, DOI 10.1016/j.cortex.2012.05.016; Kittelson AJ, 2014, EXP BRAIN RES, V232, P3991, DOI 10.1007/s00221-014-4079-6; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Liggett DR, 2000, AM J CLIN HYPN, V43, P149, DOI 10.1080/00029157.2000.10404267; McNeil CJ, 2011, J PHYSIOL-LONDON, V589, P3533, DOI 10.1113/jphysiol.2011.207191; Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045; Moran TE, 2002, AM J CLIN HYPN, V44, P221, DOI 10.1080/00029157.2002.10403482; Neyroud D, 2013, J APPL PHYSIOL, V114, P1426, DOI 10.1152/japplphysiol.01539.2012; Neyroud D, 2012, MED SCI SPORT EXER, V44, P1243, DOI 10.1249/MSS.0b013e318245cc4d; Nicholls AR., 2005, ATHL INSIGHT, V7, P43; O'Leary TJ, 2015, MUSCLE NERVE, V52, P605, DOI 10.1002/mus.24584; Oakley DA, 2007, INT J CLIN EXP HYP, V55, P32, DOI 10.1080/00207140600995844; Pates J, 2002, SPORT PSYCHOL, V16, P34, DOI 10.1123/tsp.16.1.34; Patterson DR, 2003, PSYCHOL BULL, V129, P495, DOI 10.1037/0033-2909.129.4.495; RIDDING MC, 1995, J PHYSIOL-LONDON, V487, P541, DOI 10.1113/jphysiol.1995.sp020898; Robazza C, 1995, PERCEPT MOTOR SKILL, V81, P1364, DOI 10.2466/pms.1995.81.3f.1364; Rochette L, 2003, J APPL PHYSIOL, V95, P1515, DOI 10.1152/japplphysiol.00334.2003; Roshan L, 2003, EXP BRAIN RES, V151, P330, DOI 10.1007/s00221-003-1502-9; ROUSH ES, 1951, J APPL PHYSIOL, V3, P404, DOI 10.1152/jappl.1951.3.7.404; Sidhu SK, 2013, ACTA PHYSIOL, V207, P194, DOI 10.1111/apha.12004; Stevens-Lapsley JE, 2013, ARCH GERONTOL GERIAT, V56, P279, DOI 10.1016/j.archger.2012.06.017; Strojnik V, 1998, J APPL PHYSIOL, V84, P344, DOI 10.1152/jappl.1998.84.1.344; Takahashi K, 2011, BRAIN STIMUL, V4, P90, DOI 10.1016/j.brs.2010.07.001; Takarada Y, 2014, NEUROSCI RES, V85, P28, DOI 10.1016/j.neures.2014.05.009; Temesi J, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-40; Thomson AL, 2017, J POSIT PSYCHOL, V12, P628, DOI 10.1080/17439760.2016.1269184; Vanhaudenhuyse A, 2008, Rev Med Liege, V63, P424; Williams PS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093284; Williamson JW, 2001, J APPL PHYSIOL, V90, P1392, DOI 10.1152/jappl.2001.90.4.1392; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	43	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2018	13	4							e0195437	10.1371/journal.pone.0195437	http://dx.doi.org/10.1371/journal.pone.0195437			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD7AK	29684047	gold, Green Published			2023-01-03	WOS:000430660600014
J	Rodriguez, H; Pennington, SR				Rodriguez, Henry; Pennington, Stephen R.			Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing	CELL			English	Editorial Material							REPRODUCIBILITY	The integration of proteomics into precision oncology presents opportunities that may transform the molecular analysis of cancer and accelerate basic and clinical cancer research. This Commentary discusses the importance of international collaboration and data sharing inspired by the Cancer Moonshot to accelerate the progress of multi-omic precision medicine-an approach that addresses the global diversity of people and of cancers.	[Rodriguez, Henry] NCI, Off Canc Clin Prote Res, NIH, Bethesda, MD 20892 USA; [Pennington, Stephen R.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Sch Med, Belfield Dublin 4, Ireland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University College Dublin	Rodriguez, H (corresponding author), NCI, Off Canc Clin Prote Res, NIH, Bethesda, MD 20892 USA.	henry.rodriguez@nih.gov		Pennington, Stephen/0000-0001-7529-1015	Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Addona TA, 2009, NAT BIOTECHNOL, V27, P633, DOI 10.1038/nbt.1546; Blackhall F, 2006, LANCET ONCOL, V7, P499, DOI 10.1016/S1470-2045(06)70725-2; Carr SA, 2014, MOL CELL PROTEOMICS, V13, P907, DOI 10.1074/mcp.M113.036095; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Jaffe JD, 2004, PROTEOMICS, V4, P59, DOI 10.1002/pmic.200300511; Kennedy JJ, 2014, NAT METHODS, V11, P149, DOI [10.1038/nmeth.2763, 10.1038/NMETH.2763]; Kinsinger CR, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O111.015446; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Pegram M, 2000, SEMIN ONCOL, V27, P13; Regnier FE, 2010, CLIN CHEM, V56, P165, DOI 10.1373/clinchem.2009.140087; Tabb DL, 2010, J PROTEOME RES, V9, P761, DOI 10.1021/pr9006365; Whiteaker JR, 2014, NAT METHODS, V11, P703, DOI 10.1038/nmeth.3002; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069	15	42	42	2	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	2018	173	3					533	537		10.1016/j.cell.2018.04.008	http://dx.doi.org/10.1016/j.cell.2018.04.008			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GD7GB	29677503	Green Accepted, hybrid			2023-01-03	WOS:000430677400002
J	Mobley, CB; Haun, CT; Roberson, PA; Mumford, PW; Kephart, WC; Romero, MA; Osburn, SC; Vann, CG; Young, KC; Beck, DT; Martin, JS; Lockwood, CM; Roberts, MD				Mobley, Christopher B.; Haun, Cody T.; Roberson, Paul A.; Mumford, Petey W.; Kephart, Wesley C.; Romero, Matthew A.; Osburn, Shelby C.; Vann, Christopher G.; Young, Kaelin C.; Beck, Darren T.; Martin, Jeffrey S.; Lockwood, Christopher M.; Roberts, Michael D.			Biomarkers associated with low, moderate, and high vastus lateralis muscle hypertrophy following 12 weeks of resistance training	PLOS ONE			English	Article							SKELETAL-MUSCLE; MYOFIBER HYPERTROPHY; RIBOSOME BIOGENESIS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MYONUCLEAR ADDITION; EXERCISE; MYOSTATIN; TESTOSTERONE; HUMANS	We sought to identify biomarkers which delineated individual hypertrophic responses to resistance training. Untrained, college-aged males engaged in full-body resistance training (3 d/wk) for 12 weeks. Body composition via dual x-ray absorptiometry (DXA), vastus lateralis (VL) thickness via ultrasound, blood, VL muscle biopsies, and three-repetition maximum (3-RM) squat strength were obtained prior to (PRE) and following (POST) 12 weeks of training. K-means cluster analysis based on VL thickness changes identified LOW [n = 17; change (mean +/- SD) = +0.11 +/- 0.14 cm], modest (MOD; n = 29, +0.40 +/- 0.06 cm), and high (HI; n = 21, +0.69 +/- 0.14 cm) responders. Biomarkers related to histology, ribosome biogenesis, proteolysis, inflammation, and androgen signaling were analyzed between clusters. There were main effects of time (POST>PRE, p<0.05) but no cluster x time interactions for increases in DXA lean body mass, type I and II muscle fiber cross sectional area and myonuclear number, satellite cell number, and macronutrients consumed. Interestingly, PRE VL thickness was similar to 12% greater in LOW versus HI (p = 0.021), despite POST values being similar to 12% greater in HI versus LOW (p = 0.006). However there was only a weak correlation between PRE VL thickness scores and change in VL thickness (r(2) = 0.114, p = 0.005). Forced post hoc analysis indicated that muscle total RNA levels (i.e., ribosome density) did not significantly increase in the LOW cluster (351 +/- 70 ng/mg to 380 +/- 62, p = 0.253), but increased in the MOD (369 +/- 115 to 429 +/- 92, p = 0.009) and HI clusters (356 +/- 77 to 470 +/- 134, p<0.001; POST HI>POST LOW, p = 0.013). Nonetheless, there was only a weak association between change in muscle total RNA and VL thickness (r(2) = 0.079, p = 0.026). IL-1 beta mRNA levels decreased in the MOD and HI clusters following training (p<0.05), although associations between this marker and VL thickness changes were not significant (r(2) = 0.0002, p = 0.919). In conclusion, individuals with lower pre-training VL thickness values and greater increases muscle total RNA levels following 12 weeks of resistance training experienced greater VL muscle growth, although these biomarkers individually explained only similar to 8-11% of the variance in hypertrophy.	[Mobley, Christopher B.; Haun, Cody T.; Roberson, Paul A.; Mumford, Petey W.; Kephart, Wesley C.; Romero, Matthew A.; Osburn, Shelby C.; Vann, Christopher G.; Young, Kaelin C.; Beck, Darren T.; Martin, Jeffrey S.; Roberts, Michael D.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA; [Young, Kaelin C.; Beck, Darren T.; Martin, Jeffrey S.; Roberts, Michael D.] Edward Via Coll Osteopath Med, Dept Cell Biol & Physiol, Auburn Campus, Auburn, AL 36832 USA; [Lockwood, Christopher M.] Lockwood LLC, Draper, UT USA	Auburn University System; Auburn University	Roberts, MD (corresponding author), Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.; Roberts, MD (corresponding author), Edward Via Coll Osteopath Med, Dept Cell Biol & Physiol, Auburn Campus, Auburn, AL 36832 USA.	mdr0024@auburn.edu	Mumford, Petey/GLS-9565-2022; Mobley, Christopher/AAC-2123-2020; Lockwood, Chris/A-8136-2018	Lockwood, Chris/0000-0002-4002-4301; Mumford, Petey/0000-0002-4946-9702; Mobley, C. Brooks/0000-0002-4045-9962				Antonio J, 2015, J INT SOC SPORT NUTR, V12, DOI 10.1186/s12970-015-0100-0; Antonio J, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/1550-2783-11-19; Bamman MM, 2007, J APPL PHYSIOL, V102, P2232, DOI 10.1152/japplphysiol.00024.2007; Ben-Nissan G, 2014, BIOMOLECULES, V4, P862, DOI 10.3390/biom4030862; Chaillou T, 2014, J CELL PHYSIOL, V229, P1584, DOI 10.1002/jcp.24604; Dalbo VJ, 2013, EUR J NUTR, V52, P477, DOI 10.1007/s00394-012-0349-x; De Larichaudy J, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-2; Ferrando AA, 1998, AM J PHYSIOL-ENDOC M, V275, pE864; Figueiredo VC, 2015, AM J PHYSIOL-ENDOC M, V309, pE72, DOI 10.1152/ajpendo.00050.2015; Greiwe JS, 2001, FASEB J, V15, P475, DOI 10.1096/fj.00-0274com; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004; Haff G., 2016, ESSENTIALS STRENGTH; HAMMOND HK, 1992, AM J PHYSIOL, V263, pH1675, DOI 10.1152/ajpheart.1992.263.6.H1675; Hikim IS, 2002, AM J PHYSIOL-ENDOC M, V283, pE154, DOI 10.1152/ajpendo.00502.2001; Hulmi JJ, 2009, AMINO ACIDS, V37, P297, DOI 10.1007/s00726-008-0150-6; Jain AK, 2010, PATTERN RECOGN LETT, V31, P651, DOI 10.1016/j.patrec.2009.09.011; Kim JS, 2007, J APPL PHYSIOL, V103, P1488, DOI 10.1152/japplphysiol.01194.2006; Lambert CP, 2008, J APPL PHYSIOL, V105, P473, DOI 10.1152/japplphysiol.00006.2008; LEXELL J, 1983, MUSCLE NERVE, V6, P588, DOI 10.1002/mus.880060809; Louis E, 2007, J APPL PHYSIOL, V103, P1744, DOI 10.1152/japplphysiol.00679.2007; Mayhew DL, 2009, J APPL PHYSIOL, V107, P1655, DOI 10.1152/japplphysiol.91234.2008; McFarlane C, 2008, EXP CELL RES, V314, P317, DOI 10.1016/j.yexcr.2007.09.012; McGlory C, 2017, J APPL PHYSIOL, V122, P541, DOI 10.1152/japplphysiol.00613.2016; Menon MK, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-119; Mitchell CJ, 2015, J APPL PHYSIOL, V118, P495, DOI 10.1152/japplphysiol.00609.2014; Mitchell CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078636; Mobley CB, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090972; Munoz-Canoves P, 2013, FEBS J, V280, P4131, DOI 10.1111/febs.12338; Murton AJ, 2013, INT J BIOCHEM CELL B, V45, P2209, DOI 10.1016/j.biocel.2013.07.005; Nader GA, 2014, J PHYSIOL-LONDON, V592, P5143, DOI 10.1113/jphysiol.2014.284828; Pasiakos SM, 2014, IUBMB LIFE, V66, P478, DOI 10.1002/iub.1291; Percipalle P, 2006, EMBO REP, V7, P525, DOI 10.1038/sj.embor.7400657; Petrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007; Petrella JK, 2006, AM J PHYSIOL-ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006; Raj DSC, 2008, KIDNEY INT, V73, P1054, DOI 10.1038/ki.2008.21; Rhea MR, 2002, J STRENGTH COND RES, V16, P250, DOI 10.1519/00124278-200205000-00013; Schoenfeld BJ, 2013, J STRENGTH COND RES, V27, P1720, DOI 10.1519/JSC.0b013e31828ddd53; Sinha-Hikim I, 2003, AM J PHYSIOL-ENDOC M, V285, pE197, DOI 10.1152/ajpendo.00370.2002; Snijders T, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00283; Stec MJ, 2016, AM J PHYSIOL-ENDOC M, V310, pE652, DOI 10.1152/ajpendo.00486.2015; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Terzis G, 2008, EUR J APPL PHYSIOL, V102, P145, DOI 10.1007/s00421-007-0564-y; Thalacker-Mercer A, 2013, PHYSIOL GENOMICS, V45, P499, DOI 10.1152/physiolgenomics.00167.2012; Wang DT, 2014, INT IMMUNOPHARMACOL, V19, P206, DOI 10.1016/j.intimp.2014.02.002; Wen Y, 2016, EXERC SPORT SCI REV, V44, P110, DOI 10.1249/JES.0000000000000082; White JP, 2009, ACTA PHYSIOL, V197, P321, DOI 10.1111/j.1748-1716.2009.02029.x; Yang LX, 2013, MOL CELL BIOL, V33, P3835, DOI 10.1128/MCB.00476-13; Zamir O, 1992, Mediators Inflamm, V1, P247, DOI 10.1155/S0962935192000371	50	50	50	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0195203	10.1371/journal.pone.0195203	http://dx.doi.org/10.1371/journal.pone.0195203			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6TQ	29621305	Green Submitted, Green Published, gold			2023-01-03	WOS:000429206800049
J	Bach, PB				Bach, Peter B.			National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bach, Peter B.] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Bach, PB (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, 1275 York Ave, New York, NY 10021 USA.							[Anonymous], 2017, MED B; Bach PB, 2017, JAMA-J AM MED ASSOC, V318, P1861, DOI 10.1001/jama.2017.15218; Chambers JD, 2015, HEALTH AFFAIR, V34, P253, DOI 10.1377/hlthaff.2014.1123; Hernandez I, 2018, JAMA ONCOL, V4, P994, DOI 10.1001/jamaoncol.2018.0977; United Healthcare Medicare & Retirement, 2018, FORM REQ NAT COV DAT	5	16	17	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2018	379	15					1396	1398		10.1056/NEJMp1807382	http://dx.doi.org/10.1056/NEJMp1807382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GW4VQ	30110578				2023-01-03	WOS:000446923400002
J	Fukuma, S; Kimachi, M; Omae, K; Kataoka, Y; Yamazaki, H; Muto, M; Akizawa, T; Yanagita, M; Fukuhara, S				Fukuma, Shingo; Kimachi, Miho; Omae, Kenji; Kataoka, Yuki; Yamazaki, Hajime; Muto, Manabu; Akizawa, Tadao; Yanagita, Motoko; Fukuhara, Shunichi			Dialysis physicians' referral behaviors for hemodialysis patients suspected of having cancer: A vignette-based questionnaire study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; PRACTICE PATTERNS; AMERICAN-COLLEGE; URINARY-TRACT; DIAGNOSIS; KIDNEY; POPULATION; GUIDELINES; MANAGEMENT; OUTCOMES	Background Although cancer management in dialysis patients has become a commonly encountered issue, known as "onco-nephrology", few evidence-based clinical recommendations have been proposed. Here, we examined the variation in referral behaviors adopted by dialysis physicians on encountering dialysis patients with signs/symptoms suggestive of cancer. Methods We conducted a vignette-based study in August 2015. We sent a 14-page questionnaire to 191 dialysis physicians, including the representative dialysis facilities participating in a Japanese dialysis cohort (the Japan Dialysis Outcomes and Practice Patterns Study). Using vignette scenarios for respiratory, digestive, and urological areas, we assessed the referral behaviors (expert referral or not) adopted by dialysis physicians on encountering dialysis patients with symptoms suggestive of cancer. Each scenario contained three patient functional factors: age (60 or 75 years), performance status (PS 0 or 1), and cognitive dysfunction (absence or presence). We examined the association between physician factors, patient factors, and referral behaviors. Results We obtained 94 replies (response rate: 49.2%). For the respiratory scenarios, 38.3% and 51.9% of physicians reported watchful waiting when encountering bilateral and unilateral pleural effusion, respectively. In digestive and urologic scenarios, most physicians (>85%) selected expert referral. We detected differences in referral behaviors between scenarios with different cancer biological factors. However, we found consistency in referral behaviors within the same scenario, even with different patient functional factors (intra-class correlation coefficients within each scenario all >0.7). Conclusions Physicians' referral behaviors for dialysis patients suspected of having cancer vary for different cancer biological factors (probability of having cancer). However, the referral behaviors are similar for different patient functional factors (age, PS, and cognitive dysfunction).	[Fukuma, Shingo] Kyoto Univ, Grad Sch Med, Human Hlth Sci, Kyoto, Kyoto, Japan; [Kimachi, Miho; Kataoka, Yuki; Yamazaki, Hajime; Fukuhara, Shunichi] Kyoto Univ, Sch Publ Hlth, Dept Healthcare Epidemiol, Grad Sch Med, Kyoto, Kyoto, Japan; [Omae, Kenji] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence, Fukushima, Fukushima, Japan; [Kataoka, Yuki] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan; [Muto, Manabu] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Kyoto, Japan; [Akizawa, Tadao] Showa Univ, Dept Med, Div Nephrol, Sch Med, Tokyo, Tokyo, Japan; [Yanagita, Motoko] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Kyoto, Japan	Kyoto University; Kyoto University; Fukushima Medical University; Kyoto University; Showa University; Kyoto University	Fukuma, S (corresponding author), Kyoto Univ, Grad Sch Med, Human Hlth Sci, Kyoto, Kyoto, Japan.	fukuma.shingo.3m@kyoto-u.ac.jp	KATAOKA, Yuki/I-6026-2019; Fukuma, Shingo/S-6584-2019; Omae, Kenji/AAD-3200-2022; Yanagita, Motoko/AAJ-7731-2021; Omae, Kenji/H-8620-2019; KATAOKA, Yuki/GRR-4808-2022	KATAOKA, Yuki/0000-0001-7982-5213; Fukuma, Shingo/0000-0002-8379-8761; Omae, Kenji/0000-0003-0109-7425; Omae, Kenji/0000-0003-0109-7425; KATAOKA, Yuki/0000-0001-7982-5213; Yamazaki, Hajime/0000-0002-9034-4370; Yanagita, Motoko/0000-0002-0339-9008	scientific research grants from Kyowa Hakko Kirin Co. Ltd.	scientific research grants from Kyowa Hakko Kirin Co. Ltd.	This study is supported by scientific research grants from Kyowa Hakko Kirin Co. Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakirci T, 2007, TRANSPL P, V39, P889, DOI 10.1016/j.transproceed.2007.02.020; Baldwin LM, 2012, ANN INTERN MED, V156, P182, DOI 10.7326/0003-4819-156-3-201202070-00006; Bonsib SM, 2009, CLIN J AM SOC NEPHRO, V4, P1998, DOI 10.2215/CJN.02020309; Braun V., 2013, SUCCESSFUL QUALITATI; Butler AM, 2015, AM J KIDNEY DIS, V65, P763, DOI 10.1053/j.ajkd.2014.12.013; Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Cohen EP, 2015, AM J KIDNEY DIS, V66, P869, DOI 10.1053/j.ajkd.2015.04.042; Collins AJ, 2013, AM J KIDNEY DIS, V61, pE1, DOI 10.1053/j.ajkd.2012.11.031; Davis R, 2012, J UROLOGY, V188, P2473, DOI 10.1016/j.juro.2012.09.078; Detterbeck FC, 2013, CHEST, V143, p7S, DOI 10.1378/chest.12-2377; Erickson KF, 2017, AM J KIDNEY DIS, V69, P237, DOI 10.1053/j.ajkd.2016.08.033; Holley JL, 2007, CLIN J AM SOC NEPHRO, V2, P604, DOI 10.2215/CJN.03931106; Holley JL, 2000, SEMIN DIALYSIS, V13, P369, DOI 10.1046/j.1525-139x.2000.00101.x; Hooper C, 2010, THORAX, V65, P4, DOI 10.1136/thx.2010.136978; Janus N, 2013, ANN ONCOL, V24, P501, DOI 10.1093/annonc/mds344; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kimachi M, 2015, NEPHRON, V131, P123, DOI 10.1159/000438870; Krause R, 2012, ANTICANCER RES, V32, P391; Lin HF, 2012, NEPHROL DIAL TRANSPL, V27, P1585, DOI 10.1093/ndt/gfr464; Lin JS, 2016, JAMA-J AM MED ASSOC, V315, P2576, DOI 10.1001/jama.2016.3332; Lin MY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122856; Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1; Muller-Engelmann M, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-260; Nakama H, 1999, HEPATO-GASTROENTEROL, V46, P228; Nielsen M, 2016, ANN INTERN MED, V164, P488, DOI 10.7326/M15-1496; Provenzale D, 2015, J NATL COMPR CANC NE, V13, P959, DOI 10.6004/jnccn.2015.0116; Rivera MP, 2013, CHEST, V143, pE142, DOI 10.1378/chest.12-2353; Salahudeen AK, 2013, J AM SOC NEPHROL, V24, P26, DOI 10.1681/ASN.2012070690; Shebl FM, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-65; Stewart JH, 2003, J AM SOC NEPHROL, V14, P197, DOI 10.1097/01.ASN.0000039608.81046.81; Taneja S, 2007, CLIN J AM SOC NEPHRO, V2, P1008, DOI 10.2215/CJN.00310107; Vajdic CM, 2006, JAMA-J AM MED ASSOC, V296, P2823, DOI 10.1001/jama.296.23.2823; Wong G, 2009, J AM SOC NEPHROL, V20, P1341, DOI 10.1681/ASN.2008090998; Wong G, 2009, NEPHROL DIAL TRANSPL, V24, P2136, DOI 10.1093/ndt/gfp009; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x	36	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2018	13	8							e0202322	10.1371/journal.pone.0202322	http://dx.doi.org/10.1371/journal.pone.0202322			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ5PD	30110392	Green Published, Green Submitted, gold			2023-01-03	WOS:000441738000062
J	Ho, KT; Wang, X; Chen, L				Ho, Kiti; Wang, Xia; Chen, Lei			Reasons for parental withdrawal of care in a pediatric intensive care unit in China	PLOS ONE			English	Article							ACCESS	Background The past decade saw the establishment of pediatric intensive care units (PICU) across China. This occurred in the context of increasing private shares of medical costs. Payment schemes have not kept pace with the increased availability and demand. As a result a substantial number of parents, in the face of financial constraints, choose to withdraw the medical care of children even when recovery is expected. Objective We set out to describe the experience of one PICU in Changsha, an industrialized city near the center of the country with a population of 7.3 million. Results During the two-year period 883 patients were admitted to the PICU. One hundred one (11%) patients died during their hospital stay. Of these 69 (68%) died after parents elected to withdraw care. A large proportion (33 out of 69 48%) cited economic factors as a reason behind the decision. Compared with the non-withdrawal group the cases had lower disease severity at admission and on the day of death. On the day of death 34% in the withdrawal group had lower disease severity than at admission, showing clinical improvement. The mean hospital charge for the ICU stay was RMB35,000 (similar to$5600). Conclusion A substantial proportion of patients in a Chinese urban PICU died after parents chose to withdraw their care in the face of financial hardship, even while some were showing clinical improvement. The society has an obligation, and, likely, an economic incentive, to share this burden.	[Ho, Kiti; Chen, Lei] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Wang, Xia] Cent S Univ, Xiangya Sch Med, Dept Pediat, Changsha, Hunan, Peoples R China	Yale University; Central South University	Chen, L (corresponding author), Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.	Lei.chen@yale.edu						Du B, 2010, CRIT CARE, V14, DOI 10.1186/cc8222; Li Z, 2012, BMC PUBLIC HLTH S1, V12, P59; Meng Q, 2012, LANCET, V379, P805, DOI 10.1016/S0140-6736(12)60278-5; Ren XX., 2006, APPL CLIN PEDIAT, V21, P382; Wang HL, 2007, JAMA-J AM MED ASSOC, V298, P1928, DOI 10.1001/jama.298.16.1928; Wang XF, 2012, PEDIATR CARDIOL, V33, P677, DOI 10.1007/s00246-012-0177-z; Yip W, 2014, LANCET, V384, P805, DOI 10.1016/S0140-6736(14)61120-X; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1	8	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2018	13	7							e199419	10.1371/journal.pone.0199419	http://dx.doi.org/10.1371/journal.pone.0199419			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4AN	30044777	gold, Green Published, Green Submitted			2023-01-03	WOS:000439942500012
J	Huang, DT; Yealy, DM; Filbin, MR; Brown, AM; Chang, CCH; Doi, Y; Donnino, MW; Fine, J; Fine, MJ; Fischer, MA; Holst, JM; Hou, PC; Kellum, JA; Khan, F; Kurz, MC; Lotfipour, S; LoVecchio, F; Peck-Palmer, O; Pike, F; Prunty, H; Sherwin, RL; Southerland, L; Terndrup, T; Weissfeld, LA; Yabes, J; Angus, DC				Huang, D. T.; Yealy, D. M.; Filbin, M. R.; Brown, A. M.; Chang, C-C H.; Doi, Y.; Donnino, M. W.; Fine, J.; Fine, M. J.; Fischer, M. A.; Holst, J. M.; Hou, P. C.; Kellum, J. A.; Khan, F.; Kurz, M. C.; Lotfipour, S.; LoVecchio, F.; Peck-Palmer, Om; Pike, F.; Prunty, H.; Sherwin, R. L.; Southerland, L.; Terndrup, T.; Weissfeld, L. A.; Yabes, J.; Angus, D. C.		ProACT Investigators	Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; VENTILATOR-ASSOCIATED PNEUMONIA; INTENT-TO-TREAT; DISEASES-SOCIETY; HOSPITALIZED ADULTS; CLINICAL-PRACTICE; GUIDELINES; TRIALS; MANAGEMENT; DIAGNOSIS	BACKGROUND The effect of procalcitonin-guided use of antibiotics on treatment for suspected lower respiratory tract infection is unclear. METHODS In 14 U.S. hospitals with high adherence to quality measures for the treatment of pneumonia, we provided guidance for clinicians about national clinical practice recommendations for the treatment of lower respiratory tract infections and the interpretation of procalcitonin assays. We then randomly assigned patients who presented to the emergency department with a suspected lower respiratory tract infection and for whom the treating physician was uncertain whether antibiotic therapy was indicated to one of two groups: the procalcitonin group, in which the treating clinicians were provided with real-time initial (and serial, if the patient was hospitalized) procalcitonin assay results and an antibiotic use guideline with graded recommendations based on four tiers of procalcitonin levels, or the usual-care group. We hypothesized that within 30 days after enrollment the total antibiotic-days would be lower - and the percentage of patients with adverse outcomes would not be more than 4.5 percentage points higher - in the procalcitonin group than in the usual-care group. RESULTS A total of 1656 patients were included in the final analysis cohort (826 randomly assigned to the procalcitonin group and 830 to the usual-care group), of whom 782 (47.2%) were hospitalized and 984 (59.4%) received antibiotics within 30 days. The treating clinician received procalcitonin assay results for 792 of 826 patients (95.9%) in the procalcitonin group (median time from sample collection to assay result, 77 minutes) and for 18 of 830 patients (2.2%) in the usual-care group. In both groups, the procalcitonin-level tier was associated with the decision to prescribe antibiotics in the emergency department. There was no significant difference between the procalcitonin group and the usual-care group in antibiotic-days (mean, 4.2 and 4.3 days, respectively; difference, -0.05 day; 95% confidence interval (CI), -0.6 to 0.5; P=0.87) or the proportion of patients with adverse outcomes (11.7% (96 patients] and 13.1% (109 patients]; difference, -1.5 percentage points; 95% CI, -4.6 to 1.7; P<0.001 for noninferiority) within 30 days. CONCLUSIONS The provision of procalcitonin assay results, along with instructions on their interpretation, to emergency department and hospital-based clinicians did not result in less use of antibiotics than did usual care among patients with suspected lower respiratory tract infection.	[Huang, D. T.; Chang, C-C H.; Kellum, J. A.; Peck-Palmer, Om; Angus, D. C.] Univ Pittsburgh, CRISMA Clin Res Invest & Syst Modeling Acute Illn, Pittsburgh, PA 15261 USA; [Huang, D. T.; Kellum, J. A.; Peck-Palmer, Om; Angus, D. C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Huang, D. T.; Yealy, D. M.; Brown, A. M.; Prunty, H.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA; [Peck-Palmer, Om] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; [Huang, D. T.; Yealy, D. M.; Angus, D. C.] Univ Pittsburgh, MACRO Multidisciplinary Acute Care Res Org Ctr, Pittsburgh, PA 15261 USA; [Chang, C-C H.; Fine, M. J.; Yabes, J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA; [Doi, Y.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15261 USA; [Fine, M. J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA; [Filbin, M. R.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Donnino, M. W.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Hou, P. C.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA; [Fine, J.] Norwalk Hosp, Dept Emergency Med, Norwalk, CT 06856 USA; [Fischer, M. A.; Terndrup, T.] Penn State Milton S Hershey Med Ctr, Dept Emergency Med, Hershey, PA USA; [Holst, J. M.] Essentia Hlth, Dept Emergency Med, Duluth, MN USA; [Khan, F.] Univ Maryland, Med Ctr, Dept Emergency Med, Baltimore, MD 21201 USA; [Kurz, M. C.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham Hosp, Birmingham, AL USA; [Lotfipour, S.] Univ Calif Irvine, Med Ctr, Dept Emergency Med, Irvine, CA USA; [LoVecchio, F.] Maricopa Cty Gen Hosp, Dept Emergency Med, Phoenix, AZ USA; [Pike, F.] Eli Lilly, Indianapolis, IN USA; [Sherwin, R. L.] Detroit Receiving Hosp & Univ Hlth Ctr, Dept Emergency Med, Detroit, MI USA; [Southerland, L.; Terndrup, T.] Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA; [Weissfeld, L. A.] Stat Collaborat, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University System of Maryland; University of Maryland Baltimore; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Irvine; Maricopa County General Hospital; Eli Lilly; Detroit Receiving Hospital & University Health Center; University System of Ohio; Ohio State University	Huang, DT (corresponding author), Univ Pittsburgh, Scaife Hall,Rm 606B,3550 Terrace St, Pittsburgh, PA 15261 USA.	huangdt@upmc.edu	Angus, Derek C/E-9671-2012; Kellum, John A/HCH-2944-2022; Kellum, John/AAP-3072-2020	Kellum, John A/0000-0003-1995-2653; Kellum, John/0000-0003-1995-2653; Doi, Yohei/0000-0002-9620-2525; Huang, David/0000-0001-7649-1633; Southerland, Lauren/0000-0002-3561-8332; Suffoletto, Brian/0000-0002-9628-5260	National Institute of General Medical Sciences, National Institutes of Health [1R34GM102696-01, 1R01GM101197-01A1]; University of Pittsburgh School of Medicine Dean's Faculty Advancement Award; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R34GM102696, R01GM101197] Funding Source: NIH RePORTER	National Institute of General Medical Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); University of Pittsburgh School of Medicine Dean's Faculty Advancement Award; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institute of General Medical Sciences, National Institutes of Health (1R34GM102696-01 and 1R01GM101197-01A1). Procalcitonin assays and laboratory training were provided by bioMerieux. Dr. Peck-Palmer is a recipient of a University of Pittsburgh School of Medicine Dean's Faculty Advancement Award.	Antibiotic use in the United States, 2017, 2017 PROGR OPP; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Bang H, 2007, STAT MED, V26, P954, DOI 10.1002/sim.2663; Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Barley EA, 1998, RESP MED, V92, P1207, DOI 10.1016/S0954-6111(98)90423-1; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; Branche AR, 2015, J INFECT DIS, V212, P1692, DOI 10.1093/infdis/jiv252; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC; Cunha BA, 2009, SCAND J INFECT DIS, V41, P782, DOI 10.1080/00365540903147035; Department of Health and Human Services, 2010, COMM TERM CRIT ADV E; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Food and Drug Administration, 2016, DISC REC APPL PROC E; Gonzales R, 2000, ANN INTERN MED, V133, P981, DOI 10.7326/0003-4819-133-12-200012190-00014; Hasegawa K, 2016, CHEST, V149, P1021, DOI 10.1016/j.chest.2015.12.039; Huang DT, 2008, ANN EMERG MED, V52, P48, DOI 10.1016/j.annemergmed.2008.01.003; Huang DT, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0138-1; Jacobs DM, 2018, ANN AM THORAC SOC; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; Kim MY, 2010, J BIOPHARM STAT, V20, P745, DOI 10.1080/10543401003618157; Lindenauer PK, 2010, JAMA-J AM MED ASSOC, V303, P2359, DOI 10.1001/jama.2010.796; Linder JA, 2013, JAMA INTERN MED, V173, P273, DOI 10.1001/jamainternmed.2013.1984; Loymans RJB, 2011, CURR OPIN ALLERGY CL, V11, P181, DOI 10.1097/ACI.0b013e3283466f45; Luyt CE, 2005, AM J RESP CRIT CARE, V171, P48, DOI 10.1164/rccm.200406-746Oc; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; McDonagh M, 2016, COMP EFFECTIVENESS R; Muller B, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-10; Muller B, 2001, J CLIN ENDOCR METAB, V86, P396, DOI 10.1210/jc.86.1.396; Nathan C, 2014, NEW ENGL J MED, V371, P1761, DOI 10.1056/NEJMp1408040; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Institute for Health and Care Excellence, 2018, ASS COMM ACQ PNEUM; OKelly M, 2014, STAT PRACT, P1, DOI 10.1002/9781118762516; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Riedel S, 2012, CRIT CARE MED, V40, P2499, DOI 10.1097/CCM.0b013e318256b7da; Rubin D.B., 2004, MULTIPLE IMPUTATION, V81; Schuetz P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-102; Schuetz P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub3; Schuetz P, 2009, JAMA-J AM MED ASSOC, V302, P1059, DOI 10.1001/jama.2009.1297; Seymann GB, 2006, J HOSP MED, V1, P344, DOI 10.1002/jhm.128; Shorr AF, 2013, CLIN INFECT DIS, V57, P362, DOI 10.1093/cid/cit254; Spellberg B, 2016, JAMA INTERN MED, V176, P1254, DOI 10.1001/jamainternmed.2016.3646; Stolz D, 2009, EUR RESPIR J, V34, P1364, DOI 10.1183/09031936.00053209; Stolz D, 2007, CHEST, V131, P9, DOI 10.1378/chest.06-1500; Ten Have TR, 2008, PSYCHIAT ANN, V38, P772, DOI 10.3928/00485713-20081201-10; Tonkin-Crine SK, 2017, COCHRANE DB SYST REV, V9; Vogelmeier CF, 2017, EUR RESPIR J, V49, DOI [10.1183/13993003.00214-2017, 10.1111/resp.13012, 10.1016/j.arbres.2017.02.001, 10.1164/rccm.201701-0218PP]	49	210	220	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2018	379	3					236	249		10.1056/NEJMoa1802670	http://dx.doi.org/10.1056/NEJMoa1802670			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN5CX	29781385	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000439063900007
J	Ellis-Smith, C; Higginson, IJ; Daveson, BA; Henson, LA; Evans, CJ				Ellis-Smith, Clare; Higginson, Irene J.; Daveson, Barbara A.; Henson, Lesley A.; Evans, Catherine J.		BuildCARE	How can a measure improve assessment and management of symptoms and concerns for people with dementia in care homes? A mixed-methods feasibility and process evaluation of IPOS-Dem	PLOS ONE			English	Article							QUALITY-OF-LIFE; MINIMUM DATA SET; PALLIATIVE CARE; PAIN ASSESSMENT; OUTCOME MEASURE; NURSING-HOMES; OLDER-PEOPLE; END; PREVALENCE; COMMUNICATION	Background Assessment of people with dementia is challenging; with undetected and under treated symptoms and concerns resulting in avoidable distress, and few evidence-based interventions to support this. We aimed to understand the mechanisms of action of a measure to support comprehensive assessment of people with dementia in care homes; and its acceptability, feasibility, and implementation requirements. Methods A qualitative study with an embedded quantitative component in three residential care homes, underpinned by an initial theoretical model of mechanisms of action. The measure, the Integrated Palliative care Outcome Scale for Dementia (IPOS-Dem), was introduced into the care of residents with dementia for 12 weeks. Qualitative data comprised focus groups and semi-structured interviews with family, care home staff, general practitioners and district nurses; and non-participant observations. Quantitative data comprised IPOS-Dem data. Directed content analysis for qualitative data, and descriptive statistics were used for quantitative data. Findings Key mechanisms of action were: improved observation and awareness of residents, collaborative assessment, comprehensive 'picture of the person', systematic record keeping, improved review and monitoring, care planning and changes to care provision, and facilitated multi-agency communication. Potential benefit included improved symptom management, improved comprehensive care, and increased family empowerment and engagement. IPOS-Dem was found to be acceptable and feasible. It was perceived as quick and easy to use, with proportion of overall missing data decreasing from 2.1% to 1.1% from baseline to final time points. 'Trust' in the measure was important; and leadership essential to ensure integration into care processes. Conclusions In a population with complex care needs, with challenges to assessment and barriers to multi-agency working, a measure introduced into routine care is feasible and acceptable, and supports assessment and management of symptoms and concerns. A refined theoretical model demonstrating the likely mechanisms of action was developed. Further evaluation is required to test its effectiveness.	[Ellis-Smith, Clare; Higginson, Irene J.; Daveson, Barbara A.; Henson, Lesley A.; Evans, Catherine J.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London, England; [Higginson, Irene J.] Kings Coll Hosp NHS Fdn Trust, London, England; [Evans, Catherine J.] Sussex Community NHS Fdn Trust, Brighton, E Sussex, England	University of London; King's College London; King's College Hospital NHS Foundation Trust	Ellis-Smith, C (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London, England.	alexandra.c.ellis-smith@kcl.ac.uk	Daveson, Barbara/AAO-5876-2021; Evans, Catherine J/AAS-4121-2020; Higginson, Irene Julie/C-7309-2012	Daveson, Barbara/0000-0001-8039-8749; Evans, Catherine J/0000-0003-0034-7402; Henson, Lesley/0000-0003-4799-7365; Ellis-Smith, Clare/0000-0003-3453-3203; Higginson, Irene Julie/0000-0002-3687-1313	Cicely Saunders International; Atlantic Philanthropies; Health Education England (HEE)/National Institute for Health Research (NIHR); NIHR Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust; South London and Maudsley NHS Foundation Trust Older Adults Service User and Carer Advisory Group (SUCAG); Cicely Saunders International (CSI)	Cicely Saunders International; Atlantic Philanthropies; Health Education England (HEE)/National Institute for Health Research (NIHR); NIHR Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust; South London and Maudsley NHS Foundation Trust Older Adults Service User and Carer Advisory Group (SUCAG); Cicely Saunders International (CSI)	This study was mainly funded by Cicely Saunders International (https://cicelysaundersinternational.org/) and The Atlantic Philanthropies (http://www.atlanticphilanthropies.org/). C.J.E. is funded by Health Education England (HEE)/National Institute for Health Research (NIHR) Senior Clinical Lectureship; I.J.H. is an NIHR Senior Investigator Emeritus. I.J.H. is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.; The authors would like to thank all residents, family and staff for participation in the study; and all staff at the participating centres for support in recruiting and conducting the study. The authors thank South London and Maudsley NHS Foundation Trust Older Adults Service User and Carer Advisory Group (SUCAG), Gill Peters as an expert through experience, and Caty Pannell, research nurse for their contribution and study support. BuildCARE is supported by Cicely Saunders International (CSI) and The Atlantic Philanthropies, led by King's College London, Cicely Saunders Institute, Department of Palliative Care, Policy & Rehabilitation, UK. CI: Higginson. Grant leads: Higginson, McCrone, Normand, Lawlor, Meier, Morrison. Project Co-ordinator/ PI: Daveson. Study arm PIs: Pantilat, Selman, Normand, Ryan, McQuillan, Morrison, Daveson. We thank all collaborators & advisors including service-users. BuildCARE members: Emma Bennett, Francesca Cooper, Barbara A Daveson, Susanne de Wolf-Linder, Mendwas Dzingina, Clare Ellis-Smith, Catherine J Evans, Lesley Henson, Irene J Higginson, Bridget Johnston, Paramjote Kaler, Pauline Kane, Lara Klass, Peter Lawlor, Paul McCrone, Regina McQuillan, Diane Meier, Susan Molony, Sean Morrison, Fliss E Murtagh, Charles Normand, Caty Pannell, Steve Pantilat, Karen Ryan, Lucy Selman, Melinda Smith, Katy Tobin, Gao Wei.	[Anonymous], 2005, MENT CAP ACT; [Anonymous], 1995, NEW APPROACHES EVALU; Antunes B, 2013, PALLIAT MED; Bebbington A, 2001, CARE HOMES OLDER PEO, V2; Bloor M., 2001, FOCUS GROUPS SOCIAL, DOI DOI 10.4135/9781849209175; Care Quality Commission, 2016, CAR QUAL COMM CAR HO; Cicely Saunders Institute, 2012, PALLIATIVE CARE OUTC; Cohen-Mansfield J, 1996, Int Psychogeriatr, V8, P233, DOI 10.1017/S104161029600261X; Collins ES, 2015, J PAIN SYMPTOM MANAG; Corp IBM, IBM SPSS STAT WIND V; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Creswell J. W., 2018, DESIGNING CONDUCTING, V3rd; Davies SL, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-320; De Silva MJ, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-267; Detmar SB, 2002, JAMA-J AM MED ASSOC, V288, P3027, DOI 10.1001/jama.288.23.3027; Dunckley M, 2005, INT J PALLIAT NURS, V11, P218, DOI 10.12968/ijpn.2005.11.5.218; Ellis-Smith C, 2016, 14 WORLD C EUR ASS P; Ellis-Smith C, 2017, PALLIATIVE MED, V31, P651, DOI 10.1177/0269216316675096; Ellis-Smith C, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0582-x; Etkind SN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0860-2; Etkind SN, 2015, J PAIN SYMPTOM MANAG, V49, P611, DOI 10.1016/j.jpainsymman.2014.07.010; Fuchs-Lacelle S, 2008, CLIN J PAIN, V24, P697, DOI 10.1097/AJP.0b013e318172625a; Gage H, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-71; Goodman C., 2013, STUDY DEV INTEGRATED; Goodman C, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1493-4; Goodman C, 2015, J AM MED DIR ASSOC, V16, P427, DOI 10.1016/j.jamda.2015.01.072; Goodman C, 2011, AGING MENT HEALTH, V15, P475, DOI 10.1080/13607863.2010.543659; Goodman C, 2010, INT J GERIATR PSYCH, V25, P329, DOI 10.1002/gps.2343; Greenhalgh J, 2005, SOC SCI MED, V60, P833, DOI 10.1016/j.socscimed.2004.06.022; Gysels M, 2013, PALLIATIVE MED, V27, P908, DOI 10.1177/0269216313488018; Hall S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007132.pub2; Harding R, 2011, J PAIN SYMPTOM MANAG, V42, P493, DOI 10.1016/j.jpainsymman.2011.06.008; Harwood RH, 2004, B WORLD HEALTH ORGAN, V82, P251; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Hearn J, 1999, QUAL HEALTH CARE, V8, P219, DOI 10.1136/qshc.8.4.219; Hennings J, 2019, DEMENTIA-LONDON, V18, P303, DOI 10.1177/1471301216671418; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-111; Hockley J, 2010, PALLIATIVE MED, V24, P828, DOI 10.1177/0269216310373162; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Husebo BS, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4065; International QSR, 2014, QSR INT NVIV 10 WIND; Kerr C, 2010, EXPERT REV PHARM OUT, V10, P269, DOI [10.1586/erp.10.30, 10.1586/ERP.10.30]; Kinley J, 2014, PALLIATIVE MED, V28, P1099, DOI 10.1177/0269216314539785; Krumm N, 2014, INT J PALLIAT NURS, V20, P187, DOI 10.12968/ijpn.2014.20.4.187; Kupeli N, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0103-x; Lee M, 2009, J AM MED DIR ASSOC, V10, P466, DOI 10.1016/j.jamda.2009.03.014; Lichtner V, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-138; Lund S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116629; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Mahoney RI, 1965, MD STATE MED J, P56; Manthorpe J, 2010, INT J OLDER PEOPLE N, V5, P235, DOI 10.1111/j.1748-3743.2010.00231.x; Mason P., 2007, EVALUATION-US, V13, P151, DOI [10.1177/1356389007075221, DOI 10.1177/1356389007075221]; Mathillas J, 2011, AGE AGEING, V40, P243, DOI 10.1093/ageing/afq173; Medical Research Council, 2017, FRAM DEV EV RCTS COM; Miles M. B., 2014, QUALITATIVE DATA ANA; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; Morgan DL, 1998, PLANNING FOCUS GROUP, V2; Moyle Wendy, 2002, Aust J Adv Nurs, V19, P25; Murphy E, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011513.pub2; National Institute for Health and Clinical Excellence, 2017, MULT CLIN ASS MAN; National Institute for Health and Clinical Excellence/ Social Care Institute for Excellence, 2012, DEM SUPP PEOPL DEM T; Nicklasson M, 2013, SUPPORT CARE CANCER, V21, P87, DOI 10.1007/s00520-012-1496-6; Preston NJ, 2013, PALLIAT MED; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Saliba D, 2012, J AM MED DIR ASSOC, V13, P602, DOI 10.1016/j.jamda.2012.06.002; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P179, DOI 10.1002/nur.4770180211; Schildmann EK, 2016, PALLIATIVE MED, V30, P599, DOI 10.1177/0269216315608348; Slade M, 2002, PSYCHOL MED, V32, P1339, DOI 10.1017/S0033291701004974; Steel K, 2003, Am J Hosp Palliat Care, V20, P211, DOI 10.1177/104990910302000311; Velikova G, 2004, J CLIN ONCOL, V22, P714, DOI 10.1200/JCO.2004.06.078	71	23	23	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2018	13	7							e0200240	10.1371/journal.pone.0200240	http://dx.doi.org/10.1371/journal.pone.0200240			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GM7QQ	29995932	Green Published, gold, Green Submitted			2023-01-03	WOS:000438388800047
J	Fan, L; Lukin, B; Zhao, JZ; Sun, JD; Dingle, K; Purtill, R; Tapp, S; Hou, XY				Fan, Lijun; Lukin, Bill; Zhao, Jingzhou; Sun, Jiandong; Dingle, Kaeleen; Purtill, Rhonda; Tapp, Sam; Hou, Xiang-Yu			Cost analysis of improving emergency care for aged care residents under a Hospital in the Nursing Home program in Australia	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; MINIMIZATION ANALYSIS; PATIENT TRANSFER; OUTCOMES; APPROPRIATENESS; FACILITIES; TRANSFERS; DECISION; SERVICES	Background This study aims to examine the costs associated with a Hospital in the Nursing Home (HiNH) program in Queensland Australia directed at patients from residential aged care facilities (RACFs) with emergency care needs. Methods A cost analysis was undertaken comparing the costs under the HiNH program and the current practice, in parallel with a pre-post controlled study design. The study was conducted in two Queensland public hospitals: the Royal Brisbane and Women's Hospital (intervention hospital) and the Logan Hospital (control hospital). Main outcome measures were the associated incremental costs or savings concerning the HiNH program provision and the acute hospital care utilisation over one year after intervention. Results The initial deterministic analysis calculated the total induced mean costs associated with providing the HiNH program over one year as AU$488,116, and the total induced savings relating to acute hospital care service utilisation of AU$8,659,788. The total net costs to the health service providers were thus calculated at -AU$8,171,671 per annum. Results from the probabilistic sensitivity analysis (based on 10,000 simulations) showed the mean and median annual net costs associated with the HiNH program implementation were -AU $8,444,512 and-AU$8,202,676, and a standard deviation of 2,955,346. There was 95% certainty that the values of net costs would fall within the range from -AU$15,018,055 to -AU $3,358,820. Conclusions The costs relating to implementing the HiNH program appear to be much less than the savings in terms of associated decreases in acute hospital service utilisation. The HiNH service model is likely to have the cost-saving potential while improving the emergency care provision for RACF residents.	[Fan, Lijun] Sun Yat Sen Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Guangzhou, Guangdong, Peoples R China; [Fan, Lijun; Dingle, Kaeleen; Hou, Xiang-Yu] Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld, Australia; [Lukin, Bill; Purtill, Rhonda; Tapp, Sam] Royal Brisbane & Womens Hosp, Dept Emergency Med, Brisbane, Qld, Australia; [Zhao, Jingzhou] Bur Investment Promot, Wuwei City, Gansu, Peoples R China; [Sun, Jiandong] Queensland Hlth, Brisbane, Qld, Australia	Sun Yat Sen University; Queensland University of Technology (QUT); Royal Brisbane & Women's Hospital; Queensland Health	Fan, L (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Guangzhou, Guangdong, Peoples R China.; Fan, L (corresponding author), Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld, Australia.	keirafanlj@163.com	Dingle, Kaeleen/G-4885-2010; Hou, Xiang-Yu Xiang-Yu/ACA-6525-2022	Dingle, Kaeleen/0000-0001-8210-8194; Lukin, William/0000-0001-8531-2529; Hou, Xiang-Yu/0000-0002-2015-3579; Fan, Lijun/0000-0001-5863-0169	Queensland Emergency Medicine Research Foundation (QEMRF) [QEMRF-PORJ-2009-014]; Natural Science Foundation of China [NSFC 71704192]	Queensland Emergency Medicine Research Foundation (QEMRF); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the Queensland Emergency Medicine Research Foundation (QEMRF) (Project ID: QEMRF-PORJ-2009-014, Title: A Comprehensive Evaluation of a Hospital in Nursing Home Program in Three Queensland Hospitals, URL: http://emergencyfoundation.org.au/) to BL and the Natural Science Foundation of China (Grant No.: NSFC 71704192) to LF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIHW, 2014, AUSTR HLTH 2014; Arendts G, 2013, GERIATR GERONTOL INT, V13, P825, DOI 10.1111/ggi.12053; Arendts G, 2010, AUSTRALAS J AGEING, V29, P61, DOI 10.1111/j.1741-6612.2009.00415.x; Australian Institute of Health and Welfare (AIHW), 2012, AUSTR HOSP STAT 2011; BECK-FRIIS B, 1991, Scandinavian Journal of Primary Health Care, V9, P259, DOI 10.3109/02813439109018529; BERGMAN H, 1991, J AM GERIATR SOC, V39, P1164, DOI 10.1111/j.1532-5415.1991.tb03568.x; Board N, 2000, AUST NZ J PUBL HEAL, V24, P305, DOI 10.1111/j.1467-842X.2000.tb01573.x; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; Codde J, 2010, AUSTRALAS J AGEING, V29, P150, DOI 10.1111/j.1741-6612.2010.00418.x; Crilly J, 2011, J CLIN NURS, V20, P1178, DOI 10.1111/j.1365-2702.2010.03371.x; DRANOVE D, 1985, INQUIRY-J HEALTH CAR, V22, P59; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Faddy M, 2009, VALUE HEALTH, V12, P309, DOI 10.1111/j.1524-4733.2008.00421.x; Fan LJ, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1275-z; Fan LJ, 2015, EMERG MED J, V32, P738, DOI 10.1136/emermed-2014-203770; Grabowski DC, 2007, HEALTH AFFAIR, V26, P1753, DOI 10.1377/hlthaff.26.6.1753; Gray LC, 2009, MED J AUSTRALIA, V191, P605, DOI 10.5694/j.1326-5377.2009.tb03345.x; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; IHPA, 2012, NAT HOSP COST DAT CO; Inglada V, 2007, CONTRIB ECON, P1, DOI 10.1007/978-3-7908-1765-2; Jones J, 1999, BMJ-BRIT MED J, V319, P1547, DOI 10.1136/bmj.319.7224.1547; Jones JS, 1997, ACAD EMERG MED, V4, P908, DOI 10.1111/j.1553-2712.1997.tb03818.x; MacIntyre CR, 2002, INT J QUAL HEALTH C, V14, P285, DOI 10.1093/intqhc/14.4.285; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Queensland Government, 2012, DEP COMM SAF ANN REP; Rajacich D L, 1995, J Gerontol Nurs, V21, P36; Robinson JC, 2008, HEALTH AFFAIR, V27, P1353, DOI 10.1377/hlthaff.27.5.1353; Saliba D, 2000, J AM GERIATR SOC, V48, P154, DOI 10.1111/j.1532-5415.2000.tb03906.x; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791	30	1	1	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2018	13	7							e0199879	10.1371/journal.pone.0199879	http://dx.doi.org/10.1371/journal.pone.0199879			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL5XD	29969468	gold, Green Published, Green Accepted			2023-01-03	WOS:000437246700033
J	Dintrans, PV				Dintrans, Pablo Villalobos			Do long-term care services match population needs? A spatial analysis of nursing homes in Chile	PLOS ONE			English	Article							HEALTH; ASSOCIATION; SEGREGATION; COMPETITION; REGRESSION; OWNERSHIP; STABILITY; QUALITY	Chile is experiencing a period of rapid aging, which increases the need of long-term care services in the country. Nursing homes have been the traditional alternative to deal with the increase of elderly population in the country, with services supplied by a mix of for-profit and nonprofit providers. Additionally, population exhibits a high degree of geographical concentration. The study aims to identify the determinants of the geographical location of nursing homes in Chile at municipality level. The analysis takes into account the different location criteria for different types of nursing homes as well as potential spatial effects. The paper uses spatial analysis tools to identify clusters of nursing homes and population characteristics and to estimate the determinants of nursing homes availability and coverage in the country. The analysis-based on spatial global and local tests, and spatial autoregressive models-show the existence of clusters of nursing homes as well as clusters of municipalities according to elderly population, income, poverty, population density, and public health insurance coverage. Residuals from ordinary least squares regressions were spatially autocorrelated, showing the need of using spatial models. Estimations show that availability and coverage of nursing homes are positively related with municipality income, and that for-profit and nonprofit facilities respond differently to different factors. A negative coefficient was found for poverty in nonprofit nursing homes, raising doubts about the effectiveness of giving public subsidies to incentive the installation of facilities in areas with high needs and low income.	[Dintrans, Pablo Villalobos] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Dintrans, PV (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	pav783@mail.harvard.edu	Dintrans, Pablo Villalobos/AAM-6248-2020	Dintrans, Pablo Villalobos/0000-0002-2236-6447	PLOS	PLOS	Pablo Villalobos Dintrans received PLOS publication fee assistance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON WE, 1994, GERONTOLOGIST, V34, P775, DOI 10.1093/geront/34.6.775; Allen R. G., 1998, FAO Irrigation and Drainage Paper; Amirkhanyan AA, 2008, J POLICY ANAL MANAG, V27, P326, DOI 10.1002/pam.20327; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x; Anselin L., 2001, COMPANION TOTHEORETI; Anselin L., 2005, EXPLORING SPATIAL DA; Arbia G., 2014, PRIMER SPATIAL ECONO, DOI DOI 10.1057/9781137317940; Auchincloss AH, 2012, ANNU REV PUBL HEALTH, V33, P107, DOI 10.1146/annurev-publhealth-031811-124655; Bayer P., 2004, EQUILIBRIUM MODEL SO; Chacon S., 2015, TRIMEST ECON, V82, P351, DOI DOI 10.20430/ete.v82i326.168; Chairney S, 2013, GIS CRIME MAPPING; Chaix B, 2005, J EPIDEMIOL COMMUN H, V59, P517, DOI 10.1136/jech.2004.025478; Chou SY, 2002, J HEALTH ECON, V21, P293, DOI 10.1016/S0167-6296(01)00123-0; Comber AJ, 2011, INT J HEALTH GEOGR, V10, DOI 10.1186/1476-072X-10-44; Comondore VR, BMJ, V339; CORDEN A, 1992, T I BRIT GEOGR, V17, P80, DOI 10.2307/622638; DASPREMONT C, 1983, ECON LETT, V11, P19, DOI 10.1016/0165-1765(83)90156-8; DASPREMONT C, 1979, ECONOMETRICA, V47, P1145, DOI 10.2307/1911955; de Castro MC, 2007, HEALTH PLACE, V13, P368, DOI 10.1016/j.healthplace.2006.03.006; de Castro MC, 2006, GEOGR ANAL, V38, P180; Dijkstra A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072730; Durlauf S., 1996, J ECON GROWTH, VI, P75, DOI [10.1007/BF00163343, DOI 10.1007/BF00163343]; Elacqua G, 2012, INT J EDUC DEV, V32, P444, DOI 10.1016/j.ijedudev.2011.08.003; Fisher T., 2017, IOP C SERIES MAT SCI, V245; Freedman VA, 2008, HLTH OLDER AGES CAUS; GETIS A, 1992, GEOGR ANAL, V24, P189, DOI 10.1111/j.1538-4632.1992.tb00261.x; Getis A., 2010, HDB APPL SPATIAL ANA; Gibson D, 2000, 5 AUSTR I HLTH WELF; HAMNETT C, 1992, AREA, V24, P130; Harrington C, 1988, Health Care Financ Rev, V9, P81; Harrington C, 2001, AM J PUBLIC HEALTH, V91, P1452, DOI 10.2105/AJPH.91.9.1452; Hotelling H, 1929, ECON J, V39, P41, DOI 10.2307/2224214; Manton KG, 1994, DEMOGRAPHY AGING; Bascunan MM, 2016, GEOSPATIAL HEALTH, V11, P263, DOI 10.4081/gh.2016.451; Mobley Lee R, 2006, Int J Health Geogr, V5, P19, DOI 10.1186/1476-072X-5-19; Monsalves, 2013, REV CHIL SALUD PUBLI, V17, P22, DOI [10.5354/0719-5281.2013.26633, DOI 10.5354/0717-3652.2013.26633]; Musa GJ, 2013, HEALTH SERV INSIGHTS, V6, P111, DOI 10.4137/HSI.S10471; OECD, 2013, GOOD LIFE OLD AGE MO; Oficina Nacional de Estadisticas (ONE), 2015, EST PROYECC NAC POBL, V1; ORD JK, 1995, GEOGR ANAL, V27, P286, DOI 10.1111/j.1538-4632.1995.tb00912.x; Ramos I, 2016, GEOSPATIAL HEALTH, V11, P349, DOI 10.4081/gh.2016.452; Richardson DB, 2013, SCIENCE, V339, P1390, DOI 10.1126/science.1232257; Rivera-Hernandez M, 2014, J GERONTOL B-PSYCHOL, V70, P619; Sabatini F, 2001, EURE, V27, P21; Sabatini F, 2010, TENDENCIAS SEGREGACI; SALOP SC, 1979, BELL J ECON, V10, P141, DOI 10.2307/3003323; SENAMA, 2010, EST NAC DEP AD MAYOR; SENAMA, 2017, GUIA PROGR BEN SOC S; SHAKED A, 1982, REV ECON STUD, V49, P3, DOI 10.2307/2297136; Snow J., 1949, CHALLENGE EPIDEMIOLO; Tirole, 1990, THEORY IND ORG; Villalobos P., 2018, THESIS; Voss PR, 2006, POPUL RES POLICY REV, V25, P369, DOI 10.1007/s11113-006-9007-4; World Health Organization, 2015, AG HLTH; You NL, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101102; Zainol R, 2014, J MALAYSIAN I PLANNE, VV, P49	56	6	6	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2018	13	6							e0199522	10.1371/journal.pone.0199522	http://dx.doi.org/10.1371/journal.pone.0199522			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK7JR	29944690	gold, Green Published			2023-01-03	WOS:000436377800039
J	Munafo, M; Lindson, N; Hajek, P; Aveyard, P; Lewis, S; Coleman, T; Ataya, A; Scott, A; McEwen, A; Attwood, A; Phillips, A; Dickinson, A; Wood, C; Homsey, C; Randall, C; Lycett, D; Pratt, D; Coyle, D; Pizulj, D; Anderson, E; Howell, E; Rai, G; McRobbie, H; Khouja, J; Li, JS; Parrott, S; Perdue, J; Myers, K; Evans, K; Coyle, K; Easey, K; Ahmed, K; Lacey, L; Dann, L; Munafo, M; Allen, M; Huharty, M; Hurse, M; Healy, M; Banting, M; Bisal, N; Lindson, N; Adams, R; Anderson, R; Alekna, R; Tearne, S; Khan, S; Duncombe, S; Orton, S; Pokhrel, S; Freuler, T; Ussher, M; Griffin, D; Slakes-Lampard, H; Might, J; Shahab, L; Omar, R; Harris, T				Munafo, Marcus; Lindson, Nicola; Hajek, Peter; Aveyard, Paul; Lewis, Sarah; Coleman, Tim; Ataya, Alia; Scott, Alice; McEwen, Andy; Attwood, Angela; Phillips, Anna; Dickinson, Anne; Wood, Carmen; Homsey, Celine; Randall, Clare; Lycett, Deborah; Pratt, Diana; Coyle, Doug; Przulj, Dunja; Anderson, Emma; Howell, Emma; Rai, Gurmail; McRobbie, Hayden; Khouja, Jasmine; Li, Jinshuo; Parrott, Steve; Perdue, Jo; Myers, Kate; Evans, Katherine; Coyle, Kathryn; Easey, Kayleigh; Ahmed, Khaled; Lacey, Lindsey; Dann, Lizzy; Munafo, Marcus; Allen, Mark; Huharty, Megan; Hurse, Megan; Healy, Mike; Banting, Miriam; Bisal, Natalie; Lindson, Nicola; Adams, Rachel; Anderson, Rebecca; Alekna, Rhona; Tearne, Sarah; Khan, Shahnaz; Duncombe, Sophie; Orton, Sophie; Pokhrel, Subhash; Freuler, Therese; Ussher, Michael; Griffin, Dan; Slakes-Lampard, Helen; Might, Jane; Shahab, Lion; Omar, Rumana; Harris, Tess		Preloading Investigators	Effects on abstinence of nicotine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TERM ABSTINENCE; CESSATION; VARENICLINE; WITHDRAWAL; REPLACEMENT; THERAPY; ABRUPT; AID	Objective To examine the effectiveness of a nicotine patch worn for four weeks before a quit attempt. Design Randomised controlled open label trial. Setting Primary care and smoking cessation clinics in England, 2012-15. Participants 1792 adults who were daily smokers with tobacco dependence. 899 were allocated to the preloading arm and 893 to the control arm. Interventions Participants were randomised 1: 1, using concealed randomly permuted blocks stratified by centre, to either standard smoking cessation pharmacotherapy and behavioural support or the same treatment supplemented by four weeks of 21 mg nicotine patch use before quitting: "preloading." Main outcome measures The primary outcome was biochemically confirmed prolonged abstinence at six months. Secondary outcomes were prolonged abstinence at four weeks and 12 months. Results Biochemically validated abstinence at six months was achieved by 157/899 (17.5%) participants in the preloading arm and 129/893 (14.4%) in the control arm: difference 3.0% (95% confidence interval -0.4% to 6.4%), odds ratio 1.25 (95% confidence interval 0.97 to 1.62), P=0.08 in the primary analysis. There was an imbalance between arms in the frequency of varenicline use as post-cessation treatment, and planned adjustment for this gave an odds ratio for the effect of preloading of 1.34 (95% confidence interval 1.03 to 1.73), P=0.03: difference 3.8% (0.4% to 7.2%). At four weeks, the difference in prolonged abstinence unadjusted for varenicline use was odds ratio 1.21 (1.00 to 1.48), difference 4.3% (0.0% to 8.7%), P=0.05, and adjusted for varenicline use was 1.32 (1.08 to 1.62) P=0.007. At 12 months the odds ratio was 1.28 (0.97 to 1.69), difference 2.7% (-0.4% to 5.8%), P=0.09 unadjusted for varenicline use and after adjustment was 1.36 (1.02 to 1.80) P=0.04. 5.9% of participants discontinued preloading owing to intolerance. Gastrointestinal symptoms-chiefly nausea-occurred in 4.0% (2.2% to 5.9%) more people in the preloading arm than control arm. Eight serious adverse events occurred in the preloading arm and eight in the control arm (odds ratio 0.99, 0.36 to 2.75). Conclusions Evidence was insufficient to confidently show that nicotine preloading increases subsequent smoking abstinence. The beneficial effect seems to have been masked by a concurrent reduction in the use of varenicline in people using nicotine preloading, and future studies should explore ways to mitigate this unintended effect.	[Munafo, Marcus; Lindson, Nicola; Hajek, Peter; Aveyard, Paul; Lewis, Sarah; Coleman, Tim; Ataya, Alia; Scott, Alice; McEwen, Andy; Attwood, Angela; Phillips, Anna; Dickinson, Anne; Wood, Carmen; Homsey, Celine; Randall, Clare; Lycett, Deborah; Pratt, Diana; Coyle, Doug; Przulj, Dunja; Anderson, Emma; Howell, Emma; Rai, Gurmail; McRobbie, Hayden; Khouja, Jasmine; Li, Jinshuo; Parrott, Steve; Perdue, Jo; Myers, Kate; Evans, Katherine; Coyle, Kathryn; Easey, Kayleigh; Ahmed, Khaled; Lacey, Lindsey; Dann, Lizzy; Munafo, Marcus; Allen, Mark; Huharty, Megan; Hurse, Megan; Healy, Mike; Banting, Miriam; Bisal, Natalie; Lindson, Nicola; Adams, Rachel; Anderson, Rebecca; Alekna, Rhona; Tearne, Sarah; Khan, Shahnaz; Duncombe, Sophie; Orton, Sophie; Pokhrel, Subhash; Freuler, Therese; Ussher, Michael; Griffin, Dan; Slakes-Lampard, Helen; Might, Jane; Shahab, Lion; Omar, Rumana; Harris, Tess; Preloading Investigators] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England	University of Oxford	Aveyard, P (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.	paul.aveyard@phc.ox.ac.uk	Khouja, Jasmine/H-7791-2019; Shahab, Lion/B-5835-2009; Attwood, Angela S/F-7071-2011; McRobbie, Hayden/B-4552-2018; Li, Jinshuo/C-6827-2019; Pokhrel, Subhash/AAO-8648-2020; Munafo, Marcus/AAE-2306-2020	Khouja, Jasmine/0000-0002-7944-2981; Shahab, Lion/0000-0003-4033-442X; Attwood, Angela S/0000-0003-3696-4349; McRobbie, Hayden/0000-0002-7777-1845; Li, Jinshuo/0000-0003-1496-7450; Munafo, Marcus/0000-0002-4049-993X; Lindson, Nicola/0000-0003-2539-9268; Lycett, Deborah/0000-0002-4525-6419; Aveyard, Paul/0000-0002-1802-4217; Parrott, Steven James/0000-0002-0165-1150; Orton, Sophie/0000-0002-8577-216X	National Institute for Health Research (NIHR) Health Technology Assessment [09/110/01]; University of Oxford; UK Centre for Tobacco and Alcohol Studies	National Institute for Health Research (NIHR) Health Technology Assessment(National Institute for Health Research (NIHR)); University of Oxford; UK Centre for Tobacco and Alcohol Studies	This trial was funded by the National Institute for Health Research (NIHR) Health Technology Assessment 09/110/01. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. Glaxo Smith Kline donated nicotine patches to the NHS in lieu of NHS treatment costs. GSK had no role in design, analysis, or decision to publish. The study was sponsored by the University of Oxford and the authors alone decided to publish the paper. The study was conducted with support from the UK Centre for Tobacco and Alcohol Studies.	Anthenelli RM, 2016, LANCET, V387, P2507, DOI 10.1016/S0140-6736(16)30272-0; Aveyard P, 2008, BMJ-BRIT MED J, V336, P1223, DOI 10.1136/bmj.39545.852616.BE; Aveyard P, 2007, THORAX, V62, P898, DOI 10.1136/thx.2006.071837; Bauld L, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121175; Begh R, 2015, DRUG ALCOHOL DEPEN, V149, P158, DOI 10.1016/j.drugalcdep.2015.01.041; Benowitz NL, 2009, ANNU REV PHARMACOL, V49, P57, DOI 10.1146/annurev.pharmtox.48.113006.094742; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Committee on Safety of Medicines, 2005, RIS GATH STORM EN EM, P1; Fagerstrom Karl Olov, 2002, Nicotine Tob Res, V4 Suppl 2, pS73; Fidler J, 2013, ADDICTION, V108, P1680, DOI 10.1111/add.12241; FLAXMAN J, 1978, BEHAV THER, V9, P260, DOI 10.1016/S0005-7894(78)80111-7; Gries JM, 1998, J PHARMACOL EXP THER, V285, P457; HAJEK P, 1989, BRIT J ADDICT, V84, P591; Hajek P, 2011, ARCH INTERN MED, V171, P770, DOI 10.1001/archinternmed.2011.138; Hawk LW, 2012, CLIN PHARMACOL THER, V91, P172, DOI 10.1038/clpt.2011.317; Hawk LW, 2015, NICOTINE TOB RES, V17, P1377, DOI 10.1093/ntr/ntu347; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hubbard R, 2005, TOB CONTROL, V14, P416, DOI 10.1136/tc.2005.011387; Hughes JR, 2004, ADDICTION, V99, P29, DOI 10.1111/j.1360-0443.2004.00540.x; Joseph AM, 1996, NEW ENGL J MED, V335, P1792, DOI 10.1056/NEJM199612123352402; Lindson N, 2011, PSYCHOPHARMACOLOGY, V214, P579, DOI 10.1007/s00213-010-2069-3; Lindson-Hawley N, 2016, ANN INTERN MED, V164, P585, DOI 10.7326/M14-2805; Lindson-Hawley N, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-296; Marteau TM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035249; National Institute for Health and Clinical Excellence, 2008, STOP SMOK SERV; National Institute for Health and Clinical Excellence, 2008, GUID SMOK CESS; OECD, 2014, EN EFF IND ESS POL M, P1; Parsons A, 2009, DRUG ALCOHOL DEPEN, V102, P116, DOI 10.1016/j.drugalcdep.2009.02.006; Rose JE, 2013, AM J PSYCHIAT, V170, P860, DOI 10.1176/appi.ajp.2013.12070919; Rose JE, 2011, PSYCHOPHARMACOLOGY, V217, P453, DOI 10.1007/s00213-011-2350-0; Shiffman S, 2004, NICOTINE TOB RES, V6, P599, DOI 10.1080/14622200410001734067; Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub4; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; West R, 2014, THEORY ADDICTION; West R, 2008, PSYCHOPHARMACOLOGY, V197, P371, DOI 10.1007/s00213-007-1041-3; West R, 2010, PSYCHOPHARMACOLOGY, V208, P427, DOI 10.1007/s00213-009-1742-x; Zevin S, 1998, CLIN PHARMACOL THER, V64, P87, DOI 10.1016/S0009-9236(98)90026-1	37	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	2018	361								k2164	10.1136/bmj.k2164	http://dx.doi.org/10.1136/bmj.k2164			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ8JO	29899061	Green Accepted, hybrid, Green Published, Green Submitted			2023-01-03	WOS:000435635800002
J	Pai, M; Adhikari, NKJ; Ostermann, M; Heels-Ansdell, D; Douketis, JD; Skrobik, Y; Qushmaq, I; Meade, M; Guyatt, G; Geerts, W; Walsh, MW; Crowther, MA; Friedrich, JO; Burry, L; Bellomo, R; da Silva, NB; Costa, R; Cox, MJ; Silva, SA; Cook, DJ				Pai, Menaka; Adhikari, Neill K. J.; Ostermann, Marlies; Heels-Ansdell, Diane; Douketis, James D.; Skrobik, Yoanna; Qushmaq, Ismael; Meade, Maureen; Guyatt, Gordon; Geerts, William; Walsh, Michael W.; Crowther, Mark A.; Friedrich, Jan O.; Burry, Lisa; Bellomo, Rinaldo; da Silva, Nilton Brendao; Costa Filho, Rubens; Cox, Michael J.; Silva, Suzana Alves; Cook, Deborah J.		Prophylaxis Thromboembolism Critic	Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial	PLOS ONE			English	Article							GLYCOPROTEIN-IIB-IIIA; UNFRACTIONATED HEPARIN; DALTEPARIN; INSUFFICIENCY; DISEASE; BIOACCUMULATION; PROPHYLAXIS; ACTIVATION	Introduction There is concern about excessive bleeding when low-molecular-weight heparins (LMWHs) are used for venous thromboembolism (VTE) prophylaxis in renal dysfunction. Our objective was to evaluate whether LMWH VTE prophylaxis was safe and effective in critically ill patients with renal dysfunction by conducting a subgroup analysis of PROTECT, a randomized blinded trial. Methods We studied intensive care unit (ICU) patients with pre-ICU dialysis-dependent end-stage renal disease (ESRD; pre-specified subgroup; n = 118), or severe renal dysfunction at ICU admission (defined as ESRD or non-dialysis dependent with creatinine clearance [CrCl] < 30 ml/min; post hoc subgroup; n = 590). We compared dalteparin, 5000 IU daily, with unfractionated heparin (UFH), 5000 IU twice daily, and considered outcomes of proximal leg deep vein thrombosis (DVT); pulmonary embolism (PE); any VTE; and major bleeding. Adjusted hazard ratios [HR] were calculated using Cox regression. Results In patients with ESRD, there was no significant difference in DVT (8.3% vs. 5.2%, p = 0.76), any VTE (10.0% vs. 6.9%; p = 0.39) or major bleeding (5.0% vs. 8.6%; p = 0.32) between UFH and dalteparin. In patients with severe renal dysfunction, there was no significant difference in any VTE (10.0% vs. 6.4%; p = 0.07) or major bleeding (8.9% vs. 11.0%; p = 0.66) but an increase in DVT with dalteparin (7.6% vs. 3.7%; p = 0.04). Interaction p-values for comparisons of HRs (ESRD versus not) were non-significant. Conclusions In critically ill patients with ESRD, or severe renal dysfunction, there was no significant difference in any VTE or major bleeding between UFH and dalteparin. Patients with severe renal dysfunction who received dalteparin had more proximal DVTs than those on UFH; this finding did not hold in patients with ESRD alone.	[Pai, Menaka; Douketis, James D.; Meade, Maureen; Guyatt, Gordon; Walsh, Michael W.; Crowther, Mark A.; Cook, Deborah J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Pai, Menaka; Crowther, Mark A.] Hamilton Reg Lab Med Program, Hamilton, ON, Canada; [Pai, Menaka; Crowther, Mark A.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Adhikari, Neill K. J.; Friedrich, Jan O.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Ostermann, Marlies] Guys & St Thomas Hosp, Dept Crit Care, London, England; [Heels-Ansdell, Diane; Douketis, James D.; Meade, Maureen; Guyatt, Gordon; Walsh, Michael W.; Cook, Deborah J.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Skrobik, Yoanna] Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ, Canada; [Qushmaq, Ismael] King Faisal Specialist Hosp & Res Ctr, Dept Med, Jeddah, Saudi Arabia; [Geerts, William; Friedrich, Jan O.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Burry, Lisa] Mt Sinai Hosp, Toronto, ON, Canada; [Bellomo, Rinaldo] Monash Univ, ANZIC RC, Melbourne, Vic, Australia; [da Silva, Nilton Brendao] Moinhos de Vento Hosp, Porto Alegre, RS, Brazil; [Costa Filho, Rubens; Silva, Suzana Alves] Pro Cardiaco Hosp, PROCEP, Rio De Janeiro, Brazil; [Cox, Michael J.] St Johns Mercy Med Ctr, St Louis, MO 63141 USA	McMaster University; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Guy's & St Thomas' NHS Foundation Trust; McMaster University; Universite de Montreal; King Faisal Specialist Hospital & Research Center; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Monash University; Saint Johns Mercy Medical Center	Pai, M (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.; Pai, M (corresponding author), Hamilton Reg Lab Med Program, Hamilton, ON, Canada.; Pai, M (corresponding author), McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.	mpai@mcmaster.ca	Skrobik, Yoanna/K-8165-2014; Ostermann, Marlies/AAH-8160-2021; Douketis, James/AAO-5659-2021; Ostermann, Marlies/B-8777-2015	Skrobik, Yoanna/0000-0002-5315-6020; Pai, Menaka/0000-0002-6053-689X; Carmo Costa Filho, Rubens/0000-0002-9725-3762; Ostermann, Marlies/0000-0001-9500-9080; Walsh, Michael/0000-0001-8292-2014	Canadian Institute Health Research [MCT78568]; Heart & Stroke Foundation of Canada [T6157, T6950, NA6186]; Australian and New Zealand College of Anesthetists Research Foundation [07/23]; Canadian Institutes of Health Research	Canadian Institute Health Research(Canadian Institutes of Health Research (CIHR)); Heart & Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Australian and New Zealand College of Anesthetists Research Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by the Canadian Institute Health Research (#MCT78568), Heart & Stroke Foundation of Canada (#T6157, #T6950, #NA6186) and the Australian and New Zealand College of Anesthetists Research Foundation (#07/23). Pfizer Canada provided dalteparin for Canadian centers; Eisai, Inc, provided dalteparin for centers in the United States. None of these groups played a role in the design, conduct, analysis, interpretation or write-up of this trial. M Crowther is a Career Investigator of the Heart and Stroke Foundation of Canada, and is the Leo Pharma Chair in Thromboembolism Research at McMaster University. M Meade is a Mentor of the Canadian Institutes of Health Research. DJ Cooper is a National Health Medical Research Council Practitioner Fellow. D Cook is a Research Chair of the Canadian Institutes of Health Research. M Walsh is supported by a New Investigator Award from the Canadian Institutes of Health Research.	Arnold DM, 2013, THROMB RES, V131, P204, DOI 10.1016/j.thromres.2012.12.005; Bauersachs R, 2011, THROMB HAEMOSTASIS, V105, P981, DOI 10.1160/TH10-09-0614; BENIGNI A, 1993, AM J KIDNEY DIS, V22, P668, DOI 10.1016/S0272-6386(12)80429-X; Boneu B, 1990, Baillieres Clin Haematol, V3, P531, DOI 10.1016/S0950-3536(05)80017-4; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475; Douketis J, 2008, ARCH INTERN MED, V168, P1805, DOI 10.1001/archinte.168.16.1805; GAWAZ MP, 1994, J AM SOC NEPHROL, V5, P36; Jalal DI, 2010, SEMIN THROMB HEMOST, V36, P34, DOI 10.1055/s-0030-1248722; Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296; Kaplan D, 2015, CHEST, V148, P1224, DOI 10.1378/chest.15-0287; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Lim W, 2006, ANN INTERN MED, V144, P673, DOI 10.7326/0003-4819-144-9-200605020-00011; Linkins LA, 2012, CHEST, V141, pE495S, DOI 10.1378/chest.11-2303; Rabbat CG, 2005, J CRIT CARE, V20, P357, DOI 10.1016/j.jcrc.2005.09.009; Schmid P, 2010, J THROMB HAEMOST, V8, P850, DOI 10.1111/j.1538-7836.2010.03749.x; Schmid P, 2009, J THROMB HAEMOST, V7, P552, DOI 10.1111/j.1538-7836.2009.03292.x; Xiao ZH, 1998, CIRCULATION, V97, P251, DOI 10.1161/01.CIR.97.3.251; Zytaruk N, 2009, AM J RESP CRIT CARE, V179	19	7	7	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0198285	10.1371/journal.pone.0198285	http://dx.doi.org/10.1371/journal.pone.0198285			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856817	Green Published, gold			2023-01-03	WOS:000433900800095
J	Ogino, S; Giannakis, M				Ogino, Shuji; Giannakis, Marios			Immunoscore for (colorectal) cancer precision medicine	LANCET			English	Editorial Material							RISK		[Ogino, Shuji] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Program Mol Pathol Epidemiol, Boston, MA 02215 USA; [Giannakis, Marios] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; [Ogino, Shuji] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA; [Giannakis, Marios] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Ogino, Shuji; Giannakis, Marios] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Ogino, S (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Program Mol Pathol Epidemiol, Boston, MA 02215 USA.; Ogino, S (corresponding author), Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.; Ogino, S (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.; Ogino, S (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.	shuji_ogino@dfci.harvard.edu	Giannakis, Marios/Z-4908-2019	Ogino, Shuji/0000-0002-3909-2323	US National Institutes of Health [R35 CA197735]; NATIONAL CANCER INSTITUTE [R35CA197735] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001100] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We declare no competing interests. This work was supported in part by the grant from the US National Institutes of Health (grant number R35 CA197735).	Basile D, 2017, EXPERT OPIN BIOL TH, V17, P709, DOI 10.1080/14712598.2017.1315405; Fletcher R, 2018, BBA-REV CANCER, V1869, P138, DOI 10.1016/j.bbcan.2017.12.002; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Le DT, 2017, CANCER IMMUNOL RES, V5, P942, DOI 10.1158/2326-6066.CIR-17-0375; Mehta RS, 2017, JAMA ONCOL, V3, P921, DOI 10.1001/jamaoncol.2016.6374; Ogino S, 2018, GUT, V67, P1168, DOI 10.1136/gutjnl-2017-315537; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Song MY, 2016, JAMA ONCOL, V2, P1197, DOI 10.1001/jamaoncol.2016.0605; Spira A, 2017, CANCER RES, V77, P1510, DOI 10.1158/0008-5472.CAN-16-2346; Wirta EV, 2017, J PATHOL CLIN RES, V3, P203, DOI 10.1002/cjp2.71; Zitvogel L, 2017, NAT IMMUNOL, V18, P843, DOI 10.1038/ni.3754	13	38	40	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2018	391	10135					2084	2086		10.1016/S0140-6736(18)30953-X	http://dx.doi.org/10.1016/S0140-6736(18)30953-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH2UJ	29754776	Green Accepted			2023-01-03	WOS:000433257200007
J	Shah, R; Kiriya, J; Shibanuma, A; Jimba, M				Shah, Richa; Kiriya, Junko; Shibanuma, Akira; Jimba, Masamine			Use of modern contraceptive methods and its association with QOL among Nepalese female migrants living in Japan	PLOS ONE			English	Article							UNINTENDED PREGNANCY; REPRODUCTIVE HEALTH; WOMEN; ABORTION; IMMIGRANTS; KNOWLEDGE; INFANT	Introduction Modern contraceptive use among migrants may be limited due to factors such as language barriers, socio-economic condition, and inadequate knowledge. Limited evidence is available on the factors associated with the use of modern contraceptive methods by migrants in Japan. Moreover, evidence remains scarce on the quality of life (QOL) of migrants in relation to contraceptive use. As the Nepalese migrant population in Japan is increasing, this study was conducted to address their sexual and reproductive health issues. Therefore, the objectives of this study were to examine the factors associated with the use of modern contraceptive methods and to explore the association between the use of modern contraceptive methods and QOL among married Nepalese female migrants in Japan. Methods This is a cross-sectional study conducted among 189 married Nepalese female migrants residing in five prefectures of Japan from August to October 2016. This study employed snowball sampling to recruit the migrants. Simple and multiple logistic analyses were used to examine the association between independent variables and the use of modern contraceptive methods. Similarly, multiple linear regression analysis was used to examine the association between the use of modern contraceptive methods and quality of life. Results Migrants who had higher knowledge of modern contraceptive methods were more likely to use them (Adjusted Odds Ratio [AOR] = 1.31; 95% Confidence Interval [CI]: 1.07, 1.60). The psychological domain scores were higher in those who used modern contraceptive methods (Coefficient [B] = 0.58; 95% CI: 0.05, 1.11). Conclusion This study highlights the importance of the knowledge of modern contraceptive methods to increase their use. Also, the use of modern contraceptive methods improves the psychological QOL domain scores of the migrants using them. These results suggest a need for sexual and reproductive health education for migrants, especially pertaining to modern contraceptive use.	[Shah, Richa; Kiriya, Junko; Shibanuma, Akira; Jimba, Masamine] Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan	University of Tokyo	Shibanuma, A (corresponding author), Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan.	shibanuma@m.u-tokyo.ac.jp	Shah, Richa/AAL-6051-2021; Shibanuma, Akira/C-7652-2016; Jimba, Masamine/AAF-5630-2020	Shah, Richa/0000-0002-3625-8228; Shibanuma, Akira/0000-0003-2058-1722; 	Asian Development Bank Japan Scholarship Program	Asian Development Bank Japan Scholarship Program	This study was supported by Asian Development Bank Japan Scholarship Program (http://www.adb.org/site/careers/japan-scholarship-program/main). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adanu RMK, 2009, INT J GYNECOL OBSTET, V106, P179, DOI 10.1016/j.ijgo.2009.03.036; Alvarez-Nieto C, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0071-2; [Anonymous], 2015, TRENDS CONTR US WORL; Boerleider AW, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-81; Caruso S, 2016, J ENDOCRINOL INVEST, V39, P923, DOI 10.1007/s40618-016-0460-6; Coleman PK, 2011, BRIT J PSYCHIAT, V199, P180, DOI 10.1192/bjp.bp.110.077230; Daher AM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-407; de Leon Siantz Mary Lou, 2013, Glob Adv Health Med, V2, P12, DOI 10.7453/gahmj.2013.065; DHITAL R, 2013, BMC WOMENS HEALTH, V13, DOI DOI 10.1186/14'72-68'74-13-22; Ghodsi Z, 2012, PROCD SOC BEHV, V46, P3031, DOI 10.1016/j.sbspro.2012.06.004; Gipson JD, 2008, STUD FAMILY PLANN, V39, P18, DOI 10.1111/j.1728-4465.2008.00148.x; Gissler M, 2009, ACTA OBSTET GYN SCAN, V88, P134, DOI 10.1080/00016340802603805; Grossman D, 2010, REPROD HEALTH MATTER, V18, P136, DOI 10.1016/S0968-8080(10)36534-7; IDRE, 2015, REGR STAT; Ip WY, 2011, J CLIN NURS, V20, P1685, DOI 10.1111/j.1365-2702.2010.03404.x; Jackson AV, 2017, SEMIN PERINATOL, V41, P273, DOI 10.1053/j.semperi.2017.04.003; Jacquemyn Y, 2012, CLIN EXP OBSTET GYN, V39, P181; Kessler K, 2010, FIELD ACTIONS SCI RE, P1; Keygnaert I, 2014, HEALTH POLICY, V114, P215, DOI 10.1016/j.healthpol.2013.10.007; Lindert J, 2009, SOC SCI MED, V69, P246, DOI 10.1016/j.socscimed.2009.04.032; Magalhaes L, 2010, J IMMIGR MINOR HEALT, V12, P132, DOI 10.1007/s10903-009-9280-5; Matsumoto Y, 2011, J OBSTET GYNAECOL RE, V37, P887, DOI 10.1111/j.1447-0756.2010.01461.x; Mengesha ZB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181421; Ministry of Health, 2016, NEPAL DEMOGRAPHIC HL; Ministry of Health and Population Government of Nepal., 2015, NEP HLTH SECT STRAT; Ministry of Health and Population New ERA ICF International Inc, 2012, NEP DEM HLTH SURV 20; Ministry of Health Labour and Welfare, 2007, ETHL GUID MED HLTH R; Ministry of Internal Affairs and Communication, 2016, JAP FIG; Murphy H, 2000, AUSTR WHOQOL INSTRUM; Ostrach B, 2013, J IMMIGR MINOR HEALT, V15, P262, DOI 10.1007/s10903-012-9680-9; Patel VV, 2012, J IMMIGR MINOR HEALT, V14, P767, DOI 10.1007/s10903-011-9555-5; Perez-Campos E, 2011, VALUE HEALTH, V14, P892, DOI 10.1016/j.jval.2011.08.1729; Rechel B., 2011, MIGRATION HLTH EUROP; Schwarz EB, 2008, CONTRACEPTION, V78, P204, DOI 10.1016/j.contraception.2008.04.120; Shaukat S, 2015, FWU J SOC SCI, V9, P101; Shrestha D R, 2012, J Nepal Health Res Counc, V10, P108; Southern DA, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-57; United Nations, 2015, TRENDS INT MIGR; United Nations, 2013, POP DYN REPR HLTH SU; Vangen S, 2008, BJOG-INT J OBSTET GY, V115, P1309, DOI 10.1111/j.1471-0528.2008.01832.x; World Health Organization, 2010, EQUI HLTH; World Health Organization, 2010, GEND WOM PRIM HLTH C; World Health Organization (WHO), 2009, MENTAL HLTH ASPECTS; Yadav S, 2010, QUAL LIFE RES, V19, P157, DOI 10.1007/s11136-009-9574-z; Yamanaka K, 2005, GLOBAL NETW, V5, P337, DOI 10.1111/j.1471-0374.2005.00123.x; Yoshitake N, 2016, QUAL LIFE RES, V25, P3147, DOI 10.1007/s11136-016-1352-0	46	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0197243	10.1371/journal.pone.0197243	http://dx.doi.org/10.1371/journal.pone.0197243			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF9WG	29768459	gold, Green Published, Green Submitted			2023-01-03	WOS:000432329200069
J	Robinson, RJ; Hensel, EC; al-Olayan, AA; Nonnemaker, JM; Lee, YO				Robinson, R. J.; Hensel, E. C.; al-Olayan, A. A.; Nonnemaker, J. M.; Lee, Y. O.			Effect of e-liquid flavor on electronic cigarette topography and consumption behavior in a 2-week natural environment switching study	PLOS ONE			English	Article							SMOKING TOPOGRAPHY; NICOTINE LEVELS; TOBACCO; SMOKERS; VAPERS; SWEET	Electronic Nicotine Delivery Systems (ENDS) offer an alternate means to consume nicotine in a variety of flavored aerosols. Data are needed to better understand the impact of flavors on use behavior. A natural environment observational study was conducted on experienced ENDS users to measure the effect of e-liquid flavor on topography and consumption behavior. The RIT wPUM (TM) monitor was used to record to record the date and time and puff topography (flow rate, volume, duration) for every puff taken by N = 34 participants over the course of two weeks. All participants used tobacco flavor for one week, and either berry or menthol flavor for one week. Results provide strong evidence that flavor affects the topography behaviors of mean puff flow rate and mean puff volume, and there is insufficient evidence to support an influence of flavor on mean puff duration and mean puff interval. There was insufficient evidence, due to the low power associated with the limited number of observation days, to establish a relationship between flavor and cumulative consumption behavior. While the results indicate that an effect may be evident, additional observation days are required to establish significance.	[Robinson, R. J.; Hensel, E. C.; al-Olayan, A. A.] Rochester Inst Technol, Rochester, NY 14623 USA; [Nonnemaker, J. M.; Lee, Y. O.] Res Triangle Int Inc, Res Triangle Pk, NC USA	Rochester Institute of Technology	Robinson, RJ (corresponding author), Rochester Inst Technol, Rochester, NY 14623 USA.	rjreme@rit.edu	Hensel, Edward/Q-6753-2019; Lee, Youn/ABF-9022-2021	Hensel, Edward/0000-0002-2682-0766; Lee, Youn/0000-0001-9042-5392; Robinson, Risa/0000-0001-8488-5448; nonnemaker, james/0000-0003-1044-7482	Rochester Institute of Technology Kate Gleason College of Engineering faculty research funds; RTI International institutional research and development funds	Rochester Institute of Technology Kate Gleason College of Engineering faculty research funds; RTI International institutional research and development funds	This work was supported by Rochester Institute of Technology Kate Gleason College of Engineering faculty research funds, and RTI International institutional research and development funds. The funder provided support in the form of salaries for authors [RJR ECH AM YOL JMN], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ahijevych K, 1997, RES NURS HEALTH, V20, P505, DOI 10.1002/(SICI)1098-240X(199712)20:6<505::AID-NUR5>3.0.CO;2-Q; Arndt J, 2013, HEALTH PSYCHOL, V32, P525, DOI 10.1037/a0029201; Aung AT, 2004, ADDICT BEHAV, V29, P699, DOI 10.1016/j.addbeh.2004.02.012; Barnes Andrew J, 2017, Tob Regul Sci, V3, P374, DOI 10.18001/TRS.3.4.1; Behar RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117222; Bialous SA, 2001, AM J PUBLIC HEALTH, V91, P62; Blank MD, 2009, NICOTINE TOB RES, V11, P896, DOI 10.1093/ntr/ntp083; Brauer LH, 1996, ADDICT BEHAV, V21, P233, DOI 10.1016/0306-4603(95)00054-2; Burling TA, 1996, J SUBST ABUSE, V8, P445, DOI 10.1016/S0899-3289(96)90005-X; Czoli CD, 2016, TOB CONTROL, V25, pE30, DOI 10.1136/tobaccocontrol-2015-052422; Evans SE, 2014, TOB CONTROL, V23, P23, DOI 10.1136/tobaccocontrol-2013-051489; Farsalinos KE, 2015, SCI REP-UK, V5, DOI 10.1038/srep11269; Goldenson NI, 2016, DRUG ALCOHOL DEPEN, V168, P176, DOI 10.1016/j.drugalcdep.2016.09.014; Goniewicz ML, 2013, NICOTINE TOB RES, V15, P158, DOI 10.1093/ntr/nts103; Hamilton CM, 2011, AM J EPIDEMIOL, V174, P253, DOI 10.1093/aje/kwr193; HATSUKAMI D, 1987, INT J ADDICT, V22, P719, DOI 10.3109/10826088709027453; HATSUKAMI DK, 1988, ADDICT BEHAV, V13, P91, DOI 10.1016/0306-4603(88)90031-7; Helen GS, 2017, DRUG ALCOHOL DEPEN, V178, P391, DOI 10.1016/j.drugalcdep.2017.05.042; HERNING RI, 1983, CLIN PHARMACOL THER, V33, P84, DOI 10.1038/clpt.1983.12; HERNING RI, 1981, BRIT MED J, V283, P187, DOI 10.1136/bmj.283.6285.187; Hsu G, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8550; Kim H, 2016, TOB CONTROL, V25, pii55, DOI 10.1136/tobaccocontrol-2016-053221; Korzun T, 2018, ACS OMEGA, V3, P30, DOI 10.1021/acsomega.7b01521; Lawrence D, 2011, TOBACCO INDUCED D S1, V9, pS3, DOI [10.1186/1617-9625-9-S1-S3, DOI 10.1186/1617-9625-9-S1-S3]; Lee YH, 2015, ADDICT BEHAV, V48, P1, DOI 10.1016/j.addbeh.2015.04.003; Lee YO, 2018, NICOTINE TOB RES, V20, P1283, DOI 10.1093/ntr/ntx222; Lee YO, 2011, TOB CONTROL, V20, pII1, DOI 10.1136/tc.2011.043604; Lopez AA, 2016, NICOTINE TOB RES, V18, P720, DOI 10.1093/ntr/ntv182; Lopez AA, 2015, PREV MED, V80, P101, DOI 10.1016/j.ypmed.2015.07.006; Nonnemaker J, 2016, TOB CONTROL, V25, pE37, DOI 10.1136/tobaccocontrol-2015-052511; Ossip-Klein D, 1983, BEH MED ABSTR, V4, P73; Robinson DR, 2015, PLOS ONE; Robinson RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164038; Robinson R J, 2015, PLoS One, V10, pe0129296, DOI 10.1371/journal.pone.0129296; Sazonov E, 2013, J STUD ALCOHOL DRUGS, V74, P956, DOI 10.15288/jsad.2013.74.956; Siegel MB, 2011, AM J PREV MED, V40, P472, DOI 10.1016/j.amepre.2010.12.006; Spindle TR, 2015, NICOTINE TOB RES, V17, P142, DOI 10.1093/ntr/ntu186; Wagoner KG, 2016, NICOTINE TOB RES, V18, P2006, DOI 10.1093/ntr/ntw095; Y El Sayed, 2015, CHEM ANAL CONSTITUEN	39	21	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2018	13	5							e0196640	10.1371/journal.pone.0196640	http://dx.doi.org/10.1371/journal.pone.0196640			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE5SH	29718974	Green Published, gold, Green Submitted			2023-01-03	WOS:000431281900066
J	Goroshchuk, O; Kolosenko, I; Vidarsdottir, L; Azimi, A; Palm-Apergi, C				Goroshchuk, Oksana; Kolosenko, Iryna; Vidarsdottir, Linda; Azimi, Alireza; Palm-Apergi, Caroline			Polo-like kinases and acute leukemia	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; INHIBITOR BI 2536; BOX DOMAIN; IN-VITRO; ANTITUMOR-ACTIVITY; TARGETING PLK1; RNAI PRODRUGS; AML PATIENTS; CANCER	Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic approaches. Therefore, there is a great need for the development of novel and more specific therapies with fewer side effects. The family of Polo-like kinases (Plks) is a group of five serine/threonine kinases that play an important role in cell cycle regulation and are critical targets for therapeutic invention. Plk1 and Plk4 are novel targets for cancer therapy as leukemic cells often express higher levels than normal cells. In contrast, Plk2 and Plk3 are considered to be tumor suppressors. Several small molecule inhibitors have been developed for targeting Plk1 inhibition. Despite reaching phase III clinical trials, one of the ATP-competitive Plk1 inhibitor, volasertib, did not induce an objective clinical response and even caused lethal side effects in some patients. In order to improve the specificity of the Plk1 inhibitors and reduce off-target side effects, novel RNA interference (RNAi)-based therapies have been developed. In this review, we summarize the mechanisms of action of the Plk family members in acute leukemia, describe preclinical studies and clinical trials involving Plk-targeting drugs and discuss novel approaches in Plk targeting.	[Goroshchuk, Oksana; Kolosenko, Iryna; Vidarsdottir, Linda; Azimi, Alireza; Palm-Apergi, Caroline] Karolinska Inst, Dept Lab Med, Clin Res Ctr, Stockholm, Sweden	Karolinska Institutet	Palm-Apergi, C (corresponding author), Karolinska Inst, Dept Lab Med, Clin Res Ctr, Stockholm, Sweden.	caroline.palm.apergi@ki.se		Vidarsdottir, Linda/0000-0003-3082-1320; Goroshchuk, Oksana/0000-0002-1585-1962; Azimi, Alireza/0000-0002-7398-5643; Palm Apergi, Caroline/0000-0003-2236-2099	Swedish Foundation for Strategic Research; Swedish Childhood Cancer Foundation	Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Childhood Cancer Foundation(European Commission)	This study was supported by the Swedish Foundation for Strategic Research (C.P.A.) and the Swedish Childhood Cancer Foundation (C.P.A.).	Abbou S, 2016, ANTICANCER RES, V36, P599; [Anonymous], 2008, WHO CLASSIFICATION T, V4th ed; [Anonymous], 2017, EU CLIN TRIALS REGIS, P1; Archambault V, 2017, CELL CYCLE, V16, P1220, DOI 10.1080/15384101.2017.1325043; Armstrong GT, 2014, J CLIN ONCOL, V32, P1218, DOI 10.1200/JCO.2013.51.1055; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bassan R, 2011, J CLIN ONCOL, V29, P532, DOI 10.1200/JCO.2010.30.1382; Benetatos L, 2011, ANN HEMATOL, V90, P1037, DOI 10.1007/s00277-011-1193-4; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Casolaro A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058424; Chang JE, 2010, LEUKEMIA LYMPHOMA, V49, P2298; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Dasmahapatra G, 2013, CLIN CANCER RES, V19, P404, DOI 10.1158/1078-0432.CCR-12-2799; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; de Carcer G, 2011, MOL CELL BIOL, V31, P1225, DOI 10.1128/MCB.00607-10; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; de Viron E, 2009, BRIT J HAEMATOL, V147, P641, DOI 10.1111/j.1365-2141.2009.07900.x; Dinner S, 2016, J CELL BIOCHEM, V117, P1745, DOI 10.1002/jcb.25559; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Ferlay J, 2013, IARC CANCERBASE, P11; Fey MF, 2013, ANN ONCOL, V24, P138, DOI 10.1093/annonc/mdt320; Fournier M, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2016.1270391; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; Gorlick R, 2014, PEDIATR BLOOD CANCER, V61, P158, DOI 10.1002/pbc.24616; Gustafsson G., 2013, CHILD CANC INCID SUR, V1984-2010, P1; Hartsink-Segers SA, 2013, HAEMATOLOGICA, V98, P1539, DOI 10.3324/haematol.2013.084434; Hoelzer D, 2016, ANN ONCOL, V27, pv69, DOI 10.1093/annonc/mdw025; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hu CK, 2012, MOL BIOL CELL, V23, P2702, DOI 10.1091/mbc.E12-01-0058; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Ikezoe T, 2009, LEUKEMIA, V23, P1564, DOI 10.1038/leu.2009.94; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kannan S, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2912.2912; Kantarjian HM, 2000, J CLIN ONCOL, V18, P547, DOI 10.1200/JCO.2000.18.3.547; Kazazian K, 2017, CANCER RES, V77, P434, DOI 10.1158/0008-5472.CAN-16-2060; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; Kim SM, 2014, AMINO ACIDS, V46, P2595, DOI 10.1007/s00726-014-1798-8; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kolosenko I, 2017, J CONTROL RELEASE, V261, P199, DOI 10.1016/j.jconrel.2017.07.002; Lee KS, 2015, TRENDS PHARMACOL SCI, V36, P858, DOI 10.1016/j.tips.2015.08.013; Li L, 2009, ACTA PHARMACOL SIN, V30, P1443, DOI 10.1038/aps.2009.141; Li S, 2018, MEDICINE, V97, P1; Li ZH, 2016, J CANCER, V7, P1125, DOI 10.7150/jca.14307; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu D, 2012, J CELL BIOL, V198, P491, DOI 10.1083/jcb.201205090; Maniswami RR, 2018, EXPERT OPIN THER TAR, V22, P59, DOI 10.1080/14728222.2018.1410140; Marina M, 2014, FRONT BIOSCI-LANDMRK, V19, P352, DOI 10.2741/4212; Mason JM, 2014, CANCER CELL, V26, P163, DOI 10.1016/j.ccr.2014.05.006; McArthur K, 2017, ONCOTARGE; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Metayer C, 2013, CANCER EPIDEMIOL, V37, P336, DOI 10.1016/j.canep.2012.12.011; Mross K, 2012, BRIT J CANCER, V107, P280, DOI 10.1038/bjc.2012.257; Muller-Tidow C, 2013, BRIT J HAEMATOL, V163, P214, DOI 10.1111/bjh.12518; Munch C, 2015, LEUKEMIA RES, V39, P462, DOI 10.1016/j.leukres.2015.01.007; NCNN Clinical Practice Guidelines in Oncology, 2015, NED TIJDSCHR TANDHEE, V109, P463; Nielsen SN, 2017, PEDIAT BLOOD CANC, V64, P1; Normandin K, 2016, SCI REP-UK, V6, DOI 10.1038/srep37581; Oliveira JC, 2014, PEDIATR BLOOD CANCER, V61, P1227, DOI 10.1002/pbc.24978; Olmos D, 2011, CLIN CANCER RES, V17, P3420, DOI 10.1158/1078-0432.CCR-10-2946; Osca-Gelis G, 2013, HAEMATOLOGICA, V98, pE95, DOI 10.3324/haematol.2013.084061; Pritchard-Jones K, 2014, CANCER-AM CANCER SOC, V120, P2388, DOI 10.1002/cncr.28745; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Reaman Gregory H, 2011, PRACTICAL HDB, P336; Reindl W, 2009, CHEMBIOCHEM, V10, P1145, DOI 10.1002/cbic.200900059; Renner AG, 2009, BLOOD, V114, P659, DOI 10.1182/blood-2008-12-195867; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Scharow A, 2016, CHEMBIOCHEM, V17, P759, DOI 10.1002/cbic.201500535; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Sobin L, 2000, INT CLASSIFICATION D; Spaniol K, 2011, ANTI-CANCER DRUG, V22, P531, DOI 10.1097/CAD.0b013e3283454526; Sparta AM, 2014, CELL CYCLE, V13, P2237, DOI 10.4161/cc.29267; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Syed N, 2006, BLOOD, V107, P250, DOI 10.1182/blood-2005-03-1194; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Talati C, 2016, CRIT REV ONCOL HEMAT, V98, P200, DOI 10.1016/j.critrevonc.2015.10.013; Tao YF, 2017, ONCOL REP, V37, P1419, DOI 10.3892/or.2017.5417; Thomas DA, 1999, CANCER-AM CANCER SOC, V86, P1216, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O; Tontsch-Grunt U, 2018, CANCER LETT, V421, P112, DOI 10.1016/j.canlet.2018.02.018; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; Wang NN, 2015, INT J MOL SCI, V16, P1266, DOI 10.3390/ijms16011266; Ward A, 2015, LEUKEMIA LYMPHOMA, V56, P2123, DOI 10.3109/10428194.2014.971407; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819; Zwaan CM, 2015, J CLIN ONCOL, V33, P2949, DOI 10.1200/JCO.2015.62.8289	90	36	37	8	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					1	16		10.1038/s41388-018-0443-5	http://dx.doi.org/10.1038/s41388-018-0443-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30104712				2023-01-03	WOS:000454775900001
J	Craigs, CL; West, RM; Hurlow, A; Bennett, MI; Ziegler, LE				Craigs, Cheryl L.; West, Robert M.; Hurlow, Adam; Bennett, Michael I.; Ziegler, Lucy E.			Access to hospital and community palliative care for patients with advanced cancer: A longitudinal population analysis	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; STANDARD ONCOLOGY CARE; EARLY INTEGRATION; SERVICES; OUTCOMES	Background The UK National Health Service is striving to improve access to palliative care for patients with advanced cancer however limited information exists on the level of palliative care support currently provided in the UK. We aimed to establish the duration and intensity of palliative care received by patients with advanced cancer and identify which cancer patients are missing out. Methods Retrospective cancer registry, primary care and secondary care data were obtained and linked for 2474 patients who died of cancer between 2010 and 2012 within a large metropolitan UK city. Associations between the type, duration, and amount of palliative care by demographic characteristics, cancer type, and therapies received were assessed using Chi-squared, Mann-Whitney or Kruskal-Wallis tests. Multinomial multivariate logistic regression was used to assess the odds of receiving community and/or hospital palliative care compared to no palliative care by demographic characteristics, cancer type, and therapies received. Results Overall 64.6% of patients received palliative care. The average palliative care input was two contacts over six weeks. Community palliative care was associated with more palliative care events (p<0.001) for a longer duration (p<0.001). Patients were less likely to receive palliative care if they were: male (p = 0.002), aged 80 years or over (p<0.05), diagnosed with lung cancer (p<0.05), had not received an opioid prescription (p<0.001), or had not received chemotherapy (p<0.001). Patients given radiotherapy were more likely to receive community only palliative care compared to no palliative care (Odds Ratio = 1.49, 95% Confidence Interval = 1.16-1.90). Conclusion Timely supportive care for cancer patients is advocated but these results suggest that older patients and those who do not receive anti-cancer treatment or opioid analgesics miss out. These patients should be targeted for assessment to identify unmet needs which could benefit from palliative care input.	[Craigs, Cheryl L.; Bennett, Michael I.; Ziegler, Lucy E.] Univ Leeds, Leeds Inst Hlth Sci, St Gemmas Acad Unit Palliat Care, Level 10,Clarendon Way, Leeds, W Yorkshire, England; [West, Robert M.] Univ Leeds, Hlth Serv Res, Leeds Inst Hlth Sci, Level 11,Clarendon Way, Leeds, W Yorkshire, England; [Hurlow, Adam] St James Univ Hosp, Palliat Care Team, Leeds, W Yorkshire, England	University of Leeds; University of Leeds; Saint James's University Hospital	Craigs, CL (corresponding author), Univ Leeds, Leeds Inst Hlth Sci, St Gemmas Acad Unit Palliat Care, Level 10,Clarendon Way, Leeds, W Yorkshire, England.	c.l.craigs@leeds.ac.uk	Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349; Ziegler, Lucy/0000-0001-9563-5014	Yorkshire Cancer Research [L384]	Yorkshire Cancer Research	This paper was supported by a project grant from Yorkshire Cancer Research (grant ref L384). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Bauman JR, 2014, J NATL COMPR CANC NE, V12, P1763, DOI 10.6004/jnccn.2014.0177; Bauman JR, 2014, J NATL COMPR CANC NE, V12, P71; Currow DC, 2008, PALLIATIVE MED, V22, P43, DOI 10.1177/0269216307085182; Davis MP, 2015, SUPPORT CARE CANCER, V23, P2677, DOI 10.1007/s00520-015-2630-z; Dixon J., 2015, EQUITY PROVISION PAL; Gagnon B, 2015, J PAIN SYMPTOM MANAG, V49, P36, DOI 10.1016/j.jpainsymman.2014.05.015; Gao J, 2011, J PALLIAT CARE, V27, P98, DOI 10.1177/082585971102700205; Gidwani R, 2015, ASCO ANN M P; Grande GE, 2006, AGE AGEING, V35, P267, DOI 10.1093/ageing/afj071; Greer JA, 2013, CA-CANCER J CLIN, V63, P349, DOI 10.3322/caac.21192; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Rugno FC, 2014, GYNECOL ONCOL, V135, P249, DOI 10.1016/j.ygyno.2014.08.030; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The Christie NHS Foundation Trust, 2016, ENH SUPP CAR INT SUP, P33; Tim B., 2011, J INNOVATION HLTH IN, V19, P173; Ziegler L, 2016, PAIN, V157, P2445, DOI 10.1097/j.pain.0000000000000656; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	19	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2018	13	8							e0200071	10.1371/journal.pone.0200071	http://dx.doi.org/10.1371/journal.pone.0200071			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP7NS	30089106	gold, Green Published			2023-01-03	WOS:000441090300005
J	Song, Y; Bian, Y; Zhen, TM				Song, Yan; Bian, Ying; Zhen, Tianmin			Making medicines more accessible in China: An empirical study investigating the early progress of essential medicine system	PLOS ONE			English	Article							PROVINCE; REFORM	Objective To assess changes in medicine availability and prices as well as subsequent affordability during the early years of the National Essential Medicine System (NEMS) reform in China. Methods Data were obtained from four provinces through a field survey conducted in 2010-2011. Outcome measures were percentage availability, delivery efficiency, ratios of local prices to international reference prices (MPRs), and number of days' household income needed to purchase medicines. Prices were adjusted for inflation/deflation and purchasing power parity. Results Under NEMS, the median MPR for essential medicines decreased from 3.27 times to 1.59 times from 2009 to 2010. The median medicine expenditure under standard treatments in 2010 equaled 1.06 days household income at a low-income level and 0.25 days household income at a middle-income level. A 25.67% reduction was observed in the average number of medicines stocked by primary healthcare facilities in 2011 compared with 2009 and the availability of essential medicines was 66.83%. During 2009-2011, suppliers could respond to 98.24% of the purchasing orders raised by primary healthcare facilities, and 89.32% of the order amounts could be delivered. Conclusions The market prices of essential medicines greatly decreased in China after the establishment of NEMS and showed improved affordability in the short term. However, current medicine prices remain high compared to international reference prices. Medicines were often unaffordable for economically backward residents. Future policies still need to target medicine availability as well as affordability.	[Song, Yan; Zhen, Tianmin] Shandong Acad Med Sci, Shandong Inst Med & Hlth Informat, Jinan, Shandong, Peoples R China; [Song, Yan; Bian, Ying] Univ Macau, Inst Chinese Med Sci, Taipa, Macau, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; University of Macau	Song, Y (corresponding author), Shandong Acad Med Sci, Shandong Inst Med & Hlth Informat, Jinan, Shandong, Peoples R China.; Song, Y (corresponding author), Univ Macau, Inst Chinese Med Sci, Taipa, Macau, Peoples R China.	yolanda_song@sina.com	bian, ying/ABI-8040-2020	bian, ying/0000-0002-1716-2925	National Natural Science Foundation of China [71503149]; Soft Science Research Program of Shandong Province [2016RKC03001]; Medical Science and Technology Development Program of Shandong Province [2015WS0174]; Shandong Academy of Medical Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Soft Science Research Program of Shandong Province; Medical Science and Technology Development Program of Shandong Province; Shandong Academy of Medical Sciences	This study was funded by the National Natural Science Foundation of China (http://www.nsfc.gov.cn/), No. 71503149 (YS), the Soft Science Research Program of Shandong Province (http://www.sdstc.gov.cn/), No. 2016RKC03001 (YS), the Medical Science and Technology Development Program of Shandong Province (http://www.sdwsjs.gov.cn/), No. 2015WS0174 (YS) and the Innovation Project of Shandong Academy of Medical Sciences (http://www.sdams.cn/) (TZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, CHIN NAT HLTH ACC RE; [Anonymous], 2009, CHINESE HLTH STAT DI; [Anonymous], 2013, CHINESE HLTH STAT DI; Babar ZUD, 2013, PHARMACOECONOMICS, V31, P1063, DOI 10.1007/s40273-013-0095-9; Barber SL, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010303; Charles WF, 2011, IMPLEMENTING HLTH CA; Chen W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-211; China MOHRSS, 2009, PER CAP ANN NET INC; China NDRC, 2011, GOV REP CENTR PROC E; China NDRC, 2009, IMPL PLAN REC PRIOR; China NDRC, 2006, OP FURTH PRIC MAN ME; Chinese Ministry of Health, 2011, IMPL PROGR NAT ESS M; Eggleston K, 2008, HEALTH ECON, V17, P149, DOI 10.1002/hec.1306; Fang Y, 2013, LANCET GLOB HEALTH, V1, pE227, DOI 10.1016/S2214-109X(13)70072-X; Fudan University, 2011, SPEC THEM RES NAT ES; Health Action International, 2008, GLOB REG COR LIST; Hogerzeil HV, 2013, LANCET GLOB HEALTH, V1, pE174, DOI 10.1016/S2214-109X(13)70077-9; Hu J, 2016, HEALTH POLICY, V120, P519, DOI 10.1016/j.healthpol.2016.03.014; Hu S., 2010, FINANCING PRICING UT; Kyla H, 2011, IMPROVING ACCESS ESS; Liu B, 2008, CHINA PHARM, V19, P637; Mao W, 2015, ZERO MARK UP POLICY; MSH, 2009, INT DRUG PRIC IND GU; OECD, 2013, HLTH GLANC 2013 OECD, DOI [10.1787/health_glance-2013-49-en, DOI 10.1787/HEALTH_GLANCE-2013-49-EN]; Quick JD, 2002, B WORLD HEALTH ORGAN, V80, P913; Song Yan, 2014, J Pharm Policy Pract, V7, P12, DOI 10.1186/2052-3211-7-12; Tian W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162795; Wang JY, 2015, INDIAN J PHARMACOL, V47, P535, DOI 10.4103/0253-7613.165192; WHO, WHO HLTH ACT INT PRO; WHO, 2011, MED AV SEL GEN MED; WHO Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Bank, 2010, PPP CONV FACT PRIV C; Yang L, 2013, B WORLD HEALTH ORGAN, V91, P184, DOI 10.2471/BLT.11.097998; Yang LP, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2720-3; Ye L, 2008, J CHINESE HLTH RESOU, V11, P195; Ye L., 2009, STUDY NATL ESSENTIAL	37	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2018	13	8							e0201582	10.1371/journal.pone.0201582	http://dx.doi.org/10.1371/journal.pone.0201582			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3UD	30070998	Green Submitted, Green Published, gold			2023-01-03	WOS:000440778600062
J	Luo, W; Hong, H; Wang, XF; McGoogan, JM; Rou, KM; Wu, ZY				Luo, Wei; Hong, Hang; Wang, Xiaofang; McGoogan, Jennifer M.; Rou, Keming; Wu, Zunyou			Synthetic drug use and HIV infection among men who have sex with men in China: A sixteen-city, cross-sectional survey	PLOS ONE			English	Article							EPIDEMIOLOGY; PREVENTION; BEHAVIORS; PATTERNS	Introduction Increasing evidence suggests an association between synthetic drug use and HIV infection among men who have sex with men (MSM). The aim of this study was to evaluate synthetic drug use prevalence, describe characteristics of synthetic drug users, and investigate whether synthetic drug use is associated with HIV infection among Chinese MSM. Methods A cross-sectional survey was conducted in 16 Chinese cities among males >18 years old who reported having had sex with men in the prior 3 months, but did not already have a known HIV-positive serostatus. Participants were grouped according to lifetime synthetic drug use and characteristics were compared using Chi-square test. Determinants of HIV infection were assessed using univariate and multivariate regression. Results Among 3,135 participants, 1,249 reported lifetime synthetic drug use, for a prevalence of 39.8%. Nearly all users (96.3%) reported using inhaled alkyl nitrites ("poppers"). Synthetic drug users were more likely to be younger (<30 years, p<0.001), single (p<0.001), and more educated (p<0.001), and were more likely to engage in higher risk sexual behavior compared to non-drug users. Overall HIV prevalence was 7.8% (246/3,135). However, prevalence among synthetic drug users was 10.6% (132/246) compared to 6.0% (114/246) for non-drug users (p<0.001). Factors associated with an increased odds of HIV infection included inconsistent condom use with male partners (adjusted odds ratio [OR] = 2.18, 95% confidence interval [CI] = 1.64-2.91) and synthetic drug use (adjusted OR = 2.04, CI = 1.56-2.70). Conclusion Prevalence of synthetic drug use, especially poppers use, prevalence was high in our study, and users had 2-fold greater odds of HIV acquisition. It is clear that there is an urgent need for increased prevention, testing, and treatment interventions for this key, dual-risk population in China. Moreover, we call on the Chinese Government to consider regulating poppers so that users can be properly warned about their associated risks.	[Luo, Wei; Hong, Hang; Wang, Xiaofang; McGoogan, Jennifer M.; Rou, Keming; Wu, Zunyou] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Wu, Zunyou] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA; [Hong, Hang] Ningbo Ctr Dis Control & Prevent, Ningbo, Zhejiang, Peoples R China	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; University of California System; University of California Los Angeles	Wu, ZY (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.; Wu, ZY (corresponding author), Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.	wuzy@263.net		Wu, Zunyou/0000-0002-0839-4548	Chinese National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases [2012ZX10001-007]	Chinese National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases	This study was supported by Chinese National Science and Technology Major Project on Prevention and Treatment of Major Infectious Diseases including AIDS and Viral Hepatitis (No.2012ZX10001-007) (ZW) (http://www.most. gov.cn/kjjh/gjkjjh/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beyrer C, 2016, LANCET, V388, P198, DOI 10.1016/S0140-6736(16)30781-4; Beyrer C, 2012, LANCET, V380, P367, DOI 10.1016/S0140-6736(12)60821-6; Chen X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126320; Chinese Center for Disease Control and Prevention, 2009, NAT GUID DET HIV AID; Colfax G, 2005, J URBAN HEALTH, V82, pI62, DOI 10.1093/jurban/jti025; J.U.N.P. on H. (UNAIDS), 2014, GAP REP; Lambdin BH, 2015, CURR HIV RES, V13, P244, DOI 10.2174/1570162X1303150506185423; Lea T, 2013, DRUG ALCOHOL REV, V32, P39, DOI 10.1111/j.1465-3362.2012.00494.x; Li D, 2014, INT J CORROS, V2014, DOI 10.1155/2014/565109; Lu H, 2015, PLOS ONE, V8, P123; MCCALL H, 2015, BMJ-BRIT MED J, V351, DOI DOI 10.1136/BMJ.H5790; McCall H, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5790; Melendez-Torres GJ, 2016, CURR OPIN INFECT DIS, V29, P58, DOI 10.1097/QCO.0000000000000234; Vu NTT, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19273; Office of China National Narcotics Control Commission, 2015, ANN REP DRUG SIT CHI; Shan D, 2017, Zhonghua Yu Fang Yi Xue Za Zhi, V51, P718, DOI 10.3760/cma.j.issn.0253-9624.2017.08.011; Tang SY, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1904-5; The EMIS Network, EMIS2010; UNAIDS, 2016, PREV GAP REP; UNAIDS, 2014, 90 90 90 AMB TREATM; Wei CY, 2012, DRUG ALCOHOL DEPEN, V120, P246, DOI 10.1016/j.drugalcdep.2011.07.016; Wu Z., 2016, HIV AIDS CHIN NUMB; Wu ZY, 2013, CLIN INFECT DIS, V57, P298, DOI 10.1093/cid/cit210; Xu JJ, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0178-x; Xu JJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0642-9; Xu JJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/725361; Zhang C, 2016, SUBST USE MISUSE, V51, P1821, DOI 10.1080/10826084.2016.1197264; Zhang H, 2016, DRUG ALCOHOL DEPEN, V160, P42, DOI 10.1016/j.drugalcdep.2015.11.037; Zhao PZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170024; Zhu Z P, 2017, Zhonghua Liu Xing Bing Xue Za Zhi, V38, P189, DOI 10.3760/cma.j.issn.0254-6450.2017.02.011	30	11	18	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2018	13	7							e0200816	10.1371/journal.pone.0200816	http://dx.doi.org/10.1371/journal.pone.0200816			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO7ZJ	30063747	Green Published, gold, Green Submitted			2023-01-03	WOS:000440300500020
J	Chan, E; Foster, S; Sambell, R; Leong, P				Chan, Evelyn; Foster, Samantha; Sambell, Ryan; Leong, Paul			Clinical efficacy of virtual reality for acute procedural pain management: A systematic review and meta-analysis	PLOS ONE			English	Review							BURN WOUND DEBRIDEMENT; DISTRACTION; ANXIETY; FEASIBILITY; CHILDREN; THERAPY	Background Acutely painful procedures are commonplace. Current approaches to pain most often involve pharmacotherapy, however, there is interest in virtual reality (VR) as a non-pharmacological alternative. A methodologically rigorous systematic review and meta-analysis is lacking. Methods Following PRISMA guidelines, we searched the Cochrane Library, Ovid MEDLINE, Embase, CINAHL, ERIC, NIHR Centre for Review and Dissemination, Proquest, the System for Information on Grey Literature in Europe and the WHO International Clinical Trials Registry Platform from inception to 5 November 2017. Included studies were randomised with an experimental trial design, included a non-VR control group and examined the efficacy of VR with regards to an acutely painful clinical intervention. Bias was assessed along Cochrane guidelines, with performance bias not assessed due to the non-blindable nature of VR. We extracted summary data for maximal pain score and used standard mean difference DerSimonian-Laird random-effects meta-analysis (RevMan 5.3). This review was prospectively registered (PROSPERO CRD42017058204). Findings Of the 12,450 studies identified, 20 studies were eligible for the systematic review. No trials reported in sufficient detail to judge their risk of bias, and 10 studies were at high risk of bias in at least one domain. 16 studies (9 randomised controlled trials, 7 crossover studies) examining 656 individuals were included in quantitative synthesis. Pain scales were heterogenous, but mostly employed 100-point scales. Across all trials, meta-analysis was suggestive of a -0.49 (95% CI -0.83 to -0.41, p = 0.006) standardised mean difference reduction in pain score with VR. However there was a high degree of statistical heterogeneity (chi(2) p<0.001, I-2 81%, 95% CI for I-2 70-88%), driven by randomised studies, with substantial clinical heterogeneity. Conclusion These data suggest that VR may have a role in acutely painful procedures, however included studies were clinically and statistically heterogenous. Further research is required to validate findings, establish cost efficacy and optimal clinical settings for usage. Future trials should report in accordance with established guidelines.	[Chan, Evelyn] Monash Med Ctr, Dept Paediat, Clayton, Vic, Australia; [Chan, Evelyn; Foster, Samantha; Sambell, Ryan; Leong, Paul] Monash Med Ctr, Southern Clin Sch, Clayton, Vic, Australia; [Leong, Paul] Monash Med Ctr, Monash Lung & Sleep, Clayton, Vic, Australia	Monash University; Monash University; Monash University	Leong, P (corresponding author), Monash Med Ctr, Southern Clin Sch, Clayton, Vic, Australia.; Leong, P (corresponding author), Monash Med Ctr, Monash Lung & Sleep, Clayton, Vic, Australia.	paul.leong@monash.edu.au	Foster, Samantha Michelle/GQI-0807-2022	Leong, Paul/0000-0002-7409-9328				Carrougher GJ, 2009, J BURN CARE RES, V30, P785, DOI 10.1097/BCR.0b013e3181b485d3; Chan EA, 2006, J CLIN NURS, V15, P661, DOI 10.1111/j.1365-2702.2006.01345.x; CHOINIERE M, 1994, BURNS, V20, P229, DOI 10.1016/0305-4179(94)90188-0; Cohen J., 2013, STAT POWER ANAL BEHA; Das Debashish A, 2005, BMC Pediatr, V5, P1, DOI 10.1186/1471-2431-5-1; Dascal Julieta, 2017, Innov Clin Neurosci, V14, P14; Ding H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120519; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917; Garrett B, 2014, CLIN J PAIN, V30, P1089, DOI 10.1097/AJP.0000000000000064; Gershon J, 2004, J AM ACAD CHILD PSY, V43, P1243, DOI 10.1097/01.chi.0000135621.23145.05; Gold JI, 2018, J PEDIATR PSYCHOL, V43, P266, DOI 10.1093/jpepsy/jsx129; Gold JI, 2006, CYBERPSYCHOL BEHAV, V9, P207, DOI 10.1089/cpb.2006.9.207; Guo CL, 2015, J CLIN NURS, V24, P115, DOI 10.1111/jocn.12626; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hoffman HG, 2008, CLIN J PAIN, V24, P299, DOI 10.1097/AJP.0b013e318164d2cc; Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; JahaniShoorab N, 2015, IRAN J MED SCI, V40, P219; Jeffs D, 2014, J BURN CARE RES, V35, P395, DOI 10.1097/BCR.0000000000000019; Kenney M.P., 2016, PSYCHOL CONSCIOUS, V3, P199, DOI [DOI 10.1016/J.CPR.2010.07.001, DOI 10.1037/CNS0000084]; Kipping B, 2012, BURNS, V38, P650, DOI 10.1016/j.burns.2011.11.010; Konstantatos AH, 2009, BURNS, V35, P491, DOI 10.1016/j.burns.2008.08.017; Maani CV, 2011, J TRAUMA, V71, pS125, DOI 10.1097/TA.0b013e31822192e2; Matsangidou M., BR J NEUROSCI NURS, V13, P133, DOI [10.12968/bjnn.2017.13.3.133, DOI 10.12968/BJNN.2017.13.3.133]; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; McSherry T, 2018, J BURN CARE RES, V39, P278, DOI 10.1097/BCR.0000000000000589; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morris LD, 2010, BURNS, V36, P659, DOI 10.1016/j.burns.2009.09.005; Orsini N., 2006, HETEROGI STATA MODUL; Sander Wint Suzanne, 2002, Oncol Nurs Forum, V29, pE8; SAVEDRA MC, 1993, NURS RES, V42, P5; Schmitt YS, 2011, BURNS, V37, P61, DOI 10.1016/j.burns.2010.07.007; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Tighe P, 2015, PAIN MED, V16, P1806, DOI 10.1111/pme.12760; Upp J, 2013, PAIN MED, V14, P124, DOI 10.1111/pme.12015; van Twillert B, 2007, J BURN CARE RES, V28, P694, DOI 10.1097/BCR.0B013E318148C96F; Walker MR, 2014, MIL MED, V179, P891, DOI 10.7205/MILMED-D-13-00343; Wolitzky K, 2005, PSYCHOL HEALTH, V20, P817, DOI 10.1080/14768320500143339; Won AS, 2017, CHILDREN-BASEL, V4, DOI 10.3390/children4070052; Wong D L, 1988, Pediatr Nurs, V14, P9	44	59	61	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2018	13	7							e0200987	10.1371/journal.pone.0200987	http://dx.doi.org/10.1371/journal.pone.0200987			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO4SZ	30052655	Green Published, gold, Green Submitted			2023-01-03	WOS:000440006600020
J	Augusto, O; Keyes, EE; Madede, T; Abacassamo, F; de la Corte, P; Chilundo, B; Bailey, PE				Augusto, Orvalho; Keyes, Emily E.; Madede, Tavares; Abacassamo, Fatima; de la Corte, Pilar; Chilundo, Baltazar; Bailey, Patricia E.			Progress in Mozambique: Changes in the availability, use, and quality of emergency obstetric and newborn care between 2007 and 2012	PLOS ONE			English	Article							MATERNAL MORBIDITY; PROCESS INDICATORS; NEEDS-ASSESSMENT; UNITED-STATES; SERVICES; PREGNANCY; MORTALITY	Introduction Maternal mortality in Mozambique has not declined significantly in the last 10-15 years, plateauing around 480 maternal deaths per 100,000 live births. Good quality antenatal care and routine and emergency intrapartum care are critical to reducing preventable maternal and newborn deaths. Materials and methods We compare the findings from two national cross-sectional facility-based assessments conducted in 2007 and 2012. Both were designed to measure the availability, use and quality of emergency obstetric and neonatal care. Indicators for monitoring emergency obstetric care were used as were descriptive statistics. Results The availability of facilities providing the full range of obstetric life-saving procedures (signal functions) decreased. However, an expansion in the provision of individual signal functions was highly visible in health centers and health posts, but in hospitals, performance was less satisfactory, with proportionally fewer hospitals providing assisted vaginal delivery, obstetric surgery and blood transfusions. All other key indicators showed signs of improvements: the institutional delivery rate, the cesarean delivery rate, met need for emergency obstetric care (EmOC), institutional stillbirth and early neonatal death rates, and cause-specific case fatality rates (CFRs). CFRs for most major obstetric complications declined between 17% and 69%. The contribution of direct causes to maternal deaths decreased while the proportion of indirect causes doubled during the five-year interval. Conclusions The indicator of EmOC service availability, often used for planning and developing EmONC networks, requires close examination. The standard definition can mask programmatic weaknesses and thus, fails to inform decision makers of what to target. In this case, the decline in the use of assisted vaginal delivery explained much of the difference in this indicator between the two surveys, as did faltering hospital performance. Despite this backsliding, many signs of improvement were also observed in this 5-year period, but indicator levels continue below recommended thresholds. The quality of intrapartum care and the adverse consequences from infectious diseases during pregnancy point to priority areas for programmatic improvement.	[Augusto, Orvalho; Madede, Tavares; Abacassamo, Fatima; Chilundo, Baltazar] Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique; [Keyes, Emily E.; Bailey, Patricia E.] FHI 360, Durham, NC USA; [Keyes, Emily E.; Bailey, Patricia E.] Columbia Univ, Averting Maternal Death & Disabil, New York, NY USA; [de la Corte, Pilar] UNFPA, Maputo, Mozambique	Eduardo Mondlane University; FHI 360; Columbia University	Augusto, O (corresponding author), Univ Eduardo Mondlane, Fac Med, Maputo, Mozambique.	orvaquim@gmail.com	Augusto, Orvalho/J-8767-2019; Madede, Tavares/GWD-0998-2022	Augusto, Orvalho/0000-0002-0005-3968; 	United States Agency for International Development (USAID) [GHA-A-00-08-00003-00]; MEASURE Evaluation Phase IV Project [FHI 360]	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); MEASURE Evaluation Phase IV Project	The United States Agency for International Development (USAID) funded the preparation of this publication through a cooperative agreement (GHA-A-00-08-00003-00) with the MEASURE Evaluation Phase IV Project under a contract with FHI 360. The manuscript represents the views of the authors and does not represent the views of USAID or the US Government. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, I NAC EST; Baguiya A, 2016, INT J GYNECOL OBSTET, V135, pS2, DOI 10.1016/j.ijgo.2016.09.004; Bailey P, 2017, BRIT J OBSTET GYNAEC, DOI [10.1111/1471-05-28.14477, DOI 10.1111/1471-05-28.14477]; Bailey PE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1479-1; Bailey PE, 2015, BMC PREGNANCY CHILDB, V15, DOI [10.1186/s12884-016-1035-4, 10.1186/s12884-015-0725-7]; Bang RA, 2004, BJOG-INT J OBSTET GY, V111, P231, DOI 10.1111/j.1471-0528.2004.00063.x; Bank W, 2015, GROSS NAT INC; Banke-Thomas A, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.31880; Bennett TA, 1998, AM J OBSTET GYNECOL, V178, P346, DOI 10.1016/S0002-9378(98)80024-0; Bosomprah S, 2016, INT J GYNECOL OBSTET, V132, P130, DOI 10.1016/j.ijgo.2015.11.004; Campbell OMR, 2016, LANCET, V388, P2193, DOI 10.1016/S0140-6736(16)31528-8; Chavane L, J OBSTET GYNAECOLOGY; DARMSTADT GL, 2009, BMC PREGNANCY CHI S1, V9; Gabrysch S, 2012, TROP MED INT HEALTH, V17, P2, DOI 10.1111/j.1365-3156.2011.02851.x; Holmer H, 2015, BJOG-INT J OBSTET GY, V122, P183, DOI 10.1111/1471-0528.13230; Hussein J, 2001, INT J GYNECOL OBSTET, V75, P63, DOI 10.1016/S0020-7292(01)00474-X; Instituto Nacional de Estat oA stica, 2012, AN EST 2012 MOC; Instituto Nacional de Estat oA stica Ministe A rio da Sau A de ORC Macro/ DHS Program, 2005, ORC MACR DHS PROGR M; Keyes E, 2017, IMPROVEMENTS FACILIT; Kouanda S, 2016, INT J GYNECOL OBSTET, V135, pS11, DOI 10.1016/j.ijgo.2016.08.008; Lauritsen J, 2008, EPIDATA ENTRY VERSI; Lobis S, 2005, INT J GYNECOL OBSTET, V88, P203, DOI 10.1016/j.ijgo.2004.11.025; Long Q, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0686-x; Makanga PT, 2017, INT J HEALTH GEOGR, V16, DOI 10.1186/s12942-016-0074-4; Marazzi MC, 2011, AIDS, V25, P1611, DOI 10.1097/QAD.0b013e3283493ed0; McCord C, 2001, INT J GYNECOL OBSTET, V75, P297, DOI 10.1016/S0020-7292(01)00526-4; McKinnon B, 2014, TROP MED INT HEALTH, V19, P780, DOI 10.1111/tmi.12323; Ministe A rio de Sau A de (MISAU) Instituto Nacional de Estat oA stica (INE) ICF Internacional, ICF INT INQ IND IM M; Ministerio da Saude (MISAU) Instituto Nacional de Estatistica (INE) & ICF International (ICFI), 2011, MOZ DEM HLTH SURV 20; MOXON SG, 2015, BMC PREGNANCY CHI S2, V15; Nesbitt RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081089; Nolens B, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1052-3; Ntambue AM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1224-9; Panciera R, 2016, BMC PREGNANCY CHILDB, V16; Paxton A, 2006, INT J GYNECOL OBSTET, V95, P192, DOI 10.1016/j.ijgo.2006.08.009; Pereira C, 2007, BJOG-INT J OBSTET GY, V114, P1530, DOI 10.1111/j.1471-0528.2007.01489.x; StataCorp LLC, 2015, US GUID; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World Health Organization (WHO); UNFPA; UNICEF; Columbia University. Mailman School of Public Health, 2009, MON EM OBST CAR HDB	39	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0199883	10.1371/journal.pone.0199883	http://dx.doi.org/10.1371/journal.pone.0199883			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN4SJ	30020958	Green Published, gold, Green Submitted			2023-01-03	WOS:000439022400030
J	Hirsch, C				Hirsch, Calvin			Review: Postdischarge home interventions can increase or decrease falls in older adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hirsch, Calvin] Univ Calif Davis, Sacramento, CA 95817 USA	University of California System; University of California Davis	Hirsch, C (corresponding author), Univ Calif Davis, Sacramento, CA 95817 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2018	169	2					JC10	JC10		10.7326/ACPJC-2018-169-2-010	http://dx.doi.org/10.7326/ACPJC-2018-169-2-010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN0TI	30014099				2023-01-03	WOS:000438689200010
J	Kang, JH; Kao, LT; Lin, HC; Wang, TJ; Yang, TY				Kang, Jiunn-Horng; Kao, Li-Ting; Lin, Herng-Ching; Wang, Ta-Jung; Yang, Tsung-Yeh			Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; CONVERTING ENZYME-INHIBITORS; INSURANCE RESEARCH DATABASE; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; ACE-INHIBITORS; RECEPTOR BLOCKERS; MORTALITY; OUTCOMES; SYSTEM	Whether statins and an angiotensin-converting enzyme inhibitors (ACEIs) / angiotensin receptor blockors (ARBs) are associated with reduced risks of infection events is still inconclusive. This study aimed to explore the risk of hospitalization for pneumonia among patients who had received treatment with ACEIs/ARBs and/or statins using a population-based data-set. This study included 19,281 patients as cases who were hospitalized for pneumonia and 19,281 controls. We used a logistic regression to compute the odds ratio (OR) and 95% confidence interval (CI) for having previously used statins or an ACEI/ARB between patients who were hospitalized for pneumonia treatment and controls. We found there were significant associations between hospitalization for pneumonia and statin-only users (p<0.001), ACEI/ARB-only users (p<0.001), and statin and ACEI/ARB users (p<0.001). The logistic regression analysis suggested that statin-only users (adjusted OR = 0.38, 95% CI = 0.34 similar to 0.43), ACEI/ARB-only users (adjusted OR = 0.86, 95% CI = 0.82 similar to 0.91), and statin and ACEI/ARB users (adjusted OR = 0.47, 95% CI = 0.44 similar to 0.50) were all less likely to be hospitalized for pneumonia treatment than were non-users. Furthermore, we found that statin-only users (adjusted OR = 0.44, 95% CI = 0.40 similar to 0.50) and statin and ACEI/ARB users (adjusted OR = 0.55, 95% CI = 0.52 similar to 0.58) were less likely to be hospitalized for pneumonia treatment compared to ACEI-only users. However, combined statin and ACEI/ARB users (adjusted OR = 1.24, 95% CI = 1.10 similar to 1.40) were more likely to have been hospitalized for pneumonia treatment compared to statin-only users. Although we found use of both statins and ACEI/ARB were significantly associated with a lower risk of pneumonia, the combination of the two medications did not provide additional protection against pneumonia risk.	[Kang, Jiunn-Horng] Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Coll Med, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan; [Kao, Li-Ting] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Kao, Li-Ting] Triserv Gen Hosp, Dept Pharm Practice, Taipei, Taiwan; [Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan; [Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan; [Wang, Ta-Jung; Yang, Tsung-Yeh] Taipei Med Univ Hosp, Shuang Ho Hosp, Div Cardiol, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; National Defense Medical Center; Tri-Service General Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University Hospital	Lin, HC (corresponding author), Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan.; Lin, HC (corresponding author), Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.	henry11111@tmu.edu.tw	Kao, Li-Ting/W-9287-2018	Kao, Li-Ting/0000-0003-0692-7408				Almirall J, 2014, ARCH BRONCONEUMOL, V50, P250, DOI 10.1016/j.arbres.2013.11.016; Brassard P, 2017, PHARMACOEPIDEM DR S, V26, P63, DOI 10.1002/pds.4112; Cheng CL, 2015, INT J CARDIOL, V201, P96, DOI 10.1016/j.ijcard.2015.07.075; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cheng HH, 2014, EUR REV MED PHARMACO, V18, P2294; Chung SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111268; Citgez E, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000142; de Groot MCH, 2014, EUR J EPIDEMIOL, V29, P767, DOI 10.1007/s10654-014-9941-0; Di Raimondo D, 2012, CURR PHARM DESIGN, V18, P4385, DOI 10.2174/138161212802481282; Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03; Grau I, 2014, INT J INFECT DIS, V25, P59, DOI 10.1016/j.ijid.2013.12.013; Gunnell AS, 2013, HEART, V99, P1353, DOI 10.1136/heartjnl-2013-304348; Hemila H, 2016, CLIN INTERV AGING, V11, P1379, DOI 10.2147/CIA.S114515; Hoang V, 2016, CARDIOVASC DRUG THER, V30, P189, DOI 10.1007/s10557-016-6652-7; Kahlon S, 2013, CLIN MICROBIOL INFEC, V19, P709, DOI 10.1111/j.1469-0691.2012.04003.x; Kang JH, 2015, J NEUROL SCI, V348, P89, DOI 10.1016/j.jns.2014.11.013; Kim J, 2016, INT J CHRONIC OBSTR, V11, P2159, DOI 10.2147/COPD.S104097; Lin CF, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0202-x; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; Mortensen EM, 2012, CLIN INFECT DIS, V55, P1466, DOI 10.1093/cid/cis733; Myles PR, 2009, PHARMACOEPIDEM DR S, V18, P269, DOI 10.1002/pds.1715; Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537; Papazian L, 2013, JAMA-J AM MED ASSOC, V310, P1692, DOI 10.1001/jama.2013.280031; Phung DT, 2013, OBES REV, V14, P839, DOI 10.1111/obr.12055; Polgreen LA, 2015, CLIN INFECT DIS, V60, P1760, DOI 10.1093/cid/civ190; Radaelli A, 2007, ARTERIOSCL THROM VAS, V27, P2750, DOI 10.1161/ATVBAHA.107.149039; Sekizawa K, 1998, LANCET, V352, P1069, DOI 10.1016/S0140-6736(05)60114-6; Shankar-Hari M, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-106; Shin JY, 2017, BRIT J CLIN PHARMACO, V83, P1319, DOI 10.1111/bcp.13208; Shinohara Y, 2012, ADV THER, V29, P900, DOI 10.1007/s12325-012-0049-1; Shokouhi S, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.9456; Shrikrishna D, 2012, CLIN SCI, V123, P487, DOI 10.1042/CS20120081; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Viasus D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006251; Wang HC, 2015, MOVEMENT DISORD, V30, P593, DOI 10.1002/mds.26136; Wieczorek-Surdacka E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020106; Wzgarda A, 2017, EUR J PHARMACOL, V797, P9, DOI 10.1016/j.ejphar.2016.12.031	37	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0199981	10.1371/journal.pone.0199981	http://dx.doi.org/10.1371/journal.pone.0199981			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0GK	29953536	Green Submitted, gold, Green Published			2023-01-03	WOS:000436645400106
J	Clayton, JA				Clayton, Janine A.			Dry Eye	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HORMONE REPLACEMENT THERAPY; MEIBOMIAN GLAND DYSFUNCTION; OCULAR SURFACE; POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTORS; UTILITY-ASSESSMENT; ANDROGEN RECEPTOR; EXTRACELLULAR DNA; MESSENGER-RNA; FATTY-ACIDS		[Clayton, Janine A.] NIH, Off Res Womens Hlth, 6707 Democracy Blvd,Suite 400, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Clayton, JA (corresponding author), NIH, Off Res Womens Hlth, 6707 Democracy Blvd,Suite 400, Bethesda, MD 20892 USA.	Janine.Clayton@nih.gov		Clayton, Janine/0000-0003-2981-3622				Adatia FA, 2004, CAN J OPHTHALMOL, V39, P767, DOI 10.1016/S0008-4182(04)80071-1; Agarwal P, 2016, DRUG DISCOV TODAY, V21, P977, DOI 10.1016/j.drudis.2016.04.002; Anitua E, 2015, ACTA OPHTHALMOL, V93, pE605, DOI 10.1111/aos.12710; Arita R, 2016, INVEST OPHTH VIS SCI, V57, P3928, DOI 10.1167/iovs.16-19788; Askeroglu U, 2013, PLAST RECONSTR SURG, V131, P159, DOI 10.1097/PRS.0b013e318272a00e; Baudouin C, 1999, OPHTHALMOLOGY, V106, P556, DOI 10.1016/S0161-6420(99)90116-1; Benitez-Del-Castillo J, 2017, OCUL SURF, V15, P169, DOI 10.1016/j.jtos.2016.11.003; Bremond-Gignac D, 2014, EXPERT OPIN DRUG MET, V10, P905, DOI 10.1517/17425255.2014.915026; Bron A J, 2004, Ocul Surf, V2, P149; Bron AJ, 2014, OCUL SURF, V12, pS1, DOI 10.1016/j.jtos.2014.02.002; Buchholz P, 2006, OCUL SURF, V4, P155, DOI 10.1016/S1542-0124(12)70043-5; Colligris B, 2014, EXPERT OPIN PHARMACO, V15, P1371, DOI 10.1517/14656566.2014.914492; Coursey TG, 2015, J CONTROL RELEASE, V213, P168, DOI 10.1016/j.jconrel.2015.07.007; Coursey TG, 2014, J IMMUNOL, V193, P5264, DOI 10.4049/jimmunol.1400016; Craig JP, 2017, OCUL SURF, V15, P802, DOI 10.1016/j.jtos.2017.08.003; Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008; Cumberland PM, 2015, J CATARACT REFR SURG, V41, P2466, DOI 10.1016/j.jcrs.2015.05.040; De Paiva CS, 2006, EXP EYE RES, V83, P526, DOI 10.1016/j.exer.2006.02.004; Deinema LA, 2017, OPHTHALMOLOGY, V124, P43, DOI 10.1016/j.ophtha.2016.09.023; Dogru M, 2013, EXPERT OPIN INV DRUG, V22, P1581, DOI 10.1517/13543784.2013.838557; Dry Eye Assessment Management Stud, 2018, NEW ENGL J MED, V378, P1681, DOI 10.1056/NEJMoa1709691; Esmaeli B, 2000, OPHTHALMOLOGY, V107, P180, DOI 10.1016/S0161-6420(99)00040-8; Fini ME, 2016, EXP EYE RES, V147, P57, DOI 10.1016/j.exer.2016.04.019; Fogt JS, 2016, CLIN OPHTHALMOL, V10, P2237, DOI 10.2147/OPTH.S120158; Foulks Gary N, 2003, Ocul Surf, V1, P107; Fraunfelder FT, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/285851; Fuchsjager-Mayri G, 2002, INVEST OPHTH VIS SCI, V43, P2841; Galor A, 2015, EYE, V29, P301, DOI 10.1038/eye.2014.263; Golebiowski B, 2012, OPTOMETRY VISION SCI, V89, P1443, DOI 10.1097/OPX.0b013e3182693cef; Goyal S, 2016, SEMIN OPHTHALMOL, V31, P59, DOI 10.3109/08820538.2015.1114853; Hartstein I, 2005, CURR MED RES OPIN, V21, P255, DOI 10.1185/030079905X26252; Henrik S, 1933, ACTA OPHTHALMOL, V2, P1; Hessen Michelle, 2014, J Ophthalmic Vis Res, V9, P240; Kaiserman I, 2005, AM J OPHTHALMOL, V139, P498, DOI 10.1016/j.ajo.2004.10.022; KARSON CN, 1984, NEUROLOGY, V34, P677, DOI 10.1212/WNL.34.5.677; Kim YJ, 2016, CORNEA, V35, P536, DOI 10.1097/ICO.0000000000000756; Lee YB, 2014, INVEST OPHTH VIS SCI, V55, P3525, DOI 10.1167/iovs.14-13881; Li DQ, 2004, INVEST OPHTH VIS SCI, V45, P4302, DOI 10.1167/iovs.04-0299; Lim A, 2015, TRENDS MOL MED, V21, P736, DOI 10.1016/j.molmed.2015.10.001; Ljubimov AV, 2017, VISION RES, V139, P138, DOI 10.1016/j.visres.2017.03.002; Luo Lihui, 2005, Eye Contact Lens, V31, P186, DOI 10.1097/01.ICL.0000162759.79740.46; Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276; Marshall Leisa L, 2016, Consult Pharm, V31, P96, DOI 10.4140/TCP.n.2016.96; Mastrota KM, 2008, OPTOMETRY VISION SCI, V85, P814, DOI 10.1097/OPX.0b013e3181852777; Mcmonnies Charles W, 2017, J Optom, V10, P5, DOI 10.1016/j.optom.2016.06.002; McNamara NA, 2014, INVEST OPHTH VIS SCI, V55, P7079, DOI 10.1167/iovs.14-14828; Messmer EM, 2016, OPHTHALMOLOGY, V123, P2300, DOI 10.1016/j.ophtha.2016.07.028; Messmer EM, 2015, DTSCH ARZTEBL INT, V112, P71, DOI 10.3238/arztebl.2015.0071; Miljanovic B, 2005, AM J CLIN NUTR, V82, P887, DOI 10.1093/ajcn/82.4.887; Mogil JS, 2012, NAT REV NEUROSCI, V13, P859, DOI 10.1038/nrn3360; Morgan PB, 2013, CONT LENS SPECTR, V28, P31; Morrow GL, 1998, AM FAM PHYSICIAN, V57, P735; Moshirfar M, 2014, CLIN OPHTHALMOL, V8, P1419, DOI 10.2147/OPTH.S65263; Nakamori K, 1997, AM J OPHTHALMOL, V124, P24, DOI 10.1016/S0002-9394(14)71639-3; Narayanaswamy A, 2015, JAMA OPHTHALMOL, V133, P206, DOI 10.1001/jamaophthalmol.2014.4893; Nassiri Nariman, 2013, J Ophthalmic Vis Res, V8, P351; Nelson JD, 2011, INVEST OPHTH VIS SCI, V52, P1930, DOI 10.1167/iovs.10-6997b; Ogawa Y, 2003, INVEST OPHTH VIS SCI, V44, P1888, DOI 10.1167/iovs.02-0699; Pinheiro Jr. Manuel Neuzimar, 2007, Arq. Bras. Oftalmol., V70, P649, DOI 10.1590/S0004-27492007000400016; Rocha EM, 2013, CURR OPIN OPHTHALMOL, V24, P348, DOI 10.1097/ICU.0b013e32836227bf; Rocha EM, 2000, BRIT J OPHTHALMOL, V84, P76, DOI 10.1136/bjo.84.1.76; Rosin LM, 2013, CLIN OPHTHALMOL, V7, P2131, DOI 10.2147/OPTH.S41358; Sall K, 2000, OPHTHALMOLOGY, V107, P631, DOI 10.1016/S0161-6420(99)00176-1; Savini G, 2008, CLIN OPHTHALMOL, V2, P31; Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6; Schaumberg DA, 2001, JAMA-J AM MED ASSOC, V286, P2114, DOI 10.1001/jama.286.17.2114; Schiffman RM, 2003, OPHTHALMOLOGY, V110, P1412, DOI 10.1016/S0161-6420(03)00462-7; Scuderi G, 2012, CAN J OPHTHALMOL, V47, P489, DOI 10.1016/j.jcjo.2012.08.019; Seifart U., 1994, Ophthalmologe, V91, P235; Smith JA, 2004, ARCH OPHTHALMOL-CHIC, V122, P151, DOI 10.1001/archopht.122.2.151; Smith JA, 2007, OCUL SURF, V5, P93; Smith RE, 1999, CURR EYE RES, V18, P300, DOI 10.1076/ceyr.18.4.300.5362; Sonawane S, 2012, INVEST OPHTH VIS SCI, V53, P8253, DOI 10.1167/iovs.12-10430; Sriprasert I, 2016, MENOPAUSE, V23, P343, DOI 10.1097/GME.0000000000000530; Stern ME, 2004, EXP EYE RES, V78, P409, DOI 10.1016/j.exer.2003.09.003; Sullivan BD, 2002, ARCH OPHTHALMOL-CHIC, V120, P1689; Sullivan BD, 2000, J CLIN ENDOCR METAB, V85, P4866, DOI 10.1210/jc.85.12.4866; Sullivan BD, 2012, CORNEA, V31, P1000, DOI 10.1097/ICO.0b013e318242fd60; Sullivan DA, 2002, ANN NY ACAD SCI, V966, P211, DOI 10.1111/j.1749-6632.2002.tb04217.x; Suzuki T, 2001, CURR EYE RES, V22, P28, DOI 10.1076/ceyr.22.1.28.6980; Tachibana M, 2000, INVEST OPHTH VIS SCI, V41, P64; Tibrewal S, 2014, INVEST OPHTH VIS SCI, V55, P7961, DOI 10.1167/iovs.14-15332; Tibrewal S, 2013, INVEST OPHTH VIS SCI, V54, P8051, DOI 10.1167/iovs.13-12844; TSUBOTA K, 1995, ARCH OPHTHALMOL-CHIC, V113, P155, DOI 10.1001/archopht.1995.01100020037025; Uncu G, 2006, GYNECOL ENDOCRINOL, V22, P501, DOI 10.1080/09513590600917919; Vehof J, 2014, INVEST OPHTH VIS SCI, V55, P7278, DOI 10.1167/iovs.14-15200; Vora GK, 2015, CURR OPIN OPHTHALMOL, V26, P314, DOI 10.1097/ICU.0000000000000166; Wang MTM, 2015, OPTOMETRY VISION SCI, V92, pE321, DOI 10.1097/OPX.0000000000000601; Wojtowicz JC, 2011, CORNEA, V30, P308, DOI 10.1097/ICO.0b013e3181f22e03; Wolffsohn JS, 2017, OCUL SURF, V15, P539, DOI 10.1016/j.jtos.2017.05.001; Yu JH, 2011, CORNEA, V30, P379, DOI 10.1097/ICO.0b013e3181f7f363; Zhu W, 2014, NUTR REV, V72, P662, DOI 10.1111/nure.12145	92	121	127	10	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 7	2018	378	23					2212	2223		10.1056/NEJMra1407936	http://dx.doi.org/10.1056/NEJMra1407936			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI3HS	29874529				2023-01-03	WOS:000434263000009
J	Ferreira, JPA; Miranda, I; Sousa, VB; Pereira, H				Ferreira, Joana P. A.; Miranda, Isabel; Sousa, Vicelina B.; Pereira, Helena			Chemical composition of barks from Quercus faginea trees and characterization of their lipophilic and polar extracts	PLOS ONE			English	Article							WOOD DENSITY COMPONENTS; ANTIOXIDANT ACTIVITY; CELLULAR STRUCTURE; BETULA-PENDULA; CERRIS BARK; RING WIDTH; AGE TRENDS; CORK; OAK; GROWTH	The bark from Quercus faginea mature trees from two sites was chemically characterized for the first time. The barks showed the following composition: ash 14.6%, total extractives 13.2%, suberin 2.9% and lignin 28.2%. The polysaccharides were composed mainly of glucose and xylose (50.3% and 35.1% of all monosaccharides respectively) with 4.8% of uronic acids. The suberin composition was: omega-hydroxyacids 46.3% of total compounds, alpha,omega-alkanoic diacids 22.3%, alkanoic acids 5.9%, alkanols 6.7% and aromatics 6.9% (ferulic acid 4.0%). Polar extracts (ethanol-water) had a high phenolic content of 630.3 mg of gallic acid equivalents (GAE)/g of extract, condensed tannins 220.7 mg of catechin equivalents (CE)/g extract, and flavonoids 207.7 mg CE/g of extract. The antioxidant activity was very high corresponding to 1567 mg Trolox equivalents/g of extract, and an IC50 of 2.63 mu g extract/ml. The lipophilic extracts were constituted mainly by glycerol and its derivatives (12.3% of all compounds), alkanoic acids (27.8%), sterols (11.5%) and triterpenes (17.8%). In view of an integrated valorization, Quercus faginea barks are interesting sources of polar compounds including phenols and polyphenols with possible interesting bioactivities, while the sterols and triterpenes contained in the lipophilic extracts are also valuable bioactive compounds or chemical intermediates for specific high-value market niches, such as cosmetics, pharmaceuticals and biomedicine.	[Ferreira, Joana P. A.; Miranda, Isabel; Sousa, Vicelina B.; Pereira, Helena] Univ Lisbon, Ctr Estudos Florestais, Inst Super Agron, Lisbon, Portugal	Universidade de Lisboa	Ferreira, JPA (corresponding author), Univ Lisbon, Ctr Estudos Florestais, Inst Super Agron, Lisbon, Portugal.	jpferreira@isa.ulisboa.pt	Pereira, Helena/V-5236-2019; Sousa, Vicelina/B-3067-2016; Ferreira, Joana/I-6369-2019	Pereira, Helena/0000-0002-5393-4443; Sousa, Vicelina/0000-0003-4221-0041; Ferreira, Joana/0000-0002-7637-3466; Miranda, Isabel/0000-0003-0280-5219	project OAKWOODS - Fundacao para a Ciencia e a Tecnologia (FCT) [PTDC/AGR-AAM/69077/2006]; Strategic Project of Centro de Estudos Florestais [UID/AGR/00239/2013]; national funding from FCT; FCT [SFRH /BPD/ 97970/2013]	project OAKWOODS - Fundacao para a Ciencia e a Tecnologia (FCT); Strategic Project of Centro de Estudos Florestais; national funding from FCT; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	The sampling was supported by the project OAKWOODS (PTDC/AGR-AAM/69077/2006) funded by Fundacao para a Ciencia e a Tecnologia (FCT). We thank Jose L. Louzada for providing the samples from Site 1 and Sofia Knapic for project management. We also thank Joaquina Silva and Lidia Silva for help with the chemical analysis. This work was supported by the Strategic Project (UID/AGR/00239/2013) of Centro de Estudos Florestais, by the national funding from FCT. The third author acknowledges a post-doc scholarship by FCT (SFRH /BPD/ 97970/2013).	Abdalla S, 2014, BIORESOURCES, V9, P3396; Balaban M, 2001, HOLZFORSCHUNG, V55, P478, DOI 10.1515/HF.2001.079; Baptista I, 2013, IND CROP PROD, V50, P166, DOI 10.1016/j.indcrop.2013.07.004; Barij N, 2011, IAWA J, V32, P25, DOI 10.1163/22941932-90000040; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Chu J-H, 1958, HUA HSUEH HSUEH PAO, V22, P128; Clermont LP, 1961, PULP PAPER MAGAZINE, V62, P511; Corcuera L, 2004, IAWA J, V25, P185, DOI 10.1163/22941932-90000360; Cotillas M, 2009, FOREST ECOL MANAG, V258, P1677, DOI 10.1016/j.foreco.2009.07.033; Dedrie M, 2015, IND CROP PROD, V70, P316, DOI 10.1016/j.indcrop.2015.03.071; Dickison W.C., 2000, INTEGRATIVE PLANT AN; Domingues RMA, 2011, IND CROP PROD, V33, P158, DOI 10.1016/j.indcrop.2010.10.006; EGLINTON G, 1968, PHYTOCHEMISTRY, V7, P313, DOI 10.1016/S0031-9422(00)86330-X; Fabiao A., 1996, Annali dell'Istituto Sperimentale per la Selvicoltura, V27, P77; Ferreira J, 2016, IND CROP PROD, V94, P638, DOI 10.1016/j.indcrop.2016.09.038; Ferreira JPA, 2017, J WOOD CHEM TECHNOL, V37, P10, DOI 10.1080/02773813.2016.1224248; Ferreira JPA, 2015, IND CROP PROD, V74, P998, DOI 10.1016/j.indcrop.2015.05.065; Gan RY, 2010, J MED PLANTS RES, V4, P2438; Graca J, 2000, J AGR FOOD CHEM, V48, P5476, DOI 10.1021/jf0006123; Graca J, 2004, IAWA J, V25, P325, DOI 10.1163/22941932-90000369; Guenther E., 1952, ESSENTIAL OILS, V5, P254; Iqbal Erum, 2015, Journal of King Saud University Science, V27, P224, DOI 10.1016/j.jksus.2015.02.003; Villaverde JJ, 2016, BIORESOURCES, V11, P5618; Knapic S, 2007, ANN FOREST SCI, V64, P211, DOI 10.1051/forest:2006105; Knapic S, 2011, CAN J FOREST RES, V41, P1212, DOI [10.1139/X11-038, 10.1139/x11-038]; KOLATTUKUDY PE, 1974, LIPIDS, V9, P682, DOI 10.1007/BF02532176; KULL U, 1972, Z PFLANZENPHYSIOL, V68, P55, DOI 10.1016/S0044-328X(72)80009-6; Lourenco A, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01612; Menon V, 2012, PROG ENERG COMBUST, V38, P522, DOI 10.1016/j.pecs.2012.02.002; MILLER DP, 1992, AM J ENOL VITICULT, V43, P333; Miranda I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179268; Miranda I, 2016, IND CROP PROD, V82, P81, DOI 10.1016/j.indcrop.2015.12.003; Miranda I, 2013, J WOOD SCI, V59, P1, DOI 10.1007/s10086-012-1300-8; Miranda I, 2013, IND CROP PROD, V41, P299, DOI 10.1016/j.indcrop.2012.04.024; Miranda I, 2012, IND CROP PROD, V36, P395, DOI 10.1016/j.indcrop.2011.10.035; Montserrat-Marti G, 2009, TREES-STRUCT FUNCT, V23, P787, DOI 10.1007/s00468-009-0320-5; Morison JIL, 1999, PLANT CELL ENVIRON, V22, P659, DOI 10.1046/j.1365-3040.1999.00443.x; Mota GS, 2016, IND CROP PROD, V90, P65, DOI 10.1016/j.indcrop.2016.06.014; Nunes E, 1999, ANN FOREST SCI, V56, P479, DOI 10.1051/forest:19990604; Pazhe A, 2012, LATVIAN J CHEM, V51, P415, DOI 10.2478/v10161-012-0025-8; PEREIRA H, 1988, WOOD SCI TECHNOL, V22, P211, DOI 10.1007/BF00386015; PEREIRA H, 1992, IAWA BULL, V13, P389, DOI 10.1163/22941932-90001294; Pereira H, 2015, BIORESOURCES, V10, P6207; PETTERSEN RC, 1984, ADV CHEM SER, P57; Puech J.-L, 1978, THESIS; Quilho T, 2013, TURK J BOT, V37, P561, DOI 10.3906/bot-1201-54; Reboredo F, 2014, J FORESTRY RES, V25, P249, DOI 10.1007/s11676-014-0456-z; Santos SAO, 2012, IND CROP PROD, V39, P120, DOI 10.1016/j.indcrop.2012.02.003; Santos SAO, 2010, IND CROP PROD, V31, P521, DOI 10.1016/j.indcrop.2010.02.001; Sartori C, 2016, HOLZFORSCHUNG, V70, P819, DOI 10.1515/hf-2015-0258; Sen A, 2015, J SUPERCRIT FLUID, V97, P247, DOI 10.1016/j.supflu.2014.12.008; Sen A, 2011, IND CROP PROD, V34, P929, DOI 10.1016/j.indcrop.2011.02.015; Sen A, 2010, IND CROP PROD, V31, P417, DOI 10.1016/j.indcrop.2010.01.002; SESHADRI TR, 1971, PHYTOCHEMISTRY, V10, P897, DOI 10.1016/S0031-9422(00)97169-3; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Sousa VB, 2013, WOOD FIBER SCI, V45, P405; Sousa VB, 2016, FOREST SYST, V25, DOI 10.5424/fs/2016251-08411; Sousa VB, 2014, IAWA J, V35, P293, DOI 10.1163/22941932-00000067; Touati R, 2015, IND CROP PROD, V76, P936, DOI 10.1016/j.indcrop.2015.07.074	60	24	24	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2018	13	5							e0197135	10.1371/journal.pone.0197135	http://dx.doi.org/10.1371/journal.pone.0197135			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF7AA	29763441	Green Published, Green Submitted, gold			2023-01-03	WOS:000432118800026
J	Weske, S; Vaidya, M; Reese, A; Lipinski, KV; Keul, P; Bayer, JK; Fischer, JW; Flogel, U; Nelsen, J; Epple, M; Scatena, M; Schwedhelm, E; Dorr, M; Volzke, H; Moritz, E; Hannemann, A; Rauch, BH; Graler, MH; Heusch, G; Levkau, B				Weske, Sarah; Vaidya, Mithila; Reese, Alina; Lipinski, Karin von Wnuck; Keul, Petra; Bayer, Julia K.; Fischer, Jens W.; Floegel, Ulrich; Nelsen, Jens; Epple, Matthias; Scatena, Marta; Schwedhelm, Edzard; Doerr, Marcus; Voelzke, Henry; Moritz, Eileen; Hannemann, Anke; Rauch, Bernhard H.; Graeler, Markus H.; Heusch, Gerd; Levkau, Bodo			Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss	NATURE MEDICINE			English	Article							MESENCHYMAL STEM-CELLS; ACTIVATED RECEPTOR-GAMMA; OSTEOBLAST DIFFERENTIATION; SPHINGOSINE 1-PHOSPHATE; C/EBP-ALPHA; PPAR-GAMMA; GENE-EXPRESSION; ADIPOSE-TISSUE; MICE; ADIPOGENESIS	Sphingosine-1-phosphate (S1P) signaling influences bone metabolism, but its therapeutic potential in bone disorders has remained unexplored. We show that raising S1P levels in adult mice through conditionally deleting or pharmacologically inhibiting S1P lyase, the sole enzyme responsible for irreversibly degrading S1P, markedly increased bone formation, mass and strength and substantially decreased white adipose tissue. S1P signaling through S1P(2) potently stimulated osteoblastogenesis at the expense of adipogenesis by inversely regulating osterix and PPAR-gamma, and it simultaneously inhibited osteoclastogenesis by inducing osteoprotegerin through newly discovered p38-GSK3 beta-beta-catenin and WNT5A-LRP5 pathways. Accordingly, S1P(2)-deficient mice were osteopenic and obese. In ovariectomy-induced osteopenia, S1P lyase inhibition was as effective as intermittent parathyroid hormone (iPTH) treatment in increasing bone mass and was superior to iPTH in enhancing bone strength. Furthermore, lyase inhibition in mice successfully corrected severe genetic osteoporosis caused by osteoprotegerin deficiency. Human data from 4,091 participants of the SHIP-Trend population-based study revealed a positive association between serum levels of S1P and bone formation markers, but not resorption markers. Furthermore, serum S1P levels were positively associated with serum calcium, negatively with PTH, and curvilinearly with body mass index. Bone stiffness, as determined through quantitative ultrasound, was inversely related to levels of both S1P and the bone formation marker PINP, suggesting that S1P stimulates osteoanabolic activity to counteract decreasing bone quality. S1P-based drugs should be considered as a promising therapeutic avenue for the treatment of osteoporotic diseases.	[Weske, Sarah; Vaidya, Mithila; Reese, Alina; Lipinski, Karin von Wnuck; Keul, Petra; Heusch, Gerd; Levkau, Bodo] Univ Duisburg Essen, Univ Hosp Essen, West German Heart & Vasc Ctr, Inst Pathophysiol, Essen, Germany; [Bayer, Julia K.; Fischer, Jens W.] Univ Dusseldorf, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany; [Floegel, Ulrich] Univ Dusseldorf, Inst Mol Cardiol, Dusseldorf, Germany; [Fischer, Jens W.; Floegel, Ulrich] Univ Duisburg Essen, Inst Inorgan Chem, Essen, Germany; [Scatena, Marta] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Schwedhelm, Edzard] Univ Med Ctr Hamburg Eppendorf, Inst Clin Pharmacol & Toxicol, Hamburg, Germany; [Schwedhelm, Edzard] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg, Hamburg, Germany; [Doerr, Marcus; Moritz, Eileen; Rauch, Bernhard H.] DZHK, Partner Site Greifswald, Greifswald, Germany; [Doerr, Marcus] Univ Med Greifswald, Dept Internal Med B, Greifswald, Germany; [Voelzke, Henry] Univ Med Greifswald, Inst Community Med, Greifswald, Germany; [Moritz, Eileen; Rauch, Bernhard H.] Univ Med Greifswald, Dept Gen Pharmacol, Inst Pharmacol, Greifswald, Germany; [Hannemann, Anke] Univ Med Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany; [Graeler, Markus H.] Univ Hosp Jena, Ctr Sepsis Control & Care, Dept Anesthesiol & Intens Care Med, Jena, Germany; [Graeler, Markus H.] Univ Hosp Jena, Ctr Mol Biomed, Jena, Germany	University of Duisburg Essen; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Duisburg Essen; University of Washington; University of Washington Seattle; University of Hamburg; University Medical Center Hamburg-Eppendorf; German Centre for Cardiovascular Research; German Centre for Cardiovascular Research; Greifswald Medical School; Greifswald Medical School; Greifswald Medical School; Greifswald Medical School; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Levkau, B (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, West German Heart & Vasc Ctr, Inst Pathophysiol, Essen, Germany.	bodo.levkau@uni-due.de	Heusch, Gerd/ABE-6675-2020; Gräler, Markus/ABH-1905-2021; Rauch, Bernhard/Q-6205-2018; Dörr, Marcus/F-1919-2010; Epple, Matthias/AAX-9694-2020	Gräler, Markus/0000-0001-6650-7849; Rauch, Bernhard/0000-0002-6003-4662; Dörr, Marcus/0000-0001-7471-475X; Epple, Matthias/0000-0002-1641-7068	Deutsche Forschungsgemeinschaft [GRK 2098, SFB 1116]; Alexander von Humboldt Foundation; Federal Ministry of Education and Research [01ZZ9603, 01ZZ0103, 01ZZ0403]; Ministry of Cultural Affairs; Social Ministry of the Federal State of Mecklenburg-West Pomerania; Deutsches Zentrum fur Herz-Kreislauf-Forschung e.V.	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Ministry of Cultural Affairs; Social Ministry of the Federal State of Mecklenburg-West Pomerania; Deutsches Zentrum fur Herz-Kreislauf-Forschung e.V.	We gratefully acknowledge excellent technical help by Kerstin Abou Hamed, forthcoming support by the Zentrales Tierlabor, Universitatsklinikum Essen (G. Hilken, P. Dammann, A. Wissmann, R. Waldschutz) and stimulating discussions with A. Levkau. I dedicate this work to my father, Lubomir Levkau. This work was supported in part by the Deutsche Forschungsgemeinschaft, GRK 2098, projects 9-11 (B.L., P.K.), SFB 1116, projects A08 (J.W.F.) and B02, B05 (U.F.). The work was also supported by the Alexander von Humboldt Foundation through a research fellowship awarded to M.V. The SHIP-Trend study is part of the Community Medicine Research net of the University of Greifswald, Germany, funded by the Federal Ministry of Education and Research (Grants 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. This work was also funded in part by grants from the Deutsches Zentrum fur Herz-Kreislauf-Forschung e.V. (B.H.R., M.D., E.S.).	A Kumar, 2008, Indian J Community Med, V33, P156, DOI 10.4103/0970-0218.42051; Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004-0735; Bae SJ, 2016, OSTEOPOROSIS INT, V27, P2533, DOI 10.1007/s00198-016-3565-z; Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854; Billich A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059630; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Boyce BF, 2005, CELL METAB, V2, P344, DOI 10.1016/j.cmet.2005.11.011; Burghoff S, 2013, ARCH PHYSIOL BIOCHEM, V119, P39, DOI 10.3109/13813455.2012.755547; Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242; Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198-014-2794-2; Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142-9612(03)00580-5; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Goetzl EJ, 2007, FASEB J, V21, P638, DOI 10.1096/fj.06-6624hyp; Gunther T, 2007, NAT CELL BIOL, V9, P1229, DOI 10.1038/ncb1107-1229; Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681; Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140-6736(95)11456-4; Hashimoto Y, 2015, MOL CELL BIOCHEM, V401, P39, DOI 10.1007/s11010-014-2290-1; Ishii M, 2013, BBA-MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002; Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474; Ishii T, 2011, MOL CELLS, V31, P399, DOI 10.1007/s10059-011-1010-x; Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193; Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200; Kawamoto T, 2014, METHODS MOL BIOL, V1130, P149, DOI 10.1007/978-1-62703-989-5_11; Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kim SW, 2005, BIOCHEM BIOPH RES CO, V327, P811, DOI 10.1016/j.bbrc.2004.12.076; Kowalski GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072449; Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198; Kunkel GT, 2013, NAT REV DRUG DISCOV, V12, P688, DOI 10.1038/nrd4099; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Lee SH, 2012, J CLIN ENDOCR METAB, V97, pE1421, DOI 10.1210/jc.2012-1044; Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; McClung MR, 2017, BONE, V96, P3, DOI 10.1016/j.bone.2016.12.012; Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Moritz E, 2017, CLIN CHIM ACTA, V468, P25, DOI 10.1016/j.cca.2017.01.029; Parham KA, 2015, FASEB J, V29, P3638, DOI 10.1096/fj.14-261289; Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106; Pelletier D, 2012, NEW ENGL J MED, V366, P339, DOI 10.1056/NEJMct1101691; Peptan IA, 2006, PLAST RECONSTR SURG, V117, P1462, DOI 10.1097/01.prs.0000206319.80719.74; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen H, 2013, ANNU REV BIOCHEM, V82, P637, DOI 10.1146/annurev-biochem-062411-130916; Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430; Schurer C, 2015, DTSCH ARZTEBL INT, V112, P365, DOI 10.3238/arztebl.2015.0365; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994; Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883; Stone CJ, 1985, P STAT COMP SECT AM, P45; Stubbins RE, 2012, EUR J NUTR, V51, P861, DOI 10.1007/s00394-011-0266-4; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Takahashi T, 2011, CALCIFIED TISSUE INT, V88, P336, DOI 10.1007/s00223-011-9461-9; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tucci S, 2011, AM J CLIN NUTR, V94, P439, DOI 10.3945/ajcn.111.012948; Volzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394; Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112; Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269; Wu L, 2007, MOL CELL BIOCHEM, V301, P83, DOI 10.1007/s11010-006-9399-9; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750-2187-2-11; Yu WH, 2012, INT J BIOCHEM CELL B, V44, P377, DOI 10.1016/j.biocel.2011.11.013; Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-37; Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617; Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813; Zoico E, 2016, ONCOTARGET, V7, P20223, DOI 10.18632/oncotarget.7936	73	67	71	3	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2018	24	5					667	+		10.1038/s41591-018-0005-y	http://dx.doi.org/10.1038/s41591-018-0005-y			15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GF7CY	29662200				2023-01-03	WOS:000432126800024
J	Valdes, C; Bustos, G; Martinez, JL; Lauridolt, C				Valdes, Carlos; Bustos, Gonzalo; Martinez, Jose L.; Lauridolt, Claudio			Antinociceptive antibiotics-loaded into solid lipid nanoparticles of prolonged release: Measuring pharmacological efficiency and time span on chronic monoarthritis rats	PLOS ONE			English	Article							PAIN	Pain is a sensory experience of a complex physiological nature in which is not only involved the nervous system. Among its many features is the development of chronic pain that is more complicated to treat because of the central somatization processes involved, becoming inefficient treatments used in other forms of pain. Among them is the role of glial cells, whose participation is such that some authors have proposed to chronic pain as a gliopathy. Because of this, the drug target of possible treatments focuses on modulating nociceptive response affecting transduction into the central nervous system through affecting synapses in the dorsal horn of the spinal cord. Solid lipid nanoparticles enter the central nervous system, protecting the drug, and in addition to the advantage of having greater absorption surface, all factors that improve drug activity. This work is based on the development and characterization of lipid nanoparticles of solid phase incorporating two antibiotics, minocycline, and ciprofloxacin with antinociceptive properties and challenged them with a rat monoarthritis model using Sprague-Dawley adult male rats. The solid lipid nanoparticles were prepared to modify the lipid, and surfactant amounts to obtain the best encapsulation capacity of the antibiotics, size and z potential. By using the Randall-Selitto test, we measured its pharmacological efficiency as an anti-inflammatory and measuring the time span the antibiotics are active. The encapsulated antibiotics were at least 50% more efficient than the antibiotic alone, and that is possible to measure anti-inflammatory activity up to seven days after the antibiotic application. The former is important for example, in the veterinary field, since a single application of the antibiotic will be necessary for the complete treatment, avoiding excessive stress for the animals. We can conclude that antinociceptive antibiotics encapsulation is a very effective, environmentally safe and inexpensive method for improving the pharmacological efficiency and time span the antibiotics are acting. Since these antibiotics are both anti-microbial and antinociceptive, his use in the field of veterinary presents the advantage of being adequate in single doses, with the saving of time and stress to the animals under treatment.	[Valdes, Carlos; Bustos, Gonzalo; Lauridolt, Claudio] Univ Santiago Chile, Fac Chem & Biol, Dept Biol, Neurobiol Lab, Santiago, Chile; [Martinez, Jose L.] Univ Santiago Chile, Vicerrectory Res Dev & Innovat, Santiago, Chile	Universidad de Santiago de Chile; Universidad de Santiago de Chile	Martinez, JL (corresponding author), Univ Santiago Chile, Vicerrectory Res Dev & Innovat, Santiago, Chile.	joseluis.martinez@usach.cl	Martinez, Jose/AAA-1725-2020		Dicyt, Universidad de Santiago de Chile	Dicyt, Universidad de Santiago de Chile	This study was supported by Dicyt, Universidad de Santiago de Chile.	Abdelbary G, 2009, AAPS PHARMSCITECH, V10, P211, DOI 10.1208/s12249-009-9197-2; Attama AA, 2015, THER DELIV, V6, P669, DOI [10.4155/TDE.15.23, 10.4155/tde.15.23]; Basbaum A, 2005, PAIN 2005 UPDATED RE, P3; Bustos G, 2016, PAK VET J, V36, P366; Halassa MM, 2007, TRENDS MOL MED, V13, P54, DOI 10.1016/j.molmed.2006.12.005; Haney MJ, 2011, NANOMEDICINE-UK, V6, P1215, DOI [10.2217/nnm.11.32, 10.2217/NNM.11.32]; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Hou DZ, 2003, BIOMATERIALS, V24, P1781, DOI 10.1016/S0142-9612(02)00578-1; Hu FQ, 2005, COLLOID SURFACE B, V45, P167, DOI 10.1016/j.colsurfb.2005.08.005; Ibrahim WM, 2014, INT J NANOMED, V9, P129, DOI 10.2147/IJN.S54413; KOEPPEN B.M., 2009, BERNE LEVY FISIOLOGI; Labro MT, 2000, CLIN MICROBIOL REV, V13, P615, DOI 10.1128/CMR.13.4.615-650.2000; Luger TJ, 2005, BASIC CLIN PHARMACOL, V96, P366, DOI 10.1111/j.1742-7843.2005.pto_05.x; McNeil SE, 2011, METHODS MOL BIOL, V697, P1, DOI 10.1007/978-1-60327-198-1; MESTRE C, 1994, J PHARMACOL TOX MET, V32, P197, DOI 10.1016/1056-8719(94)90087-6; Morales F, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4030; Oliphant CM, 2002, AM FAM PHYSICIAN, V65, P455; Qi JP, 2012, CURR DRUG METAB, V13, P418, DOI 10.2174/138920012800166526; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Rojewska E, 2014, J NEUROIMMUNOL, V277, P57, DOI 10.1016/j.jneuroim.2014.09.020; Venkateswarlu V, 2004, J CONTROL RELEASE, V95, P627, DOI 10.1016/j.jconrel.2004.01.005; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	22	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2018	13	4							e0187473	10.1371/journal.pone.0187473	http://dx.doi.org/10.1371/journal.pone.0187473			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4YG	29649262	Green Published, gold, Green Submitted			2023-01-03	WOS:000429791900001
J	Mittal, P; Chan, OY; Kanneppady, SK; Verma, RK; Hasan, SS				Mittal, Piyush; Chan, Oi Yun; Kanneppady, Sham Kishor; Verma, Rohit Kumar; Hasan, Syed Shahzad			Association between beliefs about medicines and self-medication with analgesics among patients with dental pain	PLOS ONE			English	Article							QUESTIONNAIRE; VALIDATION; MANAGEMENT; ADHERENCE; IMPACT	Self-medication with analgesics in dental pain management is a common practice as most of these medicines are available over-the-counter (OTC). The study aims to examine the relationship between beliefs about medicines and self-medication with analgesics in dental pain management in Malaysia. This cross-sectional study was conducted among conveniently sampled patients attending dental clinics, located in Kuala Lumpur, Malaysia to assess association between self-medication with analgesics and patient's beliefs about medicines via Beliefs about Medicines Questionnaire. Participants were evaluated for their self-medication practices via 4 items. Further assessment was done via Quantitative Analgesic Questionnaire (QAQ) regarding the analgesics taken. Statistical analyses were performed using SPSS version 24, with 0.05 as level of significance. The prevalence of self-medication with analgesics was 29.4%, with 95.6% of the participants took analgesics when necessary. Participants practising self-medication for dental pain reported more positive beliefs in General-Necessity (13.04 vs. 9.98, p = 0.001) than those not practising self-medication. However, these participants had weaker beliefs in General-Harm (12.00 vs. 10.29, p = 0.006) and General-Overuse (11.38 vs. 10.31, p = 0.032) than those not practising self-medication. Participants beliefs in General-Harm (r = -0.243; p = 0.003) and General-Overuse (r = -0.203; p = 0.012) were negatively correlated with total QAQ point. The study found that individuals who practised self-medication had stronger beliefs about the benefits of medicines and weaker beliefs in viewing medicines as harmful and overused. Findings can guide public education to improve the safety aspects of self-medication with analgesics in dental practice.	[Mittal, Piyush; Chan, Oi Yun; Verma, Rohit Kumar] Int Med Univ, Dept Pharm Practice, Kuala Lumpur, Malaysia; [Kanneppady, Sham Kishor] Int Med Univ, Sch Dent, Kuala Lumpur, Malaysia; [Hasan, Syed Shahzad] Univ Huddersfield, Dept Pharm, Huddersfield, W Yorkshire, England; [Hasan, Syed Shahzad] Univ Newcastle, Sch Biol Sci & Pharm, Newcastle, NSW, Australia	International Medical University Malaysia; International Medical University Malaysia; University of Huddersfield; University of Newcastle	Hasan, SS (corresponding author), Univ Huddersfield, Dept Pharm, Huddersfield, W Yorkshire, England.; Hasan, SS (corresponding author), Univ Newcastle, Sch Biol Sci & Pharm, Newcastle, NSW, Australia.	s.hasan@hud.ac.uk	Hasan, Syed Shahzad/V-9082-2018; Mittal, Piyush/AAF-6165-2019	Hasan, Syed Shahzad/0000-0002-4058-2215; Mittal, Piyush/0000-0002-1741-5064; VERMA, ROHIT KUMAR/0000-0003-4495-6779				Afolabi A O, 2010, Niger J Med, V19, P96; Agbor MA, 2011, INT DENT J, V61, P204, DOI 10.1111/j.1875-595X.2011.00058.x; Armfield JM, 2013, AUST DENT J, V58, P390, DOI 10.1111/adj.12118; Azodo Clement Chinedu, 2013, Stomatologija, V15, P135; Chapman SCE, 2014, EPILEPSY BEHAV, V31, P312, DOI 10.1016/j.yebeh.2013.10.016; Cicolini G, 2016, APPL NURS RES, V30, P131, DOI 10.1016/j.apnr.2015.11.011; Connors MH, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01588; Hargreaves K, 2005, AUST DENT J, V50, pS14, DOI 10.1111/j.1834-7819.2005.tb00378.x; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; Horne R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080633; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Jain A, 2016, ORAL HLTH PREV DENT, V14, P5, DOI 10.3290/j.ohpd.a35000; Jamous Raniah Majed, 2014, J Family Med Prim Care, V3, P224, DOI 10.4103/2249-4863.141615; Jayadev M, 2014, J CLIN DIAGN RES, V8, pZC10, DOI 10.7860/JCDR/2014/9645.4536; Luo Y, 2007, J OROFAC PAIN, V21, P63; Meadows Keith A, 2003, Br J Community Nurs, V8, P562; Ngeow ST, 2008, COX 2 INHIBITORS SOL, V29, P84; O'Sullivan LM, 2018, BRIT DENT J, V224, P623, DOI 10.1038/sj.bdj.2018.264; Pau A, 2005, PAIN, V119, P75, DOI 10.1016/j.pain.2005.09.016; Pau A, 2010, INT DENT J, V60, P113, DOI 10.1922/IDJ_2332Pau09; Pozzi A, 2011, ANN STOMATOL, V2, P3; Robinson-Papp J, 2015, J PAIN SYMPTOM MANAG, V50, P381, DOI 10.1016/j.jpainsymman.2015.03.013; Siddique I, 2015, BRIT DENT J, V219, DOI 10.1038/sj.bdj.2015.706; Simon AK, 2015, INDIAN J PHARMACOL, V47, P524, DOI 10.4103/0253-7613.165195; Sundell KA, 2016, INT J CLIN PRACT, V70, P277, DOI 10.1111/ijcp.12781; Vogel J, 2011, AM J EMERG MED, V29, P1125, DOI 10.1016/j.ajem.2010.08.006; Wan KY, 2012, COMMUNITY DENT HLTH, V29, P110, DOI 10.1922/CDH_2578McMillan07; Weil K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004487; World Health Organization, 2000, REG GUID TEL PROD; World Health Organization, 2000, WHO DRUG INF BEN RIS	30	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2018	13	8							e0201776	10.1371/journal.pone.0201776	http://dx.doi.org/10.1371/journal.pone.0201776			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3UD	30071006	Green Published, Green Submitted, gold			2023-01-03	WOS:000440778600097
J	Leitner, G; Zilberman, D; Papirov, E; Shefy, S				Leitner, Gabriel; Zilberman, David; Papirov, Eduard; Shefy, Sela			Assessment of acoustic pulse therapy (APT), a non-antibiotic treatment for dairy cows with clinical and subclinical mastitis	PLOS ONE			English	Article							SHOCK-WAVE THERAPY; ERECTILE DYSFUNCTION; LACTATION; MILK; STRATEGIES	Clinical and subclinical mastitis affects 30% of cows and is regarded as the most significant economic burden on the dairy farm reducing milk yield and quality and increasing culling rate. A proprietary Acoustic Pulse Therapy (APT) device was developed specifically for treating dairy cows. The APT device was designed to produce deep penetrating acoustic pulses that are distributed over a large treated area at a therapeutic level. This paper presents findings from a clinical assessment of this technology for the treatment of dairy cows with subclinical and clinical mastitis. In subclinical mastitis, a group of 116 cows from 3 herds were identified with subclinical intramammary infection and enrolled in the study; 78 cows were assigned to the treatment group and 38 cows to the control group. Significant differences (P<0.001) were found where 70.5% of the cows in the treatment group returned to normal milk production, compared with only 18.4% of the control group. Daily milk yields of the treated cows increased significantly (P<0.05) and the percentage of cows with log somatic cell count under 5.6 cells/mL was significantly higher (P<0.001). Milk of the infected quarters appeared normal with lactose greater than 4.8%, but this difference was not significant. Of the treated cows with identified bacteria, 52.6% of the quarters were cured, while in the control group only 25.0% (P<0.001). Specifically, all cows identified with Escherichia coli in the treatment group were cured, with 66.6% cured with no intervention in the control. Spontaneous cure of glands infected with coagulase negative staphylococci (CNS) and Streptococci was low while treatment successfully increased the cure of CNS from 13.3% to 53.8% and that of Streptococci from 18.2% to 36.4%. Of the 4 cows identified with Staphylococcus aureus, 3 were cured. The clinical mastitis study group included 29 infected cows that were submitted either to a gold standard antibiotic treatment subgroup of 16 cows (n = 16) or to an APT treatment subgroup of 13 cows (n = 13). A cure of 18.7% was shown for the antibiotic treatment, of which logSCC returned to <5.6 cell/mL and 56.2% were culled. A cure of 76.9% was shown for the APT treatment with only one cow culled (7.7%).	[Leitner, Gabriel] Kimron Vet Inst, Natl Mastitis Reference Ctr, Bet Dagan, Israel; [Zilberman, David] Univ Calif Berkeley, Dept Agr & Resource Econ, Berkeley, CA 94720 USA; [Papirov, Eduard; Shefy, Sela] HI Impacts, Raanana, Israel	Kimron Veterinary Institute; University of California System; University of California Berkeley	Leitner, G (corresponding author), Kimron Vet Inst, Natl Mastitis Reference Ctr, Bet Dagan, Israel.	leitnerg1@gmail.com			Hi-Impacts LTD.; Hi-Impacts LTD	Hi-Impacts LTD.; Hi-Impacts LTD	The study was funded by Hi-Impacts LTD. As employees of Hi-Impacts Papirov and Shefy conducted the treatments of the cows and collected data from the herd computers. They also were involved in writing the technical information of the device that was used for the treatment. The treatment protocol was suggested by Papirov and is based on experience from medical treatments for orthopedic disorders. Hi-Impacts LTD provided support in the form of salaries for authors EP and SS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Barlow JW, 2009, PREV VET MED, V90, P31, DOI 10.1016/j.prevetmed.2009.03.016; Blum SE, 2014, VET J, V201, P72, DOI 10.1016/j.tvjl.2014.04.008; Contreras GA, 2011, COMP IMMUNOL MICROB, V34, P281, DOI 10.1016/j.cimid.2011.01.004; Crowe O., 2002, Proceedings of the 48th Annual Convention of the American Association of Equine Practitioners, Orlando, Florida, USA, 4-8 December 2002, P322; Gruenwald I, 2013, THER ADV UROL, V5, P95, DOI 10.1177/1756287212470696; Halasa T, 2007, VET QUART, V29, P18, DOI 10.1080/01652176.2007.9695224; Hillerton JE, 2005, J APPL MICROBIOL, V98, P1250, DOI 10.1111/j.1365-2672.2005.02649.x; Huijps K, 2008, J DAIRY RES, V75, P113, DOI 10.1017/S0022029907002932; Katz G, 2007, J ANIM SCI, V85, P377; Kikuchi Y, 2010, CIRC J, V74, P589, DOI 10.1253/circj.CJ-09-1028; Kisch T, 2016, J SURG RES, V201, P440, DOI 10.1016/j.jss.2015.11.049; Le Marechal C, 2011, DAIRY SCI TECHNOL, V91, P247, DOI 10.1007/s13594-011-0009-6; Leitner G, 2006, INT DAIRY J, V16, P648, DOI 10.1016/j.idairyj.2005.10.020; Leitner G, 2014, ISR J VET MED, V69, P141; Leitner G, 2011, INT DAIRY J, V21, P279, DOI 10.1016/j.idairyj.2010.11.013; Losinger WC, 2005, JAVMA-J AM VET MED A, V226, P1652, DOI 10.2460/javma.2005.226.1652; Mariotto S, 2009, CURR MED CHEM, V16, P2366, DOI 10.2174/092986709788682119; McClure S., 2003, EXTRACORPOREAL SHOCK; McDougall S, 2009, VET MICROBIOL, V134, P177, DOI 10.1016/j.vetmic.2008.09.026; Molbak K, 2004, J VET MED B, V51, P364, DOI 10.1111/j.1439-0450.2004.00788.x; Nir O., 2003, ACTA VET SCAND, V44, pS21, DOI [10.1186/1751-0147-44-S1-S21, 10.1186/1751-0147-44-S1-P1, DOI 10.1186/1751-0147-44-S1-P1]; Oliver S.P., 2004, MICROBIOLOGICAL PROC, V4th; Pyorala S, 2002, REPROD DOMEST ANIM, V37, P211, DOI 10.1046/j.1439-0531.2002.00378.x; Pyorala S, 2009, VET MICROBIOL, V134, P3, DOI 10.1016/j.vetmic.2008.09.015; Rollin E, 2015, PREV VET MED, V122, P257, DOI 10.1016/j.prevetmed.2015.11.006; Slavich M, 2015, AC CARD CAR C VIENN; Souza ANA, 2016, VET COMP ORTHOPAED, V29, P108, DOI 10.3415/VCOT-15-01-0017; Steeneveld W, 2011, J DAIRY SCI, V94, P174, DOI 10.3168/jds.2010-3367; Steeneveld W, 2007, J DAIRY RES, V74, P459, DOI 10.1017/S0022029907002828; van den Borne BHP, 2010, J DAIRY SCI, V93, P218, DOI 10.3168/jds.2009-2567; Vardi Y, 2010, EUR UROL, V58, P243, DOI 10.1016/j.eururo.2010.04.004; Zissler A, 2017, AM J SPORT MED, V45, P676, DOI 10.1177/0363546516668622	32	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2018	13	7							e0199195	10.1371/journal.pone.0199195	http://dx.doi.org/10.1371/journal.pone.0199195			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM5IS	29990317	Green Published, gold, Green Submitted			2023-01-03	WOS:000438170300006
J	Kubota, A; Nakatani, E; Tsukahara, K; Hasegawa, Y; Takemura, H; Terada, T; Taguchi, T; Nagahara, K; Nakatani, H; Yoshino, K; Higaki, Y; Iwae, S; Beppu, T; Hanamure, Y; Tomita, K; Kohno, N; Kawabata, K; Teramukai, S; Fujii, M				Kubota, Akira; Nakatani, Eiji; Tsukahara, Kiyoaki; Hasegawa, Yasuhisa; Takemura, Hideki; Terada, Tomonori; Taguchi, Takahide; Nagahara, Kunihiko; Nakatani, Hiroaki; Yoshino, Kunitoshi; Higaki, Yuichiro; Iwae, Shigemichi; Beppu, Takeshi; Hanamure, Yutaka; Tomita, Kichinobu; Kohno, Naoyuki; Kawabata, Kazuyoshi; Teramukai, Satoshi; Fujii, Masato		ACTS-HNC Study Grp	Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study	PLOS ONE			English	Article							LOCALLY ADVANCED HEAD; PHASE-III TRIAL; ADVANCED LARYNGEAL-CANCER; INDUCTION CHEMOTHERAPY; CONCOMITANT CHEMOTHERAPY; RANDOMIZED-TRIAL; CONCURRENT CHEMORADIOTHERAPY; NASOPHARYNGEAL CANCER; OROPHARYNGEAL CANCER; RADIATION-THERAPY	Background Chemoradiotherapy (CRT) has improved organ preservation or overall survival (OS) of locoregionally advanced head and neck squamous cell cancer (LAHNSCC), but in clinical trials of conventional CRT, increasing CRT intensity has not been shown to improve OS. In the Adjuvant ChemoTherapy with S-1 after curative treatment in patients with Head and Neck Cancer (ACTS-HNC) phase III study, OS of curative locoregional treatments improved more with adjuvant chemotherapy with S-1 (tegafur gimeracil oteracil potassium) than with tegafur/ uracil (UFT). ACTS HNC study showed the significant efficacy of S-1 after curative radiotherapy in sub-analysis. We explored the efficacy of S-1 after curative CRT in a subset of patients from the ACTS-HNC study. Methods Patients with stage III, IVA, or IVB LAHNSCC were enrolled in this study to evaluate the efficacy of S-1 compared with UFT as adjuvant chemotherapy after curative CRT in the ACTSHNC study. Patients received S-1 at 80 +/- 120 mg/day in two divided doses for 2 weeks, followed by a 1-week rest, or UFT 300 or 400 mg/day in two or three divided doses daily, for 1 year. The endpoints were OS, disease-free survival, locoregional relapse-free survival, distant metastasis-free survival (DMFS), and post-locoregional relapse survival. Results One hundred eighty patients (S-1, n = 87; UFT, n = 93) were included in this study. Clinical characteristics of the S-1 and UFT arms were similar. S-1 after CRT significantly improved OS (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.22 +/- 0.93) and DMFS (HR, 0.50; 95% CI, 0.26 +/- 0.97) compared with UFT. Conclusion As adjuvant chemotherapy, S-1 demonstrated better efficacy for OS and DMFS than UFT in patients with LAHNSCC after curative CRT and may be considered a treatment option following curative CRT. For this study was not preplanned in the ACTS-HNC study, the results is hypothesis generating but not definitive.	[Kubota, Akira] Kanagawa Canc Ctr, Dept Head & Neck Surg, Yokohama, Kanagawa, Japan; [Nakatani, Eiji] Fdn Biomed Res & Innovat, Translat Res Ctr Med Innovat, Kobe, Hyogo, Japan; [Tsukahara, Kiyoaki] Tokyo Med Univ, Hachioji Med Ctr, Dept Otolaryngol Head & Neck Surg, Hachioji, Tokyo, Japan; [Hasegawa, Yasuhisa] Aichi Canc Ctr Hosp, Dept Head & Neck Surg, Nagoya, Aichi, Japan; [Takemura, Hideki] Yokohama Rosai Hosp, Dept Otolaryngol, Yokohama, Kanagawa, Japan; [Terada, Tomonori] Hyogo Coll Med, Dept Otolaryngol, Nishinomiya, Hyogo, Japan; [Taguchi, Takahide] Yokohama City Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Kanagawa, Japan; [Nagahara, Kunihiko] Kusatsu Gen Hosp, Dept Head & Neck Surg, Kusatsu, Japan; [Nakatani, Hiroaki] Tochigi Canc Ctr, Div Head & Neck Surg, Utsunomiya, Tochigi, Japan; [Yoshino, Kunitoshi] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Otolaryngol Head & Neck Surg, Osaka, Japan; [Higaki, Yuichiro] Natl Hosp Org, Kyushu Canc Ctr, Dept Head & Neck Surg, Fukuoka, Japan; [Iwae, Shigemichi] Hyogo Canc Ctr, Dept Head & Neck Surg, Akashi, Hyogo, Japan; [Beppu, Takeshi] Saitama Canc Ctr, Dept Head & Neck Surg, Saitama, Japan; [Hanamure, Yutaka] Kagoshima City Hosp, Dept Otolaryngol, Kagoshima, Japan; [Tomita, Kichinobu] Akasaka Surg Clin, Dept Otolaryngol, Fukuoka, Japan; [Kohno, Naoyuki] Kyorin Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Mitaka, Tokyo, Japan; [Kawabata, Kazuyoshi] Canc Inst Hosp, Div Head & Neck Surg, Tokyo, Japan; [Teramukai, Satoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biostat, Kyoto, Japan; [Fujii, Masato] Natl Hosp Org, Tokyo Med Ctr, Dept Otolaryngol, Tokyo, Japan; [Nakatani, Eiji] Osaka Univ, Grad Sch Med, Dept Biostat & Data Sci, Osaka, Japan; [Fujii, Masato] Eiju Gen Hosp, Dept Otolaryngol, Tokyo, Japan	Kanagawa Prefectural Cancer Center; Institute for Biomedical Research & Innovation (IBRI); Tokyo Medical University; Aichi Cancer Center; Yokohama Rosai Hospital; Hyogo College of Medicine; Yokohama City University; Tochigi Prefectural Cancer Center; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyushu Cancer Center; Hyogo Cancer Center; Kagoshima City Hospital; Kyorin University; Japanese Foundation for Cancer Research; Kyoto Prefectural University of Medicine; Osaka University	Kubota, A (corresponding author), Kanagawa Canc Ctr, Dept Head & Neck Surg, Yokohama, Kanagawa, Japan.	kubota-a@kcch.jp	Nakatani, Eiji/O-2782-2013; Teramukai, Satoshi/I-2249-2019	Nakatani, Eiji/0000-0002-4876-446X; Teramukai, Satoshi/0000-0003-2184-0597	FBRI; Taiho Pharmaceutical Co., Ltd., Japan	FBRI; Taiho Pharmaceutical Co., Ltd., Japan	This study was sponsored by the FBRI, with funding from Taiho Pharmaceutical Co., Ltd., Japan (http://www.taiho.co.jp/english/) under the study contract. The funding source of the study participated in study design but had no role in data collection, data management, data analysis, or data interpretation.	Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; [Anonymous], 1987, CANCER-AM CANCER SOC, V60, P301; Bernier J, 2005, HEAD NECK-J SCI SPEC, V27, P843, DOI 10.1002/hed.20279; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Cohen EEW, 2014, J CLIN ONCOL, V32, P2735, DOI 10.1200/JCO.2013.54.6309; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Dahlstrom KR, 2013, CANCER-AM CANCER SOC, V119, P81, DOI 10.1002/cncr.27727; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Hitt R, 2014, ANN ONCOL, V25, P216, DOI 10.1093/annonc/mdt461; Kwong DLW, 2004, J CLIN ONCOL, V22, P2643, DOI 10.1200/JCO.2004.05.173; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Nguyen-Tan PF, 2014, J CLIN ONCOL, V55, P3925, DOI DOI 10.1200/JC0.2014.55.3925; Oki E, 2016, ANN ONCOL, V27, P1266, DOI 10.1093/annonc/mdw162; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; ROSSI A, 1988, J CLIN ONCOL, V6, P1401, DOI 10.1200/JCO.1988.6.9.1401; TATSUMI K, 1987, JPN J CANCER RES, V78, P748; Team R. C, 2018, R LANG ENV STAT COMP; Tsukahara K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116965; Tsukuda M, 1994, Gan To Kagaku Ryoho, V21, P1169; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	27	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2018	13	6							e0198391	10.1371/journal.pone.0198391	http://dx.doi.org/10.1371/journal.pone.0198391			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI7ZT	29883463	Green Submitted, Green Published, gold			2023-01-03	WOS:000434728100021
J	Kuper, H; Mactaggart, I; White, S; Dionicio, C; Canas, R; Naber, J; Polack, S; Biran, A				Kuper, Hannah; Mactaggart, Islay; White, Sian; Dionicio, Carlos; Canas, Rafael; Naber, Jonathan; Polack, Sarah; Biran, Adam			Exploring the links between water, sanitation and hygiene and disability; Results from a case-control study in Guatemala	PLOS ONE			English	Article							RAPID ASSESSMENT; ACCESS; PREVALENCE; COUNTRIES; HEALTH; ISSUES	Objective To assess the Water, Sanitation and Hygiene (WASH) access and appropriateness of people with disabilities compared to those without, in Guatemala. Methods A case-control study was conducted, nested within a national survey. The study included 707 people with disabilities, and 465 age-and sex-matched controls without disabilities. Participants reported on WASH access at the household and individual level. A sub-set of 121 cases and 104 controls completed a newly designed, in-depth WASH questionnaire. Results Households including people with disabilities were more likely to use an improved sanitation facility compared to control households (age-sex-adjusted OR: 1.7, 95% CI 1.3 - 2.5), but otherwise there were no differences in WASH access at the household level. At the individual level, people with disabilities reported greater difficulties in relation to sanitation (mean score 26.2, SD 26.5) and hygiene access and quality (mean 30.7, SD 24.2) compared to those without disabilities (15.5, 21.7, p<0.001; 22.4, 19.1, p<0.01). There were no differences in different aspects of water collection between people with and without disabilities in this context where over 85% of participants had water piped into their dwelling. Among people with disabilities, older adults were more likely to experience difficulties in hygiene and sanitation than younger people with disabilities. Conclusions People with disabilities in Guatemala experience greater difficulties in accessing sanitation facilities and practicing hygienic behaviours than their peers without disabilities. More data collection is needed using detailed tools to detect these differences, highlight which interventions are needed, and to allow assessment of their effectiveness.	[Kuper, Hannah; Mactaggart, Islay; Polack, Sarah] London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London, England; [White, Sian; Biran, Adam] London Sch Hyg & Trop Med, Dept Dis Control, London, England; [Dionicio, Carlos; Canas, Rafael; Naber, Jonathan] Natl Council Disabil, Guatemala City, Guatemala	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Kuper, H (corresponding author), London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London, England.	Hannah.kuper@lshtm.ac.uk	Dionicio, Carlos/AAP-6979-2021	Mactaggart, Islay/0000-0001-6287-0384	CBM Latin America; CONADI (the National Council on Disability), Guatemala; Christoffel Blinden Mission; Australian Aid (Australian Government Department of Foreign Affairs and Trade) through the Australian Development Research Awards Scheme	CBM Latin America; CONADI (the National Council on Disability), Guatemala; Christoffel Blinden Mission; Australian Aid (Australian Government Department of Foreign Affairs and Trade) through the Australian Development Research Awards Scheme	This research has been funded by CBM Latin America and CONADI (the National Council on Disability), Guatemala and the Christoffel Blinden Mission to Sarah Polack. Additional funds for the WASH component of the study were obtained through Australian Aid (Australian Government Department of Foreign Affairs and Trade) through the Australian Development Research Awards Scheme under an award entitled 'Disability and its impact on safe hygiene and sanitation' to Adam Biran. The views expressed in this publication are those of the authors and not necessarily those of the Commonwealth of Australia. The Commonwealth of Australia accepts no responsibility for any loss, damage or injury resulting from reliance on any of the information or views contained in this publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banks LM, 2014, EC COSTS EXCLUSION G; Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Bernabe-Ortiz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011300; Biran A, 2018, AM J TROP MED HYG, V98, P984, DOI 10.4269/ajtmh.17-0435; Danquah L, 2015, DISABIL REHABIL, V37, P1082, DOI 10.3109/09638288.2014.956186; Erhard L, 2013, GLOB PUBLIC HEALTH, V8, P1000, DOI 10.1080/17441692.2013.838284; Groce N, 2011, J WATER HEALTH, V9, P617, DOI 10.2166/wh.2011.198; Hulland KRS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141883; International Centre for Evidence in Disability, 2017, GUAT NAT DIS STUD EN; International Federation of Red Cross and Red Crescent Societies, 2013, SOC ASS TOOL WAT SAN; Kuper H, OXFORD DEV STUDIES; Kuper H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144926; MacLeod M, 2014, J WATER HEALTH, V12, P885, DOI 10.2166/wh.2014.009; Mactaggart I, BMJ OPEN; Marella M, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0096-y; Marella M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2202-7; Ministerio de Salud Publica y Asistencia Social Instituto Nacional de Estadistica, 2015, ENC NAC SAL MAT INF; Plan International, 2013, INCL US STUD DIS PLA; Pruss-Ustun A, 2014, TROP MED INT HEALTH, V19, P894, DOI 10.1111/tmi.12329; Trani JF, 2011, SOC SCI MED, V73, P1477, DOI 10.1016/j.socscimed.2011.08.040; UNICEF and WHO, 2017, PROGR SAN DRINK WAT; United Nations, 2006, CONV RIGHTS PERS DIS; Washington Group, QUEST SETS WASH GROU; White S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155043; WHO, 2011, WORLD REPORT ON DISABILITY, P1	25	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0197360	10.1371/journal.pone.0197360	http://dx.doi.org/10.1371/journal.pone.0197360			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856770	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000433900800021
J	Taylor, KS; Verbakel, JY; Feakins, BG; Price, CP; Perera, R; Bankhead, C; Pluddemann, A				Taylor, Kathryn S.; Verbakel, Jan Y.; Feakins, Benjamin G.; Price, Christopher P.; Perera, Rafael; Bankhead, Clare; Pluddemann, Annette			Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PUBLICATION BIAS; NT-PROBNP; UTILITY; BNP; PATIENT	OBJECTIVE To assess the diagnostic accuracy of point-of-care natriuretic peptide tests in patients with chronic heart failure, with a focus on the ambulatory care setting. DESIGN Systematic review and meta-analysis. DATA SOURCES Ovid Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Embase, Health Technology Assessment Database, Science Citation Index, and Conference Proceedings Citation Index until 31 March 2017. STUDY SELECTION Eligible studies evaluated point-of-care natriuretic peptide testing (B-type natriuretic peptide (BNP) or N terminal fragment pro B-type natriuretic peptide (NTproBNP)) against any relevant reference standard, including echocardiography, clinical examination, or combinations of these, in humans. Studies were excluded if reported data were insufficient to construct 2x2 tables. No language restrictions were applied. RESULTS 42 publications of 39 individual studies met the inclusion criteria and 40 publications of 37 studies were included in the analysis. Of the 37 studies, 30 evaluated BNP point-of-care testing and seven evaluated NTproBNP testing. 15 studies were done in ambulatory care settings in populations with a low prevalence of chronic heart failure. Five studies were done in primary care. At thresholds >100 pg/mL, the sensitivity of BNP, measured with the point-of-care index device Triage, was generally high and was 0.95 (95% confidence interval 0.90 to 0.98) at 100 pg/mL. At thresholds <100 pg/mL, sensitivity ranged from 0.46 to 0.97 and specificity from 0.31 to 0.98. Primary care studies that used NTproBNP testing reported a sensitivity of 0.99 (0.57 to 1.00) and specificity of 0.60 (0.44 to 0.74) at 135 pg/mL. No statistically significant difference in diagnostic accuracy was found between point-of-care BNP and NTproBNP tests. CONCLUSIONS Given the lack of studies in primary care, the paucity of NTproBNP data, and potential methodological limitations in these studies, large scale trials in primary care are needed to assess the role of point-of care natriuretic peptide testing and clarify appropriate thresholds to improve care of patients with suspected or chronic heart failure.	[Taylor, Kathryn S.; Verbakel, Jan Y.; Feakins, Benjamin G.; Price, Christopher P.; Perera, Rafael; Bankhead, Clare; Pluddemann, Annette] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England	University of Oxford	Pluddemann, A (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.	annette.pludderriann@phc.ox.ac.uk	Taylor, Kathryn/ABG-1422-2020; Verbakel, Jan/E-6758-2015	Verbakel, Jan/0000-0002-7166-7211; Feakins, Benjamin/0000-0002-3928-6750; Pluddemann, Annette/0000-0003-2101-0390; Perera, Rafael/0000-0003-2418-2091	National Institute for Health Research (NIHR) [RP-PG-1210-12003]; NIHR programme for applied research; NIHR Diagnostic Evidence Co-operative (DEC); NIHR; NIHR Oxford Biomedical Research Centre programme; NIHR HPRU Gastrointestinal Infections Group; NIHR DEC; Cancer Research UK; NIHR School of Primary Care Research	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR programme for applied research; NIHR Diagnostic Evidence Co-operative (DEC); NIHR(National Institute for Health Research (NIHR)); NIHR Oxford Biomedical Research Centre programme; NIHR HPRU Gastrointestinal Infections Group; NIHR DEC; Cancer Research UK(Cancer Research UK); NIHR School of Primary Care Research	This article presents independent research funded by the National Institute for Health Research (NIHR) under the programme grants for applied research programme (RP-PG-1210-12003). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. KST receives funding from the NIHR programme for applied research. JYV and CPP receive funding from the NIHR Diagnostic Evidence Co-operative (DEC). BGF receives funding from the NIHR Monitoring Grant and Research Capability Fund. RF receives funding from the NIHR Oxford Biomedical Research Centre programme, the NIHR programme for applied research, the NIHR HPRU Gastrointestinal Infections Group, and the NIHR DEC. CB receives funding from the NIHR Oxford Biomedical Research Centre programme, the NIHR programme for applied research, and Cancer Research UK. AP receives funding from the NIHR and the NIHR School of Primary Care Research. The funders had no role in the study design; data collection; data analysis and interpretation; writing of the report; or the decision to submit for publication.	Balion C, 2006, Evid Rep Technol Assess (Full Rep), P1; Bossuyt P, 2013, COCHRANE HDB SYSTEMA; Clerico A, 2007, CLIN CHEM, V53, P813, DOI 10.1373/clinchem.2006.075713; De Vecchis R, 2016, CARDIOL RES, V7, P51, DOI 10.14740/cr468e; Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016; Dukic V, 2003, BIOMETRICS, V59, P936, DOI 10.1111/j.0006-341X.2003.00108.x; Fuat A, 2006, BRIT J GEN PRACT, V56, P327; Korenstein D, 2007, BMC EMERG MED, V7, DOI 10.1186/1471-227X-7-6; Krishnaswamy P, 2001, AM J MED, V111, P274, DOI 10.1016/S0002-9343(01)00841-5; Latour-Perez J, 2006, EUR J HEART FAIL, V8, P390, DOI 10.1016/j.ejheart.2005.10.004; Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008; Mak GS, 2004, AM HEART J, V148, P895, DOI 10.1016/j.ahj.2004.02.016; Mant J, 2009, HEALTH TECHNOL ASSES, V13, pIX, DOI 10.3310/hta13320; Monfort A, 2015, BIOMARK MED, V9, P1323, DOI 10.2217/bmm.15.95; National Clinical Guideline Centre, 2010, CHRON HEART FAIL NAT; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; Roberts E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h910; Rutjes Anne W S, 2006, CMAJ, V174, P469, DOI 10.1503/cmaj.050090; Song FJ, 2002, INT J EPIDEMIOL, V31, P88, DOI 10.1093/ije/31.1.88; Takwoingi Y, 2015, EVID-BASED MENT HEAL, V18, P103, DOI 10.1136/eb-2015-102228; Taylor CJ, 2017, BRIT J GEN PRACT, V67, pE94, DOI 10.3399/bjgp16X688393; Tomonaga Y, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-12; Townsend N, 2012, CORONARY HEART DIS S; Turner PJ, 2016, FAM PRACT, V33, P388, DOI 10.1093/fampra/cmw018; Verdu JM, 2012, REV ESP CARDIOL, V65, P613, DOI [10.1016/j.rec.2012.01.021, 10.1016/j.recesp.2012.01.019]; Villacorta Humberto, 2002, Arq. Bras. Cardiol., V79, P569, DOI 10.1590/S0066-782X2002001500002; Wang CS, 2005, JAMA-J AM MED ASSOC, V294, P1944, DOI 10.1001/jama.294.15.1944; Watson C, 2016, BIOMARKERS, V21, P538, DOI 10.3109/1354750X.2016.1160427; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Worster A, 2008, CLIN BIOCHEM, V41, P250, DOI 10.1016/j.clinbiochem.2007.08.008; Zaphiriou A, 2005, EUR J HEART FAIL, V7, P537, DOI 10.1016/j.ejheart.2005.01.022; Zuber M, 2009, SCAND CARDIOVASC J, V43, P324, DOI 10.1080/14017430902769919	33	23	24	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	2018	361								k1450	10.1136/bmj.K1450	http://dx.doi.org/10.1136/bmj.K1450			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH4WZ	29785952	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000433413900001
J	Liljenquist, D; Bai, G; Anderson, GF				Liljenquist, Dan; Bai, Ge; Anderson, Gerard F.			Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Liljenquist, Dan] Intermt Healthcare, Salt Lake City, UT 84111 USA; [Bai, Ge] Johns Hopkins Carey Business Sch, Washington, DC USA; [Anderson, Gerard F.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Intermountain Healthcare; Intermountain Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Liljenquist, D (corresponding author), Intermt Healthcare, Salt Lake City, UT 84111 USA.							Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; [Anonymous], 2018, GENERIC DRUG USER FE; Fox ER, 2014, MAYO CLIN PROC, V89, P361, DOI 10.1016/j.mayocp.2013.11.014; Greene JA, 2016, JAMA-J AM MED ASSOC, V315, P461, DOI 10.1001/jama.2015.18720; Karas L, 2018, AM J MANAG CARE, V24, pE122	5	13	13	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 17	2018	378	20					1857	1859		10.1056/NEJMp1800861	http://dx.doi.org/10.1056/NEJMp1800861			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF9LR	29768140				2023-01-03	WOS:000432299600001
J	Alcover, EA; Jaume-i-Capo, A; Moya-Alcover, B				Amengual Alcover, Esperanca; Jaume-i-Capo, Antoni; Moya-Alcover, Biel			PROGame: A process framework for serious game development for motor rehabilitation therapy	PLOS ONE			English	Article							IMPROVEMENT; CHILDREN	Serious game development for rehabilitation therapy is becoming increasingly popular because of the motivational advantages that these types of applications provide. Consequently, the need for a common process framework for this category of software development has become increasingly evident. The goal is to guarantee that products are developed and validated by following a coherent and systematic method that leads to high-quality serious games. This paper introduces a new process framework for the development of serious games for motor rehabilitation therapy. We introduce the new model and demonstrate its application for the development of a serious game for the improvement of the balance and postural control of adults with cerebral palsy. The development of this application has been facilitated by two technological transfer contracts and is being exploited by two different organizations. According to clinical measurements, patients using the application improved from high fall risk to moderate fall risk. We believe that our development strategy can be useful not only for motor rehabilitation therapy, but also for the development of serious games in many other rehabilitation areas.	[Amengual Alcover, Esperanca; Jaume-i-Capo, Antoni; Moya-Alcover, Biel] Univ Balearic Isl, Dept Math & Comp Sci, Palma De Mallorca, Spain	Universitat de les Illes Balears	Alcover, EA (corresponding author), Univ Balearic Isl, Dept Math & Comp Sci, Palma De Mallorca, Spain.	eamengual@uib.es	Amengual, Esperança/L-7065-2014; Jaume-i-Capó, Antoni/I-4053-2015; Moya-Alcover, Gabriel/L-3129-2018	Amengual, Esperança/0000-0002-0699-6684; Jaume-i-Capó, Antoni/0000-0003-3312-5347; Moya-Alcover, Gabriel/0000-0002-3412-5499	Ministerio de Economia, Industria y Competitividad (MINECO); Agencia Estatal de Investigacion (AEI); European Regional Development Funds (ERDF, EU) [TIN2016-81143R, TIN2015-67149-C3-2-R]	Ministerio de Economia, Industria y Competitividad (MINECO); Agencia Estatal de Investigacion (AEI); European Regional Development Funds (ERDF, EU)	We acknowledge the Ministerio de Economia, Industria y Competitividad (MINECO), the Agencia Estatal de Investigacion (AEI) and the European Regional Development Funds (ERDF, EU) for its support to the projects TIN2016-81143R (MINECO/AEI/ERDF, EU) and TIN2015-67149-C3-2-R (MINECO/AEI/ERDF, EU). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amengual E, 2007, 14 EUR SOFTW PROC IM, P11; Broetz D, 2013, NEUROREHABILITATION, V33, P377, DOI 10.3233/NRE-130967; Burke JW, 2009, VISUAL COMPUT, V25, P1085, DOI 10.1007/s00371-009-0387-4; Finch E, 2002, PHYS REHABILITATION; Flores E., 2008, P 2008 INT C ADV COM, P381, DOI [10.1145/1501750.1501839, DOI 10.1145/1501750.1501839]; Friedman L.M., 2015, FUNDAMENTALS CLIN TR, V5, DOI DOI 10.1007/978-3-319-18539-2; Humphrey W., 1989, MANAGING SOFTWARE PR; Humphrey WS, 1993, INTRO SOFTWARE PROCE; Jaume-i-Capo A, 2014, SCI WORLD J, DOI 10.1155/2014/964576; Jaume-i-Capo A, 2014, STUD COMPUT INTELL, V536, P12, DOI 10.1007/978-3-642-45432-5_2; Jaume-i-Capo A, 2014, IEEE T NEUR SYS REH, V22, P419, DOI 10.1109/TNSRE.2013.2279155; Kappel G, 2005, WEB ENG; King LA, 2009, PHYS THER, V89, P384, DOI 10.2522/ptj.20080214; Mesquida AL, 2012, INFORM SOFTWARE TECH, V54, P239, DOI 10.1016/j.infsof.2011.11.002; Maclean N, 2002, STROKE, V33, P444, DOI 10.1161/hs0202.102367; Mas A, 2010, COMM COM INF SC, V99, P290; MOYAAALCOVER B, 2011, P 13 INT ACM SIGAC C, P297; Pichaco AM, 2003, SERP'03: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON SOFTWARE ENGINEERING RESEARCH AND PRACTICE, VOLS 1 AND 2, P693; Pirovano M, 2016, ENTERTAIN COMPUT, V14, P55, DOI 10.1016/j.entcom.2015.10.002; Pressman R, 2000, WEB ENG SOFTWARE ENG; Pressman R.S., 2005, SOFTWARE ENG PRACTIT; Pressman RS, 1998, IEEE SOFTWARE, V15, P104, DOI 10.1109/MS.1998.714869; Pries K.H., 2010, SCRUM PROJECT MANAGE; Reyes-Amaro A., 2012, P E HLTH ENV C MIDDL, P127; Reyes-Amaro A., 2012, JACCES, V2, P62; Salem Y, 2009, NEUROREHABILITATION, V24, P307, DOI 10.3233/NRE-2009-0483; Sandlund M, 2009, DEV MED CHILD NEUROL, V51, P173, DOI 10.1111/j.1469-8749.2008.03184.x; Sommerville I, 2016, SOFTWARE ENG PEARSON; Turk M, 2004, COMMUN ACM, V47, P61, DOI 10.1145/962081.962107; Van Vliet H., 1993, SOFTWARE ENG PRINCIP, V3; Woollacott Marjorie Hines, 2005, Neural Plasticity, V12, P211, DOI 10.1155/NP.2005.211; Wulf G, 2010, RES Q EXERCISE SPORT, V81, P425	32	17	17	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0197383	10.1371/journal.pone.0197383	http://dx.doi.org/10.1371/journal.pone.0197383			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF9WG	29768472	Green Published, gold, Green Submitted			2023-01-03	WOS:000432329200078
J	Guthrie, KM; Rosen, RK; Vargas, SE; Getz, ML; Dawson, L; Guillen, M; Ramirez, JJ; Baum, MM; Vincent, KL				Guthrie, Kate M.; Rosen, Rochelle K.; Vargas, Sara E.; Getz, Melissa L.; Dawson, Lauren; Guillen, Melissa; Ramirez, Jaime J.; Baum, Marc M.; Vincent, Kathleen L.			User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences	PLOS ONE			English	Article							VAGINAL RING; SENSORY PERCEPTIONS; PRODUCT DESIGN; PREVENTION; GEL; MICROBICIDES; EFFICACY; WOMEN	Background Effective HIV prevention requires efficient delivery of safe and efficacious drugs and optimization of user adherence. The user's experiences with the drug, delivery system, and use parameters are critical to product acceptability and adherence. Prevention product developers have the opportunity to directly control a drug delivery system and its impact on acceptability and adherence, as well as product efficacy. Involvement of potential users during preclinical design and development can facilitate this process. We embedded a mixed methods user evaluation study into a safety and pharmacokinetics (PK) trial of a pod-intravaginal ring delivering antiretroviral agents. Methodology Women enrolled in two cohorts, ultimately evaluating the safety/PK of a pod-IVRs delivering TDF-alone, TDF-FTC, and/or TDF-FTC-MVC. A 7-day use period was targeted for each pod-IVR, regardless of drug or drug combination. During the clinical study, participants provided both quantitative (i.e., survey) and qualitative (i.e., in-depth interview) data capturing acceptability, perceptibility, and adherence behaviors. Initial sexual and reproductive health history surveys, daily diaries, a final acceptability and willingness to use survey, and a qualitative in-depth interview comprised the user evaluation data for each pod-IVR experienced by the participants. Findings Overall, the majority of participants (N = 10) reported being willing to use the pod-IVR platform for HIV prevention should it advance to market. Confidence to use the pod-IVR (e.g., insertion, removal) was high. There were no differences noted in the user experience of the pod-IVR platform; that is, whether the ring delivered TDF-alone, TDF-FTC, or TDF-FTCMVC, users' experiences of the ring were similar and acceptable. Participants did report specific experiences, both sensory and behavioral, that impacted their use behaviors with respect to the ring, and which could ultimately impact acceptability and adherence. These experiences, and user evaluations elicited by them, could both challenge use or be used to leverage use in future trials and product rollout once fully articulated. Conclusions High willingness-to-use data and lack of salient differences in user experiences related to use of the pod-IVR platform (regardless of agents delivered) suggests that the pod-IVR is a feasible and acceptable drug delivery device in and of itself. This finding holds promise both for an anti-HIV pod-IVR and, potentially, a multipurpose prevention pod-IVR that could deliver both prevention for sexually transmitted infections (STIs) including HIV and contraception. Given the very early clinical trial context, further acceptability, perceptibility, and adherence data should continue to be explored, in the context of longer use periods (e.g., 28-day ring use), and in the contexts of sexual activity and menses. Using early design and development contexts to gain insights into potential challenges and facilitators of drug delivery systems such as the pod-IVR could save valuable resources and time as a potential biomedical technology moves through the clinical trial pipeline and into real-world use.	[Guthrie, Kate M.; Rosen, Rochelle K.; Vargas, Sara E.; Getz, Melissa L.; Guillen, Melissa; Ramirez, Jaime J.] Miriam Hosp, Ctr Behav & Prevent Med, Providence, RI 02906 USA; [Guthrie, Kate M.; Vargas, Sara E.] Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA; [Guthrie, Kate M.; Rosen, Rochelle K.] Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA; [Dawson, Lauren; Vincent, Kathleen L.] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA; [Baum, Marc M.] Oak Crest Inst Sci, Dept Chem, Monrovia, CA USA	Lifespan Health Rhode Island; Miriam Hospital; Brown University; Brown University; University of Texas System; University of Texas Medical Branch Galveston	Guthrie, KM (corresponding author), Miriam Hosp, Ctr Behav & Prevent Med, Providence, RI 02906 USA.; Guthrie, KM (corresponding author), Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA.; Guthrie, KM (corresponding author), Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA.	kate.guthrie@lifespan.org		Guthrie, Kate M./0000-0002-5528-1212; Baum, Marc/0000-0003-1558-5649; Vargas, Sara/0000-0003-2934-4766; Vincent, Kathleen/0000-0003-3051-9551	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [U19AI113048]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K24 HD062645]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD062645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI113048] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI113048 (PI: MMB). The first and third authors were also partially funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24 HD062645, PI: KMG; SEV, post-doctoral fellow). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baeten J.M., 2016, N ENGL J MED; Barentsen R, 1997, EUR J OBSTET GYN R B, V71, P73, DOI 10.1016/S0301-2115(96)02612-7; Baum MM, 2015, INT J PHARMACEUT, V495, P579, DOI 10.1016/j.ijpharm.2015.09.028; Baum MM, 2012, J PHARM SCI-US, V101, P2833, DOI 10.1002/jps.23208; Birnbaum F, 2015, ACAD EMERG MED, V22, P754, DOI 10.1111/acem.12692; Centers for Disease Control and Prevention, 2017, HIV WOMEN2017; Chakrapani V, 2017, QUAL HEALTH RES, V27, P1236, DOI 10.1177/1049732317697947; Clinicaltrials.gov, SAF PHARM STUD HIV P; Fava JL, 2013, SEX HLTH, V28; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Guest Greg, 2011, APPL THEMAT ANAL; Guthrie KM, 2018, PHARM DEV TECHNOL, V23, P311, DOI 10.1080/10837450.2017.1339085; Guthrie KM, 2017, DRUG DELIV TRANSL RE, V7, P761, DOI 10.1007/s13346-017-0397-0; Guthrie KM, 2016, AIDS RES HUM RETROV, V32, P1022, DOI 10.1089/aid.2015.0275; Guthrie KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145642; Montgomery MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157742; Morrow KM, 2008, AIDS BEHAV, V12, P272, DOI 10.1007/s10461-007-9266-z; Morrow KM, 2014, ARCH SEX BEHAV, V43, P1459, DOI 10.1007/s10508-013-0235-5; Morrow KM, 2014, AIDS RES HUM RETROV, V30, P78, DOI [10.1089/aid.2013.0099, 10.1089/AID.2013.0099]; Moss JA, 2015, DRUG DELIVERY AND DEVELOPMENT OF ANTI-HIV MICROBICIDES, P221; Nel A, 2016, NEW ENGL J MED, V375, P2133, DOI 10.1056/NEJMoa1602046; Patel S, 2019, DRUG CHEM TOXICOL, V42, P1, DOI 10.1080/01480545.2017.1413110; QSR International Pty Ltd, 2012, QUALITATIVE ANAL USI; Ritchie J, 1994, ANAL QUALITATIVE DAT, P173, DOI DOI 10.4324/9780203413081; Rosen RK, 2008, J WOMENS HEALTH, V17, P383, DOI 10.1089/jwh.2006.0325; Rosen RK, 2015, CONTRACEPTION, V92, P596, DOI 10.1016/j.contraception.2015.08.007; Smith Joanna, 2011, Nurse Res, V18, P52; UN Women, 2017, FACTS FIG HIV AIDS 2; van den Berg JJ, 2014, AIDS BEHAV, V18, P862, DOI 10.1007/s10461-013-0652-4; Weisberg E, 2005, CLIMACTERIC, V8, P83, DOI 10.1080/13697130500087016; World Health Organization, 2017, NUMB WOM LIV HIV2017	31	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2018	13	5							e0197269	10.1371/journal.pone.0197269	http://dx.doi.org/10.1371/journal.pone.0197269			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF6MZ	29758049	Green Published, gold, Green Submitted			2023-01-03	WOS:000432082900040
J	Kastor, A; Mohanty, SK				Kastor, Anshul; Mohanty, Sanjay K.			Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: Do Indian households face distress health financing?	PLOS ONE			English	Article							LOW-INCOME; CARE; PAYMENTS; POOR; COUNTRIES; ILLNESS; URBAN	Background Rising non-communicable diseases (NCDs) coupled with increasing injuries have resulted in a significant increase in health spending in India. While out-of-pocket expenditure remains the major source of health care financing in India (two-thirds of the total health spending), the financial burden varies enormously across diseases and by the economic well-being of the households. Though prior studies have examined the variation in disease pattern, little is known about the financial risk to the families by type of diseases in India. In this context, the present study examines disease-specific out-of-pocket expenditure (OOPE), catastrophic health expenditure (CHE) and distress health financing. Methods and materials Unit data from the 71(st) round of the National Sample Survey Organization (2014) was used for this study. OOPE is defined as health spending on hospitalization net of reimbursement, and CHE is defined as household health spending exceeding 10% of household consumption expenditure. Distress health financing is defined as a situation when a household has to borrow money or sell their property/assets or when it gets contributions from friends/relatives to meet its health care expenses. OOPE was estimated for 16 selected diseases and across three broad categories- communicable diseases, NCDs and injuries. Multivariate logistic regression was used to understand the determinants of distress financing and CHE. Results Mean DOPE on hospitalization was INR 19,210 and was the highest for cancer (INR 57,232) followed by heart diseases (INR 40,947). About 28% of the households incurred CHE and faced distress financing. Among all the diseases, cancer caused the highest CHE (79%) and distress financing (43%). More than one-third of the inpatients reported distressed financing for heart diseases, neurological disorders, genito urinary problems, musculoskeletal diseases, gastro-intestinal problems and injuries. The likelihood of incurring distress financing was 3.2 times higher for those hospitalized for cancer (OR 3.23; 95% CI: 2.62-3.99) and 2.6 times for tuberculosis patients (OR 2.61; 95% CI: 2.06-3.31). A large proportion of households who had reported distress financing also incurred CHE. Recommendations Free treatment for cancer and heart diseases is recommended for the vulnerable sections of the society. Risk-pooling and social security mechanisms based on contributions from both households as well as the central and state governments can reduce the financial burden of diseases and avert households from distress health financing.	[Kastor, Anshul; Mohanty, Sanjay K.] IIPS, Dept Fertil Studies, Bombay, Maharashtra, India	International Institute for Population Sciences	Kastor, A (corresponding author), IIPS, Dept Fertil Studies, Bombay, Maharashtra, India.	anshulkastor@gmail.com	Mohanty, Sanjay K/AAR-7658-2020	Mohanty, Sanjay K/0000-0001-9041-5952				Ajay Mahal, 2002, Economic and Political Weekly, V37, P559; Baird KE, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312115623792; Berki S E, 1986, Health Aff (Millwood), V5, P138, DOI 10.1377/hlthaff.5.4.138; Berman P, 2010, EC POLIT WKLY, VXLV, P65; Binnendijk E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-23; Bloom DE, 2014, EC NONCOMMUNICABLE D; Bonu S, 2009, HEALTH POLICY PLANN, V24, P445, DOI 10.1093/heapol/czp032; Central Bureau of Health Intelligence, 2015, NAT HLTH PROF 2015; Choi JW, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0675-1; Engelgau MM, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-9; Garg CC, 2009, HEALTH POLICY PLANN, V24, P116, DOI 10.1093/heapol/czn046; Goli S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156437; Gupt A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149824; Joe W, 2015, HEALTH POLICY PLANN, V30, P728, DOI 10.1093/heapol/czu050; Karan A, 2017, SOC SCI MED, V181, P83, DOI 10.1016/j.socscimed.2017.03.053; Nguyen KT, 2012, SOC SCI MED, V74, P724, DOI 10.1016/j.socscimed.2011.10.027; Kruk ME, 2009, HEALTH AFFAIR, V28, P1056, DOI 10.1377/hlthaff.28.4.1056; Kumar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135051; Leive A, 2008, B WORLD HEALTH ORGAN, V86, P849, DOI 10.2471/BLT.07.049403; McIntyre D, 2006, SOC SCI MED, V62, P858, DOI 10.1016/j.socscimed.2005.07.001; Ministry of Health and Family Welfare, 2012, REV NAT TUB CONTR PR; Ministry of Health and Family Welfare, RASHTR SWASTH BIM YO; Ministry of Health and Family Welfare Government of India, 2016, NAT HLTH ACC EST IND; Ministry of Health Family Welfare GoI, 2017, NAT HLTH POL 2017; Ministry of Home Affairs, 2009, RE CAUS DEATH IND 20; Mohanty SK, 2016, J PUBLIC HEALTH-HEID, V24, P215, DOI 10.1007/s10389-016-0712-0; Mohanty SK, 2014, SOC INDIC RES, V115, P1137, DOI 10.1007/s11205-013-0261-7; MOHFW G, 2009, NAT HLTH ACC IND 200; Moreno-Serra R, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001087; Muniyandi M., 2005, Indian Journal of Tuberculosis, V52, P188; Nair Harish, 2011, J Glob Health, V1, P79; National Sample Survey Organization (NSSO), 2015, 71 NSSO MIN STAT PRO; Oxlade O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047533; Planning Commission, 2011, EV STUD NAT RUR HLTH; Prinja S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137315; Raban MZ, 2013, B WORLD HEALTH ORGAN, V91, P726, DOI 10.2471/BLT.12.113100; Ramachandran A, 2007, DIABETES CARE, V30, P252, DOI 10.2337/dc06-0144; Rao KD, 2011, INDIAN J MED RES, V133, P57; Rashad AS, 2015, AM J EC, V5, P526, DOI DOI 10.1093/HEAP0L/CZQ070; Reddy KS, 2011, LANCET, V377, P760, DOI 10.1016/S0140-6736(10)61960-5; Sauerborn R, 1996, SOC SCI MED, V43, P291, DOI 10.1016/0277-9536(95)00375-4; SDJS-UN, 2015, 2030 AG SUST DEV; Soumitra Ghosh, 2011, Economic and Political Weekly, V46, P63; Su TT, 2006, B WORLD HEALTH ORGAN, V84, P21, DOI 10.2471/BLT.05.023739; Taylor DW, 2010, BURD NONCOMMUNICABLE; Tripathy JP, 2016, TROP MED INT HEALTH, V21, P1019, DOI 10.1111/tmi.12732; Van Doorslaer E, 2007, HEALTH ECON, V16, P1159, DOI 10.1002/hec.1209; Wang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116897; Weraphong J, 2013, SE ASIAN J TROP MED, V44, P124; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; WHO, 2017, NONC DIS FACT SHEET; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; Xu K, 2007, HEALTH AFFAIR, V26, P972, DOI 10.1377/hlthaff.26.4.972; Yesudian CAK, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/s12992-014-0080-x	54	96	97	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0196106	10.1371/journal.pone.0196106	http://dx.doi.org/10.1371/journal.pone.0196106			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF3JM	29746481	Green Published, Green Submitted, gold			2023-01-03	WOS:000431851700008
J	Guirguis-Blake, JM; Michael, YL; Perdue, LA; Coppola, EL; Beil, TL				Guirguis-Blake, Janelle M.; Michael, Yvonne L.; Perdue, Leslie A.; Coppola, Erin L.; Beil, Tracy L.			Interventions to Prevent Falls in Older Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; VITAMIN-D SUPPLEMENTATION; HOME-BASED EXERCISE; ELDERLY-PEOPLE; REDUCE FALLS; MULTIFACTORIAL INTERVENTION; HIGH-RISK; EMERGENCY-DEPARTMENT; GENERAL-PRACTICE; TAI-CHI	IMPORTANCE Falls are the most common cause of injury-related morbidity and mortality among older adults. OBJECTIVE To systematically review literature on the effectiveness and harms of fall prevention interventions in community-dwelling older adults to inform the US Preventive Services Task Force. DATA SOURCES MEDLINE, PubMed, Cumulative Index for Nursing and Allied Health Literature, and Cochrane Central Register of Controlled Trials for relevant English-language literature published through August 2016, with ongoing surveillance through February 7, 2018. STUDY SELECTION Randomized clinical trials of interventions to prevent falls in community-dwelling adults 65 years and older. DATA EXTRACTION AND SYNTHESIS Independent critical appraisal and data abstraction by 2 reviewers. Random-effects meta-analyses using the method of DerSimonian and Laird. MAIN OUTCOMES AND MEASURES Number of falls (number of unexpected events in which a person comes to rest on the ground, floor, or lower level), people experiencing 1 or more falls, injurious falls, people experiencing injurious falls, fractures, people experiencing fractures, mortality, hospitalizations, institutionalizations, changes in disability, and treatment harms. RESULTS Sixty-two randomized clinical trials (N = 35 058) examining 7 fall prevention intervention types were identified. This article focused on the 3 most commonly studied intervention types: multifactorial (customized interventions based on initial comprehensive individualized falls risk assessment) (26 trials [n = 15 506]), exercise (21 trials [n = 7297]), and vitamin D supplementation (7 trials [n = 7531]). Multifactorial intervention trials were associated with a reduction in falls (incidence rate ratio [IRR], 0.79 [95% Cl, 0.68-0.91]) but were not associated with a reduction in other fall-related morbidity and mortality outcomes. Exercise trials were associated with statistically significant reductions in people experiencing a fall (relative risk, 0.89 [95% 13 Cl, 0.81-0.97]) and injurious falls (IRR, 0.81 [95% Cl, 0.73-0.90]) and with a statistically nonsignificant reduction in falls (IRR, 0.87 [95% Cl, 0.75-1.00]) but showed no association with mortality. Few exercise trials reported fall-related fractures. Seven heterogeneous trials of vitamin D formulations (with or without calcium) showed mixed results. One trial of annual high-dose cholecalciferol (500 000 IU), which has not been replicated, showed an increase in falls, people experiencing a fall, and injuries, while 1 trial of calcitriol showed a reduction in falls and people experiencing a fall; the remaining 5 trials showed no significant difference in falls, people experiencing a fall, or injuries. Harms of multifactorial and exercise trials were rarely reported but generally included minor musculoskeletal injuries. CONCLUSIONS AND RELEVANCE Multifactorial and exercise interventions were associated with fall-related benefit, but evidence was most consistent across multiple fall-related outcomes for exercise. Vitamin D supplementation interventions had mixed results, with a high dose being associated with higher rates of fall-related outcomes.	[Guirguis-Blake, Janelle M.; Perdue, Leslie A.; Coppola, Erin L.; Beil, Tracy L.] Kaiser Permanente, Res Affiliates Evidence based Practice Ctr Ctr Hl, Portland, OR USA; [Guirguis-Blake, Janelle M.] Univ Washington, Dept Family Med, Tacoma, WA USA; [Michael, Yvonne L.] Drexel Univ, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA	Kaiser Permanente; University of Washington; University of Washington Tacoma; Drexel University	Guirguis-Blake, JM (corresponding author), Univ Washington, Dept Family Med, Kaiser Permanente Res Affiliates EPC, 521 Martin Luther King Jr Way, Tacoma, WA 98405 USA.	jguirgui@u.washington.edu	Michael, Yvonne Louise/AAB-9995-2020		Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA-290-2012-00015-I-EPC4]	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services	This research was funded under contract HHSA-290-2012-00015-I-EPC4, Task Order 6, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the USPSTF.	Barnett A, 2003, AGE AGEING, V32, P407, DOI 10.1093/ageing/32.4.407; Barry E, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-14; Bergen G, 2016, MMWR-MORBID MORTAL W, V65, P993, DOI 10.15585/mmwr.mm6537a2; Bischoff-Ferrari HA, 2006, ARCH INTERN MED, V166, P424; Bolland MJ, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3005; Bolland MJ, 2014, J CLIN ENDOCR METAB, V99, P4265, DOI 10.1210/jc.2014-2562; Bolland MJ, 2014, LANCET DIABETES ENDO, V2, P573, DOI 10.1016/S2213-8587(14)70068-3; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Chu MML, 2017, J AM GERIATR SOC, V65, P364, DOI 10.1111/jgs.14527; Ciaschini PM, 2009, AGE AGEING, V38, P724, DOI 10.1093/ageing/afp176; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Cohen MA, 2015, HEALTH AFFAIR, V34, P971, DOI 10.1377/hlthaff.2014.1172; Conroy S, 2010, AGE AGEING, V39, P704, DOI 10.1093/ageing/afq096; Davison J, 2005, AGE AGEING, V34, P162, DOI 10.1093/ageing/afi053; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; de Vries OJ, 2010, ARCH INTERN MED, V170, P1110, DOI 10.1001/archinternmed.2010.169; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Donner A, 2003, EVAL HEALTH PROF, V26, P340, DOI 10.1177/0163278703255234; Dukas L, 2004, J AM GERIATR SOC, V52, P230, DOI 10.1111/j.1532-5415.2004.52060.x; El-Khoury F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6234; El-Khoury F, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3830; Elley CR, 2008, J AM GERIATR SOC, V56, P1383, DOI 10.1111/j.1532-5415.2008.01802.x; Fairhall N, 2014, AGE AGEING, V43, P616, DOI 10.1093/ageing/aft204; Ferrer A, 2014, CLIN INTERV AGING, V9, P383, DOI 10.2147/CIA.S57580; Fitzharris MP, 2010, AGE AGEING, V39, P728, DOI 10.1093/ageing/afq109; Freiberger E, 2012, J AM GERIATR SOC, V60, P437, DOI 10.1111/j.1532-5415.2011.03859.x; Gallagher JC, 2016, NAT REV ENDOCRINOL, V12, P680, DOI 10.1038/nrendo.2016.123; Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P3618, DOI 10.1210/jc.86.8.3618; Gates S, 2008, J REHABIL RES DEV, V45, P1105, DOI 10.1682/JRRD.2008.04.0057; Gawler S, 2016, ARCH GERONTOL GERIAT, V67, P46, DOI 10.1016/j.archger.2016.06.019; Gill TM, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i245; Gillespie L. D., 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD007146; Glendenning P, 2012, J BONE MINER RES, V27, P170, DOI 10.1002/jbmr.524; Hendriks MRC, 2008, J AM GERIATR SOC, V56, P1390, DOI 10.1111/j.1532-5415.2008.01803.x; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hogan DB, 2001, CAN MED ASSOC J, V165, P537; Imhof L, 2012, J AM GERIATR SOC, V60, P2223, DOI 10.1111/jgs.12026; Kalyani RR, 2010, J AM GERIATR SOC, V58, P1299, DOI 10.1111/j.1532-5415.2010.02949.x; Kamide Naoto, 2009, Journal of Physiological Anthropology, V28, P115, DOI 10.2114/jpa2.28.115; Karinkanta S, 2015, AGE AGEING, V44, P784, DOI 10.1093/ageing/afv064; Kovacs E, 2013, EUR J PHYS REHAB MED, V49, P301; Lamb SE, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-125; Lightbody E, 2002, AGE AGEING, V31, P203, DOI 10.1093/ageing/31.3.203; Logan PA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2102; Logghe IHJ, 2009, J AM GERIATR SOC, V57, P70, DOI 10.1111/j.1532-5415.2008.02064.x; Lord SR, 2005, J AM GERIATR SOC, V53, P1296, DOI 10.1111/j.1532-5415.2005.53425.x; Lusardi MM, 2017, J GERIATR PHYS THER, V40, P1, DOI 10.1519/JPT.0000000000000099; Luukinen H, 2007, PREV MED, V44, P265, DOI 10.1016/j.ypmed.2006.09.011; Matchar DB, 2017, ARCH PHYS MED REHAB, V98, P1086, DOI 10.1016/j.apmr.2017.01.014; Michael YL., 2010, INTERVENTIONS PREVEN; Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003-4819-153-12-201012210-00008; Moller UO, 2014, J AGING PHYS ACTIV, V22, P457, DOI [10.1123/JAPA.2013-0101, 10.1123/japa.2013-0101]; Morgan RO, 2004, J GERONTOL A-BIOL, V59, P1062; Moyer VA, 2012, ANN INTERN MED, V157, P197, DOI 10.7326/0003-4819-157-3-201208070-00462; Murad MH, 2011, J CLIN ENDOCR METAB, V96, P2997, DOI 10.1210/jc.2011-1193; Newbury JW, 2001, MED J AUSTRALIA, V175, P104, DOI 10.5694/j.1326-5377.2001.tb143541.x; Ng TP, 2015, AM J MED, V128, P1225, DOI 10.1016/j.amjmed.2015.06.017; Palvanen M, 2014, INJURY, V45, P265, DOI 10.1016/j.injury.2013.03.010; Perula LA, 2012, ARCH PHYS MED REHAB, V93, P1677, DOI 10.1016/j.apmr.2012.03.035; Porthouse J, 2005, BMJ-BRIT MED J, V330, P1003, DOI 10.1136/bmj.330.7498.1003; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Russell MA, 2010, J AM GERIATR SOC, V58, P2265, DOI 10.1111/j.1532-5415.2010.03191.x; Salminen MJ, 2009, J AM GERIATR SOC, V57, P612, DOI 10.1111/j.1532-5415.2009.02176.x; Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594; Schleicher RL, 2016, AM J CLIN NUTR, V104, P454, DOI 10.3945/ajcn.115.127985; Sherrington C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104412; Spice CL, 2009, AGE AGEING, V38, P33, DOI 10.1093/ageing/afn192; Stubbs B, 2015, PHYS THER, V95, P1095, DOI 10.2522/ptj.20140461; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tricco AC, 2017, JAMA-J AM MED ASSOC, V318, P1687, DOI 10.1001/jama.2017.15006; Trombetti A, 2011, ARCH INTERN MED, V171, P525, DOI 10.1001/archinternmed.2010.446; Uusi-Rasi K, 2015, JAMA INTERN MED, V175, P703, DOI 10.1001/jamainternmed.2015.0225; van Haastregt JCM, 2000, BMJ-BRIT MED J, V321, P994, DOI 10.1136/bmj.321.7267.994; Vind AB, 2009, J AM GERIATR SOC, V57, P971, DOI 10.1111/j.1532-5415.2009.02270.x; Voukelatos A, 2007, J AM GERIATR SOC, V55, P1185, DOI 10.1111/j.1532-5415.2007.01244.x; Voukelatos A, 2015, AGE AGEING, V44, P377, DOI 10.1093/ageing/afu186; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800	78	184	192	12	106	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2018	319	16					1705	1716		10.1001/jama.2017.21962	http://dx.doi.org/10.1001/jama.2017.21962			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD7RF	29710140	Bronze			2023-01-03	WOS:000430709300025
J	Saxena, M; Delgado, Y; Sharma, RK; Sharma, S; Guzman, SLPD; Tinoco, AD; Griebenow, K				Saxena, Manoj; Delgado, Yamixa; Sharma, Rohit Kumar; Sharma, Shweta; Guzman, Solimar Liz Ponce De Leon; Tinoco, Arthur D.; Griebenow, Kai			Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome c via a transferrin conjugate	PLOS ONE			English	Article							INTRACELLULAR DELIVERY; RECEPTOR EXPRESSION; DRUG-DELIVERY; LUNG-CANCER; APOPTOSIS; PROTEIN; NANOPARTICLES; ACTIVATION; CISPLATIN; TUMORS	One of the major drawbacks of many of the currently used cancer drugs are off-target effects. Targeted delivery is one method to minimize such unwanted and detrimental events. To actively target lung cancer cells, we have developed a conjugate of the apoptosis inducing protein cytochrome c with transferrin because the transferrin receptor is overexpressed by many rapidly dividing cancer cells. Cytochrome c and transferrin were cross-linked with a redox sensitive disulfide bond for the intra-cellular release of the protein upon endocytosis by the transferrin receptor. Confocal results demonstrated the cellular uptake of the cytochrome c-transferrin conjugate by transferrin receptor overexpressing A549 lung cancer cells. Localization studies further validated that this conjugate escaped the endosome. Additionally, an in vitro assay showed that the conjugate could induce apoptosis by activating caspase-3. The neo-conjugate not only maintained an IC50 value similar to the well known drug cisplatin (50 mu M) in A549 cancer cells but also was nontoxic to the normal lung (MRC5) cells. Our neo-conjugate holds promise for future development to target cancers with enhanced transferrin receptor expression.	[Saxena, Manoj; Sharma, Rohit Kumar; Sharma, Shweta] Univ Puerto Rico, Dept Environm Sci, Rio Piedras Campus, San Juan, PR 00936 USA; [Saxena, Manoj; Delgado, Yamixa; Guzman, Solimar Liz Ponce De Leon; Tinoco, Arthur D.; Griebenow, Kai] Univ Puerto Rico, Dept Chem, Rio Piedras Campus, San Juan, PR 00936 USA; [Delgado, Yamixa] San Juan Bautista Sch Med, Biochem & Pharmacol Dept, Caguas, PR USA	University of Puerto Rico; University of Puerto Rico Rio Piedras; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Griebenow, K (corresponding author), Univ Puerto Rico, Dept Chem, Rio Piedras Campus, San Juan, PR 00936 USA.	kai.griebenow@gmail.com	Griebenow, Kai H/AAS-2754-2021; Griebenow, Kai/AGK-1725-2022; Sharma, Rohit/L-8523-2018	Griebenow, Kai H/0000-0003-0495-9932; Delgado, Yamixa/0000-0002-0686-7145	National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) [P20GM103642]; NIH SC1 by NIGMS [5SC1CA190504-03]; NIH SC1 by NCI [5SC1CA190504-03]; Puerto Rico Science, Technology, and Research Trust [2013-000019]; University of Puerto Rico FIPI Grant from the office of the DEGI; NATIONAL CANCER INSTITUTE [SC1CA190504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103642] Funding Source: NIH RePORTER	National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH SC1 by NIGMS; NIH SC1 by NCI; Puerto Rico Science, Technology, and Research Trust; University of Puerto Rico FIPI Grant from the office of the DEGI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The confocal microscopy work was supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) under Award Number P20GM103642. A.D.T. and Y.D. are supported by the NIH SC1 (5SC1CA190504-03) provided by the NIGMS and NCI. A.D.T. is also supported by funding from the Puerto Rico Science, Technology, and Research Trust (Agreement No. 2013-000019), the University of Puerto Rico FIPI Grant from the office of the DEGI.	Abes S, 2006, J CONTROL RELEASE, V110, P595, DOI 10.1016/j.jconrel.2005.10.026; Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Ardizzoni A, 2007, J NATL CANCER I, V99, P847, DOI 10.1093/jnci/djk196; Armstrong JK, 2004, BIOPHYS J, V87, P4259, DOI 10.1529/biophysj.104.047746; Bansal R, 2011, J CONTROL RELEASE, V154, P233, DOI 10.1016/j.jconrel.2011.05.027; BLUM JS, 1991, J BIOL CHEM, V266, P22091; Cheng R, 2011, J CONTROL RELEASE, V152, P2, DOI 10.1016/j.jconrel.2011.01.030; Deming PB, 2004, MOL CELL BIOL, V24, P10289, DOI 10.1128/MCB.24.23.10289-10299.2004; Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Egbelakin A, 2011, PEDIATR BLOOD CANCER, V56, P361, DOI 10.1002/pbc.22845; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Hall MD, 2014, CANCER RES, V74, P3913, DOI 10.1158/0008-5472.CAN-14-0247; HARRIS WR, 1991, BIOCHEMISTRY-US, V30, P6930, DOI 10.1021/bi00242a017; Ichikawa Y, 2014, J CLIN INVEST, V124, P617, DOI 10.1172/JCI72931; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; IPPOLITI R, 1995, FASEB J, V9, P1220, DOI 10.1096/fasebj.9.12.7672515; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; Jiang YY, 2007, J DRUG TARGET, V15, P672, DOI 10.1080/10611860701603414; Johnson CE, 2007, P NATL ACAD SCI USA, V104, P20820, DOI 10.1073/pnas.0709101105; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones S, 2010, CHEM BIOL, V17, P735, DOI 10.1016/j.chembiol.2010.05.018; Kamb A, 2007, NAT REV DRUG DISCOV, V6, P115, DOI 10.1038/nrd2155; Kelkar SS, 2011, BIOCONJUGATE CHEM, V22, P1879, DOI 10.1021/bc200151q; Kim SK, 2012, BIOMATERIALS, V33, P3959, DOI 10.1016/j.biomaterials.2012.02.010; Lai H, 2009, ANTICANCER RES, V29, P3807; Liu D, 2016, THERANOSTICS, V6, P1306, DOI 10.7150/thno.14858; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Meier R, 2010, RADIOLOGY, V255, P527, DOI 10.1148/radiol.10090050; Mendez J, 2014, MOL PHARMACEUT, V11, P102, DOI 10.1021/mp400400j; Merlen C, 2005, FEBS J, V272, P4385, DOI 10.1111/j.1742-4658.2005.04851.x; Monni O, 1997, BLOOD, V90, P1168, DOI 10.1182/blood.V90.3.1168.1168_1168_1174; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Morales-Cruz M, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/s12951-014-0033-9; OTA E, 1995, BRIT J CANCER, V72, P550, DOI 10.1038/bjc.1995.372; Ozer I, 2017, BIOCONJUGATE CHEM, V28, P713, DOI 10.1021/acs.bioconjchem.6b00652; Piel DA, 2008, SHOCK, V29, P612, DOI 10.1097/SHK.0b013e318157e962; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; RASO V, 1984, J BIOL CHEM, V259, P1143; Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]; Santra S, 2010, MOL PHARMACEUT, V7, P1209, DOI 10.1021/mp100043h; Saxena M, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0050-9; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Stirpe F, 2006, CELL MOL LIFE SCI, V63, P1850, DOI 10.1007/s00018-006-6078-7; Taguchi T, 2005, CONTRIB NEPHROL, V148, P107, DOI 10.1159/000086055; Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181; Tinoco AD, 2016, J AM CHEM SOC, V138, P5659, DOI 10.1021/jacs.6b01966; VANDERKOOI JM, 1985, J CELL BIOL, V100, P435, DOI 10.1083/jcb.100.2.435; Voets IK, 2010, J PHYS CHEM B, V114, P11875, DOI 10.1021/jp103515b; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Wang SS, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6010003; WHITNEY JF, 1995, CANCER, V76, P20, DOI 10.1002/1097-0142(19950701)76:1<20::AID-CNCR2820760104>3.0.CO;2-3; Wiley DT, 2013, P NATL ACAD SCI USA, V110, P8662, DOI 10.1073/pnas.1307152110; Yu TN, 2001, J BIOL CHEM, V276, P13034, DOI 10.1074/jbc.M009773200; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhang Peilin, 2003, Mol Cancer, V2, P1; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	28	28	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2018	13	4							e0195542	10.1371/journal.pone.0195542	http://dx.doi.org/10.1371/journal.pone.0195542			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4YG	29649293	Green Submitted, Green Published, gold			2023-01-03	WOS:000429791900052
J	Jang, SH; Yang, DK				Jang, Seung Hee; Yang, Dong Kwon			The combination of Cassia obtusifolia L. and Foeniculum vulgare M. exhibits a laxative effect on loperamide-induced constipation of rats	PLOS ONE			English	Article							OPIOID-INDUCED CONSTIPATION; MUSCARINIC RECEPTORS; ESSENTIAL OILS; SMOOTH-MUSCLE; FENNEL; ANTIOXIDANT; EXTRACT; SEEDS; CONSTITUENTS; SECRETION	Chronic constipation is a functional gastrointestinal disease that is detrimental to the quality of patient life. Cassia obtusifolia L. (CO) and Foeniculum vulgare M. (FV) are commonly used as medicinal foods in many countries. We aimed to examine the laxative effect and their underlying mechanism of CO and FV mixture on loperamide (lop)-induced constipated rats. To determine the laxative effects of these compounds, Sprague-Dawley rats were divided into six groups: the control, lop -induced constipated (2mg/kg), and three doses (100, 300, and 500mg/kg) of CO and FV mixture-, and Bisacodyl (bis, 3.3mg/kg)-treated groups. The mixture of CO and FV and bis were orally administered once a day for 4 weeks. For induction of constipation, the lop were treated with a dose of 2 mg/kg twice a day on the 3rd week after treatments of CO and FV extracts and bis. The results were revealed that the CO and FV mixture has the laxative effects more than those in CO and FV-alone treatments on constipated rats by determining the stool parameters, including stool number and weight. Indeed, stool parameters, such as, stool number, weight, and water contents and colonic peristalsis from the intestinal transit length and ratio were dramatically improved by CO and FV mixture treatment. Histological study also revealed that CO and FV mixture enhanced the thicknesses of mucosa and muscular layers of the colon in constipated rats. For their underlying mechanism, the mRNAs and proteins expression of muscarinic acetylcholine receptors (mAchR) M2 and M3 and their downstream signaling were preserved by CO and FV mixture treatment in constipated rats. Therefore, this study suggests that treatment with CO and FV mixture has beneficial effects against constipation. We further suggest that CO and FV mixture may be utilized as an alternative therapeutic strategy for constipation.	[Jang, Seung Hee] Res & Dev TEAZEN Inc, Anyang Si, Gyeonggi Do, South Korea; [Yang, Dong Kwon] Chonbuk Natl Univ, Coll Vet Med, Dept Vet Pharmacol & Toxicol, Iksan Si, Jeollabuk Do, South Korea	Jeonbuk National University	Yang, DK (corresponding author), Chonbuk Natl Univ, Coll Vet Med, Dept Vet Pharmacol & Toxicol, Iksan Si, Jeollabuk Do, South Korea.	dkyang0502@gmail.com			Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region; TEAZEN Inc.	Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region; TEAZEN Inc.	This research was supported by the Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study. TEAZEN Inc. provided support in the form of salaries for author SHJ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	ABDULGHANI AS, 1988, J ETHNOPHARMACOL, V24, P213, DOI 10.1016/0378-8741(88)90154-7; Al-Amoudi WM, 2017, SAUDI J BIOL SCI, V24, P915, DOI 10.1016/j.sjbs.2016.10.021; Al-Huniti N, 2017, CLIN PHARMACOL THER, V102, P741, DOI 10.1002/cpt.719; Arantes S, 2017, NAT PROD RES, V31, P2183, DOI 10.1080/14786419.2017.1278598; Badgujar SB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/842674; Castro J, 2013, GASTROENTEROLOGY, V145, P1334, DOI 10.1053/j.gastro.2013.08.017; Choi EM, 2004, FITOTERAPIA, V75, P557, DOI 10.1016/j.fitote.2004.05.005; Choi J, 2014, ABSTR APPL ANAL, DOI 10.1155/2014/457620; Chokhavatia S, 2016, DRUG AGING, V33, P557, DOI 10.1007/s40266-016-0381-2; Cirillo C, 2015, PHYTOTHER RES, V29, P1488, DOI 10.1002/ptr.5410; Dadalioglu I, 2004, J AGR FOOD CHEM, V52, P8255, DOI 10.1021/jf049033e; Eglen RM, 2001, LIFE SCI, V68, P2573, DOI 10.1016/S0024-3205(01)01054-2; Ehlert FJ, 1999, LIFE SCI, V64, P387, DOI 10.1016/S0024-3205(98)00584-0; Fei GJ, 2010, J PHARMACOL EXP THER, V334, P333, DOI 10.1124/jpet.110.166116; Fukudo S, 2011, NEUROGASTROENT MOTIL, V23, P544, DOI 10.1111/j.1365-2982.2011.01668.x; Harada Y, 2017, J PHARMACOL EXP THER, V362, P78, DOI 10.1124/jpet.117.240630; Harrington AM, 2010, NEUROGASTROENT MOTIL, V22, P999, DOI 10.1111/j.1365-2982.2009.01456.x; Harrington AM, 2010, NEUROGASTROENT MOTIL, V22, pe1262; Hatano T, 1999, CHEM PHARM BULL, V47, P1121, DOI 10.1248/cpb.47.1121; Ip FCF, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1417-1; Jabri MA, 2017, BIOMED PHARMACOTHER, V89, P29, DOI 10.1016/j.biopha.2017.02.020; Jeon JR, 2010, J MED FOOD, V13, P950, DOI 10.1089/jmf.2009.1307; Johanson JF, 2007, ALIMENT PHARM THER, V25, P599, DOI 10.1111/j.1365-2036.2006.03238.x; Ju MS, 2010, FOOD CHEM TOXICOL, V48, P2037, DOI 10.1016/j.fct.2010.05.002; Kim JE, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0576-y; Kim Ji Eun, 2016, Lab Anim Res, V32, P231, DOI 10.5625/lar.2016.32.4.231; Kim JE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161144; Kim SJ, 2011, AM J CHINESE MED, V39, P565, DOI 10.1142/S0192415X11009032; KITANAKA S, 1986, YAKUGAKU ZASSHI, V106, P302, DOI 10.1248/yakushi1947.106.4_302; Kojima R, 2009, PHARMACOLOGY, V84, P227, DOI 10.1159/000236524; Kurniawan Indra, 2011, Acta Med Indones, V43, P195; Leung FW, 2007, DIGEST DIS SCI, V52, P313, DOI 10.1007/s10620-006-9298-7; McCallum IJD, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b831; Mohamad RH, 2011, J MED FOOD, V14, P986, DOI 10.1089/jmf.2008.0255; Parejo I, 2004, J AGR FOOD CHEM, V52, P3679, DOI 10.1021/jf030813h; Patil UK, 2004, J ETHNOPHARMACOL, V90, P249, DOI 10.1016/j.jep.2003.10.007; Pradeep K, 2007, CHEM-BIOL INTERACT, V167, P12, DOI 10.1016/j.cbi.2006.12.011; Ramkumar D, 2005, AM J GASTROENTEROL, V100, P936, DOI 10.1111/j.1572-0241.2005.40925.x; Sabiu S, 2016, PHARM BIOL, V54, P2901, DOI 10.1080/13880209.2016.1193885; Seo Y, 2017, FOOD RES INT, V97, P340, DOI 10.1016/j.foodres.2017.04.032; Song XD, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0668-6; Soylu S, 2007, J APPL MICROBIOL, V103, P1021, DOI 10.1111/j.1365-2672.2007.03310.x; Talley NJ, 1999, GUT, V45, P37; Tripathi VR, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-56; Walia R, 2009, CURR OPIN PEDIATR, V21, P661, DOI 10.1097/MOP.0b013e32832ff241; Wintola OA, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-95; Yang ZH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003348	47	12	13	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0195624	10.1371/journal.pone.0195624	http://dx.doi.org/10.1371/journal.pone.0195624			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6TQ	29621360	Green Submitted, Green Published, gold			2023-01-03	WOS:000429206800109
J	Wachman, EM; Schiff, DM; Silverstein, M				Wachman, Elisha M.; Schiff, Davida M.; Silverstein, Michael			Neonatal Abstinence Syndrome Advances in Diagnosis and Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LENGTH-OF-STAY; RANDOMIZED CLINICAL-TRIAL; METHADONE TREATMENT; OPIATE WITHDRAWAL; ROOMING-IN; OPIOID USE; BUPRENORPHINE; INFANTS; MORPHINE; PREGNANCY	IMPORTANCE Neonatal abstinence syndrome, which occurs as a result of in utero opioid exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial variability in how neonatal abstinence syndrome is diagnosed and managed. OBJECTIVE To summarize key studies examining the diagnosis and management (both pharmacologic and nonpharmacologic) of neonatal abstinence syndrome published during the past 10 years. EVIDENCE REVIEW PubMed, Web of Science, and CINAHL were searched for articles published between July 1, 2007, and December 31, 2017. Abstracts were screened and included in the review if they pertained to neonatal abstinence syndrome diagnosis or management and were judged by the authors to be clinical trials, cohort studies, or case series. FINDINGS A total of 53 articles were included in the review, including 9 randomized clinical trials, 35 cohort studies, 1 cross-sectional study, and 8 case series-representing a total of 11 905 unique opioid-exposed mother-infant dyads. Thirteen studies were identified that evaluated established or novel neonatal abstinence syndrome assessment methods, such as brief neonatal abstinence syndrome assessment scales or novel objective physiologic measures to predict withdrawal. None of the new techniques that measure infant physiologic parameters are routinely used in clinical practice. The most substantial number of studies of neonatal abstinence syndrome management pertain to nonpharmacologic care-specifically, interventions that promote breastfeeding or encourage parents to room-in with their newborns. Although these nonpharmacologic interventions appear to decrease the need for pharmacologic treatment and result in shorter hospitalizations, the interventions are heterogeneous and there are no high-quality clinical trials to support them. Regarding pharmacologic interventions, only 5 randomized clinical trials with prespecified sample size calculations (4 infant, 1 maternal treatment) have been published. Each of these trials was small (from 26 to 131 participants) and tested different therapies, limiting the extent to which results can be aggregated. There is insufficient evidence to support an association between any diagnostic or treatment approach and differential neurodevelopmental outcomes among infants with neonatal abstinence syndrome. CONCLUSIONS AND RELEVANCE Evidence pertaining to the optimal diagnosis and treatment strategies for neonatal abstinence syndrome is based on small or low-quality studies that focus on intermediate outcomes, such as need for pharmacologic treatment or length of hospital stay. Clinical trials are needed to evaluate health and neurodevelopmental outcomes associated with objective diagnostic approaches as well as pharmacologic and nonpharmacologic treatment modalities.	[Wachman, Elisha M.; Silverstein, Michael] Boston Med Ctr, Grayken Ctr Addict, Boston, MA USA; [Wachman, Elisha M.; Silverstein, Michael] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; [Schiff, Davida M.] Massachusetts Gen Hosp Children, Div Gen Acad Pediat, Boston, MA USA; [Schiff, Davida M.] Harvard Med Sch, Boston, MA USA	Boston Medical Center; Boston University; Harvard University; Harvard Medical School	Wachman, EM (corresponding author), Boston Med Ctr, 771 Albany St,Dowling 4103, Boston, MA 02118 USA.	elisha.wachman@bmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD081057] Funding Source: NIH RePORTER; NICHD NIH HHS [K24 HD081057] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abrahams RR, 2007, CAN FAM PHYSICIAN, V53, P1723; Abrahams RR, 2010, J OBSTET GYNAECOL CA, V32, P866, DOI 10.1016/S1701-2163(16)34659-X; Agthe AG, 2009, PEDIATRICS, V123, pE849, DOI 10.1542/peds.2008-0978; Backes CH, 2012, J PERINATOL, V32, P425, DOI 10.1038/jp.2011.114; Bada HS, 2015, PEDIATRICS, V135, pE383, DOI 10.1542/peds.2014-2377; Bier JB, 2015, J PERINATOL, V35, P656, DOI 10.1038/jp.2015.22; Binder T, 2008, NEUROENDOCRINOL LETT, V29, P80; Bogen Debra L, 2018, Hosp Pediatr, V8, P7, DOI 10.1542/hpeds.2017-0114; Bogen DL, 2017, ACAD PEDIATR, V17, P374, DOI 10.1016/j.acap.2016.10.003; Brogly SB, 2014, AM J EPIDEMIOL, V180, P673, DOI 10.1093/aje/kwu190; Brown MS, 2015, J PERINATOL, V35, P278, DOI 10.1038/jp.2014.194; Burke S, GLOB PEDIAT HLTH, DOI [10.1177/2333794X1772112, DOI 10.1177/2333794X1772112]; Chisamore B, 2016, SUBST ABUS-RES TREAT, V10, P49, DOI 10.4137/SART.S34550; Crook K, 2017, ADV NEONAT CARE, V17, P299, DOI 10.1097/ANC.0000000000000392; Dekkers OM, 2012, ANN INTERN MED, V156, P37, DOI 10.7326/0003-4819-156-1-201201030-00006; Devlin LA, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00216; Dryden C, 2009, BJOG-INT J OBSTET GY, V116, P665, DOI 10.1111/j.1471-0528.2008.02073.x; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Grossman M, 2017, REV RECENT CLIN TRIA, V12, P226, DOI 10.2174/1574887112666170816144818; Grossman MR, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-3360; Hall ES, 2018, AM J PERINAT, V35, P405, DOI 10.1055/s-0037-1608634; Hall ES, 2016, J PEDIATR-US, V170, P39, DOI 10.1016/j.jpeds.2015.11.039; Hall ES, 2015, J PEDIATR-US, V167, P1221, DOI 10.1016/j.jpeds.2015.09.038; Hall ES, 2015, PEDIATRICS, V136, pE803, DOI 10.1542/peds.2015-1141; Hodgson ZG, 2012, J OBSTET GYNAECOL CA, V34, P475, DOI 10.1016/S1701-2163(16)35245-8; Holmes AV, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2929; Howard Mary Beth, 2017, Hosp Pediatr, V7, P63, DOI 10.1542/hpeds.2016-0147; Howick J., 2009, LEVELS EVIDENCE; Hudak ML, 2012, PEDIATRICS, V129, pE540, DOI 10.1542/peds.2011-3212; Hunseler C, 2013, KLIN PADIATR, V225, P247, DOI 10.1055/s-0033-1347190; HUYBRECHTS KF, 2017, BMJ-BRIT MED J, V358, DOI DOI 10.1136/BMJ.J3326; Isemann B, 2011, J PERINATOL, V31, P25, DOI 10.1038/jp.2010.66; Isemann BT, 2017, PHARMACOTHERAPY, V37, P840, DOI 10.1002/phar.1948; Jansson LM, 2007, J MATERN-FETAL NEO M, V20, P677, DOI 10.1080/14767050701490327; Jansson Lauren M, 2009, J Opioid Manag, V5, P47; Jones HE, 2016, AM J ADDICTION, V25, P370, DOI 10.1111/ajad.12388; Jones Hendree E, 2016, J Opioid Manag, V12, P19, DOI 10.5055/jom.2016.0308; Jones HE, 2010, NEW ENGL J MED, V363, P2320, DOI 10.1056/NEJMoa1005359; Kelly LE, 2015, PEDIATR DRUGS, V17, P151, DOI 10.1007/s40272-014-0096-y; Kistin C, 2015, JAMA-J AM MED ASSOC, V314, P1561, DOI 10.1001/jama.2015.10962; Klaman SL, 2017, J ADDICT MED, V11, P178, DOI 10.1097/ADM.0000000000000308; Ko JY, 2016, MMWR-MORBID MORTAL W, V65, P799, DOI 10.15585/mmwr.mm6531a2; Konijnenberg C, 2015, CHILD NEUROPSYCHOL, V21, P570, DOI 10.1080/09297049.2014.967201; Kraft WK, 2008, PEDIATRICS, V122, pE601, DOI 10.1542/peds.2008-0571; Kraft WK, 2017, NEW ENGL J MED, V376, P2341, DOI 10.1056/NEJMoa1614835; Lee J, 2015, POPUL HEALTH MANAG, V18, P392, DOI 10.1089/pop.2014.0134; Leeman LM, 2011, J MATERN-FETAL NEO M, V24, P955, DOI 10.3109/14767058.2010.536863; Loudin S, 2017, J PERINATOL, V37, P1108, DOI 10.1038/jp.2017.101; MacMillan KDL, 2018, JAMA PEDIATR, V172, P345, DOI 10.1001/jamapediatrics.2017.5195; Maguire D, 2013, ADV NEONAT CARE, V13, P430, DOI 10.1097/ANC.0000000000000033; McQueen K, 2016, NEW ENGL J MED, V375, P2468, DOI 10.1056/NEJMra1600879; Milliren Carly E, 2018, Hosp Pediatr, V8, P15, DOI 10.1542/hpeds.2017-0077; Nagiub M, 2014, SAGE OPEN MED, V2, DOI 10.1177/2050312114556525; Nayeri F, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0377-9; Newman A, 2015, CAN FAM PHYSICIAN, V61, pE555; Nygaard E, 2015, PEDIATR RES, V78, P330, DOI 10.1038/pr.2015.95; O'Connor AB, 2013, J MIDWIFERY WOM HEAL, V58, P383, DOI 10.1111/jmwh.12009; Oei JL, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2651; Oji-Mmuo CN, 2018, BRAIN RES BULL, V138, P110, DOI 10.1016/j.brainresbull.2017.06.007; Oji-Mmuo CN, 2016, ACTA PAEDIATR, V105, pE99, DOI 10.1111/apa.13287; Patrick SW, 2015, J PERINATOL, V35, P667, DOI 10.1038/jp.2015.63; Pritham UA, 2012, JOGNN-J OBST GYN NEO, V41, P180, DOI 10.1111/j.1552-6909.2011.01330.x; Raith W, 2015, PEDIATRICS, V136, P876, DOI 10.1542/peds.2015-0676; Reddy UM, 2017, OBSTET GYNECOL, V130, P10, DOI 10.1097/AOG.0000000000002054; Saiki T, 2010, EUR J PEDIATR, V169, P95, DOI 10.1007/s00431-009-0994-0; Short VL, 2016, BREASTFEED MED, V11, P343, DOI 10.1089/bfm.2016.0084; Smirk CL, 2014, ACTA PAEDIATR, V103, P601, DOI 10.1111/apa.12603; Subedi L, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00238; Surran B, 2013, J PERINATOL, V33, P954, DOI 10.1038/jp.2013.95; Wachman EM, 2013, JAMA-J AM MED ASSOC, V309, P1821, DOI 10.1001/jama.2013.3411; Welle-Strand GK, 2013, ACTA PAEDIATR, V102, P1060, DOI 10.1111/apa.12378; Whitham JN, 2015, NEUROTOXICOL TERATOL, V52, P17, DOI 10.1016/j.ntt.2015.09.008; Young ME, 2015, AM J HEALTH-SYST PH, V72, pS162, DOI 10.2146/sp150025	73	95	95	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2018	319	13					1362	1374		10.1001/jama.2018.2640	http://dx.doi.org/10.1001/jama.2018.2640			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB4NC	29614184				2023-01-03	WOS:000429035900020
J	Hudak, J; Rosenbaum, D; Barth, B; Fallgatter, AJ; Ehlis, AC				Hudak, Justin; Rosenbaum, David; Barth, Beatrix; Fallgatter, Andreas J.; Ehlis, Ann-Christine			Functionally disconnected: A look at how study design influences neurofeedback data and mechanisms in attention-deficit/hyperactivity disorder	PLOS ONE			English	Article							NEAR-INFRARED SPECTROSCOPY; DEFAULT-MODE; COGNITIVE CONTROL; CONNECTIVITY MRI; ADHD; NETWORKS; METHYLPHENIDATE; HYPERACTIVITY; METAANALYSIS; PREVALENCE	Neurofeedback (NF) is a form of behavioral therapy used to treat e.g. attention-deficit/hyperactivity disorder (ADHD). Briefly, subjects are fed-back a putatively dysfunctional parameter of their brain activity in real time and must learn to control it in a suggested direction. NF protocols for ADHD have been used in practice for decades, though no clear standards on NF design have been implemented. Furthermore, studies often present only data from the general outcome of the NF treatment and do not look at how exactly the NF paradigm affects brain functionality, or what exactly the NF is training. The current study is two-fold: firstly, we look at how the functional connectivity (FC) patterns within key networks associated with ADHD differ between rests, feedback trials, success and failure in a complete functional near-infrared spectroscopy-based NF experiment on adults with ADHD. Secondly, due to methodological concerns discovered during the analysis of our data, we address important considerations in the design of NF that are often ignored in protocols being used widely in therapy and research today. In particular, we examine the common average reference and its impact on network activity as well as the importance of balancing the randomization in a design. Finally, we discuss how these methodological considerations may have influenced our FC results.	[Hudak, Justin; Fallgatter, Andreas J.; Ehlis, Ann-Christine] Univ Tubingen, LEAD Grad Sch & Res Network, Tubingen, Germany; [Hudak, Justin; Rosenbaum, David; Barth, Beatrix; Fallgatter, Andreas J.; Ehlis, Ann-Christine] Univ Hosp Tubingen, Dept Psychiat & Psychotherapy, Tubingen, Germany; [Barth, Beatrix] Univ Tubingen, Ctr Integrat Neurosci, Tubingen, Germany; [Fallgatter, Andreas J.] Univ Tubingen, Grad Sch Neural & Behav Sci, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Hudak, J (corresponding author), Univ Tubingen, LEAD Grad Sch & Res Network, Tubingen, Germany.; Hudak, J (corresponding author), Univ Hosp Tubingen, Dept Psychiat & Psychotherapy, Tubingen, Germany.	justin.hudak@med.uni-tuebingen.de	Barth, Beatrix/AAE-8088-2020	Barth, Beatrix/0000-0002-3792-3357; Ehlis, Ann-Christine/0000-0002-8142-9743	German Research Foundation (Deutsche Forschungsgemeinschaft [DFG]) [FA 361/21-1, STR 597/7-1]; IZKF Tubingen [2115-0-0]; LEAD Graduate School & Research Network, a project of the Excellence Initiative of the German federal and state governments [GSC1028]; Open Access Publishing Fund of the University of Tubingen; STORZ MEDICAL AG	German Research Foundation (Deutsche Forschungsgemeinschaft [DFG])(German Research Foundation (DFG)); IZKF Tubingen; LEAD Graduate School & Research Network, a project of the Excellence Initiative of the German federal and state governments; Open Access Publishing Fund of the University of Tubingen; STORZ MEDICAL AG	The multicenter study was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG] project numbers FA 361/21-1 and STR 597/7-1). Ann-Christine Ehlis was partly supported by IZKF Tubingen (Junior Research Group, grant 2115-0-0). Justin Hudak was funded by the LEAD Graduate School & Research Network (GSC1028), a project of the Excellence Initiative of the German federal and state governments. We acknowledge the support of the Open Access Publishing Fund of the University of Tubingen.; We would like to thank all participants for their patience in taking part in such an extensive study. Additionally, we extend our gratitude to Ramona Taglich, Betti Schopp, Nina Gehrer, Lisa K. Schreiber, Stefanie Kettner and Sophie Grumbach for their help and invaluable contribution with the measurements. This research was funded by the LEAD Graduate School & Research Network [GSC1028], a project of the Excellence Initiative of the German federal and state governments. Justin Hudak is a doctoral candidate at the LEAD Graduate School & Research Network. The multicenter study, which provided the data of the NIRS feedback group, was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG] project numbers FA361/21-1 and STR 597/7-1). David Rosenbaum was partly supported by STORZ MEDICAL AG. Ann-Christine Ehlis was partly supported by IZKF Tubingen (Junior Research Group, grant 2115-0-0).	Abarbanel A., 1995, J NEUROTHERAPY, V1, P15, DOI DOI 10.1300/J184V01N02_02; Alegria AA, 2017, HUM BRAIN MAPP, V38, P3190, DOI 10.1002/hbm.23584; Aranyi Gabor, 2015, Symbiotic Interaction. 4th International Workshop, Symbiotic 2015. Proceedings: LNCS 9359, P7, DOI 10.1007/978-3-319-24917-9_2; Arns M, 2014, BIOL PSYCHOL, V95, P108, DOI 10.1016/j.biopsycho.2013.11.013; Arns M, 2009, CLIN EEG NEUROSCI, V40, P180, DOI 10.1177/155005940904000311; Arnsten AFT, 2012, J AM ACAD CHILD PSY, V51, P356, DOI 10.1016/j.jaac.2012.01.008; Barth B, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00633; Blume F, 2017, TRIALS, V18, DOI 10.1186/s13063-016-1769-3; Bluschke A, 2016, PSYCHOL MED, V46, P1277, DOI 10.1017/S0033291715002822; Castellanos FX, 2012, TRENDS COGN SCI, V16, P17, DOI 10.1016/j.tics.2011.11.007; Cortese S, 2016, J AM ACAD CHILD PSY, V55, P444, DOI 10.1016/j.jaac.2016.03.007; Dodds CM, 2008, J NEUROSCI, V28, P5976, DOI 10.1523/JNEUROSCI.1153-08.2008; Egner T, 2004, J NEUROTHER, V8, P37, DOI [10.1300/J184v08n01, DOI 10.1300/J184V08N01]; Ehlis AC, 2014, NEUROIMAGE, V85, P478, DOI 10.1016/j.neuroimage.2013.03.067; Fassbender C, 2006, J PSYCHOPHYSIOL, V20, P286, DOI 10.1027/0269-8803.20.4.286; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Godwin CA, 2017, NEUROPSYCHOLOGIA, V103, P140, DOI 10.1016/j.neuropsychologia.2017.07.006; Grady CL, 2017, MULTIVARIATE ANAL AG, DOI [10.1093/cercor/bhp207, DOI 10.1093/CERCOR/BHP207]; Gruzelier JH, 2014, NEUROSCI BIOBEHAV R, V44, P124, DOI 10.1016/j.neubiorev.2013.09.015; Haller S, 2010, EUR RADIOL, V20, P696, DOI 10.1007/s00330-009-1595-z; Heinzel S, 2013, NEUROBIOL AGING, V34, P439, DOI 10.1016/j.neurobiolaging.2012.05.021; Hernandez LD, 2018, NEUROSCIENCE, V378, P146, DOI 10.1016/j.neuroscience.2016.12.005; Holtmann M, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-202; Hudak J, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00425; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; JASPER HH, 1958, ELECTROENCEPHALOGRAP, V10, P370, DOI DOI 10.1016/0013-4694(58)90053-1; Jausovec N, 2010, NEUROPSYCHOLOGIA, V48, P3918, DOI 10.1016/j.neuropsychologia.2010.09.020; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Lofthouse N, 2012, J ATTEN DISORD, V16, P351, DOI 10.1177/1087054711427530; Marx AM, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01038; Mayer K, 2016, PSYCHIAT ANN, V46, P594, DOI 10.3928/00485713-20160906-01; Mayer K, 2016, CLIN NEUROPHYSIOL, V127, P1374, DOI 10.1016/j.clinph.2015.11.013; Mayer K, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0683-4; Mehta RK, 2013, NEUROERGONOMICS REV, V7, P1, DOI [10.3389/fnhum.2013.00889, DOI 10.3389/FNHUM.2013.00889]; Nunez PL., 2006, ELECT FIELDS BRAIN N, V2nd, DOI 10.1093/acprof:oso/9780195050387.001.0001; Plichta MM, 2007, NEUROIMAGE, V35, P625, DOI 10.1016/j.neuroimage.2006.11.028; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Posner J, 2014, NEUROPSYCHOL REV, V24, P3, DOI 10.1007/s11065-014-9251-z; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Radua J, 2018, NEUROSCIENCE, V378, P11, DOI 10.1016/j.neuroscience.2016.04.003; Raichle ME, 2015, ANNU REV NEUROSCI, V38, P433, DOI 10.1146/annurev-neuro-071013-014030; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rao SM, 2000, AM J PSYCHIAT, V157, P1697, DOI 10.1176/appi.ajp.157.10.1697; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rosler M., 2008, HOMBURGER ADHS SKALE; Schonenberg M, 2017, LANCET PSYCHIAT, V4, P673, DOI 10.1016/S2215-0366(17)30291-2; Singh AK, 2005, NEUROIMAGE, V27, P842, DOI 10.1016/j.neuroimage.2005.05.019; Soekadar S, 2011, ERD BASED ONLINE BRA; Spreng RN, 2013, J COGNITIVE NEUROSCI, V25, P74, DOI 10.1162/jocn_a_00281; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Strangman G, 2002, NEUROIMAGE, V17, P719, DOI 10.1006/nimg.2002.1227; Strehl U, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00894; Thibault RT, 2017, BRAIN, V140, P862, DOI 10.1093/brain/awx033; Tsuzuki D, 2007, NEUROIMAGE, V34, P1506, DOI 10.1016/j.neuroimage.2006.10.043; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727	56	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2018	13	8							e0200931	10.1371/journal.pone.0200931	http://dx.doi.org/10.1371/journal.pone.0200931			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GQ0KU	30096196	Green Submitted, gold, Green Published			2023-01-03	WOS:000441308500009
J	Huun, MU; Garberg, H; Loberg, EM; Escobar, J; Martinez-Orgado, J; Saugstad, OD; Solberg, R				Huun, Marianne Ullestad; Garberg, Havard; Loberg, Else Marit; Escobar, Javier; Martinez-Orgado, Jose; Saugstad, Ola Didrik; Solberg, Ronnaug			DHA and therapeutic hypothermia in a short-term follow-up piglet model of hypoxia-ischemia: Effects on H plus MRS biomarkers	PLOS ONE			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; PERINATAL ASPHYXIA; N-ACETYLASPARTATE; IN-VIVO; ENCEPHALOPATHY; INJURY; BRAIN; NEUROPROTECTION; LOCALIZATION; INSULTS	Background Therapeutic hypothermia has become the standard of care for newborns with hypoxic-ischemic encephalopathy in high and middle income countries. Docosahexaenoic acid (DHA) has neuroprotective properties of reducing excitotoxicity, neuroinflammation and apoptosis in rodent models. We aim to study whether post hypoxic administration of i.v. DHA will reduce H+MRS biomarkers and gene expression of inflammation and apoptosis both with and without hypothermia in a large animal model. Methods Fifty-five piglets were randomized to severe global hypoxia (N = 48) or not (Sham, N = 7). Hypoxic piglets were further randomized by factorial design: Vehicle (VEH), DHA, VEH + Hypothermia (HT), or DHA + HT. 5 mg/kg DHA was given intravenously 210 min after end of hypoxia. Two-way ANOVA analyses were performed with DHA and hypothermia as main effects. Results Cortical lactate/N-acetylaspartate (Lac/NAA) was significantly reduced in DHA + HT compared to HT. DHA had significant main effects on increasing N-acetylaspartate and glutathione in hippocampus. Therapeutic hypothermia significantly reduced the Lac/NAA ratio and protein expression of IL-1 beta and TNF alpha in hippocampus and reduced Troponin T in serum. Neuropathology showed significant differences between sham and hypoxia, but no differences between intervention groups. Conclusion DHA and therapeutic hypothermia significantly improve specific H+MRS biomarkers in this short-term follow up model of hypoxia-ischemia. Longer recovery periods are needed to evaluate whether DHA can offer translational neuroprotection.	[Huun, Marianne Ullestad; Garberg, Havard; Escobar, Javier; Saugstad, Ola Didrik; Solberg, Ronnaug] Oslo Univ Hosp, Rikshosp, Women & Childrens Div, Dept Pediat Res, Oslo, Norway; [Huun, Marianne Ullestad; Garberg, Havard; Escobar, Javier; Saugstad, Ola Didrik; Solberg, Ronnaug] Oslo Univ Hosp, Rikshosp, Inst Surg Res, Oslo, Norway; [Huun, Marianne Ullestad; Saugstad, Ola Didrik] Univ Oslo, Oslo, Norway; [Loberg, Else Marit] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Escobar, Javier] Hlth Res Inst Hosp La Fe, Neonatal Res Unit, Valencia, Spain; [Martinez-Orgado, Jose] Hosp Clin San Carlos IdISSC, Div Neonatol, Madrid, Spain; [Solberg, Ronnaug] Vestfold Hosp Trust, Dept Pediat, Tonsberg, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; Hospital Clinico San Carlos	Huun, MU (corresponding author), Oslo Univ Hosp, Rikshosp, Women & Childrens Div, Dept Pediat Res, Oslo, Norway.; Huun, MU (corresponding author), Oslo Univ Hosp, Rikshosp, Inst Surg Res, Oslo, Norway.; Huun, MU (corresponding author), Univ Oslo, Oslo, Norway.	marianne.ullestad.huun@rr-research.no	Saugstad, Ola/AAS-9041-2021; Martinez-Orgado, Jose/ABF-6898-2021	Saugstad, Ola/0000-0002-3166-5254; Martinez-Orgado, Jose/0000-0003-4405-3545	Norwegian SIDS; Stillbirth Society; Laerdal Foundation; South East Norway Regional Health Authority [39570]	Norwegian SIDS; Stillbirth Society; Laerdal Foundation; South East Norway Regional Health Authority	This work was supported by the Norwegian SIDS and Stillbirth Society: https://www.lub.no/norwegian-sids-and-stillbirth-society; Laerdal Foundation: https://laerdalfoundation.org/; and South East Norway Regional Health Authority: https://www.helse-sorost.no/south-eastern-norway-regional-health-authority, Grant number: 39570.	Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Berman DR, 2013, NEONATOLOGY, V104, P71, DOI 10.1159/000351011; Berman DR, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.020; Chang PKY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0244-5; Cheong JLY, 2006, AM J NEURORADIOL, V27, P1546; Conrad MS, 2015, ANNU REV ANIM BIOSCI, V3, P245, DOI 10.1146/annurev-animal-022114-111049; De Smedt-Peyrusse V, 2008, J NEUROCHEM, V105, P296, DOI 10.1111/j.1471-4159.2007.05129.x; del Rio R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165744; Domoki F, 2014, J PHYSIOL PHARMACOL, V65, P551; Garberg HT, 2016, PEDIAT RES; Groenendaal F, 2001, BIOL NEONATE, V79, P254; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Huun MU, 2017, J PERINATAL MED; Jimenez-Xarrie E, 2015, J CEREBR BLOOD F MET, V35, P828, DOI 10.1038/jcbfm.2014.257; Lafuente H, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00323; Lewis MD, 2016, J AM COLL NUTR, V35, P469, DOI 10.1080/07315724.2016.1150796; Liu X, 2011, PEDIATR RES, V70, P352, DOI 10.1203/PDR.0b013e31822941ee; Liu ZH, 2015, J NEUROSCI, V35, P12733, DOI 10.1523/JNEUROSCI.0605-15.2015; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Nordengen K, 2015, BRAIN STRUCT FUNCT, V220, P899, DOI 10.1007/s00429-013-0691-7; Northington FJ, 2006, ILAR J, V47, P32, DOI 10.1093/ilar.47.1.32; Penrice J, 1997, PEDIATR RES, V41, P795, DOI 10.1203/00006450-199706000-00001; Robertson NJ, 2014, CURR PEDIATR REV, V10, P37, DOI 10.2174/157339631001140408120613; Robertson NJ, 2013, BRAIN, V136, P90, DOI 10.1093/brain/aws285; Rocha-Ferreira E, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0821-x; Roka A, 2012, ACTA PAEDIATR, V101, P319, DOI 10.1111/j.1651-2227.2011.02480.x; Sager TN, 2001, BRAIN RES, V892, P166, DOI 10.1016/S0006-8993(00)03274-1; Solberg R, 2017, NEONATOLOGY, V112, P1, DOI 10.1159/000454982; Thayyil S, 2010, PEDIATRICS, V125, pE382, DOI 10.1542/peds.2009-1046; Thoresen M, 1997, NEUROREPORT, V8, P3359, DOI 10.1097/00001756-199710200-00033; Thoresen M, 1996, PEDIATR RES, V40, P738, DOI 10.1203/00006450-199611000-00014; URENJAK J, 1992, J NEUROCHEM, V59, P55, DOI 10.1111/j.1471-4159.1992.tb08875.x; Zaigham M, 2017, EARLY HUM DEV, V112, P48, DOI 10.1016/j.earlhumdev.2017.07.015; Ziemka-Nalecz M, 2017, J NEUROPATH EXP NEUR, V76, P644, DOI 10.1093/jnen/nlx046	35	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2018	13	8							e0201895	10.1371/journal.pone.0201895	http://dx.doi.org/10.1371/journal.pone.0201895			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP7ZN	30086156	Green Published, Green Submitted, gold			2023-01-03	WOS:000441129300038
J	Romagnoli, N; Pagnanelli, G; Lambertini, C; Drayton, E; Buonacucina, A; Peli, A				Romagnoli, Noemi; Pagnanelli, Giacomo; Lambertini, Carlotta; Drayton, Emily; Buonacucina, Alessandra; Peli, Angelo			Cardiorespiratory effects of medetomidine and dexmedetomidine combined with tiletamine-zolazepam for the immobilization of Asiatic black bears (Ursus thibetanus) under isoflurane general anesthesia	PLOS ONE			English	Article							KETAMINE	The aim of this paper was to compare the cardiorespiratory effects of the two combinations (medetomidine-tiletamine-zolazepam (MTZ) or dexmedetomidine-tiletamine-zolazepam (DTZ)) used for Asiatic black bear (Ursus thibetanus) immobilization. A retrospective analysis was carried out, reviewing the anesthetic records of captive bears. Sixty-six records were reviewed. The bears were immobilized, and general anesthesia was maintained with isoflurane vaporized in 100% oxygen. The mean sedation time and score were evaluated. The cardiorespiratory parameters were recorded every 10 minutes from intubation until extubation. Mean sedation time was 26.1 +/- 14.5 minutes for the MTZ group and 25.6 +/- 19.4 minutes for the DTZ group. The heart rate and the respiratory rate were higher in the bears immobilized with DTZ (66 +/- 19 beats/min; 13 +/- 5.2 breaths/min) as compared with the bears immobilized with MTZ (57 +/- 14.5 beats/min; 10 +/- 4.7 breaths/min) whereas the mean arterial pressure did not differ significantly between the groups. The body temperature was in the normal range throughout the procedures in all bears (MTZ 36.3 +/- 0.9 degrees C; DTZ 37 +/- 1 degrees C). In conclusion, the two protocols used in this study have been proven to be safe and reliable for the immobilization of Asiatic black bears, and the DTZ combination seemed to be associated with less cardiorespiratory depression than the MTZ one.	[Romagnoli, Noemi; Pagnanelli, Giacomo; Lambertini, Carlotta; Peli, Angelo] Univ Bologna, Dept Vet Med Sci, Bologna, Italy; [Buonacucina, Alessandra] Univ Bologna, Centralized Vet Serv, Bologna, Italy; [Drayton, Emily] Chengdu Bear Rescue Ctr, Chengdu, Sichuan, Peoples R China	University of Bologna; University of Bologna	Lambertini, C (corresponding author), Univ Bologna, Dept Vet Med Sci, Bologna, Italy.	carlotta.lambertini2@unibo.it	Lambertini, Carlotta/AAY-7825-2020; PELI, ANGELO/AAX-8423-2021	Lambertini, Carlotta/0000-0002-3604-5337; PELI, ANGELO/0000-0003-3488-2948				Asano M, 2007, J VET MED SCI, V69, P433, DOI 10.1292/jvms.69.433; Cattet MRL, 1999, J ZOO WILDLIFE MED, V30, P354; Caulkett N, 2002, ZOOL RESTRAINT ANEST, P2; Caulkett NA, 1997, J WILDLIFE DIS, V33, P618, DOI 10.7589/0090-3558-33.3.618; Caulkett NA, 1999, J ZOO WILDLIFE MED, V30, P504; Coltrane JA, 2015, WILDLIFE SOC B, V39, P378, DOI 10.1002/wsb.538; Fahlman A, 2014, J WILDLIFE DIS, V50, P574, DOI 10.7589/2013-06-148; Fahlman A, 2011, J ZOO WILDLIFE MED, V42, P1, DOI 10.1638/2008-0117.1; Fandos Esteruelas N, 2017, PLOS ONE, V12, P83, DOI [10.7589/2012-11-273, DOI 10.7589/2012-11-273]; IUCN, IUCN RED LIST THREAT; Jeong DH, 2017, J VET MED SCI, V79, P153, DOI 10.1292/jvms.16-0290; Laricchiuta P, 2008, J ZOO WILDLIFE MED, V39, P558, DOI 10.1638/2007-0130.1; Onuma M, 2003, J ZOO WILDLIFE MED, V34, P202, DOI 10.1638/1042-7260(2003)034[0202:IOSBHM]2.0.CO;2; Teisberg JE, 2014, J WILDLIFE DIS, V50, P74, DOI 10.7589/2012-11-273; White TH, 1996, WILDLIFE SOC B, V24, P521	15	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2018	13	7							e0200833	10.1371/journal.pone.0200833	http://dx.doi.org/10.1371/journal.pone.0200833			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN5RC	30024923	Green Published, Green Submitted, gold			2023-01-03	WOS:000439120000057
J	Cervantes, L; Richardson, S; Raghavan, R; Hou, N; Hasnain-Wynia, R; Wynia, MK; Kleiner, C; Chonchol, M; Tong, A				Cervantes, Lilia; Richardson, Sara; Raghavan, Rajeev; Hou, Nova; Hasnain-Wynia, Romana; Wynia, Matthew K.; Kleiner, Catherine; Chonchol, Michel; Tong, Allison			Clinicians' Perspectives on Providing Emergency-Only Hemodialysis to Undocumented Immigrants A Qualitative Study	ANNALS OF INTERNAL MEDICINE			English	Article							STAGE RENAL-DISEASE; HEALTH-CARE; DIALYSIS; SATISFACTION; BURNOUT; STRESS; ACCESS; LAW	Background: In the United States, nearly half of undocumented immigrants with end-stage kidney disease receive hemodialysis only when they are evaluated in an emergency department and are found to have life-threatening renal failure ("emergency-only hemodialysis" [EOHD]). These patients experience psychosocial distress and much higher mortality than patients receiving regularly scheduled hemodialysis, but little is known about how providing EOHD affects the clinicians involved. Objective: To understand clinicians' experiences providing EOHD. Design: Qualitative study using semistructured interviews. Setting: A safety-net hospital in Denver, Colorado, and a safety-net system in Houston, Texas. Participants: Fifty interdisciplinary clinicians experienced in providing EOHD. Measurements: Interviews were analyzed using thematic analysis. Outcomes included themes and subthemes. Results: Four themes and 13 subthemes (in parentheses) were identified: 1) drivers of professional burnout (emotional exhaustion from witnessing needless suffering and high mortality, jeopardizing patient trust, detaching from patients, perceived lack of control over EOHD criteria, and physical exhaustion from over-extending to bridge care), 2) moral distress from propagating injustice (altered care based on nonmedical factors, focus on volume at the expense of quality, and need to game the system), 3) confusing and perverse financial incentives (wasting resources, confusing financial incentives, and concerns about sustainability), and 4) inspiration toward advocacy (deriving inspiration from patients and strengthened altruism). Limitation: Whether the findings apply to other settings is unknown, and social desirability response bias might have reduced reporting of negative perceptions and experiences. Conclusion: Clinicians in safety-net settings who provide EOHD to undocumented patients describe experiencing moral distress and being driven toward professional burnout. The burden of EOHD on clinicians should inform discussions of systemic approaches to support provision of adequate care based on medical need.	[Cervantes, Lilia; Wynia, Matthew K.; Kleiner, Catherine; Chonchol, Michel] Denver Hlth, 777 Bannock,MC 4000, Denver, CO 80204 USA; [Richardson, Sara] Denver Hlth, 601 Broadway,4th Floor, Denver, CO 80204 USA; [Hasnain-Wynia, Romana] Denver Hlth, 777 Bannock St,MC 6551, Denver, CO 80204 USA; [Cervantes, Lilia; Wynia, Matthew K.; Tong, Allison] Univ Colorado, Anschutz Med Campus,13080 East 19th Ave, Denver, CO 80045 USA; [Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Anschutz Med Campus,12700 East 19th Ave,Room 7015, Denver, CO 80045 USA; [Raghavan, Rajeev] Harris Hlth, Houston, TX USA; [Raghavan, Rajeev] Baylor Coll Med, Med Ctr, 7200 Cambridge St,8th Floor, Houston, TX 77030 USA; [Hou, Nova] Univ Texas McGovern Med Sch, 3011 Bell St, Houston, TX 77003 USA; [Tong, Allison] Univ Sydney, Sydney, NSW, Australia; [Tong, Allison] Childrens Hosp Westmead, Ctr Kidney Res, Corner Hawkesbury & Hainsworth St, Westmead, NSW 2145, Australia; [Kleiner, Catherine] 3921 Lions Paw St, Castle Rock, CO 80104 USA	Denver Health Medical Center; Denver Health Medical Center; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Baylor College of Medicine; University of Sydney; University of Sydney	Cervantes, L (corresponding author), Denver Hlth, 777 Bannock,MC 4000, Denver, CO 80204 USA.	lilia.cervantes@dhha.org	Wynia, Matthew/T-2210-2019	Hasnain-Wynia, Romana/0000-0001-6009-3569; Tong, Allison/0000-0001-8973-9538	Robert Wood Johnson Foundation; Doris Duke Charitable Foundation [2015212]; University of Colorado School of Medicine	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); University of Colorado School of Medicine	This study was made possible by a Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation. The project was also supported by grant 2015212 from the Doris Duke Charitable Foundation and the University of Colorado School of Medicine.	American Medical Association (AMA), 2001, AMA PRINC MED ETH; American Nurses Association, 2015, COD ETH NURS; Ansell D, 2015, HEALTH AFFAIR, V34, P781, DOI 10.1377/hlthaff.2014.1192; Berlinger N, 2017, HLTH CARE ACCESS UND; Birt L, 2016, QUAL HLTH RES; Campbell GA, 2010, AM J KIDNEY DIS, V55, P181, DOI 10.1053/j.ajkd.2009.06.039; Cervantes L, 2018, JAMA INTERN MED, V178, P188, DOI 10.1001/jamainternmed.2017.7039; Cervantes L, 2017, JAMA INTERN MED, V177, P529, DOI 10.1001/jamainternmed.2016.8865; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Corbin J., 1998, BASICS QUALITATIVE R; Coritsidis GN, 2004, AM J KIDNEY DIS, V43, P424, DOI 10.1053/j.ajkd.2003.11.004; Crigger BJ, 2017, AMA J ETHICS, V19, P564, DOI [10.1001/journalofethics.2017.19.6.coet1-1706, DOI 10.1001/JOURNALOFETHICS.2017.19.6.COET1-1706]; Earnest MA, 2010, ACAD MED, V85, P63, DOI 10.1097/ACM.0b013e3181c40d40; Fernandez A, 2017, JAMA INTERN MED, V177, P536, DOI 10.1001/jamainternmed.2016.9209; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P478, DOI 10.1001/jama.284.4.478; Hayashi AS, 2009, J HEALTH CARE POOR U, V20, P597, DOI 10.1353/hpu.0.0163; Hurley L, 2009, AM J KIDNEY DIS, V53, P940, DOI 10.1053/j.ajkd.2008.12.029; Jameton A., 1984, PRENTICE HALL, DOI DOI 10.1097/NJH.000000000000010; Johnson TL, 2015, HEALTH AFFAIR, V34, P1312, DOI 10.1377/hlthaff.2014.1186; Liamputtong P., 2013, QUALITATIVE RES METH, V4th ed.; Linden EA, 2012, AM J KIDNEY DIS, V60, P354, DOI 10.1053/j.ajkd.2012.05.016; Munnangi S, 2018, J TRAUMA NURS, V25, P4, DOI 10.1097/JTN.0000000000000335; Perni S., 2017, AMA J ETHICS, V19, P533, DOI [10.1001/journalofethics.2017.19.6.fred1-1706, DOI 10.1001/JOURNALOFETHICS.2017.19.6.FRED1-1706]; Raghavan R, 2012, SEMIN DIALYSIS, V25, P267, DOI 10.1111/j.1525-139X.2012.01066.x; Raghavan R, 2011, NEW ENGL J MED, V364, P2183, DOI 10.1056/NEJMp1101195; Rodriguez RA, 2015, ADV CHRONIC KIDNEY D, V22, P60, DOI 10.1053/j.ackd.2014.07.003; Rushton CH, 2017, AM J NURS, V117, P52, DOI 10.1097/01.NAJ.0000512203.08844.1d; Sheikh-Hamad D, 2007, TEX MED, V103, P54; Sher SJ, 2017, CLIN NEPHROL, V88, P181, DOI 10.5414/CN109137; Snyder L, 2012, ANN INTERN MED, V156, DOI 10.7326/0003-4819-156-1-201201031-00001; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Whitebird RR, 2017, GEN HOSP PSYCHIAT, V44, P91, DOI 10.1016/j.genhosppsych.2016.03.004; Wynia MK, 2000, JAMA-J AM MED ASSOC, V283, P1858, DOI 10.1001/jama.283.14.1858	33	40	40	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2018	169	2					78	+		10.7326/M18-0400	http://dx.doi.org/10.7326/M18-0400			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GN0TI	29800062				2023-01-03	WOS:000438689200013
J	Assali, DR; Hsu, CT; Gunapala, KM; Aguayo, A; McBurney, M; Steele, AD				Assali, Dina R.; Hsu, Cynthia T.; Gunapala, Keith M.; Aguayo, Antonio; McBurney, Michael; Steele, Andrew D.			Food anticipatory activity on a calorie-restricted diet is independent of Sirt1	PLOS ONE			English	Article							CIRCADIAN CLOCK; GENE; BRAIN; MICE; PGC-1-ALPHA; HOMEOSTASIS; METABOLISM; EXPRESSION; DIFFERENCE; RESPONSES	A number of studies have demonstrated that the Sirtuin family member, Sirt1, is a key integrator of growth, metabolism, and lifespan. Sirt1 directly interacts with and deacetylates key regulators of the circadian clock, positioning it to be an important link between feeding and circadian rhythms. In fact, one study suggests that Sirt1 is necessary for behavioral anticipation of limited daily food availability, a circadian process termed food anticipatory activity (FAA). In their study, mice overexpressing Sirt1 had enhanced FAA, while mice lacking Sirt1 had little to no FAA. Based on the supposition that Sirt1 was indeed required for FAA, we sought to use Sirt1 deletion to map the neural circuitry responsible for FAA. We began by inactivating Sirt1 using the cell-type specific Cre-driver lines proopiomelanocortin, but after observing no effect on body weight loss or FAA we then moved on to more broadly neuronal Cre drivers Ca2+/calmodulin-dependent protein kinase II and nestin. As neither of these neuronal deletions of Sirt1 had impaired FAA, we then tested 1) a broad postnatal tamoxifen-inducible deletion, 2) a complete, developmental knockout of Sirt1, and 3) a gene replacement, catalytically inactive, form of Sirt1; but all of these mice had FAA similar to controls. Therefore, our findings suggest that FAA is completely independent of Sirt1.	[Assali, Dina R.; Aguayo, Antonio; Steele, Andrew D.] Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA; [Hsu, Cynthia T.; Gunapala, Keith M.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [McBurney, Michael] Univ Ottawa, Dept Med, Ottawa, ON, Canada	California State University System; California State Polytechnic University Pomona; California Institute of Technology; University of Ottawa	Steele, AD (corresponding author), Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA.	adsteele@cpp.edu			Ellison Medical Foundation; Caltech Board Fellows in Brain Circuitry Program; Klarman Family Foundation; Eli and Edythe Broad Foundation; National Institute of General Medical Sciences of the National Institutes of Health [SC3GM125570]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC3GM125570] Funding Source: NIH RePORTER	Ellison Medical Foundation(Lawrence Ellison Foundation); Caltech Board Fellows in Brain Circuitry Program; Klarman Family Foundation; Eli and Edythe Broad Foundation; National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	ADS received salary support from from the Ellison Medical Foundation and the Caltech Board Fellows in Brain Circuitry Program. This work was also supported by the Klarman Family Foundation and the Eli and Edythe Broad Foundation to ADS. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number SC3GM125570. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguayo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191373; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Bass J, 2010, SCIENCE, V330, P1349, DOI 10.1126/science.1195027; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Cakir I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008322; Canto C, 2009, TRENDS ENDOCRIN MET, V20, P325, DOI 10.1016/j.tem.2009.03.008; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Caron AZ, 2014, FASEB J, V28, P1306, DOI 10.1096/fj.13-243568; Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen DE, 2009, GENE DEV, V23, P2812, DOI 10.1101/gad.1839209; Davidson AJ, 2009, EUR J NEUROSCI, V30, P1658, DOI 10.1111/j.1460-9568.2009.06961.x; Gong SC, 2007, J NEUROSCI, V27, P9817, DOI 10.1523/JNEUROSCI.2707-07.2007; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Gunapala KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018377; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hsu CT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015429; LeSauter J, 2009, P NATL ACAD SCI USA, V106, P13582, DOI 10.1073/pnas.0906426106; Li ZG, 2015, HORM BEHAV, V70, P38, DOI 10.1016/j.yhbeh.2015.02.004; Libert S, 2011, CELL, V147, P1459, DOI 10.1016/j.cell.2011.10.054; McBurney Michael W, 2013, Genes Cancer, V4, P125, DOI 10.1177/1947601912474893; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Michalik M, 2015, BEHAV NEUROSCI, V129, P351, DOI 10.1037/bne0000058; Mistlberger RE, 2011, PHYSIOL BEHAV, V104, P535, DOI 10.1016/j.physbeh.2011.04.015; Mistlberger Ralph E, 2009, J Circadian Rhythms, V7, P11, DOI 10.1186/1740-3391-7-11; Mistlberger Ralph E, 2009, J Circadian Rhythms, V7, P3, DOI 10.1186/1740-3391-7-3; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Noriega LG, 2011, EMBO REP, V12, P1069, DOI 10.1038/embor.2011.151; Orozco-Solis R, 2015, ENDOCRINOLOGY, V156, P2174, DOI 10.1210/en.2014-1805; Pendergast JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004860; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Satoh A, 2010, J NEUROSCI, V30, P10220, DOI 10.1523/JNEUROSCI.1385-10.2010; Seifert EL, 2012, FASEB J, V26, P555, DOI 10.1096/fj.11-193979; Sittig LJ, 2016, NEURON, V91, P1253, DOI 10.1016/j.neuron.2016.08.013; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X	47	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2018	13	6							e0199586	10.1371/journal.pone.0199586	http://dx.doi.org/10.1371/journal.pone.0199586			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK3YY	29940007	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000436088700027
J	Corti, C; Poggi, G; Romaniello, R; Strazzer, S; Urgesi, C; Borgatti, R; Bardoni, A				Corti, Claudia; Poggi, Geraldine; Romaniello, Romina; Strazzer, Sandra; Urgesi, Cosimo; Borgatti, Renato; Bardoni, Alessandra			Feasibility of a home-based computerized cognitive training for pediatric patients with congenital or acquired brain damage: An explorative study	PLOS ONE			English	Article							WORKING-MEMORY; EXECUTIVE DYSFUNCTION; CONSORT STATEMENT; CHILDREN; REHABILITATION; PROGRAM; CANCER; INJURY; ADOLESCENTS; ATTENTION	Objectives Pediatric brain damage is associated with various cognitive deficits. Cognitive rehabilitation may prevent and reduce cognitive impairment. In recent years, home-based computerized cognitive training (CCT) has been introduced in clinical practice to increase treatment opportunities for patients (telerehabilitation). However, limited research has been conducted thus far on investigating the effects of remote CCT for the juvenile population in contexts other than English-speaking countries. The aim of the present study was to investigate the feasibility of a home-based CCT in a group of Italian adolescents with brain damage. A commercially available CCT (Lumosity) developed in the English language was used due to the lack of telerehabilitation programs in the Italian language that allow stimulation of multiple cognitive domains and, at the same time, remote automatic collection of data. Thus, this investigation provides information on the possibility of introducing CCT programs available in foreign languages in countries with limited investment in the telerehabilitation field. Methods 32 adolescents aged 11-16 with a diagnosis of congenital or acquired (either traumatic or non-traumatic) brain damage participated in the study. They received 40 training sessions (5 days/week for 8 weeks). Before starting the training program, they received face-to-face demonstration of training exercises and written instructions in their mother tongue. The feasibility of both training and study design and procedures was assessed through 9 criteria taken from extant literature. Results All 9 feasibility criteria were met. 31 out of the 32 participants demonstrated adherence to the training program. 94.2% of training sessions were completed in the recommended time frame. No significant technical issue was found. Conclusions Telerehabilitation seems to be a feasible practice for adolescents with brain damage. A training program developed in a foreign language can be used to counter the unavailability of programs in patients' mother tongue.	[Corti, Claudia; Poggi, Geraldine; Bardoni, Alessandra] Sci Inst IRCCS Eugenio Medea, Neurooncol & Neuropsychol Rehabil Unit, Bosisio Parini, Lecco, Italy; [Romaniello, Romina; Urgesi, Cosimo; Borgatti, Renato] Sci Inst IRCCS Eugenio Medea, Neuropsychiat & Neurorehabil Unit, Bosisio Parini, Lecco, Italy; [Strazzer, Sandra] Sci Inst IRCCS Eugenio Medea, Acquired Brain Injury Unit, Bosisio Parini, Lecco, Italy; [Urgesi, Cosimo] Univ Udine, Dept Languages & Literatures Commun Educ & Soc, Lab Cognit Neurosci, Udine, Italy	IRCCS Eugenio Medea; IRCCS Eugenio Medea; IRCCS Eugenio Medea; University of Udine	Corti, C (corresponding author), Sci Inst IRCCS Eugenio Medea, Neurooncol & Neuropsychol Rehabil Unit, Bosisio Parini, Lecco, Italy.	claudia.corti@bp.lnf.it	Corti, Claudia/AAH-7222-2019; Borgatti, Renato/AEY-4481-2022; Urgesi, Cosimo/K-4688-2016; BARDONI, ALESSANDRA/AAH-7233-2019; Poggi, Geraldina/K-4490-2016; Borgatti, Renato/AAA-4108-2022; Romaniello, Romina/K-5160-2018; strazzer, sandra/AAH-5712-2019	Corti, Claudia/0000-0003-1466-3182; Borgatti, Renato/0000-0001-8165-4994; Urgesi, Cosimo/0000-0003-0572-1328; BARDONI, ALESSANDRA/0000-0001-8404-3857; Poggi, Geraldina/0000-0003-0589-6347; Borgatti, Renato/0000-0001-8165-4994; Romaniello, Romina/0000-0002-8709-6732; strazzer, sandra/0000-0001-8414-6565	Italian Ministry of Health [NET - 2013-02356160]	Italian Ministry of Health(Ministry of Health, Italy)	This study was supported by the Italian Ministry of Health (Ricerca Corrente grants 2015-2017 to AB and Ricerca Finalizzata grant NET - 2013-02356160 to RB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Bardoni A, 2013, BRAIN INJURY, V27, P1395, DOI 10.3109/02699052.2013.823652; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Bowen DJ, 2009, AM J PREV MED, V36, P452, DOI 10.1016/j.amepre.2009.02.002; Brennan DM, 2009, STUD HEALTH TECHNOL, V145, P231, DOI 10.3233/978-1-60750-018-6-231; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Chevignard M, 2016, ACTA PAEDIATR, V105, P574, DOI 10.1111/apa.13245; Conklin HM, 2015, J CLIN ONCOL, V33, P3894, DOI 10.1200/JCO.2015.61.6672; Santos Maria Tereza N. dos, 2014, Rev. paul. pediatr., V32, P136, DOI 10.1590/S0103-05822014000100020; Engvig A, 2010, NEUROIMAGE, V52, P1667, DOI 10.1016/j.neuroimage.2010.05.041; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gard G., 2001, PHYS THER REV, V6, P85; Goswami, 2019, COGNITIVE DEV COGNIT; Hardy JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134467; Hardy KK, 2013, PSYCHO-ONCOLOGY, V22, P1856, DOI 10.1002/pon.3222; Hellgren L., 2015, OPEN J THERAPY REHAB, V3, P46, DOI DOI 10.4236/OJTR.2015.32007; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; How TV, 2017, DISABIL REHABIL-ASSI, V12, P244, DOI 10.3109/17483107.2015.1129457; IRCCS Stella Maris University of Pisa University of Milan, TEL WORK MEM CHILDR; Kable JW, 2017, J NEUROSCI, V37, P7390, DOI 10.1523/JNEUROSCI.2832-16.2017; Kesler SR, 2011, BRAIN INJURY, V25, P101, DOI 10.3109/02699052.2010.536194; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kueider AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040588; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Leon AC, 2011, J PSYCHIATR RES, V45, P626, DOI 10.1016/j.jpsychires.2010.10.008; Lohaugen GCC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-269; Mulhern RK, 2003, CURR PROB CANCER, V27, P177, DOI 10.1016/S0147-0272(03)00026-6; Sadeghi M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176429; Schmeler MR, 2008, INT J TELEREHABILITA, P12; Sjo NM, 2010, ACTA PAEDIATR, V99, P230, DOI 10.1111/j.1651-2227.2009.01587.x; Souza Ligia Maria Do N, 2007, Dev Neurorehabil, V10, P35, DOI 10.1080/13638490600822239; Spevack TV, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P6; Tam Sing-Fai, 2003, Occup Ther Int, V10, P20, DOI 10.1002/oti.175; Tavano A, 2007, BRAIN, V130, P2646, DOI 10.1093/brain/awm201; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; van't Hooft I, 2003, ACTA PAEDIATR, V92, P935, DOI 10.1080/08035250310004586; van 't Hooft I, 2007, NEUROREHABILITATION, V22, P109; Verhelst H, 2017, GAMES HEALTH J, V6, P28, DOI 10.1089/g4h.2016.0043; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wechsler D, 2012, WECHSLER INTELLIGENT; Zampolini M, 2008, ANN I SUPER SANITA, V44, P125; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484	47	14	15	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2018	13	6							e0199001	10.1371/journal.pone.0199001	http://dx.doi.org/10.1371/journal.pone.0199001			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GJ8QS	29924823	Green Published, gold, Green Submitted			2023-01-03	WOS:000435655600040
J	Sivalogan, K; Semrau, KEA; Ashigbie, PG; Mwangi, S; Herlihy, JM; Yeboah-Antwi, K; Banda, B; Grogan, C; Biemba, G; Hamer, DH				Sivalogan, Kasthuri; Semrau, Katherine E. A.; Ashigbie, Paul G.; Mwangi, Sheila; Herlihy, Julie M.; Yeboah-Antwi, Kojo; Banda, Bowen; Grogan, Caroline; Biemba, Godfrey; Hamer, Davidson H.			Influence of newborn health messages on care-seeking practices and community health behaviors among participants in the Zambia Chlorhexidine Application Trial	PLOS ONE			English	Article							UMBILICAL-CORD CARE; MORTALITY	Background Identifying and understanding traditional perceptions that influence newborn care practices and care-seeking behavior are crucial to developing sustainable interventions to improve neonatal health. The Zambia Chlorhexidine Application Trial (ZamCAT), a large-scale cluster randomized trial, assessed the impact of 4% chlorhexidine on neonatal mortality and omphalitis in Southern Province, Zambia. The main purpose of this post-ZamCAT qualitative study was to understand the impact of newborn care health messages on care-seeking behavior for neonates and the acceptability, knowledge, and attitudes towards chlorhexidine cord care among community members and health workers in Southern Province. Methods & findings Five focus group discussions and twenty-six in-depth interviews were conducted with mothers and health workers from ten health centers (5 rural and 5 peri-urban/urban). Community perceptions and local realities were identified as fundamental to care-seeking decisions and influenced individual participation in particular health-seeking behaviors. ZamCAT field monitors (data collectors) disseminated health messages at the time of recruitment at the health center and during subsequent home visits. Mothers noted that ZamCAT field monitors were effective in providing lessons and education on newborn care practices and participating mothers were able to share these messages with others in their communities. Although the study found no effect of chlorhexidine cord washes on neonatal mortality, community members had positive views towards chlorhexidine as they perceived that it reduced umbilical cord infections and was a beneficial alternative to traditional cord applications. Conclusion The acceptability of health initiatives, such as chlorhexidine cord application, in community settings, is dependent on community education, understanding, and engagement. Community-based approaches, such as using community-based cadres of health workers to strengthen referrals, are an acceptable and potentially effective strategy to improve care-seeking behaviors and practices.	[Sivalogan, Kasthuri; Ashigbie, Paul G.; Mwangi, Sheila; Yeboah-Antwi, Kojo; Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA; [Sivalogan, Kasthuri] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA; [Semrau, Katherine E. A.; Grogan, Caroline] Harvard TH Chan Sch Publ Hlth, Brigham & Womens Hosp, Ariadne Labs, Boston, MA USA; [Semrau, Katherine E. A.] Harvard Med Sch, Dept Med, Boston, MA USA; [Semrau, Katherine E. A.] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA; [Herlihy, Julie M.] Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA; [Banda, Bowen; Biemba, Godfrey; Hamer, Davidson H.] Zambian Ctr Appl Hlth Res & Dev Ltd, Lusaka 8, Zambia; [Hamer, Davidson H.] Boston Med Ctr, Dept Med, Sect Infect Dis, Boston, MA 02118 USA	Boston University; Emory University; Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; Boston Medical Center	Hamer, DH (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02215 USA.; Hamer, DH (corresponding author), Zambian Ctr Appl Hlth Res & Dev Ltd, Lusaka 8, Zambia.; Hamer, DH (corresponding author), Boston Med Ctr, Dept Med, Sect Infect Dis, Boston, MA 02118 USA.	dhamer@bu.edu	Biemba, Godfrey/AAQ-4599-2020; Hamer, Davidson Howes/J-2020-2019; Yeboah-Antwi, Kojo/AAI-8519-2020; Banda, Bowen/I-6877-2018	Hamer, Davidson Howes/0000-0002-4700-1495; Banda, Bowen/0000-0002-8673-8318; Sivalogan, Kasthuri/0000-0002-8500-630X; Semrau, Katherine/0000-0002-8360-1391	Bill & Melinda Gates Foundation (Global Health Grant) [OPPGH5298]	Bill & Melinda Gates Foundation (Global Health Grant)	This work received support from the Bill & Melinda Gates Foundation (Global Health Grant Number OPPGH5298). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.; This manuscript is based on research funded by the Bill & Melinda Gates Foundation (Global Health Grant Number OPPGH5298). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.	[Anonymous], 2010, NAT AN REP; Arthur Kleinman, 1981, PATIENTS HEALERS CON; Central Statistical Office (CSO) Ministry of Health (MOH) Tropical Diseases Research Centre (TDRC) University of Zambia Macro International Inc, 2013, ZAMB DEM HLTH SURV 2; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Hamer DH, 2015, AM J TROP MED HYG, V92, P666, DOI 10.4269/ajtmh.14-0218; Herlihy JM, 2012, PED AC SOC AS SOC PE; Herlihy JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079191; Hug L, 2017, LEVELS TRENDS CHILD; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Muriuku A, ACCEPTABILITY USE CH; Republic of Zambia D Zambian Ministry of Community Development, 2014, ESS NEW BORN CAR GUI; Republic of Zambia-Zambian Ministry of Community Development, 2013, ROADM ACC RED MAT; Semrau KEA, 2016, LANCET GLOB HEALTH, V4, pE827, DOI [10.1016/S2214-109X(16)30215-7, 10.1016/s2214-109x(16)30215-7]; Sialubanje C, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0342-1; Stekelenburg J, 2005, HEALTH POLICY, V71, P67, DOI 10.1016/j.healthpol.2004.05.008; WHO/ UNICEF, 1995, WHO UNICEF APPR INT	16	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2018	13	6							e0198176	10.1371/journal.pone.0198176	http://dx.doi.org/10.1371/journal.pone.0198176			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ5MF	29902234	gold, Green Published, Green Submitted			2023-01-03	WOS:000435424900012
J	Krammel, M; Schnaubelt, S; Weidenauer, D; Winnisch, M; Steininger, M; Eichelter, J; Hamp, T; van Tulder, R; Sulzgruber, P				Krammel, Mario; Schnaubelt, Sebastian; Weidenauer, David; Winnisch, Markus; Steininger, Matthias; Eichelter, Jakob; Hamp, Thomas; van Tulder, Raphael; Sulzgruber, Patrick			Gender and age-specific aspects of awareness and knowledge in basic life support	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; AUTOMATED EXTERNAL DEFIBRILLATION; PUBLIC-ACCESS; SURVIVAL; RESUSCITATION; OUTCOMES; EUROPE	Background The 'chain of survival' including early call for help, early cardiopulmonary resuscitation (CPR) and early defibrillation represents the most beneficial approach for favourable patient outcome after out-of-hospital cardiac arrest (OHCA). Despite increasing numbers of publicly accessible automated external defibrillators (AED) and interventions to increase public awareness for basic life support (BLS), the number of their use in real-life emergency situations remains low. Methods In this prospective population-based cross-sectional study, a total of 501 registered inhabitants of Vienna (Austria) were randomly approached via telephone calls between 08/2014 and 09/2014 and invited to answer a standardized questionnaire in order to identify public knowledge and awareness of BLS and AED-use. Results We found that more than 52 percent of participants would presume OHCA correctly and would properly initiate BLS attempts. Of alarming importance, only 33 percent reported that they would be willing to perform CPR and 50 percent would use an AED device. There was a significantly lower willingness to initiate BLS attempts (male: 40% vs. female: 25%; OR: 2.03 [95%CI: 1.39-2.98]; p<0.001) and to use an AED device (male: 58% vs. female: 44%; OR: 1.76 [95%CI: 1.26-2.53]; p = 0.002) in questioned female individuals compared to their male counterparts. Interestingly, we observed a strongly decreasing level of knowledge and willingness for BLS attempts (-14%; OR: 0.72 [95%CI: 0.57-0.92]; p = 0.027) and AED-use (-19%; OR: 0.68 [95%CI: 0.54-0.85]; p = 0.001) with increasing age. Conclusion We found an overall poor knowledge and awareness concerning BLS and the use of AEDs among the Viennese population. Both female and elderly participants reported the lowest willingness to perform BLS and use an AED in case of OHCA. Specially tailored programs to increase awareness and willingness among both the female and elderly community need to be considered for future educational interventions.	[Krammel, Mario; Eichelter, Jakob] Med Univ Vienna, Dept Anesthesiol Intens Care & Pain Med, Vienna, Austria; [Krammel, Mario; Hamp, Thomas] Emergency Med Serv Vienna, Vienna, Austria; [Krammel, Mario; Schnaubelt, Sebastian; Weidenauer, David; Winnisch, Markus; Steininger, Matthias; Eichelter, Jakob; Hamp, Thomas; van Tulder, Raphael; Sulzgruber, Patrick] Austrian Cardiac Arrest Awareness Assoc PULS, Vienna, Austria; [Schnaubelt, Sebastian; Sulzgruber, Patrick] Med Univ Vienna, Dept Emergency Med, Vienna, Austria; [Weidenauer, David; Steininger, Matthias] Med Univ Vienna, Div Cardiol, Dept Med 2, Vienna, Austria; [Winnisch, Markus] Med Univ Vienna, Dept Trauma Surg, Vienna, Austria; [van Tulder, Raphael] Karl Landsteiner Univ Hlth Sci, Div Cardiol, Dept Internal Med 1, Krems, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Sulzgruber, P (corresponding author), Austrian Cardiac Arrest Awareness Assoc PULS, Vienna, Austria.; Sulzgruber, P (corresponding author), Med Univ Vienna, Dept Emergency Med, Vienna, Austria.	patrick.sulzgruber@meduniwien.ac.at	Schnaubelt, Sebastian/AAH-2560-2020	Schnaubelt, Sebastian/0000-0003-0057-8200; Sulzgruber, Patrick/0000-0001-5146-0099	Austrian Cardiac Arrest Awareness Association (PULS), Vienna, Austria; Viennese civil protection association "Die Helfer Wiens"	Austrian Cardiac Arrest Awareness Association (PULS), Vienna, Austria; Viennese civil protection association "Die Helfer Wiens"	This study was supported by the Austrian Cardiac Arrest Awareness Association (PULS), Vienna, Austria, and the Viennese civil protection association "Die Helfer Wiens". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blom MT, 2014, CIRCULATION, V130, P1868, DOI 10.1161/CIRCULATIONAHA.114.010905; Brooks B, 2015, HEART, V101, P967, DOI 10.1136/heartjnl-2015-307624; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Kozlowski D, 2013, ARCH MED SCI, V9, P27, DOI 10.5114/aoms.2013.33345; Mendis S, 2015, STROKE, V46, pE121, DOI 10.1161/STROKEAHA.115.008097; Nurnberger A, 2013, RESUSCITATION, V84, P42, DOI 10.1016/j.resuscitation.2012.07.002; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Perkins GD, 2012, EMERG MED J, V29, P3, DOI 10.1136/emermed-2011-200758; Schober P, 2011, ANN EMERG MED, V58, P240, DOI 10.1016/j.annemergmed.2010.12.016; Semeraro F, 2016, RESUSCITATION, V107, pE7, DOI 10.1016/j.resuscitation.2016.08.014; Smith KL, 2003, EMERG MED J, V20, P85, DOI 10.1136/emj.20.1.85; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; van Alem AP, 2003, BMJ-BRIT MED J, V327, P1312, DOI 10.1136/bmj.327.7427.1312; Weisfeldt ML, 2010, J AM COLL CARDIOL, V55, P1712, DOI 10.1016/j.jacc.2009.11.077; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483	16	26	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2018	13	6							e0198918	10.1371/journal.pone.0198918	http://dx.doi.org/10.1371/journal.pone.0198918			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ1PQ	29894491	Green Submitted, Green Published, gold			2023-01-03	WOS:000435030900036
J	Zhuang, KJ; Jiang, YJ; Feng, XH; Li, L; Dang, FF; Zhang, W; Man, CX				Zhuang, Kejin; Jiang, Yujun; Feng, Xiaohan; Li, Li; Dang, Fangfang; Zhang, Wei; Man, Chaoxin			Transcriptomic response to GABA-producing Lactobacillus plantarum CGMCC 1.2437(T) induced by L-MSG	PLOS ONE			English	Article							GAMMA-AMINOBUTYRIC-ACID; COMPLETE GENOME SEQUENCE; GLUTAMATE-DECARBOXYLASE; LACTOCOCCUS-LACTIS; EXPRESSION; BACTERIA; GENE; IDENTIFICATION; METABOLISM; PYRUVATE	Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter found in the central nervous system of mammals. A range of bacterial species can synthesize GABA, including Lactobacillus plantarum of which L-monosodium glutamate (L-MSG) is an inducer of its production. In order to synthesize GABA in high concentrations, L-MSG was utilized as the single inducing factor, a chemically defined medium (CDM) was used as the fermentation substrate, with L. plantarum CGMCC 1.2437(T) cultured in medium supplemented with or without L-MSG. High-throughput transcriptome sequencing was used to explore the differential genes expression of bacterial cells at 36 h of fermentation, where the GABA concentration of CDM with L-MSG reached the peak value and was 7.7 times higher than that of medium without L-MSG at the same timepoint. A total of 87 genes showed significant differential expression induced by L-MSG: of these, 69 were up-regulated genes and 18 were down-regulated. The up-regulated genes were assigned to biological processes and molecular function, while the down-regulated genes covered biological process, cellular process and molecular function. Interrogation of results using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, indicated carbohydrate metabolism, fatty acid synthesis and amino acid metabolism were closely associated with GABA synthesis induced by L-MSG. This study provides insights into L. plantarum-mediated GABA fermentation at the molecular level and will provide a new approach for further studies related to GABA production by the other Lactic acid bacteria.	[Zhuang, Kejin; Jiang, Yujun; Feng, Xiaohan; Li, Li; Dang, Fangfang; Zhang, Wei; Man, Chaoxin] Northeast Agr Univ, Coll Food Sci & Technol, Minist Educ, Key Lab Dairy Sci, Harbin, Heilongjiang, Peoples R China	Northeast Agricultural University - China	Man, CX (corresponding author), Northeast Agr Univ, Coll Food Sci & Technol, Minist Educ, Key Lab Dairy Sci, Harbin, Heilongjiang, Peoples R China.	mcxwh2006@qq.com			"Academic Backbone" Project of Northeast Agricultural University [15XG26]; National High-level Talents Special Support Program of China	"Academic Backbone" Project of Northeast Agricultural University; National High-level Talents Special Support Program of China	This study was supported by Academic Backbone Project of Northeast Agricultural University (15XG26), http://www.neau.cn/info/1175/5879.htm, and National High-level Talents Special Support Program of China, http://rencai.people.com.cn/n1/2016/0620/c244800-28463348.html.	Adeghate E, 2002, TISSUE CELL, V34, P1, DOI 10.1054/tice.2002.0217; Altermann E, 2005, P NATL ACAD SCI USA, V102, P3906, DOI 10.1073/pnas.0409188102; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Broadbent JR, 2010, J BACTERIOL, V192, P2445, DOI 10.1128/JB.01618-09; Clark SM, 2009, J EXP BOT, V60, P1743, DOI 10.1093/jxb/erp044; Cock PJA, 2010, NUCLEIC ACIDS RES, V38, P1767, DOI 10.1093/nar/gkp1137; Cotter PD, 2003, MICROBIOL MOL BIOL R, V67, P429, DOI 10.1128/MMBR.67.3.429-453.2003; Silva DMD, 2009, J NEUROSCI METH, V177, P289, DOI 10.1016/j.jneumeth.2008.10.011; Di Cagno R, 2010, APPL MICROBIOL BIOT, V86, P731, DOI 10.1007/s00253-009-2370-4; Dillies MA, 2013, BRIEF BIOINFORM, V14, P671, DOI 10.1093/bib/bbs046; DOVER S, 1972, J BACTERIOL, V110, P165, DOI 10.1128/JB.110.1.165-170.1972; Fan EY, 2012, ANN MICROBIOL, V62, P689, DOI 10.1007/s13213-011-0307-5; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Feehily C, 2013, J APPL MICROBIOL, V114, P11, DOI 10.1111/j.1365-2672.2012.05434.x; Feehily C, 2013, APPL ENVIRON MICROB, V79, P74, DOI 10.1128/AEM.02184-12; Fernandez A, 2008, PROTEOMICS, V8, P3154, DOI 10.1002/pmic.200700974; Fernandez M, 2006, CRIT REV MICROBIOL, V32, P155, DOI 10.1080/10408410600880643; Hagiwara H, 2004, BIOSCI BIOTECH BIOCH, V68, P444, DOI 10.1271/bbb.68.444; Higuchi T, 1997, J BACTERIOL, V179, P3362, DOI 10.1128/JB.179.10.3362-3364.1997; Hovik H, 2012, J BACTERIOL, V194, P100, DOI 10.1128/JB.06385-11; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Kim JY, 2009, INT J FOOD MICROBIOL, V130, P12, DOI 10.1016/j.ijfoodmicro.2008.12.028; Kleerebezem M, 2002, J BIOTECHNOL, V98, P199, DOI 10.1016/S0168-1656(02)00132-3; Kleerebezem M, 2000, ENZYME MICROB TECH, V26, P840, DOI 10.1016/S0141-0229(00)00180-0; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Komatsuzaki N, 2005, FOOD MICROBIOL, V22, P497, DOI 10.1016/j.fm.2005.01.002; Kook MC, 2010, J KOREAN SOC APPL BI, V53, P816, DOI 10.3839/jksabc.2010.123; Koponen J, 2012, J PROTEOMICS, V75, P1357, DOI 10.1016/j.jprot.2011.11.009; Leimena MM, 2012, APPL ENVIRON MICROB, V78, P4141, DOI 10.1128/AEM.00470-12; Li HX, 2010, AMINO ACIDS, V39, P1107, DOI 10.1007/s00726-010-0582-7; Li HX, 2010, AMINO ACIDS, V38, P1439, DOI 10.1007/s00726-009-0355-3; Li L, 2014, FOOD FUNCT, V5, P3261, DOI [10.1039/c4fo00565a, 10.1039/C4FO00565A]; Liao WC, 2013, J FUNCT FOODS, V5, P1108, DOI 10.1016/j.jff.2013.03.006; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mao XZ, 2005, BIOINFORMATICS, V21, P3787, DOI 10.1093/bioinformatics/bti430; Mazzoli R, 2010, AMINO ACIDS, V39, P727, DOI 10.1007/s00726-010-0507-5; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nomura M, 1999, MICROBIOL-UK, V145, P1375, DOI 10.1099/13500872-145-6-1375; Oh Suk-Heung, 2003, Journal of Medicinal Food, V6, P115; Park JY, 2014, BIOTECHNOL LETT, V36, P1791, DOI 10.1007/s10529-014-1539-9; Pearl PL, 2006, FUTUR NEUROL, V1, P631, DOI 10.2217/14796708.1.5.631; Perkins TT, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000569; Pessione E, 2005, PROTEOMICS, V5, P687, DOI 10.1002/pmic.200401116; Pessione E, 2009, PROTEOMICS, V9, P2695, DOI 10.1002/pmic.200800780; POOLMAN B, 1993, FEMS MICROBIOL REV, V12, P125, DOI 10.1111/j.1574-6976.1993.tb00015.x; Rea K, 2005, J NEUROCHEM, V94, P672, DOI 10.1111/j.1471-4159.2005.03218.x; Siragusa S, 2007, APPL ENVIRON MICROB, V73, P7283, DOI 10.1128/AEM.01064-07; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Teusink B, 2005, APPL ENVIRON MICROB, V71, P7253, DOI 10.1128/AEM.71.11.7253-7262.2005; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vadeboncoeur C, 1997, FEMS MICROBIOL REV, V19, P187, DOI 10.1016/S0168-6445(96)00029-0; Van Cauwenberghe OR, 2002, CAN J BOT, V80, P933, DOI [10.1139/b02-087, 10.1139/B02-087]; van Vliet AHM, 2010, FEMS MICROBIOL LETT, V302, P1, DOI 10.1111/j.1574-6968.2009.01767.x; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wong T, 2003, ANN NEUROLOGY, V54; Xiang LX, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-472; Yadav R, 2017, CRITICAL REV FOOD SC, P1; Yadav R, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01683; Yadav R, 2018, CURR PROTEIN PEPT SC, V19, P68, DOI 10.2174/1389203718666161111130157; Yadav R, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02116; Yadav R, 2017, CRIT REV FOOD SCI, V57, P3233, DOI 10.1080/10408398.2015.1108957; Yang SY, 2008, AMINO ACIDS, V34, P473, DOI 10.1007/s00726-007-0544-x; Yoder-Himes DR, 2009, P NATL ACAD SCI USA, V106, P3976, DOI 10.1073/pnas.0813403106; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zhai ZY, 2014, ENVIRON MICROBIOL, V16, P1524, DOI 10.1111/1462-2920.12280; Zhang YM, 2008, NAT REV MICROBIOL, V6, P222, DOI 10.1038/nrmicro1839	67	14	14	4	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2018	13	6							e0199021	10.1371/journal.pone.0199021	http://dx.doi.org/10.1371/journal.pone.0199021			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ1PQ	29894506	gold, Green Submitted, Green Published			2023-01-03	WOS:000435030900044
J	Hosny, KM; Rizg, WY				Hosny, Khaled Mohamed; Rizg, Waleed Yousof			Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis	PLOS ONE			English	Article							DRUG-DELIVERY SYSTEMS; RELEASE; VITRO; DEGRADATION; BISPHOSPHONATES; MICROSPHERES; COPOLYMER; SAFETY	There are many challenges facing the use of alendronate sodium for the treatment of osteoporosis such as low bioavailability of 0.6% and oesophageal ulceration with bleeding. Due to the aforementioned limitation, the main objective of this research is to utilize a statistical experimental design in the formulation and optimization of alendronate in the form of controlled release biodegradable intramuscular in-situ gel. A Box - Behnken experimental design employing Statgraphics (R) software was used to develop an optimized in-situ gel formulation and to estimate the effects of Poly-DL-lactide-coglycolide as a primary polymer, the copolymer polycaprolactone, and lipid surfactant capryol 90. Every system was evaluated for gellation character, and in vitro release. As a novel technique for evaluation of the in-situ gel, in-vivo biodegradability rate was estimated in rats. Pharmacokinetic parameters were assessed in rabbits. The results indicated a significant effect of the copolymer and lipid surfactant on initial burst, and a significant effect of the primary and copolymer on drug percentage released. The optimum formulation showed a 5% initial burst, an in-vivo biodegradability rate estimated at 8% every seven days in rats, and the pharmacokinetic evaluation revealed that alendronate sodium mean residence time extended to 102 days in rabbits. In conclusion, the optimum biodegradable intramuscular in-situ gel formulations is a promising approach for providing higher bioavailability, extended release for more than three months, with elimination of esophageal side effects.	[Hosny, Khaled Mohamed; Rizg, Waleed Yousof] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Jeddah, Saudi Arabia; [Hosny, Khaled Mohamed] Beni Suef Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Bani Suwayf, Egypt; [Rizg, Waleed Yousof] Univ Nottingham, Sch Pharm, Boots Sci Bldg, Nottingham, England	King Abdulaziz University; Egyptian Knowledge Bank (EKB); Beni Suef University; University of Nottingham	Hosny, KM (corresponding author), King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Jeddah, Saudi Arabia.; Hosny, KM (corresponding author), Beni Suef Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Bani Suwayf, Egypt.	Elswaify2000@yahoo.com	Hosny, Khaled M/H-9793-2012; rizg, waleed/AAS-5132-2021; Hosny, Khaled/GWC-2586-2022	Hosny, Khaled/0000-0002-4904-1378	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, [D-002-166-1438]	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah,	This work was supported by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (D-002-166-1438).	Ahmed TA, 2016, DRUG DES DEV THER, V10, P405, DOI 10.2147/DDDT.S98078; Al Deeb SK, 2004, TALANTA, V64, P695, DOI 10.1016/j.talanta.2004.03.044; Balakrishnan P, 2009, EUR J PHARM BIOPHARM, V72, P539, DOI 10.1016/j.ejpb.2009.03.001; Bauer DC, 2000, ARCH INTERN MED, V160, P517, DOI 10.1001/archinte.160.4.517; Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897; Che X, 2014, INT J PHARMACEUT, V469, P23, DOI 10.1016/j.ijpharm.2014.04.044; Cheng YH, 2010, TISSUE ENG PT A, V16, P695, DOI [10.1089/ten.tea.2009.0229, 10.1089/ten.TEA.2009.0229]; Chenite A, 2000, BIOMATERIALS, V21, P2155, DOI 10.1016/S0142-9612(00)00116-2; Goldenstein J, 2010, ANN BIOMED ENG, V38, P235, DOI 10.1007/s10439-009-9850-7; Hosny KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154926; Hosny KM, 2013, EXPERT OPIN DRUG DEL, V10, P741, DOI 10.1517/17425247.2013.799136; Hyun H, 2007, BIOMACROMOLECULES, V8, P1093, DOI 10.1021/bm060991u; Ionescu LC, 2010, BIOMATERIALS, V31, P4113, DOI 10.1016/j.biomaterials.2010.01.098; Kempe S, 2012, J CONTROL RELEASE, V161, P668, DOI 10.1016/j.jconrel.2012.04.016; Khajeh M, 2011, J SUPERCRIT FLUID, V55, P944, DOI 10.1016/j.supflu.2010.10.017; Kranz H, 2001, INT J PHARM, V212, P11, DOI 10.1016/S0378-5173(00)00568-8; Lee JY, 2010, INT J PHARMACEUT, V392, P51, DOI 10.1016/j.ijpharm.2010.03.033; Loh XJ, 2010, J CONTROL RELEASE, V143, P175, DOI 10.1016/j.jconrel.2009.12.030; Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142-9612(00)00047-8; Lu L, 1999, J BIOMED MATER RES, V46, P236, DOI 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F; Luurila S, 1999, PHARMACOL TOXICOL, V84, P24, DOI 10.1111/j.1600-0773.1999.tb02106.x; Packhaeuser CB, 2004, EUR J PHARM BIOPHARM, V58, P445, DOI 10.1016/j.ejpb.2004.03.003; Papathanasiou KE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04956-3; PARK TG, 1995, BIOMATERIALS, V16, P1123, DOI 10.1016/0142-9612(95)93575-X; Patel RB, 2010, J BIOMED MATER RES A, V94A, P476, DOI 10.1002/jbm.a.32724; Peters ML, 2001, CLEV CLIN J MED, V68, P945, DOI 10.3949/ccjm.68.11.945; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; Sinha VR, 2004, INT J PHARMACEUT, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044; Song Z., 2017, ENERG FUEL, V32, P352; Tadrous M, 2014, OSTEOPOROSIS INT, V25, P2671, DOI 10.1007/s00198-014-2789-z; Tan LP, 2004, INT J PHARMACEUT, V283, P89, DOI 10.1016/j.ijpharm.2004.06.022; Vibha B., 2014, INT J PHARM SCI, V4, P577; Yang Q, 2000, DRUG DEV IND PHARM, V26, P61, DOI 10.1081/DDC-100100328	33	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0197540	10.1371/journal.pone.0197540	http://dx.doi.org/10.1371/journal.pone.0197540			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856752	Green Submitted, Green Published, gold			2023-01-03	WOS:000433900800030
J	Lin, MY; Cheng, LJ; Chiu, YW; Hsieh, HM; Wu, PH; Lin, YT; Wang, SL; Jian, FX; Hsu, CC; Yang, SA; Lee, HL; Hwang, SJ				Lin, Ming-Yen; Cheng, Li-Jen; Chiu, Yi-Wen; Hsieh, Hui-Min; Wu, Ping-Hsun; Lin, Yi-Ting; Wang, Shu-Li; Jian, Feng-Xuan; Hsu, Chih Cheng; Yang, Shu-An; Lee, Huei-Lan; Hwang, Shang-Jyh			Effect of national pre-ESRD care program on expenditures and mortality in incident dialysis patients: A population-based study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; MULTIDISCIPLINARY CARE; PERFORMANCE; REPLACEMENT; OUTCOMES; QUALITY; PEOPLE; TAIWAN; PAY	Inadequate care of chronic kidney disease (CKD) is common and may be associated with adverse outcomes after dialysis. The nationwide pre-end-stage renal disease pay for performance program (P4P) has been implemented in Taiwan to improve quality of CKD care. However, the effectiveness of the P4P program in improving the outcomes of pre-dialysis care and dialysis is uncertain. We conducted a longitudinal cohort study. Patients who newly underwent long-term dialysis (>= 3 mo) between 2007 and 2009 were identified from the Taiwan National Health Insurance Research Database. Based on the patient enrolment of the P4P program, they were categorized into P4P or non-P4P groups. We analysed pre-dialysis care, healthcare expenditures, and mortality between two groups. Among the 26 588 patients, 25.5% participated in the P4P program. The P4P group received significantly better quality of care, including a higher frequency of glomerular filtration rate measurement and CKD complications survey, a higher rate of vascular access preparation, and more frequent use of arteriovenous fistulas than the non-P4P group did. The P4P group had a 68.4% reduction of the 4-year total healthcare expenditure (excluding dialysis fee), which is equivalent to US$345.7 million, and a significant 22% reduction in three-year mortality after dialysis (hazard ratio 0.78, 95% confidence interval: 0.75-0.82, P < 0.001) compared with the non-P4P group. P4P program improves quality of pre-dialysis CKD care, and provide survival benefit and a long-term cost saving for dialysis patients.	[Lin, Ming-Yen; Cheng, Li-Jen; Chiu, Yi-Wen; Wu, Ping-Hsun; Jian, Feng-Xuan; Yang, Shu-An; Lee, Huei-Lan; Hwang, Shang-Jyh] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Lin, Ming-Yen; Chiu, Yi-Wen; Hwang, Shang-Jyh] Kaohsiung Med Univ, Coll Med, Fac Renal Care, Kaohsiung, Taiwan; [Hsieh, Hui-Min] Kaohsiung Med Univ, Coll Hlth Sci, Dept Publ Hlth, Kaohsiung, Taiwan; [Wu, Ping-Hsun; Lin, Yi-Ting; Hwang, Shang-Jyh] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan; [Lin, Yi-Ting] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Family Med, Kaohsiung, Taiwan; [Wang, Shu-Li] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Nursing, Kaohsiung, Taiwan; [Hsu, Chih Cheng; Hwang, Shang-Jyh] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan; [Hsu, Chih Cheng] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Hsu, Chih Cheng] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; China Medical University Taiwan; National Yang Ming Chiao Tung University	Hwang, SJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan.; Hwang, SJ (corresponding author), Kaohsiung Med Univ, Coll Med, Fac Renal Care, Kaohsiung, Taiwan.; Hwang, SJ (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan.; Hwang, SJ (corresponding author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan.	sjhwang@kmu.edu.tw	Wu, Ping-Hsun/S-8746-2017; Lin, Ming Yen/A-8637-2010	Wu, Ping-Hsun/0000-0003-1021-8161; Lin, Ming Yen/0000-0002-8194-4833	National Health Insurance Administration, Ministry of Health and Welfare [M0HW103-NH-1001]; Kaohsiung Medical University Hospital [KMUH103-3R10]	National Health Insurance Administration, Ministry of Health and Welfare; Kaohsiung Medical University Hospital	This project was funded by National Health Insurance Administration, Ministry of Health and Welfare (M0HW103-NH-1001) and Kaohsiung Medical University Hospital (KMUH103-3R10) to SJH. The sponsors had no role in the study design, data collection and analysis, publication decision, and interpretation of data; writing the report; and the decision to submit the report for publication.	[Anonymous], 2001, AM J KIDNEY DIS, V37, pS137, DOI [DOI 10.1016/S0272-6386(01)70007-8, 10.1016/s0272-6386(01)70007-8]; Bayliss EA, 2011, CLIN J AM SOC NEPHRO, V6, P704, DOI 10.2215/CJN.06610810; Bello AK, 2015, AM J KIDNEY DIS, V65, P15, DOI 10.1053/j.ajkd.2014.07.033; Chan MR, 2007, AM J MED, V120, P1063, DOI 10.1016/j.amjmed.2007.04.024; Chen PM, 2015, AM J MED, V128, P68, DOI 10.1016/j.amjmed.2014.07.042; Chen Y-R, 2012, NEPHROL DIAL TRANSPL, V28, P671; Chen YR, 2014, NEPHROLOGY, V19, P699, DOI 10.1111/nep.12316; Cheng C-L, 2015, INT J CARDIOLOGY; Desai AA, 2007, CLIN J AM SOC NEPHRO, V2, P1087, DOI 10.2215/CJN.00510107; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Fishbane S, 2012, KIDNEY INT, V81, P1167, DOI 10.1038/ki.2012.138; Garcia-Garcia G, 2013, KIDNEY INT SUPPL, V3, P178, DOI 10.1038/kisup.2013.9; Gilmore J, 2006, NEPHROL NURS J, V33, P487; Hao H, 2015, KIDNEY INT; Hemmelgarn BR, 2007, J AM SOC NEPHROL, V18, P993, DOI 10.1681/ASN.2006080860; Hsieh HM, 2016, NEPHROL DIAL TRANSPL, V32, P1184; Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540; Jones SM, 2011, AM J KIDNEY DIS, V57, P449, DOI 10.1053/j.ajkd.2010.10.053; Karunaratne K, 2013, NEPHROL DIAL TRANSPL, V28, P2107, DOI 10.1093/ndt/gft093; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Lu TH, 2000, INT J EPIDEMIOL, V29, P336, DOI 10.1093/ije/29.2.336; McCulloch CE, 2011, STAT SCI, V26, P388, DOI 10.1214/11-STS361; Neuhaus JM, 2013, STAT MED, V32, P2419, DOI 10.1002/sim.5682; Ravani P, 2013, J AM SOC NEPHROL, V24, P465, DOI 10.1681/ASN.2012070643; Rayner HC, 2014, NEPHROL DIAL TRANSPL, V29, P644, DOI 10.1093/ndt/gft486; Singhal R, 2014, KIDNEY INT, V86, P399, DOI 10.1038/ki.2014.16; So Y, 2014, SAS GLOBAL FORUM; Wei SY, 2010, NEPHROLOGY, V15, P108, DOI 10.1111/j.1440-1797.2009.01154.x; Yu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112820	31	23	23	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0198387	10.1371/journal.pone.0198387	http://dx.doi.org/10.1371/journal.pone.0198387			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856821	Green Published, Green Submitted, gold			2023-01-03	WOS:000433900800110
J	Asano, S; Azuma, K; Shimizu, K; Yamamoto, R; Lee, J; Murata, H; Inoue, T; Asaoka, R; Obata, R				Asano, Shotaro; Azuma, Keiko; Shimizu, Kimiko; Yamamoto, Risako; Lee, Jinhee; Murata, Hiroshi; Inoue, Tatsuya; Asaoka, Ryo; Obata, Ryo			Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy	PLOS ONE			English	Article							MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; HEALTHY EYES; RANIBIZUMAB; THICKNESS; OUTCOMES; HYPERPERMEABILITY; BINARIZATION; AMD	Purpose To investigate the relationship between choroidal structure and visual acuity after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy (PCV). Methods We conducted a retrospective, single-centre and observational study including 18 eyes of 18 patients with PCV (73.8 +/- 10.2 years of age) who were treated with three monthly intravitreal aflibercept injections followed by additional treatments in a treat-and-extend protocol. The cross-sectional images of the macula were obtained with enhanced depth imaging optical coherence tomography at baseline, at 3 months, and at 12 months. The choroidal layer was divided into luminal or stromal segments by applying binarization processing to calculate these areas. The relationships between age, spherical equivalent, best-corrected visual acuity (BCVA), baseline value, or changes in the luminal or the stromal areas, and the BCVA change at 12 months were analysed using multiple regression analyses and model selection procedures. Results Both stromal and luminal areas were decreased at 3 and 12 months compared to baseline areas (5% and 9% at 3 months, 6% and 12% at 12 months, p < 0.0001, p < 0.0001, p < 0.0001 and p < 0.0001, respectively). Greater improvement of visual acuity (VA) at 12 months was significantly associated with younger age, greater spherical equivalent, worse baseline BCVA, greater baseline luminal area, and smaller baseline stromal area. Conclusions Choroidal structure might be useful as a new biomarker for potential Visual outcomes after intravitreal aflibercept therapy for PCV.	[Asano, Shotaro; Azuma, Keiko; Shimizu, Kimiko; Yamamoto, Risako; Murata, Hiroshi; Inoue, Tatsuya; Asaoka, Ryo; Obata, Ryo] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo, Japan; [Asano, Shotaro; Azuma, Keiko; Shimizu, Kimiko; Yamamoto, Risako; Murata, Hiroshi; Inoue, Tatsuya; Asaoka, Ryo; Obata, Ryo] Univ Tokyo, Fac Med, Tokyo, Japan; [Lee, Jinhee] Miyata Eye Hosp, Miyazaki, Japan	University of Tokyo; University of Tokyo	Obata, R (corresponding author), Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo, Japan.; Obata, R (corresponding author), Univ Tokyo, Fac Med, Tokyo, Japan.	robata-tky@umin.ac.jp			JSPS KAKENHI [JP16K11260]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was done under JSPS KAKENHI Grant Number JP16K11260. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090; Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3; Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005; Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045; Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002; Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987; Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217; Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012; Cicchetti D.V., 1994, PSYCHOL ASSESSMENT, V6, P284, DOI 10.1037/1040-3590.6.4.284; Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694; Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622; Goodenough AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034338; Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019; Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327; Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619; Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1; Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039; Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025; Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058; Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032; Mallows CL, 2000, TECHNOMETRICS, V42, P87, DOI 10.2307/1271437; Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047; Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002; Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018; Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732; Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3; Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427; Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051; Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653; Sonoda S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157190; Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005; Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447; Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43; Tibshirani RJ, 2012, ANN STAT, V40, P1198, DOI 10.1214/12-AOS1003; Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4; Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024; TORNQUIST P, 1979, ACTA PHYSIOL SCAND, V106, P351, DOI 10.1111/j.1748-1716.1979.tb06409.x; Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1; Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538; Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758; Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042; Zhang Z., 2016, ANN TRANSLATIONAL ME, V4	44	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0197042	10.1371/journal.pone.0197042	http://dx.doi.org/10.1371/journal.pone.0197042			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF3JM	29746511	Green Submitted, Green Published, gold			2023-01-03	WOS:000431851700059
J	Santer, M; Ridd, MJ; Francis, NA; Stuart, B; Rumsby, K; Chorozoglou, M; Becque, T; Roberts, A; Liddiard, L; Nollett, C; Hooper, J; Prude, M; Wood, W; Thomas, KS; Thomas-Jones, E; Williams, HC; Little, P				Santer, Miriam; Ridd, Matthew J.; Francis, Nick A.; Stuart, Beth; Rumsby, Kate; Chorozoglou, Maria; Becque, Taeko; Roberts, Amanda; Liddiard, Lyn; Nollett, Claire; Hooper, Julie; Prude, Martina; Wood, Wendy; Thomas, Kim S.; Thomas-Jones, Emma; Williams, Hywel C.; Little, Paul			Emollient bath additives for the treatment of childhood - eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ATOPIC-DERMATITIS; IMPORTANT DIFFERENCE; OUTCOME MEASURES; MEASURE POEM; SEVERITY; CHILDREN; RESPONSIVENESS; TOOL	OBJECTIVES To determine the clinical effectiveness and cost effectiveness of including emollient bath additives in the management of eczema in children. DESIGN Pragmatic randomised open label superiority trial with two parallel groups. SETTING 96 general practices in Wales and western and southern England. PARTICIPANTS 483 children aged 1 to 11 years, fulfilling UK diagnostic criteria for atopic dermatitis. Children with very mild eczema and children who bathed less than once weekly were excluded. INTERVENTIONS Participants in the intervention group were prescribed emollient bath additives by their usual clinical team to be used regularly for 12 months. The control group were asked to use no bath additives for 12 months. Both groups continued with standard eczema management, including leave-on emollients, and caregivers were given standardised advice on how to wash participants. MAIN OUTCOME MEASURES The primary outcome was eczema control measured by the patient oriented eczema measure (POEM, scores 0-7 mild, 8-16 moderate, 17-28 severe) weekly for 16 weeks. Secondary outcomes were eczema severity over one year (monthly POEM score from baseline to 52 weeks), number of eczema exacerbations resulting in primary healthcare consultation, disease specific quality of life (dermatitis family impact), generic quality of life (child health utility9D), utilisation of resources, and type and quantity of topical corticosteroid or topical calcineurin inhibitors prescribed. RESULTS 483 children were randomised and one child was withdrawn, leaving 482 children in the trial: 51% were girls (244/482), 84% were of white ethnicity (447/470), and the mean age was 5 years. 96% (461/482) of participants completed at least one post-baseline POEM, so were included in the analysis, and 77% (370/482) completed questionnaires for more than 80% of the time points for the primary outcome (12/16 weekly questionnaires to 16 weeks). The mean baseline POEM score was 9.5 (SD 5.7) in the bath additives group and 10.1 (SD 5.8) in the no bath additives group. The mean POEM score over the 16 week period was 7.5 (SD. 6.0) in the bath additives group and 8.4 (SD 6.0) in the no bath additives group. No statistically significant difference was found in weekly POEM scores between groups over 16 weeks. After controlling for baseline severity and confounders (ethnicity, topical corticosteroid use, soap substitute use) and allowing for clustering of participants within centres and responses within participants over time, POEM scores in the no bath additives group were 0.41 points higher than in the bath additives group (95% confidence interval -0.27 to 1.10), below the published minimal clinically important difference for POEM of 3 points. The groups did not differ in secondary outcomes, economic outcomes, or adverse effects. CONCLUSIONS This trial found no evidence of clinical benefit from including emollient bath additives in the standard management of eczema in children. Further research is needed into optimal regimens for leave-on emollient and soap substitutes.	[Santer, Miriam; Stuart, Beth; Rumsby, Kate; Becque, Taeko; Hooper, Julie; Prude, Martina; Little, Paul] Univ Southampton, Fac Med, Primary Care & Populat Sci, Southampton SO16 5ST, Hants, England; [Ridd, Matthew J.; Liddiard, Lyn] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Francis, Nick A.; Thomas-Jones, Emma] Cardiff Univ, Sch Med, Div Populat Med, Cardiff, S Glam, Wales; [Chorozoglou, Maria] Univ Southampton, Wessex Inst, Southampton Hlth Technol Assessments Ctr, Southampton, Hants, England; [Roberts, Amanda; Thomas, Kim S.; Williams, Hywel C.] Univ Nottingham, Sch Med, Ctr Evidence Based Dermatol, Nottingham, England; [Nollett, Claire] Coll Biomed & Life Sci, Ctr Trials Res, Cardiff, S Glam, Wales; [Wood, Wendy] Univ Southampton, Southampton Gen Hosp, NIHR Res Design Serv South Cent Primary Care & Po, Southampton, Hants, England	University of Southampton; University of Bristol; Cardiff University; University of Southampton; University of Nottingham; University of Southampton	Santer, M (corresponding author), Univ Southampton, Fac Med, Primary Care & Populat Sci, Southampton SO16 5ST, Hants, England.	m.santer@soton.ac.uk	Francis, Nick/B-7413-2009; Ridd, Matthew/E-5656-2016	Francis, Nick/0000-0001-8939-7312; Thomas-Jones, Emma/0000-0001-7716-2786; Wood, Wendy/0000-0001-9062-4455; Chorozoglou, Maria/0000-0001-5070-4653; Ridd, Matthew/0000-0002-7954-8823; Stuart, Beth/0000-0001-5432-7437; Becque, Taeko/0000-0002-0362-3794; williams, hywel/0000-0002-5646-3093; Thomas, Kim/0000-0001-7785-7465; Santer, Miriam/0000-0001-7264-5260; Rumsby, Kate/0000-0002-8573-3718; Little, Paul/0000-0003-3664-1873	National Institute for Health Research (NIHR) Health Technology Assessment Programme [11/153/01]; NIHR Clinical Research Network Service Support Costs; University of Southampton	National Institute for Health Research (NIHR) Health Technology Assessment Programme(National Institute for Health Research (NIHR)); NIHR Clinical Research Network Service Support Costs; University of Southampton	This study was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (11/153/01) with additional support from NIHR Clinical Research Network Service Support Costs. This trial will be published in full in the NIHR journals library. The University of Southampton was the research sponsor for this trial.	[Anonymous], 2007, Drug Ther Bull, V45, P73; [Anonymous], 2007, CLIN GUID 57 AT ECZ; [Anonymous], 2015, BULLETIN, V76; Batchelor JM, 2013, BRIT J DERMATOL, V168, P577, DOI 10.1111/bjd.12040; Chalmers JR, 2016, BRIT J DERMATOL, V175, P69, DOI 10.1111/bjd.14773; Chamlin SL, 2004, PEDIATRICS, V114, P607, DOI 10.1542/peds.2004-0374; Chan J, 2017, SOC AC PRIM CAR ANN; Charman CR, 2013, BRIT J DERMATOL, V169, P1326, DOI 10.1111/bjd.12590; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Fedorowicz Z, 2017, COCHRANE DB SYST REV, V2; Gaunt DM, 2016, ALLERGY, V71, P1620, DOI 10.1111/all.12942; Lawson V, 1998, BRIT J DERMATOL, V138, P107; Ling TC, 2000, J DERMATOL TREAT, V11, P263, DOI 10.1080/09546630050517216; Loudon K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2147; Nankervis H, 2017, BRIT J DERMATOL, V176, P910, DOI 10.1111/bjd.14999; Santer M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009575; Schram ME, 2012, ALLERGY, V67, P99, DOI 10.1111/j.1398-9995.2011.02719.x; Spuls PI, 2017, BRIT J DERMATOL, V176, P979, DOI 10.1111/bjd.15179; Stevens KJ, 2005, BRIT J DERMATOL, V153, P372, DOI 10.1111/j.1365-2133.2005.06736.x; Thomas KS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000395; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	22	26	26	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2018	361								k1332	10.1136/bmj.k1332	http://dx.doi.org/10.1136/bmj.k1332			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF4YI	29724749	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000431970000003
J	Shen, JF; Ju, ZL; Zhao, W; Wang, LL; Peng, Y; Ge, ZQ; Nagel, ZD; Zou, J; Wang, C; Kapoor, P; Ma, XY; Ma, D; Liang, JY; Song, SM; Liu, JS; Samson, LD; Ajani, JA; Li, GM; Liang, H; Shen, XT; Mills, GB; Peng, G				Shen, Jianfeng; Ju, Zhenlin; Zhao, Wei; Wang, Lulu; Peng, Yang; Ge, Zhongqi; Nagel, Zachary D.; Zou, Jun; Wang, Chen; Kapoor, Prabodh; Ma, Xiangyi; Ma, Ding; Liang, Jiyong; Song, Shumei; Liu, Jinsong; Samson, Leona D.; Ajani, Jaffer A.; Li, Guo-Min; Liang, Han; Shen, Xuetong; Mills, Gordon B.; Peng, Guang			ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade	NATURE MEDICINE			English	Article							MISMATCH-REPAIR DEFICIENCY; HUMAN SWI/SNF COMPLEXES; CANCER-TREATMENT; PD-1 BLOCKADE; COLON-CANCER; CELL-LINES; EXPRESSION; IMMUNOTHERAPY; TUMORS; MUTATIONS	ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer(1,2). The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression(3), which makes ARID1A a poor therapeutic target. Therefore, it is of clinical importance to identify molecular consequences of ARID1A deficiency that create therapeutic vulnerabilities in ARID1A-mutant tumors. In a proteomic screen, we found that ARID1A interacts with mismatch repair (MMR) protein MSH2. ARID1A recruited MSH2 to chromatin during DNA replication and promoted MMR. Conversely, ARID1A inactivation compromised MMR and increased mutagenesis. ARID1A deficiency correlated with microsatellite instability genomic signature and a predominant C>T mutation pattern and increased mutation load across multiple human cancer types. Tumors formed by an ARID1A-deficient ovarian cancer cell line in syngeneic mice displayed increased mutation load, elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression. Notably, treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. Together, these results suggest ARID1A deficiency contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with immune checkpoint blockade therapy.	[Shen, Jianfeng; Wang, Lulu; Peng, Yang; Peng, Guang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Ju, Zhenlin; Zhao, Wei; Liang, Jiyong; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Ge, Zhongqi; Liang, Han] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Nagel, Zachary D.; Samson, Leona D.] MIT, Ctr Environm Hlth Sci, Dept Biol Engn, Cambridge, MA 02139 USA; [Zou, Jun; Wang, Chen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China; [Kapoor, Prabodh; Shen, Xuetong] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX USA; [Ma, Xiangyi; Ma, Ding] Canc Biol Res Ctr, Wuhan, Hubei, Peoples R China; [Ma, Xiangyi; Ma, Ding] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Song, Shumei; Ajani, Jaffer A.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Liu, Jinsong] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Li, Guo-Min] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Massachusetts Institute of Technology (MIT); Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center; Huazhong University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Peng, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.	gpeng@mdanderson.org	Classen, Scott/AAY-8176-2020; Shen, Jianfeng/G-6644-2014	Shen, Jianfeng/0000-0001-9779-6225; Ajani, Jaffer A/0000-0001-9946-0629; Mills, Gordon/0000-0002-0144-9614	NCI Cancer Center Support Grant [CA016672]; Department of Defense grant [OC140431]; NIH R01 grant [CA181663, GM093104]; Cancer Prevention and Research Institute of Texas grant [RP160242]; NIH P01 grant [CA092584]; NATIONAL CANCER INSTITUTE [R01CA181663, P30CA016672, P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM093104] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense grant(United States Department of Defense); NIH R01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas grant; NIH P01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by NCI Cancer Center Support Grant CA016672 to The University of Texas MD Anderson Cancer Center, Department of Defense grant OC140431, NIH R01 grant CA181663 to G.P., Cancer Prevention and Research Institute of Texas grant RP160242 to X.S. and G.P., NIH R01 grant GM093104 to X.S, and NIH P01 grant CA092584 to Z.D.N.	Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Chou A, 2014, HUM PATHOL, V45, P1697, DOI 10.1016/j.humpath.2014.04.009; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kane MF, 1997, CANCER RES, V57, P808; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; Kim MS, 2012, APMIS, V120, P1020, DOI 10.1111/j.1600-0463.2012.02930.x; Koster BD, 2015, CURR OPIN ONCOL, V27, P482, DOI 10.1097/CCO.0000000000000221; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Nagel ZD, 2014, P NATL ACAD SCI USA, V111, pE1823, DOI 10.1073/pnas.1401182111; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Romano P, 2009, NUCLEIC ACIDS RES, V37, pD925, DOI 10.1093/nar/gkn730; Tscharke DC, 2015, NAT REV IMMUNOL, V15, P705, DOI 10.1038/nri3905; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang XM, 2004, INT J CANCER, V112, P636, DOI 10.1002/ijc.20450; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Wu RC, 2014, CANCER BIOL THER, V15, P655, DOI 10.4161/cbt.28411; Zhao H, 2014, ELIFE, V3, DOI 10.7554/eLife.02725	35	256	259	1	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2018	24	5					556	+		10.1038/s41591-018-0012-z	http://dx.doi.org/10.1038/s41591-018-0012-z			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GF7CY	29736026	Green Accepted			2023-01-03	WOS:000432126800011
J	Uminski, K; Komenda, P; Whitlock, R; Ferguson, T; Nadurak, S; Hochheim, L; Tangri, N; Rigatto, C				Uminski, Kelsey; Komenda, Paul; Whitlock, Reid; Ferguson, Thomas; Nadurak, Stewart; Hochheim, Laura; Tangri, Navdeep; Rigatto, Claudio			Effect of post-discharge virtual wards on improving outcomes in heart failure and non heart failure populations: A systematic review and meta-analysis	PLOS ONE			English	Review							HOSPITAL READMISSION; EMERGENCY-DEPARTMENT; RANDOMIZED-TRIAL; AFTER-DISCHARGE; HIGH-RISK; MANAGEMENT; HOME; MORTALITY; RATES; CARE	Background Unplanned hospital admissions in high-risk patients are common and costly in an increasingly frail chronic disease population. Virtual Wards (VW) are an emerging concept to improve outcomes in these patients. Purpose To evaluate the effect of post-discharge VWs, as an alternative to usual community based care, on hospital readmissions and mortality among heart failure and non-heart failure populations. Data sources Ovid MEDLINE, EMBASE, PubMed, the Cochrane Database of Systematic Reviews, SCO-PUS and CINAHL, from inception through to Jan 31, 2017; unpublished data, prior systematic reviews; reference lists. Study selection Randomized trials of post-discharge VW versus community based, usual care that reported all-cause hospital readmission and mortality outcomes. Data extraction Data were reviewed for inclusion and independently extracted by two reviewers. Risk of bias was assessed using the Cochrane Collaboration risk of bias tool. Data synthesis In patients with heart failure, a post-discharge VW reduced risk of mortality (six trials, n = 1634; RR 0.59, 95% CI = 0.44-0.78). Heart failure related readmissions were reduced (RR 0.61, 95% CI = 0.49-0.76), although all-cause readmission was not. In contrast, a post-discharge VW did not reduce death or hospital readmissions for patients with undifferentiated high-risk chronic diseases (four trials, n = .3186). Limitations Heterogeneity with respect to intervention and comparator, lacking consistent descriptions and utilization of standardized nomenclature for VW. Some trials had methodologic shortcomings and relatively small study populations. Conclusions A post-discharge VW can provide added benefits to usual community based care to reduce all-cause mortality and heart failure-related hospital admissions among patients with heart failure. Further research is needed to evaluate the utility of VWs in other chronic disease settings.	[Uminski, Kelsey; Komenda, Paul; Tangri, Navdeep; Rigatto, Claudio] Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada; [Komenda, Paul; Whitlock, Reid; Ferguson, Thomas; Nadurak, Stewart; Hochheim, Laura; Tangri, Navdeep; Rigatto, Claudio] Seven Oaks Gen Hosp, Chron Dis Innovat Ctr, Winnipeg, MB, Canada; [Whitlock, Reid; Ferguson, Thomas] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Hochheim, Laura] Univ Manitoba, Dept Lib Serv, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba	Rigatto, C (corresponding author), Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada.; Rigatto, C (corresponding author), Seven Oaks Gen Hosp, Chron Dis Innovat Ctr, Winnipeg, MB, Canada.	crigatto@sbgh.mb.ca						Albrecht JS, 2014, J GEN INTERN MED, V29, P1491, DOI 10.1007/s11606-014-2956-0; Angermann CE, 2012, CIRC-HEART FAIL, V5, P25, DOI 10.1161/CIRCHEARTFAILURE.111.962969; Antonicelli R, 2008, J TELEMED TELECARE, V14, P300, DOI 10.1258/jtt.2008.071213; Canadian Institute for Health Information, 2012, ALL CAUS READM AC CA; Caplan GA, 2004, J AM GERIATR SOC, V52, P1417, DOI 10.1111/j.1532-5415.2004.52401.x; Cohran WG, 1954, BIOMETRICS, p10417 ; Dendale P, 2012, EUR J HEART FAIL, V14, P333, DOI 10.1093/eurjhf/hfr144; Dhalla IA, 2014, JAMA-J AM MED ASSOC, V312, P1305, DOI 10.1001/jama.2014.11492; Dhalla Irfan A, 2012, Healthc Q, V15 Spec No, P63; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Giordano A, 2009, INT J CARDIOL, V131, P192, DOI 10.1016/j.ijcard.2007.10.027; HANSEN FR, 1995, AGING-CLIN EXP RES, V7, P202, DOI 10.1007/BF03324316; Hastings SN, 2010, ACAD EMERG MED, V17, P1086, DOI 10.1111/j.1553-2712.2010.00870.x; Hesselink G, 2012, BMJ QUAL SAF, V21, P39, DOI 10.1136/bmjqs-2012-001165; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Horwitz LI, 2013, JAMA INTERN MED, V173, P1715, DOI 10.1001/jamainternmed.2013.9318; Huntington Mark K, 2013, S D Med, V66, P370; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; Kitsiou S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4174; Kobb R, 2003, TELEMED J E-HEALTH, V9, P189, DOI 10.1089/153056203766437525; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Leung DYP, 2015, CLIN INTERV AGING, V10, P413, DOI 10.2147/CIA.S68937; Leventhal ME, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13171; Lewis G, 2013, INT J INTEGR CARE, V13; Lewis G, 2012, POPUL HEALTH MANAG, V15, P315, DOI 10.1089/pop.2011.0086; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Monette M, 2012, CAN MED ASSOC J, V184, pE651, DOI 10.1503/cmaj.109-4245; Mudge AM, 2011, J HOSP MED, V6, P61, DOI 10.1002/jhm.811; Pare G, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1357; Rytter L, 2010, SCAND J PRIM HEALTH, V28, P146, DOI 10.3109/02813431003764466; Shepperd S, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007491; Takeda A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002752.pub3; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117	38	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196114	10.1371/journal.pone.0196114	http://dx.doi.org/10.1371/journal.pone.0196114			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE3RI	29708997	gold, Green Published, Green Submitted			2023-01-03	WOS:000431130100016
J	Grossman, DC; Curry, SJ; Owens, DK; Barry, M; Caughey, AB; Davidson, KW; Doubeni, CA; Epling, JW; Kemper, AR; Krist, AH; Kubik, M; Landefeld, S; Mangione, CM; Pignone, M; Silverstein, M; Simon, MA; Tseng, CW				Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael; Caughey, Aaron B.; Davidson, Karina W.; Doubeni, Chyke A.; Epling, John W., Jr.; Kemper, Alex R.; Krist, Alex H.; Kubik, Martha; Landefeld, Seth; Mangione, Carol M.; Pignone, Michael; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen		US Preventive Services Task Force	Interventions to Prevent Falls in Community-Dwelling Older Adults US Preventive Services Task Force Recommendation Statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							VITAMIN-D; WOMEN; INJURIES; FRACTURES	IMPORTANCE Falls are the leading cause of injury-related morbidity and mortality among older adults in the United States. In 2014.28.7% of community-dwelling adults 65 years or older reported falling, resulting in 29 million falls (37.5% of which needed medical treatment or restricted activity for a day or longer) and an estimated 33 000 deaths in 2015. OBJECTIVE To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on the prevention of falls in community-dwelling older adults. EVIDENCE REVIEW The USPSTF reviewed the evidence on the effectiveness and harms of primary care-relevant interventions to prevent falls and fall-related morbidity and mortality in community-dwelling older adults 65 years or older who are not known to have osteoporosis or vitamin D deficiency. FINDINGS The USPSTF found adequate evidence that exercise interventions have a moderate benefit in preventing falls in older adults at increased risk for falls and that multifactorial interventions have a small benefit. The USPSTF found adequate evidence that vitamin D supplementation has no benefit in preventing falls in older adults. The USPSTF found adequate evidence to bound the harms of exercise and multifactorial interventions as no greater than small. The USPSTF found adequate evidence that the overall harms of vitamin D supplementation are small to moderate. CONCLUSIONS AND RECOMMENDATION The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls. (B recommendation) The USPSTF recommends that clinicians selectively offer multifactorial interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls. Existing evidence indicates that the overall net benefit of routinely offering multifactorial interventions to prevent falls is small. When determining whether this service is appropriate for an individual, patients and clinicians should consider the balance of benefits and harms based on the circumstances of prior falls, presence of comorbid medical conditions, and the patient's values and preferences. (C recommendation) The USPSTF recommends against vitamin D supplementation to prevent falls in community-dwelling adults 65 years or older. (D recommendation) These recommendations apply to community-dwelling adults who are not known to have osteoporosis or vitamin D deficiency.	[Grossman, David C.] Kaiser Permanente, Washington Hlth Res Inst, Seattle, WA 98109 USA; [Curry, Susan J.] Univ Iowa, Iowa City, IA USA; [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA; [Barry, Michael] Harvard Med Sch, Boston, MA USA; [Caughey, Aaron B.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Davidson, Karina W.] Columbia Univ, New York, NY USA; [Doubeni, Chyke A.] Univ Penn, Philadelphia, PA 19104 USA; [Epling, John W., Jr.] Virginia Tech, Carilion Sch Med, Roanoke, VA USA; [Kemper, Alex R.] Nationwide Childrens Hosp, Columbus, OH USA; [Krist, Alex H.] Fairfax Family Practice Residency, Fairfax, VA USA; [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Kubik, Martha] Temple Univ, Philadelphia, PA 19122 USA; [Landefeld, Seth] Univ Alabama Birmingham, Birmingham, AL USA; [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA; [Pignone, Michael] Univ Texas Austin, Austin, TX 78712 USA; [Silverstein, Michael] Boston Univ, Boston, MA 02215 USA; [Simon, Melissa A.] Northwestern Univ, Evanston, IL USA; [Tseng, Chien-Wen] Univ Hawaii, Honolulu, HI 96822 USA; [Tseng, Chien-Wen] Pacific Hlth Res & Educ Inst, Honolulu, HI USA	Kaiser Permanente; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Harvard University; Harvard Medical School; Oregon Health & Science University; Columbia University; University of Pennsylvania; Virginia Polytechnic Institute & State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; University of Texas System; University of Texas Austin; Boston University; Northwestern University; University of Hawaii System; Pacific Health Research & Education Institute	Grossman, DC (corresponding author), Kaiser Permanente, Washington Hlth Res Inst, Seattle, WA 98109 USA.	chair@uspstf.net	Davidson, Karina/AAG-2388-2019; Davidson, Karina/GWC-0996-2022; Epling, John W/J-1097-2019	Davidson, Karina/0000-0002-9162-477X; Davidson, Karina/0000-0002-9162-477X; Epling, John W/0000-0001-9445-8669; Kemper, Alex/0000-0001-5491-3997	Agency for Healthcare Research and Quality (AHRQ)	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.	ALEXANDER BH, 1992, AM J PUBLIC HEALTH, V82, P1020, DOI 10.2105/AJPH.82.7.1020; American Academy of Family Physicians, 2012, CLIN PREV SERV REC F; Arnold Catherine M, 2007, BMC Geriatr, V7, P17; Barry E, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-14; Bergen G, 2016, MMWR-MORBID MORTAL W, V65, P993, DOI 10.15585/mmwr.mm6537a2; Bischoff-Ferrari HA, 2006, ARCH INTERN MED, V166, P424; Calonge N, 2011, ANN INTERN MED, V154, P356, DOI 10.7326/0003-4819-154-5-201103010-00307; Centers for Disease Control and Prevention, 2016, WEB BAS INJ STAT QUE; El-Khoury F, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3830; Fuller GF, 2000, AM FAM PHYSICIAN, V61, P2159; Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P3618, DOI 10.1210/jc.86.8.3618; Gill TM, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i245; Guirguis-Blake JM, 2018, JAMA-J AM MED ASSOC, V319, P1705, DOI 10.1001/jama.2017.21962; Guirguis-Blake JM, 2018, AHRQ PUBLICATION 17; Institute of Medicine, 2011, DIETARY REFERENCE IN; Kahwati LC, 2018, AHRQ PUBLICATION; Kahwati LC, 2018, JAMA-J AM MED ASSOC, V319, P1600, DOI 10.1001/jama.2017.21640; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Kochanek Kenneth D, 2016, Natl Vital Stat Rep, V65, P1; National Center for Injury Prevention and Control, 2015, PREV FALLS GUID IMPL; National Institute on Aging, 2017, PREV FALLS FRACT; Parkkari J, 1999, CALCIFIED TISSUE INT, V65, P183; Pike JW, 2016, ENDOCRINOLOGY, V157, P48, DOI 10.1210/en.2015-2009; Pojednic RM, 2015, CALCIFIED TISSUE INT, V96, P256, DOI 10.1007/s00223-014-9932-x; Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Thomas JI, 2005, ARCH PHYS MED REHAB, V86, P1636, DOI 10.1016/j.apmr.2005.03.004; US Department of Health and Human Services, 2008, 2008 PHYS ACT GUID A; US Preventive Services Task Force, JAMA-J AM MED ASSOC, DOI [10.1001/jaina.2018.3185, DOI 10.1001/JAINA.2018.3185]; Uusi-Rasi K, 2015, JAMA INTERN MED, V175, P703, DOI 10.1001/jamainternmed.2015.0225; Zijlstra GAR, 2009, J AM GERIATR SOC, V57, P2020, DOI 10.1111/j.1532-5415.2009.02489.x	31	169	177	6	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2018	319	16					1696	1704		10.1001/jama.2018.3097	http://dx.doi.org/10.1001/jama.2018.3097			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD7RF	29710141	Bronze			2023-01-03	WOS:000430709300024
J	Neira, RAQ; Hamacher, S; Japiassu, AM				Quintano Neira, Ricardo Alfredo; Hamacher, Silvio; Japiassu, Andre Miguel			Epidemiology of sepsis in Brazil: Incidence, lethality, costs, and other indicators for Brazilian Unified Health System hospitalizations from 2006 to 2015	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; DEFINITIONS; MULTICENTER; COMMUNITY; OUTCOMES; STATES	Background Sepsis is considered a major worldwide health burden, with high mortality and associated costs. Health indicators are essential to define strategies to improve the treatment of diseases, and the epidemiology information of sepsis in developing countries is scarce. Thus, the aim of this work is to assess trends in the incidence, lethality, costs, and other indicators of sepsis for Brazilian Unified Health System (SUS-Sistema Unico de Saude) hospitalizations for the period from January 2006 to December 2015. Materials and methods We conducted this study using data from the SUS hospital information system. We selected registries of SUS hospitalizations of patients diagnosed with sepsis (total of 724,458 cases from 4,271 public and private Brazilian hospitals). Results From 2006 to 2015, the annual sepsis incidence increased 50.5% from 31.5/100,000 to 47.4/100,000 persons. The mean hospital length of stay (LOS) was 9.0 days. A total of 29.1% of the hospitalizations had admission to the intensive care unit (ICU) with a mean ICU LOS of 8.0 days. The mean cost per hospitalization was US$624.0 and for hospitalizations requiring intensive care was U$1,708.1. The overall sepsis lethality rate was 46.3%, and for hospitalizations with admission to the ICU, it was 64.5%. During the study period, the lethality rate for children/teenagers decreased 40.1%, but for all other age groups it increased 11.4%. The sepsis lethality rate in public hospitals (55.5%) was higher than private hospitals (37.0%) (p < 0.001). The mean hospitalization LOS for public hospitals (10.3 days) was higher than private hospitals (7.6 days) (p < 0.001). Conclusions The incidence and lethality rate of sepsis increased in SUS hospitalizations during the study period. The SUS's low reimbursement to hospitals for treating sepsis may be one of the reasons for the high lethality rate.	[Quintano Neira, Ricardo Alfredo; Hamacher, Silvio] Pontificia Univ Catolica Rio de Janeiro, Dept Ind Engn, Rio De Janeiro, RJ, Brazil; [Quintano Neira, Ricardo Alfredo] Philips Res Brazil, Sao Paulo, Brazil; [Japiassu, Andre Miguel] Fundacao Oswaldo Cruz, Inst Nacl Infectol, Rio De Janeiro, RJ, Brazil	Philips; Philips Research; Fundacao Oswaldo Cruz	Japiassu, AM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol, Rio De Janeiro, RJ, Brazil.	andre.japiassu@ini.fiocruz.br	hamacher, silvio/C-3325-2013	hamacher, silvio/0000-0002-3980-0342	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Philips Research; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [306802/2015-5, 403863/2016-3]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Philips Research; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	RAQN is currently receiving a grant from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, http://www.capes.gov and another grant from Philips Research (https://www.philips.com/a-w/research/home.html). SH is currently receiving two grants (306802/2015-5, 403863/2016-3) from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, http.//cnpq.br/). RAQN is affiliated with Philips Research Brazil to participate in the Clinical Pathways project. His affiliation with Philips Research Brazil does not affect or create any bias in the research study presented in this manuscript. The funders provided support in the form of grants for authors RAQN and SH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Acosta CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067175; Adrie C, 2005, J CRIT CARE, V20, P46, DOI 10.1016/j.jcrc.2004.10.005; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Canadian Institute for Health Information, 2009, FOC NAT LOOK SEPS; Carrillo-Esper R, 2009, CIR CIR, V77, P301; Carrillo-Esper R, 2009, CIR CIR, V77, P279; Chalupka AN, 2012, CRIT CARE CLIN, V28, P57, DOI 10.1016/j.ccc.2011.09.003; Cheng BL, 2007, CRIT CARE MED, V35, P2538, DOI 10.1097/01.CCM.0000284492.30800.00; Gaieski DF, 2013, CRIT CARE MED, V41, P1167, DOI 10.1097/CCM.0b013e31827c09f8; Grozdanovski K, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/182324; Instituto Brasileiro de Geografia e Estat o A stica (IBGE), 2017, PROJ POP SEX ID; Instituto Brasileiro de Geografia e Estat o A stica (IBGE), 2017, IND NAC PERC CONS AM; Instituto Brasileiro de Geografia e Estat o stica (IBGE), 2017, BRAS SINT DISTR POP; Jolley RJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009487; Jolley RJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0847-3; Kempker JA, 2016, CLIN CHEST MED, V37, P165, DOI 10.1016/j.ccm.2016.01.002; Kumar G, 2011, CHEST, V140, P1223, DOI 10.1378/chest.11-0352; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Liao XL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.51; Machado FR, 2017, LANCET INFECT DIS, V17, P1180, DOI 10.1016/S1473-3099(17)30322-5; Ministe A rio da Sau A de. Secretaria Geral, 1985, TERM BAS SAUD; Gobatto ALN, 2017, SHOCK, V47, P6, DOI 10.1097/SHK.0000000000000703; Papali A, 2017, J CRIT CARE, V38, P35, DOI 10.1016/j.jcrc.2016.09.031; Conde KAP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064790; R Core Team, 2021, R LANG ENV STAT COMP; Rodriguez F, 2011, CRIT CARE MED, V39, P1675, DOI 10.1097/CCM.0b013e318218a35e; Salluh JIF, 2017, INTENS CARE MED, V43, P1703, DOI 10.1007/s00134-017-4760-x; Santos AO, 2009, THESIS, V69 f; Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sogayar AMC, 2008, PHARMACOECONOMICS, V26, P425, DOI 10.2165/00019053-200826050-00006; Stoller J, 2016, J CRIT CARE, V31, P58, DOI 10.1016/j.jcrc.2015.09.034; Taniguchi LU, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0608-8; The World Bank, 2017, WORLD DEV IND EXCH R; Tsertsvadze A, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0243-3; United Nations Development Programme, 2017, HUM DEV REP WORK HUM; UOL economia, 2017, COT CAMB DOL COM; Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X; Watts J, 2016, LANCET, V387, P1603, DOI 10.1016/S0140-6736(16)30249-5; World Health Organization, 2017, PREVALENCE OBESITY A	40	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2018	13	4							e0195873	10.1371/journal.pone.0195873	http://dx.doi.org/10.1371/journal.pone.0195873			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC8EX	29652944	gold, Green Submitted, Green Published			2023-01-03	WOS:000430026900042
J	Short, NJ; Rytting, ME; Cortes, JE				Short, Nicholas J.; Rytting, Michael E.; Cortes, Jorge E.			Acute myeloid leukaemia	LANCET			English	Review							MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; RANDOMIZED PHASE-III; MULTIPARAMETER FLOW-CYTOMETRY; RISK MYELODYSPLASTIC SYNDROME; HIGH-DOSE CYTARABINE; NEWLY-DIAGNOSED AML; CLONAL HEMATOPOIESIS; OLDER PATIENTS; ADULT PATIENTS	For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval. In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies. Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease. Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.	[Short, Nicholas J.; Rytting, Michael E.; Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Rytting, Michael E.] Univ Texas MD Anderson Canc Ctr, Dept Pediat Patient Care, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Cortes, JE (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	jcortes@mdanderson.org	Short, Nicholas/I-3319-2019	Short, Nicholas/0000-0002-2983-2738	NATIONAL CANCER INSTITUTE [K12CA088084] Funding Source: NIH RePORTER; NCI NIH HHS [K12 CA088084] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ades L, 2014, LANCET, V383, P2239, DOI 10.1016/S0140-6736(13)61901-7; Amadori S, 2016, J CLIN ONCOL, V34, P972, DOI 10.1200/JCO.2015.64.0060; Amatangelo MD, 2017, BLOOD, V130, P732, DOI 10.1182/blood-2017-04-779447; Araki D, 2016, J CLIN ONCOL, V34, P329, DOI 10.1200/JCO.2015.63.3826; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Balsat M, 2017, J CLIN ONCOL, V35, P185, DOI 10.1200/JCO.2016.67.1875; Bloomfield CD, 1998, CANCER RES, V58, P4173; Breems DA, 2005, J CLIN ONCOL, V23, P1969, DOI 10.1200/JCO.2005.06.027; Bullinger L, 2017, J CLIN ONCOL, V35, P934, DOI 10.1200/JCO.2016.71.2208; Burnett AK, 2007, CANCER, V109, P1114, DOI 10.1002/cncr.22496; Castaigne S, 2012, LANCET, V379, P1508, DOI 10.1016/S0140-6736(12)60485-1; Chao MP, 2017, CELL STEM CELL, V20, P329, DOI 10.1016/j.stem.2016.11.018; Chen XY, 2015, J CLIN ONCOL, V33, P1258, DOI 10.1200/JCO.2014.58.3518; Cornelissen JJ, 2016, BLOOD, V127, P62, DOI 10.1182/blood-2015-07-604546; Cortes J, 2018, LANCET ONCOL, V19, P889, DOI 10.1016/S1470-2045(18)30240-7; Cortes JE, 2015, CANCER-AM CANCER SOC, V121, P234, DOI 10.1002/cncr.28974; Creutzig U, 2016, CANCER-AM CANCER SOC, V122, P3821, DOI 10.1002/cncr.30220; Dhulipala VC, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.2505.2505; DiNardo CD, 2015, AM J HEMATOL, V90, P732, DOI 10.1002/ajh.24072; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dohner K, 2014, HEMATOL-AM SOC HEMAT, P34, DOI 10.1182/asheducation-2014.1.34; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Elsawy M, 2016, BONE MARROW TRANSPL, V51, P1283, DOI 10.1038/bmt.2016.141; ESTEY E, 1995, LEUKEMIA, V9, P972; Estey E, 2015, BLOOD, V125, P2461, DOI 10.1182/blood-2015-01-561373; Falini B, 2010, BLOOD, V115, P3776, DOI 10.1182/blood-2009-08-240457; Freeman SD, 2013, J CLIN ONCOL, V31, P4123, DOI 10.1200/JCO.2013.49.1753; Gaidzik VI, 2016, LEUKEMIA, V30, P2160, DOI 10.1038/leu.2016.126; Gamis AS, 2014, J CLIN ONCOL, V32, P3021, DOI 10.1200/JCO.2014.55.3628; Ganzel C, 2016, J CLIN ONCOL, V34, P3544, DOI 10.1200/JCO.2016.67.5892; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Gibson CJ, 2017, J CLIN ONCOL, V35, P1598, DOI 10.1200/JCO.2016.71.6712; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grimwade D, 2014, BLOOD, V124, P3345, DOI [10.1182/blood-2014-05-577593, 10.1182/asheducation-2014.1.222]; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Grosso DA, 2015, CANCER-AM CANCER SOC, V121, P2689, DOI 10.1002/cncr.29378; Gupta V, 2011, BLOOD, V117, P2307, DOI 10.1182/blood-2010-10-265603; Haferlach C, 2009, BLOOD, V114, P3024, DOI 10.1182/blood-2009-01-197871; Hann IM, 1997, BLOOD, V89, P2311, DOI 10.1182/blood.V89.7.2311; Hills RK, 2014, LANCET ONCOL, V15, P986, DOI 10.1016/S1470-2045(14)70281-5; Hokland P, 2015, SEMIN HEMATOL, V52, P184, DOI 10.1053/j.seminhematol.2015.04.001; Hourigan CS, 2017, LEUKEMIA, V31, P1482, DOI 10.1038/leu.2017.113; Inaba H, 2012, J CLIN ONCOL, V30, P3625, DOI 10.1200/JCO.2011.41.5323; Itzykson R, 2014, LEUKEMIA, V28, P497, DOI 10.1038/leu.2013.343; Ivey A, 2016, NEW ENGL J MED, V374, P422, DOI [10.1056/NEJMoa1507471, 10.1056/NEJMc1603847]; Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jongen-Lavrencic M, 2018, NEW ENGL J MED, V378, P1189, DOI 10.1056/NEJMoa1716863; Kadia TM, 2016, CANCER-AM CANCER SOC, V122, P3484, DOI 10.1002/cncr.30203; Kadia TM, 2015, JAMA ONCOL, V1, P820, DOI 10.1001/jamaoncol.2015.0617; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1090, DOI 10.1002/cncr.21723; Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429; Kihara R, 2014, LEUKEMIA, V28, P1586, DOI 10.1038/leu.2014.55; Klco JM, 2015, JAMA-J AM MED ASSOC, V314, P811, DOI 10.1001/jama.2015.9643; Klepin HD, 2014, J CLIN ONCOL, V32, P2541, DOI 10.1200/JCO.2014.55.1564; Kolb EA, 2015, HEMATOL-AM SOC HEMAT, P507, DOI 10.1182/asheducation-2015.1.507; Koreth J, 2009, JAMA-J AM MED ASSOC, V301, P2349, DOI 10.1001/jama.2009.813; Kronke J, 2013, BLOOD, V122, P100, DOI 10.1182/blood-2013-01-479188; Kurosawa S, 2010, HAEMATOL-HEMATOL J, V95, P1857, DOI 10.3324/haematol.2010.027516; Lam SSY, 2017, BLOOD REV, V31, P418, DOI 10.1016/j.blre.2017.08.001; Lamba JK, 2017, J CLIN ONCOL, V35, P2674, DOI 10.1200/JCO.2016.71.2513; Lancet JE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.7000; Lancet JE, 2014, BLOOD, V123, P3239, DOI 10.1182/blood-2013-12-540971; Lane SW, 2010, SEMIN CANCER BIOL, V20, P71, DOI 10.1016/j.semcancer.2009.12.001; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Leonard JP, 2017, J CLIN ONCOL, V35, P2708, DOI 10.1200/JCO.2017.72.6745; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lichtman MA, 2017, J CLIN ONCOL, V35, P1376, DOI [10.1200/JCO.2017.74.4102, 10.1200/JCO.2016.70.4056]; Lindsley RC, 2015, BLOOD, V125, P1367, DOI 10.1182/blood-2014-11-610543; Loken MR, 2012, BLOOD, V120, P1581, DOI 10.1182/blood-2012-02-408336; Lowenberg B, 2013, BLOOD, V121, P26, DOI 10.1182/blood-2012-07-444851; Luskin MR, 2017, J ONCOL PRACT, V13, P471, DOI 10.1200/JOP.2017.021675; Martelli MP, 2013, BLOOD REV, V27, P13, DOI 10.1016/j.blre.2012.11.001; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; McNerney ME, 2017, NAT REV CANCER, V17, P513, DOI 10.1038/nrc.2017.60; Meshinchi S, 2007, ONCOLOGIST, V12, P341, DOI 10.1634/theoncologist.12-3-341; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Ok CY, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0139-z; Ossenkoppele G, 2015, BLOOD, V125, P767, DOI 10.1182/blood-2014-08-551499; Ostgard LSG, 2015, J CLIN ONCOL, V33, P3641, DOI 10.1200/JCO.2014.60.0890; Othus M, 2014, LEUKEMIA, V28, P289, DOI 10.1038/leu.2013.176; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Parkin B, 2017, J CLIN INVEST, V127, P3490, DOI 10.1172/JCI91964; Paschka P, 2016, OUTCOME PATIENTS REF, pS809; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Pemmaraju N, 2015, AM J HEMATOL, V90, P27, DOI 10.1002/ajh.23858; Perl AE, 2017, LANCET ONCOL, V18, P1061, DOI 10.1016/S1470-2045(17)30416-3; Peters JM, 2011, ARCH PATHOL LAB MED, V135, P44, DOI 10.1043/2010-0387-RAR.1; Podoltsev NA, 2017, BLOOD REV, V31, P43, DOI 10.1016/j.blre.2016.09.005; Pollyea DA, 2017, BLOOD, V129, P1627, DOI 10.1182/blood-2016-10-696039; Pratcorona M, 2013, BLOOD, V121, P2734, DOI 10.1182/blood-2012-06-431122; Preudhomme C, 2009, BLOOD, V113, P5583, DOI 10.1182/blood-2008-07-168260; Quintas-Cardama A, 2012, BLOOD, V120, P4840, DOI 10.1182/blood-2012-06-436055; Rashidi A, 2016, BLOOD, V128, P763, DOI 10.1182/blood-2016-03-674127; Ravandi F, 2017, CANCER-AM CANCER SOC, V123, P426, DOI 10.1002/cncr.30361; Ravandi F, 2012, J NATL COMPR CANC NE, V10, P1029, DOI 10.6004/jnccn.2012.0105; Ravandi F, 2010, J CLIN ONCOL, V28, P1856, DOI 10.1200/JCO.2009.25.4888; Roboz GJ, 2014, J CLIN ONCOL, V32, P1919, DOI 10.1200/JCO.2013.52.8562; Schlenk RF, 2014, HAEMATOLOGICA, V99, P1663, DOI 10.3324/haematol.2014.114611; Schlenk RF, 2014, BLOOD, V124, P3441, DOI 10.1182/blood-2014-05-578070; Schlenk RF, 2013, BLOOD, V122, P1576, DOI 10.1182/blood-2013-05-503847; Shafer D, 2016, BLOOD REV, V30, P275, DOI 10.1016/j.blre.2016.02.001; Shlush LI, 2017, NATURE, V547, P104, DOI 10.1038/nature22993; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Short NJ, 2016, CL LYMPH MYELOM LEUK, V16, pS25, DOI 10.1016/j.clml.2016.02.007; Sorror ML, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.216.216; Steensma DP, 2015, BLOOD, V126, P9, DOI 10.1182/blood-2015-03-631747; Steffen B, 2005, CRIT REV ONCOL HEMAT, V56, P195, DOI 10.1016/j.critrevonc.2004.10.012; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Stein EM, 2016, BLOOD, V127, P71, DOI 10.1182/blood-2015-07-604538; Stelljes M, 2014, J CLIN ONCOL, V32, P288, DOI 10.1200/JCO.2013.50.5768; Stone RM, 2017, NEW ENGL J MED, V377, P454, DOI 10.1056/NEJMoa1614359; Stone RM, 2012, LEUKEMIA, V26, P2061, DOI 10.1038/leu.2012.115; Sung L, 2013, BLOOD, V121, P3573, DOI 10.1182/blood-2013-01-476614; Taga T, 2016, PEDIATR INT, V58, P71, DOI 10.1111/ped.12865; Takahashi K, 2017, LANCET ONCOL, V18, P100, DOI 10.1016/S1470-2045(16)30626-X; Taksin AL, 2007, LEUKEMIA, V21, P66, DOI 10.1038/sj.leu.2404434; Taskesen E, 2011, BLOOD, V117, P2469, DOI 10.1182/blood-2010-09-307280; Tawana K, 2017, SEMIN HEMATOL, V54, P87, DOI 10.1053/j.seminhematol.2017.04.001; Tefferi A, 2015, JAMA ONCOL, V1, P97, DOI 10.1001/jamaoncol.2015.89; Terwijn M, 2013, J CLIN ONCOL, V31, P3889, DOI 10.1200/JCO.2012.45.9628; Thomas X, 2017, J CLIN ONCOL, V35, P1223, DOI 10.1200/JCO.2016.70.4551; van der Velden VHJ, 2010, LEUKEMIA, V24, P1599, DOI 10.1038/leu.2010.153; Walter RB, 2011, J CLIN ONCOL, V29, P1190, DOI 10.1200/JCO.2010.31.8121; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Weintraub K, 2016, CANCER DISCOV, V6, P1297; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Wong TN, 2015, NATURE, V518, P552, DOI 10.1038/nature13968; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; YATES J, 1982, BLOOD, V60, P454; YATES JW, 1973, CANCER CHEMOTH REP 1, V57, P485; Zuckerman T, 2012, BLOOD, V120, P1993, DOI 10.1182/blood-2012-04-424440	135	331	344	25	164	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 18	2018	392	10147					593	606		10.1016/S0140-6736(18)31041-9	http://dx.doi.org/10.1016/S0140-6736(18)31041-9			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ8MN	30078459				2023-01-03	WOS:000442009500025
J	Won, JS; Nam, H; Lee, HW; Hwang, JY; Noh, YJ; Nam, DH; Lee, SH; Joo, KM				Won, Jeong-Seob; Nam, Hyun; Lee, Hye Won; Hwang, Ji-Yoon; Noh, Yu-Jeong; Nam, Do-Hyun; Lee, Sun-Ho; Joo, Kyeung Min			In vivo distribution of U87MG cells injected into the lateral ventricle of rats with spinal cord injury	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; CEREBROSPINAL-FLUID; CSF FLOW; TRANSPLANTATION; DELIVERY; THERAPY; REGENERATION; CIRCULATION; MIGRATION; BRAIN	Stem cells could be the next generation therapeutic option for neurodegenerative diseases including spinal cord injury (SCI). However, several critical factors such as delivery method should be determined before their clinical applications. Previously, we have demonstrated that lateral ventricle (LV) injection as preclinical simulation could be used for intrathecal administration in clinical trials using rodent animal models. In this study, we further analyzed in vivo distribution of cells that were injected into LVs of rats with SCI at thoracic level using in vivo imaging techniques. When 5 x 10(6) U87MG cells labelled with fluorescent magnetic nanoparticle (FMNP-labelled U87MG) were administrated into LVs at 7 days after SCI, FMNP-labelled U87MG cells were observed in all regions of the spinal cord at 24 hours after the injection. Compared to water-soluble Cy5.5 fluorescent dye or rats without SCI, in vivo distribution pattern of FMNP-labelled U87MG cells was not different, although migration to the spinal cord was significantly reduced in both Cy5.5 fluorescent dye and FMNP-labelled U87MG cells caused by the injury. The presence of FMNP-labelled U87MG cells in the spinal cord was confirmed by quantitative PCR for human specific sequence and immunohistochemistry staining using antibody against human specific antigen. These data indicate that LV injection could recapitulate intrathecal administration of stem cells for SCI patients. Results of this study might be applied further to the planning of optimal preclinical and clinical trials of stem cell therapeutics for SCI.	[Won, Jeong-Seob; Nam, Do-Hyun; Lee, Sun-Ho; Joo, Kyeung Min] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea; [Won, Jeong-Seob; Nam, Hyun; Lee, Hye Won; Hwang, Ji-Yoon; Noh, Yu-Jeong; Joo, Kyeung Min] Sungkyunkwan Univ, Sch Med, Single Cell Network Res Ctr, Suwon, South Korea; [Won, Jeong-Seob; Nam, Hyun; Hwang, Ji-Yoon; Noh, Yu-Jeong; Nam, Do-Hyun; Lee, Sun-Ho; Joo, Kyeung Min] Samsung Med Ctr, Res Inst Future Med, Stem Cell & Regenerat Med Ctr, Seoul, South Korea; [Nam, Hyun; Nam, Do-Hyun; Lee, Sun-Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea; [Lee, Hye Won; Hwang, Ji-Yoon; Noh, Yu-Jeong; Joo, Kyeung Min] Sungkyunkwan Univ, Sch Med, Dept Anat & Cell Biol, Seoul, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU)	Lee, SH; Joo, KM (corresponding author), Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea.; Joo, KM (corresponding author), Sungkyunkwan Univ, Sch Med, Single Cell Network Res Ctr, Suwon, South Korea.; Lee, SH; Joo, KM (corresponding author), Samsung Med Ctr, Res Inst Future Med, Stem Cell & Regenerat Med Ctr, Seoul, South Korea.; Lee, SH (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea.; Joo, KM (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Anat & Cell Biol, Seoul, South Korea.	sobotta72@gmail.com; kmjoo@skku.edu	Lee, Sun-ho/AAD-6712-2022; joo, kyeung min/A-1270-2018	joo, kyeung min/0000-0003-2750-405X; Lee, Hye Won/0000-0002-0303-4658	Ministry of Food and Drug Safety [18172MFDS182]; National Research Foundation [NRF-2016R1A5A2945889, NRF-2016R1D1A1B03933833, NRF-2016R1A6A3A11930396]; National Research Foundation (Ministry of Food and Drug Safety)	Ministry of Food and Drug Safety(Ministry of Food & Drug Safety (MFDS), Republic of Korea); National Research Foundation; National Research Foundation (Ministry of Food and Drug Safety)	This research was supported by grants from Ministry of Food and Drug Safety in 2018 (18172MFDS182) to KMJ and National Research Foundation (NRF-2016R1A5A2945889 to KMJ, NRF-2016R1D1A1B03933833 to S-HL, and NRF-2016R1A6A3A11930396 to HN) (Ministry of Food and Drug Safety: http://www.mfds.go.kr/index.do; National Research Foundation: http://www.nrf.re.kr/index).; This research was supported by grants from Ministry of Food and Drug Safety in 2018 (18172MFDS182) and National Research Foundation (NRF-2016R1A5A2945889, NRF-2016R1D1A1B03933833, and NRF-2016R1A6A3A11930396).	Arezi B, 2003, ANAL BIOCHEM, V321, P226, DOI 10.1016/S0003-2697(03)00465-2; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P330, DOI 10.3171/spi.2004.1.3.0330; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BERING EA, 1962, J NEUROSURG, V19, P405, DOI 10.3171/jns.1962.19.5.0405; Bulte JWM, 2009, AM J ROENTGENOL, V193, P314, DOI 10.2214/AJR.09.3107; Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gao GH, 2012, BIOMATERIALS, V33, P9157, DOI 10.1016/j.biomaterials.2012.09.016; GRUNDY HF, 1962, J PHYSIOL-LONDON, V163, P457, DOI 10.1113/jphysiol.1962.sp006989; Han SM, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-145; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hastings CL, 2015, ADV DRUG DELIVER REV, V84, P85, DOI 10.1016/j.addr.2014.08.006; Holmes D, 2017, NATURE, V552, pS49, DOI 10.1038/d41586-017-07550-9; Kim HS, 2017, BIOCHEM BIOPH RES CO, V493, P751, DOI 10.1016/j.bbrc.2017.08.115; Kwon YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085736; Lee KH, 2018, J KOREAN NEUROSURG S, V61, P434, DOI 10.3340/jkns.2017.0252; Lee NK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155912; MILHORAT TH, 1971, SCIENCE, V173, P330, DOI 10.1126/science.173.3994.330; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Oraee-Yazdani S, 2016, SPINAL CORD, V54, P102, DOI 10.1038/sc.2015.142; Park SE, 2016, NEUROBIOL AGING, V47, P192, DOI 10.1016/j.neurobiolaging.2016.08.002; Patki G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117498; Paul C, 2009, SPINE, V34, P328, DOI 10.1097/BRS.0b013e31819403ce; Perel P, 2007, BMJ-BRIT MED J, V334, P197, DOI 10.1136/bmj.39048.407928.BE; Piltti KM, 2017, STEM CELL REP, V8, P1534, DOI 10.1016/j.stemcr.2017.04.009; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Rosenzweig ES, 2018, NAT MED, V24, P484, DOI 10.1038/nm.4502; Saito F, 2008, J TRAUMA, V64, P53, DOI 10.1097/TA.0b013e31815b847d; Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a; SHERMAN JL, 1986, AM J NEURORADIOL, V7, P3; Simon MJ, 2016, BBA-MOL BASIS DIS, V1862, P442, DOI 10.1016/j.bbadis.2015.10.014; Szabo S, 2012, INT J LEGAL MED, V126, P63, DOI 10.1007/s00414-011-0566-5; Tsuji O, 2010, P NATL ACAD SCI USA, V107, P12704, DOI 10.1073/pnas.0910106107; Visted T, 2003, FRONT BIOSCI-LANDMRK, V8, pE289, DOI 10.2741/1026; Yang HY, 2017, ACS APPL MATER INTER, V9, P19184, DOI 10.1021/acsami.7b03747; Zhao H, 2016, MOL NEUROBIOL, V53, P187, DOI 10.1007/s12035-014-9000-6	37	5	5	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0202307	10.1371/journal.pone.0202307	http://dx.doi.org/10.1371/journal.pone.0202307			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ6RF	30114270	gold, Green Published, Green Submitted			2023-01-03	WOS:000441850400056
J	Furlong, L; Morris, M; Serry, T; Erickson, S				Furlong, Lisa; Morris, Meg; Serry, Tanya; Erickson, Shane			Mobile apps for treatment of speech disorders in children: An evidence-based analysis of quality and efficacy	PLOS ONE			English	Article							INTERVENTION; FEASIBILITY	Background Recently there has been exponential growth in mobile health (mHealth) applications (apps) for children with speech disorders. A challenge for health professionals and families is knowing how to find high quality apps that are therapeutically beneficial. We systematically search and critique the quality of mobile apps for childhood speech disorders. An evidence based method for identifying suitable apps in the Google Play and Apple iTunes stores is also proposed. Methods and findings A systematic search of the Google Play and Apple iTunes app stores was conducted from November 2016 to May 2017. Twelve pre-defined search terms were applied, identifying 5076 apps. Systematic screening resulted in 132 unique apps for full appraisal. These were appraised by two raters using the Mobile Application Rating scale. None were of excellent quality. Twenty-five were of good quality, 105 average and 2 were poor or very poor. Discussion It can be challenging for consumers to locate high quality speech therapy apps for children. Although we found more than 5000 apps, less than 3% met criteria for evaluation. Difficulties sourcing valid apps included: (i) Boolean operators were not available and therefore only one search term could be used each time (ii) the order of app listings in online stores continually changed (iii) apps were organised in online stores according to relevance and popularity (iv) there was no easy way to extract app titles and eliminate duplicates (v) app cost did not always correlate with therapeutic quality. Conclusions The rapid growth of mHealth heightens the need to develop rigorous and efficientaccessing speech therapy services worldwide, mHealth promises therapy benefits when apps are reliable, valid and easily found.	[Furlong, Lisa; Serry, Tanya; Erickson, Shane] La Trobe Univ, Sch Allied Hlth, Coll Sci Hlth & Engn, Discipline Speech Pathol, Melbourne, Vic, Australia; [Morris, Meg] Healthscope Northpk Private Hosp, Bundoora, Vic, Australia; [Morris, Meg] La Trobe Univ, Sch Allied Hlth, Ctr Sport & Exercise Med Res, Melbourne, Vic, Australia	La Trobe University; La Trobe University	Furlong, L (corresponding author), La Trobe Univ, Sch Allied Hlth, Coll Sci Hlth & Engn, Discipline Speech Pathol, Melbourne, Vic, Australia.	l.furlong@latrobe.edu.au	Serry, Tanya/Y-7132-2019	Serry, Tanya/0000-0003-1538-7327; Furlong, Lisa/0000-0003-2596-8395; Morris, Meg/0000-0002-0114-4175	Australian Research Training Program Scholarship	Australian Research Training Program Scholarship	This work was supported by an Australian Research Training Program Scholarship. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman DG, 1991, PRACTICAL STAT MED R; Anderson K, 2016, MOBILE HLTH APPS FAC, V11; de la Vega R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101312; Edgar DL, 2007, LANG SPEECH HEAR SER, V38, P31, DOI 10.1044/0161-1461(2007/004); Furlong LM, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.6505; Grundy QH, 2016, AM J PREV MED, V51, P1051, DOI 10.1016/j.amepre.2016.07.009; Health Workforce Australia, 2014, AUSTR HLTH WORKF SER; Law J, 2000, INT J LANG COMM DIS, V35, P165, DOI 10.1080/136828200247133; Lewis BA, 2000, J LEARN DISABIL-US, V33, P433, DOI 10.1177/002221940003300504; McCormack J., 2010, ACQUIRING KNOWLEDGE, V12, P10; McLeod S, 2009, J SPEECH LANG HEAR R, V52, P1213, DOI 10.1044/1092-4388(2009/08-0085); Microsoft Corporation, 2013, MICR EXC; Microsoft Corporation, 2013, MICR OFF WORD; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nordness AS, 2010, J MED SPEECH-LANG PA, V18, P104; Royal College of Speech and Language Therapists, 2016, APPS ADV DIS; Saz O, 2009, SPEECH COMMUN, V51, P948, DOI 10.1016/j.specom.2009.04.006; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Stoyanov SR, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.3422; Wenze SJ, 2014, BEHAV MODIF, V38, P497, DOI 10.1177/0145445513518421	21	29	29	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0201513	10.1371/journal.pone.0201513	http://dx.doi.org/10.1371/journal.pone.0201513			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP9JF	30092095	Green Published, gold, Green Submitted			2023-01-03	WOS:000441232600032
J	Kamuf, J; Garcia-Bardon, A; Ziebart, A; Thomas, R; Folkert, K; Frauenknecht, K; Thal, SC; Hartmann, EK				Kamuf, Jens; Garcia-Bardon, Andreas; Ziebart, Alexander; Thomas, Rainer; Folkert, Konstantin; Frauenknecht, Katrin; Thal, Serge C.; Hartmann, Erik K.			Lung injury does not aggravate mechanical ventilation-induced early cerebral inflammation or apoptosis in an animal model	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; SYSTEMIC INFLAMMATION; COGNITIVE IMPAIRMENT; PORCINE MODELS; BRAIN-INJURY; OLEIC-ACID; OUTCOMES; SEPSIS; LIFE	Introduction The acute respiratory distress syndrome is not only associated with a high mortality, but also goes along with cognitive impairment in survivors. The cause for this cognitive impairment is still not clear. One possible mechanism could be cerebral inflammation as result of a "lung-brain-crosstalk". Even mechanical ventilation itself can induce cerebral inflammation. We hypothesized, that an acute lung injury aggravates the cerebral inflammation induced by mechanical ventilation itself and leads to neuronal damage. Methods After approval of the institutional and state animal care committee 20 pigs were randomized to one of three groups: lung injury by central venous injection of oleic acid (n = 8), lung injury by bronchoalveolar lavage in combination with one hour of injurious ventilation (n = 8) or control (n = 6). Brain tissue of four native animals from a different study served as native group. For six hours all animals were ventilated with a tidal volume of 7 ml kg-land a scheme for positive end-expiratory pressure and inspired oxygen fraction, which was adapted from the ARDS network tables. Afterwards the animals were killed and the brains were harvested for histological (number of neurons and microglia) and molecular biologic (TNFalpha, IL-1beta, and IL-6) examinations. Results There was no difference in the number of neurons or microglia cells between the groups. TNFalpha was significantly higher in all groups compared to native (p < 0.05), IL-6 was only increased in the lavage group compared to native (p < 0.05), IL-1beta showed no difference between the groups. Discussion With our data we can confirm earlier results, that mechanical ventilation itself seems to trigger cerebral inflammation. This is not aggravated by acute lung injury, at least not within the first 6 hours after onset. Nevertheless, it seems too early to dismiss the idea of lung-injury induced cerebral inflammation, as 6 hours might be just not enough time to see any profound effect.	[Kamuf, Jens; Garcia-Bardon, Andreas; Ziebart, Alexander; Thomas, Rainer; Folkert, Konstantin; Thal, Serge C.; Hartmann, Erik K.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany; [Frauenknecht, Katrin] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neuropathol, Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Kamuf, J (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany.	kamuf@uni-mainz.de	Frauenknecht, Katrin/AAF-1638-2020; Thal, Serge/D-6593-2011	Frauenknecht, Katrin/0000-0002-1372-3297; Thal, Serge/0000-0002-1222-8729				Ballard-Croft C, 2012, ANN THORAC SURG, V93, P1331, DOI 10.1016/j.athoracsur.2011.06.107; BANKS WA, 1994, NEUROSCI LETT, V179, P53, DOI 10.1016/0304-3940(94)90933-4; Bickenbach J, 2011, RESP PHYSIOL NEUROBI, V179, P174, DOI 10.1016/j.resp.2011.08.003; Chen T, 2016, BRAIN BEHAV IMMUN, V56, P42, DOI 10.1016/j.bbi.2016.04.004; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Goncalves-de-Albuquerque CF, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/260465; Goncalves-de-Albuquerque CF, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/956509; Gonzalez-Lopez A, 2013, AM J RESP CRIT CARE, V188, P693, DOI 10.1164/rccm.201304-0691OC; Grotjohan HP, 1996, INTENS CARE MED, V22, P336, DOI 10.1007/BF01700456; Hartmann EK, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0002-6; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Heuer JF, 2012, CRIT CARE, V16, DOI 10.1186/cc11214; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Kamuf J, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0585-y; Kandikattu HK, 2017, PHYSIOL BEHAV, V175, P56, DOI 10.1016/j.physbeh.2017.03.035; Karmrodt J, 2006, BRIT J ANAESTH, V97, P883, DOI 10.1093/bja/ael275; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Klein KU, 2016, CRIT CARE MED, V44, pE253, DOI 10.1097/CCM.0000000000001399; Laffey JG, 2017, AM J RESP CRIT CARE, V196, P18, DOI 10.1164/rccm.201612-2415CI; Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4; Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008; Meier T, 2008, ANESTH ANALG, V107, P1265, DOI 10.1213/ane.0b013e3181806212; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Popa-Wagner A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/963520; Sensen B, 2017, MED KLIN-INTENSIVMED, V112, P605, DOI 10.1007/s00063-017-0350-5; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Songarj P, 2015, NEUROSCI LETT, V584, P253, DOI 10.1016/j.neulet.2014.10.037; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Wang HM, 2010, EUR SURG RES, V45, P121, DOI 10.1159/000318599; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Ziebart A, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0101-6	34	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0202131	10.1371/journal.pone.0202131	http://dx.doi.org/10.1371/journal.pone.0202131			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP9JF	30092082	Green Published, Green Submitted, gold			2023-01-03	WOS:000441232600092
J	Long, TM; Rath, SR; Wallman, KE; Howie, EK; Straker, LM; Bullock, A; Walwyn, TS; Gottardo, NG; Cole, CH; Choong, CS; Naylor, LH				Long, Treya M.; Rath, Shoshana R.; Wallman, Karen E.; Howie, Erin K.; Straker, Leon M.; Bullock, Andrew; Walwyn, Thomas S.; Gottardo, Nicholas G.; Cole, Catherine H.; Choong, Catherine S.; Naylor, Louise H.			Exercise training improves vascular function and secondary health measures in survivors of pediatric oncology related cerebral insult	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD-CANCER; ADULT SURVIVORS; PHYSICAL-ACTIVITY; GROWTH-HORMONE; ENDOTHELIAL FUNCTION; 5-YEAR SURVIVORS; LATE MORTALITY; FINAL HEIGHT; BRAIN-TUMOR	Adolescent and young adult (AYA) survivors of pediatric oncology related cerebral insult are vulnerable to numerous treatment-induced deficits that significantly enhance cardiovascular disease risk. Regular exercise improves endothelial function, fitness, body composition and musculoskeletal function which may reduce predisposition for cardiovascular disease. Here we assessed the feasibility and effectiveness of a 24-week exercise intervention on cardiovascular, physical and metabolic outcomes in this population. Thirteen survivors (6 male, 7 female; median age 19 y (range 16-23 y) were recruited to participate in a 48-week study consisting of a 24-week control period (regular care) followed by a 24-week exercise intervention. Outcome measures were collected at entry (week 0) and following regular care (24 week) and exercise (48-week). Assessed variables included endothelial function (flow mediated dilation, FMD), blood pressure, heart rate (HR), aerobic capacity, anthropometry, body composition, muscular strength (3 repetition maximum testing), muscular endurance (repetitions/min) and physical activity levels (accelerometry). Compared to baseline, delta diameter (p = 0.008) and FMD (p = 0.029) of the brachial artery increased following exercise. Bicep-curl strength also increased following exercise compared to baseline (p = 0.019), while submaximal (6 min mark) measures of ventilation (p = 0.012), rating of perceived exertion (p = 0.012), HR (p = 0.001), absolute (p = 0.000) and relative (p = 0.000) aerobic capacity decreased. Breaks in sedentary time increased (p = 0.043) following exercise compared to regular care. Although the sample was small and heterogeneous, this study demonstrates that exercise is achievable and has positive effects on vascular function, submaximal fitness, local strength and physical activity in a population of AYA survivors of pediatric oncology related cerebral insult.	[Long, Treya M.; Wallman, Karen E.; Naylor, Louise H.] Univ Western Australia, Sch Human Sci Exercise & Sport Sci, Perth, WA, Australia; [Rath, Shoshana R.; Choong, Catherine S.] Perth Childrens Hosp, Dept Endocrinol, Perth, WA, Australia; [Rath, Shoshana R.; Walwyn, Thomas S.; Gottardo, Nicholas G.; Cole, Catherine H.; Choong, Catherine S.] Univ Western Australia, Sch Med, Pediat, Perth, WA, Australia; [Howie, Erin K.; Straker, Leon M.] Curtin Univ, Sch Physiotherapy & Exercise Sci, Perth, WA, Australia; [Bullock, Andrew] Perth Childrens Hosp, Dept Cardiol, Perth, WA, Australia; [Walwyn, Thomas S.; Gottardo, Nicholas G.; Cole, Catherine H.] Perth Childrens Hosp, Dept Hematol & Oncol, Perth, WA, Australia; [Gottardo, Nicholas G.; Cole, Catherine H.] Telethon Kids Inst, Perth, WA, Australia; [Cole, Catherine H.] PathWest Lab Serv, Hematol, Perth, WA, Australia	University of Western Australia; University of Western Australia; Curtin University; Telethon Kids Institute	Naylor, LH (corresponding author), Univ Western Australia, Sch Human Sci Exercise & Sport Sci, Perth, WA, Australia.	louise.naylor@uwa.edu.au	Choong, Catherine/J-4646-2014; choong, catherine S/D-4051-2012; Naylor, Louise H/B-8186-2013; Straker, Leon M/B-2407-2013	Choong, Catherine/0000-0002-3982-271X; choong, catherine S/0000-0002-3982-271X; Naylor, Louise H/0000-0002-6210-912X; Straker, Leon M/0000-0002-7786-4128; Gottardo, Nicholas/0000-0002-1082-6776	Princess Margaret Hospital Foundation "Early Career Investigator Grant" [9324]; Telethon New Children's Hospital Research Fund [4749600]; Perron Family Foundation; NHMRC Early Career Fellowship [1072593]; Cancer Council of Western Australia Research Fellowship	Princess Margaret Hospital Foundation "Early Career Investigator Grant"; Telethon New Children's Hospital Research Fund; Perron Family Foundation; NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Western Australia Research Fellowship(Cancer Council Western Australia)	This work was supported by a Princess Margaret Hospital Foundation "Early Career Investigator Grant" No. 9324 awarded to SRR, the Telethon New Children's Hospital Research Fund (No. 4749600, to CSC, CHC & NGG) and the Perron Family Foundation which supports the Chair of Pediatric Hematology/Oncology (CHC). AB is supported by an NHMRC Early Career Fellowship (No. 1072593). NGG is supported by a Cancer Council of Western Australia Research Fellowship. None of these funding sources contributed to or influenced the design of the study, collection, analysis or interpretation of data, writing of the paper, decision to publish or preparation of the manuscript.	American College of Sports M, 2014, ACSMS GUIDELINES EXE; [Anonymous], 2017, GLOB DAT BOD MASS IN; Armstrong GT, 2014, J CLIN ONCOL, V32, P1218, DOI 10.1200/JCO.2013.51.1055; Australian Government, 2014, AUSTR PHYS ACT SED B; Australian Institute of Health and Welfare, 2014, CANC AUSTR OV 2014; Baechle TR, 2008, ESSENTIALS STRENGTH, P395; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brownstein CM, 2004, J CLIN ENDOCR METAB, V89, P4422, DOI 10.1210/jc.2004-0160; Cameron AC, 2016, CAN J CARDIOL, V32, P852, DOI 10.1016/j.cjca.2015.12.023; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colley Rachel C, 2011, Health Rep, V22, P15; Colley Rachel C, 2011, Health Rep, V22, P7; Fiuza-Luces C, 2017, MED SCI SPORT EXER, V49, P223, DOI 10.1249/MSS.0000000000001094; Florin TA, 2007, CANCER EPIDEM BIOMAR, V16, P1356, DOI 10.1158/1055-9965.EPI-07-0048; Freedson P.S., 1997, MED SCI SPORT EXER S, V29, P45, DOI DOI 10.1097/00005768-199705001-00256; Galvao DA, 2005, J CLIN ONCOL, V23, P899, DOI 10.1200/JCO.2005.06.085; Gleeson H, 2007, CLIN ENDOCRINOL, V66, P466, DOI 10.1111/j.1365-2265.2007.02753.x; Green DJ, 2011, HYPERTENSION, V57, P363, DOI 10.1161/HYPERTENSIONAHA.110.167015; Greving Dawn M, 2005, J Pediatr Oncol Nurs, V22, P38, DOI 10.1177/1043454204272531; Gurney JG, 2003, J CLIN ENDOCR METAB, V88, P4731, DOI 10.1210/jc.2003-030784; Hamilton MT, 2008, CURR CARDIOVASC RISK, V2, P292, DOI 10.1007/s12170-008-0054-8; Healy GN, 2008, DIABETES CARE, V31, P661, DOI 10.2337/dc07-2046; Hojan K, 2014, REP PRACT ONCOL RADI, V19, P1, DOI 10.1016/j.rpor.2013.07.007; Hsu HY, 1998, RADIAT RES, V149, P482, DOI 10.2307/3579788; Huang TT, 2011, INT J PEDIAT, V2011, DOI 10.1155/2011/461512; Inaba Y, 2010, INT J CARDIOVAS IMAG, V26, P631, DOI 10.1007/s10554-010-9616-1; Jarvela LS, 2013, PEDIATR BLOOD CANCER, V60, P1546, DOI 10.1002/pbc.24565; JETTE M, 1990, CLIN CARDIOL, V13, P555, DOI 10.1002/clc.4960130809; Keats MR, 2008, J PEDIAT HEMATOL ONC, V30, P272, DOI 10.1097/MPH.0b013e318162c476; Liesse K, 2018, J PEDIAT HEMATOL ONC; Long TM, 2017, INT J ADOLESC MED HL; Mertens AC, 2001, J CLIN ONCOL, V19, P3163, DOI 10.1200/JCO.2001.19.13.3163; Mertens AC, 2008, JNCI-J NATL CANCER I, V100, P1368, DOI 10.1093/jnci/djn310; Mueller S, 2013, INT J RADIAT ONCOL, V86, P649, DOI 10.1016/j.ijrobp.2013.03.034; National Cancer Intelligence Network, 2012, NAT REG CHILDH TUM; Naylor LH, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12713; Ness KK, 2007, PEDIATR BLOOD CANCER, V49, P975, DOI 10.1002/pbc.21091; Ness KK, 2015, CANCER-AM CANCER SOC, V121, P1540, DOI 10.1002/cncr.29211; Noonan V, 2000, PHYS THER, V80, P782, DOI 10.1093/ptj/80.8.782; Noorda EM, 2001, EUR J CANCER, V37, P605, DOI 10.1016/S0959-8049(00)00438-X; Norton K, 2010, J SCI MED SPORT, V13, P496, DOI 10.1016/j.jsams.2009.09.008; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Packer RJ, 2003, J CLIN ONCOL, V21, P3255, DOI 10.1200/JCO.2003.01.202; Pereira AM, 2005, CLIN ENDOCRINOL, V62, P197, DOI 10.1111/j.1365-2265.2004.02196.x; Piscione PJ, 2017, EUR J CANCER, V80, P63, DOI 10.1016/j.ejca.2017.04.020; Poreba M, 2016, CARDIOVASC TOXICOL, V16, P156, DOI 10.1007/s12012-015-9324-0; San Juan AF, 2008, INT J SPORTS MED, V29, P439, DOI 10.1055/s-2007-965571; San Juan AF, 2007, MED SCI SPORT EXER, V39, P13, DOI 10.1249/01.mss.0000240326.54147.fc; Sklar C, 2011, J CLIN ONCOL, V29, P4743, DOI 10.1200/JCO.2011.38.9833; Soussain C, 2009, LANCET, V374, P1639, DOI 10.1016/S0140-6736(09)61299-X; Straker LM, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-54; Takase B, 1998, AM J CARDIOL, V82, P1535, DOI 10.1016/S0002-9149(98)00702-4; Thijssen DHJ, 2011, AM J PHYSIOL-HEART C, V300, pH2, DOI 10.1152/ajpheart.00471.2010; Wolin KY, 2010, LEUKEMIA, V24, P1113, DOI 10.1038/leu.2010.54	55	17	19	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0201449	10.1371/journal.pone.0201449	http://dx.doi.org/10.1371/journal.pone.0201449			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP9JF	30092052	Green Published, gold, Green Submitted			2023-01-03	WOS:000441232600028
J	Okamura, T; Shimmei, M; Takase, A; Toishiba, S; Hayashida, K; Yumiyama, T; Ogawa, Y				Okamura, Tsuyoshi; Shimmei, Masaya; Takase, Akinori; Toishiba, Shiho; Hayashida, Kojun; Yumiyama, Tatsuya; Ogawa, Yukan			A positive attitude towards provision of end of-life care may protect against burnout: Burnout and religion in a super-aging society	PLOS ONE			English	Article								Aim The aim of our study was to investigate factors associated with burnout of nurses and care workers in nursing homes and geriatric hospitals in Japan. The use of Buddhist priests, the major religion in Japan, was also explored. Methods Questionnaires for nurses and care workers were sent to 10 care facilities. The survey questions included basic demographic information, the Japanese Burnout Index and the Japanese version of the Frommelt Attitude Toward Care Of Dying Scale Form B. They also asked questions about use of Buddhist priests for tasks such as helping to manage the anxiety or distress of patients, families, and staff, or providing sutra chanting. Results In total, 323 questionnaires were returned, of which 260 were used for analysis. Only 18 (6.9%) answered that they had any religious beliefs, which was relatively low compared to 27% from governmental survey data. In total, however, 71% expressed a need for Buddhist priests to help with anxiety or distress among patients. A positive attitude towards providing end-of-life care was a protective factor against depersonalization. It was, however, also related to lower feelings of personal accomplishment. Conclusion Care homes and geriatric hospitals may want to consider calling more on religious resources as a support for staff and patients.	[Okamura, Tsuyoshi] Tokyo Metropolitan Inst Gerontol, Res Team Promoting Independence Elderly, Tokyo, Japan; [Shimmei, Masaya] Inst Future Engn, Tokyo, Japan; [Takase, Akinori; Ogawa, Yukan] Taisho Univ, Inst Reg Dev, Tokyo, Japan; [Toishiba, Shiho] Univ Tsukuba, Grad Sch Humanities & Social Sci, Tsukuba, Ibaraki, Japan; [Hayashida, Kojun] Taisho Univ, Dept Buddhist Studies, Tokyo, Japan; [Yumiyama, Tatsuya] Tokyo Inst Technol, Dept Social & Human Sci, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; University of Tsukuba; Tokyo Institute of Technology	Okamura, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Res Team Promoting Independence Elderly, Tokyo, Japan.	t.okamura.jp@gmail.com			JSPS KAKENHI [JP15K12814]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number JP15K12814. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, JAPAN TIMES; Bernardi L, 2001, BRIT MED J, V323, P1446, DOI 10.1136/bmj.323.7327.1446; Cooper SL., 2016, BURNOUT RES, V3, P76, DOI [10.1016/j.burn.2016.06.003., DOI 10.1016/J.BURN.2016.06.003, 10.1016/j.burn.2016.06.003]; Frommelt K H, 1991, Am J Hosp Palliat Care, V8, P37, DOI 10.1177/104990919100800509; Ghaligi S., 2006, INDIAN J TRADIT KNOW, V5, P177; Hayashi F., 2010, P I STAT MATH, V58, P39; Kubo M., 1994, JAPANESE J EXPT SOCI, V34, P33, DOI [DOI 10.2130/JJESP.34.33, 10.2130/jjesp.34.33]; MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205; Maslach C, 2016, WORLD PSYCHIATRY, V15, P103, DOI 10.1002/wps.20311; Ministry of Education Culture Sports Science and Technology, REL YB 2016; Murphy PE, 2000, J CONSULT CLIN PSYCH, V68, P1102, DOI 10.1037/0022-006X.68.6.1102; Nakai Y., 2006, JAPANESE J CANC NURS, V11, P723, DOI DOI 10.15106/J03022.2007018347; Odbehr L, 2014, BMC NURS, V13, DOI 10.1186/1472-6955-13-12; OECD, 2014, INT MIGR OUTL 2014, DOI [10.1787/migr_outlook-2014-en, DOI 10.1787/MIGR_OUTLOOK-2014-EN]; Pargament KI, 2004, J HEALTH PSYCHOL, V9, P713, DOI 10.1177/1359105304045366; Takeda, 2006, KAWASAKI MED WELFARE, V16, P53; Tanaka K, 2015, INT J GERONTOL, V9, P161, DOI 10.1016/j.ijge.2015.04.001; The Cabinet Office, AG SOC CURR SIT IMPL; The Cabinet Office, ANN REP AG SOC 2013; The Ministry of Health Labor and Welfare, DOC C 29 MARCH 2017; The Ministry of Internal Affairs and Communications Statistics Bureau Japan, MONTHL REP	21	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0202277	10.1371/journal.pone.0202277	http://dx.doi.org/10.1371/journal.pone.0202277			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP9JF	30092065	Green Published, gold, Green Submitted			2023-01-03	WOS:000441232600106
J	Wyllie, S; Thomas, M; Patterson, S; Crouch, S; De Rycker, M; Lowe, R; Gresham, S; Urbaniak, MD; Otto, TD; Stojanovski, L; Simeons, FRC; Manthri, S; MacLean, LM; Zuccotto, F; Homeyer, N; Pflaumer, H; Boesche, M; Sastry, L; Connolly, P; Albrecht, S; Berriman, M; Drewes, G; Gray, DW; Ghidelli-Disse, S; Dixon, S; Fiandor, JM; Wyatt, PG; Ferguson, MAJ; Fairlamb, AH; Miles, TJ; Read, KD; Gilbert, IH				Wyllie, Susan; Thomas, Michael; Patterson, Stephen; Crouch, Sabrinia; De Rycker, Manu; Lowe, Rhiannon; Gresham, Stephanie; Urbaniak, Michael D.; Otto, Thomas D.; Stojanovski, Laste; Simeons, Frederick R. C.; Manthri, Sujatha; MacLean, Lorna M.; Zuccotto, Fabio; Homeyer, Nadine; Pflaumer, Hannah; Boesche, Markus; Sastry, Lalitha; Connolly, Paul; Albrecht, Sebastian; Berriman, Matt; Drewes, Gerard; Gray, David W.; Ghidelli-Disse, Sonja; Dixon, Susan; Fiandor, Jose M.; Wyatt, Paul G.; Ferguson, Michael A. J.; Fairlamb, Alan H.; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.			Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis	NATURE			English	Article							TRYPANOSOMA-BRUCEI; INHIBITORS; DONOVANI; IDENTIFICATION; MILTEFOSINE; INFECTIONS; MECHANISMS; STRATEGIES; DISCOVERY; IDENTIFY	Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-of-action studies indicate that compounds from this series act principally by inhibiting the parasite cdc - 2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.	[Wyllie, Susan; Thomas, Michael; Patterson, Stephen; De Rycker, Manu; Urbaniak, Michael D.; Stojanovski, Laste; Simeons, Frederick R. C.; Manthri, Sujatha; MacLean, Lorna M.; Zuccotto, Fabio; Homeyer, Nadine; Sastry, Lalitha; Albrecht, Sebastian; Gray, David W.; Wyatt, Paul G.; Ferguson, Michael A. J.; Fairlamb, Alan H.; Read, Kevin D.; Gilbert, Ian H.] Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Drug Discovery Unit,Wellcome Ctr Antiinfect Res, Dundee, Scotland; [Crouch, Sabrinia; Fiandor, Jose M.; Miles, Timothy J.] GlaxoSmithKline, Global Hlth R&D, Tres Cantos, Spain; [Lowe, Rhiannon; Gresham, Stephanie] GlaxoSmithKline, David Jack Ctr R&D, Ware, Herts, England; [Urbaniak, Michael D.] Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster, England; [Otto, Thomas D.; Berriman, Matt] Wellcome Sanger Inst, Cambridge, England; [Pflaumer, Hannah; Boesche, Markus; Drewes, Gerard; Ghidelli-Disse, Sonja] Cellzome GmbH, Heidelberg, Germany; [Connolly, Paul] GlaxoSmithKline, New Frontiers Sci Pk, Harlow, Essex, England; [Dixon, Susan] GlaxoSmithKline, Global Hlth R&D, Stockley Pk West, Uxbridge, Middx, England; [Otto, Thomas D.] Univ Glasgow, Coll Med Vet & Life Sci, Ctr Immunobiol, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland	University of Dundee; GlaxoSmithKline; GlaxoSmithKline; Lancaster University; Wellcome Trust Sanger Institute; GlaxoSmithKline; Cellzome GmbH; GlaxoSmithKline; GlaxoSmithKline; University of Glasgow	Read, KD; Gilbert, IH (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Drug Discovery Unit,Wellcome Ctr Antiinfect Res, Dundee, Scotland.; Miles, TJ (corresponding author), GlaxoSmithKline, Global Hlth R&D, Tres Cantos, Spain.	tim.j.miles@gsk.com; k.read@dundee.ac.uk; i.h.gilbert@dundee.ac.uk	Otto, Thomas/ABE-7632-2020; Wyllie, Susan/AAI-4430-2021; Fairlamb, Alan/A-5272-2009; Gray, David W/F-6674-2011; albrecht, sebastien/ABD-7790-2020; Zuccotto, Fabio/E-7144-2017	Fairlamb, Alan/0000-0001-5134-0329; Gray, David W/0000-0001-9512-3828; albrecht, sebastien/0000-0002-1016-0193; Otto, Thomas/0000-0002-1246-7404; Wyllie, Susan/0000-0001-8810-5605; Ferguson, Michael/0000-0003-1321-8714; Gilbert, Ian/0000-0002-5238-1314; Dixon, Susan/0000-0003-4432-4261; Zuccotto, Fabio/0000-0002-3888-7423; De Rycker, Manu/0000-0002-3171-3519	Wellcome Trust [092340, 105021, 100476, 101842, 079838, 098051]	Wellcome Trust(Wellcome TrustEuropean Commission)	The authors acknowledge the Wellcome Trust for funding (grants 092340, 105021, 100476, 101842, 079838 and 098051).	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bergamini G, 2012, NAT CHEM BIOL, V8, P576, DOI [10.1038/nchembio.957, 10.1038/NCHEMBIO.957]; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P119; Croft SL, 1996, J ANTIMICROB CHEMOTH, V38, P1041, DOI 10.1093/jac/38.6.1041; De Rycker M, 2013, ANTIMICROB AGENTS CH, V57, P2913, DOI 10.1128/AAC.02398-12; den Boer ML, 2009, EXPERT OPIN EMERG DR, V14, P395, DOI 10.1517/14728210903153862; Ding Q, 2005, WIPO patent, Patent No. [WO/2005/121107, 2005121107]; Don R, 2014, PARASITOLOGY, V141, P140, DOI 10.1017/S003118201300142X; Downing T, 2011, GENOME RES, V21, P2143, DOI 10.1101/gr.123430.111; Escobar P, 2001, ANTIMICROB AGENTS CH, V45, P1872, DOI 10.1128/AAC.45.6.1872-1875.2001; Freyne E.J.E, 2006, WIPO patent, Patent No. [WO/2006/074984, 2006074984]; Hassan P, 2001, MOL BIOCHEM PARASIT, V113, P189, DOI 10.1016/S0166-6851(01)00220-1; Henderson CJ, 2006, TOXICOL LETT, V162, P111, DOI 10.1016/j.toxlet.2005.10.016; Khare S, 2016, NATURE, V537, P229, DOI 10.1038/nature19339; Lee H, 2016, ARCH PHARM RES, V39, P1193, DOI 10.1007/s12272-016-0791-z; Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799; Medard G, 2015, J PROTEOME RES, V14, P1574, DOI 10.1021/pr5012608; Miles T.J., 2016, WIPO patent, Patent No. [WO/2016/116563, 2016116563WO]; Monnerat S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067327; Mueller M, 2007, T ROY SOC TROP MED H, V101, P19, DOI 10.1016/j.trstmh.2006.02.005; Nuhs A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004094; Park J, 2013, MOL BIOSYST, V9, P544, DOI 10.1039/c2mb25502b; Ritmeijer K, 2003, T ROY SOC TROP MED H, V97, P609, DOI 10.1016/S0035-9203(03)80047-0; Rogers MB, 2011, GENOME RES, V21, P2129, DOI 10.1101/gr.122945.111; Seifert K, 2006, ANTIMICROB AGENTS CH, V50, P73, DOI 10.1128/AAC.50.1.73-79.2006; Sundar S, 2012, CLIN INFECT DIS, V55, P543, DOI 10.1093/cid/cis474; Terstappen GC, 2007, NAT REV DRUG DISCOV, V6, P891, DOI 10.1038/nrd2410; Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005; Urbaniak MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036619; Ursu A, 2015, BIOORG MED CHEM LETT, V25, P3079, DOI 10.1016/j.bmcl.2015.06.023; Woodland A, 2013, CHEMMEDCHEM, V8, P1127, DOI 10.1002/cmdc.201300072; Zhang L, 2011, BIOORG MED CHEM LETT, V21, P5633, DOI 10.1016/j.bmcl.2011.06.129	34	78	78	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 9	2018	560	7717					192	+		10.1038/s41586-018-0356-z	http://dx.doi.org/10.1038/s41586-018-0356-z			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP7UJ	30046105	Green Accepted, Green Submitted			2023-01-03	WOS:000441115200040
J	Sundararajan, A; Rane, HS; Ramaraj, T; Sena, J; Howell, AB; Bernardo, SM; Schilkey, FD; Lee, SA				Sundararajan, Anitha; Rane, Hallie S.; Ramaraj, Thiruvarangan; Sena, Johnny; Howell, Amy B.; Bernardo, Stella M.; Schilkey, Faye D.; Lee, Samuel A.			Cranberry-derived proanthocyanidins induce a differential transcriptomic response within Candida albicans urinary biofilms	PLOS ONE			English	Article							FIMBRIATED ESCHERICHIA-COLI; TRACT-INFECTIONS; INHIBIT ADHERENCE; GENE-EXPRESSION; ANTIFUNGAL SUSCEPTIBILITY; IRON; CYTOSCAPE; DIAGNOSIS; PRODUCTS; CLONING	Candida albicans is one of the most common causes of hospital-acquired urinary tract infections (UTIs). However, azoles are poorly active against biofilms, echinocandins do not achieve clinically useful urinary concentrations, and amphotericin B exhibits severe toxicities. Thus, novel strategies are needed to prevent Candida UTIs, which are often associated with urinary catheter biofilms. We previously demonstrated that cranberry-derived proanthocyanidins (PACs) prevent C. albicans biofilm formation in an in vitro urinary model. To elucidate functional pathways unique to urinary biofilm development and PAC inhibition, we investigated the transcriptome of C. albicans in artificial urine (AU), with and without PACs. C. albicans biofilm and planktonic cells were cultivated with or without PACs. Genome-wide expression analysis was performed by RNA sequencing. Differentially expressed genes were determined using DESeq2 software; pathway analysis was performed using Cytoscape. Approximately 2,341 of 6,444 total genes were significantly expressed in biofilm relative to planktonic cells. Functional pathway analysis revealed that genes involved in filamentation, adhesion, drug response and transport were up-regulated in urinary biofilms. Genes involved in carbon and nitrogen metabolism and nutrient response were down-regulated. In PAC-treated urinary biofilms compared to untreated control biofilms, 557 of 6,444 genes had significant changes in gene expression. Genes downregulated in PAC-treated biofilms were implicated in iron starvation and adhesion pathways. Although urinary biofilms share key features with biofilms formed in other environments, many genes are uniquely expressed in urinary biofilms. Cranberry-derived PACs interfere with the expression of iron acquisition and adhesion genes within urinary biofilms.	[Sundararajan, Anitha; Ramaraj, Thiruvarangan; Sena, Johnny; Schilkey, Faye D.] Natl Ctr Genome Resources, Santa Fe, NM USA; [Rane, Hallie S.; Lee, Samuel A.] New Mexico VA Healthcare Syst, Infect Dis Sect, Albuquerque, NM 87108 USA; [Howell, Amy B.] Rutgers State Univ, Marucci Ctr Blueberry & Cranberry Res & Extens, Chatsworth, NJ USA; [Bernardo, Stella M.; Lee, Samuel A.] Univ New Mexico, Hlth Sci Ctr, Div Infect Dis, Albuquerque, NM 87131 USA	National Center for Genome Resources (NCGR); Rutgers State University New Brunswick; University of New Mexico; University of New Mexico's Health Sciences Center	Lee, SA (corresponding author), New Mexico VA Healthcare Syst, Infect Dis Sect, Albuquerque, NM 87108 USA.; Lee, SA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Div Infect Dis, Albuquerque, NM 87131 USA.	SamALee@salud.unm.edu		Lee, Samuel/0000-0002-4772-4757; Howell, Amy/0000-0002-8069-7017	Department of Veterans' Affairs [5I01BX001130-03]; Biomedical Research Institute of New Mexico; New Mexico INBRE through an Institutional Development Award (IDeA) from NIH-NIGMS [P20GM103451]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103451] Funding Source: NIH RePORTER	Department of Veterans' Affairs(US Department of Veterans Affairs); Biomedical Research Institute of New Mexico; New Mexico INBRE through an Institutional Development Award (IDeA) from NIH-NIGMS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by grants from the Department of Veterans' Affairs (Merit Award 5I01BX001130-03 to SAL), and Biomedical Research Institute of New Mexico (to SAL). RNA-Seq data was obtained through a pilot award funded by New Mexico INBRE through an Institutional Development Award (IDeA) from NIH-NIGMS grant P20GM103451.	Achkar JM, 2010, CLIN MICROBIOL REV, V23, P253, DOI 10.1128/CMR.00076-09; Araujo D, 2017, TRENDS MICROBIOL, V25, P62, DOI 10.1016/j.tim.2016.09.004; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Bensen ES, 2004, MOL MICROBIOL, V54, P1335, DOI 10.1111/j.1365-2958.2004.04350.x; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; Bonhomme J, 2013, CURR OPIN MICROBIOL, V16, P398, DOI 10.1016/j.mib.2013.03.007; Bouza E, 2001, CLIN MICROBIOL INFEC, V7, P532, DOI 10.1046/j.1198-743x.2001.00324.x; Davis D, 2003, CURR GENET, V44, P1, DOI [10.1007/s00294-003-0415-2, 10.1007/s00294-003-0431-2]; Du H, 2015, ACTA BIOCH BIOPH SIN, V47, P335, DOI 10.1093/abbs/gmv011; Eck R, 1999, MICROBIOL-UK, V145, P2415, DOI 10.1099/00221287-145-9-2415; Eydelnant IA, 2008, LANGMUIR, V24, P10273, DOI 10.1021/la801525d; Feldman M, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-6; Finkel JS, 2011, NAT REV MICROBIOL, V9, P109, DOI 10.1038/nrmicro2475; Fisher JF, 2011, CLIN INFECT DIS, V52, pS457, DOI 10.1093/cid/cir112; Fisher JF, 2011, CLIN INFECT DIS, V52, pS429, DOI 10.1093/cid/cir108; FONZI WA, 1993, GENETICS, V134, P717; Foo LY, 2000, J NAT PROD, V63, P1225, DOI 10.1021/np000128u; Foo LY, 2000, PHYTOCHEMISTRY, V54, P173, DOI 10.1016/S0031-9422(99)00573-7; Fox EP, 2015, MOL MICROBIOL, V96, P1226, DOI 10.1111/mmi.13002; Foxman B, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.04.003; Garcia-Sanchez S, 2004, EUKARYOT CELL, V3, P536, DOI 10.1128/EC.3.2.536-545.2004; Gardner A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005099; Gulati M, 2016, MICROBES INFECT, V18, P310, DOI 10.1016/j.micinf.2016.01.002; Gupta K, 2007, J UROLOGY, V177, P2357, DOI 10.1016/j.juro.2007.01.114; Hidalgo G, 2011, APPL ENVIRON MICROB, V77, P6852, DOI 10.1128/AEM.05561-11; Hidalgo G, 2011, APPL ENVIRON MICROB, V77, P1532, DOI 10.1128/AEM.02201-10; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Howell AB, 2005, PHYTOCHEMISTRY, V66, P2281, DOI 10.1016/j.phytochem.2005.05.022; Howell AB, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-94; Jain N, 2007, APPL ENVIRON MICROB, V73, P1697, DOI 10.1128/AEM.02439-06; Johnson JR, 2006, ANN INTERN MED, V144, P116, DOI 10.7326/0003-4819-144-2-200601170-00009; Kauffman CA, 2000, CLIN INFECT DIS, V30, P14, DOI 10.1086/313583; Kauffman CA, 2014, INFECT DIS CLIN N AM, V28, P61, DOI 10.1016/j.idc.2013.09.004; Kelly MT, 2004, MOL MICROBIOL, V53, P969, DOI 10.1111/j.1365-2958.2004.04185.x; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; Lan CY, 2004, MOL MICROBIOL, V53, P1451, DOI 10.1111/j.1365-2958.2004.04214.x; Lee Soo-Hyun, 2004, [The Journal of Modern British & American Language & Literature, 현대영미어문학], V22, P97; Li Y, 2017, SOURCE CODE BIOL MED, V12, DOI 10.1186/s13029-017-0063-4; Lin BC, 2011, BIOFACTORS, V37, P121, DOI 10.1002/biof.110; Liu NN, 2017, P NATL ACAD SCI USA, V114, P6346, DOI 10.1073/pnas.1617799114; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maki DG, 2001, EMERG INFECT DIS, V7, P342, DOI 10.3201/eid0702.010240; Miller Neil A, 2008, J Comput Sci Syst Biol, V1, P132; Murillo LA, 2005, EUKARYOT CELL, V4, P1562, DOI 10.1128/EC.4.9.1562-1573.2005; Nett JE, 2014, INFECT IMMUN, V82, P4931, DOI 10.1128/IAI.02284-14; Nett JE, 2009, J INFECT DIS, V200, P307, DOI 10.1086/599838; Nobile CJ, 2012, CELL, V148, P126, DOI 10.1016/j.cell.2011.10.048; Oliveros J.C., 2007, VENNY INTERACTIVE TO; Protchenko O, 2006, J BIOL CHEM, V281, P21445, DOI 10.1074/jbc.M512812200; Ramage G, 2005, EUKARYOT CELL, V4, P633, DOI 10.1128/EC.4.4.633-638.2005; Ramage G, 2005, METH MOLEC MED, V118, P71; Ramage G, 2009, CRIT REV MICROBIOL, V35, P340, DOI 10.3109/10408410903241436; Ramanan N, 2000, SCIENCE, V288, P1062, DOI 10.1126/science.288.5468.1062; Rane HS, 2014, J ANTIMICROB CHEMOTH, V69, P428, DOI 10.1093/jac/dkt398; Raz R, 2004, CLIN INFECT DIS, V38, P1413, DOI 10.1086/386328; Schweizer A, 2000, MOL MICROBIOL, V38, P435, DOI 10.1046/j.1365-2958.2000.02132.x; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Skrzypek MS, 2017, NUCLEIC ACIDS RES, V45, pD592, DOI 10.1093/nar/gkw924; Sobel JD, 2011, CLIN INFECT DIS, V52, pS433, DOI 10.1093/cid/cir109; Staab JF, 2004, J BIOL CHEM, V279, P40737, DOI 10.1074/jbc.M406005200; Tambyah PA, 2002, INFECT CONT HOSP EP, V23, P27, DOI 10.1086/501964; Tempesta M, 2009, BOTANICAL MEDICINE: FROM BENCH TO BEDSIDE, P202; Uppuluri P, 2009, J CLIN MICROBIOL, V47, P4078, DOI 10.1128/JCM.01377-09; Wang CH, 2012, ARCH INTERN MED, V172, P988, DOI 10.1001/archinternmed.2012.3004; Wang XB, 2011, J MED MICROBIOL, V60, P1523, DOI 10.1099/jmm.0.026294-0; Westermann AJ, 2016, NATURE, V529, P496, DOI 10.1038/nature16547; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Xu N, 2012, FEMS YEAST RES, V12, P844, DOI 10.1111/j.1567-1364.2012.00835.x; Yeater KM, 2007, MICROBIOL-SGM, V153, P2373, DOI 10.1099/mic.0.2007/006163-0	70	2	2	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2018	13	8							e0201969	10.1371/journal.pone.0201969	http://dx.doi.org/10.1371/journal.pone.0201969			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP7NS	30089157	Green Published, Green Submitted, gold			2023-01-03	WOS:000441090300062
J	Schakel, L; Veldhuijzen, DS; van Middendorp, H; Van Dessel, P; De Houwer, J; Bidarra, R; Evers, AWM				Schakel, Lemmy; Veldhuijzen, Dieuwke S.; van Middendorp, Henriet; Van Dessel, Pieter; De Houwer, Jan; Bidarra, Rafael; Evers, Andrea W. M.			The effects of a gamified approach avoidance training and verbal suggestions on food outcomes	PLOS ONE			English	Article							VEGETABLE CONSUMPTION; PLACEBO ANALGESIA; APPROACH BIAS; HEALTH; EXPECTATION; BEHAVIOR; INTERVENTION; EXPECTANCIES; METAANALYSIS; OVERWEIGHT	There is initial support for the effectiveness of approach-avoidance trainings in altering food-related health behaviors. Furthermore, outcome expectancies induced by verbal suggestions might optimize the effectiveness of these interventions, as shown in placebo research. The present study investigated the effectiveness of a gamified approach-avoidance training on food-related outcomes and whether verbal suggestions could strengthen those effects. A total of 120 participants were randomly assigned to 1 of 4 conditions: serious gaming only, verbal suggestions only, serious gaming combined with verbal suggestions, or a gaming control condition. Virtual food preference and food choice were assessed with a food choice task, with pairs differing in healthiness or in healthiness and attractiveness. Implicit food preference was assessed with an Implicit Association Test and food intake with a bogus taste test. Participants in both serious gaming conditions made healthier food choices for pairs differing in healthiness and attractiveness and had healthier implicit food preferences compared to gaming control. No effects were found on food intake. These findings provide the first preliminary support for the effects of a gamified approach-avoidance training on virtual food choice and implicit food preference. Future studies should further elucidate these effects, also in other health domains such as physical activity.	[Schakel, Lemmy; Veldhuijzen, Dieuwke S.; van Middendorp, Henriet; Evers, Andrea W. M.] Leiden Univ, Fac Social & Behav Sci, Inst Psychol, Hlth Med & Neuropsychol Unit, Leiden, Netherlands; [Schakel, Lemmy; Veldhuijzen, Dieuwke S.; van Middendorp, Henriet; Evers, Andrea W. M.] Leiden Univ, Leiden Inst Brain & Cognit, Leiden, Netherlands; [Van Dessel, Pieter; De Houwer, Jan] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium; [Bidarra, Rafael] Delft Univ Technol, Dept Intelligent Syst, Delft, Netherlands; [Evers, Andrea W. M.] Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ghent University; Delft University of Technology; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schakel, L (corresponding author), Leiden Univ, Fac Social & Behav Sci, Inst Psychol, Hlth Med & Neuropsychol Unit, Leiden, Netherlands.; Schakel, L (corresponding author), Leiden Univ, Leiden Inst Brain & Cognit, Leiden, Netherlands.	l.schakel@fsw.leidenuniv.nl	De Houwer, Jan/ABF-6866-2021; van Middendorp, Henriet/B-8300-2013; Evers, Andrea/U-8983-2019; Evers, Andrea/GWV-9705-2022; Van Dessel, Pieter/Q-1917-2019	De Houwer, Jan/0000-0003-0488-5224; Evers, Andrea/0000-0002-0090-5091; Van Dessel, Pieter/0000-0002-3401-780X; Veldhuijzen, Dieuwke S. (Judy)/0000-0001-9046-1019; Bidarra, Rafael/0000-0003-4281-6019	European Research Council [617700]; Scientific Research Foundation, Flanders (FWO-Vlaanderen) [FWO16/PDO/201]	European Research Council(European Research Council (ERC)European Commission); Scientific Research Foundation, Flanders (FWO-Vlaanderen)(FWO)	This study is funded by a European Research Council Consolidator Grant (ID: 617700, granted to A Evers; https://ec.europa.eu/commission/index_en). P Van Dessel is supported by a Post-Doctoral fellowship of the Scientific Research Foundation, Flanders (FWO-Vlaanderen, ID: FWO16/PDO/201; http://www.fwo.be). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adriaanse MA, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00444; Bartels DJP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091727; Beard C, 2012, BEHAV COGN PSYCHOTH, V40, P618, DOI 10.1017/S1352465811000671; Becker D, 2015, APPETITE, V85, P58, DOI 10.1016/j.appet.2014.11.017; Blackburne T, 2016, JMIR SERIOUS GAMES, V4, DOI 10.2196/games.5708; Boendermaker WJ, 2016, JMIR SERIOUS GAMES, V4, DOI 10.2196/games.6464; Cohen Deborah, 2008, Prev Chronic Dis, V5, pA23; Cohen-Kdoshay O, 2009, EXP PSYCHOL, V56, P128, DOI 10.1027/1618-3169.56.2.128; Colloca L, 2014, Z PSYCHOL, V222, P124, DOI 10.1027/2151-2604/a000177; Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398; Cristea IA, 2015, BRIT J PSYCHIAT, V206, P7, DOI 10.1192/bjp.bp.114.146761; Dassen FCM, 2018, APPETITE, V124, P89, DOI 10.1016/j.appet.2017.05.009; DeSmet A, 2014, PREV MED, V69, P95, DOI 10.1016/j.ypmed.2014.08.026; Dickson H, 2016, APPETITE, V99, P46, DOI 10.1016/j.appet.2015.12.026; Drenowatz C, 2015, ADV NUTR, V6, P592, DOI 10.3945/an.115.008615; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Greenwald AG, 2003, J PERS SOC PSYCHOL, V85, P197, DOI 10.1037/0022-3514.85.2.197; Havermans RC, 2013, CURR OBES REP, V2, P165, DOI 10.1007/s13679-013-0053-z; Hollands GJ, 2011, HEALTH PSYCHOL, V30, P195, DOI 10.1037/a0022261; Horwath CC, 2010, AM J HEALTH PROMOT, V24, P324, DOI 10.4278/ajhp.071218138; Kakoschke N, 2017, J BEHAV THER EXP PSY, V55, P99, DOI 10.1016/j.jbtep.2017.01.002; Kakoschke N, 2014, EAT BEHAV, V15, P120, DOI 10.1016/j.eatbeh.2013.11.001; Kato PM, 2010, REV GEN PSYCHOL, V14, P113, DOI 10.1037/a0019441; KIRSCH I, 1985, AM PSYCHOL, V40, P1189, DOI 10.1037/0003-066X.40.11.1189; Marteau TM, 2012, SCIENCE, V337, P1492, DOI 10.1126/science.1226918; O'Donnell S, 2014, J NUTR EDUC BEHAV, V46, P570, DOI 10.1016/j.jneb.2014.03.005; Pearson ES, 2012, PATIENT EDUC COUNS, V87, P32, DOI 10.1016/j.pec.2011.07.018; Peerdeman KJ, 2017, EUR J PAIN, V21, P1366, DOI 10.1002/ejp.1035; Peerdeman KJ, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01270; Peerdeman KJ, 2016, PAIN, V157, P1179, DOI 10.1097/j.pain.0000000000000540; Pollo A, 2001, PAIN, V93, P77, DOI 10.1016/S0304-3959(01)00296-2; Richetin J, 2007, INT J PSYCHOL, V42, P166, DOI 10.1080/00207590601067078; Robinson E, 2017, APPETITE, V116, P223, DOI 10.1016/j.appet.2017.05.002; Salmon SJ, 2014, HEALTH PSYCHOL, V33, P103, DOI 10.1037/a0031785; Sardi L, 2017, J BIOMED INFORM, V71, P31, DOI 10.1016/j.jbi.2017.05.011; Schakel L, OPTIMIZING HLT UNPUB; Schumacher SE, 2016, APPETITE, V96, P219, DOI 10.1016/j.appet.2015.09.014; Shiyko M, 2016, JMIR SERIOUS GAMES, V4, pE8, DOI 10.2196/games.4977; Spagnolo PA, 2015, ALCOHOL ALCOHOLISM, V50, P282, DOI 10.1093/alcalc/agv015; Tangney JP, 2004, J PERS, V72, P271, DOI 10.1111/j.0022-3506.2004.00263.x; van den Akker K, 2016, CONTEMP CLIN TRIALS, V49, P85, DOI 10.1016/j.cct.2016.06.008; Van Dessel P, DO ACTIONS INF UNPUB; Van Dessel P, 2018, ACTA PSYCHOL, V184, P137, DOI 10.1016/j.actpsy.2017.03.016; Van Dessel P, 2017, J EXP SOC PSYCHOL, V69, P23, DOI 10.1016/j.jesp.2016.10.004; Van Dessel P, 2016, PERS SOC PSYCHOL B, V42, P81, DOI 10.1177/0146167215615335; Van Dessel P, 2015, EXP PSYCHOL, V62, P161, DOI 10.1027/1618-3169/a000282; Vase L, 2005, PAIN, V115, P338, DOI 10.1016/j.pain.2005.03.014; Wilson-Barlow L, 2014, EAT BEHAV, V15, P490, DOI 10.1016/j.eatbeh.2014.06.004	48	10	10	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2018	13	7							e0201309	10.1371/journal.pone.0201309	http://dx.doi.org/10.1371/journal.pone.0201309			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO4DQ	30048511	Green Published, Green Submitted, gold			2023-01-03	WOS:000439952400073
J	Corp, N; Jordan, JL; Croft, PR				Corp, Nadia; Jordan, Joanne L.; Croft, Peter R.			Justifications for using complementary and alternative medicine reported by persons with musculoskeletal conditions: A narrative literature synthesis	PLOS ONE			English	Article							LOW-BACK-PAIN; HEALTH-CARE; RHEUMATOID-ARTHRITIS; PATIENTS PERCEPTIONS; GENERAL-POPULATION; CHINESE IMMIGRANTS; TELEPHONE SURVEY; NATIONAL-SURVEY; THERAPIES; SATISFACTION	Background Complementary and alternative medicine (CAM) is very popular with patients frequently combining it with orthodox health care. The high prevalence of CAM use and satisfaction with CAM reported by patients directly challenges an orthodox system that can only approve such use if it results from the application of biomedical concepts and science. Studies highlighting this as a cultural, sociological and historical phenomenon emphasise the value of choice for consumers of health care. Musculoskeletal conditions typify common problems for which the effectiveness of orthodox care is often unclear. We postulated that the reasons people give for using or not using CAM for musculoskeletal conditions, would therefore indicate the full range of expectations that people have of health care. Furthermore, these reasons would indicate how much people feel orthodox health care is or is not meeting their expectations. Therefore, this study aims to investigate people's reasons for choosing or avoiding CAM for non-traumatic musculoskeletal conditions. Methods A systematic search and narrative synthesis was conducted of published qualitative and quantitative studies related to CAM and non-traumatic musculoskeletal conditions. Results We identified 169 relevant papers detailing 152 separate studies, from which 1486 justifications were extracted concerning CAM use. Content analysis resulted in 11 distinct categories across four themes: practical aspects of care, clinical effectiveness, non-clinical outcomes of care, and a person's philosophy of illness and care. People provided similar rationales for both using and avoiding CAM, emphasising that, whilst CAM is perceived by many patients with musculoskeletal conditions to fill gaps in care (such as practitioner time or quality of the therapeutic relationship), orthodox care also seeks to deliver these aspects of care. However, people who used CAM also highlighted its alignment with their general philosophy and ideas about illness and health care, and often emphasised CAM's capacity to give them control over their condition and its treatment. Conclusion Currently, CAM appears to have a significant role for patients with common painful long-term conditions in providing choices to enable individual needs to be met.	[Corp, Nadia; Jordan, Joanne L.; Croft, Peter R.] Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England	Keele University	Corp, N (corresponding author), Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England.	n.corp@keele.ac.uk	Corp, Nadia/N-3498-2019; Corp, Nadia/G-8618-2012; Jordan, Joanne/E-8186-2014	Corp, Nadia/0000-0002-6758-9513; Jordan, Joanne/0000-0002-7191-2977	Arthritis Research UK Strategic Award	Arthritis Research UK Strategic Award	The literature searches and synthesis were supported by an Arthritis Research UK Strategic Award (http://www.arthritisresearchuk.org/) awarded to PRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbot N. C., 1997, FORSCH KOMPLEMENTMED, V4, P164, DOI [10.1159/000210318, DOI 10.1159/000210318]; Afari N, 1999, INTEGR MED, V2, P97; Alami S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019634; Arcury TA, 1999, AM J HEALTH PROMOT, V14, P7, DOI 10.4278/0890-1171-14.1.7; Artus M, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-26; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Augello JDB, 2002, THESIS; Barcan R, 2011, COMPLEMENTARY ALTERN; Barnes PM, 2008, 12 CDC NAT HLTH STAT; Barrett B, 2003, J ALTERN COMPLEM MED, V9, P937, DOI 10.1089/107555303771952271; Barry CA, 2006, SOC SCI MED, V62, P2646, DOI 10.1016/j.socscimed.2005.11.025; Bishop FL, 2008, AM J PUBLIC HEALTH, V98, P1700, DOI 10.2105/AJPH.2007.110072; Bishop FL, 2007, J HEALTH PSYCHOL, V12, P851, DOI 10.1177/1359105307082447; Bishop FL, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-129; Bivins R., 2007, ALTERNATIVE MED HIST; BLACK C, 2009, ASSESSING COMPLEMENT; Bovey M, 2005, J ALTERN COMPLEM MED, V11, P293, DOI 10.1089/acm.2005.11.293; Braunack-Mayer A, 2009, BRIT J GEN PRACT, V59, P478, DOI 10.3399/bjgp09X453495; Brown M, 2010, DISABIL REHABIL, V32, P1645, DOI 10.3109/09638281003649896; Bucker B, 2008, GESUNDHEITSWESEN, V70, P559, DOI 10.1055/s-2008-1081505; Calnan M, 2006, FAM PRACT, V23, P91, DOI 10.1093/fampra/cmi077; Candib L. M, 2004, FAMILIES SYSTEMS HLT, V22, P139; Caspi O, 2004, MED DECIS MAKING, V24, P64, DOI 10.1177/0272989X03261567; Cassidy CM, 1998, J ALTERN COMPLEM MED, V4, P17, DOI 10.1089/acm.1998.4.1-17; Chambers S, 2008, LUPUS, V17, P761, DOI 10.1177/0961203308089404; Chan HK., 2002, HONG KONG NURSING J, V38, P7; Chaudhry SI, 2013, JAMA INTERN MED, V173, P1534, DOI 10.1001/jamainternmed.2013.8732; Choi Y., 2002, REPRESENTATION COPIN; DARZI A, 2007, OUR NHS OUR FUTURE; DeBar LL, 2003, J OROFAC PAIN, V17, P224; Dessio W, 2004, ETHNIC DIS, V14, P189; Dewar AL, 2009, CHRONIC DIS CAN, V29, P162; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Eisenberg DM, 2001, ANN INTERN MED, V135, P344, DOI 10.7326/0003-4819-135-5-200109040-00011; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Erickson BE, 2007, J ALTERN COMPLEM MED, V13, P375, DOI 10.1089/acm.2006.6213; Figaro MK, 2004, HEALTH PSYCHOL, V23, P324, DOI 10.1037/0278-6133.23.3.324; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Gale N, 2014, SOCIOL COMPASS, V8, P805, DOI 10.1111/soc4.12182; Gerrits MMJG, 2014, PAIN, V155, P53, DOI 10.1016/j.pain.2013.09.005; Goldstein MS, 1998, ALTERN THER HEALTH M, V4, P60; GRAY D, 1985, SOC SCI MED, V21, P507, DOI 10.1016/0277-9536(85)90034-6; Hasan Shahzad S., 2010, Journal of Pharmacy Practice and Research, V40, P294; Haslam D, 2004, INNER CONSULTATION D; Herman Carla J, 2004, Prev Chronic Dis, V1, pA12; Ho KY, 2009, PAIN PHYSICIAN, V12, P685; Howell S L, 1994, Nurse Pract Forum, V5, P98; Ikuyama S, 2009, MOD RHEUMATOL, V19, P253, DOI 10.1007/s10165-009-0156-2; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kim C, 1998, ARCH INTERN MED, V158, P2245, DOI 10.1001/archinte.158.20.2245; Kleinman A., 1980, PATIENTS HEALERS CON; la Cour P, 2008, JCR-J CLIN RHEUMATOL, V14, P332, DOI 10.1097/RHU.0b013e31817a7e1f; Lam TP, 2001, J EPIDEMIOL COMMUN H, V55, P762, DOI 10.1136/jech.55.10.762; Lewis D, 2001, J ALTERN COMPLEM MED, V7, P681, DOI 10.1089/10755530152755234; Liberati A, 2009, PLOS MED, V9; Lim ASH, 1999, PSYCHOL HEALTH, V14, P965; Lim MK, 2005, COMPLEMENT THER MED, V13, P16, DOI 10.1016/j.ctim.2004.11.002; Ma GX, 1999, J COMMUN HEALTH, V24, P421, DOI 10.1023/A:1018742505785; Marsh J, 2009, CLIN ORTHOP RELAT R, V467, P2705, DOI 10.1007/s11999-009-0764-3; Mitzdorf U, 1999, J ALTERN COMPLEM MED, V5, P463, DOI 10.1089/acm.1999.5.463; Natural Therapy Pages UK, ALT MED FIND COMPL T; Nayak S, 2001, J Spinal Cord Med, V24, P54; Palinkas LA, 2000, J FAM PRACTICE, V49, P1121; Paskins Z, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-195; Paterson C, 2004, J ALTERN COMPLEM MED, V10, P791; Paterson C, 1999, BRIT J GEN PRACT, V49, P626; Peleg R, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-36; Peters D, 2001, ONLINE J RURAL NURS, V2; Popay J, 2006, GUIDANCE CONDUCT NAR, V1, pb92; PORTER R, 1985, THEOR SOC, V14, P175, DOI 10.1007/BF00157532; Qidwai Waris, 2003, J Ayub Med Coll Abbottabad, V15, P33; Randall C, 1999, Complement Ther Med, V7, P126, DOI 10.1016/S0965-2299(99)80119-8; Rao JK, 2003, ARTHRIT RHEUM-ARTHR, V49, P619, DOI 10.1002/art.11377; Rao JK, 1999, ANN INTERN MED, V131, P409, DOI 10.7326/0003-4819-131-6-199909210-00003; Rao JK, 1998, ARTHRIT CARE RES, V11, P253, DOI 10.1002/art.1790110406; Rose G, 2006, MUSCULOSKELET CARE, V4, P101, DOI 10.1002/msc.82; Shah SFUH, 2010, J PAK MED ASSOC, V60, P667; Sharples FMC, 2003, COMPLEMENT THER MED, V11, P243, DOI 10.1016/S0965-2299(03)00107-9; Shmueli A, 2006, EVID-BASED COMPL ALT, V3, P273, DOI 10.1093/ecam/nel009; Shumay DM, 2001, J FAM PRACTICE, V50, P1097; Simpson N, 2001, BRIT J GEN PRACT, V51, P914; Skelton AM, 1996, BRIT J GEN PRACT, V46, P153; Smith JM, 2009, COMPLEMENT THER MED, V17, P281, DOI 10.1016/j.ctim.2009.07.001; Soler JK, 2012, FAM PRACT, V29, P272, DOI 10.1093/fampra/cmr101; Strutt R, 2008, MANUAL THER, V13, P456, DOI 10.1016/j.math.2007.05.013; Thomas K, 2004, J PUBLIC HEALTH, V26, P152, DOI 10.1093/pubmed/fdh139; US National Collaboration on Complementary and Alternative Medicine, 2008, COMPL ALT INT HLTH W; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x; von Peter S, 2002, CEPHALALGIA, V22, P395, DOI 10.1046/j.1468-2982.2002.00376.x; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wieland LS, 2011, ALTERN THER HEALTH M, V17, P50; Yamashita H, 2002, COMPLEMENT THER MED, V10, P84, DOI 10.1054/ctim.2002.0519; Young AE, 2011, PAIN, V152, P204, DOI 10.1016/j.pain.2010.10.033; Zhang JJ, 2002, SOC SCI MED, V55, P1795, DOI 10.1016/S0277-9536(01)00311-2	94	10	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2018	13	7							e0200879	10.1371/journal.pone.0200879	http://dx.doi.org/10.1371/journal.pone.0200879			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN5RC	30024952	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000439120000063
J	Williams, MR				Williams, Matthew R.			A pilot study into reaching performance after severe to moderate stroke using upper arm support	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; UPPER-LIMB; UPPER EXTREMITY; REHABILITATION; INDIVIDUALS; STIMULATION; THERAPY; ORTHOSIS; IMPACT; WRIST	Stroke effects millions of people each year and can have a significant impact on the ability to use the impaired arm and hand. One of the results of stroke is the development of an abnormal shoulder-elbow flexion synergy, where lifting the arm can cause the elbow, wrist, and finger flexors to involuntarily contract, reducing the ability to reach with the arm and hand opening. This study explored the effect of using support at the upper arm to improve hand and arm reaching performance. Nine participants were studied while performing a virtual reaching task under three conditions: while the weight of their impaired arm was supported by a robot arm, while unsupported, and while using their non-impaired arm. Most subjects exhibited faster and more accurate reaching while supported compared to unsupported. For the subjects who could voluntarily open their hand, most were able to more swiftly open their hand when using upper arm support. In many cases, performance with support was not statistically different than the unaffected arm and hand. Muscle activity of the impaired limb with upper arm support showed decreased effort to lift the arm and reduced biceps activity in most subjects, pointing to a reduction in the abnormal flexion synergy while using upper arm support. While arm support can help to reduce the activation of abnormal synergies, weakness resulting from hemiparesis remains an issue impacting performance. Future systems will need to address both of these causes of disability to more fully restore function after stroke.	[Williams, Matthew R.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH 44106 USA; [Williams, Matthew R.] Cleveland FES Ctr, Cleveland, OH 44106 USA; [Williams, Matthew R.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Williams, MR (corresponding author), Louis Stokes Cleveland VA Med Ctr, Cleveland, OH 44106 USA.; Williams, MR (corresponding author), Cleveland FES Ctr, Cleveland, OH 44106 USA.; Williams, MR (corresponding author), Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.	mwilliams@fescenter.org			U.S. Department of Veterans Affairs Office of Research and Development, Rehabilitation Research and Development Service as part of the Small Projects in Rehabilitation Research (SPiRE) program;  [1I21RX002196-01]; Veterans Affairs [I21RX002196] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs Office of Research and Development, Rehabilitation Research and Development Service as part of the Small Projects in Rehabilitation Research (SPiRE) program; ; Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the U.S. Department of Veterans Affairs Office of Research and Development, Rehabilitation Research and Development Service as part of the Small Projects in Rehabilitation Research (SPiRE) program. MRW is the recipient of the funding under award number 1I21RX002196-01, "Effect of Upper Arm Support on the Hemiparetic Arm". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1999, ENABLING ENV MEASURI; Arling G, 2012, CIRC-CARDIOVASC QUAL, V5, P44, DOI 10.1161/CIRCOUTCOMES.111.961474; Balasubramanian S, 2008, 2008 VIRTUAL REHABILITATION, P163, DOI 10.1109/ICVR.2008.4625154; Beer RF, 2007, MUSCLE NERVE, V36, P242, DOI 10.1002/mus.20817; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Cauraugh J, 2000, STROKE, V31, P1360, DOI 10.1161/01.STR.31.6.1360; Chen J, 2017, IEEE T NEUR SYS REH, V25, P2305, DOI 10.1109/TNSRE.2017.2695379; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Cohen J., 2013, APPL MULTIPLE REGRES; Dewald JPA, 2001, MUSCLE NERVE, V24, P273, DOI 10.1002/1097-4598(200102)24:2<273::AID-MUS130>3.0.CO;2-Z; Ellis MD, 2007, EXP BRAIN RES, V176, P594, DOI 10.1007/s00221-006-0637-x; Ellis MD, 2017, CLIN NEUROPHYSIOL, V128, P1308, DOI 10.1016/j.clinph.2017.04.028; Glenn MB, 2010, J HEAD TRAUMA REHAB, V25, P68, DOI 10.1097/HTR.0b013e3181be1eab; Gresham G, 1997, FUNCTIONAL ASSESSMEN; He JP, 2005, INT C REHAB ROBOT, P95; Iwamuro BT, 2008, ARCH PHYS MED REHAB, V89, P2121, DOI 10.1016/j.apmr.2008.04.022; Jarrasse N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00947; Knutson JS, 2009, NEUROREHAB NEURAL RE, V23, P17, DOI 10.1177/1545968308317577; Krebs Hermano I, 2004, J Neuroeng Rehabil, V1, P5, DOI 10.1186/1743-0003-1-5; Kumar A, 2013, J REHABIL RES DEV, V50, P61, DOI 10.1682/JRRD.2012.03.0047; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Makowski NS, 2015, IEEE T NEUR SYS REH, V23, P221, DOI 10.1109/TNSRE.2014.2364273; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Mihelj M, 2007, IEEE INT CONF ROBOT, P4120, DOI 10.1109/ROBOT.2007.364112; Miller LC, 2012, CLIN NEUROPHYSIOL, V123, P1216, DOI 10.1016/j.clinph.2012.01.009; Moubarak S, 2010, IEEE ENG MED BIO, P4489, DOI 10.1109/IEMBS.2010.5626036; Nef T, 2005, INT C REHAB ROBOT, P57; Nef T, 2006, IEEE INT CONF ROBOT, P3152, DOI 10.1109/ROBOT.2006.1642181; Oguntosin VW, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00352; Peters HT, 2017, ARCH PHYS MED REHAB, V98, P1821, DOI 10.1016/j.apmr.2016.12.016; Polygerinos P, 2015, ROBOT AUTON SYST, V73, P135, DOI 10.1016/j.robot.2014.08.014; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Roh J, 2013, J NEUROPHYSIOL, V109, P768, DOI 10.1152/jn.00670.2012; Sanchez RJ, 2005, INT C REHAB ROBOT, P500; Seo NJ, 2009, J NEUROPHYSIOL, V101, P3108, DOI 10.1152/jn.91108.2008; Thrasher TA, 2008, NEUROREHAB NEURAL RE, V22, P706, DOI 10.1177/1545968308317436; Umemura Atushi, 2009, 2009 IEEE International Conference on Rehabilitation Robotics: Reaching Users & the Community (ICORR), P451, DOI 10.1109/ICORR.2009.5209512; Williams MR, 2008, IEEE T NEUR SYS REH, V16, P485, DOI 10.1109/TNSRE.2008.2006216	39	4	4	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2018	13	7							e0200787	10.1371/journal.pone.0200787	http://dx.doi.org/10.1371/journal.pone.0200787			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2XR	30016364	gold, Green Submitted, Green Published			2023-01-03	WOS:000438866600043
J	Muilwijk, M; Nicolaou, M; Qureshi, SA; Celis-Morales, C; Gill, JMR; Sheikh, A; Sattar, N; Beune, E; Jenum, AK; Stronks, K; van Valkengoed, IGM				Muilwijk, Mirthe; Nicolaou, Mary; Qureshi, Samera A.; Celis-Morales, Carlos; Gill, Jason M. R.; Sheikh, Aziz; Sattar, Naveed; Beune, Erik; Jenum, Anne Karen; Stronks, Karien; van Valkengoed, Irene G. M.			Dietary and physical activity recommendations to prevent type 2 diabetes in South Asian adults: A systematic review	PLOS ONE			English	Review							IMPAIRED GLUCOSE-TOLERANCE; VITAMIN-D SUPPLEMENTATION; LIFE-STYLE-INTERVENTION; INSULIN-RESISTANCE; EDUCATION-PROGRAM; COMMUNITY; RISK; CONSENSUS; HEALTHY; OBESITY	Intervention trials and guidelines for the prevention of type 2 diabetes (T2D) in populations of South Asian origin often include strategies to improve diet and physical activity that are based on those developed for other populations. These may be suboptimal for the South Asian target populations. We aimed to provide an overview of included recommended dietary and physical activity components, and to identify whether these were supported by evidence of their effectiveness. Databases were searched until September 2017 for intervention studies and guidelines with an adult South Asian population without T2D. The protocol was registered in PROSPERO, registration number: CRD42015207067. The quality of included studies and guidelines was assessed. Dietary and physical activity components, and effects on T2D incidence, glycemic status and adiposity measures, were summarized in tabular format and evaluated narratively. Eighteen intervention studies and four guidelines were identified. Dietary and physical activity components were similar to recommendations for the general population. Intervention studies and guidelines did not reference evidence to support the effectiveness of components included in the intervention for South Asian populations in particular. Moreover, we were unable to assess patterns of components to determine the effects of specific components. Evaluation of current and emerging components among South Asian populations and subgroups seems necessary to formulate more specific recommendations in future intervention studies and guidelines.	[Muilwijk, Mirthe; Nicolaou, Mary; Beune, Erik; Stronks, Karien; van Valkengoed, Irene G. M.] Univ Amsterdam, Acad Med Ctr, Dept Publ Hlth, Amsterdam, Netherlands; [Qureshi, Samera A.] Norwegian Ctr Migrant & Minor Hlth Res, Oslo, Norway; [Celis-Morales, Carlos; Gill, Jason M. R.; Sattar, Naveed] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Sheikh, Aziz] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Jenum, Anne Karen] Inst Hlth & Soc, Dept Gen Practice, Fac Med, Oslo, Norway	University of Amsterdam; Academic Medical Center Amsterdam; University of Glasgow; University of Edinburgh	Muilwijk, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Publ Hlth, Amsterdam, Netherlands.	m.muilwijk@amc.uva.nl	van Valkengoed, Irene G.M./B-2974-2013; Celis-Morales, Carlos/AAJ-5103-2020; van Valkengoed, Irene/ABA-1551-2021	van Valkengoed, Irene G.M./0000-0002-9306-7831; van Valkengoed, Irene/0000-0002-9306-7831; Sheikh, Aziz/0000-0001-7022-3056; Stronks, Karien/0000-0002-0921-2232	European Union [664609 HP-PJ-2014]	European Union(European Commission)	This work was sponsored by the Health Programme 2014-2020 from the European Union, grant number 664609 HP-PJ-2014 (https://ec.europa.eu/health/programme/policy/2014-2020_en). KS and IV received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Admiraal WM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068605; Agrawal S, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-89; Agrawal S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-706; Alberti KGMM, 2007, DIABETIC MED, V24, P451, DOI 10.1111/j.1464-5491.2007.02157.x; Ambady R, 2013, DIABETIC MED, V30, P26, DOI 10.1111/j.1464-5491.2012.03753.x; Andersen E, 2015, MED SCI SPORT EXER, V47, P775, DOI 10.1249/MSS.0000000000000460; Andersen E, 2013, J IMMIGR MINOR HEALT, V15, P101, DOI 10.1007/s10903-012-9686-3; Anjana RM, 2015, DIABETES RES CLIN PR, V109, P253, DOI 10.1016/j.diabres.2015.05.039; [Anonymous], 2011, ACTRN12611000262909; [Anonymous], 2011, DIABETES PREVENTION; [Anonymous], 2009, S ASIAN DIABETES PRE; [Anonymous], 2015, DIET CHART PREV MAN; [Anonymous], 2012, CTRI201209002974; [Anonymous], 2015, CTRI201507006011; [Anonymous], 2015, CTRI201506005832; [Anonymous], 2016, CHOOSE HLTH STAY HLT; [Anonymous], 2015, CTRI201512006429 NAT; [Anonymous], 2015, ISRCTN12337078; [Anonymous], 2015, PREVENT DIABETES 201; [Anonymous], 2006, ISRCTN37781193; [Anonymous], 2011, ISRCTN18522562; [Anonymous], 2013, CTRI20130103316 IPDS; [Anonymous], 2012, SLCTR2012010; Armijo-Olivo S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/j.1365-2753.2010.01516.x; Bakker LEH, 2014, DIABETES, V63, P248, DOI 10.2337/db13-0696; Balagopal P, 2008, DIABETES CARE, V31, P1097, DOI 10.2337/dc07-1680; Balagopal P, 2012, DIABETES EDUCATOR, V38, P822, DOI 10.1177/0145721712459890; Bhopal RS, 2014, LANCET DIABETES ENDO, V2, P218, DOI 10.1016/S2213-8587(13)70204-3; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Brown T, 2015, INT J ENV RES PUB HE, V12, P566, DOI 10.3390/ijerph120100566; Celis-Morales CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082568; Cene CW, 2013, DIABETES EDUCATOR, V39, P776, DOI 10.1177/0145721713507114; Chapman J, 2013, BRIT J GEN PRACT, V63, pE104, DOI 10.3399/bjgp13X663064; Chowdhury TA, 2007, BR J DIABETES VASC D, V7, P279, DOI DOI 10.1177/14746514070070060401; Cuijpers P, 2014, DEPRESS ANXIETY, V31, P374, DOI 10.1002/da.22249; Davidson EM, 2014, EUR J PUBLIC HEALTH, V24, P508, DOI 10.1093/eurpub/ckt093; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Dutta D, 2014, DIABETES RES CLIN PR, V103, pE18, DOI 10.1016/j.diabres.2013.12.044; Gill JMR, 2011, DIABETES CARE, V34, P1214, DOI 10.2337/dc10-2313; Green R, 2016, BRIT J NUTR, V116, P142, DOI 10.1017/S0007114516001598; Gujral UP, 2013, ANN NY ACAD SCI, V1281, P51, DOI 10.1111/j.1749-6632.2012.06838.x; Hague HCotNT, 2011, GUIDELINES HLTH DIET; Hegde SV, 2013, COMPLEMENT THER MED, V21, P571, DOI 10.1016/j.ctim.2013.08.013; Holmboe-Ottesen G, 2012, FOOD NUTR RES, V56, DOI 10.3402/fnr.v56i0.18891; Iliodromiti S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160024; Islam MR, 2016, DIABETES RES CLIN PR, V115, P39, DOI 10.1016/j.diabres.2016.03.010; Islam NS, 2013, DIABETES EDUCATOR, V39, P462, DOI 10.1177/0145721713491438; Islam NS, 2014, INT J ENV RES PUB HE, V11, P5462, DOI 10.3390/ijerph110505462; Jayawardena R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-380; Kandola K, 2016, J DIABETES COMPLICAT, V30, P1462, DOI 10.1016/j.jdiacomp.2016.08.003; Kemper HGC, 2000, TIJDSCHR SOC GEZONDH, V78, P180; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Madsen C, 2015, J DEV ORIG HLTH DIS, V6, P27, DOI 10.1017/S2040174414000609; McDermott KA, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-212; Meeks KAC, 2016, INTERN EMERG MED, V11, P327, DOI 10.1007/s11739-015-1302-9; Mensink M, 2003, DIABETES RES CLIN PR, V61, P49, DOI 10.1016/S0168-8227(03)00067-6; Misra A, 2014, DIABETIC MED, V31, P1153, DOI 10.1111/dme.12540; Misra A, 2011, INT J OBESITY, V35, P167, DOI 10.1038/ijo.2010.135; Misra A, 2012, DIABETES TECHNOL THE, V14, P83, DOI 10.1089/dia.2011.0111; Misra A, 2011, DIABETES TECHNOL THE, V13, P683, DOI 10.1089/dia.2010.0198; Misra R, 2011, INDIAN FOODS AAPIS G; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Muilwijk M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012783; National Diabetes Education Program, POW PREV FAM LIF APP; National Institute of Nutrition (NIN), 2011, DIET GUID IND MAN; NICE, 2011, TYP 2 DIAB PREV POP; Patel RM, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/2751980; Ram J, 2014, DIABETES RES CLIN PR, V106, P491, DOI 10.1016/j.diabres.2014.09.043; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Ramachandran A, 2009, DIABETOLOGIA, V52, P1019, DOI 10.1007/s00125-009-1315-x; Ramachandran A, 2013, LANCET DIABETES ENDO, V1, P191, DOI 10.1016/S2213-8587(13)70067-6; Ranasinghe CD, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-116; Ranasinghe P, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-52; Razak F, 2007, CIRCULATION, V115, P2111, DOI 10.1161/CIRCULATIONAHA.106.635011; Sathish T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1035; Sattar N, 2015, LANCET DIABETES ENDO, V3, P1004, DOI 10.1016/S2213-8587(15)00326-5; Sehat A, 2008, HLTH S ASIAN MEALS G; Simonsen KA, 2012, FAM PRACT, V29, P139, DOI 10.1093/fampra/cmr064; Telle-Hjellset V, 2013, BRIT J NUTR, V109, P529, DOI 10.1017/S000711451200133X; Thirunavukkarasu D, 2017, INDIAN J PHARM EDUC, V51, P349, DOI 10.5530/ijper.51.2.42; Thomas H, 2003, QUAL ASS TOOL QUANT; von Hurst PR, 2010, BRIT J NUTR, V103, P549, DOI 10.1017/S0007114509992017; Wallia S, 2014, HEALTH PROMOT INT, V29, P768, DOI 10.1093/heapro/dat015; World Bank, 2006, MIGRATION REMITTANCE	84	8	9	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2018	13	7							e0200681	10.1371/journal.pone.0200681	http://dx.doi.org/10.1371/journal.pone.0200681			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2LQ	30011314	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000438829800041
J	Kikuchi, K; Yasuoka, J; Nanishi, K; Ahmed, A; Nohara, Y; Nishikitani, M; Yokota, F; Mizutani, T; Nakashima, N				Kikuchi, Kimiyo; Yasuoka, Junko; Nanishi, Keiko; Ahmed, Ashir; Nohara, Yasunobu; Nishikitani, Mariko; Yokota, Fumihiko; Mizutani, Tetsuya; Nakashima, Naoki			Postnatal care could be the key to improving the continuum of care in maternal and child health in Ratanakiri, Cambodia	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; VILLAGE MALARIA WORKERS; NEWBORN BABIES; SERVICE; INTERVENTIONS; STILLBIRTHS; DELIVERY; QUALITY	In South-East Asia, the maternal and child mortality rate has declined over the past decades; however, it varies among and within the countries in the region, including Cambodia. The continuum of care is an integrated series of care that women and children are required to avail continuously from pregnancy to the child/motherhood period. This study aimed to assess the completion rate of the continuum of care and examine the factors associated with the continuum of care in Ratanakiri, Cambodia. A cross-sectional study was conducted in Ratanakiri. Overall, 377 women were included, and data were collected via faceto-face interviews using a semi-structured questionnaire. Among them, 5.0% completed the continuum of care (antenatal care at least four times, delivery by skilled birth attendant, and postnatal care at least once). Meanwhile, 18.8% did not receive any care during pregnancy, delivery, and after birth. The highest discontinuation rate was at the postnatal care stage (73.6%). Not receiving any perinatal care was associated with neonatal complications at 6 weeks after birth (adjusted odds ratio [AOR]: 3.075; 95% confidence interval [CI]: 1.3107.215). Furthermore, a long distance to the health center was negatively associated with completion of the continuum of care (AOR: 0.877; 95% CI: 0.791-0.972). This study indicates the need for efforts to reduce the number of women who discontinue from the continuum of care, as well as who do not receive any care to avoid neonatal complications. Since the discontinuation rate was highest at the postnatal care, postnatal care needs to be promoted more through the antenatal care and delivery services. Furthermore, given that long distance to health facilities was a barrier for receiving the care continuously, our findings suggest the need for a village-based health care system that can provide the basic continuum of care in remote areas.	[Kikuchi, Kimiyo; Nishikitani, Mariko; Yokota, Fumihiko] Kyushu Univ, Inst Decis Sci Sustainable Soc, Fukuoka, Japan; [Yasuoka, Junko; Mizutani, Tetsuya] Tokyo Univ Agr & Technol, Res & Educ Ctr Prevent Global Infect Dis Anim, Tokyo, Japan; [Nanishi, Keiko] Univ Tokyo, Off Int Acad Affairs, Grad Sch Med, Tokyo, Japan; [Ahmed, Ashir; Nakashima, Naoki] Kyushu Univ, Dept Adv Informat Technol, Fukuoka, Japan; [Nohara, Yasunobu] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan	Kyushu University; Tokyo University of Agriculture & Technology; University of Tokyo; Kyushu University; Kyushu University	Kikuchi, K (corresponding author), Kyushu Univ, Inst Decis Sci Sustainable Soc, Fukuoka, Japan.	Kikuchi.kimiyo.715@m.kyushu-u.ac.jp	Yasuoka, Junko/GVT-8950-2022; MIZUTANI, Tetsuya/G-1086-2013	MIZUTANI, Tetsuya/0000-0003-2570-0452; Nohara, Yasunobu/0000-0002-2805-6597; Nanishi, Keiko/0000-0001-7067-8413	JSPS KAKENHI [JP15H05284]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was funded by JSPS KAKENHI Grant Number JP15H05284. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acuin CS, 2011, LANCET, V377, P516, DOI 10.1016/S0140-6736(10)62049-1; Amooti-Kaguna B, 2000, SOC SCI MED, V50, P203, DOI 10.1016/S0277-9536(99)00275-0; [Anonymous], GLOB HLTH OBS DAT 20; Anson O, 2004, HEALTH POLICY, V70, P197, DOI 10.1016/j.healthpol.2004.03.001; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; Canavati SE, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1322-6; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dingle A, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-51; Enuameh YAK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152235; Froen JF, 2016, LANCET, V387, P574, DOI 10.1016/S0140-6736(15)00818-1; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Glenton C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010414.pub2; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hasegawa A, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-292; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kikuchi K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164965; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Langlois EV, 2015, B WORLD HEALTH ORGAN, V93, P259, DOI 10.2471/BLT.14.140996; Ministry of Planning RGoC, 2013, ANN PROGR REP ACH MI; Munjanja SP, 1996, LANCET, V348, P364, DOI 10.1016/S0140-6736(96)01250-0; National Institute of Statistics Directorate General for Health The DHS Program ICF International, 2014, DIR GEN HLTH DHS PRO; Okawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130712; Rosato M, 2008, LANCET, V372, P962, DOI 10.1016/S0140-6736(08)61406-3; Sakeah E, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1291879; Stekelenburg J, 2004, TROP MED INT HEALTH, V9, P390, DOI 10.1111/j.1365-3156.2004.01202.x; ten Hoope-Bender P, 2013, LANCET, V382, P1685, DOI 10.1016/S0140-6736(13)61793-6; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; The Partnership for Maternal N and Child Health, 2010, PMNCH KNOWL SUMM 02; United Nations, SUST DEV GOALS; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; WHO, 2022, WHO RECOMMENDATIONS; WHO, CAMB WHO STAT PROF 2; WHO UNICEF UNFPA, 2003, PREGN CHILDB POSTP N; World Health Organization Department of Maternal N, 2013, WHO REC POSTN CAR MO; Yasuoka J, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-4; Yasuoka J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-109	37	25	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2018	13	6							e019882	10.1371/journal.pone.0198829	http://dx.doi.org/10.1371/journal.pone.0198829			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI8PJ	29889894	Green Published, Green Submitted, gold			2023-01-03	WOS:000434786600057
J	Graham, KL; Auerbach, AD; Schnipper, JL; Flanders, SA; Kim, CS; Robinson, EJ; Ruhnke, GW; Thomas, LR; Kripalani, S; Vasilevskis, EE; Fletcher, GS; Sehgal, NJ; Lindenauer, PK; Williams, MV; Metlay, JP; Davis, RB; Yang, J; Marcantonio, ER; Herzig, SJ				Graham, Kelly L.; Auerbach, Andrew D.; Schnipper, Jeffrey L.; Flanders, Scott A.; Kim, Christopher S.; Robinson, Edmondo J.; Ruhnke, Gregory W.; Thomas, Larissa R.; Kripalani, Sunil; Vasilevskis, Eduard E.; Fletcher, Grant S.; Sehgal, Neil J.; Lindenauer, Peter K.; Williams, Mark V.; Metlay, Joshua P.; Davis, Roger B.; Yang, Julius; Marcantonio, Edward R.; Herzig, Shoshana J.			Preventability of Early Versus Late Hospital Readmissions in a National Cohort of General Medicine Patients	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; RETROSPECTIVE COHORT; 30-DAY READMISSIONS; AFTER-DISCHARGE; CARE; EVENTS; RATES; PNEUMONIA; ASSOCIATION	Background: Many experts believe that hospitals with more frequent readmissions provide lower-quality care, but little is known about how the preventability of readmissions might change over the postdischarge time frame. Objective: To determine whether readmissions within 7 days of discharge differ from those between 8 and 30 days after discharge with respect to preventability. Design: Prospective cohort study. Setting: 10 academic medical centers in the United States. Patients: 822 adults readmitted to a general medicine service. Measurements: For each readmission, 2 site-specific physician adjudicators used a structured survey instrument to determine whether it was preventable and measured other characteristics. Results: Overall, 36.2% of early readmissions versus 23.0% of late readmissions were preventable (median risk difference, 13.0 percentage points [interquartile range, 5.5 to 26.4 percentage points]). Hospitals were identified as better locations for preventing early readmissions (47.2% vs. 25.5%; median risk difference, 22.8 percentage points [interquartile range, 17.9 to 31.8 percentage points]), whereas outpatient clinics (15.2% vs. 6.6%; median risk difference, 10.0 percentage points [interquartile range, 4.6 to 12.2 percentage points]) and home (19.4% vs. 14.0%; median risk difference, 5.6 percentage points [interquartile range, -6.1 to 17.1 percentage points]) were better for preventing late readmissions. Limitation: Physician adjudicators were not blinded to readmission timing, community hospitals were not included in the study, and readmissions to nonstudy hospitals were not included in the results. Conclusion: Early readmissions were more likely to be preventable and amenable to hospital-based interventions. Late readmissions were less likely to be preventable and were more amenable to ambulatory and home-based interventions.	[Graham, Kelly L.; Davis, Roger B.; Yang, Julius; Marcantonio, Edward R.; Herzig, Shoshana J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Graham, Kelly L.; Schnipper, Jeffrey L.; Davis, Roger B.; Yang, Julius; Marcantonio, Edward R.; Herzig, Shoshana J.] Harvard Med Sch, Boston, MA 02215 USA; [Auerbach, Andrew D.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Schnipper, Jeffrey L.] Brigham & Womens Hosp, Boston, MA USA; [Flanders, Scott A.] Univ Michigan, Med Sch, Ann Arbor, MI 48109 USA; [Kim, Christopher S.] Univ Washington, Seattle, WA 98195 USA; [Robinson, Edmondo J.] Value Inst, Christiana Care Hlth Syst, Wilmington, DE USA; [Ruhnke, Gregory W.] Univ Chicago, Chicago, IL 60637 USA; [Thomas, Larissa R.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA; [Kripalani, Sunil] Vanderbilt Univ, Med Ctr, Ctr Clin Qual & Implementat Res, Nashville, TN USA; [Vasilevskis, Eduard E.] Univ Med Ctr, Ctr Qual Aging Vanderbilt, Nashville, TN USA; [Vasilevskis, Eduard E.] VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA; [Fletcher, Grant S.] Univ Washington, Harborview Med Ctr, 325 9Th Ave, Seattle, WA 98104 USA; [Sehgal, Neil J.] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA; [Lindenauer, Peter K.] Univ Massachusetts, Med Sch Baystate, Inst Healthcare Delivery & Populat Sci, Springfield, MA USA; [Williams, Mark V.] Univ Kentucky, Ctr Hlth Serv Res, Lexington, KY USA; [Metlay, Joshua P.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; Christiana Care Health System; University of Chicago; University of California System; University of California San Francisco; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Harborview Medical Center; University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland College Park; University of Massachusetts System; University of Kentucky; Harvard University; Massachusetts General Hospital	Graham, KL (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,E Shapiro 607D, Boston, MA 02215 USA.	kgraham@bidmc.harvard.edu; sherzig@bidmc.harvard.edu	Marcantonio, Edward R/U-3929-2017; Vasilevskis, Eduard/AAA-3065-2019	Marcantonio, Edward R/0000-0002-2911-4250; Vasilevskis, Eduard/0000-0001-8165-5321; Robinson, Edmondo/0000-0001-9625-6235; Williams, Mark V/0000-0001-6107-0457; Auerbach, Andrew/0000-0001-8440-0527	Association of American Medical Colleges; The Harvard Clinical and Translational Science Center [UL1 TR001102]; Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine at Beth Israel Deaconess Medical Center; Harvard Medical School; National Institute on Aging [R01AG030618, K24AG035075, K23AG040157]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS022241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445, UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG030618, K23AG042459, K23AG040157, K24AG035075] Funding Source: NIH RePORTER	Association of American Medical Colleges; The Harvard Clinical and Translational Science Center; Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine at Beth Israel Deaconess Medical Center; Harvard Medical School; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By an unrestricted research grant from the Association of American Medical Colleges. This work was done with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center, through award UL1 TR001102 from the National Institutes of Health and financial contributions from Harvard University and its affiliated academic health care centers. Dr. Graham is funded by the Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Herzig is funded by grant K23AG042459 from the National Institute on Aging. Dr. Marcantonio was supported in part by grants R01AG030618 and K24AG035075 from the National Institute on Aging. Dr. Vasilevskis was supported by National Institute on Aging award K23AG040157, the Veterans Affairs Clinical Research Center of Excellence, and the Geriatric Research Education and Clinical Center.	Auerbach AD, 2016, JAMA INTERN MED, V176, P484, DOI 10.1001/jamainternmed.2015.7863; Burke RE, 2013, J HOSP MED, V8, P102, DOI 10.1002/jhm.1990; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Centers for Medicare and Medicaid Services (CMS) HHS, 2011, Fed Regist, V76, P51476; Chin DL, 2016, HEALTH AFFAIR, V35, P1867, DOI 10.1377/hlthaff.2016.0205; Fontanarosa PB, 2013, JAMA-J AM MED ASSOC, V309, P398, DOI 10.1001/jama.2013.42; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gerhardt Geoffrey, 2013, Medicare Medicaid Res Rev, V3, DOI 10.5600/mmrr.003.02.b01; Goodwin AJ, 2015, CRIT CARE MED, V43, P738, DOI 10.1097/CCM.0000000000000859; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Graham KL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178718; Graham KL, 2015, ANN INTERN MED, V162, P741, DOI 10.7326/M14-2159; Herrin J, 2015, HEALTH SERV RES, V50, P20, DOI 10.1111/1475-6773.12177; Herzig SJ, 2016, J GEN INTERN MED, V31, P1287, DOI 10.1007/s11606-016-3764-5; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2012, NEW ENGL J MED, V366, P1366, DOI 10.1056/NEJMp1201598; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kahlon S, 2015, CAN MED ASSOC J, V187, P799, DOI 10.1503/cmaj.150100; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Lavenberg JG, 2014, J HOSP MED, V9, P598, DOI 10.1002/jhm.2226; Lindenauer PK, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f521; Localio AR, 1996, ANN INTERN MED, V125, P457, DOI 10.7326/0003-4819-125-6-199609150-00005; Odonkor CA, 2015, AM J PHYS MED REHAB, V94, P555, DOI 10.1097/PHM.0000000000000213; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Parina RP, 2015, J AM COLL SURGEONS, V220, P169, DOI 10.1016/j.jamcollsurg.2014.10.020; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Stefan MS, 2013, J GEN INTERN MED, V28, P377, DOI 10.1007/s11606-012-2229-8; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Wijlaars LPMM, 2015, ARCH DIS CHILD, V100, P845, DOI 10.1136/archdischild-2014-307771	33	60	60	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 5	2018	168	11					766	+		10.7326/M17-1724	http://dx.doi.org/10.7326/M17-1724			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI3EK	29710243	Green Accepted			2023-01-03	WOS:000434254100003
J	Wright, T; Jowsey, T; Stanton, J; Elder, H; Stevens, S; Wouldes, TA				Wright, Tanya; Jowsey, Tanisha; Stanton, Josephine; Elder, Hinemoa; Stevens, Suzanne; Wouldes, Trecia A.			Patient experience of a psychiatric Mother Baby Unit	PLOS ONE			English	Article							MENTAL-HEALTH; WOMEN; ILLNESS; DISORDERS; FRAMEWORK; RECOVERY; FATHERS	Background Mothers with severe mental illness are vulnerable and engage with services cautiously due to fears of stigma and custody loss. To develop best practice standards and patient-centred services, the subjective experience of those who use it must inform service improvement and policy. Method This study utilised exploratory concurrent mixed methods design with primarily qualitative data. Women admitted between April 2015 and December 2016 to a newly developed psychiatric Mother Baby Unit (MBU) in New Zealand were invited to participate in this study. Qualitative data were collected in three ways: (i) semi-structured interviews incorporating Maori concepts of health and wellness by research assistants near discharge; (ii) invitation to provide anonymous feedback in writing using an open format; (iii) unsolicited verbal feedback provided during a home visit three months after discharge. Thematic analysis was undertaken. Demographic and clinical information was collected prospectively for mother-infant pairs during the course of admission and three months post-discharge. Results Forty-five people participated in the study. High rates of satisfaction were described. Strengths of the service-as perceived by mothers-included co-admission of mother and infant, staff warmth and availability, transparent practice, inclusion of families, and having a comfortable environment. Mothers described intense distress and confusion, as well as negative self-perceptions when acutely unwell. Infant co-admission and the inclusion of partners and other family members alleviated mothers' distress. Personal attributes of staff, practical support with caregiving, a range of therapeutic approaches and holistic care were all valued. Feedback collected three months after discharge was the most reflective. Significant inter-ethnic differences were not apparent. Conclusions The experience of inpatient care can have lasting influence on recovery and wellbeing. Employing a Maori model of health broadened the holistic nature of enquiry. The approach and timing taken in seeking the views of participants' yielded different information, all of which is of value to service evaluation and refinement. The findings suggest that keeping mothers and infants together during health service utilisation such as MBUs should be a priority for policy makers and service designers. This approach is consistent with Maori values, combining the importance of whanau relationships (kinship), wairua (spiritual connectivity), hinengaro (the mind) and tinana (physical health). These findings suggest that 'holistic care'-in this case following a Maori holistic health model-is important in mental health settings.	[Wright, Tanya; Stevens, Suzanne; Wouldes, Trecia A.] Univ Auckland, Dept Psychol Med, Fac Med & Hlth Sci, Auckland, New Zealand; [Wright, Tanya; Stanton, Josephine] Auckland Dist Hlth Board, Starship Hosp, Child & Family Unit, Auckland, New Zealand; [Jowsey, Tanisha] Univ Auckland, Fac Med & Hlth Sci, Ctr Med & Hlth Serv Educ, Auckland, New Zealand; [Elder, Hinemoa] Te Whare Wananga Anuiarangi, Whakatane, New Zealand	University of Auckland; Auckland District Health Board; Starship Children's Hospital; University of Auckland	Wright, T (corresponding author), Univ Auckland, Dept Psychol Med, Fac Med & Hlth Sci, Auckland, New Zealand.; Wright, T (corresponding author), Auckland Dist Hlth Board, Starship Hosp, Child & Family Unit, Auckland, New Zealand.	tanya@adhb.govt.nz			A+ Trust, Auckland District Health Board [6429]	A+ Trust, Auckland District Health Board	The research on which this paper is based was funded by A+ Trust, Auckland District Health Board, Grant no 6429.	Abel S, 2001, SOC SCI MED, V53, P1135, DOI 10.1016/S0277-9536(00)00408-1; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th; Antonysamy A, 2009, ARCH WOMEN MENT HLTH, V12, P359, DOI 10.1007/s00737-009-0085-2; Austin M.P., 2017, MENTAL HLTH CARE PER; Bassett J.L., 1999, J MENTAL HLTH, V8, P597, DOI DOI 10.1080/09638239917067; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Connellan K, 2017, ARCH WOMEN MENT HLTH, P1; Connerty TJ, 2015, COMMUNITY MENT HLTH, P1; Crowe M, 2015, AUST NZ J PSYCHIAT, V49, P616, DOI 10.1177/0004867415582053; Dolman C, 2013, ARCH WOMEN MENT HLTH, V16, P173, DOI 10.1007/s00737-013-0336-0; Drake RE, 2014, CAN J PSYCHIAT, V59, P236, DOI 10.1177/070674371405900502; Durie M, 2004, INT J EPIDEMIOL, V33, P1138, DOI 10.1093/ije/dyh250; Durie M., 1994, WHAIORA MAORI DEV; Durie MH, 1996, AUSTRALAS PSYCHIATRY, V4, P189; Elder H, 2013, BRAIN IMPAIR, V14, P415, DOI 10.1017/BrImp.2013.29; Geertz C, 1966, INTERPRETATION CULTU, P360; Gillham R, 2015, INT J WOMENS HEALTH, V7, P459, DOI 10.2147/IJWH.S69472; Howard L, 2003, SOC PSYCH PSYCH EPID, V38, P450, DOI 10.1007/s00127-003-0663-y; Howden-Chapman P, 2000, SOCIAL INEQUALITIES, P76; Johannsen BMW, 2016, AM J PSYCHIAT, V173, P635, DOI 10.1176/appi.ajp.2015.14121510; Johansson H, 2003, SCAND J CARING SCI, V17, P339, DOI 10.1046/j.0283-9318.2003.00233.x; Jones CP, 2000, AM J PUBLIC HEALTH, V90, P1212, DOI 10.2105/AJPH.90.8.1212; Leamy M, 2011, BRIT J PSYCHIAT, V199, P445, DOI 10.1192/bjp.bp.110.083733; Marrs J, 2014, J REPROD INFANT PSYC, V32, P340, DOI 10.1080/02646838.2014.920951; Ministry of Health, 2017, REP MAT 2015; Munk-Olsen T, 2006, JAMA-J AM MED ASSOC, V296, P2582, DOI 10.1001/jama.296.21.2582; Nair R, 2010, AUSTRALAS PSYCHIATRY, V18, P573, DOI 10.3109/10398562.2010.499946; Neil S, 2006, ARCH WOMEN MENT HLTH, V9, P109, DOI 10.1007/s00737-005-0116-6; New Zealand Ministry of Health, 2013, 7 ANN REV PER MAT MO; Onwuegbuzie AJ, 2007, QUAL QUANT, V41, P233, DOI 10.1007/s11135-006-9000-3; Patton M. Q., 2005, QUALITATIVE RES; Reid H, 2017, CLIN PSYCHOL PSYCHOT, V24, P919, DOI 10.1002/cpp.2056; Rothbauer P., 2008, SAGE ENCY QUALITATIV, P892, DOI DOI 10.4135/9781412963909.N468; Sacristan JA, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-6; SCAMBLER G, 1986, SOCIOL HEALTH ILL, V8, P26, DOI 10.1111/1467-9566.ep11346455; Smylie J, 2006, LANCET, V367, P2029, DOI 10.1016/S0140-6736(06)68893-4; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Tamasese K, 2005, AUST NZ J PSYCHIAT, V39, P300, DOI 10.1111/j.1440-1614.2005.01572.x; Turbott J, 1996, AUST NZ J PSYCHIAT, V30, P720, DOI 10.3109/00048679609065037; UK National Institute for Health and Care Excellence, 2014, ANT POSTN MENT HLTH; Wan MW, 2008, GEN HOSP PSYCHIAT, V30, P177, DOI 10.1016/j.genhosppsych.2007.12.001; WINNICOTT DW, 1960, INT J PSYCHOANAL, V41, P585	42	6	6	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2018	13	5							e0198241	10.1371/journal.pone.0198241	http://dx.doi.org/10.1371/journal.pone.0198241			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GH7NG	29847584	gold, Green Submitted, Green Published			2023-01-03	WOS:000433634800060
J	Leng, RI				Leng, Rhodri Ivor			A network analysis of the propagation of evidence regarding the effectiveness of fatcontrolled diets in the secondary prevention of coronary heart disease (CHD): Selective citation in reviews	PLOS ONE			English	Review							SERUM-CHOLESTEROL; LONG-TERM; RISK-FACTORS; UNDERLYING MECHANISMS; MYOCARDIAL-INFARCTION; FATS; BLOOD; ARTERIAL; LIPIDS; ATHEROSCLEROSIS	Objective To examine how the first randomised controlled trials (RCTs) evaluating the efficacy of cholesterol-lowering diets in the secondary prevention of coronary heart disease were interpreted in reviews of the literature prior to the National Institutes of Health consensus conference in 1984. Design Claim-specific citation network analysis was used to study the network of citations between reviews and RCTs over a defined period (1969-1984). RCTs were identified and classified according to whether their conclusions supported or opposed the use of dietary fat modification/restriction in the secondary prevention of coronary heart disease. Each review published in this period that cited any of the RCTs was classified as supportive, neutral, or unsupportive to the use of dietary fat modification based on a quotation analysis of its evaluation of the findings of these RCTs. Citation bias and underutilisation were detected by applying a comparative density measure, in-degree centrality, and out-degree in a series of sub-graph analyses. Results In total, 66 unique publications were identified (four RCTs-one supportive, three unsupportive; 62 reviews-28 supportive, 17 neutral, 17 unsupportive). On average, supportive reviews underutilised the available RCTs to a greater degree than other reviews. Amongst the supportive group, citation bias was common-23 (82%) reviews cited only the one RCT that was supportive. Conclusion Most reviews that disseminated a supportive evaluation of the results of RCTs in the context of secondary prevention cited only data that supported this position.	[Leng, Rhodri Ivor] Univ Edinburgh, Sch Social & Polit Sci, Dept Sci Technol & Innovat Studies, Edinburgh, Midlothian, Scotland	University of Edinburgh	Leng, RI (corresponding author), Univ Edinburgh, Sch Social & Polit Sci, Dept Sci Technol & Innovat Studies, Edinburgh, Midlothian, Scotland.	rleng@exseed.ed.ac.uk	Leng, Rhodri/AAV-7229-2021	Leng, Rhodri/0000-0002-4861-826X	Economic and Social Research Council (ESRC) doctoral studentship; ESRCs Advanced Quantitative Methods (AQM) enhanced stipend	Economic and Social Research Council (ESRC) doctoral studentship; ESRCs Advanced Quantitative Methods (AQM) enhanced stipend	This work was supported by the Economic and Social Research Council (ESRC) doctoral studentship and the ESRCs Advanced Quantitative Methods (AQM) enhanced stipend (URL: http://www.esrc.ac.uk/skills-and-careers/studentships/esrc-students/advanced-quantitative-methods-aqm-enhanced-stipend/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMSON JH, 1976, PREV MED, V5, P32, DOI 10.1016/0091-7435(76)90006-2; AHRENS EH, 1976, ANN INTERN MED, V85, P87, DOI 10.7326/0003-4819-85-1-87; ANDERSON JT, 1973, J AM DIET ASSOC, V62, P133; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1972, Prev Med, V1, P255; Bastian M., 2009, INT AAAI C WEBL SOC; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BIERENBAUM ML, 1970, CIRCULATION, V42, P943, DOI 10.1161/01.CIR.42.5.943; BORHANI NO, 1977, AM J CARDIOL, V40, P251, DOI 10.1016/0002-9149(77)90016-9; BROWN DF, 1969, AM J MED, V46, P691, DOI 10.1016/0002-9343(69)90021-7; BUCHWALD H, 1982, CONTROL CLIN TRIALS, V3, P271, DOI 10.1016/0197-2456(82)90011-3; Bushman BJ, 2001, PERS SOC PSYCHOL B, V27, P1123, DOI 10.1177/0146167201279005; CARNIE JA, 1972, SCI PROG, V60, P231; CHRISTAKIS G, 1966, AM J PUBLIC HEALTH N, V56, P299, DOI 10.2105/AJPH.56.2.299; COATES ME, 1983, J DAIRY RES, V50, P541, DOI 10.1017/S0022029900032787; CORNFIELD J, 1969, ARCH ENVIRON HEALTH, V19, P382, DOI 10.1080/00039896.1969.10666860; DAYTON S, 1969, AM J MED, V46, P751, DOI 10.1016/0002-9343(69)90026-6; EATON RP, 1978, J CHRON DIS, V31, P131, DOI 10.1016/0021-9681(78)90027-9; Fanelli D, 2013, SCIENTOMETRICS, V94, P701, DOI 10.1007/s11192-012-0757-y; Frantz ID, 1975, CIRCULATION S2, V41, P2; FURBERG CD, 1984, AM J MED, V76, P76, DOI 10.1016/0002-9343(84)91047-7; Garrety K, 1997, SOC STUD SCI, V27, P727, DOI 10.1177/030631297027005002; GLUECK CJ, 1978, NEW ENGL J MED, V298, P1471, DOI 10.1056/NEJM197806292982610; GLUECK CJ, 1979, WESTERN J MED, V130, P117; GOLDMAN GJ, 1983, PROG CARDIOVASC DIS, V25, P513, DOI 10.1016/0033-0620(83)90022-1; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GRANDE F, 1974, S AFR MED J, V48, P1660; Greenberg Steven A, 2009, BMJ, V339, pb2680, DOI 10.1136/bmj.b2680; GRUNDY S M, 1982, Circulation, V65, p839A; GRUNDY SM, 1977, AM J CLIN NUTR, V30, P985, DOI 10.1093/ajcn/30.6.985; Hamley S, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0254-5; Handcock MS, 2003, SOFTWARE TOOLS STAT; HANSEN PF, 1962, LANCET, V2, P1193; Harcombe Z, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000196; HEGSTED DM, 1978, AM J CLIN NUTR, V31, P1504, DOI 10.1093/ajcn/31.9.1504; HEGSTED DM, 1979, CANCER, V43, P1996, DOI 10.1002/1097-0142(197905)43:5+<1996::AID-CNCR2820430707>3.0.CO;2-Z; Heider F., 1958, PSYCHOL INTERPERSONA, DOI [DOI 10.1037/10628-004, DOI 10.1037/14200-000]; HJERMANN I, 1981, LANCET, V2, P1303; HOOD B, 1965, ACTA MED SCAND, V178, P161; Hooper Lee, 2015, Cochrane Database Syst Rev, pCD011737, DOI 10.1002/14651858.CD011737; HORNSTRA G, 1980, POSTGRAD MED J, V56, P563, DOI 10.1136/pgmj.56.658.563; HORNSTRA G, 1981, Progress in Lipid Research, V20, P407, DOI 10.1016/0163-7827(81)90072-2; Howard A N, 1975, J Clin Pathol Suppl (R Coll Pathol), V9, P106; HULLEY SB, 1981, WESTERN J MED, V135, P25; HULLEY SB, 1983, ARCH INTERN MED, V143, P667, DOI 10.1001/archinte.143.4.667; HYMOWITZ N, 1980, INT J MENT HEALTH, V9, P27, DOI 10.1080/00207411.1980.11448851; INKELES S, 1981, MEDICINE, V60, P110, DOI 10.1097/00005792-198103000-00004; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; JACOBSON NL, 1974, BIOSCIENCE, V24, P141, DOI 10.2307/1296759; Jacomy M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098679; JOLLIFFE N, 1959, CIRCULATION, V20, P109, DOI 10.1161/01.CIR.20.1.109; JONES RJ, 1983, JAMA-J AM MED ASSOC, V250, P1873; KANNEL WB, 1984, CIRCULATION, V70, P160; Kannel WB, 1976, CURR PROB CARDIOLOGY, V1, P1; KEYS A, 1957, LANCET, V2, P959; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KRITCHEVSKY D, 1976, AM J PATHOL, V84, P615; Kuhn T., 1962, STRUCTURE SCI REVOLU; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEES RS, 1971, NEW ENGL J MED, V284, P186, DOI 10.1056/NEJM197101282840406; LEREN P, 1968, B NEW YORK ACAD MED, V44, P1012; LEREN P, 1969, Minnesota Medicine, V52, P1231; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; LEWIS B, 1978, J ROY SOC MED, V71, P809, DOI 10.1177/014107687807101108; LITTLE JA, 1971, C J PUBLIC HEALTH, V62, P27; LOGUE RB, 1972, CIRCULATION, V46, P1132, DOI 10.1161/01.CIR.46.6.1132; LYON T P, 1956, Calif Med, V84, P325; MALMROS H, 1969, LANCET, V2, P479; MANN GV, 1957, AM J MED, V23, P463, DOI 10.1016/0002-9343(57)90325-X; MANN GV, 1977, NEW ENGL J MED, V297, P644, DOI 10.1056/NEJM197709222971206; MANN GV, 1978, AM HEART J, V96, P569, DOI 10.1016/0002-8703(78)90191-6; MANN JI, 1979, BMJ-BRIT MED J, V1, P732, DOI 10.1136/bmj.1.6165.732; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; MCBEAN LD, 1974, PEDIATR RES, V8, P837, DOI 10.1203/00006450-197410000-00004; MCMICHAEL J, 1979, AM HEART J, V98, P409; MCMICHAEL J, 1979, BMJ-BRIT MED J, V1, P173, DOI 10.1136/bmj.1.6157.173; Misemer BS, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1595-7; MORRISON LM, 1960, JAMA-J AM MED ASSOC, V173, P884, DOI 10.1001/jama.1960.03020260024006; National Diet-Heart Study Research Group. The National Diet-Heart Study Final Report, 1968, CIRCULATION S, V37, pI1; National Research Council Diet and Health, 1989, IMPL RED CHRON DIS R; Nelson AM, 1965, NW MED, V55, P643; Newman M, 2010, NETWORKS INTRO, DOI 10.1162/artl_r_00062; Nieminen P, 2007, J CLIN EPIDEMIOL, V60, P939, DOI 10.1016/j.jclinepi.2006.11.014; NORA JJ, 1980, J PEDIATR-US, V97, P706, DOI 10.1016/S0022-3476(80)80251-4; OLIVER MF, 1981, LANCET, V2, P1090; OLIVER MF, 1984, BRIT MED J, V289, P1641, DOI 10.1136/bmj.289.6459.1641; PAGE IH, 1961, CIRCULATION, V23, P133, DOI 10.1161/01.CIR.23.1.133; Parolo PD, 2015, J INFORMETR, V9, P734, DOI 10.1016/j.joi.2015.07.006; PILKINGTON TRE, 1960, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.5165.23; Price Derek John de Solla, 1963, LITTLE SCI BIG SCI, V5, DOI [DOI 10.7312/PRIC91844, 10.7312/pric91844]; Ramsden CE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8707; Rathmann DM, 1970, CRC CRIT REV FOOD TE, V1, P331; Ravetz J., 1971, SCI KNOWLEDGE ITS SO; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RAVNSKOV U, 1995, J CLIN EPIDEMIOL, V48, P713, DOI 10.1016/0895-4356(94)00222-C; Ravnskov U, 2003, BRIT MED J, V327, P1348, DOI 10.1136/bmj.327.7427.1348-b; RENAUD S, 1974, THROMB RES, V4, P25, DOI 10.1016/0049-3848(74)90145-5; Robinson KA, 2011, ANN INTERN MED, V154, P50, DOI 10.7326/0003-4819-154-1-201101040-00007; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; Schwingshackl L, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004487; Seymour D, 1969, CIRCULATION       S2, V40, P1, DOI DOI 10.1161/01.CIR.40.1S2.II-1; SHAPER AG, 1976, POSTGRAD MED J, V52, P464, DOI 10.1136/pgmj.52.609.464; SIMBORG DW, 1970, J CHRON DIS, V22, P515, DOI 10.1016/0021-9681(70)90031-7; Simkin M., 2003, COMPLEX SYST, V14, P269; Song F, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14080; STALLONES RA, 1983, ANNU REV NUTR, V3, P155, DOI 10.1146/annurev.nu.03.070183.001103; STAMLER J, 1980, ACTA MED SCAND, V207, P433; STAMLER J, 1973, MED CLIN N AM, V57, P5, DOI 10.1016/S0025-7125(16)32300-8; STEINBERG D, 1981, J PATHOL, V133, P75, DOI 10.1002/path.1711330108; STEINBERG D, 1979, CIRCULATION, V60, P1559, DOI 10.1161/01.CIR.60.7.1559; STORMORKEN H, 1973, HAEMOSTASIS, V2, P1; Team R.C., 2021, R FOUN DATION STAT C; Trinquart L, 2016, INT J EPIDEMIOL, V45, P251, DOI 10.1093/ije/dyv184; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; VERGROESEN AJ, 1972, P NUTR SOC, V31, P323, DOI 10.1079/PNS19720059; WALKER A R P, 1969, South African Medical Journal, V43, P768; WALKER ARP, 1980, S AFR MED J, V58, P7; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; YERUSHALMY J, 1957, N Y State J Med, V57, P2343; YESHURUN D, 1976, AM J MED, V60, P379, DOI 10.1016/0002-9343(76)90755-5; Young NS, 2008, PLOS MED, V5, P1418, DOI 10.1371/journal.pmed.0050201; YUDKIN J, 1957, LANCET, V2, P154; ZELIS R, 1970, CALIF MED, V112, P32	125	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197716	10.1371/journal.pone.0197716	http://dx.doi.org/10.1371/journal.pone.0197716			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GH0HY	29795624	Green Published, Green Submitted, gold			2023-01-03	WOS:000433084300065
J	Durand, CM; Bowring, MG; Thomas, AG; Kucirka, LM; Massie, AB; Cameron, A; Desai, NM; Sulkowski, M; Segev, DL				Durand, Christine M.; Bowring, Mary G.; Thomas, Alvin G.; Kucirka, Lauren M.; Massie, Allan B.; Cameron, Andrew; Desai, Niraj M.; Sulkowski, Mark; Segev, Dorry L.			The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-C; KIDNEY; RISK; VIRUS; RECIPIENTS; INCREASES; INFECTION; SURVIVAL; OUTCOMES; DISCARD	Background: The epidemic of drug overdose deaths in the United States has led to an increase in organ donors. Objective: To characterize donors who died of overdose and to analyze outcomes among transplant recipients. Design: Prospective observational cohort study. Setting: Scientific Registry of Transplant Recipients, 1 January 2000 to 1 September 2017. Participants: 138 565 deceased donors; 337 934 transplant recipients at 297 transplant centers. Measurements: The primary exposure was donor mechanism of death (overdose-death donor [ODD], trauma-death donor [TDD], or medical-death donor [MDD]). Patient and graft survival and organ discard (organ recovered but not transplanted) were compared using propensity score-weighted standardized risk differences (sRDs). Results: A total of 7313 ODDs and 19 897 ODD transplants (10 347 kidneys, 5707 livers, 2471 hearts, and 1372 lungs) were identified. Overdose-death donors accounted for 1.1% of donors in 2000 and 13.4% in 2017. They were more likely to be white (85.1%), aged 21 to 40 years (66.3%), infected with hepatitis C virus (HCV) (18.3%), and increased-infectious risk donors (IRDs) (56.4%). Standardized 5-year patient survival was similar for ODD organ recipients compared with TDD organ recipients (sRDs ranged from 3.1% lower to 3.9% higher survival) and MDD organ recipients (sRDs ranged from 2.1% to 5.2% higher survival). Standardized 5-year graft survival was similar between ODD and TDD grafts (minimal difference for kidneys and lungs, marginally lower [sRD, -3.2%] for livers, and marginally higher [sRD, 1.9%] for hearts). Kidney discard was higher for ODDs than TDDs (sRD, 5.2%) or MDDs (sRD, 1.5%); standardization for HCV and IRD status attenuated this difference. Limitation: Inability to distinguish between opioid and nonopioid overdoses. Conclusion: In the United States, transplantation with ODD organs has increased dramatically, with noninferior outcomes in transplant recipients. Concerns about IRD behaviors and hepatitis C among donors lead to excess discard that should be minimized given the current organ shortage.	[Durand, Christine M.] Johns Hopkins Univ, Sch Med, Dept Med, 725 North Wolfe St,Suite 211, Baltimore, MD 21205 USA; [Bowring, Mary G.; Thomas, Alvin G.; Massie, Allan B.; Segev, Dorry L.] Johns Hopkins Univ, Dept Surg, 2000 East Monument St, Baltimore, MD 21205 USA; [Kucirka, Lauren M.] Johns Hopkins Univ, Sch Med, Dept Surg, 2215 East Pratt St, Baltimore, MD 21231 USA; [Cameron, Andrew; Desai, Niraj M.] Johns Hopkins Univ, Dept Med, 720 Rutland Ave,Ross 765,Ross 771, Baltimore, MD 21205 USA; [Sulkowski, Mark] Johns Hopkins Univ, Sch Med, 1830 East Monument St,Room 445, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Durand, CM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 725 North Wolfe St,Suite 211, Baltimore, MD 21205 USA.	cdurand2@jhmi.edu; mbowrin1@jhmi.edu	Thomas, Alvin/R-9391-2016	Thomas, Alvin/0000-0003-4911-8192	National Institutes of Health; Division of Intramural Research, National Cancer Institute [K23CA177321-01A1]; National Institute of Diabetes and Digestive and Kidney Diseases [F30DK095545, K23DK101677, R01DK111966, K24DK101828, R01AI120938]; National Institute of Allergy and Infectious Diseases [K24DA034621]; NATIONAL CANCER INSTITUTE [K23CA177321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI120938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F30DK095545, R01DK111966, K24DK101828, K01DK101677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016065, K24DA034621] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Division of Intramural Research, National Cancer Institute; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Dr. Durand is supported by the Division of Intramural Research, National Cancer Institute (grant K23CA177321-01A1). Drs. Kucirka, Massie, Cameron, and Segev are supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grants F30DK095545 [Dr. Kucirka], K23DK101677 [Dr. Massie], R01DK111966 [Dr. Cameron], and K24DK101828 and R01AI120938 [Dr. Segev]). Dr. Sulkowski is supported by the National Institute of Allergy and Infectious Diseases (grant K24DA034621).	[Anonymous], 1994, MMWR Recomm Rep, V43, P1; [Anonymous], 2017, ORG PROC TRANSPL NET; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Ballarin R, 2011, TRANSPLANTATION, V91, P1265, DOI 10.1097/TP.0b013e318219eb8f; Bowring MG, 2017, AM J TRANSPLANT, V17, P519, DOI 10.1111/ajt.13976; Bowring MG, 2018, AM J TRANSPLANT, V18, P617, DOI 10.1111/ajt.14577; Brown RS, 2016, LIVER TRANSPLANT, V22, P24, DOI 10.1002/lt.24366; Centers for Disease Control and Prevention National Center for Health Statistics, 2017, UND CAUS DEATH 1999; Cohen JB, 2017, CLIN KIDNEY J, V10, P564, DOI 10.1093/ckj/sfx048; Cole SR, 2004, COMPUT METH PROG BIO, V75, P45, DOI 10.1016/j.cmpb.2003.10.004; Danovitch GM, 2005, AM J TRANSPLANT, V5, P904, DOI 10.1111/j.1600-6135.2005.00835.x; Dumortier J, 2016, LIVER TRANSPLANT, V22, P1367, DOI 10.1002/lt.24505; Durand CM, 2018, ANN INTERN MED, V168, P533, DOI 10.7326/M17-2871; Friedewald JJ, 2012, AM J TRANSPLANT, V12, P1971, DOI 10.1111/j.1600-6143.2012.04149.x; Gill JS, 2007, KIDNEY INT, V71, P442, DOI 10.1038/sj.ki.5002072; Gok MA, 2004, CLIN TRANSPLANT, V18, P541, DOI 10.1111/j.1399-0012.2004.00207.x; Goldberg DS, 2016, AM J TRANSPLANT, V16, P2836, DOI 10.1111/ajt.13971; Goldberg DS, 2017, NEW ENGL J MED, V376, P2394, DOI 10.1056/NEJMc1705221; Gordon EJ, 2014, TRANSPL INFECT DIS, V16, P251, DOI 10.1111/tid.12199; Goss M, 2017, LIVER TRANSPLANT, V23, P698, DOI 10.1002/lt.24761; Kucirka LM, 2011, AM J TRANSPLANT, V11, P1176, DOI 10.1111/j.1600-6143.2010.03329.x; Kucirka LM, 2011, AM J TRANSPLANT, V11, P1188, DOI 10.1111/j.1600-6143.2011.03460.x; Kucirka LM, 2010, AM J TRANSPLANT, V10, P1238, DOI 10.1111/j.1600-6143.2010.03091.x; Marrero WJ, 2017, TRANSPLANTATION, V101, P1690, DOI 10.1097/TP.0000000000001238; Massie AB, 2010, AM J TRANSPLANT, V10, P2472, DOI 10.1111/j.1600-6143.2010.03294.x; Metzger RA, 2003, AM J TRANSPLANT, V3, P114, DOI 10.1034/j.1600-6143.3.s4.11.x; Montenovo MI, 2015, ANN TRANSPL, V20, P44, DOI 10.12659/AOT.892530; Rao PS, 2009, TRANSPLANTATION, V88, P231, DOI 10.1097/TP.0b013e3181ac620b; Reese PP, 2015, NEW ENGL J MED, V373, P303, DOI 10.1056/NEJMp1505074; Reese PP, 2010, CLIN J AM SOC NEPHRO, V5, P917, DOI 10.2215/CJN.08251109; Ros RL, 2012, CLIN TRANSPLANT, V26, P247, DOI 10.1111/j.1399-0012.2011.01469.x; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Rudd RA, 2014, MMWR-MORBID MORTAL W, V63, P849; Saxena V, 2017, HEPATOLOGY, V66, P1090, DOI 10.1002/hep.29258; Scientific Registry of Transplant Recipients, 2018, SRTR RISK ADJ MOD DO; Seem DL, 2013, PUBLIC HEALTH REP, V128, P247, DOI 10.1177/003335491312800403; Sutter ME, 2010, WEST J EMERG MED, V11, P506; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Weiner SG, 2017, TRANSPLANTATION, V101, P678, DOI 10.1097/TP.0000000000001671; Weinkauf JG, 2013, TRANSPL P, V45, P2375, DOI 10.1016/j.transproceed.2012.11.004	42	132	132	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2018	168	10					702	+		10.7326/M17-2451	http://dx.doi.org/10.7326/M17-2451			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI3DE	29710288	Green Accepted			2023-01-03	WOS:000434250700014
J	Barker, M; Dombrowski, SU; Colbourn, T; Fall, CHD; Kriznik, NM; Lawrence, WT; Norris, SA; Ngaiza, G; Patel, D; Skordis-Worrall, J; Sniehotta, FF; Steegers-Theunissen, R; Vogel, C; Woods-Townsend, K; Stephenson, J				Barker, Mary; Dombrowski, Stephan U.; Colbourn, Tim; Fall, Caroline H. D.; Kriznik, Natasha M.; Lawrence, Wendy T.; Norris, Shane A.; Ngaiza, Gloria; Patel, Dilisha; Skordis-Worrall, Jolene; Sniehotta, Falko F.; Steegers-Theunissen, Regine; Vogel, Christina; Woods-Townsend, Kathryn; Stephenson, Judith			Intervention strategies to improve nutrition and health behaviours before conception	LANCET			English	Article							OBESITY-RELATED BEHAVIORS; LOW-BIRTH-WEIGHT; LIFE-STYLE; PHYSICAL-ACTIVITY; ADOLESCENT GIRLS; POSTPARTUM WOMEN; MATERNAL NUTRITION; CONTROLLED-TRIAL; CHILD NUTRITION; SOUTH-AFRICA	The nutritional status of both women and men before conception has profound implications for the growth, development, and long-term health of their offspring. Evidence of the effectiveness of preconception interventions for improving outcomes for mothers and babies is scarce. However, given the large potential health return, and relatively low costs and risk of harm, research into potential interventions is warranted. We identified three promising strategies for intervention that are likely to be scalable and have positive effects on a range of health outcomes: supplementation and fortification; cash transfers and incentives; and behaviour change interventions. On the basis of these strategies, we suggest a model specifying pathways to effect. Pathways are incorporated into a life-course framework using individual motivation and receptiveness at different preconception action phases, to guide design and targeting of preconception interventions. Interventions for individuals not planning immediate pregnancy take advantage of settings and implementation platforms outside the maternal and child health arena, since this group is unlikely to be engaged with maternal health services. Interventions to improve women's nutritional status and health behaviours at all preconception action phases should consider social and environmental determinants, to avoid exacerbating health and gender inequalities, and be underpinned by a social movement that touches the whole population. We propose a dual strategy that targets specific groups actively planning a pregnancy, while improving the health of the population more broadly. Modern marketing techniques could be used to promote a social movement based on an emotional and symbolic connection between improved preconception maternal health and nutrition, and offspring health. We suggest that speedy and scalable benefits to public health might be achieved through strategic engagement with the private sector. Political theory supports the development of an advocacy coalition of groups interested in preconception health, to harness the political will and leadership necessary to turn high-level policy into effective coordinated action.	[Barker, Mary; Fall, Caroline H. D.; Lawrence, Wendy T.; Vogel, Christina] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England; [Barker, Mary; Lawrence, Wendy T.; Vogel, Christina; Woods-Townsend, Kathryn] Southampton Gen Hosp, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England; [Dombrowski, Stephan U.] Univ Stirling, Div Psychol, Fac Nat Sci, Stirling, Scotland; [Colbourn, Tim; Ngaiza, Gloria; Skordis-Worrall, Jolene] UCL, UCL Inst Global Hlth, London, England; [Patel, Dilisha; Stephenson, Judith] UCL, UCL EGA Inst Womens Hlth, Fac Populat Hlth Sci, London, England; [Kriznik, Natasha M.] Univ Cambridge, Healthcare Improvement Studies Inst, Cambridge, England; [Norris, Shane A.] Univ Witwatersrand, Sch Clin Med, Dept Paediat, MRC Dev Pathways Hlth Res Unit,Fac Hlth Sci, Johannesburg, South Africa; [Sniehotta, Falko F.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Sniehotta, Falko F.] Fuse, Newcastle Upon Tyne, Tyne & Wear, England; [Steegers-Theunissen, Regine] Univ Med Ctr, Erasmus MC, Dept Obstet & Gynaecol, Rotterdam, Netherlands; [Steegers-Theunissen, Regine] Univ Med Ctr, Erasmus MC, Dept Pediat, Div Neonatol, Rotterdam, Netherlands; [Woods-Townsend, Kathryn] Univ Southampton, Southampton Educ Sch, Fac Social & Human Sci, Southampton, Hants, England	University of Southampton; University of Southampton; University of Stirling; University of London; University College London; University of London; University College London; University of Cambridge; University of Witwatersrand; Newcastle University - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Southampton	Stephenson, J (corresponding author), UCL, Inst Womens Hlth, Fac Populat Hlth Sci, Med Sch Bldg,74 Huntley St, London WC1E 6AU, England.	judith.stephenson@ucl.ac.uk	Norris, Shane/C-4664-2014; Sniehotta, Falko F/C-5481-2008; Sniehotta, Falko/ABF-7131-2021; Colbourn, Tim/AAE-6645-2019	Norris, Shane/0000-0001-7124-3788; Sniehotta, Falko F/0000-0003-1738-4269; Sniehotta, Falko/0000-0003-1738-4269; Colbourn, Tim/0000-0002-6917-6552; Skordis, Jolene/0000-0002-8633-0208; Fall, Caroline/0000-0003-4402-5552; Woods-Townsend, Kathryn/0000-0003-3376-6988; Barker, Mary/0000-0003-2976-0217; Vogel, Christina/0000-0002-3897-3786; Lawrence, Wendy/0000-0003-1264-0438; Kriznik, Natasha/0000-0002-4291-0614	Rank Prize Funds, on Preconception Nutrition and Lifelong Health in Grasmere, UK; MRC [MC_UP_A620_1017, MC_UU_12011/4, MC_UU_12011/3, MC_PC_MR/R018545/1, MR/N011848/1] Funding Source: UKRI	Rank Prize Funds, on Preconception Nutrition and Lifelong Health in Grasmere, UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The idea for this Series was conceived by JS and developed during a 4-day symposium, led by MB and JS and funded by The Rank Prize Funds, on Preconception Nutrition and Lifelong Health in Grasmere, UK, February, 2016. We thank a number of individuals who have contributed their thoughts and time to this paper: Nicola Heslehurst (Newcastle University, Newcastle, UK) for her contribution to an early draft of the paper; Zulfi Bhutta (Aga Khan University, Karachi, Pakistan) for his perspectives on interventions in LMICs; Chandni Jacob and Mark Hanson (University of Southampton, Southampton, UK) for their contribution to the review; Jayne Hutchinson and Janet Cade (University of Leeds, Leeds, UK) for advice on fortification; Matthijs van Dijk (Erasmus MC, Rotterdam, Netherlands) for data from Smarter Pregnancy; Julius Cheah and the Jom Mama project partners comprised of the Ministry of Health of Malaysia (Putrajaya, Malaysia), University of Southampton (Southampton, UK), University of Witwatersrand (Johannesburg, South Africa), Steno Diabetes Center (Gentofte, Denmark), and Novo Nordisk (Gentofte, Denmark); Mike Kelly (University of Cambridge, Cambridge, UK) for discussions on the value of social practices; and Andy Last (MullenLowe salt, London, UK) for his insights into how a social movement might be created around preconception health.	Acosta AM, 2011, EXAMINING POLITICAL; Adams J, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1001990, 10.1371/journal.pmed.1002045]; Bachrach CA, 2013, POPUL DEV REV, V39, P459, DOI 10.1111/j.1728-4457.2013.00612.x; Baird J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005290; Barker M, 2006, J NUTR, V136, P3062, DOI 10.1093/jn/136.12.3062; Bates B., 2014, NATL DIET NUTR SURVE; Bhutta ZA, 2017, ANN NY ACAD SCI, V1393, P61, DOI 10.1111/nyas.13352; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; BIRDWELL AE, 1968, J BUS, V41, P76, DOI 10.1086/295047; Black C, 2014, PUBLIC HEALTH NUTR, V17, P700, DOI 10.1017/S1368980012004089; Black RE, 2013, LANCET, V382, P372, DOI 10.1016/S0140-6736(13)60988-5; Blakemore SJ, 2014, ANNU REV PSYCHOL, V65, P187, DOI 10.1146/annurev-psych-010213-115202; Brady JP, 2012, ARCH DIS CHILD, V97, P529, DOI 10.1136/archdischild-2011-301299; CAAN B, 1987, AM J CLIN NUTR, V45, P29, DOI 10.1093/ajcn/45.1.29; Ceschia A, 2016, LANCET, V388, P2064, DOI 10.1016/S0140-6736(16)31534-3; Chorghade GP, 2006, PUBLIC HEALTH NUTR, V9, P9, DOI 10.1079/PHN2005762; Compernolle S, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0147-3; Craigie AM, 2011, MATURITAS, V70, P266, DOI 10.1016/j.maturitas.2011.08.005; Crider KS, 2011, NUTRIENTS, V3, P370, DOI 10.3390/nu3030370; De-Regil LM, 2016, J NUTR, V146, p1461S, DOI 10.3945/jn.115.223487; Dennison L, 2014, J MED INTERNET RES, V16, P130, DOI 10.2196/jmir.3199; Dodd JM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0161-y; Draper CE, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-S2-S5; Elsinga J, 2008, WOMEN HEALTH ISS, V18, pS117, DOI 10.1016/j.whi.2008.09.003; Fenn B, 2015, RES FOOD ASSISTANCE; Fenn B, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002305; Flynn AC, 2016, INT J BEHAV NUTR PHY, V13, DOI 10.1186/s12966-016-0450-2; Food Fortification Initiative, 2017, SAY HELL FORT FUT 20; Gaglio B, 2013, AM J PUBLIC HEALTH, V103, pE38, DOI 10.2105/AJPH.2013.301299; Gardner B, 2011, OBES REV, V12, pE602, DOI 10.1111/j.1467-789X.2011.00884.x; Gaziano TA, 2015, LANCET GLOB HEALTH, V3, pE556, DOI 10.1016/S2214-109X(15)00143-6; Godfrey KM, 2010, TRENDS ENDOCRIN MET, V21, P199, DOI 10.1016/j.tem.2009.12.008; Grace M, 2012, HEALTH EDUC, V112, P543, DOI 10.1108/09654281211275890; Hammiche F, 2011, HUM REPROD, V26, P2432, DOI 10.1093/humrep/der225; Hawkes C., 2017, GLOBAL NUTR REPORT 2; Hawkes C, 2008, DEV POLICY REV, V26, P657, DOI 10.1111/j.1467-7679.2008.00428.x; Heckhausen H., 1991, MOTIVATION ACTION; Heckhausen J, 2006, DEV REGULATION ADULT; Herman DR, 2006, J AM DIET ASSOC, V106, P740, DOI 10.1016/j.jada.2006.02.004; Huseinovic E, 2016, AM J CLIN NUTR, V104, P362, DOI 10.3945/ajcn.116.135673; Hussein N, 2016, EUR J GEN PRACT, V22, P42, DOI 10.3109/13814788.2015.1099039; Kelly MP, 2016, PUBLIC HEALTH, V136, P109, DOI 10.1016/j.puhe.2016.03.030; King JC, 2016, J NUTR, V146, p1437S, DOI 10.3945/jn.115.223479; Kirkpatrick S, 2017, FASEB J, V31; Kwasnicka D, 2016, HEALTH PSYCHOL REV, V10, P277, DOI 10.1080/17437199.2016.1151372; Lassi ZS, 2012, INT J WOMENS HEALTH, V4, P185, DOI 10.2147/IJWH.S18611; Last A., 2016, BUSINESS MISSION BUI; Lawrence W, 2016, J HEALTH PSYCHOL, V21, P138, DOI 10.1177/1359105314523304; Lee SH, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010401; Lim S, 2015, OBES REV, V16, P972, DOI 10.1111/obr.12312; Lorenc T, 2013, J EPIDEMIOL COMMUN H, V67, P190, DOI 10.1136/jech-2012-201257; Lumley J, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-299; Manley J, 2012, EFFECTIVE ARE CASH T; Mastroiacovo P, 2011, BIOFACTORS, V37, P272, DOI 10.1002/biof.172; MCDONALD EC, 1981, AM J CLIN NUTR, V34, P2133, DOI 10.1093/ajcn/34.10.2133; Michie S, 2013, HEALTH PSYCHOL REV, V7, P1, DOI 10.1080/17437199.2011.649445; Miller W B, 1994, Genet Soc Gen Psychol Monogr, V120, P223; Monteiro CA, 2010, B WORLD HEALTH ORGAN, V88, P305, DOI 10.2471/BLT.09.069195; Morrison J, 2018, PUBLIC HEALTH NUTR, V21, P377, DOI 10.1017/S1368980017002646; Muktabhant B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007145.pub3; Nair N, 2017, LANCET GLOB HEALTH, V5, pE1004, DOI 10.1016/S2214-109X(17)30339-X; Nair N, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1655-z; Nettle D, 2011, PHILOS T R SOC B, V366, P357, DOI 10.1098/rstb.2010.0073; Neville CE, 2014, BIRTH-ISS PERINAT C, V41, P223, DOI 10.1111/birt.12111; Norris SA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3827-x; Patel V, 2017, LANCET, V389, P176, DOI 10.1016/S0140-6736(16)31589-6; Patton GC, 2016, LANCET, V387, P2423, DOI 10.1016/S0140-6736(16)00579-1; Peacock AS, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/423717; Pechey R, 2015, AM J PREV MED, V49, P868, DOI 10.1016/j.amepre.2015.04.020; Pena-Rosas JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub4; Phelan S, 2017, JAMA-J AM MED ASSOC, V317, P2381, DOI 10.1001/jama.2017.7119; Poston L, 2016, LANCET DIABETES ENDO, V4, P1025, DOI 10.1016/S2213-8587(16)30217-0; Potdar RD, 2014, AM J CLIN NUTR, V100, P1257, DOI 10.3945/ajcn.114.084921; Prost A, 2013, LANCET, V381, P1736, DOI 10.1016/S0140-6736(13)60685-6; Ramakrishnan U, 2012, PAEDIATR PERINAT EP, V26, P285, DOI 10.1111/j.1365-3016.2012.01281.x; Rawlings LB, 2005, WORLD BANK RES OBSER, V20, P29, DOI 10.1093/wbro/lki001; Ritchie LD, 2010, J NUTR EDUC BEHAV, V42, pS2, DOI 10.1016/j.jneb.2010.02.014; Ruel MT, 2013, LANCET, V382, P536, DOI 10.1016/S0140-6736(13)60843-0; Sahariah SA, 2016, J NUTR, V146, p1453S, DOI 10.3945/jn.115.223461; Santos I, 2017, OBES REV, V18, P32, DOI 10.1111/obr.12466; Saville NM, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1102-x; Scientific Advisory Committee on Nutrition (SACN), 2017, FOL AC UPD SACN REC; Shove E., 2012, DYNAMICS SOCIAL PRAC, DOI DOI 10.4135/9781446250655; Steegers EAP, 2016, PAEDIATR PERINAT EP, V30, P201, DOI 10.1111/ppe.12275; Swinburn B, 2015, LANCET, V385, P2534, DOI 10.1016/S0140-6736(14)61747-5; Tanentsapf I, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-81; Tuomainen H, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002977; Twigt JM, 2012, HUM REPROD, V27, P2526, DOI 10.1093/humrep/des157; UN Department of Economic and Social Affairs, 2016, SUST DEV GOAL 2, V2; Unilever, 2015, KNORRS GREEN FOOD ST; United Nations Secretary-General, 2015, GLOB STRAT WOM CHILD; US Centers for Disease Control and Prevention, 2014, MY REPR LIF PLAN; van der Pligt P, 2013, OBES REV, V14, P792, DOI 10.1111/obr.12053; van Dijk MR, 2017, REPROD BIOMED ONLINE, V35, P453, DOI 10.1016/j.rbmo.2017.06.014; Van Dijk Matthijs R, 2016, JMIR Mhealth Uhealth, V4, pe53, DOI 10.2196/mhealth.5197; Vansteenkiste M, 2004, J PERS SOC PSYCHOL, V87, P246, DOI 10.1037/0022-3514.87.2.246; Viner RM, 2015, J EPIDEMIOL COMMUN H, V69, P719, DOI 10.1136/jech-2014-205300; Vogel C, 2016, AM J PREV MED, V51, pE27, DOI 10.1016/j.amepre.2016.02.030; Weible CM, 2007, PUBLIC ADM PUBLIC PO, V125, P123; Whitworth M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007536.pub2; WHO, 2014, GUID FORT FOOD GRAD, P1; WHO, 2017, GLOBAL ACCELERATED A; Woods-Townsend K, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0890-z; World Health Organisation, 2013, M DEV GLOB CONS PREC; World Health Organization, 2014, GLOB NUTR TARG 2025, DOI [10.1057/9781137477699_6, DOI 10.1057/9781137477699_6]	105	173	174	8	90	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2018	391	10132					1853	1864		10.1016/S0140-6736(18)30313-1	http://dx.doi.org/10.1016/S0140-6736(18)30313-1			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE7NY	29673875	Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000431421300030
J	You, CH; Choi, JH; Kang, S; Oh, EH; Kwon, YD				You, Chang Hoon; Choi, Ji Heon; Kang, Sungwook; Oh, Eun-Hwan; Kwon, Young Dae			Association between supplementary private health insurance and visits to physician offices versus hospital outpatient departments among adults with diabetes in the universal public insurance system	PLOS ONE			English	Article							CARE; DEMAND; DETERMINANTS; SELECTION; SERVICES; COVERAGE	Background Diabetes mellitus is a chronic disease with a high prevalence across the world as well as in South Korea. Most cases of diabetes can be adequately managed at physician offices, but many diabetes patients receive outpatient care at hospitals. This study examines the relationship between supplementary private health insurance (SPHI) ownership and the use of hospitals among diabetes outpatients within the universal public health insurance scheme. Methods Data from the 2011 Korea Health Panel, a nationally representative sample of Korean individuals, was used. For the study, 6,379 visits for diabetes care were selected while controlling for clustered errors. Multiple logistic regression models were used to examine determinants of hospital outpatient services. Results This study demonstrated that the variables of self-rated health status, comorbidity, unmet need, and alcohol consumption significantly correlated with the choice to use a hospital services. Patients with SPHI were more likely to use medical services at hospitals by 1.71 times (95% CI 1.068-2.740, P = 0.026) compared to patients without SPHI. Conclusions It was confirmed that diabetic patients insured by SPHI had more use of hospital services than those who were not insured. People insured by SPHI seem to be more likely to use hospital services because SPHI lightens the economic burden of care.	[You, Chang Hoon] Catholic Univ Korea, Grad Sch Healthcare Management & Policy, Seoul, South Korea; [Choi, Ji Heon] Int Inst Hlth, Seoul, South Korea; [Kang, Sungwook] Daegu Haany Univ, Dept Publ Hlth, Gyongsan, South Korea; [Oh, Eun-Hwan] Hyupsung Univ, Dept Healthcare Management, Hwaseong, South Korea; [Kwon, Young Dae] Catholic Univ Korea, Coll Med, Dept Humanities & Social Med, Seoul, South Korea; [Kwon, Young Dae] Catholic Univ Korea, Catholic Inst Healthcare Management, Seoul, South Korea	Catholic University of Korea; Daegu Haany University; Catholic University of Korea; Catholic University of Korea	Kwon, YD (corresponding author), Catholic Univ Korea, Coll Med, Dept Humanities & Social Med, Seoul, South Korea.; Kwon, YD (corresponding author), Catholic Univ Korea, Catholic Inst Healthcare Management, Seoul, South Korea.	snukyd1@naver.com	Kwon, Young Dae/T-1591-2017	Kwon, Young Dae/0000-0002-8781-6832; You, Chang Hoon/0000-0001-7938-266X				Bausell RB, 2001, MED CARE, V39, P190, DOI 10.1097/00005650-200102000-00009; Bryan RN, 2013, EUR RADIOL, V23, P1, DOI 10.1007/s00330-012-2713-x; Buchmueller TC, 2004, HEALTH ECON, V13, P669, DOI 10.1002/hec.879; CAMERON AC, 1988, REV ECON STUD, V55, P85, DOI 10.2307/2297531; Casagrande SS, 2012, DIABETES CARE, V35, P2243, DOI 10.2337/dc12-0257; Doiron D, 2008, HEALTH ECON, V17, P317, DOI 10.1002/hec.1267; Emmerson C., 2001, SHOULD PRIVATE MEDIC, P49; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; Jeon B, 2013, HEALTH POLICY, V113, P69, DOI 10.1016/j.healthpol.2013.05.007; Jung Y., 2010, REPORT KOREA HLTH PA; Kang S, 2009, J FORMOS MED ASSOC, V108, P912, DOI 10.1016/S0929-6646(10)60003-4; Kiil A, 2014, EUR J HEALTH ECON, V15, P813, DOI 10.1007/s10198-013-0526-8; King D, 2005, HEALTH SERV RES, V40, P195, DOI 10.1111/j.1475-6773.2005.00349.x; Korean Diabetes Association National Health Insurance Service, 2015, KOR DIAB FACT SHEET; Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037; Lee JC, 2012, J KOREAN MED ASSOC, V55, P1215, DOI 10.5124/jkma.2012.55.12.1215; Liu TC, 2002, SOC SCI MED, V55, P755, DOI 10.1016/S0277-9536(01)00201-5; LOHR KN, 1986, MED CARE, V24, pUS1; MANNING WG, 1987, AM ECON REV, V77, P251; Oh HJ, 2011, J KOREAN MED ASSOC, V54, P205, DOI 10.5124/jkma.2011.54.2.205; POHLMEIER W, 1995, J HUM RESOUR, V30, P339, DOI 10.2307/146123; Rodriguez M, 2004, HEALTH ECON, V13, P689, DOI 10.1002/hec.832; Sapelli C, 2003, J HEALTH ECON, V22, P459, DOI 10.1016/S0167-6296(02)00121-2; Song YJ, 2009, JPN MED ASS J, V52, P206; Vera-Hernandez AM, 1999, HEALTH ECON, V8, P579, DOI 10.1002/(SICI)1099-1050(199911)8:7<579::AID-HEC478>3.0.CO;2-P; Victoor A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-272; Wooldridge J.M., 2002, ECONOMETRIC ANAL CRO; Yip WC, 1998, HEALTH POLICY PLANN, V13, P311, DOI 10.1093/heapol/13.3.311; Yoon Chai-Hyun, 2007, J Prev Med Public Health, V40, P51; You CH, 2012, J KOREAN MED ASSOC, V55, P898, DOI 10.5124/jkma.2012.55.9.898; 박영희, 2012, [The Korean Journal of Health Service Management, 보건의료산업학회지], V6, P83	31	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2018	13	4							e0192205	10.1371/journal.pone.0192205	http://dx.doi.org/10.1371/journal.pone.0192205			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GC8EX	29652882	Green Submitted, gold, Green Published			2023-01-03	WOS:000430026900002
J	Yurchenko, KS; Zhou, PP; Kovner, AV; Zavjalov, EL; Shestopalova, LV; Shestopalov, AM				Yurchenko, Kseniya S.; Zhou, Peipei; Kovner, Anna V.; Zavjalov, Evgenii L.; Shestopalova, Lidiya V.; Shestopalov, Alexander M.			Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model	PLOS ONE			English	Article							PANCREATIC ADENOCARCINOMA; INFECTION; APOPTOSIS; REPLICATION; VIROTHERAPY; RESPONSES; MTH-68/H; GLIOMA; DEATH; TRIAL	Oncolyic virotherapy is one of the modern experimental techniques to treat human cancers. Here we studied the antitumor activity of wild-type Newcastle disease virus (NDV) isolates from Russian migratory birds. We showed that NDV could selectively kill malignant cells without affecting healthy cells. We evaluated the oncolytic effect of 44 NDV isolates in 4 histogenetically different human cell lines (HCT116, HeLa, A549, MCF7). The safety of the isolates was also tested in normal peripheral blood mononuclear (PBMC) cells. The viability of tumor cell lines after incubation with NDV isolates was evaluated by MTT. All cell lines, except for normal PBMC primary cells, had different degrees of susceptibility to NDV infection. Seven NDV strains had the highest oncolytic activity, and some NDV strains demonstrated oncolytic selectivity for different cell lines. In vivo, we described the intratumoral activity of NDV/Altai/pigeon/770/2011 against subcutaneous non-small cell lung carcinoma using xenograft SCID mice model. All animals were responsive to therapy. Histology confirmed therapy-induced destructive changes and growing necrotic bulk density in tumor tissue. Our findings indicate that wild-type NDV strains selectively kill tumor cells with no effect on healthy PBMC cells, and intratumoral virotherapy with NDV suppresses the subcutaneous tumor growth in SCID mice.	[Yurchenko, Kseniya S.; Kovner, Anna V.; Shestopalov, Alexander M.] Res Inst Expt & Clin Med, Subdiv FRC FTM, Novosibirsk, Novosibirsk Reg, Russia; [Zhou, Peipei; Shestopalova, Lidiya V.] Novosibirsk State Univ, Novosibirsk, Novosibirsk Reg, Russia; [Zhou, Peipei] Heilongjiang Univ, Harbin, Heilongjiang, Peoples R China; [Zavjalov, Evgenii L.] Russian Acad Sci, Ctr Genet Resources Lab Anim, Inst Cytol & Genet, Siberian Branch, Novosibirsk, Novosibirsk Reg, Russia	Novosibirsk State University; Heilongjiang University; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Yurchenko, KS (corresponding author), Res Inst Expt & Clin Med, Subdiv FRC FTM, Novosibirsk, Novosibirsk Reg, Russia.	xenia7yurchenko@gmail.com	Yurchenko, Kseniya/S-2821-2019; Zavjalov, Evgenii/X-2415-2019; Shestopalova, Lidiya V/E-4056-2014; Shestopalov, Alexander/AAO-5569-2020; kovner, anna/L-9133-2015	Shestopalova, Lidiya V/0000-0002-6619-2135; Yurchenko, Kseniya/0000-0002-0679-8493; kovner, anna/0000-0001-9543-9005	Russian Scientific Foundation [17-44-07001]; small grant of the mayoralty of the city of Novosibirsk for young scientists; Ministry of Education and Science of Russia [RFMEFI62117X0015]; Russian Science Foundation [17-44-07001] Funding Source: Russian Science Foundation	Russian Scientific Foundation(Russian Science Foundation (RSF)); small grant of the mayoralty of the city of Novosibirsk for young scientists; Ministry of Education and Science of Russia(Ministry of Education and Science, Russian Federation); Russian Science Foundation(Russian Science Foundation (RSF))	The study was supported partially by a grant of Russian Scientific Foundation (project No. 17-44-07001) in the part of monitoring and analysis of viral samples isolated from migratory birds in the framework of monitoring of influenza virus. The animal study was financed by a small grant of the mayoralty of the city of Novosibirsk for young scientists. The animal study was carried out in the Center for Genetic Resources of Laboratory Animals at the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, supported by the Ministry of Education and Science of Russia (RFMEFI62117X0015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander D. J., 2008, DIS POULTRY, P74; Altomonte J, 2010, MOL THER, V18, P275, DOI 10.1038/mt.2009.231; An Y, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0273-0; Apostolidis L, 2007, INT J ONCOL, V31, P1009; Arifin MA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/586363; Bai FL, 2014, CANCER BIOL THER, V15, P1226, DOI 10.4161/cbt.29686; Bian JC, 2011, ARCH VIROL, V156, P1335, DOI 10.1007/s00705-011-0987-y; Buijs PRA, 2014, CANCER GENE THER, V21, P24, DOI 10.1038/cgt.2013.78; Buijs P, 2015, VIRUSES-BASEL, V7, P2980, DOI 10.3390/v7062756; Cox RM, 2017, CURR OPIN VIROL, V24, P105, DOI 10.1016/j.coviro.2017.05.004; Csatary LK, 2004, J NEURO-ONCOL, V67, P83, DOI 10.1023/B:NEON.0000021735.85511.05; Elankumaran S, 2006, J VIROL, V80, P7522, DOI 10.1128/JVI.00241-06; Elankumaran S, 2010, J VIROL, V84, P3835, DOI 10.1128/JVI.01553-09; Fournier P, 2012, METHODS MOL BIOL, V797, P177, DOI 10.1007/978-1-61779-340-0_13; Freeman AI, 2006, MOL THER, V13, P221, DOI 10.1016/j.ymthe.2005.08.016; Ghrici M, 2013, INT J MOL MED, V31, P525, DOI 10.3892/ijmm.2013.1244; Grimes S.E., 2002, BASIC LAB MANUAL SMA; Kabilov M. R., 2016, GENOME ANNOUNC, V4; Koks CA, 2015, INT J CANCER, V136, pE313, DOI 10.1002/ijc.29202; Krishnamurthy S, 2006, J VIROL, V80, P5145, DOI 10.1128/JVI.02618-05; Lam HY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/718710; Laurie SA, 2006, CLIN CANCER RES, V12, P2555, DOI 10.1158/1078-0432.CCR-05-2038; Lazar I, 2010, J VIROL, V84, P639, DOI 10.1128/JVI.00401-09; Li PD, 2011, HEAD NECK-J SCI SPEC, V33, P1394, DOI 10.1002/hed.21609; Mayo MA, 2002, ARCH VIROL, V147, P1655, DOI 10.1007/s007050200039; Meng CC, 2012, ARCH VIROL, V157, P1011, DOI 10.1007/s00705-012-1270-6; Miller P., 2013, DIS POULTRY, P89, DOI DOI 10.1002/9781119421481.CH3.(HTTPS://D0I.0RG/); Miller PJ, 2010, INFECT GENET EVOL, V10, P26, DOI 10.1016/j.meegid.2009.09.012; Molouki A, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-179; Molouki A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-385; MOORE AE, 1952, P SOC EXP BIOL MED, V81, P498; NIH National Cancer Institute, TOP INT ALT COMPL TH; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Puhlmann J, 2010, ONCOGENE, V29, P2205, DOI 10.1038/onc.2009.507; Ravindra PV, 2009, VIRUS RES, V141, P13, DOI 10.1016/j.virusres.2008.12.008; REICHARD KW, 1992, J SURG RES, V52, P448, DOI 10.1016/0022-4804(92)90310-V; Schirrmacher V, 1999, GENE THER, V6, P63, DOI 10.1038/sj.gt.3300787; Schirrmacher V, 2016, BIOMEDICINES, V4, DOI 10.3390/biomedicines4030016; Song KY, 2010, J MOL MED, V88, P589, DOI 10.1007/s00109-010-0605-6; Wagner S, 2006, APMIS, V114, P731, DOI 10.1111/j.1600-0463.2006.apm_516.x; Walter RJ, 2012, J PANCREAS, V13, P45; Yaacov B, 2012, J GEN VIROL, V93, P1664, DOI 10.1099/vir.0.043281-0; Yurchenko K. S, 2015, GENOME ANNOUNC, V3, P1514, DOI DOI 10.1128/GEN0MEA.01514-14; Yurchenko KS, 2015, GENOME ANNOUNC, V3; Zamarin D, 2009, MOL THER, V17, P697, DOI 10.1038/mt.2008.286	46	23	28	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0195425	10.1371/journal.pone.0195425	http://dx.doi.org/10.1371/journal.pone.0195425			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6TQ	29621357	Green Submitted, Green Published, gold			2023-01-03	WOS:000429206800077
J	Han, Q; Chen, R; Wang, FJ; Chen, S; Sun, XS; Guan, X; Yang, Y; Peng, BJ; Pan, XD; Li, JF; Yi, WJ; Li, P; Zhang, HW; Feng, DF; Chen, A; Li, XH; Li, SH; Yin, ZM				Han, Qi; Chen, Rui; Wang, Fangjie; Chen, Sha; Sun, Xiongshan; Guan, Xiao; Yang, Yao; Peng, Bingjie; Pan, Xiaodong; Li, Jinfang; Yi, Weijing; Li, Peng; Zhang, Hongwei; Feng, Dongfang; Chen, An; Li, Xiaohui; Li, Shuhui; Yin, Zuoming			Pre-exposure to 50 Hz-electromagnetic fields enhanced the antiproliferative efficacy of 5-fluorouracil in breast cancer MCF-7 cells	PLOS ONE			English	Article							MULTICENTER RANDOMIZED-TRIAL; METASTATIC COLORECTAL-CANCER; ALTERNATING ELECTRIC-FIELDS; 1ST-LINE TREATMENT; DRUG-RESISTANCE; MAGNETIC-FIELDS; EXPOSURE; PROLIFERATION; CYCLE; COMMUNICATION	Resistance to 5-fluorouracil (5-FU) and its induced immune suppression have prevented its extensive application in the clinical treatment of breast cancer. In this study, the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer was explored. MCF-7 and MCF10A cells were pre-exposed to 50 Hz-EMFs for 0, 2, 4, 8 and 12 h and then treated with different concentrations of 5-FU for 24 h; cell viability was analyzed by MTT assay and flow cytometry. After pre-exposure to 50 Hz-EMFs for 12 h, apoptosis and cell cycle distribution in MCF-7 and MCF10A cells were detected via flow cytometry and DNA synthesis was measured by EdU incorporation assay. Apoptosis-related and cell cycle-related gene and protein expression levels were monitored by qPCR and western blotting. Pre-exposure to 50 Hz-EMFs for 12 h enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but not in normal human breast epithelial cell line MCF10A. Exposure to 50 Hz-EMFs had no effect on apoptosis and P53 expression of MCF-7 and MCF10A cells, whereas it promoted DNA synthesis, induced entry of MCF-7 cells into the S phase of cell cycle, and upregulated the expression levels of cell cycle-related proteins Cyclin D1 and Cyclin E. Considering the pharmacological mechanisms of 5-FU in specifically disrupting DNA synthesis, this enhanced inhibitory effect might have resulted from the specific sensitivity of MCF7 cells in active S phase to 5-FU. Our findings demonstrate the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, which provides a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.	[Han, Qi; Zhang, Hongwei; Feng, Dongfang; Yin, Zuoming] Gen Hosp Tibet Area Mil Command, Lhasa, Peoples R China; [Han, Qi; Chen, Sha; Peng, Bingjie; Li, Jinfang; Yi, Weijing; Chen, An; Li, Shuhui] Third Mil Med Univ, Southwest Hosp, Fac Med Lab Sci, Dept Clin Biochem, Chongqing, Peoples R China; [Han, Qi; Wang, Fangjie; Sun, Xiongshan; Guan, Xiao; Yang, Yao; Pan, Xiaodong; Li, Xiaohui] Third Mil Med Univ, Inst Mat Med, Coll Pharm, Chongqing, Peoples R China; [Chen, Rui] Tibetan Tradit Med Coll, Lhasa, Peoples R China; [Li, Peng] 201th Hosp Peoples Liberat Army, Urol, Liaoyang, Peoples R China	Army Medical University; Army Medical University; University of Tibetan Medicine	Yin, ZM (corresponding author), Gen Hosp Tibet Area Mil Command, Lhasa, Peoples R China.; Li, SH (corresponding author), Third Mil Med Univ, Southwest Hosp, Fac Med Lab Sci, Dept Clin Biochem, Chongqing, Peoples R China.; Li, XH (corresponding author), Third Mil Med Univ, Inst Mat Med, Coll Pharm, Chongqing, Peoples R China.	lpsh008@aliyun.com; lishuhui316@yeah.net; yinzuoming@163.com		Xiongshan, Sun/0000-0002-7958-0620	National Natural Science Foundation of China [81472481, 81272909, 81402513]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (81472481 to SL, 81272909 to SL, and 81402513 to SC). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by National Natural Science Foundation of China (81472481, 81272909 and 81402513). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali FM, 2011, TECHNOL HEALTH CARE, V19, P455, DOI 10.3233/THC-2011-0649; Barbault A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-51; Berg H, 2010, ELECTROMAGN BIOL MED, V29, P132, DOI 10.3109/15368371003776725; Bourthoumieu S, 2013, BIOELECTROMAGNETICS, V34, P52, DOI 10.1002/bem.21744; Chen S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.380; Crocetti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072944; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Destefanis M, 2015, INT J RADIAT BIOL, V91, P964, DOI 10.3109/09553002.2015.1101648; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Gomez MJR, 2001, BIOELECTROCHEMISTRY, V53, P137, DOI 10.1016/S0302-4598(00)00119-7; Griffin GD, 2000, BIOELECTROCHEMISTRY, V51, P117, DOI 10.1016/S0302-4598(99)00085-9; Hirata M, 2001, ANTICANCER RES, V21, P317; Hirose H, 2006, BIOELECTROMAGNETICS, V27, P494, DOI 10.1002/bem.20238; Hu CMJ, 2012, BIOCHEM PHARMACOL, V83, P1104, DOI 10.1016/j.bcp.2012.01.008; Jin ZD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046102; Jordan VC, 2016, CANCER RES, V76, P767, DOI 10.1158/0008-5472.CAN-16-0150; Kang L, 2015, ACTA PHARM SIN B, V5, P169, DOI 10.1016/j.apsb.2015.03.001; Kheifets L, 2010, BRIT J CANCER, V103, P1128, DOI 10.1038/sj.bjc.6605838; Kirson ED, 2004, CANCER RES, V64, P3288, DOI 10.1158/0008-5472.CAN-04-0083; Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104; Kirson ED, 2009, CLIN EXP METASTAS, V26, P633, DOI 10.1007/s10585-009-9262-y; Li JR, 1999, RADIAT RES, V151, P710, DOI 10.2307/3580210; Lim S, 2015, BIOMED ENVIRON SCI, V28, P231, DOI 10.3967/bes2015.032; Liu YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042332; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011; Jimenez-Garcia MN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-159; Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x; Percherancier Y, 2015, BIOELECTROMAGNETICS, V36, P287, DOI 10.1002/bem.21908; Schuz J, 2011, PROG BIOPHYS MOL BIO, V107, P339, DOI 10.1016/j.pbiomolbio.2011.09.008; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569; Taghi M, 2013, RECENT PATENTS ENDOC, V7, P252, DOI 10.2174/18722148113079990007; Taghi M, 2012, RECENT PATENTS ENDOC, V6, P251, DOI 10.2174/187221412802481757; Visweswaran M, 2018, INT J BIOCHEM CELL B, V95, P63, DOI 10.1016/j.biocel.2017.12.013; Wolf FI, 2005, BBA-MOL CELL RES, V1743, P120, DOI 10.1016/j.bbamcr.2004.09.005; Yan Y, 2012, ACS NANO, V6, P3663, DOI 10.1021/nn3016162; Yang Min-li, 2015, Zhejiang Da Xue Xue Bao Yi Xue Ban, V44, P323; Zhao G, 2014, EUR J GYNAECOL ONCOL, V35, P264; Zimmerman JW, 2012, BRIT J CANCER, V106, P307, DOI 10.1038/bjc.2011.523	42	15	16	4	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2018	13	4							e0192888	10.1371/journal.pone.0192888	http://dx.doi.org/10.1371/journal.pone.0192888			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6SR	29617363	gold, Green Published, Green Submitted			2023-01-03	WOS:000429203800005
J	Pao, W; Fodor, I				Pao, William; Fodor, Imola			Catalyzing the field of precision oncology, one basket at a time	NATURE MEDICINE			English	Editorial Material								A bedside strategy to overcome the limitations of testing in preclinical models and to determine the role of gene mutations and their targetability directly in patients is presented.	[Pao, William] F Hoffmann La Roche & Cie AG, Roche Innovat Ctr Basel, Basel, Switzerland; [Fodor, Imola] Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Roche Holding; Genentech	Pao, W (corresponding author), F Hoffmann La Roche & Cie AG, Roche Innovat Ctr Basel, Basel, Switzerland.	william.pao@roche.com						Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062	5	3	3	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2018	24	4					387	388		10.1038/nm.4530	http://dx.doi.org/10.1038/nm.4530			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GC2VD	29634693				2023-01-03	WOS:000429639800007
J	Johnson, CE; Dunlop, EA; Seifan, S; McCann, HD; Hay, T; Parfitt, GJ; Jones, AT; Giles, PJ; Shen, MH; Sampson, JR; Errington, RJ; Davies, DM; Tee, AR				Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Hay, Trevor; Parfitt, Geraint J.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.			Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir - bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death	ONCOGENE			English	Article							HIV PROTEASE INHIBITOR; RENAL ANGIOMYOLIPOMA; ER STRESS; AUTOPHAGY; MTOR	Cancer cells lose homeostatic flexibility because of mutations and dysregulated signaling pathways involved in maintaining homeostasis. Tuberous Sclerosis Complex 1 (TSC1) and TSC2 play a fundamental role in cell homeostasis, where signal transduction through TSC1/TSC2 is often compromised in cancer, leading to aberrant activation of mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 hyperactivation increases the basal level of endoplasmic reticulum (ER) stress via an accumulation of unfolded protein, due to heightened de novo protein translation and repression of autophagy. We exploit this intrinsic vulnerability of tumor cells lacking TSC2, by treating with nelvinavir to further enhance ER stress while inhibiting the proteasome with bortezomib to prevent effective protein removal. We show that TSC2-deficient cells are highly dependent on the proteosomal degradation pathway for survival. Combined treatment with nelfinavir and bortezomib at clinically relevant drug concentrations show synergy in selectively killing TSC2-deficient cells with limited toxicity in control cells. This drug combination inhibited tumor formation in xenograft mouse models and patient-derived cell models of TSC and caused tumor spheroid death in 3D culture. Importantly, 3D culture assays differentiated between the cytostatic effects of the mTORC1 inhibitor, rapamycin, and the cytotoxic effects of the nelfinavir/bortezomib combination. Through RNA sequencing, we determined that nelfinavir and bortezomib tip the balance of ER protein homeostasis of the already ER-stressed TSC2-deficient cells in favor of cell death. These findings have clinical relevance in stratified medicine to treat tumors that have compromised signaling through TSC and are inflexible in their capacity to restore ER homeostasis.	[Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.] Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales; [Hay, Trevor; Parfitt, Geraint J.] Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Davies, D. Mark] Singleton Hosp, South West Wales Canc Ctr, Dept Oncol, Swansea SA2 8QA, W Glam, Wales	Cardiff University; Cardiff University; Singleton Hospital	Tee, AR (corresponding author), Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk	/J-6218-2019; Parfitt, Geraint/J-2778-2018	/0000-0002-9209-7561; Davies, Mark/0000-0002-0688-3129; Parfitt, Geraint/0000-0002-8704-7906	Health and Care Research Wales (Wales Cancer Research Centre); Tuberous Sclerosis Association; Cancer Research Wales; Tuberous Sclerosis Alliance; BBSRC; Hospital Saturday Fund	Health and Care Research Wales (Wales Cancer Research Centre); Tuberous Sclerosis Association; Cancer Research Wales; Tuberous Sclerosis Alliance; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Hospital Saturday Fund	This work was supported by Health and Care Research Wales (the Wales Cancer Research Centre) (to EAD, ART, PJG and TH), the Tuberous Sclerosis Association (to EAD, ART, and MHS), Cancer Research Wales (to CEJ, RJE, and ART), the Tuberous Sclerosis Alliance (to EAD and ART), the Hospital Saturday Fund (to ART) and BBSRC (to RJE). We would like to thank the Wales Gene Park for their contribution to this study.	Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Auricchio N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031900; Babcock JT, 2013, J BIOL CHEM, V288, P15687, DOI 10.1074/jbc.M112.431056; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Crawford LJA, 2006, CANCER RES, V66, P6379, DOI 10.1158/0008-5472.CAN-06-0605; Dabora SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023379; Driessen C, 2016, HAEMATOLOGICA, V101, P346, DOI 10.3324/haematol.2015.135780; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Dunlop EA, 2017, ONCOTARGET, V8, P48711, DOI 10.18632/oncotarget.16232; Dunlop EA, 2011, AUTOPHAGY, V7, P737, DOI 10.4161/auto.7.7.15491; Gandolfi S, 2017, CANCER METAST REV, V36, P561, DOI 10.1007/s10555-017-9707-8; Gills J, 2007, CLIN CANCER RES, V13, P5183, DOI 10.1158/1078-0432.CCR-07-0161; Johnson CE, 2015, MOL ONCOL, V9, P675, DOI 10.1016/j.molonc.2014.11.005; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kawabata S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.87; Kraus M, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.2; Kraus M, 2014, LEUKEMIA RES, V38, P383, DOI 10.1016/j.leukres.2013.12.017; Lam HC, 2017, J PATHOL, V241, P219, DOI 10.1002/path.4827; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Peng ZF, 2014, J UROLOGY, V192, P1424, DOI 10.1016/j.juro.2014.04.096; Shim JS, 2012, JNCI-J NATL CANCER I, V104, P1576, DOI 10.1093/jnci/djs396; Siroky BJ, 2012, AM J PHYSIOL-RENAL, V303, pF831, DOI 10.1152/ajprenal.00441.2011; Stengel S, 2017, BBA-MOL CELL RES, V1864, P2183, DOI 10.1016/j.bbamcr.2017.07.008; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492	27	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5913	5925		10.1038/s41388-018-0381-2	http://dx.doi.org/10.1038/s41388-018-0381-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980790	hybrid, Green Accepted			2023-01-03	WOS:000449562500001
J	Szyszkowicz, M; Thomson, EM; Colman, I; Rowe, BH				Szyszkowicz, Mieczyslaw; Thomson, Errol M.; Colman, Ian; Rowe, Brian H.			Ambient air pollution exposure and emergency department visits for substance abuse	PLOS ONE			English	Article							CASE-CROSSOVER; PARTICULATE MATTER; SUICIDE; RISK; DEPRESSION; HEALTH; COHORT; OZONE; EXPRESSION; DEPENDENCE	There is growing evidence supporting the notion that exposure to air pollution can contribute to cognitive and psychiatric disorders, including depression and suicide. Given the relationship between exposure to acute stressors and substance abuse, the present study assessed the association between exposure to ambient air pollution and emergency department (ED) visits for alcohol and drug abuse. ED visit data selected according to International Classification of Disease (ICD-9) coding 303 (alcohol dependence syndromes) and 305 (non-dependent abuse of drugs) were collected in five hospitals in Edmonton, Canada. A time-stratified case crossover design was used. Conditional logistic regression was applied to calculate odds ratios (OR) and 95% confidence intervals (95% CI). Season, temperature, and relative humidity were adjusted for using natural splines. Results are reported for an increase in pollutant concentrations equivalent to one interquartile range (IQR). Statistically significant positive associations with substance abuse were observed for CO, NO2 and particulate matter with an aerodynamic diameter less than 10 mu m (PM10) and 2.5 mu m (PM2.5). The strongest results were obtained in the cold period (October-March) for 1-day lagged CO (OR = 1.03, 95% CI: 1.01, 1.05, IQR = 0.4 ppm) and NO2 (OR = 1.04, 95% CI: 1.01, 1.07, IQR = 12.8 ppb); ORs were also significant for CO and NO2 with lags of 2 to 6 days and 2 to 7 days, respectively. The study suggests that, even at low levels, increases in ambient CO, NO2, and PMs are associated with increased hospital admissions for substance abuse, possibly as a result of impacts of air quality on mental health or depression.	[Szyszkowicz, Mieczyslaw] Hlth Canada, Populat Studies Div, Ottawa, ON, Canada; [Thomson, Errol M.] Hlth Canada, Hazard Identificat Div, Ottawa, ON, Canada; [Colman, Ian] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada; [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Fac Med Dent, Edmonton, AB, Canada; [Rowe, Brian H.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada	Health Canada; Health Canada; University of Ottawa; University of Alberta; University of Alberta	Szyszkowicz, M (corresponding author), Hlth Canada, Populat Studies Div, Ottawa, ON, Canada.	mietek.szyszkowicz@canada.ca	Szyszkowicz, Mieczysław/N-2490-2019	Szyszkowicz, Mieczyslaw/0000-0001-7022-3267; Colman, Ian/0000-0001-5924-0277; Thomson, Errol/0000-0003-1295-5384	Health Canada; Canada Research Chairs program	Health Canada; Canada Research Chairs program(Canada Research Chairs)	This work was supported by Health Canada. The authors acknowledge Environment Canada for providing the air pollution data from the National Air Pollution Surveillance (NAPS) network. This research was also supported by the Canada Research Chairs program for Dr. Colman and Dr. Rowe. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JL, 2013, ENVIRON HEALTH PERSP, V121, P32, DOI [10.1289/ehp.1205505, 10.1289/ehp.121-a32]; Amitai Y, 1998, ARCH NEUROL-CHICAGO, V55, P845, DOI 10.1001/archneur.55.6.845; Bakian AV, 2015, AM J EPIDEMIOL, V181, P295, DOI 10.1093/aje/kwu341; Bickel WK, 2012, PHARMACOL THERAPEUT, V134, P287, DOI 10.1016/j.pharmthera.2012.02.004; Biermann T, 2009, MED HYPOTHESES, V72, P338, DOI 10.1016/j.mehy.2008.09.042; Block ML, 2012, NEUROTOXICOLOGY, V33, P972, DOI 10.1016/j.neuro.2012.08.014; Calderon-Garciduenas L, 2008, BRAIN COGNITION, V68, P117, DOI 10.1016/j.bandc.2008.04.008; Casas L, 2017, EUR J EPIDEMIOL, V32, P973, DOI 10.1007/s10654-017-0273-8; Chen JC, 2017, EUR J EPIDEMIOL, V32, P943, DOI 10.1007/s10654-017-0329-9; Chen JC, 2009, NEUROTOXICOLOGY, V30, P231, DOI 10.1016/j.neuro.2008.12.011; Dales RE, 2009, AM J EPIDEMIOL, V170, P1057, DOI 10.1093/aje/kwp217; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI 10.1001/archgenpsychiatry.2008.543; Fonken LK, 2011, MOL PSYCHIATR, V16, P987, DOI 10.1038/mp.2011.76; Herrnstadt E., 2015, NBER WORK PAP SER, V40, DOI [10.3386/w21787, DOI 10.3386/W21787]; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.ede.0000181315.18836.9d; Kim C, 2010, AM J PSYCHIAT, V167, P1100, DOI 10.1176/appi.ajp.2010.09050706; Lee WJ, 2007, ENVIRON HEALTH PERSP, V115, P528, DOI 10.1289/ehp.9662; Lenze EJ, 2011, AM J GERIAT PSYCHIAT, V19, P482, DOI 10.1097/JGP.0b013e3181ec806c; Lopuszanska U, 2017, CURRENT PROBLEMS PSY, V18, P2100; Lu JG, 2018, PSYCHOL SCI, V29, P340, DOI 10.1177/0956797617735807; Lukassen J, 2005, SOC SCI MED, V61, P1658, DOI 10.1016/j.socscimed.2005.03.019; Lundberg A, 1996, OTOLARYNG HEAD NECK, V114, P227, DOI 10.1016/S0194-5998(96)70172-9; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Makris GD, 2013, ACTA PSYCHIAT SCAND, V127, P117, DOI 10.1111/j.1600-0447.2012.01891.x; Margai F, 2003, SOC SCI MED, V56, P1073, DOI 10.1016/S0277-9536(02)00104-1; Matsushita Sachio, 2009, Seishin Shinkeigaku Zasshi, V111, P1191; Mitra R, 2008, P NATL ACAD SCI USA, V105, P5573, DOI 10.1073/pnas.0705615105; Nasari MM, 2016, AIR QUAL ATMOS HLTH, V9, P961, DOI 10.1007/s11869-016-0398-z; Oudin A, 2018, ENVIRON HEALTH-GLOB, V17, DOI 10.1186/s12940-017-0348-8; Partonen T, 1996, PSYCHOL MED, V26, P1075, DOI 10.1017/S003329170003539X; Petridou E, 2002, EPIDEMIOLOGY, V13, P106, DOI 10.1097/00001648-200201000-00017; Power MC, 2011, ENVIRON HEALTH PERSP, V119, P682, DOI 10.1289/ehp.1002767; Pruessner M, 2003, PSYCHOSOM MED, V65, P92, DOI 10.1097/01.PSY.0000040950.22044.10; Ranft U, 2009, ENVIRON RES, V109, P1004, DOI 10.1016/j.envres.2009.08.003; Stallones Lorann, 2006, J Agromedicine, V11, P107, DOI 10.1300/J096v11n03_11; Suglia SF, 2008, AM J EPIDEMIOL, V167, P280, DOI 10.1093/aje/kwm308; Sussman S, 2015, EVAL HEALTH PROF, V38, P53, DOI 10.1177/0163278713501692; Szyszkowicz M., 2014, PEERJ PREPRINTS, V2, P553, DOI [10.7287/peerj.preprints.757v1, DOI 10.7287/PEERJ.PREPRINTS.757V1]; Szyszkowicz M, 2016, ENVIRON HEALTH INSIG, V10, P155, DOI [10.4137/EHI.S40493, 10.4137/ehi.s40493]; Szyszkowicz M, 2010, ENVIRON HEALTH INSIG, V4, P79, DOI 10.4137/EHI.S5662; Szyszkowicz M, 2009, INT J OCCUP MED ENV, V22, P355, DOI 10.2478/v10001-009-0031-6; Szyszkowicz M, 2009, INT J OCCUP MED ENV, V22, P235, DOI 10.2478/v10001-009-0024-5; Thomson EM, 2014, ENDOCRINE DISRUPTORS, V1, DOI [10.4161/endo.25066, DOI 10.4161/ENDO.25066]; Thomson EM, 2016, TOXICOL SCI, V152, P17, DOI 10.1093/toxsci/kfw061; Thomson EM, 2013, TOXICOL SCI, V135, P169, DOI 10.1093/toxsci/kft137; van Wijngaarden E, 2003, J OCCUP ENVIRON MED, V45, P96, DOI 10.1097/00043764-200301000-00018; Wang SV, 2011, AM J EPIDEMIOL, V174, P118, DOI 10.1093/aje/kwr038; Wang SQ, 2009, ENVIRON HEALTH PERSP, V117, P1612, DOI 10.1289/ehp.0800023; Weuve J, 2012, ARCH INTERN MED, V172, P219, DOI 10.1001/archinternmed.2011.683; Yang AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013728; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	51	21	21	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2018	13	6							e0199826	10.1371/journal.pone.0199826	http://dx.doi.org/10.1371/journal.pone.0199826			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL0PZ	29958279	Green Published, Green Submitted, gold			2023-01-03	WOS:000436793500020
J	Iftikhar, S; Sarwar, MR; Saqib, A; Sarfraz, M				Iftikhar, Sadia; Sarwar, Muhammad Rehan; Saqib, Anum; Sarfraz, Muhammad			Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT; PEDIATRIC-PATIENTS; PHARMACOVIGILANCE; PREVALENCE; IMPACT; INDICATORS; SEVERITY; ENGLAND; RISK	Background and objectives Adverse drug events (ADEs) are the fifth leading cause of death and thus responsible for a large number of hospital admissions in all over the globe. This study was aimed to assess the antibiotics associated preventability of ADEs and causality of adverse drug reactions (ADRs) among hospitalized patients. Methods A prospective, cross-sectional, observational study was conducted in four tertiary care public sector hospitals of Lahore, Pakistan. Study population consisted of hospitalized patients who were prescribed with one or more antibiotics. Data were collected between 1 st January, 2017 and 31 st June, 2017 from 1,249 patients (384 patients aged < 18 years and 865 patients aged >18 years). Schumock and Thornton scale was used to assess the preventability of the ADEs. Medication errors (MEs) that caused preventable ADEs were assessed by MEs tracking form while Naranjo score was used to evaluate the causal relation of ADRs with the antibiotics. Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.) and Microsoft Excel (MS Office, 2010) were used for data analysis. Results 2,686 antibiotics were prescribed to 1,249 patients. Among them, fluoroquinolones (11.8%), macrolides (11.6%) and cephalosporins (10.9%) were the most frequently prescribed antibiotics. The most affected organ system by antibiotics associated ADEs was gastrointestinal tract. A total of 486 ADEs were found. The preventability assessment revealed that most of the ADEs (58.4%) were preventable (43.6% of the ADEs were definitely preventable while 14.8% were probably preventable) and caused by MEs including wrong drug (40.1%) and monitoring errors (25.0%), during the stage of physician ordering (22.2%) and patient monitoring (21.1%). The errors were caused due to non-adherence of policies (38.4%) and lack of information about antibiotics (32%). Most of the non-preventable ADEs or ADRs among adults and children were "probable" (35.5%) and "possible" (35.8%), respectively. Logistic regression analysis revealed that ADEs were significantly less among females (OR = 0.047, 95%CI = 0.018-0.121, p-value = <0.001), patients aged 18-52 years (OR = 0.041, 95%CI = 0.013-0.130, p-value = <0.001), tuberculosis patients (OR = 0.304, 95%CI = 0.186-0.497, p-value = <0.001), patients with acute respiratory tract infections (OR = 0.004, 95%CI = 0.01-0.019, p-value = <0.001) and among the patients prescribed with 2 antibiotics per prescription (OR = 0.455, 95%CI = 0.319-0.650, p-value = <0.001). Conclusion According to preventability assessment most of the ADEs were definitely preventable and caused by MEs due to non-adherence of policies and lack of information about antibiotics. The causality assessment of non-preventable ADEs showed that most of the ADRs were probable and possible.	[Iftikhar, Sadia; Sarwar, Muhammad Rehan] Akhtar Saeed Coll Pharmaceut Sci, Lahore, Pakistan; [Sarwar, Muhammad Rehan; Saqib, Anum; Sarfraz, Muhammad] Islamia Univ Bahawalpur, Dept Pharm, Bahawalpur, Punjab, Pakistan; [Sarfraz, Muhammad] Al Ain Univ Sci & Technol, Coll Pharm, Abu Dhabi, U Arab Emirates	Islamia University of Bahawalpur	Sarwar, MR (corresponding author), Akhtar Saeed Coll Pharmaceut Sci, Lahore, Pakistan.; Sarwar, MR (corresponding author), Islamia Univ Bahawalpur, Dept Pharm, Bahawalpur, Punjab, Pakistan.	rehansarwaralvi@gmail.com	Sarfraz, Muhammad/GLS-0139-2022; Sarfraz, Dr Muhamad/GRS-2564-2022	Sarfraz, Muhammad/0000-0002-0516-4966; Sarfraz, Dr Muhamad/0000-0002-0516-4966; Sarwar, Muhammad Rehan/0000-0003-4312-9157				Alomar MJ, 2014, SAUDI PHARM J, V22, P83, DOI 10.1016/j.jsps.2013.02.003; Lobo MGAD, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-5; America IDSo, 2008, ADVERSE REACTIONS AN; Anderson M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008298; [Anonymous], 1998, AM J HEALTH-SYST PH, V55, P165; Atif M, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3615-1; Atif M, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1932-2; Atif Muhammad, 2016, J Pharm Policy Pract, V9, P27, DOI 10.1186/s40545-016-0076-4; Blumenthal KG, 2016, J ALLER CL IMM-PRACT, V4, P740, DOI 10.1016/j.jaip.2016.03.008; Committee JF, 2016, BRIT NATL FORMULARY; Committee PF, 2014, BNF CHILDR 2014 2015; Doshi K, 2017, CURR DRUG SAF, V12, P46, DOI 10.2174/157488631201170210194817; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Factbook CW, 2017, PAK DEM PROF; Fushiki Y, 2014, J GEN FAM MED, V15, P110; Gallelli L, 2002, PHARMACOL RES, V46, P395, DOI 10.1016/S1043661802002104; Haile DB, 2013, ETHIOP J HEALTH SCI, V23, P39; Hammond DA, 2017, CLIN INFECT DIS, V64, P666, DOI 10.1093/cid/ciw811; Hepler CD, 2003, PREVENTING MEDICATIO; Hoonhout LHF, 2010, DRUG SAFETY, V33, P853, DOI 10.2165/11536800-000000000-00000; Hussain MM, PHARM LETT, V2, P358; Ji HH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20868-2; Jose Jimmy, 2008, INT J RISK SAF MED, V20, P169, DOI DOI 10.3233/JRS-2008-0441; Kaur S, 2011, INDIAN J PHARMACOL, V43, P22, DOI 10.4103/0253-7613.75661; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Khan F. A., 2013, PROSPECTIVE STUDY PR; Khan LM, 2013, SAUDI PHARM J, V21, P261, DOI 10.1016/j.jsps.2012.09.004; Khan LM, 2012, SAUDI MED J, V33, P863; Kiguba R, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.298; Kurian J, 2016, INDIAN J PEDIATR, V83, P414, DOI 10.1007/s12098-015-2002-1; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lin Robert Y, 2009, J Hosp Med, V4, pE7, DOI 10.1002/jhm.414; Macedo AF, 2005, PHARMACOEPIDEM DR S, V14, P885, DOI 10.1002/pds.1138; Macy E, 2015, J ALLERGY CLIN IMMUN, V135, P745, DOI 10.1016/j.jaci.2014.07.062; Macy Eric, 2011, Perm J, V15, P31; Mahabadi VP, 2017, PHYSIOL PHARMACOL, V21, P172; Martin RM, 1998, BRIT J CLIN PHARMACO, V46, P505, DOI 10.1046/j.1365-2125.1998.00817.x; McDonnell PJ, 2002, ANN PHARMACOTHER, V36, P1331, DOI 10.1345/aph.1A333; McPhee S.J., 2010, CURRENT MED DIAGNOSI; Mudigubba MK, 2017, INT J PHARM SCI RES, V8, P3847, DOI 10.13040/IJPSR.0975-8232.8(9).3847-54; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nazir SUR, 2014, VALUE HEALTH, V17, pA166; Padmavathi S, 2013, J CLIN DIAGN RES, V7, P2765, DOI 10.7860/JCDR/2013/7430.3753; Pakistan TIDSo, 2007, GUID US ANT; Pathak AK, 2016, J CLIN DIAGNOSTIC RE, V10; Pretorius RW, 2013, AM FAM PHYSICIAN, V87, P329; Prevention NCCfMERa, 2015, CONT VIEW MED REL HA; Price AB, 2003, BRIT J CLIN PHARMACO, V56, P477, DOI 10.1046/j.1365-2125.2003.01980.x; Review WP, 2017, POP CIT PAK; SALEEM KHAN HUMA, 2015, PAKISTAN PEDIAT J; Munoz-Torrero JFS, 2010, EUR J CLIN PHARMACOL, V66, P1257, DOI 10.1007/s00228-010-0866-6; Sarwar MR, 2018, INFECT DRUG RESIST, V11, P133, DOI 10.2147/IDR.S148102; Sarwar Muhammad Rehan, 2017, J Pharm Policy Pract, V10, P23, DOI 10.1186/s40545-017-0112-z; Schumock G T, 1992, Hosp Pharm, V27, P538; Scienes P, 2001, ADDR MED ERR HOSP 10; Sellick J, 2017, PSYCHOSOMATICS; Shamim S, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3337-4; Shamna M, 2014, SAUDI PHARM J, V22, P303, DOI 10.1016/j.jsps.2013.06.004; Shehab N, 2008, CLIN INFECT DIS, V47, P735, DOI 10.1086/591126; Shehin M., 2016, INT J CONT PEDIAT, V3, P1071, DOI DOI 10.18203/2349-3291.IJCP20162393; Silva DCB, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001868; Stausberg J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-125; Stavreva G., 2008, Trakia Journal of Sciences, V6, P7; Tan T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a437; Trubiano JA, 2016, J ALLER CL IMM-PRACT, V4, P1187, DOI 10.1016/j.jaip.2016.04.026; Trubiano JA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1303-3; Varallo FR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171470; Werner NL, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-187; Wester K, 2008, BRIT J CLIN PHARMACO, V65, P573, DOI 10.1111/j.1365-2125.2007.03064.x; World Health Organization, 2006, AN THER CHEM CLASS S; [No title captured]	72	13	13	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2018	13	6							e0199456	10.1371/journal.pone.0199456	http://dx.doi.org/10.1371/journal.pone.0199456			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK9FZ	29949616	gold, Green Published, Green Submitted			2023-01-03	WOS:000436549200052
J	Fraietta, JA; Nobles, CL; Sammons, MA; Lundh, S; Carty, SA; Reich, TJ; Cogdill, AP; Morrissette, JJD; DeNizio, JE; Reddy, S; Hwang, Y; Gohil, M; Kulikovskaya, I; Nazimuddin, F; Gupta, M; Chen, F; Everett, JK; Alexander, KA; Lin-Shiao, E; Gee, MH; Liu, XJ; Young, RM; Ambrose, D; Wang, Y; Xu, J; Jordan, MS; Marcucci, KT; Levine, BL; Garcia, KC; Zhao, YB; Kalos, M; Porter, DL; Kohli, RM; Lacey, SF; Berger, SL; Bushman, FD; June, CH; Melenhorst, JJ				Fraietta, Joseph A.; Nobles, Christopher L.; Sammons, Morgan A.; Lundh, Stefan; Carty, Shannon A.; Reich, Tyler J.; Cogdill, Alexandria P.; Morrissette, Jennifer J. D.; DeNizio, Jamie E.; Reddy, Shantan; Hwang, Young; Gohil, Mercy; Kulikovskaya, Irina; Nazimuddin, Farzana; Gupta, Minnal; Chen, Fang; Everett, John K.; Alexander, Katherine A.; Lin-Shiao, Enrique; Gee, Marvin H.; Liu, Xiaojun; Young, Regina M.; Ambrose, David; Wang, Yan; Xu, Jun; Jordan, Martha S.; Marcucci, Katherine T.; Levine, Bruce L.; Garcia, K. Christopher; Zhao, Yangbing; Kalos, Michael; Porter, David L.; Kohli, Rahul M.; Lacey, Simon F.; Berger, Shelley L.; Bushman, Frederic D.; June, Carl H.; Melenhorst, J. Joseph			Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells	NATURE			English	Article							CD28 COSTIMULATION; DNA INTEGRATION; B-CELL; 5-METHYLCYTOSINE; MUTATIONS; PROTEINS; 5-HYDROXYMETHYLCYTOSINE; 5-FORMYLCYTOSINE; LYMPHOCYTES; CONVERSION	Cancer immunotherapy based on genetically redirecting T cells has been used successfully to treat B cell malignancies(1-3). In this strategy, the T cell genome is modified by integration of viral vectors or transposons encoding chimaeric antigen receptors (CARs) that direct tumour cell killing. However, this approach is often limited by the extent of expansion and persistence of CAR T cells(4,5). Here we report mechanistic insights from studies of a patient with chronic lymphocytic leukaemia treated with CAR T cells targeting the CD19 protein. Following infusion of CAR T cells, anti-tumour activity was evident in the peripheral blood, lymph nodes and bone marrow; this activity was accompanied by complete remission. Unexpectedly, at the peak of the response, 94% of CAR T cells originated from a single clone in which lentiviral vector-mediated insertion of the CAR transgene disrupted the methylcytosine dioxygenase TET2 gene. Further analysis revealed a hypomorphic mutation in this patient's second TET2 allele. TET2-disrupted CAR T cells exhibited an epigenetic profile consistent with altered T cell differentiation and, at the peak of expansion, displayed a central memory phenotype. Experimental knockdown of TET2 recapitulated the potency-enhancing effect of TET2 dysfunction in this patient's CAR T cells. These findings suggest that the progeny of a single CAR T cell induced leukaemia remission and that TET2 modification may be useful for improving immunotherapies.	[Fraietta, Joseph A.; Lundh, Stefan; Reich, Tyler J.; Cogdill, Alexandria P.; Gohil, Mercy; Kulikovskaya, Irina; Nazimuddin, Farzana; Gupta, Minnal; Chen, Fang; Liu, Xiaojun; Young, Regina M.; Ambrose, David; Wang, Yan; Xu, Jun; Marcucci, Katherine T.; Levine, Bruce L.; Zhao, Yangbing; Kalos, Michael; Porter, David L.; Lacey, Simon F.; June, Carl H.; Melenhorst, J. Joseph] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA; [Fraietta, Joseph A.; Lundh, Stefan; Carty, Shannon A.; Reich, Tyler J.; Cogdill, Alexandria P.; Gohil, Mercy; Kulikovskaya, Irina; Nazimuddin, Farzana; Gupta, Minnal; Chen, Fang; Liu, Xiaojun; Young, Regina M.; Ambrose, David; Wang, Yan; Xu, Jun; Jordan, Martha S.; Marcucci, Katherine T.; Levine, Bruce L.; Zhao, Yangbing; Kalos, Michael; Porter, David L.; Lacey, Simon F.; June, Carl H.; Melenhorst, J. Joseph] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Fraietta, Joseph A.; Morrissette, Jennifer J. D.; Jordan, Martha S.; Levine, Bruce L.; Kalos, Michael; Lacey, Simon F.; June, Carl H.; Melenhorst, J. Joseph] Univ Penn, Perelman Sch Med, Pathol & Lab Med, Philadelphia, PA 19104 USA; [Fraietta, Joseph A.; June, Carl H.; Melenhorst, J. Joseph] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Nobles, Christopher L.; Reddy, Shantan; Hwang, Young; Everett, John K.; Kohli, Rahul M.; Bushman, Frederic D.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sammons, Morgan A.; Alexander, Katherine A.; Lin-Shiao, Enrique; Berger, Shelley L.] Univ Penn, Perelman Sch Med, Epigenet Program, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [DeNizio, Jamie E.; Porter, David L.; Kohli, Rahul M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [DeNizio, Jamie E.; Kohli, Rahul M.] Univ Penn, Dept Biochem & Biophys, Perelman Sch Med, Philadelphia, PA 19104 USA; [Gee, Marvin H.; Garcia, K. Christopher] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA USA; [Sammons, Morgan A.] SUNY Albany, Dept Biol, Albany, NY 12222 USA; [Carty, Shannon A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Carty, Shannon A.] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Albany; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	June, CH; Melenhorst, JJ (corresponding author), Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.; June, CH; Melenhorst, JJ (corresponding author), Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.; June, CH; Melenhorst, JJ (corresponding author), Univ Penn, Perelman Sch Med, Pathol & Lab Med, Philadelphia, PA 19104 USA.; June, CH; Melenhorst, JJ (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.	cjune@upenn.edu; mej@upenn.edu	Carty, Shannon/ABF-9536-2020; Melenhorst, Jan/AAW-2546-2020	Carty, Shannon/0000-0003-2286-8014; Melenhorst, Jan/0000-0001-7677-537X; Reich, Tyler/0000-0003-0178-1411; Cogdill, Alexandria/0000-0001-8917-9462; Lin Shiao, Enrique/0000-0001-5396-9614	NCI [T32CA009140, P01CA214278, AI104400, AI 082020, AI045008, AI117950]; NIAID [K08AI101008]; NIGMS [R01GM118501, R01CA165206]; Stand Up to Cancer Phillip A. Sharp Innovation in Collaboration Award; Novartis; NATIONAL CANCER INSTITUTE [T32CA009140, P01CA214278, R01CA165206, R01CA078831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI101008, P30AI045008, U19AI117950, R01AI082020, R01AI104400, U01AI104400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM118501] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Stand Up to Cancer Phillip A. Sharp Innovation in Collaboration Award; Novartis(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	L. Tian, V. Gonzalez, N. Kengle, J. Scholler, Y. Wu, A. Bagg, C. Pletcher, B. Carreno, A. Bigdeli and A. Chew are acknowledged for research support. D. Campana and C. Imai provided the CD19-directed CAR under material transfer agreements. B. Jena and L. Cooper provided the CAR anti- idiotypic antibody. The OSU-CLL cell line was a kind gift from J. C. Byrd. This work was supported by funding from NCI T32CA009140 (J.A.F.), P01CA214278 (C.H.J.), AI104400, AI 082020, AI045008, AI117950 (F.D.B), NIAID K08AI101008 (S.A.C.), NIGMS R01GM118501 (R.M.K.), R01CA165206 (D.L.P. and C.H.J.), a Stand Up to Cancer Phillip A. Sharp Innovation in Collaboration Award (S.L.B. and C.H.J.) and Novartis.	Aslanyan MG, 2014, ANN HEMATOL, V93, P1401, DOI 10.1007/s00277-014-2055-7; Barrett DM, 2011, HUM GENE THER, V22, P1575, DOI 10.1089/hum.2011.070; Berry C, 2006, PLOS COMPUT BIOL, V2, P1450, DOI 10.1371/journal.pcbi.0020157; Berry CC, 2014, BIOINFORMATICS, V30, P1493, DOI 10.1093/bioinformatics/btu035; Berry CC, 2012, BIOINFORMATICS, V28, P755, DOI 10.1093/bioinformatics/bts004; Brady T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr140; Brady T, 2009, GENE DEV, V23, P633, DOI 10.1101/gad.1762309; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Busque L, 2012, NAT GENET, V44, P1179, DOI 10.1038/ng.2413; Carty SA, 2018, J IMMUNOL, V200, P82, DOI 10.4049/jimmunol.1700559; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Daber R, 2013, CANCER GENET-NY, V206, P441, DOI 10.1016/j.cancergen.2013.11.005; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Fraietta JA, 2016, BLOOD, V127, P1117, DOI 10.1182/blood-2015-11-679134; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hertlein E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076607; Hu LL, 2013, CELL, V155, P1545, DOI 10.1016/j.cell.2013.11.020; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jena B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057838; Jin JJ, 2012, J IMMUNOTHER, V35, P283, DOI 10.1097/CJI.0b013e31824e801f; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Laport GG, 2003, BLOOD, V102, P2004, DOI 10.1182/blood-2003-01-0095; Liu MY, 2016, METHOD ENZYMOL, V573, P365, DOI 10.1016/bs.mie.2015.12.006; Liu MY, 2017, NAT CHEM BIOL, V13, P181, DOI [10.1038/nchembio.2250, 10.1038/NCHEMBIO.2250]; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Moskowitz DM, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag0192; Ocwieja KE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001313; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Pfaffeneder T, 2011, ANGEW CHEM INT EDIT, V50, P7008, DOI 10.1002/anie.201103899; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Savoldo B, 2011, J CLIN INVEST, V121, P1822, DOI 10.1172/JCI46110; Scharer CD, 2013, J IMMUNOL, V191, P3419, DOI 10.4049/jimmunol.1301395; Scholler J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003761; Schuster SJ, 2017, NEW ENGL J MED, V377, P2545, DOI 10.1056/NEJMoa1708566; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tefferi A, 2009, LEUKEMIA, V23, P1343, DOI 10.1038/leu.2009.59; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Xu J, 2017, NAT GENET, V49, P377, DOI 10.1038/ng.3769; Yeh CH, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0500-z; Zang SB, 2017, J CLIN INVEST, V127, P2998, DOI 10.1172/JCI92026; Zhang H, 2007, J IMMUNOL, V179, P4910, DOI 10.4049/jimmunol.179.7.4910	47	386	403	10	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 14	2018	558	7709					307	+		10.1038/s41586-018-0178-z	http://dx.doi.org/10.1038/s41586-018-0178-z			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ2BI	29849141	Green Accepted			2023-01-03	WOS:000435071400057
J	Kuppermann, N; Ghetti, S; Schunk, JE; Stoner, MJ; Rewers, A; McManemy, JK; Myers, SR; Nigrovic, LE; Garro, A; Brown, KM; Quayle, KS; Trainor, JL; Tzimenatos, L; Bennett, JE; DePiero, AD; Kwok, MY; Perry, CS; Olsen, CS; Casper, TC; Dean, JM; Glaser, NS				Kuppermann, Nathan; Ghetti, Simona; Schunk, Jeff E.; Stoner, Michael J.; Rewers, Arleta; McManemy, Julie K.; Myers, Sage R.; Nigrovic, Lise E.; Garro, Aris; Brown, Kathleen M.; Quayle, Kimberly S.; Trainor, Jennifer L.; Tzimenatos, Leah; Bennett, Jonathan E.; DePiero, Andrew D.; Kwok, Maria Y.; Perry, Clinton S., III; Olsen, Cody S.; Casper, T. Charles; Dean, J. Michael; Glaser, Nicole S.		PECARN DKA FLUID Study Grp	Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL EDEMA; BRAIN HERNIATION; RISK-FACTORS; CHILDREN; INSULIN; YOUTH; HYPERGLYCEMIA; BUMETANIDE; MANAGEMENT; CHILDHOOD	BACKGROUND Diabetic ketoacidosis in children may cause brain injuries ranging from mild to severe. Whether intravenous fluids contribute to these injuries has been debated for decades. METHODS We conducted a 13-center, randomized, controlled trial that examined the effects of the rate of administration and the sodium chloride content of intravenous fluids on neurologic outcomes in children with diabetic ketoacidosis. Children were randomly assigned to one of four treatment groups in a 2-by-2 factorial design (0.9% or 0.45% sodium chloride content and rapid or slow rate of administration). The primary outcome was a decline in mental status (two consecutive Glasgow Coma Scale scores of <14, on a scale ranging from 3 to 15, with lower scores indicating worse mental status) during treatment for diabetic ketoacidosis. Secondary outcomes included clinically apparent brain injury during treatment for diabetic ketoacidosis, short-term memory during treatment for diabetic ketoacidosis, and memory and IQ 2 to 6 months after recovery from diabetic ketoacidosis. RESULTS A total of 1389 episodes of diabetic ketoacidosis were reported in 1255 children. The Glasgow Coma Scale score declined to less than 14 in 48 episodes (3.5%), and clinically apparent brain injury occurred in 12 episodes (0.9%). No significant differences among the treatment groups were observed with respect to the percentage of episodes in which the Glasgow Coma Scale score declined to below 14, the magnitude of decline in the Glasgow Coma Scale score, or the duration of time in which the Glasgow Coma Scale score was less than 14; with respect to the results of the tests of short-term memory; or with respect to the incidence of clinically apparent brain injury during treatment for diabetic ketoacidosis. Memory and IQ scores obtained after the children's recovery from diabetic ketoacidosis also did not differ significantly among the groups. Serious adverse events other than altered mental status were rare and occurred with similar frequency in all treatment groups. CONCLUSIONS Neither the rate of administration nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes in children with diabetic ketoacidosis.	[Kuppermann, Nathan; Tzimenatos, Leah] Univ Calif Davis, Sch Med, Univ Calif Davis Hlth, Dept Emergency Med, Sacramento, CA 95817 USA; [Kuppermann, Nathan; Glaser, Nicole S.] Univ Calif Davis, Sch Med, Univ Calif Davis Hlth, Dept Pediat, Sacramento, CA 95817 USA; [Ghetti, Simona; Perry, Clinton S., III] Univ Calif Davis, Sch Med, Univ Calif Davis Hlth, Dept Psychol, Sacramento, CA 95817 USA; [Schunk, Jeff E.; Olsen, Cody S.; Casper, T. Charles; Dean, J. Michael] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Stoner, Michael J.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Div Emergency Med,Dept Pediat, Columbus, OH 43210 USA; [Rewers, Arleta] Univ Colorado, Denver Sch Med, Colorado Childrens Hosp, Div Emergency Med,Dept Pediat, Aurora, CO USA; [McManemy, Julie K.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Div Emergency Med, Houston, TX 77030 USA; [Myers, Sage R.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Emergency Med,Dept Pediat, Philadelphia, PA 19104 USA; [Bennett, Jonathan E.; DePiero, Andrew D.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Nemours AI duPont Hosp Children, Div Emergency Med, Philadelphia, PA 19107 USA; [Nigrovic, Lise E.] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Div Emergency Med, Boston, MA USA; [Garro, Aris] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA; [Garro, Aris] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Pediat, Providence, RI 02903 USA; [Brown, Kathleen M.] George Washington Sch Med & Hlth Sci, Childrens Natl Med Ctr, Dept Pediat, Div Emergency Med, Washington, DC USA; [Quayle, Kimberly S.] Washington Univ, St Louis Childrens Hosp, Sch Med, Div Emergency Med,Dept Pediat, St Louis, MO 63110 USA; [Trainor, Jennifer L.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Div Emergency Med,Dept Pediat, Chicago, IL 60611 USA; [Kwok, Maria Y.] Columbia Univ, Coll Phys & Surg, New York Presbyterian Morgan Stanley Childrens Ho, Div Emergency Med,Dept Pediat, New York, NY USA; [Perry, Clinton S., III] Tufts Univ, Dept Psychol, Medford, MA 02155 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Utah System of Higher Education; University of Utah; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor College of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Jefferson University; Nemours Alfred I. duPont Hospital for Children; Harvard University; Boston Children's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Children's National Health System; George Washington University; St. Louis Children's Hospital; Washington University (WUSTL); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Tufts University	Kuppermann, N (corresponding author), Univ Calif Davis, Sch Med, Dept Emergency Med, 2315 Stockton Blvd, Sacramento, CA 95817 USA.	nkuppermann@ucdavis.edu	Rewers, Arleta/AAE-2484-2019; Stoner, Michael/AAU-8224-2020	Nigrovic, Lise/0000-0002-6369-3997; Trainor, Jennifer/0000-0003-3566-9735	Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01HD062417]; Emergency Medical Services for Children Network Development Demonstration Program of the Maternal and Child Health Bureau, Health Resources and Services Administration [U03MC00008, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC22684, U03MC22685]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD062417] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD062417] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Emergency Medical Services for Children Network Development Demonstration Program of the Maternal and Child Health Bureau, Health Resources and Services Administration; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant U01HD062417) and the Emergency Medical Services for Children Network Development Demonstration Program of the Maternal and Child Health Bureau, Health Resources and Services Administration, under cooperative agreement (awards U03MC00008, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC22684, and U03MC22685).	Antenor-Dorsey JAV, 2013, DIABETES, V62, P581, DOI 10.2337/db12-0696; ARIEFF AI, 1974, J CLIN ENDOCR METAB, V38, P1057, DOI 10.1210/jcem-38-6-1057; Baddeley A., 1986, WORKING MEMORY; Cameron FJ, 2014, DIABETES CARE, V37, P1554, DOI 10.2337/dc13-1904; Cato MA, 2016, J INT NEUROPSYCH SOC, V22, P293, DOI 10.1017/S1355617715001289; Close TE, 2013, MICROCIRCULATION, V20, P534, DOI 10.1111/micc.12053; COUCH RM, 1991, DIABETES CARE, V14, P78, DOI 10.2337/diacare.14.1.78b; Daneman D, 2001, DIABETES CARE, V24, P801, DOI 10.2337/diacare.24.5.801; DUCK SC, 1988, J PEDIATR-US, V113, P10, DOI 10.1016/S0022-3476(88)80521-3; Edge JA, 1999, ARCH DIS CHILD, V81, P318, DOI 10.1136/adc.81.4.318; Edge JA, 2001, ARCH DIS CHILD, V85, P16, DOI 10.1136/adc.85.1.16; Garro A, 2017, PEDIATR DIABETES, V18, P95, DOI 10.1111/pedi.12359; Ghetti S, 2010, J PEDIATR-US, V156, P109, DOI 10.1016/j.jpeds.2009.07.054; Glaser N, 2001, NEW ENGL J MED, V344, P264, DOI 10.1056/NEJM200101253440404; Glaser N, 2010, DIABETES, V59, P702, DOI 10.2337/db09-0635; Glaser NS, 2008, J PEDIATR-US, V153, P541, DOI 10.1016/j.jpeds.2008.04.048; Glaser NS, 2013, J PEDIATR-US, V163, P1111, DOI 10.1016/j.jpeds.2013.06.008; Glaser NS, 2013, PEDIATR DIABETES, V14, P435, DOI 10.1111/pedi.12027; Glaser NS, 2006, PEDIATR DIABETES, V7, P75, DOI 10.1111/j.1399-543X.2006.00156.x; Glaser NS, 2004, J PEDIATR-US, V145, P164, DOI 10.1016/j.jpeds.2004.03.045; HARRIS GD, 1990, J PEDIATR-US, V117, P22, DOI 10.1016/S0022-3476(05)82439-4; HARRIS GD, 1988, J PEDIATR-US, V113, P65, DOI 10.1016/S0022-3476(88)80529-8; Hoffman WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071905; Lam TL, 2005, DIABETES, V54, P510, DOI 10.2337/diabetes.54.2.510; Lawrence SE, 2005, J PEDIATR-US, V146, P688, DOI 10.1016/j.jpeds.2004.12.041; MEL JM, 1995, J PAEDIATR CHILD H, V31, P17, DOI 10.1111/j.1440-1754.1995.tb02905.x; Muir AB, 2004, DIABETES CARE, V27, P1541, DOI 10.2337/diacare.27.7.1541; Omatsu T, 2014, AM J PHYSIOL-ENDOC M, V306, pE1077, DOI 10.1152/ajpendo.00659.2013; Patel A, 2016, CLIN PEDIATR, V55, P943, DOI 10.1177/0009922815617975; PROCKOP LD, 1971, ARCH NEUROL-CHICAGO, V25, P126, DOI 10.1001/archneur.1971.00490020044005; SCIBILIA J, 1986, ACTA ENDOCRINOL-COP, V113, P326; Semenkovich K, 2016, PEDIATR DIABETES, V17, P492, DOI 10.1111/pedi.12314; Siller AF, 2017, PEDIATR DIABETES, V18, P686, DOI 10.1111/pedi.12420; Stentz FB, 2004, DIABETES, V53, P2079, DOI 10.2337/diabetes.53.8.2079; TSUSHIMA WT, 1994, J CLIN PSYCHOL, V50, P877, DOI 10.1002/1097-4679(199411)50:6<877::AID-JCLP2270500610>3.0.CO;2-R; Wechsler D., 1999, WECHSLER ABBREVIATED; White PC, 2015, PEDIATR DIABETES, V16, P317, DOI 10.1111/pedi.12274; Yuen N, 2008, DIABETES, V57, P2588, DOI 10.2337/db07-1410	38	100	104	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2018	378	24					2275	2287		10.1056/NEJMoa1716816	http://dx.doi.org/10.1056/NEJMoa1716816			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ2KR	29897851	Green Accepted, Bronze			2023-01-03	WOS:000435099900005
J	Wilson, L; Turkistani, FA; Huang, W; Tran, DM; Lin, TK				Wilson, Leslie; Turkistani, Fatema A.; Huang, Wei; Tran, Dang M.; Lin, Tracy Kuo			The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing	PLOS ONE			English	Article								Introduction California's Workers' Compensation System (CAWCS) Department of Industrial Relations questioned the adequacy of the current Medi-Cal fee-schedule pricing and requested analysis of alternatives that maximize price availability and maintain budget neutrality. Objectives To compare CAWCS pharmacy-dispensed (PD) drug prices under alternative fee schedules, and identify combinations of alternative benchmarks that have prices available for the largest percentage of PD drugs and that best reach budget neutrality. Methods Claims transaction-level data (2011-2013) from CAWCS were used to estimate total annual PD pharmaceutical payments. Medi-Cal pricing data was from the Workman's Compensation Insurance System (WCIS). Average Wholesale Prices (AWP), Wholesale Acquisition Costs (WAC), Direct Prices (DP), Federal Upper Limit (FUL) prices, and National Average Drug Acquisition Costs (NADAC) were from Medi-Span. We matched National Drug Codes (NDCs), pricing dates, and drug quantity for comparisons. We report pharmacy-dispensed (PD) claims frequency, reimbursement matching rate, and paid costs by CAWCS as the reference price against all alternative price benchmarks. Results Of 12,529,977 CAWCS claims for pharmaceutical products 11.6% (1,462,814) were for PD drugs. Prescription drug cost for CAWCS was over $152M; $63.9M, $47.9M, and $40.6M in 2011-2013. Ninety seven percent of these CAWCS PD claims had a Medi-Cal price. Alternative mechanisms provided a price for fewer claims; NADAC 94.23%, AWP 90.94%, FUL 73.11%, WAC 66.98%, and DP 14.33%. Among CAWCS drugs with no Medi-Cal price in PD claims, AWP, WAC, NADAC, DP, and FUL provided prices for 96.7%, 63.14%, 24.82%, 20.83%, and 15.08% of claims. Overall CAWCS paid 100.52% of Medi-Cal, 60% of AWP, 97% of WAC, 309.53% of FUL, 103.83% of DP, and 136.27% of NADAC. Conclusions CAWCS current Medi-Cal fee-schedule price list for PD drugs is more complete than all alternative fee-schedules. However, all reimbursement approaches would require combinations of pricing benchmarks. We suggest keeping primary reimbursement at 100% of Medi-Cal and for drugs without a primary Medi-Cal price calculating the maximum fee as 60% of AWP and then 97% of WAC. Alternatively, we suggest using NADAC as a primary fee schedule followed by either 60% AWP and 97% WAC or AWP-40% for drugs with no NADAC price. Fee-schedules may not offer the best price and a formulary approach may provide more flexibility.	[Wilson, Leslie; Turkistani, Fatema A.; Huang, Wei; Tran, Dang M.; Lin, Tracy Kuo] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA; [Turkistani, Fatema A.] Taibah Univ, Coll Pharm, Dept Clin & Hosp Pharm, Al Madinah, Saudi Arabia; [Lin, Tracy Kuo] London Sch Econ & Polit Sci, Dept Social Policy, London, England	University of California System; University of California San Francisco; Taibah University; University of London; London School Economics & Political Science	Wilson, L (corresponding author), Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA.	Leslie.Wilson@ucsf.edu			California Department of Industrial Relations, Division of Workers' Compensation; California Division of Workers' Compensation	California Department of Industrial Relations, Division of Workers' Compensation; California Division of Workers' Compensation	Funded by California Department of Industrial Relations, Division of Workers' Compensation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by a contract with the California Division of Workers' Compensation and with data from CWCI. We thank Duyen-Anh Pham and Osama A. Shoair for their major contributions.	[Anonymous], 2004, MEDICAID MEDICARE DR; [Anonymous], MED US SPEND US REV; California Health Care Foundation, HLTH CAR WORKS ALL C; Center for Evidence-based Policy Medicaid Evidence-based Decisions Project (MED), 2016, MED SPEC DRUGS CURR; Center for Medicare and Medicaid Services, 2016, FED UPP LIM; Center for Medicare & Meddicaid Services, STAT PRESCR DRUG RES; Center for Medicare & Medicaid Services, SURV RET PRIC; Center of Medicare and Medicaid Services (CMS), 2013, METH CALC NAT AV DRU; Danzon P. M., 2014, ENCY HLTH EC, V3, P127; Division of Workers' Compensation, 2011, DIV WORK COMP EMPL I; Division of Workers' Compensation State of California, DIV WORK COMP INJ WO; Express Scripts, 2015, DRUG TREND REP; Fein AJ, NADAC MOMENTUM CALIF; Gencarelli DM, 2002, NAT HLTH POL FOR JUN; Hartman M, 2018, HEALTH AFFAIR, V37, P150, DOI 10.1377/hlthaff.2017.1299; Healthcare Solutions, 2014, WORKCOMPWIRE; Kuschner Beth, 2006, Case Manager, V17, P63, DOI 10.1016/j.casemgr.2006.07.003; Levinson DR, 2013, MEDICAID DRUG PRICIN; Messer M., 2012, ANAL DRUG PRICING ME; Microsoft Office, EXC 2013 QUICK START; Millman Inc, 2015, MILLM MED IND RES RE; System CW, 2015, C CHRONICLES; Tag H, 2013, AMCP GUIDE PHARM PAY; Victor RA, 2006, COST USE PHARM WORKE; Wei A, 2014, CHSWC 2014 ANN REPOR; Wilson L, 2005, AM J IND MED, V48, P239, DOI 10.1002/ajim.20208; Wolters Kluwer, MED SPAN PRIC RX; Workers' Compensation Insurance Rating Bureau of California, 2016, WCIRB REP STAT CAL W; Wynn BO, 2016, IMPLEMENTING DRUG FO	29	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2018	13	5							e0197449	10.1371/journal.pone.0197449	http://dx.doi.org/10.1371/journal.pone.0197449			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH1HI	29799850	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000433153400011
J	Meroni, E; Stakenborg, N; Gomez-Pinilla, PJ; De Hertogh, G; Goverse, G; Matteoli, G; Verheijden, S; Boeckxstaens, GE				Meroni, Elisa; Stakenborg, Nathalie; Gomez-Pinilla, Pedro J.; De Hertogh, Gert; Goverse, Gera; Matteoli, Gianluca; Verheijden, Simon; Boeckxstaens, Guy E.			Functional characterization of oxazolone-induced colitis and survival improvement by vagus nerve stimulation	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; MURINE MODEL; ULCERATIVE-COLITIS; VAGAL INNERVATION; CROHNS-DISEASE; CELLS; ACTIVATION; PATHWAY; SEPSIS; HMGB1	Background Oxazolone-induced colitis has been frequently used in literature as a model of IBD, but insights into the underlying immune response and pathological features are surprisingly still very limited. Vagus nerve stimulation (VNS) has proven to be effective in innate and Th1/Th17 predominant inflammatory models, including pre-clinical models of colitis, however to what extent VNS is also effective in ameliorating Th2-driven colitis remains to be studied. In the present study, we therefore further characterized the immune response in oxazolone-induced colitis and investigated the potential therapeutic effect of VNS. Methods Colitis was induced in Balb/c mice by cutaneous sensitization with 3% oxazolone followed by intracolonic administration of 1% oxazolone 7 days later. To evaluate the effect of VNS on the development of Th2-driven colitis, VNS and sham-treated mice were challenged with 1% oxazolone. Results Intracolonic oxazolone administration resulted in a severe destruction of the colonic mucosa and a rapid drop in body temperature leading to a 65% mortality rate at day 5. Severe infiltration of neutrophils and monocytes was detected 6h after oxazolone administration which was associated with a Th2-type inflammatory response. VNS significantly improved survival rate which correlated with decreased levels of HMGB1 and reduced colonic (iI6 and cxcii mRNA) and serum cytokine levels (IL-6, TNF alpha and CXCL1) compared to sham treated mice. Conclusions Oxazolone-induced colitis rather represents a model of sepsis and, at best, may resemble a severe type of ulcerative colitis, associated with early and severe mucosal damage and a high mortality rate. VNS reduces colonic inflammation and improves survival in this model, supporting the anti-inflammatory properties of VNS, even in an aggressive model as oxazolone-induced colitis.	[Meroni, Elisa; Stakenborg, Nathalie; Gomez-Pinilla, Pedro J.; Goverse, Gera; Matteoli, Gianluca; Verheijden, Simon; Boeckxstaens, Guy E.] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Translat Res Ctr Gastrointestinal Disorders TARGI, Leuven, Belgium; [De Hertogh, Gert] Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium	KU Leuven; KU Leuven	Boeckxstaens, GE (corresponding author), Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Translat Res Ctr Gastrointestinal Disorders TARGI, Leuven, Belgium.	guy.boeckxstaens@kuleuven.be	Boeckxstaens, Guy/AAP-2502-2020	Matteoli, Gianluca/0000-0002-2902-4976	European Research Council (ERC) Advanced Grant [340101]; Flanders Fund for Innovation by Science and Technology (IWT-TBM) [110699]; Research Foundation-Flanders (FWO): Odysseus program [G.0905.07]; FWO grant [G.0566.12N]; FWO [G.0D83.17N]	European Research Council (ERC) Advanced Grant(European Research Council (ERC)); Flanders Fund for Innovation by Science and Technology (IWT-TBM); Research Foundation-Flanders (FWO): Odysseus program; FWO grant(FWO); FWO(FWO)	This work was supported by the European Research Council (ERC) Advanced Grant (ERC-2013-Adg: 340101 Cholstim) to GEB. GEB is also supported by Flanders Fund for Innovation by Science and Technology (IWT-TBM; 110699), and Research Foundation-Flanders (FWO): Odysseus program (G.0905.07) and FWO grant (G.0566.12N). PJGP, GG and SV are supported by a postdoctoral research fellowship of FWO. GM is supported by a FWO grant (G.0D83.17N).	[Anonymous], 2017, J INTERN MED, DOI DOI 10.1111/joim.12611; Beekwilder JP, 2010, J CLIN NEUROPHYSIOL, V27, P130, DOI 10.1097/WNP.0b013e3181d64d8a; BERTHOUD HR, 1991, AM J PHYSIOL, V260, pR200, DOI 10.1152/ajpregu.1991.260.1.R200; BERTHOUD HR, 1990, J COMP NEUROL, V301, P65, DOI 10.1002/cne.903010107; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Bonaz B, 2016, NEUROGASTROENT MOTIL, V28, P948, DOI 10.1111/nmo.12792; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Chassaing Benoit, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1525s104; Danese S, 2009, GASTROEN CLIN BIOL, V33, pS217, DOI 10.1016/S0399-8320(09)73157-4; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Di Giovangiulio M, 2016, MOL MED, V22, P464, DOI 10.2119/molmed.2016.00062; Farro G, 2017, GUT, V66, P2098, DOI 10.1136/gutjnl-2016-313144; Gerlach K, 2014, NAT IMMUNOL, V15, P676, DOI 10.1038/ni.2920; Ghia JE, 2006, GASTROENTEROLOGY, V131, P1122, DOI 10.1053/j.gastro.2006.08.016; Ghia JE, 2007, AM J PHYSIOL-GASTR L, V293, pG711, DOI 10.1152/ajpgi.00240.2007; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Huston JM, 2007, CRIT CARE MED, V35, P2762, DOI 10.1097/01.CCM.0000288102.15975.BA; Ji H, 2014, MUCOSAL IMMUNOL, V7, P335, DOI 10.1038/mi.2013.52; Jin HF, 2017, AM J PHYSIOL-GASTR L, V313, pG192, DOI 10.1152/ajpgi.00254.2016; Kennedy RJ, 2000, BRIT J SURG, V87, P1346, DOI 10.1046/j.1365-2168.2000.01615.x; Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113; Lakatos PL, 2006, WORLD J GASTROENTERO, V12, P6102, DOI 10.3748/wjg.v12.i38.6102; Meregnani J, 2011, AUTON NEUROSCI-BASIC, V160, P82, DOI 10.1016/j.autneu.2010.10.007; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; Nolte T, 2013, CLIN EXP IMMUNOL, V172, P349, DOI 10.1111/cei.12057; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Pavlov VA, 2006, P NATL ACAD SCI USA, V103, P5219, DOI 10.1073/pnas.0600506103; Pavlov VA, 2009, BRAIN BEHAV IMMUN, V23, P41, DOI 10.1016/j.bbi.2008.06.011; Peters EG, 2015, NEUROGASTROENT MOTIL, V27, P743, DOI 10.1111/nmo.12579; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Stakenborg N, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13075; Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Sun P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069424; Ulloa L, 2006, CYTOKINE GROWTH F R, V17, P189, DOI 10.1016/j.cytogfr.2006.01.003; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wedlake L, 2014, INFLAMM BOWEL DIS, V20, P576, DOI 10.1097/01.MIB.0000437984.92565.31; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Zhu SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100167	43	29	29	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2018	13	5							e0197487	10.1371/journal.pone.0197487	http://dx.doi.org/10.1371/journal.pone.0197487			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH0FF	29791477	Green Published, gold, Green Submitted			2023-01-03	WOS:000433077000040
J	Kahsay, ZH; Tegegne, D; Mohammed, E; Kiros, G				Kahsay, Znabu Hadush; Tegegne, Dessie; Mohammed, Ebrahim; Kiros, Getachew			Application of individual behavioral models to predict willingness to use modern contraceptives among pastoralist women in Afar region, Northern Ethiopia	PLOS ONE			English	Article							PERCEPTIONS; PREGNANCY; WORLDWIDE	Background Use of modern contraceptive methods reduces the risk of unwanted pregnancy, and is influenced by individual-level factors. Willingness to use modern contraceptive methods maybe a useful metric when considering health outcomes as it could predict health behaviors. Therefore, the current study aimed to assess the willingness of women to use modern contraceptives in Afar pastoralist communities. Methods A community-based cross-sectional study was conducted from May 1 to 30, 2016. Three hundred forty-five women of childbearing age (15-49 years) were systematically sampled with proportionate allocation from seven randomly selected kebeles (neighborhoods) in Aballa District of Afar Region, Ethiopia. All women meeting the inclusion criteria in each selected household were interviewed at home using a semi-structured questionnaire. Construct validity was assured using factor analysis. A combination of individual behavioral models were applied in order to measure willingness to use modern contraceptive methods. Multiple logistic regressions were utilized to identify factors associated with willingness to use contraceptive at P-value of less than 0.05. Results Three hundred twenty-two women participated in the study, for a response rate of 93.3%. The mean age of respondents was 27 (6) years. About one-third (N = 106, 32.9%) of the participants reported that they were willing to use modern contraceptives. Orthodox Christians (AOR = 4.22, 95% CI 1.94-8.92), women aged 19 or older at first marriage (AOR = 2.89, 95% CI 1.16-7.23), and women who had never experienced a stillbirth (AOR = 3.85, 95%Cl 1.37-10.78) were more likely to report being willing to use modern contraceptives. Additionally, perceived severity of an unwanted pregnancy (AOR = 1.71, 95% CI 1.57-1.93) and perceived self-efficacy to use contraceptives (AOR = 1.26, 95% CI 1.17-1.65) were positively associated with the willingness. Women who had never had an abortion were less likely to express willingness to use modern contraceptives (AOR = 0.41, 95% CI 0.19-0.92) and perceived importance of cultural and religious norms (AOR = 0.85, 95% CI 0.62-0.90) was also negatively associated with willingness. Conclusions The majority of women in this study were not willing to use modern contraceptive methods. A previous pregnancy outcome of stillbirth was associated with reduced willingness, while a prior abortion was associated with increased willingness. Perceived severity of unwanted pregnancy and higher self-efficacy surrounding contraceptive use were strong predictors of increased willingness to use contraceptives. Religious and cultural norms also appear to influence perception towards modern contraception. Thus, involvement of cultural and religious leaders and consideration of a woman's reproductive history are recommended when designing health education messages on contraception for Afar pastoralist women.	[Kahsay, Znabu Hadush] Mekelle Univ, Sch Publ Hlth, Hlth Educ & Behav Sci Unit, Mekelle, Ethiopia; [Tegegne, Dessie] Debre Tabor Univ, Dept Med Lab Sci, Debre Tabor, Ethiopia; [Mohammed, Ebrahim] Samara Univ, Dept Publ Hlth, Coll Hlth Sci, Samara, Ethiopia; [Kiros, Getachew] Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, Ethiopia	Mekelle University; Samara University; Jimma University	Kahsay, ZH (corresponding author), Mekelle Univ, Sch Publ Hlth, Hlth Educ & Behav Sci Unit, Mekelle, Ethiopia.	hadiszinabu@gmail.com		Afework, Dessie/0000-0003-3469-017X	Samara University	Samara University	Samara University funded the study as small scale research in recurrent budget for 2015.; We would like to thank Samara University for financial support and study participants for their participation in the study. The authors want to thank Mr. Haftu Kahsay (BA, MSc, Ph.D. fellow in literature) for his immense support in copy-editing the manuscript mainly for English usage.	Abraham C., PREDICTING HLTH BEHA, P28; Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; Ajzen I., 1988, ATTITUDES PERSONALIT; Alemayehu M, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0321-7; [Anonymous], 2014, ETHIOPIAN MINI ETHIO; [Anonymous], 2007, 2007 CENS; Askew I, 2012, REV EVIDENCE IDENTIF; Babalola S, 2015, DEMOGR RES, P33; Bartholomew LK, 2011, PLANNING HLTH PROMOT; Belda SS, 2017, BMC HEALTH SERV RES, V17, P1, DOI [10.1186/s12913-016-1943-z, DOI 10.1186/S12913-016-1943-Z]; Cates W, 2010, CONTRACEPTION, V81, P460, DOI 10.1016/j.contraception.2010.01.002; Central Statistical Agency, 2011, ETH DEM HLTH SURV; Central Statistical Authority, 2016, ETH DEM HLTH SURV 20; County M, 2016, SOCIO EC CULTURAL BA, V6, P12; El Shiekh B, 2015, PASTORALISM, V5, DOI 10.1186/s13570-015-0041-x; Ernest H., 2011, Exchange on HIV/AIDS, Sexuality and Gender, P9; Frohwirth L, 2013, SOC SCI MED, V99, P18, DOI 10.1016/j.socscimed.2013.10.010; Kokeb L, 2015, J FAM MED DIS PREV, V1, DOI DOI 10.23937/2469-5793/1510022; Lakew Y, 2013, GEOGRAPHICAL VARIATI, P1; Lee T, 2014, J CLIN NURS, V23, P1086, DOI 10.1111/jocn.12348; Ministry of finance and economic development and UNICEF in Ethiopia, 2012, UNICEF ETH PROGR AB; Muhindo R, 2015, INT J POPULATION RES; Onega, 2001, ED THEOR MOD PRINC C; Poverty P. Constrained Agency, 2012, CONSTRAINED AGENCY P; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Serizawa A, 2014, INT J NURS STUD, V51, P572, DOI 10.1016/j.ijnurstu.2013.08.007; Shiferaw A, ASSESSMENT POST ABOR; Singh S, 2009, ADDING IT COSTS BENE; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Srikanthan A, 2008, J OBSTET GYNAECOL CA, V30, P129, DOI 10.1016/S1701-2163(16)32736-0; Tewodros Tewodros DM, THESIS; Tsui AO, 2010, EPIDEMIOL REV, V32, P152, DOI 10.1093/epirev/mxq012; United Nations (UN), 2008, WORLD CONTR US 2007	33	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2018	13	5							e0197366	10.1371/journal.pone.0197366	http://dx.doi.org/10.1371/journal.pone.0197366			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GG6DG	29787587	Green Published, Green Submitted, gold			2023-01-03	WOS:000432785700024
J	Elkin, DJ; Pravder, HD				Elkin, David J.; Pravder, Harrison D.			Bridging magic and medicine	LANCET			English	Editorial Material									[Elkin, David J.] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA; MagicAid Inc, Great Neck, NY 11021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Elkin, DJ (corresponding author), SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA.			Pravder, Harrison/0000-0001-5535-017X				Hojat M, 2004, MED EDUC, V38, P934, DOI 10.1111/j.1365-2929.2004.01911.x; Lam MT, 2017, COMPLEMENT THER CLIN, V26, P5, DOI 10.1016/j.ctcp.2016.11.002	2	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 31	2018	391	10127					1254	1255		10.1016/S0140-6736(18)30707-4	http://dx.doi.org/10.1016/S0140-6736(18)30707-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB1DR	29619952				2023-01-03	WOS:000428791600012
J	Heinicke, U; Haydn, T; Kehr, S; Vogler, M; Fulda, S				Heinicke, Ulrike; Haydn, Tinka; Kehr, Sarah; Vogler, Meike; Fulda, Simone			BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis	ONCOGENE			English	Article							MITOCHONDRIAL PATHWAY; ANTITUMOR-ACTIVITY; CANCER-THERAPY; MCL-1; JNJ-26481585; DISCOVERIES; RESISTANCE; CHILDREN; LEUKEMIA; OVERCOME	BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities. Previously, we demonstrated that JNJ-26481585 (JNJ), a second-generation histone deacetylase inhibitor (HDACI), engages mitochondrial apoptosis via upregulation of several BH3-only proteins. In the present study, we describe synergistic interactions of JNJ with BH3 mimetics (i.e. ABT-737, ABT-199) in rhabdomyosarcoma (RMS) cells. Importantly, JNJ synergizes with ABT-199 to trigger apoptosis in primary-derived RMS cells isolated from tumor samples, underlining the translational importance of combining these compounds and their potential to improve cancer therapy. Importantly, JNJ/ABT-199 cotreatment also significantly inhibits long-term survival of RMS cells. Mechanistically, JNJ increases expression levels of the BH3-only protein BIM, while exposure to ABT-199 displaces BIM from BCL-2 and shuttles BIM to MCL-1, which also constitutively sequesters NOXA. Both BIM and NOXA contribute to JNJ/ABT-199-mediated cell death, as individual knockdown of NOXA or BIM significantly prevents cell death. Further, JNJ and ABT-199 act in concert to activate BAK and BAX, resulting in loss of the mitochondrial membrane potential (MMP) and caspase activation. These events are required for JNJ/ABT-199-mediated apoptosis, since BAK or BAX silencing or inhibition of caspases significantly protects from JNJ/ABT-199-induced cell death. Rescue experiments demonstrate that overexpression of MCL-1, but not overexpression of BCL-2, blocks JNJ/ABT-199-induced apoptosis. In conclusion, this study provides the first demonstration of ABT-199-induced priming, which sensitizes RMS cells to HDACI, such as JNJ, by engaging mitochondrial apoptosis, highlighting that BH3 mimetics show great promise for the treatment of RMS.	[Heinicke, Ulrike; Haydn, Tinka; Kehr, Sarah; Vogler, Meike; Fulda, Simone] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany; [Haydn, Tinka; Fulda, Simone] German Canc Consortium DKTK Partner Site, Frankfurt, Germany; [Haydn, Tinka; Fulda, Simone] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Consortium DKTK Partner Site, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	simone.fulda@kgu.de		Vogler, Meike/0000-0003-2650-586X; Fulda, Simone/0000-0002-0459-6417	BMBF; Deutsche Krebshilfe; Deutsche Kinderkrebsstiftung; Medical Faculty, Goethe-University Frankfurt	BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Kinderkrebsstiftung; Medical Faculty, Goethe-University Frankfurt	We thank D. Bruecher for expert technical assistance and C. Hugenberg for excellent secretarial assistance. This work has been partially supported by grants from the BMBF, the Deutsche Krebshilfe and the Deutsche Kinderkrebsstiftung (to SF) and a grant from the Medical Faculty, Goethe-University Frankfurt (to MV).	Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carol H, 2014, PEDIATR BLOOD CANCER, V61, P245, DOI 10.1002/pbc.24724; Carter BZ, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.512.512; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Choudhary GS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.525; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson Grant, 2015, Cold Spring Harb Protoc, V2015, P481, DOI 10.1101/pdb.prot086470; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2016, ONCOGENE, V35, P3729, DOI 10.1038/onc.2015.440; Heinicke U, 2015, ONCOTARGET, V6, P37836, DOI 10.18632/oncotarget.6097; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Hugle M, 2015, CELL DEATH DIFFER, V22, P1946, DOI 10.1038/cdd.2015.59; Khaw SL, 2014, LEUKEMIA, V28, P1207, DOI 10.1038/leu.2014.1; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Matthews GM, 2012, ADV CANCER RES, V116, P165, DOI 10.1016/B978-0-12-394387-3.00005-7; Michels J, 2014, BIOCHEM PHARMACOL, V92, P55, DOI 10.1016/j.bcp.2014.07.029; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; Niu XJ, 2016, CLIN CANCER RES, V22, P4440, DOI 10.1158/1078-0432.CCR-15-3057; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Pazzaglia L, 2009, HISTOL HISTOPATHOL, V24, P61, DOI 10.14670/HH-24.61; Peirs S, 2014, BLOOD, V124, P3738, DOI 10.1182/blood-2014-05-574566; Phillips DC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.88; Portell CA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.509.509; Preuss E, 2013, J BIOL CHEM, V288, P35287, DOI 10.1074/jbc.M113.495986; Sarosiek KA, 2016, FEBS J, V283, P3523, DOI 10.1111/febs.13714; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242	39	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5325	5339		10.1038/s41388-018-0212-5	http://dx.doi.org/10.1038/s41388-018-0212-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858601				2023-01-03	WOS:000445759700006
J	Cozzi, L; Comito, T; Fogliata, A; Franzese, C; Tomatis, S; Scorsetti, M				Cozzi, Luca; Comito, Tiziana; Fogliata, Antonella; Franzese, Ciro; Tomatis, Stefano; Scorsetti, Marta			Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma	PLOS ONE			English	Article							BEAM THERAPY; ARC THERAPY; RADIOTHERAPY; OPTIMIZATION; MITIGATION; SYSTEM; CANCER; MODEL	Purpose To investigate the role of intensity modulated proton therapy (IMPT) for advanced hepatocellular carcinoma in comparison with volumetric modulated arc therapy (VMAT). Methods An in-silico planning study was performed on 20 patients. The prescription dose was 60Gy in 6 fractions. Patients were planned with abdominal compression. IMPT plans were optimized with or without the inclusion of CT calibration (3%) and isocenter positioning (2,4,6mm) uncertainties. Plan robustness was appraised comparing rubust optimized plans vs standard plans and also in terms of the worst-case scenario. VMAT plans were optimized for 10FFF photon beams using 2 partial arcs. Results Target coverage was fully achieved by both VMAT and IMPT plans with a significant improvement in homogeneity (similar to 25%) with IMPT. Integral dose was reduced of similar to 60% with IMPT while the conformality of the dose distributions was similar among techniques. The sparing of the organs at risk was strongly improved with IMPT although all clinical objectives were met for both techniques. The inclusion of the uncertainties in the optimization lead to some deterioration in the target dose homogeneity (from 40 to 80% worse with 4 or 6mm position uncertainty) while none of the coverage parameters or OAR objective was violated. The worst-case scenario analysis demonstrated the risk of a major target underdosage only in the case of the most extreme errors (6mm) with D(98% )in average similar to 12% lower than the threshold. Conclusion IMPT with the support of abdominal compression, can be considered a viable solution also for advanced hepatocellular carcinoma patients. Great care shall be put in the minimization of the residual respiration and positioning uncertainties but the dosimetric advantage for organs at risk and the relative robustness on target coverage are promising factors.	[Cozzi, Luca; Comito, Tiziana; Fogliata, Antonella; Franzese, Ciro; Tomatis, Stefano; Scorsetti, Marta] Humanitas Res Hosp & Canc Ctr, Radiotherapy & Radiosurg, Milan, Italy; [Cozzi, Luca; Scorsetti, Marta] Humanitas Univ, Dept Biomed Sci, Milan, Italy	Humanitas University	Cozzi, L (corresponding author), Humanitas Res Hosp & Canc Ctr, Radiotherapy & Radiosurg, Milan, Italy.; Cozzi, L (corresponding author), Humanitas Univ, Dept Biomed Sci, Milan, Italy.	luca.cozzi@humanitas.it	cozzi, luca/GZL-4895-2022; Tomatis, Stefano/AAA-6002-2021; Franzese, Ciro/AAJ-7311-2020; franzese, ciro/P-5195-2019	cozzi, luca/0000-0001-7862-898X; Franzese, Ciro/0000-0001-6893-6284; comito, tiziana/0000-0002-5667-0535; Fogliata, Antonella/0000-0002-2282-9894; Scorsetti, Marta/0000-0003-0320-559X; Tomatis, Stefano/0000-0002-4791-0373				Arjomandy B, 2010, MED PHYS, V37, P5831, DOI 10.1118/1.3505011; Bernatowicz K, 2013, PHYS MED BIOL, V58, P7905, DOI 10.1088/0031-9155/58/22/7905; Bernatowicz K, 2017, PHYS MED BIOL, V62, P6595, DOI 10.1088/1361-6560/aa7ab8; Choi BO, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-351; Culleton S, 2014, RADIOTHER ONCOL, V111, P412, DOI 10.1016/j.radonc.2014.05.002; Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fogliata A, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0236-0; Gillin MT, 2010, MED PHYS, V37, P154, DOI 10.1118/1.3259742; Granovetter M, 2016, LANCET ONCOL, V17, pE49, DOI 10.1016/S1470-2045(15)00616-6; Hong TS, 2016, J CLIN ONCOL, V34, P460, DOI 10.1200/JCO.2015.64.2710; Igaki H, 2017, INT J CLIN ONCOL, DOI [10.1007/s10147-017-1190-2cancer, DOI 10.1007/S10147-017-1190-2CANCER]; Jacob R, 2014, ADJUVANT STEREOTACTI; Kwon JH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-475; Lin LY, 2017, MED PHYS, V44, P703, DOI 10.1002/mp.12040; Nocedal J, 2006, SPRINGER SER OPER RE, P1, DOI 10.1007/978-0-387-40065-5; Poulsen PR, 2018, INT J RADIAT ONCOL, V100, P226, DOI 10.1016/j.ijrobp.2017.09.043; Rah JE, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0717-4; Scorsetti M, 2015, J CANCER RES CLIN, V141, P1301, DOI 10.1007/s00432-015-1929-y; Vassiliev ON, 2010, PHYS MED BIOL, V55, P581, DOI 10.1088/0031-9155/55/3/002; Wang PM, 2013, STRAHLENTHER ONKOL, V189, P301, DOI 10.1007/s00066-012-0298-6; Wang PM, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-18; Wang PM, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-207; Yeung RH, 2017, EXPERT REV ANTICANC, V17, P911, DOI 10.1080/14737140.2017.1368392; Zhang Y, 2018, RADIOTHER ONCOL; Zhang Y, 2016, RADIOTHER ONCOL, V121, P281, DOI 10.1016/j.radonc.2016.09.011; Zhang Y, 2015, PHYS MED BIOL, V60, P8141, DOI 10.1088/0031-9155/60/20/8141; Zhang Y, 2012, PHYS MED BIOL, V57, P1779, DOI 10.1088/0031-9155/57/7/1779; Zhong NB, 2014, MOL CLIN ONCOL, V2, P839, DOI 10.3892/mco.2014.304	29	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2018	13	8							e0201992	10.1371/journal.pone.0201992	http://dx.doi.org/10.1371/journal.pone.0201992			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ2CL	30102749	Green Published, Green Submitted			2023-01-03	WOS:000441452200026
J	Doctor, JN; Nguyen, A; Lev, R; Lucas, J; Knight, T; Zhao, HN; Menchine, M				Doctor, Jason N.; Nguyen, Andy; Lev, Roneet; Lucas, Jonathan; Knight, Tara; Zhao, Henu; Menchine, Michael			Opioid prescribing decreases after learning of a patient's fatal overdose	SCIENCE			English	Article							UNITED-STATES; HEROIN USE; ADDICTION; RISK	Most opioid prescription deaths occur among people with common conditions for which prescribing risks outweigh benefits. General psychological insights offer an explanation: People may judge risk to be low without available personal experiences, may be less careful than expected when not observed, and may falter without an injunction from authority. To test these hypotheses, we conducted a randomized trial of 861 clinicians prescribing to 170 persons who subsequently suffered fatal overdoses. Clinicians in the intervention group received notification of their patients' deaths and a safe prescribing injunction from their county's medical examiner, whereas physicians in the control group did not. Milligram morphine equivalents in prescriptions filled by patients of letter recipients versus controls decreased by 9.7% (95% confidence interval: 6.2 to 13.2%; P < 0.001) over 3 months after intervention. We also observed both fewer opioid initiates and fewer high-dose opioid prescriptions by letter recipients.	[Doctor, Jason N.; Nguyen, Andy; Knight, Tara; Zhao, Henu] Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90007 USA; [Lev, Roneet] Scripps Mercy Hosp San Diego, Emergency Dept, San Diego, CA USA; [Lucas, Jonathan] Dept Med Examiner Coroner, Los Angeles, CA USA; [Menchine, Michael] Univ Southern Calif, Dept Emergency Med, Los Angeles, CA USA	University of Southern California; University of Southern California	Doctor, JN (corresponding author), Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90007 USA.	jdoctor@usc.edu		Zhao, Henu/0000-0001-6797-8802; Nguyen, Andy/0000-0002-0207-0323	California Health Care Foundation [19413]; National Institute on Aging at the National Institutes of Health [R21-AG057395-01]; NATIONAL INSTITUTE ON AGING [R21AG057395] Funding Source: NIH RePORTER	California Health Care Foundation; National Institute on Aging at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the California Health Care Foundation (grant 19413) and the National Institute on Aging at the National Institutes of Health (grant R21-AG057395-01).	Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Cialdini RB, 2003, CURR DIR PSYCHOL SCI, V12, P105, DOI 10.1111/1467-8721.01242; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; de Bruin WB, 2016, J EXP PSYCHOL-APPL, V22, P261, DOI 10.1037/xap0000083; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Leung PTM, 2017, NEW ENGL J MED, V376, P2194, DOI 10.1056/NEJMc1700150; McCambridge J, 2014, J CLIN EPIDEMIOL, V67, P267, DOI 10.1016/j.jclinepi.2013.08.015; MCDONALD JF, 1980, REV ECON STAT, V62, P318, DOI 10.2307/1924766; Meara E, 2016, NEW ENGL J MED, V375, P44, DOI 10.1056/NEJMsa1514387; Pollini RA, 2011, SUBST ABUSE REHABIL, V2, P173, DOI 10.2147/SAR.S24800; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; PORTER J, 1980, NEW ENGL J MED, V302, P123; Sacarny A, 2016, HEALTH AFFAIR, V35, P471, DOI 10.1377/hlthaff.2015.1025; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Stata Corp, 2015, STAT STAT SOFTW REL; TVERSKY A, 1973, COGNITIVE PSYCHOL, V5, P207, DOI 10.1016/0010-0285(73)90033-9	17	45	45	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2018	361	6402					588	590		10.1126/science.aat4595	http://dx.doi.org/10.1126/science.aat4595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP8YO	30093595				2023-01-03	WOS:000441202700034
J	Ke, YT; Feng, IJ; Hsu, CC; Wang, JJ; Su, SB; Huang, CC; Lin, HJ				Ke, Ya-Ting; Feng, I-Jung; Hsu, Chien-Chin; Wang, Jhi-Joung; Su, Shih-Bin; Huang, Chien-Cheng; Lin, Hung-Jung			Nurses have a four-fold risk for overdose of sedatives, hypnotics, and antipsychotics than other healthcare providers in Taiwan	PLOS ONE			English	Article								Nurses have high work stress that may contribute to an increased overdose for sedatives, hypnotics, and antipsychotics (OSHA). We conducted this nationwide population-based cross-sectional study to clarify this still unclear issue. We used a nationwide database to identify 110,379 nurses, 22,032 other healthcare providers (HCPs), and an identical number of individuals from the general population matched by age and sex. We compared the period prevalence of OSHA between nurses and the general population, other HCPs and the general population, and nurses and other HCPs, among nurse subgroups from 2006 to 2012. The risk for OSHA in nurses and in the general population was not significantly different after adjusting for anxiety, insomnia, depression, schizophrenia, and affective disorders (adjusted odds ratio [AOR]: 1.145; 95% confidence interval [CI]: 0.974-1.346). However, in the age subgroups < 35 years, nurses had higher risk than the general population of having OSHA (AOR: 1.333; 95% CI: 1.109-1.601). Other HCPs had a significantly lower risk for OSHA than the general population (AOR: 0.237; 95% CI: 0.122-0.460). Nurses had a significantly higher risk for OSHA than other HCPs (AOR: 3.902; 95% CI: 2.159-7.048). Comparison among nurses showed that younger nurses (< 35 years) had a significantly higher risk for OSHA than the older nurses (>= 50 years) (AOR: 3.569; 95% CI: 1.252-10.330). Registered nurses had significantly higher risk for OSHA than registered professional nurses (AOR: 1.810; 95% CI: 1.405-2.332); and nurses from clinics, local hospitals, and regional hospitals had significantly higher risk than nurses from medical centers. This study delineated that nurses had a nearly four-fold risk for OSHA when compared to other HCPs. Younger nurses, registered nurses, and nurses from clinics, local hospitals, and regional hospitals had higher risks for OSHA than their respective nurse controls; it suggests that more attention should be given to the occupational health of these populations.	[Ke, Ya-Ting] Chi Mei Med Ctr, Dept Nursing, Tainan, Taiwan; [Ke, Ya-Ting] Kaohsiung Med Univ, Sch Nursing, Kaohsiung, Taiwan; [Feng, I-Jung; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Hsu, Chien-Chin; Huang, Chien-Cheng; Lin, Hung-Jung] Chi Mei Med Ctr, Dept Emergency Med, Tainan, Taiwan; [Hsu, Chien-Chin; Lin, Hung-Jung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Su, Shih-Bin] Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management, Tainan, Taiwan; [Su, Shih-Bin; Huang, Chien-Cheng] Chi Mei Med Ctr, Dept Occupat Med, Tainan, Taiwan; [Huang, Chien-Cheng] Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Coll Med, Tainan, Taiwan; [Huang, Chien-Cheng] Southern Taiwan Univ Sci & Technol, Dept Senior Serv, Tainan, Taiwan; [Huang, Chien-Cheng] Chi Mei Med Ctr, Dept Geriatr & Gerontol, Tainan, Taiwan; [Lin, Hung-Jung] Taipei Med Univ, Dept Emergency Med, Taipei, Taiwan	Chi Mei Hospital; Kaohsiung Medical University; Chi Mei Hospital; Chi Mei Hospital; Southern Taiwan University of Science & Technology; Southern Taiwan University of Science & Technology; Chi Mei Hospital; National Cheng Kung University; Southern Taiwan University of Science & Technology; Chi Mei Hospital; Taipei Medical University	Huang, CC; Lin, HJ (corresponding author), Chi Mei Med Ctr, Dept Emergency Med, Tainan, Taiwan.; Lin, HJ (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.; Huang, CC (corresponding author), Chi Mei Med Ctr, Dept Occupat Med, Tainan, Taiwan.; Huang, CC (corresponding author), Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Coll Med, Tainan, Taiwan.; Huang, CC (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Senior Serv, Tainan, Taiwan.; Huang, CC (corresponding author), Chi Mei Med Ctr, Dept Geriatr & Gerontol, Tainan, Taiwan.; Lin, HJ (corresponding author), Taipei Med Univ, Dept Emergency Med, Taipei, Taiwan.	chienchenghuang@yahoo.com.tw; hjlin52@gmail.com			Chi-Mei Medical Center [CMFHR10635]; National Health Research Institutes [NHIRD-102-024, NHIRD-100-057]	Chi-Mei Medical Center; National Health Research Institutes(National Health Research Institutes, JapanNational Health Research Institutes - Taiwan)	This study was supported by grant CMFHR10635 from Chi-Mei Medical Center (http://www.chimei.org.tw/main/cmh_department/54220/english/) to C-CH. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Miss Ti Hsu for English revision and the National Health Insurance Administration, Ministry of Health and Welfare (managed by the National Health Research Institutes-Registered number NHIRD-102-024 and NHIRD-100-057) for access to the Taiwan National Health Insurance Research Database. The conclusions in this study do not represent those of the National Health Insurance Administration, Ministry of Health and Welfare, or National Health Research Institutes.	Aparasu RR, 2003, J AM GERIATR SOC, V51, P671, DOI 10.1034/j.1600-0579.2003.00212.x; Ayala E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054408; Buchan J, 2008, J CLIN NURS, V17, P3262, DOI 10.1111/j.1365-2702.2008.02636.x; Chen MH, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1539-7; Daprix Jean, 2003, Fla Nurse, V51, P28; Dunn D., 2005, AORN J, V82, P572, DOI DOI 10.1016/S0001-2092(06)60028-8; Huang CC, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0416-7; Kenna GA, 2008, SUBST ABUSE TREAT PR, V3, DOI 10.1186/1747-597X-3-3; Kuo WY, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0585-6; Lin HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135456; McCabe R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036080; Mowry JB, 2015, CLIN TOXICOL, V53, P962, DOI 10.3109/15563650.2015.1102927; National Health Insurance Administration Ministry of Health and Welfare Taiwan ROC, 2014, NATL HLTH INSURANCE; Pilgrim JL, 2017, ADDICTION, V112, P486, DOI 10.1111/add.13619; Shah Divyang, 2009, Indian J Occup Environ Med, V13, P77, DOI 10.4103/0019-5278.55123; Tam HP, 2017, EPIDEMIOLOGY, V28, pS48, DOI [10.1097/EDE.0000000000000720, 10.1097/ede.0000000000000720]; Trinkoff AM, 1998, AM J PUBLIC HEALTH, V88, P581, DOI 10.2105/AJPH.88.4.581; Yang M S, 2001, Kaohsiung J Med Sci, V17, P261; Young Linda J, 2008, Nurs Adm Q, V32, P331, DOI 10.1097/01.NAQ.0000336732.02996.f7	19	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2018	13	8							e0202004	10.1371/journal.pone.0202004	http://dx.doi.org/10.1371/journal.pone.0202004			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP7NS	30089164	Green Submitted, Green Published, gold			2023-01-03	WOS:000441090300063
J	Li, HJ; Kuo, CC; Yao, YC; Tsai, CH; Chow, PC; Li, YC				Li, Hsing-Jung; Kuo, Chao-Chan; Yao, Yi-Chien; Tsai, Ching-Hong; Chow, Philip C.; Li, Ying-Chun			Outpatient rehabilitation resources and medical expenditure in children with attention-deficit hyperactivity disorder in Taiwan	PLOS ONE			English	Article							DEFICIT/HYPERACTIVITY DISORDER; ECONOMIC-IMPACT; PREVALENCE; CHILDHOOD; COSTS; ADHD; ADOLESCENTS; BURDEN; YOUTH; CARE	Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder in children. This study investigated the use of rehabilitation treatment in Taiwan. We selected children aged 3 - 12 years from the National Health Insurance Research Database from 2008 to 2012 and included them in the analysis. The children who received a diagnosis according to the International Classification of Diseases, Ninth Revision, Clinical Modification were divided into two groups: ADHD and non-ADHD. We used the chi-squared test, independent sample t test, and multiple regression analysis to conduct the analysis. The utilisation of rehabilitation resources was higher in the ADHD group than in the non-ADHD group. The number of school-aged children with ADHD was higher than the number of preschool-aged children (p < 0.001). The highest utilisation of rehabilitation resources was observed in clinics (p < 0.001). In terms of region, Taipei exhibited the highest utilisation of rehabilitation resources, and the East exhibited the lowest resource utilisation (p < 0.001). Prediction of the use of rehabilitation resources, average cost, average frequency of visits, and total annual cost was affected by factors such as the average frequency of rehabilitation use, demographic characteristics, and the hospital characteristics and location (p < 0.001). The number of children with ADHD and rehabilitation use are increasing yearly; however, limitations in payment restrict the growth of rehabilitation resource use in hospitals. Supplementation of rehabilitation resources at clinics accounts for more than 60%, however, the total annual cost is less than what is observed for hospitals (p < 0.001). Policies should be established to aid in the early detection and treatment of children with ADHD to improve treatment outcomes and reduce the family burden and treatment expenditure in the future.	[Li, Hsing-Jung; Tsai, Ching-Hong] Kai Syuan Psychiat Hosp, Dept Child & Adolescent Psychiat, Kaohsiung, Taiwan; [Li, Hsing-Jung; Yao, Yi-Chien; Li, Ying-Chun] Natl Sun Yat Sen Univ, Inst Hlth Care Management, Dept Business Management, Kaohsiung, Taiwan; [Kuo, Chao-Chan] Kai Syuan Psychiat Hosp, Dept Adult Psychiat, Kaohsiung, Taiwan; [Chow, Philip C.] Conde Sao Januario Cent Hosp, Dept Psychiat, Macau, Peoples R China	National Sun Yat Sen University	Li, YC (corresponding author), Natl Sun Yat Sen Univ, Inst Hlth Care Management, Dept Business Management, Kaohsiung, Taiwan.	ycli@mail.nsysy.edu.tw		Li, Ying-Chun/0000-0001-8516-970X				American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Austerman J, 2015, CLEV CLIN J MED, V82, pS2, DOI 10.3949/ccjm.82.s1.01; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Birnbaum HG, 2005, CURR MED RES OPIN, V21, P195, DOI 10.1185/030079904X20303; Burd L, 2003, J CHILD NEUROL, V18, P555, DOI 10.1177/08830738030180080101; Chien IC, 2012, SOC PSYCH PSYCH EPID, V47, P1885, DOI 10.1007/s00127-012-0501-1; Chorozoglou M, 2015, J CHILD PSYCHOL PSYC, V56, P966, DOI 10.1111/jcpp.12437; Dopheide JA, 2009, PHARMACOTHERAPY, V29, P656, DOI 10.1592/phco.29.6.656; Doshi JA, 2012, J AM ACAD CHILD PSY, V51, P990, DOI 10.1016/j.jaac.2012.07.008; Gau SSF, 2010, AUST NZ J PSYCHIAT, V44, P135, DOI 10.3109/00048670903282733; Guevara J, 2001, PEDIATRICS, V108, P71, DOI 10.1542/peds.108.1.71; Klassen A, 1999, CAN J PSYCHIAT, V44, P1007, DOI 10.1177/070674379904401007; Klora M, 2015, HEALTH ECON REV, V5, DOI 10.1186/s13561-015-0078-y; Kooij SJJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-67; Korsgaard HO, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0871-0; Larson K, 2011, PEDIATRICS, V127, P462, DOI 10.1542/peds.2010-0165; Le HH, 2014, EUR CHILD ADOLES PSY, V23, P587, DOI 10.1007/s00787-013-0477-8; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Lin JD, 2013, RES DEV DISABIL, V34, P2127, DOI 10.1016/j.ridd.2013.03.034; Marks DJ, 2009, J PEDIATR PSYCHOL, V34, P681, DOI 10.1093/jpepsy/jsn112; Page TF, 2016, J CLIN CHILD ADOLESC, V45, P416, DOI 10.1080/15374416.2015.1055859; Pelham WE, 2007, AMBUL PEDIATR, V7, P121, DOI 10.1016/j.ambp.2006.08.002; Remschmidt H, 2005, EUR CHILD ADOLES PSY, V14, P127, DOI 10.1007/s00787-005-0439-x; Rowe Donald L., 2004, Journal of Integrative Neuroscience, V3, P453, DOI 10.1142/S0219635204000592; Schoffski O, 2008, GESUNDHEITSWESEN, V70, P398, DOI 10.1055/s-0028-1082049; Tai YM, 2013, RES DEV DISABIL, V34, P1100, DOI 10.1016/j.ridd.2012.11.027; Tsai CC, 2009, TAWAN J PSYCHIAT, V23, P296; Willcutt E, 2012, NEUROTHERAPEUTICS, V9, P490, DOI 10.1007/s13311-012-0135-8	28	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0199877	10.1371/journal.pone.0199877	http://dx.doi.org/10.1371/journal.pone.0199877			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL0GK	29953532	Green Published, Green Submitted, gold			2023-01-03	WOS:000436645400085
J	El Seifi, OS; Mortada, EM; Abdo, NM				El Seifi, Omnia S.; Mortada, Eman M.; Abdo, Naglaa M.			Effect of community-based intervention on knowledge, attitude, and self-efficacy toward home injuries among Egyptian rural mothers having preschool children	PLOS ONE			English	Article								Background Parent's level of knowledge, state of their attitude, and their self-efficacy are the most incriminated reasons for the faulty application of the first aid measures, particularly in children's home injuries. Objectives To assess the effect of a health education intervention on improving knowledge, attitude and self-efficacy of mothers having preschool children about home injuries and the basic first aid measures. Methods A pre-posttest evaluation of the effect of a health education intervention on changing knowledge, attitude, and self-efficacy about home injuries and the basic first aid measures of 244 rural Egyptian mothers having preschool children. Results About 35% of the male children had home injuries 8 weeks earlier to the study. Mean score of total knowledge increased from 10.21 +/- 3.1 in pretest to 18.90 +/- 2.6 in posttest, total attitude from 6.19 +/- 1.8 to 10.26 +/- 2.3 and self-efficacy from 20.75 +/- 6.1 to 34.43 +/- 10.1 with (p < 0.001) for all changes. Age, education level and previous home injuries were the significant predicting factors for total knowledge, attitude and self-efficacy of the mothers. Conclusion Health education improves knowledge, attitude, and self-efficacy of the mothers which were obvious regarding home injuries than first aid measures. There is a need for including knowledge about home injuries in the educational curriculum of high schools and universities and to perform training courses to mothers about first aid measures.	[El Seifi, Omnia S.; Mortada, Eman M.; Abdo, Naglaa M.] Zagazig Univ, Fac Med, Dept Community Environm & Occupat Med, Zagazig, Egypt; [Mortada, Eman M.] Princess Nourah Bint Abdulrahman Univ, Hlth & Rehabil Sci Coll, Hlth Sci Dept, Riyadh, Saudi Arabia	Egyptian Knowledge Bank (EKB); Zagazig University; Princess Nourah bint Abdulrahman University	El Seifi, OS (corresponding author), Zagazig Univ, Fac Med, Dept Community Environm & Occupat Med, Zagazig, Egypt.	omnia2200@yahoo.com	Elseifi, Omnia Samir/A-9264-2018; Mortada, Eman/AAP-4354-2020	Elseifi, Omnia Samir/0000-0002-0510-7128; Mortada, Eman/0000-0002-8660-4299				Abd El-Aty NS, 2005, AUBER J, V8, P11; Abd El-Wahed MA, 2000, ALEXANDRIA J PEDIAT, V14, P65; Aggarwal R, 2010, INTERNET J HEAL, V11, DOI [10.5580/1d1f, DOI 10.5580/1D1F]; Amin M, 1998, EGYPTIAN J COMMUNITY, V16, P31; [Anonymous], 2010, PROTECT ONES YOU LOV; [Anonymous], 2010, IBM SPSS STAT 19 COR; Bayomi SS, 2013, J AM SCI, V9, P203; CAPMAS. Central Agency for Public Mobilization And Statistics, 2016, NAT ANN REP 2016; Chatsantiprapa K, 2001, SAFETY PROMOTION INJ, V7, P214; Eldosoky RSH, 2010, E MEDITERR HEALTH J, V18, P1021; Fardazar FE, 2016, INT J PEDIATR-MASSHA, V4, P2051; Fathi Shekhi M, 2015, J SAF PROM INJ PREV, V3, P199; Golshiri P., 2011, IRAN J MED ED, V10, P927; Grossman D., 2000, PEDIATR CLIN N AM, V39, P471; Kamal NN, 2013, J COMMUN HEALTH, V38, P873, DOI 10.1007/s10900-013-9692-y; Kamel EG, 2014, SCI J PUBLIC HEAL, V2, P653, DOI [10.11648/j.sjph.20140206.35, DOI 10.11648/J.SJPH.20140206.35]; Kendrick D., 2007, COCHRANE DB SYST REV, V24; Kendrick Denise, 2013, Evid Based Child Health, V8, P761, DOI 10.1002/ebch.1911; Kluwer W., 2010, COMMUNITY HLTH NURSI, P577; Mack KA, 2010, AM J LIFESTYLE MED, V4, P75, DOI 10.1177/1559827609348476; Mahalakshmy T, 2011, INDIAN J PEDIATR, V78, P821, DOI 10.1007/s12098-010-0343-3; Mason M, 2007, ARCH PEDIAT ADOL MED, V161, P759, DOI 10.1001/archpedi.161.8.759; Mohammed Ahmed WA, 2014, PRIM HLTH CARE, V4, P156, DOI DOI 10.4172/2167-1079.1000156; Morrongiello BA, 2009, SOC SCI MED, V68, P1030, DOI 10.1016/j.socscimed.2008.12.019; Nansel TR, 2002, PATIENT EDUC COUNS, V46, P175, DOI 10.1016/S0738-3991(01)00211-7; Nits AM, 2007, COMMUNITY PUBLIC HLT, P267; Ozturk C, 2010, ANATOL J CLIN INVEST, V4, P15; Rafiefar SH, 2005, SYSTEMATIC EMPOWERME; Royal Society for the Prevention of Accidents home, DEL ACC PREV LOC LEV; SHERER M, 1982, PSYCHOL REP, V51, P663, DOI 10.2466/pr0.1982.51.2.663; Suguna TC, 2015, INT J DEV RES, V5, P3729; Tomrulk O, 2007, ADV THER, V24, P691, DOI 10.1007/BF02849962; Vahdaninya Z, 2015, MOD CARE J, V12, P119; WHO, 2008, 10 FACTS INJ VIOL	34	6	6	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2018	13	6							e0198964	10.1371/journal.pone.0198964	http://dx.doi.org/10.1371/journal.pone.0198964			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GK0LV	29927950	Green Published, gold, Green Submitted			2023-01-03	WOS:000435802500039
J	Qi, K; Li, XD; Geng, YJ; Cui, HH; Jin, C; Wang, PH; Li, Y; Yang, YJ				Qi, Kang; Li, Xiangdong; Geng, Yongjian; Cui, Hehe; Jin, Chen; Wang, Peihe; Li, Yue; Yang, Yuejin			Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-alpha pathway	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ISCHEMIA/REPERFUSION INJURY; NO-REFLOW; SIGNALING PATHWAY; TOTAL GLUCOSIDES; ISCHAEMIA/REPERFUSION INJURY; INFLAMMATORY CYTOKINES; INSULIN-TREATMENT; OXIDATIVE STRESS; SWINE HEARTS	Objective Endothelial barrier function in the onset and Tongxinluo (TXL) protection of myocardial ischemia/reperfusion (I/R) injury, and TXL can induce the secretion of Angiopoietin-like 4 (Angptl4) in human cardiac microvascular endothelial cells during hypoxia/reoxygenation. We intend to demonstrate whether TXL can attenuate myocardial I/R injury in diabetes, characterized with microvascular endothelial barrier disruption, by induction of Angptl4-mediated protection of endothelial barrier integrity. Methods and results I/R injury was created by coronary ligation in ZDF diabetic and non-diabetic control rats. The animals were anesthetized and randomized to sham operation or I/R injury with or without the exposure to insulin, rhAngptl4, TXL, Angptl4 siRNA, and the PPAR-alpha inhibitor MK886. Tongxinluo, insulin and rhAngptl4 have the similar protective effect on diabetic hearts against I/R injury. In I/R-injured diabetic hearts, TXL treatment remarkably reduced the infarct size, and protected endothelial barrier integrity demonstrated by decreased endothelial cells apoptosis, microvascular permeability, and myocardial hemorrhage, fortified tight junction, and upregulated expression of JAM-A, integrin-alpha 5, and VE-cadherin, and these effects of TXL were as effective as insulin and rhAngptl4. However, Angptl4 knock-down with siRNA interference and inhibition of PPAR-alpha with MK886 partially diminished these beneficial effects of TXL and rhAngptl4. TXL induced the expression of Angptl4 in I/R-injured diabetic hearts, and was canceled by Angptl4 siRNA and MK886. TXL treatment increased myocardial PPAR-a activity, and was abolished by MK886 but not by Angptl4 siRNA. Conclusions TXL protects diabetic hearts against I/R injury by activating Angptl4-mediated restoration of endothelial barrier integrity via the PPAR-alpha pathway.	[Qi, Kang; Li, Xiangdong; Cui, Hehe; Jin, Chen; Yang, Yuejin] Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China; [Qi, Kang; Li, Xiangdong; Cui, Hehe; Jin, Chen; Wang, Peihe; Li, Yue; Yang, Yuejin] Peking Union Med Coll, Beijing, Peoples R China; [Geng, Yongjian] Univ Texas Hlth Sci Ctr Houston, Div Cardiovasc Med, Houston, TX 77030 USA; [Wang, Peihe; Li, Yue] Chinese Acad Med Sci, Peking Key Lab Preclin Evaluat Cardiovasc Implant, State Key Lab Cardiovasc Dis, Natl Ctr Cardiovasc Dis,Anim Expt Ctr,Fuwai Hosp, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Texas System; University of Texas Health Science Center Houston; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS	Yang, YJ (corresponding author), Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China.; Yang, YJ (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.	yangyjfw@126.com			National Basic Research Program (973 Program) in China [2012CB518602]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-009]; National Science Foundation of China [81370223, 81573957]; Postgraduates Innovative Foundation of PUMC, China [2013-1002-39]	National Basic Research Program (973 Program) in China(National Basic Research Program of China); CAMS Innovation Fund for Medical Sciences (CIFMS); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postgraduates Innovative Foundation of PUMC, China	This study was supported by National Basic Research Program (973 Program) in China (No. 2012CB518602), CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-009), the National Science Foundation of China (No. 81370223 and 81573957) and Postgraduates Innovative Foundation of PUMC, China (2013-1002-39).	Barrabes JA, 1998, AM J PHYSIOL-HEART C, V274, pH1767, DOI 10.1152/ajpheart.1998.274.5.H1767; Baumuller S, 2015, PEDIATR DEVEL PATHOL, V18, P17, DOI 10.2350/13-11-1400-OA.1; Beker MC, 2015, ONCOTARGET, V6, P30604, DOI 10.18632/oncotarget.5773; Bouleti C, 2015, INT J CARDIOL, V187, P511, DOI 10.1016/j.ijcard.2015.03.263; Canfield SG, 2016, ANESTH ANALG, V122, P1269, DOI 10.1213/ANE.0000000000001254; Chen YN, 2016, CELL PHYSIOL BIOCHEM, V40, P1094, DOI 10.1159/000453164; Cheng YT, 2009, CHINESE MED J-PEKING, V122, P1529, DOI 10.3760/cma.j.issn.0366-6999.2009.13.011; Cui HH, 2016, AM J TRANSL RES, V8, P4370; Cui HH, 2014, J CARDIOVASC PHARM, V64, P180, DOI 10.1097/FJC.0000000000000104; de Resende MM, 2006, PHYSIOL GENOMICS, V25, P325, DOI 10.1152/physiolgenomics.00253.2005; Eldor R, 2013, DIABETES CARE, V36, pS162, DOI 10.2337/dcS13-2003; Galaup A, 2012, CIRCULATION, V125, P140, DOI 10.1161/CIRCULATIONAHA.111.049072; Gunduz D, 2010, ARTERIOSCL THROM VAS, V30, P1237, DOI 10.1161/ATVBAHA.110.203901; Hafstad AD, 2006, AM J PHYSIOL-HEART C, V290, pH1763, DOI 10.1152/ajpheart.01063.2005; Hillis LD, 2006, NEW ENGL J MED, V355, P2475, DOI 10.1056/NEJMe068251; Hu CF, 2017, CHIN J INTEGR MED, V23, P438, DOI 10.1007/s11655-016-2617-8; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Oidor-Chan VH, 2016, PPAR RES, V2016, DOI 10.1155/2016/8237264; Javanmard Shaghayegh Haghjooy, 2016, Adv Biomed Res, V5, P174, DOI 10.4103/2277-9175.194801; Jiao SJ, 2016, BIOMED PHARMACOTHER, V84, P1533, DOI 10.1016/j.biopha.2016.11.028; Karalliedde LD, 2009, AM J PHYSIOL-HEART C, V297, pH1967, DOI 10.1152/ajpheart.00944.2009; Larter CZ, 2012, J GASTROEN HEPATOL, V27, P341, DOI 10.1111/j.1440-1746.2011.06939.x; Lee TI, 2013, DIABETES RES CLIN PR, V100, P330, DOI 10.1016/j.diabres.2013.01.008; Lejay A, 2016, J MOL CELL CARDIOL, V91, P11, DOI 10.1016/j.yjmcc.2015.12.020; Li XD, 2013, INT J CARDIOL, V167, P2657, DOI 10.1016/j.ijcard.2012.06.121; Li XD, 2013, CHINESE MED J-PEKING, V126, P1469, DOI 10.3760/cma.j.issn.0366-6999.20130224; Li XD, 2010, AM J PHYSIOL-HEART C, V299, pH1255, DOI 10.1152/ajpheart.00459.2010; Liu BS, 2017, ONCOTARGET, V8, P19413, DOI 10.18632/oncotarget.14297; Mangialardi G, 2013, ARTERIOSCL THROM VAS, V33, P555, DOI 10.1161/ATVBAHA.112.300424; Mather KJ, 2013, J CLIN INVEST, V123, P1003, DOI 10.1172/JCI67166; Pei HF, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0322-0; Prasad A, 2005, J AM COLL CARDIOL, V45, P508, DOI 10.1016/j.jacc.2004.10.054; Qi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119846; Rangasamy S, 2011, INVEST OPHTH VIS SCI, V52, P3784, DOI 10.1167/iovs.10-6386; Rausch WD, 2006, ACTA NEUROBIOL EXP, V66, P369; Rui T, 2012, CARDIOVASC RES, V94, P370, DOI 10.1093/cvr/cvs015; Slettom G, 2017, J CARDIOVASC PHARM T, V22, P179, DOI 10.1177/1074248416657611; Su H, 2013, J CELL MOL MED, V17, P181, DOI 10.1111/j.1582-4934.2012.01661.x; Su J, 2010, PHYTOMEDICINE, V17, P254, DOI 10.1016/j.phymed.2009.07.005; Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124; Wang C, 2015, INT IMMUNOPHARMACOL, V24, P325, DOI 10.1016/j.intimp.2014.12.026; Wang HQ, 2012, CHINESE MED J-PEKING, V125, P3675, DOI 10.3760/cma.j.issn.0366-6999.2012.20.014; Wang JY, 2013, ADV EDUC RES, V10, P528; Wang YN, 2016, INT IMMUNOPHARMACOL, V36, P67, DOI 10.1016/j.intimp.2016.04.010; Xie R, 2017, FOOD FUNCT, V8, P299, DOI 10.1039/c6fo01601d; Yin T, 2010, J MOL CELL CARDIOL, V49, P354, DOI 10.1016/j.yjmcc.2010.05.002; Zeng XC, 2002, TOXICON, V40, P1719, DOI 10.1016/S0041-0101(02)00134-4; Zhang HT, 2010, CHINESE MED J-PEKING, V123, P2858, DOI 10.3760/cma.j.issn.0366-6999.2010.20.021; Zhang L, 2009, AM J PHYSIOL-HEART C, V297, pH2004, DOI 10.1152/ajpheart.00208.2009; Zhang Y, 2014, AM J PHYSIOL-GASTR L, V306, pG289, DOI 10.1152/ajpgi.00168.2013	50	13	15	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2018	13	6							e0198403	10.1371/journal.pone.0198403	http://dx.doi.org/10.1371/journal.pone.0198403			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ6XV	29912977	Green Published, gold, Green Submitted			2023-01-03	WOS:000435528600027
J	Socinski, MA; Jotte, RM; Cappuzzo, F; Orlandi, F; Stroyakovskiy, D; Nogami, N; Rodriguez-Abreu, D; Moro-Sibilot, D; Thomas, CA; Barlesi, F; Finley, G; Kelsch, C; Lee, A; Coleman, S; Deng, Y; Shen, Y; Kowanetz, M; Lopez-Chavez, A; Sandler, A; Reck, M; Ahualli, A; Jarchum, G; Kaen, DL; Kahl, S; Kotliar, M; Kowalyszyn, RD; Lerzo, G; Magri, I; Martin, C; Pastor, A; Picon, P; Streich, G; Varela, M; Blinman, P; Boyer, M; Crombie, C; Gauden, S; Gill, S; Hughes, B; John, T; Joshi, A; Kosmider, S; Lewis, C; Millward, M; Nordman, I; Nott, L; O'Byrne, K; Parnis, F; Potasz, N; Richardson, G; Singhal, N; Eckmayr, J; Greil, R; Goeminne, JC; Paulus, A; Aragao, B; Bruno, LA; Campos, C; Costamilan, RD; Dettino, A; Faccio, A; Girotto, G; Matias, D; Murad, AM; Schwartsmann, G; Silva, C; Tadokoro, H; Dimitrov, B; Ilieva, R; Kalev, D; Kanarev, V; Koleva, M; Koynov, K; Mihaylova, Z; Cohen, V; Cournoyer, G; Rorke, S; Rothenstein, J; Spadafora, S; Aren, O; Ulunque, EO; Yanez, E; Valette, CA; Bennouna, J; Berard, H; Coudert, B; Dayen, C; Denis, F; Guillevin, EF; Foa, C; Gazaille, V; Le Moulec, S; Mazieres, J; Morere, JF; Veillon, R; Bargon, J; Behringer, D; Dickgreber, NJ; Engel-Riedel, W; Fischer, JR; Hackanson, B; Kokowski, K; Kollmeier, J; Loges, S; Schulz, C; Schutte, W; Serke, M; Stauder, H; Steppert, C; Wehler, T; Weissinger, F; Wermke, M; Wesseler, C; Allegrini, G; Amoroso, D; Barone, C; Borra, G; Carteni, G; Defraia, E; Falcone, A; Grossi, F; Mencoboni, M; Migliorino, MR; Pazzola, A; Parra, HS; Tonini, G; Azuma, K; Fukuhara, T; Ichiki, M; Ikeda, S; Kawaguchi, T; Kim, YH; Kishi, K; Otani, S; Seto, T; Takeda, Y; Tanaka, H; Yamamoto, N; Yokota, S; Yokoyama, T; Purkalne, G; Zvirbule, Z; Cicenas, S; Filipauskiene, J; Dominguez, A; Gomez, A; Leon, JML; Lopez, Y; Aerts, JGJV; Barlo, N; Biesma, B; Dingemans, AM; Hashemi, S; Keizer-van't Westeinde, S; Lammers, E; Mansour, K; Schramel, F; Snijders, D; van Haarst, JM; van Lindert, A; Wilschut, F; Aleman, D; Tipismana, RC; Kobashigawa, A; Mas, L; Escobar, HDM; Almodovar, T; Araujo, A; Azevedo, I; Barata, F; Queiroga, H; de Brito, USD; Teixeira, E; Biakhov, M; Galiulin, R; Gorbunova, V; Karaseva, N; Kovalenko, N; Penkov, K; Poltoratskiy, A; Vasiliev, A; Zhiltsova, E; Leong, SS; Lim, D; Beniak, J; Chovanec, J; Godal, R; Kasan, P; Porubska, M; Alvarez, R; Manrique, MDA; Aranda, ICB; Carpeno, JD; Gomez, JHCNNMD; Font, EF; Garcia, YG; Lopez, PG; Sarrio, RG; Larriba, JLG; Molla, AI; Munarriz, BJ; Piqueras, MLB; Nadal, E; Aix, SP; Garcia, AT; Pons, JT; Estevez, SV; Segarra, NV; Vikstrom, A; Frueh, M; Gautschi, O; Lohri, A; Ochsenbein, A; Chang, GC; Chen, CH; Chen, WT; Chen, YM; Ho, CL; Hsia, TC; Hsieh, RK; Huang, MS; Li, CT; Lin, YC; Liu, CY; Su, WC; Yu, CJ; Adamchuk, H; Andrusenko, O; Bondarenko, I; Chornobai, A; Hotko, Y; Ivashchuk, O; Kolesnik, O; Kryzhanivska, A; Odarchenko, S; Ogorodnikova, N; Rusyn, A; Shamrai, V; Shapovalov, D; Vasylyev, L; Vynnychenko, I; Karim, NA; Almubarak, M; Al-Nsour, M; Assikis, V; Baker, S; Batus, M; Beatty, P; Becker, K; Belman, N; Bernicker, E; Braiteh, F; Bui, L; Carr, L; Chaudhry, A; Cheng, H; Chitneni, S; Cohenuram, M; Daniels, G; Dean-Colomb, W; DeVore, R; DiStefano, A; Dobrescu, A; Drew, DZ; Eisenberg, P; Erickson, B; Eskander, E; Fabregas, J; Faller, B; Fiorillo, J; Goldschmidt, J; Goueli, B; Gurubhagavatula, S; Halibey, B; Hamm, J; Herman, J; Hoffman, P; Hooberman, A; Jhangiani, H; Kabbinavar, F; Karnad, A; Keogh, GP; Kirshner, E; Koh, H; Kono, S; Kosty, M; Kotiah, S; Kozloff, M; Kuzma, C; Lakhani, N; Lukas, J; Martin, W; Masood, N; Matthews-Smith, V; McCann, J; Menefee, M; Mitchell, BR; Naidu, S; Narang, M; Natale, R; Niederman, T; Nissenblatt, M; Ou, SH; Paschold, JC; Raez, LE; Rafiyath, S; Rodriguez, E; Rosales, J; Rothman, J; Sabbath, K; Sanz-Altamira, P; Schnell, FM; Shtivelband, M; Silberberg, J; Socoteanu, M; Spira, AI; Stella, P; Subramanian, J; Swanson, PM; Telivala, B; Tsai, F; Tummala, M; VanderWalde, A; Velcheti, V; West, H; Yanagihara, R; Zylla, D				Socinski, M. A.; Jotte, R. M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.; Finley, G.; Kelsch, C.; Lee, A.; Coleman, S.; Deng, Y.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.; Reck, M.; Ahualli, A.; Jarchum, G.; Kaen, D. L.; Kahl, S.; Kotliar, M.; Kowalyszyn, R. D.; Lerzo, G.; Magri, I; Martin, C.; Pastor, A.; Picon, P.; Streich, G.; Varela, M.; Blinman, P.; Boyer, M.; Crombie, C.; Gauden, S.; Gill, S.; Hughes, B.; John, T.; Joshi, A.; Kosmider, S.; Lewis, C.; Millward, M.; Nordman, I; Nott, L.; O'Byrne, K.; Parnis, F.; Potasz, N.; Richardson, G.; Singhal, N.; Eckmayr, J.; Greil, R.; Goeminne, J. C.; Paulus, A.; Aragao, B.; Bruno, L. A.; Campos, C.; Costamilan, RdC; Dettino, A.; Faccio, A.; Girotto, G.; Matias, D.; Murad, A. M.; Schwartsmann, G.; Silva, C.; Tadokoro, H.; Dimitrov, B.; Ilieva, R.; Kalev, D.; Kanarev, V; Koleva, M.; Koynov, K.; Mihaylova, Z.; Cohen, V; Cournoyer, G.; Rorke, S.; Rothenstein, J.; Spadafora, S.; Aren, O.; Ulunque, Orellana E.; Yanez, E.; Valette, Audigier C.; Bennouna, J.; Berard, H.; Coudert, B.; Dayen, C.; Denis, F.; Guillevin, Fabre E.; Foa, C.; Gazaille, V; Le Moulec, S.; Mazieres, J.; Morere, J. F.; Veillon, R.; Bargon, J.; Behringer, D.; Dickgreber, N. J.; Engel-Riedel, W.; Fischer, J. R.; Hackanson, B.; Kokowski, K.; Kollmeier, J.; Loges, S.; Schulz, C.; Schutte, W.; Serke, M.; Stauder, H.; Steppert, C.; Wehler, T.; Weissinger, F.; Wermke, M.; Wesseler, C.; Allegrini, G.; Amoroso, D.; Barone, C.; Borra, G.; Carteni, G.; Defraia, E.; Falcone, A.; Grossi, F.; Mencoboni, M.; Migliorino, M. R.; Pazzola, A.; Parra, Soto H.; Tonini, G.; Azuma, K.; Fukuhara, T.; Ichiki, M.; Ikeda, S.; Kawaguchi, T.; Kim, Y. H.; Kishi, K.; Otani, S.; Seto, T.; Takeda, Y.; Tanaka, H.; Yamamoto, N.; Yokota, S.; Yokoyama, T.; Purkalne, G.; Zvirbule, Z.; Cicenas, S.; Filipauskiene, J.; Dominguez, A.; Gomez, A.; Leon, Lazaro J. M.; Lopez, Y.; Aerts, J. G. J., V; Barlo, N.; Biesma, B.; Dingemans, A. M.; Hashemi, S.; Keizer-van't Westeinde, S.; Lammers, E.; Mansour, K.; Schramel, F.; Snijders, D.; van Haarst, J. M.; van Lindert, A.; Wilschut, F.; Aleman, D.; Tipismana, Cisneros R.; Kobashigawa, A.; Mas, L.; Escobar, Moron H. D.; Almodovar, T.; Araujo, A.; Azevedo, I; Barata, F.; Queiroga, H.; de Brito, Saturnino Duarte U.; Teixeira, E.; Biakhov, M.; Galiulin, R.; Gorbunova, V; Karaseva, N.; Kovalenko, N.; Penkov, K.; Poltoratskiy, A.; Vasiliev, A.; Zhiltsova, E.; Leong, S. S.; Lim, D.; Beniak, J.; Chovanec, J.; Godal, R.; Kasan, P.; Porubska, M.; Alvarez, R.; Manrique, Areses MdC; Aranda, Barneto I. C.; Carpeno, De Castro J.; Gomez, Domine J. H. C. N. N. M.; Font, Felip E.; Garcia, Garcia Y.; Lopez, Garrido P.; Sarrio, Girones R.; Larriba, Gonzalez J. L.; Molla, Insa A.; Munarriz, Jimenez B.; Piqueras, Lopez-Brea M.; Nadal, E.; Aix, Ponce S.; Garcia, Taus A.; Pons, Terrasa J.; Estevez, Vazquez S.; Segarra, Vinolas N.; Vikstrom, A.; Frueh, M.; Gautschi, O.; Lohri, A.; Ochsenbein, A.; Chang, G. C.; Chen, C. H.; Chen, W. T.; Chen, Y. M.; Ho, C. L.; Hsia, T. C.; Hsieh, R. K.; Huang, M. S.; Li, C. T.; Lin, Y. C.; Liu, C. Y.; Su, W. C.; Yu, C. J.; Adamchuk, H.; Andrusenko, O.; Bondarenko, I; Chornobai, A.; Hotko, Y.; Ivashchuk, O.; Kolesnik, O.; Kryzhanivska, A.; Odarchenko, S.; Ogorodnikova, N.; Rusyn, A.; Shamrai, V; Shapovalov, D.; Vasylyev, L.; Vynnychenko, I; Karim, Abdel N.; Almubarak, M.; Al-Nsour, M.; Assikis, V; Baker, S.; Batus, M.; Beatty, P.; Becker, K.; Belman, N.; Bernicker, E.; Braiteh, F.; Bui, L.; Carr, L.; Chaudhry, A.; Cheng, H.; Chitneni, S.; Cohenuram, M.; Daniels, G.; Dean-Colomb, W.; DeVore, R., III; DiStefano, A.; Dobrescu, A.; Drew, D. Z.; Eisenberg, P.; Erickson, B.; Eskander, E.; Fabregas, J.; Faller, B.; Fiorillo, J.; Goldschmidt, J., Jr.; Goueli, B.; Gurubhagavatula, S.; Halibey, B.; Hamm, J.; Herman, J.; Hoffman, P.; Hooberman, A.; Jhangiani, H.; Kabbinavar, F.; Karnad, A.; Keogh, G. P.; Kirshner, E.; Koh, H.; Kono, S.; Kosty, M.; Kotiah, S.; Kozloff, M.; Kuzma, C.; Lakhani, N.; Lukas, J.; Martin, W.; Masood, N.; Matthews-Smith, V; McCann, J.; Menefee, M.; Mitchell, B. R.; Naidu, S.; Narang, M.; Natale, R.; Niederman, T.; Nissenblatt, M.; Ou, S. H.; Paschold, J. C.; Raez, L. E.; Rafiyath, S.; Rodriguez, E.; Rosales, J.; Rothman, J.; Sabbath, K.; Sanz-Altamira, P.; Schnell, F. M.; Shtivelband, M.; Silberberg, J.; Socoteanu, M.; Spira, A., I; Stella, P.; Subramanian, J.; Swanson, P. M.; Telivala, B.; Tsai, F.; Tummala, M.; VanderWalde, A.; Velcheti, V.; West, H.; Yanagihara, R.; Zylla, D.		IMpower150 Study Grp	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; OPEN-LABEL; CANCER; BEVACIZUMAB; THERAPY; DOCETAXEL; ANTIBODY; CELLS; CHEMOTHERAPY; MULTICENTER	BACKGROUND The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy. METHODS We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) every 3 weeks for four or six cycles, followed by maintenance therapy with atezolizumab, bevacizumab, or both. The two primary end points were investigator-assessed progression-free survival both among patients in the intention-to-treat population who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded) and among patients in the WT population who had high expression of an effector T-cell (Teff) gene signature in the tumor (Teff-high WT population) and overall survival in the WT population. The ABCP group was compared with the BCP group before the ACP group was compared with the BCP group. RESULTS In the WT population, 356 patients were assigned to the ABCP group, and 336 to the BCP group. The median progression-free survival was longer in the ABCP group than in the BCP group (8.3 months vs. 6.8 months; hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.52 to 0.74; P<0.001); the corresponding values in the Teff-high WT population were 11.3 months and 6.8 months (hazard ratio, 0.51 [95% CI, 0.38 to 0.68]; P<0.001). Progression-free survival was also longer in the ABCP group than in the BCP group in the entire intention-to-treat population (including those with EGFR or ALK genetic alterations) and among patients with low or negative programmed death ligand 1 (PD-L1) expression, those with low Teff gene-signature expression, and those with liver metastases. Median overall survival among the patients in the WT population was longer in the ABCP group than in the BCP group (19.2 months vs. 14.7 months; hazard ratio for death, 0.78; 95% CI, 0.64 to 0.96; P = 0.02). The safety profile of ABCP was consistent with previously reported safety risks of the individual medicines. CONCLUSIONS The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status.	[Socinski, M. A.] Florida Hosp Canc Inst, Orlando, FL USA; [Jotte, R. M.] Rocky Mt Canc Ctr, Denver, CO USA; [Jotte, R. M.] US Oncol, Houston, TX USA; [Cappuzzo, F.] Azienda Unita Sanit Locale Romagna, Ravenna, Italy; [Orlandi, F.] Inst Nacl Torax, Santiago, Chile; [Stroyakovskiy, D.] Moscow City Oncol Hosp, Moscow, Russia; [Nogami, N.] Shikoku Canc Ctr, Natl Hosp Org, Matsuyama, Ehime, Japan; [Rodriguez-Abreu, D.] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfantil Gran, Las Palmas Gran Canaria, Spain; [Moro-Sibilot, D.] Ctr Hosp Univ Grenoble Alpes, Grenoble, France; [Barlesi, F.] Aix Marseille Univ, AP HM, Marseille, France; [Thomas, C. A.] New England Canc Specialists, Scarborough, ME USA; [Finley, G.] Allegheny Hlth Network Canc Inst, Pittsburgh, PA USA; [Kelsch, C.; Lee, A.; Coleman, S.; Deng, Y.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.] Genentech Inc, San Francisco, CA USA; [Reck, M.] German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Grosshansdorf, Germany	Adventist Health Services; AdventHealth; Rocky Mountain Cancer Centers; US Oncology Network; Universidad de Las Palmas de Gran Canaria; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Roche Holding; Genentech	Reck, M (corresponding author), German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Dept Thorac Oncol, Wohrendamm 80, D-22927 Grosshansdorf, Germany.	m.reck@lungenclinic.de	Rusyn, Andriy/AFS-4172-2022; Raez, Luis/AAL-8829-2020; Kovalenko, Nadezhda/AAG-6298-2021; Grossi, Francesco/AAL-5024-2021; Kosty, Michael/AAR-6169-2021; Shtivelband, Mikhail/GXN-0194-2022; SOTO PARRA, HECTOR J/ABC-6273-2021; LA DETTINO, Aldo/A-1288-2014; Reck, Martin/ABF-5721-2020; Thomas, Christian/AAI-6276-2020; GARRIDO, PILAR/D-5187-2017; Vynnychenko, Ihor O/E-1684-2012; Kryzhanivska, Anna/ABG-4997-2020; Wehler, Thomas Christian/AAY-6362-2020; Hotko, Yevhen/F-9068-2019; Cappuzzo, federico/R-2827-2016	Raez, Luis/0000-0003-2669-5771; Grossi, Francesco/0000-0001-8412-3136; SOTO PARRA, HECTOR J/0000-0001-7966-4472; LA DETTINO, Aldo/0000-0002-1186-941X; Reck, Martin/0000-0002-5348-4462; GARRIDO, PILAR/0000-0002-5899-6125; Vynnychenko, Ihor O/0000-0002-2339-6509; Kryzhanivska, Anna/0000-0001-7720-7374; Hotko, Yevhen/0000-0002-4533-4210; Cappuzzo, federico/0000-0002-6295-6767; Nadal, Ernest/0000-0002-9674-5554; Kollmeier, Jens/0000-0002-8048-3895; O'Byrne, Kenneth/0000-0002-6754-5633; MORO-SIBILOT, Denis/0000-0001-6776-8610; Bennouna, Jaafar/0000-0002-5034-1108; Stroyakovskiy, Daniil/0000-0003-1973-1092; Rodriguez-Abreu, Delvys/0000-0003-0506-1366; INSA, AMELIA/0000-0002-3438-6170; , CLARISSE/0000-0002-9518-9162; Ochsenbein, Adrian/0000-0003-1773-5436; Vikstrom, Anders/0000-0003-3549-3944	F. Hoffmann-La Roche/Genentech	F. Hoffmann-La Roche/Genentech(Hoffmann-La RocheRoche HoldingGenentech)	Funded by F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143.	Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen DS, 2012, CLIN CANCER RES, V18, P6580, DOI 10.1158/1078-0432.CCR-12-1362; Dmitrienko A, 2013, STAT MED, V32, P5172, DOI 10.1002/sim.5990; Dmitrienko A, 2013, STAT MED, V32, P1079, DOI 10.1002/sim.5642; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gadgeel S, 2017, ANN ONCOL, V28, pv460, DOI DOI 10.1093/annonc/mdx380.001; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Hegde PS, 2017, SEMIN CANC BIOL; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Kowanetz M, 2017, J THORAC ONCOL, V12, pS1817, DOI 10.1016/j.jtho.2017.09.485; Liu SV, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9092; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; National Comprehensive Cancer Net-work, 2018, NCCN CLIN PRACT GUID, V2; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Oyama T, 1998, J IMMUNOL, V160, P1224; Paz-Ares LG, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3038; Peters S, 2017, J CLIN ONCOL, V35, P2781, DOI 10.1200/JCO.2016.71.9476; Pillai RN, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.e20665; Reck M, 2010, ANN ONCOL, V21, P1804, DOI 10.1093/annonc/mdq020; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Roland CL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007669; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Syrigos K, 2017, ANN ONCOL          S, V28, P468; Tumeh PC, 2017, CANCER IMMUNOL RES, V5, P417, DOI 10.1158/2326-6066.CIR-16-0325; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Wallin JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12624	38	1874	1958	22	207	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2018	378	24					2288	2301		10.1056/NEJMoa1716948	http://dx.doi.org/10.1056/NEJMoa1716948			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ2KR	29863955	Green Published, Bronze			2023-01-03	WOS:000435099900006
J	Yue, WZ; Sun, CC; Shi, P; Engel, A; Wang, YS; He, WH				Yue, Wei-zhong; Sun, Cui-ci; Shi, Ping; Engel, Anja; Wang, You-shao; He, Wei-hong			Effect of temperature on the accumulation of marine biogenic gels in the surface microlayer near the outlet of nuclear power plants and adjacent areas in the Daya Bay, China	PLOS ONE			English	Article							TRANSPARENT EXOPOLYMER PARTICLES; DISSOLVED ORGANIC-MATTER; SEA-SURFACE; WATER-QUALITY; POTENTIAL IMPLICATIONS; SIZE DISTRIBUTION; AMINO-ACIDS; UV-B; PHYTOPLANKTON; OCEAN	The surface microlayer (SML) in marine systems is often characterized by an enrichment of biogenic, gel-like particles, such as the polysaccharide-containing transparent exopolymer particles (TEP) and the protein-containing Coomassie stainable particles (CSP). This study investigated the distribution of TEP and CSP, in the SML and underlying water, as well as their bio-physical controlling factors in Daya Bay, an area impacted by warm discharge from two Nuclear power plants (Npp's) and aquaculture during a research cruise in July 2014. The SML had higher proportions of cyanobacteria and of pico-size Chl a contrast to the underlayer water, particularly at the nearest outlet station characterized by higher temperature. Diatoms, dinoflagellates and chlorophyll a were depleted in the SML. Both CSP and TEP abundance and total area were enriched in the SML relative to the underlying water, with enrichment factors (EFs) of 1.5-3.4 for CSP numbers and 1.32-3.2 for TEP numbers. Although TEP and CSP showed highest concentration in the region where high productivity and high nutrient concertation were observed, EFs of gels and of dissolved organic carbon (DOC) and dissolved acidic polysaccharide (> 1 kDa), exhibited higher values near the outlet of the Npp's than in the adjacent waters. The positive relation between EF's of gels and temperature and the enrichment of cyanobacteria in the SML may be indicative of future conditions in a warmer ocean, suggesting potential effects on adjusting phytoplankton community, biogenic element cycling and air-sea exchange processes.	[Yue, Wei-zhong; Sun, Cui-ci; Shi, Ping; Wang, You-shao] Chinese Acad Sci, South China Sea Inst Oceanol, State Key Lab Trop Oceanog, Guangzhou, Guangdong, Peoples R China; [Sun, Cui-ci; Wang, You-shao] Chinese Acad Sci, Daya Bay Marine Biol Res Stn, Shenzhen, Peoples R China; [Engel, Anja] GEOMAR Helmholtz Ctr Ocean Res Kiel, Kiel, Germany; [He, Wei-hong] Chinese Acad Sci, South China Sea Inst Oceanol, Guangzhou, Guangdong, Peoples R China	Chinese Academy of Sciences; South China Sea Institute of Oceanology, CAS; Chinese Academy of Sciences; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; Chinese Academy of Sciences; South China Sea Institute of Oceanology, CAS	Sun, CC (corresponding author), Chinese Acad Sci, South China Sea Inst Oceanol, State Key Lab Trop Oceanog, Guangzhou, Guangdong, Peoples R China.; Sun, CC (corresponding author), Chinese Acad Sci, Daya Bay Marine Biol Res Stn, Shenzhen, Peoples R China.	scuici@scsio.ac.cn		Engel, Anja/0000-0002-1042-1955	Special Fund for Public Welfare Research and Capacity Building in Guangdong Province [2016A020222018]; National Natural Science Foundation of China [CN41106106, 41430966]; National Key Research and Development Plan [2017FY100700]; China Scholarship Council [201408440016]	Special Fund for Public Welfare Research and Capacity Building in Guangdong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Plan; China Scholarship Council(China Scholarship Council)	This study was supported by Special Fund for Public Welfare Research and Capacity Building in Guangdong Province (2016A020222018), National Natural Science Foundation of China (CN41106106 and No. 41430966), the National Key Research and Development Plan (No. 2017FY100700) and China Scholarship Council 201408440016.	Aller JY, 2017, ATMOS ENVIRON, V154, P331, DOI 10.1016/j.atmosenv.2017.01.053; Bar-Zeev E, 2011, MAR ECOL PROG SER, V431, P107, DOI 10.3354/meps09110; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P319, DOI 10.1016/S0065-3233(08)60022-4; Behrenfeld MJ, 2006, NATURE, V444, P752, DOI 10.1038/nature05317; Berman-Frank I, 2016, BIOGEOSCIENCES, V13, P3793, DOI 10.5194/bg-13-3793-2016; Biermann A, 2014, J PLANKTON RES, V36, P658, DOI 10.1093/plankt/fbu005; Bopp L, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023653; Borchard C, 2012, BIOGEOSCIENCES, V9, P3405, DOI 10.5194/bg-9-3405-2012; Burd AB, 2009, ANNU REV MAR SCI, V1, P65, DOI 10.1146/annurev.marine.010908.163904; Campbell D, 1998, P NATL ACAD SCI USA, V95, P364, DOI 10.1073/pnas.95.1.364; Capone DG, 1998, MAR ECOL PROG SER, V172, P281, DOI 10.3354/meps172281; CARLUCCI AF, 1992, J GEOPHYS RES-OCEANS, V97, P5271, DOI 10.1029/91JC02614; CARPENTER EJ, 1977, LIMNOL OCEANOGR, V22, P739, DOI 10.4319/lo.1977.22.4.0739; Chen CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118300; Chin WC, 1998, NATURE, V391, P568, DOI 10.1038/35345; Cisternas-Novoa C, 2015, MAR CHEM, V175, P56, DOI 10.1016/j.marchem.2015.03.009; Claquin P, 2008, AQUAT MICROB ECOL, V51, P1, DOI 10.3354/ame01187; Cunliffe M, 2013, PROG OCEANOGR, V109, P104, DOI 10.1016/j.pocean.2012.08.004; Cunliffe M, 2011, FEMS MICROBIOL REV, V35, P233, DOI 10.1111/j.1574-6976.2010.00246.x; Cunliffe M, 2009, ISME J, V3, P1001, DOI 10.1038/ismej.2009.69; Ding YX, 2008, MAR CHEM, V112, P11, DOI 10.1016/j.marchem.2008.05.003; Engel A, 2015, BIOGEOSCIENCES, V12, P5647, DOI 10.5194/bg-12-5647-2015; Engel A, 2004, NATURE, V428, P929, DOI 10.1038/nature02453; Engel A, 2002, ESTUAR COAST SHELF S, V55, P729, DOI 10.1006/ecss.2001.0927; Engel A., 2009, PRACTICAL GUIDELINES, V1st, DOI [10.1201/9781420073072, DOI 10.1201/9781420073072]; Engel A, 2016, BIOGEOSCIENCES, V13, P989, DOI 10.5194/bg-13-989-2016; Engel A, 2011, J PLANKTON RES, V33, P357, DOI 10.1093/plankt/fbq122; Flombaum P, 2013, P NATL ACAD SCI USA, V110, P9824, DOI 10.1073/pnas.1307701110; Fukao T, 2012, J APPL PHYCOL, V24, P181, DOI 10.1007/s10811-011-9666-3; Galgani L, 2014, J GEOPHYS RES-OCEANS, V119, P7911, DOI 10.1002/2014JC010188; Gao Q, 2012, OCEAN SCI, V8, P401, DOI 10.5194/os-8-401-2012; GESAMP, 1995, REP STUD; Grossart HP, 1997, LIMNOL OCEANOGR, V42, P1651, DOI 10.4319/lo.1997.42.8.1651; Haidacher D, 1996, P NATL ACAD SCI USA, V93, P2290, DOI 10.1073/pnas.93.6.2290; HARVEY GW, 1972, LIMNOL OCEANOGR, V17, P156, DOI 10.4319/lo.1972.17.1.0156; HERBLAND A, 1985, DEEP-SEA RES, V32, P819, DOI 10.1016/0198-0149(85)90118-9; HSJD,RPT, 1972, PRACTICAL HDB SEAWAT; Jackson GA, 1998, ENVIRON SCI TECHNOL, V32, P2805, DOI 10.1021/es980251w; JIANG Q, 1991, ENVIRON SCI TECHNOL, V25, P2031, DOI 10.1021/es00024a007; Kamykowski D, 2005, DEEP-SEA RES PT I, V52, P1719, DOI 10.1016/j.dsr.2005.04.007; Kuznetsova M, 2004, LIMNOL OCEANOGR, V49, P1605, DOI 10.4319/lo.2004.49.5.1605; Kuznetsova M, 2001, MAR CHEM, V73, P319, DOI 10.1016/S0304-4203(00)00116-X; Lass K, 2013, BIOGEOSCIENCES, V10, P5325, DOI 10.5194/bg-10-5325-2013; Leck C, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023651; Li XY, 2004, WATER RES, V38, P1305, DOI 10.1016/j.watres.2003.11.010; Liu KW, 1998, J GEOPHYS RES-ATMOS, V103, P10571, DOI 10.1029/97JD03736; Long RA, 1996, AQUAT MICROB ECOL, V10, P213, DOI 10.3354/ame010213; Ma YE, 2014, CONT SHELF RES, V72, P10, DOI 10.1016/j.csr.2013.10.012; Mari X, 1996, J PLANKTON RES, V18, P969, DOI 10.1093/plankt/18.6.969; Mari X, 2017, PROG OCEANOGR, V151, P13, DOI 10.1016/j.pocean.2016.11.002; Mohlin M, 2012, MICROB ECOL, V63, P736, DOI 10.1007/s00248-011-9964-y; Moran XAG, 2010, GLOBAL CHANGE BIOL, V16, P1137, DOI 10.1111/j.1365-2486.2009.01960.x; Orellana MV, 2011, P NATL ACAD SCI USA, V108, P13612, DOI 10.1073/pnas.1102457108; Orellana MV, 2003, LIMNOL OCEANOGR, V48, P1618, DOI 10.4319/lo.2003.48.4.1618; Passow U, 2002, PROG OCEANOGR, V55, P287, DOI 10.1016/S0079-6611(02)00138-6; Passow U, 1995, LIMNOL OCEANOGR, V40, P1326, DOI 10.4319/lo.1995.40.7.1326; PASSOW U, 1995, DEEP-SEA RES PT II, V42, P99, DOI 10.1016/0967-0645(95)00006-C; Passow U, 2012, MAR ECOL PROG SER, V470, P249, DOI 10.3354/meps09985; Piontek J, 2009, AQUAT MICROB ECOL, V54, P305, DOI 10.3354/ame01273; Prairie JC, 2013, MAR ECOL PROG SER, V487, P185, DOI 10.3354/meps10387; Richardson AJ, 2004, SCIENCE, V305, P1609, DOI 10.1126/science.1100958; Romano JC, 1996, DEEP-SEA RES PT I, V43, P411, DOI 10.1016/0967-0637(96)00024-6; Santos AL, 2012, APPL ENVIRON MICROB, V78, P2066, DOI 10.1128/AEM.06344-11; Seebah S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112379; Shatwell T, 2008, GLOBAL CHANGE BIOL, V14, P2194, DOI 10.1111/j.1365-2486.2008.01630.x; Simon M, 2002, AQUAT MICROB ECOL, V28, P175, DOI 10.3354/ame028175; Sommer U, 2017, BIOL REV, V92, P1011, DOI 10.1111/brv.12266; Sun C-C, 2017, BIOGEOSCIENCES DISCU, DOI [10.5194/bg-2017-419, DOI 10.5194/BG-2017-419.]; Sun CC, 2011, INT J ENV RES PUB HE, V8, P2951, DOI 10.3390/ijerph8072951; Tang DL, 2003, REMOTE SENS ENVIRON, V84, P506, DOI 10.1016/S0034-4257(02)00149-9; Thornton DCO, 2007, LIMNOL OCEANOGR-METH, V5, P73, DOI 10.4319/lom.2007.5.73; Thornton DCO, 2016, FRONT MAR SCI, V3, DOI 10.3389/fmars.2016.00135; Tilstone GH, 2010, LIMNOL OCEANOGR, V55, P1835, DOI 10.4319/lo.2010.55.5.1835; Verdugo P, 2012, ANNU REV MAR SCI, V4, P375, DOI 10.1146/annurev-marine-120709-142759; Wang HH, 2014, J SEA RES, V85, P474, DOI 10.1016/j.seares.2013.08.002; Wang YS, 2012, ENVIRON EARTH SCI, V66, P655, DOI 10.1007/s12665-011-1274-7; Wang YS, 2008, MAR POLLUT BULL, V56, P1871, DOI 10.1016/j.marpolbul.2008.07.017; Wannicke N, 2009, AQUAT MICROB ECOL, V57, P175, DOI 10.3354/ame01343; Wei X, 2013, MAR POLLUT BULL, V75, P105, DOI 10.1016/j.marpolbul.2013.07.056; Wu ML, 2016, MAR POLLUT BULL, V112, P341, DOI 10.1016/j.marpolbul.2016.07.042; Wurl O, 2011, BIOGEOSCIENCES, V8, P121, DOI 10.5194/bg-8-121-2011; Wurl O, 2008, MAR CHEM, V110, P89, DOI 10.1016/j.marchem.2008.02.009; Wurl O, 2016, PROG OCEANOGR, V144, P15, DOI 10.1016/j.pocean.2016.03.002; Wurl O, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2011JC007342; [殷建平 YIN Jianping], 2006, [海洋通报, Marine Science Bulletin], V25, P1; Zhang ZB, 2003, J COLLOID INTERF SCI, V264, P148, DOI 10.1016/S0021-9797(03)00390-4	86	7	7	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2018	13	6							e0198735	10.1371/journal.pone.0198735	http://dx.doi.org/10.1371/journal.pone.0198735			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI8PJ	29889860	Green Published, Green Accepted, gold			2023-01-03	WOS:000434786600040
J	Patten, C; Levine, J; Pavlidis, I; Balls-Berry, J; Shah, A; Hughes, C; Brockman, T; Soto, MV; Witt, D; Koepp, G; Sinicrope, P; Richard, J				Patten, Christi; Levine, James; Pavlidis, Ioannis; Balls-Berry, Joyce; Shah, Arya; Hughes, Christine; Brockman, Tabetha; Soto, Miguel Valdez; Witt, Daniel; Koepp, Gabriel; Sinicrope, Pamela; Richard, Jamie			Survey of potential receptivity to robotic-assisted exercise coaching in a diverse sample of smokers and nonsmokers	PLOS ONE			English	Article							SMOKING-CESSATION; CIGARETTE-SMOKING; RANDOMIZED-TRIAL; INTERVENTION; TECHNOLOGY; WOMEN; PARTICIPATION; ACCEPTANCE; EFFICACY; ADULTS	A prior project found that an intensive (12 weeks, thrice weekly sessions) in-person, supervised, exercise coaching intervention was effective for smoking cessation among depressed women smokers. However, the sample was 90% White and of high socioeconomic status, and the intensity of the intervention limits its reach. One approach to intervention scalability is to deliver the supervised exercise coaching using a robotic human exercise trainer. This is done in real time via an iPad tablet placed on a mobile robotic wheel base and controlled remotely by an iOS device or computer. As an initial step, this preliminary study surveyed potential receptivity to a robotic-assisted exercise coaching intervention among 100 adults recruited in two community settings, and explored the association of technology acceptance scores with smoking status and other demographics. Participants watched a brief demonstration of the robot-delivered exercise coaching and completed a 19-item survey assessing socio-demographics and technology receptivity measured by the 8-item Technology Acceptance Scale (TAS). Open-ended written feedback was obtained, and content analysis was used to derive themes from these data. Respondents were: 40% female, 56% unemployed, 41% racial minority, 38% current smoker, and 58% depression history. Mean total TAS score was 34.0 (SD = 5.5) of possible 40, indicating overall very good receptivity to the robotic-assisted exercise intervention concept. Racial minorities and unemployed participants reported greater technology acceptance than White (p = 0.015) and employed (p<0.001) respondents. No association was detected between the TAS score and smoking status, depression, gender or age groups. Qualitative feedback indicated the robot was perceived as a novel, motivating, way to increase intervention reach and accessibility, and the wave of the future. Robotic technology has potential applicability for exercise coaching in a broad range of populations, including depressed smokers. Our next step will be to conduct a pilot trial to assess acceptability and potential efficacy of the robotic assisted exercise coaching intervention for smoking cessation.	[Patten, Christi; Hughes, Christine; Sinicrope, Pamela] Mayo Clin, Dept Psychol & Psychiat, Rochester, MN 55905 USA; [Levine, James; Koepp, Gabriel] Mayo Clin, Dept Obes Solut, Scottsdale, AZ USA; [Levine, James] Arizona State Univ, Obes Solut, Tempe, AZ USA; [Pavlidis, Ioannis] Univ Houston, Dept Comp Sci, Houston, TX 77204 USA; [Balls-Berry, Joyce] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Balls-Berry, Joyce; Brockman, Tabetha; Soto, Miguel Valdez] Mayo Clin, Off Community Engagement Res, Ctr Clin & Translat Sci, Rochester, MN USA; [Shah, Arya; Witt, Daniel] Mayo Clin, Sch Med, Rochester, MN USA; [Richard, Jamie] Rochester Area Family YMCA, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Arizona State University; Arizona State University-Tempe; University of Houston System; University of Houston; Mayo Clinic; Mayo Clinic; Mayo Clinic	Patten, C (corresponding author), Mayo Clin, Dept Psychol & Psychiat, Rochester, MN 55905 USA.	patten.christi@mayo.edu	Pavlidis, Ioannis/AAH-3817-2019	Witt, Daniel/0000-0002-9770-8042; Pavlidis, Ioannis/0000-0001-8025-2600; Patten, Christi/0000-0002-7194-8160	CTSA Grant from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 TR000135]	CTSA Grant from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and the funders had no role in the work of this manuscript.	American College of Sports Medicine, 2010, ACSMS GUIDELINES EXE; Anderson M., 2016, PEW RES CTR; Andrade AO, 2014, BIOMED SIGNAL PROCES, V10, P65, DOI 10.1016/j.bspc.2013.12.009; Barbash GI, 2010, NEW ENGL J MED, V363, P701, DOI 10.1056/NEJMp1006602; Bartlett Yvonne Kiera, 2017, J Med Internet Res, V19, pe124, DOI 10.2196/jmir.6616; Bernard P, 2015, J DUAL DIAGN, V11, P205, DOI 10.1080/15504263.2015.1113842; Bize R, 2010, TOB CONTROL, V19, P488, DOI 10.1136/tc.2009.030288; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; Brown RA, 2014, NICOTINE TOB RES, V16, P197, DOI 10.1093/ntr/ntt134; Chuttur M, 2009, WORK PAPERS INF SYST, P9, DOI DOI 10.1097/00001756-199612200-00068; DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008; Evins AE, 2008, J CLIN PSYCHOPHARM, V28, P660, DOI 10.1097/JCP.0b013e31818ad7d6; French SA, 1998, J AM DIET ASSOC, V98, P198, DOI 10.1016/S0002-8223(98)00050-9; Giuseffi DL, 2011, STRESS HEALTH, V27, pE269, DOI 10.1002/smi.1389; Hall SM, 2006, AM J PUBLIC HEALTH, V96, P1808, DOI 10.2105/AJPH.2005.080382; Hulley S.B., 2013, DESIGNING CLIN RES E, V4th ed., P73; Jamal A, 2016, MMWR-MORBID MORTAL W, V65, P1205, DOI 10.15585/mmwr.mm6544a2; King WR, 2006, INFORM MANAGE-AMSTER, V43, P740, DOI 10.1016/j.im.2006.05.003; Krippendorff KH, 2013, CONTENT ANAL INTRO I, P42; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Levine JA, 2011, DIABETES, V60, P2667, DOI 10.2337/db11-1118; MacPherson L, 2010, J CONSULT CLIN PSYCH, V78, P55, DOI 10.1037/a0017939; Maddison R, 2014, ANN BEHAV MED, V48, P194, DOI 10.1007/s12160-014-9588-9; Marcus BH, 1999, ARCH INTERN MED, V159, P1229, DOI 10.1001/archinte.159.11.1229; Pampel FC, 2010, ANNU REV SOCIOL, V36, P349, DOI 10.1146/annurev.soc.012809.102529; Passey M, 2014, ADDICTION, V109, P1049, DOI 10.1111/add.12548; Patten CA, 2017, NICOTINE TOB RES, V19, P77, DOI 10.1093/ntr/ntw208; Pew Research Center, 2022, MOB FACT SHEET; Provoost S, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6553; Ramsey A, 2016, J BEHAV HEALTH SER R, V43, P54, DOI 10.1007/s11414-014-9436-5; Skoogh J, 2010, ANN ONCOL, V21, P1905, DOI 10.1093/annonc/mdq058; Sorbi MJ, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.5.e38; Studts JL, 2006, CANCER EPIDEM BIOMAR, V15, P1825, DOI 10.1158/1055-9965.EPI-06-0393; Ussher MH, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub5; Vickers KS, 2009, NICOTINE TOB RES, V11, P985, DOI 10.1093/ntr/ntp101; Whiteley JA, 2012, AM J PREV MED, V43, P256, DOI 10.1016/j.amepre.2012.05.025; Wilcox S, 2011, CONTEMP CLIN TRIALS, V32, P931, DOI 10.1016/j.cct.2011.08.003; Williams JM, 2013, AM J PUBLIC HEALTH, V103, P1549, DOI 10.2105/AJPH.2013.301232	38	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0197090	10.1371/journal.pone.0197090	http://dx.doi.org/10.1371/journal.pone.0197090			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF3JM	29746530	Green Published, gold			2023-01-03	WOS:000431851700065
J	Silva, NCBS; Gill, DP; Owen, AM; Liu-Ambrose, T; Hachinski, V; Shigematsu, R; Petrella, RJ				Silva, Narlon Cassio Boa Sorte; Gill, Dawn P.; Owen, Adrian M.; Liu-Ambrose, Teresa; Hachinski, Vladimir; Shigematsu, Ryosuke; Petrella, Robert J.			Cognitive changes following multiple-modality exercise and mind-motor training in older adults with subjective cognitive complaints: The M4 study	PLOS ONE			English	Article							SQUARE-STEPPING EXERCISE; MEMORY COMPLAINTS; ALZHEIMERS-DISEASE; PHYSICAL-ACTIVITY; AEROBIC EXERCISE; RISK-FACTORS; IMPAIRMENT; DECLINE; COMMUNITY; ASSOCIATION	Background We investigated the effects of multiple-modality exercise with additional mind-motor training on cognition in community-dwelling older adults with subjective cognitive complaints. Methods Participants (n = 127, mean age 67.5 [7.3] years, 71% women) were randomized to receive 45 minutes of multiple-modality exercise with additional 15 minutes of either mind-motor training (M4, n = 63) or control (balance, range of motion and breathing exercises [M2, n = 64]). In total, both groups exercised 60 minutes/day, 3 days/week, for 24 weeks. Standardized global cognitive functioning (GCF), concentration, reasoning, planning, and memory were assessed at 24 weeks and after a 28-week no-contact follow-up. Results There were no significant differences in the study primary outcomes. The M4 group, however, showed trends for greater improvements in GCF and memory (both, P = .07) compared to the M2 group at 24 weeks. Significant differences between group in GCF (P = .03) and memory (P = .02) were observed after the 28-week no-contact follow-up favouring the M4 group. Discussion Additional mind-motor training did not impart immediate greater benefits to cognition among the study participants.	[Silva, Narlon Cassio Boa Sorte; Petrella, Robert J.] Western Univ, Sch Kinesiol, Fac Hlth Sci, London, ON, Canada; [Silva, Narlon Cassio Boa Sorte; Gill, Dawn P.; Petrella, Robert J.] Lawson Hlth Res Inst, London, ON, Canada; [Gill, Dawn P.; Petrella, Robert J.] Western Univ, Grad Program Hlth & Rehabil Sci, Fac Hlth Sci, London, ON, Canada; [Gill, Dawn P.; Petrella, Robert J.] Western Univ, Sch Hlth Studies, Fac Hlth Sci, London, ON, Canada; [Gill, Dawn P.; Petrella, Robert J.] Western Univ, Dept Family Med, Ctr Studies Family Med, London, ON, Canada; [Gill, Dawn P.; Petrella, Robert J.] Western Univ, Canadian Ctr Act & Aging, London, ON, Canada; [Owen, Adrian M.] Western Univ, Brain & Mind Inst, Dept Psychol, London, ON, Canada; [Liu-Ambrose, Teresa] Univ British Columbia, Dept Phys Therapy, Fac Med, Vancouver, BC, Canada; [Liu-Ambrose, Teresa] Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada; [Hachinski, Vladimir] Western Univ, London Hlth Sci Ctr, Dept Clin Neurol Sci, London, ON, Canada; [Shigematsu, Ryosuke] Mie Univ, Fac Educ, Tsu, Mie, Japan	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of British Columbia; London Health Sciences Centre; Western University (University of Western Ontario); Mie University	Petrella, RJ (corresponding author), Western Univ, Sch Kinesiol, Fac Hlth Sci, London, ON, Canada.; Petrella, RJ (corresponding author), Lawson Hlth Res Inst, London, ON, Canada.; Petrella, RJ (corresponding author), Western Univ, Grad Program Hlth & Rehabil Sci, Fac Hlth Sci, London, ON, Canada.; Petrella, RJ (corresponding author), Western Univ, Sch Hlth Studies, Fac Hlth Sci, London, ON, Canada.; Petrella, RJ (corresponding author), Western Univ, Dept Family Med, Ctr Studies Family Med, London, ON, Canada.; Petrella, RJ (corresponding author), Western Univ, Canadian Ctr Act & Aging, London, ON, Canada.	robert.petrella@schulich.uwo.ca	Boa Sorte Silva, Nárlon/ABH-1468-2021; Liu-Ambrose, Teresa/W-2332-2019; Shigematsu, Ryosuke/AAW-7348-2021	Boa Sorte Silva, Nárlon/0000-0002-4847-3742; Liu-Ambrose, Teresa/0000-0002-8297-5308; Shigematsu, Ryosuke/0000-0002-4852-1265	Canadian Institutes of Health Research [MOP 130474]; St. Joseph's Health Care Foundation [048-1415]; Mitacs Globalink Graduate Fellowship (NCBSS); Fellowship in the Care of the Elderly Research, a training award through the Aging, Rehabilitation, and Geriatric Care Research Centre of the Lawson Health Research Institute; St. Joseph's Health Care Foundation (MAG)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); St. Joseph's Health Care Foundation; Mitacs Globalink Graduate Fellowship (NCBSS); Fellowship in the Care of the Elderly Research, a training award through the Aging, Rehabilitation, and Geriatric Care Research Centre of the Lawson Health Research Institute; St. Joseph's Health Care Foundation (MAG)	This work was supported by the Canadian Institutes of Health Research (RJP; grant number: MOP 130474), St. Joseph's Health Care Foundation (RJP; grant number: 048-1415) (http://www.cihr-irsc.gc.ca/e/193.html). The other funding sources listed were studentships and fellowships awards to students: Mitacs Globalink Graduate Fellowship (NCBSS) http://www.mitacs.ca/en/programs/globalink/globalink-graduate-fellowship <http://www.mitacs.ca/en/programs/globalink/globalink-graduate-fellowship>, and Fellowship in the Care of the Elderly Research, a training award through the Aging, Rehabilitation, and Geriatric Care Research Centre of the Lawson Health Research Institute in partnership with the St. Joseph's Health Care Foundation (MAG) https://www.sjhcfoundation.org/ <https://www.spcfoundatiortorg/>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amariglio RE, 2012, NEUROPSYCHOLOGIA, V50, P2880, DOI 10.1016/j.neuropsychologia.2012.08.011; Amariglio RE, 2011, J AM GERIATR SOC, V59, P1612, DOI 10.1111/j.1532-5415.2011.03543.x; Barnes DE, 2013, JAMA INTERN MED, V173, P797, DOI 10.1001/jamainternmed.2013.189; Baumgart Matthew, 2015, Alzheimers Dement, V11, P718, DOI 10.1016/j.jalz.2015.05.016; Buckley RF, 2015, NEUROPSYCHOLOGY, V29, P571, DOI 10.1037/neu0000156; Cespon J, 2018, AGEING RES REV, V43, P81, DOI 10.1016/j.arr.2018.03.001; Chao LL, 2010, NEUROBIOL AGING, V31, P368, DOI 10.1016/j.neurobiolaging.2008.05.004; Chen ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098630; Chodzko-Zajko WJ, 2009, MED SCI SPORT EXER, V41, P1510, DOI 10.1249/MSS.0b013e3181a0c95c; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Erickson KI, 2009, BRIT J SPORT MED, V43, P22, DOI 10.1136/bjsm.2008.052498; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Fitzmaurice GM., 2011, APPL LONGITUDINAL AN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gates N, 2013, AM J GERIAT PSYCHIAT, V21, P1086, DOI 10.1016/j.jagp.2013.02.018; Gray JR, 2003, NAT NEUROSCI, V6, P316, DOI 10.1038/nn1014; Gregory MA, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0190-9; Gregory MA, 2013, CURR SPORT MED REP, V12, P256, DOI 10.1249/JSR.0b013e31829a74fd; Hampshire A, 2012, NEURON, V76, P1225, DOI 10.1016/j.neuron.2012.06.022; Heyward V. H., 2014, ADV FITNESS ASSESSME, V7th; Jessen F, 2014, ALZHEIMERS DEMENT, V10, P844, DOI 10.1016/j.jalz.2014.01.001; Jessen F, 2010, ARCH GEN PSYCHIAT, V67, P414, DOI 10.1001/archgenpsychiatry.2010.30; Jonasson LS, 2017, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00336; Kaup AR, 2015, NEUROLOGY, V85, P1852, DOI 10.1212/WNL.0000000000002153; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lewinsohn PM, 1997, PSYCHOL AGING, V12, P277, DOI 10.1037/0882-7974.12.2.277; Teixeira CVL, 2013, PSYCHOGERIATRICS, V13, P148, DOI 10.1111/psyg.12017; Liu C, 2014, MATH PROBL ENG, V2014, DOI 10.1155/2014/730652; Liu-Ambrose T, 2016, NEUROLOGY, V87, P2082, DOI 10.1212/WNL.0000000000003332; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Monsell SE, 2012, INT PSYCHOGERIATR, V24, P1553, DOI 10.1017/S1041610212000452; Mortimer JA, 2012, J ALZHEIMERS DIS, V30, P757, DOI 10.3233/JAD-2012-120079; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nishiguchi S, 2015, J AM GERIATR SOC, V63, P1355, DOI 10.1111/jgs.13481; Northey JM, 2018, BRIT J SPORT MED, V52, P154, DOI 10.1136/bjsports-2016-096587; Perrotin A, 2017, ALZHEIMERS DEMENT, V13, P550, DOI 10.1016/j.jalz.2016.08.011; Saykin AJ, 2012, OLDER ADULTS COGNITI, V67, P834; Shigematsu R, 2014, J GERONTOL GERIAT RE, V3, P2, DOI DOI 10.4172/2167-7182.1000147; Shigematsu R, 2008, J GERONTOL A-BIOL, V63, P76, DOI 10.1093/gerona/63.1.76; Shigematsu R, 2008, AGING CLIN EXP RES, V20, P19; Silva NCBS, 2018, EXP GERONTOL, V103, P17, DOI 10.1016/j.exger.2017.12.011; Silva NCBS, 2017, ARCH GERONTOL GERIAT, V68, P149, DOI 10.1016/j.archger.2016.10.009; Sink KM, 2015, JAMA-J AM MED ASSOC, V314, P781, DOI 10.1001/jama.2015.9617; Smith JC, 2013, J ALZHEIMERS DIS, V37, P197, DOI 10.3233/JAD-130467; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Stuckey M, 2012, CRIT REV PHYS REHAB, V24, P109, DOI DOI 10.1615/CRITREVPHYSREHABILMED.2013006823; ten Brinke LF, 2015, BRIT J SPORT MED, V49, P248, DOI 10.1136/bjsports-2013-093184; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Waldofff FB, 2009, INT J GERIATR PSYCH, V24, P602, DOI 10.1002/gps.2163; Young J, 2015, AEROBIC EXERCISE IMP, V4, DOI [10.1002/14651858.CD005381.pub4, DOI 10.1002/14651858.CD005381.PUB4]	53	12	12	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2018	13	4							e0196356	10.1371/journal.pone.0196356	http://dx.doi.org/10.1371/journal.pone.0196356			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE1WN	29698440	Green Submitted, Green Published, gold			2023-01-03	WOS:000431007600067
J	Jena, AB; Olenski, AR; Khullar, D; Bonica, A; Rosenthal, H				Jena, Anupam B.; Olenski, Andrew R.; Khullar, Dhruv; Bonica, Adam; Rosenthal, Howard			Physicians' political preferences and the delivery of end of life care in the United States: retrospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							US MEDICAL-SCHOOLS; SEX-DIFFERENCES; MORTALITY	OBJECTIVES To compare the delivery of end of life care given to US Medicare beneficiaries in hospital by internal medicine physicians with Republican versus Democrat political affiliations. DESIGN Retrospective observational study. SETTING US Medicare. PARTICIPANTS Random sample of Medicare beneficiaries, who were admitted to hospital in 2008-12 with a general medical condition, and died in hospital or shortly thereafter. MAIN OUTCOME MEASURES Total inpatient spending, intensive care unit use, and intensive end of life treatments (eg, mechanical ventilation and gastrostomy tube insertion) among patients dying in hospital, and hospice referral among patients discharged but at high predicted risk of 30 day mortality after discharge. Physicians were categorized as Democrat, Republican, or non-donors, using federal political contribution data. RESULTS Among 1 480 808 patients, 93 976 (6.3%) were treated by 1523 Democratic physicians, 58 876 (4.0%) by 768 Republican physicians, and 1 327 956 (89.6%) by 23 627 non-donor physicians. Patient demographics and clinical characteristics were similar between groups. Democrat physicians were younger, more likely to be female, and more likely to have graduated from a top 20 US medical school than Republican physicians. Mean end of life spending, after adjustment for patient covariates and hospital specific fixed effects, was US$17938 ((sic)12872; (sic)14612) among Democrat physicians (95% confidence interval $17176 to $18700) and $18409 among Republican physicians ($17362 to $19 456; adjusted Republican v Democrat difference, $ 47(-$803 to $1747), P = 0.47). Intensive end of life treatments for patients who died in hospital did not vary by physician political affiliation. The proportion of patients discharged from hospital to hospice did not vary with physician political affiliation. Among patients in the top 5% of predicted risk of death 30 days after hospital discharge, adjusted proportions of patients discharged to hospice were 15.8%, 15.0%, and 15.2% among Democrat, Republican, and nondonor physicians, respectively (adjusted difference in proportion between Republicans v Democrats, -0.8% (-2.7% to 0.9%), P= 0.43). CONCLUSIONS This study provided no evidence that physician political affiliation is associated with the intensity of end of life care received by patients in hospital. Other treatments for politically polarised healthcare issues should be investigated.	[Jena, Anupam B.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Olenski, Andrew R.] Columbia Univ, Dept Econ, New York, NY 10027 USA; [Khullar, Dhruv] Weill Cornell Med Coll, Dept Heallhcare Policy & Res, New York, NY USA; [Khullar, Dhruv] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Bonica, Adam] Stanford Univ, Dept Polit Sci, Stanford, CA 94305 USA; [Rosenthal, Howard] NYU, Dept Polit, New York, NY USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Bureau of Economic Research; Columbia University; Cornell University; Cornell University; Stanford University; New York University	Jena, AB (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA.; Jena, AB (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Jena, AB (corresponding author), Natl Bur Econ Res, Cambridge, MA 02138 USA.	jena@hcp.med.harvard.edu	Bonica, Adam/AAQ-1776-2021	Bonica, Adam/0000-0002-3004-9441; Olenski, Andrew/0000-0002-7461-0536				Antiel RM, 2014, J GEN INTERN MED, V29, P399, DOI [10.1007/s11606-013-2718-4, 10.1007/s11606-013-2523-0]; Baker LC, 2014, HEALTH AFFAIR, V33, P957, DOI 10.1377/hlthaff.2013.1184; Barnato AE, 2009, MED CARE, V47, P1098, DOI 10.1097/MLR.0b013e3181993191; Barnett ML, 2017, JAMA INTERN MED, V177, P693, DOI 10.1001/jamainternmed.2016.9685; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Bonica A, 2015, JAMA INTERN MED, V175, P1236, DOI 10.1001/jamainternmed.2015.1332; Bonica A, 2014, JAMA INTERN MED, V174, P1308, DOI 10.1001/jamainternmed.2014.2105; Bonica A, 2014, AM J POLIT SCI, V58, P367, DOI 10.1111/ajps.12062; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; Cutler D, 2013, NATL BUREAU EC RES W, V19320; Halpern SD, 2015, NEW ENGL J MED, V373, P2001, DOI 10.1056/NEJMp1509664; Hersh ED, 2016, P NATL ACAD SCI USA, V113, P11811, DOI 10.1073/pnas.1606609113; Jena AB, 2016, JAMA INTERN MED, V176, P1294, DOI 10.1001/jamainternmed.2016.3284; Jena AB, 2015, JAMA-J AM MED ASSOC, V314, P1149, DOI 10.1001/jama.2015.10680; Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Obermeyer Z, 2015, HEALTH AFFAIR, V34, P993, DOI 10.1377/hlthaff.2014.1055; Pew Research Center, 2013, VIEWS END OF LIF MED; Schroeder SA, 2014, J GEN INTERN MED, V29, P267, DOI 10.1007/s11606-013-2722-8; Tsugawa Y, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1797; Tsugawa Y, 2017, JAMA INTERN MED, V177, P675, DOI 10.1001/jamainternmed.2017.0059; Tsugawa Y, 2017, JAMA INTERN MED, V177, P206, DOI 10.1001/jamainternmed.2016.7875; Tsugawa Y, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j273; Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209	23	6	6	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	2018	361								k1161	10.1136/bmj.k1161	http://dx.doi.org/10.1136/bmj.k1161			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD1WH	29643089	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000430291500001
J	Ferraris, A; Bouisse, C; Mottard, N; Thiolliere, F; Anselin, S; Piriou, V; Allaouchiche, B				Ferraris, Arnaud; Bouisse, Camille; Mottard, Nicolas; Thiolliere, Fabrice; Anselin, Sophie; Piriou, Vincent; Allaouchiche, Bernard			Mottling score and skin temperature in septic shock: Relation and impact on prognosis in ICU	PLOS ONE			English	Article							CAPILLARY REFILL; SEPSIS; DYSFUNCTION; PERFUSION; FAILURE; TISSUE; AREA; KNEE	Introduction Mottling score, defined by 5 areas over the knee is developed to evaluate tissue perfusion at bedside. Because of the subjective aspect of the score, we aimed to compare mottling score and skin temperature in septic shock with infrared thermography in ICU and the correlation to survival. Methods We conducted a prospective and observational study in a teaching hospital in France during 8 months in ICU. All patients with sepsis requiring vasoactive drugs were included. We recorded epidemiologic data, hemodynamic parameters, mottling score and skin temperature with a thermic camera of the 5 mottling areas around the knee (temperatures recorded with FLIR (TM) software) at bedside. Measures were performed at ICU admission (HO) and six hours after initial resuscitation (H6). Results 46 patients were included. Median age was 69 (60-78), SOFA score 11 (8-12) mean SAPS II was 57 +/- 20 and 28-day mortality rate was 30%. Patients with mottling (score >= 1), had a skin temperature of the knee significantly lower (30.7 vs 33,2 degrees C p = 0.01 at H6) than patients without mottling (score = 0). Skin temperatures of the knee in mottling groups 1 to 5 were similar at HO and H6. Neither mottling score nor skin temperature of the knee were associated with prognostic regarding day-28 mortality. Conclusions Skin temperature measured with infrared thermography technology around the knee is lower when mottling sign is present and sign microcirculation alterations. This method, compared to standard mottling score is objective and allows data collections. However, this method failed to predict mortality in ICU patients.	[Ferraris, Arnaud; Bouisse, Camille; Mottard, Nicolas; Thiolliere, Fabrice; Anselin, Sophie; Piriou, Vincent; Allaouchiche, Bernard] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Anesthesie Reanimat, Lyon, France; [Piriou, Vincent; Allaouchiche, Bernard] Univ Lyon 1 Claude Bernard, Lyon, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ferraris, A (corresponding author), Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Anesthesie Reanimat, Lyon, France.	arnaud.ferraris@chu-lyon.fr	Piriou, Vincent/AFV-4922-2022	piriou, vincent/0000-0001-6900-1480				Ait-Oufella H, 2014, INTENS CARE MED, V40, P958, DOI 10.1007/s00134-014-3326-4; Ait-Oufella H, 2012, INTENS CARE MED, V38, P976, DOI 10.1007/s00134-012-2555-7; Ait-Oufella H, 2011, INTENS CARE MED, V37, P801, DOI 10.1007/s00134-011-2163-y; Ait-Oufella H, 2015, CURR OPIN CRIT CARE, V21, P271, DOI 10.1097/MCC.0000000000000217; Ait-Oufella H, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-31; Bourcier S, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0164-2; Coudroy R, 2015, INTENS CARE MED, V41, P452, DOI 10.1007/s00134-014-3600-5; De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC; De Backer D, 2004, AM HEART J, V147, P91, DOI 10.1016/j.ahj.2003.07.006; De Backer D, 2010, INTENS CARE MED, V36, P1813, DOI 10.1007/s00134-010-2005-3; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Ince C, 2005, CRIT CARE, V9, pS13, DOI 10.1186/cc3753; Jiang L. J., 2005, Journal of Medical Engineering & Technology, V29, P257, DOI 10.1080/03091900512331333158; Langemo DK, 2017, ADV SKIN WOUND CARE, V30, P109, DOI 10.1097/01.ASW.0000511535.31486.bb; Lee YLL, 2015, AM SURGEON, V81, P1272; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lima A, 2011, CRIT CARE MED, V39, P1649, DOI 10.1097/CCM.0b013e3182186675; Miranda M, 2016, AM J PHYSIOL-HEART C, V311, pH24, DOI 10.1152/ajpheart.00034.2016; SCHRIGER DL, 1988, ANN EMERG MED, V17, P932, DOI 10.1016/S0196-0644(88)80675-9; Vincent JL, 2013, NEW ENGL J MED, V369, P1726, DOI 10.1056/NEJMra1208943; Vincent JL, 2005, CRIT CARE, V9, pS9, DOI 10.1186/cc3748; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	22	10	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0202329	10.1371/journal.pone.0202329	http://dx.doi.org/10.1371/journal.pone.0202329			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ6RF	30114284	gold, Green Submitted, Green Published			2023-01-03	WOS:000441850400058
J	Muri-Gama, AS; Figueras, A; Secoli, SR				Muri-Gama, Abel Santiago; Figueras, Albert; Secoli, Silvia Regina			Inappropriately prescribed and over-the-counter antimicrobials in the Brazilian Amazon Basin: We need to promote more rational use even in remote places	PLOS ONE			English	Article							ANTIBIOTICS	Background Being aware of consumption patterns of antimicrobials is the first step in designing and implementing strategies to change behaviors and, thus, to reduce the occurrence of antimicrobial resistance. The present survey was carried out to identify and describe the use of antimicrobials without prescription in riverside dwellers of the Brazilian Amazon Basin. Methods A cross-sectional study was carried out from a conglomerate stratified sample in the rural municipality of Coari, Amazonas State, Brazil, between April and July 2016. The survey was conducted in the riverside dwellers' homes, and information was collected on all antimicrobials taken with and without medical or dental prescription for a 30-day period, together with indications of their use before the interview. Results A total of 492 riverside dwellers were included in the present survey; 346 (70.3%) had taken at least one medication during the previous month, and 74 (21.3% of those taking a medicine) used an antimicrobial. Two-thirds of the patients treated with an antimicrobial (49; 66.2%) obtained it without a prescription. Additionally, one-third of the antimicrobials consumed by the study sample (25) were used for non-infectious or non-bacterial conditions. Discussion The present survey showed not only that inappropriate use of antimicrobials is present in remote places such as the Amazon Basin, but also that one-third of those antimicrobials were taken to treat non-infectious or non-bacterial conditions. In addition to an unnecessary risk of adverse effects to the exposed populations, the inappropriate use of antibiotics without prescription helps to increase antibiotic-resistant strains. In the present case, this was happening near one of Latin America's most important water supplies, which could contribute to the global impact of antimicrobial resistance.	[Muri-Gama, Abel Santiago] Univ Fed Amazonas UFAM, ISB, Coari, Brazil; [Figueras, Albert] Univ Barcelona, Fundacio Inst Catala Farmacol, Dept Farmacol Toxicol & Terapeut, Barcelona, Spain; [Secoli, Silvia Regina] Univ Sao Paulo, Escola Enfermagem, Sao Paulo, Brazil	Universidade Federal de Amazonas; University of Barcelona; Universidade de Sao Paulo	Muri-Gama, AS (corresponding author), Univ Fed Amazonas UFAM, ISB, Coari, Brazil.; Figueras, A (corresponding author), Univ Barcelona, Fundacio Inst Catala Farmacol, Dept Farmacol Toxicol & Terapeut, Barcelona, Spain.	abelgama@usp.br; afs@icf.uab.cat	Figueras, Albert/H-7743-2012; Secoli, Silvia/H-2890-2012	Figueras, Albert/0000-0002-2740-2013; Secoli, Silvia/0000-0003-4135-6241; Gama, Abel/0000-0001-5089-6990	Fundacao de Amparo a Pesquisa do Estado do Amazonas - FAPEAM	Fundacao de Amparo a Pesquisa do Estado do Amazonas - FAPEAM	The present study received financial support from the Fundacao de Amparo a Pesquisa do Estado do Amazonas - FAPEAM to ASM-G. This funding allowed travels to the study area (Coari) in the heart of the Brazilian State of Amazonas.	Ashraf Muhammad Salman, 2016, N C Med J, V77, P346, DOI 10.18043/ncm.77.5.346; Bassetti M, 2000, INT J ANTIMICROB AG, V16, P295, DOI 10.1016/S0924-8579(00)00249-1; Fraxe TJP, 2007, COMUNIDADES RIBEIRIN; Guinovart MC, 2015, J ANTIMICROB CHEMOTH, V70, P1270, DOI 10.1093/jac/dku526; Hollis A, 2013, NEW ENGL J MED, V369, P2474, DOI 10.1056/NEJMp1311479; Instituto Brasileiro de Geografia e Estatfstica, 2016, SIN CENS DEM 2010; Khan LH, 2017, NATURE, V543, P547, DOI [10.1038/nature21709, DOI 10.1038/NATURE21709]; Luiz RR, 2000, CIENC SAUDE COLETIVA, V8, P9; Gama ASM, 2018, CAD SAUDE PUBLICA, V34, DOI 10.1590/0102-311X00002817; Rossi F, 2011, CLIN INFECT DIS, V52, P1138, DOI 10.1093/cid/cir120; Santa-Ana-Tellez Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075550; United Nations, WORLD LEAD COMM ACT; World Health Organization, 2014, ANTIMICROBIAL RESIST; Worldbank, 2016, DRUG RES INF THREAT	14	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2018	13	8							e0201579	10.1371/journal.pone.0201579	http://dx.doi.org/10.1371/journal.pone.0201579			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP3QP	30075021	Green Published, Green Submitted, gold			2023-01-03	WOS:000440768100021
J	Sperry, JL; Guyette, FX; Brown, JB; Yazer, MH; Triulzi, DJ; Early-Young, BJ; Adams, PW; Daley, BJ; Miller, RS; Harbrecht, BG; Claridge, JA; Phelan, HA; Witham, WR; Putnam, AT; Duane, TM; Alarcon, LH; Callaway, CW; Zuckerbraun, BS; Neal, MD; Rosengart, MR; Forsythe, RM; Billiar, TR; Yealy, DM; Peitzman, AB; Zenati, MS				Sperry, J. L.; Guyette, F. X.; Brown, J. B.; Yazer, M. H.; Triulzi, D. J.; Early-Young, B. J.; Adams, P. W.; Daley, B. J.; Miller, R. S.; Harbrecht, B. G.; Claridge, J. A.; Phelan, H. A.; Witham, W. R.; Putnam, A. T.; Duane, T. M.; Alarcon, L. H.; Callaway, C. W.; Zuckerbraun, B. S.; Neal, M. D.; Rosengart, M. R.; Forsythe, R. M.; Billiar, T. R.; Yealy, D. M.; Peitzman, A. B.; Zenati, M. S.		PAMper Study Grp	Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FRESH-FROZEN PLASMA; DAMAGE CONTROL RESUSCITATION; MULTIPLE-ORGAN FAILURE; RED-BLOOD-CELLS; MASSIVE TRANSFUSION; MULTICENTER; TRIALS; INJURY; TIME; INFLAMMATION	BACKGROUND After a person has been injured, prehospital administration of plasma in addition to the initiation of standard resuscitation procedures in the prehospital environment may reduce the risk of downstream complications from hemorrhage and shock. Data from large clinical trials are lacking to show either the efficacy or the risks associated with plasma transfusion in the prehospital setting. METHODS To determine the efficacy and safety of prehospital administration of thawed plasma in injured patients who are at risk for hemorrhagic shock, we conducted a pragmatic, multicenter, cluster-randomized, phase 3 superiority trial that compared the administration of thawed plasma with standard-care resuscitation during air medical transport. The primary outcome was mortality at 30 days. RESULTS A total of 501 patients were evaluated: 230 patients received plasma (plasma group) and 271 received standard-care resuscitation (standard-care group). Mortality at 30 days was significantly lower in the plasma group than in the standard-care group (23.2% vs. 33.0%; difference, -9.8 percentage points; 95% confidence interval, -18.6 to -1.0%; P=0.03). A similar treatment effect was observed across nine prespecified subgroups (heterogeneity chi-square test, 12.21; P=0.79). Kaplan-Meier curves showed an early separation of the two treatment groups that began 3 hours after randomization and persisted until 30 days after randomization (log-rank chi-square test, 5.70; P=0.02). The median prothrombintime ratio was lower in the plasma group than in the standard-care group (1.2 [interquartile range, 1.1 to 1.4] vs. 1.3 [interquartile range, 1.1 to 1.6], P<0.001) after the patients' arrival at the trauma center. No significant differences between the two groups were noted with respect to multiorgan failure, acute lung injury-acute respiratory distress syndrome, nosocomial infections, or allergic or transfusion-related reactions. CONCLUSIONS In injured patients at risk for hemorrhagic shock, the prehospital administration of thawed plasma was safe and resulted in lower 30-day mortality and a lower median prothrombintime ratio than standard-care resuscitation.	[Sperry, J. L.; Brown, J. B.; Alarcon, L. H.; Zuckerbraun, B. S.; Neal, M. D.; Rosengart, M. R.; Forsythe, R. M.; Billiar, T. R.; Peitzman, A. B.; Zenati, M. S.] Univ Pittsburgh, Med Ctr, Div Trauma & Gen Surg, Dept Surg, Pittsburgh, PA 15260 USA; [Guyette, F. X.; Callaway, C. W.; Yealy, D. M.] Univ Pittsburgh, Med Ctr, Dept Emergency Med, Pittsburgh, PA 15260 USA; [Early-Young, B. J.; Adams, P. W.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Yazer, M. H.; Triulzi, D. J.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Yazer, M. H.; Triulzi, D. J.] Inst Transfus Med, Pittsburgh, PA USA; [Putnam, A. T.] Univ Pittsburgh, Med Ctr, Altoona Hosp, Altoona, PA USA; [Daley, B. J.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Knoxville, TN USA; [Miller, R. S.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN USA; [Harbrecht, B. G.] Univ Louisville, Dept Surg, Louisville, KY 40292 USA; [Claridge, J. A.] Case Western Reserve Univ, MetroHlth Med Ctr, Cleveland, OH 44106 USA; [Phelan, H. A.] Univ Texas Southwestern, Dept Surg, Parkland Mem Hosp, Dallas, TX USA; [Witham, W. R.] Texas Hlth Harris Methodist Hosp, Ft Worth, TX USA; [Duane, T. M.] John Peter Smith Hlth Network, Ft Worth, TX USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Institute for Transfusion Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University; University of Louisville; Case Western Reserve University; MetroHealth System; University of Texas System; University of Texas Southwestern Medical Center Dallas	Sperry, JL (corresponding author), Univ Pittsburgh, Dept Surg & Crit Care Med, 200 Lothrop St, Pittsburgh, PA 15213 USA.	sperryjl@upmc.edu	Neal, Matthew/GMW-5601-2022; , Francis/AAE-1586-2022; Brown, Joshua/AFN-0988-2022; Zenati, Mazen S/C-2020-2012	Neal, Matthew/0000-0001-8931-6236; Brown, Joshua/0000-0002-6936-035X; Adams, Peter/0000-0003-3267-4977	U.S. Army Medical Research and Materiel Command	U.S. Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	Funded by the U.S. Army Medical Research and Materiel Command	BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brown JB, 2015, PREHOSP EMERG CARE, V19, P343, DOI 10.3109/10903127.2014.995851; Brown JB, 2013, J TRAUMA ACUTE CARE, V74, P1207, DOI 10.1097/TA.0b013e31828c44fd; Cardenas JC, 2017, TRANSFUSION, V57, P869, DOI 10.1111/trf.14019; Chang R, 2017, WILD ENVIRON MED, V28, pS124, DOI 10.1016/j.wem.2017.02.002; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; Etchill E, 2016, TRANSFUSION, V56, P2478, DOI 10.1111/trf.13755; FDA Center for Biologics Evaluation and Research, 2013, GUID I REV BOARDS CL; Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059; Fox EE, 2017, SHOCK, V47, P567, DOI 10.1097/SHK.0000000000000788; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Harris T, 2018, EMERG MED CLIN N AM, V36, P85, DOI 10.1016/j.emc.2017.08.009; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Henriksen HH, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0327-z; Hernandez MC, 2017, J TRAUMA ACUTE CARE, V83, P398, DOI 10.1097/TA.0000000000001581; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2017, J TRAUMA ACUTE CARE, V83, pS83, DOI 10.1097/TA.0000000000001484; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holena DN, 2017, J AM COLL SURGEONS, V224, P255, DOI 10.1016/j.jamcollsurg.2016.11.016; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940; Minei JP, 2012, CRIT CARE MED, V40, P1129, DOI 10.1097/CCM.0b013e3182376e9f; Naumann DN, 2018, SHOCK, V49, P420, DOI 10.1097/SHK.0000000000000999; Naumann DN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189870; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pati S, 2016, J TRAUMA ACUTE CARE, V80, P576, DOI 10.1097/TA.0000000000000961; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Potter DR, 2015, J TRAUMA ACUTE CARE, V78, pS7, DOI 10.1097/TA.0000000000000630; Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147; Shackelford SA, 2017, JAMA-J AM MED ASSOC, V318, P1581, DOI 10.1001/jama.2017.15097; Teixeira PGR, 2009, J TRAUMA, V66, P693, DOI 10.1097/TA.0b013e31817e5c77; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	35	352	356	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 26	2018	379	4					315	326		10.1056/NEJMoa1802345	http://dx.doi.org/10.1056/NEJMoa1802345			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GO1YK	30044935	Bronze			2023-01-03	WOS:000439757700005
J	Desjardins, A; Gromeier, M; Herndon, JE; Beaubier, N; Bolognesi, DP; Friedman, AH; Friedman, HS; McSherry, F; Muscat, AM; Nair, S; Peters, KB; Randazzo, D; Sampson, JH; Vlahovic, G; Harrison, WT; McLendon, RE; Ashley, D; Bigner, DD				Desjardins, Annick; Gromeier, Matthias; Herndon, James E., II; Beaubier, Nike; Bolognesi, Dani P.; Friedman, Allan H.; Friedman, Henry S.; McSherry, Frances; Muscat, Andrea M.; Nair, Smita; Peters, Katherine B.; Randazzo, Dina; Sampson, John H.; Vlahovic, Gordana; Harrison, William T.; McLendon, Roger E.; Ashley, David; Bigner, Darell D.			Recurrent Glioblastoma Treated with Recombinant Poliovirus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVECTION-ENHANCED DELIVERY; NEWLY-DIAGNOSED GLIOBLASTOMA; RIBOSOME ENTRY SITE; MALIGNANT GLIOMAS; BEVACIZUMAB; RECEPTOR; TRIAL; NEUROVIRULENCE; MOLECULES; HUMANS	BACKGROUND The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating convectionenhanced, intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO). PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment. METHODS We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma, confirmed on histopathological testing, with measurable disease (contrast-enhancing tumor of = 1 cm and = 5.5 cm in the greatest dimension). The study evaluated seven doses, ranging between 10(7) and 10(10) 50% tissue-culture infectious doses (TCID50), first in a dose-escalation phase and then in a dose-expansion phase. RESULTS From May 2012 through May 2017, a total of 61 patients were enrolled and received a dose of PVSRIPO. Dose level -1 (5.0x10(7) TCID50) was identified as the phase 2 dose. One dose-limiting toxic effect was observed; a patient in whom dose level 5 (10(10) TCID50) was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed. To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use, dose level 5 was de-escalated to reach the phase 2 dose. In the dose-expansion phase, 19% of the patients had a PVSRIPO-related adverse event of grade 3 or higher. Overall survival among the patients who received PVSRIPO reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 months that was sustained at 36 months. CONCLUSIONS Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential. The survival rate among patients who received PVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls.	[Desjardins, Annick; Gromeier, Matthias; Friedman, Allan H.; Friedman, Henry S.; Peters, Katherine B.; Randazzo, Dina; Sampson, John H.; Vlahovic, Gordana; Ashley, David; Bigner, Darell D.] Duke Univ, Med Ctr, Dept Neurosurg, 177 MSRB,Box 3156, Durham, NC 27710 USA; [Herndon, James E., II; McSherry, Frances] Duke Univ, Med Ctr, Dept Biostat, Durham, NC 27710 USA; [Bolognesi, Dani P.; Nair, Smita] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Harrison, William T.; McLendon, Roger E.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Desjardins, Annick; Gromeier, Matthias; Herndon, James E., II; Bolognesi, Dani P.; Friedman, Allan H.; Friedman, Henry S.; McSherry, Frances; Nair, Smita; Peters, Katherine B.; Randazzo, Dina; Sampson, John H.; Vlahovic, Gordana; Harrison, William T.; McLendon, Roger E.; Ashley, David; Bigner, Darell D.] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA; [Bolognesi, Dani P.] Istari Oncol, Durham, NC USA; [Beaubier, Nike] Deakin Univ, Tempus Labs Chicago, Geelong, Vic, Australia; [Muscat, Andrea M.] Deakin Univ, Sch Med, Geelong, Vic, Australia	Duke University; Duke University; Duke University; Duke University; Duke University; Deakin University; Deakin University	Bigner, DD (corresponding author), Duke Univ, Med Ctr, Dept Neurosurg, 177 MSRB,Box 3156, Durham, NC 27710 USA.; Bigner, DD (corresponding author), Duke Univ, Med Ctr, 177 MSRB,Box 3156,Res Dr, Durham, NC 27710 USA.	darell.bigner@duke.edu	Nair, Smita/GYR-2993-2022; Peters, Katherine/AAT-3133-2020	Nair, Smita/0000-0001-5615-7056; Sampson, John/0000-0002-0104-7658	Brain Tumor Research Charity; Tisch family through the Jewish Communal Fund; Uncle Kory Foundation; Department of Defense [W81X-WH-16-1-0354]; National Institutes of Health [R35CA197264, P01CA154291, P50CA190991, R01CA124756, R01NS099463]; Angels among Us (Brain Tumor Research); Asness family (Brain Tumor Research); NATIONAL CANCER INSTITUTE [R35CA197264, P50CA190991, P01CA154291, R01CA124756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS099463] Funding Source: NIH RePORTER	Brain Tumor Research Charity; Tisch family through the Jewish Communal Fund; Uncle Kory Foundation; Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Angels among Us (Brain Tumor Research); Asness family (Brain Tumor Research); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from the Brain Tumor Research Charity, the Tisch family through the Jewish Communal Fund, Uncle Kory Foundation, the Department of Defense (W81X-WH-16-1-0354), and the National Institutes of Health (R35CA197264, P01CA154291, P50CA190991, R01CA124756, and R01NS099463), and by Angels among Us and the Asness family (both in support of Brain Tumor Research).	Brown MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan4220; Chandramohan V, 2017, ARCH PATHOL LAB MED, V141, P1697, DOI 10.5858/arpa.2016-0580-OA; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Dobrikova EY, 2012, J VIROL, V86, P2750, DOI 10.1128/JVI.06427-11; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Levin VA, 2011, INT J RADIAT ONCOL, V79, P1487, DOI 10.1016/j.ijrobp.2009.12.061; Mandel JJ, 2016, J NEURO-ONCOL, V129, P147, DOI 10.1007/s11060-016-2157-2; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Merrill MK, 2006, J VIROL, V80, P6936, DOI 10.1128/JVI.00243-06; Merrill MK, 2006, J VIROL, V80, P3147, DOI 10.1128/JVI.80.7.3147-3156.2006; Sampson JH, 2007, NEUROSURGERY, V60, P89, DOI 10.1227/01.NEU.0000249256.09289.5F; Sampson JH, 2011, NEUROSURGERY, V69, P668, DOI 10.1227/NEU.0b013e3182181ba8; Shen L, 2017, J VIROL, V91, DOI 10.1128/JVI.02310-16; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Stengel KF, 2012, P NATL ACAD SCI USA, V109, P5399, DOI 10.1073/pnas.1120606109; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Taal W, 2014, LANCET ONCOL, V15, P943, DOI 10.1016/S1470-2045(14)70314-6; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Vredenburgh JJ, 2010, ONCOLOGIST, V15, P1329, DOI 10.1634/theoncologist.2010-0105; Wefel JS, 2011, NEURO-ONCOLOGY, V13, P660, DOI 10.1093/neuonc/nor024	24	382	393	4	101	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2018	379	2					150	161		10.1056/NEJMoa1716435	http://dx.doi.org/10.1056/NEJMoa1716435			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM6DL	29943666	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000438249800011
J	Galilea-Zabalza, I; Buil-Cosiales, P; Salas-Salvado, J; Toledo, E; Ortega-Azorin, C; Diez-Espino, J; Vazquez-Ruiz, Z; Zomeno, MD; Vioque, J; Martinez, JA; Romaguera, D; Perez-Farinos, N; Lopez-Miranda, J; Estruch, R; Bueno-Cavanillas, A; Aros, F; Tur, JA; Tinahones, F; Serra-Majem, L; Marcos-Delgado, A; Ortega-Calvo, M; Vazquez, C; Pinto, X; Vidal, J; Daimiel, L; Delgado-Rodriguez, M; Matia, P; Corella, D; Diaz-Lopez, A; Babio, N; Munoz, MA; Fito, M; Gonzalez-Palacios, S; Abete, I; Garcia-Rios, A; Ros, E; Martinez-Gonzalez, MA				Galilea-Zabalza, Inigo; Buil-Cosiales, Pilar; Salas-Salvado, Jordi; Toledo, Estefania; Ortega-Azorin, Carolina; Diez-Espino, Javier; Vazquez-Ruiz, Zenaida; Dolores Zomeno, Maria; Vioque, Jesus; Alfredo Martinez, Jose; Romaguera, Dora; Perez-Farinos, Napoleon; Lopez-Miranda, Jose; Estruch, Ramon; Bueno-Cavanillas, Aurora; Aros, Fernando; Antoni Tur, Josep; Tinahones, Francisco; Serra-Majem, Lluis; Marcos-Delgado, Alba; Ortega-Calvo, Manuel; Vazquez, Clotilde; Pinto, Xavier; Vidal, Josep; Daimiel, Lidia; Delgado-Rodriguez, Miguel; Matia, Pilar; Corella, Dolores; Diaz-Lopez, Andres; Babio, Nancy; Angel Munoz, Miguel; Fito, Montse; Gonzalez-Palacios, Sandra; Abete, Itziar; Garcia-Rios, Antonio; Ros, Emilio; Angel Martinez-Gonzalez, Miguel		PREDIMED-PLUS Study Investigators	Mediterranean diet and quality of life: Baseline cross-sectional analysis of the PREDIMED-PLUS trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY QUESTIONNAIRE; CARDIOVASCULAR-DISEASE; HEALTH-STATUS; MORTALITY; ASSOCIATION; VALIDATION; PREVENTION; DEPRESSION; ADHERENCE; BENEFITS	We assessed if a 17-item score capturing adherence to a traditional Mediterranean diet (MedDiet) was associated with better health-related quality of life among older Spanish men and women with overweight or obesity harboring the metabolic syndrome. We analyzed baseline data from 6430 men and women (age 55-70 years) participating in the PREDIMED-Plus study. PREDIMED-Plus is a multi-centre randomized trial testing an energy-restricted MedDiet combined with promotion of physical activity and behavioral therapy for primary cardiovascular prevention compared to a MedDiet alone. Participants answered a 36-item questionnaire about health-related quality of life (HRQoL) and a 17-item questionnaire that assessed adherence to an MedDiet. We used ANCOVA and multivariable-adjusted linear regression models to compare baseline adjusted means of the quality of life scales according to categories of adherence to the MedDiet. Higher adherence to the MedDiet was independently associated with significantly better scores in the eight dimensions of HRQoL. Adjusted differences of > = 3 points between the highest and the lowest dietary adherence groups to the MedDiet were observed for vitality, emotional role, and mental health and of > = 2 points for the other dimensions. In conclusion, this study shows a positive association between adherence to a MedDiet and several dimensions of quality of life.	[Galilea-Zabalza, Inigo; Buil-Cosiales, Pilar; Diez-Espino, Javier] Atenc Primaria Osasunbidea Serv Navarro Salud, Pamplona, Spain; [Galilea-Zabalza, Inigo; Buil-Cosiales, Pilar; Salas-Salvado, Jordi; Toledo, Estefania; Ortega-Azorin, Carolina; Diez-Espino, Javier; Vazquez-Ruiz, Zenaida; Alfredo Martinez, Jose; Romaguera, Dora; Lopez-Miranda, Jose; Estruch, Ramon; Aros, Fernando; Antoni Tur, Josep; Tinahones, Francisco; Serra-Majem, Lluis; Ortega-Calvo, Manuel; Vazquez, Clotilde; Pinto, Xavier; Corella, Dolores; Diaz-Lopez, Andres; Angel Munoz, Miguel; Fito, Montse; Ros, Emilio; Angel Martinez-Gonzalez, Miguel] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBERobn, Madrid, Spain; [Buil-Cosiales, Pilar; Toledo, Estefania; Diez-Espino, Javier; Vazquez-Ruiz, Zenaida; Angel Martinez-Gonzalez, Miguel] Univ Navarra IdiSNA, Dept Prevent Med & Publ Hlth, Pamplona, Spain; [Salas-Salvado, Jordi; Diaz-Lopez, Andres; Babio, Nancy] Univ Rovira & Virgili, Human Nutr Unit, IISPV, Reus, Spain; [Ortega-Azorin, Carolina; Corella, Dolores] Univ Valencia, Dept Prevent Med, Valencia, Spain; [Dolores Zomeno, Maria] IMIM Hosp del Mar Med Res Inst, Cardiovasc Risk & Nutr, Barcelona, Spain; [Dolores Zomeno, Maria; Bueno-Cavanillas, Aurora; Marcos-Delgado, Alba; Delgado-Rodriguez, Miguel] Univ Ramon Llull, Blanquerna Sch Life Sci, Barcelona, Spain; [Vioque, Jesus; Gonzalez-Palacios, Sandra] Inst Salud Carlos III, CIBER Epidemiol & Salud Publ, Madrid, Spain; [Vioque, Jesus; Gonzalez-Palacios, Sandra] Miguel Hernandez Univ, Nur Epidemiol Unit, ISABIAL FISABIO, Alicante, Spain; [Alfredo Martinez, Jose; Abete, Itziar] Univ Navarra, Dept Nutr & Food Sci Physiol & Toxicol, Pamplona, Spain; [Romaguera, Dora] Univ Hosp Son Espases, Hlth Res Inst Balearic Isl IdISBa, Palma De Mallorca, Spain; [Perez-Farinos, Napoleon] Univ Malaga, Sch Nursing, Malaga, Spain; [Lopez-Miranda, Jose; Garcia-Rios, Antonio] Univ Cordoba IMIBIC, Reina Sofia Univ Hosp, Dept Internal Med, Cordoba, Spain; [Estruch, Ramon] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Internal Med, Barcelona, Spain; [Bueno-Cavanillas, Aurora] Univ Granada, Dept Prevent Med, Granada, Spain; [Aros, Fernando] OSI ABABA Univ Hosp Araba, Dept Cardiol, Vitoria, Spain; [Aros, Fernando] Univ Basque Country UPV EHU, Vitoria, Spain; [Antoni Tur, Josep; Tinahones, Francisco] Univ Malaga, Dept Endocrinol, Univ Hosp, Malaga, Spain; [Serra-Majem, Lluis] Univ Las Palmas Gran Canaria, Inst Biomed Res, Las Palmas Gran Canaria, Spain; [Marcos-Delgado, Alba] Univ Leon, Inst Biomed IBIOMED, Leon, Spain; [Ortega-Calvo, Manuel] Ctr Salud Las Palmeritas, Dept Family Med, Dist Sanitario Atenc Primaria, Seville, Spain; [Vazquez, Clotilde] Fdn Jimenez Diaz, Dept Endocrinol, Madrid, Spain; [Pinto, Xavier] Hosp Univ Bellvitge, Lipids & Vasc Risk Unit, Internal Med, Barcelona, Spain; [Vidal, Josep] Inst Salud Carlos III, CIBER Diabet & Enfermedades Metab, Madrid, Spain; [Vidal, Josep] Univ Barcelona, Dept Endocrinol, IDIBAPS, Hosp Clin, Barcelona, Spain; [Daimiel, Lidia] CEI UAM CSIC, Nutr Genom & Epigen Grp, IMDEA Food, Madrid, Spain; [Delgado-Rodriguez, Miguel] Univ Jaen, Div Prevent Med, Jaen, Spain; [Matia, Pilar] Hosp Clin San Carlos, Inst Invest Sanitaria, Madrid, Spain; [Angel Munoz, Miguel; Fito, Montse] Inst Municipal Invest Med, Lipids & Cardiovasc Epidemiol Res Unit, Barcelona, Spain; [Ros, Emilio] Hosp Clin Barcelona, Lipid Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain; [Angel Martinez-Gonzalez, Miguel] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; University of Navarra; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); University of Valencia; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Universitat Ramon Llull; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Instituto de Salud Carlos III; General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); University of Navarra; Hospital Universitari Son Espases; Institut Investigacio Sanitaria Illes Balears (IdISBa); Universidad de Malaga; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Granada; University of Basque Country; Universidad de Malaga; Universidad de Las Palmas de Gran Canaria; Universidad de Leon; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Jaen; Hospital Clinico San Carlos; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Harvard University; Harvard T.H. Chan School of Public Health	Martinez-Gonzalez, MA (corresponding author), Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBERobn, Madrid, Spain.; Martinez-Gonzalez, MA (corresponding author), Univ Navarra IdiSNA, Dept Prevent Med & Publ Hlth, Pamplona, Spain.; Martinez-Gonzalez, MA (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.	mamartinez@unav.es	Corbella, Emili/AGI-4105-2022; Serra-Majem, Lluis/I-6708-2019; Martin, Vicente/GRE-8306-2022; Gabucio, Laura M Compañ/AAN-6068-2020; Marcos-Delgado, Alba/AAN-4297-2020; Martin, Vicente/ABF-2276-2021; García, José Carlos Fernández/B-3723-2013; Camacho-Barcia, Lucía/AAB-2096-2021; Estruch, Ramon/AAZ-3723-2020; Tinahones, Francisco José/AAB-2882-2020; GALLEGO, BLANCA RIQUELME/AAB-1710-2020; Toledo, Estefania/H-6211-2014; García, José Carlos Fernández/X-3910-2019; de la Hera, Manuela Garcia/N-8908-2019; Salas-Salvado, Jordi/C-7229-2017; Capó, Xavier/AAD-6322-2022; Vázquez-Ruiz, Zenaida/AAB-7202-2020; vioque, jesus/A-1066-2008; Tur, Josep/AAE-5748-2020; perez, miguel/GXF-5077-2022; Ortega-Calvo, Manuel/I-4089-2019; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Hernandez rivas, Pablo Ignacio/AAA-3727-2021; Tosca-Segura, Ricardo/N-8680-2019; Ortega-Azorín, Carolina/AAB-2355-2019; Romaguera, Dora/AAB-2852-2020; Lopez-Miranda, Jose/Y-8306-2019; Romaguera, Dora/ABE-7004-2020; Botella, Cristina/F-9230-2010; de la Torre, Rafael/D-3561-2018; Ortega-Calvo, Manuel/D-6960-2015; López, Jessica Pérez/N-2880-2019; Muñoz, Miguel Angel/X-3511-2019; Salas-Huetos, Albert/A-8509-2011; Palacios, Sandra González/AAA-9585-2021; Pintó, Xavier/AGI-4297-2022; Fernandez, Antoni Colom/ABG-1017-2021; Sanchez-Villegas, Almudena/T-6733-2019; Ruiz-Canela, Miguel/I-7738-2016; Bueno-Cavanillas, Aurora/O-1513-2015; Mariscal, Alberto/ABH-5409-2020; Babio, Nancy/AAN-2715-2020; Canudas, Silvia/AAC-3163-2022; Pons, Antoni/L-4844-2014; Forcano Gamazo, Laura/B-1154-2017; Warnberg, Julia/G-1390-2011; MACIAS-GONZALEZ, MANUEL/E-7584-2016; Camafort-Babkowski, Miguel/H-6310-2014; Moreno Morales, Noelia/E-1141-2018; Prieto, Rafel M./J-3995-2017; Gutierrez-Bedmar, Mario/F-2364-2018; BES-RASTROLLO, MAIRA/A-1329-2009; Daimiel-Ruiz, Lidia Angeles/M-7779-2014	Corbella, Emili/0000-0001-8818-1907; Serra-Majem, Lluis/0000-0002-9658-9061; Martin, Vicente/0000-0003-0552-2804; Gabucio, Laura M Compañ/0000-0001-5324-1535; Marcos-Delgado, Alba/0000-0002-7852-1282; García, José Carlos Fernández/0000-0003-2308-2865; Camacho-Barcia, Lucía/0000-0002-5989-936X; GALLEGO, BLANCA RIQUELME/0000-0003-3422-7310; Toledo, Estefania/0000-0002-6263-4434; García, José Carlos Fernández/0000-0003-2308-2865; de la Hera, Manuela Garcia/0000-0001-5742-2704; Salas-Salvado, Jordi/0000-0003-2700-7459; Capó, Xavier/0000-0002-3499-5494; Vázquez-Ruiz, Zenaida/0000-0002-6828-9627; vioque, jesus/0000-0002-2284-148X; Tur, Josep/0000-0002-6940-0761; Ortega-Calvo, Manuel/0000-0003-2391-0106; Hernandez rivas, Pablo Ignacio/0000-0002-6691-7618; Tosca-Segura, Ricardo/0000-0003-2271-8171; Ortega-Azorín, Carolina/0000-0001-6719-9358; Lopez-Miranda, Jose/0000-0002-8844-0718; Romaguera, Dora/0000-0002-5762-8558; Botella, Cristina/0000-0001-8783-6959; de la Torre, Rafael/0000-0002-6765-1866; Ortega-Calvo, Manuel/0000-0003-2391-0106; Muñoz, Miguel Angel/0000-0002-4083-3248; Salas-Huetos, Albert/0000-0001-5914-6862; Palacios, Sandra González/0000-0003-3358-472X; Pintó, Xavier/0000-0002-2216-2444; Fernandez, Antoni Colom/0000-0001-5041-0778; Sanchez-Villegas, Almudena/0000-0001-7733-9238; Ruiz-Canela, Miguel/0000-0002-7684-2787; Bueno-Cavanillas, Aurora/0000-0002-0649-3016; Mariscal, Alberto/0000-0002-4684-2161; Babio, Nancy/0000-0003-3527-5277; Canudas, Silvia/0000-0002-5630-1588; Sabate, Joan/0000-0002-9063-9785; Boronat, Anna/0000-0003-0852-3634; Tormo, Nuria/0000-0002-4514-7730; Garcia-Gavilan, Jesus Francisco/0000-0002-3707-5255; Saez, Guillermo/0000-0002-8164-4048; Zomeno, M. Dolores/0000-0003-1280-7680; Tinahones, Francisco J/0000-0001-6871-4403; Salaverria Lete, Itziar/0000-0002-9504-4668; iturralde iriso, jesus/0000-0002-7800-3928; Castaner Nino, Olga/0000-0003-3169-997X; Hernaez, Alvaro/0000-0001-8593-1477; Pons, Antoni/0000-0003-2447-3868; ELOSUA, ROBERTO/0000-0001-8235-0095; Cuenca Royo, Aida/0000-0001-8551-5457; Vila-Domenech, Joan Salvador/0000-0002-0413-9291; Bautista-Castano, Inmaculada/0000-0001-9257-8739; Forcano Gamazo, Laura/0000-0002-8478-1451; TELLO, SUSANNA/0000-0002-0423-8281; Abbate, Manuela/0000-0001-9905-2414; JULIBERT, ALICIA/0000-0002-6040-0482; Cabre Vila, Juan Jose/0000-0003-1082-6861; Estan Capell, Nuria/0000-0001-8768-3139; Fernandez-Crehuet Navajas, Joaquin/0000-0002-1173-9906; Abellan Cano, Ivan/0000-0002-9587-5445; Warnberg, Julia/0000-0002-8408-316X; MACIAS-GONZALEZ, MANUEL/0000-0002-6475-4704; Vidal, Josep/0000-0002-4564-4518; Camafort-Babkowski, Miguel/0000-0002-8669-6410; Moreno Morales, Noelia/0000-0001-5907-9735; Romeo-Ollora, Jorge/0000-0003-0378-8908; Prieto, Rafel M./0000-0001-8814-900X; Bouzas Velasco, Cristina/0000-0002-1407-8461; Gutierrez-Bedmar, Mario/0000-0003-0898-8212; Orozco-Beltran, Domingo/0000-0002-8231-2635; BES-RASTROLLO, MAIRA/0000-0002-9139-4206; Torres Pena, Jose D./0000-0003-1366-5549; Mestres, Gaspar/0000-0002-8699-7037; Buil-Cosiales, Pilar/0000-0002-8586-577X; Ortega Martinez de Victoria, Emilio/0000-0002-2217-8905; Domenech, Monica/0000-0001-5447-6686; Tojal Sierra, Lucas/0000-0001-5338-9601; Daimiel-Ruiz, Lidia Angeles/0000-0001-9898-6629	European Research Council [340918]; Spanish Ministry of Health - Institute de Salud Carlos III (ISCIII) through the Fondo de Investigacion para la Salud (FIS); European Regional Development Fund [P113/00673, P113/00492, P113/00272, PI13/01123, P113/00462, P113/00233, P113/02184, P113/00728, P113/01090, P113/01056, P114/01722, P114/00636, P114/00618, PI14/00696, P114/01206, P114/01374, P114/01919, P114/00853, P116/00743, P116/00501, P117/000508]; Recercaixa grant [2013ACUP00194]; Consejeria de Salud de la Junta de Andalucia [P10458/2013]; SEMERGEN grant	European Research Council(European Research Council (ERC)European Commission); Spanish Ministry of Health - Institute de Salud Carlos III (ISCIII) through the Fondo de Investigacion para la Salud (FIS); European Regional Development Fund(European Commission); Recercaixa grant; Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); SEMERGEN grant	This project is funded by the European Research Council (Advanced Research Grant 2013-2018; 340918) granted to MAM-G, the Spanish Ministry of Health - Institute de Salud Carlos III (ISCIII) for the periods 2014-2016, 2015-2017, 2017-2019 and 2018-2020, through the Fondo de Investigacion para la Salud (FIS), which is co-funded by the European Regional Development Fund (four coordinated FIS grants lead by Jordi Salas-Salvado and Josep Vidal, including the following projects: P113/00673, P113/00492, P113/00272, PI13/01123, P113/00462, P113/00233, P113/02184, P113/00728 P113/01090 P113/01056, P114/01722, P114/00636, P114/00618, PI14/00696, P114/01206, P114/01374, P114/01919, P114/00853, P116/00743 P116/00501, P117/000508), by a Recercaixa grant 2013 (2013ACUP00194), by a grant from the Consejeria de Salud de la Junta de Andalucia (P10458/2013), and a SEMERGEN grant. None of these funding sources plays any role in the design, collection, analysis, or interpretation of the data or in the decision to submit manuscripts for publication.	Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Bjorner J., 2007, USERS MANUAL SF 36V2; Bonaccio M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003003; Buckland G, 2008, OBES REV, V9, P582, DOI 10.1111/j.1467-789X.2008.00503.x; Carson TL, 2014, J NUTR EDUC BEHAV, V46, P90, DOI 10.1016/j.jneb.2013.09.005; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197, DOI 10.1093/oxfordjournals.aje.a116966; Elosua R, 2000, MED SCI SPORT EXER, V32, P1431, DOI 10.1097/00005768-200008000-00011; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Finger JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078390; Fransen HP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111480; Galbete C, 2015, J NUTR HEALTH AGING, V19, P305, DOI 10.1007/s12603-015-0441-z; Heistaro S, 2001, J EPIDEMIOL COMMUN H, V55, P227, DOI 10.1136/jech.55.4.227; Sanchez PH, 2012, EUR J CLIN NUTR, V66, P360, DOI 10.1038/ejcn.2011.146; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Liu CH, 2007, PHYSIOL BEHAV, V92, P748, DOI 10.1016/j.physbeh.2007.05.068; Martinez-Gonzalez M.A., 2017, NUTRIENTS, V9; Martinez-Gonzalez MA, 2015, PROG CARDIOVASC DIS, V58, P50, DOI 10.1016/j.pcad.2015.04.003; Martinez-Lapiscina EH, 2013, J NEUROL NEUROSUR PS, V84, P1318, DOI 10.1136/jnnp-2012-304792; Munoz MA, 2009, BRIT J NUTR, V101, P1821, DOI 10.1017/S0007114508143598; Perez-Tasigchana RF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151596; Ruano C, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-121; Ruano C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061490; Ruano-Rodriguez C, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00101; Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003; Sanchez-Aguadero N, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0572-x; Sanchez-Villegas A, 2009, ARCH GEN PSYCHIAT, V66, P1090, DOI 10.1001/archgenpsychiatry.2009.129; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Segui-Gomez M, 2006, INT J EPIDEMIOL, V35, P1417, DOI 10.1093/ije/dyl223; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Tong TYN, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0677-4; Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; Valls-Pedret C, 2015, JAMA INTERN MED, V175, P1094, DOI 10.1001/jamainternmed.2015.1668; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	36	71	71	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2018	13	6							e0198974	10.1371/journal.pone.0198974	http://dx.doi.org/10.1371/journal.pone.0198974			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ6XV	29912978	Green Published, gold, Green Submitted			2023-01-03	WOS:000435528600065
J	Lien, MY; Chou, CH; Lin, CC; Bai, LY; Chiu, CF; Yeh, SP; Ho, MW				Lien, Ming-Yu; Chou, Chia-Hui; Lin, Ching-Chan; Bai, Li-Yuan; Chiu, Chang-Fang; Yeh, Su-Peng; Ho, Mao-Wang			Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study	PLOS ONE			English	Article							PARENTERAL-NUTRITION; CANDIDEMIA; DISEASES; MULTICENTER; CANDIDIASIS; STRATEGIES; MANAGEMENT; RECIPIENTS; UPDATE	This study investigated the epidemiology and risk factors associated with invasive fungal infections (IFIs) during induction chemotherapy in a cohort of Taiwanese patients with newly-diagnosed acute myeloid leukemia (AML). IFIs are a significant complication in the management of immunocompromised cancer patients; such infections are associated with a high incidence of morbidity and mortality, particularly in many South-Asian countries, where IFI rates are increasing. We retrospectively analyzed IFI incidence data from 105 patients with newly diagnosed AML at a single center undergoing their first course of induction chemotherapy without primary antifungal prophylaxis between November 2008 and December 2014. Of 21 cases documented as proven/provable IFIs 16 (76%) were invasive aspergillosis, 2 (10%) were mucormycosis infections, and 3 (14%) were proven yeast infections. The lung was the most commonly affected site (n = 16; 76%); 2 patients (10%) developed fungal sinusitis. IFI cases were more often males (P = 0.020). In multivariate analysis, patients with neutropenia lasting>30 days were more than twice as likely to develop IFI (OR, 2.24 [95% CI, 2.81 +/- 31.11], P<0.001). We also confirmed patients with smoker and receiving parenteral nutrition during chemotherapy were significant associated with IFIs. Our findings suggest that antifungal prophylaxis should be considered for patients with AML during induction chemotherapy, particularly in patients from Southeastern Asia, an area of potentially high IFI rates. We recommend that clinicians determine which patients receiving induction chemotherapy for AML are at high risk of developing IFI, to allow for targeted therapeutic prophylaxis.	[Lien, Ming-Yu; Lin, Ching-Chan; Bai, Li-Yuan; Chiu, Chang-Fang; Yeh, Su-Peng] China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan; [Lien, Ming-Yu] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Chou, Chia-Hui; Ho, Mao-Wang] China Med Univ Hosp, Div Infect Dis, Dept Internal Med, Taichung, Taiwan; [Bai, Li-Yuan; Chiu, Chang-Fang; Yeh, Su-Peng] China Med Univ, Grad Inst Clin Med, Dept Internal Med, Clin Hematol & Oncol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan	Yeh, SP (corresponding author), China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan.; Ho, MW (corresponding author), China Med Univ Hosp, Div Infect Dis, Dept Internal Med, Taichung, Taiwan.; Yeh, SP (corresponding author), China Med Univ, Grad Inst Clin Med, Dept Internal Med, Clin Hematol & Oncol, Taichung, Taiwan.	supengyeh@gmail.com; d7905@mail.cmuh.org.tw						Ananda-Rajah MR, 2012, HAEMATOL-HEMATOL J, V97, P459, DOI 10.3324/haematol.2011.051995; Buyukcelik A, 2004, CANCER, V101, P1100, DOI 10.1002/cncr.20461; Chen CY, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-250; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073; Garnica M, 2015, CLIN INFECT DIS, V60, P875, DOI 10.1093/cid/ciu947; Gaspar GG, 2015, REV SOC BRAS MED TRO, V48, P77, DOI 10.1590/0037-8682-0292-2014; Hammond SP, 2010, AM J HEMATOL, V85, P695, DOI 10.1002/ajh.21776; Hsu L Y, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.02.019; Khan AAH, 2012, SAUDI J BIOL SCI, V19, P405, DOI 10.1016/j.sjbs.2012.06.002; Kontoyiannis DP, 2012, AM J MED, V125, pS25, DOI 10.1016/j.amjmed.2011.10.009; Leon C, 2009, CRIT CARE MED, V37, P1624, DOI 10.1097/CCM.0b013e31819daa14; Lewis RE, 2013, MYCOSES, V56, P638, DOI 10.1111/myc.12081; Luzzati R, 2013, MYCOSES, V56, P664, DOI 10.1111/myc.12090; Malagola M, 2008, EUR J HAEMATOL, V81, P354, DOI 10.1111/j.1600-0609.2008.01122.x; Michallet M, 2012, EUR J CLIN MICROBIOL, V31, P991, DOI 10.1007/s10096-011-1397-5; Neofytos D, 2013, DIAGN MICR INFEC DIS, V75, P144, DOI 10.1016/j.diagmicrobio.2012.10.001; Nielsen Xiaohui Chen, 2012, Open Microbiol J, V6, P98, DOI 10.2174/1874285801206010098; Ostrosky-Zeichner L, 2007, EUR J CLIN MICROBIOL, V26, P271, DOI 10.1007/s10096-007-0270-z; Pagano L, 2011, J ANTIMICROB CHEMOTH, V66, pi5, DOI 10.1093/jac/dkq437; Pagano L, 2010, HAEMATOL-HEMATOL J, V95, P644, DOI 10.3324/haematol.2009.012054; Perfect JR, 2014, CLIN INFECT DIS, V59, pS352, DOI 10.1093/cid/ciu639; Richardson MD, 2005, J ANTIMICROB CHEMOTH, V56, P5, DOI 10.1093/jac/dki218; Ruping MJGT, 2008, DRUGS, V68, P1941, DOI 10.2165/00003495-200868140-00002; Stratman RC, 2010, NUTR CLIN PRACT, V25, P282, DOI 10.1177/0884533610368704; Tang JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128410	26	32	35	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2018	13	6							e0197851	10.1371/journal.pone.0197851	http://dx.doi.org/10.1371/journal.pone.0197851			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI7ZT	29883443	Green Submitted, Green Published, gold			2023-01-03	WOS:000434728100008
J	Nyrnes, SA; Garnaes, KK; Salvesen, O; Timilsina, AS; Moholdt, T; Ingul, CB				Nyrnes, Siri Ann; Garnaes, Kirsti Krohn; Salvesen, Oyvind; Timilsina, Anita Sharma; Moholdt, Trine; Ingul, Charlotte Bjork			Cardiac function in newborns of obese women and the effect of exercise during pregnancy. A randomized controlled trial	PLOS ONE			English	Article							NEONATES REFERENCE VALUES; CONGENITAL HEART-DEFECTS; MATERNAL OBESITY; VENTRICULAR FUNCTION; PHYSICAL-ACTIVITY; SPECKLE TRACKING; FETAL; HYPERTROPHY; PRETERM; INFANTS	Background The prevalence of maternal obesity is rising. Pre-pregnancy obesity is associated with later cardiovascular disease in the child and the underlying pathogenesis begins in early life. Therefore, pregnancy and infancy are key periods for potential intervention. The aim of this study was to study the cardiac function in newborns of obese women compared to newborns of normal-weight women, and to determine if exercise intervention during pregnancy could have an effect on cardiac function of newborns to obese women. Material and methods Fifty-five pregnant women, 51 obese (BMI >= 30 kg/m(2)) and four overweight (BMI 28-30 kg/m(2)), were randomized to an exercise training group (n = 27) or a control group (standard maternity care, n = 28). From gestational week 14 until delivery participants in the intervention group were offered supervised training sessions three times weekly. In addition, they were told to exercise at home once weekly. All newborns had an echocardiogram performed 1-3 days and 6-8 weeks after delivery. The results were compared with newborns of normal weight women (n = 20, standard maternity care). Results Newborns of obese women had an impaired systolic and diastolic cardiac function with reduced global strain, strain rate, tissue Doppler velocities and a thicker intraventricular septum at birth and after 6-8 weeks after delivery compared to newborns of normal weight women. Exercise had no statistically significant effect on either of the cardiac function parameters. The mean (+/- standard deviation) adherence to the exercise protocol was 1.3 +/- 0.8 sessions per week for supervised training and 0.8 +/- 0.7 sessions per week for homebased exercise training. Conclusions Newborns of obese women had reduced cardiac function and thicker intraventricular septum compared to newborns of normal weight women. Exercise training during pregnancy had no significant effect, potentially due to a low number of subjects and low adherence to the exercise protocol.	[Nyrnes, Siri Ann; Garnaes, Kirsti Krohn; Timilsina, Anita Sharma; Moholdt, Trine; Ingul, Charlotte Bjork] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, NTNU, Trondheim, Norway; [Nyrnes, Siri Ann] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Pediat, Trondheim, Norway; [Salvesen, Oyvind] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, NTNU, Trondheim, Norway; [Moholdt, Trine] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Obstet & Gynecol, Trondheim, Norway; [Ingul, Charlotte Bjork] Helse Midt Norge RHF, Stordal, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Nyrnes, SA (corresponding author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, NTNU, Trondheim, Norway.; Nyrnes, SA (corresponding author), Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Pediat, Trondheim, Norway.	siri.a.nyrnes@ntnu.no	Moholdt, Trine/ABC-8674-2021; Nyrnes, Siri Ann Ann/AAW-5601-2021; Moholdt, Trine/J-5884-2014	Moholdt, Trine/0000-0003-1024-8088; Ingul, Charlotte/0000-0002-3251-9494	Liaison Committee [46056728, 10364200]; Norwegian Fund for Postgraduate Training and Physiotherapy [47060000]; Heise Midt-Norge RHF	Liaison Committee; Norwegian Fund for Postgraduate Training and Physiotherapy; Heise Midt-Norge RHF	Funding Sources list (registered electronically at first submission): The Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. Award Number: 46056728. Recipient Kirsti Krohn Garnaes; The Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. Award Number: 10364200. Recipient Charlotte Bjork Ingul; The Norwegian Fund for Postgraduate Training and Physiotherapy, Award number: 47060000. Recipient Trine Moholdt. The first (SAN) and third (OS) author had no specific funding for this work. The fourth author (AT) received salary from the Award number 10364200. The funders of the second (KKG), fifth (TM) and last author (CBI) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Heise Midt-Norge RHF provided support in the form of salaries for the clinical work of the last author (CBI), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of these authors are articulated in the 'author contributions' section.	Al-Biltagi M, 2015, PEDIATR CARDIOL, V36, P445, DOI 10.1007/s00246-014-1033-0; Alexander BT, 2015, COMPR PHYSIOL, V5, P997, DOI 10.1002/cphy.c140036; Aman J, 2011, NEONATOLOGY, V100, P147, DOI 10.1159/000323741; Artal R, 2003, BRIT J SPORT MED, V37, P6, DOI 10.1136/bjsm.37.1.6; Barakat R, 2015, BRIT J SPORT MED, V49, P1377, DOI 10.1136/bjsports-2015-094756; Brite J, 2014, INT J OBESITY, V38, P878, DOI 10.1038/ijo.2013.244; Cade WT, 2017, PEDIATR RES, V82, P768, DOI 10.1038/pr.2017.140; Comm Obstet Practice, 2015, OBSTET GYNECOL, V126, pe135, DOI 10.1097/AOG.0000000000001214; Di Cesare M, 2016, LANCET, V387, P1377, DOI 10.1016/S0140-6736(16)30054-X; Ece I, 2014, PEDIATR CARDIOL, V35, P838, DOI 10.1007/s00246-014-0863-0; El-Khuffash AF, 2012, J AM SOC ECHOCARDIOG, V25, P1058, DOI 10.1016/j.echo.2012.07.016; Flegal KM, 2016, JAMA-J AM MED ASSOC, V315, P2284, DOI 10.1001/jama.2016.6458; Gaillard R, 2015, EUR J EPIDEMIOL, V30, P1141, DOI 10.1007/s10654-015-0085-7; GANDHI JA, 1995, AM J OBSTET GYNECOL, V173, P1132, DOI 10.1016/0002-9378(95)91339-4; Garnaes KK, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-017-1653-5; Garnaes KK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173937; Garns KK, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002079; Gluckman PD, 2004, PEDIATR RES, V56, P311, DOI 10.1203/01.PDR.0000135998.08025.FB; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Hoang TT, 2017, AM J EPIDEMIOL, V186, P118, DOI 10.1093/aje/kwx033; Huang Y, 2010, AM J PHYSIOL-ENDOC M, V299, pE968, DOI 10.1152/ajpendo.00434.2010; Ingul CB, 2016, ULTRASOUND OBST GYN, V47, P433, DOI 10.1002/uog.14841; Jain A, 2017, J PEDIATR-US, V182, P197, DOI 10.1016/j.jpeds.2016.11.003; Kandadi MR, 2013, J NUTR BIOCHEM, V24, P1982, DOI 10.1016/j.jnutbio.2013.07.003; Koestenberger M, 2015, PEDIATR CARDIOL, V36, P20, DOI 10.1007/s00246-014-0959-6; Koestenberger M, 2011, NEONATOLOGY, V100, P85, DOI 10.1159/000322006; Kulkarni A, 2017, ULTRASOUND OBST GYN, V49, P630, DOI 10.1002/uog.15971; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Leirgul E, 2016, OBSTET GYNECOL, V128, P1116, DOI 10.1097/AOG.0000000000001694; Leite CF, 2017, ARCH GYNECOL OBSTET, V295, P273, DOI 10.1007/s00404-016-4204-9; Madsen NL, 2013, CONGENIT HEART DIS, V8, P131, DOI 10.1111/j.1747-0803.2012.00714.x; May LE, 2016, EARLY HUM DEV, V94, P49, DOI 10.1016/j.earlhumdev.2016.01.005; Mills JL, 2010, AM J CLIN NUTR, V91, P1543, DOI 10.3945/ajcn.2009.28865; Moholdt TT, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-154; Moyer C, 2016, CLIN MED INSIGHTS-WO, V9, P37, DOI 10.4137/CMWh.s34670; Nwankwo MU, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e10; Penfold NC, 2015, HORM BEHAV, V76, P143, DOI 10.1016/j.yhbeh.2015.06.015; Reynolds RM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4539; Roberts VHJ, 2015, PHYSIOLOGY, V30, P224, DOI 10.1152/physiol.00021.2014; Sui ZX, 2013, INT J WOMENS HEALTH, V5, P389, DOI 10.2147/IJWH.S34042; Szymanski LM, 2012, OBSTET GYNECOL, V119, P603, DOI 10.1097/AOG.0b013e31824760b5; Voigt JU, 2015, EUR HEART J-CARD IMG, V16, P1, DOI 10.1093/ehjci/jeu184; von Ehr J, 2016, ARCH GYNECOL OBSTET, V294, P673, DOI 10.1007/s00404-016-4178-7; Wang JY, 2010, FASEB J, V24, P2066, DOI 10.1096/fj.09-142315; Zielinsky P, 2012, EARLY HUM DEV, V88, P273, DOI 10.1016/j.earlhumdev.2012.02.006	45	10	10	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0197334	10.1371/journal.pone.0197334	http://dx.doi.org/10.1371/journal.pone.0197334			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856768	gold, Green Published, Green Submitted			2023-01-03	WOS:000433900800020
J	Kim, MY; Yu, KR; Kenderian, SS; Ruella, M; Chen, S; Shin, TH; Aljanahi, AA; Schreeder, D; Klichinsky, M; Shestova, O; Kozlowski, MS; Cummins, KD; Shan, XH; Shestov, M; Bagg, A; Morrissette, JJD; Sekhri, P; Lazzarotto, CR; Calvo, KR; Kuhns, DB; Donahue, RE; Behbehani, GK; Tsai, SQ; Dunbar, CE; Gill, S				Kim, Miriam Y.; Yu, Kyung-Rok; Kenderian, Saad S.; Ruella, Marco; Chen, Shirley; Shin, Tae-Hoon; Aljanahi, Aisha A.; Schreeder, Daniel; Klichinsky, Michael; Shestova, Olga; Kozlowski, Miroslaw S.; Cummins, Katherine D.; Shan, Xinhe; Shestov, Maksim; Bagg, Adam; Morrissette, Jennifer J. D.; Sekhri, Palak; Lazzarotto, Cicera R.; Calvo, Katherine R.; Kuhns, Douglas B.; Donahue, Robert E.; Behbehani, Gregory K.; Tsai, Shengdar Q.; Dunbar, Cynthia E.; Gill, Saar			Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia	CELL			English	Article							CHIMERIC ANTIGEN RECEPTORS; CLONAL TRACKING; CYTOMETRY DATA; SPECIFICITY; TARGET; CAS9; PHOSPHATASES; BINDING; LECTIN; SHP-1	The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity.	[Kim, Miriam Y.; Ruella, Marco; Klichinsky, Michael; Shestova, Olga; Kozlowski, Miroslaw S.; Cummins, Katherine D.; Shan, Xinhe; Gill, Saar] Hosp Univ Penn, Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA; [Yu, Kyung-Rok; Chen, Shirley; Shin, Tae-Hoon; Aljanahi, Aisha A.; Donahue, Robert E.; Dunbar, Cynthia E.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; [Kenderian, Saad S.] Mayo Clin, Div Hematol, Rochester, MN 55905 USA; [Aljanahi, Aisha A.] Georgetown Univ, Dept Chem & Mol & Cellular Biol, Washington, DC 20057 USA; [Schreeder, Daniel; Gill, Saar] Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Shestov, Maksim] Univ Penn, Genom & Computat Biol Grad Grp, Philadelphia, PA 19104 USA; [Bagg, Adam; Morrissette, Jennifer J. D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Sekhri, Palak; Behbehani, Gregory K.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Lazzarotto, Cicera R.; Tsai, Shengdar Q.] St Jude Childrens Res Hosp, Dept Hematol, 332 N Lauderdale, Memphis, TN 38105 USA; [Calvo, Katherine R.] NIH, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Kuhns, Douglas B.] Frederick Natl Lab Canc Res, Leidos Biomed Res, Clin Serv Program, Frederick, MD 21701 USA; [Behbehani, Gregory K.] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA; [Kim, Miriam Y.] Washington Univ, Sch Med, Dept Med, Oncol Div, St Louis, MO 63110 USA	University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic; Georgetown University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; Ohio State University; Washington University (WUSTL)	Gill, S (corresponding author), Hosp Univ Penn, Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.; Dunbar, CE (corresponding author), NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.; Gill, S (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	dunbarc@nhlbi.nih.gov; saargill@pennmedicine.upenn.edu	Ruella, Marco/GQP-8473-2022; Bagg, Adam/R-8450-2019; Tsai, Shengdar Q./G-4600-2012; Sekhri, Palak/AAF-3636-2021; Lazzarotto, Cicera/AAG-4259-2020; Yu, Kyung-Rok/AAR-6227-2021	Tsai, Shengdar Q./0000-0001-9161-3993; Sekhri, Palak/0000-0001-8178-8562; Yu, Kyung-Rok/0000-0002-4685-3223; AlJanahi, Aisha/0000-0002-2345-5070; Ruella, Marco/0000-0003-4301-5811; Cummins, Katherine/0000-0001-9041-0828; Calvo, Katherine/0000-0002-0771-4191; Kim, Miriam Yunhee/0000-0001-9609-0685	Leukemia & Lymphoma Society (SCOR grant); National Institute of Health [1 K08 CA194256-01]; Korean Visiting Scientist Training Award; Intramural Research Program of the NHLBI; NATIONAL CANCER INSTITUTE [P30CA016058, K08CA194256] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZICHL002338, ZIGHL006020, ZIAHL002339] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL090025] Funding Source: NIH RePORTER	Leukemia & Lymphoma Society (SCOR grant); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korean Visiting Scientist Training Award; Intramural Research Program of the NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER	We thank Peter Klein, Robert Vonderheide, and Carl June for constructive comments; Yangbing Zhao, Jiangtao Ren, and Jian Huang for technical assistance; Sam Sadigh for photomicroscopy; Amy Ziober and Li Ping for immunocytochemistry; Vania Aikawa for cytogenetic analysis; Taehyong Kim, Zhiping (Paul) Wang, and Jonathan Schug for assistance with analysis of NGS; Mary Sell and Sam Mignogno for providing human apheresis specimens; NHLBI DNA Sequencing and Genomics and the NHLBI Flow Cytometry Cores; Naoya Uchida and John Tisdale for providing control bone marrow; Mark Raffeld, Liqiang Xi, and Chingiz Underbayev for ddPCR consultation and technical assistance; Keyvan Keyvanfar, Stephanie Sellers, Lemlem Alemu, and Jun Zhu for technical assistance; Ilker Tunc for off-target prediction; Aylin Bonifacino for RM CD34+ immunoselections; and Allen Krouse, Mark Metzger, Sandra Price, and the veterinary staff for care of the macaques. This work was supported by the Leukemia & Lymphoma Society (SCOR grant; S.G.), the National Institute of Health (1 K08 CA194256-01; S.G.), the Korean Visiting Scientist Training Award (K.-R.Y.), and the Intramural Research Program of the NHLBI.	Appelbaum FR, 2017, BLOOD, V130, P2373, DOI 10.1182/blood-2017-09-797712; Brinkman-Vand der Linden ECM, 2003, MOL CELL BIOL, V23, P4199, DOI 10.1128/MCB.23.12.4199-4206.2003; Cao HA, 2011, IMMUNOLOGY, V132, P18, DOI 10.1111/j.1365-2567.2010.03368.x; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026; Donahue Robert E, 2005, Curr Protoc Immunol, VChapter 22, DOI 10.1002/0471142735.im22a01s69; Dutour A, 2012, Adv Hematol, V2012, P683065, DOI 10.1155/2012/683065; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808; Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420; Gill S, 2014, BLOOD, V123, P2343, DOI 10.1182/blood-2013-09-529537; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Ishida A, 2014, J BIOL CHEM, V289, P25341, DOI 10.1074/jbc.M113.523480; Kenderian SS, 2015, LEUKEMIA, V29, P1637, DOI 10.1038/leu.2015.52; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; Kotecha N., 2010, CURR PROTOC CYTOM, DOI DOI 10.1002/0471142956.CY1017S53; Laszlo GS, 2014, BLOOD REV, V28, P143, DOI 10.1016/j.blre.2014.04.001; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Leong SR, 2017, BLOOD, V129, P609, DOI 10.1182/blood-2016-08-735365; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Mardiros A, 2013, BLOOD, V122, P3138, DOI 10.1182/blood-2012-12-474056; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Narasimhan VM, 2016, SCIENCE, V352, P474, DOI 10.1126/science.aac8624; Nguyen DH, 2006, EXP HEMATOL, V34, P728, DOI 10.1016/j.exphem.2006.03.003; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; Ornatsky OI, 2008, J ANAL ATOM SPECTROM, V23, P463, DOI 10.1039/b710510j; Paul SP, 2000, BLOOD, V96, P483; Peterson CW, 2016, BLOOD, V127, P2416, DOI 10.1182/blood-2015-09-672337; Pinello L, 2016, NAT BIOTECHNOL, V34, P695, DOI 10.1038/nbt.3583; Pizzitola I, 2014, LEUKEMIA, V28, P1596, DOI 10.1038/leu.2014.62; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Saleheen D, 2017, NATURE, V544, P235, DOI 10.1038/nature22034; Scott DA, 2017, NAT MED, V23, P1095, DOI 10.1038/nm.4377; Shen B, 2014, NAT METHODS, V11, P399, DOI [10.1038/NMETH.2857, 10.1038/nmeth.2857]; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Stemmer M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124633; Sulem P, 2015, NAT GENET, V47, P448, DOI 10.1038/ng.3243; Tashiro H, 2017, MOL THER, V25, P2202, DOI 10.1016/j.ymthe.2017.05.024; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Tsai SQ, 2017, NAT METHODS, V14, P607, DOI [10.1038/nmeth.4278, 10.1038/NMETH.4278]; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Wang QS, 2015, MOL THER, V23, P184, DOI 10.1038/mt.2014.164; Wu CF, 2018, J EXP MED, V215, P217, DOI 10.1084/jem.20171341; Wu CF, 2014, CELL STEM CELL, V14, P486, DOI 10.1016/j.stem.2014.01.020; Yang LH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6507; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	49	213	235	3	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	2018	173	6					1439	+		10.1016/j.cell.2018.05.013	http://dx.doi.org/10.1016/j.cell.2018.05.013			34	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GH9KU	29856956	Bronze, Green Accepted			2023-01-03	WOS:000433989100016
J	Sabbatini, AK; Wright, B				Sabbatini, Amber K.; Wright, Brad			Excluding Observation Stays from Readmission Rates - What Quality Measures Are Missing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REDUCTION PROGRAM		[Sabbatini, Amber K.] Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA; [Wright, Brad] Univ Iowa, Dept Hlth Management & Policy, Iowa City, IA USA	University of Washington; University of Washington Seattle; University of Iowa	Sabbatini, AK (corresponding author), Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA.		Wright, Brad/AAA-5844-2019; Wright, Brad/H-1330-2013	Wright, Brad/0000-0002-2674-4951				Burke RE, 2013, JAMA INTERN MED, V173, P695, DOI 10.1001/jamainternmed.2013.171; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Micklos J, 2017, EC INVESTMENT JOURNE; Nuckols TK, 2017, J HOSP MED, V12, P443, DOI 10.12788/jhm.2751; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	5	25	25	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2018	378	22					2062	2065		10.1056/NEJMp1800732	http://dx.doi.org/10.1056/NEJMp1800732			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH5AL	29847758				2023-01-03	WOS:000433428000003
J	Moghadam, MG; Lamers-Karnebeek, FBG; Vonkeman, HE; ten Klooster, PM; Tekstra, J; Schilder, AM; Visser, H; Sasso, EH; Chernoff, D; Lems, WF; van Schaardenburg, DJ; Landewe, R; Moens, HJB; Radstake, TRDJ; van Riel, PLCM; van de Laar, MAFJ; Jansen, TL				Moghadam, Marjan Ghiti; Lamers-Karnebeek, Femke B. G.; Vonkeman, Harald E.; ten Klooster, Peter M.; Tekstra, Janneke; Schilder, Annemarie M.; Visser, Henk; Sasso, Eric H.; Chernoff, David; Lems, Willem F.; van Schaardenburg, Dirk-Jan; Landewe, Robert; Moens, Hein J. Bernelot; Radstake, Timothy R. D. J.; van Riel, Piet L. C. M.; van de Laar, Mart A. F. J.; Jansen, Tim L.		Dutch Natl POET Collaboration	Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment	PLOS ONE			English	Article							RADIOGRAPHIC PROGRESSION; RA; INFLIXIMAB; REMISSION; VALIDATION; THERAPY; DISCONTINUATION; ETANERCEPT; ADALIMUMAB; EFFICACY	Objective Successfully stopping or reducing treatment for patients with rheumatoid arthritis (RA) in low disease activity (LDA) may improve cost-effectiveness of care. We evaluated the multi-bio-marker disease activity (MBDA) score as a predictor of disease relapse after discontinuation of TNF inhibitor (TNFi) treatment. Methods 439 RA patients who were randomized to stop TNFi treatment in the POET study were analyzed post-hoc. Three indicators of disease relapse were assessed over 12 months: 1) restarting TNFi treatment, 2) escalation of any DMARD therapy and 3) physician-reported flare. MBDA score was assessed at baseline. Associations between MBDA score and disease relapse were examined using univariate analysis and multivariate logistic regression. Results At baseline, 50.1%, 35.3% and 14.6% of patients had low (<30), moderate (30-44) or high (>44) MBDA scores. Within 12 months, 49.9% of patients had restarted TNFi medication, 59.0% had escalation of any DMARD and 57.2% had >= 1 physician-reported flare. MBDA score was associated with each indicator of relapse. At least one indicator of relapse was observed in 59.5%, 68.4% and 81.3% of patients with low, moderate or high MBDA scores, respectively (P = 0.004). Adjusted for baseline DAS28-ESR, disease duration, BMI and erosions, high MBDA scores were associated with increased risk for restarting TNFi treatment (OR = 1.85, 95% CI 1.00-3.40), DMARD escalation (OR = 1.99, 95% CI 1.01-3.94) and physician-reported flare (OR = 2.00, 95% 1.06-3.77). Conclusion For RA patients with stable LDA who stopped TNFi, a high baseline MBDA score was independently predictive of disease relapse within 12 months. The MBDA score may be useful for identifying patients at risk of relapse after TNFi discontinuation.	[Moghadam, Marjan Ghiti; Vonkeman, Harald E.; van de Laar, Mart A. F. J.] Med Spectrum Twente, Dept Rheumatol, Enschede, Netherlands; [Moghadam, Marjan Ghiti; Vonkeman, Harald E.; ten Klooster, Peter M.; van de Laar, Mart A. F. J.] Univ Twente, Dept Psychol Hlth & Technol, Enschede, Netherlands; [Lamers-Karnebeek, Femke B. G.] Radboud Univ Nijmegen, Dept Rheumatol, Med Ctr, Nijmegen, Netherlands; [Tekstra, Janneke; Radstake, Timothy R. D. J.] Univ Med Ctr Utrecht, Dept Rheumatol, Utrecht, Netherlands; [Schilder, Annemarie M.] Med Ctr Leeuwarden, Dept Rheumatol, Leeuwarden, Netherlands; [Visser, Henk] Rijnstate, Dept Rheumatol, Arnhem, Netherlands; [Sasso, Eric H.; Chernoff, David] Crescendo Biosci Inc, San Francisco, CA USA; [Lems, Willem F.] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands; [van Schaardenburg, Dirk-Jan] Jan Breemen Res Inst Reade, Dept Rheumatol, Amsterdam, Netherlands; [Landewe, Robert] AMC Amsterdam, Dept Rheumatol, Amsterdam, Netherlands; [Moens, Hein J. Bernelot] Ziekenhuis Groep Twente, Dept Rheumatol, Hengelo, Netherlands; [van Riel, Piet L. C. M.] Radboud Univ Nijmegen, Med Ctr, Dept IQ Healthcare, Nijmegen, Netherlands; [Jansen, Tim L.] VieCuri Med Ctr, Dept Rheumatol, Venlo, Netherlands	Medical Spectrum Twente; University of Twente; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Medical Center Leeuwarden; Rijnstate Hospital; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen; VieCuri Medical Center	Moghadam, MG (corresponding author), Med Spectrum Twente, Dept Rheumatol, Enschede, Netherlands.; Moghadam, MG (corresponding author), Univ Twente, Dept Psychol Hlth & Technol, Enschede, Netherlands.	M.Ghiti@mst.nl	LANDEWE, ROBERT B.M./ABD-7388-2021; Jansen, Tim/ABE-8812-2020; Klooster, Peter M. ten/D-2905-2009	LANDEWE, ROBERT B.M./0000-0002-0577-6620; Klooster, Peter M. ten/0000-0002-2565-5439	Crescendo Bioscience	Crescendo Bioscience	ZonMw/VVVS had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Crescendo Bioscience funded the shipping of serum samples to its laboratory and the generation of biomarker data, and provided support in the form of salary for one author [EHS] and consulting fee for another [DC], but did not have any additional role in the study design, data collection or decision to publish the manuscript. Authors EHS and DC participated in designing analyses and preparing the manuscript for this study. The specific roles of these authors are articulated in the 'author contributions' section.	Bakker MF, 2012, ANN RHEUM DIS, V71, P1692, DOI 10.1136/annrheumdis-2011-200963; Centola M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060635; Chen YF, 2006, HEALTH TECHNOL ASSES, V10, P1, DOI 10.3310/hta10420; Curtis JR, 2012, ARTHRIT CARE RES, V64, P1794, DOI 10.1002/acr.21767; Eastman PS, 2012, J PHARMACEUT BIOMED, V70, P415, DOI 10.1016/j.jpba.2012.06.003; Ghiti Moghadam Marjan, 2016, Arthritis Rheumatol, V68, P1810, DOI 10.1002/art.39626; Hambardzumyan K, 2015, ANN RHEUM DIS, V74, P1102, DOI 10.1136/annrheumdis-2013-204986; Harigai M, 2012, MOD RHEUMATOL, V22, P814, DOI 10.1007/s10165-011-0586-5; Hirata S, 2015, MOD RHEUMATOL, V25, P344, DOI 10.3109/14397595.2014.958893; Hirata S, 2013, RHEUMATOLOGY, V52, P1202, DOI 10.1093/rheumatology/kes362; Kavanaugh A, 2015, ANN RHEUM DIS, V74, P1150, DOI 10.1136/annrheumdis-2014-206435; Kvien TK, 2004, PHARMACOECONOMICS, V22, P1, DOI 10.2165/00019053-200422001-00002; Lee YC, 2016, RHEUMATOLOGY, V55, P640, DOI 10.1093/rheumatology/kev388; Li WY, 2016, RHEUMATOLOGY, V55, P357, DOI 10.1093/rheumatology/kev341; McInnes IB, 2010, ANN RHEUM DIS, V69, P1898, DOI 10.1136/ard.2010.134684; van der Helm-van Mil AHM, 2013, RHEUMATOLOGY, V52, P839, DOI 10.1093/rheumatology/kes378; Nam JL, 2014, ANN RHEUM DIS, V73, P516, DOI 10.1136/annrheumdis-2013-204577; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Rech J, 2016, ANN RHEUM DIS, V75, P1637, DOI 10.1136/annrheumdis-2015-207900; Saleem B, 2010, ANN RHEUM DIS, V69, P1636, DOI 10.1136/ard.2009.117341; Tanaka Y, 2010, ANN RHEUM DIS, V69, P1286, DOI 10.1136/ard.2009.121491; Tanaka Y, 2013, ANN RHEUM DIS, V72, P124, DOI 10.1136/annrheumdis-2012-202350; Tanaka Y, 2012, CURR OPIN RHEUMATOL, V24, P319, DOI 10.1097/BOR.0b013e3283524e4c; van den Broek M, 2011, ANN RHEUM DIS, V70, P1389, DOI 10.1136/ard.2010.147751; van den Broek M, 2013, CURR OPIN PHARMACOL, V13, P463, DOI 10.1016/j.coph.2013.03.006; van der Maas A, 2013, ANN RHEUM DIS, V72, P1800, DOI 10.1136/annrheumdis-2012-202281; van Ingen ILA, 2014, EXPERT OPIN BIOL TH, V14, P1761, DOI 10.1517/14712598.2014.955009; Wiens A, 2010, PHARMACOTHERAPY, V30, P339, DOI 10.1592/phco.30.4.339	28	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2018	13	5							e0192425	10.1371/journal.pone.0192425	http://dx.doi.org/10.1371/journal.pone.0192425			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH0FF	29791439	Green Published, Green Submitted, gold			2023-01-03	WOS:000433077000001
J	Adams, JM				Adams, Jerome M.			Increasing Naloxone Awareness and Use The Role of Health Care Practitioners	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROGRAMS; OVERDOSE		[Adams, Jerome M.] US PHS, Washington, DC 20201 USA	United States Public Health Service	Adams, JM (corresponding author), Indiana State Dept Hlth, 2 N Meridian St,Sect 3A, Indianapolis, IN 46204 USA.	Jerome.Adams@hhs.gov						Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Center for Disease Control and Prevention, WID RANG ONL DAT EP; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; Office of the Surgeon General; US Department of Health and Human Services, SURG GEN ADV NAL OP; Substance Abuse and Mental Health Services Administration, HHS PUBL	7	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	2018	319	20					2073	2074		10.1001/jama.2018.4867	http://dx.doi.org/10.1001/jama.2018.4867			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG4PT	29621389				2023-01-03	WOS:000432679400014
J	Zeng, ZX; Jiang, X; Li, XY; Wells, A; Luo, Y; Neapolitan, R				Zeng, Zexian; Jiang, Xia; Li, Xiaoyu; Wells, Alan; Luo, Yuan; Neapolitan, Richard			Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; HYSTERECTOMY; MENOPAUSE; MORTALITY; SYMPTOMS; SOCIETY	Objective By the 1990s it became popular for women to use hormone therapy (HT) to ease menopause symptoms. Bioidentical estrogen and progesterone are supplements whose molecular structures are identical to what is made in the human body, while synthetic supplements are ones whose structures are not. After the Women's Health Initiative found that the combined use of the synthetics conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increased breast cancer risk, prescriptions for synthetic HT declined considerably. Since then there has been an increased interest in bioidentical HT; today there are a plethora of websites touting their benefits. However, no peer-reviewed articles support these claims. We performed a retrospective study with the objective of verifying the hypothesis that bioidentical HT is associated with decreased breast cancer risk than CEE & MPA. Methods We searched The Northwestern Medicine Enterprise Data Warehouse for women who initiated HT use after age 50. Women who did not take any HT drug after age 50 served as controls. Nine HT protocols were investigated for breast cancer risk. Results Significant results include CEE Alone is associated with decreased breast cancer risk (HR = 0.31), Other Synthetic Estrogen Alone is associated with increased breast cancer risk (HR = 1.49), Bioidentical Estrogen Alone is associated with decreased breast cancer risk(HR = 0.65), CEE & MPA is associated with reduced breast cancer risk (HR = 0.43), and CEE & MPA is associated with reduced breast cancer risk relative to Bioidentical Estrogen & Progesterone (HR = 0.25). Discussion Our results indicate CEE & MPA is superior to bioidentical HT as far as breast cancer risk. Furthermore, this combination is associated with decrease of breast cancer risk, contrary to previous findings. Additional retrospective studies are needed to confirm our results.	[Zeng, Zexian; Luo, Yuan; Neapolitan, Richard] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Jiang, Xia] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA; [Li, Xiaoyu] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA; [Wells, Alan] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Wells, Alan] Pittsburgh VA Hlth Syst, Pittsburgh, PA USA	Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Neapolitan, R (corresponding author), Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.	richard.neapolitan@northwestern.edu	zeng, zexian/AAK-4651-2021; Luo, Yuan/K-5563-2016	Luo, Yuan/0000-0003-0195-7456	National Library of Medicine [R01LM011663, R01LM011962]; NATIONAL LIBRARY OF MEDICINE [R01LM011962, R01LM011663] Funding Source: NIH RePORTER	National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This work was supported by the National Library of Medicine (https://www.nlm.nih.gov/, R01LM011663; and by the National Library of Medicine (https://www.nlm.nih.gov/), R01LM011962.	Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Avis NE, 2015, JAMA INTERN MED, V175, P531, DOI 10.1001/jamainternmed.2014.8063; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Files JA, 2011, MAYO CLIN PROC, V86, P673, DOI 10.4065/mcp.2010.0714; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Lyytinen H, 2006, OBSTET GYNECOL, V108, P1354, DOI 10.1097/01.AOG.0000241091.86268.6e; Lyytinen H, 2009, OBSTET GYNECOL, V113, P65, DOI 10.1097/AOG.0b013e31818e8cd6; Pinkerton JV, 2017, MENOPAUSE, V24, P728, DOI 10.1097/GME.0000000000000921; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Sood R, 2014, INT J WOMENS HEALTH, V6, P47, DOI 10.2147/IJWH.S38342; Stuenkel CA, 2015, J CLIN ENDOCR METAB, V100, P3975, DOI 10.1210/jc.2015-2236	17	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0197064	10.1371/journal.pone.0197064	http://dx.doi.org/10.1371/journal.pone.0197064			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF9WG	29768475	Green Published, gold, Green Submitted			2023-01-03	WOS:000432329200054
J	Qi, ZP; Xia, P; Pan, S; Zheng, S; Fu, C; Chang, YX; Ma, Y; Wang, JC; Yang, XY				Qi, Zhiping; Xia, Peng; Pan, Su; Zheng, Shuang; Fu, Chuan; Chang, Yuxin; Ma, Yue; Wang, Jincheng; Yang, Xiaoyu			Combined treatment with electrical stimulation and insulin-like growth factor-1 promotes bone regeneration in vitro	PLOS ONE			English	Article							MARROW STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST PROLIFERATION; TRANSGENIC MICE; STEM-CELLS; IGF-I; SCAFFOLDS; METAANALYSIS; KNOCKOUT; DELIVERY	Electrical stimulation (ES) and insulin-like growth factor-1 (IGF-1) are widely used in bone regeneration because of their osteogenic activity. However, the combined effects of ES and supplemental IGF-1 on the whole bone formation process remain unclear. In this study, fluorescence staining and an MTT assay were first utilized to observe the influence of ES and IGF-1 on MC3T3-E1 cell proliferation and adhesion in vitro. Subsequently, osteogenic differentiation was evaluated by the alkaline phosphatase activity (ALP) and the expression of osteogenic marker genes. In addition, cell mineralization was determined by alizarin red staining and scanning electron microscopy (SEM). We demonstrated that the MC3T3-E1 cell proliferation was significantly higher for treatments combining IGF-1 and ES than for treatments with IGF-1 alone. The combination of IGF-1 and ES increased the MC3T3-E1 cell ALP activity, the expression of osteogenesis-related genes and the calcium deposition with a clear dose-dependent effect. Our data show the synergistic effect of IGF-1 and ES in promoting the proliferation, differentiation and mineralization of MC3T3-E1 cells, which suggests that it would be more effective to combine the proper dose of IGF-1 with ES to promote local bone damage repair and regeneration.	[Qi, Zhiping; Xia, Peng; Pan, Su; Zheng, Shuang; Fu, Chuan; Chang, Yuxin; Wang, Jincheng; Yang, Xiaoyu] Jilin Univ, Dept Orthoped Surg, Hosp 2, Changchun, Jilin, Peoples R China; [Ma, Yue] Jilin Univ, Dept Gynecol Oncol, Hosp 1, Changchun, Jilin, Peoples R China	Jilin University; Jilin University	Wang, JC; Yang, XY (corresponding author), Jilin Univ, Dept Orthoped Surg, Hosp 2, Changchun, Jilin, Peoples R China.	jinchengwang@hotmail.com; yangxiaoyu88@sina.com		Wang, Jincheng/0000-0002-1217-5962	National Natural Science Foundation of China [81672263, 31572217]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81672263 to XY, and No. 31572217).; This study was supported by the by the National Natural Science Foundation of China, No.81672263, No.31572217.	Aleem IS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31724; Azimi O, 2011, MOLECULES, V16, P9792, DOI 10.3390/molecules16129792; Blanquer A, 2018, J BIOMED MATER RES B, V106, P834, DOI 10.1002/jbm.b.33892; Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243; Chen FM, 2009, BIOMATERIALS, V30, P5215, DOI 10.1016/j.biomaterials.2009.06.009; Chen L, 2016, BMB REP, V49, P122, DOI 10.5483/BMBRep.2016.49.2.228; Chisalita SI, 2017, ORTHOP SURG, V9, P380, DOI 10.1111/os.12358; Choi GH, 2014, MACROMOL BIOSCI, V14, P496, DOI 10.1002/mabi.201300368; Ciombor Deborah McK, 2005, Foot Ankle Clin, V10, P579, DOI 10.1016/j.fcl.2005.06.006; Cook JJ, 2015, CLIN PODIATR MED SUR, V32, P45, DOI 10.1016/j.cpm.2014.09.003; Di Luca A, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700072; Doorn J, 2013, TISSUE ENG PT A, V19, P1817, DOI [10.1089/ten.tea.2012.0522, 10.1089/ten.TEA.2012.0522]; Duruel T, 2017, INT J BIOL MACROMOL, V104, P232, DOI 10.1016/j.ijbiomac.2017.06.029; Ebrahim S, 2014, CAN J SURG, V57, pE105, DOI 10.1503/cjs.010113; Eriksen EF, 1996, EUR J CLIN INVEST, V26, P525, DOI 10.1046/j.1365-2362.1996.00292.x; Feng XM, 2014, DEV GROWTH DIFFER, V56, P615, DOI 10.1111/dgd.12179; Goldstein C, 2010, J ORTHOP TRAUMA, V24, pS62, DOI 10.1097/BOT.0b013e3181cdde1b; Griffin MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023085; Guerra-Menendez L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-271; Haddad JB, 2007, J ALTERN COMPLEM MED, V13, P485, DOI 10.1089/acm.2007.5270; Jeong WK, 2008, J BIOMED MATER RES A, V86A, P1137, DOI 10.1002/jbm.a.32068; Jiang J, 2006, BONE, V39, P494, DOI 10.1016/j.bone.2006.02.068; Kim S, 2012, ACTA BIOMATER, V8, P1768, DOI 10.1016/j.actbio.2012.01.009; Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441-009-0832-8; Kotwal A, 2001, BIOMATERIALS, V22, P1055, DOI 10.1016/S0142-9612(00)00344-6; Levin M, 2009, SEMIN CELL DEV BIOL, V20, P543, DOI 10.1016/j.semcdb.2009.04.013; Mobini S, 2017, PEERJ, V5, DOI 10.7717/peerj.2821; Naskar D, 2017, BIOMATERIALS, V136, P67, DOI 10.1016/j.biomaterials.2017.05.014; Park HR, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421205; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Ren Q, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176520, 10.1590/1414-431x20176520]; Rico-Llanos GA, 2017, J BIOMED MATER RES A, V105, P1867, DOI 10.1002/jbm.a.36051; Shu XL, 2017, J BIOMATER APPL, V32, P547, DOI 10.1177/0885328217737654; Sugumar A, 2004, INT J CANCER, V111, P293, DOI 10.1002/ijc.20253; Tahimic Candice G T, 2013, Front Endocrinol (Lausanne), V4, P6, DOI 10.3389/fendo.2013.00006; Thomas T, 1999, ENDOCRINOLOGY, V140, P5036, DOI 10.1210/en.140.11.5036; Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041; Walsh S, 2003, BONE, V33, P80, DOI 10.1016/S8756-3282(03)00165-0; Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005; Wang YP, 2016, PLOS GENET, V12, DOI [10.1371/journal.pgen.1005803, 10.1371/journal.pgen.1006390]; Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879; Wiesmann HP, 2001, BBA-MOL CELL RES, V1538, P28, DOI 10.1016/S0167-4889(00)00135-X; Yao WG, 2008, GROWTH HORM IGF RES, V18, P517, DOI 10.1016/j.ghir.2008.04.006; Yu M, 2017, J PERIODONTOL, V88, pE159, DOI 10.1902/jop.2017.170016; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhang W, 2012, CELL BIOCHEM FUNCT, V30, P297, DOI 10.1002/cbf.2801; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674	47	23	24	4	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0197006	10.1371/journal.pone.0197006	http://dx.doi.org/10.1371/journal.pone.0197006			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF3JM	29746517	Green Submitted, gold, Green Published			2023-01-03	WOS:000431851700054
J	Yu, N; Wei, YL; Zhu, Y; Zhu, N; Wang, YL; Zhang, HP; Sun, AD				Yu, Ning; Wei, Yu-long; Zhu, Yue; Zhu, Ning; Wang, Yan-li; Zhang, Hai-ping; Sun, Ai-dong			Integrated approach for identifying and evaluating the quality of Marsdenia tenacissima in the medicine market	PLOS ONE			English	Article							POLYOXYPREGNANE GLYCOSIDES; IDENTIFICATION; AUTHENTICATION; HERBS; LEAVES; PLANTS; ITS2	The accurate identification and quality evaluation of herbal medical plants is highly necessary to ensure their safety and efficacy. In present study, a new strategy combining DNA barcoding techniques with thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC) was proposed to facilitate the identification and quality control of M. tenacissima. In present work, the internal transcribed spacer 2 (ITS2) barcode was successfully used to identify 58 M. tenacissima samples and its adulterants. TLC successfully identified the other three M. tenacissima samples that failed to produce ITS2 regions. An adulterant was found in all the 62 samples. Moreover, the content of active medicinal ingredients is important for herbal plants quality. The content of tenacissoside H (TS-H) of M. tenacissima samples was determined by HPLC to range from 0.39% to 1.09%, which meets the criterion of the Chinese Pharmacopoeia. Thus, DNA barcoding coupled with TLC and HPLC is very promising to identify and evaluate the quality of M. tenacissima in the medicine market.	[Yu, Ning; Wei, Yu-long; Zhu, Yue; Zhu, Ning; Wang, Yan-li; Zhang, Hai-ping; Sun, Ai-dong] Beijing Forestry Univ, Coll Biol Sci & Technol, Beijing, Peoples R China; [Yu, Ning; Wei, Yu-long; Zhu, Yue; Zhu, Ning; Wang, Yan-li; Zhang, Hai-ping; Sun, Ai-dong] Beijing Forestry Univ, Beijing Key Lab Forest Food Proc & Safety, Beijing, Peoples R China	Beijing Forestry University; Beijing Forestry University	Sun, AD (corresponding author), Beijing Forestry Univ, Coll Biol Sci & Technol, Beijing, Peoples R China.; Sun, AD (corresponding author), Beijing Forestry Univ, Beijing Key Lab Forest Food Proc & Safety, Beijing, Peoples R China.	adsun@bjfu.edu.cn			Forestry public welfare industry research special funds [201504606]	Forestry public welfare industry research special funds	This research work was supported by Forestry public welfare industry research special funds (No. 201504606).	Briskin DP, 2000, PLANT PHYSIOL, V124, P507, DOI 10.1104/pp.124.2.507; Chen JJ, 2008, TALANTA, V77, P152, DOI 10.1016/j.talanta.2008.05.054; Chen SL, 2014, BIOTECHNOL ADV, V32, P1237, DOI 10.1016/j.biotechadv.2014.07.004; Chen SL, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008613, 10.1371/journal.pone.0015633]; Chiou SJ, 2007, PLANTA MED, V73, P1421, DOI 10.1055/s-2007-990227; Coleman AW, 2007, NUCLEIC ACIDS RES, V35, P3322, DOI 10.1093/nar/gkm233; Deng J, 2005, PHYTOCHEMISTRY, V66, P1040, DOI 10.1016/j.phytochem.2005.03.018; Deng J, 2006, J CHROMATOGR A, V1116, P83, DOI 10.1016/j.chroma.2006.03.021; Donno D, 2015, J FUNCT FOODS, V18, P1070, DOI 10.1016/j.jff.2014.05.020; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Gao T, 2010, J ETHNOPHARMACOL, V130, P116, DOI 10.1016/j.jep.2010.04.026; Han JP, 2016, SCI REP, P6; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; Jiang LL, 2016, J PHARMACEUT BIOMED, V129, P398, DOI 10.1016/j.jpba.2016.07.030; Keller A, 2009, GENE, V430, P50, DOI 10.1016/j.gene.2008.10.012; Kim HJ, 2010, ARCH PHARM RES, V33, P1355, DOI 10.1007/s12272-010-0909-7; Kress WJ, 2005, P NATL ACAD SCI USA, V102, P8369, DOI 10.1073/pnas.0503123102; Lahaye R, 2008, P NATL ACAD SCI USA, V105, P2923, DOI 10.1073/pnas.0709936105; Li M, 2011, J SYST EVOL, V49, P271, DOI 10.1111/j.1759-6831.2011.00132.x; Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035146; Lo YT, 2015, CHIN MED-UK, V10, DOI 10.1186/s13020-015-0029-x; LUO SQ, 1993, PHYTOCHEMISTRY, V34, P1615, DOI 10.1016/S0031-9422(00)90856-2; Marichamy K., 2014, SCI PARK, V1, P23218045, DOI [DOI 10.9780/23218045/1202013/49, 10.9780/23218045/1202013/49]; Meyer CP, 2005, PLOS BIOL, V3, P2229, DOI 10.1371/journal.pbio.0030422; Mishra P, 2016, PLANT BIOTECHNOL J, V14, P8, DOI 10.1111/pbi.12419; Newmaster SG, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-222; Poornima B., 2010, IJRAP, V1, P8; Sasidharan S, 2011, AFR J TRADIT COMPLEM, V8, P1; State Pharmacopoeia Committee, 2015, MARSD TEN ROXB, P296; Sun ZY, 2013, J NAT MED-TOKYO, V67, P296, DOI 10.1007/s11418-012-0681-8; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]; van Beek TA, 2009, J CHROMATOGR A, V1216, P2002, DOI 10.1016/j.chroma.2009.01.013; Xin TY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08337; Xin TY, 2013, FOOD RES INT, V54, P1699, DOI 10.1016/j.foodres.2013.10.007; Xu CJ, 2015, FOOD CHEM, V186, P83, DOI 10.1016/j.foodchem.2014.11.042; Yu N, 2016, MOLECULES, V21, DOI 10.3390/molecules21091221; Zhang Hailing, 2009, BMJ Case Rep, V2009, DOI 10.1136/bcr.09.2008.1016	37	11	11	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2018	13	4							e0195240	10.1371/journal.pone.0195240	http://dx.doi.org/10.1371/journal.pone.0195240			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB9FN	29624609	gold, Green Published, Green Submitted			2023-01-03	WOS:000429379600020
J	Wang, E; Sorolla, A; Cunningham, PT; Bogdawa, HM; Beck, S; Golden, E; Dewhurst, RE; Florez, L; Cruickshank, MN; Hoffmann, K; Hopkins, RM; Kim, J; Woo, AJ; Watt, PM; Blancafort, P				Wang, Edina; Sorolla, Anabel; Cunningham, Paula T.; Bogdawa, Heique M.; Beck, Samuel; Golden, Emily; Dewhurst, Robert E.; Florez, Laura; Cruickshank, Mark N.; Hoffmann, Katrin; Hopkins, Richard M.; Kim, Jonghwan; Woo, Andrew J.; Watt, Paul M.; Blancafort, Pilar			Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers	ONCOGENE			English	Article							BET BROMODOMAIN INHIBITORS; C-MYC; TRANSCRIPTION FACTOR; RESISTANCE; OMOMYC; MAX; CHEMOTHERAPY; ACTIVATION; EFFICACY; PROTEIN	Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome. Despite decades of research, attempts to effectively inhibit MYC, particularly with small molecules, still remain challenging due to the featureless nature of its protein structure. Herein, we describe the engineering of the dominant-negative MYC peptide (OmoMYC) linked to a functional penetrating 'Phylomer' peptide (FPPa) as a therapeutic strategy to inhibit MYC in TNBC. We found FPPa-OmoMYC to be a potent inducer of apoptosis (with IC50 from 1-2 mu M) in TNBC cells with negligible effects in non-tumorigenic cells. Transcriptome analysis of FPPa-OmoMYC-treated cells indicated that the fusion protein inhibited MYC-dependent networks, inducing dynamic changes in transcriptional, metabolic, and apoptotic processes. We demonstrated the efficacy of FPPa-OmoMYC in inhibiting breast cancer growth when injected orthotopically in TNBC allografts. Lastly, we identified strong pharmacological synergisms between FPPa-OmoMYC and chemotherapeutic agents. This study highlights a novel therapeutic approach to target highly aggressive and chemoresistant MYC-activated cancers.	[Wang, Edina; Sorolla, Anabel; Golden, Emily; Woo, Andrew J.; Blancafort, Pilar] QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia; [Wang, Edina; Sorolla, Anabel; Golden, Emily; Woo, Andrew J.; Blancafort, Pilar] Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia; [Wang, Edina; Sorolla, Anabel; Golden, Emily; Blancafort, Pilar] Univ Western Australia, Sch Human Sci, Crawley, WA 6009, Australia; [Cunningham, Paula T.; Bogdawa, Heique M.; Dewhurst, Robert E.; Florez, Laura; Hoffmann, Katrin; Hopkins, Richard M.; Watt, Paul M.] Phylog Pty Ltd, Subiaco, WA 6008, Australia; [Cunningham, Paula T.; Bogdawa, Heique M.; Dewhurst, Robert E.; Florez, Laura; Cruickshank, Mark N.; Hoffmann, Katrin; Watt, Paul M.] Univ Western Australia, Telethon Kids Inst, Subiaco, WA 6008, Australia; [Beck, Samuel; Kim, Jonghwan] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA; [Beck, Samuel] Kathryn W Davis Ctr Regenerat Biol & Med, MDI Biol Lab, Salsbury Cove, ME 04672 USA	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Texas System; University of Texas Austin	Blancafort, P (corresponding author), QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia.; Blancafort, P (corresponding author), Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia.; Blancafort, P (corresponding author), Univ Western Australia, Sch Human Sci, Crawley, WA 6009, Australia.; Watt, PM (corresponding author), Phylog Pty Ltd, Subiaco, WA 6008, Australia.; Watt, PM (corresponding author), Univ Western Australia, Telethon Kids Inst, Subiaco, WA 6008, Australia.	paul.watt@telethonkids.org.au; pilar.blancafort@uwa.edu.au	Sorolla, Anabel/E-2546-2012; Kim, Jonghwan/AAR-2815-2021; Wang, Edina/AAC-5455-2019	Sorolla, Anabel/0000-0001-8238-8763; Woo, Andrew/0000-0003-1198-6373; Golden, Emily/0000-0001-6386-201X; Blancafort, Pilar/0000-0002-3881-7396; Kim, Jonghwan/0000-0002-9919-9843; Wang, Edina/0000-0002-9652-3513; Dewhurst, Robert/0000-0001-8441-4427; Beck, Samuel/0000-0002-0184-8367; Cruickshank, Mark/0000-0002-1869-1175	ARC Future Fellowship [FT130101767]; CCWA Research Fellowship; NHMRC [APP1069308]; NIH [R01CA170370, R01DA036906]; NCBF [NC-14-024]; RPHMRF; CCWA;  [R01GM112722]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104318, R01GM112722] Funding Source: NIH RePORTER	ARC Future Fellowship(Australian Research Council); CCWA Research Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCBF; RPHMRF; CCWA(Cancer Council Western Australia); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following grants awarded to PB: the ARC Future Fellowship FT130101767, the CCWA Research Fellowship, NHMRC grant APP1069308, NIH grants R01CA170370, R01DA036906, and the NCBF NC-14-024. JK is supported by R01GM112722. AJW is supported by the RPHMRF and the CCWA. AS is supported by NCBF. We would like to acknowledge the Centre for Microscopy, Characterisation & Analysis, the FACS facility and the AGFR at Harry Perkins Institute.	Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bid HK, 2016, MOL CANCER THER, V15, P1018, DOI 10.1158/1535-7163.MCT-15-0567; Bidwell GL, 2006, BIOCHEM PHARMACOL, V71, P248, DOI 10.1016/j.bcp.2005.10.041; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cinar M, 2015, LEUKEMIA RES, V39, P730, DOI 10.1016/j.leukres.2015.04.003; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2016, CELL, V146, P904; DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Fletcher S, 2015, BBA-GENE REGUL MECH, V1849, P525, DOI 10.1016/j.bbagrm.2014.03.005; Galardi S, 2016, EMBO REP, V17, P1872, DOI 10.15252/embr.201541489; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Giorello L, 1998, CANCER RES, V58, P3654; Green AR, 2016, BRIT J CANCER, V114, P917, DOI 10.1038/bjc.2016.46; Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Hart JR, 2014, P NATL ACAD SCI USA, V111, P12556, DOI 10.1073/pnas.1319488111; HENDERSON IC, 1989, J CLIN ONCOL, V7, P560, DOI 10.1200/JCO.1989.7.5.560; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; HSU B, 1995, ONCOGENE, V11, P175; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jung LA, 2017, ONCOGENE, V36, P1911, DOI 10.1038/onc.2016.354; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Pereira CBL, 2017, CLIN BREAST CANCER, V17, P188, DOI 10.1016/j.clbc.2016.12.005; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Milech N, 2015, SCI REP-UK, V5, DOI 10.1038/srep18329; Milech Nadia, 2012, Methods Mol Biol, V899, P43, DOI 10.1007/978-1-61779-921-1_3; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Pan XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105381; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Sharma P, 2017, CLIN CANCER RES, V23, P649, DOI 10.1158/1078-0432.CCR-16-0162; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shi XR, 2016, P NATL ACAD SCI USA, V113, pE4558, DOI 10.1073/pnas.1608319113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sorolla A, 2016, NANOSCALE, V8, P9343, DOI 10.1039/c5nr08331a; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stellas D, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju320; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Watt PM, 2017, CURR OPIN CHEM BIOL, V38, P127, DOI 10.1016/j.cbpa.2017.03.016; Watt PM, 2009, FUTURE MED CHEM, V1, P257, DOI [10.4155/fmc.09.28, 10.4155/FMC.09.28]; Watt PM, 2006, NAT BIOTECHNOL, V24, P177, DOI 10.1038/nbt1190; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	74	37	38	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					140	150		10.1038/s41388-018-0421-y	http://dx.doi.org/10.1038/s41388-018-0421-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076412	hybrid, Green Accepted, Green Published			2023-01-03	WOS:000454775900010
J	Abbasi, J				Abbasi, Jennifer			Can Acupuncture Keep Women on Their Breast Cancer Drugs?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	1	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	2018	320	8					744	746		10.1001/jama.2018.11068	http://dx.doi.org/10.1001/jama.2018.11068			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR8HM	30090939				2023-01-03	WOS:000442958800002
J	Seyedsadjadi, N; Berg, J; Bilgin, AA; Braidy, N; Salonikas, C; Grant, R				Seyedsadjadi, Neda; Berg, Jade; Bilgin, Ayse A.; Braidy, Nady; Salonikas, Chris; Grant, Ross			High protein intake is associated with low plasma NAD(+) levels in a healthy human cohort	PLOS ONE			English	Article							OXIDATIVE STRESS; ENDOTHELIAL DYSFUNCTION; CALORIC RESTRICTION; KYNURENINE PATHWAY; LIFE-SPAN; METABOLISM; CELLS; CD38; INFLAMMATION; PERFORMANCE	High protein intake and reduced levels of the essential pyridine nucleotide nicotinamide adenine dinucleotide (NAD(+)) have both been independently associated with promotion of the ageing phenotype. However, it has not yet been shown whether these two independent observations are biochemically linked. To investigate this possibility, we used a cross-sectional study design of 100 apparently healthy middle-aged males (n = 48) and females, in which we assessed average dietary intakes of multiple components using a validated questionnaire. We also analysed fasting blood levels of urea, NAD(+) and its metabolites, and inflammation-linked biomarkers, including interleukin-6 (IL-6), Kynurenine (Kyn), and Tryptophan (Trp). One-way ANOVA and ANCOVA were then performed for statistical analysis. Our results have shown for the first time that plasma levels of NAD(+) and Total NAD(H) were lower with increasing protein intake (F (2, 92) = 4.61, P = 0.012; F (2, 92) = 4.55, P = 0.013, respectively). The associated decrease in NAD(+) and NAD(H) levels was even stronger with increasing plasma levels of the protein breakdown product urea (F (2, 93) = 25.11, P <= 0.001; F (2, 93) = 21.10, P <= 0.001). These associations were all independent of age, gender and energy intake. However, no significant association was observed between protein intake or plasma urea, and plasma levels of NAD(+) metabolites. We also observed that plasma levels of the inflammatory cytokine IL-6, and both Kyn, and Trp, but not the Kyn/Trp ratio were higher with increasing plasma urea levels (F (2, 94) = 3.30, P = 0.041; F (2, 95) = 7.41, P <= 0.001; F (2, 96) = 4.23, P = 0.017, respectively). These associations were dependent on eGFR and energy intake, except for the urea and Trp association that was independent of all. In conclusion, we report for the first time, a novel association between protein intake, its metabolism, and plasma NAD(+) levels with a possible link to inflammation. These findings provide further insight into how protein restriction may contribute to the anti-ageing process observed in several studies.	[Seyedsadjadi, Neda; Grant, Ross] Univ New South Wales, Fac Med, Sch Med Sci, Sydney, NSW, Australia; [Seyedsadjadi, Neda; Berg, Jade; Salonikas, Chris; Grant, Ross] Sydney Adventist Hosp, Australasian Res Inst, Sydney, NSW, Australia; [Bilgin, Ayse A.] Macquarie Univ, Dept Stat, Sydney, NSW, Australia; [Braidy, Nady] Univ New South Wales, Fac Med, Ctr Hlth Brain Ageing, Sch Psychiat, Sydney, NSW, Australia; [Grant, Ross] Univ Sydney, Sydney Adventist Hosp Clin Sch, Sydney, NSW, Australia	University of New South Wales Sydney; Sydney Adventist Hospital; Macquarie University; University of New South Wales Sydney; University of Sydney	Grant, R (corresponding author), Univ New South Wales, Fac Med, Sch Med Sci, Sydney, NSW, Australia.; Grant, R (corresponding author), Sydney Adventist Hosp, Australasian Res Inst, Sydney, NSW, Australia.; Grant, R (corresponding author), Univ Sydney, Sydney Adventist Hosp Clin Sch, Sydney, NSW, Australia.	r.grant@unsw.edu.au		Bilgin, Ayse/0000-0001-8760-5763; Braidy, Nady/0000-0002-0497-5572	Australasian Research Institute; University of New South Wales	Australasian Research Institute; University of New South Wales	This study was funded by internal funding from the Australasian Research Institute (received by RG) and student allocated funding from the University of New South Wales (received by NS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berger F, 2005, J BIOL CHEM, V280, P36334, DOI 10.1074/jbc.M508660200; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Braidy N, 2017, NEURAL REGEN RES, V12, P39, DOI 10.4103/1673-5374.198971; Braidy N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019194; Bustamante S, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-017-1310-z; Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023; Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222; CLARK JB, 1966, NATURE, V210, P631, DOI 10.1038/210631b0; D'Apolito M, 2015, ATHEROSCLEROSIS, V239, P393, DOI 10.1016/j.atherosclerosis.2015.01.034; De Ingeniis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039115; Eskelinen MH, 2011, DEMENT GER COGN D EX, V1, P103, DOI 10.1159/000327518; Fanson BG, 2009, AGING CELL, V8, P514, DOI 10.1111/j.1474-9726.2009.00497.x; Fontana L, 2016, CELL REP, V16, P520, DOI 10.1016/j.celrep.2016.05.092; Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020; Frasca L, 2006, BLOOD, V107, P2392, DOI 10.1182/blood-2005-07-2913; Gambini J, 2011, ARCH BIOCHEM BIOPHYS, V512, P24, DOI 10.1016/j.abb.2011.04.020; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; IBM Corp, 2015, IBM SPSS STAT WINDOW; Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19; KUBOTA H, 1982, J NUTR SCI VITAMINOL, V28, P57, DOI 10.3177/jnsv.28.57; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levine ME, 2014, CELL METAB, V19, P407, DOI 10.1016/j.cmet.2014.02.006; MacKay D, 2012, NUTR REV, V70, P357, DOI 10.1111/j.1753-4887.2012.00479.x; Massudi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042357; Massudi H, 2012, REDOX REP, V17, P28, DOI 10.1179/1351000212Y.0000000001; Menon RM, 2007, INT J CLIN PHARM TH, V45, P448; Merksamer PI, 2013, AGING-US, V5, P144, DOI 10.18632/aging.100544; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Pamplona R, 2006, BBA-BIOENERGETICS, V1757, P496, DOI 10.1016/j.bbabio.2006.01.009; Parrella E, 2013, AGING CELL, V12, P257, DOI 10.1111/acel.12049; Partida-Sanchez S, 2007, J IMMUNOL, V179, P7827, DOI 10.4049/jimmunol.179.11.7827; Pawlak D., 2001, International Urology and Nephrology, V33, P399, DOI 10.1023/A:1015238418500; Polletta L, 2015, AUTOPHAGY, V11, P253, DOI 10.1080/15548627.2015.1009778; Schweitzer K, 2001, ANAL BIOCHEM, V299, P218, DOI 10.1006/abio.2001.5419; Solon-Biet SM, 2014, CELL METAB, V19, P418, DOI 10.1016/j.cmet.2014.02.009; Song H, 2011, INT IMMUNOPHARMACOL, V11, P932, DOI 10.1016/j.intimp.2011.02.005; Speakman JR, 2016, EXP GERONTOL, V86, P28, DOI 10.1016/j.exger.2016.03.011; Nguyen-Pham TN, 2011, CELL MOL IMMUNOL, V8, P341, DOI 10.1038/cmi.2011.7; Thorpe JM, 1999, J NUTR, V129, P343, DOI 10.1093/jn/129.2.343; Wang QX, 2015, FRONT BIOSCI-LANDMRK, V20, P1116, DOI 10.2741/4363; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Zhao X, 2013, J MED CHEM, V56, P963, DOI 10.1021/jm301431y; Zhen QN, 2011, CLIN BIOCHEM, V44, P226, DOI 10.1016/j.clinbiochem.2010.10.011; Zhu XH, 2015, P NATL ACAD SCI USA, V112, P2876, DOI 10.1073/pnas.1417921112	48	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0201968	10.1371/journal.pone.0201968	http://dx.doi.org/10.1371/journal.pone.0201968			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ6RF	30114226	Green Published, gold, Green Submitted			2023-01-03	WOS:000441850400035
J	Choi, S; Park, SG; Lee, HH				Choi, Suvin; Park, Sang-Gue; Lee, Hyung-Hwan			The analgesic effect of music on cold pressor pain responses: The influence of anxiety and attitude toward pain	PLOS ONE			English	Article							RELAXING MUSIC; PERCEPTION; ATTENTION; TRIALS; MODULATION; GUIDELINES; EMOTION; DESIGN; WOMEN; MOOD	Objective The analgesic effect of music has been recognized for pain relief, but individual differences and adjuvant methods are poorly understood. This study employed a cold-pressor task (CPT) to observe the effects of music (without considering personal preferences) on pain experience and how this is affected by individuals' general (and pain-specific) anxiety symptomology. Methods Fifty participants were each presented with three conditions (randomized into different orders): music-listening, news-listening, and no sound (control). Pain responses, including pain tolerance time (PT), pain intensity (PI), and pain unpleasantness (PU), were assessed using CPT and compared with a 3x3 crossover design. Participants also completed the anxiety sensitivity index (ASI-16) and pain anxiety symptom scale (PASS-20). Results CPT pain responses during the music intervention were significantly different from responses during the news intervention and control conditions, respectively. Among participants with normal anxiety levels, pain responses during the music condition differed significantly from the news and control groups; this was not the case for the anxiety risk group. Pain responses during the music condition for those with normal levels of pain-specific anxiety differed significantly from the control, but this was not the case for the risk group. Conclusions Music appears to influence diminished pain responses relative to the absence of an intervention. However, this was not the case when individuals listened to news stories. These effects were more robust for individuals experiencing normal levels of general and pain-specific anxiety. Thus, music (even outside one's own preferences) was an effective adjuvant method for managing pain, especially among those without significant anxiety symptomology.	[Choi, Suvin] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul, South Korea; [Choi, Suvin] Seoul Natl Univ, Inst Hlth & Environm, Seoul, South Korea; [Choi, Suvin] Chung Ang Univ, Da Vinci Coll Gen Educ, Seoul, South Korea; [Park, Sang-Gue] Chung Ang Univ, Dept Appl Stat, Seoul, South Korea; [Lee, Hyung-Hwan] Chung Ang Univ, Dept Tradit Mus, Anseong, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University; Chung Ang University	Park, SG (corresponding author), Chung Ang Univ, Dept Appl Stat, Seoul, South Korea.	spark@cau.ac.kr	PARK, Sang-Gue/V-7768-2019		National Research Foundation of Korea [900-20170053]	National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by National Research Foundation of Korea (https://www.nrf.re.kr/index) 900-20170053, Suvin Choi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Research was supported by National Research Foundation of Korea (900-20170053, awarded to Choi S). Authors thank the anonymous reviewers and the editor for their careful reading of the manuscript and their many valuable comments and suggestions.	Abrams MP, 2007, J PAIN, V8, P879, DOI 10.1016/j.jpain.2007.06.004; Baker M, 2016, NATURE, V531, P151, DOI 10.1038/nature.2016.19503; Bellan L, 2002, CAN J OPHTHALMOL, V37, P155, DOI 10.1016/S0008-4182(02)80057-6; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Bradt J, 2013, MUSIC INTERVENTIONS; Bradt J, 2012, J MUSIC THER, V49, P120, DOI 10.1093/jmt/49.2.120; Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Choi S, 2017, IEEEAAIA DIGIT AVION; Craig AD, 2011, ANN NY ACAD SCI, V1225, P72, DOI 10.1111/j.1749-6632.2011.05990.x; de Wied M, 2001, PAIN, V90, P163, DOI 10.1016/S0304-3959(00)00400-0; Finlay KA, 2016, PSYCHOL MUSIC, V44, P493, DOI 10.1177/0305735615577247; Fritz TH, 2018, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.02312; Garcia RL, 2016, PSYCHOL MUSIC, V44, P967, DOI 10.1177/0305735615602144; Guo W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136446; Janssen SA, 1998, PAIN, V76, P309, DOI 10.1016/S0304-3959(98)00060-8; Jones B., 2014, DESIGN ANAL CROSS OV; La Cesa S, 2014, MAGN RESON IMAGING, V32, P236, DOI 10.1016/j.mri.2013.12.003; Lim NK, 2005, BIOMETRICAL J, V47, P635, DOI 10.1002/bimj.200410144; McCracken Lance M, 2002, Pain Res Manag, V7, P45; Meeuse JJ, 2010, EUR J GASTROEN HEPAT, V22, P942, DOI 10.1097/MEG.0b013e328336ec6e; MERSKEY H, 1994, QUAL LIFE RES, V3, pS69, DOI 10.1007/BF00433379; Mitchell LA, 2006, EUR J PAIN, V10, P343, DOI 10.1016/j.ejpain.2005.03.005; Mitchell LA, 2006, J MUSIC THER, V43, P295, DOI 10.1093/jmt/43.4.295; Nilsson Ulrica, 2008, AORN J, V87, P780, DOI 10.1016/j.aorn.2007.09.013; RAUSCHER FH, 1993, NATURE, V365, P611, DOI 10.1038/365611a0; REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9; Roy M, 2008, PAIN, V134, P140, DOI 10.1016/j.pain.2007.04.003; Roy M, 2009, INT J PSYCHOPHYSIOL, V71, P37, DOI 10.1016/j.ijpsycho.2008.07.010; 최수빈, 2017, [Journal of Health Informatics and Statistics, 보건정보통계학회지], V42, P101, DOI 10.21032/jhis.2017.42.2.101; Schafer T., 2013, FRONTIERS PSYCHOL, V4; Tan XL, 2010, J BURN CARE RES, V31, P590, DOI 10.1097/BCR.0b013e3181e4d71b; Thibodeau MA, 2013, PAIN, V154, P419, DOI 10.1016/j.pain.2012.12.001; Thoma MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070156; Ventura T, 2012, PSYCHONEUROENDOCRINO, V37, P148, DOI 10.1016/j.psyneuen.2011.05.016; Villarreal EAG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029397; Villemure C, 2002, PAIN, V95, P195, DOI 10.1016/S0304-3959(02)00007-6; Villemure C, 2009, J NEUROSCI, V29, P705, DOI 10.1523/JNEUROSCI.3822-08.2009; von Baeyer CL, 2005, J PAIN, V6, P218, DOI 10.1016/j.jpain.2005.01.349; Warth M, 2015, NORD J MUSIC THER, V24, P344, DOI 10.1080/08098131.2014.987803; Weisenberg M, 1998, PAIN, V76, P365, DOI 10.1016/S0304-3959(98)00069-4; Won H., 1995, KOREAN J CLIN PSYCHO, V14, P95; Zusman M, 1986, Aust J Physiother, V32, P244, DOI 10.1016/S0004-9514(14)60658-9	43	4	4	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2018	13	8							e0201897	10.1371/journal.pone.0201897	http://dx.doi.org/10.1371/journal.pone.0201897			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP3UO	30080889	gold, Green Submitted, Green Published			2023-01-03	WOS:000440780000026
J	Sridhar, S; Luedtke, A; Langevin, E; Zhu, M; Bonaparte, M; Machabert, T; Savarino, S; Zambrano, B; Moureau, A; Khromava, A; Moodie, Z; Westling, T; Mascarenas, C; Frago, C; Cortes, M; Chansinghakul, D; Noriega, F; Bouckenooghe, A; Chen, J; Ng, SP; Gilbert, PB; Gurunathan, S; DiazGranados, CA				Sridhar, S.; Luedtke, A.; Langevin, E.; Zhu, M.; Bonaparte, M.; Machabert, T.; Savarino, S.; Zambrano, B.; Moureau, A.; Khromava, A.; Moodie, Z.; Westling, T.; Mascarenas, C.; Frago, C.; Cortes, M.; Chansinghakul, D.; Noriega, F.; Bouckenooghe, A.; Chen, J.; Ng, S. -P.; Gilbert, P. B.; Gurunathan, S.; DiazGranados, C. A.			Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; COHORT	BACKGROUND In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk estimates according to observed dengue serostatus could not be ascertained because of the limited numbers of samples collected at baseline. We developed a dengue anti-nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay and used samples from month 13 to infer serostatus for a post hoc analysis of safety and efficacy. METHODS In a case-cohort study, we reanalyzed data from three efficacy trials. For the principal analyses, we used baseline serostatus determined on the basis of measured (when baseline values were available) or imputed (when baseline values were missing) titers from a 50% plaque-reduction neutralization test (PRNT 50), with imputation conducted with the use of covariates that included the month 13 anti-NS1 assay results. The risk of hospitalization for virologically confirmed dengue (VCD), of severe VCD, and of symptomatic VCD according to dengue serostatus was estimated by weighted Cox regression and targeted minimum loss-based estimation. RESULTS Among dengue-seronegative participants 2 to 16 years of age, the cumulative 5-year incidence of hospitalization for VCD was 3.06% among vaccine recipients and 1.87% among controls, with a hazard ratio (vaccine vs. control) through data cutoff of 1.75 (95% confidence interval [CI], 1.14 to 2.70). Among dengue-seronegative participants 9 to 16 years of age, the cumulative incidence of hospitalization for VCD was 1.57% among vaccine recipients and 1.09% among controls, with a hazard ratio of 1.41 (95% CI, 0.74 to 2.68). Similar trends toward a higher risk among seronegative vaccine recipients than among seronegative controls were also found for severe VCD. Among dengue-seropositive participants 2 to 16 years of age and those 9 to 16 years of age, the cumulative incidence of hospitalization for VCD was 0.75% and 0.38%, respectively, among vaccine recipients and 2.47% and 1.88% among controls, with hazard ratios of 0.32 (95% CI, 0.23 to 0.45) and 0.21 (95% CI, 0.14 to 0.31). The risk of severe VCD was also lower among seropositive vaccine recipients than among seropositive controls. CONCLUSIONS CYD-TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated persons who had not been exposed to dengue.	[Sridhar, S.; Langevin, E.; Moureau, A.] Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France; [Machabert, T.] Soladis, Lyon, France; [Luedtke, A.; Moodie, Z.; Westling, T.; Gilbert, P. B.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Westling, T.; Gilbert, P. B.] Univ Washington, Seattle, WA 98195 USA; [Zhu, M.; Bonaparte, M.; Savarino, S.; Noriega, F.; Chen, J.; Gurunathan, S.; DiazGranados, C. A.] Sanofi Pasteur, Swiftwater, PA USA; [Zambrano, B.] Sanofi Pasteur, Montevideo, Uruguay; [Khromava, A.] Sanofi Pasteur, Toronto, ON, Canada; [Mascarenas, C.] Sanofi Pasteur, Mexico City, DF, Mexico; [Frago, C.; Bouckenooghe, A.; Ng, S. -P.] Sanofi Pasteur, Singapore, Singapore; [Cortes, M.] Sanofi Pasteur, Bogota, Colombia; [Chansinghakul, D.] Sanofi Pasteur, Bangkok, Thailand	Sanofi-Aventis; Sanofi France; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis	Sridhar, S (corresponding author), Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.	saranya.sridhar@sanofi.com		Luedtke, Alex/0000-0002-9936-3236; Sridhar, Saranya/0000-0002-4267-3102	Sanofi Pasteur	Sanofi Pasteur	Funded by Sanofi Pasteur	Arredondo-Garcia JL, 2018, CLIN MICROBIOL INFEC; BARLOW WE, 1994, BIOMETRICS, V50, P1064, DOI 10.2307/2533444; Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6; Coudeville L, 2016, VACCINE, V34, P6426, DOI 10.1016/j.vaccine.2016.08.050; Flasche S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002181; Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014; Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004; Hanna-Wakim R, 2009, J INFECT DIS, V200, P1921, DOI 10.1086/648375; HOLM S, 1979, SCAND J STAT, V6, P65; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Mizumoto K, 2014, J VECTOR DIS, V51, P153; Nascimento EJM, 2018, J VIROL METHODS, V257, P48, DOI 10.1016/j.jviromet.2018.03.007; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Stanaway JD, 2016, LANCET INFECT DIS, V16, P712, DOI 10.1016/S1473-3099(16)00026-8; van der Laan MJ, 2007, STAT APPL GENET MOL, V6, DOI 10.2202/1544-6115.1309; Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037; World Health Organization, 2018, REV SAGE REC US DENG; World Health Organization, 2017, UPD QUEST ANSW REL D	24	381	395	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 26	2018	379	4					327	340		10.1056/NEJMoa1800820	http://dx.doi.org/10.1056/NEJMoa1800820			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GO1YK	29897841	Bronze			2023-01-03	WOS:000439757700006
J	Hong, WS; Haimovich, AD; Taylor, RA				Hong, Woo Suk; Haimovich, Adrian Daniel; Taylor, R. Andrew			Predicting hospital admission at emergency department triage using machine learning	PLOS ONE			English	Article							HEALTH INFORMATION EXCHANGE; MEDICAL-RECORDS; BIG DATA; INDEX; VALIDITY; TEXT	Objective To predict hospital admission at the time of ED triage using patient history in addition to information collected at triage. Methods This retrospective study included all adult ED visits between March 2014 and July 2017 from one academic and two community emergency rooms that resulted in either admission or discharge. A total of 972 variables were extracted per patient visit. Samples were randomly partitioned into training (80%), validation (10%), and test (10%) sets. We trained a series of nine binary classifiers using logistic regression (LR), gradient boosting (XGBoost), and deep neural networks (DNN) on three dataset types: one using only triage information, one using only patient history, and one using the full set of variables. Next, we tested the potential benefit of additional training samples by training models on increasing fractions of our data. Lastly, variables of importance were identified using information gain as a metric to create a low-dimensional model. Results A total of 560,486 patient visits were included in the study, with an overall admission risk of 29.7%. Models trained on triage information yielded a test AUC of 0.87 for LR (95% Cl 0.860.87), 0.87 for XGBoost (95% Cl 0.87-0.88) and 0.87 for DNN (95% Cl 0.87-0.88). Models trained on patient history yielded an AUC of 0.86 for LR (95% Cl 0.86-0.87), 0.87 for XGBoost (95% Cl 0.87-0.87) and 0.87 for DNN (95% Cl 0.87-0.88). Models trained on the full set of variables yielded an AUC of 0.91 for LR (95% Cl 0.91-0.91), 0.92 for XGBoost (95% Cl 0.92-0.93) and 0.92 for DNN (95% Cl 0.92-0.92). All algorithms reached maximum performance at 50% of the training set or less. A low-dimensional XGBoost model built on ESI level, outpatient medication counts, demographics, and hospital usage statistics yielded an AUC of 0.91 (95% Cl 0.91-0.91). Conclusion Machine learning can robustly predict hospital admission using triage information and patient history. The addition of historical information improves predictive performance significantly compared to using triage information alone, highlighting the need to incorporate these variables into prediction models.	[Hong, Woo Suk; Haimovich, Adrian Daniel] Yale Sch Med, New Haven, CT USA; [Taylor, R. Andrew] Yale Sch Med, Dept Emergency Med, New Haven, CT 06510 USA	Yale University; Yale University	Taylor, RA (corresponding author), Yale Sch Med, Dept Emergency Med, New Haven, CT 06510 USA.	richard.taylor@yale.edu	PAN, ZEQIANG/X-6341-2018	/0000-0002-9082-6644	James G. Hirsch Endowed Medical Student Research Fellowship at Yale University School of Medicine; National Institutes of Health [1F30CA196191, T32GM007205]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	James G. Hirsch Endowed Medical Student Research Fellowship at Yale University School of Medicine; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	WH is supported by the James G. Hirsch Endowed Medical Student Research Fellowship at Yale University School of Medicine. AH is supported by National Institutes of Health grants 1F30CA196191 and T32GM007205. RT received no specific funding for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acuna E, 2004, ST CLASS DAT ANAL, P639; Adams JG, 2016, JAMA-J AM MED ASSOC, V315, P659, DOI 10.1001/jama.2015.19484; Arnold TB, 2017, J OPEN SOURCE SOFTWA, DOI [10.21105/joss.00231, DOI 10.21105/JOSS.00231, 10.21105/joss.00296, DOI 10.21105/JOSS.00296]; Banerjee A, 2011, INT J EMERG MED, V4, DOI 10.1186/1865-1380-4-22; Bara-Corren Y, 2017, EMERG MED J, V34, P308, DOI 10.1136/emermed-2014-203819; Barak-Corren Y, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2785; Baumann MR, 2007, ANN EMERG MED, V49, P234, DOI 10.1016/j.annemergmed.2006.04.011; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Cameron A, 2018, EMERG MED J, V35, P247, DOI 10.1136/emermed-2017-207246; Cameron A, 2017, EMERG MED J, V34, P2, DOI 10.1136/emermed-2014-204455; Chen Tianqi, 2016, KDD 16 P 22 ACM SIGK; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Desautels T, 2016, JMIR MED INF, V4, P67, DOI 10.2196/medinform.5909; Dinh MM, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0111-4; Ebker-White AA, 2018, EMERG MED AUSTRALAS, V30, P511, DOI 10.1111/1742-6723.12940; Ford E, 2016, J AM MED INFORM ASSN, V23, P1007, DOI 10.1093/jamia/ocv180; Guyon I., 2003, J MACH LEARN RES, V3, P1157, DOI 10.5555/944919.944968; Hohl CM, 2001, ANN EMERG MED, V38, P666, DOI 10.1067/mem.2001.119456; Horng S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174708; Jiang HJ, 2009, HCUP STAT BRIEF 72; Kangovi S, 2013, HEALTH AFFAIR, V32, P1196, DOI 10.1377/hlthaff.2012.0825; Kuhn M., 2013, APPL PREDICTIVE MODE, P27; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Leegon Jeffrey, 2006, AMIA Annu Symp Proc, P1004; Leegon Jeffrey, 2005, AMIA Annu Symp Proc, P1022; Levin S, 2018, ANN EMERG MED, V71, P565, DOI 10.1016/j.annemergmed.2017.08.005; Lin JH, 2008, J BIOMED INFORM, V41, P1, DOI 10.1016/j.jbi.2007.06.001; Lucini FR, 2017, INT J MED INFORM, V100, P1, DOI 10.1016/j.ijmedinf.2017.01.001; Lucke JA, 2018, EMERG MED J, V35, P18, DOI 10.1136/emermed-2016-205846; Moons KGM, 2012, HEART, V98, P683, DOI 10.1136/heartjnl-2011-301246; Obermeyer Z, 2016, NEW ENGL J MED, V375, P1216, DOI 10.1056/NEJMp1606181; Peck JS, 2012, ACAD EMERG MED, V19, pE1045, DOI 10.1111/j.1553-2712.2012.01435.x; Poulin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085733; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415; Sabbatini AK, 2016, JAMA-J AM MED ASSOC, V315, P663, DOI 10.1001/jama.2016.0649; Savage D., 2017, CAN J EMERG MED, V19, pS116, DOI [10.1017/cem.2017.314, DOI 10.1017/CEM.2017.314]; Schenkel SM, 2018, ANN EMERG MED, V71, P578, DOI 10.1016/j.annemergmed.2018.02.010; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; Shapiro JS, 2006, ANN EMERG MED, V48, P426, DOI 10.1016/j.annemergmed.2006.03.032; Shapiro JS, 2013, HEALTH AFFAIR, V32, P2193, DOI 10.1377/hlthaff.2013.0167; Stekhoven DJ, 2015, ASTROPHYS SOURCE COD; Sun Y, 2011, ACAD EMERG MED, V18, P844, DOI 10.1111/j.1553-2712.2011.01125.x; Tanabe P, 2004, ACAD EMERG MED, V11, P59, DOI 10.1197/S1069-6563(03)00585-2; Taylor RA, 2016, ACAD EMERG MED, V23, P269, DOI 10.1111/acem.12876; Weng SF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174944; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	52	97	98	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2018	13	7							e0201016	10.1371/journal.pone.0201016	http://dx.doi.org/10.1371/journal.pone.0201016			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN8GG	30028888	Green Published, Green Submitted, gold			2023-01-03	WOS:000439396900031
J	McGregor, G; Ennis, S; Powell, R; Hamborg, T; Raymond, NT; Owen, W; Aldridge, N; Evans, G; Goodby, J; Hewins, S; Banerjee, P; Krishnan, NS; Ting, SMS; Zehnder, D				McGregor, Gordon; Ennis, Stuart; Powell, Richard; Hamborg, Thomas; Raymond, Neil T.; Owen, William; Aldridge, Nicolas; Evans, Gail; Goodby, Josie; Hewins, Sue; Banerjee, Prithwish; Krishnan, Nithya S.; Ting, Stephen M. S.; Zehnder, Daniel			Feasibility and effects of intra-dialytic low-frequency electrical muscle stimulation and cycle training: A pilot randomized controlled trial	PLOS ONE			English	Article							ENDOTHELIAL FUNCTION; KIDNEY-DISEASE; EXERCISE; MORTALITY; STRENGTH; FAILURE; CKD	Background and objectives Exercise capacity is reduced in chronic kidney failure (CKF). Intra-dialytic cycling is beneficial, but comorbidity and fatigue can prevent this type of training. Low-frequency electrical muscle stimulation (LF-EMS) of the quadriceps and hamstrings elicits a cardiovascular training stimulus and may be a suitable alternative. The main objectives of this trial were to assess the feasibility and efficacy of intra-dialytic LF-EMS vs. cycling Design, setting, participants, and measurements Assessor blind, parallel group, randomized controlled pilot study with sixty-four stable patients on maintenance hemodialysis. Participants were randomized to 10 weeks of 1) intra-dialytic cycling, 2) intra-dialytic LF-EMS, or 3) non-exercise control. Exercise was performed for up to one hour three times per week. Cycling workload was set at 40-60% oxygen uptake (VO2) reserve, and LF-EMS at maximum tolerable intensity. The control group did not complete any intra-dialytic exercise. Feasibility of intra-dialytic LF-EMS and cycling was the primary outcome, assessed by monitoring recruitment, retention and tolerability. At baseline and 10 weeks, secondary outcomes including cardio-respiratory reserve, muscle strength, and cardio-arterial structure and function were assessed. Results Fifty-one (of 64 randomized) participants completed the study (LF-EMS = 17 [77%], cycling = 16 [80%], control = 18 [82%]). Intra-dialytic LF-EMS and cycling were feasible and well tolerated (9% and 5% intolerance respectively, P= 0.9). At 10-weeks, cardio-respiratory reserve (V-O2 peak) (Difference vs. control: LF-EMS +2.0 [95% CI, 0.3 to 3.7] ml.kg(-1).min(-1), P = 0.02, and cycling +3.0 [95% CI, 1.2 to 4.7] ml.kg(-1).min(-1), P= 0.001) and leg strength (Difference vs. control: LF-EMS, +94 [95% CI, 35.6 to 152.3] N, P= 0.002 and cycling, +65.1 [95% CI, 6.4 to 123.8] N, P= 0.002) were improved. Arterial structure and function were unaffected. Conclusions Ten weeks of intra-dialytic LF-EMS or cycling improved cardio-respiratory reserve and muscular strength. For patients who are unable or unwilling to cycle during dialysis, LF-EMS is a feasible alternative.	[McGregor, Gordon] Coventry Univ, Hlth & Life Sci Fac, Res Ctr, Coventry, W Midlands, England; [McGregor, Gordon; Raymond, Neil T.; Aldridge, Nicolas; Evans, Gail; Goodby, Josie; Hewins, Sue; Krishnan, Nithya S.; Ting, Stephen M. S.; Zehnder, Daniel] Univ Hosp, Dept Nephrol, Coventry, W Midlands, England; [Ennis, Stuart] Cardiff Metropolitan Univ, Cardiff Ctr Exercise & Hlth, Cardiff, S Glam, Wales; [Ennis, Stuart; Powell, Richard; Owen, William] Univ Hosp, Ctr Exercise & Hlth, Dept Cardiac Rehabil, Coventry, W Midlands, England; [Hamborg, Thomas] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Stat & Epidemiol, Warwick, England; [Banerjee, Prithwish] Univ Hosp, Dept Cardiol, Coventry, W Midlands, England; [Krishnan, Nithya S.; Ting, Stephen M. S.] Univ Warwick, Warwick Med Sch, Warwick, England; [Zehnder, Daniel] North Cumbria Univ Hosp NHS Trust, Dept Acute Med, Carlisle, Cumbria, England	Coventry University; University of Warwick; Cardiff Metropolitan University; University of Warwick; University of Warwick; University of Warwick; University of Warwick	McGregor, G (corresponding author), Coventry Univ, Hlth & Life Sci Fac, Res Ctr, Coventry, W Midlands, England.; McGregor, G (corresponding author), Univ Hosp, Dept Nephrol, Coventry, W Midlands, England.	gordon.mcgregor@uhcw.nhs.uk	McGregor, Gordon/AAP-1917-2020	McGregor, Gordon/0000-0001-8963-9107; Banerjee, Prithwish/0000-0001-7793-1733	West Midlands Comprehensive Local Research Network	West Midlands Comprehensive Local Research Network	This study was funded by West Midlands Comprehensive Local Research Network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashor AW, 2015, SPORTS MED, V45, P279, DOI 10.1007/s40279-014-0272-9; Banerjee P, 2005, J APPL PHYSIOL, V99, P2307, DOI 10.1152/japplphysiol.00891.2004; Blacher J, 1998, HYPERTENSION, V32, P570, DOI 10.1161/01.HYP.32.3.570; Briet M, 2012, CLIN SCI, V123, P399, DOI 10.1042/CS20120074; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; CHARYTAN D, 2006, AM J KIDNEY DIS, V10, P1053, DOI DOI 10.1053/J.AJKD.2006; Cheema B, 2007, AM J KIDNEY DIS, V50, P574, DOI 10.1053/j.ajkd.2007.07.005; Colson M, 2012, BRIT J ANAESTH, V109, P735, DOI 10.1093/bja/aes263; Desmeules S, 2004, NEPHROL DIAL TRANSPL, V19, P1182, DOI 10.1093/ndt/gfh016; Dobsak P, 2006, CIRC J, V70, P75, DOI 10.1253/circj.70.75; DOBSAK P, 1971, ARTIF ORGANS, V1111, P8, DOI DOI 10.1111/J; Edwards NC, 2006, QJM-INT J MED, V99, P723, DOI 10.1093/qjmed/hcl101; Ennis S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016148; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; GIELEN S, 2010, CIRCULATION, V1161, P110, DOI DOI 10.1161/CIRCULATI0NAHA.110; Graham-Brown MPM, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0294-7; Grosset JF, 2013, APPL PHYSIOL NUTR ME, V38, P57, DOI 10.1139/apnm-2011-0367; Hamada T, 2003, J APPL PHYSIOL, V94, P2107, DOI 10.1152/japplphysiol.00486.2002; Headley S, 2014, AM J KIDNEY DIS, V64, P222, DOI 10.1053/j.ajkd.2014.02.022; Heiwe Susanne, 2003, Physiother Res Int, V8, P167, DOI 10.1002/pri.287; Heiwe S, 2014, AM J KIDNEY DIS, V64, P383, DOI 10.1053/j.ajkd.2014.03.020; Heiwe S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003236.pub2; HTTPS, 2009, ASN, P80834, DOI DOI 10.1681/ASN.2005080834; HULTMAN E, 1986, J PHYSIOL-LONDON, V374, P493, DOI 10.1113/jphysiol.1986.sp016093; Jhamb M, 2008, AM J KIDNEY DIS, V52, P353, DOI 10.1053/j.ajkd.2008.05.005; Johansen KL, 2012, AM J KIDNEY DIS, V59, P126, DOI 10.1053/j.ajkd.2011.10.008; Karavidas A, 2013, AM HEART J, V166, P760, DOI 10.1016/j.ahj.2013.06.021; KIM CK, 1995, SCAND J REHABIL MED, V27, P51; Koh KP, 2010, AM J KIDNEY DIS, V55, P88, DOI 10.1053/j.ajkd.2009.09.025; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Lenk K, 2010, J CACHEXIA SARCOPENI, V1, P9, DOI 10.1007/s13539-010-0007-1; Minogue CM, 2014, ARCH PHYS MED REHAB, V95, P1750, DOI 10.1016/j.apmr.2014.04.004; MUSTATA S, 1997, ASN, V1, P8, DOI DOI 10.1097/01.ASN; Older P, 1999, CHEST, V116, P355, DOI 10.1378/chest.116.2.355; Older P, 2013, PERIOPER MED, V2, DOI 10.1186/2047-0525-2-2; Rogan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183926; Sandri M, 2012, EUR HEART J, V33, P1758, DOI 10.1093/eurheartj/ehr469; Segura-Orti E, 2010, NEFROLOGIA, V30, P236, DOI 10.3265/Nefrologia.pre2010.Jan.10229; Sheng KX, 2014, AM J NEPHROL, V40, P478, DOI 10.1159/000368722; Singh MAF, 2002, J GERONTOL A-BIOL, V57, pM262, DOI 10.1093/gerona/57.5.M262; Smart NA, 2013, INT J CARDIOL, V167, P80, DOI 10.1016/j.ijcard.2011.12.019; Stam F, 2006, J AM SOC NEPHROL, V17, P537, DOI 10.1681/ASN.2005080834; Thijssen DHJ, 2011, AM J PHYSIOL-HEART C, V300, pH2, DOI 10.1152/ajpheart.00471.2010; TING SM, 1948, ASN, P40348, DOI DOI 10.1681/ASN.2013040348; Ting SMS, 2015, AM J KIDNEY DIS, V66, P274, DOI 10.1053/j.ajkd.2015.02.335; Ting SMS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064335; Van Craenenbroeck A. H., 2016, NEPHROL DIAL TRANSPL; Van Craenenbroeck AH, 2014, CLIN J AM SOC NEPHRO, V9, P1305, DOI 10.2215/CJN.13031213; VANCRAENENBROEC.AH, 2015, AM J KIDNEY DIS, V66, P4; Vaziri ND, 2001, AM J KIDNEY DIS, V38, P1, DOI 10.1053/ajkd.2001.25174; Wang XNH, 2013, INT J BIOCHEM CELL B, V45, P2230, DOI 10.1016/j.biocel.2013.06.027; Wasserman K.H.J., 2004, PRINCIPLES EXERCISE; WILSON RJ, 1928, R J, P73634, DOI DOI 10.1093/BJA/AEQ128	54	19	19	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2018	13	7							e0200354	10.1371/journal.pone.0200354	http://dx.doi.org/10.1371/journal.pone.0200354			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM7QQ	29995947	Green Published, gold, Green Submitted			2023-01-03	WOS:000438388800057
J	Bourke, L; Turner, R; Greasley, R; Sutton, E; Steed, L; Smith, D; Brown, J; Kelly, B; Hulme, C; Greenfield, D; Persad, R; Farrin, A; Hewison, J; Rosario, DJ				Bourke, Liam; Turner, Rebecca; Greasley, Rosa; Sutton, Eileen; Steed, Liz; Smith, Dianna; Brown, Janet; Kelly, Ben; Hulme, Claire; Greenfield, Diana; Persad, Raj; Farrin, Amanda; Hewison, Jenny; Rosario, Derek J.		STAMINA Investigators	A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS	PLOS ONE			English	Article							RISK; PREVALENCE; FATIGUE; TIME	Background National guidelines (NICE-CG175) recommended 12 weeks of supervised exercise training for men treated with androgen deprivation therapy (ADT) for prostate cancer to counter debilitating adverse effects of castration. As with other chronic conditions where exercise is indicated, it is uncertain if these services are being delivered in the health services. The aim of this multi-centre investigation was to examine what exercise referral is currently available for men on ADT as provided by the NHS and if a supervised, individually-tailored exercise training package (as per the national NICE guidelines CG175) is embedded within prostate cancer care. Methods A multi-centre investigation of current National Health Service (NHS) care involving a web-based survey of NHS prostate cancer care, five focus groups involving 26 men on ADT and 37 semi-structured interviews with healthcare professionals (HCPs) involved in the management of prostate cancer. Descriptive statistics and thematic analysis evaluated quantitative and qualitative data, respectively. Qualitative methods followed COREQ standards. Results HCPs and men on ADT asserted that medical castration has a serious and debilitating impact on many features of men's quality of life. There is support for exercise training programmes as part of cancer care and patients would support their initiation soon after diagnosis. Involving the Multidisciplinary Team (MDT) is proposed as key to this. Critically, traditional values in oncology would need to be overcome for widespread acceptance. Specialist further training for HCPs around behaviour change support could encourage this. Given that these schemes are seen as a fundamental part of cancer care, it is felt the NHS should commission and support provision. 79 representatives of 154 NHS trusts (51%) provided survey data on current delivery: only 17% could provide supervised exercise as per CG175. Conclusions Evidence-based national exercise guidelines are not being delivered to men on ADT as intended. Traditional values in oncology and the need for NHS financial support are seen as major barriers to provision of current best practice guidelines. Despite this both HCPs and men on ADT are in favour of such programmes being a fundamental part of their cancer care.	[Bourke, Liam; Turner, Rebecca; Greasley, Rosa] Sheffield Hallam Univ, Hlth & Wellbeing, Sheffield, S Yorkshire, England; [Sutton, Eileen] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Steed, Liz] Queen Mary Univ London, Ctr Primary Care & Publ Hlth, London, England; [Smith, Dianna] Univ Southampton, Dept Geog & Environm, Southampton, Hants, England; [Brown, Janet; Rosario, Derek J.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England; [Kelly, Ben] Epsom Gateway, Nuffield Hlth Res Grp, Epsom, Surrey, England; [Hulme, Claire; Farrin, Amanda; Hewison, Jenny] Univ Leeds, Fac Med & Hlth, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England; [Greenfield, Diana] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Persad, Raj] Southmead Hosp, Dept Urol Surg, Bristol, Avon, England	Sheffield Hallam University; University of Bristol; University of London; Queen Mary University London; University of Southampton; University of Sheffield; University of Leeds; University of Sheffield; Southmead Hospital	Rosario, DJ (corresponding author), Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.	d.j.rosario@shef.ac.uk	Rosario, Derek/C-2028-2017; Greenfield, Diana/AAG-1250-2021	Rosario, Derek/0000-0002-9086-3592; Greenfield, Diana/0000-0002-3733-2717; Turner, Rebecca/0000-0002-0480-4626; Hulme, Claire/0000-0003-2077-0419; Farrin, Amanda/0000-0002-2876-0584; Smith, Dianna/0000-0002-0650-6606	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme [RP-DG-1213-10010]	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme(National Institute for Health Research (NIHR))	This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-DG-1213-10010). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Anderson L, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1016/j.jacc.2015.10.044]; [Anonymous], 2014, CRUK PROSTATE CANC S; Armes J, 2009, J CLIN ONCOL, V27, P6172, DOI 10.1200/JCO.2009.22.5151; Beebe-Dimmer JL, 2012, PHARMACOEPIDEM DR S, V21, P70, DOI 10.1002/pds.2258; Bourke L, 2013, BRIT J CANCER, V108, P9, DOI 10.1038/bjc.2012.523; Bourke L, 2016, EUR UROL, V69, P693, DOI 10.1016/j.eururo.2015.10.047; Bourke L, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-208; CRUK, 2010, IMPR CANC OUTC AN IM; Dalal HM, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5000; DiBlasio CJ, 2008, CAN J UROL, V15, P4249; DOH, 2011, IMPR OUTC STRAT CANC; Doherty P, 2012, HEART, V98, P605, DOI 10.1136/heartjnl-2012-301728; Galvao DA, 2008, BJU INT, V102, P44, DOI 10.1111/j.1464-410X.2008.07539.x; Gandaglia G, 2014, EUR UROL, V66, P1125, DOI 10.1016/j.eururo.2014.01.026; Garin O, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-51; GODIN G, 1986, CAN J PUBLIC HEALTH, V77, P359; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Independent Cancer Taskforce, 2015, ACH WORLD CLASS CANC; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; King AJL, 2015, EUR J CANCER CARE, V24, P618, DOI 10.1111/ecc.12286; Lapi F, 2013, JAMA-J AM MED ASSOC, V310, P289, DOI 10.1001/jama.2013.8638; Levine GN, 2010, CA-CANCER J CLIN, V60, P194, DOI 10.3322/caac.20061; Louda M, 2012, NEUROENDOCRINOL LETT, V33, P761; Maddams J, 2012, BRIT J CANCER, V107, P1195, DOI 10.1038/bjc.2012.366; Newschaffer CJ, 2000, JNCI-J NATL CANCER I, V92, P613, DOI 10.1093/jnci/92.8.613; Nguyen PL, 2015, EUR UROL, V67, P825, DOI 10.1016/j.eururo.2014.07.010; NICE National Institute for Health and Care Excellence, 2014, 175 NICE, P1; O'Farrell S, 2015, J CLIN ONCOL, V33, P1243, DOI 10.1200/JCO.2014.59.1792; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [DOI 10.4324/9780203413081_CHAPTER_9, 10.4324/9780203413081_chapter_9]; Stone P, 2000, EUR J CANCER, V36, P1134, DOI 10.1016/S0959-8049(00)00084-8; Storey DJ, 2012, ANN ONCOL, V23, P1542, DOI 10.1093/annonc/mdr447; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042	33	14	14	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2018	13	7							e0197606	10.1371/journal.pone.0197606	http://dx.doi.org/10.1371/journal.pone.0197606			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL7YG	29975707	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000437424500005
J	Buontempo, F; Orsini, E; Zironi, I; Stolen, L; Cappellini, A; Rapino, S; Tartari, A; Mostacci, D; Cucchi, G; Martelli, AM; Sumini, M; Castellani, G				Buontempo, Francesca; Orsini, Ester; Zironi, Isabella; Stolen, Lorenzo; Cappellini, Alessandra; Rapino, Stefania; Tartari, Agostino; Mostacci, Domiziano; Cucchi, Giorgio; Martelli, Alberto Maria; Sumini, Marco; Castellani, Gastone			Enhancing radiosensitivity of melanoma cells through very high dose rate pulses released by a plasma focus device	PLOS ONE			English	Article							DNA-DAMAGE; E-CADHERIN; RADIATION; RADIOTHERAPY; RESISTANCE; SENESCENCE; P53; MECHANISMS; CHECKPOINT; STRATEGIES	Radiation therapy is a useful and standard tumor treatment strategy. Despite recent advances in delivery of ionizing radiation, survival rates for some cancer patients are still low because of recurrence and radioresistance. This is why many novel approaches have been explored to improve radiotherapy outcome. Some strategies are focused on enhancement of accuracy in ionizing radiation delivery and on the generation of greater radiation beams, for example with a higher dose rate. In the present study we proposed an in vitro research of the biological effects of very high dose rate beam on SK-Me128 and A375, two radioresistant human melanoma cell lines. The beam was delivered by a pulsed plasma device, a "Mather type" Plasma Focus for medical applications. We hypothesized that this pulsed X-rays generator is significantly more effective to impair melanoma cells survival compared to conventional X-ray tube. Very high dose rate treatments were able to reduce clonogenic efficiency of SK-Me128 and A375 more than the X-ray tube and to induce a greater, less easy-to-repair DNA double-strand breaks. Very little is known about biological consequences of such dose rate. Our characterization is preliminary but is the first step toward future clinical considerations.	[Buontempo, Francesca; Orsini, Ester; Martelli, Alberto Maria] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Zironi, Isabella; Castellani, Gastone] Univ Bologna, Dept Phys & Astron, Bologna, Italy; [Zironi, Isabella; Sumini, Marco; Castellani, Gastone] Univ Bologna, Dept Chem G Ciamician, Bologna, Italy; [Zironi, Isabella; Rapino, Stefania; Castellani, Gastone] Interdept Ctr L Galvani CIG Integrated Studies Bi, Bologna, Italy; [Stolen, Lorenzo; Tartari, Agostino; Mostacci, Domiziano; Cucchi, Giorgio; Sumini, Marco] European Inst Oncol, Milan, Italy; [Stolen, Lorenzo; Tartari, Agostino; Mostacci, Domiziano; Cucchi, Giorgio; Sumini, Marco] Monzino Cardiac Ctr Fdn IEO CCM, Milan, Italy; [Stolen, Lorenzo] Univ Bologna, Dept Ind Engn, Bologna, Italy; [Cappellini, Alessandra] Univ Cassino & Southern Lazio, Dept Human Social & Hlth Sci, Cassino, Italy; [Rapino, Stefania] Natl Inst Nucl Phys INFN, Bologna, Italy	University of Bologna; University of Bologna; University of Bologna; IRCCS European Institute of Oncology (IEO); University of Bologna; University of Cassino; Gran Sasso Science Institute (GSSI); Istituto Nazionale di Fisica Nucleare (INFN)	Buontempo, F (corresponding author), Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.	francesca.buontempo3@unibo.it	isolan, lorenzo/S-5285-2018; Zironi, Isabella/AAA-7451-2020	isolan, lorenzo/0000-0003-2320-5925; Zironi, Isabella/0000-0001-7870-0267	MIUR FIRB [RBAP11ZJFA_001]; COMECER S.p.A. (Alberazzo-Canalvecchio, RA, Italy); Alma Mater Foundation (FAM) of the University of Bologna	MIUR FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); COMECER S.p.A. (Alberazzo-Canalvecchio, RA, Italy); Alma Mater Foundation (FAM) of the University of Bologna	This work was supported by MIUR FIRB 2011 (RBAP11ZJFA_001) to Alberto Maria Martelli. INFN ETHICS 2015 (Pre-clinical experimental and theoretical studies to improve treatment and protection by charged particles) to Dr. Giorgio Cucchi.; The authors wish to thank Mr. S. Zanella, for his kind collaboration in the X-rays experiments carried out in COMECER S.p.A. (Alberazzo-Canalvecchio, RA, Italy), the Alma Mater Foundation (FAM) of the University of Bologna, for the support given to the setting up of the Plasma Focus Laboratory of the Industrial Engineering Department. We also thank Professor R. Orecchia, Dr. Marta Cremonesi, Dr. Cristina Garibaldi and Prof. Ugo Cavallaro from IEO (European Institute for Oncology) for the A375 cell line.	Abend M, 2003, INT J RADIAT BIOL, V79, P927, DOI 10.1080/09553000310001632958; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Auer S, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-139; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Baumann M, 2016, NAT REV CANCER, V16, P234, DOI 10.1038/nrc.2016.18; BEDFORD JS, 1973, RADIAT RES, V54, P316, DOI 10.2307/3573709; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Bentzen SM, 2005, RADIOTHER ONCOL, V76, P1, DOI 10.1016/j.radonc.2005.06.009; Bhide SA, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-25; Borgmann K, 2004, INT J RADIAT ONCOL, V58, P445, DOI 10.1016/j.ijrobp.2003.09.036; Bravata V, 2015, ANTICANCER RES, V35, P2577; BRENNER DJ, 1991, INT J RADIAT ONCOL, V20, P181, DOI 10.1016/0360-3016(91)90158-Z; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Ceccolini E, 2012, J APPL PHYS, V112, DOI 10.1063/1.4748179; Ceccolini E, 2011, AIP CONF PROC, V1412, DOI 10.1063/1.3665299; Ceccolini E, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3622523; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EPP ER, 1968, RADIAT RES, V34, P320, DOI 10.2307/3572557; Farooqui R, 2005, J CELL SCI, V118, P51, DOI 10.1242/jcs.01577; Favaudon V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008973; FitzGerald TJ, 2008, EXPERT REV ANTICANC, V8, P967, DOI 10.1586/14737140.8.6.967; Gregoire V, 2015, J CLIN ONCOL, V33, P3277, DOI 10.1200/JCO.2015.61.2994; Grimaldi C, 2012, LEUKEMIA, V26, P91, DOI 10.1038/leu.2011.269; HALL EJ, 1972, BRIT J RADIOL, V45, P81, DOI 10.1259/0007-1285-45-530-81; HALL EJ, 1991, INT J RADIAT ONCOL, V21, P1403, DOI 10.1016/0360-3016(91)90314-T; Holler M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154745; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kim BM, 2015, INT J MOL SCI, V16, P26880, DOI 10.3390/ijms161125991; Klein LE, 2005, CELL CYCLE, V4, P501, DOI 10.4161/cc.4.3.1550; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Ling CC, 2010, RADIOTHER ONCOL, V95, P261, DOI 10.1016/j.radonc.2010.03.014; Lonetti A, 2015, ONCOTARGET, V6, P10399, DOI 10.18632/oncotarget.3295; Luo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079940; Maier P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010102; MITCHELL JB, 1979, RADIAT RES, V79, P552, DOI 10.2307/3575180; Muller M, 2009, ANTIOXID REDOX SIGN, V11, P59, DOI 10.1089/ars.2008.2104; Niessen CM, 2011, PHYSIOL REV, V91, P691, DOI 10.1152/physrev.00004.2010; Nunez MI, 1996, RADIOTHER ONCOL, V39, P155, DOI 10.1016/0167-8140(96)01732-X; Qureshi HS, 2006, AM J CLIN PATHOL, V125, P377, DOI 10.1309/WMX7DRWTFVQP2LOT; Rao SS, 2014, RADIOTHER ONCOL, V111, P88, DOI 10.1016/j.radonc.2014.02.010; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; RICE GC, 1986, CANCER RES, V46, P6105; Rodriguez Luis G., 2004, V294, P23; Sambade MJ, 2011, RADIOTHER ONCOL, V98, P394, DOI 10.1016/j.radonc.2010.12.017; Schick U, 2015, RADIOTHER ONCOL, V117, P364, DOI 10.1016/j.radonc.2015.06.026; Selzer E, 2013, EXPERT REV CLIN PHAR, V6, P663, DOI 10.1586/17512433.2013.841540; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sobol WT, 2002, MED PHYS, V29, P132, DOI 10.1118/1.1445415; Sorensen BS, 2011, RADIOTHER ONCOL, V101, P223, DOI 10.1016/j.radonc.2011.06.018; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Sumini M, 2017, RADIAT PHYS CHEM, V140, P452, DOI 10.1016/j.radphyschem.2017.03.022; Sumini M, 2015, X-RAY SPECTROM, V44, P289, DOI 10.1002/xrs.2621; Tian X, 2015, NANOSCALE, V7, P20211, DOI 10.1039/c5nr05869d; Virelli A, 2015, RADIAT PROT DOSIM, V166, P383, DOI 10.1093/rpd/ncv163; Wambersie A, 1996, CERN REPORT, V96, P610; Wang T, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00017; Wilson P, 2012, BRIT J RADIOL, V85, pE933, DOI 10.1259/bjr/17827549; Yue GZ, 2002, APPL PHYS LETT, V81, P355, DOI 10.1063/1.1492305; Zahnreich S, 2010, MUTAT RES-GEN TOX EN, V701, P60, DOI 10.1016/j.mrgentox.2010.03.010	61	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2018	13	6							e0199312	10.1371/journal.pone.0199312	http://dx.doi.org/10.1371/journal.pone.0199312			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0PZ	29958291	gold, Green Published, Green Submitted			2023-01-03	WOS:000436793500008
J	Siriwardhana, DD; Walters, K; Rait, G; Bazo-Alvarez, JC; Weerasinghe, MC				Siriwardhana, Dhammika Deepani; Walters, Kate; Rait, Greta; Carlos Bazo-Alvarez, Juan; Weerasinghe, Manuj Chrishantha			Cross-cultural adaptation and psychometric evaluation of the Sinhala version of Lawton Instrumental Activities of Daily Living Scale	PLOS ONE			English	Article							CONFIRMATORY FACTOR-ANALYSIS; INTERRATER RELIABILITY; FIT ASSESSMENT; OLDER-ADULTS; HEALTH; QUALITY; VALIDATION; AGREEMENT; POPULATION; IMPAIRMENT	Introduction Instrumental activities of daily living (IADL) are cognitively complex activities related to independent living in the community. Robust IADL scales are needed, however the psychometric properties of instruments have been little evaluated. There is no validated instrument for Sri Lankan older populations. Sri Lanka has the highest proportion of older people in South Asia with rapid population ageing. Therefore, it is essential to have standard instruments to assess activity limitations. We aimed to cross-culturally adapt the original Lawton Instrumental Activities of Daily Living Scale from English to Sinhala and evaluate the psychometric properties of the Sinhala version. Methods Cross-cultural adaptation of the instrument was performed. The instrument was validated in a sample of 702 community-dwelling older adults aged 60 years and above in Sri Lanka. Reliability (internal consistency and inter-rater reliability) was assessed. Construct validity of the scale was evaluated by performing exploratory and confirmatory factor analysis and testing convergent and divergent validity. Results The Lawton IADL scale was successfully adapted to Sri Lankan context. Internal consistency of the scale was very high (Cronbach's alpha = 0.91). Very good inter-rater reliability was observed with very good agreement for all items. Inter-class correlations for overall IADL score ranged from 0.57 to 0.91. Results of the exploratory and confirmatory factor analyses supported the unidimensionality of the scale. Goodness of fit indices in confirmatory factor analysis were in acceptable range (CFI = 0.98, SRMR = 0.06, NNFI = 0.97). Strength of associations were significant and in the expected direction. Results of the known group validity were also significant, confirming the convergent and divergent validity. Conclusion The Lawton IADL scale was successfully translated and culturally adapted to Sinhala language. The Sinhala version demonstrated excellent reliability and construct validity. Given good psychometric properties, this scale would be recommended for use in future research.	[Siriwardhana, Dhammika Deepani; Walters, Kate; Rait, Greta; Carlos Bazo-Alvarez, Juan] UCL, Res Dept Primary Care & Populat Hlth, London, England; [Siriwardhana, Dhammika Deepani] Univ Kelaniya, Fac Med, Dept Disabil Studies, Ragama, Sri Lanka; [Carlos Bazo-Alvarez, Juan] Univ Catolica Los Angeles Chimbote, ULADECH Catolica, Ctr Estudios Poblac, Chimbote, Peru; [Weerasinghe, Manuj Chrishantha] Univ Colombo, Fac Med, Dept Community Med, Colombo, Sri Lanka	University of London; University College London; University Kelaniya; Universidad Catolica Los Angeles De Chimbote; University of Colombo	Siriwardhana, DD (corresponding author), UCL, Res Dept Primary Care & Populat Hlth, London, England.; Siriwardhana, DD (corresponding author), Univ Kelaniya, Fac Med, Dept Disabil Studies, Ragama, Sri Lanka.	deepani.sirwardhana.15@ucl.ac.uk	Bazo-Alvarez, Juan Carlos/AAE-3742-2019; Siriwardhana, Deepani/AAJ-8847-2021	Bazo-Alvarez, Juan Carlos/0000-0002-6169-8049; Siriwardhana, Deepani/0000-0003-2313-3095; Walters, Kate/0000-0003-2173-2430	UK government [LKCS-2015-678]	UK government	DDS is a Commonwealth Scholar, funded by UK government (LKCS-2015-678). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrett P, 2007, PERS INDIV DIFFER, V42, P815, DOI 10.1016/j.paid.2006.09.018; Basto M, 2012, J STAT SOFTW, V46, P1; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Comrey A. L., 1992, 1 COURSE FACTOR ANAL; Costello A., 2005, PRACTICAL ASSESSMENT, V10, P1, DOI [10.4135/9781412995627.d8, DOI 10.4135/9781412995627.D8]; de Winter JCF, 2012, J APPL STAT, V39, P695, DOI 10.1080/02664763.2011.610445; Department of Census and Statistics, 2015, INCR ELD POP SR LANK; Garrido LE, 2013, PSYCHOL METHODS, V18, P454, DOI 10.1037/a0030005; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Farias ST, 2013, J INT NEUROPSYCH SOC, V19, P430, DOI 10.1017/S1355617712001609; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; Fernando DN, 1993, J MED SCI, V36, P9; Fusco O, 2012, AGING CLIN EXP RES, V24, P68, DOI 10.1007/BF03325356; Gold DA, 2012, J CLIN EXP NEUROPSYC, V34, P11, DOI 10.1080/13803395.2011.614598; Goodwin L.D., 1999, MEAS PHYS EDUC EXERC, V3, P85, DOI [DOI 10.1207/S15327841MPEE0302_2, DOI 10.1207/S15327841MPEE0302_]; Graf C, 2008, AM J NURS, V108, P52, DOI 10.1097/01.NAJ.0000314810.46029.74; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Gwet K., 2012, HDB INTERRATER RELIA; Gwet KL, 2008, BRIT J MATH STAT PSY, V61, P29, DOI 10.1348/000711006X126600; Hassani Mehraban Afsoon, 2014, Med J Islam Repub Iran, V28, P25; Hill J, 2006, PHARMACOECONOMICS, V24, P265, DOI 10.2165/00019053-200624030-00006; Hinkle D.E., 1988, APPL STAT BEHAV SCI; Hokoishi K, 2001, AGING MENT HEALTH, V5, P38, DOI 10.1080/13607860020020627; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Hutcheson GD, 1999, MULTIVARIATE SOCIAL, P218; Jackson DL, 2009, PSYCHOL METHODS, V14, P6, DOI 10.1037/a0014694; Jekel K, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0099-0; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Kottner J, 2011, J CLIN EPIDEMIOL, V64, P96, DOI 10.1016/j.jclinepi.2010.03.002; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lawton M. P., 2003, MULTILEVEL ASSESSMEN; LAWTON MP, 1988, PSYCHOPHARMACOL BULL, V24, P609; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; Li CH, 2016, PSYCHOL METHODS, V21, P369, DOI 10.1037/met0000093; MAHONEY F I, 1965, Md State Med J, V14, P61; McIntosh CN, 2007, PERS INDIV DIFFER, V42, P859, DOI 10.1016/j.paid.2006.09.020; Ministry of Economic Affairs and Climate Policy, 2019, CLIM POLICY; Mokkink LB, 2010, QUAL LIFE RES, V19, P539, DOI 10.1007/s11136-010-9606-8; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Ng TP, 2006, J GERONTOL A-BIOL, V61, P726, DOI 10.1093/gerona/61.7.726; NUGEGODA DB, 1995, SOC SCI MED, V40, P437, DOI 10.1016/0277-9536(94)00144-I; Nunnally JC, 1994, PSYCHOMETRIC THEORY, V3, P248; Nye CD, 2011, ORGAN RES METHODS, V14, P548, DOI 10.1177/1094428110368562; Ostbye T, 2009, J AM GERIATR SOC, V57, P1376, DOI 10.1111/j.1532-5415.2009.02350.x; Pfeiffer E., 1975, MULTIDIMENSIONAL FUN; Rajapakse S., 2012, IND J GERONTOL, V26, P351; Ramaker C, 2002, MOVEMENT DISORD, V17, P867, DOI 10.1002/mds.10248; Schreiber JB, 2006, J EDUC RES, V99, P323, DOI 10.3200/JOER.99.6.323-338; Sikkes SAM, 2009, J NEUROL NEUROSUR PS, V80, P7, DOI 10.1136/jnnp.2008.155838; Sousa LB, 2015, RES AGING, V37, P787, DOI 10.1177/0164027514564469; Steiger JH, 2007, PERS INDIV DIFFER, V42, P893, DOI 10.1016/j.paid.2006.09.017; Streiner D. L., 2015, HLTH MEASUREMENT SCA, V5<feminine, DOI [10.1093/med/9780199685219.001.0001, DOI 10.1093/MED/9780199685219.001.0001, 10.1093/MED/9780199685219.001.0001]; Telecommunications Regulatory Commission of Sri Lanka, 2014, STAT 2014; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Theotoka I, 2007, PERCEPT MOTOR SKILL, V104, P958, DOI 10.2466/PMS.104.3.958-960; Tong AYC, 2002, OTJR-OCCUP PART HEAL, V22, P132, DOI 10.1177/153944920202200402; TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170; United Nations, 2017, AGEING POPULATION SR; van der Vorst A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165127; Vergara I, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-130; Wheaton B., 1977, SOCIOL METHODOL, P84, DOI [DOI 10.2307/270754, 10.2307/270754]	64	11	11	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0199820	10.1371/journal.pone.0199820	http://dx.doi.org/10.1371/journal.pone.0199820			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GL0GK	29953501	Green Published, gold, Green Submitted			2023-01-03	WOS:000436645400077
J	Saleh, AA; El-Far, AH; Abdel-Latif, MA; Emam, MA; Ghanem, R; Abd El-Hamid, HS				Saleh, Ahmed A.; El-Far, Ali H.; Abdel-Latif, Mervat A.; Emam, Mohamed A.; Ghanem, Rania; Abd El-Hamid, Hatem S.			Exogenous dietary enzyme formulations improve growth performance of broiler chickens fed a low-energy diet targeting the intestinal nutrient transporter genes	PLOS ONE			English	Article							XYLANASE SUPPLEMENTATION; CLOSTRIDIUM-PERFRINGENS; NONSTARCH POLYSACCHARIDES; ACID-TRANSPORT; EXPRESSION; PROTEASE; DIGESTIBILITY; HEALTH; COMBINATION; NUTRITION	Diminishing the cost of broiler chicken diet is a critical issue in the poultry industry. Numerous studies were performed to achieve this pivotal objective by diet supplementation with alternative feed additives. In the current study, low-energy broiler rations were supplemented with different commercial multienzyme formulations to minimize the cost, and increase the digestibility and absorption of the digested macronutrients. Cobb Avian 48 broiler chicks (mixed sex, 1-d-old, n = 3120) were randomly allocated into six groups, and each group was subdivided into four replicates (130 birds per replicate). The birds were randomly allocated into a control group fed basal diet (CB); control group fed low-energy diet (CL); and birds fed low-energy diets supplemented with different enzyme formulations. The enzyme formulations used were Xylam 500 (R) (CLX group), Hemicell (R) (CLH group), Avizyme (R) (CLA group), and Megazyme (R) (CLM group,) following the doses recommended by the manufacturers. The growth performance of CLA and CLH group birds was significantly improved when compared with CL. In comparison with CB, Avizyme (R) significantly (p < 0.001) increased the intestinal PEPT1, GLUT2, ACC, and IL-2 expression; PEPT1 facilitates the absorption of micronutrients. In conclusion, exogenous multienzyme complexes may be included in the low-energy diet to enhance the performance of broiler chickens (Avizyme (R) > Hemicell (R) > Megazyme (R)), and reduce the diet cost by up-regulating the expression of intestinal nutrient transporter genes, and improving the immunity and serum biochemical parameters of broiler chickens.	[Saleh, Ahmed A.] Kafrelsheikh Univ, Dept Poultry Prod, Fac Agr, Kafrelsheikh, Egypt; [El-Far, Ali H.] Damanhour Univ, Fac Vet Med, Dept Biochem, Damanhour, El Beheira, Egypt; [Abdel-Latif, Mervat A.] Damanhour Univ, Fac Vet Med, Dept Nutr & Vet Clin Nutr, Damanhour, El Beheira, Egypt; [Emam, Mohamed A.] Damanhour Univ, Fac Vet Med, Dept Nutr & Vet Clin Nutr, Damanhour, El Beheira, Egypt; [Ghanem, Rania] Mansoura Lab, Anim Hlth Res Inst, Mansoura, Egypt; [Abd El-Hamid, Hatem S.] Damanhour Univ, Fac Vet Med, Dept Poultry Dis, Damanhour, El Beheira, Egypt	Egyptian Knowledge Bank (EKB); Kafrelsheikh University; Egyptian Knowledge Bank (EKB); Damanhour University; Egyptian Knowledge Bank (EKB); Damanhour University; Egyptian Knowledge Bank (EKB); Damanhour University; Animal Health Research Institute (AHRI); Egyptian Knowledge Bank (EKB); Damanhour University	El-Far, AH (corresponding author), Damanhour Univ, Fac Vet Med, Dept Biochem, Damanhour, El Beheira, Egypt.; Abdel-Latif, MA (corresponding author), Damanhour Univ, Fac Vet Med, Dept Nutr & Vet Clin Nutr, Damanhour, El Beheira, Egypt.	ali.elfar@damanhour.edu.eg; mervat.abdellatif@vetmed.dmu.edu.eg	Saleh, Ahmed/J-4965-2019; El-Far, Prof Dr/Ali H./L-7946-2017; Saleh, Ahmed Ali/H-7928-2014; Abdel-Latif, Mervat/ABG-8943-2021; Abdel-Latif, Mervat A./AAC-5685-2019	Saleh, Ahmed/0000-0002-2052-5248; El-Far, Prof Dr/Ali H./0000-0001-9721-4360; Saleh, Ahmed Ali/0000-0002-2052-5248; Abdel-Latif, Mervat/0000-0002-7996-0121; 				Abdalla M. O., 1999, Malaysian Applied Biology, V28, P73; Abdel-Latif MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185153; Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; Ahmad Z, 2013, PAK VET J, V33, P388; ALLAN WH, 1974, VET REC, V95, P120, DOI 10.1136/vr.95.6.120; ALMIRALL M, 1995, J NUTR, V125, P947; Amerah AM, 2017, POULTRY SCI, V96, P807, DOI 10.3382/ps/pew297; AOAC, 2007, OFFICIAL METHODS ANA, V18th; Bedford MR, 1996, WORLD POULTRY SCI J, V52, P61, DOI 10.1079/WPS19960007; Bedford MR, 2000, ANIM FEED SCI TECH, V86, P1, DOI 10.1016/S0377-8401(00)00155-3; Broer S, 2008, PHYSIOL REV, V88, P249, DOI 10.1152/physrev.00018.2006; Cafe MB, 2002, J APPL POULTRY RES, V11, P29, DOI 10.1093/japr/11.1.29; Choct M, 1996, BRIT POULTRY SCI, V37, P609, DOI 10.1080/00071669608417891; Coles E.H., 1986, VET CLIN PATH, V4th; Deng YX, 2011, BIOL TRACE ELEM RES, V144, P647, DOI 10.1007/s12011-011-9018-9; Dignass AU, 1996, EXP CELL RES, V225, P422, DOI 10.1006/excr.1996.0193; Donohue M, 2009, J APPL POULTRY RES, V18, P325, DOI 10.3382/japr.2008-00134; Ebrahimi R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/149745; Field CJ, 2000, MED SCI SPORT EXER, V32, pS377, DOI 10.1097/00005768-200007001-00002; Flores C, 2016, J APPL POULTRY RES, V25, P328, DOI 10.3382/japr/pfw016; Fotiadis D, 2013, MOL ASPECTS MED, V34, P139, DOI 10.1016/j.mam.2012.10.007; Freitas DM, 2011, J APPL POULTRY RES, V20, P322, DOI 10.3382/japr.2010-00295; Gilbert ER, 2008, J ANIM SCI, V86, P2135, DOI 10.2527/jas.2007-0826; Guo SS, 2014, POULTRY SCI, V93, P94, DOI 10.3382/ps.2013-03188; Horvatovic MP, 2015, BRAZ J POULTRY SCI, V17, P25, DOI 10.1590/1516-635x170125-30; Hosseini SM, 2017, J POULT SCI, V54, P149, DOI 10.2141/jpsa.0160099; Iji PA, 2004, J SCI FOOD AGR, V84, P1451, DOI 10.1002/jsfa.1816; JIN G, 2001, ASIAN POULT, V5, P26; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Kaiser P, 2000, MICROBIOL-UK, V146, P3217, DOI 10.1099/00221287-146-12-3217; Kalmendal R, 2012, POULTRY SCI, V91, P1387, DOI 10.3382/ps.2011-02064; Lana GRQ, 2015, RURAL, V45, P111, DOI [10.1590/0103-8478cr20131544, DOI 10.1590/0103-8478CR20131544]; Lee CY, 2013, CLIN TRANSL GASTROEN, V4, DOI 10.1038/ctg.2013.11; Lee S.A., 2017, J WORLDS POULTRY RES, V7, P35; Lu H, 2016, J ANIM SCI S5, V94, P447, DOI [10.2527/jam2016-0928, DOI 10.2527/JAM2016-0928]; Marcu A., 2013, ANIM SCI BIOTECHNOL, V46, P339; Mueckler M, 2013, MOL ASPECTS MED, V34, P121, DOI 10.1016/j.mam.2012.07.001; Nian F, 2011, ASIAN AUSTRAL J ANIM, V24, P1282, DOI 10.5713/ajas.2011.10441; Olukosi OA, 2015, POULTRY SCI, V94, P2662, DOI 10.3382/ps/pev260; Phillips I, 2004, J ANTIMICROB CHEMOTH, V53, P28, DOI 10.1093/jac/dkg483; Prandini F, 2008, ZOOTECH INT, V9, P25; Prentice A M, 2003, Obes Rev, V4, P187, DOI 10.1046/j.1467-789X.2003.00117.x; Ravindran R., 2005, POULTRY 2010; Romero LF, 2014, POULTRY SCI, V93, P2501, DOI 10.3382/ps.2013-03789; Ruhnke I, 2015, J ANIM PHYSIOL AN N, V99, P29, DOI 10.1111/jpn.12313; Suzuki K, 2009, J VIROL, V83, P7475, DOI 10.1128/JVI.01434-08; Tong L, 2005, CELL MOL LIFE SCI, V62, P1784, DOI 10.1007/s00018-005-5121-4; Williams MP, 2014, J APPL POULTRY RES, V23, P188, DOI 10.3382/japr.2013-00856; Yuan JM, 2007, ASIAN AUSTRAL J ANIM, V20, P1222, DOI 10.5713/ajas.2007.1222; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zhou MJ, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0219-2	51	30	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2018	13	5							e0198085	10.1371/journal.pone.0198085	http://dx.doi.org/10.1371/journal.pone.0198085			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH7NG	29847558	Green Submitted, Green Published, gold			2023-01-03	WOS:000433634800052
J	Knaul, FM; Bhadelia, A; Horton, R				Knaul, Felicia Marie; Bhadelia, Afsan; Horton, Richard			Health-related suffering: from Lancet Commission to DeclarAction	LANCET			English	Editorial Material									[Knaul, Felicia Marie; Bhadelia, Afsan] Univ Miami, Inst Adv Study Amer, Coral Gables, FL 33146 USA; [Horton, Richard] The Lancet, London, England	University of Miami	Knaul, FM (corresponding author), Univ Miami, Inst Adv Study Amer, Coral Gables, FL 33146 USA.	fknaul@miami.edu		Knaul, Felicia/0000-0002-0512-4788	L&L Copeland Foundation; United States Cancer Pain Relief Committee; Open Society Foundations; F Hoffman-La Roche Ltd; VITAS Healthcare; Mayday Foundation	L&L Copeland Foundation; United States Cancer Pain Relief Committee; Open Society Foundations; F Hoffman-La Roche Ltd; VITAS Healthcare; Mayday Foundation	FMK received grants from L&L Copeland Foundation, United States Cancer Pain Relief Committee, Open Society Foundations, F Hoffman-La Roche Ltd, and unrestricted gift funds from VITAS Healthcare as support to the University of Miami for the global symposium to launch the report of the Lancet Commission and other Commission-related follow-up activities, outside the scope of the submitted work. AB received personal fees from Mayday Foundation and F Hoffman-La Roche Ltd through support to the University of Miami for the global symposium to launch the report of the Lancet Commission and other Commission-related follow-up activities, outside the scope of the submitted work. RH declares no competing interests. We thank Julio Frenk (University of Miami) and Liliana De Lima (International Association for Hospice and Palliative Care) for their comments and suggestions.	Callahan D., 1997, EQUITY GOALS MED; Connor S.R., 2014, WHO GLOBAL ATLAS PAL; Knaul FM, 2018, LANCET, V391, P1391, DOI 10.1016/S0140-6736(17)32513-8	3	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2018	391	10135					2088	2089		10.1016/S0140-6736(18)31123-1	http://dx.doi.org/10.1016/S0140-6736(18)31123-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH2UJ	29784148				2023-01-03	WOS:000433257200009
J	Seo, DH; Kim, MJ; Kim, KH; Park, J; Shin, DW; Kim, H; Jeon, W; Kim, H; Park, JM				Seo, Dong Hyun; Kim, Min Joung; Kim, Kyung Hwan; Park, Junseok; Shin, Dong Wun; Kim, Hoon; Jeon, Woochan; Kim, Hyunjong; Park, Joon Min			The characteristics of pediatric emergency department visits in Korea: An observational study analyzing Korea Health Panel data	PLOS ONE			English	Article							PROFILE	Objective We investigated the characteristics of pediatric emergency department (ED) patients in Korea and determined factors associated with hospital admission after ED treatment. Methods Korea Health Panel data from 2008 through 2013 were analyzed retrospectively; we included patients under 18 years old who visited the ED at least once. We collected patient and household epidemiologic data such as sex, age group, region of residence, disability, chronic disease, household income quintile, national health insurance type, use of private insurance, and annual frequency of ED visits. We also examined data related to each ED visit, such as reason for visit, medical service provided, and hospital size/ownership. We then investigated which factors were correlated with case disposition (discharge home or hospital admission) after ED treatment. Results In total, 3,160 pediatric ED visits occurred during the six-year period. Males (57.5%) and children aged 0-5 years (47.7%) made more visits than females and older children, respectively. The proportion of ED visits for disease (67.7%) was much higher than for injury or poisoning (32.2%), and 452 cases (14.3%) required hospital admission. For hospital admission, the odds ratio (OR) of females was 0.73 compared to males, and the OR of children aged 6-11 was 0.68 compared to children aged 0-5. The OR of capital residents was 0.69 compared to province residents, and the OR of the highest income quintile was 0.51 compared to the lowest quintile. The OR of children with private insurance coverage was 0.49 compared to those lacking private insurance, and the OR of ED visits due to disease was 1.82 compared to visits due to injury/poisoning. Conclusion This analysis of clinical and demographic characteristics of pediatric ED visits and hospital admissions can serve as the foundation of future prospective studies required for establishing appropriate policies for the Korean pediatric emergency medical system.	[Seo, Dong Hyun; Kim, Kyung Hwan; Park, Junseok; Shin, Dong Wun; Kim, Hoon; Jeon, Woochan; Kim, Hyunjong; Park, Joon Min] Inje Univ, Ilsan Paik Hosp, Dept Emergency Med, Goyang, South Korea; [Kim, Min Joung] Yonsei Univ, Coll Med, Dept Emergency Med, Seoul, South Korea	Inje University; Yonsei University; Yonsei University Health System	Park, JM (corresponding author), Inje Univ, Ilsan Paik Hosp, Dept Emergency Med, Goyang, South Korea.	aero7@outlook.kr		Kim, Min Joung/0000-0003-1634-5209; Jeon, woochan/0000-0003-2674-3593; gim, gyeonghwan/0000-0002-1915-3643; Park, Joon Min/0000-0001-7258-8892; Kim, Hyunjong/0000-0001-6473-9646				Ben-Isaac E, 2010, PEDIATRICS, V125, P454, DOI 10.1542/peds.2009-0544; Billings J, 2000, Issue Brief (Commonw Fund), P1; Boyle A, 2016, EMERG MED J, V33, P307, DOI 10.1136/emermed-2014-203616; Boyle A, 2012, EMERG MED INT, V2012, DOI 10.1155/2012/838610; Branche C., 2008, WORLD REPORT CHILD I; Falik M, 2001, MED CARE, V39, P551, DOI 10.1097/00005650-200106000-00004; Fong C, 1999, ACAD EMERG MED, V6, P744, DOI 10.1111/j.1553-2712.1999.tb00446.x; HADDY RI, 1987, J FAM PRACTICE, V24, P389; Kubicek K, 2012, PEDIATR EMERG CARE, V28, P977, DOI 10.1097/PEC.0b013e31826c9aab; Kwak YH, 2012, J KOREAN MED SCI, V27, P1222, DOI 10.3346/jkms.2012.27.10.1222; Nawar Eric W, 2007, Adv Data, P1; Niska Richard, 2010, Natl Health Stat Report, P1; Salami O, 2012, PEDIATR EMERG CARE, V28, P43, DOI 10.1097/PEC.0b013e31823f2412; Thompson C, 2010, EMERG MED J, V27, P22, DOI 10.1136/emj.2008.068817; 유재욱, 2010, Clinical and Experimental Pediatrics, V53, P314	15	7	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197929	10.1371/journal.pone.0197929	http://dx.doi.org/10.1371/journal.pone.0197929			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH0HY	29795653	Green Published, gold, Green Submitted			2023-01-03	WOS:000433084300098
J	Vugts, MAP; Joosen, MCW; van der Geer, JE; Zedlitz, AMEE; Vrijhoef, HJM				Vugts, Miel A. P.; Joosen, Margot C. W.; van der Geer, Jessica E.; Zedlitz, Aglaia M. E. E.; Vrijhoef, Hubertus J. M.			The effectiveness of various computer-based interventions for patients with chronic pain or functional somatic syndromes: A systematic review and meta-analysis	PLOS ONE			English	Review							COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; IRRITABLE-BOWEL-SYNDROME; INTERNET-BASED TREATMENT; GUIDED SELF-HELP; COMMITMENT THERAPY; BACK-PAIN; MANAGEMENT INTERVENTIONS; PSYCHOLOGICAL TREATMENTS; MENTAL-HEALTH	Computer-based interventions target improvement of physical and emotional functioning in patients with chronic pain and functional somatic syndromes. However, it is unclear to what extent which interventions work and for whom. This systematic review and meta-analysis (registered at PROSPERO, 2016: CRD42016050839) assesses efficacy relative to passive and active control conditions, and explores patient and intervention factors. Controlled studies were identified from MEDLINE, EMBASE, PsychInfo, Web of Science, and Cochrane Library. Pooled standardized mean differences by comparison type, and somatic symptom, health-related quality of life, functional interference, catastrophizing, and depression outcomes were calculated at post-treatment and at 6 or more months follow-up. Risk of bias was assessed. Sub-group analyses were performed by patient and intervention characteristics when heterogeneous outcomes were observed. Maximally, 30 out of 46 eligible studies and 3,387 participants were included per meta-analysis. Mostly, internet-based cognitive behavioral therapies were identified. Significantly higher patient reported outcomes were found in comparisons with passive control groups (standardized mean differences ranged between -.41 and -.18), but not in comparisons with active control groups (SMD = -.26 - -.14). For some outcomes, significant heterogeneity related to patient and intervention characteristics. To conclude, there is a minority of good quality evidence for small positive average effects of computer-based (cognitive) behavior change interventions, similar to traditional modes. These effects may be sustainable. Indications were found as of which interventions work better or more consistently across outcomes for which patients. Future process analyses are recommended in the aim of better understanding individual chances of clinically relevant outcomes.	[Vugts, Miel A. P.; Joosen, Margot C. W.] Tilburg Univ, Tilburg Sch Social & Behav Sci, Tranzo Sci Ctr Care & Welf, Tilburg, Netherlands; [van der Geer, Jessica E.; Zedlitz, Aglaia M. E. E.] Leiden Univ, Dept Hlth Med & Neuropsychol, Leiden, Netherlands; [Vrijhoef, Hubertus J. M.] Maastricht Univ, Dept Patient & Care, Med Ctr, Maastricht, Netherlands; [Vrijhoef, Hubertus J. M.] Vrije Univ Brussel, Dept Family Med & Chron Care, Brussels, Belgium; [Vrijhoef, Hubertus J. M.] Panaxea BV, Amsterdam, Netherlands	Tilburg University; Leiden University; Leiden University - Excl LUMC; Maastricht University; Vrije Universiteit Brussel	Vugts, MAP (corresponding author), Tilburg Univ, Tilburg Sch Social & Behav Sci, Tranzo Sci Ctr Care & Welf, Tilburg, Netherlands.	m.a.p.vugts@tilburguniversty.edu	zedlitz, aglaia/AAT-9594-2020; Vrijhoef, Hubertus/AAR-2387-2020	zedlitz, aglaia/0000-0002-8983-361X; Vrijhoef, Hubertus/0000-0002-5539-4671; /0000-0001-5367-9334	Ciran	Ciran	Ciran sponsored the research and had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish. No grant numbers are available.	Abbott Jo-Anne M., 2009, Cognitive Behaviour Therapy, V38, P162, DOI 10.1080/16506070902763174; Andersson G, 2003, HEADACHE, V43, P353, DOI 10.1046/j.1526-4610.2003.03070.x; Andersson G, 2002, PSYCHOSOM MED, V64, P810, DOI 10.1097/01.PSY.0000031577.42041.F8; Andersson G, 2014, WORLD PSYCHIATRY, V13, P288, DOI 10.1002/wps.20151; Andrews G, 2015, CLIN PSYCHOL REV, V41, P40, DOI 10.1016/j.cpr.2014.05.006; Bailey JV, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006483.pub2; Beatty L, 2013, CLIN PSYCHOL REV, V33, P609, DOI 10.1016/j.cpr.2013.03.004; Bender JL, 2011, PAIN, V152, P1740, DOI 10.1016/j.pain.2011.02.012; Berger VW, 2009, REV RECENT CLIN TRIA, V4, P79, DOI 10.2174/157488709788186021; Boyers D, 2013, CLIN J PAIN, V29, P366, DOI 10.1097/AJP.0b013e318250f539; Brattberg G, 2007, INT J REHABIL RES, V30, P231, DOI 10.1097/MRR.0b013e32829fa545; Brattberg G, 2006, INT J REHABIL RES, V29, P221, DOI 10.1097/01.mrr.0000210055.17291.f5; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Brown M, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6200; Buhrman M, 2004, PAIN, V111, P368, DOI 10.1016/j.pain.2004.07.021; Buhrman M, 2013, EUR J PAIN, V17, P753, DOI 10.1002/j.1532-2149.2012.00244.x; Buhrman Monica, 2016, Internet Interv, V4, P17, DOI 10.1016/j.invent.2015.12.001; Buhrman M, 2015, CLIN J PAIN, V31, P504, DOI 10.1097/AJP.0000000000000176; Buhrman M, 2013, BEHAV RES THER, V51, P307, DOI 10.1016/j.brat.2013.02.010; Buhrman M, 2011, J REHABIL MED, V43, P500, DOI 10.2340/16501977-0805; Camerini L, 2012, J MED INTERNET RES, V14, P60, DOI 10.2196/jmir.1953; Carnes D, 2012, CLIN J PAIN, V28, P344, DOI 10.1097/AJP.0b013e31822ed2f3; Carpenter KM, 2012, CLIN J PAIN, V28, P14, DOI 10.1097/AJP.0b013e31822363db; Cavanagh K, 2014, CLIN PSYCHOL REV, V34, P118, DOI 10.1016/j.cpr.2014.01.001; Chiauzzi E, 2010, PAIN MED, V11, P1044, DOI 10.1111/j.1526-4637.2010.00879.x; DasMahapatra P, 2015, CLIN J PAIN, V31, P404, DOI 10.1097/AJP.0000000000000125; Davis MC, 2013, ANN BEHAV MED, V46, P273, DOI 10.1007/s12160-013-9513-7; de Boer MJ, 2014, EUR J PAIN, V18, P1440, DOI 10.1002/ejp.509; Dear BF, 2016, PAIN, V157, P2257, DOI 10.1097/j.pain.0000000000000639; Dear BF, 2015, PAIN, V156, P1920, DOI 10.1097/j.pain.0000000000000251; Dear BF, 2013, PAIN, V154, P942, DOI 10.1016/j.pain.2013.03.005; Deeks J.J., 2010, STAT ALGORITHMS REV, V1; Devineni T, 2005, BEHAV RES THER, V43, P277, DOI 10.1016/j.brat.2004.01.008; Donkin L, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.100; Dowd H, 2015, CLIN J PAIN, V31, P517, DOI 10.1097/AJP.0000000000000201; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Ebert DD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119895; Eccleston C., 2014, COCHRANE LIB; Eccleston C, 2011, PAIN, V152, P1701, DOI 10.1016/j.pain.2011.05.004; Ehde DM, 2014, AM PSYCHOL, V69, P153, DOI 10.1037/a0035747; Everitt H, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-68; Eysenbach G, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1923; Garg S, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4932; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Grist R, 2013, J CONTEMP PSYCHOTHER, V43, P243, DOI 10.1007/s10879-013-9243-y; Heapy AA, 2015, CLIN J PAIN, V31, P470, DOI 10.1097/AJP.0000000000000185; Heber E, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5774; Hedman E, 2012, EXPERT REV PHARM OUT, V12, P745, DOI [10.1586/ERP.12.67, 10.1586/erp.12.67]; Henningsen P, 2007, LANCET, V369, P946, DOI 10.1016/S0140-6736(07)60159-7; Hesser H, 2012, J CONSULT CLIN PSYCH, V80, P649, DOI 10.1037/a0027021; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hoedeman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006524.pub2; Hunt MG, 2015, COGNITIVE THER RES, V39, P215, DOI 10.1007/s10608-014-9647-3; Hunt MG, 2009, BEHAV RES THER, V47, P797, DOI 10.1016/j.brat.2009.05.002; Janse A, 2016, J CONSULT CLIN PSYCH, V84, P377, DOI 10.1037/ccp0000085; Jasper K, 2014, PSYCHOTHER PSYCHOSOM, V83, P234, DOI 10.1159/000360705; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Johnston Samantha, 2013, Clin Epidemiol, V5, P105, DOI 10.2147/CLEP.S39876; Kaldo V, 2008, BEHAV THER, V39, P348, DOI 10.1016/j.beth.2007.10.003; Knowles SR, 2014, SCAND J GASTROENTERO, V49, P387, DOI 10.3109/00365521.2013.865259; Krein SL, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2605; Kristjansdottir OB, 2013, J MED INTERNET RES, V15, P41, DOI 10.2196/jmir.2249; Kulkarni AV, 2009, JAMA-J AM MED ASSOC, V302, P1092, DOI 10.1001/jama.2009.1307; Lackner JM, 2007, GASTROENTEROLOGY, V133, P433, DOI 10.1053/j.gastro.2007.05.014; Lalloo C, 2015, CLIN J PAIN, V31, P557, DOI 10.1097/AJP.0000000000000171; Langguth B, 2013, LANCET NEUROL, V12, P920, DOI 10.1016/S1474-4422(13)70160-1; Lee MH, 2014, INT J UROL, V21, P62, DOI 10.1111/iju.12336; Liegl G, 2015, EUR J GASTROEN HEPAT, V27, P1209, DOI 10.1097/MEG.0000000000000428; Ljotsson B, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-160; Ljotsson B, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-110; Ljotsson B, 2011, AM J GASTROENTEROL, V106, P1481, DOI 10.1038/ajg.2011.139; Ljotsson B, 2010, BEHAV RES THER, V48, P531, DOI 10.1016/j.brat.2010.03.003; Lorig KR, 2008, ARTHRIT RHEUM-ARTHR, V59, P1009, DOI 10.1002/art.23817; Macea DD, 2010, J PAIN, V11, P917, DOI 10.1016/j.jpain.2010.06.005; Mair FS, 2012, B WORLD HEALTH ORGAN, V90, P357, DOI 10.2471/BLT.11.099424; Martlew J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006370.pub2; Mayou R, 2002, BRIT MED J, V325, P265, DOI 10.1136/bmj.325.7358.265; McCombie A, 2015, J CLIN PSYCHOL MED S, V22, P20, DOI 10.1007/s10880-015-9420-0; Menga G, 2014, OCHSNER J, V14, P343; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Miles CL, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2011.01.016; Moessner M, 2014, PSYCHOTHER PSYCH MED, V64, P47, DOI 10.1055/s-0033-1351266; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mourad G, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1491-1; Naylor MR, 2008, PAIN, V134, P335, DOI 10.1016/j.pain.2007.11.001; Oerlemans S, 2011, J PSYCHOSOM RES, V70, P267, DOI 10.1016/j.jpsychores.2010.09.018; Pajak R, 2013, J PSYCHOSOM RES, V75, P103, DOI 10.1016/j.jpsychores.2013.05.007; Pots WTM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0841-6; Richards D, 2012, CLIN PSYCHOL REV, V32, P329, DOI 10.1016/j.cpr.2012.02.004; Richmond H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134192; Rief W, 2014, ANNU REV CLIN PSYCHO, V10, P339, DOI 10.1146/annurev-clinpsy-032813-153745; Rini Christine, 2014, J Med Internet Res, V16, pe245, DOI 10.2196/jmir.3374; Ritter PL, 2011, CHRONIC ILLN, V7, P162, DOI 10.1177/1742395311399127; Riva S, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3474; Rosendal M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008142.pub2; Ruehlman LS, 2012, PAIN, V153, P319, DOI 10.1016/j.pain.2011.10.025; Schubart JR, 2011, CIN-COMPUT INFORM NU, V29, P81, DOI 10.1097/NCN.0b013e3182065eed; Schulz PJ, 2007, INT J PUBLIC HEALTH, V52, P286, DOI 10.1007/s00038-007-5127-9; Shafran R, 2009, BEHAV RES THER, V47, P902, DOI 10.1016/j.brat.2009.07.003; Smeets RJEM, 2006, J PAIN, V7, P261, DOI 10.1016/j.jpain.2005.10.011; Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009; Strom L, 2000, J CONSULT CLIN PSYCH, V68, P722, DOI 10.1037//0022-006X.68.4.722; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; Trompetter HR, 2015, J BEHAV MED, V38, P66, DOI 10.1007/s10865-014-9579-0; Turner JA, 2007, PAIN, V127, P276, DOI 10.1016/j.pain.2006.09.005; Vallejo MA, 2015, J PSYCHIATR RES, V68, P106, DOI 10.1016/j.jpsychires.2015.06.006; van Beugen S, 2014, J MED INTERNET RES, V16, P251, DOI 10.2196/jmir.2777; van der Feltz-Cornelis CM, 2012, J PSYCHOSOM RES, V72, P168, DOI 10.1016/j.jpsychores.2011.11.007; van Gils A, 2016, PSYCHOSOM MED, V78, P728, DOI 10.1097/PSY.0000000000000325; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Veehof MM, 2011, PAIN, V152, P533, DOI 10.1016/j.pain.2010.11.002; Waller R, 2009, PSYCHOL MED, V39, P705, DOI 10.1017/S0033291708004224; Webb TL, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1376; Weise C, 2016, PSYCHOSOM MED, V78, P501, DOI 10.1097/PSY.0000000000000310; Williams DA, 2010, PAIN, V151, P694, DOI 10.1016/j.pain.2010.08.034; Wilson M, 2015, PAIN MANAG NURS, V16, P503, DOI 10.1016/j.pmn.2014.09.009	118	41	41	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0196467	10.1371/journal.pone.0196467	http://dx.doi.org/10.1371/journal.pone.0196467			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF9WG	29768436	Green Published, gold, Green Submitted			2023-01-03	WOS:000432329200028
J	Hirsch, C				Hirsch, Calvin			Review: In adults with normal cognition or MCI, drugs do not prevent or delay cognitive decline	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hirsch, Calvin] Univ Calif, Davis Med Ctr, Sacramento, CA 95819 USA		Hirsch, C (corresponding author), Univ Calif, Davis Med Ctr, Sacramento, CA 95819 USA.							Edmonds EC, 2017, ALZHEIMERS DEMENT NY, V4, P11; Meng XF, 2014, J ALZHEIMERS DIS, V42, P1295, DOI 10.3233/JAD-140954; Petersen RC, 2018, NEUROLOGY, V90, P126, DOI 10.1212/WNL.0000000000004826	3	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 17	2018	168	8					JC39	JC39		10.7326/ACPJC-2018-168-8-039	http://dx.doi.org/10.7326/ACPJC-2018-168-8-039			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC8XZ	29677246				2023-01-03	WOS:000430083100005
J	Iheonu, FO; Fajolu, IB; Ezeaka, CV; Oyibo, WA				Iheonu, Franca Ogechi; Fajolu, Iretiola Bamikeolu; Ezeaka, Chinyere Veronica; Oyibo, Wellington Aghoghovwia			Transfusional malaria in the neonatal period in Lagos, South-West Nigeria	PLOS ONE			English	Article							TRANSMITTED MALARIA; BLOOD-TRANSFUSION	Background and objectives Sick neonates in malaria endemic areas are frequently transfused with donor blood unscreened for malaria parasite. Consequently, they are at risk of transfusional malaria which can lead to increased neonatal mortality. The study aimed to determine the burden of transfusional malaria in neonates to help in policy formulation on prevention of transfusional malaria. Materials and methods One hundred and sixty four neonates admitted into the neonatal unit of a tertiary hospital over a 10 month period who were scheduled for blood transfusion were screened for malaria parasites pre-transfusion, at three and 14 days post transfusion using Giemsa stained thick and thin films. Donor blood was screened for malaria parasites at the point of transfusion. Neonates who developed malaria parasitaemia post transfusion were followed up for signs of malaria. Results All recruited neonates tested negative to malaria parasite pre-transfusion. One hundred and twenty (73.2%) were term neonates with 94(57.3%) aged 1-7days. Four (2.4%) neonates developed malaria parasitaemia three days post transfusion and all four developed fever that resolved on treatment for malaria. Three (1.8%) of 164 donor blood samples had malaria parasitaemia and all three (100%) neonates who were transfused with the infected donor blood developed malaria parasitaemia post transfusion. However, one neonate who developed malaria parasitaemia post transfusion was transfused with non-infected donor blood. Conclusions The prevalence of transfusional malaria in this study is low (2.4%). However, 100% of neonates who received malaria infected donor blood developed transfusional malaria. We therefore recommend routine screening of donor pre-transfusion, testing of neonates who develop fever post transfusion and treatment of those who test positive to malaria.	[Iheonu, Franca Ogechi; Fajolu, Iretiola Bamikeolu; Ezeaka, Chinyere Veronica] Lagos Univ Teaching Hosp, Dept Paediat, Lagos, Nigeria; [Fajolu, Iretiola Bamikeolu; Ezeaka, Chinyere Veronica] Univ Lagos, Dept Paediat, Coll Med, Lagos, Nigeria; [Oyibo, Wellington Aghoghovwia] Univ Lagos, Dept Med Microbiol & Parasitol, Coll Med, Lagos, Nigeria	University of Lagos; University of Lagos	Iheonu, FO (corresponding author), Lagos Univ Teaching Hosp, Dept Paediat, Lagos, Nigeria.	francaiheonu@yahoo.com	Fajolu, Iretiola Bamikeolu/P-5759-2019	Fajolu, Iretiola Bamikeolu/0000-0003-3045-9616; Ezeaka, Veronica Chinyere/0000-0003-1880-4616; Oyibo, Wellington/0000-0002-5730-5396				Agboola T. F., 2010, Annals of Biological Research, V1, P72; AKINBOYE DO, 1987, T ROY SOC TROP MED H, V81, P398, DOI 10.1016/0035-9203(87)90147-7; Ali M. S. M., 2004, Ethiopian Journal of Health Development, V18, P70; Allain JP, 2016, LANCET, V387, P1753, DOI 10.1016/S0140-6736(16)00581-X; Alli J. A., 2010, Research Journal of Medical Sciences, V4, P255, DOI 10.3923/rjmsci.2010.255.275; [Anonymous], S LEONE J BIOMED RES; Ayede A I, 2011, Ann Ib Postgrad Med, V9, P30; Baye Gelaw, 2008, Ethiopian Journal of Health Development, V22, P3; Chattopadhyay R, 2011, TRANSFUSION, V51, P630, DOI 10.1111/j.1537-2995.2010.02872.x; Ghimire P, 2007, SCI WORLD, V5, P81, DOI [10.3126/sw.v5i5.2661, DOI 10.3126/SW.V5I5.2661]; Ibhanesebhor S. E., 1996, Postgraduate Doctor - Africa, V18, P38; Ibhanesebhor SE, 1995, J TROP PEDIATRICS, V41, P330, DOI 10.1093/tropej/41.6.330; Mukhtar M, 2007, Niger J Med, V16, P25; Nansseu JRN, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-465; Ogunlesi TA, 2011, NIGER J CLIN PRACT, V14, P354, DOI 10.4103/1119-3077.86783; Ogunlesi T, 2016, J TROP PEDIATRICS, V62, P107, DOI 10.1093/tropej/fmv083; Okechukwu AA, 2011, J MED MED SCI, V2, P722; Okorafor UP, 2015, ARJ, V1, P354; Owusu-Ofori AK, 2013, CLIN INFECT DIS, V56, P1735, DOI 10.1093/cid/cit130; Owusu-Ofori AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034201; Owusu-Ofori AK, 2010, CLIN INFECT DIS, V51, P1192, DOI 10.1086/656806; WHO, MICR DET ID QUANT MA, P1; World Health Organization, WORLD MAL REP 2015; Zama I, 2013, INTERNAL MED INSIDE, V1	24	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2018	13	4							e0195319	10.1371/journal.pone.0195319	http://dx.doi.org/10.1371/journal.pone.0195319			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB5DC	29614095	Green Submitted, Green Published, gold			2023-01-03	WOS:000429081600045
J	Martinez, SA; Nguyen, ND; Bailey, E; Doyle-Green, D; Hauser, HA; Handrakis, JP; Knezevic, S; Marett, C; Weinman, J; Romero, AF; Santiago, TM; Yang, AH; Yung, L; Asselin, PK; Weir, JP; Kornfeld, SD; Bauman, WA; Spungen, AM; Harel, NY				Martinez, Stephanie A.; Nguyen, Nhuquynh D.; Bailey, Eric; Doyle-Green, Denis; Hauser, Henry A.; Handrakis, John P.; Knezevic, Steven; Marett, Casey; Weinman, Jennifer; Romero, Angelica F.; Santiago, Tiffany M.; Yang, Ajax H.; Yung, Lok; Asselin, Pierre K.; Weir, Joseph P.; Kornfeld, Stephen D.; Bauman, William A.; Spungen, Ann M.; Harel, Noam Y.			Multimodal cortical and subcortical exercise compared with treadmill training for spinal cord injury	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; RANDOMIZED CLINICAL-TRIAL; WEIGHT-SUPPORTED TREADMILL; RETICULAR-FORMATION; H-REFLEX; RECOVERY; BALANCE; WALKING; SYSTEM; TRACT	Background and purpose Spared fibers after spinal cord injury (SCI) tend to consist predominantly of subcortical circuits that are not under volitional (cortical) control. We aim to improve function after SCI by using targeted physical exercises designed to simultaneously stimulate cortical and spared subcortical neural circuits. Methods Participants with chronic motor-incomplete SCI enrolled in a single-center, prospective interventional crossover study. Participants underwent 48 sessions each of weight-supported robotic-assisted treadmill training and a novel combination of balance and fine hand exercises, in randomized order, with a 6-week washout period. Change post-intervention was measured for lower extremity motor score, soleus H-reflex facilitation; seated balance function; ambulation; spasticity; and pain. Results Only 9 of 21 enrolled participants completed both interventions. Thirteen participants completed at least one intervention. Although there were no statistically significant differences, multimodal training tended to increase short-interval H-reflex facilitation, whereas treadmill training tended to improve dynamic seated balance. Discussion The low number of participants who completed both phases of the crossover intervention limited the power of this study to detect significant effects. Other potential explanations for the lack of significant differences with multimodal training could include insufficient engagement of lower extremity motor cortex using skilled upper extremity exercises; and lack of skill transfer from upright postural stability during multimodal training to seated dynamic balance during testing. To our knowledge, this is the first published study to report seated posturography outcomes after rehabilitation interventions in individuals with SCI. Conclusion In participants with chronic incomplete SCI, a novel mix of multimodal exercises incorporating balance exercises with skilled upper extremity exercises showed no benefit compared to an active control program of body weight-supported treadmill training. To improve participant retention in long-term rehabilitation studies, subsequent trials would benefit from a parallel group rather than crossover study design.	[Martinez, Stephanie A.; Nguyen, Nhuquynh D.; Bailey, Eric; Doyle-Green, Denis; Hauser, Henry A.; Handrakis, John P.; Knezevic, Steven; Romero, Angelica F.; Santiago, Tiffany M.; Yang, Ajax H.; Yung, Lok; Asselin, Pierre K.; Kornfeld, Stephen D.; Bauman, William A.; Spungen, Ann M.; Harel, Noam Y.] James J Peters VA Med Ctr, Bronx, NY 10468 USA; [Handrakis, John P.; Marett, Casey; Weinman, Jennifer] New York Inst Technol, Old Westbury, NY 11568 USA; [Yang, Ajax H.; Bauman, William A.; Spungen, Ann M.; Harel, Noam Y.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Weir, Joseph P.] Univ Kansas, Lawrence, KS 66045 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; New York Institute Technology; Icahn School of Medicine at Mount Sinai; University of Kansas	Harel, NY (corresponding author), James J Peters VA Med Ctr, Bronx, NY 10468 USA.; Harel, NY (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.	noam.harel@va.gov	Handrakis, John/AAQ-4407-2020; Harel, Noam Y./I-5268-2019	Handrakis, John/0000-0001-6919-7356; Harel, Noam Y./0000-0003-3085-2194	United States Department of Veterans Affairs [B0881-W, B9212-C]	United States Department of Veterans Affairs(US Department of Veterans Affairs)	NYH received funding from United States Department of Veterans Affairs (B0881-W), and WAB and AMS received funding from United States Department of Veterans Affairs (B9212-C). The funders played a role in study design through critiquing and requiring revision of the original grant proposal. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.	Adams MM, 2007, ARCH PHYS MED REHAB, V88, P1185, DOI 10.1016/j.apmr.2007.06.012; Adams MM, 2006, J SPINAL CORD MED, V29, P167, DOI 10.1080/10790268.2006.11753860; Alexeeva N, 2011, J SPINAL CORD MED, V34, P362, DOI 10.1179/2045772311Y.0000000018; Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barriere G, 2008, J NEUROSCI, V28, P3976, DOI 10.1523/JNEUROSCI.5692-07.2008; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Behrman AL, 2012, ARCH PHYS MED REHAB, V93, P1518, DOI 10.1016/j.apmr.2011.04.027; Penalva JB, 2010, SPINAL CORD, V48, P400, DOI 10.1038/sc.2009.151; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Bernhardt KA, 2012, AM J PHYS MED REHAB, V91, P300, DOI 10.1097/PHM.0b013e31824aab03; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BORG G, 1990, SCAND J WORK ENV HEA, V16, P55, DOI 10.5271/sjweh.1815; Brazg G, 2017, NEUROREHAB NEURAL RE, V31, P944, DOI 10.1177/1545968317731538; Brogardh C, 2010, J REHABIL MED, V42, P789, DOI 10.2340/16501977-0588; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Ferris DP, 2006, EXERC SPORT SCI REV, V34, P113, DOI 10.1249/00003677-200607000-00005; Field-Fote EC, 2011, PHYS THER, V91, P48, DOI 10.2522/ptj.20090359; Filli L, 2014, J NEUROSCI, V34, P13399, DOI 10.1523/JNEUROSCI.0701-14.2014; Floyd AG, 2009, NEUROLOGY, V72, P498, DOI 10.1212/01.wnl.0000341933.97883.a4; Forrest GF, 2008, J SPINAL CORD MED, V31, P509, DOI 10.1080/10790268.2008.11753646; Fregosi M, 2017, EUR J NEUROSCI, V45, P1379, DOI 10.1111/ejn.13576; Harel NY, 2015, J ELECTROMYOGR KINES, V25, P438, DOI 10.1016/j.jelekin.2015.02.009; Harel NY, 2013, BRAIN RES, V1538, P17, DOI 10.1016/j.brainres.2013.07.012; Harel NY, 2013, J SPINAL CORD MED, V36, P127, DOI 10.1179/2045772312Y.0000000053; Harel NY, 2010, J NEUROTRAUM, V27, P2055, DOI 10.1089/neu.2010.1491; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; Herbert WJ, 2015, EXP BRAIN RES, V233, P3231, DOI 10.1007/s00221-015-4390-x; Hubli M, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-5; Iles JF, 2004, BRAIN, V127, P1584, DOI 10.1093/brain/awh173; Jankowska E, 2003, J NEUROSCI, V23, P1867; Jensen JL, 2005, J APPL PHYSIOL, V99, P1558, DOI 10.1152/japplphysiol.01408.2004; Kakulas B A, 1999, J Spinal Cord Med, V22, P119; Kirshblum S, 2014, PHYS MED REH CLIN N, V25, P505, DOI 10.1016/j.pmr.2014.04.001; Knikou M., 2013, EXP BRAIN RES, DOI [10.1002/mus.20333, DOI 10.1002/MUS.20333PMID:15806550]; Labruyere R, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-4; Lalonde R, 2007, PROG NEUROBIOL, V81, P45, DOI 10.1016/j.pneurobio.2006.11.005; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Morawietz C, 2013, ARCH PHYS MED REHAB, V94, P2297, DOI 10.1016/j.apmr.2013.06.023; Navarrete-Opazo A, 2017, ARCH PHYS MED REHAB, V98, P415, DOI 10.1016/j.apmr.2016.09.114; Perez MA, 2004, EXP BRAIN RES, V159, P197, DOI 10.1007/s00221-004-1947-5; Reed WR, 2008, NEUROSCIENCE, V151, P505, DOI 10.1016/j.neuroscience.2007.10.025; Riddle CN, 2009, J NEUROSCI, V29, P4993, DOI 10.1523/JNEUROSCI.3720-08.2009; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sand Sivertsen M, 2014, J NEUROPHYSIOL; Sasaki S, 2004, J NEUROPHYSIOL, V92, P3142, DOI 10.1152/jn.00342.2004; Serranova T, 2008, NEUROSCI LETT, V437, P15, DOI 10.1016/j.neulet.2008.03.068; SHERWOOD AM, 1992, J NEUROL SCI, V110, P90, DOI 10.1016/0022-510X(92)90014-C; Sindhurakar A, 2017, NEUROREHAB NEURAL RE, V31, P122, DOI 10.1177/1545968316662528; Taube W, 2015, CORTEX, V64, P102, DOI 10.1016/j.cortex.2014.09.022; Thomas SL, 2005, J NEUROPHYSIOL, V94, P2844, DOI 10.1152/jn.00532.2005; van den Brand R, 2012, SCIENCE, P336, DOI [10.1523/JNEUROSCI.0701-14.2014, DOI 10.1523/JNEUROSCI.0701-14.2014]; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004; Wolfe DL, 1996, J NEUROTRAUM, V13, P281, DOI 10.1089/neu.1996.13.281; Yang JF, 2014, NEUROREHAB NEURAL RE, V28, P314, DOI 10.1177/1545968313508473; Yukawa Y, 1976, SPINE, V34, P39, DOI [10.1016/j.clinph.2009.08.016, DOI 10.1016/J.CLINPH.2009.08.016]	60	2	2	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0202130	10.1371/journal.pone.0202130	http://dx.doi.org/10.1371/journal.pone.0202130			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP9JF	30092092	Green Submitted, Green Published, gold			2023-01-03	WOS:000441232600091
J	Prakash, K; Gianella, S; Dube, K; Taylor, J; Lee, G; Smith, DM				Prakash, Katya; Gianella, Sara; Dube, Karine; Taylor, Jeff; Lee, GaYoung; Smith, Davey M.			Willingness to participate in HIV research at the end of life (EOL)	PLOS ONE			English	Article							I CANCER TRIALS; CURE RESEARCH; ETHICAL CONSIDERATIONS; CLINICAL-RESEARCH; PHASE-1 ONCOLOGY; PALLIATIVE CARE; ALTRUISM; VACCINE; CHALLENGES; PREVENTION	Introduction Animal models have been vital for scientific discovery but have limitations, especially in infectious disease research. It is essential to develop a means to study these diseases in human models. We hypothesized that altruistic people would willingly participate in research near the end-of-life (EOL), for the benefit of science and to provide one last gift to society. Methodology Two surveys were administered to 377 self-reported HIV-negative and 96 HIV-positive individuals. Hypothetical questions assessed their willingness to participate in altruistic research in the last 6 months of life, which might result in a shortened lifespan or physical discomforts. The self-reported HIV-negative group was also asked about willingness to be exposed to infectious pathogens for the sake of research. Results Almost all responders expressed willingness to participate in research at the EOL, regardless of HIV-status. The majority of participants were willing to endure physical discomfort for the sake of research. 'Blood draws' was identified as the most tolerable physical discomfort (>70% in both groups). In both groups, >60% were willing to shorten their lifespans for the sake of research. A third of the self-reported HIV-negative group expressed willingness to be exposed to at least one infectious agent to participate in EOL research. Conclusions Our exploratory study demonstrates that people would welcome the opportunity to participate in altruistic research near the EOL. Such research could greatly impact the way infectious disease research is conducted. This study is limited however by its hypothetical nature. Further research is necessary to confirm this interest in those with terminal illness before any further clinical research effort at the EOL can be performed.	[Prakash, Katya; Gianella, Sara; Smith, Davey M.] Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA; [Dube, Karine] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA; [Taylor, Jeff] AntiViral Res Ctr AVRC San Diego, CAB, San Diego, CA USA; [Lee, GaYoung] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol Immunol, Baltimore, MD USA; [Smith, Davey M.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Gianella, S (corresponding author), Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA.	gianella@ucsd.edu	Prakash, Katya/ABB-2140-2021; Smith, David/GQQ-8257-2022	Gianella, Sara/0000-0002-9927-0849; Prakash, Katya/0000-0002-8653-4657; Smith, Davey/0000-0003-3603-1733	National Institutes of Health; University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research, California HIV Reserch Program [P30-AI027763]; department of Veterans Affairs; James B. Pendleton Charitable Trust; National Institutes of Health [AI100665, MH100974, MH097520, DA034978, AI007384, AI027763, AI106039, AI43638, AI074621, AI036214, MH101012, UL1TR000100, CARE U19 AI096113, AI068636-09]; California HIV Reserch Program Ideal award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, T32AI007036, U19AI096113, P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research, California HIV Reserch Program(University of California System); department of Veterans Affairs(US Department of Veterans Affairs); James B. Pendleton Charitable Trust; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California HIV Reserch Program Ideal award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported primarily by a grant from the National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research, P30-AI027763 (CNIHR), California HIV Reserch Program Ideal award to Sara Gianella, by the department of Veterans Affairs, the James B. Pendleton Charitable Trust and additional grants from the National Institutes of Health: AI100665, MH100974, MH097520, DA034978, AI007384, AI027763, AI106039, AI43638, AI074621, AI036214, MH101012, UL1TR000100, CARE U19 AI096113 and AI068636-09. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal M, 2003, J PAIN SYMPTOM MANAG, V25, pS25, DOI 10.1016/S0885-3924(03)00057-5; Agrawal M, 2003, JAMA-J AM MED ASSOC, V290, P1075, DOI 10.1001/jama.290.8.1075; Allmark P, 2016, TRANSL LUNG CANCER R, V5, P219, DOI 10.21037/tlcr.2016.03.04; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; Bolt EE, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1879-3; Casarett D, 2001, J Palliat Med, V4, P441, DOI 10.1089/109662101753381566; Cassel JB, 2016, J PAIN SYMPTOM MANAG, V52, P437, DOI 10.1016/j.jpainsymman.2016.02.014; County of San Diego Health and Human Services Agency (HHSA), MONTHL STD REP, V1; Crump MJC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057410; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; de Waal FBM, 2008, ANNU REV PSYCHOL, V59, P279, DOI 10.1146/annurev.psych.59.103006.093625; Dezzutti CS, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20301; Doukas DJ, 2014, CAMB Q HEALTHC ETHIC, V23, P397, DOI 10.1017/S0963180114000073; Dube K, 2017, J VIRUS ERAD, V3, P40; Dube K, 2014, TRENDS MICROBIOL, V22, P547, DOI 10.1016/j.tim.2014.08.003; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Enzinger AC, 2014, J PAIN SYMPTOM MANAG, V47, P1078, DOI 10.1016/j.jpainsymman.2013.07.004; Estelles-Arolas E, 2012, J INF SCI, V38, P189, DOI 10.1177/0165551512437638; Faden R.R., 1986, HIST THEORY INFORM C; Fitzgerald DW, 2011, J INFECT DIS, V203, P765, DOI 10.1093/infdis/jiq114; FREIREICH EJ, 1979, ANNU REV PHARMACOL, V19, P547, DOI 10.1146/annurev.pa.19.040179.002555; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gianella S, 2017, AIDS, V31, P1, DOI 10.1097/QAD.0000000000001300; Grande GE, 2000, PALLIATIVE MED, V14, P69, DOI 10.1191/026921600677940614; Gysels MH, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-123; Hajar Rachel, 2011, Heart Views, V12, P42, DOI 10.4103/1995-705X.81548; Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911; Henderson, 2014, AIDS RES HUM RETROV, V31, P1; Henry B, 2012, ACCOUNT RES, V19, P1, DOI 10.1080/08989621.2011.622173; Holm S., 2001, PRINCIPLES BIOMEDICA, P454, DOI 10.1136/jme.28.5.332-a[332-a-332]; Horng Sam, 2003, IRB, V25, P11, DOI 10.2307/3564408; Jansen Lynn A, 2006, IRB, V28, P13; Jansen LA, 2011, J MED ETHICS, V37, P563, DOI 10.1136/jme.2010.038943; Joffe S, 2006, J CLIN ONCOL, V24, P2987, DOI 10.1200/JCO.2005.04.9296; Lo B, 2013, CURR OPIN HIV AIDS, V8, P243, DOI 10.1097/COH.0b013e32835ea1c5; Mackin ML, 2009, RES GERONTOL NURS, V2, P162, DOI 10.3928/19404921-20090421-05; Miller FG, 2008, CLIN TRIALS, V5, P617, DOI 10.1177/1740774508097576; Pentz RD, 2012, CANCER-AM CANCER SOC, V118, P4571, DOI 10.1002/cncr.27397; Policicchio BB, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00012; PRATT CB, 1991, MED PEDIATR ONCOL, V19, P304, DOI 10.1002/mpo.2950190417; Quinn GP, 2013, MED HEALTH CARE PHIL, V16, P857, DOI 10.1007/s11019-013-9480-6; Rinck GC, 1997, J CLIN ONCOL, V15, P1697, DOI 10.1200/JCO.1997.15.4.1697; Roberts TG, 2004, JAMA-J AM MED ASSOC, V292, P2130, DOI 10.1001/jama.292.17.2130; Sanghavi DM, NYTIMES; Shilts R., 1987, BAND PLAYED POLITICS; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Sprouse J, 2011, BEHAV RES METHODS, V43, P155, DOI 10.3758/s13428-010-0039-7; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stiel S, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0020-4; Sugarman J, 2013, ANN INTERN MED, V159, P490, DOI 10.7326/00030003-4819-159-7-201310010-00694; Weber JS, 2015, J CLIN ONCOL, V33, P278, DOI 10.1200/JCO.2014.58.2635	53	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2018	13	7							e0199670	10.1371/journal.pone.0199670	http://dx.doi.org/10.1371/journal.pone.0199670			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN8PM	30036365	Green Submitted, gold, Green Published			2023-01-03	WOS:000439429200006
J	Mayhew, E				Mayhew, Emily			Defiant gardens: from Helmand to Headley Court	LANCET			English	Editorial Material									[Mayhew, Emily] Imperial Coll London, Dept Bioengn, TRBL Ctr Blast Injury Studies, London SW7 2AZ, England	Imperial College London	Mayhew, E (corresponding author), Imperial Coll London, Dept Bioengn, TRBL Ctr Blast Injury Studies, London SW7 2AZ, England.	e.mayhew@imperial.ac.uk						Helphand Kenneth I., 2006, DEFIANT GARDENS MAKI; Hickman C, 2013, THERAPEUTIC LANDSCAP; Mayhew E, 2017, A HEAVY RECKONING; Wilson E.O, 1984, BIOPHILIA, DOI DOI 10.2307/J.CTVK12S6H	4	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2018	392	10142					114	115		10.1016/S0140-6736(18)31511-3	http://dx.doi.org/10.1016/S0140-6736(18)31511-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM8RQ	30017125				2023-01-03	WOS:000438501300018
J	Ricci, F; Casiraghi, C; Storti, M; D'Alo, F; Catozzi, C; Ciccimarra, R; Ravanetti, F; Cacchioli, A; Villetti, G; Civelli, M; Murgia, X; Carnielli, V; Salomone, F				Ricci, Francesca; Casiraghi, Costanza; Storti, Matteo; D'Alo, Francesco; Catozzi, Chiara; Ciccimarra, Roberta; Ravanetti, Francesca; Cacchioli, Antonio; Villetti, Gino; Civelli, Maurizio; Murgia, Xabi; Carnielli, Virgilio; Salomone, Fabrizio			Surfactant replacement therapy in combination with different non-invasive ventilation techniques in spontaneously-breathing, surfactant-depleted adult rabbits	PLOS ONE			English	Article							POSITIVE-PRESSURE VENTILATION; RESPIRATORY-DISTRESS-SYNDROME; AIRWAY PRESSURE; RANDOMIZED-TRIAL; PRETERM INFANTS; TREATING APNEA; OPEN-LABEL; PREMATURITY; NEBULIZATION; EXTUBATION	Nasal intermittent positive pressure ventilation (NIPPV) holds great potential as a primary ventilation support method for Respiratory Distress Syndrome (RDS). The use of NIPPV may also be of great value combined with minimally invasive surfactant delivery. Our aim was to implement an in vivo model of RDS, which can be managed with different non-invasive ventilation (NIV) strategies, including non-synchronized NIPPV, synchronized NIPPV (SNIPPV), and nasal continuous positive airway pressure (NCPAP). Forty-two surfactant-depleted adult rabbits were allocated in six different groups: three groups of animals were treated with only NIV for three hours (NIPPV, SNIPPV, and NCPAP groups), while three other groups were treated with surfactant (SF) followed by NIV (NIPPV+SF, SNIPPV+SF, and NCPAP+SF groups). Arterial gas exchange, ventilation indices, and dynamic compliance were assessed. Post-mortem the lungs were sampled for histological evaluation. Surfactant depletion was successfully achieved by repeated broncho-alveolar lavages (BALs). After BALs, all animals developed a moderate respiratory distress, which could not be reverted by merely applying NIV. Conversely, surfactant administration followed by NIV induced a rapid improvement of arterial oxygenation in all surfactant-treated groups. Breath synchronization was associated with a significantly better response in terms of gas exchange and dynamic compliance compared to non-synchronized NIPPV, showing also the lowest injury scores after histological assessment. The proposed in vivo model of surfactant deficiency was successfully managed with NCPAP, NIPPV, or SNIPPV; this model resembles a moderate respiratory distress and it is suitable for the preclinical testing of less invasive surfactant administration techniques.	[Ricci, Francesca; Casiraghi, Costanza; Storti, Matteo; D'Alo, Francesco; Catozzi, Chiara; Villetti, Gino; Civelli, Maurizio; Salomone, Fabrizio] Chiesi Farmaceut, R&D Dept, Parma, Italy; [Ciccimarra, Roberta; Ravanetti, Francesca; Cacchioli, Antonio] Univ Parma, Dept Vet Sci, Parma, Italy; [Murgia, Xabi] Helmholtz Inst Pharmaceut Res Saarland, Dept Drug Delivery, Saarbrucken, Germany; [Carnielli, Virgilio] Polytech Univ Marche, Div Neonatol, Ancona, Italy; [Carnielli, Virgilio] Salesi Childrens Hosp, Ancona, Italy	Chiesi Pharmaceuticals Inc; University of Parma; Helmholtz Association; Helmholtz-Center for Infection Research; Marche Polytechnic University	Casiraghi, C (corresponding author), Chiesi Farmaceut, R&D Dept, Parma, Italy.	c.casiraghi@chiesi.com	Ciccimarra, Roberta/AAC-4086-2020	Ravanetti, Francesca/0000-0001-8729-3237; salomone, fabrizio/0000-0002-9083-3932; CASIRAGHI, COSTANZA/0000-0001-6225-5250; Ciccimarra, Roberta/0000-0001-9431-143X	Chiesi Farmaceutici	Chiesi Farmaceutici(Chiesi Pharmaceuticals Inc)	Chiesi Farmaceutici has funded this study and provided support in the form of salaries for authors [FR, CC, MS, FDA, CC, GV, MC, FS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Barrington KJ, 2001, PEDIATRICS, V107, P638, DOI 10.1542/peds.107.4.638; Berggren E, 2000, ACTA PAEDIATR, V89, P460, DOI 10.1080/080352500750028195; Bhandari V, 2007, J PERINATOL, V27, P697, DOI 10.1038/sj.jp.7211805; Chang HY, 2011, PEDIATR RES, V69, P84, DOI 10.1203/PDR.0b013e3181ff6770; Chen L, 2015, SCI REP-UK, V5, DOI 10.1038/srep14483; Dargaville PA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3985; Dargaville PA, 2011, ARCH DIS CHILD-FETAL, V96, pF243, DOI 10.1136/adc.2010.192518; Davis Peter G, 2012, NEWBORN LUNG NEONATO, P265; Dijk PH, 1997, INTENS CARE MED, V23, P1077, DOI 10.1007/s001340050459; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Finer NN, 2010, J AEROSOL MED PULM D, V23, P303, DOI 10.1089/jamp.2009.0758; Gizzi C, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/301818; Gizzi C, 2015, ARCH DIS CHILD-FETAL, V100, pF17, DOI 10.1136/archdischild-2013-305892; Gopel W, 2011, LANCET, V378, P1627, DOI 10.1016/S0140-6736(11)60986-0; Hayes D, 2010, RESPIRATION, V79, P425, DOI 10.1159/000242497; Hutten MC, 2015, PEDIATR RES, V78, P664, DOI 10.1038/pr.2015.165; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Jorch G, 1997, PEDIATR PULM, V24, P222, DOI 10.1002/(SICI)1099-0496(199709)24:3<222::AID-PPUL9>3.0.CO;2-O; KATTWINKEL J, 1975, J PEDIATR-US, V86, P588, DOI 10.1016/S0022-3476(75)80158-2; Khalaf MN, 2001, PEDIATRICS, V108, P13, DOI 10.1542/peds.108.1.13; Kishore MSS, 2009, ACTA PAEDIATR, V98, P1412, DOI 10.1111/j.1651-2227.2009.01348.x; Lin CH, 1998, PEDIATR PULM, V26, P349, DOI 10.1002/(SICI)1099-0496(199811)26:5<349::AID-PPUL8>3.0.CO;2-7; Mazela J, 2007, CURR OPIN PEDIATR, V19, P155, DOI 10.1097/MOP.0b013e32807fb013; Mazela J, 2011, EUR J PEDIATR, V170, P433, DOI 10.1007/s00431-010-1292-6; Moretti C, 2016, NEONATOLOGY, V109, P359, DOI 10.1159/000444898; MORLEY CJ, 1988, EARLY HUM DEV, V17, P41, DOI 10.1016/S0378-3782(88)80056-2; Mrozek JD, 1997, AM J RESP CRIT CARE, V156, P1058, DOI 10.1164/ajrccm.156.4.9610104; Nkadi PO, 2009, MOL GENET METAB, V97, P95, DOI 10.1016/j.ymgme.2009.01.015; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Owen LS, 2011, ARCH DIS CHILD-FETAL, V96, pF422, DOI 10.1136/adc.2010.205195; Owen LS, 2016, SEMIN FETAL NEONAT M, V21, P146, DOI 10.1016/j.siny.2016.01.003; Pedersen M, 1998, INHALATION AEROSOL N; Ricci F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169190; Roberts KD, 2010, PEDIATR RES, V68, P414, DOI 10.1203/PDR.0b013e3181ef7619; SAUNDERS RA, 1976, BIOL NEONATE, V29, P178; SPEER CP, 1992, PEDIATRICS, V89, P13; Stoll BJ, 2010, PEDIATRICS, V126, P443, DOI 10.1542/peds.2009-2959; Sweet DG, 2016, NEONATOLOGY, P107, DOI [10.1159/000448985, DOI 10.1159/000448985]; Walsh BK, 2013, RESP CARE, V58, P367, DOI 10.4187/respcare.02189; Walther FJ, 2014, PEERJ, V2, DOI 10.7717/peerj.403; Rojas-Reyes MX, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000510.pub2; Zimmermann AM, 2010, PEDIATR PULM, V45, P782, DOI 10.1002/ppul.21252; Zimmermann L J I, 2005, Biol Neonate, V87, P296, DOI 10.1159/000084877	43	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2018	13	7							e0200542	10.1371/journal.pone.0200542	http://dx.doi.org/10.1371/journal.pone.0200542			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM8FT	30001410	Green Published, gold, Green Submitted			2023-01-03	WOS:000438457400076
J	Lin, ZX; Yang, Z; He, BH; Wang, DD; Gao, XY; Tam, SY; Wu, VWC				Lin, Zhixiong; Yang, Zhining; He, Binghui; Wang, Dangdang; Gao, Xiaoyin; Tam, Shing-yau; Wu, Vincent Wing Cheung			Pattern of radiation-induced thyroid gland changes in nasopharyngeal carcinoma patients in 48 months after radiotherapy	PLOS ONE			English	Article							NECK-CANCER PATIENTS; RETROSPECTIVE ANALYSIS; DOSIMETRIC PREDICTORS; HYPOTHYROIDISM; HEAD; THERAPY; DISORDERS; IRRADIATION; COHORT; RISK	Objectives Radiation-induced hypothyroidism is the most common thyroid disorder after radiotherapy in nasopharyngeal carcinoma (NPC) patients. This study evaluated the pattern of radiation-induced thyroid gland changes in 48 months after radiotherapy in NPC patients and the association of hypothyroidism incidence with thyroid dose. Methods Fifty-six NPC patients treated by intensity modulated radiotherapy in 2013 were recruited. All patients received baseline thyroid hormones (fT3, fT4 and TSH) tests and CT scan before radiotherapy. Repeated measures of the thyroid hormones and gland volume were performed at 3, 6, 12, 18, 24, 30, 36 and 48 months after treatment. Trend lines of the thyroid volume and hormone level changes against time were plotted. The incidence of hypothyroidism patients and its relationship with the dose were also evaluated. Results The mean thyroid volume followed a decreasing trend after radiotherapy, reaching a minimum (-39.8%) at 30 months and slightly increased afterward. The fT4 level followed a similar pattern with its mean value dropped by 21.5% at 30 months and became steady after 36 months. TSH level showed gradual rise from just after radiotherapy, reaching a peak at 24 months and became relatively steady after 36 months. The incidence of hypothyroidism increased to a maximum at 24 months (28.6%) and dropped afterwards. Thyroid D-mean and D-50 were significantly correlated with hypothyroidism incidence in 12 to 30 months (p > 0.40, p < 0.05). Conclusion The patterns of radiation induced thyroid volume shrinkage and fT4 level reduction were similar, with both of them showed decreasing trend from 0 to 30 months. The thyroid volume and function reached a relatively steady state after 36 months. The incidence of hypothyroidism increased up to 24 months and its frequency was associated with the thyroid dose.	[Lin, Zhixiong; Yang, Zhining; He, Binghui; Wang, Dangdang; Gao, Xiaoyin; Wu, Vincent Wing Cheung] Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China; [Tam, Shing-yau; Wu, Vincent Wing Cheung] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China	Shantou University; Hong Kong Polytechnic University	Wu, VWC (corresponding author), Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China.; Wu, VWC (corresponding author), Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China.	htvinwu@polyu.edu.hk	Tam, Shing Yau/AAZ-1345-2020; Tam, Shing Yau/AAN-4109-2020	Tam, Shing Yau/0000-0002-5899-1041; Lin, Zhixiong/0000-0003-4898-7441; WU, Wing Cheung Vincent/0000-0002-1257-4154	Hong Kong Polytechnic University [G-YN45]	Hong Kong Polytechnic University(Hong Kong Polytechnic University)	This study was funded by Internal Central Research Grant of the Hong Kong Polytechnic University (Project code: G-YN45); Hong Kong Polytechnic University Internal Grant No: G-YN45	Alterio D, 2007, INT J RADIAT ONCOL, V67, P144, DOI 10.1016/j.ijrobp.2006.08.051; Bakhshandeh M, 2012, INT J RADIAT ONCOL, V83, P198, DOI 10.1016/j.ijrobp.2011.05.064; Berges O, 2010, CANCER RADIOTHER, V14, P307, DOI 10.1016/j.canrad.2010.03.005; Bhandare N, 2007, INT J RADIAT ONCOL, V68, P1131, DOI 10.1016/j.ijrobp.2007.01.029; CANNON CR, 1994, LARYNGOSCOPE, V104, P1, DOI 10.1288/00005537-199411001-00001; El-Shebiney M, 2016, DAN MED J, V63; Fan CY, 2017, RADIOTHER ONCOL, V123, P394, DOI 10.1016/j.radonc.2017.04.025; Fujiwara M, 2015, J RADIAT RES, V56, P577, DOI 10.1093/jrr/rrv006; Jereczek-Fossa BA, 2004, CANCER TREAT REV, V30, P369, DOI 10.1016/j.ctrv.2003.12.003; Khandelwal D, 2012, DRUGS, V72, P17, DOI 10.2165/11598070-000000000-00000; Lee V, 2016, CLIN ONCOL-UK, V28, pE52, DOI 10.1016/j.clon.2016.05.004; Lin Zhi-Xiong, 2009, Ai Zheng, V28, P1029; Lin ZX, 2014, HEAD NECK-J SCI SPEC, V36, P171, DOI 10.1002/hed.23285; Lin ZX, 2013, J MED IMAG RADIAT ON, V57, P713, DOI 10.1111/1754-9485.12074; Lin ZX, 2011, THYROID, V21, P19, DOI 10.1089/thy.2010.0229; Miller MC, 2009, CURR OPIN OTOLARYNGO, V17, P111, DOI 10.1097/MOO.0b013e328325a538; Nishiyama K, 1996, INT J RADIAT ONCOL, V34, P439, DOI 10.1016/0360-3016(95)02079-9; Ozawa H, 2007, AM J OTOLARYNG, V28, P46, DOI 10.1016/j.amjoto.2006.06.011; Siala W, 2011, ANN ENDOCRINOL-PARIS, V72, P19, DOI 10.1016/j.ando.2010.06.005; Sommat K, 2017, INT J RADIAT ONCOL, V98, P574, DOI 10.1016/j.ijrobp.2017.03.007; UY HL, 1995, AM J MED, V99, P173, DOI 10.1016/S0002-9343(99)80137-5; Wu YH, 2010, INT J RADIAT ONCOL, V76, P1133, DOI 10.1016/j.ijrobp.2009.03.011; Zhai RP, 2017, ORAL ONCOL, V68, P44, DOI 10.1016/j.oraloncology.2017.03.005	23	14	14	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2018	13	7							e0200310	10.1371/journal.pone.0200310	http://dx.doi.org/10.1371/journal.pone.0200310			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM3UN	29985952	gold, Green Published, Green Submitted			2023-01-03	WOS:000438035500031
J	Okamoto, T; Hatakeyama, S; Hosogoe, S; Tanaka, Y; Imanishi, K; Takashima, T; Saitoh, F; Suzuki, T; Ohyama, C				Okamoto, Teppei; Hatakeyama, Shingo; Hosogoe, Shogo; Tanaka, Yoshimi; Imanishi, Kengo; Takashima, Toru; Saitoh, Fumitada; Suzuki, Tadashi; Ohyama, Chikara			Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis	PLOS ONE			English	Article							CORONARY-ARTERY CALCIFICATION; CHRONIC KIDNEY-DISEASE; VASCULAR CALCIFICATION; CARDIOVASCULAR RISK; SERUM MAGNESIUM; HYPOMAGNESEMIA; RESISTANCE; CELLS; CKD	Backgrounds Proton pump inhibitors (PPIs) can be associated with vascular calcification in patients undergoing dialysis through hypomagnesemia. However, only few studies have demonstrated the influence of PPIs on vascular calcification in patients on maintenance hemodialysis (HD). This study aimed to investigate whether the use of PPIs accelerates vascular calcification in patients on HD. Materials and methods We retrospectively evaluated 200 HD patients who underwent regular blood tests and computed tomography (CT) between 2016 and 2017. The abdominal aortic calcification index (ACI) was measured using abdominal CT. The difference in the ACI values between 2016 and 2017 was evaluated as Delta ACI. Patients were divided into PPI and non-PPI groups, and variables, such as patient background, medication, laboratory data, and Delta ACI were compared. Factors independently associated with higher Delta ACI progression (>= third tertile value of Delta ACI in this study) were determined using multivariate logistic regression analysis. Results The PPI and non-PPI groups had 112 (56%) and 88 (44%) patients, respectively. Median and third tertile value of Delta ACIs were 4.2% and 5.8%, respectively. Serum magnesium was significantly lower in the PPI (2.1 mg/dL) than in the non-PPI (2.3 mg/dL) group (P < 0.001). Median Delta ACI was significantly higher in the PPI (5.0%) than in the non-PPI (3.8%) group (P = 0.009). A total of 77 (39%) patients had a higher Delta ACI. Multivariate analysis revealed that PPIs (odds ratio = 2.23; 95% confidence interval = 1.11-4.49), annual mean calcium phosphorus product, ACI in 2016, baseline serum magnesium levels, and HD vintage were independent factors associated with higher Delta ACI progression after adjusting for confounders. Conclusion PPI use may accelerate vascular calcification in patients on HD. Further studies are necessary to elucidate their influence on vascular calcification.	[Okamoto, Teppei; Tanaka, Yoshimi; Imanishi, Kengo; Takashima, Toru; Saitoh, Fumitada] Aomori Hosp, Oyokyo Kidney Res Inst, Dept Urol, Aomori, Japan; [Hatakeyama, Shingo; Hosogoe, Shogo; Ohyama, Chikara] Hirosaki Univ, Grad Sch Med, Dept Urol, Aomori, Japan; [Suzuki, Tadashi] Oyokyo Kidney Res Inst, Dept Urol, Aomori, Japan	Hirosaki University	Okamoto, T (corresponding author), Aomori Hosp, Oyokyo Kidney Res Inst, Dept Urol, Aomori, Japan.	tepperococcus@yahoo.co.jp	Hatakeyama, Shingo/E-9234-2013; Hatakeyama, Shingo/AAQ-2583-2020	Hatakeyama, Shingo/0000-0002-0026-4079; Okamoto, Teppei/0000-0002-3750-3811				Alhosaini M, 2014, AM J NEPHROL, V39, P204, DOI 10.1159/000360011; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; Chen NC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9035193; Coen G, 2009, J NEPHROL, V22, P616; Costarelli L, 2017, BIOGERONTOLOGY, V18, P217, DOI 10.1007/s10522-016-9675-3; Devasia RA, 2009, AM J RESP CRIT CARE, V180, P365, DOI 10.1164/rccm.200901-0146OC; FDA Drug Safety Communication, LOW MAGN LEV CAN BE; Forgacs I, 2008, BMJ-BRIT MED J, V336, P2, DOI 10.1136/bmj.39406.449456.BE; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Fukushi K, 2017, INT J UROL, V24, P361, DOI 10.1111/iju.13318; Fusaro M, 2013, DRUG SAFETY, V36, P635, DOI 10.1007/s40264-013-0062-6; Garland JS, 2008, AM J KIDNEY DIS, V52, P849, DOI 10.1053/j.ajkd.2008.04.012; Ghebremariam YT, 2015, VASC MED, V20, P309, DOI 10.1177/1358863X14568444; Ghebremariam YT, 2013, CIRCULATION, V128, P845, DOI 10.1161/CIRCULATIONAHA.113.003602; Iribarren C, 2007, EUR J CARDIOV PREV R, V14, P222, DOI 10.1097/01.hjr.0000230108.86147.40; Johnsen SP, 2001, THROMB HAEMOSTASIS, V86, P563; Kim HG, 2011, HEMODIAL INT, V15, P460, DOI 10.1111/j.1542-4758.2011.00571.x; Kircelli F, 2012, NEPHROL DIAL TRANSPL, V27, P514, DOI 10.1093/ndt/gfr321; Kobayashi S, 2008, CLIN J AM SOC NEPHRO, V3, P1289, DOI 10.2215/CJN.00010108; Lazarus B, 2016, JAMA INTERN MED, V176, P238, DOI 10.1001/jamainternmed.2015.7193; Li L, 2015, AM J KIDNEY DIS, V66, P1047, DOI 10.1053/j.ajkd.2015.05.024; Louvet L, 2013, NEPHROL DIAL TRANSPL, V28, P869, DOI 10.1093/ndt/gfs520; MEEMA HE, 1987, KIDNEY INT, V32, P388, DOI 10.1038/ki.1987.222; Mishima K, 2015, EBIOMEDICINE, V2, P2046, DOI 10.1016/j.ebiom.2015.11.024; Molnar AO, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0549-y; Nakashima A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143656; Naunton M, 2000, J CLIN PHARM THER, V25, P333, DOI 10.1046/j.1365-2710.2000.00312.x; Perazella MA, 2013, KIDNEY INT, V83, P553, DOI 10.1038/ki.2012.462; Shah NH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124653; Shroff RC, 2008, CIRCULATION, V118, P1748, DOI 10.1161/CIRCULATIONAHA.108.783738; Song YR, 2015, WORLD J GASTROENTERO, V21, P4919, DOI 10.3748/wjg.v21.i16.4919; Taniwaki H, 2005, NEPHROL DIAL TRANSPL, V20, P2472, DOI 10.1093/ndt/gfi039; Tsushima M, 2008, INT J UROL, V15, P48, DOI 10.1111/j.1442-2042.2007.01925.x; van Zuijdewijn CLMD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143104; Yamada K, 2007, NEPHROL DIAL TRANSPL, V22, P2032, DOI 10.1093/ndt/gfm031; Yepuri G, 2016, CIRC RES, V118, pE36, DOI 10.1161/CIRCRESAHA.116.308807	36	11	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2018	13	7							e0199160	10.1371/journal.pone.0199160	http://dx.doi.org/10.1371/journal.pone.0199160			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL5XD	29969455	gold, Green Published, Green Submitted			2023-01-03	WOS:000437246700011
J	Koyama, N; Katayanagi, S; Kawachi, S				Koyama, Nobuyuki; Katayanagi, Sou; Kawachi, Shigeyuki			Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia	PLOS ONE			English	Article							PROGNOSTIC-SIGNIFICANCE; HISTOLOGIC PATTERN; ACUTE EXACERBATION; GUIDELINES	Objective Combination treatment with ramucirumab and paclitaxel shows significant efficacy in patients with advanced gastric cancer as a second-line standard therapy. However, limited information is available about the development of pneumonitis associated with this treatment in clinical practice. This study aimed to characterize this form of pneumonitis and identify the risk factors for its onset. Methods We retrospectively analyzed the medical records of 44 patients with gastric cancer who received combination treatment with ramucirumab and paclitaxel from 2016 to 2017. Then, the clinicopathological characteristics of patients who developed treatment-related pneumonitis were evaluated and further compared with those of patients who did not. Results Six patients (13.6%) developed pneumonitis within five treatment cycles, and in five cases, remission was observed after cessation of combination treatment alone. The onset of pneumonitis was independently associated with pre-existing interstitial lung disease (ILD) (p = 0.025; odds ratio = 206.4). Patients with pneumonitis showed reduced time to treatment failure (median 56 vs. 138 days; p = 0.008), as compared with those without pneumonitis. Most patients with pre-existing ILD with a usual interstitial pneumonia (UIP) pattern developed pneumonitis. Conclusions In clinical practice, pneumonitis associated with the combination treatment of ramucirumab and paclitaxel was generally mild, but common. Patients with gastric cancer with pre-existing ILD, particularly those presenting with a UIP pattern, undergoing this combination treatment, should be carefully monitored for the development of treatment-related pneumonitis.	[Koyama, Nobuyuki] Tokyo Med Univ, Hachioji Med Ctr, Dept Clin Oncol, Hachioji, Tokyo, Japan; [Katayanagi, Sou; Kawachi, Shigeyuki] Tokyo Med Univ, Hachioji Med Ctr, Dept Digest & Transplantat Surg, Hachioji, Tokyo, Japan	Tokyo Medical University; Tokyo Medical University	Koyama, N (corresponding author), Tokyo Med Univ, Hachioji Med Ctr, Dept Clin Oncol, Hachioji, Tokyo, Japan.	nkoyama@tokyo-med.ac.jp		Koyama, Nobuyuki/0000-0002-3989-2275	Japan Society for the Promotion of Science KAKENHI [JP17K09671]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	NK was funded by the Japan Society for the Promotion of Science KAKENHI Grant Number JP17K09671 (https://www.jsps.go.jp/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Thoracic S, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; Chen YJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001451; Daniil ZD, 1999, AM J RESP CRIT CARE, V160, P899, DOI 10.1164/ajrccm.160.3.9903021; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5, DOI 10.1164/ajrccm.161.1.9906062; Japanese Gastric Canc Assoc, 2017, GASTRIC CANCER, V20, P1, DOI [10.1007/s10120-016-0622-4, 10.1007/s10120-020-01042-y]; Kenmotsu H, 2011, J THORAC ONCOL, V6, P1242, DOI 10.1097/JTO.0b013e318216ee6b; Nicholson AC, 2000, AM J RESP CRIT CARE, V162, P2213, DOI 10.1164/ajrccm.162.6.2003049; Qiu Haibo, 2018, Zhonghua Wei Chang Wai Ke Za Zhi, V21, P160; Ryerson CJ, 2015, EUR RESPIR J, V46, P512, DOI 10.1183/13993003.00419-2015; Sekimoto Y, 2016, RESPIROL CASE REP, V4, DOI 10.1002/rcr2.151; Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Usui K, 2011, JPN J CLIN ONCOL, V41, P498, DOI 10.1093/jjco/hyr006; Vancheri C, 2013, EUR RESPIR J, V41, P262, DOI 10.1183/09031936.00115112; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Wilcox BE, 2008, RESP MED, V102, P273, DOI 10.1016/j.rmed.2007.09.001; Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6; Yasuda Y, 2017, MOL CLIN ONCOL, V7, P677, DOI 10.3892/mco.2017.1373	22	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198886	10.1371/journal.pone.0198886	http://dx.doi.org/10.1371/journal.pone.0198886			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879213	Green Published, Green Submitted, gold			2023-01-03	WOS:000434384900094
J	Willink, A; DuGoff, EH				Willink, Amber; DuGoff, Eva H.			Integrating Medical and Nonmedical Services - The Promise and Pitfalls of the CHRONIC Care Act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HOME		[Willink, Amber] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [DuGoff, Eva H.] Univ Maryland, Dept Hlth Serv Adm, College Pk, MD 20742 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland College Park	Willink, A (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.			DuGoff, Eva/0000-0001-6673-8428				Cooper AL, 2012, NEW ENGL J MED, V366, P150, DOI 10.1056/NEJMsa1104273; Davis K, 2016, AM J MANAG CARE, V22, P764; Kan HJ, 2018, MED CARE, V56, P233, DOI 10.1097/MLR.0000000000000865; Park S, 2017, SERVICE LEVEL SELECT; Ruiz S, 2017, HEALTH AFFAIR, V36, P425, DOI 10.1377/hlthaff.2016.1305	5	34	34	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 7	2018	378	23					2153	2155		10.1056/NEJMp1803292	http://dx.doi.org/10.1056/NEJMp1803292			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GI3HS	29874539				2023-01-03	WOS:000434263000001
J	Ziakas, PD; Kourbeti, IS; Poulou, LS; Vlachogeorgos, GS; Mylonakis, E				Ziakas, Panayiotis D.; Kourbeti, Irene S.; Poulou, Loukia S.; Vlachogeorgos, Georgios S.; Mylonakis, Eleftherios			Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect"	PLOS ONE			English	Article							ATRIAL-FIBRILLATION; NATIONAL TRENDS; WARFARIN; PREVENTION; DABIGATRAN; DISEASE; STROKE	Introduction Direct oral anticoagulants (DOAC) have gained an increased share over warfarin for prevention and treatment of thromboembolic disease. We studied DOAC adoption across providers and medical specialties. Methods Retrospective, cross-sectional analysis of Medicare Part D public use files (PUF), 2013 to 2015. We summarized prescription data for claims and drug payment, stratified by drug class, specialty and calendar year. We treated DOAC claims as a count outcome and explored patterns of expansion across prescribers via a truncated negative binomial regression. We described dispersion and spread in DOAC prescribing, across hospital referral regions (HRRs), including the p90/p10 ratios, and the median absolute deviation from the median. Results In 2015 part D PUF, oral anticoagulant claims have climbed to approximately 24.4 million with a payment cost of approximately $3.3 billion. DOAC claims comprised 31.0% of oral anticoagulant claims, showing a relative increase of approximately 127% compared to 2013. The upper decile of prescribers accounted for half of the oral anticoagulant prescriptions and the resulting cost. The median cost per DOAC claim in 2015 was $367.4 (inter quartile range 323.9 to 445.9), as opposed to $12.3 (interquartile range 9.2 to 16.5) for warfarin. The median cost per standardized (30-day supply) prescription was $317.0 (interquartile range 303.8 to 324.3) and $8.0 (6.7 to 9.8) for DOACs and warfarin, respectively. DOAC adoption differs by specialty. Cardiologists, cardiac electrophysiologists and orthopedics had the highest predicted DOAC share per 100 claims (53.8, 72.9 and 71.5, respectively in 2015); nephrologists, family practitioners and geriatricians the lowest (22.3, 21.5 and 20.7, respectively in 2015). The p90/p10 ratio and the median absolute deviation from the median varied across HRRs and correlated positively with the prevalence of stroke and atrial fibrillation in the Medicare population. Conclusions DOACs have been increasing their share year-over-year, but adoption varies across specialties. In prevalent areas for stroke and atrial fibrillation, prescription dispersion magnifies, and this may signify a rapid adoption by top providers.	[Ziakas, Panayiotis D.] Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA; [Kourbeti, Irene S.] Univ Athens, Dept Internal Med 1, Sch Med, Athens, Greece; [Poulou, Loukia S.] IASO Matern Clin, Div Med Imaging & Intervent Radiol, Athens, Greece; [Vlachogeorgos, Georgios S.] Iatriki Frontida Med Ctr, Chalkida, Greece; [Mylonakis, Eleftherios] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA	Brown University; Athens Medical School; National & Kapodistrian University of Athens; Brown University	Mylonakis, E (corresponding author), Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.	emylonakis@lifespan.org		Mylonakis, Eleftherios/0000-0002-4624-0777; Ziakas, Panayiotis/0000-0002-5943-8635				Abohelaika S, 2014, AGE AGEING, V43, P708, DOI 10.1093/ageing/afu074; Alpert JS, 2014, AM J MED, V127, P1027, DOI 10.1016/j.amjmed.2014.07.028; Baik Seo Hyon, 2016, J Manag Care Spec Pharm, V22, P281, DOI 10.18553/jmcp.2016.22.3.281; Barnes GD, 2015, AM J MED, V128, P1300, DOI 10.1016/j.amjmed.2015.05.044; Bauer KA, 2013, HEMATOL-AM SOC HEMAT, P464, DOI 10.1182/asheducation-2013.1.464; Canestaro WJ, 2013, CIRC-CARDIOVASC QUAL, V6, P724, DOI 10.1161/CIRCOUTCOMES.113.000661; Chen JH, 2016, JAMA INTERN MED, V176, P259, DOI 10.1001/jamainternmed.2015.6662; Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Desai NR, 2014, AM J MED, V127, P1075, DOI 10.1016/j.amjmed.2014.05.013; Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615; Freeman JV, 2017, CIRCULATION, V135, P1227, DOI 10.1161/CIRCULATIONAHA.116.022388; Gibson CM, 2016, NEW ENGL J MED, V375, P2423, DOI 10.1056/NEJMoa1611594; Gilligan AM, 2018, CURR MED RES OPIN, V34, P285, DOI 10.1080/03007995.2017.1409425; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hilbe J.M., 2007, NEGATIVE BINOMIAL RE; Hoadley J., 2016, MEDICARE D; Lauffenburger JC, 2013, PHARMACOEPIDEM DR S, V22, P899, DOI 10.1002/pds.3458; Leys C, 2013, J EXP SOC PSYCHOL, V49, P764, DOI 10.1016/j.jesp.2013.03.013; Lo-Ciganic WH, 2016, MED CARE, V54, P725, DOI 10.1097/MLR.0000000000000549; Lopez-Lopez JA, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5058; Lubloy A, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-469; Lutz J, 2017, INT J NEPHROL RENOV, V10, P135, DOI 10.2147/IJNRD.S105771; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Reeves R.V., 2015, STRETCHY ENDS SHAPE; Sterne JAC, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21090; Wennberg J. E., 1996, DARTMOUTH ATLAS HLTH; Wysowski DK, 2007, ARCH INTERN MED, V167, P1414, DOI 10.1001/archinte.167.13.1414; Yazdan-Ashoori P, 2017, PRIM HEALTH CARE RES, V18, P472, DOI 10.1017/S1463423617000196	31	36	36	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198674	10.1371/journal.pone.0198674	http://dx.doi.org/10.1371/journal.pone.0198674			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879194	Green Published, gold, Green Submitted			2023-01-03	WOS:000434384900068
J	Loeb, S; Byrne, N; Makarov, DV; Lepor, H; Walter, D				Loeb, Stacy; Byrne, Nataliya; Makarov, Danil V.; Lepor, Herbert; Walter, Dawn			Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Loeb, Stacy; Makarov, Danil V.] Manhattan Vet Affairs Med Ctr, New York, NY USA; [Byrne, Nataliya; Lepor, Herbert] NYU, Dept Urol, New York, NY USA; [Walter, Dawn] NYU, Dept Populat Hlth, New York, NY USA	New York University; New York University	Loeb, S (corresponding author), 227 E 30th St,Ste 612, New York, NY 10016 USA.	stacyloeb@gmail.com		Makarov, Danil/0000-0002-0565-9272; Loeb, Stacy/0000-0003-3933-9207	Edward Blank and Sharon Cosloy Blank Family Foundation; Gertrude and Louis Feil Family; New York State Department of Health [DOH01-C30697GG-3450000]; Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center [P30CA016087]; Prostate Cancer Foundation; National Institutes of Health (NIH) [K07CA178258]; US Department of Veterans Affairs [CDA11-257, COP 11-254]; NATIONAL CANCER INSTITUTE [K07CA178258] Funding Source: NIH RePORTER	Edward Blank and Sharon Cosloy Blank Family Foundation; Gertrude and Louis Feil Family; New York State Department of Health; Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center; Prostate Cancer Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Edward Blank and Sharon Cosloy Blank Family Foundation, the Gertrude and Louis Feil Family; and by grants DOH01-C30697GG-3450000 from the New York State Department of Health, P30CA016087 from the Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center, the Prostate Cancer Foundation, K07CA178258 from the National Institutes of Health (NIH) (Dr Loeb), and CDA11-257 and COP 11-254 from the US Department of Veterans Affairs (Dr Makarov).		0	44	44	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	2018	319	21					2231	2233		10.1001/jama.2018.5616	http://dx.doi.org/10.1001/jama.2018.5616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI1MA	29800017	Green Published, Bronze			2023-01-03	WOS:000434133400023
J	Kim, KI; Jun, JH; Baek, H; Kim, JH; Lee, BJ; Jung, HJ				Kim, Kwan-Il; Jun, Ji Hee; Baek, Hyunjung; Kim, Jae-Hyo; Lee, Beom-Joon; Jung, Hee-Jae			Oral administration of herbal medicines for radiation pneumonitis in lung cancer patients: A systematic review and meta-analysis	PLOS ONE			English	Review							AMERICAN-SOCIETY; THERAPY; CHEMOTHERAPY; GUIDELINE; QLQ-C30; TRIALS	Background Radiation pneumonitis is a common and serious complication of radiotherapy. Many published randomized controlled studies (RCTs) reveal a growing trend of using herbal medicines as adjuvant therapy to prevent radiation pneumonitis; however, their efficacy and safety remain unexplored. Objective The aim of this systematic review is to evaluate the efficacy and safety of herbal medicines as adjunctive therapy for the prevention of radiation pneumonitis in patients with lung cancer who undergo radiotherapy. Methods We searched the following 11 databases: three English medical databases [MEDLINE (PubMed), EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL)], five Korean medical databases (Korean Studies Information, Research information Service System, KoreaMed, DBPIA, National Digital Science Library), and three Chinese medical databases [the China National Knowledge Database (CNKI), Journal Integration Platform (VIP), and WanFang Database]. The primary outcome was the incidence of radiation pneumonitis. The risk of bias was assessed using the Cochrane risk-of-bias tool. Results Twenty-two RCTs involving 1819 participants were included. The methodological quality was poor for most of the studies. Meta-analysis showed that herbal medicines combined with radiotherapy significantly reduced the incidence of radiation pneumonitis (n = 1819; RR 0.53, 95% CI 0.45-0.63, I-2 = 8%) and the incidence of severe radiation pneumonitis (n = 903; RR 0.22, 95% CI 0.11-0.41, I-2 = 0%). Combined therapy also improved the Karnofsky performance score (n = 420; WMD 4.62, 95% CI 1.05-8.18, I-2 = 82%). Conclusion There is some encouraging evidence that oral administration of herbal medicines combined with radiotherapy may benefit patients with lung cancer by preventing or minimizing radiation pneumonitis. However, due to the poor methodological quality of the identified studies, definitive conclusion could not be drawn. To confirm the merits of this approach, further rigorously designed large scale trials are warranted.	[Kim, Kwan-Il] Kyung Hee Univ, Coll Korean Med, Dept Clin Korean Med, Seoul, South Korea; [Kim, Kwan-Il; Baek, Hyunjung; Kim, Jae-Hyo; Lee, Beom-Joon; Jung, Hee-Jae] Kyung Hee Univ, Coll Korean Med, Dept Internal Med, Div Allergy Immune & Resp Syst, Seoul, South Korea; [Jun, Ji Hee] Korean Inst Oriental Med, Div Med Res, Daejeon, South Korea; [Jun, Ji Hee] Daejeon Univ, Coll Korea Med, Dept Prevent Med, Daejeon, South Korea; [Kim, Jae-Hyo] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Korea Institute of Oriental Medicine (KIOM); Daejeon University; Kyung Hee University	Jung, HJ (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Internal Med, Div Allergy Immune & Resp Syst, Seoul, South Korea.	hanfish@khmc.or.kr	Kim, Kwan-Il/GXM-4190-2022	Baek, Hyunjung/0000-0002-5793-1821; Lee, Beom-Joon/0000-0003-4205-1175; Kim, Kwan-Il/0000-0002-8071-3881	Convergence of Conventional Medicine and Traditional Korean Medicine R&D program - Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI) [HI5C0214, HI15C0171]	Convergence of Conventional Medicine and Traditional Korean Medicine R&D program - Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI)	This study was supported by the Convergence of Conventional Medicine and Traditional Korean Medicine R&D program funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI) (HI5C0214). This study was supported by the Convergence of Conventional Medicine and Traditional Korean Medicine R&D program funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI) (HI15C0171).	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abid SH, 2001, CURR OPIN ONCOL, V13, P242, DOI 10.1097/00001622-200107000-00006; BERGMAN B, 1994, EUR J CANCER, V30A, P635, DOI 10.1016/0959-8049(94)90535-5; Bledsoe TJ, 2017, CLIN CHEST MED, V38, P201, DOI 10.1016/j.ccm.2016.12.004; Cao W, 2013, HUNAN J TCM, V29, P33; CELLA DF, 1995, LUNG CANCER-J IASLC, V12, P199, DOI 10.1016/0169-5002(95)00450-F; Chargari Cyrus, 2013, Presse Med, V42, pe342, DOI 10.1016/j.lpm.2013.06.012; Chen S, 2010, LUNG CANCER, V68, P137, DOI 10.1016/j.lungcan.2009.11.008; Cheng CW, 2017, ANN INTERN MED, V167, P112, DOI [10.7326/M16-2977, 10.7326/IsTranslatedFrom_M17-2977_2, 10.7326/IsTranslatedFrom_M17-2977_1]; Devine A, 2016, ANTICANCER RES, V36, P5; Du XZ, 2013, HUNAN J TCM, V29, P32; Fu TX, 2008, CHIN J PHARMACOEPIDE, V17, P4; Gagnier JJ, 2006, J CLIN EPIDEMIOL, V59, P1134, DOI 10.1016/j.jclinepi.2005.12.020; Gao YW, 2012, CHINESE J CLIN ONCOL, V19, P397; He HL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/426207; Hensley ML, 2009, J CLIN ONCOL, V27, P127, DOI 10.1200/JCO.2008.17.2627; Jiang LJ, 2011, PRACTICAL CLIN J INT, V11, P54; Kim KI, 2017, EUR J INTEGR MED, V11, P1, DOI 10.1016/j.eujim.2017.03.007; Kim M, 2011, RADIAT ONCOL J, V29, P181, DOI 10.3857/roj.2011.29.3.181; Kocak Z, 2005, INT J RADIAT ONCOL, V62, P635, DOI 10.1016/j.ijrobp.2004.12.023; Li JH, 2014, SHANXI J TCM, V35, P943; Li SH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0083037, 10.1371/journal.pone.0067928, 10.1371/journal.pone.0057604]; Liu H, 2016, CHIN MED MODRN DISTA, V14, P69; Lu X, 2016, J TAISHAN MED COLL, V37, P14; Mehta V, 2005, INT J RADIAT ONCOL, V63, P5, DOI 10.1016/j.ijrobp.2005.03.047; Meng LF, 2012, W J TCM, V25, P4; Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110; Oh CM, 2016, CANCER RES TREAT, V48, P436, DOI 10.4143/crt.2016.089; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; ROACH M, 1995, J CLIN ONCOL, V13, P2606, DOI 10.1200/JCO.1995.13.10.2606; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simone CB, 2017, SEMIN RADIAT ONCOL, V27, P370, DOI 10.1016/j.semradonc.2017.04.009; Song X., 2007, J SHANXI MED U, V38, P818; Sterne J, 2011, COCHRANE HDB SYSTEMA; Sun FC, 2017, MORDERN J INTEG TRAD; Tang ZL, 2009, CLIN OBSEVATION YIQI; Tucker SL, 2010, INT J RADIAT ONCOL, V77, P691, DOI 10.1016/j.ijrobp.2009.05.055; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Wang H.J., 2006, CHIN ARCH TRADIT CHI, V24, P1920; Wang TC, 2016, CHIN J DIFFIC COMPL, V15, P61; Wang YZ, 2011, J CHIN ONCOLOGY, V17, P770; Xiao Chun, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P624, DOI 10.3736/jcim20100704; Xu JL, 2013, CJGMCM, V28, P2066; Yin XD, 2013, SHANDOGN MED J, V53, P58; Zhang GM, 2006, CHINESE J CLIN ONCOL, V13, P325; Zhang JG, 2017, HEILONGJIANG SCI, V8, P56; Zhang YY, 2016, WORLD CHIN MED, V11, P1221; Zhou YF, 2009, CHIN MED FACTORY MIN, V22, P16	48	7	9	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2018	13	5							e0198015	10.1371/journal.pone.0198015	http://dx.doi.org/10.1371/journal.pone.0198015			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH7NG	29847598	Green Submitted, Green Published, gold			2023-01-03	WOS:000433634800047
J	Schultheiss, M; Hartig, F; Spitzer, MS; Feltgen, N; Spitzer, B; Husing, J; Rupp, A; Ziemann, U; Bartz-Schmidt, KU; Poli, S				Schultheiss, Maximilian; Haertig, Florian; Spitzer, Martin S.; Feltgen, Nicolas; Spitzer, Bernhard; Huesing, Johannes; Rupp, Andre; Ziemann, Ulf; Bartz-Schmidt, Karl U.; Poli, Sven			Intravenous thrombolysis in acute central retinal artery occlusion - A prospective interventional case series	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; FIBRINOLYTIC THERAPY; METAANALYSIS; STROKE; TRIAL	Background No evidence-based therapy exists for non-arteritic central retinal artery occlusion (NA-CRAO). Retinal ischemic tolerance is low; irreversible damage occurs within four hours of experimental NA-CRAO. In previous randomized trials evaluating intra-arterial or intravenous thrombolysis (IVT) in NA-CRAO, only one patient was treated this early. In December 2013, the Departments of Neurology & Stroke and Ophthalmology at University Hospital Tuebingen, Germany, decided to treat patients using IVT within 4.5 hours of NA-CRAO, the therapeutic window established for ischemic stroke. Materials and methods Consecutive NA-CRAO patients with severe visual loss received IVT after exclusion of intracranial hemorrhage. Follow-up was conducted at day 5 (d5) and day 30 (d30). Visual outcomes were compared to the conservative standard treatment (CST) arm of the EAGLE-trial. Results Until August 2016, 20 patients received IVT within 4.5 hours after NA-CRAO with a median onset-to-treatment time of 210 minutes (IQR 120 +/- 240). Visual acuity improved from baseline mean logarithm of the minimum angle of resolution 2.46 +/- 0.33 (SD) (light perception) to 1.52 +/- 1.09 (Snellen equivalent: 6/200) at d5 (p = 0.002) and 1.60 +/- 1.08 (Snellen equivalent: 6/240) at d30. Compared to the EAGLE CST-arm, functional recovery to reading ability occurred more frequently after IVT: 6/20 (30%) versus 1/39 (3%) at d5 (p = 0.005) and at d30 5/20 (25%) versus 2/37 (5%) (p = 0.045). Two patients experienced serious adverse events (one angioedema and one bleeding from an abdominal aortic aneurysm) but recovered without sequelae. Conclusions IVT within 4.5 hours after symptom onset may represent an effective treatment of NA-CRAO. Randomized trials are warranted to evaluate efficacy and safety of early IVT in acute NA-CRAO.	[Schultheiss, Maximilian; Spitzer, Martin S.] Univ Med Ctr Hamburg Eppendorf UKE, Dept Ophthalmol, Hamburg, Germany; [Schultheiss, Maximilian; Spitzer, Martin S.; Bartz-Schmidt, Karl U.] Univ Tubingen, Univ Eye Hosp Tubingen, Tubingen, Germany; [Haertig, Florian; Ziemann, Ulf; Poli, Sven] Univ Hosp Tubingen, Dept Neurol & Stroke, Tubingen, Germany; [Haertig, Florian; Ziemann, Ulf; Poli, Sven] Univ Hosp Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Feltgen, Nicolas] Univ Med Ctr Goettingen, Dept Ophthalmol, Gottingen, Germany; [Spitzer, Bernhard] Univ Oxford, Dept Expt Psychol, Oxford, England; [Huesing, Johannes] Univ Hosp Heidelberg, Coordinat Ctr Clin Trials, Heidelberg, Germany; [Rupp, Andre] Univ Hosp Heidelberg, Dept Neurol, Heidelberg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Gottingen; University of Oxford; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Poli, S (corresponding author), Univ Hosp Tubingen, Dept Neurol & Stroke, Tubingen, Germany.; Poli, S (corresponding author), Univ Hosp Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany.	sven.poli@uni-tuebingen.de	Poli, Sven/ACY-0995-2022; Ziemann, Ulf/AAY-9125-2020; Spitzer, Bernhard/L-5665-2013	Poli, Sven/0000-0002-0286-8781; Spitzer, Bernhard/0000-0001-9752-932X	Deutsche Forschungsgemeinschaft; University of Tubingen	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Tubingen	We acknowledge support from Deutsche Forschungsgemeinschaft and the Open Access Publishing Fund of the University of Tubingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Alberts MJ, 2012, ANN NY ACAD SCI, V1268, P45, DOI 10.1111/j.1749-6632.2012.06722.x; Biousse V, 2007, J NEURO-OPHTHALMOL, V27, P215, DOI 10.1097/WNO.0b013e31814b1f66; Chen CS, 2011, STROKE, V42, P2229, DOI 10.1161/STROKEAHA.111.613653; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Hattenrach LO, 2008, AM J OPHTHALMOL, V146, P700, DOI 10.1016/j.ajo.2008.06.016; Hayreh SS, 2005, AM J OPHTHALMOL, V140, P376, DOI 10.1016/j.ajo.2005.03.038; Hayreh SS, 2004, EXP EYE RES, V78, P723, DOI 10.1016/S0014-4835(03)00214-8; Helenius J, 2012, ANN NEUROL, V72, P286, DOI 10.1002/ana.23597; JONES LA, 1947, J OPT SOC AM, V37, P217, DOI 10.1364/JOSA.37.000217; Kattah JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1234; Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0; McLeod D, 2015, PROG RETIN EYE RES, V49, P82, DOI 10.1016/j.preteyeres.2015.06.001; Nedelmann M, 2015, STROKE, V46, P2322, DOI 10.1161/STROKEAHA.115.009839; Olsen TW, 2017, OPHTHALMOLOGY, V37, P1345; Preterre C, 2017, INT J STROKE; Schrag M, 2015, JAMA NEUROL, V72, P1148, DOI 10.1001/jamaneurol.2015.1578; Schumacher M, 2010, OPHTHALMOLOGY, V117, P1367, DOI 10.1016/j.ophtha.2010.03.061; Shi L, 2014, MED SCI MONITOR, V20, P2117, DOI 10.12659/MSM.892259; World health organization, 2016, INT STAT CLASS DIS R; Yeo LLL, 2014, J STROKE CEREBROVASC, V23, P2156, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.008	21	31	31	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2018	13	5							e0198114	10.1371/journal.pone.0198114	http://dx.doi.org/10.1371/journal.pone.0198114			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH6AR	29813111	Green Submitted, gold, Green Published			2023-01-03	WOS:000433521800044
J	Yang, XH; Xia, XZ; Zeng, Y; Nong, BX; Zhang, ZQ; Wu, YY; Xiong, FQ; Zhang, YX; Liang, HF; Deng, GF; Li, DT				Yang, Xinghai; Xia, Xiuzhong; Zeng, Yu; Nong, Baoxuan; Zhang, Zongqiong; Wu, Yanyan; Xiong, Faqian; Zhang, Yuexiong; Liang, Haifu; Deng, Guofu; Li, Danting			Identification of candidate genes for gelatinization temperature, gel consistency and pericarp color by GWAS in rice based on SLAF-sequencing	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; GRAIN QUALITY TRAITS; ORYZA-SATIVA L.; NATURAL VARIATION; EATING QUALITY; AGRONOMIC TRAITS; ENCODES; QTL; SYNTHASE; COOKING	Rice is an important cereal in the world. The study of the genetic basis of important agronomic traits in rice landraces and identification of genes will facilitate the breed improvement. Gelatinization temperature (GT), gel consistency (GC) and pericarp color (PC) are important indices of rice cooking and eating quality evaluation and potential nutritional importance, which attract wide attentions in the application of genetic and breeding. To dissect the genetic basis of GT, GC and PC, a total of 419 rice landraces core germplasm collections consisting of 330 indica lines, 78 japonica lines and 11 uncertain varieties were planted, collected, then GT, GC, PC were measured for two years, and sequenced using specific-locus amplified fragment sequencing (SLAF-seq) technology. In this study, 261,385,070 clean reads and 56,768 polymorphic SLAF tags were obtained, which a total of 211,818 single nucleotide polymorphisms (SNPs) were discovered. With 208,993 SNPs meeting the criterion of minor allele frequency (MAF) > 0.05 and integrity> 0.5, the phylogenetic tree and population structure analysis were performed for all 419 rice landraces, and the whole panel mainly separated into six subpopulations based on population structure analysis. Genome-wide association study (GWAS) was carried out for the whole panel, indica subpanel and japonica subpanel with subset SNPs respectively. One quantitative trait locus (QTL) on chromosome 6 for GT was detected in the whole panel and indica subpanel, and one QTL associated with GC was located on chromosome 6 in the whole panel and indica subpanel. For the PC trait, 8 QTLs were detected in the whole panel on chromosome 1, 3, 4, 7, 8, 10 and 11, and 7 QTLs in the indica subpanel on chromosome 3, 4, 7, 8, 10 and 11. For the three traits, no QTL was detected in japonica subpanel, probably because of the polymorphism repartition between the subpanel, or small population size of japonica subpanel. This paper provides new gene resources and insights into the molecular mechanisms of important agricultural trait of rice phenotypic variation and genetic improvement of rice quality variety breeding.	[Yang, Xinghai; Xia, Xiuzhong; Zeng, Yu; Nong, Baoxuan; Zhang, Zongqiong; Zhang, Yuexiong; Liang, Haifu; Deng, Guofu; Li, Danting] Guangxi Acad Agr Sci, Rice Res Inst, Nanning, Guangxi, Peoples R China; [Wu, Yanyan] Guangxi Acad Agr Sci, Biotechnol Res Inst, Nanning, Guangxi, Peoples R China; [Xiong, Faqian] Guangxi Acad Agr Sci, Cash Crops Res Inst, Nanning, Guangxi, Peoples R China	Guangxi Academy of Agricultural Sciences; Guangxi Academy of Agricultural Sciences; Guangxi Academy of Agricultural Sciences	Li, DT (corresponding author), Guangxi Acad Agr Sci, Rice Res Inst, Nanning, Guangxi, Peoples R China.	ricegl@163.com	Ynag, Xinghai/G-4232-2018	Ynag, Xinghai/0000-0002-3476-2578	National key R D projects [2016YFD0100101-03]; Guangxi's Ministry of Science and Technology [AB16380117]; Guangxi Natural Science Foundation of China [2015GXNSFAA139054]; Guangxi Academy of Agricultural Sciences [2015YT15, 2016JM09]	National key R D projects; Guangxi's Ministry of Science and Technology; Guangxi Natural Science Foundation of China; Guangxi Academy of Agricultural Sciences	This study was financially supported by National key R & D projects (2016YFD0100101-03), Guangxi's Ministry of Science and Technology (AB16380117), Guangxi Natural Science Foundation of China (2015GXNSFAA139054) and Guangxi Academy of Agricultural Sciences (2015YT15; 2016JM09).	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Bao JS, 2000, THEOR APPL GENET, V100, P280, DOI 10.1007/s001220050037; Bao JS, 2002, THEOR APPL GENET, V104, P408, DOI 10.1007/s001220100688; Bradbury PJ, 2007, BIOINFORMATICS, V23, P2633, DOI 10.1093/bioinformatics/btm308; BROWN AHD, 1989, GENOME, V31, P818, DOI 10.1139/g89-144; CAGAMPANG GB, 1973, J SCI FOOD AGR, V24, P1589, DOI 10.1002/jsfa.2740241214; Chen LH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122722; Chen W, 2014, NAT GENET, V46, P714, DOI 10.1038/ng.3007; Chin HS, 2016, RICE, V9, DOI 10.1186/s12284-016-0080-y; Dias ALD, 2017, CURR OPIN CLIN NUTR, V20, P470, DOI 10.1097/MCO.0000000000000417; Druka A, 2003, GENE, V302, P171, DOI 10.1016/S0378-1119(02)01105-8; Fan CC, 2005, THEOR APPL GENET, V110, P1445, DOI 10.1007/s00122-005-1975-y; Furukawa T, 2007, PLANT J, V49, P91, DOI 10.1111/j.1365-313X.2006.02958.x; Gao ZY, 2011, J INTEGR PLANT BIOL, V53, P756, DOI 10.1111/j.1744-7909.2011.01065.x; Gao ZY, 2003, SCI CHINA SER C, V46, P661, DOI 10.1360/03yc0099; Han LZ, 2006, DESCRIPTORS DATA STA, V4, P70; Hardy OJ, 2002, MOL ECOL NOTES, V2, P618, DOI 10.1046/j.1471-8286.2002.00305.x; Huang XH, 2014, ANNU REV PLANT BIOL, V65, P531, DOI 10.1146/annurev-arplant-050213-035715; Huang XH, 2012, NATURE, V490, P497, DOI 10.1038/nature11532; Huang XH, 2012, NAT GENET, V44, P32, DOI 10.1038/ng.1018; Huang XH, 2010, NAT GENET, V42, P961, DOI 10.1038/ng.695; Ji H, 2016, SCI REP-UK, V6, DOI 10.1038/srep34376; Jiao YQ, 2010, NAT GENET, V42, P541, DOI 10.1038/ng.591; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202. Article published online before March 2002, 10.1101/gr.229202]; Kim JH, 2008, MOL CELLS, V25, P312; Korte A, 2013, PLANT METHODS, V9, DOI 10.1186/1746-4811-9-29; Li DT, 2017, CRIT REV FOOD SCI, V57, P1729, DOI 10.1080/10408398.2015.1030064; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li H, 2013, NAT GENET, V45, P43, DOI 10.1038/ng.2484; Li JM, 2004, GENOME, V47, P697, DOI [10.1139/g04-029, 10.1139/G04-029]; Li WT, 2017, CELL, V170, P114, DOI 10.1016/j.cell.2017.06.008; Li YB, 2014, NAT GENET, V46, P398, DOI 10.1038/ng.2923; Li YB, 2011, NAT GENET, V43, P1266, DOI 10.1038/ng.977; Lipka AE, 2012, BIOINFORMATICS, V28, P2397, DOI 10.1093/bioinformatics/bts444; LITTLE RR, 1958, CEREAL CHEM, V35, P111; Maeda H, 2014, BREEDING SCI, V64, P134, DOI 10.1270/jsbbs.64.134; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meyer RS, 2016, NAT GENET, V48, P1083, DOI 10.1038/ng.3633; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Nakamura Y, 2005, PLANT MOL BIOL, V58, P213, DOI 10.1007/s11103-005-6507-2; Phung NTP, 2016, BMC PLANT BIOL, V16, DOI 10.1186/s12870-016-0747-y; Oikawa T, 2015, PLANT CELL, V27, P2401, DOI 10.1105/tpc.15.00310; Pasaniuc B, 2012, NAT GENET, V44, P631, DOI 10.1038/ng.2283; Peng Y, 2016, MOL GENET GENOMICS, V291, P297, DOI 10.1007/s00438-015-1104-9; Platt A, 2010, GENETICS, V186, P1045, DOI 10.1534/genetics.110.121665; Reddy AR, 1996, PLANT MOL BIOL, V32, P735, DOI 10.1007/BF00020214; Sakamoto T, 2008, CURR OPIN PLANT BIOL, V11, P209, DOI 10.1016/j.pbi.2008.01.009; Sakamoto W, 2001, PLANT CELL PHYSIOL, V42, P982, DOI 10.1093/pcp/pce128; Salvi S, 2005, TRENDS PLANT SCI, V10, P297, DOI 10.1016/j.tplants.2005.04.008; Septiningsih EM, 2003, THEOR APPL GENET, V107, P1433, DOI 10.1007/s00122-003-1376-z; Shih CH, 2008, PLANTA, V228, P1043, DOI 10.1007/s00425-008-0806-1; Si LZ, 2016, NAT GENET, V48, P447, DOI 10.1038/ng.3518; Song XJ, 2007, NAT GENET, V39, P623, DOI 10.1038/ng2014; Su Y, 2011, THEOR APPL GENET, V123, P859, DOI 10.1007/s00122-011-1632-6; Sun X, 2018, J EXP BOT; Sun XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058700; Sun XL, 2004, PLANT J, V37, P517, DOI 10.1046/j.1365-313X.2003.01976.x; Swamy BPM, 2012, J HERED, V103, P442, DOI 10.1093/jhered/esr145; Sweeney MT, 2006, PLANT CELL, V18, P283, DOI 10.1105/tpc.105.038430; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tan YF, 1999, THEOR APPL GENET, V99, P642, DOI 10.1007/s001220051279; Tian R, 2005, MOL BREEDING, V15, P117, DOI 10.1007/s11032-004-3270-z; Tian ZX, 2009, P NATL ACAD SCI USA, V106, P21760, DOI 10.1073/pnas.0912396106; Tran NA, 2011, THEOR APPL GENET, V123, P519, DOI 10.1007/s00122-011-1604-x; Umemoto T, 2004, FUNCT PLANT BIOL, V31, P671, DOI 10.1071/FP04009; Wang HR, 2016, MOL PLANT, V9, P975, DOI 10.1016/j.molp.2016.04.018; Wang SK, 2012, NAT GENET, V44, P950, DOI 10.1038/ng.2327; Wang XQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17347-5; Wang YH, 2010, PLANT J, V64, P812, DOI 10.1111/j.1365-313X.2010.04370.x; Wang ZX, 1999, PLANT J, V19, P55, DOI 10.1046/j.1365-313X.1999.00498.x; Xu WJ, 2014, NEW PHYTOL, V202, P132, DOI 10.1111/nph.12620; Yang F, 2014, MOL BREEDING, V34, P1747, DOI 10.1007/s11032-014-0135-y; Yano K, 2016, NAT GENET, V48, P927, DOI 10.1038/ng.3596	74	13	17	3	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2018	13	5							e0196690	10.1371/journal.pone.0196690	http://dx.doi.org/10.1371/journal.pone.0196690			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF3JM	29746484	Green Submitted, Green Published, gold			2023-01-03	WOS:000431851700030
J	Bai, J; Bai, F; Zhu, HB; Xue, D				Bai, Jie; Bai, Fei; Zhu, Hongbo; Xue, Di			The perceived and objectively measured effects of clinical pathways' implementation on medical care in China	PLOS ONE			English	Article							OUTCOMES; IMPACT; GUIDELINES; MANAGEMENT; SURGERY; PATIENT	Introduction Substantial resources have been expended on clinical pathways (CPs), but the reported effects of CPs on medical care vary considerably. This study sought to determine the effects of CPs on medical care in Chinese hospitals, including the perceived effects of CPs on medical care and the objectively measured patient outcomes. Methods Study data were obtained from 54 public hospitals in three provinces of China in 2015. Hospital questionnaires, employee surveys, and chart reviews were used to collect data related to hospital characteristics, the implementation of CPs and compliance status, perceived effects of CPs, and objectively measured patient outcomes. Logistic regression models and linear regression models were adopted in this study. Results The effects of CPs were not highly perceived by the hospitals or by the managers and physicians in China. The relatively low involvement in the implementation of and adherence to CPs resulted in CPs having no significant effects on hospital medical care as a whole. However, a chart review of 5 conditions in Chinese hospitals demonstrated that compliance with national CPs reduced the length of stay (LOS) and inpatient medical costs. Conclusions CPs should be implemented widely and followed closely to improve hospital medical care as a whole, and further studies should be conducted to identify the key elements of the effects of CPs on patient clinical outcomes.	[Bai, Jie; Xue, Di] Fudan Univ, Natl Hlth Commiss, Key Lab Hlth Technol Assessment, Dept Hosp Management,Sch Publ Hlth, Shanghai, Peoples R China; [Bai, Fei] Natl Hlth Commiss China, Ctr Med Serv Adm, Beijing, Peoples R China; [Zhu, Hongbo] Hlth & Family Planning Commiss Hubei Prov, Med Adm & Management, Wuhan, Hubei, Peoples R China	Fudan University	Xue, D (corresponding author), Fudan Univ, Natl Hlth Commiss, Key Lab Hlth Technol Assessment, Dept Hosp Management,Sch Publ Hlth, Shanghai, Peoples R China.	xuedi@shmu.edu.cn			National Natural Science Foundation of China [71473047]; China Medical Board-Collaborating Program in Health Technology Assessment [13-153]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Medical Board-Collaborating Program in Health Technology Assessment	This work was supported by National Natural Science Foundation of China, DX, grant number 71473047, http://www.nsfc.gov.cn/; and China Medical Board-Collaborating Program in Health Technology Assessment, DX, grant number 13-153, https://www.chinamedicalboard.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjurling-Sjoberg P, 2015, J EVAL CLIN PRACT, V21, P255, DOI 10.1111/jep.12301; [陈永聪 Chen Yongcong], 2017, [中华医院管理杂志, Chinese Journal of Hospital Administration], V33, P21; De Allegri M, 2011, BMJ QUAL SAF, V20, P203, DOI 10.1136/bmjqs.2010.042465; Duncan CM, 2013, REGION ANESTH PAIN M, V38, P533, DOI 10.1097/AAP.0000000000000014; El Baz N, 2007, J EVAL CLIN PRACT, V13, P920, DOI 10.1111/j.1365-2753.2006.00774.x; Hassaballa H, 1998, Qual Manag Health Care, V7, P13; He XY, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1121-8; Lemmens L, 2008, J EVAL CLIN PRACT, V14, P880, DOI 10.1111/j.1365-2753.2008.01079.x; Lin DX, 2011, CELL BIOCHEM BIOPHYS, V61, P413, DOI 10.1007/s12013-011-9203-7; Little A B, 1996, J Nurs Care Qual, V11, P54; Lodewijckx C, 2011, INT J NURS STUD, V48, P1445, DOI 10.1016/j.ijnurstu.2011.06.006; Mamolen NL, 2000, J BURN CARE REHABIL, V21, P440, DOI 10.1097/00004630-200021050-00010; McCallum GB, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006595.pub3; McConnell T, 2013, WORLDV EVID-BASED NU, V10, P218, DOI 10.1111/wvn.12003; Ng BJH, 2011, INTERN MED J, V41, P251, DOI 10.1111/j.1445-5994.2009.02134.x; Passot G, 2017, ANN SURG, V265, P806, DOI 10.1097/SLA.0000000000001723; Petrakis M, 2011, J EVAL CLIN PRACT, V17, P722, DOI 10.1111/j.1365-2753.2010.01548.x; Ranasinghe I, 2014, CIRC-CARDIOVASC QUAL, V7, P209, DOI 10.1161/CIRCOUTCOMES.113.000527; Ransom SB, 2003, OBSTET GYNECOL, V101, P751, DOI 10.1016/S0029-7844(02)03129-0; Richter-Ehrenstein C, 2012, ARCH GYNECOL OBSTET, V285, P515, DOI 10.1007/s00404-011-1994-7; Ronellenfitsch U, 2008, LANGENBECK ARCH SURG, V393, P449, DOI 10.1007/s00423-008-0303-9; Rotter T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006632.pub2; Saint S, 2003, AM J MANAG CARE, V9, P758; Xia JL, 2017, CHINESE HOSP MANAGEM, P37; Zhang M, 2014, HEPATOB PANCREAT DIS, V13, P348, DOI 10.1016/S1499-3872(14)60279-4; Zheng XF, 2014, J EVAL CLIN PRACT, V20, P288, DOI 10.1111/jep.12127; Zuckermann J, 2008, ANN HEMATOL, V87, P139, DOI 10.1007/s00277-007-0390-7	27	4	4	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2018	13	5							e0196776	10.1371/journal.pone.0196776	http://dx.doi.org/10.1371/journal.pone.0196776			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE8KX	29734350	gold, Green Published, Green Submitted			2023-01-03	WOS:000431481700026
J	Darnall, B				Darnall, Beth			To treat pain, study people in all their complexity	NATURE			English	Editorial Material									[Darnall, Beth] Stanford Univ Calif, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA		Darnall, B (corresponding author), Stanford Univ Calif, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA.			Darnall, Beth D./0000-0003-3590-511X					0	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 3	2018	557	7703					7	7		10.1038/d41586-018-04994-5	http://dx.doi.org/10.1038/d41586-018-04994-5			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE5BW	29717254	Bronze			2023-01-03	WOS:000431234500004
J	Pellikaan, P; Giarmatzis, G; Vander Sloten, J; Verschueren, S; Jonkers, I				Pellikaan, Pim; Giarmatzis, Georgios; Vander Sloten, Jos; Verschueren, Sabine; Jonkers, Ilse			Ranking of osteogenic potential of physical exercises in postmenopausal women based on femoral neck strains	PLOS ONE			English	Article							BONE-MINERAL DENSITY; HIGH-IMPACT EXERCISE; TRABECULAR BONE; CORTICAL BONE; HIP FRACTURE; PROXIMAL FEMUR; OLDER MEN; WALKING; PRESERVATION; OSTEOPOROSIS	The current study aimed to assess the potential of different exercises triggering an osteogenic response at the femoral neck in a group of postmenopausal women. The osteogenic potential was determined by ranking the peak hip contact forces (HCFs) and consequent peak tensile and compressive strains at the superior and inferior part of the femoral neck during activities such as (fast) walking, running and resistance training exercises. Results indicate that fast walking (5-6 km/h) running and hopping induced significantly higher strains at the femoral neck than walking at 4 km/h which is considered a baseline exercise for bone preservation. Exercises with a high fracture risk such as hopping, need to be considered carefully especially in a frail elderly population and may therefore not be suitable as a training exercise. Since superior femoral neck frailness is related to elevated hip fracture risk, exercises such as fast walking (above 5 km/h) and running can be highly recommended to stimulate this particular area. Our results suggest that a training program including fast walking (above 5 km/h) and running exercises may increase or preserve the bone mineral density (BMD) at the femoral neck.	[Pellikaan, Pim; Vander Sloten, Jos] Katholieke Univ Leuven, Dept Mech Engn, Biomech Sect, Leuven, Belgium; [Giarmatzis, Georgios; Verschueren, Sabine] Katholieke Univ Leuven, Dept Rehabil Sci, Res Grp Musculoskeletal Rehabil, Leuven, Belgium; [Jonkers, Ilse] Katholieke Univ Leuven, Dept Movement Sci, Human Movement Biomech Res Grp, Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven	Pellikaan, P (corresponding author), Katholieke Univ Leuven, Dept Mech Engn, Biomech Sect, Leuven, Belgium.	pim.pellikaan@kuleuven.be	Giarmatzis, Georgios/AAC-1725-2022; Verschueren, Sabine/K-4213-2015	Giarmatzis, Georgios/0000-0003-1387-2134; Verschueren, Sabine/0000-0003-2592-494X	Fund for Scientific Research (FWO-Vlaanderen) [G0526512]; Materialise NV through the Materialise chair for patient-specific biomechanics	Fund for Scientific Research (FWO-Vlaanderen)(FWO); Materialise NV through the Materialise chair for patient-specific biomechanics	This study was supported by grant G0526512 from the Fund for Scientific Research (FWO-Vlaanderen www.fwo.be) to S. Verschueren and by the funding of Materialise NV through the Materialise chair for patient-specific biomechanics (www.materialise.com). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison SJ, 2015, J BONE MINER RES, V30, P1709, DOI 10.1002/jbmr.2499; Allison SJ, 2013, BONE, V53, P321, DOI 10.1016/j.bone.2012.12.045; Anderson DE, 2013, J APPL BIOMECH, V29, P505, DOI 10.1123/jab.29.5.505; Anderson FC, 2001, J BIOMECH, V34, P153, DOI 10.1016/S0021-9290(00)00155-X; Bailey CA, 2010, BONE, V46, P1043, DOI 10.1016/j.bone.2009.12.001; Baker R, 2003, J BIOMECH, V36, P300, DOI 10.1016/S0021-9290(02)00336-6; BASSETT CAL, 1962, SCIENCE, V137, P1063, DOI 10.1126/science.137.3535.1063; Bell KL, 1999, J BONE MINER RES, V14, P111, DOI 10.1359/jbmr.1999.14.1.111; BIEWENER AA, 1993, CALCIFIED TISSUE INT, V53, pS68, DOI 10.1007/BF01673406; Bitsakos C, 2005, J BIOMECH, V38, P133, DOI 10.1016/j.jbiomech.2004.03.005; Boonen S, 2008, BEST PRACT RES CL EN, V22, P765, DOI 10.1016/j.beem.2008.07.002; Brown LE, 2001, J EXERC PHYSL ONLINE, V4, P1; CARTER DR, 1984, CALCIFIED TISSUE INT, V36, pS19, DOI 10.1007/BF02406129; Chen JC, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt318; COWIN SC, 1984, CALCIFIED TISSUE INT, V36, pS98, DOI 10.1007/BF02406141; De Groote F, 2008, J BIOMECH, V41, P3390, DOI 10.1016/j.jbiomech.2008.09.035; Edwards WB, 2016, J BIOMECH, V49, P1206, DOI 10.1016/j.jbiomech.2016.03.007; Engelke K, 2016, CLIN REV BONE MINER, V14, P26, DOI 10.1007/s12018-015-9201-1; Frost HM, 2001, ANAT RECORD, V262, P398, DOI 10.1002/ar.1049; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Garcia J M, 2001, Comput Methods Biomech Biomed Engin, V4, P355, DOI 10.1080/10255840108908014; Giarmatzis G, 2017, GAIT POSTURE, V53, P155, DOI 10.1016/j.gaitpost.2017.01.020; Giarmatzis G, 2015, J BONE MINER RES, V30, P1431, DOI 10.1002/jbmr.2483; Gomez-Cabello A, 2012, SPORTS MED, V42, P301, DOI 10.2165/11597670-000000000-00000; Hamner SR, 2010, J BIOMECH, V43, P2709, DOI 10.1016/j.jbiomech.2010.06.025; HERNLUND E, 2013, ARCH OSTEOPOROS, V8, DOI DOI 10.1007/S11657-013-0136-1; Howe TE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000333, 10.1002/14651858.CD000333.pub2]; HUISKES R, 1987, J BIOMECH, V20, P1135, DOI 10.1016/0021-9290(87)90030-3; Johannesdottir F, 2011, BONE, V48, P1268, DOI 10.1016/j.bone.2011.03.776; Kelley GA, 2001, AM J PHYS MED REHAB, V80, P65, DOI 10.1097/00002060-200101000-00017; Kemmler W, 2011, PHYSICIAN SPORTSMED, V39, P142, DOI 10.3810/psm.2011.02.1872; Kerr D, 2001, J BONE MINER RES, V16, P175, DOI 10.1359/jbmr.2001.16.1.175; Kim WS, 2014, ANN REHABIL MED-ARM, V38, P101, DOI 10.5535/arm.2014.38.1.101; Loveridge N, 2004, BONE, V35, P929, DOI 10.1016/j.bone.2004.05.025; Ma D, 2013, MENOPAUSE, V20, P1216, DOI [10.1097/GME.0000000000000100, 10.1097/gme.0000000000000100]; Martelli S, 2014, J BIOMECH, V47, P1784, DOI 10.1016/j.jbiomech.2014.03.036; Martyn-St James M, 2006, OSTEOPOROSIS INT, V17, P1225, DOI 10.1007/s00198-006-0083-4; Martyn-St James M, 2009, BRIT J SPORT MED, V43, P898, DOI 10.1136/bjsm.2008.052704; Martyn-St James M, 2008, BONE, V43, P521, DOI 10.1016/j.bone.2008.05.012; Mayhew PM, 2005, LANCET, V366, P129, DOI 10.1016/S0140-6736(05)66870-5; Milovanovic P, 2012, BONE, V50, P63, DOI 10.1016/j.bone.2011.09.044; Modenese L, 2012, MULTIBODY SYST DYN, V28, P157, DOI 10.1007/s11044-011-9274-7; Mokhtarzadeh H, 2014, J BIOMECH, P1; Morgan EF, 2003, J BIOMECH, V36, P897, DOI 10.1016/S0021-9290(03)00071-X; Nikander R, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-47; Poole KES, 2010, J BONE MINER RES, V25, P482, DOI 10.1359/jbmr.090734; Speirs AD, 2007, J BIOMECH, V40, P2318, DOI 10.1016/j.jbiomech.2006.10.038; Steele KM, 2012, GAIT POSTURE, V35, P556, DOI 10.1016/j.gaitpost.2011.11.023; Taylor ME, 1996, MED ENG PHYS, V18, P122, DOI 10.1016/1350-4533(95)00031-3; Thomas CDL, 2009, J BONE MINER RES, V24, P1808, DOI [10.1359/jbmr.090504, 10.1359/JBMR.090504]; Vahdati A, 2014, J MECH BEHAV BIOMED, V30, P244, DOI 10.1016/j.jmbbm.2013.11.015; van Arkel RJ, 2013, J ORTHOP RES, V31, P1172, DOI 10.1002/jor.22364	52	20	20	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2018	13	4							e0195463	10.1371/journal.pone.0195463	http://dx.doi.org/10.1371/journal.pone.0195463			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB6SR	29617448	Green Published, Green Submitted, gold			2023-01-03	WOS:000429203800087
J	Mijwel, S; Cardinale, DA; Norrbom, J; Chapman, M; Ivarsson, N; Wengstrom, Y; Sundberg, CJ; Rundqvist, H				Mijwel, Sara; Cardinale, Daniele A.; Norrbom, Jessica; Chapman, Mark; Ivarsson, Niklas; Wengstrom, Yvonne; Sundberg, Carl Johan; Rundqvist, Helene			Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer	FASEB JOURNAL			English	Article						concurrent training; high-intensity interval training; oxidative phosphorylation; exercise training adaptation	AUTOPHAGY; ASSOCIATION; SPECIFICITY; DYSFUNCTION; ADAPTATION; GUIDELINES; PROTECTS; ATROPHY; QUALITY; CELLS	Exercise has been suggested to ameliorate the detrimental effects of chemotherapy on skeletal muscle. The aim of this study was to compare the effects of different exercise regimens with usual care on skeletal muscle morphology and mitochondrial markers in patients being treated with chemotherapy for breast cancer. Specifically, we compared moderate-intensity aerobic training combined with high-intensity interval training (AT-HIIT) and resistance training combined with high-intensity interval training (RT-HIIT) with usual care (UC). Resting skeletal muscle biopsies were obtained pre- and postintervention from 23 randomly selected women from the OptiTrain breast cancer trial who underwent RT-HIIT, AT-HIIT, or UC for 16 wk. Over the intervention, citrate synthase activity, muscle fiber cross-sectional area, capillaries per fiber, and myosin heavy chain isoform type I were reduced in UC, whereas RT-HIIT and AT-HIIT were able to counteract these declines. AT-HIIT promoted up-regulation of the electron transport chain protein levels vs. UC. RT-HIIT favored satellite cell count vs. UC and AT-HIIT. There was a significant association between change in citrate synthase activity and self-reported fatigue. AT-HIIT and RT-HIIT maintained or improved markers of skeletal muscle function compared with the declines found in the UC group, indicating a sustained trainability in addition to the preservation of skeletal muscle structural and metabolic characteristics during chemotherapy. These findings highlight the importance of supervised exercise programs for patients with breast cancer during chemotherapy.Mijwel, S., Cardinale, D. A., Norrbom, J., Chapman, M., Ivarsson, N., Wengstrom, Y., Sundberg, C. J., Rundqvist, H. Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer.	[Mijwel, Sara; Norrbom, Jessica; Chapman, Mark; Ivarsson, Niklas; Sundberg, Carl Johan] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; [Mijwel, Sara; Wengstrom, Yvonne] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Sundberg, Carl Johan] Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden; [Rundqvist, Helene] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Cardinale, Daniele A.] Swedish Sch Sport & Hlth Sci, Astrand Lab, Stockholm, Sweden; [Wengstrom, Yvonne] Karolinska Univ Hosp, Canc Theme, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Swedish School of Sport & Health Sciences; Karolinska Institutet; Karolinska University Hospital	Mijwel, S (corresponding author), Karolinska Inst, von Eulers Vag 8, S-17176 Stockholm, Sweden.	sara.mijwel@ki.se	Sundberg, Carl Johan/B-9356-2013; Rundqvist, Helene/AAE-7334-2020	Rundqvist, Helene/0000-0002-5617-9076; Mijwel, Sara/0000-0002-6718-5797; Cardinale, Daniele/0000-0002-8607-550X; Chapman, Mark/0000-0001-9905-4022	Swedish Cancer Society [130452]; Cancer Society of Stockholm Grant [131242]; Swedish Cancer and Traffic Accident Foundation Grant [F-C-001225]; Swedish Society for Medical Research Grants [SLS 505141, 692641]	Swedish Cancer Society(Swedish Cancer Society); Cancer Society of Stockholm Grant; Swedish Cancer and Traffic Accident Foundation Grant; Swedish Society for Medical Research Grants	The authors thank the participants in the OptiTrain trial, Malin Backman (Karolinska Institute) for assistance during muscle biopsy collection and supervision of exercise sessions, Marcus Moberg (Swedish School of Health and Sports Sciences) for Western blot technical support, Rocio Paublete (Karolinska Institutet) for microscopy technical support, and Eric Emanuelsson (Orebro University) for the MHC immunohistochemitry protocol. This work was supported by Swedish Cancer Society Grant 130452 (to Y.W.), Cancer Society of Stockholm Grant 131242 (to Y.W.), Swedish Cancer and Traffic Accident Foundation Grant F-C-001225 (to Y.W.), and Swedish Society for Medical Research Grants SLS 505141 and 692641 (to H.R.). S.M. and D.A.C. are shared first authors. C.J.S. and H.R. are shared last authors. The authors declare no conflicts of interest.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ansenberger-Fricano K, 2013, FREE RADICAL BIO MED, V54, P116, DOI 10.1016/j.freeradbiomed.2012.08.573; Antharavally BS, 2004, ANAL BIOCHEM, V329, P276, DOI 10.1016/j.ab.2004.02.049; Batchelor TT, 1997, NEUROLOGY, V48, P1234, DOI 10.1212/WNL.48.5.1234; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; BIANCHI C, 1987, EXP MOL PATHOL, V46, P123, DOI 10.1016/0014-4800(87)90036-0; Bishop DJ, 2014, BBA-GEN SUBJECTS, V1840, P1266, DOI 10.1016/j.bbagen.2013.10.012; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Borjesson M, 2011, EUR J CARDIOV PREV R, V18, P446, DOI 10.1097/HJR.0b013e32833bo969; Bozzetti F, 2017, ANN ONCOL, V28, P2107, DOI 10.1093/annonc/mdx271; Brooks NE, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00099; Chaillou T, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13261; Christensen JF, 2016, ACTA ONCOL, V55, P1246, DOI 10.3109/0284186X.2016.1170200; Christensen JF, 2014, BRIT J CANCER, V111, P8, DOI 10.1038/bjc.2014.273; Ciciliot S, 2013, INT J BIOCHEM CELL B, V45, P2191, DOI 10.1016/j.biocel.2013.05.016; Crouch ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181086; Dirks-Naylor AJ, 2013, J CACHEXIA SARCOPENI, V4, P239, DOI 10.1007/s13539-013-0104-z; Filler K, 2014, BBA CLIN, V1, P12, DOI 10.1016/j.bbacli.2014.04.001; Furmaniak AC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005001.pub3; Gilliam LAA, 2011, ANTIOXID REDOX SIGN, V15, P2543, DOI 10.1089/ars.2011.3965; Gilliam LAA, 2009, J APPL PHYSIOL, V107, P1935, DOI 10.1152/japplphysiol.00776.2009; Gouspillou G, 2015, SCI REP-UK, V5, DOI 10.1038/srep08717; Green N., 2017, J STRENGTH COND RES, DOI [10. 1519/JSC. 0000000000002154, DOI 10.1519/JSC.0000000000002154]; Grumati P, 2011, AUTOPHAGY, V7, P1415, DOI 10.4161/auto.7.12.17877; Hikida RS, 2000, J GERONTOL A-BIOL, V55, pB347, DOI 10.1093/gerona/55.7.B347; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; Lira VA, 2013, FASEB J, V27, P4184, DOI 10.1096/fj.13-228486; McLoon LK, 1998, MUSCLE NERVE, V21, P1457, DOI 10.1002/(SICI)1097-4598(199811)21:11<1457::AID-MUS14>3.3.CO;2-U; Mijwel S, 2018, BREAST CANCER RES TR, V169, P93, DOI 10.1007/s10549-018-4663-8; Mijwel S, 2018, BREAST CANCER RES TR, V168, P79, DOI 10.1007/s10549-017-4571-3; Mizunoya W, 2008, ANAL BIOCHEM, V377, P111, DOI 10.1016/j.ab.2008.02.021; Moriscot AS, 2010, J STRUCT BIOL, V170, P344, DOI 10.1016/j.jsb.2010.02.001; Mustian KM, 2017, JAMA ONCOL, V3, P961, DOI 10.1001/jamaoncol.2016.6914; Nilsen TS, 2016, SCAND J MED SCI SPOR, V26, P1026, DOI 10.1111/sms.12543; Nilwik R, 2013, EXP GERONTOL, V48, P492, DOI 10.1016/j.exger.2013.02.012; Romanello V, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00422; SCHANTZ P, 1983, CLIN PHYSIOL, V3, P141, DOI 10.1111/j.1475-097X.1983.tb00685.x; Scheede-Bergdahl C, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00049; Schmitt J, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12693; Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Siebrands CC, 2004, CELL MOTIL CYTOSKEL, V58, P39, DOI 10.1002/cm.10177; Smuder AJ, 2011, J APPL PHYSIOL, V111, P1190, DOI 10.1152/japplphysiol.00429.2011; Smuder AJ, 2011, J APPL PHYSIOL, V110, P935, DOI 10.1152/japplphysiol.00677.2010; Sorensen JC, 2016, CANCER CHEMOTH PHARM, V78, P673, DOI 10.1007/s00280-016-3045-3; TESCH PA, 1988, MED SCI SPORT EXER, V20, pS132, DOI 10.1249/00005768-198810001-00008; Toth MJ, 2016, CLIN NUTR, V35, P1359, DOI 10.1016/j.clnu.2016.02.016; Wang YC, 2013, CURR OPIN CLIN NUTR, V16, P243, DOI 10.1097/MCO.0b013e328360272d; Wengstrom Y, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3079-x; Yan Z, 2012, EXERC SPORT SCI REV, V40, P159, DOI 10.1097/JES.0b013e3182575599	51	55	56	10	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2018	32	10					5495	5505		10.1096/fj.201700968R	http://dx.doi.org/10.1096/fj.201700968R			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GX7RI	29750574	hybrid			2023-01-03	WOS:000447972500025
J	Pun, KD; Rishal, P; Infanti, JJ; Bjorngaard, JH; Koju, R; Schei, B; Darj, E				Pun, Kunta Devi; Rishal, Poonam; Infanti, Jennifer Jean; Bjorngaard, Johan Hakon; Koju, Rajendra; Schei, Berit; Darj, Elisabeth		ADVANCE Study Grp	Exposure to domestic violence influences pregnant women's preparedness for childbirth in Nepal: A cross-sectional study	PLOS ONE			English	Article							INTIMATE PARTNER VIOLENCE; BIRTH-PREPAREDNESS; COMPLICATION READINESS; MIDWIVES; DISTRICT	Objective This study aimed to evaluate if domestic violence affected women's ability to prepare for childbirth. Birth preparedness and complication readiness (BP/CR) includes saving money, arranging transportation, identifying a skilled birth attendant, a health facility, and a blood donor before childbirth. During data collection, Nepal experienced two earthquakes and therefore it was possible to examine associations between domestic violence, women's BP/CR and effects of the earthquakes. Methods Women who were between 12 and 28 weeks of gestation participated in a descriptive crosssectional study at a hospital antenatal clinic in Nepal, where they completed a structured questionnaire on sociodemographic characteristics, obstetric history, experiences of domestic violence, and BP/CR. The 5-item Abuse Assessment Screen was used to assess prevalence of domestic violence, and a questionnaire on safe motherhood obtained from Jhpiego was used to assess BP/CR status. The participants self-completed the questionnaire on a tablet computer. Those who reported at least three out of five BP/CR activities were considered prepared for childbirth. Results A total of 1011 women participated in the study: 433 pre-earthquakes and 578 post-earthquakes. With respect to BP/CR, 78% had identified a health facility for childbirth and 65% had saved money prior to childbirth. Less than 50% had identified a birth attendant to assist with the delivery, transportation to a health facility, or arranged for a potential blood donor. Prior to the earthquakes, 38% were unprepared; by contrast, almost 62% were not prepared after the earthquakes. A significant association was found between exposure to violence and not being prepared for childbirth (AOR = 2.3, 95% CI: 1.4-3.9). The women with increased odds of not being prepared for childbirth were illiterate (AOR = 9.9, 95% CI: 5.7-17), young (AOR = 3.4, 95% CI: 1.6-7.2), from the most oppressed social classes (AOR = 3.0, 95% CI: 1.2-7.6), were married to illiterate husbands (AOR = 2.5, 95% CI: 1.2-5.2), had attended fewer than four antenatal visits (AOR = 2.0, 95% CI: 1.4-2.6), had low incomes (AOR = 1.7, 95% CI: 1.1-2.9) or lived in rural settings (AOR = 1.5, 95% confidence interval CI: 1.2-2.1). Conclusion The paper identifies vulnerable women who require extra care from the health system, and draws attention to the need for interventions to reduce the harmful effects of domestic violence on women's preparations for childbirth.	[Pun, Kunta Devi; Koju, Rajendra] Kathmandu Univ, Sch Med Sci, Dhulikhel, Kavre, Nepal; [Pun, Kunta Devi; Rishal, Poonam; Infanti, Jennifer Jean; Bjorngaard, Johan Hakon; Schei, Berit; Darj, Elisabeth] Norwegian Univ Sci & Technol, Dept Publ Hlth & Nursing, Fac Med & Hlth Sci, Trondheim, Norway; [Pun, Kunta Devi; Rishal, Poonam; Darj, Elisabeth] Cent Norway Reg Hlth Author, Stjordal, Norway; [Bjorngaard, Johan Hakon] St Olavs Univ Hosp, Res Ctr Broset, Trondheim, Norway; [Schei, Berit; Darj, Elisabeth] St Olavs Univ Hosp, Dept Obstet & Gynecol, Trondheim, Norway; [Darj, Elisabeth] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Kathmandu University; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Uppsala University	Pun, KD (corresponding author), Kathmandu Univ, Sch Med Sci, Dhulikhel, Kavre, Nepal.; Pun, KD (corresponding author), Norwegian Univ Sci & Technol, Dept Publ Hlth & Nursing, Fac Med & Hlth Sci, Trondheim, Norway.; Pun, KD (corresponding author), Cent Norway Reg Hlth Author, Stjordal, Norway.	kunta.devi.pun@ntnu.no			Research Council of Norway [220893]; Samarbeidsorganet [16/29034]; Research Council of Norway; Liaison Committee; Samarbeidsorganet HMN-NTNU	Research Council of Norway(Research Council of Norway); Samarbeidsorganet; Research Council of Norway(Research Council of Norway); Liaison Committee; Samarbeidsorganet HMN-NTNU	This study was funded by the Research Council of Norway, grant number 220893, http://www.forskningsradet.no/en/The_Research_ Council/1138785832539, to BS. Research Council of Norway has funded the project under its Global Health and Vaccination Research (GLOBVAC) Program: 'Evaluating interventions in antenatal care to identify and assist victims of gender based violence in Nepal and Sri Lanka'. This study is also funded by the Samarbeidsorganet, grant number 16/29034, https://helse-midt.no/samarbeidsorganet, to ED. Along with Research Council of Norway, this project was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology; Samarbeidsorganet HMN-NTNU.	Agarwal S, 2010, J HEALTH POPUL NUTR, V28, P383; Ahmad J, 2016, J INTERPERS VIOLENCE, V31, P3111, DOI 10.1177/0886260515584341; August F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125978; Basile H., 2007, EDITED CTR DIS CONTR; Bhatnagar T, 2013, AIDS BEHAV, V17, P2260, DOI 10.1007/s10461-013-0414-3; Bhatta DN, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-14; Bintabara D, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0041-8; Campbell J, 2004, VIOLENCE AGAINST WOM, V10, P770, DOI 10.1177/1077801204265551; Central Bureau of Statistics, 2016, DISTR PROF KAVR 2074; Chan KL, 2011, VIOLENCE VICTIMS, V26, P364, DOI 10.1891/0886-6708.26.3.364; Debelew GT, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.272.4244; Del Barco R., 2004, TOOLS INDICATORS MAT, P330; Garcia-Moreno C, 2005, WHO MULTI COUNTRY ST; Gebre M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137570; Hailu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021432; Idowu A, 2015, INT J MCH AIDS, V4, P47, DOI DOI 10.21106/ijma.55; Jahanfar S., 2014, INTERVENTIONS PREVEN, pCD009414; Jayatilleke AC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1674-9; Kabakyenga JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035747; Kabakyenga JK, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-33; Karkee R, 2013, MIDWIFERY, V29, P1206, DOI 10.1016/j.midw.2013.05.002; Kaso M, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-55; Markos D, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-282; Mazumdar R, 2014, INDIA AL AMEEN J MED, V7, P52; McPherson RA, 2006, J HEALTH POPUL NUTR, V24, P479; Ministry of Health and Population (MOHP) [Nepal] New ERA & ICF International Inc, 2012, NEP DEM HLTH SURV 20; Ministry of Health New ERA Nepal Health Sector Support Program (NHSSP) Inner City fund (ICF), 2017, NEP HLTH FAC SURV 20; Mukhopadhyay Dipta Kanti, 2016, J Family Med Prim Care, V5, P404; Mukhopadhyay Dipta Kanti, 2013, Indian J Public Health, V57, P147, DOI 10.4103/0019-557X.119827; Nawal D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060957; Nursing department of Dhulikhel Hospital, 2015, REP OBST GYN WARD; O'Reilly R, 2010, TRAUMA VIOLENCE ABUS, V11, P190, DOI 10.1177/1524838010378298; Omari PK, 2016, KENYA AM J MED SCI, V6, P123; Palladino CL, 2011, OBSTET GYNECOL, V118, P1056, DOI 10.1097/AOG.0b013e31823294da; Pandey J.P., 2013, MATERNAL CHILD HLTH; Parkinson D., 2017, J INTERPERS VIOLENCE; Pun KD, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.31964; Rabin RF, 2009, AM J PREV MED, V36, P439, DOI 10.1016/j.amepre.2009.01.024; Rajib Saha APS., 2014, INT J PUBLIC HLTH RE, V4, P510; Rathod SD, 2011, J INTERPERS VIOLENCE, V26, P2437, DOI 10.1177/0886260510385125; Sakurai K, 2017, DISASTER MED PUBLIC, V11, P216, DOI 10.1017/dmp.2016.109; Stenson K, 2005, MIDWIFERY, V21, P311, DOI 10.1016/j.midw.2005.01.002; Stenson K, 2001, MIDWIFERY, V17, P2, DOI 10.1054/midw.2000.0241; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; United Nations, 2016, SUSTAINABLE SEVELOPM; Urassa DP, 2012, TANZAN J HLTH RES, V14, P42; Whitney R, 2017, J STRUCT ENG, V143, DOI 10.1061/(ASCE)ST.1943-541X.0001717; World Health Organization, 2002, ANT CAR RAND TRIAL M; World Health Organization, 2013, LONDON SCH HYGIENE T	49	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2018	13	7							e0200234	10.1371/journal.pone.0200234	http://dx.doi.org/10.1371/journal.pone.0200234			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO4DQ	30048459	Green Published, gold, Green Submitted			2023-01-03	WOS:000439952400005
J	Hachul, ACL; Boldarine, VT; Neto, NIP; Moreno, MF; Ribeiro, EB; do Nascimento, CMO; Oyama, LM				Hachul, Ana C. L.; Boldarine, Valter T.; Neto, Nelson I. P.; Moreno, Mayara F.; Ribeiro, Eliane B.; do Nascimento, Claudia M. O.; Oyama, Lila M.			Maternal consumption of green tea extract during pregnancy and lactation alters offspring's metabolism in rats	PLOS ONE			English	Article							HIGH-FAT-DIET; TOLL-LIKE RECEPTOR; INDUCED OBESITY; GUT MICROBIOTA; INSULIN-RESISTANCE; POLYPHENOL EPIGALLOCATECHIN-3-GALLATE; GLUCOSE-TOLERANCE; PREVENTS OBESITY; ADIPOSE-TISSUE; INFLAMMATION	Introduction Green tea extract has anti-inflammatory and antioxidant effects which improve dyslipidemia and decrease adipose tissue depots associated with hyperlipidic diet consumption. Objective To evaluate the effect of green tea extract consumption by rats during pregnancy and lactation on the metabolism of their offspring that received control or high-fat diet with water during 10 weeks after weaning. Methods Wistar rats received water (W) or green tea extract diluted in water (G) (400 mg/kg body weight/day), and control diet (10 animals in W and G groups) during pregnancy and lactation. After weaning, offspring received water and a control (CW) or a high-fat diet (HW), for 10 weeks. One week before the end of treatment, oral glucose tolerance test was performed. The animals were euthanized and the samples were collected for biochemical, hormonal and antioxidant enzymes activity analyses. In addition, IL-10, TNF-alpha, IL-6, and IL-1 beta were quantified by ELISA while p-NF-kappa Bp50 was analyzed by Western Blotting. Repeated Measures ANOVA, followed by Tukey's test were used to find differences between data (p < 0.05). Results The consumption of high-fat diet by rats for 10 weeks after weaning promoted hyperglycemia and hyperinsulinemia, and increased fat depots. The ingestion of a high-fat diet by the offspring of mothers who consumed green tea extract during pregnancy and lactation decreased the inflammatory cytokines in adipose tissue, while the ingestion of a control diet increased the same cytokines. Conclusion Our results demonstrate that prenatal consumption of green tea associated with consumption of high-fat diet by offspring after weaning prevented inflammation. However, maternal consumption of the green tea extract induced a pro-inflammatory status in the adipose tissue of the adult offspring that received the control diet after weaning.	[Hachul, Ana C. L.; Boldarine, Valter T.; Neto, Nelson I. P.; Moreno, Mayara F.; Ribeiro, Eliane B.; do Nascimento, Claudia M. O.; Oyama, Lila M.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Fisiol, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Oyama, LM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Fisiol, Sao Paulo, Brazil.	lmoyama@gmail.com	Nascimento, Claudia Maria Oller do/T-4151-2019; Oyama, Lila M/B-7609-2012; Hachul, Ana C. L./N-4082-2017; Ribeiro, Eliane B/C-8124-2012; Neto, Nelson Inácio Pinto NIP/N-3269-2018; Moreno, Mayara F/N-4433-2017; Boldarine, Valter/AAC-9086-2020; Moreno, Mayara Franzoi/AAB-6151-2020	Nascimento, Claudia Maria Oller do/0000-0001-5755-3392; Hachul, Ana C. L./0000-0003-4044-9382; Ribeiro, Eliane B/0000-0002-3071-9134; Moreno, Mayara F/0000-0001-9078-2795; Moreno, Mayara Franzoi/0000-0001-9078-2795; Inacio Pinto Neto, Nelson/0000-0003-2634-359X	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2014/19508-7]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); CNPq	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo 2014/19508-7-grant to: Dr Lila Missae Oyama and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)-grant to: Ana Claudia Losinskas Hachul. EBR, CMON and LMO are recipientes of CNPq fellowships.	AEBI H, 1984, METHOD ENZYMOL, V105, P121; Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c; Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4; Bechmann LP, 2012, J HEPATOL, V56, P952, DOI 10.1016/j.jhep.2011.08.025; Berk ES, 2005, OBES RES, V13, P1566, DOI 10.1038/oby.2005.192; Moreira APB, 2012, BRIT J NUTR, V108, P801, DOI 10.1017/S0007114512001213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byun EH, 2010, J IMMUNOL, V185, P33, DOI 10.4049/jimmunol.0903742; Byun EB, 2012, BIOCHEM BIOPH RES CO, V426, P480, DOI 10.1016/j.bbrc.2012.08.096; Caesar R, 2010, J INTERN MED, V268, P320, DOI 10.1111/j.1365-2796.2010.02270.x; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cano P, 2009, OBESITY, V17, P1866, DOI 10.1038/oby.2009.200; Champ M, 2009, CURR OPIN CLIN NUTR, V12, P565, DOI 10.1097/MCO.0b013e328331b4aa; Chen N, 2009, NUTR RES, V29, P784, DOI 10.1016/j.nutres.2009.10.003; Chen ZY, 2001, J AGR FOOD CHEM, V49, P477, DOI 10.1021/jf000877h; Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005; Cunha CA, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/635470; Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040; FRAYN KN, 1995, AM J CLIN NUTR, V62, p250S, DOI 10.1093/ajcn/62.1.250S; GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F; Jang HJ, 2013, AM J PHYSIOL-ENDOC M, V305, pE1444, DOI 10.1152/ajpendo.00434.2013; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926; Li JL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-161; Loche E, 2016, CURR OPIN LIPIDOL, V27, P449, DOI 10.1097/MOL.0000000000000338; Louis P, 2010, ENVIRON MICROBIOL, V12, P304, DOI 10.1111/j.1462-2920.2009.02066.x; Machado MV, 2012, ANN HEPATOL, V11, P440, DOI 10.1016/S1665-2681(19)31457-7; del Bas JM, 2015, J NUTR BIOCHEM, V26, P1670, DOI 10.1016/j.jnutbio.2015.08.015; Maron DJ, 2003, ARCH INTERN MED, V163, P1448, DOI 10.1001/archinte.163.12.1448; Moreno MF, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-84; Mukai Y, 2013, NUTRITION, V29, P291, DOI 10.1016/j.nut.2012.06.005; Muralimanoharan S, 2017, J MOL CELL CARDIOL, V108, P181, DOI 10.1016/j.yjmcc.2017.06.006; Nakamura YK, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-60; Okuda MH, 2014, J NUTR BIOCHEM, V25, P1084, DOI 10.1016/j.jnutbio.2014.05.012; Phillips LK, 2008, CURR HYPERTENS REP, V10, P156, DOI 10.1007/s11906-008-0029-7; Batista GDP, 2009, ARQ BRAS CARDIOL, V93, P121; Ravussin Y, 2012, OBESITY, V20, P738, DOI 10.1038/oby.2011.111; Reeves P G, 1997, J Nutr, V127, p838S, DOI 10.1093/jn/127.5.838S; Santamarina AB, 2015, J NUTR BIOCHEM, V26, P1348, DOI 10.1016/j.jnutbio.2015.07.002; Santana A, 2015, J NUTR BIOCHEM, V26, P893, DOI 10.1016/j.jnutbio.2015.03.001; Sato S, 2013, NUTRITION, V29, P1152, DOI 10.1016/j.nut.2013.03.021; Shen CL, 2011, OSTEOPOROSIS INT, V22, P327, DOI 10.1007/s00198-010-1209-2; Shen CL, 2010, J NUTR BIOCHEM, V21, P968, DOI 10.1016/j.jnutbio.2009.08.002; Singh DP, 2017, PHARMACOL RES, V123, P103, DOI 10.1016/j.phrs.2017.06.015; TRUSWELL AS, 1994, AM J CLIN NUTR, V59, p710S, DOI 10.1093/ajcn/59.3.710S; Tsukumo DM, 2015, ARCH ENDOCRIN METAB, V59, P154, DOI 10.1590/2359-3997000000029; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778; Voshol PJ, 2009, BBA-MOL CELL BIOL L, V1791, P479, DOI 10.1016/j.bbalip.2008.12.015; Waki H, 2007, ANNU REV PATHOL-MECH, V2, P31, DOI 10.1146/annurev.pathol.2.010506.091859; Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178; Yamashita AS, 2010, CYTOKINE, V52, P168, DOI 10.1016/j.cyto.2010.07.006; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P850, DOI 10.1016/j.bcp.2006.06.021; Zou TD, 2017, J PHYSIOL-LONDON, V595, P1547, DOI 10.1113/JP273478; Zvonic S, 2006, DIABETES, V55, P962, DOI 10.2337/diabetes.55.04.06.db05-0873	57	9	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0199969	10.1371/journal.pone.0199969	http://dx.doi.org/10.1371/journal.pone.0199969			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN4SJ	30020947	Green Published, gold, Green Submitted			2023-01-03	WOS:000439022400033
J	Ro, SY; Ross, MO; Deng, YW; Batelu, S; Lawton, TJ; Hurley, JD; Stemmler, TL; Hoffman, BM; Rosenzweig, AC				Ro, Soo Y.; Ross, Matthew O.; Deng, Yue Wen; Batelu, Sharon; Lawton, Thomas J.; Hurley, Joseph D.; Stemmler, Timothy L.; Hoffman, Brian M.; Rosenzweig, Amy C.			From micelles to bicelles: Effect of the membrane on particulate methane monooxygenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						copper monooxygenase; metalloenzyme; crystal structure; biofuel; biotechnology; protein-lipid interaction; membrane protein; bicelle; copper metalloenzyme; methane oxidation; methanotroph; particulate methane monooxygenase	CRYSTAL-STRUCTURE; METAL CENTERS; PROTEIN; OXIDATION; COPPER; LIPIDS; PURIFICATION; DETERGENTS; BACTERIA; COMPLEX	Particulate methane monooxygenase (pMMO) is a copper-dependent integral membrane metalloenzyme that converts methane to methanol in methanotrophic bacteria. Studies of isolated pMMO have been hindered by loss of enzymatic activity upon its removal from the native membrane. To characterize pMMO in a membrane-like environment, we reconstituted pMMOs from Methylococcus (Mcc.) capsulatus (Bath) and Methylomicrobium (Mm.) alcaliphilum 20Z into bicelles. Reconstitution into bicelles recovers methane oxidation activity lost upon detergent solubilization and purification without substantial alterations to copper content or copper electronic structure, as observed by electron paramagnetic resonance (EPR) spectroscopy. These findings suggest that loss of pMMO activity upon isolation is due to removal from the membranes rather than caused by loss of the catalytic copper ions. A 2.7 resolution crystal structure of pMMO from Mm. alcaliphilum 20Z reveals a mononuclear copper center in the PmoB subunit and indicates that the transmembrane PmoC subunit may be conformationally flexible. Finally, results from extended X-ray absorption fine structure (EXAFS) analysis of pMMO from Mm. alcaliphilum 20Z were consistent with the observed monocopper center in the PmoB subunit. These results underscore the importance of studying membrane proteins in a membrane-like environment and provide valuable insight into pMMO function.	[Ro, Soo Y.; Ross, Matthew O.; Deng, Yue Wen; Lawton, Thomas J.; Hurley, Joseph D.; Hoffman, Brian M.; Rosenzweig, Amy C.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA; [Ro, Soo Y.; Ross, Matthew O.; Deng, Yue Wen; Lawton, Thomas J.; Hurley, Joseph D.; Hoffman, Brian M.; Rosenzweig, Amy C.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Batelu, Sharon; Stemmler, Timothy L.] Wayne State Univ, Dept Pharmaceut Sci, Detroit, MI 48201 USA	Northwestern University; Northwestern University; Wayne State University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA.; Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.	amyr@northwestern.edu		Stemmler, Timothy/0000-0002-6298-088X; Deng, Yue Wen/0000-0003-3344-6837; Hurley, Joseph/0000-0002-3903-318X; Rosenzweig, Amy/0000-0001-8472-4134	Department of Energy Office of Science [DE-AC02-06CH11357]; Michigan Economic Development Corp.; Michigan Technology Tri-Corridor [085P1000817]; Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-76SF00515]; Department of Energy Office of Biological and Environmental Research; NIGMS, National Institutes of Health [P41GM103393]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM118035, P41GM103393, R01GM111097, R01GM070473, T32GM008382] Funding Source: NIH RePORTER	Department of Energy Office of Science(United States Department of Energy (DOE)); Michigan Economic Development Corp.; Michigan Technology Tri-Corridor; Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Department of Energy Office of Biological and Environmental Research(United States Department of Energy (DOE)); NIGMS, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work used the Advanced Photon Source, a Department of Energy Office of Science User Facility operated for the Department of Energy Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Use of LS-CAT Sector 21 was supported by the Michigan Economic Development Corp. and the Michigan Technology Tri-Corridor (grant 085P1000817). Data were collected at the LS-CAT beamline 21-ID-D. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the Department of Energy Office of Biological and Environmental Research and by the NIGMS, National Institutes of Health (including P41GM103393). We also thank Dr. Marina Kalyuzhnaya at San Diego State University for providing Mm. alcaliphilum 20Z cultures.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Agah Sayeh, 2012, Methods Mol Biol, V914, P3, DOI 10.1007/978-1-62703-023-6_1; Ankudinov AL, 1997, PHYS REV B, V56, pR1712, DOI 10.1103/PhysRevB.56.R1712; Balasubramanian R, 2010, NATURE, V465, P115, DOI 10.1038/nature08992; Bayburt TH, 2010, FEBS LETT, V584, P1721, DOI 10.1016/j.febslet.2009.10.024; Blanchette CD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11900; Cao LL, 2018, ANGEW CHEM INT EDIT, V57, P162, DOI 10.1002/anie.201708977; Chan SI, 2008, ACCOUNTS CHEM RES, V41, P969, DOI 10.1021/ar700277n; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Choi DW, 2003, J BACTERIOL, V185, P5755, DOI 10.1128/JB.185.19.5755-5764.2003; Cotelesage JJH, 2012, J INORG BIOCHEM, V115, P127, DOI 10.1016/j.jinorgbio.2012.06.019; Culpepper MA, 2014, J AM CHEM SOC, V136, P11767, DOI 10.1021/ja5053126; Czerski L, 2000, ANAL BIOCHEM, V284, P327, DOI 10.1006/abio.2000.4720; Durr UHN, 2012, CHEM REV, V112, P6054, DOI 10.1021/cr300061w; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Fei Q, 2014, BIOTECHNOL ADV, V32, P596, DOI 10.1016/j.biotechadv.2014.03.011; Frandsen KEH, 2016, IUCRJ, V3, P448, DOI 10.1107/S2052252516014147; Frey L, 2017, ANGEW CHEM INT EDIT, V56, P380, DOI 10.1002/anie.201608246; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; George G. N., 2001, EXAFSPAK; Gruss F, 2015, METHODS MOL BIOL, V1329, P259, DOI 10.1007/978-1-4939-2871-2_20; Hakemian AS, 2008, BIOCHEMISTRY-US, V47, P6793, DOI 10.1021/bi800598h; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Hunte C, 2008, CURR OPIN STRUC BIOL, V18, P406, DOI 10.1016/j.sbi.2008.03.008; Jiang H, 2010, BIOCHEM ENG J, V49, P277, DOI 10.1016/j.bej.2010.01.003; Kaluzhnaya M, 2001, SYST APPL MICROBIOL, V24, P166, DOI 10.1078/0723-2020-00028; Kalyuzhnaya MG, 2015, METAB ENG, V29, P142, DOI 10.1016/j.ymben.2015.03.010; Khmelenina VN, 1997, CURR MICROBIOL, V35, P257, DOI 10.1007/s002849900249; Lawton TJ, 2016, J AM CHEM SOC, V138, P9327, DOI 10.1021/jacs.6b04568; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; Lieberman RL, 2006, INORG CHEM, V45, P8372, DOI 10.1021/ic060739v; Lieberman RL, 2003, P NATL ACAD SCI USA, V100, P3820, DOI 10.1073/pnas.0536703100; Lieberman RL, 2005, NATURE, V434, P177, DOI 10.1038/nature03311; Liew EF, 2014, MICROBIOL-SGM, V160, P1267, DOI 10.1099/mic.0.078584-0; MAKULA RA, 1978, J BACTERIOL, V134, P771, DOI 10.1128/JB.134.3.771-777.1978; Ojala DS, 2011, METHOD ENZYMOL, P99, DOI 10.1016/B978-0-12-386905-0.00007-3; Orwick-Rydmark Marcella, 2016, Curr Protoc Protein Sci, V84, DOI 10.1002/0471140864.ps0408s84; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puri AW, 2015, APPL ENVIRON MICROB, V81, P1766, DOI 10.1128/AEM.03795-14; RIGGSGELASCO PJ, 1995, COORDIN CHEM REV, V144, P245, DOI 10.1016/0010-8545(95)01144-E; Ross MO, 2017, J BIOL INORG CHEM, V22, P307, DOI 10.1007/s00775-016-1419-y; Seddon AM, 2004, BBA-BIOMEMBRANES, V1666, P105, DOI 10.1016/j.bbamem.2004.04.011; Shen HH, 2013, INT J MOL SCI, V14, P1589, DOI 10.3390/ijms14011589; Simmons TJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01247-3; Sirajuddin S, 2015, BIOCHEMISTRY-US, V54, P2283, DOI 10.1021/acs.biochem.5b00198; Sirajuddin S, 2014, J BIOL CHEM, V289, P21782, DOI 10.1074/jbc.M114.581363; Smith SM, 2011, BIOCHEMISTRY-US, V50, P10231, DOI 10.1021/bi200801z; Stemmler TL, 1997, BIOCHEMISTRY-US, V36, P9847, DOI 10.1021/bi9702795; Stoll S, 2006, J MAGN RESON, V178, P42, DOI 10.1016/j.jmr.2005.08.013; Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103; United States Environmental Protection Agency, 2017, 430P17001 EPA US ENV; Walton PH, 2016, CURR OPIN CHEM BIOL, V31, P195, DOI 10.1016/j.cbpa.2016.04.001; Wang VCC, 2017, CHEM REV, V117, P8574, DOI 10.1021/acs.chemrev.6b00624; Yang ZR, 2014, PROTEIN SCI, V23, P769, DOI 10.1002/pro.2460	55	31	31	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2018	293	27					10457	10465		10.1074/jbc.RA118.003348	http://dx.doi.org/10.1074/jbc.RA118.003348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM1LI	29739854	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000437828400007
J	Carey, CM; Jena, AB; Barnett, ML				Carey, C. M.; Jena, A. B.; Barnett, M. L.			Patterns of Potential Opioid Misuse and Subsequent Adverse Outcomes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													Barnett, Michael/ABA-4159-2021; Barnett, Michael/AAF-4017-2019	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609; carey, colleen/0000-0003-0069-9707					0	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2018	168	12					I18	I18		10.7326/P18-0007	http://dx.doi.org/10.7326/P18-0007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK1TE	29800059				2023-01-03	WOS:000435903500002
J	Zuckerman, A; Douglas, A; Nwosu, S; Choi, L; Chastain, C				Zuckerman, Autumn; Douglas, Andrew; Nwosu, Sam; Choi, Leena; Chastain, Cody			Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era	PLOS ONE			English	Article							VIRUS-INFECTION; UNITED-STATES; ACCESS; FACILITATORS; COMPLETION; ADHERENCE; THERAPY; RISK	Barriers remain in the hepatitis C virus (HCV) cascade of care (CoC), limiting the overall impact of direct acting antivirals. This study examines movement between the stages of the HCV CoC and identifies reasons why patients and specific patient populations fail to advance through care in a real world population. We performed a single-center, ambispective cohort study of patients receiving care in an outpatient infectious diseases clinic between October 2015 and September 2016. Patients were followed from treatment referral through sustained virologic response. Univariate and multivariate analyses were performed to identify factors related to completion of each step of the CoC. Of 187 patients meeting inclusion criteria, 120 (64%) completed an evaluation for HCV treatment, 119 (64%) were prescribed treatment, 114 (61%) were approved for treatment, 113 (60%) initiated treatment, 107 (57%) completed treatment, and 100 (53%) achieved a sustained virologic response. In univariate and multivariate analyses, patients with Medicaid insurance were less likely to complete an evaluation and were less likely to be approved for treatment. Treatment completion and SVR rates are much improved from historical CoC reports. However, linkage to care following referral continues to be a formidable challenge for the HCV CoC in the DAA era. Ongoing efforts should focus on linkage to care to capitalize on DAA treatment advances and improving access for patients with Medicaid insurance.	[Zuckerman, Autumn] Vanderbilt Univ, Med Ctr, Vanderbilt Specialty Pharm Serv, Nashville, TN 37235 USA; [Douglas, Andrew] Belmont Univ, Coll Pharm, Nashville, TN USA; [Nwosu, Sam; Choi, Leena] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Chastain, Cody] Vanderbilt Univ, Med Ctr, Div Infect Dis, Dept Med, Nashville, TN USA	Vanderbilt University; Belmont University; Vanderbilt University; Vanderbilt University	Zuckerman, A (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Specialty Pharm Serv, Nashville, TN 37235 USA.	Autumn.Zuckerman@vanderbilt.edu						AASLD-IDSA, 2017, WHOM IN HCV THER REC; Bagwell AC, 2016, HEPATITIS C TREATMEN, DOI [10.1007/s40506-016-0097-1, DOI 10.1007/S40506-016-0097-1]; Barua S, 2015, ANN INTERN MED, V163, P215, DOI 10.7326/M15-0406; Belperio PS, 2017, ANN INTERN MED, V167, P499, DOI 10.7326/M17-1073; Bourgi K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161241; Cachay ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102883; Canary LA, 2015, ANN INTERN MED, V163, P226, DOI 10.7326/M15-0320; Clough B, 2017, TRIO HLTH REAL WORLD; Committee on a National Strategy for the Elimination of Hepatitis B and C Board on Population Health and Public Health Practice Health and Medicine Division National Academies of Sciences E and Medi-cine Eliminating the Public Health Problem of Hepatitis B and C in the United States, 2016, COMM NAT STRAT EL HE; Dever JB, 2017, DIGEST DIS SCI, V62, P1472, DOI 10.1007/s10620-017-4548-4; Dimova RB, 2013, CLIN INFECT DIS, V56, P806, DOI 10.1093/cid/cis1007; Do A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135645; Jonas MC, 2016, CLIN INFECT DIS, V62, P1290, DOI 10.1093/cid/ciw086; Kim AY, 2017, CLIN INFECT DIS, V65, P709, DOI 10.1093/cid/cix501; Koneru A, 2016, MMWR-MORBID MORTAL W, V65, P705, DOI 10.15585/mmwr.mm6528a2; Lo Re V, 2016, CLIN GASTROENTEROL H, V14, P1035, DOI 10.1016/j.cgh.2016.03.040; Loy V, 2016, ANTIVIR THER, V21, P731, DOI 10.3851/IMP3068; Machado SM, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006468, 10.1590/s1518-8787.2017051006468]; Millman Alexander J, 2017, Top Antivir Med, V25, P110; Rogal SS, 2017, DIGEST DIS SCI, V62, P1933, DOI 10.1007/s10620-017-4608-9; Souliotis K, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0601-3; Sublette VA, 2017, J HEALTH PSYCHOL, V22, P1300, DOI 10.1177/1359105315626786; Wade AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142770; WHOGhssovh, 2016, 2016 2021 WHOGHSSOVH; Yehia BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101554; Younossi Z, 2017, LIV M WASH DC; Younossi ZM, 2016, J VIRAL HEPATITIS, V23, P447, DOI 10.1111/jvh.12506; Zhou K, 2016, LANCET INFECT DIS, V16, P1409, DOI 10.1016/S1473-3099(16)30208-0	28	58	58	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2018	13	6							e0199174	10.1371/journal.pone.0199174	http://dx.doi.org/10.1371/journal.pone.0199174			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ6XV	29912944	Green Published, gold, Green Submitted			2023-01-03	WOS:000435528600082
J	Rockett, IRH; Caine, ED; Stack, S; Connery, HS; Nolte, KB; Lilly, CL; Miller, TR; Nelson, LS; Putnam, SL; Nestadt, PS; Jia, HM				Rockett, Ian R. H.; Caine, Eric D.; Stack, Steven; Connery, Hilary S.; Nolte, Kurt B.; Lilly, Christa L.; Miller, Ted R.; Nelson, Lewis S.; Putnam, Sandra L.; Nestadt, Paul S.; Jia, Haomiao			Method overtness, forensic autopsy, and the evidentiary suicide note: A multilevel National Violent Death Reporting System analysis	PLOS ONE			English	Article							UNDETERMINED DEATHS; MORTALITY DATA; PUBLIC-HEALTH; RATES; CERTIFICATION; CORONERS; VALIDITY; SURVEILLANCE; STATISTICS; FINLAND	Objective Higher prevalence of suicide notes could signify more conservatism in accounting and greater proneness to undercounting of suicide by method. We tested two hypotheses: (1) an evidentiary suicide note is more likely to accompany suicides by drug-intoxication and by other poisoning, as less violent and less forensically overt methods, than suicides by firearm and hanging/suffocation; and (2) performance of a forensic autopsy attenuates any observed association between overtness of method and the reported presence of a note. Methods This multilevel (individual/county), multivariable analysis employed a generalized linear mixed model (GLMM). Representing the 17 states participating in the United States National Violent Death Reporting System throughout 2011-2013, the study population comprised registered suicides, aged 15 years and older. Decedents totaled 32,151. The outcome measure was relative odds of an authenticated suicide note. Results An authenticated suicide note was documented in 31% of the suicide cases. Inspection of the full multivariable model showed a suicide note was more likely to manifest among drug intoxication (adjusted odds ratio [OR], 1.70; 95% CI, 1.56, 1.85) and other poisoning suicides (OR, 2.12; 1.85, 2.42) than firearm suicides, the referent. Respective excesses were larger when there was no autopsy or autopsy status was unknown (OR, 1.86; 95% CI, 1.61, 2.14) and (OR, 2.25; 95% CI, 1.86, 2.72) relative to the comparisons with a forensic autopsy (OR, 1.62, 95% CI, 1.45, 1.82 and OR, 2.01; 95% CI, 1.66, 2.43). Hanging/suffocation suicides did not differ from the firearm referent given an autopsy. Conclusions Suicide requires substantial affirmative evidence to establish manner of death, and affirmation of drug intoxication suicides appears to demand an especially high burden of proof. Findings and their implications argue for more stringent investigative standards, better training, and more resources to support comprehensive and accurate case ascertainment, as the foundation for developing evidence-based suicide prevention initiatives.	[Rockett, Ian R. H.] West Virginia Univ, Dept Epidemiol, Morgantown, WV 26506 USA; [Rockett, Ian R. H.; Putnam, Sandra L.] West Virginia Univ, Injury Control Res Ctr, Morgantown, WV 26506 USA; [Caine, Eric D.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA; [Caine, Eric D.] Univ Rochester, Med Ctr, Injury Control Res Ctr Suicide Prevent, Rochester, NY 14642 USA; [Stack, Steven] Wayne State Univ, Dept Criminal Justice, Detroit, MI USA; [Stack, Steven] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48207 USA; [Connery, Hilary S.] McLean Hosp, Div Alcohol & Drug Abuse, Boston, MA USA; [Connery, Hilary S.] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Nolte, Kurt B.] Univ New Mexico, Sch Med, Off Med Investigator, Albuquerque, NM 87131 USA; [Lilly, Christa L.] West Virginia Univ, Dept Biostat, Morgantown, WV USA; [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA; [Miller, Ted R.] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia; [Nelson, Lewis S.] Rutgers New Jersey Med Sch, Dept Emergency Med, Newark, NJ USA; [Nestadt, Paul S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Nestadt, Paul S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY USA; [Jia, Haomiao] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA	West Virginia University; West Virginia University; University of Rochester; University of Rochester; Wayne State University; Wayne State University; Harvard University; McLean Hospital; Harvard University; Harvard Medical School; University of New Mexico; West Virginia University; Pacific Institute for Research & Evaluation (PIRE); Curtin University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Columbia University; Columbia University	Rockett, IRH (corresponding author), West Virginia Univ, Dept Epidemiol, Morgantown, WV 26506 USA.; Rockett, IRH (corresponding author), West Virginia Univ, Injury Control Res Ctr, Morgantown, WV 26506 USA.	irockett@hsc.wvu.edu	Jia, Haomiao/AAU-8276-2021; Lilly, Christa L/R-6644-2017; Nestadt, Paul/ABG-6191-2021	Lilly, Christa L/0000-0002-0009-0638; Nestadt, Paul/0000-0002-2479-703X; Miller, Ted/0000-0002-0958-2639; Rockett, Ian/0000-0002-4584-9337	National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention [R49CE002109, R49CE002093]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL [R49CE002109, R49CE002093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by Grants R49CE002109 and R49CE002093 from the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention. They provided salary support for three authors (IRHR, EDC, HJ) and consulting fees for another (SS). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Blair JM, 2016, MMWR SURVEILL SUMM, V65, P1, DOI [10.15585/mmwr.ss6510a1, DOI 10.15585/MMWR.SS6510A1]; Breiding M J, 2006, Inj Prev, V12 Suppl 2, pii49, DOI 10.1136/ip.2006.012591; Byard RW., 2007, SCAND J FORENSIC SCI, V13, P10; Callanan VJ, 2009, SUICIDE LIFE-THREAT, V39, P558, DOI 10.1521/suli.2009.39.5.558; Carpenter B, 2009, MED SCI LAW, V49, P101, DOI 10.1258/rsmmsl.49.2.101; Center for Disease Control and Prevention, 2017, WEB BAS INJ STAT QUE; Centers for Disease Control and Prevention, NAT VIOL DEATH REP S; Centers for Disease Control and Prevention, 2015, PUBL HLTH LAW PROGR; Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P721; COHEN SL, 1974, LIFE THREATENING BEH, V4, P75; Committee on Identifying the Needs of the Forensic Sciences Community National Research Council, 2009, STRENGTHENING FORENS; Cooper PN, 1995, MED SCI LAW, V35, P319, DOI 10.1177/002580249503500409; Croft PR, 2006, J FORENSIC SCI, V51, P651, DOI 10.1111/j.1556-4029.2006.00128.x; Donaldson AE, 2006, INJURY PREV, V12, P338, DOI 10.1136/ip.2005.011171; Eisenwort B, 2006, NERVENARZT, V77, P1355, DOI 10.1007/s00115-005-1965-y; Fisher D., 2000, FORENSIC EXAM, V9, P24; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; Hanzlick RL., 2014, ACAD FORENSIC PATHOL, V4, P2, DOI [10.23907/2014.001, DOI 10.23907/2014.001]; Health Resources and Services Administration Bureau of Health Workforce National Center for Health Workforce Analysis, 2015, COUNT AR HLTH RES FI; Hedegaard H, 2017, NCHS DATA BRIEF, V273, p1 ; Hoyert DL, 2007, VITAL HLTH STAT, V20, P1; Hoyert Donna L, 2011, NCHS Data Brief, P1; Huguet N, 2012, SUICIDE LIFE-THREAT, V42, P185, DOI 10.1111/j.1943-278X.2012.00081.x; Institute of Medicine, 2006, HOSP BAS EM CAR BREA; Institute of Medicine, 2006, EM MED SERV CROSSR; Institute of Medicine, 2003, MED DEATH INV SYST W; Jougla E, 2002, REV EPIDEMIOL SANTE, V50, P49; Kaplan MS, 2017, AM J PREV MED, V53, P130, DOI 10.1016/j.amepre.2017.01.043; Kapusta ND, 2011, ARCH GEN PSYCHIAT, V68, P1050, DOI 10.1001/archgenpsychiatry.2011.66; Karch D., 2006, Morbidity and Mortality Weekly Report, V55, P1245; Linsley KR, 2001, BRIT J PSYCHIAT, V178, P465, DOI 10.1192/bjp.178.5.465; Logan JE, 2009, HOMICIDE STUD, V13, P385, DOI 10.1177/1088767909348323; Lunetta P, 2007, INJURY PREV, V13, P282, DOI 10.1136/ip.2006.012922; National Association of Medical Examiners, 2016, FOR AUT PERF STAND; NELSON FL, 1978, SUICIDE LIFE-THREAT, V8, P75; Neuilly MA, 2013, HOMICIDE STUD, V17, P339, DOI 10.1177/1088767913494387; OCARROLL PW, 1989, SUICIDE LIFE-THREAT, V19, P1; Ohberg A, 1998, ACTA PSYCHIAT SCAND, V98, P214, DOI 10.1111/j.1600-0447.1998.tb10069.x; OVENSTONE IM, 1973, BRIT J PSYCHIAT, V123, P15, DOI 10.1192/bjp.123.1.15; Palmer BS, 2015, J PUBLIC HEALTH-UK, V37, P157, DOI 10.1093/pubmed/fdu024; Parai JL, 2006, ANN EPIDEMIOL, V16, P805, DOI 10.1016/j.annepidem.2006.01.006; Parks SE, 2014, MMWR SURVEILL SUMM, V63, P1; Acinas MP, 2015, ACTAS ESP PSIQUIATRI, V43, P69; Paulozzi LJ, 2004, INJURY PREV, V10, P47, DOI 10.1136/ip.2003.003434; PLATT S, 1988, SOC PSYCH PSYCH EPID, V23, P217, DOI 10.1007/BF01787820; Rockett IRH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190200; Rockett Ian R H, 2012, Am J Public Health, V102, pe84, DOI 10.2105/AJPH.2012.300960; Rockett IRH, 2010, CRISIS, V31, P227, DOI 10.1027/0227-5910/a000071; Rockett IRH, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-35; Rockett IRH, 1999, SUICIDE LIFE-THREAT, V29, P141; Scourfield J, 2012, SOC SCI MED, V74, P466, DOI 10.1016/j.socscimed.2010.01.054; Shields LBE, 2006, AM J FOREN MED PATH, V27, P106, DOI 10.1097/01.paf.0000220913.19508.99; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; Sorenson SB, 1997, EVALUATION REV, V21, P43, DOI 10.1177/0193841X9702100103; Stack S, 2018, SUICIDE LIFE-THREAT, V48, P12, DOI 10.1111/sltb.12320; Steenkamp M, 2006, Inj Prev, V12 Suppl 2, pii3, DOI 10.1136/ip.2006.012518; Stone DM, 2017, AM J PUBLIC HEALTH, V107, P1233, DOI [10.2105/AJPH.2017.303863, 10.2105/ajph.2017.303863]; Stone DH, 2002, FINAL REPORT EUROPEA; Timmermans S, 2005, AM SOCIOL REV, V70, P311, DOI 10.1177/000312240507000206; TUCKMAN J, 1959, AM J PSYCHIAT, V116, P59, DOI 10.1176/ajp.116.1.59; Varnik P, 2012, INJURY PREV, V18, P321, DOI 10.1136/injuryprev-2011-040070; Waldhoer T, 2003, J CLIN EPIDEMIOL, V56, P891, DOI 10.1016/S0895-4356(03)00076-3; WARSHAUER ME, 1978, AM J PUBLIC HEALTH, V68, P383, DOI 10.2105/AJPH.68.4.383; Ylijoki-Sorensen S, 2014, FORENSIC SCI INT, V244, P289, DOI 10.1016/j.forsciint.2014.09.016; Ylijoki-Sorensen S, 2014, FORENSIC SCI INT, V244, P158, DOI 10.1016/j.forsciint.2014.08.035	65	25	25	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2018	13	5							e0197805	10.1371/journal.pone.0197805	http://dx.doi.org/10.1371/journal.pone.0197805			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GG6DG	29787584	Green Submitted, Green Published, gold			2023-01-03	WOS:000432785700048
J	Kleijn, G; Lissenberg-Witte, BI; Bohlmeijer, ET; Steunenberg, B; Knipscheer-Kuijpers, K; Willemsen, V; Becker, A; Smit, EF; Eeltink, CM; Bruynzeel, AME; van der Vorst, M; de Bree, R; Leemans, CR; van den Brekel, MWM; Cuijpers, P; Verdonck-de Leeuw, IM				Kleijn, Gitta; Lissenberg-Witte, Birgit, I; Bohlmeijer, Ernst T.; Steunenberg, Bas; Knipscheer-Kuijpers, Kitty; Willemsen, Vincent; Becker, Annemarie; Smit, Egbert F.; Eeltink, Corien M.; Bruynzeel, Anna M. E.; van der Vorst, Maurice; de Bree, Remco; Leemans, C. Rene; van den Brekel, Michiel W. M.; Cuijpers, Pim; Verdonck-de Leeuw, Irma M.			The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trial	PLOS ONE			English	Article							TERMINALLY-ILL PATIENTS; DIGNITY THERAPY; AUTOBIOGRAPHICAL MEMORY; EGO INTEGRITY; REMINISCENCE; DEPRESSION; ANXIETY; END; VALIDATION; INTERVIEWS	Background The aim of this study was to evaluate the efficacy of an intervention combining Life Review Therapy (LRT) and Memory Specificity Training (MST) (LRT-MST) to improve ego-integrity and despair among cancer patients in palliative care. Methods In this multicentre randomized controlled trial, cancer patients in palliative care were randomized to the intervention group (LRT-MST; n = 55) or waiting-list control group (n = 52). LRT-MST is a 4-session home-based psychological intervention that aims to retrieve specific positive memories, to re-evaluate life events and to reconstruct the story of a patient's life, including the diagnosis of incurable cancer. Outcome measures were ego-integrity and despair (NEIS), psychological distress, anxiety and depression (HADS), quality of life (EORTC QLQ-C15-PAL), and specificity of the autobiographical memory (AMT). NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (TO), 1 month later (post-treatment; T1), and at 1 month follow-up (T2). AMT was assessed at TO and Ti. Linear mixed models (intention to treat) were used to assess group differences in changes over time. Independent samples t-tests were used to assess group differences at TO, T1, and T2, and effect sizes (ES) were calculated at T1 and T2. Results The course of ego-integrity (not despair) improved significantly over time (p = .007) in the intervention group compared to the waiting-list control group, with moderate, but insignificant, effect sizes at T1 (ES = .42) and T2 (ES = .48). Compliance rate was 69% and total dropout rate was 28%, both primarily related to disease progression and death. Conclusions LRT-MST seems effective among cancer patients in palliative care to improve the course of ego-integrity.	[Kleijn, Gitta; Cuijpers, Pim; Verdonck-de Leeuw, Irma M.] Vrije Univ Amsterdam, Dept Clin Neuro & Dev Psychol, Amsterdam, Netherlands; [Lissenberg-Witte, Birgit, I] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Bohlmeijer, Ernst T.] Univ Twente, Dept Mental Hlth, Enschede, Netherlands; [Steunenberg, Bas] Univ Appl Sci Utrecht, Fac Hlth Sci, Utrecht, Netherlands; [Knipscheer-Kuijpers, Kitty; Willemsen, Vincent] Ingeborg Douwes Ctr, Ctr Psychosocial Oncol Care, Amsterdam, Netherlands; [Becker, Annemarie; Smit, Egbert F.] Vrije Univ Amsterdam Med Ctr, Dept Pulm Dis, Amsterdam, Netherlands; [Eeltink, Corien M.] Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands; [Bruynzeel, Anna M. E.] Vrije Univ Amsterdam Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands; [van der Vorst, Maurice] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; [de Bree, Remco; Leemans, C. Rene; Verdonck-de Leeuw, Irma M.] Vrije Univ Amsterdam Med Ctr, Dept Head & Neck Surg, Amsterdam, Netherlands; [van den Brekel, Michiel W. M.] Netherlands Canc Inst, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Twente; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Netherlands Cancer Institute	Verdonck-de Leeuw, IM (corresponding author), Vrije Univ Amsterdam, Dept Clin Neuro & Dev Psychol, Amsterdam, Netherlands.; Verdonck-de Leeuw, IM (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Head & Neck Surg, Amsterdam, Netherlands.	im.verdonck@vumc.nl	Cuijpers, Pim/G-1703-2013	Verdonck-de Leeuw, Irma/0000-0002-4507-4607; van den Brekel, Michiel/0000-0002-6338-6743	ZonMw, The Netherlands Organisation for Health Research and Development [11510003]	ZonMw, The Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	This work was supported by ZonMw (https://www,zonmw.nl/nl/), The Netherlands Organisation for Health Research and Development [grant number: 11510003]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso RM, 2011, EDUC GERONTOL, V37, P1063, DOI 10.1080/03601277.2010.500585; American Psychiatric Association, 2000, DIAGNOSTIC STAT MANU; Ando M, 2008, PSYCHO-ONCOL, V17, P885, DOI 10.1002/pon.1299; Ando M, 2007, SUPPORT CARE CANCER, V15, P225, DOI 10.1007/s00520-006-0121-y; Ando M, 2010, J PAIN SYMPTOM MANAG, V39, P993, DOI 10.1016/j.jpainsymman.2009.11.320; Bohlmeijer E.T., 2010, DIERBARE HERINNERING; Breitbart W, 2012, J CLIN ONCOL, V30, P1304, DOI 10.1200/JCO.2011.36.2517; Breitbart W, 2010, PSYCHO-ONCOLOGY, V19, P21, DOI 10.1002/pon.1556; BUTLER RN, 1963, PSYCHIATR, V26, P65, DOI 10.1080/00332747.1963.11023339; Chochinov HM, 2011, LANCET ONCOL, V12, P753, DOI 10.1016/S1470-2045(11)70153-X; Chochinov HM, 2005, J CLIN ONCOL, V23, P5520, DOI 10.1200/JCO.2005.08.391; Cohen J., 2013, STAT POWER ANAL BEHA; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Erikson E ., 1950, CHILDHOOD SOC; Erikson EH, 1988, LIFE CYCLE COMPLETED; Field MJ, 1997, APPROACHING DEATH IM; Fishman S, 1992, Int Psychogeriatr, V4 Suppl 2, P267; FITCHETT G, 2015, BMC PALLIAT CARE, V14, DOI DOI 10.1186/1472-684X-14-1; Haber D, 2006, INT J AGING HUM DEV, V63, P153, DOI 10.2190/DA9G-RHK5-N9JP-T6CC; Holland Jimmie, 2009, Palliat Support Care, V7, P271, DOI 10.1017/S1478951509990198; Houmann LJ, 2014, PALLIATIVE MED, V28, P448, DOI 10.1177/0269216313514883; Janis L, 2011, DEV VALIDATION NW EG; Juliao M, 2014, J PALLIAT MED, V17, P688, DOI 10.1089/jpm.2013.0567; Kaur J, 2011, INDIAN J PALLIAT CAR, V17, P1, DOI 10.4103/0973-1075.78442; Kleijn G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156003; Lamers SMA, 2015, J GERONTOL B-PSYCHOL, V70, P24, DOI 10.1093/geronb/gbu030; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X; Neshat-Doost HT, 2013, CLIN PSYCHOL SCI, V1, P84, DOI 10.1177/2167702612454613; PICKREL J, 1989, DEATH STUD, V13, P127, DOI 10.1080/07481188908252290; Pinquart M, 2012, AGING MENT HEALTH, V16, P541, DOI 10.1080/13607863.2011.651434; Raes F, 2009, J BEHAV THER EXP PSY, V40, P24, DOI 10.1016/j.jbtep.2008.03.001; Rudilla D, 2016, PALLIAT SUPPORT CARE, V14, P321, DOI 10.1017/S1478951515001182; Sallnow L, 2012, INT PERSPECTIVES PUB; Serrano JP, 2004, PSYCHOL AGING, V19, P272, DOI 10.1037/0882-7974.19.2.272; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sneed JR, 2006, J ADULT DEV, V13, P148, DOI 10.1007/s10804-007-9026-3; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; van Vreeswijk MF, 2004, BEHAV RES THER, V42, P731, DOI 10.1016/S0005-7967(03)00194-3; Webster JD, 2010, J ADULT DEV, V17, P70, DOI 10.1007/s10804-009-9081-z; Westerhof GJ, 2014, J AGING STUD, V29, P107, DOI 10.1016/j.jaging.2014.02.003; Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987; WILLIAMS JMG, 1986, J ABNORM PSYCHOL, V95, P144, DOI 10.1037/0021-843X.95.2.144; Xiao HM, 2013, CANCER NURS, V36, P274, DOI 10.1097/NCC.0b013e318268f7ba	44	17	17	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2018	13	5							e0197277	10.1371/journal.pone.0197277	http://dx.doi.org/10.1371/journal.pone.0197277			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF7AA	29763431	Green Published, gold, Green Submitted			2023-01-03	WOS:000432118800034
J	Straus, SE; Dolovich, L				Straus, Sharon E.; Dolovich, Lisa			In hospitalized adults with polypharmacy, a multifaceted pharmacist intervention reduced readmissions at 180 days	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Question In patients with an acute hospital admission and polypharmacy, does an in-hospital, multifaceted pharmacist intervention reduce readmissions compared with usual care? Methods Design: Randomized controlled trial (Odense Pharmacist Trial Investigating Medication Interventions at Sector Transfer [OPTIMIST]). ClinicalTrials.gov NCT03079375. Allocation: Concealed.* Blinding: Blinded* (patients and pharmacists for medication review). Follow-up period: 6 months. Setting: 4 hospitals in Denmark. Patients: 1499 patients >= 18 years of age (median age 72 y, 54% women) who had a new acute hospital admission and polypharmacy (>= 5 prescription drugs used daily). Exclusion criteria included aphasia, severe dementia, terminal illness, suicidality, need for isolation precautions, or incarceration. Intervention: Extended pharmacist intervention (EPI) including a structured, patient-centered medication review; medical reconciliation on discharge; motivational patient interviews (1 in hospital and 2 by telephone after discharge); and follow-up with primary care physicians, pharmacists, and nursing homes if relevant (n = 497); basic pharmacist intervention (BPI) including a single medication review (n = 498); or usual care (n = 503). All interventions were done by trained clinical pharmacists. Outcomes: Primary outcomes were readmission at 30 and 180 days, and a composite of readmission or emergency department visit at 180 days. Secondary outcomes included all-cause mortality. Patient follow-up: 98% included in intention-to-treat analysis. Main results The main results are in the Table. Conclusion In hospitalized adults with polypharmacy, a multifaceted pharmacist intervention reduced readmissions at 30 and 180 days compared with usual care.	[Straus, Sharon E.; Dolovich, Lisa] Univ Toronto, Toronto, ON, Canada	University of Toronto	Straus, SE (corresponding author), Univ Toronto, Toronto, ON, Canada.				Hospitals Pharmacies' and Amgros' Research Development Foundation; Actavis Foundation; public regional research foundation for Southern Denmark; public regional research foundation for Zealand	Hospitals Pharmacies' and Amgros' Research Development Foundation; Actavis Foundation; public regional research foundation for Southern Denmark; public regional research foundation for Zealand	Hospitals Pharmacies' and Amgros' Research Development Foundation; Actavis Foundation; public regional research foundations for Southern Denmark and Zealand.	Christensen M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008986.pub3; McNab D, 2018, BMJ QUAL SAF, V27, P308, DOI 10.1136/bmjqs-2017-007087; Patterson SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008165.pub3, 10.1002/14651858.CD008165.pub4]	3	0	0	4	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2018	168	10					JC59	JC59		10.7326/ACPJC-2018-168-10-059	http://dx.doi.org/10.7326/ACPJC-2018-168-10-059			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI3DE	29800435				2023-01-03	WOS:000434250700011
J	Gomez, BI; McIntyre, MK; Gurney, JM; Chung, KK; Cancio, LC; Dubick, MA; Burmeister, DM				Gomez, Belinda, I; McIntyre, Matthew K.; Gurney, Jennifer M.; Chung, Kevin K.; Cancio, Leopoldo C.; Dubick, Michael A.; Burmeister, David M.			Enteral resuscitation with oral rehydration solution to reduce acute kidney injury in burn victims: Evidence from a porcine model	PLOS ONE			English	Article							ABDOMINAL COMPARTMENT SYNDROME; SEVERE TRAUMA; FLUID RESUSCITATION; RENAL DYSFUNCTION; RANDOMIZED-TRIAL; END-POINTS; BLOOD; SHOCK; MORTALITY; THERAPY	Intravenous (IV) resuscitation of burn patients has greatly improved outcomes and become a cornerstone of modern burn care. However, the heavy fluids and vascular access required may not be feasible in austere environments, mass casualty, or delayed transport scenarios. Enteral resuscitation has been proposed for these situations; we sought to examine the effectiveness of this strategy on improving burn-induced kidney injury. Anesthetized Yorkshire swine sustaining 40% TBSA full-thickness contact burns were randomized to three groups (n = 6/group): fluid deprivation, ad libitum water access, or 70 mL/kg/d Oral Rehydration Salt solution (ORS). Urine and blood were collected at baseline (BL), 6, 12, 24, 32, and 48h post-burn, at which point tissue was harvested and CT angiography performed. Although fluid consumption by ad libitum and ORS groups were matched (132 +/- 54mL/kg versus 120 +/- 24mL/kg, respectively), ORS intake increased urine output compared with water and no water (47.3 +/- 9.0 mL/kg versus 16.1 +/- 2.5 mL/kg, and 24.5 +/- 1.7 mL/kg respectively). Plasma creatinine peaked 6h following burn (1.67 +/- 0.07mg/dL) in all animals, but at 48h was comparable to BL in animals receiving water (1.23 +/- 0.06mg/dL) and ORS (1.30 +/- 0.09mg/dL), but not fluid deprived animals (1.56 +/- 0.05mg/dL) (P<0.05). Circulating levels of blood urea nitrogen steadily increased, but also decreased by 48h in animals receiving enteral fluids (P<0.05). Water deprivation reduced renal artery diameter (-1.4 +/- 0.17mm), whereas resuscitation with water (-0.44 +/- 0.14 mm) or ORS maintained it (-0.63 +/- 0.20 mm; P<0.02). Circulating cytokines IL-1 beta, IL-6, IFN gamma, and GM-CSF were moderately elevated in the fluid-deprived group. Taken together, the data suggest that enteral resuscitation with ORS rescues kidney function following burn injury. Incorporating enteral fluids may improve outcomes in resource-poor environments and possibly reduce IV fluid requirements to prevent co-morbidities associated with over-resuscitation. Studies into different volumes/types of enteral fluids are warranted. While ORS has saved many lives in cholera-associated dehydration, it should be investigated further for use in burn patients.	[Gomez, Belinda, I; McIntyre, Matthew K.; Gurney, Jennifer M.; Cancio, Leopoldo C.; Dubick, Michael A.; Burmeister, David M.] US Army Inst Surg Res, Ft Sam Houston, TX 78234 USA; [Gurney, Jennifer M.; Chung, Kevin K.; Cancio, Leopoldo C.] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; [Chung, Kevin K.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; San Antonio Military Medical Center; United States Department of Defense; United States Army; Uniformed Services University of the Health Sciences - USA	Burmeister, DM (corresponding author), US Army Inst Surg Res, Ft Sam Houston, TX 78234 USA.	David.m.burmeister3.civ@mail.mil		Burmeister, David/0000-0002-1256-0158	CDMRP [W81XWH-16-2-0041]	CDMRP(United States Department of Defense)	CDMRP (http://cdmrp.army.mil/) award #W81XWH-16-2-0041 provided funding for this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balogh Z, 2003, ARCH SURG-CHICAGO, V138, P637, DOI 10.1001/archsurg.138.6.637; Balogh Z, 2003, ARCH SURG-CHICAGO, V138, P42, DOI DOI 10.1001/ARCHSURG.138.6.637; Binder Henry J, 2014, Curr Gastroenterol Rep, V16, P376, DOI 10.1007/s11894-014-0376-2; BISHOP MH, 1995, J TRAUMA, V38, P780, DOI 10.1097/00005373-199505000-00018; Brakenridge SC, 2011, J TRAUMA, V71, P299, DOI 10.1097/TA.0b013e318224d328; Burmeister DM, 2017, BBA-MOL BASIS DIS, V1863, P2661, DOI 10.1016/j.bbadis.2017.04.011; Burmeister DM, 2017, BURNS, V43, P1295, DOI 10.1016/j.burns.2017.03.010; Burmeister DM, 2016, SHOCK, V46, P137, DOI 10.1097/SHK.0000000000000662; Burmeister DM, 2015, BURNS, V41, P1242, DOI 10.1016/j.burns.2015.03.001; Cancio LC, 2006, J BURN CARE RES, V27, P561, DOI 10.1097/01.BCR.0000235449.05828.B8; Cartotto R, 2017, J BURN CARE RES, V38, pE596, DOI 10.1097/BCR.0000000000000541; Cartotto R, 2016, CRIT CARE CLIN, V32, P507, DOI 10.1016/j.ccc.2016.06.002; Chrysopoulo MT, 1999, J TRAUMA, V46, P141, DOI 10.1097/00005373-199901000-00024; Coca SG, 2007, AM J KIDNEY DIS, V49, P517, DOI 10.1053/j.ajkd.2006.12.018; Earley ZM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129996; El-Sonbaty M., 1991, ANN MBC, V4, P29; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; Fleming A, 1992, ARCH SURG CHICAGO IL, V127, P9; Fox CL, 1944, J AMER MED ASSOC, V124, P207, DOI 10.1001/jama.1944.02850040007002; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Hu S, 2014, BURNS, V40, P693, DOI 10.1016/j.burns.2013.09.030; Ivy ME, 2000, J TRAUMA, V49, P387, DOI 10.1097/00005373-200009000-00001; Ivy ME, 1999, J BURN CARE REHABIL, V20, P351, DOI 10.1097/00004630-199909000-00003; KELLEY KW, 1973, J ANIM SCI, V36, P927; Kramer GC, 2010, EPLASTY, V10; Liu LM, 2003, J TRAUMA, V54, pS159, DOI 10.1097/01.TA.0000054649.46525.A5; MARKLEY K, 1956, JAMA-J AM MED ASSOC, V161, P1465, DOI 10.1001/jama.1956.02970150033008; Michell MW, 2006, J BURN CARE RES, V27, P819, DOI 10.1097/01.BCR.0000245422.33787.18; Milner SM, 2011, J HEALTH POPUL NUTR, V29, P648; Moghazy A M, 2016, Ann Burns Fire Disasters, V29, P43; Mosier MJ, 2010, J BURN CARE RES, V31, P83, DOI 10.1097/BCR.0b013e3181cb8c87; Moyer CA, 1944, ANN SURG, V120, P367, DOI 10.1097/00000658-194409000-00008; Palmieri T, 2010, BURNS, V36, P205, DOI 10.1016/j.burns.2009.08.012; Peck MD, 2011, BURNS, V37, P1087, DOI 10.1016/j.burns.2011.06.005; Popkin BM, 2010, NUTR REV, V68, P439, DOI 10.1111/j.1753-4887.2010.00304.x; Rex S, 2012, CURR OPIN CRIT CARE, V18, P671, DOI 10.1097/MCC.0b013e328359fd6e; RUXIN JN, 1994, MED HIST, V38, P363, DOI 10.1017/S0025727300036905; Shah SK, 2010, J TRAUMA, V68, P682, DOI 10.1097/TA.0b013e3181c453cb; Sondeen JL, 2011, TRANSFUSION, V51, P779, DOI 10.1111/j.1537-2995.2010.02928.x; SORENSEN B, 1968, ANN NY ACAD SCI, V150, P865, DOI 10.1111/j.1749-6632.1968.tb14737.x; Steinvall I, 2008, CRIT CARE, V12, DOI 10.1186/cc7032; Velmahos GC, 2000, ANN SURG, V232, P409, DOI 10.1097/00000658-200009000-00013; WILSON BJ, 1960, JAMA-J AM MED ASSOC, V173, P509, DOI 10.1001/jama.1960.73020230008008; World Health Organization G, 2016, GLOB HLTH EST 2015 D; Wright EM, 2011, PHYSIOL REV, V91, P733, DOI 10.1152/physrev.00055.2009; Yin LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep37220; Yin LJ, 2014, HEALTH PHYS, V106, P734, DOI 10.1097/HP.0000000000000117	48	24	24	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2018	13	5							e0195615	10.1371/journal.pone.0195615	http://dx.doi.org/10.1371/journal.pone.0195615			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE5SH	29718928	Green Submitted, Green Published, gold			2023-01-03	WOS:000431281900024
J	Gent, TC; Detotto, C; Vyssotski, AL; Bettschart-Wolfensberger, R				Gent, Thomas C.; Detotto, Carlotta; Vyssotski, Alexei L.; Bettschart-Wolfensberger, Regula			Epileptiform activity during inert gas euthanasia of mice	PLOS ONE			English	Article							CARBON-DIOXIDE; RATS; XENON; ANESTHESIA; HELIUM; NITROGEN; SLEEP; ARGON; PAIN	Carbon dioxide (CO2) is one of the most commonly used euthanasia agents for mice, yet it is highly aversive and nociceptive. Inert gases are a possible alternative, however there are qualitative reports of seizures resulting from exposure. Here we evaluate epileptiform activity caused by inert gases (N-2, He, Ar and Xe) and CO2 in mice chronically instrumented for EEG/EMG undergoing single-gas euthanasia. We found that N-2, He and Ar caused epileptiform activity in all animals, CO2 in half of animals and no epileptiform activity produced by Xe. Atmospheric O-2 concentrations at epileptiform activity onset were significantly higher for CO2 than for all other gases and occurred soon after loss of motion, whereas N-2 and Ar epileptiform activity occurred at cessation of neocortical activity. Helium caused the longest epileptiform activity and these commenced significantly before isoelectric EEG. We did not detect any epileptiform activity during active behaviour. Taken together, these results demonstrate that whilst epileptiform activity from inert gases and particularly Ar and N-2 are more prevalent than for CO2, their occurrence at the onset of an isoelectric EEG is unlikely to impact on the welfare of the animal. Epileptiform activity from these gases should not preclude them from further investigation as euthanasia agents. The genesis of epileptiform activity from CO2 is unlikely to result from hypoxia as with the inert gases. Helium caused epileptiform activity before cessation of neocortical activity and for a longer duration and is therefore less suitable as an alternative to CO2.	[Gent, Thomas C.; Detotto, Carlotta; Bettschart-Wolfensberger, Regula] Univ Zurich, Vetsuisse Fac, Anaesthesiol Sect, Zurich, Switzerland; [Vyssotski, Alexei L.] ETH, Inst Neuroinformat, Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Gent, TC (corresponding author), Univ Zurich, Vetsuisse Fac, Anaesthesiol Sect, Zurich, Switzerland.	tgent@vetclinics.uzh.ch		Gent, Thomas/0000-0002-0478-5461	Swiss Federal Veterinary Office (Bundesamt fur Lebensmittelwirtschaft and Veterinarwiesen) [2.16.01]	Swiss Federal Veterinary Office (Bundesamt fur Lebensmittelwirtschaft and Veterinarwiesen)	Funding from this work was provided by a grant from the Swiss Federal Veterinary Office (Bundesamt fur Lebensmittelwirtschaft and Veterinarwiesen). Grant number: 2.16.01 "Tierschurtgerechte Euthanasie von Nagern mittels inerten Gasen" to Thomas C. Gent. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azzopardi D, 2013, ARCH DIS CHILD-FETAL, V98, pF437, DOI 10.1136/archdischild-2013-303786; Burkholder TH, 2010, J AM ASSOC LAB ANIM, V49, P448; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Conlee KM, 2005, LAB ANIM-UK, V39, P137, DOI 10.1258/0023677053739747; Danneman PJ, 1997, LAB ANIM SCI, V47, P376; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Fries M, 2012, CRIT CARE MED, V40, P1297, DOI 10.1097/CCM.0b013e31823c8ce7; Gent T, 2017, CLIN TRANSL IN PRESS, V1; Gent TC, 2016, ASS VET ANAESTHETIST; Hawkins P, 2016, ANIMALS, V6, DOI 10.3390/ani6090050; Hobbs C, 2008, STROKE, V39, P1307, DOI 10.1161/STROKEAHA.107.499822; Hwang E, 2010, J NEUROSCI METH, V188, P14, DOI 10.1016/j.jneumeth.2010.01.028; Koblin DD, 1998, ANESTH ANALG, V87, P419, DOI 10.1097/00000539-199808000-00035; Kroeger D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075257; Leary S., 2013, AVMA GUIDELINES EUTH; Misonou H, 2005, J NEUROSCI, V25, P11184, DOI 10.1523/JNEUROSCI.3370-05.2005; Pang DSJ, 2009, P NATL ACAD SCI USA, V106, P17546, DOI 10.1073/pnas.0907228106; Schob OM, 1996, AM J SURG, V172, P248, DOI 10.1016/S0002-9610(96)00101-8; Sekar K, 2013, P NATL ACAD SCI USA, V110, P5642, DOI 10.1073/pnas.1302229110; Sharp J, 2006, J AM ASSOC LAB ANIM, V45, P21; Thomas AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032290; Valentine H, 2012, J AM ASSOC LAB ANIM, V51, P50; Vyssotski AL, 2009, CURR BIOL, V19, P1159, DOI 10.1016/j.cub.2009.05.070	23	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2018	13	4							e0195872	10.1371/journal.pone.0195872	http://dx.doi.org/10.1371/journal.pone.0195872			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD4BF	29672545	gold, Green Accepted, Green Published			2023-01-03	WOS:000430446800053
J	Yeung, S; Downing, NL; Li, FF; Milstein, A				Yeung, Serena; Downing, N. Lance; Li Fei-Fei; Milstein, Arnold			Bedside Computer Vision - Moving Artificial Intelligence from Driver Assistance to Patient Safety	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Yeung, Serena; Li Fei-Fei] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Downing, N. Lance] Stanford Univ, Ctr Biomed Informat Res, Stanford, CA 94305 USA; [Milstein, Arnold] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Yeung, Serena; Downing, N. Lance; Li Fei-Fei; Milstein, Arnold] Stanford Univ, Clin Excellence Res Ctr, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Yeung, S (corresponding author), Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.; Yeung, S (corresponding author), Stanford Univ, Clin Excellence Res Ctr, Stanford, CA 94305 USA.		Downing, N Lance/W-2812-2019	Downing, N Lance/0000-0002-2133-9244				Chen JH, 2017, NEW ENGL J MED, V376, P2507, DOI 10.1056/NEJMp1702071; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Haque A, 2017, MACH LEARN HEALTHC C, P75; He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123; Kahneman D., 2011, THINKING FAST SLOW	5	52	53	0	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 5	2018	378	14					1271	1273		10.1056/NEJMp1716891	http://dx.doi.org/10.1056/NEJMp1716891			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB5LN	29617592				2023-01-03	WOS:000429105700002
J	Hamaidi, M; Coquard, C; Danilin, S; Dormoy, V; Beraud, C; Rothhut, S; Barthelmebs, M; Benkirane-Jessel, N; Lindner, V; Lang, H; Massfelder, T				Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Beraud, Claire; Rothhut, Sylvie; Barthelmebs, Mariette; Benkirane-Jessel, Nadia; Lindner, Veronique; Lang, Herve; Massfelder, Thierry			The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma	ONCOGENE			English	Article							MOUSE; LHX1; PATHWAY; DIFFERENTIATION; REQUIREMENT; EXPRESSION; GROWTH; LDB1	Metastatic clear cell renal cell carcinoma (CCC) remains incurable despite advances in the development of anti-angiogenic targeted therapies and the emergence of immune checkpoint inhibitors. We have previously shown that the sonic hedgehog-Gli signaling pathway is oncogenic in CCC allowing us to identify the developmental Lim1 transcription factor as a Gli target and as a new oncogene in CCC regulating cell proliferation and apoptosis, and promoting tumor growth. In this previous study, preliminary in vitro results also suggested that Lim1 may be implicated in metastatic spread. Here we investigated the potential pro-metastatic role of Lim1 in advanced CCC (1) in vitro using a panel of CCC cell lines expressing or not the von Hippel-Lindau (VHL) tumor suppressor gene either naturally or by gene transfer and (2) ex vivo in 30 CCC metastatic tissues, including lymph nodes, lung, skin, bone, and adrenal metastases, and (3) in vivo, using a metastatic model by intravenous injection of siRNA-transfected cells into Balb/c nude. Our in vitro results reveal that Lim1 knockdown time-dependently decreased CCC cell motility, migration, invasion, and clonogenicity by up to 50% regardless of their VHL status. Investigating the molecular machinery involved in these processes, we identified a large panel of Lim1 targets known to be involved in cell adhesion (paxillin and fibronectin), epithelial-mesenchymal transition (Twist1/2 and snail), invasion (MMP1/2/3/8/9), and metastatic progression (CXCR4, SDF-1, and ANG-1). Importantly, Lim1 was found constitutively expressed in all metastatic tissues. The H-score in metastatic tissues being significantly superior to the score in the corresponding primary tumor tissues (P value = 0.009). Furthermore, we showed that Lim1 silencing decreases pulmonary metastasis development in terms of number and size in the in vivo metastatic model of human CCC. Taken together, these experiments strengthen the potential therapeutic value of Lim1 targeting as a promising novel approach for treating metastatic human CCC.	[Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Rothhut, Sylvie; Barthelmebs, Mariette; Massfelder, Thierry] INSERM, INSERM UMR S1113, Sect Cell Signalisat & Commun Kidney & Prostate C, F-67085 Strasbourg, France; [Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Rothhut, Sylvie; Barthelmebs, Mariette; Benkirane-Jessel, Nadia; Massfelder, Thierry] Univ Strasbourg, Sch Med, FMTS, F-67085 Strasbourg, France; [Beraud, Claire] UROLEAD SAS, Sch Med, F-67085 Strasbourg, France; [Benkirane-Jessel, Nadia] INSERM, UMR S1260, Regenerat Nanomed Lab, F-67085 Strasbourg, France; [Lindner, Veronique] Hop Univ Strasbourg, Dept Pathol, Hop Strasbourg Hautepierre, F-67200 Strasbourg, France; [Lang, Herve] Hop Univ Strasbourg, Dept Urol, Nouvel Hop Civil, F-67200 Strasbourg, France; [Danilin, Sabrina] Firalis, F-68330 Huningue, France; [Dormoy, Valerian] URCA, INSERM UMR S1250, CHU Maison Blanche, 45 Rue Cognacq Jay, F-51092 Reims, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte; CHU Strasbourg; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Reims; Universite de Reims Champagne-Ardenne	Massfelder, T (corresponding author), INSERM, INSERM UMR S1113, Sect Cell Signalisat & Commun Kidney & Prostate C, F-67085 Strasbourg, France.; Massfelder, T (corresponding author), Univ Strasbourg, Sch Med, FMTS, F-67085 Strasbourg, France.	massfeld@unistra.fr	Massfelder, Thierry/I-1260-2016; Benkirane-Jessel, Nadia/H-6438-2016; Dormoy, Valerian/P-5109-2016	Dormoy, Valerian/0000-0003-1725-371X	INSERM; University of Strasbourg; Ligue Contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Strasbourg; Ligue Contre le Cancer(Ligue nationale contre le cancer)	This study was sponsored by INSERM (recipient TM), the University of Strasbourg (recipient TM), and the Ligue Contre le Cancer (recipient TM). The authors thank Martine MUCKENSTURM, Fabienne REYMANN, and Angelique WERCK, from the Department of Pathology, University Hospital, Strasbourg, for their technical assistance in immunohistochemistry.	BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Beksac AT, 2017, UROL ONCOL, pS1078; Beraud C, 2015, INT J CANCER, V137, P1549, DOI 10.1002/ijc.29522; Cheah SS, 2000, GENESIS, V27, P12, DOI 10.1002/1526-968X(200005)27:1<12::AID-GENE30>3.0.CO;2-X; Cirio MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018858; Costello I, 2015, GENE DEV, V29, P2108, DOI 10.1101/gad.268979.115; Delahunt B, 2017, HISTOPATHOLOGY, V71, P5, DOI 10.1111/his.13200; Dormoy V, 2011, ONCOGENE, V30, P1753, DOI 10.1038/onc.2010.557; Dormoy V, 2012, ANTICANCER RES, V32, P3609; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Escudier B, 2014, J CLIN ONCOL, V32, P1412, DOI 10.1200/JCO.2013.50.8267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao Y, 2017, CANCER RES, V77, P330, DOI 10.1158/0008-5472.CAN-16-0348; Guertl B, 2011, PATHOBIOLOGY, V78, P210, DOI 10.1159/000326769; Huang CC, 2014, DEV BIOL, V389, P124, DOI 10.1016/j.ydbio.2014.01.025; Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2; Jeong DE, 2015, ONCOTARGET, V6, P33046, DOI 10.18632/oncotarget.5422; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Ledig S, 2012, HUM REPROD, V27, P2872, DOI 10.1093/humrep/des206; Li H, 2016, ONCOTARGET, V7, P80415, DOI 10.18632/oncotarget.11246; Li JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0681-0; Lin TC, 2015, J PATHOL, V237, P50, DOI 10.1002/path.4552; Lin YW, 2016, J PINEAL RES, V60, P277, DOI 10.1111/jpi.12308; Liu LQ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711951; Mehta K, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0457-4; Mikami S, 2016, PATHOL INT, V66, P481, DOI 10.1111/pin.12433; Mumert M, 2012, CANCER RES, V72, P4944, DOI 10.1158/0008-5472.CAN-12-1629; Neuberg P, 2018, NANOSCALE, V10, P1587, DOI 10.1039/c7nr09202d; Posadas EM, 2017, NAT REV NEPHROL, V13, P496, DOI 10.1038/nrneph.2017.82; Qu LS, 2016, ONCOL LETT, V11, P624, DOI 10.3892/ol.2015.3958; Ruan HL, 2017, INT J ONCOL, V51, P336, DOI 10.3892/ijo.2017.4010; Sato N, 2003, CANCER RES, V63, P3735; Scelo G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15724; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a; Tong Wei-Gang, 2010, Epigenetics, V5, P499; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varis A, 2002, CANCER RES, V62, P2625; Wang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01084-w; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Yang HL, 2017, ONCOL LETT, V13, P4755, DOI 10.3892/ol.2017.6084; Ye L, 2012, HISTOCHEM CELL BIOL, V137, P527, DOI 10.1007/s00418-011-0909-9; Yerokhin VA, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.233002; Zhao Y, 2007, P NATL ACAD SCI USA, V104, P13182, DOI 10.1073/pnas.0705464104; Zhao ZH, 2017, ONCOL RES, V25, P773, DOI 10.3727/096504016X14774889687280; Zhu JD, 2017, ONCOTARGET, V8, P51559, DOI 10.18632/oncotarget.18086	48	7	7	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					60	72		10.1038/s41388-018-0413-y	http://dx.doi.org/10.1038/s41388-018-0413-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076415	Green Submitted			2023-01-03	WOS:000454775900005
J	Lowenstein, M; Grande, D; Delgado, MK				Lowenstein, Margaret; Grande, David; Delgado, M. Kit			Opioid Prescribing Limits for Acute Pain - Striking the Right Balance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lowenstein, Margaret; Grande, David] Univ Penn, Perelman Sch Med, Natl Clinician Scholars Program, Philadelphia, PA 19104 USA; [Lowenstein, Margaret; Grande, David; Delgado, M. Kit] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA; [Grande, David] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Delgado, M. Kit] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Delgado, M. Kit] Univ Penn, Dept Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Delgado, M. Kit] Univ Penn, Dept Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Delgado, M. Kit] Univ Penn, Dept Informat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lowenstein, Margaret] Corporal Michael J Crescenz Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Lowenstein, M (corresponding author), Univ Penn, Perelman Sch Med, Natl Clinician Scholars Program, Philadelphia, PA 19104 USA.; Lowenstein, M (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA.; Lowenstein, M (corresponding author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA.		Grande, David/AAJ-8191-2021	Grande, David/0000-0002-6717-6735				Chiu AS, 2018, JAMA SURG; Delgado MK, 2018, J GEN INTERN MED, V33, P409, DOI 10.1007/s11606-017-4286-5; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Scully RE, 2018, JAMA SURG, V153, P37, DOI 10.1001/jamasurg.2017.3132; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1	5	34	34	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 9	2018	379	6					504	506		10.1056/NEJMp1803661	http://dx.doi.org/10.1056/NEJMp1803661			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP7TB	30089064				2023-01-03	WOS:000441110600002
J	Armoiry, X; Tsertsvadze, A; Connock, M; Royle, P; Melendez-Torres, GJ; Souquet, PJ; Clarke, A				Armoiry, Xavier; Tsertsvadze, Alexander; Connock, Martin; Royle, Pamela; Melendez-Torres, G. J.; Souquet, Pierre-Jean; Clarke, Aileen			Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis	PLOS ONE			English	Review							RANDOMIZED PHASE-III; EGFR MOLECULAR ABERRATIONS; TRIAL CHECKMATE 057; PLUS DOCETAXEL DOC; 2ND-LINE TREATMENT; NIVOLUMAB NIVO; EXPLORATORY ANALYSIS; FRONTLINE THERAPIES; SUBGROUP ANALYSES; NSCLC HISTOLOGY	Purpose This systematic review with network meta-analysis compared the efficacy and safety of currently licensed second-line treatments in patients with late stage non-small cell lung cancer (NSCLC). Methods Randomised controlled trials (RCTs) of participants with advanced/metastatic NSCLC receiving second/third line treatments were screened. We searched electronic databases (MEDLINE; EMBASE; Web of Science) from January, 2000 to July, 2017. Two reviewers screened bibliographic records, extracted data, and assessed risk of bias of included studies. The outcomes were overall survival (OS), progression-free survival (PFS), and drug-related grade 3 +/- 5 adverse-events (AEs). We pooled study-specific hazard ratios (HR; for OS and PFS) and risk ratios (RR; for AEs) using conventional and network-meta-analyses, and ranked interventions by the surface under the cumulative ranking curve. Findings We included 11 RCTs (7,581 participants) comparing nine drugs. All drugs except for erlotinib significantly improved OS compared to docetaxel. Nivolumab was the highest ranking drug followed by atezolizumab and pembrolizumab. There was no significant difference in OS across these three drugs (HR = 0.98, 95% CI 0.79, 1.21 for nivolumab vs atezolizumab; HR = 0.98, 95% CI 0.77, 1.25 for nivolumab vs pembrolizumab). For PFS, ramucirumab + docetaxel and nivolumab were the drugs with the highest ranking. All interventions except ramucirumab + docetaxel had a reduced risk for severe drug-related AEs vs. docetaxel. Of the drugs with the highest ranking on AEs, nivolumab was significantly safer compared to atezolizumab (RR = 0.55, 95% CI 0.38, 0.79) or pembrolizumab (RR = 0.52, 95% CI 0.34, 0.81).	[Armoiry, Xavier; Tsertsvadze, Alexander; Connock, Martin; Royle, Pamela; Melendez-Torres, G. J.; Clarke, Aileen] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry, W Midlands, England; [Tsertsvadze, Alexander] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Souquet, Pierre-Jean] Hosp Civils Lyon, Grp Hosp Sud, Serv Pneumol Oncol, Pierre Benite, France	University of Warwick; University of Ottawa; CHU Lyon	Armoiry, X (corresponding author), Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry, W Midlands, England.	armoiryxa@gmail.com	Clarke, Aileen/I-5679-2012	Clarke, Aileen/0000-0001-8299-3146; Melendez-Torres, G.J./0000-0002-9823-4790	NIHR CLAHRC West Midlands+ initiative	NIHR CLAHRC West Midlands+ initiative	A.C. is funded by the NIHR CLAHRC West Midlands+ initiative. This paper presents independent research and the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. X.A., A.C., M.C. and P.R. are commissioned by the NIHR HTA Programme to undertake reviews and evidence synthesis on the clinical and cost-effectiveness of health care interventions for a range of research funders and policy makers, including the National Institute for Health and Care Excellence (NICE). The views expressed in this report are those of the authors and not necessarily those of the NIHR HTA Programme. Any errors are the responsibility of the authors.	Barlesi F, 2016, ANN ONC C 41 EUR SOC, V27; Barlesi F, 2016, ASIA-PAC J CLIN ONCO, V12, P115; Bidoli P, 2015, ANN ONC C 17 NAT C M, V26; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Clegg A, 2001, Health Technol Assess, V5, P1; Crequit P, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0954-x; Demarinis F, 2006, J CLIN ONCOLOGY, V24; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Garon EB, 2016, J CLIN ONCOLOGY C, V34; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Goss GD, 2015, EUR J CANCER, V51, pS626, DOI 10.1016/S0959-8049(16)31725-7; Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Heigener D, 2016, ANN ONC C 41 EUR SOC, V27; Herbst RS, 2015, ANN ONCOL, V26, P162; Herbst RS, 2016, ANN ONC C 41 EUR SOC, V27; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Horn L, 2016, ONCOL RES TREAT, V39, P27; Horn L, 2015, ANN ONCOL, V26, P125; Horn L, 2015, EUR J CANCER, V51, pS599, DOI 10.1016/S0959-8049(16)31655-0; Jansen JP, 2011, VALUE HEALTH, V14, P417, DOI 10.1016/j.jval.2011.04.002; Karampeazis A, 2013, CANCER-AM CANCER SOC, V119, P2754, DOI 10.1002/cncr.28132; Loveman E, 2016, WARWICK EVIDENCE; Mellemgaard A, 2015, SUPPORT CARE CANCER, pS349; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Park K, 2015, ANN ONCOL, V26, P135; Park K, 2016, CANCER RES TREAT, V48, P1177, DOI 10.4143/crt.2015.401; Paz-Ares L, 2015, J CLIN ONCOLOGY, V33; Paz-Ares L, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.18_suppl.lba109; Peng TR, 2017, INT IMMUNOPHARMACOL, V49, P85, DOI 10.1016/j.intimp.2017.05.019; Perol M, 2014, J CLIN ONCOLOGY, V32; Pujol JL, 2007, J THORAC ONCOL, V2, P397, DOI 10.1097/01.JTO.0000268672.57002.69; Rechamp K, 2015, ASIA-PAC J CLIN ONCO, V11, P130; Reck M, 2016, ONCOL RES TREAT, V39, P166; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reck M, 2015, J THORAC ONCOL, V10, pS324; Reck M, 2015, LUNG CANCER, V90, P267, DOI 10.1016/j.lungcan.2015.08.003; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Royal College of Physicians, 2015, NAT LUNG CANC AUD; Salanti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099682; Scagliotti G, 2009, J THORAC ONCOL, V4, pS325; Scagliotti G, 2009, ONCOLOGIST, V14, P253, DOI 10.1634/theoncologist.2008-0232; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Schuette W, 2016, ONCOL RES TREAT, V39, P90; Schulz C, 2016, ONCOL RES TREAT, V39, P104; Smith DA, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9028; Soria JC, 2015, J CLIN ONCOLOGY, V33; Soria JC, 2015, LANCET ONCOL, V16, P897, DOI 10.1016/S1470-2045(15)00006-6; Spigel DR, 2015, J CLIN ONCOLOGY, V33; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Vamvakas L, 2010, J CLIN ONCOLOGY, V28; Vansteenkiste J, 2015, EUR J CANCER, V51, pS716, DOI 10.1016/S0959-8049(15)30072-1; Weiss, 2006, J CLIN ONCOL, V24, P5477, DOI 10.1200/JCO.2006.10.001	59	8	8	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2018	13	7							e0199575	10.1371/journal.pone.0199575	http://dx.doi.org/10.1371/journal.pone.0199575			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4AN	30044785	Green Published, Green Submitted, gold			2023-01-03	WOS:000439942500013
J	Liu, WS; Lai, YT; Chan, HL; Li, SY; Lin, CC; Liu, CK; Tsou, HH; Liu, TY				Liu, Wen-Sheng; Lai, Yen-Ting; Chan, Hsiang-Lin; Li, Szu-Yuan; Lin, Chih-Ching; Liu, Chih-Kuang; Tsou, Han-Hsing; Liu, Tsung-Yun			Associations between perfluorinated chemicals and serum biochemical markers and performance status in uremic patients under hemodialysis	PLOS ONE			English	Article							PERFLUOROOCTANE SULFONATE PFOS; PERSISTENT ORGANIC POLLUTANTS; CHRONIC KIDNEY-DISEASE; PERFLUOROALKYL CHEMICALS; GLUCOSE-HOMEOSTASIS; US ADULTS; ACID; EXPOSURE; ADOLESCENTS; CHILDREN	Perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA) are commonly used perfluorinated chemicals (PFCs). PFCs are mainly excreted by urine. Uremic patients tend to accumulate toxins in their body and have poor functional status. We investigated the associations between PFCs and the clinical profile of uremic patients under hemodialysis (HD). Liquid chromatography tandem mass spectrometry coupled with isotope dilution was used to quantify PFOA and PFOS. We enrolled 126 patients under regular HD. Compared with previous research, the concentration of PFOA was lower, but that of PFOS was higher in uremic patients than in the general population. The levels of PFOA and PFOS in uremic patients before dialysis were 0.52 (ng/ml) and 21.84 (ng/ml) respectively. The PFOA level remained unchanged but that of PFOS decreased to 1.85 ng/mL after dialysis. PFOS can be removed by HD. Patients using hypertensive medication had a lower PFOS then those who did not. The PFOS level was negatively correlated with the duration of the HD session and patient performance status, but positively correlated with levels of cholesterol, chloride (an indicator of acidemia), ferritin, and total protein. (p < 0.05). The association with serum protein may explain the long half-life of PFCs in humans. This is the first study which investigated PFCs in uremic patients and showed PFCs are associated with adverse effects in this population.	[Liu, Wen-Sheng] Taipei City Hosp, Dept Med, Div Nephrol, Zhongxing Branch, Taipei, Taiwan; [Liu, Wen-Sheng; Li, Szu-Yuan; Lin, Chih-Ching] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Liu, Wen-Sheng] Fu Jen Catholic Univ, Coll Sci & Engn, New Taipei, Taiwan; [Liu, Wen-Sheng; Tsou, Han-Hsing; Liu, Tsung-Yun] Natl Yang Ming Univ, Sch Med, Inst Environm & Occupat Hlth Sci, Taipei, Taiwan; [Lai, Yen-Ting] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Hsin Chu Branch, Hsinchu, Taiwan; [Lai, Yen-Ting] Yuanpei Univ, Dept Nursing, Hsinchu, Taiwan; [Chan, Hsiang-Lin] Chang Gung Mem Hosp & Univ, Dept Child Psychiat, Taoyuan, Taiwan; [Li, Szu-Yuan; Lin, Chih-Ching] Taipei Vet Gen Hosp, Div Nephrol, Taipei, Taiwan; [Li, Szu-Yuan; Lin, Chih-Ching] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan; [Liu, Chih-Kuang] Fu Jen Catholic Univ, Coll Med, New Taipei, Taiwan; [Liu, Chih-Kuang] Fu Jen Catholic Univ, Grad Inst Business Adm, New Taipei, Taiwan; [Liu, Tsung-Yun] Natl Yang Ming Univ, Inst Food Safety & Hlth Risk Assessment, Taipei, Taiwan	Taipei City Hospital; National Yang Ming Chiao Tung University; Fu Jen Catholic University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital; Chang Gung Memorial Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Fu Jen Catholic University; Fu Jen Catholic University; National Yang Ming Chiao Tung University	Liu, TY (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Environm & Occupat Hlth Sci, Taipei, Taiwan.; Liu, TY (corresponding author), Natl Yang Ming Univ, Inst Food Safety & Hlth Risk Assessment, Taipei, Taiwan.	tyliu@ym.edu.tw	liu, wen/HGE-3071-2022	Tsou, HanHsing/0000-0002-8542-0201; Liu, Tsung-Yun/0000-0003-1641-7866; Lai, Yen-Ting/0000-0001-8043-5183	Taipei Veteran General Hospital [201010007IC]; Taipei City Hospital [TPCH-103-028, 10401-62-039]	Taipei Veteran General Hospital; Taipei City Hospital	This study was supported by Taipei Veteran General Hospital (Grant No 201010007IC) and Taipei City Hospital (Grant No TPCH-103-028 & 10401-62-039). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apelberg BJ, 2007, ENVIRON HEALTH PERSP, V115, P1670, DOI 10.1289/ehp.10334; Bao J, 2014, ENVIRON SCI POLLUT R, V21, P7650, DOI 10.1007/s11356-014-2594-4; Barton CA, 2006, J AIR WASTE MANAGE, V56, P48, DOI 10.1080/10473289.2006.10464429; Butenhoff JL, 2004, TOXICOL SCI, V82, P394, DOI 10.1093/toxsci/kfh302; Chen MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042474; Dallaire R, 2009, ENVIRON HEALTH PERSP, V117, P1380, DOI 10.1289/ehp.0900633; Ehresman DJ, 2007, ENVIRON RES, V103, P176, DOI 10.1016/j.envres.2006.06.008; Holzer J, 2008, ENVIRON HEALTH PERSP, V116, P651, DOI 10.1289/ehp.11064; Hsu JY, 2013, CHEMOSPHERE, V93, P532, DOI 10.1016/j.chemosphere.2013.06.047; Hsu TW, 2014, JAMA INTERN MED, V174, P347, DOI 10.1001/jamainternmed.2013.12700; Jensen AA, 2008, INT J ANDROL, V31, P161, DOI 10.1111/j.1365-2605.2008.00870.x; Joensen UN, 2009, ENVIRON HEALTH PERSP, V117, P923, DOI 10.1289/ehp.0800517; Johansson N, 2008, NEUROTOXICOLOGY, V29, P160, DOI 10.1016/j.neuro.2007.10.008; Kemper RA, 2005, DRUG CHEM TOXICOL, V28, P281, DOI 10.1081/DCT-200064468; Lee JH, 2017, INT J HYG ENVIR HEAL, V220, P1046, DOI 10.1016/j.ijheh.2017.06.005; Li SY, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-89; Lin AYC, 2009, ENVIRON POLLUT, V157, P1365, DOI 10.1016/j.envpol.2008.11.033; Lin CY, 2013, INT J CARDIOL, V168, P3309, DOI 10.1016/j.ijcard.2013.04.042; Lin CY, 2010, AM J GASTROENTEROL, V105, P1354, DOI 10.1038/ajg.2009.707; Lin CY, 2009, DIABETES CARE, V32, P702, DOI 10.2337/dc08-1816; Lin LY, 2014, J CLIN ENDOCR METAB, V99, P2173, DOI 10.1210/jc.2013-3409; Liu WS, 2016, CLIN EXP PHARMACOL P, V43, P875, DOI 10.1111/1440-1681.12618; Liu WS, 2016, ENVIRON TOXICOL PHAR, V45, P108, DOI 10.1016/j.etap.2016.05.021; Liu WS, 2012, SCI WORLD J, P1, DOI 10.1100/2012/157437; Lopez-Espinosa MJ, 2012, REPROD TOXICOL, V33, P552, DOI 10.1016/j.reprotox.2011.04.002; Magulova K, 2016, ENVIRON POLLUT, V217, P82, DOI 10.1016/j.envpol.2016.01.022; Meng D, 2017, J ENVIRON SCI HEAL B, V52, P690, DOI 10.1080/03601234.2017.1331672; Modesto AP, 2018, PERITON DIALYSIS INT, V38, P24, DOI 10.3747/pdi.2015.00241; Naruse S, 1984, Neurol Res, V6, P169; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; SCHNEEBERGER EE, 1988, BIOMATER ARTIF CELL, V16, P565, DOI 10.3109/10731198809132611; Shankar Anoop, 2011, Clin Epidemiol, V3, P251, DOI 10.2147/CLEP.S21677; Shankar A, 2011, AM J EPIDEMIOL, V174, P893, DOI 10.1093/aje/kwr171; Watkins DJ, 2014, ENVIRON INT, V63, P71, DOI 10.1016/j.envint.2013.10.018; Wu LL, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472-6807-9-31; Yan S, 2015, SCI REP-UK, V5, DOI [10.1038/srep15917, 10.1038/srep11029]; Yang YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137914; Zhang Y, 2013, NANOSCALE RES LETT, V8, DOI [10.1186/1556-276X-8-471, 10.1186/1556-276X-8-544]	38	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2018	13	7							e0200271	10.1371/journal.pone.0200271	http://dx.doi.org/10.1371/journal.pone.0200271			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2XR	30016344	gold, Green Published, Green Submitted			2023-01-03	WOS:000438866600019
J	Feghali, MN; Scifres, CM				Feghali, Maisa N.; Scifres, Christina M.			Novel therapies for diabetes mellitus in pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SUBCUTANEOUS INSULIN INFUSION; MULTIPLE DAILY INJECTIONS; GLUCOSE-SENSING TECHNOLOGY; TOFU BODY-COMPOSITION; GLYCEMIC CONTROL; DOUBLE-BLIND; FOLLOW-UP; CARBOHYDRATE-DIET; GUT MICROBIOME; WOMEN	Diabetes is a common complication of pregnancy, and the prevalence of all types of the disease is increasing worldwide. Diabetes in pregnancy is associated with short term and long term adverse effects for mother and child. The goal of treatment of diabetes in pregnancy is to minimize maternal and fetal adverse events related to hyperglycemia. Treatment options vary by type of diabetes, from a focus on lifestyle modifications in gestational diabetes to continuous glucose monitoring and insulin pumps in pregestational diabetes. Nevertheless, given the commonality of hyperglycemia, considerable overlap exists in the treatment of different types of diabetes in pregnancy. Also, despite ongoing research on treatment of diabetes in pregnancy for decades, changes in the characteristics of the patient population have highlighted the limited effectiveness of different therapies. Specifically, despite the co-occurrence of obesity and diabetes, treatment recommendations including glycemic targets are not altered in such cases and a single optimal treatment strategy for each type of diabetes in pregnancy does not seem to exist. Rather, the approach to treating pregnant women with diabetes likely needs to be individualized to maximize the short term and long term health of mother and child. This article will review recent clinical studies to summarize established treatment strategies and introduce novel therapies for diabetes in pregnancy.	[Feghali, Maisa N.] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15260 USA; [Scifres, Christina M.] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73190 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center	Feghali, MN (corresponding author), Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15260 USA.	maisafeghali@gmail.com	Feghali, Maisa/ABG-2333-2020		National Institutes of Health [KL2 TR001856]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	MNF is supported by the National Institutes of Health through grant number KL2 TR001856. The funding source had no involvement in the preparation, analysis, and interpretation of the data or submission of this review.	ACOG Committee on Practice Bulletins, 2005, OBSTET GYNECOL, V105, P675; Ainuddin JA, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/325851; Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS137, DOI 10.2337/dc18-S013; Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002; [Anonymous], 2018, Obstet Gynecol, V131, pe49, DOI 10.1097/AOG.0000000000002501; Asemi Z, 2013, BRIT J NUTR, V109, P2024, DOI 10.1017/S0007114512004242; Balsells M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h102; Barbour LA, 2017, DIABETES CARE, V40, pE115, DOI 10.2337/dc17-0554; Barbour LA, 2012, DIABETES CARE, V35, pE28, DOI 10.2337/dc11-2107; Bassols J, 2016, PEDIATR RES, V80, P777, DOI 10.1038/pr.2016.155; Bertini AM, 2005, J PERINAT MED, V33, P519, DOI 10.1515/JPM.2005.092; Blumer I, 2013, J CLIN ENDOCR METAB, V98, P4227, DOI 10.1210/jc.2013-2465; Bolinder J, 2016, LANCET, V388, P2254, DOI 10.1016/S0140-6736(16)31535-5; Brown J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011967.pub2; Brown J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012048.pub2; Bruttomesso D, 2011, DIABETES METAB, V37, P426, DOI 10.1016/j.diabet.2011.02.002; Butalia S, 2017, DIABETIC MED, V34, P27, DOI 10.1111/dme.13150; Callesen NF, 2013, J MATERN-FETAL NEO M, V26, P588, DOI 10.3109/14767058.2012.743523; Caritis SN, 2013, OBSTET GYNECOL, V121, P1309, DOI 10.1097/AOG.0b013e31829007f0; Castillo WC, 2015, JAMA PEDIATR, V169, P452, DOI 10.1001/jamapediatrics.2015.74; Castillo WC, 2014, OBSTET GYNECOL, V123, P1177, DOI 10.1097/AOG.0000000000000285; Catalano PM, 2012, DIABETES CARE, V35, P780, DOI 10.2337/dc11-1790; Charles B, 2006, THER DRUG MONIT, V28, P67, DOI 10.1097/01.ftd.0000184161.52573.0e; Chiswick C, 2015, LANCET DIABETES ENDO, V3, P778, DOI 10.1016/S2213-8587(15)00219-3; Chmait Ramen, 2004, J Perinatol, V24, P617, DOI 10.1038/sj.jp.7211147; Clausen TD, 2008, DIABETES CARE, V31, P340, DOI 10.2337/dc07-1596; Conway D L, 2004, J Matern Fetal Neonatal Med, V15, P51; Coton SJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009494; Croze ML, 2013, BIOCHIMIE, V95, P1811, DOI 10.1016/j.biochi.2013.05.011; Croze ML, 2013, J NUTR BIOCHEM, V24, P457, DOI 10.1016/j.jnutbio.2012.01.008; Cummins E, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14110; D'Anna R, 2012, GYNECOL ENDOCRINOL, V28, P440, DOI 10.3109/09513590.2011.633665; D'Anna R, 2015, OBSTET GYNECOL, V126, P310, DOI 10.1097/AOG.0000000000000958; Dabelea D, 2000, J Matern Fetal Med, V9, P83, DOI 10.1002/(SICI)1520-6661(200001/02)9:1<83::AID-MFM17>3.0.CO;2-O; Dabelea D, 2000, DIABETES, V49, P2208, DOI 10.2337/diabetes.49.12.2208; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Dhulkotia JS, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.044; Diaz P, 2017, PLACENTA, V57, P52, DOI 10.1016/j.placenta.2017.05.016; ELLIOTT BD, 1994, AM J OBSTET GYNECOL, V171, P653, DOI 10.1016/0002-9378(94)90078-7; Elliott BD, 1997, AM J OBSTET GYNECOL, V176, P527, DOI 10.1016/S0002-9378(97)70541-6; Engen Hanem LG, 2018, J CLIN ENDOCRINOL ME; Eyal S, 2010, DRUG METAB DISPOS, V38, P833, DOI 10.1124/dmd.109.031245; Facco FL, 2017, OBSTET GYNECOL, V129, P31, DOI 10.1097/AOG.0000000000001805; Fadl HE, 2016, BMJ OPEN DIAB RES CA, V4, DOI 10.1136/bmjdrc-2016-000221; Farrar D, 2016, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD005542.PUB3; Farrar D, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015557; Farren M, 2017, DIABETES CARE, V40, P759, DOI 10.2337/dc16-2449; Feghali MN, 2017, AM J PERINAT, V34, P697, DOI 10.1055/s-0036-1597625; Feig DS, 2017, LANCET, V390, P2347, DOI 10.1016/S0140-6736(17)32400-5; Feig DS, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0954-4; Fugmann M, 2015, SCI REP-UK, V5, DOI 10.1038/srep13212; Gonzalez-Romero S, 2010, DIABETES TECHNOL THE, V12, P263, DOI 10.1089/dia.2009.0140; Griss T, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002309; Haak T, 2017, DIABETES THER, V8, P573, DOI 10.1007/s13300-017-0255-6; Harmon KA, 2011, DIABETES CARE, V34, P2198, DOI 10.2337/dc11-0723; Hasan S, 2018, ACTA OBSTET GYN SCAN, V97, P38, DOI 10.1111/aogs.13252; Hebert MF, 2009, CLIN PHARMACOL THER, V85, P607, DOI 10.1038/clpt.2009.5; Hernandez TL, 2016, DIABETES CARE, V39, P39, DOI 10.2337/dc15-0515; Hernandez TL, 2014, DIABETES CARE, V37, P1254, DOI 10.2337/dc13-2411; Hernandez TL, 2013, CLIN OBSTET GYNECOL, V56, P803, DOI 10.1097/GRF.0b013e3182a8e0e5; Hernandez TL, 2011, DIABETES CARE, V34, P1660, DOI 10.2337/dc11-0241; Holmes VA, 2011, DIABETES CARE, V34, P1683, DOI 10.2337/dc11-0244; Hughes RCE, 2006, DIABETIC MED, V23, P323, DOI 10.1111/j.1464-5491.2005.01769.x; Ibrahim MI, 2014, ARCH GYNECOL OBSTET, V289, P959, DOI 10.1007/s00404-013-3090-7; Ijas H, 2015, BJOG-INT J OBSTET GY, V122, P994, DOI 10.1111/1471-0528.12964; Ilmonen J, 2011, CLIN NUTR, V30, P156, DOI 10.1016/j.clnu.2010.09.009; Jacobson GF, 2005, AM J OBSTET GYNECOL, V193, P118, DOI 10.1016/j.ajog.2005.03.018; Jelic S, 2008, TRENDS CARDIOVAS MED, V18, P253, DOI 10.1016/j.tcm.2008.11.008; Kahn BF, 2006, OBSTET GYNECOL, V107, P1303, DOI 10.1097/01.AOG.0000218704.28313.36; Koren R, 2015, EXPERT OPIN DRUG SAF, V14, P593, DOI 10.1517/14740338.2015.1013533; Kovo M, 2008, PRENATAL DIAG, V28, P544, DOI 10.1002/pd.2026; Kuang YS, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix058; Langer O, 2000, NEW ENGL J MED, V343, P1134, DOI 10.1056/NEJM200010193431601; Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085; Lindsay KL, 2014, AM J CLIN NUTR, V99, P1432, DOI 10.3945/ajcn.113.079723; Loftin Ryan W, 2010, Rev Obstet Gynecol, V3, P10; Malek R, 2016, EXPERT OPIN DRUG MET, V12, P691, DOI 10.1080/17425255.2016.1187131; Markowicz-Piasecka M, 2017, CURR PHARM DESIGN, V23, P2532, DOI 10.2174/1381612822666161201152941; McCurdy CE, 2009, J CLIN INVEST, V119, P323, DOI 10.1172/JCI32661; Mello G, 2015, J MATERN-FETAL NEO M, V28, P276, DOI 10.3109/14767058.2014.914922; Metzger BE, 2007, DIABETES CARE, V30, pS251, DOI 10.2337/dc07-s225; Milluzzo A, 2017, J DIABETES INVESTIG; Moore LE, 2010, OBSTET GYNECOL, V115, P55, DOI 10.1097/AOG.0b013e3181c52132; Moreno-Castilla C, 2013, DIABETES CARE, V36, P2233, DOI 10.2337/dc12-2714; Moster D, 2008, NEW ENGL J MED, V359, P262, DOI 10.1056/NEJMoa0706475; Moy FM, 2017, COCHRANE DB SYST REV, V6; Mukhopadhyay A, 2007, AM J OBSTET GYNECOL, V197, P447, DOI 10.1016/j.ajog.2007.03.062; Nachum Z, 2017, DIABETES CARE, V40, P332, DOI 10.2337/dc16-2307; National Collaborating Centre for Women's and Children's Health (UK), 2015, DIAB PREGN MAN DIAB; O'Neill SM, 2017, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD011880.PUB2; Poolsup N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109985; Ranasinghe PD, 2015, J WOMENS HEALTH, V24, P237, DOI 10.1089/jwh.2014.4939; Rasmussen KM, 2009, WEIGHT GAIN DURING PREGNANCY: REEXAMINING THE GUIDELINES, P1; Rautava S, 2012, NEONATOLOGY, V102, P178, DOI 10.1159/000339182; Reddy M, 2018, DIABETIC MED, V35, P483, DOI 10.1111/dme.13561; Rijpert M, 2009, DIABETES CARE, V32, P2099, DOI 10.2337/dc09-0652; Rowan J, 2015, AUST NZ J OBSTET GYN, V55, P17, DOI 10.1111/ajo.12302; Rowan JA, 2008, NEW ENGL J MED, V358, P2003, DOI 10.1056/NEJMoa0707193; Rowan JA, 2011, DIABETES CARE, V34, P2279, DOI 10.2337/dc11-0660; Sacco F, 2016, BRIT J CANCER, V115, P1451, DOI 10.1038/bjc.2016.385; Sacks DA, 2012, DIABETES CARE, V35, P526, DOI 10.2337/dc11-1641; Santamaria A, 2016, J MATERN-FETAL NEO M, V29, P3234, DOI 10.3109/14767058.2015.1121478; Schaefer-Graf UM, 2008, DIABETES CARE, V31, P1858, DOI 10.2337/dc08-0039; Schaiff WT, 2007, ENDOCRINOLOGY, V148, P3625, DOI 10.1210/en.2007-0211; Schwartz RA, 2015, OBSTET GYNECOL, V125, P583, DOI 10.1097/AOG.0000000000000672; Scifres C, 2015, OBSTET GYNECOL, V126, P316, DOI 10.1097/AOG.0000000000000928; Scott EM, 2018, DIABETES TECHNOL THE, V20, P180, DOI 10.1089/dia.2017.0386; Silva JC, 2012, J PERINAT MED, V40, P225, DOI 10.1515/jpm-2011-0175; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; Soc Maternal-Fetal Med SMFM, 2018, AM J OBSTET GYNECOL, V218, pB2, DOI 10.1016/j.ajog.2018.01.041; Stewart ZA, 2016, NEW ENGL J MED, V375, P644, DOI 10.1056/NEJMoa1602494; Syngelaki A, 2016, NEW ENGL J MED, V374, P434, DOI 10.1056/NEJMoa1509819; Toledano Y, 2016, EXPERT OPIN DRUG SAF, V15, P963, DOI 10.1080/14740338.2016.1182153; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Twedt R, 2015, OBSTET GYNECOL, V126, P326, DOI 10.1097/AOG.0000000000000959; Vanky E, 2005, FERTIL STERIL, V83, P1575, DOI 10.1016/j.fertnstert.2004.11.051; Voormolen DN, 2018, DIABETES OBES METAB, V20, P1894, DOI 10.1111/dom.13310; Wanitcharoenkul E, 2017, SLEEP MED, V39, P101, DOI 10.1016/j.sleep.2017.08.010; Weiss PAM, 2001, AM J OBSTET GYNECOL, V184, P470, DOI 10.1067/mob.2001.109592; Whyte K, 2013, EUR J OBSTET GYN R B, V170, P67, DOI 10.1016/j.ejogrb.2013.04.015; Wouldes TA, 2016, ARCH DIS CHILD FETAL; Yu F, 2014, J CLIN ENDOCR METAB, V99, P4674, DOI 10.1210/jc.2013-4332; Zarate A, 2000, Ginecol Obstet Mex, V68, P42; Zeng YC, 2014, ADV MED SCI-POLAND, V59, P95, DOI 10.1016/j.advms.2014.03.001	124	9	11	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 16	2018	362								k2034	10.1136/bmj.k2034	http://dx.doi.org/10.1136/bmj.k2034			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP7UM	30012851				2023-01-03	WOS:000441115600001
J	Stefler, D; Hu, YY; Malyutina, S; Pajak, A; Kubinova, R; Peasey, A; Pikhart, H; Rodriguez-Artalejo, F; Bobak, M				Stefler, Denes; Hu, Yaoyue; Malyutina, Sofia; Pajak, Andrzej; Kubinova, Ruzena; Peasey, Anne; Pikhart, Hynek; Rodriguez-Artalejo, Fernando; Bobak, Martin			Mediterranean diet and physical functioning trajectories in Eastern Europe: Findings from the HAPIEE study	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; FOLLOW-UP; PATTERNS; DECLINE; DISABILITY; ADHERENCE; COUNTRIES; INDICATORS; DEMENTIA; HEALTH	Background Unhealthy diet may increase the risk of impaired physical functioning in older age. Although poor diet and limited physical functioning both seem to be particularly common in Eastern Europe, no previous study has assessed the relationship between these two factors in this region. The current analysis examined the association between overall diet quality and physical functioning in Eastern European populations. Methods We used data on 25,504 persons (aged 45-69 years at baseline) who participated in the Health Alcohol and Psychosocial factors in Eastern Europe (HAPIEE) study. Dietary assessment at baseline used food frequency questionnaire, and the overall diet quality was evaluated by the Mediterranean diet score (MDS). Physical functioning (PF) was measured by the physical functioning subscale (PF-10) of the 36-item Short-Form Health Survey at baseline and three subsequent occasions over a 10-year period. The cross-sectional and longitudinal relationships between the MDS and PF were examined simultaneously using growth curve models. Results Men and women with higher adherence to the Mediterranean diet had significantly better PF at baseline; after multivariable adjustment, the regression coefficient per 1-unit increase in the MDS was 0.39 (95% CI: 0.25, 0.52) in men and 0.50 (0.36, 0.64) in women. However, we found no statistically significant link between baseline MDS and the subsequent slope of PF decline in neither gender; the coefficients were -0.02 (-0.04, 0.00) in men and -0.01 (-0.03, 0.02) in women. Discussion Our results do not support the hypothesis that the Mediterranean diet has a substantial impact on the trajectories of physical functioning, although the differences existing at baseline may be related to dietary habits in earlier life.	[Stefler, Denes; Hu, Yaoyue; Peasey, Anne; Pikhart, Hynek; Bobak, Martin] UCL, Dept Epidemiol & Publ Hlth, London, England; [Hu, Yaoyue] Max Planck Inst Demog Res, Rostock, Germany; [Malyutina, Sofia] Russian Acad Med Sci, Inst Internal & Prevent Med, Siberian Branch, Novosibirsk, Russia; [Pajak, Andrzej] Jagiellonian Univ, Dept Epidemiol & Populat Studies, Coll Med, Krakow, Poland; [Kubinova, Ruzena] Natl Inst Publ Hlth, Prague, Czech Republic; [Rodriguez-Artalejo, Fernando] Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Sch Med, IdiPaz, Madrid, Spain; [Rodriguez-Artalejo, Fernando] CIBERESP, Madrid, Spain	University of London; University College London; Max Planck Society; Russian Academy of Medical Sciences; Russian Academy of Sciences; Jagiellonian University; Collegium Medicum Jagiellonian University; National Institute of Public Health (SZU) - Czech Republic; Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Stefler, D (corresponding author), UCL, Dept Epidemiol & Publ Hlth, London, England.	denes.stefler@ucl.ac.uk	Pikhart, Hynek/E-3074-2010; Malyutina, Sofia/J-1651-2018; Stefler, Denes/H-5394-2019	Pikhart, Hynek/0000-0001-5277-4049; Malyutina, Sofia/0000-0001-6539-0466; Stefler, Denes/0000-0002-4482-148X; Hu, Yaoyue/0000-0001-6517-1503; Bobak, Martin/0000-0002-2633-6851	Wellcome Trust [WT064947, WT081081]; US National Institute of Aging [1R01AG23522]; MacArthur Foundation Initiative on Social Upheaval and Health; Russian Scientific Foundation [14-45-00030]; ATHLOS Project, a European Union Horizon 2020 Research and Innovation Program [635316]; Russian Science Foundation [17-45-00002] Funding Source: Russian Science Foundation	Wellcome Trust(Wellcome TrustEuropean Commission); US National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MacArthur Foundation Initiative on Social Upheaval and Health; Russian Scientific Foundation(Russian Science Foundation (RSF)); ATHLOS Project, a European Union Horizon 2020 Research and Innovation Program; Russian Science Foundation(Russian Science Foundation (RSF))	The HAPIEE study was supported by the Wellcome Trust [grant numbers WT064947, WT081081], the US National Institute of Aging [grant number 1R01AG23522] and the MacArthur Foundation Initiative on Social Upheaval and Health. The current analysis was partly supported by the Russian Scientific Foundation [grant number 14-45-00030]. This work was also supported by the ATHLOS Project, a European Union Horizon 2020 Research and Innovation Program [grant number 635316]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Artaud F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4240; Barrea L, 2018, CLIN NUTR; Bloomfield HE, 2016, ANN INTERN MED, V165, P491, DOI 10.7326/M16-0361; Bobak M, 2004, J EPIDEMIOL COMMUN H, V58, P238, DOI 10.1136/jech.2003.011825; Bobak M, 2004, BRIT MED J, V329, P767, DOI 10.1136/bmj.38202.667130.55; Boylan S, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-439; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Cosco TD, 2014, INT PSYCHOGERIATR, V26, P373, DOI 10.1017/S1041610213002287; Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]; European Food Safety Authority (EFSA), 2011, 215 EFSA; Feart C, 2011, EUR J EPIDEMIOL, V26, P747, DOI 10.1007/s10654-011-9611-4; Gilmore A, 2004, AM J PUBLIC HEALTH, V94, P2177, DOI 10.2105/AJPH.94.12.2177; Ginter E, 1998, NUTRITION, V14, P452, DOI 10.1016/S0899-9007(98)00017-3; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Hagan KA, 2016, J NUTR, V146, P1341, DOI 10.3945/jn.115.227900; Houston DK, 2005, AM J CLIN NUTR, V81, P515; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Hu YY, 2016, J GERONTOL A-BIOL, V71, P1063, DOI 10.1093/gerona/glv233; Imamura F, 2015, LANCET GLOB HEALTH, V3, pE132, DOI 10.1016/S2214-109X(14)70381-X; Kant AK, 2004, J AM DIET ASSOC, V104, P615, DOI 10.1016/j.jada.2004.01.010; Kojima G, 2018, J AM GERIATR SOC, V66, P783, DOI 10.1111/jgs.15251; Lourida I, 2013, EPIDEMIOLOGY, V24, P479, DOI 10.1097/EDE.0b013e3182944410; Milaneschi Y, 2011, EXP GERONTOL, V46, P303, DOI 10.1016/j.exger.2010.11.030; Milaneschi Y, 2010, CURR OPIN CLIN NUTR, V13, P625, DOI 10.1097/MCO.0b013e32833e337d; Mirowsky J, 2008, RES AGING, V30, P93, DOI 10.1177/0164027507309649; Mirowsky J, 2007, SOCIOL METHOD RES, V35, P497, DOI 10.1177/0049124106296015; Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255; Perez-Tasigchana RF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151596; Pomerleau J, 2006, PUBLIC HEALTH NUTR, V9, P575, DOI 10.1079/PHN2005910; Raczek AE, 1998, J CLIN EPIDEMIOL, V51, P1203, DOI 10.1016/S0895-4356(98)00112-7; Semba RD, 2003, AGING CLIN EXP RES, V15, P482, DOI 10.1007/BF03327377; Shahar DR, 2012, J AM GERIATR SOC, V60, P1881, DOI 10.1111/j.1532-5415.2012.04167.x; Singer JD, 2005, ENCY STAT BEHAV SCI; Slattery ML, 2010, APPL PHYSIOL NUTR ME, V35, P207, DOI 10.1139/H10-006; Sofi F, 2014, PUBLIC HEALTH NUTR, V17, P2769, DOI 10.1017/S1368980013003169; Stefler D, 2017, EUR J NUTR, V56, P421, DOI 10.1007/s00394-015-1092-x; Stoel RD., 2003, METODOLOGIA CIENCIAS, V5, P21; Struijk EA, 2018, J GERONTOL A-BIOL, V73, P333, DOI 10.1093/gerona/glw208; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Tomkins S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030274; Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; Tucker KL, 2010, APPL PHYSIOL NUTR ME, V35, P211, DOI 10.1139/H10-010; van de Rest O, 2015, ADV NUTR, V6, P154, DOI 10.3945/an.114.007617; Vercambre MN, 2009, BRIT J NUTR, V102, P419, DOI 10.1017/S0007114508201959; WA, 2011, ANN AGR ENV MED, V18, P194; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wu W, 2009, PSYCHOL METHODS, V14, P183, DOI 10.1037/a0015858; Zbeida M, 2014, J NUTR HEALTH AGING, V18, P411, DOI 10.1007/s12603-014-0003-9	48	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2018	13	7							e0200460	10.1371/journal.pone.0200460	http://dx.doi.org/10.1371/journal.pone.0200460			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GM8FT	30001406	Green Published, Green Submitted, gold			2023-01-03	WOS:000438457400059
J	Jacko, D; Bersiner, K; Friederichs, G; Ritter, P; Nirenberg, L; Eisenbraun, J; de Marees, M; Bloch, W; Gehlert, S				Jacko, Daniel; Bersiner, Kaethe; Friederichs, Gerrit; Ritter, Patrick; Nirenberg, Linnea; Eisenbraun, Jan; de Marees, Markus; Bloch, Wilhelm; Gehlert, Sebastian			Resistance exercise-induced muscle fatigue is not accompanied by increased phosphorylation of ryanodine receptor 1 at serine 2843	PLOS ONE			English	Article							CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; ECCENTRIC CONTRACTIONS; INTRACELLULAR CALCIUM; PLASMA-CATECHOLAMINE; PROTEIN-KINASE; HEART-FAILURE; RESPONSES; STRESS	Skeletal muscle fatigue has been shown to be associated with hyperphosphorylation of the ryanodine receptor 1 at serine 2843 ((p)RyR1(Ser2843)), due to chronic overloading exercise. We investigated whether (p)RyR1(Ser2843), is a mechanism relevant for muscle fatigue also under acute, in contrast to chronic, muscle loading. 24 male subjects (age: 24,8 +/- 3,8; height: 182,8 +/- 7,2 cm; weight: 82,5 +/- 9,9 kg) were evenly (n = 6) assigned to the following four different resistance exercise (RE) groups: hypertrophy-(HYP), strength endurance-(SE), maximum power-(MAX) at the subjects' 10, 25 and 3 repetition maximum, respectively, and low intensity (LI) RE with 70% of the 10 repetition maximum. Each group completed three different RE volumes (1 set, 5, and 10 sets). Muscle biopsies from the vastus lateralis were taken before and after exercise, analyzed for (p)RyR1(Ser2843) and examined for association with RE-induced muscle fatigue which was determined as reduction in maximum isometric force (F-iso(max)) in the quadriceps femoris muscle also before and after exercise. The degree of RE-induced muscle fatigue was specific in terms of set volume as well as of RE mode. F-iso(max) was not reduced in any group after one set of RE. Five sets led to a significant reduction of F-iso(max) in HYP and SE but not in LI and MAX (p< 0,05). Ten sets of RE, as compared to five sets, exclusively induced further muscle fatigue in LI. In terms of RE mode differences, F-iso(max) reduction was generally higher in HYP and SE than in MAX and Li after five and ten sets of RE (p< 0,05). However, (p)RyR1(Ser2843) did not show any significant regulation, regardless of exercise condition. We conclude that despite its relevance in reducing muscle contractility in chronic overloading, (p)RyR1(Ser2843) does not reflect the degree of muscle fatigue exerted by acute hypertrophy-, strength endurance-, maximum power and low intensity-oriented exercise.	[Jacko, Daniel; Friederichs, Gerrit; Ritter, Patrick; Nirenberg, Linnea; Eisenbraun, Jan; Bloch, Wilhelm; Gehlert, Sebastian] German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Sect Mol & Cellular Sport Med, Cologne, Germany; [Jacko, Daniel] Olymp Base Ctr Rhineland, Cologne, Germany; [Bersiner, Kaethe; Gehlert, Sebastian] Univ Hildesheim, Inst Sport Sci, Hildesheim, Germany; [de Marees, Markus] Ruhr Univ Bochum, Fac Sport Sci, Sect Sports Med & Sports Nutr, Bochum, Germany	German Sport University Cologne; University of Hildesheim; Ruhr University Bochum	Jacko, D (corresponding author), German Sport Univ Cologne, Inst Cardiovasc Res & Sport Med, Sect Mol & Cellular Sport Med, Cologne, Germany.; Jacko, D (corresponding author), Olymp Base Ctr Rhineland, Cologne, Germany.	d.jacko@dshs-koeln.de	Gehlert, Sebastian/AAU-7086-2021; Gehlert, Sebastian/P-7687-2016	Gehlert, Sebastian/0000-0001-6940-3084; Bersiner, Kaethe/0000-0002-8107-7899	Federal Institute of Sports Science (BISp) [AZ 070105/15-16]	Federal Institute of Sports Science (BISp)	This investigation was funded by the Federal Institute of Sports Science (BISp), Grant Number: AZ 070105/15-16 (www.bisp.de) to DJ. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen DG, 2008, J APPL PHYSIOL, V104, P296, DOI 10.1152/japplphysiol.00908.2007; Allen DG, 2005, J PHYSIOL-LONDON, V567, P723, DOI 10.1113/jphysiol.2005.091694; Andersson DC, 2012, J PHYSIOL-LONDON, V590, P6381, DOI 10.1113/jphysiol.2012.237925; BAKER AJ, 1993, AM J PHYSIOL, V264, pC577, DOI 10.1152/ajpcell.1993.264.3.C577; Bellinger AM, 2008, P NATL ACAD SCI USA, V105, P2198, DOI 10.1073/pnas.0711074105; Bellinger AM, 2008, J CLIN INVEST, V118, P445, DOI 10.1172/JCI34006; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Bracken RM, 2009, AMINO ACIDS, V36, P209, DOI 10.1007/s00726-008-0049-2; Bush JA, 1999, MED SCI SPORTS EXERC, V31; Favero TG, 1995, J APPL PHYSL, V78; Friden J, 1983, INT J SPORTS MED; Gehlert S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049326; Goto K, 2009, EUR J APPL PHYSIOL, V106, P731, DOI 10.1007/s00421-009-1075-9; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; Lamboley CR, 2016, J PHYSIOL-LONDON, V594, P469, DOI 10.1113/JP271382; MAYRLEITNER M, 1995, CELL CALCIUM, V18, P197, DOI 10.1016/0143-4160(95)90064-0; McBride TA, 2000, J APPL PHYSIOL, V88, P91, DOI 10.1152/jappl.2000.88.1.91; Pullinen T, 2002, MED SCI SPORT EXER, V34, P806, DOI 10.1097/00005768-200205000-00013; Pullinen T, 1999, EUR J APPL PHYSIOL, V80, P125, DOI 10.1007/s004210050568; Rebbeck RT, 2014, INT J BIOCHEM CELL B, V48, P28, DOI 10.1016/j.biocel.2013.12.001; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Rullman E, 2013, J HEART LUNG TRANSPL, V32, P925, DOI 10.1016/j.healun.2013.06.026; Sonobe T, 2008, AM J PHYSIOL-REG I, V294, pR1329, DOI 10.1152/ajpregu.00815.2007; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; Zalk R, 2007, ANNU REV BIOCHEM, V76, P367, DOI 10.1146/annurev.biochem.76.053105.094237; Zalk R, 2015, NATURE, V517, P44, DOI 10.1038/nature13950; Zhang B-T, 2012, J APPL PHYSIOL, V112, P2077	28	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2018	13	6							e0199307	10.1371/journal.pone.0199307	http://dx.doi.org/10.1371/journal.pone.0199307			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0GK	29953482	gold, Green Published, Green Submitted			2023-01-03	WOS:000436645400024
J	Ranaweera, S; Amarasinghe, H; Chandraratne, N; Thavorncharoensap, M; Ranasinghe, T; Karunaratna, S; Kumara, D; Santatiwongchai, B; Chaikledkaew, U; Abeykoon, P; De Silva, A				Ranaweera, Sajeeva; Amarasinghe, Hemantha; Chandraratne, Nadeeka; Thavorncharoensap, Montarat; Ranasinghe, Thushara; Karunaratna, Sumudu; Kumara, Dinesh; Santatiwongchai, Benjarin; Chaikledkaew, Usa; Abeykoon, Palitha; De Silva, Amala			Economic costs of alcohol use in Sri Lanka	PLOS ONE			English	Article							CONSUMPTION; TOBACCO; DISEASE; CANCER	Aim Alcohol related disease conditions are responsible for a significant proportion of morbidity and mortality in Sri Lanka. This study quantified the economic cost of selected alcohol related disease conditions in Sri Lanka in 2015. Methods This study uses the prevalence-based cost of illness methodology specified by the World Health Organization, and uses the gross costing approach. The direct costs includes the costs of curative care (inpatient and outpatient care borne by the state and out of pocket expenditure borne by patients) for alcohol related diseases, weighted by the respective population attributable fractions. Indirect costs consist of lost earnings due to absenteeism of the patient and carers due to seeking care and recuperation, and the loss of income due to mortality. Data form the Ministry of Health, Registrar General's Department, Department of Census and Statistics and the National Cancer Registry was used. Systemic and house costs and population attributable fractions were obtained from research studies. Economists, Public Health Experts, Medical Administrators and Clinical Specialists were iteratively consulted during the estimation and validation of the costs and the results. Results The estimated present value of current and future economic cost of the alcohol-related conditions for Sri Lanka in 2015 was USD 885.86 million, 1.07% of the GDP of that year. The direct cost of alcohol related disease conditions was USD 388.35 million, which was 44% of the total cost, while the indirect cost was USD 497.50 million, which was 66% of the total cost. Road Injury cost was the highest cost category among the conditions studied. Conclusion Addressing alcohol use and its harms through effective implementation of evidence-based polices and interventions is urgently required to address the economic costs of alcohol use in Sri Lanka as it imposes a significant burden to the country.	[Ranaweera, Sajeeva; Amarasinghe, Hemantha; Chandraratne, Nadeeka] Sri Lanka Med Assoc, Colombo, Sri Lanka; [Amarasinghe, Hemantha] Minist Hlth Nutr & Indigenous Med, Inst Oral Hlth, Maharagama, Sri Lanka; [Thavorncharoensap, Montarat; Chaikledkaew, Usa] Mahidol Univ, Dept Pharm, Fac Pharm, Bangkok, Thailand; [Ranasinghe, Thushara] World Hlth Org Country Off, Colombo, Sri Lanka; [Karunaratna, Sumudu] Minist Hlth Nutr & Indigenous Med, Colombo, Sri Lanka; [Kumara, Dinesh; Abeykoon, Palitha] Minist Hlth Nutr & Indigenous Med, Natl Author Tobacco & Alcohol, Battaramulla, Sri Lanka; [Santatiwongchai, Benjarin] Minist Publ Hlth, Hlth Intervent & Technol Assessment Program, Nonthaburi, Thailand; [De Silva, Amala] Univ Colombo, Colombo, Sri Lanka	Mahidol University; World Health Organization; Ministry of Public Health - Thailand; University of Colombo	Chandraratne, N (corresponding author), Sri Lanka Med Assoc, Colombo, Sri Lanka.	nadkamil@yahoo.com		Chandraratne, Nadeeka/0000-0002-3093-9102; Karunaratna, Sumudu/0000-0001-6482-4007; Ranaweera, Sajeeva/0000-0001-5034-5021; Kumara, Dinesh/0000-0002-6411-3528; Abeykoon, Palitha/0000-0003-0545-3829; ranasinghe, Thushara/0000-0002-8789-7337	World Health Organization Regional Office for South East Asia; Thailand Research Fund (TRF); International Decision Support Initiative (iDSI); TRF [RTA5980011]; Bill & Melinda Gates Foundation; UK's Department for International Development; Rockefeller Foundation	World Health Organization Regional Office for South East Asia; Thailand Research Fund (TRF)(Thailand Research Fund (TRF)); International Decision Support Initiative (iDSI); TRF(Thailand Research Fund (TRF)); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); UK's Department for International Development; Rockefeller Foundation	This project is supported by the World Health Organization Regional Office for South East Asia and partly supported by the Thailand Research Fund (TRF) and the International Decision Support Initiative (iDSI). The Health Intervention and Technology Assessment Program (HITAP) is funded by the TRF under a grant for Senior Research Scholar (RTA5980011). HITAP's International Unit is supported by iDSI to provide technical assistance on health intervention and technology assessment to governments in low and middle-income countries. iDSI is funded by the Bill & Melinda Gates Foundation, the UK's Department for International Development, and the Rockefeller Foundation. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the funding agencies.	Anderson P, 2009, ALCOHOL WORK PRODUCT; Anderson P.Anderson, 2008, ALCOHOL EUROPE PUBLI; Australian Institute of Health and Welfare, 2008, EFF COST EFF POL PRO; Bagnardi V, 2015, BRIT J CANCER, V112, P580, DOI 10.1038/bjc.2014.579; Baklien Bergljot, 2003, ALCOHOL POVERTY SRI; Barrio P, 2017, DRUG ALCOHOL REV, V36, P578, DOI 10.1111/dar.12504; Centers for Disease Control and Prevention (CDC), 2016, ALC PUBL HLTH ALC RE; Central Bank of Sri Lanka, 2017, CENTR BANK SRI LANK; Chikritzhs T, 2003, AUSTR ALCOHOL INDICA, P200; de Silva V., 2009, Ceylon Medical Journal, V54, P119; de Silva V, 2011, DRUG ALCOHOL REV, V30, P69, DOI 10.1111/j.1465-3362.2010.00202.x; Family Health Bureau Ministry of Health, 2015, NAT HLTH YOUTH SURV; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI 10.1001/archgenpsychiatry.2008.543; International Agency for Research on Cancer, 2012, GLOB 2012 EST CANC I; Johnston MC, 2012, ALCOHOL ALCOHOLISM, V47, P725, DOI 10.1093/alcalc/ags092; Jones L., 2016, UNDERSTANDING RELATI; Katulanda P, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-612; Leong DP, 2014, CIRCULATION, V130, P390, DOI 10.1161/CIRCULATIONAHA.113.007627; Lucas DL, 2005, J AM COLL CARDIOL, V45, P1916, DOI 10.1016/j.jacc.2005.02.075; Medical Statistics Unit Ministry of Health, 2016, MIN HLTH NUTR IND ME; Ministry of Health Nutrition and Indigenous Medicine World Health Organization, 2015, NONC DIS RISK FACT S; National Cancer Control Programme Sri Lanka, 2015, CANC INC DAT SRI LAN; Ogden GR, 1998, BRIT J ORAL MAX SURG, V36, P247, DOI 10.1016/S0266-4356(98)90707-0; Organisation for Economic Co-operation and Development and World Health Organization, 2003, DEV ASS COMM DAC GUI; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Single E, 2000, CAN MED ASSOC J, V162, P1669; Single E., 2003, INT GUIDELINES ESTIM, V2nd ed.; Sornpaisarn B, 2017, RESOURCE TOOL ALCOHO; Thavorncharoensap M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-323; Thavorncharoensap M, 2009, SUBST ABUSE TREAT PR, V4, DOI 10.1186/1747-597X-4-20; Tramacere I, 2010, ORAL ONCOL, V46, P497, DOI 10.1016/j.oraloncology.2010.03.024; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; World Health Organisation, 2016, INT CLASS DIS REL HL; Zeisser C, 2013, ALCOHOLISM CLIN EX S, pE1, DOI [10.1111/J.1530-0277.2012, DOI 10.1111/J.1530-0277.2012]	35	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2018	13	6							e0198640	10.1371/journal.pone.0198640	http://dx.doi.org/10.1371/journal.pone.0198640			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI5BF	29879178	gold, Green Submitted, Green Published			2023-01-03	WOS:000434384900064
J	Fujioka, R; Mochizuki, N; Ikeda, M; Sato, A; Nomura, S; Owade, S; Yomoda, S; Tsuchihara, K; Kishino, S; Esumi, H				Fujioka, Rumi; Mochizuki, Nobuo; Ikeda, Masafumi; Sato, Akihiro; Nomura, Shogo; Owade, Satoshi; Yomoda, Satoshi; Tsuchihara, Katsuya; Kishino, Satoshi; Esumi, Hiroyasu			Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer	PLOS ONE			English	Article							SPRAGUE-DAWLEY RATS; NUTRIENT DEPRIVATION; CELLS; TOLERANCE; STARVATION; GLUCOSE; INFLAMMATION; METABOLISM; THERAPY; PATHWAY	Arctigenin is evaluated for antitumor efficacy in patients with pancreatic cancer. It has an inhibitory activity on mitochondrial complex I .Therefore, plasma lactate level of patients after arctigenin administration was evaluated for biomarker of clinical response and/or adverse effect. Plasma lactate level in 15 patients enrolled in a Phase I clinical trial of GBS-01 rich in arctigenin was analyzed by colorimetric assay. Statistical analyses for association of plasma lactate and clinical responses, pharmacokinetics of arctigenin, and background factors of each patient by multivariate and univariate analyses. In about half of the patients, transient increase of lactate was observed. Correlation between plasma lactate level and pharmacokinetic parameters of arctigenin and its glucuronide conjugate, and clinical outcome was not detected. Regarding to the determinant of lactate level, only slight association with liver function test was detected. Plasma lactate level is primary determined by reutilization rather than production for antitumor effect and dose not serve as a biomarker. Arctigenin, inhibition of mitochondrial complex I, plasma lactate concentration, phase I clinical trial of GBS-01, Cori cycle.	[Fujioka, Rumi; Tsuchihara, Katsuya] Natl Canc Ctr, Exploratory Oncol & Clin Trial Ctr, Div Translat Res, Kashiwa, Chiba, Japan; [Mochizuki, Nobuo; Kishino, Satoshi] Meiji Pharmaceut Univ, Dept Medicat Use Anal & Clin Res, Tokyo, Japan; [Ikeda, Masafumi] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Hosp East, Kashiwa, Chiba, Japan; [Sato, Akihiro] Natl Canc Ctr, Clin Res Support Off, Hosp East, Kashiwa, Chiba, Japan; [Nomura, Shogo] Ctr Res Adm & Support, Natl Canc Ctr, Biostat Div, Kashiwa, Chiba, Japan; [Owade, Satoshi; Esumi, Hiroyasu] Tokyo Univ Sci, Res Inst Biomed Sci, Noda, Chiba, Japan; [Yomoda, Satoshi] Kracie Pharmaceut Co, Kanpo Res Inst, Toyama, Japan	National Cancer Center - Japan; Meiji Pharmaceutical University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Tokyo University of Science	Esumi, H (corresponding author), Tokyo Univ Sci, Res Inst Biomed Sci, Noda, Chiba, Japan.	hesumi@rs.tus.ac.jp		Nomura, Shogo/0000-0001-8734-6984	Ministry of Health, Labor and Welfare and Project for Development of Innovative Research on Cancer Therapeutics from Ministry of Education, Culture, Sports, Science and Technology; Kracie Pharmaceutical Company	Ministry of Health, Labor and Welfare and Project for Development of Innovative Research on Cancer Therapeutics from Ministry of Education, Culture, Sports, Science and Technology; Kracie Pharmaceutical Company	This work was supported in part by grants for Clinical Trial on Development of New Drugs and Medical Devices from the Ministry of Health, Labor and Welfare and Project for Development of Innovative Research on Cancer Therapeutics from Ministry of Education, Culture, Sports, Science and Technology. S. Kishino have received the commissioned research funding from Kracie Pharmaceutical Company within one year. S.Y. is an employee of Kracie Pharmaceutical Company. Kracie pharmaceutical company developed GBS-01 under the collaboration with M. I. and H. E. and made GBS-01 available for a phase I clinical trial (UMIN000005785) as described in Materials and methods of the manuscript. The funder provided support in the form of salaries for S.Y., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Antunes IF, 2012, MOL PHARMACEUT, V9, P3277, DOI 10.1021/mp300327w; Awale S, 2006, CANCER RES, V66, P1751, DOI 10.1158/0008-5472.CAN-05-3143; Calixto RD, 2014, BIOL SPORT, V31, P289, DOI 10.5604/20831862.1127287; El Hage M, 2013, NEUROSCIENCE, V248, P243, DOI 10.1016/j.neuroscience.2013.05.064; Esumi H, 2004, CANCER SCI, V95, P685, DOI 10.1111/j.1349-7006.2004.tb03330.x; Heestand GM, 2015, J CLIN ONCOL, V33, P1770, DOI 10.1200/JCO.2014.59.7930; Hermansen L, 1981, Ciba Found Symp, V82, P75; Hirose M, 2000, CANCER LETT, V155, P79, DOI 10.1016/S0304-3835(00)00411-0; Hsieh CJ, 2014, FREE RADICAL BIO MED, V67, P159, DOI 10.1016/j.freeradbiomed.2013.10.004; Huang SL, 2012, DIABETOLOGIA, V55, P1469, DOI 10.1007/s00125-011-2366-3; Hyam SR, 2013, EUR J PHARMACOL, V708, P21, DOI 10.1016/j.ejphar.2013.01.014; Ikeda M, 2016, CANCER SCI, V107, P1818, DOI 10.1111/cas.13086; Izuishi K, 2000, CANCER RES, V60, P6201; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Ko AH, 2015, J CLIN ONCOL, V33, P1779, DOI 10.1200/JCO.2014.59.7625; Lu J, 2004, CANCER SCI, V95, P547, DOI 10.1111/j.1349-7006.2004.tb03247.x; Lu LC, 2012, PLANTA MED, V78, P1317, DOI 10.1055/s-0032-1314998; Masafumi Ikeda, 2013, J CLIN ONCOL S, V31; Newsholme EA, 1996, EXPERIENTIA, V52, P421, DOI 10.1007/BF01919310; Piel S, 2015, ACTA PHYSIOL, V213, P171, DOI 10.1111/apha.12311; Tomitsuka E, 2010, ANN NY ACAD SCI, V1201, P44, DOI 10.1111/j.1749-6632.2010.05620.x; Yamashita T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085878; Zechner D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1047-x; Zhu ZY, 2013, J NEUROSCI, V33, P13138, DOI 10.1523/JNEUROSCI.4790-12.2013	24	7	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2018	13	6							e0198219	10.1371/journal.pone.0198219	http://dx.doi.org/10.1371/journal.pone.0198219			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH8ES	29856804	gold, Green Published, Green Submitted			2023-01-03	WOS:000433900800089
J	Radvanyi, LG				Radvanyi, Laszlo G.			IMMUNOTHERAPY Targeting the cancer mutanome of breast cancer	NATURE MEDICINE			English	Editorial Material							T-CELLS	A metastatic hormone receptor-positive breast cancer, usually resistant to immunotherapy, is successfully treated with tumor-infiltrating lymphocytes enriched for neoantigen reactivity, underscoring the broad potential of this immunotherapeutic approach.	[Radvanyi, Laszlo G.] Ontario Inst Canc Res, Toronto, ON, Canada	Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Radvanyi, LG (corresponding author), Ontario Inst Canc Res, Toronto, ON, Canada.	laszlo.radvanyi@oicr.on.ca						Alvarez B, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700252; Bobisse S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03301-0; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Efremova M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01679; Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Rosenberg SA, 2011, NAT REV CLIN ONCOL, V8, P577, DOI 10.1038/nrclinonc.2011.116; Schumacher TN, 2016, CURR OPIN IMMUNOL, V41, P98, DOI 10.1016/j.coi.2016.07.005; Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8	12	7	8	4	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2018	24	6					703	704		10.1038/s41591-018-0065-z	http://dx.doi.org/10.1038/s41591-018-0065-z			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GI3OQ	29867234				2023-01-03	WOS:000434281300011
J	Rudrabhatla, P; Deepanjali, S; Mandal, J; Swaminathan, RP; Kadhiravan, T				Rudrabhatla, Pavankumar; Deepanjali, Surendran; Mandal, Jharna; Swaminathan, Rathinam Palamalai; Kadhiravan, Tamilarasu			Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial	PLOS ONE			English	Article							URINARY-TRACT-INFECTIONS; ESCHERICHIA-COLI; DOUBLE-BLIND; TRIMETHOPRIM-SULFAMETHOXAZOLE; ANTIMICROBIAL RESISTANCE; DISEASES-SOCIETY; CIPROFLOXACIN; THERAPY; EPIDEMIOLOGY; METAANALYSIS	Objective To evaluate whether stopping the effective antibiotic treatment following clinical improvement at Day 7 (Truncated treatment) would be non-inferior to continued treatment until Day 14 (Continued treatment) in patients with acute pyelonephritis (APN) requiring hospitalization treated with non-fluoroquinolone (non-FQ) antibiotics. Methods Hospitalized adult men and non-pregnant women with culture-confirmed APN were eligible for participation after they had clinically improved following empirical or culture-guided treatment with intravenous non-FQ antibiotic(s). We excluded patients with severe sepsis, abscesses, prostatitis, recurrent or catheter-associated urinary tract infection, or urinary tract obstruction. We randomized eligible patients on Day 7 of effective treatment and assessed them at Weeks 1 and 6 after treatment completion. The primary outcome was retreatment for recurrent urinary tract infection. The prespecified non-inferiority margin was 15%. Results Between March 17, 2015 and August 22, 2016, we randomly allocated 54 patients-27 patients in each arm. Twenty-four (44%) patients were male, and 26 (48%) had diabetes mellitus. Escherichia coli was the most common urinary isolate (47 [87%] patients); 36 (78%) were resistant to ciprofloxacin. In all, 41 (76%) patients received amikacin-based treatment. At the end of 6 weeks, no patient in the truncated treatment arm required retreatment, whereas 1 patient in the continued treatment arm was retreated. Difference (90% CI) in retreatment was -3.7% (-15.01% to 6.15%). Upper bound of the difference (6.15%) was below the prespecified limit, establishing non-inferiority of truncated treatment. Asymptomatic bacteriuria at Week 6 was similar between the two arms (3/24 vs. 3/26; P = 1.0). Patients in the truncated treatment arm had significantly shorter hospital stay (8 [7-10] vs. 14 [14-15] days; P < 0.001) and less antibiotic consumption per patient (8.4 +/- 2.8 vs. 17.4 +/- 8.3 DDDs; P < 0.001). Conclusion Stopping the effective non-FQ antibiotics following clinical improvement at Day 7 is non-inferior to continued treatment until Day 14 in selected patients with APN requiring hospitalization.	[Rudrabhatla, Pavankumar; Deepanjali, Surendran; Swaminathan, Rathinam Palamalai; Kadhiravan, Tamilarasu] Jawaharlal Inst Postgrad Med Educ & Res, Dept Med, Pondicherry, India; [Mandal, Jharna] Jawaharlal Inst Postgrad Med Educ & Res, Dept Microbiol, Pondicherry, India	Jawaharlal Institute of Postgraduate Medical Education & Research; Jawaharlal Institute of Postgraduate Medical Education & Research	Deepanjali, S (corresponding author), Jawaharlal Inst Postgrad Med Educ & Res, Dept Med, Pondicherry, India.	deepanjali.s@jipmer.edu.in	Mandal, Jharna/AAF-5908-2020; Kadhiravan, Tamilarasu/AAU-8104-2020; Deepanjali, Surendran/GQP-5858-2022; Deepanjali, Surendran/AAR-6341-2021	Deepanjali, Surendran/0000-0003-2151-4273; Rudrabhatla, Pavan Kumar/0000-0003-4076-4008	JIPMER	JIPMER	The authors received no specific funding for this work. JIPMER is a publicly-funded hospital that provides free treatment to patients, including the trial participants.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; American College of Obstetricians and Gynecologists, 2008, Obstet Gynecol, V111, P785, DOI 10.1097/AOG.0b013e318169f6ef; [Anonymous], 2017, TREATM GUID ANT US C; BAILEY RR, 1987, ANN INTERN MED, V107, P430, DOI 10.7326/0003-4819-107-2-430_1; BAILEY RR, 1992, NEW ZEAL MED J, V105, P102; Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; Bouchillon Sam, 2012, Open Microbiol J, V6, P74; Center for Disease Dynamics Economics & Policy, 2015, ANT RES ESCH COL IND; Charalabopoulos K, 2003, CHEMOTHERAPY, V49, P269, DOI 10.1159/000074526; Cho SY, 2016, KOREAN J INTERN MED, V31, P156, DOI 10.3904/kjim.2016.31.1.156; Davey P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003543.pub3; Eliakim-Raz N, 2013, J ANTIMICROB CHEMOTH, V68, P2183, DOI 10.1093/jac/dkt177; Fisher D, 2017, J ANTIMICROB CHEMOTH, V72, P1221, DOI 10.1093/jac/dkw551; Food and Drug Administration U. S. Department of Health and Human Services, 2015, COMPL UR TRACT INF D; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Havey TC, 2011, CRIT CARE, V15, DOI 10.1186/cc10545; Hsueh PR, 2011, J INFECTION, V63, P114, DOI 10.1016/j.jinf.2011.05.015; Infectious Diseases Society of America, 2012, IDSA COMM FDA DRAFT; Jean SS, 2016, INT J ANTIMICROB AG, V47, P328, DOI 10.1016/j.ijantimicag.2016.01.008; Johnson JR, 2018, NEW ENGL J MED, V378, P48, DOI 10.1056/NEJMcp1702758; JOHNSON JR, 1991, J INFECT DIS, V163, P325, DOI 10.1093/infdis/163.2.325; Kahlmeter G, 2015, INFECT DIS THER, V4, P417, DOI 10.1007/s40121-015-0095-5; Ki M, 2004, AM J EPIDEMIOL, V160, P985, DOI 10.1093/aje/kwh308; Lipsky BA, 2010, CLIN INFECT DIS, V50, P1641, DOI 10.1086/652861; Mandal J, 2012, INDIAN J MED RES, V136, P842; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Mazzariol A, 2017, J CHEMOTHERAPY, V29, P2, DOI [10.1080/1120009X.2017.1380395, 10.1080/1120009x.2017.1380395]; MELEKOS MD, 1991, J CHEMOTHERAPY, V3, P376; Meletiadis J, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00473-17, 10.1128/aac.00473-17]; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Morrill HJ, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.02236-16, 10.1128/AAC.02236-16]; Naber KG, 2009, ANTIMICROB AGENTS CH, V53, P3782, DOI 10.1128/AAC.00837-08; National Centre for Disease Control. Directorate General of Health Services. Ministry of Health & Family Welfare, 2016, NAT TREATM GUID ANT; Park SH, 2014, J ANTIMICROB CHEMOTH, V69, P2848, DOI 10.1093/jac/dku215; Peterson J, 2008, UROLOGY, V71, P17, DOI 10.1016/j.urology.2007.09.002; Polat M, 2017, INFECT DRUG RESIST, V10, P393, DOI 10.2147/IDR.S148703; Popejoy MW, 2017, J ANTIMICROB CHEMOTH, V72, P268, DOI 10.1093/jac/dkw374; Saghaei M., 2011, J BIOMED SCI ENG, V4, P734, DOI [10.4236/jbise.2011.411090, DOI 10.4236/JBISE.2011.411090]; SANDBERG T, 1990, EUR J CLIN MICROBIOL, V9, P317, DOI 10.1007/BF01973737; Sandberg T, 2012, LANCET, V380, P484, DOI 10.1016/S0140-6736(12)60608-4; Sealed Envelope Ltd, 2012, POW CALC BIN OUTC NO; Singh KP, 2013, ANTIMICROB AGENTS CH, V57, P5284, DOI 10.1128/AAC.01257-13; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; Talan DA, 2016, EMERG INFECT DIS, V22, P1594, DOI 10.3201/eid2209.160148; Tandberg D, 2014, IMPROVED CONFIDENCE; TIMMERMAN C, 1992, INFECTION, V20, P34, DOI 10.1007/BF01704892; van der Starre Willize E, 2011, Curr Infect Dis Rep, V13, P571, DOI 10.1007/s11908-011-0211-y; van Nieuwkoop C, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0835-3; Vidal L, 2007, J ANTIMICROB CHEMOTH, V60, P247, DOI 10.1093/jac/dkm193; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; WHO Collaborating Centre for Drug Statistics Methodology, 2013, GUIDELINES ATC CLASS	52	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2018	13	5							e0197302	10.1371/journal.pone.0197302	http://dx.doi.org/10.1371/journal.pone.0197302			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF9WG	29768465	gold, Green Published, Green Submitted			2023-01-03	WOS:000432329200074
J	Kurita, K; Lachs, MS; Adelman, RD; Siegler, EL; Reid, MC; Prigerson, HG				Kurita, Keiko; Lachs, Mark S.; Adelman, Ronald D.; Siegler, Eugenia L.; Reid, M. Cary; Prigerson, Holly G.			Mild cognitive dysfunction of caregivers and its association with care recipients' end-of-life plans and preferences	PLOS ONE			English	Article							SPOUSAL CAREGIVERS; OLDER-ADULTS; CANCER; HEALTH; FAMILY; PATIENT; DECLINE; STRESS; DEATH	Little is known about the association between cognitive dysfunction among informal caregivers and patients' plans and preferences for patients' end of life care. We report on the frequency of cognitive dysfunction among both patients and caregivers and examine associations between caregivers' cognitive screening scores and end of life plans and preferences of patients with advanced cancer. The current sample was derived from a National Cancer Institute- and National Institute of Mental Health-funded study of patients with distant metastasis who had disease progression on at least first-line chemotherapy, and their informal caregivers (n = 550 pairs). The Pfeiffer Short Portable Mental Status, a validated cognitive screen, was administered to patients and caregivers. Patients were interviewed about their end of life plans and preferences. Logistic regression models regressed patients' advance care planning and treatment preferences on caregivers' cognitive screen scores. Patients' cognitive screen scores were included as covariates. Most caregivers (55%) were spouses. Almost 30% of patients scored worse on the cognitive screen than their caregivers and 12% of caregivers scored worse than the patients. For each additional error that caregivers made on the cognitive screen, patients were more likely (AOR = 1.59, p = 0.002) to report that they preferred that everything possible be done to keep them alive and were less likely (AOR = 0.75, p = 0.04) to have a living will or a health care proxy/durable power of attorney. Worse caregiver cognitive screening scores were associated with higher likelihood of patients' reporting that they wanted everything done to save their lives and a lower likelihood of having a living will or other type of advanced care plan. Future studies should confirm these findings in other populations and determine the mechanisms that may underlie the identified relationships.	[Kurita, Keiko; Prigerson, Holly G.] Weill Cornell Med, Ctr Res End Of Life Care, New York, NY USA; [Kurita, Keiko; Lachs, Mark S.; Adelman, Ronald D.; Siegler, Eugenia L.; Reid, M. Cary; Prigerson, Holly G.] Weill Cornell Med, Dept Med, Div Geriatr & Palliat Med, New York, NY USA	Cornell University; Cornell University	Prigerson, HG (corresponding author), Weill Cornell Med, Ctr Res End Of Life Care, New York, NY USA.; Prigerson, HG (corresponding author), Weill Cornell Med, Dept Med, Div Geriatr & Palliat Med, New York, NY USA.	hgp2001@med.cornell.edu	Prigerson, Holly/GWV-3283-2022; Prigerson, Holly/L-3800-2019	Prigerson, Holly/0000-0002-7075-4268; Siegler, Eugenia/0000-0001-9449-5873	National Cancer Institute [R01 CA106370, R35 CA197730, CA218313]; National Institute of Mental Health [R01 MH63892]; National Institute on Aging [T32 AG049666, P30 AG022845, K24 AG053462]; Howard and Phyllis Schwartz Philanthropic Fund; Independent Grant for Learning and Change from Pfizer Inc [28540451]; Gilead Sciences [IN-US-311-4182]; Fan Fox and Leslie R. Samuels Foundation; NATIONAL CANCER INSTITUTE [R35CA197730] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Howard and Phyllis Schwartz Philanthropic Fund; Independent Grant for Learning and Change from Pfizer Inc; Gilead Sciences(Gilead Sciences); Fan Fox and Leslie R. Samuels Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study was supported by a grant from the National Cancer Institute (R01 CA106370, awarded to Dr. Prigerson) and from the National Institute of Mental Health (R01 MH63892, awarded to Dr. Prigerson). Dr. Kurita is supported by a grant from the National Institute on Aging (T32 AG049666). Dr. Prigerson is supported by grants from the National Cancer Institute (R35 CA197730, CA218313). Dr. Reid is supported by grants from the National Institute on Aging (P30 AG022845 and K24 AG053462), the Howard and Phyllis Schwartz Philanthropic Fund, and an Independent Grant for Learning and Change from Pfizer Inc (28540451). Dr. Siegler is an investigator on an investigator initiated research grant from Gilead Sciences [IN-US-311-4182] and receives support from the Fan Fox and Leslie R. Samuels Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boucher L, 1996, J AM GERIATR SOC, V44, P828, DOI 10.1111/j.1532-5415.1996.tb03742.x; Braun UK, 2008, J GEN INTERN MED, V23, P267, DOI 10.1007/s11606-007-0487-7; Brazil K, 2003, AGING MENT HEALTH, V7, P376, DOI 10.1080/1360786031000150649; Caswell LW, 2003, EXP AGING RES, V29, P303, DOI 10.1080/03610730303721; Chen P, 2013, TOP STROKE REHABIL, V20, P369, DOI 10.1310/tsr2004-369; Correa MS, 2015, NEUROSCIENCE, V286, P371, DOI 10.1016/j.neuroscience.2014.11.052; de Vugt ME, 2006, AGE AGEING, V35, P160, DOI 10.1093/ageing/afj044; Gao X, 2013, J PAIN SYMPTOM MANAG, V45, P650, DOI 10.1016/j.jpainsymman.2012.03.003; Garlo K, 2010, J AM GERIATR SOC, V58, P2315, DOI 10.1111/j.1532-5415.2010.03177.x; Janelsins MC, 2011, SEMIN ONCOL, V38, P431, DOI 10.1053/j.seminoncol.2011.03.014; Kreling B, 2006, PSYCHO-ONCOLOGY, V15, P1065, DOI 10.1002/pon.1042; Kurita K, 2018, J PALLIAT MED, V21, P536, DOI 10.1089/jpm.2017.0385; Lavela SL, 2010, CHRONIC ILLN, V6, P67, DOI 10.1177/1742395309356943; Nielsen MK, 2017, PSYCHO-ONCOLOGY, V26, P2048, DOI 10.1002/pon.4416; Oken BS, 2011, J GERIATR PSYCH NEUR, V24, P191, DOI 10.1177/0891988711422524; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Schafer C, 2006, SUPPORT CARE CANCER, V14, P952, DOI 10.1007/s00520-006-0025-x; Sklenarova H, 2015, CANCER-AM CANCER SOC, V121, P1513, DOI 10.1002/cncr.29223; Tomarken A, 2008, PSYCHO-ONCOLOGY, V17, P105, DOI 10.1002/pon.1188; Vitaliano PP, 2011, J AM GERIATR SOC, V59, P900, DOI 10.1111/j.1532-5415.2011.03368.x; Vitaliano PP, 2009, GERONTOLOGIST, V49, P12, DOI 10.1093/geront/gnp004; Wolff JL, 2016, JAMA INTERN MED, V176, P372, DOI 10.1001/jamainternmed.2015.7664; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	23	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196147	10.1371/journal.pone.0196147	http://dx.doi.org/10.1371/journal.pone.0196147			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE3RI	29708996	Green Published, gold, Green Submitted			2023-01-03	WOS:000431130100017
J	Sethi, SK; Bansal, SB; Khare, A; Dhaliwal, M; Raghunathan, V; Wadhwani, N; Nandwani, A; Yadav, DK; Mahapatra, AK; Raina, R				Sethi, Sidharth Kumar; Bansal, Shyam B.; Khare, Anshika; Dhaliwal, Maninder; Raghunathan, Veena; Wadhwani, Nikita; Nandwani, Ashish; Yadav, Dinesh Kumar; Mahapatra, Amit Kumar; Raina, Rupesh			Heparin free dialysis in critically sick children using sustained low efficiency dialysis (SLEDD-f): A new hybrid therapy for dialysis in developing world	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; RENAL REPLACEMENT THERAPY; PERITONEAL-DIALYSIS; HEMODIALYSIS; OUTCOMES; ALPHA; ICU	Background In critically sick adults, sustained low efficiency dialysis [SLED] appears to be better tolerated hemodynamically and outcomes seem to be comparable to CRRT. However, there is paucity of data in critically sick children. In children, two recent studies from Taiwan (n = 11) and India (n = 68) showed benefits of SLED in critically sick children. Aims and objectives The objective of the study was to look at the feasibility and tolerability of sustained low efficiency daily dialysis-filtration [SLEDD-f] in critically sick pediatric patients. Material and methods Design: Retrospective study Inclusion criteria: All pediatric patients who had undergone heparin free SLEDD-f from January 2012 to October 2017. Measurements: Data collected included demographic details, vital signs, PRISM III at admission, ventilator parameters (where applicable), number of inotropes, blood gas and electrolytes before, during, and on conclusion of SLED therapy. Technical information was gathered regarding SLEDD-f prescription and complications. Results Between 2012-2017, a total of 242 sessions of SLEDD-f were performed on 70 patients, out of which 40 children survived. The median age of patients in years was 12 (range 0.8-17 years), and the median weight was 39 kg (range 8.5-66 kg). The mean PRISM score at admission was 8.77 +/- 7.22. SLEDD-f sessions were well tolerated, with marked improvement in fluid status and acidosis. Premature terminations had to be done in 23 (9.5%) of the sessions. There were 21 sessions (8.6%) terminated due to hypotension and 2 sessions (0.8%) terminated due to circuit clotting. Post-SLEDD-f hypocalcemia occurred in 15 sessions (6.2%), post-SLEDD-f hypophosphatemia occurred in 1 session (0.4%), and post-SLEDD-f hypokalemia occurred in 17 sessions (7.0%). Conclusions This study is the largest compiled data on pediatric SLEDD-f use in critically ill patients. Our study confirms the feasibility of heparin free SLEDD-f in a larger pediatric population, and even in children weighing <20 kg on inotropic support.	[Sethi, Sidharth Kumar; Bansal, Shyam B.; Wadhwani, Nikita; Nandwani, Ashish; Yadav, Dinesh Kumar; Mahapatra, Amit Kumar] Medanta, Kidney Inst, Gurgaon, Haryana, India; [Khare, Anshika] Northeast Ohio Med Univ, Rootstown, OH USA; [Dhaliwal, Maninder; Raghunathan, Veena] Medanta, Pediat Crit Care, Gurgaon, Haryana, India; [Raina, Rupesh] Akron Childrens Hosp, Pediat Nephrol, Akron, OH 44308 USA	Northeast Ohio Medical University (NEOMED); Akron Children's Hospital	Raina, R (corresponding author), Akron Childrens Hosp, Pediat Nephrol, Akron, OH 44308 USA.	RRaina@akronchildrens.org	raina, rupesh/AAE-6660-2020	Sethi, Sidharth/0000-0002-1516-3393				Bagga A, 2007, PEDIATR NEPHROL, V22, P1655, DOI 10.1007/s00467-007-0565-4; Basu RK, 2011, INT J NEPHROL, V2011, DOI 10.4061/2011/785392; Berbece AN, 2006, KIDNEY INT, V70, P963, DOI 10.1038/sj.ki.5001700; BUNCHMAN TE, 1994, PEDIATR NEPHROL, V8, P96, DOI 10.1007/BF00868282; Callegari JG, 2012, KIDNEY INT, V81, P331, DOI 10.1038/ki.2011.408; Cullis B, 2014, PERITON DIALYSIS INT, V34, P494, DOI 10.3747/pdi.2013.00222; Fiaccadori E, 2013, CLIN J AM SOC NEPHRO, V8, P1670, DOI 10.2215/CJN.00510113; Fieghen HE, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-32; Finkelstein FO, 2014, PERITON DIALYSIS INT, V34, P478, DOI 10.3747/pdi.2014.00041; Goldstein B, 2006, PEDIATR CRIT CARE ME, V7, P200, DOI 10.1097/01.PCC.0000217470.68764.36; Goldstein SL, 2005, KIDNEY INT, V67, P653, DOI 10.1111/j.1523-1755.2005.67121.x; Kielstein JT, 2010, J NEPHROL, V23, P494; Lee CY, 2012, PEDIATR NEPHROL, V27, P2301, DOI 10.1007/s00467-012-2254-1; Legrand M, 2013, INTENS CARE MED, V39, P101, DOI 10.1007/s00134-012-2706-x; Lonnemann G, 1999, KIDNEY INT, V56, pS84, DOI 10.1046/j.1523-1755.56.s72.8.x; Marshall MR, 2004, NEPHROL DIAL TRANSPL, V19, P877, DOI 10.1093/ndt/gfg625; Marshall MR, 2001, KIDNEY INT, V60, P777, DOI 10.1046/j.1523-1755.2001.060002777.x; Paganini EP, 1996, AM J KIDNEY DIS, V28, pS81, DOI 10.1016/S0272-6386(96)90084-0; Ponce D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126436; Ponce D, 2012, CLIN J AM SOC NEPHRO, V7, P887, DOI 10.2215/CJN.11131111; Raina R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178233; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Ronco C, 1998, NEPHROL DIAL TRANSPL, V13, P79, DOI 10.1093/ndt/13.suppl_6.79; Santiago MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8172; Schetz M, 1999, KIDNEY INT, V56, pS88, DOI 10.1046/j.1523-1755.56.s72.12.x; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Sethi SK, 2018, HEMODIAL INT, V22, P228, DOI 10.1111/hdi.12605; Sinha R, 2018, PEDIATR NEPHROL, V33, P1283, DOI 10.1007/s00467-017-3732-2; Sutherland SM, 2012, PEDIATR NEPHROL, V27, P2007, DOI 10.1007/s00467-011-2080-x; Sutherland SM, 2010, AM J KIDNEY DIS, V55, P316, DOI 10.1053/j.ajkd.2009.10.048; Zhang L, 2015, AM J KIDNEY DIS, V66, P322, DOI 10.1053/j.ajkd.2015.02.328	31	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2018	13	4							e0195536	10.1371/journal.pone.0195536	http://dx.doi.org/10.1371/journal.pone.0195536			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE1WN	29698409	Green Submitted, Green Published, gold			2023-01-03	WOS:000431007600011
J	Wood, E				Wood, Evan			Strategies for Reducing Opioid-Overdose Deaths - Lessons from Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY		[Wood, Evan] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Wood, Evan] British Columbia Ctr Substance Use, Vancouver, BC, Canada	University of British Columbia	Wood, E (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.; Wood, E (corresponding author), British Columbia Ctr Substance Use, Vancouver, BC, Canada.							Hickman M, 2011, J PUBLIC HEALTH-UK, V33, P332, DOI 10.1093/pubmed/fdr055; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; National Center on Addiction and Substance Abuse at Columbia University, 2012, ADD MED CLOS GAP SCI; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635	4	39	39	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2018	378	17					1565	1567		10.1056/NEJMp1800216	http://dx.doi.org/10.1056/NEJMp1800216			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD8XP	29694813	Bronze			2023-01-03	WOS:000430797900001
J	Bartelds, R; Nematollahi, MH; Pols, T; Stuart, MCA; Pardakhty, A; Asadikaram, G; Poolman, B				Bartelds, Rianne; Nematollahi, Mohammad Hadi; Pols, Tjeerd; Stuart, Marc C. A.; Pardakhty, Abbas; Asadikaram, Gholamreza; Poolman, Bert			Niosomes, an alternative for liposomal delivery	PLOS ONE			English	Article							LIPID-PROTEIN INTERACTIONS; OF-THE-ART; PHOSPHOLIPID-VESICLES; MEMBRANE-PROTEINS; DRUG-DELIVERY; UNILAMELLAR LIPOSOMES; SURFACTANT VESICLES; TRANSPORT-SYSTEM; INDUCED LEAKAGE; MELITTIN	Niosomes are used in studies for drug delivery or gene transfer. However, their physical properties and features relative to liposomes are not well documented. To characterize and more rationally optimize niosome formulations, the properties of these vesicle systems are compared to those of liposomes composed of phosphatidylcholine and phosphatidylethanolamine lipids plus cholesterol. Niosomes are highly stable and only slightly more leaky than liposomes as assayed by calcein leakage; the permeability for ions (KCl) is higher than that of liposomes. Contrary to liposomes, the size of niosomes decreases substantially upon freezing in liquid nitrogen and subsequent thawing, as shown by cryo-EM and dynamic light scattering. The packing of niosomal membranes was determined by laurdan fluorescence and is slightly lower than that of liposomes. We did not succeed in the functional reconstitution of the L-arginine/L-ornithine antiporter ArcD2 in niosomes, which we attribute to the non-ionic nature of the surfactants. The antimicrobial peptides alamethicin and melittin act similarly on niosomes and liposomes composed of unsaturated components, whereas both niosomes and liposomes are unaffected when saturated amphiphiles are used. In conclusion, in terms of stability and permeability for drug-size molecules niosomes are comparable to liposomes and they may offer an excellent, inexpensive alternative for delivery purposes.	[Bartelds, Rianne; Pols, Tjeerd; Poolman, Bert] Univ Groningen, Dept Biochem, Groningen, Netherlands; [Nematollahi, Mohammad Hadi] Sch Med, Dept Clin Biochem, Med Univ Campus, Kerman, Iran; [Stuart, Marc C. A.] Univ Groningen, Dept Electron Microscopy, Groningen, Netherlands; [Pardakhty, Abbas] Kerman Univ Med Sci, Pharmaceut Res Ctr, Inst Neuropharmacol, Med Univ Campus, Kerman, Iran; [Asadikaram, Gholamreza] Kerman Univ Med Sci, Inst Basic & Clin Physiol Sci, Endocrinol & Metab Res Ctr, Kerman, Iran	University of Groningen; University of Groningen; Kerman University of Medical Sciences; Kerman University of Medical Sciences	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen, Netherlands.	bpoolman@rug.nl	Nematollahi, Hadi/AAD-5922-2019; Pardakhty, Abbas/Y-7245-2018; Asadikaram, Gholamreza/AAG-4437-2021	Pardakhty, Abbas/0000-0002-1848-5961; Asadikaram, Gholamreza/0000-0002-9100-0756; Nematollahi, Mohammad Hadi/0000-0002-9529-4077; Poolman, Bert/0000-0002-1455-531X	European Research Council; Netherlands Organization for Scientific Research (NWO)	European Research Council(European Research Council (ERC)European Commission); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This work was supported by the European Research Council, and the Netherlands Organization for Scientific Research (NWO).	ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; Allende D, 2005, BIOPHYS J, V88, P1828, DOI 10.1529/biophysj.104.049817; BAILLIE AJ, 1985, J PHARM PHARMACOL, V37, P863, DOI 10.1111/j.2042-7158.1985.tb04990.x; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; CROMMELIN DJA, 1984, PHARMACEUT RES, P159, DOI 10.1023/A:1016344523988; Dawidczyk CM, 2014, J CONTROL RELEASE, V187, P133, DOI 10.1016/j.jconrel.2014.05.036; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; DEAMER DW, 1986, CHEM PHYS LIPIDS, V40, P167, DOI 10.1016/0009-3084(86)90069-1; DEGIER J, 1968, BIOCHIM BIOPHYS ACTA, V150, P666, DOI 10.1016/0005-2736(68)90056-4; DEMEL RA, 1972, BIOCHIM BIOPHYS ACTA, V255, P321, DOI 10.1016/0005-2736(72)90031-4; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; Geertsma ER, 2008, P NATL ACAD SCI USA, V105, P5722, DOI 10.1073/pnas.0802190105; Geertsma ER, 2008, NAT PROTOC, V3, P256, DOI 10.1038/nprot.2007.519; Hamann S, 2002, J FLUORESC, V12, P139, DOI 10.1023/A:1016832027325; HAUSER H, 1973, BIOCHEMISTRY-US, V12, P4507, DOI 10.1021/bi00746a032; Hayashi K, 2013, COLLOID SURFACE B, V106, P258, DOI 10.1016/j.colsurfb.2012.12.022; Hayashi K, 2011, COLLOID SURFACE B, V87, P28, DOI 10.1016/j.colsurfb.2011.04.029; Jibry N, 2004, PHARM RES-DORDR, V21, P1852, DOI 10.1023/B:PHAM.0000045239.22049.70; Kaiser HJ, 2009, P NATL ACAD SCI USA, V106, P16645, DOI 10.1073/pnas.0908987106; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kato K, 2008, LANGMUIR, V24, P10762, DOI 10.1021/la801581f; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; Laouini A, 2012, J COLLOID SCI BIOTEC, V1, P147, DOI 10.1166/jcsb.2012.1020; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Manosroi A, 2003, COLLOID SURFACE B, V30, P129, DOI 10.1016/S0927-7765(03)00080-8; Moghassemi S, 2014, J CONTROL RELEASE, V185, P22, DOI 10.1016/j.jconrel.2014.04.015; MONETTE M, 1993, BIOCHIM BIOPHYS ACTA, V1149, P319, DOI 10.1016/0005-2736(93)90217-N; Muzzalupo R, 2005, COLLOID SURFACE B, V46, P78, DOI 10.1016/j.colsurfb.2005.09.003; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; NOZAKI Y, 1981, P NATL ACAD SCI-BIOL, V78, P4324, DOI 10.1073/pnas.78.7.4324; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P639, DOI 10.1016/0005-2736(67)90095-8; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; POTT T, 1995, BIOPHYS J, V68, P965, DOI 10.1016/S0006-3495(95)80272-9; Raghuraman H, 2004, BIOPHYS J, V87, P2419, DOI 10.1529/biophysj.104.043596; Rath A, 2009, P NATL ACAD SCI USA, V106, P1760, DOI 10.1073/pnas.0813167106; Rex S, 1996, BIOPHYS CHEM, V58, P75, DOI 10.1016/0301-4622(95)00087-9; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; SENIOR J, 1982, LIFE SCI, V30, P2123, DOI 10.1016/0024-3205(82)90455-6; Sezgin E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123930; STANKOWSKI S, 1989, FEBS LETT, V250, P556, DOI 10.1016/0014-5793(89)80795-1; Stromstedt AA, 2007, J COLLOID INTERF SCI, V311, P59, DOI 10.1016/j.jcis.2007.02.070; SUBBARAO NK, 1994, BBA-BIOMEMBRANES, V1189, P101, DOI 10.1016/0005-2736(94)90286-0; Uchegbu IF, 1998, INT J PHARM, V172, P33, DOI 10.1016/S0378-5173(98)00169-0; van den Bogaart G, 2007, BIOPHYS J, V93, P154, DOI 10.1529/biophysj.107.106005; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Wessman P, 2008, BIOPHYS J, V95, P4324, DOI 10.1529/biophysj.108.130559; Wessman P, 2010, J COLLOID INTERF SCI, V346, P127, DOI 10.1016/j.jcis.2010.02.032; YAMAUCHI K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P178, DOI 10.1016/0005-2736(93)90353-2; YOSHIOKA T, 1994, INT J PHARM, V105, P1, DOI 10.1016/0378-5173(94)90228-3	54	102	106	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2018	13	4							e0194179	10.1371/journal.pone.0194179	http://dx.doi.org/10.1371/journal.pone.0194179			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4YG	29649223	Green Published, gold, Green Submitted			2023-01-03	WOS:000429791900007
J	Godai, K; Hasegawa-Moriyama, M; Matsunaga, A; Kanmura, Y				Godai, Kohei; Hasegawa-Moriyama, Maiko; Matsunaga, Akira; Kanmura, Yuichi			Phenylephrine does not improve oxygenation during one-lung ventilation: A randomized, double-blind, cross-over study	PLOS ONE			English	Article							PULSE PRESSURE VARIATION; FLUID RESPONSIVENESS; MANAGEMENT; ANESTHESIA; HYPOXEMIA	Background Phenylephrine is an alpha(1) adrenergic receptor agonist that causes pulmonary vasoconstriction, and so may effectively enhance hypoxic pulmonary vasoconstriction (HPV). However, there is little evidence that phenylephrine augments HPV in clinical situations. This study aimed to evaluate the clinical effects of phenylephrine infusion on oxygenation during one-lung ventilation (OLV) in patients undergoing thoracic surgery. Methods This was a prospective, randomized, double-blind, cross-over study. Included patients were those undergoing elective thoracic surgery in the lateral decubitus position with OLV. Patients were randomly allocated to two groups. The N-P group initially had OLV with normal saline infusion for 30 minutes; after a 10 minute interval, OLV was then maintained with phenylephrine infusion for 30 minutes. The P-N group had the drug-infusion in the reverse order. The primary outcome was arterial partial pressure of oxygen. Secondary outcomes were mean arterial pressure, heart rate, pulse pressure variation, perfusion index, and difference between bladder and skin temperature. Statistical analysis was performed using the student t-test, Fisher's exact test, and ANOVA for Cross-over design. P < 0.05 was considered statistically significant. Results Twenty-nine patients were analyzed. Although phenylephrine infusion significantly increased mean arterial pressure (P < 0.001), arterial partial pressure of oxygen did not differ between the two timepoints (P = 0.19). There was no carryover effect in arterial partial pressure of oxygen (P = 0.14). Phenylephrine infusion significantly decreased heart rate (P = 0.02) and pulse pressure variation (P < 0.001). Conclusions Phenylephrine infusion did not improve oxygenation during OLV. The present results indicate that phenylephrine does not have clinically meaningful effects on HPV.	[Godai, Kohei; Hasegawa-Moriyama, Maiko; Matsunaga, Akira; Kanmura, Yuichi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Anesthesiol & Crit Care Med, Kagoshima, Japan	Kagoshima University	Godai, K (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Anesthesiol & Crit Care Med, Kagoshima, Japan.	kxg179@icloud.com	Godai, Kohei/T-4675-2018	Godai, Kohei/0000-0002-5333-9417				Allen TK, 2010, ANESTH ANALG, V111, P1221, DOI 10.1213/ANE.0b013e3181e1db21; APPLETON C, 1985, J PHARMACOL EXP THER, V233, P729; Biais M, 2012, ANESTHESIOLOGY, V116, P1354, DOI 10.1097/ALN.0b013e318256ee28; Brassard CL, 2014, CAN J ANESTH, V61, P1103, DOI 10.1007/s12630-014-0246-2; Unzueta MC, 2007, ANESTH ANALG, V104, P1029, DOI 10.1213/01.ane.0000260313.63893.2f; Doering EB, 1997, ANESTHESIOLOGY, V87, P18, DOI 10.1097/00000542-199707000-00004; Fu Q, 2015, DRUG DISCOV THER, V9, P296, DOI 10.5582/ddt.2015.01046; Karzai W, 2009, ANESTHESIOLOGY, V110, P1402, DOI 10.1097/ALN.0b013e31819fb15d; Lee JH, 2011, EUR J ANAESTH, V28, P39, DOI 10.1097/EJA.0b013e32834089cf; Li T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004327; Lumb AB, 2015, ANESTHESIOLOGY, V122, P932, DOI 10.1097/ALN.0000000000000569; Montes FR, 2010, J CARDIOTHORAC SURG, V5, DOI 10.1186/1749-8090-5-99; Raphael J, 2017, CURR OPIN ANESTHESIO, V30, P7, DOI 10.1097/ACO.0000000000000408; Rebet O, 2016, EUR J ANAESTH, V33, P638, DOI 10.1097/EJA.0000000000000470; Sato K, 2001, Masui, V50, P1118; Schloss B, 2013, THORAC CARD SURG REP, V2, P16, DOI 10.1055/s-0033-1343734; Tanaka M, 1994, Masui, V43, P1124; Xia JY, 2016, EXP THER MED, V12, P1141, DOI 10.3892/etm.2016.3432	18	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2018	13	4							e0195576	10.1371/journal.pone.0195576	http://dx.doi.org/10.1371/journal.pone.0195576			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC0YY	29630639	Green Submitted, Green Published, gold			2023-01-03	WOS:000429505000059
J	Johnson, S; Lamb, D; Marston, L; Osborn, D; Mason, O; Henderson, C; Ambler, G; Milton, A; Davidson, M; Christoforou, M; Sullivan, S; Hunter, R; Hindle, D; Paterson, B; Leverton, M; Piotrowski, J; Forsyth, R; Mosse, L; Goater, N; Kelly, K; Lean, M; Pilling, S; Morant, N; Lloyd-Evans, B				Johnson, Sonia; Lamb, Danielle; Marston, Louise; Osborn, David; Mason, Oliver; Henderson, Claire; Ambler, Gareth; Milton, Alyssa; Davidson, Michael; Christoforou, Marina; Sullivan, Sarah; Hunter, Rachael; Hindle, David; Paterson, Beth; Leverton, Monica; Piotrowski, Jonathan; Forsyth, Rebecca; Mosse, Liberty; Goater, Nicky; Kelly, Kathleen; Lean, Mel; Pilling, Stephen; Morant, Nicola; Lloyd-Evans, Brynmor			Peer-supported self-management for people discharged from a mental health crisis team: a randomised controlled trial	LANCET			English	Article							RESOLUTION; RECOVERY; ILLNESS; CARE	Background High resource expenditure on acute care is a challenge for mental health services aiming to focus on supporting recovery, and relapse after an acute crisis episode is common. Some evidence supports self-management interventions to prevent such relapses, but their effect on readmissions to acute care following a crisis is untested. We tested whether a self-management intervention facilitated by peer support workers could reduce rates of readmission to acute care for people discharged from crisis resolution teams, which provide intensive home treatment following a crisis. Methods We did a randomised controlled superiority trial recruiting participants from six crisis resolution teams in England. Eligible participants had been on crisis resolution team caseloads for at least a week, and had capacity to give informed consent. Participants were randomly assigned to intervention and control groups by an unmasked data manager. Those collecting and analysing data were masked to allocation, but participants were not. Participants in the intervention group were offered up to ten sessions with a peer support worker who supported them in completing a personal recovery workbook, including formulation of personal recovery goals and crisis plans. The control group received the personal recovery workbook by post. The primary outcome was readmission to acute care within 1 year. This trial is registered with ISRCTN, number 01027104. Findings 221 participants were assigned to the intervention group versus 220 to the control group; primary outcome data were obtained for 218 versus 216. 64 (29%) of 218 participants in the intervention versus 83 (38%) of 216 in the control group were readmitted to acute care within 1 year (odds ratio 0.66, 95% CI 0.43-0.99; p=0.0438). 71 serious adverse events were identified in the trial (29 in the treatment group; 42 in the control group). Interpretation Our findings suggest that peer-delivered self-management reduces readmission to acute care, although admission rates were lower than anticipated and confidence intervals were relatively wide. The complexity of the study intervention limits interpretability, but assessment is warranted of whether implementing this intervention in routine settings reduces acute care readmission. Copyright (c) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.	[Johnson, Sonia; Lamb, Danielle; Osborn, David; Davidson, Michael; Christoforou, Marina; Hindle, David; Paterson, Beth; Leverton, Monica; Forsyth, Rebecca; Mosse, Liberty; Lean, Mel; Morant, Nicola; Lloyd-Evans, Brynmor] UCL, Div Psychiat, London W1T 7NF, England; [Marston, Louise; Hunter, Rachael] UCL, Res Dept Primary Care & Populat Hlth, London, England; [Mason, Oliver; Pilling, Stephen] UCL, Div Psychol & Language Sci, London, England; [Johnson, Sonia; Osborn, David; Pilling, Stephen] Camden & Islington NHS Fdn Trust, London, England; [Mason, Oliver] Univ Surrey, Sch Psychol, Guildford, Surrey, England; [Henderson, Claire] Kings Coll London, Hlth Serv & Populat Res, London, England; [Milton, Alyssa] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Sullivan, Sarah] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Piotrowski, Jonathan] Avon & Wiltshire Mental Hlth Partnership NHS Trus, Bath, Avon, England; [Goater, Nicky] West London Mental Hlth Trust, London, England; [Kelly, Kathleen] Oxford Hlth NHS Fdn Trust, Oxford, England	University of London; University College London; University of London; University College London; University of London; University College London; University of Surrey; University of London; King's College London; University of Sydney; University of Bristol	Johnson, S (corresponding author), UCL, Div Psychiat, London W1T 7NF, England.	s.johnson@ucl.ac.uk	Mason, oliver/B-3432-2013; Hunter, Rachael Maree/H-7846-2019; Paterson, Beth/ABD-1717-2020; Johnson, Sonia/A-5220-2008; Johnson, Sonia/ABF-1457-2020; Milton, Alyssa/AAE-1151-2021; Marston, Louise/A-8535-2012; Osborn PhD FRCPsych, David/B-8165-2009	Hunter, Rachael Maree/0000-0002-7447-8934; Johnson, Sonia/0000-0002-2219-1384; Johnson, Sonia/0000-0002-2219-1384; Marston, Louise/0000-0002-9973-1131; Lloyd-Evans, Brynmor/0000-0001-9866-788X; Morant, Nicola/0000-0003-4022-8133; Mason, Oliver/0000-0002-4529-8029; Osborn PhD FRCPsych, David/0000-0003-2519-1539; Milton, Alyssa/0000-0002-4326-0123; Sullivan, Sarah/0000-0002-1446-8478; Christoforou, Marina/0000-0003-4841-2736; Leverton, Monica/0000-0001-6678-5865	National Institute for Health Research	National Institute for Health Research(National Institute for Health Research (NIHR))	National Institute for Health Research.	[Anonymous], 2009, EPIDEMIOL PSICHIAT S, V18, P54, DOI 10.1017/S1121189X00001469; Attkisson C. C., 1982, EVAL PROGRAM PLANN, V5, P233; Barbic S, 2009, PSYCHIAT SERV, V60, P491, DOI 10.1176/appi.ps.60.4.491; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Care Quality Commission, 2015, RIGHT HER RIGHT NOW; Cook JA, 2012, PSYCHIAT SERV, V63, P541, DOI 10.1176/appi.ps.201100125; Davidson L, 2006, SCHIZOPHRENIA BULL, V32, P443, DOI 10.1093/schbul/sbj043; Department of Health, 2000, NHS PLAN A PLAN INV; Gilburt H., 2015, MENTAL HLTH PRESSURE; HAYS RD, 1987, J PERS ASSESS, V51, P69, DOI 10.1207/s15327752jpa5101_6; Jethwa K, 2007, PSYCHIATR BULL, V31, P170, DOI 10.1192/pb.bp.106.010389; Johnson S, 2005, BRIT MED J, V331, P599, DOI 10.1136/bmj.38519.678148.8F; Johnson S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015665; Johnson Sonia, 2013, ADV PSYCHIAT TREATME, V19, P115, DOI [10.1192/apt.bp.107.004192, DOI 10.1192/APT.BP.107.004192]; Lloyd-Evans B, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1139-4; Lloyd-Evans B, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-39; Lubben J, 2006, GERONTOLOGIST, V46, P503, DOI 10.1093/geront/46.4.503; McGuire AB, 2014, PSYCHIAT SERV, V65, P171, DOI 10.1176/appi.ps.201200274; Milton Alyssa, 2017, BMC Res Notes, V10, P588, DOI 10.1186/s13104-017-2900-6; Mueser K.T., 2005, MEASURING PROMISE CO, P124, DOI [10.1037/t21500-000, DOI 10.1037/T21500-000]; National Institute for Health and Care Excellence, 2011, 136 NICE; National Institute for Health and Care Excellence (NICE), PSYCH SCHIZ AD PREV; Neil ST, 2009, PSYCHOSIS, V1, P145, DOI 10.1080/17522430902913450; NHS Confederation, 2012, IMPL REC ORG CHANG; Nicholson, 2016, OLD PROBLEMS NEW SOL; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Paton F, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20030; Perkins R, 2007, TAKING BACK CONTROL; Repper J, 2011, J MENT HEALTH, V20, P392, DOI 10.3109/09638237.2011.583947; Scanlan JN, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1469-x; Taylor SJ., 2014, HEALTH SERV DELIVERY, DOI [10.3310/hsdr02530, DOI 10.3310/HSDR02530]; Werbeloff N, 2017, LANCET PSYCHIAT, V4, P49, DOI 10.1016/S2215-0366(16)30416-3; Wheeler C, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0441-x	33	68	68	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	2018	392	10145					409	418		10.1016/S0140-6736(18)31470-3	http://dx.doi.org/10.1016/S0140-6736(18)31470-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP1SM	30102174	Green Published, hybrid			2023-01-03	WOS:000440597100022
J	Kummerer, K; Dionysiou, DD; Olsson, O; Fatta-Kassinos, D				Kuemmerer, Klaus; Dionysiou, Dionysios D.; Olsson, Oliver; Fatta-Kassinos, Despo			A path to clean water	SCIENCE			English	Editorial Material							PHARMACEUTICALS; BIODEGRADABILITY; SYSTEMS		[Kuemmerer, Klaus; Olsson, Oliver] Leuphana Univ Luneburg, Inst Sustainable & Environm Chem, D-21335 Luneburg, Germany; [Dionysiou, Dionysios D.] Univ Cincinnati, Dept Chem & Environm Engn, Environm Engn & Sci Program, Cincinnati, OH 45221 USA; [Fatta-Kassinos, Despo] Univ Cyprus, Dept Civil & Environm Engn, CY-1678 Nicosia, Cyprus; [Fatta-Kassinos, Despo] Univ Cyprus, Nireas Int Water Res Ctr, CY-1678 Nicosia, Cyprus	Leuphana University Luneburg; University System of Ohio; University of Cincinnati; University of Cyprus; University of Cyprus	Kummerer, K (corresponding author), Leuphana Univ Luneburg, Inst Sustainable & Environm Chem, D-21335 Luneburg, Germany.	klaus.kuemmerer@uni.leuphana.de	Olsson, Oliver/C-2710-2014; Fatta-Kassinos, Despo/G-2331-2016; Dionysiou, Dionysios D./K-1193-2019	Olsson, Oliver/0000-0003-0082-1442; Fatta-Kassinos, Despo/0000-0003-1173-0941; Dionysiou, Dionysios D./0000-0002-6974-9197				Alexander J, 2016, SCI TOTAL ENVIRON, V559, P103, DOI 10.1016/j.scitotenv.2016.03.154; Bernhardt ES, 2017, FRONT ECOL ENVIRON, V15, P84, DOI 10.1002/fee.1450; Boethling RS, 2007, CHEM REV, V107, P2207, DOI 10.1021/cr050952t; Christou A, 2017, WATER RES, V109, P24, DOI 10.1016/j.watres.2016.11.033; Daughton CG, 2014, SCI TOTAL ENVIRON, V493, P392, DOI 10.1016/j.scitotenv.2014.06.013; Haiss A, 2016, GREEN CHEM, V18, P4361, DOI 10.1039/c6gc00417b; Hanigan D, 2015, ENVIRON SCI TECH LET, V2, P151, DOI 10.1021/acs.estlett.5b00096; Kummerer K, 2017, ANGEW CHEM INT EDIT, V56, P16420, DOI 10.1002/anie.201709949; Linthorst J.A., 2010, FOUND CHEM, P55, DOI [10.1007/s10698-009-9079-4., 10.1007/s10698-009-9079-4]; Murphy F, 2016, ENVIRON SCI TECHNOL, V50, P5800, DOI 10.1021/acs.est.5b05416; Paltiel O, 2016, ENVIRON SCI TECHNOL, V50, P4476, DOI 10.1021/acs.est.5b06256; Rastogi T, 2015, ENVIRON SCI TECHNOL, V49, P11756, DOI 10.1021/acs.est.5b03051; Schmidt CK, 2008, ENVIRON SCI TECHNOL, V42, P6340, DOI 10.1021/es7030467; Schwarzenbach RP, 2006, SCIENCE, V313, P1072, DOI 10.1126/science.1127291; United Nations Industrial Development Organization, 2016, GLOB PROM IMPL CHEM	15	97	99	10	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2018	361	6399					222	224		10.1126/science.aau2405	http://dx.doi.org/10.1126/science.aau2405			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN5YR	30026210	Green Published			2023-01-03	WOS:000439145800020
J	Luben, R; Hayat, S; Mulligan, A; Lentjes, M; Wareham, N; Pharoah, P; Khaw, KT				Luben, Robert; Hayat, Shabina; Mulligan, Angela; Lentjes, Marleen; Wareham, Nicholas; Pharoah, Paul; Khaw, Kay-Tee			Alcohol consumption and future hospital usage: The EPIC-Norfolk prospective population study	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; DIFFERENT DIMENSIONS; REDUCED MORTALITY; SOCIAL-CLASS; RISK; MEN; METAANALYSIS; ASSOCIATION; DRINKERS	Background Heavy drinkers of alcohol are reported to use hospitals more than non-drinkers, but it is unclear whether light-to-moderate drinkers use hospitals more than non-drinkers. Objective We examined the relationship between alcohol consumption in 10,883 men and 12,857 women aged 40-79 years in the general population and subsequent admissions to hospital and time spent in hospital. Methods Participants from the EPIC-Norfolk prospective population-based study were followed for ten years (1999-2009) using record linkage. Results Compared to current non-drinkers, men who reported any alcohol drinking had a lower risk of spending more than twenty days in hospital multivariable adjusted OR 0.80 (95%CI 0.68-0.94) after adjusting for age, smoking status, education, social class, body mass index and prevalent diseases. Women who were current drinkers were less likely to have any hospital admissions multivariable adjusted OR 0.84 (95%CI 0.74-0.95), seven or more admissions OR 0.77 (95% CI 0.66-0.88) or more than twenty hospital days OR 0.70 (95%CI 0.62-0.80). However, compared to lifelong abstainers, men who were former drinkers had higher risk of any hospital admissions multivariable adjusted OR 2.22 (95%CI 1.51-3.28) and women former drinkers had higher risk of seven or more admissions OR 1.30 (95%CI 1.01-1.67). Conclusion Current alcohol consumption was associated with lower risk of future hospital usage compared with non-drinkers in this middle aged and older population. In men, this association may in part be due to whether former drinkers are included in the non-drinker reference group but in women, the association was consistent irrespective of the choice of reference group. In addition, there were few participants in this cohort with very high current alcohol intake. The measurement of past drinking, the separation of non-drinkers into former drinkers and lifelong abstainers and the choice of reference group are all influential in interpreting the risk of alcohol consumption on future hospitalisation.	[Luben, Robert; Hayat, Shabina; Mulligan, Angela; Lentjes, Marleen; Pharoah, Paul; Khaw, Kay-Tee] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England; [Wareham, Nicholas] Univ Cambridge, Sch Clin Med, MRC Epidemiol Unit, Cambridge, England	University of Cambridge; University of Cambridge	Luben, R (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.	robert.luben@phpc.cam.ac.uk	Pharoah, Paul/V-6658-2019; Khaw, Kay-Tee/AAZ-3209-2021; Luben, Robert N/H-5519-2015	Pharoah, Paul/0000-0001-8494-732X; Luben, Robert N/0000-0002-5088-6343; Lentjes, Marleen/0000-0003-4713-907X	Medical Research Council UK [G9502233, G0401527]; Cancer Research UK [C864/A8257, C864/A2883]; MRC [MC_UU_12015/1, MR/N003284/1] Funding Source: UKRI	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The design and conduct of the EPIC-Norfolk study and collection and management of the data was supported by programme grants from the Medical Research Council UK (G9502233, G0401527) and Cancer Research UK (C864/A8257, C864/A2883). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors are independent from funders and sponsors and had access to all the data.	[Anonymous], 2011, GSS METH SER; Bell S, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j909; Bergmann MM, 2013, INT J EPIDEMIOL, V42, P1772, DOI 10.1093/ije/dyt154; BLAND R, 1979, SOCIOLOGY, V13, P283, DOI 10.1177/003803857901300209; Boniface S, 2013, EUR J PUBLIC HEALTH, V23, P1076, DOI 10.1093/eurpub/ckt016; Burton R., 2016, PUBLIC HLTH BURDEN A; Chief Medical Officers, 2016, ALC GUID REV REP GUI; Dawson DA, 2000, ALCOHOL CLIN EXP RES, V24, P72, DOI 10.1111/j.1530-0277.2000.tb04556.x; Day N, 1999, BRIT J CANCER, V80, P95; Degerud E, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002476; Di Castelnuovo A, 2006, ARCH INTERN MED, V166, P2437, DOI 10.1001/archinte.166.22.2437; Ferrari P, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005245; Fillmore KM, 2007, ANN EPIDEMIOL, V17, pS16, DOI 10.1016/j.annepidem.2007.01.005; Hart CL, 1999, BMJ-BRIT MED J, V318, P1725, DOI 10.1136/bmj.318.7200.1725; Hayat SA, 2014, INT J EPIDEMIOL, V43, P1063, DOI 10.1093/ije/dyt086; Holst C, 2017, DIABETOLOGIA, V60, P1941, DOI 10.1007/s00125-017-4359-3; House of Commons Science and Technology Committee, 2011, 11 REP SESS 2010 12; Jones L, 2013, UPDATING ENGLAND SPE; Kalinowski A, 2016, ADDICTION, V111, P1293, DOI 10.1111/add.13341; Katikireddi SV, 2017, LANCET PUBLIC HEALTH, V2, pE267, DOI 10.1016/S2468-2667(17)30078-6; Knott C, 2015, DIABETES CARE, V38, P1804, DOI 10.2337/dc15-0710; Luben R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009461; McFadden E, 2009, EUR J EPIDEMIOL, V24, P231, DOI 10.1007/s10654-009-9332-0; Naimi TS, 2017, ADDICTION, V112, P207, DOI 10.1111/add.13451; Public Health England, 2014, LOC ALC PROF ENGL LA; Rehm J, 2008, AM J EPIDEMIOL, V168, P866, DOI 10.1093/aje/kwn093; Rehm J, 2003, ALCOHOL RES HEALTH, V27, P39; Rehm J, 2017, ADDICTION, V112, P968, DOI 10.1111/add.13757; Rehm J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x; Robinson M, 2013, ALCOHOL ALCOHOLISM, V48, P231, DOI 10.1093/alcalc/ags098; Roerecke M, 2012, ADDICTION, V107, P1246, DOI 10.1111/j.1360-0443.2012.03780.x; Ronksley Paul E, 2011, BMJ, V342, pd671, DOI 10.1136/bmj.d671; SHAPER AG, 1988, LANCET, V2, P1267; Smyth A, 2015, LANCET, V386, P1945, DOI 10.1016/S0140-6736(15)00235-4; Stockwell T, 2004, ADDICTION, V99, P1024, DOI 10.1111/j.1360-0443.2004.00815.x; Stockwell T, 2016, J STUD ALCOHOL DRUGS, V77, P185, DOI 10.15288/jsad.2016.77.185; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; Wannamethee SG, 1997, INT J EPIDEMIOL, V26, P523, DOI 10.1093/ije/26.3.523; Williams R, 2014, LANCET, V384, P1953, DOI 10.1016/S0140-6736(14)61838-9; Wood AM, 2018, LANCET, V391, P1513, DOI 10.1016/S0140-6736(18)30134-X	40	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0200747	10.1371/journal.pone.0200747	http://dx.doi.org/10.1371/journal.pone.0200747			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN4SJ	30020973	Green Published, gold, Green Submitted			2023-01-03	WOS:000439022400070
J	Hampton, T				Hampton, Tracy			New Genetic Links to Depression May Pave the Way for Novel Treatment Strategies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2018	320	1					20	21		10.1001/jama.2017.12862	http://dx.doi.org/10.1001/jama.2017.12862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL5PC	29971377				2023-01-03	WOS:000437219400004
J	Qato, DM; Ozenberger, K; Olfson, M				Qato, Dima Mazen; Ozenberger, Katharine; Olfson, Mark			Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-BLOCKERS; INTERFERON-ALPHA; EPIDEMIOLOGY; ASSOCIATION; DISORDER; EVENTS; RISK	IMPORTANCE Prescription medications are increasingly used among adults in the United States and many have a potential for causing depression. OBJECTIVES To characterize use of prescription medications with depression as a potential adverse effect and to assess associations between their use and concurrent depression. DESIGN, SETTING, AND PARTICIPANTS Five 2-year cycles (2005-2006 through 2013-2014) of the National Health and Nutrition Examination Survey, representative cross-sectional surveys of US adults aged 18 years or older, were analyzed for use of medications with depression as a potential adverse effect. Multivariable logistic regression examined associations between use of these medications and concurrent depression. Analyses were performed among adults overall, excluding antidepressant users, and among adults treated with antidepressants and with hypertension. EXPOSURES Prescription medications with depression as a potential adverse effect (listed in Micromedex). MAIN OUTCOMES AND MEASURES Prevalence of any use and concurrent use of medications with a potential to cause depression and prevalence of depression (PHQ-9 score >= 10). RESULTS The study included 26 192 adults (mean age, 46.2 years [95% CI, 45.6-46.7]; women, 51.1%) and 7.6%(95% CI, 7.1%-8.2%) reported depression. The overall estimated prevalence of use of medications with depression as an adverse effect was 37.2%, increasing from 35.0%(95% CI, 32.2%-37.9%) in the cycle years 2005 and 2006 to 38.4%(95% CI, 36.5%-40.3%) in 2013 and 2014 (P for trend = .03). An estimated 6.9% (95% CI, 6.2%-7.6%) reported use of 3 or more concurrent medications with a potential for depression as an adverse effect in 2005 and 2006 and 9.5%(95% CI, 8.4%-10.7%) reported such use in 2013 and 2014 (P for trend = .001). In adjusted analyses excluding users of antidepressants, the number of medications used with depression as possible adverse effects was associated with increased prevalence of concurrent depression. The estimated prevalence of depression was 15% for those reporting use of 3 or more medications with depression as an adverse effect vs 4.7% for those not using such medications (difference, 10.7%[95% CI, 7.2%-14.1%]). These patterns persisted in analyses restricted to adults treated with antidepressants, among hypertensive adults, and after excluding users of any psychotropic medication. CONCLUSIONS AND RELEVANCE In this cross-sectional survey study, use of prescription medications that have depression as a potential adverse effect was common. Use of multiple medications was associated with greater likelihood of concurrent depression.	[Qato, Dima Mazen; Ozenberger, Katharine] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, 833 S Wood St,Ste 266, Chicago, IL 60612 USA; [Qato, Dima Mazen] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA; [Olfson, Mark] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Columbia University	Qato, DM (corresponding author), Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, 833 S Wood St,Ste 266, Chicago, IL 60612 USA.	dimaqato@uic.edu	Olfson, Mark/AAA-8547-2021	Qato, Dima/0000-0001-5411-6998	Robert Wood Johnson Foundation (RWJF) as part of the Clinical Scholars Leadership program	Robert Wood Johnson Foundation (RWJF) as part of the Clinical Scholars Leadership program	Dr Qato is supported in part by the Robert Wood Johnson Foundation (RWJF) as part of the Clinical Scholars Leadership program.	[Anonymous], 2006, FDA Consum, V40, P4; AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; Barrons R, 2004, AM J HEALTH-SYST PH, V61, P380, DOI 10.1093/ajhp/61.4.380; Boal AH, 2016, HYPERTENSION, V68, P1132, DOI 10.1161/HYPERTENSIONAHA.116.08188; BRIGHT RA, 1992, JAMA-J AM MED ASSOC, V267, P1783; Casagrande Tango Rodrigo, 2003, Dialogues Clin Neurosci, V5, P155; Cheng CM, 2010, ARCH INTERN MED, V170, P831, DOI 10.1001/archinternmed.2010.91; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Friedman RA, 2014, NEW ENGL J MED, V371, P1666, DOI 10.1056/NEJMp1408480; Gorton HC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009074; Hampton LM, 2014, JAMA PSYCHIAT, V71, P1006, DOI 10.1001/jamapsychiatry.2014.436; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; Jorgensen TSH, 2016, JAMA PSYCHIAT, V73, P1032, DOI 10.1001/jamapsychiatry.2016.1932; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Laudisio A, 2018, INT PSYCHOGERIATR, V30, P153, DOI 10.1017/S1041610217001715; Lavigne JE, 2016, J AM PHARM ASSOC, V56, P203, DOI 10.1016/j.japh.2015.12.011; Maatouk I, 2016, J HYPERTENS, V34, P1711, DOI 10.1097/HJH.0000000000001006; Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303; Olfson M, 2016, JAMA INTERN MED, V176, P1482, DOI 10.1001/jamainternmed.2016.5057; Pratt Laura A, 2014, NCHS Data Brief, P1; Raison CL, 2005, J CLIN PSYCHIAT, V66, P41, DOI 10.4088/JCP.v66n0106; Schaefer M, 2012, J HEPATOL, V57, P1379, DOI 10.1016/j.jhep.2012.07.037; Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P380, DOI 10.1001/jama.2015.18392; Skovlund C, 2016, JAMA PSYCHIAT, V73, P1154, DOI 10.1001/jamapsychiatry.2016.2387; Statacorp, 2013, STAT 13 BAS REF MAN; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Yesavage JA, 2003, J GERIATR PSYCH NEUR, V16, P131, DOI 10.1177/0891988703255684; Zipf George, 2013, Vital Health Stat 1, P1; Zipursky JS, 2017, J CLIN PSYCHOPHARM, V37, P381, DOI 10.1097/JCP.0000000000000695	31	45	45	3	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2018	319	22					2289	2298		10.1001/jama.2018.6741	http://dx.doi.org/10.1001/jama.2018.6741			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ2UP	29896627	Green Published, Bronze			2023-01-03	WOS:000435129300015
J	Cuperus, T; Kraaij, MD; Zomer, AL; van Dijk, A; Haagsman, HP				Cuperus, Tryntsje; Kraaij, Marina D.; Zomer, Aldert L.; van Dijk, Albert; Haagsman, Henk P.			Immunomodulation and effects on microbiota after in ovo administration of chicken cathelicidin-2	PLOS ONE			English	Article							HOST-DEFENSE PEPTIDES; ANTIMICROBIAL PEPTIDE; SMALL-INTESTINE; GOBLET CELLS; PERFORMANCE; MORPHOLOGY; LL-37; INFLAMMATION; PARAMETERS; PROTECTION	Host Defense Peptides (HDPs) such as cathelicidins are multifunctional effectors of the innate immune system with both antimicrobial and pleiotropic immunomodulatory functions. Chicken cathelicidin-2 (CATH-2) has multiple immunomodulatory effects in vitro and the D-amino acid analog of this peptide has been shown to partially protect young chicks from a bacterial infection. However, the mechanisms responsible for CATH-2 mediated in vivo protection have not been investigated so far. In this study, D-CATH-2 was administered in ovo and the immune status and microbiota of the chicks were investigated at 7 days posthatch to elucidate the in vivo mechanisms of the peptide. In three consecutive studies, no effects on numbers and functions of immune cells were found and only small changes were seen in gene expression of Peripheral Blood Mononuclear Cells (PBMCs). In two studies, intestinal microbiota composition was determined which was highly variable, suggesting that it was strongly influenced by environmental factors. In both studies, in ovo D-CATH-2 treatment caused significant reduction of Ruminococcaceae and Butyricicoccus in the cecum and Escherichia/Shigella in both ileum and cecum. In conclusion, this study shows that, in the absence of an infectious stimulus, in ovo administration of a CATH-2 analog alters the microbiota composition but does not affect the chicks' immune system posthatch.	[Cuperus, Tryntsje; Kraaij, Marina D.; van Dijk, Albert; Haagsman, Henk P.] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Mol Host Def, Utrecht, Netherlands; [Zomer, Aldert L.] Univ Utrecht, Div Clin Infectiol, Dept Infect Dis & Immunol, Fac Vet Med, Utrecht, Netherlands	Utrecht University; Utrecht University	Haagsman, HP (corresponding author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Mol Host Def, Utrecht, Netherlands.	h.p.haagsman@uu.nl	Haagsman, Henk P/F-8919-2010	Haagsman, Henk/0000-0002-4931-5201; Zomer, Aldert/0000-0002-0758-5190	Immuno Valley ALTernatives to ANTibiotics (ALTANT) Animal Specific Immunomodulatory Antimicrobials (ASIA) program of the Dutch Ministry of Economic Affairs	Immuno Valley ALTernatives to ANTibiotics (ALTANT) Animal Specific Immunomodulatory Antimicrobials (ASIA) program of the Dutch Ministry of Economic Affairs	The work was supported by the Immuno Valley ALTernatives to ANTibiotics (ALTANT) Animal Specific Immunomodulatory Antimicrobials (ASIA) program of the Dutch Ministry of Economic Affairs. This program is a public-private partnership. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baranska-Rybak W, 2006, J ANTIMICROB CHEMOTH, V57, P260, DOI 10.1093/jac/dki460; Bassett SA, 2015, NUTRIENTS, V7, P1798, DOI 10.3390/nu7031798; Baurhoo B, 2009, POULTRY SCI, V88, P2262, DOI 10.3382/ps.2008-00562; Biesbroek G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032942; Brown KL, 2011, J IMMUNOL, V186, P5497, DOI 10.4049/jimmunol.1002508; Cheled-Shoval SL, 2011, POULTRY SCI, V90, P2301, DOI 10.3382/ps.2011-01488; Chen LP, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000051; CHENG GY, 2014, FRONT MICROBIOL, V0005; Cole JR, 2003, NUCLEIC ACIDS RES, V31, P442, DOI 10.1093/nar/gkg039; Coorens M, 2015, J IMMUNOL, V195, P3970, DOI 10.4049/jimmunol.1501242; Cuperus T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26622; Czerwinski J, 2012, ARCH ANIM NUTR, V66, P102, DOI 10.1080/1745039X.2012.663668; Fasina YO, 2010, AVIAN DIS, V54, P841, DOI 10.1637/9055-090809-Reg.1; Funkhouser LJ, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001631; Guard BC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127259; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Hildebrand F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r4; Hou M, 2013, CELL PHYSIOL BIOCHEM, V32, P614, DOI 10.1159/000354465; Kabat AM, 2014, TRENDS IMMUNOL, V35, P507, DOI 10.1016/j.it.2014.07.010; Kandasamy SK, 2006, BBA-BIOMEMBRANES, V1758, P1274, DOI 10.1016/j.bbamem.2006.02.030; Kizerwetter-Swida M, 2008, J ANIM FEED SCI, V17, P224, DOI 10.22358/jafs/66602/2008; Kogut MH, 2007, INT IMMUNOPHARMACOL, V7, P912, DOI 10.1016/j.intimp.2007.02.011; Kogut MH, 2010, FOODBORNE PATHOG DIS, V7, P23, DOI 10.1089/fpd.2009.0346; Kovach MA, 2012, J IMMUNOL, V189, P304, DOI 10.4049/jimmunol.1103196; Lu J, 2008, ANIMAL, V2, P669, DOI 10.1017/S1751731108001894; Luna L, 1968, AFIP MANUAL OF HISTO; Mansour SC, 2014, TRENDS IMMUNOL, V35, P443, DOI 10.1016/j.it.2014.07.004; Margaritis T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.21; McCafferty J, 2013, ISME J, V7, P2116, DOI 10.1038/ismej.2013.106; Murakami T, 2009, INT IMMUNOL, V21, P905, DOI 10.1093/intimm/dxp057; Nijnik A, 2010, J IMMUNOL, V184, P2539, DOI 10.4049/jimmunol.0901813; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Pound LD, 2015, DIABETES, V64, P4135, DOI 10.2337/db15-0788; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Rubio LA, 2015, J ANIM PHYSIOL AN N, V99, P418, DOI 10.1111/jpn.12256; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schubert AM, 2014, MBIO, V5, DOI 10.1128/mBio.01021-14; Scott MG, 2007, NAT BIOTECHNOL, V25, P465, DOI 10.1038/nbt1288; Stanley D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084290; Stecher B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000711; Steinstraesser L, 2011, IMMUNOBIOLOGY, V216, P322, DOI 10.1016/j.imbio.2010.07.003; Tai EKK, 2008, J CELL BIOCHEM, V104, P251, DOI 10.1002/jcb.21615; Tamburini S, 2016, NAT MED, V22, P713, DOI 10.1038/nm.4142; Thorkildsen LT, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/636785; Tomkovich S, 2016, IMMUNOLOGY, V147, P1, DOI 10.1111/imm.12538; Uni Z, 2003, POULTRY SCI, V82, P1747, DOI 10.1093/ps/82.11.1747; Uni Z, 2003, POULTRY SCI, V82, P320, DOI 10.1093/ps/82.2.320; UNI Z, 1995, POULTRY SCI, V74, P1622, DOI 10.3382/ps.0741622; van Dijk A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147919; van Wageningen S, 2010, CELL, V143, P991, DOI 10.1016/j.cell.2010.11.021; Wang L, 2014, J MOL MICROB BIOTECH, V24, P234, DOI 10.1159/000365572; Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115; Wu ZG, 2010, IMMUNOLOGY, V129, P133, DOI 10.1111/j.1365-2567.2009.03129.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yi HB, 2016, SCI REP-UK, V6, DOI 10.1038/srep25679	57	8	8	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2018	13	6							e0198188	10.1371/journal.pone.0198188	http://dx.doi.org/10.1371/journal.pone.0198188			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GI1KD	29870564	Green Published, gold			2023-01-03	WOS:000434128400014
J	Gaube, S; Tsivrikos, D; Dollinger, D; Lermer, E				Gaube, Susanne; Tsivrikos, Dimitrios; Dollinger, Daniel; Lermer, Eva			How a smiley protects health: A pilot intervention to improve hand hygiene in hospitals by activating injunctive norms through emoticons	PLOS ONE			English	Article							CARE WORKERS; BEHAVIOR-CHANGE; TRANSMISSION; ADHERENCE; FEEDBACK; PERCEPTIONS; TECHNOLOGY; GUIDELINES; ATTITUDES; VISITORS	Hand hygiene practice in hospitals is unfortunately still widely insufficient, even though it is known that transmitting pathogens via hands is the leading cause of healthcare-associated infections. Previous research has shown that improving knowledge, providing feedback on past behaviour and targeting social norms are promising approaches to improve hand hygiene practices. The present field experiment was designed to direct people on when to perform hand hygiene and prevent forgetfulness. This intervention is the first to examine the effect of inducing injunctive social norms via an emoticon-basedfeed back system on hand hygiene behaviour. Electronic monitoring and feedback devices were installed in hospital patient rooms on top of hand-rub dispensers, next to the doorway, for a period of 17 weeks. In the emoticon condition, screens at the devices activated whenever a person entered or exited the room. Before using the alcohol-based hand-rub dispenser, a frowny face was displayed, indicating that hand hygiene should be performed. If the dispenser was subsequently used, this picture changed to a smiley face to positively reinforce the correct behaviour. Hand hygiene behaviour in the emoticon rooms significantly outperformed the behaviour in three other tested conditions. The strong effect in this field experiment indicates that activating injunctive norms may be a promising approach to improve hand hygiene behaviour. Theoretical and practical implications of these findings are discussed.	[Gaube, Susanne; Lermer, Eva] Univ Regensburg, Dept Expt Psychol, Regensburg, Germany; [Tsivrikos, Dimitrios] UCL, Div Psychol & Language Sci, London, England; [Dollinger, Daniel] Tech Univ Munich, Inst Flight Syst Dynam, Garching, Germany; [Lermer, Eva] FOM Univ Appl Sci, Munich, Germany	University of Regensburg; University of London; University College London; Technical University of Munich	Gaube, S (corresponding author), Univ Regensburg, Dept Expt Psychol, Regensburg, Germany.	susanne.gaube@psychologie.uni-regensburg.de	Lermer, Eva/AAG-7647-2019	Lermer, Eva/0000-0002-6600-9580; Gaube, Susanne/0000-0002-1633-4772	German Research Foundation (DFG)	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG) within the funding programme Open Access Publishing.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Allegranzi B, 2013, J HOSP INFECT, V83, pS3, DOI 10.1016/S0195-6701(13)60003-1; Allegranzi B, 2009, J HOSP INFECT, V73, P305, DOI 10.1016/j.jhin.2009.04.019; Ardizzone LL, 2013, AM J INFECT CONTROL, V41, P487, DOI 10.1016/j.ajic.2012.05.029; Arien C, 2013, 92 TRB ANN M 2013 20, P1; Armellino D, 2012, CLIN INFECT DIS, V54, P1, DOI 10.1093/cid/cir773; Barnes SL, 2014, INFECT CONT HOSP EP, V35, P1156, DOI 10.1086/677632; Bateson M, 2006, BIOL LETTERS, V2, P412, DOI 10.1098/rsbl.2006.0509; Bateson M, 2015, PEERJ, V3, DOI 10.7717/peerj.1443; Bateson M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082055; Beyfus TA, 2016, AM J INFECT CONTROL, V44, P496, DOI 10.1016/j.ajic.2015.12.021; Birnbach DJ, 2017, J INFECT PUBLIC HEAL, V10, P295, DOI 10.1016/j.jiph.2016.05.015; Birnbach DJ, 2015, J INFECT PUBLIC HEAL, V8, P570, DOI 10.1016/j.jiph.2015.04.027; Birnbach DJ, 2012, AM J INFECT CONTROL, V40, P340, DOI 10.1016/j.ajic.2011.05.006; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; CIALDINI RB, 1990, J PERS SOC PSYCHOL, V58, P1015, DOI 10.1037/0022-3514.58.6.1015; Conway LJ, 2016, AM J INFECT CONTROL, V44, pE7, DOI 10.1016/j.ajic.2015.11.031; ECDC, ECDC ANN REP EUR ANT; Eiamsitrakoon T, 2013, INFECT CONT HOSP EP, V34, P1137, DOI 10.1086/673446; Ekstrom M, 2012, EXP ECON, V15, P530, DOI 10.1007/s10683-011-9312-6; Ellingson K, 2011, INFECT CONT HOSP EP, V32, P1091, DOI 10.1086/662179; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Ernest-Jones M, 2011, EVOL HUM BEHAV, V32, P172, DOI 10.1016/j.evolhumbehav.2010.10.006; European Centre for Disease Prevention and Control, ANN EP REP COMM DIS; Fisher DA, 2013, INFECT CONT HOSP EP, V34, P919, DOI 10.1086/671738; Fuller C, 2014, AM J INFECT CONTROL, V42, P106, DOI 10.1016/j.ajic.2013.07.019; Fuller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041617; Godin G, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-36; Gould DJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005186.pub3; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Haley KJ, 2005, EVOL HUM BEHAV, V26, P245, DOI 10.1016/j.evolhumbehav.2005.01.002; Huis A, 2013, INT J NURS STUD, V50, P464, DOI 10.1016/j.ijnurstu.2012.08.004; Huis A, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-92; Hysong SJ, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-9; Istenes N, 2013, AM J INFECT CONTROL, V41, P793, DOI 10.1016/j.ajic.2012.11.012; King D, 2016, HEALTH PSYCHOL, V35, P96, DOI 10.1037/hea0000239; Kommission fur Krankenhaushygiene und Infektionspravention (KRINKO), 2016, BUNDESGESUNDHEITSBLA, V59, P1189, DOI [DOI 10.1007/S00103-016-2416-6, 10.1007/s00103-016-2416-6]; Kuliga S, 2011, P ENV 2 0 P 9 BIENN; Luangasanatip N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3728; Marra AR, 2014, AM J INFECT CONTROL, V42, P608, DOI 10.1016/j.ajic.2014.02.006; McLaws ML, 2012, AM J INFECT CONTROL, V40, P336, DOI 10.1016/j.ajic.2011.04.004; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Naikoba S, 2001, J HOSP INFECT, V47, P173, DOI 10.1053/jhin.2000.0882; Nettle D, 2013, EVOL HUM BEHAV, V34, P35, DOI 10.1016/j.evolhumbehav.2012.08.004; Nomura H, 2011, LOCAL ENVIRON, V16, P637, DOI 10.1080/13549839.2011.586026; Northover SB, 2017, EVOL HUM BEHAV, V38, P144, DOI 10.1016/j.evolhumbehav.2016.07.001; O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.18405; Oda R, 2015, EVOL PSYCHOL-US, V13, DOI 10.1177/1474704915594959; Pessoa-Silva CL, 2005, INFECT CONT HOSP EP, V26, P305, DOI 10.1086/502544; Pittet D, 2004, ANN INTERN MED, V141, P1, DOI 10.7326/0003-4819-141-1-200407060-00008; Porzig-Drummond R, 2009, SOC SCI MED, V68, P1006, DOI 10.1016/j.socscimed.2009.01.013; Powell KL, 2012, ETHOLOGY, V118, P1096, DOI 10.1111/eth.12011; Sax H, 2007, INFECT CONT HOSP EP, V28, P1267, DOI 10.1086/521663; Schultz PW, 2007, PSYCHOL SCI, V18, P429, DOI 10.1111/j.1467-9280.2007.01917.x; Schultz PW, 2016, ENVIRON BEHAV, V48, P686, DOI 10.1177/0013916514553835; Schweizer ML, 2014, CLIN INFECT DIS, V58, P248, DOI 10.1093/cid/cit670; Shlomai NO, 2015, EUR J CLIN MICROBIOL, V34, P887, DOI 10.1007/s10096-015-2313-1; Srigley JA, 2015, J HOSP INFECT, V91, P202, DOI 10.1016/j.jhin.2015.06.019; Srigley JA, 2015, J HOSP INFECT, V89, P51, DOI 10.1016/j.jhin.2014.10.005; Sroka S, 2010, J HOSP INFECT, V74, P204, DOI 10.1016/j.jhin.2009.08.023; Storey SJ, 2014, J HOSP INFECT, V88, P84, DOI 10.1016/j.jhin.2014.06.014; Venkatesh AK, 2008, AM J INFECT CONTROL, V36, P199, DOI 10.1016/j.ajic.2007.11.005; von Lengerke T, 2016, PSYCHOL HANDEHYGIENE, DOI [10.1055/s-0042-107371, DOI 10.1055/S-0042-107371]; Whitby M, 2006, INFECT CONT HOSP EP, V27, P484, DOI 10.1086/503335; World Health Organization, REP BURD END HLTH CA; World Health Organization (WHO), WHO GUID HAND HYG HL	67	18	18	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2018	13	5							e0197465	10.1371/journal.pone.0197465	http://dx.doi.org/10.1371/journal.pone.0197465			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GG2QJ	29782516	Green Published, Green Submitted, gold			2023-01-03	WOS:000432537100024
J	Gama, ADS; de Paula, M; da Silva, RRV; Ferreira, WS; de Medeiros, PM				Sena Gama, Aline Dourado; de Paula, Marcelo; Vasconcelos da Silva, Rafael Ricardo; Ferreira Junior, Washington Soares; de Medeiros, Patricia Muniz			Exotic species as models to understand biocultural adaptation: Challenges to mainstream views of human-nature relations	PLOS ONE			English	Article							LOCAL ECOLOGICAL KNOWLEDGE; COST-BENEFIT-ANALYSIS; MAPUCHE COMMUNITY; GENETIC-VARIATION; MEDICINAL-PLANTS; TEHUACAN VALLEY; CLIMATE-CHANGE; EVOLUTION; DOMESTICATION; ENVIRONMENTS	A central argument in the research on traditional knowledge, which persists in the scientific literature, is that the entrance of exotic plants in local medical systems is directly associated with acculturation. However, this logic has put an end for a long period to efforts to understand why such species have so successfully entered socio-ecological systems or even their real role in such systems. This study provides evidence that (1) in some socio-environmental contexts, exotic medicinal species usually confer greater adaptive advantages to local populations, and (2) despite their general importance, exotic species only excel in medical systems when cost-benefit ratio is favorable to them. Thus, in order to avoid the loss of knowledge about native plants and to ensure biocultural conservation, it is necessary to create strategies to amplify the advantages of these species.	[Sena Gama, Aline Dourado; de Paula, Marcelo] Univ Fed Oeste Bahia, Programa Posgrad Ciencias Ambientais, Estr Barrocao, Barreiras, BA, Brazil; [Vasconcelos da Silva, Rafael Ricardo; de Medeiros, Patricia Muniz] Univ Fed Alagoas, Ctr Ciencias Agr, Rio Largo, Alagoas, Brazil; [Ferreira Junior, Washington Soares] Univ Pernambuco, Campus Petrolina, Petrolina, PE, Brazil	Universidade Federal do Oeste da Bahia; Universidade Federal de Alagoas; Universidade de Pernambuco (UPE)	de Medeiros, PM (corresponding author), Univ Fed Alagoas, Ctr Ciencias Agr, Rio Largo, Alagoas, Brazil.	patricia.medeiros@ceca.ufal.br	Júnior, Washington Soares Ferreira/F-8600-2018; de Medeiros, Patricia Muniz/H-7198-2012; da Silva, Rafael Ricardo Vasconcelos/AAS-2412-2020	Júnior, Washington Soares Ferreira/0000-0002-3128-0514; de Medeiros, Patricia Muniz/0000-0002-3835-5232; da Silva, Rafael Ricardo Vasconcelos/0000-0003-4296-0117	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [441550/2014-2, 302786/2016-3]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (proc. 441550/2014-2 and proc. 302786/2016-3), http://www.cnpq.br/.; The authors thank the community of Morrao de Cima for the reception and willingness to participate in the study. The authors also thank Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) for the research grant (proc. 441550/2014-2) and productivity grant (proc. 302786/2016-3) given to P.M.M.	Albuquerque Ulysses Paulino, 2015, EVOLUTIONARY ETHNOBI; Alencar NL, 2014, REV BRAS FARMACOGN, V24, P506, DOI 10.1016/j.bjp.2014.09.003; Alencar NL, 2010, ECON BOT, V64, P68, DOI 10.1007/s12231-009-9104-5; Alexiades MN., 1996, SELECTED GUIDELINES; Atallah DG, 2016, INT J DISAST RISK RE, V19, P92, DOI 10.1016/j.ijdrr.2016.08.027; Barton L, 2016, ARCHAEOL RES ASIA, V5, P4, DOI 10.1016/j.ara.2016.01.001; BEGOSSI A, 1993, INTERCIENCIA, V18, P121; Bennett BC, 2000, ECON BOT, V54, P90, DOI 10.1007/BF02866603; Berkes F, 2000, ECOL APPL, V10, P1251, DOI 10.2307/2641280; Blanco J, 2016, J ARID ENVIRON, V127, P30, DOI 10.1016/j.jaridenv.2015.10.021; Casas A, 1997, ECON BOT, V51, P279, DOI 10.1007/BF02862097; Chou CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107869; de Albuquerque UP, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-30; de Medeiros PM, 2015, J ETHNOPHARMACOL, V159, P43, DOI 10.1016/j.jep.2014.11.001; de Medeiros PM, 2013, ETHNOBIOL CONSERV, V2, DOI 10.15451/ec2013-8-2.3-1-05; Estomba D, 2006, J ETHNOPHARMACOL, V103, P109, DOI 10.1016/j.jep.2005.07.015; Ferreira Junior WS., 2015, EVOLUTIONARY ETHNOBI, P105, DOI DOI 10.1007/978-3-319-19917-7; GUIMARAES M. P., 2016, THESIS; HAWKES K, 1982, AM ETHNOL, V9, P379, DOI 10.1525/ae.1982.9.2.02a00100; Hu Y, 2007, BIOMED CHROMATOGR, V21, P967, DOI 10.1002/bmc.841; IBGE, 2015, CID I BRAS GEOGR EST; JOHNS T, 1990, ORIGINS HUMAN DIET M; Kameda T, 2002, EVOL HUM BEHAV, V23, P373, DOI 10.1016/S1090-5138(02)00101-0; Kendal RL, 2005, ADV STUD BEHAV, V35, P333, DOI 10.1016/S0065-3454(05)35008-X; Kormondy Edward John, 1998, FUNDAMENTALS HUMAN E; Ladio AH, 2004, BIODIVERS CONSERV, V13, P1153, DOI 10.1023/B:BIOC.0000018150.79156.50; Ladio AH, 2003, BIODIVERS CONSERV, V12, P937, DOI 10.1023/A:1022873725432; Levine J, 2015, ECOL ECON, V114, P22, DOI 10.1016/j.ecolecon.2015.03.010; Linstadter A, 2013, J ARID ENVIRON, V95, P30, DOI 10.1016/j.jaridenv.2013.03.008; Medeiros P. M., 2015, EVOLUTIONARY ETHNOBI, P7; MEDEIROS P. V. Q., 2012, THESIS; Moro MF, 2012, ACTA BOT BRAS, V26, P991, DOI 10.1590/S0102-33062012000400029; Orlove B, 2005, ENVIRON SCI POLICY, V8, P589, DOI 10.1016/j.envsci.2005.06.009; Otero-Arnaiz A, 2005, MOL ECOL, V14, P1603, DOI 10.1111/j.1365-294X.2005.02494.x; Pavlovic A, 2015, ANN BOT-LONDON, V115, P1075, DOI 10.1093/aob/mcv050; Peroni N, 2007, GENET RESOUR CROP EV, V54, P1333, DOI 10.1007/s10722-006-9116-2; PHILLIPS O, 1993, ECON BOT, V47, P33, DOI 10.1007/BF02862204; REYER HU, 1984, ANIM BEHAV, V32, P1163, DOI 10.1016/S0003-3472(84)80233-X; ROUGHGARDEN J, 1975, ECOLOGY, V56, P1201, DOI 10.2307/1936160; Goncalves PHS, 2016, ECOL APPL, V26, P2238, DOI 10.1002/eap.1364; Saslis-Lagoudakis CH, 2012, P NATL ACAD SCI USA, V109, P15835, DOI 10.1073/pnas.1202242109; Schluter M, 2017, ECOL ECON, V131, P21, DOI 10.1016/j.ecolecon.2016.08.008; Sieber SS, 2011, J AGR ENVIRON ETHIC, V24, P511, DOI 10.1007/s10806-010-9277-z; Sih A, 2001, ANIM BEHAV, V61, P379, DOI 10.1006/anbe.2000.1592; SMITH EA, 1983, CURR ANTHROPOL, V24, P625, DOI 10.1086/203066; Winterhalder B, 2000, EVOL ANTHROPOL, V9, P51; Worm B, 2016, TRENDS ECOL EVOL, V31, P600, DOI 10.1016/j.tree.2016.05.008; Wu Xiaoxu, 2016, Environ Int, V86, P14, DOI 10.1016/j.envint.2015.09.007; Yang ST, 2011, PLANTA MED, V77, P865, DOI 10.1055/s-0030-1250601	49	16	18	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2018	13	4							e0196091	10.1371/journal.pone.0196091	http://dx.doi.org/10.1371/journal.pone.0196091			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE3RI	29708981	gold, Green Published, Green Submitted			2023-01-03	WOS:000431130100014
J	Wu, WC; Taveira, TH; Jeffery, S; Jiang, L; Tokuda, L; Musial, J; Cohen, LB; Uhrle, F				Wu, Wen-Chih; Taveira, Tracey H.; Jeffery, Sean; Jiang, Lan; Tokuda, Lisa; Musial, Joanna; Cohen, Lisa B.; Uhrle, Fred			Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial	PLOS ONE			English	Article							CHRONIC ILLNESS; HEART-DISEASE; PRIMARY-CARE; MANAGEMENT; MODEL	Objectives The effectiveness and costs associated with addition of pharmacist- led group medical visits to standard care for patients with Type-2 Diabetes Mellitus (T2DM) is unknown. Methods Randomized-controlled-trial in three US Veteran Health Administration (VHA) Hospitals, where 250 patients with T2DM, HbA1c >7% and either hypertension, active smoking or hyperlipidemia were randomized to either (1) addition of pharmacist- led group-medical-visits or (2) standard care alone for 13 months. Group (4-6 patients) visits consisted of 2-hour, education and comprehensive medication management sessions once weekly for 4 weeks, followed by quarterly visits. Change from baseline in cardiovascular risk estimated by the UKPDS-risk-score, health-related quality-of-life (SF36v) and institutional healthcare costs were compared between study arms. Results After 13 months, both groups had similar and significant improvements from baseline in UKPDS-risk-score (-0.02 +/- 0.09 and -0.04 +/- 0.09, group visit and standard care respectively, adjusted p<0.05 for both); however, there was no significant difference between the study arms (adjusted p = 0.45). There were no significant differences on improvement from baseline in A1c, systolic-blood-pressure, and LDL as well as health-related quality-of-life measures between the study arms. Compared to 13 months prior, the increase in per-person outpatient expenditure from baseline was significantly lower in the group visit versus the standard care arm, both during the study intervention period and at 13-months after study interventions. The overall VHA healthcare costs/person were comparable between the study arms during the study period (p = 0.15); then decreased by 6% for the group visit but increased by 13% for the standard care arm 13 months post-study (p<0.01). Conclusions Addition of pharmacist-led group medical visits in T2DM achieved similar improvements from baseline in cardiovascular risk factors than usual care, but with reduction in the health-care costs in the group visit arm 13 months after completion compared to the steady rise in cost for the usual care arm.	[Wu, Wen-Chih; Taveira, Tracey H.; Jiang, Lan; Cohen, Lisa B.] VA Med Ctr, Ctr Innovat Long Term Serv & Supports Vulnerable, Providence, RI 02908 USA; [Wu, Wen-Chih; Taveira, Tracey H.] Brown Univ, Dept Med, Providence, RI 02912 USA; [Wu, Wen-Chih; Taveira, Tracey H.; Cohen, Lisa B.] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA; [Jeffery, Sean; Musial, Joanna] Univ Connecticut, Sch Pharm, Storrs, CT USA; [Jeffery, Sean] West Haven VA Med Ctr, West Haven, CT USA; [Tokuda, Lisa; Uhrle, Fred] VA Pacific Isl Hlth Care Syst, Honolulu, HI USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Brown University; University of Rhode Island; University of Connecticut	Wu, WC (corresponding author), VA Med Ctr, Ctr Innovat Long Term Serv & Supports Vulnerable, Providence, RI 02908 USA.; Wu, WC (corresponding author), Brown Univ, Dept Med, Providence, RI 02912 USA.; Wu, WC (corresponding author), Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA.	Wen-Chih.Wu@va.gov	Musiał, Jacek/U-5930-2018	Musiał, Jacek/0000-0002-8994-0036	US Department of Veterans Affairs Health Services Research & Development Merit Review Award [IAB - 06-269]	US Department of Veterans Affairs Health Services Research & Development Merit Review Award	This work is supported by the US Department of Veterans Affairs Health Services Research & Development Merit Review Award IAB - 06-269. Support includes study execution funds and staff salary support.	[Anonymous], 2016, Diabetes Care, V39 Suppl 1, pS4, DOI 10.2337/dc16-S003; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2010, HEALTH AFFAIR, V29, P799, DOI 10.1377/hlthaff.2010.0026; Casagrande SS, 2013, AM J PREV MED, V45, P167, DOI 10.1016/j.amepre.2013.02.026; Centers for Disease Control, 2004, BURD CHRON DIS THEIR; Edelman D, 2012, SHARED MED APPOINMEN; Edelman D, 2010, ANN INTERN MED, V152, P689, DOI 10.7326/0003-4819-152-11-201006010-00001; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Giberson S, 2011, 50 US PUBL HLTH SERV, DOI [10.1002/phar.1563, DOI 10.1002/PHAR.1563]; Haas L, 2012, DIABETES CARE, V35, P2393, DOI 10.2337/dc12-1707; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Housden L, 2013, CAN MED ASSOC J, V185, pE635, DOI 10.1503/cmaj.130053; Jackson GL, 2013, JAMA INTERN MED, V173, P590, DOI 10.1001/jamainternmed.2013.2803; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Kazis LE, 2004, HEALTH CARE FINANC R, V25, P43; McBane SE, 2015, PHARMACOTHERAPY, V35, pE39, DOI 10.1002/phar.1563; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Noffsinger E., 1999, GROUP PRACT J, V358, P12; Oddone E, 2012, SHARED MED APPOINTME; Riley SB, 2010, DIABETES EDUCATOR, V36, P936, DOI 10.1177/0145721710385013; Rosenzweig JL, 2002, AM J MANAG CARE, V8, P950; Smith M, 2013, HEALTH AFFAIR, V32, P1963, DOI 10.1377/hlthaff.2013.0542; Smith MW, 2005, MICRO COST METHODS D; Society MM, 2011, ACC HLTH CAR MASS IM; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Taveira TH, 2011, ANN PHARMACOTHER, V45, P1346, DOI 10.1345/aph.1Q212; Taveira TH, 2010, DIABETES EDUCATOR, V36, P109, DOI 10.1177/0145721709352383; UK Prospective Diabetes Study (UKPDS) Group, 1998, BMJ, V317; VA/ DoD Clinical Practice Guideline, 2010, MAN DIAB MELL PRIM C; Veterans Health Administration, 2005, DEC SUPP OFF DEC SUP; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Weinger K, 2003, DIABETES SPECTRUM, V16, P104, DOI DOI 10.2337/	33	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2018	13	4							e0195898	10.1371/journal.pone.0195898	http://dx.doi.org/10.1371/journal.pone.0195898			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD4BF	29672567	Green Published, gold			2023-01-03	WOS:000430446800057
J	Pairet, N; Mang, S; Fois, G; Keck, M; Kuhnbach, M; Gindele, J; Frick, M; Dietl, P; Lamb, DJ				Pairet, N.; Mang, S.; Fois, G.; Keck, M.; Kuehnbach, M.; Gindele, J.; Frick, M.; Dietl, P.; Lamb, D. J.			TRPV4 inhibition attenuates stretch-induced inflammatory cellular responses and lung barrier dysfunction during mechanical ventilation	PLOS ONE			English	Article							POTENTIAL VANILLOID 4; RESPIRATORY-DISTRESS-SYNDROME; RUTHENIUM RED; ALVEOLAR MACROPHAGES; CYTOKINE RELEASE; CATION CHANNEL; IN-VITRO; EPITHELIAL-CELLS; PULMONARY-EDEMA; INJURY	Mechanical ventilation is an important tool for supporting critically ill patients but may also exert pathological forces on lung cells leading to Ventilator-Induced Lung Injury (VILI). We hypothesised that inhibition of the force-sensitive transient receptor potential vanilloid (TRPV4) ion channel may attenuate the negative effects of mechanical ventilation. Mechanical stretch increased intracellular Ca2+ influx and induced release of pro-inflammatory cytokines in lung epithelial cells that was partially blocked by about 30% with the selective TRPV4 inhibitor GSK2193874, but nearly completely blocked with the pan-calcium channel blocker ruthenium red, suggesting the involvement of more than one calcium channel in the response to mechanical stress. Mechanical stretch also induced the release of pro-inflammatory cytokines from M1 macrophages, but in contrast this was entirely dependent upon TRPV4. In a murine ventilation model, TRPV4 inhibition attenuated both pulmonary barrier permeability increase and pro-inflammatory cytokines release due to high tidal volume ventilation. Taken together, these data suggest TRPV4 inhibitors may have utility as a prophylactic pharmacological treatment to improve the negative pathological stretch-response of lung cells during ventilation and potentially support patients receiving mechanical ventilation.	[Pairet, N.; Mang, S.; Keck, M.; Kuehnbach, M.; Gindele, J.; Lamb, D. J.] Boehringer Ingelheim Pharma GmbH & Co KG, Immunol & Resp Dis Res, Biberach, Germany; [Pairet, N.; Fois, G.; Gindele, J.; Frick, M.; Dietl, P.] Univ Ulm, Dept Gen Physiol, Ulm, Germany; [Mang, S.] Hannover Med Sch, Inst Immunol, Hannover, Germany	Boehringer Ingelheim; Ulm University; Hannover Medical School	Pairet, N (corresponding author), Boehringer Ingelheim Pharma GmbH & Co KG, Immunol & Resp Dis Res, Biberach, Germany.; Pairet, N (corresponding author), Univ Ulm, Dept Gen Physiol, Ulm, Germany.	nicolas.pairet@web.de	Frick, Manfred/E-1374-2012; Fois, Giorgio/AAD-5657-2022	Frick, Manfred/0000-0002-4763-1104; Fois, Giorgio/0000-0001-5414-1149	Boehringer Ingelheim Pharma GmbH Co. KG	Boehringer Ingelheim Pharma GmbH Co. KG(Boehringer Ingelheim)	Boehringer Ingelheim Pharma GmbH & Co. KG did not play a role in the study and only provided financial support in the form of authors' salaries and/or research materials. The funder provided support in the form of salaries for authors [N Pairet, D Lamb, J Gindele, M Keck, S Mang, M Kuhnbach], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alvarez DF, 2006, CIRC RES, V99, P988, DOI 10.1161/01.RES.0000247065.11756.19; Balakrishna S, 2014, AM J PHYSIOL-LUNG C, V307, pL158, DOI 10.1152/ajplung.00065.2014; Beitler JR, 2016, CRIT CARE MED, V44, P91, DOI 10.1097/CCM.0000000000001355; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; Carrasco Loza R, 2015, Open Respir Med J, V9, P112, DOI 10.2174/1874306401509010112; Cheung M, 2017, ACS MED CHEM LETT, V8, P549, DOI 10.1021/acsmedchemlett.7b00094; DEINUM J, 1985, BIOCHIM BIOPHYS ACTA, V838, P197, DOI 10.1016/0304-4165(85)90079-0; Dos Santos CC, 2000, J APPL PHYSIOL, V89, P1645, DOI 10.1152/jappl.2000.89.4.1645; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; Eyal FG, 2007, INTENS CARE MED, V33, P1212, DOI 10.1007/s00134-007-0651-x; Frank J, 2002, CRITICAL CARE, V7, P233, DOI DOI 10.1186/CC1829; Frank JA, 2006, AM J PHYSIOL-LUNG C, V291, pL1191, DOI 10.1152/ajplung.00055.2006; Gerstmair A, 2009, J APPL PHYSIOL, V107, P613, DOI 10.1152/japplphysiol.00012.2009; Halbertsma FJJ, 2005, NETH J MED, V63, P382; Hamanaka K, 2007, AM J PHYSIOL-LUNG C, V293, pL923, DOI 10.1152/ajplung.00221.2007; Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009; Hegeman MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057374; Henry CO, 2016, AM J PHYSIOL-LUNG C, V311, pL664, DOI 10.1152/ajplung.00442.2015; Jurek SC, 2014, AM J RESP CELL MOL, V50, P1107, DOI 10.1165/rcmb.2013-0163OC; Kuebler WM, 2002, AM J PHYSIOL-LUNG C, V282, pL917, DOI 10.1152/ajplung.00275.2001; Mang S, 2018, AM J RESP C IN PRESS; Matthews BD, 2010, INTEGR BIOL-UK, V2, P435, DOI 10.1039/c0ib00034e; Michalick L, 2017, ANESTHESIOLOGY, V126, P300, DOI 10.1097/ALN.0000000000001443; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; Nayak PS, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0224-4; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Parker JC, 1998, J APPL PHYSIOL, V84, P1113, DOI 10.1152/jappl.1998.84.4.1113; Protti A, 2014, CURR OPIN CRIT CARE, V20, P33, DOI 10.1097/MCC.0000000000000047; Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040, DOI 10.1152/ajplung.1998.275.6.L1040; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; ROYALL JA, 1989, AM J PHYSIOL, V257, pL399, DOI 10.1152/ajplung.1989.257.6.L399; SASAKI T, 1992, J BIOL CHEM, V267, P21518; Scheraga RG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00503; Scheraga RG, 2016, J IMMUNOL, V196, P428, DOI 10.4049/jimmunol.1501688; Schneider C, 2014, NAT IMMUNOL, V15, P1026, DOI 10.1038/ni.3005; Slutsky AS, 2003, INTENS CARE MED, V29, P1218, DOI 10.1007/s00134-003-1793-0; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Takahashi N, 2011, CELL CALCIUM, V50, P279, DOI 10.1016/j.ceca.2011.04.006; Tao F, 2002, AM J RESP CELL MOL, V26, P499, DOI 10.1165/ajrcmb.26.4.4749; Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Vincent F, 2009, BIOCHEM BIOPH RES CO, V389, P490, DOI 10.1016/j.bbrc.2009.09.007; Vlahakis NE, 1999, AM J PHYSIOL-LUNG C, V277, pL167, DOI 10.1152/ajplung.1999.277.1.L167; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Yamada A, 2000, BIOCHEM J, V349, P797, DOI 10.1042/bj3490797; Yamashiro K, 2010, BIOCHEM BIOPH RES CO, V398, P284, DOI 10.1016/j.bbrc.2010.06.082; Yin J, 2016, AM J RESP CELL MOL, V54, P370, DOI 10.1165/rcmb.2014-0225OC; Yin J, 2010, CELL BIOCHEM BIOPHYS, V56, P1, DOI 10.1007/s12013-009-9067-2; Zhang F, 2007, J CELL PHYSIOL, V213, P730, DOI 10.1002/jcp.21141	55	30	34	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2018	13	4							e0196055	10.1371/journal.pone.0196055	http://dx.doi.org/10.1371/journal.pone.0196055			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD1LV	29664963	Green Published, Green Submitted, gold			2023-01-03	WOS:000430262300052
J	Shimada, T; Ohori, M; Inagaki, Y; Shimooka, Y; Sugimura, N; Ishihara, I; Yoshida, T; Kobayashi, M				Shimada, Takeshi; Ohori, Manami; Inagaki, Yusuke; Shimooka, Yoko; Sugimura, Naoya; Ishihara, Ikuyo; Yoshida, Tomotaka; Kobayashi, Masayoshi			A multicenter, randomized controlled trial of individualized occupational therapy for patients with schizophrenia in Japan	PLOS ONE			English	Article							INTRINSIC MOTIVATION; PREDICTIVE-VALIDITY; SOCIAL FUNCTION; COGNITION; NEUROCOGNITION; INPATIENTS; DEFICITS; SCALE; METACOGNITION; METAANALYSIS	The individualized occupational therapy (IOT) program is a psychosocial program that we developed to facilitate proactive participation in treatment and improve cognitive functioning and other outcomes for inpatients with acute schizophrenia. The program consists of motivational interviewing, self-monitoring, individualized visits, handicraft activities, individualized psychoeducation, and discharge planning. This multicenter, open-labeled, blinded-endpoint, randomized controlled trial evaluated the impact of adding IOT to a group OT (GOT) program as usual for outcomes in recently hospitalized patients with schizophrenia in Japanese psychiatric hospitals setting compared with GOT alone. Patients with schizophrenia were randomly assigned to the GOT+IOT group or the GOT alone group. Among 136 randomized patients, 129 were included in the intent-to-treat population: 66 in the GOT+IOT and 63 in the GOT alone groups. Outcomes were administered at baseline and discharge or 3 months following hospitalization including the Brief Assessment of Cognition in Schizophrenia Japanese version (BACS-J), the Schizophrenia Cognition Rating Scale Japanese version, the Social Functioning Scale Japanese version, the Global Assessment of Functioning scale, the Intrinsic Motivation Inventory Japanese version (IMI-J), the Morisky Medication Adherence Scale-8 (MMAS-8), the Positive and Negative Syndrome Scale (PANSS), and the Japanese version of Client Satisfaction Questionnaire-8 (CSQ-8J). Results of linear mixed effects models indicated that the IOT+GOT showed significant improvements in verbal memory (p <0.01), working memory (p = 0.02), verbal fluency (p < 0.01), attention (p < 0.01), and composite score (p < 0.01) on the BACS-J; interest/enjoyment (p < 0.01), value/usefulness (p < 0.01), perceived choice (p < 0.01), and IMI-J total (p < 0.01) on the IMI-J; MMAS-8 score (p < 0.01) compared with the GOT alone. Patients in the GOT+IOT demonstrated significant improvements on the CSQ-8J compared with the GOT alone (p < 0.01). The present findings provide support for the feasibility in implementing an IOT program and its effectiveness for improving cognitive impairment and other outcomes in patients with schizophrenia.	[Shimada, Takeshi; Yoshida, Tomotaka] Mental Support Soyokaze Hosp, Med Corp Seitaikai, Dept Occupat Therapy, Nagano, Japan; [Shimada, Takeshi; Kobayashi, Masayoshi] Shinshu Univ, Grad Sch Med, Dept Hlth Sci, Nagano, Japan; [Ohori, Manami] Azumi Hosp, North Alps Med Ctr, Dept Occupat Therapy, Nagano, Japan; [Inagaki, Yusuke] Nagano Prefectural Mental Wellness Ctr Komagane, Dept Occupat Therapy, Nagano, Japan; [Shimooka, Yoko] Iida Hosp, Social Med Corp Ritsuzankai, Dept Occupat Therapy, Nagano, Japan; [Sugimura, Naoya] Nanshin Hosp, Med Corp Akitsukai, Dept Occupat Therapy, Nagano, Japan; [Ishihara, Ikuyo] Matsuoka Hosp, Med Corp Aiseikai, Dept Occupat Therapy, Nagano, Japan	Shinshu University	Kobayashi, M (corresponding author), Shinshu Univ, Grad Sch Med, Dept Hlth Sci, Nagano, Japan.	mkobaya@shinshu-u.ac.jp			Japanese Association of Occupational Therapists [2016-01]	Japanese Association of Occupational Therapists	This study received a research grant from the Japanese Association of Occupational Therapists (http://www jaot.or.jp/). The grant was obtained by TS, and the grant number was 2016-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addington J, 2010, CURR DIR PSYCHOL SCI, V19, P260, DOI 10.1177/0963721410377743; Allen CK., 1985, OCCUPATIONAL THERAPY; Almerie MQ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009006.pub2; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th; Attkisson C C, 1982, Eval Program Plann, V5, P233, DOI 10.1016/0149-7189(82)90074-X; Barch DM, 2008, J ABNORM PSYCHOL, V117, P776, DOI 10.1037/a0013944; BIRCHWOOD M, 1990, BRIT J PSYCHIAT, V157, P853, DOI 10.1192/bjp.157.6.853; Chan KKS, 2012, CLIN PSYCHOL REV, V32, P535, DOI 10.1016/j.cpr.2012.06.001; Choi J, 2010, SCHIZOPHR RES, V118, P12, DOI 10.1016/j.schres.2009.08.001; Choi J, 2010, SCHIZOPHRENIA BULL, V36, P966, DOI 10.1093/schbul/sbp030; Dickey B, 2003, ARCH GEN PSYCHIAT, V60, P340, DOI 10.1001/archpsyc.60.4.340; Duncombe LW, 2004, AM J OCCUP THER, V58, P272, DOI 10.5014/ajot.58.3.272; Emsley R, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-50; Ferri F, 2012, CONSCIOUS COGN, V21, P1365, DOI 10.1016/j.concog.2012.05.001; Fervaha G, 2014, JAMA PSYCHIAT, V71, P1058, DOI 10.1001/jamapsychiatry.2014.1105; FIDLER GS, 1981, AM J OCCUP THER, V35, P566, DOI 10.5014/ajot.35.9.567; Flavell J. H., 1976, NATURE INTELLIGENCE, DOI DOI 10.1038/HDY.1976.85; Foruzandeh N, 2013, JPN J NURS SCI, V10, P136, DOI 10.1111/j.1742-7924.2012.00211.x; Foussias G, 2015, SCHIZOPHR RES, V166, P276, DOI 10.1016/j.schres.2015.05.019; Goncalves-Bradley DC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub5; Green MF, 1996, AM J PSYCHIAT, V153, P321; Green Michael F, 2014, Schizophr Res Cogn, V1, pe1; Haddock G, 2005, SCHIZOPHRENIA BULL, V31, P697, DOI 10.1093/schbul/sbi029; Harvey PD, 2004, J CLIN PSYCHIAT, V65, P361; Horghagen S, 2014, SCAND J OCCUP THER, V21, P145, DOI 10.3109/11038128.2013.866691; Hoshii J, 2013, CLIN REHABIL, V27, P638, DOI 10.1177/0269215512473136; Johnstone P, 1999, BRIT MED J, V318, P1387, DOI 10.1136/bmj.318.7195.1387; Kahn RS, 2013, JAMA PSYCHIAT, V70, P1107, DOI 10.1001/jamapsychiatry.2013.155; Kaneda Y., 2010, CLIN PSYCHIATR, V52, P1027; Kaneda Y, 2007, PSYCHIAT CLIN NEUROS, V61, P602, DOI 10.1111/j.1440-1819.2007.01725.x; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kayama A, 2014, OCCUPATIONAL THERAPY; Keefe RSE, 2007, ARCH GEN PSYCHIAT, V64, P633, DOI 10.1001/archpsyc.64.6.633; Keefe RSE, 2015, EUR NEUROPSYCHOPHARM, V25, P176, DOI 10.1016/j.euroneuro.2014.06.009; Keefe RSE, 2014, JAMA PSYCHIAT, V71, P987, DOI 10.1001/jamapsychiatry.2014.1281; Keefe Richard S E, 2012, Handb Exp Pharmacol, P11, DOI 10.1007/978-3-642-25758-2_2; Keefe RSE, 2006, AM J PSYCHIAT, V163, P426, DOI 10.1176/appi.ajp.163.3.426; Keefe RSE, 2004, SCHIZOPHR RES, V68, P283, DOI 10.1016/j.schres.2003.09.011; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kreyenbuhl Julie, 2010, Schizophr Bull, V36, P94, DOI 10.1093/schbul/sbp130; Kurtz MM, 2011, CLIN PSYCHOL REV, V31, P663, DOI 10.1016/j.cpr.2011.02.008; Lepage M, 2014, CAN J PSYCHIAT, V59, P5, DOI 10.1177/070674371405900103; Leucht S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008016.pub2; Lysaker PH, 2010, ACTA PSYCHIAT SCAND, V122, P405, DOI 10.1111/j.1600-0447.2010.01554.x; Lysaker PH, 2015, J NERV MENT DIS, V203, P530, DOI 10.1097/NMD.0000000000000323; Lysaker PH, 2011, SCHIZOPHR RES, V131, P214, DOI 10.1016/j.schres.2011.06.011; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Medalia A, 2002, REMEDIATION COGNITIV; Medalia A, 2011, SCHIZOPHRENIA BULL, V37, pS122, DOI 10.1093/schbul/sbr063; Miller WR, 2002, MOTIVATIONAL INTERVI, V2nd, DOI DOI 10.1097/01445442-200305000-00013; Ministry of Health Labour and Welfare, 2015, PAT SURV 2014; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Moritz S, 2011, PSYCHOL MED, V41, P1823, DOI 10.1017/S0033291710002618; Moritz S, 2007, CURR OPIN PSYCHIATR, V20, P619, DOI 10.1097/YCO.0b013e3282f0b8ed; Morriss R, 2013, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858; Murphy SM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001087.pub5; Nakagami E, 2010, SCHIZOPHRENIA BULL, V36, P935, DOI 10.1093/schbul/sbq043; Nelson TO, 1990, PSYCHOL LEARNING MOT; Nemoto T., 2008, JPN B SOC PSYCHIATR, V17, P188; Nuechterlein KH, 2014, AM J PSYCHIATR REHAB, V17, P225, DOI 10.1080/15487768.2014.935674; Nurjannah I, 2014, J CLIN NURS, V23, P1175, DOI 10.1111/jocn.12297; Odes H, 2011, AM J OCCUP THER, V65, P314, DOI 10.5014/ajot.2011.001362; Pekkala ET., 2002, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD002831, 10.1002/14651858.CD002831]; Shimada T, 2016, HONG KONG J OCCUP TH, V28, P7, DOI 10.1016/j.hkjot.2016.10.002; Shimada T, 2016, OCCUP THER INT, V23, P425, DOI 10.1002/oti.1445; Szoke A, 2008, BRIT J PSYCHIAT, V192, P248, DOI 10.1192/bjp.bp.106.029009; TACHIMORI H, 1999, CLIN PSYCHIATR, V41, P711; Tanaka C, 2014, CLIN REHABIL, V28, P740, DOI 10.1177/0269215514521440; Uchiyama N, 2012, CLIN PSYCHIATR, V54, P1201; Velligan DI, 2000, AM J PSYCHIAT, V157, P1317, DOI 10.1176/appi.ajp.157.8.1317; Waters F, 2012, SCHIZOPHRENIA BULL, V38, P741, DOI 10.1093/schbul/sbq144; Woodward ND, 2005, INT J NEUROPSYCHOPH, V8, P457, DOI 10.1017/S146114570500516X; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855	75	18	18	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2018	13	4							e0193869	10.1371/journal.pone.0193869	http://dx.doi.org/10.1371/journal.pone.0193869			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB6TQ	29621261	Green Published, Green Submitted, gold			2023-01-03	WOS:000429206800009
J	Masse, M; Maton, M; Genay, S; Blanchemain, N; Barthelemy, C; Decaudin, B; Odon, P				Masse, Morgane; Maton, Mickael; Genay, Stephanie; Blanchemain, Nicolas; Barthelemy, Christine; Decaudin, Bertrand; Odon, Pascal			In vitro assessment of the influence of intravenous extension set materials on insulin aspart drug delivery	PLOS ONE			English	Article							QUANTITATIVE ANALYTICAL PROCEDURES; PHYSICOCHEMICAL PROPERTIES; LIQUID-CHROMATOGRAPHY; SFSTP PROPOSAL; ADSORPTION; STABILITY; HARMONIZATION; PLASTICIZERS; DEGRADATION; VALIDATION	Insulin is a frequently prescribed drug in hospitals and is usually administered by syringe pumps with an extension line which can be made of various materials. Two insulin solutions were studied: an insulin analogue, Novorapid (R) which contains insulin aspart and two phenolic preservatives (e.g. phenol and metacresol) and Umuline rapide (R) with human insulin and metacresol as preservative. Some studies have indicated interactions between insulin, polyvinyl chloride (PVC) and polyethylene (PE). The aim of this work was to study such interactions between Novorapid (R) or Umuline rapide (R) and infusion extension line materials (PVC, PE and coextruded (PE/PVC)). Insulin solution at 1 IU/mL was infused at 2 mL/h over 24 hours with 16 different extension lines (8 in PVC, 3 in PE and 5 in PE/PVC). Ultra-Fast Liquid Chromatography with diode array detection (UFLC-DAD) was performed to quantify insulin (human and aspart) and preservatives (metacresol and phenol). Limited human insulin sorption was observed thirty minutes after the onset of infusion: 24.3 +/- 12.9%, 3.1 +/- 1.6% and 18.6 +/- 10.0% for PVC, PE and PE/PVC respectively. With insulin aspart, sorption of about 5% was observed at the onset of infusion for all materials. However, there were interactions between phenol and especially metacresol with PVC, but no interactions with PE and PE/PVC. This study shows that insulin interacts with PVC, PE and PE/PVC at the onset of infusion. It also demonstrates that insulin preservatives interact with PVC, which may result in problems of insulin conservation and conformation. Some more studies are required to understand the clinical impact of the latter during infusion.	[Masse, Morgane; Genay, Stephanie; Barthelemy, Christine; Decaudin, Bertrand; Odon, Pascal] Univ Lille, EA 7365, GRITA, Lille, France; [Masse, Morgane; Genay, Stephanie; Decaudin, Bertrand; Odon, Pascal] CHU Lille, Inst Pharm, Lille, France; [Maton, Mickael; Blanchemain, Nicolas] Univ Lille, Controlled Drug Delivery Syst & Biomat U1008, Inserm, CHU Lille, Lille, France	Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille	Genay, S (corresponding author), Univ Lille, EA 7365, GRITA, Lille, France.; Genay, S (corresponding author), CHU Lille, Inst Pharm, Lille, France.	stephanie.genay@univ-lille.fr	masse, morgane/AAF-2140-2020; Nicolas, Blanchemain/GWV-3651-2022; Decaudin, Bertrand/E-5828-2010	masse, morgane/0000-0002-6761-9444; Decaudin, Bertrand/0000-0001-8267-5594				Al Salloum H, 2015, INT J PHARMACEUT, V496, P664, DOI 10.1016/j.ijpharm.2015.11.004; Berchtold H, 1999, BIOPOLYMERS, V51, P165, DOI 10.1002/(SICI)1097-0282(1999)51:2<165::AID-BIP6>3.3.CO;2-O; BRANGE J, 1990, DIABETES CARE, V13, P923, DOI 10.2337/diacare.13.9.923; Brange J., 1987, RASMUSSEN GALENICS O; Fuloria M, 1998, PEDIATRICS, V102, P1401, DOI 10.1542/peds.102.6.1401; Genay S, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0298-x; Havelund S, 2015, PHARM RES-DORDR, V32, P2250, DOI 10.1007/s11095-014-1614-x; Hewson MP, 2000, J PAEDIATR CHILD H, V36, P216, DOI 10.1046/j.1440-1754.2000.00488.x; Hubert P, 2004, J PHARMACEUT BIOMED, V36, P579, DOI 10.1016/j.jpba.2004.07.027; Hubert P, 2007, J PHARMACEUT BIOMED, V45, P82, DOI 10.1016/j.jpba.2007.06.032; ICH, HARM TRIP GUID STAB; Jakobsson Therese, 2009, J Diabetes Sci Technol, V3, P213; KANG S, 1991, DIABETES CARE, V14, P942, DOI 10.2337/diacare.14.11.942; Kerr David, 2013, J Diabetes Sci Technol, V7, P1595; Ling J, 1999, DIABETES EDUCATOR, V25, P237; Lisi GP, 2014, BIOCHEMISTRY-US, V53, P3576, DOI 10.1021/bi401678n; Masse M, 2017, TALANTA, V162, P187, DOI 10.1016/j.talanta.2016.10.029; MELBERG SG, 1988, DIABETIC MED, V5, P243, DOI 10.1111/j.1464-5491.1988.tb00977.x; Mollmann SH, 2006, EUR J PHARM SCI, V27, P194, DOI 10.1016/j.ejps.2005.09.010; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; Poulsen C, 2008, PHARM RES-DORDR, V25, P2534, DOI 10.1007/s11095-008-9670-8; Smith GD, 1996, PROTEIN SCI, V5, P1502, DOI 10.1002/pro.5560050806; Teska BM, 2015, J PHARM SCI-US, V104, P1555, DOI 10.1002/jps.24330; Teska BM, 2014, J PHARM SCI-US, V103, P2255, DOI 10.1002/jps.24039; Weber C, 2015, TOXICOL REP, V2, P194, DOI 10.1016/j.toxrep.2014.11.019; Xu XL, 2006, J PHARMACEUT BIOMED, V41, P266, DOI 10.1016/j.jpba.2005.10.016; Zahid Najam, 2008, Diabetes Res Clin Pract, V80, pe11, DOI 10.1016/j.diabres.2008.02.013	27	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2018	13	8							e0201623	10.1371/journal.pone.0201623	http://dx.doi.org/10.1371/journal.pone.0201623			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ6RF	30114258	Green Published, Green Submitted, gold			2023-01-03	WOS:000441850400019
J	Schneider, F; Martin, J; Schneider, G; Schulz, CM				Schneider, Frederick; Martin, Jan; Schneider, Gerhard; Schulz, Christian M.			The impact of the patient's initial NACA score on subjective and physiological indicators of workload during pre-hospital emergency care	PLOS ONE			English	Article							ANESTHETISTS WORKLOAD; HEART-RATE; EXPERIENCE; SEVERITY; PROVIDERS; QUALITY; STRESS; STRAIN	Background Excessive workload may impair patient safety. However, little is known about emergency care providers' workload during the treatment of life-threatening cases including cardiopulmonary resuscitation (CPR). Therefore, we tested the hypothesis that subjective and physiological indicators of workload are associated with the patient's initial NACA score and that workload is particularly high during CPR. Methods NASA task load index (NASA-tlx) and alarm codes were obtained for 216 sorties of pre-hospital emergency medical care. Furthermore, initial NACA scores of 140 patients were extracted from the physicians' protocols. The physiological workload indicators mean heart rate (HR) and permutation entropy (PeEn) were calculated for 51 sorties of primary care. General linear mixed models were used to analyze the association of NACA scores with subjective (NASA-tlx) and physiological (mean HR, PeEn) measures of workload. Results In contrast to the physiological variables PeEn (p = 0.10) and HR (p = 0.19), the mental (p<0.001) and temporal demands (p<0.001) as well as the effort (p<0.001) and frustration (p = 0.04) subscale of the NASA-tlx were significantly associated with initial NACA scores. Compared to NACA = I, an initial NACA score of VI (representing CPR) increased workload by a mean of 389.5% (p = 0.001) in the mental and 345.9% (p<0.001) in the temporal demands, effort by a mean of 446,8% (p = 0.002) and frustration by 190.0% (p = 0.03). In line with the increase in NASA-tlx, PeEn increased by 20.6% (p = 0.01) and HR by 6.4% (p = 0.57). Conclusions Patients' initial NACA scores are associated with subjective workload. Workload was highest during CPR.	[Schneider, Frederick; Martin, Jan; Schneider, Gerhard; Schulz, Christian M.] Tech Univ Munich, Sch Med, Klinikum Rechts Isar, Dept Anesthesiol, Munich, Germany	Technical University of Munich	Schneider, F (corresponding author), Tech Univ Munich, Sch Med, Klinikum Rechts Isar, Dept Anesthesiol, Munich, Germany.	frederick.schneider@tum.de		Schneider, Frederick/0000-0002-1952-0124; Schneider, Gerhard/0000-0002-4903-0118				Alessandrini H, 2012, NOTFALL RETTUNGSMED, V15, P42, DOI 10.1007/s10049-010-1386-8; [Anonymous], 2005, NOTF RETT; Arztetag B., 2017, WEITERBILDUNGSORDNUN; Bernhardt M, 2012, PRAKLINISCHES TRAUMA; Bjorkli CA, 2012, APPL ERGON, V43, P799, DOI 10.1016/j.apergo.2011.11.015; BONATTI J, 1995, RESUSCITATION, V30, P133, DOI 10.1016/0300-9572(95)00883-U; Byrne AJ, 2013, ANAESTHESIA, V68, P1266, DOI 10.1111/anae.12455; Cinaz B, 2013, PERS UBIQUIT COMPUT, V17, P229, DOI 10.1007/s00779-011-0466-1; DEANDA A, 1991, ANESTH ANALG, V72, P308; Estryn-Behar M, 2011, EMERG MED J, V28, P397, DOI 10.1136/emj.2009.082594; GABA DM, 1994, ANESTHESIOLOGY, V81, P488, DOI 10.1097/00000542-199408000-00028; HART S G, 1988, P139; Hart SG, 1988, NASA TLX PAPER PENCI, DOI [10.1007/s00420-013-0847-z, DOI 10.1007/S00420-013-0847-Z]; Havel C, 2008, RESUSCITATION, V77, P81, DOI 10.1016/j.resuscitation.2007.09.010; Henelius Andreas, 2009, Annu Int Conf IEEE Eng Med Biol Soc, V2009, P1836, DOI 10.1109/IEMBS.2009.5332602; Huber S, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0252-1; Karhula K, 2014, CHRONOBIOL INT, V31, P1179, DOI 10.3109/07420528.2014.957294; Knapp J, 2008, ANAESTHESIST, V57, P1069, DOI 10.1007/s00101-008-1454-3; Leary M, 2008, RESUSCITATION, V77, P1, DOI 10.1016/j.resuscitation.2008.02.005; Leedal JM, 2005, BRIT J ANAESTH, V94, P702, DOI 10.1093/bja/aei131; Martin J, 2016, BRIT J ANAESTH, V117, P767, DOI 10.1093/bja/aew342; Mazur LM, 2012, INT J RADIAT ONCOL, V83, pE571, DOI 10.1016/j.ijrobp.2012.01.063; McNeer RR, 2016, ANESTH ANALG, V122, P512, DOI 10.1213/ANE.0000000000001067; Parsons SE, 2012, J TRAUMA ACUTE CARE, V73, P1267, DOI 10.1097/Ta.0b013e318265d15a; Pitts S, 2004, LANCET, V364, P313, DOI 10.1016/S0140-6736(04)16740-8; Prytz Erik G, 2016, J Emerg Manag, V14, P289, DOI 10.5055/jem.2016.0294; Raatiniemi L, 2017, ACTA ANAESTH SCAND, V61, P557, DOI 10.1111/aas.12881; Raatiniemi L, 2013, ACTA ANAESTH SCAND, V57, P1253, DOI 10.1111/aas.12208; Rieger A, 2014, INT ARCH OCC ENV HEA, V87, P165, DOI 10.1007/s00420-013-0847-z; Schneider F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188635; Schoenenberger S, 2014, INT J OCCUP SAF ERGO, V20, P551, DOI 10.1080/10803548.2014.11077071; Schulz CM, 2011, BRIT J ANAESTH, V106, P44, DOI 10.1093/bja/aeq307; Tur FC, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0225-4; Wallace SK, 2013, CIRCULATION, V127, P1591, DOI 10.1161/CIRCULATIONAHA.113.002058; Weinger MB, 2004, ANESTH ANALG, V98, P1419, DOI 10.1213/01.ANE.0000106838.66901.D2; WEINGER MB, 1994, ANESTHESIOLOGY, V80, P77, DOI 10.1097/00000542-199401000-00015; Weiss M, 2001, ANAESTHESIST, V50, P150, DOI 10.1007/s001010170030; Wheelock A, 2015, ANN SURG, V261, P1079, DOI 10.1097/SLA.0000000000001051	39	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0202215	10.1371/journal.pone.0202215	http://dx.doi.org/10.1371/journal.pone.0202215			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP9JF	30092090	Green Published, gold, Green Submitted			2023-01-03	WOS:000441232600102
J	Gonzalez, LM; Garcia-Masso, X; Pardo-Ibanez, A; Peset, F; Devis-Devis, J				Gonzalez, Luis-Millan; Garcia-Masso, Xavier; Pardo-Ibanez, Alberto; Peset, Fernanda; Devis-Devis, Jose			An author keyword analysis for mapping Sport Sciences	PLOS ONE			English	Article							PHYSICAL-EDUCATION; TEXT; KINESIOLOGY; INFORMATION; DYNAMICS; IMPACT	Scientific production has increased exponentially in recent years. It is necessary to find methodological strategies for understanding holistic or macro views of the major research trends developed in specific fields. Data mining is a useful technique to address this task. In particular, our study presents a global analysis of the information generated during last decades in the Sport Sciences Category (SSC) included in the Web of Science database. An analysis of the frequency of appearance and the dynamics of the Author Keywords (AKs) has been made for the last thirty years. Likewise, the network of co-occurrences established between words and the survival time of new words that have appeared since 2001 has also been analysed. One of the main findings of our research is the identification of six large thematic clusters in the SSC. There are also two major terms that coexist ('REHABILITATION' and 'EXERCISE') and show a high frequency of appearance, as well as a key behaviour in the calculated co-occurrence networks. Another significant finding is that AKs are mostly accepted in the SSC since there has been high percentage of new terms during 2001-2006, although they have a low survival period. These results support a multidisciplinary perspective within the Sport Sciences field of study and a colonization of the field by rehabilitation according to our AK analysis.	[Gonzalez, Luis-Millan; Pardo-Ibanez, Alberto; Devis-Devis, Jose] Univ Valencia, Dept Educ Fis & Deport, Valencia, Spain; [Garcia-Masso, Xavier] Univ Valencia, Dept Didact Expres Mus Plast & Corporal, Valencia, Spain; [Peset, Fernanda] Univ Politecn Valencia, Inst Univ Matemat Pura & Aplicada, Valencia, Spain	University of Valencia; University of Valencia; Universitat Politecnica de Valencia	Devis-Devis, J (corresponding author), Univ Valencia, Dept Educ Fis & Deport, Valencia, Spain.	jose.devis@uv.es	Devis-Devis, Jose/G-8758-2015; González, Luis-Millán/L-4779-2014; PESET, FERNANDA/A-8491-2008; García-Massó, Xavier/L-8222-2014; Pardo-Ibanez, Alberto/K-7051-2014	Devis-Devis, Jose/0000-0003-4599-3782; González, Luis-Millán/0000-0002-6478-4014; Garcia-Masso, Xavier/0000-0002-5925-4537; Pardo-Ibanez, Alberto/0000-0002-1884-715X				Aguinis H, 2013, ACAD MANAG LEARN EDU, V12, P564, DOI 10.5465/amle.2012.0066; Aizawa A., 2003, Systems and Computers in Japan, V34, P85, DOI 10.1002/scj.1197; [Anonymous], 1985, J PHYS ED RECREATION, DOI [10.1080/07303084.1985.10603786, DOI 10.1080/07303084.1985.10603786]; [Anonymous], J HLTH PHYS ED RECRE, DOI 10.1080/00221473.1964.10621849; Arnold P.J., 1979, MEANING MOVEMENT SPO; Booth A, 2011, LANCET, V377, P108, DOI 10.1016/S0140-6736(10)60903-8; Bornmann L, 2015, J ASSOC INF SCI TECH, V66, P2215, DOI 10.1002/asi.23329; Bouchard C., 1974, MOUVEMMENT, V9, P117; Box-Steffensmeier JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143093; Bressan ES, 1982, P NAT ASS PHYS ED HI, P26; Cagigal JM, 1968, CITIUS ALTIUS FORTIU, VX, P5; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Champely S, 2017, EUR J SPORT SCI, V17, P5, DOI 10.1080/17461391.2016.1197318; Cooper ID, 2013, J MED LIBR ASSOC, V101, P268, DOI 10.3163/1536-5050.101.4.008; de Price DJSolla, 1961, AM J PHYS, V29, P863, DOI [10.1119/1, DOI 10.1119/1]; Dotsika F, 2017, TECHNOL FORECAST SOC, V119, P114, DOI 10.1016/j.techfore.2017.03.020; Feldman R., 1995, KDD-95 Proceedings. First International Conference on Knowledge Discovery and Data Mining, P112; Freedson P., 2014, KINESIOL REV, V3, P1, DOI [10.1123/kr.2014-0044, DOI 10.1123/KR.2014-0044]; Gil-Leiva I, 2007, J AM SOC INF SCI TEC, V58, P1175, DOI 10.1002/asi.20595; Glenisson P, 2005, INFORM PROCESS MANAG, V41, P1548, DOI 10.1016/j.ipm.2005.03.021; Greendorfer S. L., 1987, QUEST, V39, P56, DOI [DOI 10.1080/00336297.1987.10483856, 10.1080/00336297.1987.10483856]; Hall CM, 2011, TOURISM MANAGE, V32, P16, DOI 10.1016/j.tourman.2010.07.001; Harris JC, 1987, QUEST, V39, P282; He W, 2013, INT J INFORM MANAGE, V33, P464, DOI 10.1016/j.ijinfomgt.2013.01.001; Henry F. M., 1978, QUEST, V29, DOI [DOI 10.1080/00336297.1978.10519907, 10.1080/00336297.1978.10519907]; Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102; Hristovski R, 2017, EUR J SPORT SCI, V17, P19, DOI 10.1080/17461391.2016.1207709; Hung JL, 2012, BRIT J EDUC TECHNOL, V43, P5, DOI 10.1111/j.1467-8535.2010.01144.x; Jones K. S., 1970, Information Storage and Retrieval, V5, P175, DOI 10.1016/0020-0271(70)90046-X; KAMADA T, 1989, INFORM PROCESS LETT, V31, P7, DOI 10.1016/0020-0190(89)90102-6; Ke Q, 2015, P NATL ACAD SCI USA, V112, P7426, DOI 10.1073/pnas.1424329112; Kevork EK, 2009, MARK INTELL PLAN, V27, P48, DOI 10.1108/02634500910928362; Lawson H. A., 1979, QUEST, V31, P222, DOI [10.1080/00336297.1979.10519939, DOI 10.1080/00336297.1979.10519939]; Lee S, 2016, LIBRI, V66, P263, DOI 10.1515/libri-2016-0052; Lehningher A. L., 2013, PRINCIPLES BIOCH, V6th; Liu XH, 2010, J AM SOC INF SCI TEC, V61, P1105, DOI 10.1002/asi.21312; Lungeanu A, 2014, J INFORMETR, V8, P59, DOI 10.1016/j.joi.2013.10.006; McGinty S., 1999, GATEKEEPERS KNOWLEDG; Mela CF, 2013, MARKET SCI, V32, P8, DOI 10.1287/mksc.1120.0764; Morillo F, 2003, J AM SOC INF SCI TEC, V54, P1237, DOI 10.1002/asi.10326; Mrvar A., 2012, EXPLORATORY SOCIAL N; Neveol Aurelie, 2010, AMIA Annu Symp Proc, V2010, P537; NEWELL KM, 1990, QUEST, V42, P227; Norman D. A., 1993, THINGS MAKE US SMART; Nosek BA, 2012, PERSPECT PSYCHOL SCI, V7, P615, DOI 10.1177/1745691612459058; Perez-Gutierrez M, 2016, MOVIMENTO-PORTO ALEG, V22, P1121, DOI 10.22456/1982-8918.64654; Peset F, 2013, ARCH BUDO, V9, P81, DOI 10.12659/AOB.883883; Radhakrishnan S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172778; Rajman M, 1998, TEXT MINING NATURAL, P50; Reeve TG, 2007, QUEST, V59, P1; Renshaw P., 1973, QUEST, V20, P79; RENSON R, 1989, QUEST, V41, P235, DOI 10.1080/00336297.1989.10483973; Rikli R, 2006, QUEST, V58, P287, DOI 10.1080/00336297.2006.10491884; Santos J, 2002, REV ESP DOC CIENTIFI, V25, P141; Santos JB, 2005, SCIENTOMETRICS, V62, P329, DOI 10.1007/s11192-005-0025-5; Schwartz MD, 2003, WILD ENVIRON MED, V14, P24, DOI 10.1580/1080-6032(2003)014[0024:FITRTP]2.0.CO;2; SINGER JD, 1993, J EDUC STAT, V18, P155, DOI 10.3102/10769986018002155; Spiliopoulou M, 2000, COMMUN ACM, V43, P127, DOI 10.1145/345124.345167; Stone MH, 2004, STRENGTH COND J, V26, P72, DOI 10.1519/1533-4295(2004)026<0072:TDOSSI>2.0.CO;2; Su HN, 2010, SCIENTOMETRICS, V85, P65, DOI 10.1007/s11192-010-0259-8; Tabah AN, 1999, ANNU REV INFORM SCI, V34, P249; Thomas J. R., 1987, QUEST, V39, P114, DOI [10.1080/00336297.1987.10483863, DOI 10.1080/00336297.1987.10483863]; Thomas JR, 2014, QUEST, V66, P313, DOI 10.1080/00336297.2014.918894; Tseng YH, 2007, INFORM PROCESS MANAG, V43, P1216, DOI 10.1016/j.ipm.2006.11.011; Uddin S, 2016, J INFORMETR, V10, P1166, DOI 10.1016/j.joi.2016.10.004; van Eck NJ, 2010, J AM SOC INF SCI TEC, V61, P2405, DOI 10.1002/asi.21421; Waltman L, 2013, EUR PHYS J B, V86, DOI 10.1140/epjb/e2013-40829-0; Waltman L, 2010, J INFORMETR, V4, P629, DOI 10.1016/j.joi.2010.07.002; Yang SL, 2016, J INFORMETR, V10, P132, DOI 10.1016/j.joi.2015.12.003	69	19	19	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2018	13	8							e0201435	10.1371/journal.pone.0201435	http://dx.doi.org/10.1371/journal.pone.0201435			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GO9GY	30067822	Green Submitted, gold, Green Published			2023-01-03	WOS:000440415500089
J	Jun, BG; Kim, YD; Kim, SG; Kim, YS; Jeong, SW; Jang, JY; Lee, SH; Kim, HS; Kang, SH; Kim, MY; Baik, SK; Lee, M; Kim, TS; Choi, DH; Choi, SH; Suk, KT; Kim, DJ; Cheon, GJ				Jun, Baek Gyu; Kim, Young Don; Kim, Sang Gyune; Kim, Young Seok; Jeong, Soung Won; Jang, Jae Young; Lee, Sae Hwan; Kim, Hong Soo; Kang, Seong Hee; Kim, Moon Young; Baik, Soon Koo; Lee, Minjong; Kim, Tae-Suk; Choi, Dae Hee; Choi, Sang-Hyeon; Suk, Ki Tae; Kim, Dong Joon; Cheon, Gab Jin			Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; DNA LEVELS; TRANSARTERIAL CHEMOEMBOLIZATION; HBV REACTIVATION; LIVER-FUNCTION; THERAPY; RADIATION; RISK; REPLICATION	Convincing data that support routine use of preventive therapy against hepatitis B virus (HBV) reactivation in radiotherapy (RT) for hepatocellular carcinoma (HCC) are lacking. The aim of this study was to investigate the incidence, clinical significance, and risk factors of HBV reactivation after RT. Medical records of 133 HBsAg (+) HCC patients who received radiotherapy from March 2009 to February 2016 were reviewed. Patients were divided into two groups: 1) non-antiviral group, those who did not receive antiviral therapy before RT (n=27); and antiviral group (those who underwent antiviral therapy before RT) (n=106). Factors related to HBV reactivation in HCC patients were evaluated. 17 (12.7%) of 133 patients developed HBV reactivation after RT. Patients in the antiviral group had significantly lower rates of HBV reactivation than those in the non-antiviral group (7.5% vs. 33.3%, p<0.001). HBV related hepatitis was also lower in the antiviral group (3.8% vs. 14.8%, p= 0.031). In multivariate analysis, absence of antiviral treatment (OR: 8.339, 95% CI: 2.532-27.470, p<0.001) and combined treatment of RT with transarterial chemoembolizatoin (TACE) (OR: 5.313, 95% CI: 1.548-18.232, p=0.008) were risk factors for HBV reactivation. HBV reactivation can occur after radiotherapy. Combination treatment of RT with TACE and non-antiviral treatment are major risk factors for HBV reactivation during or after RT. Therefore, preventive antiviral therapy should be recommended for patients with HCC who are scheduled to receive RT.	[Jun, Baek Gyu; Kim, Young Don; Cheon, Gab Jin] Univ Ulsan, Dept Internal Med, Coll Med, Gangneung Asan Hosp, Kangnung, South Korea; [Kim, Sang Gyune; Kim, Young Seok] Soonchunhyang Univ, Dept Internal Med, Coll Med, Bucheon Hosp, Bucheon, South Korea; [Jeong, Soung Won; Jang, Jae Young] Soonchunhyang Univ, Dept Internal Med, Coll Med, Seoul Hosp, Seoul, South Korea; [Lee, Sae Hwan; Kim, Hong Soo] Soonchunhyang Univ, Dept Internal Med, Coll Med, Cheonan Hosp, Cheonan, South Korea; [Kang, Seong Hee; Kim, Moon Young; Baik, Soon Koo] Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea; [Lee, Minjong; Kim, Tae-Suk; Choi, Dae Hee] Kangwon Natl Univ Hosp, Dept Internal Med, Chunchon, South Korea; [Choi, Sang-Hyeon; Suk, Ki Tae; Kim, Dong Joon] Hallym Univ, Coll Med, Dept Internal Med, Chunchon, South Korea	University of Ulsan; Soonchunhyang University; Soonchunhyang University; Soonchunhyang University; Yonsei University; Kangwon National University; Kangwon National University Hospital; Hallym University	Cheon, GJ (corresponding author), Univ Ulsan, Dept Internal Med, Coll Med, Gangneung Asan Hosp, Kangnung, South Korea.	1000@gnah.co.kr	Kim, Young Don/AAK-7948-2020; Kim, Young Don/T-8521-2019; Kim, Sang gyune/AAI-5704-2020	Kim, Young Don/0000-0001-9003-9862; Kim, Sang gyune/0000-0001-8694-777X; JUN, BAEKGYU/0000-0003-4693-9542; , minjong/0000-0002-3159-5444	Korean Association for the Study of the Liver, Gangwon branch	Korean Association for the Study of the Liver, Gangwon branch	This research was supported by The Korean Association for the Study of the Liver, Gangwon branch to BGJ.	Chae SM, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-72; Chen J, 2016, INT J CLIN EXP MED, V9, P4533; Chou CH, 2007, CLIN CANCER RES, V13, P851, DOI 10.1158/1078-0432.CCR-06-2459; Chou CH, 2009, INT J RADIAT ONCOL, V75, P1545, DOI 10.1016/j.ijrobp.2008.12.072; Dan JQ, 2013, EJSO-EUR J SURG ONC, V39, P865, DOI 10.1016/j.ejso.2013.03.020; Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8; Huang L, 2013, J VIRAL HEPATITIS, V20, P336, DOI 10.1111/jvh.12036; Huang L, 2012, J GASTROEN HEPATOL, V27, P158, DOI 10.1111/j.1440-1746.2011.06888.x; Huang W, 2014, CANCER SCI, V105, P697, DOI 10.1111/cas.12400; Jang JW, 2011, ANTIVIR THER, V16, P969, DOI 10.3851/IMP1840; Jang JW, 2006, HEPATOLOGY, V43, P233, DOI 10.1002/hep.21024; Jun B, 2017, KOREAN J INTERNAL ME; KASL, 2012, CLIN MOL HEPATOL, V18, P109, DOI 10.3350/cmh.2012.18.2.109; Kim JH, 2007, INT J RADIAT ONCOL, V69, P813, DOI 10.1016/j.ijrobp.2007.04.005; Koo JE, 2010, INT J RADIAT ONCOL, V78, P180, DOI 10.1016/j.ijrobp.2009.07.1730; Lao XM, 2013, LIVER INT, V33, P595, DOI 10.1111/liv.12112; Lao XM, 2011, HEPATOL RES, V41, P553, DOI 10.1111/j.1872-034X.2011.00796.x; Lawrence TS, INT J RAD ONCOLOGY B, V31, P1237; LIANG RHS, 1990, HEMATOL ONCOL, V8, P261, DOI 10.1002/hon.2900080504; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; Park JW, 2005, AM J GASTROENTEROL, V100, P2194, DOI 10.1111/j.1572-0241.2005.00232.x; Xie ZB, 2016, ONCOTARGETS THER, V9, P4593, DOI 10.2147/OTT.S104300; Xu XJ, 2014, J GASTROEN HEPATOL, V29, P1273, DOI 10.1111/jgh.12554; Yeo W, 2003, J MED VIROL, V70, P553, DOI 10.1002/jmv.10430; Yoo SH, 2016, CLIN MOL HEPATOL, V22, P458, DOI 10.3350/cmh.2016.0054; Yoon SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079854	26	15	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2018	13	7							e0201316	10.1371/journal.pone.0201316	http://dx.doi.org/10.1371/journal.pone.0201316			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO7MT	30059513	Green Submitted, Green Published, gold			2023-01-03	WOS:000440251600033
J	Soares, AMS; Oliveira, JTA; Rocha, CQ; Ferreira, ATS; Perales, J; Zanatta, AC; Vilegas, W; Silvan, CR; Costa, LM				Soares, Alexandra M. S.; Oliveira, Jose T. A.; Rocha, Claudia Q.; Ferreira, Andre T. S.; Perales, Jonas; Zanatta, Ana Caroline; Vilegas, Wagner; Silvan, Carolina R.; Costa-Junior, Livio M.			Myracrodruon urundeuva seed exudates proteome and anthelmintic activity against Haemonchus contortus	PLOS ONE			English	Article							PLANT CYSTEINE PROTEINASES; IN-VITRO; GASTROINTESTINAL NEMATODES; CAENORHABDITIS-ELEGANS; DEFENSE; RESISTANCE; PROTEASES; SHEEP; VIVO; CHITINASES	Seed exudates are plant-derived natural bioactive compounds consisting of a complex mixture of organic and inorganic molecules. Plant seed exudates have been poorly studied against parasite nematodes. This study was undertaken to identify proteins in the Myracrodruon urundeuva seed exudates and to assess the anthelmintic activity against Haemonchus contortus, an important parasite of small ruminants. M. urundeuva seed exudates (SEX) was obtained after immersion of seeds in sodium acetate buffer. SEX was fractionated with ammonium sulfate at 0-90% concentration to generate the ressuspended pellet (SEXF1) and the supernatant (SEXF2). SEX, SEXF1, and SEXF2 were exhaustively dialyzed against distilled water (cut-off: 12 kDa) and the protein contents determined. Mass spectrometry analyses of SEX, SEXF1, and SEXF2 were done to identify proteins and secondary metabolites. The seed exudates contained protease, protease inhibitor, peptidase, chitinase, and lipases as well as the low molecular weight secondary compounds ellagic acid and quercetin rhamnoside. SEX inhibited H. contortus larval development (LDA) (IC50 = 0.29 mg mL(-1)), but did not affect larval exsheathment (LEIA). On the other hand, although SEXF1 and SEXF2 inhibited H. contortus LEIA (IC50 = 1.04 and 0.93 mg mL(-1), respectively), they showed even greater inhibition efficiency of H. contortus larval development (IC50 = 0.29 and 0.42 mg mL(-1), respectively). To the best of our knowledge, this study is the first to show the anthelmintic activity of plant exudates against a gastrointestinal nematode. Moreover, it suggests the potential of exuded proteins as candidates to negatively interfere with H. contortus life cycle.	[Soares, Alexandra M. S.] Univ Fed Maranhao, Exact Sci Ctr & Technol, Lab Plant Biochem, Chem Engn Program, Sao Luis, Maranhao, Brazil; [Oliveira, Jose T. A.] Univ Fed Ceara, Lab Plant Def Prot, Campus Pici, Fortaleza, Ceara, Brazil; [Rocha, Claudia Q.] Univ Fed Maranhao, Ctr Exact Sci & Technol, Dept Chem, Lab Adv Studies Phytomed, Sao Luis, Maranhao, Brazil; [Ferreira, Andre T. S.; Perales, Jonas] Fundacao Oswaldo Cruz, Lab Toxinol, Rio De Janeiro, RJ, Brazil; [Zanatta, Ana Caroline; Vilegas, Wagner] Inst Biosci, Bioprospecting, Lab Nat Prod, Coastal Campus Sao Vicente, Sao Vicente, SP, Brazil; [Silvan, Carolina R.; Costa-Junior, Livio M.] Univ Fed Maranhao, Ctr Biol & Hlth Sci, Dept Pathol, Lab Parasite Control, Sao Luis, Maranhao, Brazil	Universidade Federal do Maranhao; Universidade Federal do Ceara; Universidade Federal do Maranhao; Fundacao Oswaldo Cruz; Universidade Federal do Maranhao	Soares, AMS (corresponding author), Univ Fed Maranhao, Exact Sci Ctr & Technol, Lab Plant Biochem, Chem Engn Program, Sao Luis, Maranhao, Brazil.; Costa, LM (corresponding author), Univ Fed Maranhao, Ctr Biol & Hlth Sci, Dept Pathol, Lab Parasite Control, Sao Luis, Maranhao, Brazil.	alexandra.ufma@gmail.com; livio.martins@ufma.br	Zanatta, Ana C./ABA-7695-2020; Vilegas, Wagner/S-3209-2019; Rocha, Cláudia Quintino da/C-2320-2013; Costa-Junior, Livio M/H-7530-2012	Zanatta, Ana C./0000-0003-0199-4521; Rocha, Cláudia Quintino da/0000-0002-3578-1869; Costa-Junior, Livio M/0000-0002-1475-049X; Rocha e Silva, Carolina/0000-0001-8667-1064	CNPq (The Brazilian National Council for Scientific and Technological Development) [447877/2014-3]; FAPEMA (Maranhao State Research Foundation) [PRONEM-01773/14]; CNPq; CNPq (The Brazilian National Council for Scientific and Technological Development); FAPEMA (Maranhao State Research Foundation)	CNPq (The Brazilian National Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPEMA (Maranhao State Research Foundation); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq (The Brazilian National Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPEMA (Maranhao State Research Foundation)	The authors acknowledge the CNPq (The Brazilian National Council for Scientific and Technological Development) 447877/2014-3, and FAPEMA (Maranhao State Research Foundation) PRONEM-01773/14, for financial support. We also thank CNPq for awarding a fellowship to L.M. Costa-Junior and J. Perales. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors wish to thank the CNPq (The Brazilian National Council for Scientific and Technological Development) and FAPEMA (Maranhao State Research Foundation) for financial support. We also thank CNPq for awarding a fellowship to L.M. Costa-Junior and J. Perales.	Al-Whaibi Mohamed H., 2011, Journal of King Saud University Science, V23, P139, DOI 10.1016/j.jksus.2010.06.022; Anusuya Sathiyanarayanan, 2014, Archives of Phytopathology and Plant Protection, V47, P1611, DOI 10.1080/03235408.2013.853457; Araujo SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189803; Barros M, 2010, BRAZ J CHEM ENG, V27, P15, DOI 10.1590/S0104-66322010000100002; Bauri RK, 2015, INDIAN J NAT PROD RE, V6, P268; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga FR, 2014, RES VET SCI, V97, P527, DOI 10.1016/j.rvsc.2014.09.005; Carvalho CES, 2017, EXP PARASITOL, V175, P59, DOI 10.1016/j.exppara.2017.02.012; COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U; Day B, 2011, ANNU REV PHYTOPATHOL, V49, P483, DOI 10.1146/annurev-phyto-072910-095426; Demeler J, 2010, VET PARASITOL, V174, P58, DOI 10.1016/j.vetpar.2010.08.020; Duarte N.F., 2006, Planta daninha, V24, P329, DOI 10.1590/S0100-83582006000200016; Eltelib HA, 2011, J PLANT PHYSIOL, V168, P619, DOI 10.1016/j.jplph.2010.09.003; Faccin H, 2016, J CHROMATOGR A, V1427, P111, DOI 10.1016/j.chroma.2015.12.017; Feofilova EP, 2010, MICROBIOLOGY+, V79, P711, DOI 10.1134/S0026261710060019; Gadahi JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159796; Grover A, 2012, CRIT REV PLANT SCI, V31, P57, DOI 10.1080/07352689.2011.616043; Harder A, 2016, ADV PARASIT, V93, P69, DOI 10.1016/bs.apar.2016.02.010; Heim C, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1032-x; HUBERT J, 1992, VET REC, V130, P442, DOI 10.1136/vr.130.20.442; Jackson F, 2010, IN VITRO SCREENING OF PLANT RESOURCES FOR EXTRA-NUTRITIONAL ATTRIBUTES IN RUMINANTS: NUCLEAR AND RELATED METHODOLOGIES, P25, DOI 10.1007/978-90-481-3297-3_3; Jiang L, 2004, J CHROMATOGR A, V1023, P317, DOI 10.1016/j.chroma.2003.10.029; Kasprzewska A, 2003, CELL MOL BIOL LETT, V8, P809; Klongsiriwet C, 2015, INT J PARASITOL-DRUG, V5, P127, DOI 10.1016/j.ijpddr.2015.06.001; Kohli A, 2012, PHYSIOL PLANTARUM, V145, P165, DOI 10.1111/j.1399-3054.2012.01573.x; Levecke B, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-255; Lica ICL, 2018, FOOD RES INT, V105, P1039, DOI 10.1016/j.foodres.2017.11.051; Mali R. G., 2008, Natural Product Radiance, V7, P466; MANSFIELD LS, 1992, COMP BIOCHEM PHYS B, V103, P681, DOI 10.1016/0305-0491(92)90390-D; Martinez M, 2012, PHYSIOL PLANTARUM, V145, P85, DOI 10.1111/j.1399-3054.2012.01569.x; Mondal H, 2015, PAK VET J, V35, P58; Monteiro JM, 2006, J ETHNOPHARMACOL, V105, P173, DOI 10.1016/j.jep.2005.10.016; Monteiro JM, 2012, ACTA BOT BRAS, V26, P125, DOI 10.1590/S0102-33062012000100014; Ndjonka D, 2014, J HELMINTHOL, V88, P481, DOI 10.1017/S0022149X1300045X; Pahoja V. M., 2002, Pakistan Journal of Applied Sciences, V2, P474; Pesquet E, 2012, PHYSIOL PLANTARUM, V145, P1, DOI 10.1111/j.1399-3054.2012.01614.x; de Araujo IDR, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1918-6; Rios-de Alvarez L, 2012, VET PARASITOL, V187, P267, DOI 10.1016/j.vetpar.2012.01.005; ROBERTS FHS, 1950, AUST J AGR RES, V1, P99, DOI 10.1071/AR9500099; Rocha RO, 2015, J AGR FOOD CHEM, V63, P5335, DOI 10.1021/acs.jafc.5b01109; Rose Hannah, 2014, International Journal for Parasitology Parasites and Wildlife, V3, P209, DOI 10.1016/j.ijppaw.2014.01.001; Scarafoni A, 2013, FEBS J, V280, P1443, DOI 10.1111/febs.12140; Schiltz S, 2015, J APPL MICROBIOL, V119, P1467, DOI 10.1111/jam.12946; Souza TM, 2015, ACTA TROP, V152, P49, DOI 10.1016/j.actatropica.2015.08.010; Stepek G, 2007, PARASITOLOGY, V134, P103, DOI 10.1017/S0031182006001302; Stepek G, 2006, PARASITOLOGY, V132, P681, DOI 10.1017/S003118200500973X; Tariq KA, 2008, J HELMINTHOL, V82, P227, DOI 10.1017/S0022149X08972515; Ueno H., 1998, MANUAL DIAGNOSTICO H; Vermeire JJ, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030039; Veronico P, 2001, MOL GENET GENOMICS, V266, P28, DOI 10.1007/s004380100513	50	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2018	13	7							e0200848	10.1371/journal.pone.0200848	http://dx.doi.org/10.1371/journal.pone.0200848			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN5RC	30024949	Green Published, gold, Green Submitted			2023-01-03	WOS:000439120000060
J	Cilloniz, C; Liapikou, A; Martin-Loeches, I; Garcia-Vidal, C; Gabarrus, A; Ceccato, A; Magdaleno, D; Mensa, J; Marco, F; Torres, A				Cilloniz, Catia; Liapikou, Adamantia; Martin-Loeches, Ignacio; Garcia-Vidal, Carolina; Gabarrus, Albert; Ceccato, Adrian; Magdaleno, Daniel; Mensa, Josep; Marco, Francesc; Torres, Antoni			Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia	PLOS ONE			English	Article							SEVERE SEPSIS; GUIDELINES; MANAGEMENT; ADULTS; SEVERITY; DIAGNOSIS; THERAPY; FAILURE; BURDEN; SCORE	Background There is only limited information on mortality over extended periods in hospitalized patients with pneumococcal community-acquired pneumonia (CAP). We aimed to evaluate the 30-day mortality and whether is changed over a 20-year period among immunocompetent adults hospitalized with pneumococcal CAP. Methods We conducted a retrospective observational study of data that were prospectively collected at the Hospital Clinic of Barcelona of all adult patients hospitalized with diagnosis of pneumococcal CAP over a 20-year period. To aid analysis, results were divided into four periods of 5 years each (1997-2001, 2002-2006, 2007-2011, 2012-2016). The primary outcome was 30-day mortality, but secondary outcomes included intensive care unit (ICU) admission, lengths of hospital and ICU-stays, ICU-mortality, and need of mechanical ventilation. Results From a cohort of 6,403 patients with CAP, we analyzed the data for 1,120 (17%) adults with a diagnosis of pneumococcal CAP. Over time, we observed decreases in the rates of alcohol consumption, smoking, influenza vaccination, and older patients (age >65 years), but increases in admissions to ICU and the need for non-invasive mechanical ventilation. The overall 30-day mortality rate was 8% (95% confidence interval, 6%-9%; 84 of 1,120 patients) and did not change significantly between periods (p = 0.33). Although, we observed a decrease in ICU-mortality comparing the first period (26%) to the second one (10%), statistical differences disappeared with adjustment (p0.38). Conclusion Over time, 30-day mortality of hospitalized pneumococcal CAP did not change significantly. Nor did it change in the propensity-adjusted multivariable analysis. Since mortality in pneumococcal pneumonia has remained unaltered for many years despite the availability of antimicrobial agents with proven in vitro activity, other non-antibiotic strategies should be investigated.	[Cilloniz, Catia; Gabarrus, Albert; Ceccato, Adrian; Torres, Antoni] Univ Barcelona, Hosp Clin Barcelona, SGR Ciber Enfermedades Resp Ciberes,Dept Pneumol, Inst Invest Biomed August Pi & Sunyer IDIBAPS,Ins, Barcelona, Spain; [Liapikou, Adamantia] Sotiria Chest Dis Hosp, Resp Dept, Athens, Greece; [Martin-Loeches, Ignacio] Trinity Coll Dublin, St Jamess Univ Hosp, Dept Clin Med, MICRO, Dublin, Ireland; [Garcia-Vidal, Carolina; Mensa, Josep] Hosp Clin Barcelona, Dept Infect Dis, Barcelona, Spain; [Magdaleno, Daniel] Natl Polytech Inst Mexico City, Super Med Sch, Mexico City, DF, Mexico; [Marco, Francesc] Univ Barcelona, Hosp Clin Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Dept Microbiol Biomed Diagnost Ctr CDB,ISGlobal, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Trinity College Dublin; University of Barcelona; Hospital Clinic de Barcelona; Instituto Politecnico Nacional - Mexico; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona	Torres, A (corresponding author), Univ Barcelona, Hosp Clin Barcelona, SGR Ciber Enfermedades Resp Ciberes,Dept Pneumol, Inst Invest Biomed August Pi & Sunyer IDIBAPS,Ins, Barcelona, Spain.	atorres@clinic.cat	, Ceccato/O-8785-2018; Torres, Antoni/H-6128-2017; Lliapikou, Adamadia/H-8512-2019; Cillóniz, Catia/Y-1898-2018; Marco, Francesc/K-2900-2017; martin-loeches, Prof. Ignacio/Q-6645-2018	, Ceccato/0000-0001-9454-062X; Torres, Antoni/0000-0002-8643-2167; Marco, Francesc/0000-0002-1863-6379; martin-loeches, Prof. Ignacio/0000-0002-5834-4063; cilloniz, catia/0000-0002-4646-9838; Gabarrus, Albert/0000-0003-3492-1310; Garcia-Vidal, Carolina/0000-0002-8915-0683	Ciber de Enfermedades Respiratorias, 2009 Support to Research Groups of Catalonia 911, IDIBAPS (CERCA Programme / Generalitat de Catalunya) [CibeRes CB06/06/0028]	Ciber de Enfermedades Respiratorias, 2009 Support to Research Groups of Catalonia 911, IDIBAPS (CERCA Programme / Generalitat de Catalunya)	This work was supported by Ciber de Enfermedades Respiratorias (CibeRes CB06/06/0028), 2009 Support to Research Groups of Catalonia 911, IDIBAPS (CERCA Programme / Generalitat de Catalunya). The funding sources had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Cilloniz C, 2012, CLIN MICROBIOL INFEC, V18, P1134, DOI 10.1111/j.1469-0691.2011.03692.x; Cilloniz C, 2017, RESPIROL CARLTON VIC; Cilloniz C, 2011, THORAX, V66, P340, DOI 10.1136/thx.2010.143982; Daniel P, 2016, THORAX, V71, P1061, DOI 10.1136/thoraxjnl-2016-208937; de Miguel-Diez J, 2017, EUR J INTERN MED, V40, P64, DOI 10.1016/j.ejim.2016.12.010; Dean NC, 2001, AM J MED, V110; Dela Cruz CS, 2018, AM J RESP CRIT CARE; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z; Efron B., 1994, INTRO BOOTSTRAP, DOI DOI 10.1201/9780429246593; Fatykhova D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137108; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Gattarello S, 2014, CHEST, V146, P22, DOI 10.1378/chest.13-1531; Georges H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-196; Htar MTT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1147-x; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kurt OK, 2016, CURR OPIN PULM MED, V22, P138, DOI 10.1097/MCP.0000000000000248; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Lopez-de-Andres A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013097; Ma JM, 2015, JAMA-J AM MED ASSOC, V314, P1731, DOI 10.1001/jama.2015.12319; Mandell LA, 2003, CLIN INFECT DIS, V37, P1405, DOI 10.1086/380488; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Martinez E, 2017, ERJ OPEN RES, V3; Mongardon N, 2012, CRIT CARE, V16, DOI 10.1186/cc11471; Moore D, INTRO PRACTICE STAT; Moraga-Llop F, 2016, PEDIATR INFECT DIS J, V35, P460, DOI 10.1097/INF.0000000000001041; Munoz-Almagro C, 2008, CLIN INFECT DIS, V46, P174, DOI 10.1086/524660; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Pletz M W, 2012, Pneumologie, V66, P470; Psaty BM, 2010, JAMA-J AM MED ASSOC, V304, P897, DOI 10.1001/jama.2010.1205; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Ruhnke GW, 2010, MED CARE, V48, P1111, DOI 10.1097/MLR.0b013e3181f38006; Simonetti AF, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.03.015; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Van Houwelingen H., 1994, MODELLING SURVIVAL D, V14, P1147; Vila-Corcoles A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3096-7; Vila-Corcoles A, 2016, HUM VACC IMMUNOTHER, V12, P2953, DOI 10.1080/21645515.2016.1210744; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502; Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x; Woodhead M, 2006, CRIT CARE, V10, DOI 10.1186/cc4927	45	22	22	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2018	13	7							e0200504	10.1371/journal.pone.0200504	http://dx.doi.org/10.1371/journal.pone.0200504			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN4SJ	30020995	Green Published, gold			2023-01-03	WOS:000439022400051
J	Franca, DDD; Alves Del-Rios, NHA; Carneiro, MAD; Guimaraes, RA; Caetano, KAA; Reis, MND; Martins, RMB; Motta-Castro, ARC; Stefani, MMD; Teles, SA				da Silva Franca, Divania Dias; Alves Del-Rios, Native Helena; dos Santos Carneiro, Megmar Aparecida; Guimaraes, Rafael Alves; Amorim Caetano, Karlla Antonieta; da Guarda Reis, Monica Nogueira; Bringel Martins, Regina Maria; Coimbra Motta-Castro, Ana Rita; de Araujo Stefani, Mariane Martins; Teles, Sheila Araujo			HIV-1 infection among crack cocaine users in a region far from the epicenter of the HIV epidemic in Brazil: Prevalence and molecular characteristics	PLOS ONE			English	Article							SEXUAL RISK BEHAVIORS; INJECTION-DRUG USE; TRANSMISSION; PREVENTION; SALVADOR; DISEASE; IMPACT	Brazil has the largest cocaine market in South America, and crack cocaine use is closely associated with HIV-1 infection. This study investigated the prevalence, risk factors, and HIV-1 subtypes, including recombinant forms and mutations associated with drug resistance, among crack cocaine users in Central-West Brazil. We recruited 600 crack cocaine users admitted to a referral hospital in Goiania for psychiatric disorders. The participants were interviewed; blood samples were collected for anti-HIV-1/2 serological screening. HIV-1 pol gene sequences (entire protease [PR] and partial reverse transcriptase [RT]) were obtained from plasma RNA. HIV-1 subtypes, recombinant viruses, transmitted drug resistance (TDR), and secondary drug resistance mutations were investigated. The median participant age was 30 years (range, 18-68 years); most were male, single, unemployed, and of mixed races. Among them, 2.8% (17/600) were HIV-1 positive: 2.2% of men (11/507) and 6.5% of women (6/93). The main predictors of HIV-1 seropositivity were a sexual partner with HIV infection, irregular condom use, and previous homelessness. HIV-1 pol sequences (12/17) indicated the predominance of subtype B (n = 7), followed by recombinant forms F-PR/B-RT (n = 1) and B-PR/F-RT (n = 2) and subtypes F1 (n = 1) and C (n = 1). TDR prevalence was 58.3% (7/12). Isolates from two participants showed mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTI) only (M41L, T125C, T125F, M184V), while an isolate from one patient who had received antiretroviral therapy (ART) since 2008 had a mutation associated with resistance to non-NRTI (G190S). Five isolates had secondary mutations to protease inhibitors (K20M, L10V, L33I, A71T, A71V). In conclusion, the findings of HIV-1 circulation, TDR to NRTI, and secondary mutations to protease inhibitors in ART-naive crack cocaine users support the importance of monitoring this population in regions far from the epicenter of the HIV epidemic.	[da Silva Franca, Divania Dias] Municipal Secretary Hlth Goiania, Dept Epidemiol, Goiania, Go, Brazil; [Alves Del-Rios, Native Helena; dos Santos Carneiro, Megmar Aparecida; da Guarda Reis, Monica Nogueira; Bringel Martins, Regina Maria; de Araujo Stefani, Mariane Martins] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil; [Guimaraes, Rafael Alves; Amorim Caetano, Karlla Antonieta; Teles, Sheila Araujo] Univ Fed Goias, Fac Nursing, Goiania, Go, Brazil; [Coimbra Motta-Castro, Ana Rita] Univ Fed Mato Grosso do Sul, Ctr Biol & Hlth Sci, Campo Grande, MS, Brazil	Universidade Federal de Goias; Universidade Federal de Goias; Universidade Federal de Mato Grosso do Sul	Teles, SA (corresponding author), Univ Fed Goias, Fac Nursing, Goiania, Go, Brazil.	Sheila.fen@gmail.com	Caetano, Karlla Antonieta A/M-4025-2016; Teles, Sheila Araujo/D-8837-2015; Carneiro, Megmar/O-6482-2018; TELES, SHEILA/X-7998-2019	Caetano, Karlla Antonieta A/0000-0003-4818-4753; Teles, Sheila Araujo/0000-0003-4030-6947; Carneiro, Megmar/0000-0003-0569-477X; TELES, SHEILA/0000-0002-7059-4241; Motta-Castro, Ana Rita/0000-0003-3070-1337	Brazilian National Research Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico in portuguese - CNPq); Foundation for Research Support of Goias State (Fundacao de Amparo a Pesquisa do Estado de Goias in Portuguese - FAPEG); FUNDECT/CNPq PRONEM - MS [074/2015]	Brazilian National Research Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico in portuguese - CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Foundation for Research Support of Goias State (Fundacao de Amparo a Pesquisa do Estado de Goias in Portuguese - FAPEG); FUNDECT/CNPq PRONEM - MS(Fundacao de Apoio ao Desenvolvimento do Ensino Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT MS))	The authors express their gratitude to Brazilian National Research Council (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico in portuguese - CNPq) and Foundation for Research Support of Goias State (Fundacao de Amparo a Pesquisa do Estado de Goias in Portuguese - FAPEG) for funding. The authors also received funding from FUNDECT/CNPq PRONEM - MS. Process no 074/2015.	Abdalla RR, 2014, ADDICT BEHAV, V39, P297, DOI 10.1016/j.addbeh.2013.10.019; Aldous JL, 2012, CLIN INFECT DIS, V55, P1135, DOI 10.1093/cid/cis612; [Anonymous], 2009, RELATORIO BRASILEIRO; Atkinson JS, 2010, AIDS BEHAV, V14, P48, DOI 10.1007/s10461-007-9346-0; Bastos FI, 2014, PESQUISA NACL USO CR; Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129; Bertoni N, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0070-x; Brenner B, 2013, AIDS, V27, P1045, DOI 10.1097/QAD.0b013e32835cffd9; Cruz M, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-2; Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012; de Carvalho HB, 2009, CLINICS, V64, P857, DOI 10.1590/S1807-59322009000900006; DeBeck K, 2009, CAN MED ASSOC J, V181, P585, DOI 10.1503/cmaj.082054; Departamento de DST AeHV, 2014, B EP HIV AIDS, P77; Dickson-Gomez J, 2012, SUBST USE MISUSE, V47, P265, DOI 10.3109/10826084.2011.635325; Diehl A, 2014, ADICCIONES, V26, P208, DOI 10.20882/adicciones.2; Duailibi Lígia Bonacim, 2008, Cad. Saúde Pública, V24, ps545, DOI 10.1590/S0102-311X2008001600007; Duff P, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-29; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; Fischer B, 2013, INT J DRUG POLICY, V24, P631, DOI 10.1016/j.drugpo.2013.09.003; Frost SDW, 2015, J INFECT DIS, V211, P856, DOI 10.1093/infdis/jiu563; Gomez MP, 2002, SEX TRANSM DIS, V29, P259, DOI 10.1097/00007435-200205000-00002; Grabowski MK, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001610; Guimaraes ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141372; Hwang LY, 2000, CLIN INFECT DIS, V31, P920, DOI 10.1086/318131; Khan MR, 2013, AIDS BEHAV, V17, P1185, DOI 10.1007/s10461-012-0276-0; Malta Monica, 2008, Rev. Saúde Pública, V42, P830, DOI 10.1590/S0034-89102008000500007; McCoy CB, 2004, ANN EPIDEMIOL, V14, P535, DOI 10.1016/j.annepidem.2003.10.001; Narvaez JCM, 2014, SOC PSYCH PSYCH EPID, V49, P1249, DOI 10.1007/s00127-014-0830-3; Narvaez JCM, 2014, COMPR PSYCHIAT, V55, P1369, DOI 10.1016/j.comppsych.2014.04.021; Nunes CLX, 2007, BRAZ J INFECT DIS, V11, P561, DOI 10.1590/S1413-86702007000600007; Perez AO, 2015, EUR ADDICT RES, V21, P53, DOI 10.1159/000363737; Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499; Poon AFY, 2015, J INFECT DIS, V211, P926, DOI 10.1093/infdis/jiu560; Prevention CDC, 2017, DET INV RESP HIV TRA, P57; Ribeiro M, 2006, REV BRAS PSIQUIATR, V28, P196, DOI 10.1590/S1516-44462006000300010; UNODC, 2015, UNITED NATIONS PUBL, P162; Cardoso LPV, 2011, AIDS RES HUM RETROV, V27, P1349, DOI 10.1089/aid.2011.0153; Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009; von Diemen L, 2010, ARCH WOMEN MENT HLTH, V13, P185, DOI 10.1007/s00737-009-0089-y; Wertheim JO, 2014, J INFECT DIS, V209, P304, DOI 10.1093/infdis/jit524	40	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2018	13	7							e0199606	10.1371/journal.pone.0199606	http://dx.doi.org/10.1371/journal.pone.0199606			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GN2XR	30016324	Green Published, gold, Green Submitted			2023-01-03	WOS:000438866600010
J	Teno, JM; Gozalo, P; Trivedi, AN; Bunker, J; Lima, J; Ogarek, J; Mor, V				Teno, Joan M.; Gozalo, Pedro; Trivedi, Amal N.; Bunker, Jennifer; Lima, Julie; Ogarek, Jessica; Mor, Vincent			Site of Death, Place of Care, and Health Care Transitions Among US Medicare Beneficiaries, 2000-2015	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-OF-LIFE; NURSING-HOME RESIDENTS; FAMILY PERSPECTIVES; HOSPICE ENROLLEES; INTENSIVE-CARE; HIGH-COST; QUALITY; OUTCOMES; CANCER; ADVANTAGE	IMPORTANCE End-of-life care costs are high and decedents often experience poor quality of care. Numerous factors influence changes in site of death, health care transitions, and burdensome patterns of care. OBJECTIVE To describe changes in site of death and patterns of care among Medicare decedents. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study among a 20% random sample of 1 361 870 decedents who had Medicare fee-for-service (2000, 2005, 2009, 2011, and 2015) and a 100% sample of 871 845 decedents who had Medicare Advantage (2011 and 2015) and received care at an acute care hospital, at home or in the community, at a hospice inpatient care unit, or at a nursing home. EXPOSURES Secular changes between 2000 and 2015. MAIN OUTCOMES AND MEASURES Medicare administrative data were used to determine site of death, place of care, health care transitions, which are changes in location of care, and burdensome patterns of care. Burdensome patterns of care were based on health care transitions during the last 3 days of life and multiple hospitalizations for infections or dehydration during the last 120 days of life. RESULTS The site of death and patterns of care were studied among 1 361 870 decedents who had Medicare fee-for-service (mean [SD] age, 82.8 [8.4] years; 58.7% female) and 871 845 decedents who had Medicare Advantage (mean [SD] age, 82.1 [8.5] years; 54.0% female). Among Medicare fee-for-service decedents, the proportion of deaths that occurred in an acute care hospital decreased from 32.6%(95% CI, 32.4%-32.8%) in 2000 to 19.8%(95% CI, 19.6%-20.0%) in 2015, and deaths in a home or community setting that included assisted living facilities increased from 30.7%(95% CI, 30.6%-30.9%) in 2000 to 40.1%(95% CI, 39.9%-30.3%) in 2015. Use of the intensive care unit during the last 30 days of life among Medicare fee-for-service decedents increased from 24.3%(95% CI, 24.1%-24.4%) in 2000 and then stabilized between 2009 and 2015 at 29.0%(95% CI, 28.8%-29.2%). Among Medicare fee-for-service decedents, health care transitions during the last 3 days of life increased from 10.3%(95% CI, 10.1%-10.4%) in 2000 to a high of 14.2%(95% CI, 14.0%-14.3%) in 2009 and then decreased to 10.8%(95% CI, 10.6%-10.9%) in 2015. The number of decedents enrolled in Medicare Advantage during the last 90 days of life increased from 358 600 in 2011 to 513 245 in 2015. Among decedents with Medicare Advantage, similar patterns in the rates for site of death, place of care, and health care transitions were observed. CONCLUSIONS AND RELEVANCE Among Medicare fee-for-service beneficiaries who died in 2015 compared with 2000, there was a lower likelihood of dying in an acute care hospital, an increase and then stabilization of intensive care unit use during the last month of life, and an increase and then decline in health care transitions during the last 3 days of life.	[Teno, Joan M.; Bunker, Jennifer] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA; [Gozalo, Pedro; Trivedi, Amal N.; Lima, Julie; Ogarek, Jessica; Mor, Vincent] Brown Univ, Dept Hlth Serv Policy & Practice, Sch Publ Hlth, Providence, RI 02912 USA; [Gozalo, Pedro; Trivedi, Amal N.; Mor, Vincent] Providence VA Med Ctr, Providence, RI USA	Oregon Health & Science University; Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Teno, JM (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Ste L475, Portland, OR 97239 USA.	teno@ohsu.edu			Robert Wood Johnson Foundation; National Institute on Aging [P01AG027296]; NATIONAL INSTITUTE ON AGING [P01AG027296] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was funded by grants from the Robert Wood Johnson Foundation (awarded to Dr Teno) and grant P01AG027296 from the National Institute on Aging.	Aldridge MD, 2015, AM J PUBLIC HEALTH, V105, P2411, DOI 10.2105/AJPH.2015.302889; Barnato AE, 2008, AM J RESP CRIT CARE, V177, P279, DOI 10.1164/rccm.200703-480OC; Blumenthal D, 2016, JAMA-J AM MED ASSOC, V316, P1657, DOI 10.1001/jama.2016.12388; Cartwright Juliana C, 2002, Annu Rev Nurs Res, V20, P231; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Dumanovsky T, 2016, J PALLIAT MED, V19, P8, DOI 10.1089/jpm.2015.0351; Enguidanos S, 2005, J AM GERIATR SOC, V53, P1411, DOI 10.1111/j.1532-5415.2005.53410.x; Huckfeldt PJ, 2017, HEALTH AFFAIR, V36, P91, DOI 10.1377/hlthaff.2016.1027; Institute of Medicine, 2015, DYING AM IMPR QUAL H; Intrator O, 2011, HEALTH SERV RES, V46, P120, DOI 10.1111/j.1475-6773.2010.01194.x; Johnson KS, 2005, J AM GERIATR SOC, V53, P2209, DOI 10.1111/j.1532-5415.2005.00502.x; Khandelwal N, 2017, J PALLIAT MED, V20, P1400, DOI 10.1089/jpm.2017.0065; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koroukian SM, 2017, J GERIATR ONCOL, V8, P117, DOI 10.1016/j.jgo.2016.10.001; Makaroun LK, 2018, J AM GERIATR SOC, V66, P1730, DOI 10.1111/jgs.15455; Mularski RA, 2005, CHEST, V128, P280, DOI 10.1378/chest.128.1.280; Villar SR, 2012, CHEST, V141, P1635, DOI 10.1378/chest.11-3099; Stevenson DG, 2015, HEALTH AFFAIR, V34, P30, DOI 10.1377/hlthaff.2014.0599; Stevenson DG, 2013, MED CARE, V51, P931, DOI 10.1097/MLR.0b013e3182a50278; Teno JM, 2005, J AM GERIATR SOC, V53, P1905, DOI 10.1111/j.1532-5415.2005.53563.x; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2013, JAMA-J AM MED ASSOC, V310, P319, DOI 10.1001/jama.2013.8392; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Tolle SW, 2017, NEW ENGL J MED, V376, P1078, DOI 10.1056/NEJMsb1612511; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Welch LC, 2005, J AM GERIATR SOC, V53, P1145, DOI 10.1111/j.1532-5415.2005.53357.x; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	28	199	200	3	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2018	320	3					264	271		10.1001/jama.2018.8981	http://dx.doi.org/10.1001/jama.2018.8981			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GN3JE	29946682	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000438900300020
J	Shin, SW; Jeon, JH; Jeong, SA; Kim, JA; Park, DS; Shin, Y; Oh, HW				Shin, Sang Woon; Jeon, Jun Hyoung; Jeong, Seon Ah; Kim, Ji-Ae; Park, Doo-Sang; Shin, Yunhee; Oh, Hyun-Woo			A plant diterpene counteracts juvenile hormone-mediated gene regulation during Drosophila melanogaster larval development	PLOS ONE			English	Article							MALE ACCESSORY-GLANDS; RED FLOUR BEETLE; METHOPRENE-TOLERANT; PROTEIN-SYNTHESIS; METAMORPHOSIS; TRANSCRIPTION; EXPRESSION; RECEPTOR; MET; KRUPPEL-HOMOLOG-1	Many plant species possess compounds with juvenile hormone disruptor (JHD) activity. In some plant species, such activity has been attributed to diterpene secondary metabolites. Plant JHD diterpenes disrupt insect development by interfering with the juvenile hormone (JH)-mediated formation of JH receptor complexes. Here, we demonstrate that a plant extract and a diterpene from Lindera erythrocarpa (methyl lucidone) interfere with the formation of both methoprene-tolerant (Met)/Taiman and Germ cell-expressed (GCE)/Taiman heterodimer complexes in yeast two-hybrid assays in vitro. In addition to the in vitro JHD activity, the diterpene and the plant extract from L. erythrocarpa also disrupt the development of larvae and pupae in Drosophila melanogaster. Comparing the transcriptomes of juvenile hormone analog (JHA, methoprene)- and JHD (methyl lucidone)-fed wandering third-instar larvae revealed a large number of genes that were coregulated by JHA and JHD. Moreover, most (83%) of the genes that were repressed by methyl lucidone were significantly activated by methoprene, indicating that JHDs and JHAs have opposing effects on the transcriptional regulation of many JH-dependent genes. Gene ontology analysis also suggested that some of the genes activated-by-JHA/repressed-by-JHD play roles in spermatogenesis. Affymetrix microarray-based analysis indicated that the expression of genes activated-by-JHA/repressed-by-JHD was testis-specific. Together, these results suggest that JH is involved in testis-specific gene expression and that plant JHD diterpenes function as JH antagonists in such JHA-mediated gene regulation.	[Shin, Sang Woon; Kim, Ji-Ae; Oh, Hyun-Woo] Korea Res Inst Biosci & Biotechnol, Core Facil Management Ctr, Daejeon, South Korea; [Jeon, Jun Hyoung; Jeong, Seon Ah; Park, Doo-Sang] Korea Res Inst Biosci & Biotechnol, Biol Resource Ctr, Jeongeup, South Korea; [Shin, Yunhee] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of California System; University of California Berkeley	Shin, SW; Oh, HW (corresponding author), Korea Res Inst Biosci & Biotechnol, Core Facil Management Ctr, Daejeon, South Korea.	shinwoongg@gmail.com; hwoh@kribb.re.kr		Shin, Sang Woon/0000-0001-9467-0803	KRIBB Research Initiative Program [KGM4981814]; National Research Foundation of Korea [2016M3A9A5919255]	KRIBB Research Initiative Program; National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the KRIBB Research Initiative Program (KGM4981814), awarded to H.O., and the National Research Foundation of Korea (2016M3A9A5919255), awarded to DP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdou M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026772; Abdou MA, 2011, INSECT BIOCHEM MOLEC, V41, P938, DOI 10.1016/j.ibmb.2011.09.003; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashok M, 1998, P NATL ACAD SCI USA, V95, P2761, DOI 10.1073/pnas.95.6.2761; Barry J, 2008, INSECT BIOCHEM MOLEC, V38, P346, DOI 10.1016/j.ibmb.2007.12.001; Baumann A, 2010, J INSECT PHYSIOL, V56, P1445, DOI 10.1016/j.jinsphys.2010.05.001; Charles JP, 2011, P NATL ACAD SCI USA, V108, P21128, DOI 10.1073/pnas.1116123109; CHEN PS, 1984, ANNU REV ENTOMOL, V29, P233, DOI 10.1146/annurev.en.29.010184.001313; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; COUCHE GA, 1985, CAN J ZOOL, V63, P2789, DOI 10.1139/z85-417; Davey K.G., 1985, P1; Godlewski J, 2006, BIOCHEM BIOPH RES CO, V342, P1305, DOI 10.1016/j.bbrc.2006.02.097; GOLD SMW, 1989, INSECT BIOCHEM, V19, P139, DOI 10.1016/0020-1790(89)90084-X; Hempel LU, 2006, DEV DYNAM, V235, P1053, DOI 10.1002/dvdy.20698; Hiller M, 2004, DEVELOPMENT, V131, P5297, DOI 10.1242/dev.01314; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Jensen LJ, 2008, NUCLEIC ACIDS RES, V36, pD250, DOI 10.1093/nar/gkm796; Jindra M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005394; Jindra M, 2013, ANNU REV ENTOMOL, V58, P181, DOI 10.1146/annurev-ento-120811-153700; Kayukawa T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01570; Kayukawa T, 2012, P NATL ACAD SCI USA, V109, P11729, DOI 10.1073/pnas.1204951109; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091; Lee SH, 2015, P NATL ACAD SCI USA, V112, P1733, DOI 10.1073/pnas.1424386112; LEOPOLD RA, 1976, ANNU REV ENTOMOL, V21, P199, DOI 10.1146/annurev.en.21.010176.001215; Li M, 2011, P NATL ACAD SCI USA, V108, P638, DOI 10.1073/pnas.1013914108; Liu Y, 2009, DEVELOPMENT, V136, P2015, DOI 10.1242/dev.033712; Lozano J, 2011, SCI REP-UK, V1, DOI 10.1038/srep00163; Lyne R, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r129; Minakuchi C, 2009, DEV BIOL, V325, P341, DOI 10.1016/j.ydbio.2008.10.016; Minakuchi C, 2008, MECH DEVELOP, V125, P91, DOI 10.1016/j.mod.2007.10.002; Miura K, 2005, FEBS J, V272, P1169, DOI 10.1111/j.1742-4658.2005.04552.x; Oh HW, 2017, J CHEM ECOL, V43, P703, DOI 10.1007/s10886-017-0861-9; Parthasarathy R, 2009, MECH DEVELOP, V126, P563, DOI 10.1016/j.mod.2009.03.005; REGIS L, 1985, INSECT SCI APPL, V6, P579, DOI 10.1017/S1742758400009139; RIDDIFORD LM, 1994, J NEUROBIOL, V25, P819, DOI 10.1002/neu.480250707; RIDDIFORD LM, 1991, GEN COMP ENDOCR, V82, P172, DOI 10.1016/0016-6480(91)90181-5; Robinson SW, 2013, NUCLEIC ACIDS RES, V41, pD744, DOI 10.1093/nar/gks1141; SHEMSHEDINI L, 1990, J BIOL CHEM, V265, P1913; Shin SW, 2012, P NATL ACAD SCI USA, V109, P16576, DOI 10.1073/pnas.1214209109; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; Wang SL, 2007, J INSECT PHYSIOL, V53, P246, DOI 10.1016/j.jinsphys.2006.07.011; White-Cooper H, 1998, DEVELOPMENT, V125, P125; Wilson TG, 1998, P NATL ACAD SCI USA, V95, P14040, DOI 10.1073/pnas.95.24.14040; Wilson TG, 2003, INSECT BIOCHEM MOLEC, V33, P1167, DOI 10.1016/j.ibmb.2003.06.007; YAMAMOTO K, 1988, SCIENCE, V239, P916, DOI 10.1126/science.3124270; Zhang ZL, 2011, J BIOL CHEM, V286, P8437, DOI 10.1074/jbc.M110.191684	48	2	3	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2018	13	7							e0200706	10.1371/journal.pone.0200706	http://dx.doi.org/10.1371/journal.pone.0200706			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2LQ	30011330	Green Submitted, gold, Green Published			2023-01-03	WOS:000438829800046
J	Ma, K; Gong, YY; Aubert, T; Turker, MZ; Kao, T; Doerschuk, PC; Wiesner, U				Ma, Kai; Gong, Yunye; Aubert, Tangi; Turker, Melik Z.; Kao, Teresa; Doerschuk, Peter C.; Wiesner, Ulrich			Self-assembly of highly symmetrical, ultrasmall inorganic cages directed by surfactant micelles	NATURE			English	Article							PROTEIN NANOMATERIALS; SILICA NANOPARTICLES; MESOPOROUS SILICA; DNA; MICROSCOPY; POLYHEDRA; MECHANISM; CLUSTERS; DESIGN; GROWTH	Nanometre-sized objects with highly symmetrical, cage-like polyhedral shapes, often with icosahedral symmetry, have recently been assembled from DNA(1-3), RNA(4) or proteins(5,6) for applications in biology and medicine. These achievements relied on advances in the development of programmable self-assembling biological materials(7-10), and on rapidly developing techniques for generating three-dimensional (3D) reconstructions from cryo-electron microscopy images of single particles, which provide high-resolution structural characterization of biological complexes(11-13). Such single-particle 3D reconstruction approaches have not yet been successfully applied to the identification of synthetic inorganic nanomaterials with highly symmetrical cage-like shapes. Here, however, using a combination of cryo-electron microscopy and single-particle 3D reconstruction, we suggest the existence of isolated ultrasmall (less than 10 nm) silica cages ('silicages') with dodecahedral structure. We propose that such highly symmetrical, self-assembled cages form through the arrangement of primary silica clusters in aqueous solutions on the surface of oppositely charged surfactant micelles. This discovery paves the way for nanoscale cages made from silica and other inorganic materials to be used as building blocks for a wide range of advanced functional-materials applications.	[Ma, Kai; Aubert, Tangi; Turker, Melik Z.; Kao, Teresa; Wiesner, Ulrich] Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA; [Gong, Yunye; Doerschuk, Peter C.] Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY USA; [Aubert, Tangi] Univ Ghent, Dept Chem, Ghent, Belgium; [Doerschuk, Peter C.] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY USA	Cornell University; Cornell University; Ghent University; Cornell University	Wiesner, U (corresponding author), Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA.	ubw1@cornell.edu	Turker, Melik Ziya/AAJ-4589-2021; Ma, Kai/C-4055-2017; Aubert, Tangi/J-1979-2014; Turker, Melik Ziya/AAG-6617-2021	Turker, Melik Ziya/0000-0001-7801-4275; Ma, Kai/0000-0003-4415-6894; Aubert, Tangi/0000-0003-0905-3822; Turker, Melik Ziya/0000-0001-7801-4275	National Cancer Institute of the National Institutes of Health [U54CA199081]; National Science Foundation (NSF) [1217867]; Google PhD Fellowship in Machine Learning; Ghent University Special Research Fund [BOF14/PDO/007]; European Union [MSCA-IF-2015-702300, MSCA-RISE-691185]; Ministry of National Education of the Republic of Turkey; NSF Materials Research Science and Engineering Center program [DMR-1719875]; Nanobiotechnology Center's shared research facilities at Cornell; NATIONAL CANCER INSTITUTE [U54CA199081] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation (NSF)(National Science Foundation (NSF)); Google PhD Fellowship in Machine Learning(Google Incorporated); Ghent University Special Research Fund(Ghent University); European Union(European Commission); Ministry of National Education of the Republic of Turkey(Ministry of National Education - Turkey); NSF Materials Research Science and Engineering Center program(National Science Foundation (NSF)); Nanobiotechnology Center's shared research facilities at Cornell; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by the National Cancer Institute of the National Institutes of Health under award number U54CA199081. Y.G. and P.C.D. acknowledge financial support from the National Science Foundation (NSF) under grant number 1217867, and Y.G. acknowledges financial support from a 2017 Google PhD Fellowship in Machine Learning. T.A. acknowledges financial support from the Ghent University Special Research Fund (BOF14/PDO/007) and the European Union's Horizon 2020 research and innovation program (MSCA-IF-2015-702300 and MSCA-RISE-691185). M.Z.T. acknowledges fellowship support from the Ministry of National Education of the Republic of Turkey. This work used shared facilities of the Cornell Center for Materials Research, with funding from the NSF Materials Research Science and Engineering Center program (DMR-1719875), as well as the Nanobiotechnology Center's shared research facilities at Cornell. The authors thank V. Elser, Y. Jiang and D. Zhang for helpful discussions.	Afonin KA, 2010, NAT NANOTECHNOL, V5, P676, DOI [10.1038/nnano.2010.160, 10.1038/NNANO.2010.160]; Carcouet CCMC, 2014, NANO LETT, V14, P1433, DOI 10.1021/nl404550d; Dai XH, 2017, NATURE, V541, P112, DOI 10.1038/nature20589; Douglas SM, 2009, NATURE, V459, P1154, DOI 10.1038/nature08165; DUFF DG, 1993, LANGMUIR, V9, P2301, DOI 10.1021/la00033a010; Fernandez-Leiro R, 2016, NATURE, V537, P339, DOI 10.1038/nature19948; Gong YY, 2016, J STRUCT BIOL, V193, P188, DOI 10.1016/j.jsb.2015.12.012; HARAUZ G, 1986, OPTIK, V73, P146; He Y, 2008, NATURE, V452, P198, DOI 10.1038/nature06597; Hsia Y, 2016, NATURE, V540, DOI 10.1038/nature20108; Hsia Y, 2016, NATURE, V535, P136, DOI 10.1038/nature18010; Iinuma R, 2014, SCIENCE, V344, P65, DOI 10.1126/science.1250944; Ji BT, 2015, NAT NANOTECHNOL, V10, P170, DOI [10.1038/NNANO.2014.298, 10.1038/nnano.2014.298]; Ke YG, 2012, SCIENCE, V338, P1177, DOI 10.1126/science.1227268; King NP, 2014, NATURE, V510, P103, DOI 10.1038/nature13404; King NP, 2012, SCIENCE, V336, P1171, DOI 10.1126/science.1219364; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Ma K, 2016, CHEM MATER, V28, P1537, DOI 10.1021/acs.chemmater.6b00030; Ma K, 2015, CHEM MATER, V27, P4119, DOI 10.1021/acs.chemmater.5b01222; Ma K, 2012, J AM CHEM SOC, V134, P13180, DOI 10.1021/ja3049783; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phillips E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009524; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Sullivan LM, 2014, J CLUST SCI, V25, P313, DOI 10.1007/s10876-013-0665-1; Sun Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00351-8; Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009; Westcott SL, 1998, LANGMUIR, V14, P5396, DOI 10.1021/la980380q; Xiao CH, 2012, NATURE, V487, P349, DOI 10.1038/nature11230; Yin P, 2008, NATURE, V451, P318, DOI 10.1038/nature06451; Zandi R, 2004, P NATL ACAD SCI USA, V101, P15556, DOI 10.1073/pnas.0405844101; Zhao ML, 2015, NATURE, V518, P61, DOI 10.1038/nature14148	33	63	64	15	364	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2018	558	7711					577	+		10.1038/s41586-018-0221-0	http://dx.doi.org/10.1038/s41586-018-0221-0			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK9SN	29925942	Green Submitted, Green Published			2023-01-03	WOS:000436594300058
J	Aghaizu, A; Tosswill, J; De Angelis, D; Ward, H; Hughes, G; Murphy, G; Delpech, V				Aghaizu, Adamma; Tosswill, Jennifer; De Angelis, Daniela; Ward, Helen; Hughes, Gwenda; Murphy, Gary; Delpech, Valerie			HIV incidence among sexual health clinic attendees in England: First estimates for black African heterosexuals using a biomarker, 2009-2013	PLOS ONE			English	Article							TESTING ALGORITHM; MEN; INFECTIONS; ACCURACY; ASSAYS	Introduction The HIV epidemic in England is largely concentrated among heterosexuals who are predominately black African and men who have sex with men (MSM). We present for the first time trends in annual HIV incidence for adults attending sexual health clinics, where 80% of all HIV diagnoses are made. Methods We identified newly diagnosed incident HIV using a recent infection testing algorithm (RITA) consisting of a biomarker (AxSYM assay, modified to determine antibody avidity), epidemiological and clinical information. We estimated HIV incidence using the WHO RITA formula for cross-sectional studies, with HIV testing data from sexual health clinics as the denominator. Results From 2009 to 2013, each year, between 9,700 and 26,000 black African heterosexuals (of between 161,000 and 231,000 heterosexuals overall) were included in analyses. For the same period, annually between 19,000 and 55,000 MSM were included. Estimates of HIV incidence among black Africans increased slightly (although non-significantly) from 0.15% (95% C.I. 0.05%-0.26%) in 2009 to 0.19% (95% C.I. 0.04%-0.34%) in 2013 and was 4-5-fold higher than among all heterosexuals among which it remained stable between 0.03% (95% C.I. 0.02%-0.05%) and 0.05% (95% C.I. 0.03%-0.07%) over the period. Among MSM incidence was highest and increased (non-significantly) from 1.24% (95% C.I 0.96 +/- 1.52%) to 1.46% (95% C.I 1.23%-1.70%) after a peak of 1.52% (95% C.I 1.30%-1.75%) in 2012. Conclusion These are the first nationwide estimates for trends in HIV incidence among black African and heterosexual populations in England which show black Africans, alongside MSM, remain disproportionately at risk of infection. Although people attending sexual health clinics may not be representative of the general population, nearly half of black Africans and MSM had attended in the previous 5 years. Timely and accurate incidence estimates will be critical in monitoring the impact of the reconfiguration of sexual health services in England, and any prevention programmes such as pre- exposure prophylaxis.	[Aghaizu, Adamma; Tosswill, Jennifer; De Angelis, Daniela; Hughes, Gwenda; Murphy, Gary; Delpech, Valerie] Publ Hlth England, Natl Infect Serv, Colindale Ave, London, England; [Aghaizu, Adamma; Ward, Helen] Imperial Coll London, Dept Infect Dis Epidemiol, Sch Publ Hlth, Norfolk Pl, London, England; [De Angelis, Daniela] Inst Publ Hlth, RC Biostat Unit, Forvie Site, Cambridge, England	Public Health England; Imperial College London; University of Cambridge	Aghaizu, A (corresponding author), Publ Hlth England, Natl Infect Serv, Colindale Ave, London, England.; Aghaizu, A (corresponding author), Imperial Coll London, Dept Infect Dis Epidemiol, Sch Publ Hlth, Norfolk Pl, London, England.	adamma.aghaizu@phe.gov.uk	Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036; delpech, valerie/0000-0002-9952-8109; Hughes, Gwenda/0000-0003-2090-7702; De Angelis, Daniela/0000-0001-6619-6112	Public Health England; MRC [MC_UU_00002/11] Funding Source: UKRI	Public Health England; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by Public Health England. The research is secondary analysis of surveillance data collected by Public Health England.	AGHAIZU A, 2011, EUROSURVEILLANCE, V19, P20673; [Anonymous], 2014, CEPHIA CONSORTIUM EV; Birrell PJ, 2013, LANCET INFECT DIS, V13, P313, DOI 10.1016/S1473-3099(12)70341-9; CEPHIA, 2015, INC INF US BIOM REC; Dunn D, 2014, AIDS, V28, P773, DOI 10.1097/QAD.0000000000000119; England NHS, 2016, CLIN COMM POL PROP P; Fenton KA, 2001, AIDS, V15, P1442, DOI 10.1097/00002030-200107270-00017; Fisher M, 2007, AIDS, V21, P2309, DOI 10.1097/QAD.0b013e3282ef9fed; Guy R, 2009, LANCET INFECT DIS, V9, P747, DOI 10.1016/S1473-3099(09)70300-7; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Hallet TB, 2014, PLOS ONE, V4, pe5720; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429; Kirwan PDC, 2016, HIV UK 2016 REPORT; Le Vu S, 2010, LANCET INFECT DIS, V10, P682, DOI 10.1016/S1473-3099(10)70167-5; Mammone A, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-65; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; Medical Research Council, 2007, REV RES BLACK AFR CO; Mortimer J Y, 1995, Commun Dis Rep CDR Rev, V5, pR183; Murphy G, 2008, Euro Surveill, V13; Murphy G, 2004, AIDS, V18, P265, DOI 10.1097/00002030-200401230-00016; National AIDS Trust, 2014, HIV BLACK AFR COMM U; Office for National Statistics, 2017, CENS COUNTR BIRTH ET; Phillips AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055312; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Presanis AM, 2011, BIOSTATISTICS, V12, P666, DOI 10.1093/biostatistics/kxr006; Public Health England, 2015, SEX TRANSM INF STIS; Remis RS, 2009, AIDS, V23, P493, DOI 10.1097/QAD.0b013e328323ad5f; Rice BD, 2012, AIDS, V26, P1961, DOI 10.1097/QAD.0b013e3283578b80; Romero A, 2014, EUR J PUBLIC HEALTH, V6, P808; Savage EJ, 2014, EUROSURVEILLANCE, V19, P23, DOI 10.2807/1560-7917.ES2014.19.48.20981; Sonnenberg P, 2013, LANCET, V382; Suligoi B, 2002, J CLIN MICROBIOL, V40, P4015, DOI 10.1128/JCM.40.11.4015-4020.2002; UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, 2011, US ASS REC INF EST H	34	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2018	13	6							e0197939	10.1371/journal.pone.0197939	http://dx.doi.org/10.1371/journal.pone.0197939			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ8QS	29924799	Green Accepted, Green Published, gold			2023-01-03	WOS:000435655600008
J	Sarpatwari, A; Avorn, J; Kesselheim, AS				Sarpatwari, Ameet; Avorn, Jerry; Kesselheim, Aaron S.			An Incomplete Prescription President Trump's Plan to Address High Drug Prices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sarpatwari, Ameet; Avorn, Jerry; Kesselheim, Aaron S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon,PORTAL, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sarpatwari, A (corresponding author), Brigham & Womens Hosp, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	asarpatwari@bwh.harvard.edu			Laura and John Arnold Foundation; Harvard Program in Therapeutic Science; Engelberg Foundation	Laura and John Arnold Foundation; Harvard Program in Therapeutic Science; Engelberg Foundation	This work was supported by the Laura and John Arnold Foundation, with additional support from the Harvard Program in Therapeutic Science and the Engelberg Foundation.	Avorn J, 2017, JAMA-J AM MED ASSOC, V317, P361, DOI 10.1001/jama.2016.16036; Cuckler GA, 2018, HEALTH AFFAIR, V37, P482, DOI 10.1377/hlthaff.2017.1655; Hwang TJ, 2017, JAMA-J AM MED ASSOC, V318, P609, DOI 10.1001/jama.2017.8255; Kaltenboeck A, 2018, JAMA; Kleutghen P, 2018, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20180205, DOI 10.1377/HBLOG20180205]; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; US Department of Health & Human Services, 2018, AM PAT 1 TRUMP ADM B; US Senate Homeland Security and Governmental Affairs Committee Minority Office, 2018, MAN CRIS DEV DRUG PR	8	7	7	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	2018	319	23					2373	2374		10.1001/jama.2018.7424	http://dx.doi.org/10.1001/jama.2018.7424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ7JX	29800027				2023-01-03	WOS:000435564100011
J	Davis, DM				Davis, Daniel M.			The art of medicine How studying the immune system leads us to new medicines	LANCET			English	Editorial Material									[Davis, Daniel M.] Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Manchester M13 9NT, Lancs, England	University of Manchester	Davis, DM (corresponding author), Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Manchester M13 9NT, Lancs, England.	daniel.davis@manchester.ac.uk		Davis, Daniel/0000-0002-9182-291X					0	1	2	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 2	2018	391	10136					2205	2206		10.1016/S0140-6736(18)31166-8	http://dx.doi.org/10.1016/S0140-6736(18)31166-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH8GC	29804630	Green Submitted			2023-01-03	WOS:000433904700014
J	Falcone, B; Wada, A; Parasuraman, R; Callan, DE				Falcone, Brian; Wada, Atsushi; Parasuraman, Raja; Callan, Daniel E.			Individual differences in learning correlate with modulation of brain activity induced by transcranial direct current stimulation	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; FUNCTIONAL CONNECTIVITY; PARIETAL CORTEX; CORTICAL EXCITABILITY; ELECTRIC-FIELDS; COLOR CONSTANCY; TDCS; ATTENTION; NETWORKS; POLARIZATION	Transcranial direct current stimulation (tDCS) has been shown to enhance cognitive performance on a variety of tasks. It is hypothesized that tDCS enhances performance by affecting task related cortical excitability changes in networks underlying or connected to the site of stimulation facilitating long term potentiation. However, many recent studies have called into question the reliability and efficacy of tDCS to induce modulatory changes in brain activity. In this study, our goal is to investigate the individual differences in tDCS induced modulatory effects on brain activity related to the degree of enhancement in performance, providing insight into this lack of reliability. In accomplishing this goal, we used functional magnetic resonance imaging (fMRI) concurrently with tDCS stimulation (1 mA, 30 minutes duration) using a visual search task simulating real world conditions. The experiment consisted of three fMRI sessions: pre-training (no performance feedback), training (performance feedback which included response accuracy and target location and either real tDCS or sham stimulation given), and post-training (no performance feedback). The right posterior parietal cortex was selected as the site of anodal tDCS based on its known role in visual search and spatial attention processing. Our results identified a region in the right precentral gyrus, known to be involved with visual spatial attention and orienting, that showed tDCS induced task related changes in cortical excitability that were associated with individual differences in improved performance. This same region showed greater activity during the training session for target feedback of incorrect (target-error feedback) over correct trials for the tDCS stim over sham group indicating greater attention to target features during training feedback when trials were incorrect. These results give important insight into the nature of neural excitability induced by tDCS as it relates to variability in individual differences in improved performance shedding some light the apparent lack of reliability found in tDCS research.	[Falcone, Brian; Parasuraman, Raja] George Mason Univ, Ctr Excellence Neuroergon Technol & Cognit CENTEC, Fairfax, VA 22030 USA; [Wada, Atsushi; Callan, Daniel E.] Osaka Univ, Natl Inst Informat & Commun Technol NICT, Ctr Informat & Neural Networks CiNet, Osaka, Japan	George Mason University; National Institute of Information & Communications Technology (NICT) - Japan; Osaka University	Falcone, B (corresponding author), George Mason Univ, Ctr Excellence Neuroergon Technol & Cognit CENTEC, Fairfax, VA 22030 USA.; Callan, DE (corresponding author), Osaka Univ, Natl Inst Informat & Commun Technol NICT, Ctr Informat & Neural Networks CiNet, Osaka, Japan.	BrianLFalcone@gmail.com; dcallan@nict.go.jp		Callan, Daniel/0000-0002-8851-6065	National Institute of Information and Communications Technology; National Science Foundation [1414852]; Japan Society for the Promotion of Science; Air Force Office of Sponsored Research grant [FA9550-10-1-0385]; Japan Society for the Promotion of Science, Kakenhi [18K12024]	National Institute of Information and Communications Technology; National Science Foundation(National Science Foundation (NSF)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Air Force Office of Sponsored Research grant(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Japan Society for the Promotion of Science, Kakenhi(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by National Institute of Information and Communications Technology, DC, AW; National Science Foundation sponsored East Asia and Pacific Summer Institutes fellowship award 1414852, funded in collaboration with Japan Society for the Promotion of Science, BF; Air Force Office of Sponsored Research grant FA9550-10-1-0385, RP; and Japan Society for the Promotion of Science, Kakenhi, Grant Number (18K12024), DC, AW.	Amadi U, 2014, NEUROIMAGE, V88, P155, DOI 10.1016/j.neuroimage.2013.11.037; Antal A, 2012, RESTOR NEUROL NEUROS, V30, P255, DOI 10.3233/RNN-2012-110208; Antal A, 2011, NEUROIMAGE, V55, P590, DOI 10.1016/j.neuroimage.2010.11.085; Barbur JL, 2008, NEUROPSYCHOLOGIA, V46, P853, DOI 10.1016/j.neuropsychologia.2007.11.032; Bartels A, 2000, EUR J NEUROSCI, V12, P172, DOI 10.1046/j.1460-9568.2000.00905.x; Baudewig J, 2001, MAGN RESON MED, V45, P196, DOI 10.1002/1522-2594(200102)45:2<196::AID-MRM1026>3.0.CO;2-1; Bikson M, 2004, J PHYSIOL-LONDON, V557, P175, DOI 10.1113/jphysiol.2003.055772; Bolognini N, 2010, BRAIN RES, V1349, P76, DOI 10.1016/j.brainres.2010.06.053; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Callan D, NEUROERGONIMCS BRAIN; Callan DE, 2016, FRONTIERS HUMAN NEUR, V10; Clark VP, 2011, NEUROSCI LETT, V500, P67, DOI 10.1016/j.neulet.2011.05.244; Clarke S, 1998, EXP BRAIN RES, V123, P154, DOI 10.1007/s002210050556; Coffman BA, 2014, NEUROIMAGE, V85, P895, DOI 10.1016/j.neuroimage.2013.07.083; Coffman BA, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-108; Cogiamanian F, 2007, EUR J NEUROSCI, V26, P242, DOI 10.1111/j.1460-9568.2007.05633.x; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Coull JT, 1998, J NEUROSCI, V18, P7426; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cumming G, 2014, PSYCHOL SCI, V25, P7, DOI 10.1177/0956797613504966; Dumoulin SO, 2007, VISION RES, V47, P1608, DOI 10.1016/j.visres.2007.01.031; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eklund A., 2016, P NATL ACAD SCI USA; Ellison A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093767; Falcone B, NEUROERGONIMCS BRAIN; Falcone B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034993; Faria P, 2012, EPILEPSY BEHAV, V25, P417, DOI 10.1016/j.yebeh.2012.06.027; Garcia-Cossio E, 2016, NEUROIMAGE, V140, P33, DOI 10.1016/j.neuroimage.2015.09.068; Grefkes C, 2011, BRAIN, V134, P1264, DOI 10.1093/brain/awr033; Hanley CJ, 2016, NEUROIMAGE, V140, P20, DOI 10.1016/j.neuroimage.2015.12.021; Holland R, 2016, NEUROIMAGE, V140, P126, DOI 10.1016/j.neuroimage.2016.01.037; Holland R, 2011, CURR BIOL, V21, P1403, DOI 10.1016/j.cub.2011.07.021; Horvath JC, 2015, BRAIN STIMUL, V8, P535, DOI 10.1016/j.brs.2015.01.400; Horvath JC, 2015, NEUROPSYCHOLOGIA, V66, P213, DOI 10.1016/j.neuropsychologia.2014.11.021; Hunter MA, 2015, BRAIN RES, V1594, P92, DOI 10.1016/j.brainres.2014.09.066; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jalali R, 2017, J NEUROPHYSIOL, V118, P655, DOI 10.1152/jn.00896.2016; Jefferys JGR, 2003, RADIAT PROT DOSIM, V106, P321, DOI 10.1093/oxfordjournals.rpd.a006367; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; KENNARD C, 1995, P ROY SOC B-BIOL SCI, V260, P169, DOI 10.1098/rspb.1995.0076; Khan B, 2013, PROC SPIE, V8565, DOI 10.1117/12.2003446; Kim CR, 2012, BRAIN STIMUL, V5, P462, DOI 10.1016/j.brs.2011.08.002; Ko MH, 2008, NEUROSCI LETT, V448, P171, DOI 10.1016/j.neulet.2008.10.050; Krishnamurthy V, 2015, NEUROSCI LETT, V604, P80, DOI 10.1016/j.neulet.2015.07.042; Kwon YH, 2011, NEUROSCI LETT, V492, P105, DOI 10.1016/j.neulet.2011.01.066; Lauro LJR, 2014, CORTEX, V58, P99, DOI 10.1016/j.cortex.2014.05.003; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Mannion DJ, 2010, NEUROIMAGE, V52, P600, DOI 10.1016/j.neuroimage.2010.04.248; Marshall TR, 2016, NEUROIMAGE, V140, P41, DOI 10.1016/j.neuroimage.2015.09.069; Meinzer M, 2012, J NEUROSCI, V32, P1859, DOI 10.1523/JNEUROSCI.4812-11.2012; Nakano T, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000670; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2004, CLIN NEUROPHYSIOL, V115, P2419, DOI 10.1016/j.clinph.2004.05.001; Nobre AC, 2000, NEUROIMAGE, V11, P210, DOI 10.1006/nimg.2000.0539; Parasuraman R, 2013, FRONTIERS HUMAN NEUR, V7; Pena-Gomez C, 2012, BRAIN STIMUL, V5, P252, DOI 10.1016/j.brs.2011.08.006; Polania R, 2012, HUM BRAIN MAPP, V33, P2499, DOI 10.1002/hbm.21380; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Polania R, 2011, NEUROIMAGE, V54, P2287, DOI 10.1016/j.neuroimage.2010.09.085; Radman T, 2009, BRAIN STIMUL, V2, P215, DOI 10.1016/j.brs.2009.03.007; Roy A, 2014, IEEE T BIO-MED ENG, V61, P1967, DOI 10.1109/TBME.2014.2311071; Schestatsky P, 2013, JOVE-J VIS EXP, DOI 10.3791/50426; Song M, 2014, NEUROREPORT, V25, P1433, DOI 10.1097/WNR.0000000000000283; Stagg CJ, 2009, EUR J NEUROSCI, V30, P1412, DOI 10.1111/j.1460-9568.2009.06937.x; Sun HC, 2015, VISION RES, V109, P149, DOI 10.1016/j.visres.2014.11.012; Thielscher A, 2008, NEUROSCIENCE, V151, P730, DOI 10.1016/j.neuroscience.2007.11.040; Tseng P, 2012, J NEUROSCI, V32, P10554, DOI 10.1523/JNEUROSCI.0362-12.2012; Underwood E, 2016, SCIENCE, V352, P397, DOI 10.1126/science.352.6284.397; Utz KS, 2010, NEUROPSYCHOLOGIA, V48, P2789, DOI 10.1016/j.neuropsychologia.2010.06.002; Vernet M, 2014, FRONTIERS INTEGRATIV, V8; Vinberg J, 2008, J NEUROPHYSIOL, V99, P1380, DOI 10.1152/jn.01223.2007; Wada A, 2014, NEUROIMAGE, V98, P243, DOI 10.1016/j.neuroimage.2014.05.001; Walsh VQ, 2013, BRAIN STIMUL, V6, P715, DOI 10.1016/j.brs.2013.08.001; Weber MJ, 2014, HUM BRAIN MAPP, V35, P3673, DOI 10.1002/hbm.22429; Westwood SJ, 2017, NEUROPSYCHOLOGIA, V104, P234, DOI 10.1016/j.neuropsychologia.2017.07.031; Westwood SJ, 2017, CORTEX, V86, P64, DOI 10.1016/j.cortex.2016.10.016; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018	82	11	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2018	13	5							e0197192	10.1371/journal.pone.0197192	http://dx.doi.org/10.1371/journal.pone.0197192			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG2QJ	29782510	Green Published, gold, Green Submitted			2023-01-03	WOS:000432537100016
J	Lamb, SE; Sheehan, B; Atherton, N; Nichols, V; Collins, H; Mistry, D; Dosanjh, S; Slowther, AM; Khan, I; Petrou, S; Lall, R				Lamb, Sarah E.; Sheehan, Bart; Atherton, Nicky; Nichols, Vivien; Collins, Helen; Mistry, Dipesh; Dosanjh, Sukhdeep; Slowther, Anne Marie; Khan, Iftekhar; Petrou, Stavros; Lall, Ranjit		DAPA Trial Investigators	Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; IMPROVE COGNITION; CLINICAL-TRIALS; INTERVENTION; BALANCE; ADULTS; SCALE	OBJECTIVE To estimate the effect of a moderate to high intensity aerobic and strength exercise training programme on cognitive impairment and other outcomes in people with mild to moderate dementia. DESIGN Multicentre, pragmatic, investigator masked, randomised controlled trial. SETTING National Health Service primary care, community and memory services, dementia research registers, and voluntary sector providers in 15 English regions. PARTICIPANTS 494 people with dementia: 329 were assigned to an aerobic and strength exercise programme and 165 were assigned to usual care. Random allocation was 2: 1 in favour of the exercise arm. INTERVENTIONS Usual care plus four months of supervised exercise and support for ongoing physical activity, or usual care only. Interventions were delivered in community gym facilities and NHS premises. MAIN OUTCOME MEASURES The primary outcome was score on the Alzheimer's disease assessment scale-cognitive subscale (ADAScog) at 12 months. Secondary outcomes included activities of daily living, neuropsychiatric symptoms, health related quality of life, and carer quality of life and burden. Physical fitness (including the six minute walk test) was measured in the exercise arm during the intervention. RESULTS The average age of participants was 77 (SD 7.9) years and 301/494 (61%) were men. By 12 months the mean ADAS-cog score had increased to 25.2 (SD 12.3) in the exercise arm and 23.8 (SD 10.4) in the usual care arm (adjusted between group difference -1.4, 95% confidence interval -2.6 to -0.2, P= 0.03). This indicates greater cognitive impairment in the exercise group, although the average difference is small and clinical relevance uncertain. No differences were found in secondary outcomes or preplanned subgroup analyses by dementia type (Alzheimer's disease or other), severity of cognitive impairment, sex, and mobility. Compliance with exercise was good. Over 65% of participants (214/329) attended more than three quarters of scheduled sessions. Six minute walking distance improved over six weeks (mean change 18.1 m, 95% confidence interval 11.6 m to 24.6 m). CONCLUSION A moderate to high intensity aerobic and strength exercise training programme does not slow cognitive impairment in people with mild to moderate dementia. The exercise training programme improved physical fitness, but there were no noticeable improvements in other clinical outcomes.	[Lamb, Sarah E.] Univ Oxford, Ctr Rehabil Res, Oxford OX3 7LD, England; [Lamb, Sarah E.] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England; [Lamb, Sarah E.; Nichols, Vivien; Mistry, Dipesh; Dosanjh, Sukhdeep; Khan, Iftekhar; Petrou, Stavros; Lall, Ranjit] Univ Warwick, Warwick Clin Trials Unit, Coventry, W Midlands, England; [Sheehan, Bart; Atherton, Nicky] Coventry & Warwickshire Partnership Trust, Coventry, W Midlands, England; [Collins, Helen] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Oxford, England; [Slowther, Anne Marie] Univ Warwick, Div Hlth Sci, Coventry, W Midlands, England	University of Oxford; University of Oxford; University of Warwick; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Warwick	Lamb, SE (corresponding author), Univ Oxford, Ctr Rehabil Res, Oxford OX3 7LD, England.; Lamb, SE (corresponding author), Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England.	sarah.lamb@ndorms.ox.ac.uk	Tucker, James/F-8641-2018; Petrou, Stavros/ABD-8323-2021; Thompson, Jacqueline/I-5118-2019	Tucker, James/0000-0001-7645-0815; Petrou, Stavros/0000-0003-3121-6050; Thompson, Jacqueline/0000-0002-9775-361X; Lall, Ranjit/0000-0003-1737-2866; Lamb, Sarah/0000-0003-4349-7195; Byrne, Chris/0000-0003-4935-6588; Griffiths, Frances/0000-0002-4173-1438; Hall, Charlotte/0000-0002-4516-4610; Khan, Iftekhar/0000-0001-6041-8837	National Institute for Health Research (NIHR Health Technology Assessment programme) [09/80/04]; NIHR Local Clinical Research Networks; NIHR Oxford CLAHRC and Biomedical Research Centre; NIHR; MRC [G0501681, G0700452] Funding Source: UKRI	National Institute for Health Research (NIHR Health Technology Assessment programme)(National Institute for Health Research (NIHR)); NIHR Local Clinical Research Networks; NIHR Oxford CLAHRC and Biomedical Research Centre; NIHR(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This trial was funded by the National Institute for Health Research (NIHR Health Technology Assessment programme 09/80/04) and received additional support from the NIHR Local Clinical Research Networks and NIHR Oxford CLAHRC and Biomedical Research Centre. NIHR funded the study. It developed a commissioning brief but had no role in the study design, data acquisition, analysis, or manuscript preparation. The chief investigator (SEL) assumes overall responsibility for the data in the manuscript. All named investigators had full access to the trial dataset. There are no contractual agreements that limit access for investigators. Companies and the sponsor (University of Warwick) had no role in the funding, design, analysis, or interpretation. The views expressed are those of the authors and are not an official view of the institutions or funders.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Atherton N, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1288-2; Bean JF, 2004, J AM GERIATR SOC, V52, P799, DOI 10.1111/j.1532-5415.2004.52222.x; Beecham JK, 1992, COSTING PSYCHIAT INT; Bohannon RW, 2017, J EVAL CLIN PRACT, V23, P377, DOI 10.1111/jep.12629; Brookes S T, 2001, Health Technol Assess, V5, P1; Brown D, 2015, PHYSIOTHERAPY, V101, P126, DOI 10.1016/j.physio.2015.01.002; Bucks RS, 1996, AGE AGEING, V25, P113, DOI 10.1093/ageing/25.2.113; Cipryan L, 2017, J SPORT SCI MED, V16, P219; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dunn G, 2003, BRIT J PSYCHIAT, V183, P323, DOI 10.1192/bjp.183.4.323; Elder GA, 2010, MT SINAI J MED, V77, P69, DOI 10.1002/msj.20159; Forbes D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub4; Gallaway PJ, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7020022; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Kaduszkiewicz H, 2005, BMJ-BRIT MED J, V331, P321, DOI 10.1136/bmj.331.7512.321; Little RJ., 1986, STAT ANAL MISSING DA; Logsdon R.G., 1999, J MENTAL HLTH AGING, V5, P21, DOI DOI 10.1037/T03352-000; Luxton N, 2008, RESPIROLOGY, V13, P856, DOI 10.1111/j.1440-1843.2008.01355.x; Mohs RC, 1997, ALZ DIS ASSOC DIS, V11, pS13; Moore KM, 2016, NEUROBIOL DIS, V85, P218, DOI 10.1016/j.nbd.2015.11.004; National Institute for Clinical Excellence (NICE), 2011, NICE TECHN APPR GUID, P217; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Prince MJ., 2015, WORLD ALZHEIMER REPO; Sudo M, 2017, EUR J APPL PHYSIOL, V117, P2029, DOI 10.1007/s00421-017-3692-z; Toots A, 2016, J AM GERIATR SOC, V64, P55, DOI 10.1111/jgs.13880; Valenzuela M, 2011, AM J EPIDEMIOL, V173, P1004, DOI 10.1093/aje/kwq476; Verma N, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0151-0; Vertesi A, 2001, CAN FAM PHYSICIAN, V47, P2018; W.H.O, 2010, MENTAL BEHAVIOURAL D; Webster L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179521; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	33	156	161	10	85	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	2018	361								k1675	10.1136/bmj.k1675	http://dx.doi.org/10.1136/bmj.k1675			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG6IR	29769247	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000432800300003
J	Mellor, R; Bennell, K; Grimaldi, A; Nicolson, P; Kasza, J; Hodges, P; Wajswelner, H; Vicenzino, B				Mellor, Rebecca; Bennell, Kim; Grimaldi, Alison; Nicolson, Philippa; Kasza, Jessica; Hodges, Paul; Wajswelner, Henry; Vicenzino, Bill			Education plus exercise versus corticosteroid injection use versus a wait and see approach on global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; FUNCTIONAL SCALE; GREATER; QUESTIONNAIRE; EPIDEMIOLOGY; VALIDATION; MANAGEMENT; VALIDITY; LOAD	OBJECTIVE To compare the effects of a programme of load management education plus exercise, corticosteroid injection use, and no treatment on pain and global improvement in individuals with gluteal tendinopathy. DESIGN Prospective, three arm, single blinded, randomised clinical trial. SETTING Brisbane and Melbourne, Australia. PARTICIPANTS Individuals aged 35-70 years, with lateral hip pain for more than three months, at least 4/10 on the pain numerical rating scale, and gluteal tendinopathy confirmed by clinical diagnosis and magnetic resonance imaging; and with no corticosteroid injection use in previous 12 months, current physiotherapy, total hip replacement, or neurological conditions. INTERVENTIONS A physiotherapy led education and exercise programme of 14 sessions over eight weeks (EDX; n=69), one corticosteroid injection (CSI; n=66), and a wait and see approach (WS; n=69). MAIN OUTCOMES Primary outcomes were patient reported global rating of change in hip condition (on an 11 point scale, dichotomised to success and non-success) and pain intensity in the past week (0=no pain, 10=worst pain) at eight weeks, with longer term follow-up at 52 weeks. RESULTS Of 204 randomised participants (including 167 women; mean age 54.8 years (standard deviation 8.8)), 189 (92.6%) completed 52 week follow-up. Success on the global rating of change was reported at eight weeks by 51/66 EDX, 38/65 CSI, and 20/68 WS participants. EDX and CSI had better global improvement scores than WS (risk difference 49.1% (95% confidence interval 34.6% to 63.5%), number needed to treat 2.0 (95% confidence interval 1.6 to 2.9); 29.2% (13.2% to 45.2%), 3.4 (2.2 to 7.6); respectively). EDX had better global improvement scores than CSI (19.9% (4.7% to 35.0%); 5.0 (2.9 to 21.1)). At eight weeks, reported pain on the numerical rating scale was mean score 1.5 (standard deviation 1.5) for EDX, 2.7 (2.4) for CSI, and 3.8 (2.0) for WS. EDX and CSI participants reported less pain than WS (mean difference -2.2 (95% confidence interval -2.89 to -1.54); -1.2 (-1.85 to -0.50); respectively), and EDX participants reported less pain than CSI (-1.04 (-1.72 to -0.37)). Success on the global rating of change was reported at 52 weeks by 51/65 EDX, 36/63 CSI, and 31/60 WS participants; EDX was better than CSI (20.4% (4.9% to 35.9%); 4.9 (2.8 to 20.6)) and WS (26.8% (11.3% to 42.3%); 3.7 (2.4 to 8.8)). Reported pain at 52 weeks was 2.1 (2.2) for EDX, 2.3 (1.9) for CSI, and 3.2 (2.6) for WS; EDX did not differ from CSI (-0.26 (-1.06 to 0.55)), but both treatments did better than WS (1.13 (-1.93 to -0.33); 0.87 (-1.68 to -0.07); respectively). CONCLUSIONS For gluteal tendinopathy, education plus exercise and corticosteroid injection use resulted in higher rates of patient reported global improvement and lower pain intensity than no treatment at eight weeks. Education plus exercise performed better than corticosteroid injection use. At 52 week followup, education plus exercise led to better global improvement than corticosteroid injection use, but no difference in pain intensity. These results support EDX as an effective management approach for gluteal tendinopathy.	[Mellor, Rebecca; Vicenzino, Bill] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Bennell, Kim; Nicolson, Philippa] Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Carlton, Vic, Australia; [Kasza, Jessica] Monash Univ, Alfred Ctr, Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Hodges, Paul] Univ Queensland, Sch Hlth & Rehabil Sci, Ctr Clin Res Excellence Spinal Pain Injury & Hlth, NHMRC, Brisbane, Qld, Australia; [Wajswelner, Henry] La Trobe Univ, Sch Allied Hlth, Discipline Physiotherapy, Bundoora, Vic, Australia	University of Queensland; University of Melbourne; Monash University; University of Queensland; La Trobe University	Vicenzino, B (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	b.vicenzino@uq.edu.au	Hodges, Paul W/B-6578-2008; Vicenzino, Bill/A-8492-2011; /AAB-3060-2019; Mellor, Rebecca/A-1363-2011	Hodges, Paul W/0000-0002-1206-9107; Vicenzino, Bill/0000-0003-0253-5933; Mellor, Rebecca/0000-0001-8198-5291; Nicolson, Philippa/0000-0003-2394-4867; Grimaldi, Alison/0000-0001-6689-3153	National Health and Medical Research Council (NHMRC) [631717]; NHMRC [1058440, 1002190]	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This trial is funded by a National Health and Medical Research Council (NHMRC) programme grant (#631717). KB is supported by an NHMRC principal research fellowship (#1058440) and PH by an NHMRC senior principal research fellowship (#1002190). The funders of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript or the decision to submit for publication.	Abbott JH, 2014, J ORTHOP SPORT PHYS, V44, P560, DOI 10.2519/jospt.2014.5248; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Brinks A, 2011, ANN FAM MED, V9, P226, DOI 10.1370/afm.1232; Brown WJ, 2008, AUST NZ J PUBL HEAL, V32, P535, DOI 10.1111/j.1753-6405.2008.00305.x; Carpenter JA, 2013, STUD WORLD CHR SER, P1; Cook JL, 2012, BRIT J SPORT MED, V46, P163, DOI 10.1136/bjsports-2011-090414; Fearon AM, 2015, MANUAL THER, V20, P805, DOI 10.1016/j.math.2015.03.009; Fearon AM, 2014, J ARTHROPLASTY, V29, P383, DOI 10.1016/j.arth.2012.10.016; Grimaldi A, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-096175; Grimaldi A, 2015, J ORTHOP SPORT PHYS, V45, P910, DOI 10.2519/jospt.2015.5829; Grimaldi A, 2015, SPORTS MED, V45, P1107, DOI 10.1007/s40279-015-0336-5; Gusi N, 2010, HDB DIS BURDENS QUAL, P87, DOI [DOI 10.1007/978-0-387-78665-0_5, 10.1007/978-0-387-78665-0_5, DOI 10.1007/978-0-387-786650_6466]; Horn KK, 2012, J ORTHOP SPORT PHYS, V42, P30, DOI 10.2519/jospt.2012.3727; Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Mellor R, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1043-6; PETRI M, 1987, ARTHRITIS RHEUM-US, V30, P1040, DOI 10.1002/art.1780300911; Rio E, 2016, BRIT J SPORT MED, V50, P209, DOI 10.1136/bjsports-2015-095215; Rio E, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094386; Rompe JD, 2009, AM J SPORT MED, V37, P1981, DOI 10.1177/0363546509334374; Schulz KF, 2005, LANCET, V365, P1591, DOI 10.1016/S0140-6736(05)66461-6; Segal NA, 2007, ARCH PHYS MED REHAB, V88, P988, DOI 10.1016/j.apmr.2007.04.014; Smidt N, 2002, LANCET, V359, P657, DOI 10.1016/S0140-6736(02)07811-X; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Tonkin L, 2008, AUST J PHYSIOTHER, V54, P77, DOI 10.1016/S0004-9514(08)70073-4; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; Williams BS, 2009, ANESTH ANALG, V108, P1662, DOI 10.1213/ane.0b013e31819d6562; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	28	49	49	4	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 2	2018	361								k1662	10.1136/bmj.k1662	http://dx.doi.org/10.1136/bmj.k1662			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF4YF	29720374	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000431969500004
J	Bowden, B; John, A; Trefan, L; Morgan, J; Farewel, D; Fone, D				Bowden, Bethan; John, Ann; Trefan, Laszlo; Morgan, Jennifer; Farewel, Daniel; Fone, David			Risk of suicide following an alcohol-related emergency hospital admission: An electronic cohort study of 2.8 million people	PLOS ONE			English	Article							ASSOCIATION; DISORDERS; BEHAVIOR	Objective Alcohol misuse is a well-known risk factor for suicide however, the relationship between alcohol-related hospital admission and subsequent risk of death from suicide is unknown. We aimed to determine the risk of death from suicide following emergency admission to hospital with an alcohol-related cause. Methods We established an electronic cohort study of all 2,803,457 residents of Wales, UK, aged from 10 to under 100 years on 1 January 2006 with six years' follow-up. The outcome event was death from suicide defined as intentional self-harm (ICD-10 X 60-84) or undetermined intent (Y10-34). The main exposure was an alcohol-related admission defined as a 'wholly attributable' ICD-10 alcohol code in the admission record. Admissions were coded for the presence or absence of co-existing psychiatric morbidity. The analysis was by Cox regression with adjustments for confounding variables within the dataset. Results During the study follow-up period, there were 15,546,355 person years at risk with 28,425 alcohol-related emergency admissions and 1562 suicides. 125 suicides followed an admission (144.6 per 100,000 person years), of which 11 (9%) occurred within 4 weeks of discharge. The overall adjusted hazard ratio (HR) for suicide following admission was 26.8 (95% confidence interval (CI) 18.8 to 38.3), in men HR 9.83 (95% CI 7.91 to 12.2) and women HR 28.5 (95% CI 19.9 to 41.0). The risk of suicide remained substantial in subjects without known co-existing psychiatric morbidity: HR men 8.11 (95% CI 6.30 to 10.4) and women HR 24.0 (95% CI 15.5 to 37.3). The analysis was limited by the absence in datasets of potentially important confounding variables and the lack of information on alcohol-related harm and psychiatric morbidity in subjects not admitted to hospital. Conclusion Emergency alcohol-related hospital admission is associated with an increased risk of suicide. Identifying individuals in hospital provides an opportunity for psychosocial assessment and suicide prevention of a targeted at-risk group before their discharge to the community.	[Bowden, Bethan; John, Ann] Publ Hlth Wales NHS Trust, Swansea, W Glam, Wales; [Bowden, Bethan; John, Ann] Swansea Univ Med Sch, Inst Life Sci 2, Swansea, W Glam, Wales; [Trefan, Laszlo; Morgan, Jennifer; Farewel, Daniel; Fone, David] Cardiff Univ, Sch Med, Div Populat Med, Cardiff, S Glam, Wales	Swansea University; Cardiff University	Farewel, D (corresponding author), Cardiff Univ, Sch Med, Div Populat Med, Cardiff, S Glam, Wales.	farewelld@cardiff.ac.uk		Fone, David/0000-0002-6476-4881; Farewell, Daniel/0000-0002-8871-1653	Public Health Research programme [PHR 09/3007/02]	Public Health Research programme	This project uses a dataset funded by the Public Health Research programme (PHR 09/3007/02) to David Fone. Further information available at: http://www.nets.nihr.ac.uk/projects/phr/09300702. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bedford D, 2006, Ir Med J, V99, P80; Beghi M, 2013, NEUROPSYCH DIS TREAT, V9, P1725, DOI 10.2147/NDT.S40213; Blakely TA, 2003, J EPIDEMIOL COMMUN H, V57, P594, DOI 10.1136/jech.57.8.594; Cherpitel CJ, 2004, ALCOHOL CLIN EXP RES, V28, p18S, DOI 10.1097/01.ALC.0000127411.61634.14; Darvishi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126870; Flensborg-Madsen T, 2009, PSYCHIAT RES, V167, P123, DOI 10.1016/j.psychres.2008.01.008; Fone D., 2016, PUBLIC HLTH RES, V4; Ford DV, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-157; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gunnarsdottir AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006327; Gunnell D, 2013, PSYCHOL MED, V43, P1415, DOI 10.1017/S0033291712002401; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hawton K, 2000, BRIT J PSYCHIAT, V177, P484, DOI 10.1192/bjp.177.6.484; Inskip HM, 1998, BRIT J PSYCHIAT, V172, P35, DOI 10.1192/bjp.172.1.35; John A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006780; Juurlink DN, 2004, ARCH INTERN MED, V164, P1179, DOI 10.1001/archinte.164.11.1179; Kaplan MS, 2014, ANN EPIDEMIOL, V24, P588, DOI 10.1016/j.annepidem.2014.05.008; Lyons RA, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-3; Malone D, 2005, POSTGRAD MED J, V81, P161, DOI 10.1136/pgmj.2004.024703; Miller IW, 2017, JAMA PSYCHIAT, V74, P563, DOI 10.1001/jamapsychiatry.2017.0678; National Institute of Clinical Excellence, 2011, ALC US DIS DIAGN ASS; Office for National Statistics, 2004, RUR URB DEF ENGL WAL; Office for National Statistics, 2016, STAT B; Office for National Statistics, WHAT AR TOP CAUS DEA; Office for National Statistics, 2015, MORT STAT MET; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; Welsh Government, WELSH IND MULT DEPR; Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003; World Health Organisation, 2014, REC PER CAP 15 CONS; World Health Organization, INT CLASS DIS ICD; Wyllie C, 2012, MEN SUICIDE SOC	31	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2018	13	4							e0194772	10.1371/journal.pone.0194772	http://dx.doi.org/10.1371/journal.pone.0194772			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GE1YS	29702655	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000431013300003
J	Zhu, LP; Ma, YH; Deng, XY				Zhu, Lingping; Ma, Yunhui; Deng, Xiaoyan			Comparison of acupuncture and other drugs for chronic constipation: A network meta-analysis	PLOS ONE			English	Article							PLACEBO-CONTROLLED TRIAL; CHRONIC IDIOPATHIC CONSTIPATION; DOUBLE-BLIND; EFFICACY; SAFETY; PRUCALOPRIDE; MULTICENTER; LACTULOSE; ELECTROACUPUNCTURE; LUBIPROSTONE	The objective of this study was to compare the efficacy and side effects of acupuncture, sham acupuncture and drugs in the treatment of chronic constipation. Randomized controlled trials (RCTs) assessing the effects of acupuncture and drugs for chronic constipation were comprehensively retrieved from electronic databases (such as PubMed, Cochrane Library, Embase, CNKI, Wanfang Database, VIP Database and CBM) up to December 2017. Additional references were obtained from review articles. With quality evaluations and data extraction, a network meta-analysis (NMA) was performed using a random-effects model under a frequentist framework. A total of 40 studies (n = 11032) were included: 39 were highquality studies and 1 was a low-quality study. NMA showed that (1) acupuncture improved the symptoms of chronic constipation more effectively than drugs; (2) the ranking of treatments in terms of efficacy in diarrhoea-predominant irritable bowel syndrome was acupuncture, polyethylene glycol, lactulose, linaclotide, lubiprostone, bisacodyl, prucalopride, sham acupuncture, tegaserod, and placebo; (3) the ranking of side effects were as follows: lactulose, lubiprostone, bisacodyl, polyethylene glycol, prucalopride, linaclotide, placebo and tegaserod; and (4) the most commonly used acupuncture point for chronic constipation was ST25. Acupuncture is more effective than drugs in improving chronic constipation and has the least side effects. In the future, large-scale randomized controlled trials are needed to prove this. Sham acupuncture may have curative effects that are greater than the placebo effect. In the future, it is necessary to perform high-quality studies to support this finding. Polyethylene glycol also has acceptable curative effects with fewer side effects than other drugs.	[Zhu, Lingping; Ma, Yunhui] Shenzhen Longhua Dist Cent Hosp, Gen Practice Dept, Shenzhen, Guangdong, Peoples R China; [Zhu, Lingping] Fudan Univ, Zhongshan Hosp, Gen Practice Dept, Shanghai, Peoples R China; [Deng, Xiaoyan] Shenzhen Longhua Dist Cent Hosp, Endocrinol Dept, Shenzhen, Guangdong, Peoples R China	Fudan University	Zhu, LP (corresponding author), Shenzhen Longhua Dist Cent Hosp, Gen Practice Dept, Shenzhen, Guangdong, Peoples R China.; Zhu, LP (corresponding author), Fudan Univ, Zhongshan Hosp, Gen Practice Dept, Shanghai, Peoples R China.	zlp597@aliyun.com						Barish CF, 2010, DIGEST DIS SCI, V55, P1090, DOI 10.1007/s10620-009-1068-x; Bouhnik Y, 2004, ALIMENT PHARM THER, V19, P889, DOI 10.1111/j.1365-2036.2004.01918.x; Camilleri M, 2008, NEW ENGL J MED, V358, P2344, DOI 10.1056/NEJMoa0800670; Candy DCA, 2006, J PEDIATR GASTR NUTR, V43, P65, DOI 10.1097/01.mpg.0000228097.58960.e6; Chen CY, 2013, AM J CHINESE MED, V41, P301, DOI 10.1142/S0192415X13500225; Cleveland MV, 2001, SOUTHERN MED J, V94, P478; Corazziari E, 2000, GUT, V46, P522, DOI 10.1136/gut.46.4.522; Coremans G, 2003, DIGESTION, V67, P82, DOI 10.1159/000070202; Daniel G L, 1997, DIS COLON RECTUM, V40, P280; DiPalma JA, 2000, AM J GASTROENTEROL, V95, P446; DiPalma JA, 2007, AM J GASTROENTEROL, V102, P1436, DOI 10.1111/j.1572-0241.2007.01199.x; Fried M, 2007, AM J GASTROENTEROL, V102, P362, DOI 10.1111/j.1572-0241.2006.00988.x; Fukudo S, 2015, CLIN GASTROENTEROL H, V13, P294, DOI 10.1016/j.cgh.2014.08.026; Gao X, 2015, NEUROGASTROENT MOTIL, V27, P1817, DOI 10.1111/nmo.12694; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jin Wenyu, 2010, OBSERVATION CLIN EFF; Johanson JF, 2008, AM J GASTROENTEROL, V103, P170, DOI 10.1111/j.1572-0241.2007.01524.x; Kamm MA, 2005, AM J GASTROENTEROL, V100, P362, DOI 10.1111/j.1572-0241.2005.40749.x; Kamm MA, 2011, CLIN GASTROENTEROL H, V9, P577, DOI 10.1016/j.cgh.2011.03.026; Katelaris P, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0457-9; Ke M, 2012, NEUROGASTROENT MOTIL, V24, DOI 10.1111/j.1365-2982.2012.01983.x; Kienzle-Horn S, 2006, ALIMENT PHARM THER, V23, P1479, DOI 10.1111/j.1365-2036.2006.02903.x; Lacy BE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134349; Lee-Robichaud H., 2011, EVID BASED CHILD HLT, V6, P824, DOI [10.1002/ebch.741, DOI 10.1002/EBCH.741]; Lembo A, 2003, NEW ENGL J MED, V349, P1360, DOI 10.1056/NEJMra020995; Lembo A, 2010, GASTROENTEROLOGY, V138, pS53, DOI 10.1053/j.gastro.2009.12.050; Lembo AJ, 2011, NEW ENGL J MED, V365, P527, DOI 10.1056/NEJMoa1010863; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin Rongzhi, 2010, CLIN STUDY DEEP ACUP; Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118; Lu Chen, 2010, CLIN OBSERVATION LIM; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7; Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356; Muller-Lissner S, 2010, NEUROGASTROENT MOTIL, V22, P991, DOI 10.1111/j.1365-2982.2010.01533.x; Mugie SM, 2011, BEST PRACT RES CL GA, V25, P3, DOI 10.1016/j.bpg.2010.12.010; Nelson AD, 2017, GUT, V66, P1611, DOI 10.1136/gutjnl-2016-311835; Paquette IM, 2016, DIS COLON RECTUM, V59, P479, DOI 10.1097/DCR.0000000000000599; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Peng Wei-Na, 2013, Zhongguo Zhen Jiu, V33, P865; Piessevaux H, 2015, NEUROGASTROENT MOTIL, V27, P805, DOI 10.1111/nmo.12553; Quigley EMM, 2009, ALIMENT PHARM THER, V29, P315, DOI 10.1111/j.1365-2036.2008.03884.x; SANDERS JF, 1978, J AM GERIATR SOC, V26, P236, DOI 10.1111/j.1532-5415.1978.tb01967.x; SONNENBERG A, 1989, DIGEST DIS SCI, V34, P606, DOI 10.1007/BF01536339; Su Shaoyun, 2014, CLIN STUDY TREATMENT; Suares NC, 2011, AM J GASTROENTEROL, V106, P1582, DOI 10.1038/ajg.2011.164; Tack J, 2009, GUT, V58, P357, DOI 10.1136/gut.2008.162404; Tu YK, 2016, VALUE HEALTH, V19, P957, DOI 10.1016/j.jval.2016.07.005; Wald A, 2016, JAMA-J AM MED ASSOC, V315, P185, DOI 10.1001/jama.2015.16994; Wang Cheng-Wei, 2010, Zhen Ci Yan Jiu, V35, P375; Wang Jinmei, 2016, SHANGHAI J ACUPUNCTU, V35, P36; Warn DE, 2002, STAT MED, V21, P1601, DOI 10.1002/sim.1189; WESSELIU.A, 1968, GUT, V9, P84, DOI 10.1136/gut.9.1.84; [吴佳霓 Wu Jiani], 2014, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V29, P1424; Yiannakou Y, 2015, AM J GASTROENTEROL, V110, P741, DOI 10.1038/ajg.2015.115; Zhang T, 2013, AM J CHINESE MED, V41, P717, DOI 10.1142/S0192415X13500493; [张维 Zhang Wei], 2006, [中医杂志, Journal of Traditional Chinese Medicine], V47, P105	58	5	6	4	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2018	13	4							e0196128	10.1371/journal.pone.0196128	http://dx.doi.org/10.1371/journal.pone.0196128			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD8ZI	29694378	gold, Green Published			2023-01-03	WOS:000430802400066
J	Sarandy, MM; Miranda, LL; Altoe, LS; Novaes, RD; Zanuncio, VV; Leite, JPV; Goncalves, RV				Sarandy, Mariaurea Matias; Miranda, Lyvia Lopes; Altoe, Luciana Schultheis; Novaes, Romulo Dias; Zanuncio, Virginia Vinha; Viana Leite, Joo Paulo; Goncalves, Reggiani Vilela			Strychnos pseudoquina modulates the morphological reorganization of the scar tissue of second intention cutaneous wounds in rats	PLOS ONE			English	Article							MAST-CELLS; OXIDATIVE DAMAGE; REACTIVE OXYGEN; HUMAN BLOOD; LATE-PHASE; EXTRACT; PROLIFERATION; INFLAMMATION; ANTIOXIDANTS; MODEL	Natural substances are used in folk medicines to treat injuries. Strychnos pseudoquina has scarring, antipyretic, and antimalarial actions. The present study aimed to analyze the effect of S. pseudoquina on cutaneous wound healing in rats. The S. pseudoquina extract was submitted to phytochemical prospection. The levels of flavonoids and total phenolic compounds in the extract were 50.7 mg/g and 2.59 mg/g, respectively. Thirty Wistar rats were individualized in cages with food and water ad libitum (registration no. 730/2014). After anesthesia, three circular wounds (12mm diameter) were made in the animals, which were randomly separated into five treatments: Sal, saline; VO, ointment vehicles (lanolin and Vaseline); SS, positive control (silver sulfadiazine 1%); LE 5, freeze-dried extract 5%; and LE 10, lyophilized extract 10%. The animals were treated with the ointment daily for 21 days. Every seven days, the area and the rate of wound contraction were evaluated. Tissue samples were removed for histopathological analysis of the number of mast cells, elastic and collagen fibers, and biochemical analyses, quantification of malondialdehyde (MDA), carbonylated proteins (PCN), superoxide dismutase (SOD), catalase (CAT), transforming growth factor beta (TGF-beta), Interleukin 10 (IL-10) and tumor necrosis factor (TNF). The number of mast cells, collagen and elastic fibers in the rat wounds were higher in the treatments with the plant. The extract also stimulated the activity of antioxidant enzymes, particularly SOD, presenting high levels, and maintained low levels of PCN. The TGF-beta and IL-10 concentration was higher in the LE5 and LE10 treatment of the extract than in the Sal, OV and SS treatments on day 7. The ointment based on S. pseudoquina closed the wound faster and accelerated wound healing in animals.	[Sarandy, Mariaurea Matias; Goncalves, Reggiani Vilela] Univ Fed Vicosa, Dept Anim Biol, Vicosa, MG, Brazil; [Miranda, Lyvia Lopes; Altoe, Luciana Schultheis] Univ Fed Vicosa, Inst Biomed Sci, Dept Gen Biol, Vicosa, MG, Brazil; [Novaes, Romulo Dias] Univ Fed Alfenas, Dept Biol Struct, Alfenas, MG, Brazil; [Zanuncio, Virginia Vinha] Univ Fed Vicosa, Dept Med & Nursing, Vicosa, MG, Brazil; [Viana Leite, Joo Paulo] Univ Fed Vicosa, Dept Agr Biochem, Vicosa, MG, Brazil	Universidade Federal de Vicosa; Universidade Federal de Vicosa; Universidade Federal de Alfenas; Universidade Federal de Vicosa; Universidade Federal de Vicosa	Goncalves, RV (corresponding author), Univ Fed Vicosa, Dept Anim Biol, Vicosa, MG, Brazil.	reggiani.goncalves@ufv.br	SOUZA, MARIAUREA/GQP-7833-2022; Gonçalves, Reggiani V/J-1550-2016; Novaes, Romulo D/F-1210-2015	Gonçalves, Reggiani V/0000-0002-5831-3590; Novaes, Romulo D/0000-0002-3186-5328	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) [PPM 00687-17]; CNPq [303972/2017-3]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The study was supported by the following Brazilian agencies Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (RVG), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) (edital PPM 00687-17) (RVG). The author Romulo Dias Novaes thanks CNPq for the fellowship granted to the research in productivity (process 303972/2017-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abood WN, 2015, BOSNIAN J BASIC MED, V15, P25, DOI 10.17305/bjbms.2015.39; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Al-Khamis A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006213.pub3; Andrade-Neto VF, 2003, J ETHNOPHARMACOL, V87, P253, DOI 10.1016/S0378-8741(03)00141-7; Arcanjo DDR, 2012, BRAZ J BIOL, V72, P505, DOI 10.1590/S1519-69842012000300013; de Brito TLA, 2014, LIFE SCI, V100, P138, DOI [10.1016/j.lfs.2014.02.007, 10.1016/j.lfs2014.02.007]; Baltzis D, 2014, ADV THER, V31, P817, DOI 10.1007/s12325-014-0140-x; Barreiros A.L.B.S, 2003, Rev. bras. farmacogn., V13, P8; Belhadj F, 2016, FOOD CHEM, V204, P29, DOI 10.1016/j.foodchem.2016.02.111; Bladt S, 2009, SSBM, V2, P74; Bonamin F, 2011, J ETHNOPHARMACOL, V138, P47, DOI 10.1016/j.jep.2011.08.020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryan N, 2012, EUR CELLS MATER, V24, P249, DOI 10.22203/eCM.v024a18; Carocho M, 2013, FOOD CHEM TOXICOL, V51, P15, DOI 10.1016/j.fct.2012.09.021; Cheng PG, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/671252; Cortes MA, 2013, POLIMEROS, V23, P402, DOI 10.4322/polimeros.2013.085; Curtis BJ, 2014, ALCOHOL CLIN EXP RES, V38, P1347, DOI 10.1111/acer.12369; da Silva MA, 2005, CHEM PHARM BULL, V53, P881, DOI 10.1248/cpb.53.881; da Silva MAB, 2010, REV BRAS FARMACOGN, V20, P549, DOI 10.1590/S0102-695X2010000400014; Dalmolin F, 2016, ARQ BRAS MED VET ZOO, V68, P687, DOI 10.1590/1678-4162-8276; Carvalho Camilo Amaro de, 2011, Arq. Gastroenterol., V48, P276, DOI 10.1590/S0004-28032011000400011; DOLBER PC, 1993, J HISTOCHEM CYTOCHEM, V41, P465, DOI 10.1177/41.3.7679127; Dong XL, 2012, MOL MED REP, V5, P1487, DOI 10.3892/mmr.2012.851; Fujiwara T, 2016, EXP DERMATOL, V25, P206, DOI 10.1111/exd.12909; Gharibi S, 2013, IND CROP PROD, V50, P154, DOI 10.1016/j.indcrop.2013.07.038; Goncalves RV, 2010, BRAZ J MED BIOL RES, V43, P350, DOI 10.1590/S0100-879X2010007500022; Goncalves RV, 2016, LIFE SCI, V152, P67, DOI 10.1016/j.lfs.2016.03.019; Goncalves RV, 2014, CELLS TISSUES ORGANS, V199, P266, DOI 10.1159/000365504; Goncalves RV, 2012, INT J EXP PATHOL, V93, P370, DOI 10.1111/j.1365-2613.2012.00835.x; Goncalves RV, 2010, PHOTOMED LASER SURG, V28, P597, DOI 10.1089/pho.2009.2669; Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Hartmann RM, 2012, DIGEST DIS SCI, V57, P2038, DOI 10.1007/s10620-012-2134-3; Heal C, 2014, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.CD011426; Houreld NN, 2010, LASER SURG MED, V42, P494, DOI 10.1002/lsm.20812; Iba Y, 2004, INT IMMUNOPHARMACOL, V4, P1873, DOI 10.1016/j.intimp.2004.08.009; Jana K, 2014, MOL REPROD DEV, V81, P833, DOI 10.1002/mrd.22354; Junqueira LCU, 2005, BIOL CELULAR MOL; Kant V, 2015, J SURG RES, V193, P978, DOI 10.1016/j.jss.2014.10.019; Kiraithe MN, 2016, J ETHNOPHARMACOL, V178, P266, DOI 10.1016/j.jep.2015.12.013; Kurek-Gorecka A, 2014, MOLECULES, V19, P78, DOI 10.3390/molecules19010078; Landen NX, 2016, CELL MOL LIFE SCI, V73, P3861, DOI 10.1007/s00018-016-2268-0; Lee Soo-Jin, 2012, Evid Based Complement Alternat Med, V2012, P190370, DOI 10.1155/2012/190370; Lorenzi H, 2002, PLANTAS MED BRASIL N; Martin A, 1996, DERMATOL SURG, V22, P156, DOI 10.1111/j.1524-4725.1996.tb00499.x; Martinez Carlos Augusto Real, 2015, J. Coloproctol. (Rio J.), V35, P90, DOI 10.1016/j.jcol.2015.02.007; Mohan S., 2015, INTERNATIONALJOURNAL, V3, P599; Mukai K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115564; Muthusubramaniam L, 2014, TISSUE ENG PT A, V20, P2728, DOI [10.1089/ten.tea.2013.0539, 10.1089/ten.TEA.2013.0539]; Ng MFY, 2010, INT WOUND J, V7, P55, DOI 10.1111/j.1742-481X.2009.00651.x; Novaes RD, 2016, INT J EXP PATHOL, V97, P114, DOI 10.1111/iep.12183; Nunan R, 2014, DIS MODEL MECH, V7, P1205, DOI 10.1242/dmm.016782; Pomari E, 2015, FASEB J, V29, P508, DOI 10.1096/fj.14-251363; Reddy GK, 2003, LASER SURG MED, V33, P344, DOI 10.1002/lsm.10227; Sarandy M. M., 2015, EVID-BASED COMPL ALT, V2015, P1; Schreml S, 2010, BRIT J DERMATOL, V163, P257, DOI 10.1111/j.1365-2133.2010.09804.x; Shiota N, 2010, INT ARCH ALLERGY IMM, V151, P80, DOI 10.1159/000232573; Siddiqui IA, 2005, CANCER LETT, V227, P125, DOI 10.1016/j.canlet.2004.10.046; SILAEVA S A, 1990, Byulleten' Eksperimental'noi Biologii i Meditsiny, V109, P180; Su YJ, 2015, ADV WOUND CARE, V4, P631, DOI 10.1089/wound.2014.0559; Sydow AKV, 2016, J CELL BIOCHEM, V117, P1622, DOI [10.1002/jcb.25455, DOI 10.1002/JCB.25455]; de Jesus NZT, 2009, REV BRAS FARMACOGN, V19, P130, DOI 10.1590/S0102-695X2009000100023; Urb M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002619; Vasconcelos SML, 2007, QUIM NOVA, V30, P1323, DOI 10.1590/S0100-40422007000500046; Webster J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009261.pub2; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Wetzler C, 2000, J INVEST DERMATOL, V115, P245, DOI 10.1046/j.1523-1747.2000.00029.x; Wu YJ, 2010, STEM CELLS, V28, P905, DOI 10.1002/stem.420; Xie ZW, 2013, ACTA BIOMATER, V9, P9351, DOI 10.1016/j.actbio.2013.07.030; Younan GJ, 2011, PLAST RECONSTR SURG, V128, p649E, DOI 10.1097/PRS.0b013e318230c55d	70	12	12	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2018	13	4							e0195786	10.1371/journal.pone.0195786	http://dx.doi.org/10.1371/journal.pone.0195786			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC4YG	29649320	Green Published, Green Submitted, gold			2023-01-03	WOS:000429791900089
J	Schenker, Y; Merlin, JS; Quill, TE				Schenker, Yael; Merlin, Jessica S.; Quill, Timothy E.			Use of Palliative Care Earlier in the Disease Course in the Context of the Opioid Epidemic Educational, Research, and Policy Issues	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; GUIDELINE; PAIN		[Schenker, Yael] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA; [Merlin, Jessica S.] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA USA; [Quill, Timothy E.] Univ Rochester, Sch Med, Dept Med, Palliat Care Div, Rochester, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Rochester	Schenker, Y (corresponding author), Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.	yas28@pitt.edu			NIH career development award - National Institute of Mental Health [K23MH104073]; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH104073] Funding Source: NIH RePORTER	NIH career development award - National Institute of Mental Health; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Dr Merlin was supported by an NIH career development award granted by the National Institute of Mental Health (K23MH104073).	Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Childers JW, 2012, J PAIN SYMPTOM MANAG, V43, P253, DOI 10.1016/j.jpainsymman.2011.03.009; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474; Jones CM, 2018, JAMA-J AM MED ASSOC, V319, P1819, DOI 10.1001/jama.2018.2844; Kerr K., 2018, CALIFORNIA HLTH CARE; Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012592.pub2	7	18	18	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	2018	320	9					871	872		10.1001/jama.2018.9739	http://dx.doi.org/10.1001/jama.2018.9739			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GS4OQ	30098170				2023-01-03	WOS:000443627300008
J	Wilson, MJA; MacArthur, C; Hewitt, CA; Handley, K; Gao, F; Beeson, L; Daniels, J				Wilson, Matthew J. A.; MacArthur, Christine; Hewitt, Catherine A.; Handley, Kelly; Gao, Fang; Beeson, Leanne; Daniels, Jane		RESPITE Trial Collaborative Grp	Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial	LANCET			English	Article							CHILDBIRTH; MEPERIDINE; HEALTH	Background About a third of women receiving pethidine for labour pain subsequently require an epidural, which provides effective pain relief but increases the risk of instrumental vaginal delivery. Remifentanil patient-controlled analgesia (PCA) in labour is an alternative to pethidine, but is not widely used. We aimed to evaluate epidural analgesia progression among women using remifentanil PCA compared with pethidine. Methods We did an open-label, multicentre, randomised controlled trial in 14 UK maternity units. We included women aged 16 years or older, beyond 37 weeks' gestation, in labour with a singleton cephalic presentation, and who requested opioid pain relief. We randomly assigned eligible participants (1: 1) to either the intravenous remifentanil PCA group (40 mu g bolus on demand with a 2 min lockout) or the intramuscular pethidine group (100 mg every 4 h, up to 400 mg in 24 h), using a web-based or telephone randomisation service with a minimisation algorithm for parity, maternal age, ethnicity, and mode of labour onset. Because of the differences in routes of drug administration, study participants and health-care providers were not masked to the group allocation. The primary outcome was the proportion of women who received epidural analgesia after enrolment for pain relief in labour. Primary analyses were unadjusted and analysed by the intention-to-treat principle. This study is registered with the ISRCTN registry, number ISRCTN29654603. Findings Between May 13, 2014, and Sept 2, 2016, 201 women were randomly assigned to the remifentanil PCA group and 200 to the pethidine group. One participant in the pethidine group withdrew consent, leaving 199 for analyses. The proportions of epidural conversion were 19% (39 of 201) in the remifentanil PCA group and 41% (81 of 199) in the pethidine group (risk ratio 0.48, 95% CI 0.34-0.66; p<0.0001). There were no serious adverse events or drug reactions directly attributable to either analgesic during the study. Interpretation Intravenous remifentanil PCA halved the proportion of epidural conversions compared with intramuscular pethidine. This finding challenges routine pethidine use as standard of care in labour. Copyright (c) 2018 Elsevier Ltd. All rights reserved.	[Wilson, Matthew J. A.] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; [MacArthur, Christine; Hewitt, Catherine A.; Handley, Kelly; Beeson, Leanne] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Gao, Fang] Univ Birmingham, Queen Elizabeth Hosp, Inst Inflammat & Ageing, Res Labs, Birmingham, W Midlands, England; [Daniels, Jane] Univ Nottingham, Nottingham Clin Trials Unit, Nottingham, England	University of Sheffield; University of Birmingham; University of Birmingham; University of Nottingham	Wilson, MJA (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	m.j.wilson@sheffield.ac.uk	MacArthur, Christine/ABA-8601-2021; Smith, Fang G/H-8451-2018	MacArthur, Christine/0000-0003-0434-2158; Smith, Fang G/0000-0002-8095-0609; Handley, Kelly/0000-0003-4036-2375; Wilson, Matthew/0000-0002-9704-5189	National Institute for Health Research Clinician Scientist Award	National Institute for Health Research Clinician Scientist Award	National Institute for Health Research Clinician Scientist Award.	Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; Barrett G, 2000, BRIT J OBSTET GYNAEC, V107, P186, DOI 10.1111/j.1471-0528.2000.tb11689.x; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Calderón E., 2006, Rev. Soc. Esp. Dolor, V13, P462; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; Howie KM, 2011, INT J OBSTET ANESTH, V20, pS36; Kranke P, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-139; MacArthur C, 2013, BJOG-INT J OBSTET GY, V120, P169, DOI 10.1111/1471-0528.12039; MacArthur C, 2001, LANCET, V358, P19; Ng TKT, 2011, ANAESTHESIA, V66, P796, DOI 10.1111/j.1365-2044.2011.06790.x; Reynolds F, 2011, INT J OBSTET ANESTH, V20, P38, DOI 10.1016/j.ijoa.2010.08.004; Saurel-Cubizolles MJ, 2000, BRIT J OBSTET GYNAEC, V107, P1202, DOI 10.1111/j.1471-0528.2000.tb11608.x; Schnabel A, 2011, ANAESTHESIST, V60, P995, DOI 10.1007/s00101-011-1933-9; Schnabel A, 2012, EUR J ANAESTH, V29, P177, DOI 10.1097/EJA.0b013e32834fc260; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Tveit TO, 2009, ACTA ANAESTH SCAND, V53, P794, DOI 10.1111/j.1399-6576.2009.01988.x; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2; Volikas I, 2001, INT J OBSTET ANESTH, V10, P86, DOI 10.1054/ijoa.2000.0831; Wee MYK, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-51; Weibel S, 2017, COCHRANE DB SYST REV, V4; Wilson M, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1708-3	22	40	46	4	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 25	2018	392	10148					662	672		10.1016/S0140-6736(18)31613-1	http://dx.doi.org/10.1016/S0140-6736(18)31613-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR4MP	30115484	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000442585300030
J	Luoh, SW; Flaherty, KT				Luoh, Shiuh-Wen; Flaherty, Keith T.			When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age	ANNALS OF INTERNAL MEDICINE			English	Review							CELL LUNG-CANCER; HER2-POSITIVE BREAST-CANCER; METASTATIC COLORECTAL-CANCER; DABRAFENIB PLUS TRAMETINIB; BRAF-MUTATED MELANOMA; DNA MISMATCH REPAIR; OPEN-LABEL; PROSTATE-CANCER; MICROSATELLITE INSTABILITY; ADJUVANT CHEMOTHERAPY	Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these vulnerabilities range from specific molecular alterations pointing to direct drug strategies to harnessing immune recognition of genetically altered epitopes produced by the cancer cells. Recent advances have found that the success of biomarker-driven cancer therapy may be relevant across sites of origin. For example, cancer types that show DNA mismatch repair deficiency, such as colon, biliary, and endometrial cancer, are more sensitive to immune checkpoint inhibition. Several large, ongoing clinical trials with a "basket" design are combining tumor tissue genomics with potential off-the-shelf therapies in drug development, and more tissue-agnostic biomarker therapies are reaching the bedside.	[Luoh, Shiuh-Wen] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,R&D 47, Portland, OR 97239 USA; [Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Flaherty, Keith T.] Massachusetts Gen Hosp, Canc Ctr, 55 Fruit St, Boston, MA 02114 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University; Harvard University; Massachusetts General Hospital	Luoh, SW (corresponding author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,R&D 47, Portland, OR 97239 USA.	luohs@OHSU.edu						Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bang YJ, 2010, LANCET, V376, P1302; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Brown JS, 2016, BRIT J CANCER, V114, P713, DOI 10.1038/bjc.2016.67; Campesato LF, 2015, ONCOTARGET, V6, P34221, DOI 10.18632/oncotarget.5950; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Coyne GO, 2017, DRUGS, V77, P113, DOI 10.1007/s40265-016-0688-7; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Funkhouser WK, 2012, J MOL DIAGN, V14, P91, DOI 10.1016/j.jmoldx.2011.11.001; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Janku F, 2017, CLIN CANCER RES, V23, P5648, DOI 10.1158/1078-0432.CCR-17-0291; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; King MC, 2014, JAMA-J AM MED ASSOC, V312, P1091, DOI 10.1001/jama.2014.12483; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283; Liu DK, 2017, MUTAT RES-REV MUTAT, V773, P174, DOI 10.1016/j.mrrev.2017.07.001; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Lynch HT, 2009, CLIN GENET, V76, P1, DOI 10.1111/j.1399-0004.2009.01230.x; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; MERCK, 2018, HIGHL PRESCR INF KEY; Meric-Bernstam F, 2014, MOL CANCER THER, V13, P1382, DOI 10.1158/1535-7163.MCT-13-0482; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Roszik J, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0705-4; Salem ME, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11517; Sanmamed MF, 2015, CLIN CHEM, V61, P297, DOI 10.1373/clinchem.2014.230235; Santiago-Walker A, 2016, CLIN CANCER RES, V22, P567, DOI 10.1158/1078-0432.CCR-15-0321; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Simon R, 2016, ANN INTERN MED, V165, P270, DOI 10.7326/M15-2413; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Strickler JH, 2017, CANCER TREAT REV, V60, P109, DOI 10.1016/j.ctrv.2017.08.006; Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; Teplinsky E, 2014, GYNECOL ONCOL, V135, P364, DOI 10.1016/j.ygyno.2014.09.003; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Walsh CS, 2015, GYNECOL ONCOL, V137, P343, DOI 10.1016/j.ygyno.2015.02.017; Wilson PM, 2010, CANCER J, V16, P262, DOI 10.1097/PPO.0b013e3181e07738; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA	65	14	14	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 21	2018	169	4					233	+		10.7326/M17-2832	http://dx.doi.org/10.7326/M17-2832			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR4LO	30073297				2023-01-03	WOS:000442580400018
J	Ferguson, CTJ; Al-Khalaf, AA; Isaac, RE; Cayre, OJ				Ferguson, Calum T. J.; Al-Khalaf, Areej A.; Isaac, R. Elwyn; Cayre, Olivier J.			pH-responsive polymer microcapsules for targeted delivery of biomaterials to the midgut of Drosophila suzukii	PLOS ONE			English	Article							SPOTTED WING DROSOPHILA; SPIDER-VENOM PEPTIDES; PROTEIN-BASED VACCINES; BIODEGRADABLE MICROSPHERES; INSECT; ANALOGS; ACID; CONJUGATION; ANTAGONIST; PARTICLES	Drosophila suzukii or spotted wing Drosophila is an economically important pest which can have a devastating impact on soft and stone fruit industries. Biological pesticides are being sought as alternatives to synthetic chemicals to control this invasive pest, but many are subject to degradation either in the environment or in the insect gut and as a result require protection. In this study we identified a sharp change in pH of the adult midgut from neutral to acidic (pH <3), which we then exploited to develop poly(2-vinylpyridine) (P2VP) microcapsules that respond to the change in midgut pH by dissolution and release of their cargo for uptake into the insect. First, we used labelled solid poly(methyl methacrylate) (PMMA) particles to show that microcapsules with a diameter less than 15 pm are readily ingested by the adult insect. To encapsulate water-soluble biological species in an aqueous continuous phase, a multiple emulsion template was used as a precursor for the synthesis of pH responsive P2VP microcapsules with a fluorescent (FITC-dextran) cargo. The water-soluble agent was initially separated from the aqueous continuous phase by an oil barrier, which was subsequently polymerised. The P2VP microcapsules were stable at pH > 6, but underwent rapid dissolution at pH < 4.2. In vivo studies showed that the natural acidity of the mid gut of D. suzukii also induced the breakdown of the responsive P2VP microcapsules to release FITC-dextran which was taken up into the body of the insect and accumulated in the renal tubules.	[Ferguson, Calum T. J.; Isaac, R. Elwyn] Univ Leeds, Sch Biol Sci, Leeds, W Yorkshire, England; [Ferguson, Calum T. J.; Cayre, Olivier J.] Univ Leeds, Sch Chem & Proc Engn, Leeds, W Yorkshire, England; [Al-Khalaf, Areej A.] Princess Nourah Bint Abdulrahman Univ, Coll Sci, Riyadh, Saudi Arabia	University of Leeds; University of Leeds; Princess Nourah bint Abdulrahman University	Cayre, OJ (corresponding author), Univ Leeds, Sch Chem & Proc Engn, Leeds, W Yorkshire, England.	o.j.cayre@leeds.ac.uk	Ferguson, Calum/GRR-8006-2022; Al-Khalaf, Areej/GNW-4096-2022; Cayre, Olivier/AAY-2996-2020	Isaac, Richard/0000-0003-4792-6559; Ferguson, Calum/0000-0002-6168-4624; Cayre, Olivier/0000-0003-1339-3686	European Union's 7th Framework research and innovation programme as part of the Dropsa project [613678]	European Union's 7th Framework research and innovation programme as part of the Dropsa project	This work was funded from the European Union's 7th Framework research and innovation programme: grant agreement 613678, as part of the Dropsa project (http://dropsaproject.eu/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apidianakis Y, 2011, DIS MODEL MECH, V4, P21, DOI 10.1242/dmm.003970; Asplen MK, 2015, J PEST SCI, V88, P469, DOI 10.1007/s10340-015-0681-z; Atallah J, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2840; Bolda M.P., 2010, AGR RESOUR EC UPDATE, V13, P5, DOI DOI 10.1016/J.JFF.2015.04.027; Bonning BC, 2014, TRENDS BIOTECHNOL, V32, P91, DOI 10.1016/j.tibtech.2013.08.001; Bravo A, 2011, INSECT BIOCHEM MOLEC, V41, P423, DOI 10.1016/j.ibmb.2011.02.006; CHANCE M M, 1970, Quaestiones Entomologicae, V6, P245; Chowanski S, 2014, POLISH J ENV STUDIES, V23; Coronado-Gonzalez PA, 2008, J INSECT SCI, V8, DOI 10.1673/031.008.7301; Cuthbertson Andrew G S, 2014, Insects, V5, P488, DOI 10.3390/insects5020488; De Ros G, 2015, J BERRY RES, V5, P89, DOI 10.3233/JBR-150092; Depra M, 2014, J PEST SCI, V87, P379, DOI 10.1007/s10340-014-0591-5; Diepenbrock LM, 2016, CROP PROT, V81, P76, DOI 10.1016/j.cropro.2015.12.012; Dupin D, 2006, LANGMUIR, V22, P3381, DOI 10.1021/la053258h; Fujii S, 2010, SOFT MATTER, V6, P635, DOI 10.1039/b914997j; Gabarra R, 2015, BIOCONTROL, V60, P331, DOI 10.1007/s10526-014-9646-z; Gade G, 2003, PEST MANAG SCI, V59, P1063, DOI 10.1002/ps.755; Glare T, 2012, TRENDS BIOTECHNOL, V30, P250, DOI 10.1016/j.tibtech.2012.01.003; Goodhue RE, 2011, PEST MANAG SCI, V67, P1396, DOI 10.1002/ps.2259; Hardy MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073136; Haye T, 2016, J PEST SCI, V89, P643, DOI 10.1007/s10340-016-0737-8; JACKSON JB, 1969, EUR J BIOCHEM, V10, P226; Jeffers LA, 2014, PESTIC BIOCHEM PHYS, V115, P58, DOI 10.1016/j.pestbp.2014.08.006; Jeffers LA, 2012, PEST MANAG SCI, V68, P49, DOI 10.1002/ps.2219; Jiang S, 2015, ACS BIOMATER SCI ENG, V1, P1077, DOI 10.1021/acsbiomaterials.5b00163; Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441; Khaja SD, 2007, BIOMACROMOLECULES, V8, P1391, DOI 10.1021/bm061234z; Kim JW, 2003, COLLOID POLYM SCI, V281, P157, DOI 10.1007/s00396-002-0763-3; King GF, 2013, ANNU REV ENTOMOL, V58, P475, DOI 10.1146/annurev-ento-120811-153650; Lange AB, 2016, PEPTIDES, V80, P108, DOI 10.1016/j.peptides.2016.01.012; Lee JC, 2011, PEST MANAG SCI, V67, P1349, DOI 10.1002/ps.2271; Lee KY, 2007, PROG POLYM SCI, V32, P669, DOI 10.1016/j.progpolymsci.2007.04.001; Lemaitre B, 2013, ANNU REV GENET, V47, P377, DOI 10.1146/annurev-genet-111212-133343; Morishita M, 2006, DRUG DISCOV TODAY, V11, P905, DOI 10.1016/j.drudis.2006.08.005; Morita T, 2000, J CONTROL RELEASE, V69, P435, DOI 10.1016/S0168-3659(00)00326-6; Murdock LL, 2002, J AGR FOOD CHEM, V50, P6605, DOI 10.1021/jf020192c; Murthy N, 2003, P NATL ACAD SCI USA, V100, P4995, DOI 10.1073/pnas.0930644100; Nachman RJ, 2002, PEPTIDES, V23, P2035, DOI 10.1016/S0196-9781(02)00191-2; Nachman RJ, 2014, ACS SYM SER, V1172, P83; Nachman RJ, 2012, PEPTIDES, V34, P266, DOI 10.1016/j.peptides.2011.11.009; Nachman RJ, 2011, PEPTIDES, V32, P587, DOI 10.1016/j.peptides.2010.09.013; Nachman RJ, 2009, PEPTIDES, V30, P616, DOI 10.1016/j.peptides.2008.09.024; Nakasu EYT, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0619; Nuruzzaman M, 2016, J AGR FOOD CHEM, V64, P1447, DOI 10.1021/acs.jafc.5b05214; Overend G, 2016, SCI REP-UK, V6, DOI 10.1038/srep27242; Pfeiffer D, 2016, 2016 SPRAY B COMMERC; Saez NJ, 2010, TOXINS, V2, P2851, DOI 10.3390/toxins2122851; Shalev AH, 2015, PEPTIDES, V63, P81, DOI 10.1016/j.peptides.2014.10.014; Shanbhag S, 2009, J EXP BIOL, V212, P1731, DOI 10.1242/jeb.029306; Sinha VR, 2003, J CONTROL RELEASE, V90, P261, DOI 10.1016/S0168-3659(03)00194-9; Smagghe G, 2010, PEPTIDES, V31, P498, DOI 10.1016/j.peptides.2009.07.001; Standley SM, 2004, BIOCONJUGATE CHEM, V15, P1281, DOI 10.1021/bc049956f; Swevers Luc, 2012, P177; Takei T, 2010, POLYM BULL, V65, P283, DOI 10.1007/s00289-010-0253-6; TALMADGE JE, 1993, ADV DRUG DELIVER REV, V10, P247, DOI 10.1016/0169-409X(93)90049-A; Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2; Vladisavljevic GT, 2006, J COLLOID INTERF SCI, V299, P396, DOI 10.1016/j.jcis.2005.01.061; Whyard S, 2009, INSECT BIOCHEM MOLEC, V39, P824, DOI 10.1016/j.ibmb.2009.09.007; Windley MJ, 2012, TOXINS, V4, P191, DOI 10.3390/toxins4030191; Zhang QR, 2015, PEPTIDES, V72, P196, DOI 10.1016/j.peptides.2015.05.005; ZLOTKIN E, 1992, ARCH INSECT BIOCHEM, V21, P41, DOI 10.1002/arch.940210105	61	9	9	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2018	13	8							e0201294	10.1371/journal.pone.0201294	http://dx.doi.org/10.1371/journal.pone.0201294			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GP9JF	30091982	Green Published, gold, Green Submitted			2023-01-03	WOS:000441232600019
J	King, C; Atwood, S; Lozada, M; Nelson, AK; Brown, C; Sabo, S; Curley, C; Muskett, O; Orav, EJ; Shin, S				King, Caroline; Atwood, Sidney; Lozada, Mia; Nelson, Adrianne Katrina; Brown, Chris; Sabo, Samantha; Curley, Cameron; Muskett, Olivia; Orav, Endel John; Shin, Sonya			Identifying risk factors for 30-day readmission events among American Indian patients with diabetes in the Four Corners region of the southwest from 2009 to 2016	PLOS ONE			English	Article							HOSPITAL READMISSIONS; DISPARITIES; RATES	Objective The objective of this study was to identify risk factors for 30-day readmission events for American Indian patients with diabetes in the southwest. Research design and methods Data from patients with diabetes admitted to Gallup Indian Medical Center between 2009 and 2016 were analyzed using logistic regression analyses. Results Of 2,660 patients, 394 (14.8%) patients had at least one readmission within 30 days of discharge. Older age (OR (95% CI) = 1.26, (1.17,1.36)), longer length of stay (OR (95% CI) = 1.01, (1.0001,1.0342)), and a history of substance use disorder (OR (95% CI) = 1.80, (1.25, 2.60)) were risk factors for 30-day readmission. An American Indian language preference was protective against readmission. Conclusions Readmission events are complex and may reflect broad and interwoven disparities in community systems. Future research should work to support community-defined interventions to address both in hospital and external factors that impact risk factors for readmission.	[King, Caroline] Univ Arizona, Mel & Enid Zukerman Coll Publ Hlth, Tucson, AZ USA; [King, Caroline; Nelson, Adrianne Katrina; Brown, Chris; Curley, Cameron; Muskett, Olivia; Shin, Sonya] COPE, Gallup, NM 87301 USA; [Atwood, Sidney; Brown, Chris; Curley, Cameron; Muskett, Olivia; Shin, Sonya] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA; [Lozada, Mia; Shin, Sonya] Gallup Indian Med Ctr, Gallup, NM 87301 USA; [Sabo, Samantha] Univ Arizona, Hlth Promot Sci Dept, Tucson, AZ USA; [Orav, Endel John] Harvard Sch Publ Hlth, Boston, MA USA; [Shin, Sonya] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA	University of Arizona; Harvard University; Brigham & Women's Hospital; University of Arizona; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Shin, S (corresponding author), COPE, Gallup, NM 87301 USA.; Shin, S (corresponding author), Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA.; Shin, S (corresponding author), Gallup Indian Med Ctr, Gallup, NM 87301 USA.; Shin, S (corresponding author), Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA.	sshin@bwh.harvard.edu	King, Caroline/AAX-2164-2020	King, Caroline/0000-0002-9913-6340	Patient-Centered Outcomes Research Institute (PCORI) [AD1304-6566]; COPE Project; CHAP (the Community Health Advisory Panel); CAG (the COPE Advisory Group)	Patient-Centered Outcomes Research Institute (PCORI)(Patient-Centered Outcomes Research Institute - PCORI); COPE Project; CHAP (the Community Health Advisory Panel); CAG (the COPE Advisory Group)	This work was supported by the Patient-Centered Outcomes Research Institute (PCORI) (AD1304-6566). www.pcori.org. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.; We would like to thank the COPE Project, CHAP (the Community Health Advisory Panel) and CAG (the COPE Advisory Group) for supporting this work and for their input throughout the entire study.	Albrecht JS, 2012, AM J MED QUAL, V27, P503, DOI 10.1177/1062860612436576; Bennett KJ, 2012, J RURAL HEALTH, V28, P227, DOI 10.1111/j.1748-0361.2011.00399.x; Census, 2011, AM IND AL NAT HER MO; Centers for M Medicaid S, 2016, CMS IND HLTH SERV EX; Definitive h, 2016, IND HLTH SERV HOSP D; Devi S, 2011, LANCET, V377, P1481, DOI 10.1016/S0140-6736(11)60586-2; Frank JW, 2000, AM J PUBLIC HEALTH, V90, P344, DOI 10.2105/AJPH.90.3.344; Gampa V, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-016-1956-7; Gomez-Huelgas R, 2015, J DIABETES COMPLICAT, V29, P1050, DOI 10.1016/j.jdiacomp.2015.07.018; Healy SJ, 2013, DIABETES CARE, V36, P2960, DOI 10.2337/dc13-0108; IHS, 2017, RPMS SYST; Indian Health S, 2017, GALL IND MED CTR 201; Indian Health S, FIND HLTH CAR IHS HL; Indian Health S, 2016, IHS RECR; Indian Health S. Disparities, 2016, DISP; Jiang HJ, 2005, AM J PUBLIC HEALTH, V95, P1561, DOI 10.2105/AJPH.2004.044222; Jones DS, 2006, AM J PUBLIC HEALTH, V96, P2122, DOI 10.2105/AJPH.2004.054262; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Lindholm M, 2012, J GEN INTERN MED, V27, P1294, DOI 10.1007/s11606-012-2041-5; Medicine USNLo, IND HLTH SERV TOD; Nagasako EM, 2014, HEALTH AFFAIR, V33, P786, DOI 10.1377/hlthaff.2013.1148; Navajo N, 2010, NAV NAT CENS; Navajo Nation C, 2014, 22 NAV NAT COUNC 4 Y; Olsen B., 2002, S POL RAC CULT HLTH; Partners in H, 2016, NAV NAT; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Robbins JM, 2006, MED CARE, V44, P292, DOI 10.1097/01.mlr.0000199639.20342.87; Rubin DJ, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0584-7; Rubin DJ, 2016, ENDOCRINE PRACTICE O, DOI [10.4158/EP161391.OR, DOI 10.4158/EP161391.OR]; Strack B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/781670; Thomas KS, 2014, AM J MANAG CARE, V20, pE523	31	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2018	13	8								10.1371/journal.pone.0195476	http://dx.doi.org/10.1371/journal.pone.0195476			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GP3UD	30070989	Green Published, gold, Green Submitted			2023-01-03	WOS:000440778600001
J	Magis, AT; Earls, JC; Glusman, G; Omenn, GS; Lovejoy, JC; Price, ND; Hood, L				Magis, Andrew T.; Earls, John C.; Glusman, Gustavo; Omenn, Gilbert S.; Lovejoy, Jennifer C.; Price, Nathan D.; Hood, Leroy			Precision medicine in the clouds Reply	NATURE BIOTECHNOLOGY			English	Letter							DIABETES PREVENTION; FOLLOW-UP; RISK; HEALTH		[Magis, Andrew T.; Lovejoy, Jennifer C.; Price, Nathan D.; Hood, Leroy] Arivale, Seattle, WA 98104 USA; [Earls, John C.; Glusman, Gustavo; Lovejoy, Jennifer C.; Price, Nathan D.; Hood, Leroy] Inst Syst Biol, Seattle, WA 98109 USA; [Omenn, Gilbert S.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Hood, Leroy] Providence St Joseph Hlth, Seattle, WA USA	Institute for Systems Biology (ISB); University of Michigan System; University of Michigan	Price, ND; Hood, L (corresponding author), Arivale, Seattle, WA 98104 USA.; Price, ND; Hood, L (corresponding author), Inst Syst Biol, Seattle, WA 98109 USA.; Hood, L (corresponding author), Providence St Joseph Hlth, Seattle, WA USA.	nathan.price@systemsbiology.org; lhood@systemsbiology.org		Glusman, Gustavo/0000-0001-8060-5955; Magis, Andrew/0000-0003-0576-677X; Price, Nathan/0000-0002-4157-0267				Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS81, DOI 10.2337/dc14-S081; Bouchard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037887; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Chen R, 2012, CELL, V148, P1293, DOI 10.1016/j.cell.2012.02.009; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Danaei G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000058; David LA, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-7-r89; Green RC, 2009, NEW ENGL J MED, V361, P245, DOI 10.1056/NEJMoa0809578; Holick MF, 2012, J CLIN ENDOCR METAB, V97, P1153, DOI 10.1210/jc.2011-2601; Hollands GJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1102; Hood L, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0238-7; Jorgensen T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3617; Li GW, 2008, LANCET, V371, P1783, DOI 10.1016/S0140-6736(08)60766-7; Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029; Piening BD, 2018, CELL SYST, V6, P157, DOI 10.1016/j.cels.2017.12.013; Price ND, 2017, NAT BIOTECHNOL, V35, P747, DOI 10.1038/nbt.3870; Rice T, 2002, CIRCULATION, V105, P1904, DOI 10.1161/01.CIR.0000014969.85364.9F; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Smarr L, 2012, BIOTECHNOL J, V7, P980, DOI 10.1002/biot.201100495; Vogt H, 2018, NAT BIOTECHNOL, V36, P678, DOI 10.1038/nbt.4210; Xu X, 2018, INT J OBESITY, V42, P794, DOI 10.1038/ijo.2017.223; Yong PL, 2010, HEALTHCARE IMPERATIV; Zhang XP, 2010, DIABETES CARE, V33, P1665, DOI 10.2337/dc09-1939	23	1	1	2	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2018	36	8					680	682		10.1038/nbt.4211	http://dx.doi.org/10.1038/nbt.4211			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	GQ1AH	30080845				2023-01-03	WOS:000441353500010
J	Mazar, J; Li, YJ; Rosado, A; Phelan, P; Kedarinath, K; Parks, GD; Alexander, KA; Westmoreland, TJ				Mazar, Joseph; Li, Yujia; Rosado, Amy; Phelan, Peter; Kedarinath, Kritika; Parks, Griffith D.; Alexander, Kenneth A.; Westmoreland, Tamarah J.			Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24	PLOS ONE			English	Article							RISK GROUP; INFECTION; SYSTEM; CANCER; ACTIVATION; HEPATITIS; CARCINOMA	Neuroblastoma is the second most common childhood tumor. Survival is poor even with intensive therapy. In a search for therapies to neuroblastoma, we assessed the oncolytic potential of Zika virus. Zika virus is an emerging mosquito-borne pathogen unique among flaviviruses because of its association with congenital defects. Recent studies have shown that neuronal progenitor cells are likely the human target of Zika virus. Neuroblastoma has been shown to be responsive to infection. In this study, we show that neuroblastoma cells are widely permissive to Zika infection, revealing extensive cytopathic effects (CPE) and producing high titers of virus. However, a single cell line appeared poorly responsive to infection, producing undetectable levels of non-structural protein 1 (NS1), limited CPE, and low virus titers. A comparison of these poorly permissive cells to highly permissive neuroblastoma cells revealed a dramatic loss in the expression of the cell surface glycoprotein CD24 in poorly permissive cells. Complementation of CD24 expression in these cells led to the production of detectable levels of NS1 expression after infection with Zika, as well as dramatic increases in viral titers and CPE. Complementary studies using the Zika virus index strain and a north African isolate confirmed these phenotypes. These results suggest a possible role for CD24 in host cell specificity by Zika virus and offer a potential therapeutic target for its treatment. In addition, Zika viral therapy can serve as an adjunctive treatment for neuroblastoma by targeting tumor cells that can lead to recurrent disease and treatment failure.	[Mazar, Joseph; Rosado, Amy; Phelan, Peter; Alexander, Kenneth A.; Westmoreland, Tamarah J.] Nemours Childrens Hosp, Dept Biomed Res, Orlando, FL 32827 USA; [Li, Yujia; Kedarinath, Kritika; Parks, Griffith D.; Alexander, Kenneth A.; Westmoreland, Tamarah J.] Univ Cent Florida, Coll Med, Burnett Sch Biol Sci, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Mazar, J; Westmoreland, TJ (corresponding author), Nemours Childrens Hosp, Dept Biomed Res, Orlando, FL 32827 USA.; Westmoreland, TJ (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biol Sci, Orlando, FL 32816 USA.	jm0151@nemours.org; tamarah.westmoreland@nemours.org	Mazar, Joseph/AAQ-8199-2020	Mazar, Joseph/0000-0002-3713-4251	Nemours Foundation; Nemours Children's Hospital; Florida High Tech Corridor	Nemours Foundation; Nemours Children's Hospital; Florida High Tech Corridor	The Nemours Foundation and Nemours Children's Hospital along with the regional economic development initiative of the Florida High Tech Corridor supported all funding for these studies. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, ONCOTARGET, V8, P6589; [Anonymous], 2017, ONCOTARGET, V8, P6589; Aref S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100294; Bayless NL, 2016, CELL HOST MICROBE, V20, P423, DOI 10.1016/j.chom.2016.09.006; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Centers for Disease Control and Prevention, 2016, ZIK VIR SYMPT TEST T; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014; Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233; Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824; Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119; Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116; Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381; GEORGIADES JERZY, 1959, BIUL INST MED MORSKIEJ W GDANSKU, V10, P49; Gilliam DT, 2017, NEUROBIOL DIS, V99, P133, DOI 10.1016/j.nbd.2016.12.011; Hadac EM, 2004, VIROLOGY, V329, P217, DOI 10.1016/j.virol.2004.08.036; Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15; HOSTER HA, 1949, CANCER RES, V9, P473; HOUGH MR, 1994, GENOMICS, V22, P154, DOI 10.1006/geno.1994.1356; Hughes BW, 2016, EBIOMEDICINE, V10, P65, DOI 10.1016/j.ebiom.2016.06.026; Institute NC, 2017, NEUR TREATM PDQ PAT; Kaid C, 2018, CANC RES; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Lacroix J, 2010, INT J CANCER, V127, P1230, DOI 10.1002/ijc.25168; Latchman DS, 2005, CURR OPIN MOL THER, V7, P415; Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017; Li DL, 2009, HEPATOLOGY, V50, P735, DOI 10.1002/hep.23047; Li Y, 2013, J CANCER RES CLIN, V139, P933, DOI 10.1007/s00432-013-1406-4; Lim SC, 2005, BIOMED PHARMACOTHER, V59, pS351, DOI 10.1016/S0753-3322(05)80076-9; London WB, 2005, J CLIN ONCOL, V23, P6459, DOI 10.1200/JCO.2005.05.571; Luplertlop N, 2017, J VECTOR DIS, V54, P207, DOI 10.4103/0972-9062.217611; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Mazar J, 2017, ONCOTARGET, V8, P6589, DOI 10.18632/oncotarget.14244; Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Nakamura T, 2005, NAT BIOTECHNOL, V23, P209, DOI 10.1038/nbt1060; Papaioannou Georgia, 2005, Cancer Imaging, V5, P116, DOI 10.1102/1470-7330.2005.0104; Poncet C, 1996, ACTA NEUROPATHOL, V91, P400, DOI 10.1007/s004010050442; Pruszak J, 2009, STEM CELLS, V27, P2928, DOI 10.1002/stem.211; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sarmiento-Ospina A, 2016, LANCET INFECT DIS, V16, P523, DOI 10.1016/S1473-3099(16)30006-8; Shen YQ, 2005, MOL THER, V11, P180, DOI 10.1016/j.ymthe.2004.10.015; Smith MA, 2014, CANCER-AM CANCER SOC, V120, P2497, DOI 10.1002/cncr.28748; SMITH RR, 1956, CANCER, V9, P1211, DOI 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7; SOUTHAM CM, 1952, CANCER, V5, P1025, DOI 10.1002/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q; Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016; TAYLOR AW, 1953, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.4810.589; Toyoda H, 2011, INT J ONCOL, V38, P81, DOI 10.3892/ijo_00000826; Ventura CV, 2016, JAMA OPHTHALMOL, V134, P912, DOI 10.1001/jamaophthalmol.2016.1784; Zhang SC, 2012, CANCER LETT, V325, P227, DOI 10.1016/j.canlet.2012.07.008; Zhu Z, 2017, J EXP MED, V214, P2843, DOI 10.1084/jem.20171093	53	13	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2018	13	7							e0200358	10.1371/journal.pone.0200358	http://dx.doi.org/10.1371/journal.pone.0200358			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GO4AN	30044847	Green Published, Green Submitted, gold			2023-01-03	WOS:000439942500047
J	Johnston, SC; Easton, JD; Farrant, M; Barsan, W; Conwit, RA; Elm, JJ; Kim, AS; Lindblad, AS; Palesch, YY				Johnston, S. Claiborne; Easton, J. Donald; Farrant, Mary; Barsan, William; Conwit, Robin A.; Elm, Jordan J.; Kim, Anthony S.; Lindblad, Anne S.; Palesch, Yuko Y.		Clinical Res Collaboration; Neurological Emergencies Treatment; POINT Investigators	Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINOR STROKE; ATTACK; EFFICACY; TICAGRELOR; SAFETY; TRIAL	BACKGROUND Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a reduction in the risk of recurrent stroke. We tested this combination in an international population. METHODS In a randomized trial, we assigned patients with minor ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. The dose of aspirin in each group was selected by the site investigator. The primary efficacy outcome in a time-to-event analysis was the risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event, at 90 days. RESULTS A total of 4881 patients were enrolled at 269 international sites. The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days. Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval (CI], 0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event. Major hemorrhage occurred in 23 patients (0.996) receiving clopidogrel plus aspirin and in 10 patients (0.4%) receiving aspirin plus placebo (hazard ratio, 2.32; 95% CI, 1.10 to 4.87; P=0.02). CONCLUSIONS In patients with minor ischemic stroke or high-risk TIA, those who received a combination of clopidogrel and aspirin had a lower risk of major ischemic events but a higher risk of major hemorrhage at 90 days than those who received aspirin alone.	[Johnston, S. Claiborne] Univ Texas Austin, Dell Med Sch, Deans Off, Austin, TX 78701 USA; [Easton, J. Donald; Farrant, Mary; Kim, Anthony S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Barsan, William] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Conwit, Robin A.] NINDS, Div Clin Res, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Lindblad, Anne S.] Emmes, Rockville, MD USA; [Elm, Jordan J.; Palesch, Yuko Y.] Univ South Carolina, Data Coordinat Unit, Dept Publ Hlth Sci, Charleston, SC USA	University of Texas System; University of Texas Austin; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Johnston, SC (corresponding author), Univ Texas Austin, Dell Med Sch, 1501 Red River St, Austin, TX 78701 USA.	clay.johnston@utexas.edu	Leppert, Michelle/H-6116-2019; Carrera, Joseph/U-7401-2019; Spratt, Neil J/K-4208-2012; Youn, Teddy Si/ABH-9887-2020; Reynolds, Alexandra/ABB-7782-2020; Brunner, Freimuth/AAE-9651-2021; Martinez-Sanchez, Patricia/O-5687-2016; Guisado-Alonso, Daniel/F-3399-2018; Ois, Angel/X-2922-2019; Field, Thalia/G-8477-2019; Mullaguri, Naresh/M-2061-2017; Zhang, Jiaying/M-4845-2016; Thijs, Vincent/M-9048-2019	Leppert, Michelle/0000-0002-0679-7634; Carrera, Joseph/0000-0003-2487-4506; Spratt, Neil J/0000-0002-9023-6177; Reynolds, Alexandra/0000-0002-6364-6250; Shepherd, Starane/0000-0003-2796-4726; Buckwalter, Marion/0000-0003-2807-2447; Parikh, Neal/0000-0002-8802-2380; Yu, Amy Ying Xin/0000-0002-7276-9551; Faigle, Roland/0000-0002-9074-1915; Androulakis, X. Michelle/0000-0002-1833-3474; Morris, Nicholas/0000-0002-1270-9805; Brunner, Freimuth/0000-0002-2818-2665; Sotoca, Javier/0000-0003-3400-1434; Tirschwell, David/0000-0002-8059-2901; Martinez-Sanchez, Patricia/0000-0003-1945-4435; Wijeratne, Tissa/0000-0002-1701-7111; Guisado-Alonso, Daniel/0000-0002-5799-3184; Ois, Angel/0000-0002-1375-5950; Curtze, Sami/0000-0003-1545-8500; Field, Thalia/0000-0002-1176-0633; Marinkovic, Ivan/0000-0002-0950-8623; Ylikallio, Emil/0000-0001-5178-0703; Vibbert, Matthew/0000-0001-6699-6646; Kalashyan, Hayrapet/0000-0002-7714-696X; Gutmann, Laurie/0000-0003-3926-4209; Mullaguri, Naresh/0000-0001-6850-3294; Derex, Laurent/0000-0002-0909-8900; Martinez-Domeno, Alejandro/0000-0002-9933-3192; CAMPS-RENOM, POL/0000-0001-6587-6271; Malkoff, Marc/0000-0002-6665-3114; Kulhari, Ashish/0000-0003-4614-4643; Zhang, Jiaying/0000-0003-2725-1259; Marti-Fabregas, Joan/0000-0001-9229-8649; Dandapat, Sudeepta/0000-0003-3744-7845; Mazzillo, Justin/0000-0001-7534-3882; Quinn, James/0000-0002-3694-2118; Sergot, Paulina/0000-0003-0796-8009; Bashir Viturro, Saima/0000-0002-2019-467X; wein, theodore/0000-0002-8994-8628; Bellolio, Fernanda/0000-0002-1632-4750; MUCHADA, MARIAN/0000-0002-9876-285X; Becker, Brent/0000-0001-6057-053X; Hsia, Amie/0000-0002-0214-9736; Grosse, Gerrit M./0000-0002-5335-9880; Das, Shubhabrata/0000-0002-1423-169X; Roquer Gonzalez, Jaume/0000-0001-5992-2606; Thijs, Vincent/0000-0002-6614-8417; Hobeanu, Cristina/0000-0002-9131-3496	National Institute of Neurological Disorders and Stroke [U01 NS062835, U01 NS056975, U01 NS059041]; AstraZeneca; Boehringer Ingelheim; SanBio; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS062835, U01NS059041, U01NS056975] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); SanBio; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants (U01 NS062835, U01 NS056975, and U01 NS059041) from the National Institute of Neurological Disorders and Stroke. Sanofi provided clopidogrel and placebo for 75% of the patients in the trial.; Dr. Johnston reports receiving grant support from AstraZeneca; Dr. Easton, receiving grant support from AstraZeneca and consulting fees from Boehringer Ingelheim; Ms. Farrant, receiving grant support from AstraZeneca; and Dr. Kim, receiving grant support from SanBio and fees for serving as a member of a data and safety monitoring board from Neuravi. No other potential conflict of interest relevant to this article was reported.	Amarenco P, 2017, LANCET NEUROL, V16, P301, DOI 10.1016/S1474-4422(17)30038-8; Amarenco P, 2016, NEW ENGL J MED, V374, P1533, DOI 10.1056/NEJMoa1412981; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bath PM, 2018, LANCET, V391, P850, DOI 10.1016/S0140-6736(17)32849-0; Bowry ADK, 2008, AM J CARDIOL, V101, P960, DOI 10.1016/j.amjcard.2007.11.057; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; Dienert HC, 2008, LANCET NEUROL, V7, P875, DOI 10.1016/S1474-4422(08)70198-4; Giles MF, 2007, LANCET NEUROL, V6, P1063, DOI 10.1016/S1474-4422(07)70274-0; Johnston SC, 2007, LANCET, V369, P283, DOI 10.1016/S0140-6736(07)60150-0; Johnston SC, 2016, NEW ENGL J MED, V375, P35, DOI 10.1056/NEJMoa1603060; Johnston SC, 2013, INT J STROKE, V8, P479, DOI 10.1111/ijs.12129; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Sandercock P, 1997, LANCET, V349, P1569; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Wang YL, 2016, JAMA-J AM MED ASSOC, V316, P70, DOI 10.1001/jama.2016.8662; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Wu CM, 2007, ARCH INTERN MED, V167, P2417, DOI 10.1001/archinte.167.22.2417	20	528	551	14	124	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2018	379	3					215	225		10.1056/NEJMoa1800410	http://dx.doi.org/10.1056/NEJMoa1800410			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN5CX	29766750	Green Submitted, Bronze, Green Accepted			2023-01-03	WOS:000439063900005
J	Seo, KH; Lee, JY; Yoon, K; Do, JG; Park, HJ; Lee, SY; Park, YS; Lee, YT				Seo, Kyoung-Ho; Lee, Joon-Youn; Yoon, Kyungjae; Do, Jong Geol; Park, Hee-Jin; Lee, So-Yeon; Park, Young Sook; Lee, Yong-Taek			Long-term outcome of low-energy extracorporeal shockwave therapy on gluteal tendinopathy documented by magnetic resonance imaging	PLOS ONE			English	Article							TROCHANTERIC-PAIN-SYNDROME; MEDIUS TENDON TEARS; GREATER TROCHANTER; WAVE THERAPY; MRI; HIP; MANAGEMENT; PATHOLOGY	Background Previous outcome studies for extracorporeal Shockwave therapy (ESWT) have included clinically diagnosed greater trochanteric pain syndrome (GTPS). The purpose of this study is to investigate outcome of ESWT on GTPS with gluteal tendinopathy documented by magnetic resonance imaging (MRI). Methods Medical records of 38 consecutive patients were retrospectively reviewed, who underwent ESWT for GTPS with MRI-documented gluteal tendinopathy (> 6 months). ESWT was conducted (1/week) when the Roles-Maudsley score (RMS) showed "Poor" or "Fair" grade after conservative treatment until RMS had reached "Good" or "Excellent" grade (treatment success) or until 12 treatments had been applied. Numeric rating scale (NRS) and RMS were evaluated before, 1 week after (immediate follow-up) and mean 27 months after ESWT program (long-term follow-up). Success rate was calculated at each follow-up point. Results Initial NRS (5.9 +/- 1.6) significantly decreased at immediate (2.5 +/- 1.5, p < 0.01) and long-term follow-up (3.3 +/- 3.0, p < 0.01), respectively. Success rates were 83.3% (immediate) and 55.6% (long-term), respectively. There was no correlation among age, symptom duration and NRS. Conclusion Low-energy ESWT can be an effective treatment for pain relief in chronic GTPS with MRI-documented gluteal tendinopathy. However, its long-term effect appears to decrease with time.	[Seo, Kyoung-Ho] Hallym Univ, Dongtan Sacred Heart Hosp, Dept Phys Med & Rehabil, Coll Med, Hwaseong Si, Gyeonggi Do, South Korea; [Lee, Joon-Youn; Yoon, Kyungjae; Do, Jong Geol; Lee, Yong-Taek] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Phys & Rehabil Med, Sch Med, Seoul, South Korea; [Park, Hee-Jin; Lee, So-Yeon] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Radiol, Sch Med, Seoul, South Korea; [Park, Young Sook] Sungkyunkwan Univ, Samsung Changwon Hosp, Dept Phys & Rehabil Med, Sch Med, Changwon Si, Gyeongsangnam D, South Korea	Hallym University; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, YT (corresponding author), Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Phys & Rehabil Med, Sch Med, Seoul, South Korea.	yongtaek1.lee@gmail.com	Lee, Yong-Taek/ABB-3200-2020	Lee, Yong-Taek/0000-0001-6611-0999; Kyoung-Ho, Seo/0000-0002-9139-1638				Barratt PA, 2017, BRIT J SPORT MED, V51, P97, DOI 10.1136/bjsports-2015-095858; Bird PA, 2001, ARTHRITIS RHEUM, V44, P2138, DOI 10.1002/1529-0131(200109)44:9<2138::AID-ART367>3.0.CO;2-M; Blankenbaker DG, 2008, SKELETAL RADIOL, V37, P903, DOI 10.1007/s00256-008-0514-8; Chowdhury R, 2014, POSTGRAD MED J, V90, P576, DOI 10.1136/postgradmedj-2013-131828; Chung CB, 1999, AM J ROENTGENOL, V173, P351, DOI 10.2214/ajr.173.2.10430134; Cvitanic O, 2004, AM J ROENTGENOL, V182, P137, DOI 10.2214/ajr.182.1.1820137; Del Buono A, 2012, BRIT MED BULL, V102, P115, DOI 10.1093/bmb/ldr038; Farr D, 2007, ARTHROSCOPY, V23, DOI 10.1016/j.arthro.2006.10.021; Fearon AM, 2010, CLIN ORTHOP RELAT R, V468, P1838, DOI 10.1007/s11999-009-1174-2; Furia JP, 2009, AM J SPORT MED, V37, P1806, DOI 10.1177/0363546509333014; Grimaldi A, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-096175; Haliloglu N, 2010, EUR J RADIOL, V75, P64, DOI 10.1016/j.ejrad.2009.03.039; Klontzas ME, 2014, EUR J RADIOL, V83, P1850, DOI 10.1016/j.ejrad.2014.06.009; Kong A, 2007, EUR RADIOL, V17, P1772, DOI 10.1007/s00330-006-0485-x; Korakakis V, 2018, BRIT J SPORT MED, V52, P387, DOI 10.1136/bjsports-2016-097347; Lee JY, 2017, ANN REHABIL MED-ARM, V41, P42, DOI 10.5535/arm.2017.41.1.42; Mani-Babu S, 2015, AM J SPORT MED, V43, P752, DOI 10.1177/0363546514531911; Ozcakar L, 2004, CLIN RHEUMATOL, V23, P464, DOI 10.1007/s10067-004-0917-4; Peters J, 2004, SKELETAL RADIOL, V33, P712, DOI 10.1007/s00256-004-0849-8; Pfirrmann CWA, 2001, RADIOLOGY, V221, P469, DOI 10.1148/radiol.2211001634; Rompe JD, 2009, AM J SPORT MED, V37, P1981, DOI 10.1177/0363546509334374; Rompe JD, 1998, J BONE JOINT SURG BR, V80B, P546, DOI 10.1302/0301-620X.80B3.8434; Sayegh Fares, 2004, Acta Orthop Belg, V70, P423; Tortolani P Justin, 2002, Spine J, V2, P251, DOI 10.1016/S1529-9430(02)00198-5; Wilson SA, 2014, INT J RHEUM DIS, V17, P621, DOI 10.1111/1756-185X.12250	25	10	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2018	13	7							e0197460	10.1371/journal.pone.0197460	http://dx.doi.org/10.1371/journal.pone.0197460			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN2XR	30016333	Green Submitted, gold, Green Published			2023-01-03	WOS:000438866600002
J	Saeys, W; Herssens, N; Verwulgen, S; Truijen, S				Saeys, Wim; Herssens, Nolan; Verwulgen, Stijn; Truijen, Steven			Sensory information and the perception of verticality in post-stroke patients. Another point of view in sensory reweighting strategies	PLOS ONE			English	Article							INNERVATING OTOLITH ORGANS; PUSHER SYNDROME; SQUIRREL-MONKEY; STATIC TILTS; STROKE; ORIENTATION; BALANCE; VARIABILITY; HEMISPACE; DISORDERS	Introduction Perception of verticality is highly related to balance control in human. Head-on-body tilt <60 degrees results in the E-effect, meaning that a tilt of the perceived vertical is observed contralateral to the head tilt in the frontal plane. Furthermore, somatosensory loss also impacts the accuracy of verticality perception. However, when several input sources are absent or biased, less options for sensory weighting and balance control occur. Therefore, this study aims to identify the E-effect and assess the effect of somatosensory loss on the extent of the E-effect. Methods All patients with a first stroke admitted to a Belgian rehabilitation hospital were eligible for inclusion. Patients aged above 80 with other neurological and orthopaedic impairments as well as brainstem, cerebellar or multiple lesions were excluded. In addition, patients with visuospatial neglect and pusher behaviour were also excluded as this can affect verticality perception. The Rivermead Assessment of Somatosensory Performance (RASP), the Subjective Visual (SVV) and Subjective Postural (SPV) Vertical Test were administered. Results In total, 37 patients were included in the analysis of which 24 patients completed both SVV and SPV assessment. Results show that the E-effect occurred in our sample of stroke survivors for both SVV and SPV. In addition, the presence of somatosensory loss will increase the E-effect in both SVV as SPV assessment. A significant difference in verticality perception was noted for both SVV and SPV between the group with no (SVV: 5.13 degrees(6.92); SPV: 0.30 degrees (1.85)) and highly severe (SVV: 10.54 degrees (13.19); SPV: 5.96 degrees (9.27)) sensory loss. Conclusions The E-effect occurs in stroke subjects and increases when patients experience somatosensory loss. This suggests that the lack of available afferent information impede estimation of verticality. Therefore, stroke survivors have fewer alternative input sources as a result of impairments, leading to fewer options about sensory reweighting strategies and balance recovery after perturbations.	[Saeys, Wim; Herssens, Nolan; Truijen, Steven] Univ Antwerp, Dept Rehabil Sci & Physiotherapy, Antwerp, Belgium; [Saeys, Wim] Rehabil Hosp Revarte, Antwerp, Belgium; [Verwulgen, Stijn] Univ Antwerp, Dept Prod Dev, Antwerp, Belgium	University of Antwerp; University of Antwerp	Saeys, W (corresponding author), Univ Antwerp, Dept Rehabil Sci & Physiotherapy, Antwerp, Belgium.; Saeys, W (corresponding author), Rehabil Hosp Revarte, Antwerp, Belgium.	wim.saeys@uantwerpen.be	Herssens, Nolan/AAC-1197-2021; Herssens, Nolan/AAA-1903-2019	Herssens, Nolan/0000-0003-0074-5814				Anastasopoulos D, 1999, ANN NY ACAD SCI, V871, P379, DOI 10.1111/j.1749-6632.1999.tb09199.x; Angelaki DE, 2008, ANNU REV NEUROSCI, V31, P125, DOI 10.1146/annurev.neuro.31.060407.125555; Angelaki DE, 2009, NEURON, V64, P448, DOI 10.1016/j.neuron.2009.11.010; Barra J, 2010, BRAIN, V133, P3552, DOI 10.1093/brain/awq311; Bisdorff AR, 1996, BRAIN, V119, P1523, DOI 10.1093/brain/119.5.1523; Bonan IV, 2006, ARCH PHYS MED REHAB, V87, P642, DOI 10.1016/j.apmr.2006.01.019; Bonan IV, 2004, ARCH PHYS MED REHAB, V85, P274, DOI 10.1016/j.apmr.2003.06.016; Brandt T, 1999, EEG CL N SU, V50, P221; De Vrijer M, 2008, J NEUROPHYSIOL, V99, P915, DOI 10.1152/jn.00921.2007; De Vrijer M, 2009, J VISION, V9, DOI 10.1167/9.2.9; DICHGANS J, 1974, ACTA OTO-LARYNGOL, V78, P391, DOI 10.3109/00016487409126371; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; FERNANDEZ C, 1972, J NEUROPHYSIOL, V35, P978, DOI 10.1152/jn.1972.35.6.978; FERNANDEZ C, 1976, J NEUROPHYSIOL, V39, P970, DOI 10.1152/jn.1976.39.5.970; Green AM, 2007, PROG BRAIN RES, V165, P155, DOI 10.1016/S0079-6123(06)65010-3; Hoppenbrouwers M, 2004, NEUROREPORT, V15, P325, DOI 10.1097/00001756-200402090-00023; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; Jaggi-Schwarz K, 2003, ANN NY ACAD SCI, V1004, P516, DOI 10.1196/annals.1303.065; Johannsen L, 2006, J NEUROL, V253, P1367, DOI 10.1007/s00415-006-0216-x; Karnath HO, 2007, NEUROREHAB NEURAL RE, V21, P370, DOI 10.1177/1545968307300702; Karnath HO, 2007, J NEUROL, V254, P415, DOI 10.1007/s00415-006-0341-6; Knill DC, 2004, TRENDS NEUROSCI, V27, P712, DOI 10.1016/j.tins.2004.10.007; Lafosse C, 2007, NEUROPSYCHOL REHABIL, V17, P374, DOI 10.1080/09602010601058854; Lafosse C, 2005, J CLIN EXP NEUROPSYC, V27, P460, DOI 10.1080/13803390490520463; Lafosse C, 2004, NEUROREPORT, V15, P887, DOI 10.1097/00001756-200404090-00031; MacNeilage PR, 2007, EXP BRAIN RES, V179, P263, DOI 10.1007/s00221-006-0792-0; Mittelstaedt H, 1996, BIOL PSYCHOL, V42, P53, DOI 10.1016/0301-0511(95)05146-5; MITTELSTAEDT H, 1983, NATURWISSENSCHAFTEN, V70, P272, DOI 10.1007/BF00404833; MITTELSTAEDT H, 1992, ANN NY ACAD SCI, V656, P124, DOI 10.1111/j.1749-6632.1992.tb25204.x; Muller G., 1916, Z SINNESPHYSIOL, V49, P109; Pavlou M, 2003, J NEUROPHYSIOL, V90, P622, DOI 10.1152/jn.00960.2002; ROSENHALL U, 1972, ANN OTO RHINOL LARYN, V81, P339, DOI 10.1177/000348947208100305; Saeys W, 2012, DISABIL REHABIL, V34, P1965, DOI 10.3109/09638288.2012.671883; Saeys W, 2010, EUR J APPL PHYSIOL, V109, P297, DOI 10.1007/s00421-010-1355-4; Saj A, 2005, J NEUROL, V252, P885, DOI 10.1007/s00415-005-0716-0; Schuler JR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-83; Shumway-Cook A, 2016, MOTOR CONTROL TRANSL; Sullivan JE, 2008, TOP STROKE REHABIL, V15, P200, DOI 10.1310/tsr1503-200; Tarnutzer AA, 2009, J NEUROPHYSIOL, V102, P1657, DOI 10.1152/jn.00007.2008; Tarnutzer AA, 2009, EXP BRAIN RES, V195, P621, DOI 10.1007/s00221-009-1823-4; WADE NJ, 1970, Q J EXP PSYCHOL, V22, P420, DOI 10.1080/14640747008401915; Winward CE, 2002, CLIN REHABIL, V16, P523, DOI 10.1191/0269215502cr522oa; YARDLEY L, 1990, PERCEPT PSYCHOPHYS, V48, P131, DOI 10.3758/BF03207079	43	6	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2018	13	6							e0199098	10.1371/journal.pone.0199098	http://dx.doi.org/10.1371/journal.pone.0199098			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL0PZ	29958286	gold, Green Published, Green Submitted			2023-01-03	WOS:000436793500005
J	Navaro, M; Vezzosi, L; Santagati, G; Angelillo, IF				Navaro, Monica; Vezzosi, Luigi; Santagati, Gabriella; Angelillo, Italo Francesco		Collaborative Working Grp	Knowledge, attitudes, and practice regarding medication use in pregnant women in Southern Italy	PLOS ONE			English	Article							PRIMARY-CARE; DRUG-USE; PREVALENCE; HEALTH; CHILDBIRTH	The study assessed knowledge, attitudes, and medication use of a random sample of pregnant women attending outpatient Gynecology and Obstetrics clinics at randomly selected public General and Teaching hospitals in Naples, Italy. A total of 503 women participated. Those more likely to know that a pregnant woman with chronic condition must discuss whether or not to take a medication with the physician were Italian, aged 31-40 years, employed, with no history of abortion, having had a medical problem within the previous year, with a better self-perceived health status, who knew how to use medications during pregnancy, and who needed information on medications. The knowledge of the potential risk of using non-prescribed medications during pregnancy was significantly higher in employed women, who received information from physicians, who knew how to use medications during pregnancy, and who knew the possible damages related to medications use. More than half had used at least one medication. Those aged 26-35 years, Italian, nongraduated, in the third trimester, having had a medical problem within the previous year, with a risky pregnancy, and with a knowledge that women with chronic condition must discuss whether or not to take a medication with the physician were more likely to use medication. Less than half had used medication without a physician's advice. Those who were more likely to self-medicate were older, Italian, multiparous, with no history of abortion, who knew that women with chronic condition must discuss whether or not to take a medication with the physician, who did not know the potential risk of using non-prescribed medication during pregnancy, who had used prescribed medication during pregnancy, and who needed information about medications. Educational programs for women about medication use are important to increase their knowledge of the potential risks to the pregnant women and the unborn child in order to reduce self-medication.	[Navaro, Monica; Vezzosi, Luigi; Santagati, Gabriella; Angelillo, Italo Francesco; Collaborative Working Grp] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy	Universita della Campania Vanvitelli	Angelillo, IF (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.	italof.angelillo@unicampania.it	Vezzosi, Luigi/HHZ-4047-2022; Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602; Vezzosi, Luigi/0000-0001-6461-2231				Axelsdottir TO, 2014, SCAND J PRIM HEALTH, V32, P139, DOI 10.3109/02813432.2014.965884; Berard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093870; Bercaw J, 2010, BIRTH-ISS PERINAT C, V37, P3, DOI [10.1111/j.1523-536X.2009.00372.x, DOI 10.1111/J.1523-536X.2009.00372.X]; Bjorn AMB, 2015, BASIC CLIN PHARMACOL, V116, P308, DOI 10.1111/bcpt.12367; Cleary BJ, 2010, PHARMACOEPIDEM DR S, V19, P408, DOI 10.1002/pds.1906; Coomarasamy A, 2015, NEW ENGL J MED, V373, P2141, DOI 10.1056/NEJMoa1504927; de Jonge L, 2015, DRUG SAFETY, V38, P737, DOI 10.1007/s40264-015-0302-z; Devkota R, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1316-6; Dillon P, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0489-0; Donati S, 2000, EUR J CLIN PHARMACOL, V56, P323, DOI 10.1007/s002280000149; Gagne JJ, 2008, EUR J CLIN PHARMACOL, V64, P1125, DOI 10.1007/s00228-008-0546-y; Garofalo L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/580650; Hameen-Anttila K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002594; Hameen-Anttila K, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2939; Heitmann K, 2015, BMC PREGNANCY CHILDB, V15, P321, DOI [10.1186/s12884-015-0746-2, DOI 10.1111/J.1479-828X.2011.01312.2]; Irvine L, 2010, DRUG SAFETY, V33, P593, DOI 10.2165/11532330-000000000-00000; Lupattelli A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004365; Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Nordeng H, 2012, ARCH WOMEN MENT HLTH, V15, P203, DOI 10.1007/s00737-012-0278-y; Palmsten K, 2015, OBSTET GYNECOL, V126, P465, DOI 10.1097/AOG.0000000000000982; Sawicki E, 2011, AUST NZ J OBSTET GYN, V51, P333, DOI 10.1111/j.1479-828X.2011.01312.x; Smedberg J, 2016, EUR J CLIN PHARMACOL, V72, P849, DOI 10.1007/s00228-016-2042-0; Stata Corporation, 2007, STAT REF MAN REL 10; Twigg MJ, 2016, INT J CLIN PHARM-NET, V38, P968, DOI 10.1007/s11096-016-0322-5; Verstappen GMPJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-185; Ystrom E, 2012, EUR J CLIN PHARMACOL, V68, P845, DOI 10.1007/s00228-011-1197-y; Yusuff KB, 2011, INT J CLIN PHARM, V33, P868, DOI 10.1007/s11096-011-9556-4; Zaki NM, 2014, SAUDI PHARM J, V22, P419, DOI 10.1016/j.jsps.2013.09.001	29	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2018	13	6							e0198618	10.1371/journal.pone.0198618	http://dx.doi.org/10.1371/journal.pone.0198618			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ7CA	29920515	Green Submitted, Green Published, gold			2023-01-03	WOS:000435541300007
J	Gandhi, L; Rodriguez-Abreu, D; Gadgeel, S; Esteban, E; Felip, E; De Angelis, F; Domine, M; Clingan, P; Hochmair, MJ; Powell, SF; Cheng, SYS; Bischoff, HG; Peled, N; Grossi, F; Jennens, RR; Reck, M; Hui, R; Garon, EB; Boyer, M; Rubio-Viqueira, B; Novello, S; Kurata, T; Gray, JE; Vida, J; Wei, Z; Yang, J; Raftopoulos, H; Pietanza, MC; Garassino, MC				Gandhi, L.; Rodriguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M. J.; Powell, S. F.; Cheng, S. Y. -S.; Bischoff, H. G.; Peled, N.; Grossi, F.; Jennens, R. R.; Reck, M.; Hui, R.; Garon, E. B.; Boyer, M.; Rubio-Viqueira, B.; Novello, S.; Kurata, T.; Gray, J. E.; Vida, J.; Wei, Z.; Yang, J.; Raftopoulos, H.; Pietanza, M. C.; Garassino, M. C.		KEYNOTE-189 Investigators	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PEMETREXED PLUS; OPEN-LABEL; INDUCTION TREATMENT; PHASE-III; DOCETAXEL; CISPLATIN; NIVOLUMAB; 1ST-LINE; THERAPY	BACKGROUND First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial. METHODS In this double-blind, phase 3 trial, we randomly assigned (in a 2: 1 ratio) 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy. Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo-combination group who had verified disease progression. The primary end points were overall survival and progression-free survival, as assessed by blinded, independent central radiologic review. RESULTS After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% (95% confidence interval [CI], 64.1 to 73.8) in the pembrolizumab-combination group versus 49.4% (95% CI, 42.1 to 56.2) in the placebocombination group (hazard ratio for death, 0.49; 95% CI, 0.38 to 0.64; P< 0.001). Improvement in overall survival was seen across all PD-L1 categories that were evaluated. Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P< 0.001). Adverse events of grade 3 or higher occurred in 67.2% of the patients in the pembrolizumab-combination group and in 65.8% of those in the placebo-combination group. CONCLUSIONS In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.	[Gandhi, L.] NYU, Perlmutter Canc Ctr, New York, NY USA; [Rodriguez-Abreu, D.] Univ Las Palmas Gran Canaria, Univ Insular Maternoinfantil Gran Canaria, Complejo Hosp, Las Palmas Gran Canaria, Spain; [Esteban, E.] Hosp Univ Cent Asturias, Oviedo, Spain; [Felip, E.] Vall dHebron Univ, Vall dHebron Inst Oncol, Barcelona, Spain; [Domine, M.] Fdn Jimenez Diaz, Madrid, Spain; [Rubio-Viqueira, B.] Hosp Univ Quiron Madrid, Madrid, Spain; [Gadgeel, S.] Karmanos Canc Inst, Detroit, MI USA; [De Angelis, F.] Monteregie Ctr, Integrated Hlth & Social Serv Ctr, Greenfield Pk, PQ, Canada; [Cheng, S. Y. -S.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Clingan, P.] Southern Med Day Care Ctr, Wollongong, NSW, Australia; [Jennens, R. R.] Epworth Healthcare, Richmond, Vic, Australia; [Hui, R.] Westmead Hosp, Sydney, NSW, Australia; [Hui, R.] Univ Sydney, Sydney, NSW, Australia; [Boyer, M.] Chris OBrien Lifehouse, Camperdown, NSW, Australia; [Hochmair, M. J.] Otto Wagner Hosp, Vienna, Austria; [Powell, S. F.] Sanford Hlth, Sioux Falls, SD USA; [Bischoff, H. G.] Thoraxklin, Heidelberg, Germany; [Reck, M.] German Ctr Lung Res, Airway Res Ctr North, Lungen Clin, Grosshansdorf, Germany; [Peled, N.] Tel Aviv Univ, Davidoff Canc Ctr, Petah Tiqwa, Israel; [Grossi, F.] Osped Policlin San Martino, Genoa, Italy; [Novello, S.] Univ San Luigi, Univ Turin, Azienda Osped, Orbassano, Italy; [Garassino, M. C.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Garon, E. B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Kurata, T.] Kansai Med Univ Hosp, Osaka, Japan; [Gray, J. E.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Vida, J.; Wei, Z.; Yang, J.; Raftopoulos, H.; Pietanza, M. C.] Merck, Kenilworth, NJ USA	New York University; Universidad de Las Palmas de Gran Canaria; Central University Hospital Asturias; Vall d'Hebron Institut d'Oncologia (VHIO); Barbara Ann Karmanos Cancer Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Sydney; University of Sydney; University of Sydney; Sanford Health; Ruprecht Karls University Heidelberg; Tel Aviv University; University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kansai Medical University; H Lee Moffitt Cancer Center & Research Institute; Merck & Company	Gandhi, L (corresponding author), New York Univ Langone Hlth, Laura & Isaac Perlmutter Canc Ctr, 160 E 34th St, New York, NY 10016 USA.	leena.gandhi@nyumc.org	Esteban, Emilio/AAB-2188-2019; novello, silvia/K-6335-2016; Miquel, Josep Maria/AAG-3508-2019; Powell, Steven/ABD-1472-2021; Grossi, Francesco/AAL-5024-2021; Reck, Martin/ABF-5721-2020; Hui, Rina/L-6114-2019; Blackhall, Fiona/N-2186-2015	Esteban, Emilio/0000-0002-2980-5254; Grossi, Francesco/0000-0001-8412-3136; Reck, Martin/0000-0002-5348-4462; Peled, Nir/0000-0003-3714-4377; Zer, Alona/0000-0001-6597-5261; Myllarniemi, L Marjukka/0000-0001-9343-0867; Blackhall, Fiona/0000-0001-8716-3395; Bray, Victoria/0000-0002-6357-3899; Castonguay, Vincent/0000-0001-8053-4026; Gandhi, Leena/0000-0002-2398-9179; Rodriguez-Abreu, Delvys/0000-0003-0506-1366; Rybkin, Igor/0000-0002-8434-1093; Kollmeier, Jens/0000-0002-8048-3895; FELIP, ENRIQUETA/0000-0002-7620-0098; Bambury, Richard/0000-0002-2189-6972	Merck; Genentech/Roche; Pfizer; Ignyta; Syndax; AbbVie; AstraZeneca; Bristol-Myers Squibb; Merck Sharp Dohme; Roche/Genentech; Boehringer Ingelheim; Ariad/Takeda; Eli Lilly; Roche; Novartis; Regeneron; Incyte; Vyriad; Genentech; Foundation Medicine; Guardant360; NovellusDx; Takeda; Pierre Fabre; Amgen; Hoffmann-La Roche; Celgene; Mirati; Dynavax; Peregrine Pharmaceuticals; Array	Merck(Merck & Company); Genentech/Roche(Roche HoldingGenentech); Pfizer(Pfizer); Ignyta; Syndax; AbbVie(AbbVie); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Merck Sharp Dohme(Merck & Company); Roche/Genentech(Roche HoldingGenentech); Boehringer Ingelheim(Boehringer Ingelheim); Ariad/Takeda; Eli Lilly(Eli Lilly); Roche(Roche Holding); Novartis(Novartis); Regeneron(Regeneron); Incyte; Vyriad; Genentech(Roche HoldingGenentech); Foundation Medicine; Guardant360; NovellusDx; Takeda(Takeda Pharmaceutical Company Ltd); Pierre Fabre; Amgen(Amgen); Hoffmann-La Roche(Hoffmann-La Roche); Celgene(Bristol-Myers SquibbCelgene Corporation); Mirati; Dynavax; Peregrine Pharmaceuticals; Array	Supported by Merck.; Dr. Gandhi reports receiving grant support and advisory board fees from Merck, advisory board fees from Genentech/Roche, Pfizer, Ignyta, Syndax, AbbVie, and AstraZeneca, and grant support from Bristol-Myers Squibb; Dr. Rodriguez-Abreu, receiving lecture fees, advisory board fees, and travel support from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche/Genentech, and Boehringer Ingelheim; Dr. Gadgeel, receiving advisory fees from AbbVie, AstraZeneca, Genentech/Roche, and Ariad/Takeda; Dr. Felip, receiving consulting fees from Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, Merck Sharp & Dohme, and AbbVie and lecture fees from AstraZeneca, Bristol-Myers Squibb, and Novartis; Dr. Clingan, receiving funding for study patient visits from Merck Sharp & Dohme, AbbVie, Regeneron, and Bristol- Myers Squibb; Dr. Powell, receiving grant support, paid to his institution, from Merck Sharp & Dohme, Bristol-Myers Squibb, Incyte, Pfizer, Vyriad, and Genentech; Dr. Peled, receiving grant support, advisory fees, and honoraria from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and Roche and advisory fees and honoraria from Boehringer Ingelheim, Eli Lilly, Foundation Medicine, Guardant360, Novartis, NovellusDx, Pfizer, and Takeda; Dr. Grossi, receiving lecture fees and advisory board fees from Merck, Pierre Fabre, Pfizer, Novartis, and Boehringer Ingelheim, grant support, lecture fees, and advisory board fees from Bristol-Myers Squibb, and lecture fees from AstraZeneca, Amgen, and Roche; Dr. Reck, receiving lecture fees and consulting fees from Hoffmann-La Roche, Eli Lilly, AstraZeneca, Celgene, Bristol-Myers Squibb, Merck, Boehringer Ingelheim, Pfizer, Novartis, and Merck Sharp & Dohme; Dr. Hui, receiving advisory board fees and lecture fees from Merck Sharp & Dohme, AstraZeneca, and Novartis, advisory board fees from Roche, and lecture fees from Bristol-Myers Squibb and Boehringer Ingelheim; Dr. Garon, receiving grant support, paid to his institution, from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, Boehringer Ingelheim, Pfizer, Novartis, Mirati, Dynavax, and Merck; Dr. Boyer, receiving grant support and travel support from AstraZeneca, Bristol-Myers Squibb, and Pfizer and grant support from Genentech/Roche, Amgen, Novartis, and Peregrine Pharmaceuticals; Dr. Rubio-Viqueira, receiving advisory board fees and lecture fees from Eli Lilly and lecture fees from Roche and Pfizer; Dr. Novello, receiving lecture fees from Boehringer Ingelheim, AstraZeneca, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, and Eli Lilly; Dr. Kurata, receiving honoraria from Merck Sharp & Dohme, Eli Lilly, Chugai, Ono, Bristol-Myers Squibb, AstraZeneca, and Boehringer Ingelheim; Dr. Gray, receiving grant support from Merck, Bristol-Myers Squibb, and Array, grant support and honoraria from AstraZeneca, Genentech, and Boehringer Ingelheim, and honoraria from Celgene and Eli Lilly; Drs. Vida, Wei, Yang, and Pietanza, being employed by Merck; Dr. Rafto-poulos, being employed by Bayer and being employed by Merck during the conduct of the study; and Dr. Garassino, receiving consulting fees and lecture fees from AstraZeneca, Roche, and Boehringer Ingelheim. No other potential conflict of interest relevant to this article was reported.	Ahn MJ, 2015, ANN ONCOL, V26, P140; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brahmer JR, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9000; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Cutica I, 2014, EUR J INTERN MED, V25, P685, DOI 10.1016/j.ejim.2014.07.002; Davies J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175679; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/eoph.4.6.889.22200; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Lazzari C, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00004; Lesterhuis WJ, 2011, J CLIN INVEST, V121, P3100, DOI 10.1172/JCI43656; Li GZ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328339; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Paz-Ares L, 2012, LANCET ONCOL, V13, P247, DOI 10.1016/S1470-2045(12)70063-3; Paz-Ares LG, 2013, J CLIN ONCOL, V31, P2895, DOI 10.1200/JCO.2012.47.1102; Perol M, 2017, J CLIN ONCOL S, V35; Peters S, 2017, J CLIN ONCOL, V35, P2781, DOI 10.1200/JCO.2016.71.9476; Reck M, 2017, ANN ONCOL, V28, P31; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Roselli M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27025; Scagliotti GV, 2014, LUNG CANCER, V85, P408, DOI 10.1016/j.lungcan.2014.07.005; Tomasini P, 2016, THER ADV MED ONCOL, V8, P198, DOI 10.1177/1758834016644155; Zattera Tito, 2017, J Nephropathol, V6, P43, DOI 10.15171/jnp.2017.07; Zinner RG, 2015, J THORAC ONCOL, V10, P134, DOI 10.1097/JTO.0000000000000366	31	3258	3362	31	402	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2018	378	22					2078	2092		10.1056/NEJMoa1801005	http://dx.doi.org/10.1056/NEJMoa1801005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH5AL	29658856	Green Published, Bronze			2023-01-03	WOS:000433428000006
J	Gaffney, A; Lexchin, J				Gaffney, Adam; Lexchin, Joel		US Canadian Pharmaceutical Policy	Healing an ailing pharmaceutical system: prescription for reform for United States and Canada	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONFLICTS-OF-INTEREST; CLINICAL-TRIALS; DRUG APPROVALS; CANCER DRUGS; HIGH-COST; HEALTH; SAFETY; INNOVATION; OUTCOMES; PRICES		[Gaffney, Adam] Cambridge Hosp, Harvard Med Sch, Dept Med, Cambridge, MA 02139 USA; [Lexchin, Joel] York Univ, Sch Hlth Policy & Management, Toronto, ON, Canada	Harvard University; Cambridge Health Alliance; Cambridge Hospital; York University - Canada	Gaffney, A (corresponding author), Cambridge Hosp, Harvard Med Sch, Dept Med, Cambridge, MA 02139 USA.	agaffney@challiance.org		Gaffney, Adam/0000-0001-7326-0661; Gagnon, Marc-Andre/0000-0001-6113-4772				Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; Angus Reid Institute, 2017, PRESCR DRUG ACC AFF; [Anonymous], 2012, NY TIMES; [Anonymous], 2017, FORTUNE; [Anonymous], 2016, PHARM J; Attaran A, 2014, LANCET, V384, P477, DOI 10.1016/S0140-6736(13)60845-4; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Avorn J, 2017, JAMA-J AM MED ASSOC, V317, P361, DOI 10.1001/jama.2016.16036; Avorn J, 2015, NEW ENGL J MED, V372, P2473, DOI 10.1056/NEJMp1506964; BAKER D, 2002, PROMOTING GOOD IDEAS; Baker D, 2008, INT J HEALTH SERV, V38, P731, DOI 10.2190/HS.38.4.i; Bhutta Z, 2010, LANCET, V376, P1375; Bikdeli B, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005285; Carpenter D, 2008, NEW ENGL J MED, V358, P1354, DOI 10.1056/NEJMsa0706341; Carroll J, 2001, WALL STREET J; Choudhry NK, 2014, HEALTH AFFAIR, V33, P863, DOI 10.1377/hlthaff.2013.0654; Cochrane AL., 1972, EFFECTIVENESS EFFICI; Collins Sara R, 2015, Issue Brief (Commonw Fund), V2, P1; Committee on Economic Social and Cultural Rights, 2000, GEN COMM NO 14; Congressional Budget Office, 2005, PRIC BRAND NAM DRUGS; Congressional Budget Office, 2017, FED SUBS HLTH INS CO; Conti RM, 2016, NEW ENGL J MED, V374, P703, DOI 10.1056/NEJMp1515068; Correa C, 2001, TRENDS DRUG PATENTIN; Cosgrove L, 2013, J EVAL CLIN PRACT, V19, P674, DOI 10.1111/jep.12016; DAVIS C, 2017, BMJ-BRIT MED J, V359, DOI DOI 10.1136/BMJ.J4530; Downing NS, 2017, JAMA-J AM MED ASSOC, V317, P1854, DOI 10.1001/jama.2017.5150; Downing NS, 2012, ARCH INTERN MED, V172, P724, DOI 10.1001/archinternmed.2012.187; Evans David, 2009, BLOOMBERG MARKETS, P72; Experts in Chronic Myeloid Leukemia, 2013, Blood, V121, P4439, DOI 10.1182/blood-2013-03-490003; Fain K, 2013, JAMA-J AM MED ASSOC, V310, P202, DOI 10.1001/jama.2013.7900; Finkelstein SN, 2008, REASONABLE RX; Foss K, 2001, GLOVE AND MAIL  1019; Frank C, 2014, HEALTH AFFAIR, V33, P1453, DOI 10.1377/hlthaff.2014.0122; Friedberg MW, 2017, JAMA INTERN MED, V177, P1058, DOI 10.1001/jamainternmed.2017.2142; Gagnon M-A, 2015, MIRROR ON THE WALL; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Greene JA, 2010, AM J PUBLIC HEALTH, V100, P793, DOI 10.2105/AJPH.2009.181255; Hager M, 2007, C CONCLUSIONS RECOMM; Herder M, 2014, CAN MED ASSOC J, V186, pE287, DOI 10.1503/cmaj.131850; Himmelstein DU, 2014, INT J HEALTH SERV, V44, P7, DOI 10.2190/HS.44.1.b; Himmelstein DU, 2009, AM J MED, V122, P741, DOI 10.1016/j.amjmed.2009.04.012; Hwang TJ, 2016, JAMA INTERN MED, V176, P1826, DOI 10.1001/jamainternmed.2016.6008; Institute of Medicine, 2011, CLIN PRACTICE GUIDEL; Jayadev A, 2009, HEALTH AFFAIR, V28, pW165, DOI 10.1377/hlthaff.28.1.w165; Kanavos P, 2013, HEALTH AFFAIR, V32, P753, DOI 10.1377/hlthaff.2012.0920; Kapczynski A, 2016, HEALTH AFFAIR, V35, P791, DOI 10.1377/hlthaff.2015.1120; Kesselheim AS, 2017, JAMA-J AM MED ASSOC, V317, P581, DOI 10.1001/jama.2016.20640; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Kesselheim AS, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4633; Kesselheim AS, 2015, AM J PUBLIC HEALTH, V105, pE17, DOI 10.2105/AJPH.2014.302240; Kiester M., 2011, DDMAC SUBMISSIONS; Kim C, 2015, JAMA INTERN MED, V175, P1992, DOI 10.1001/jamainternmed.2015.5868; Kirzinger A, 2017, KAISER HLTH TRACKING; Korenstein D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023336; Kornfield R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055504; Kumar H, 2016, JAMA ONCOL, V2, P1238, DOI 10.1001/jamaoncol.2016.0931; Langret R, 2015, BLOOMBERG; Lanthier M, 2013, HEALTH AFFAIR, V32, P1433, DOI 10.1377/hlthaff.2012.0541; Law MR, 2014, HEALTH POLICY, V116, P154, DOI 10.1016/j.healthpol.2014.03.003; Lexchin Joel, 2016, Healthc Policy, V12, P65; Lexchin J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006816; Lexchin J, 2015, BRIT J CLIN PHARMACO, V79, P847, DOI 10.1111/bcp.12552; Lexchin Joel, 2014, Int J Risk Saf Med, V26, P213, DOI 10.3233/JRS-140635; Lexchin J, 2012, ARCH INTERN MED, V172, P1680, DOI 10.1001/archinternmed.2012.4444; Lexchin J, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-24; Lexchin J, 2012, SCI ENG ETHICS, V18, P247, DOI 10.1007/s11948-011-9265-3; Light DW, 2013, J LAW MED ETHICS, V41, P590, DOI 10.1111/jlme.12068; Lohr KN, 1986, MED CARE S, V24; Love J., 2015, KNOWLEDGE ECOLOGY IN; Love J, 2015, PLOS ONE BLOG   1019; Mailankody S, 2015, JAMA ONCOL, V1, P539, DOI 10.1001/jamaoncol.2015.0373; Making Medicines Affordable, 2017, MAKING MED AFFORDABL; Markel H, 2013, NEW ENGL J MED, V369, P794, DOI 10.1056/NEJMp1306553; McKinnell H, 2005, CALL ACTION TAKING B; Mintzes B, 2015, BRIT MED BULL, V116, P43, DOI 10.1093/bmb/ldv042; Moise P, 2007, OECD HLTH WORKING PA; Moore T, 2015, DRUG SAFETY, V38, P601, DOI 10.1007/s40264-015-0305-9; Moore TJ, 2014, JAMA INTERN MED, V174, P90, DOI 10.1001/jamainternmed.2013.11813; Morgan SG, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014287; Morgan Steven G, 2016, Healthc Policy, V12, P18; Morgan SG, 2015, CAN MED ASSOC J, V187, P491, DOI 10.1503/cmaj.141564; Mostaghim SR, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3837; Mundy A, 2016, WASH MON; O'Sullivan BP, 2013, JAMA-J AM MED ASSOC, V310, P1343, DOI 10.1001/jama.2013.278129; OECD, HLTH GLANC 2015, DOI [10.1787/health_glance-2015-en, DOI 10.1787/HEALTH_GLANCE-2015-EN]; Olson MK, 2008, J HEALTH ECON, V27, P175, DOI 10.1016/j.jhealeco.2007.10.007; Othman N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006350; Outterson K, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002043; Parker-Pope T, 2016, NY TIMES; Patented Medicine Prices Review Board, 2017, ANN REP 2016 PMPRB; Pham-Kanter G, 2014, MILBANK Q, V92, P446, DOI 10.1111/1468-0009.12073; Pollack A, 2015, NY TIMES, pB2; RAVEN R J, 1988, American Museum Novitates, P1; Reichman JH, 2009, J LAW MED ETHICS, V37, P247, DOI 10.1111/j.1748-720X.2009.00369.x; Roughead EE, 2007, VALUE HEALTH, V10, P514, DOI 10.1111/j.1524-4733.2007.00206.x; Rupp T, 2017, JAMA INTERN MED, V177, P276, DOI 10.1001/jamainternmed.2016.7761; Sarpatwari A, 2016, JAMA-J AM MED ASSOC, V316, P2431, DOI 10.1001/jama.2016.17299; Shuchman M, 2007, NEW ENGL J MED, V356, P2236, DOI 10.1056/NEJMp078080; Sinnott SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064914; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352; Svensson S, 2013, JAMA INTERN MED, V173, P611, DOI 10.1001/jamainternmed.2013.3037; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Treasure CL, 2016, JAMA INTERN MED, V176, P729, DOI 10.1001/jamainternmed.2016.1867; Turner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779; Vokinger KN, 2017, JAMA INTERN MED, V177, P1665, DOI 10.1001/jamainternmed.2017.4650; Ward DJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006235; Wilson D., 2010, NY TIMES	109	15	15	5	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2018	361								k1039	10.1136/bmj.k1039	http://dx.doi.org/10.1136/bmj.k1039			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG6IZ	29773533				2023-01-03	WOS:000432801100001
J	Mauka, WI; Mtuy, TB; Mahande, MJ; Msuya, SE; Mboya, IB; Juma, A; Philemon, RN				Mauka, Wilhellmuss, I; Mtuy, Tara B.; Mahande, Michael J.; Msuya, Sia E.; Mboya, Innocent B.; Juma, Abdul; Philemon, Rune N.			Risk factors for inappropriate blood requisition among hospitals in Tanzania	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; SUB-SAHARAN AFRICA; TRANSFUSION SERVICES; CELL TRANSFUSION; CHILDREN; APPROPRIATENESS; MORTALITY; ANEMIA; SURGERY; NIGERIA	Background Blood is a critical aspect of treatment in life saving situations, increasing demand. Blood requisition practices greatly effect sufficient supply in blood banks. This study aimed to determine the risk factors for inappropriate blood requisition in Tanzania. Methods This was a cross sectional study using secondary data of 14,460 patients' blood requests from 42 transfusion hospitals. Primary data were obtained by using cluster-sampling design. Data were analysed using a two-level mixed-effects Poisson regression to determine fixedeffects of individual-level factors and hospital level factors associated with inappropriate blood requests. P-value < 0.05 (2-tails) was considered statistically significant. Results Inappropriate requisition was 28.8%. Factors significantly associated with inappropriate requisition were; reporting pulse rate and capillary refill decrease the risk (RR 0.74; 95% CI 0.64, 0.84) and (RR 0.73; 95% CI 0.63, 0.85) respectively and the following increased the risk; having surgery during hospital stay (RR 1.22; 95% C11.06,1.4); being in general surgical ward (RR 3.3; 95% CI 2.7, 4.2), paediatric ward (RR 1.8; 95% C11.2, 2.7), obstetric ward (RR2.5; 95% CI 2.0, 3.1), gynaecological ward (RR2.1; 95% C11.5, 2.9), orthopaedics ward (RR 3.8; 95% CI 2.2, 6.7). Age of the patient, pallor and confirmation of pre-transfusion haemoglobin level were also significantly associated with inappropriate requisition. Majority of appropriate requisitions within the wards were marked in internal medicine (91.7%) and gynaecological wards (77.8%). Conclusions The proportion of inappropriate blood requests was high. Blood requisition was determined by clinical and laboratory findings and the ward patients were admitted to. Adherence to transfusion guidelines is recommended to assure the best use of limited blood supply.	[Mauka, Wilhellmuss, I; Mtuy, Tara B.; Mahande, Michael J.; Msuya, Sia E.; Mboya, Innocent B.; Philemon, Rune N.] Kilimanjaro Christian Med Univ Coll, Inst Publ Hlth, Dept Epidemiol & Biostat, Moshi, Tanzania; [Juma, Abdul] Natl Blood Transfus Serv, Dar Es Salaam, Tanzania; [Mauka, Wilhellmuss, I] Northern Zone Blood Transfus Serv, Moshi, Tanzania; [Philemon, Rune N.] Kilimanjaro Christian Med Ctr, Dept Paediat, Moshi, Tanzania; [Mtuy, Tara B.] London Sch Hyg & Trop Med, Dept Clin Res, London, England	Kilimanjaro Christian Medical Centre; University of London; London School of Hygiene & Tropical Medicine	Mauka, WI (corresponding author), Kilimanjaro Christian Med Univ Coll, Inst Publ Hlth, Dept Epidemiol & Biostat, Moshi, Tanzania.; Mauka, WI (corresponding author), Northern Zone Blood Transfus Serv, Moshi, Tanzania.	wilhemauka@yahoo.com	Mahande, Michael Johnson J/I-6359-2015; Mboya, Innocent/AAE-6488-2020	Mahande, Michael Johnson J/0000-0002-7750-7657; Mboya, Innocent/0000-0001-9861-5879				Akoko LO, 2015, TANZAN J HLTH RES, V17, P1; Allain JP, 2011, BRIT J HAEMATOL, V154, P763, DOI 10.1111/j.1365-2141.2011.08708.x; Arewa OP, 2009, NIGER J CLIN PRACT, V12, P429; Ayantunde AA, 2008, BMC SURG, V8, P1, DOI [10.1001/jama.2010.1446, DOI 10.1001/JAMA.2010.1446]; Barr PJ, 2011, TRANSFUSION, V51, P1684, DOI 10.1111/j.1537-2995.2011.03130.x; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Bates I, 2008, BJOG-INT J OBSTET GY, V115, P1331, DOI 10.1111/j.1471-0528.2008.01866.x; Bugge HF, 2013, VOX SANG, V104, P37, DOI 10.1111/j.1423-0410.2012.01628.x; Butler EK, 2015, TRANSFUSION, V55, P1058, DOI 10.1111/trf.13010; Chalya PL, 2016, TANZAN J HLTH RES, V18, P1, DOI DOI 10.4314/THRB.V18I4; Chen DW, 2012, INT J GERONTOL, V6, P16, DOI 10.1016/j.ijge.2011.09.022; Desalu I, 2008, TRANSFUSION MED, V18, P211, DOI 10.1111/j.1365-3148.2008.00858.x; Diaz-Quijano FA, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-14; Drammeh B, 2017, TRANSFUS MED REV; Du Pont-Thibodeau G, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-16; Ebose EM, 2009, AFR J BIOTECHNOL, V8, P5922; Friedman MT, 2006, ARCH PATHOL LAB MED, V130, P474; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Katsaliaki K, 2008, HEALTH POLICY, V86, P276, DOI 10.1016/j.healthpol.2007.11.004; Kerkhoff AD, 2015, OPEN FORUM INFECT DI, V2, P10; Kiguli S, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0246-7; Korenromp EL, 2004, TROP MED INT HEALTH, V9, P1050, DOI 10.1111/j.1365-3156.2004.01317.x; Lackritz EM, 1997, AIDS, V11, P1487, DOI 10.1097/00002030-199712000-00013; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; Lingegowda Jyothi B, 2016, J Lab Physicians, V8, P41, DOI 10.4103/0974-2727.176232; Makroo R N, 2007, Asian J Transfus Sci, V1, P59, DOI 10.4103/0973-6247.33847; Mauka WI, 2015, J BLOOD TRANSFUS, V2015, P6; MOHCDGCE, 2015, CLIN GUID APPR US BL; MOHSW, 2005, TANZ NAT BLOOD TRANS, P1; Mpoya A, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1112-4; Mueller Y, 2012, TROP MED INT HEALTH, V17, P1457, DOI 10.1111/j.1365-3156.2012.03095.x; Mwambungu A, 2015, INT J HLTH SCI, V3, P278; Natukunda B, 2010, TRANSFUSION MED, V20, P134, DOI 10.1111/j.1365-3148.2010.00992.x; Niraj G, 2003, BRIT J ANAESTH, V91, P586, DOI 10.1093/bja/aeg207; Osei EN, 2013, TRANSFUSION MED, V23, P160, DOI 10.1111/tme.12028; Paramjit K, 2013, NATL J INTEGR RES ME, V4, P123; Pitman JP, 2015, TRANSFUS MED REV, V29, P45, DOI 10.1016/j.tmrv.2014.11.003; Pule PI, 2014, BLOOD TRANSFUS, V2014, P7; Roberts DJ, 2016, HEMATOL ONCOL CLIN N, V30, P477, DOI 10.1016/j.hoc.2015.11.011; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Shander A, 2011, TRANSFUS MED REV, V25, P232, DOI 10.1016/j.tmrv.2011.02.001; Smithson P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141112; Thompson ML, 1998, OCCUP ENVIRON MED, V55, P272, DOI 10.1136/oem.55.4.272; Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643; WHO, 2002, CLIN US BLOOD; WHO, 2002, CLIN US BLOOD, P349; Wilson K, 2002, TRANSFUSION, V42, P1224, DOI 10.1046/j.1537-2995.2002.00185.x; World Health Organization, 2001, CLIN US BLOOD MED OB; Yong Mellissa, 2011, Clin Epidemiol, V3, P91, DOI 10.2147/CLEP.S17146; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220	50	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2018	13	5							e0196453	10.1371/journal.pone.0196453	http://dx.doi.org/10.1371/journal.pone.0196453			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG0DP	29771998	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000432348900012
J	Aung, K				Aung, Koko			Guideline: TMP-SMX is recommended after uncomplicated skin abscess incision and drainage	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESISTANT STAPHYLOCOCCUS-AUREUS; ANTIBIOTICS		[Aung, Koko] Paul L Foster Sch Med, El Paso, TX 79905 USA		Aung, K (corresponding author), Paul L Foster Sch Med, El Paso, TX 79905 USA.		Aung, KoKo/I-1236-2019	Aung, KoKo/0000-0002-3152-0610				David MZ, 2010, CLIN MICROBIOL REV, V23, P616, DOI 10.1128/CMR.00081-09; Esposito S, 2017, J CHEMOTHERAPY, V29, P197, DOI 10.1080/1120009X.2017.1311398; Fahimi J, 2015, CAN J EMERG MED, V17, P420, DOI 10.1017/cem.2014.52; Li SP, 2014, INDIAN J PATHOL MICR, V57, P418, DOI 10.4103/0377-4929.138737; Singer AJ, 2014, EMERG MED J, V31, P576, DOI 10.1136/emermed-2013-202571; Stevens DL, 2014, CLIN INFECT DIS, V59, P147, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]; Vermandere M, AUTHORS RESPONSE ANT	7	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2018	168	10					JC50	JC50		10.7326/ACPJC-2018-168-10-050	http://dx.doi.org/10.7326/ACPJC-2018-168-10-050			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI3DE	29800426				2023-01-03	WOS:000434250700002
J	Wise, LM; Bodaan, CJ; Stuart, GS; Real, NC; Lateef, Z; Mercer, AA; Riley, CB; Theoret, CL				Wise, Lyn M.; Bodaan, Christa J.; Stuart, Gabriella S.; Real, Nicola C.; Lateef, Zabeen; Mercer, Andrew A.; Riley, Christopher B.; Theoret, Christine L.			Treatment of limb wounds of horses with orf virus IL-10 and VEGF-E accelerates resolution of exuberant granulation tissue, but does not prevent its development	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; AMINO-ACID-SEQUENCE; MICROVASCULAR OCCLUSION; VASCULAR-PERMEABILITY; HYPERTROPHIC SCARS; HYALURONIC-ACID; EQUINE MODEL; SKIN WOUNDS; ANGIOGENESIS; INFLAMMATION	Bandaging of limb wounds in horses leads to formation of exuberant granulation tissue (EGT) that retards healing due to protracted inflammation, aberrant vascularisation and delayed epithelialisation. EGT is not observed if wounds are left undressed or when wounds are on the body. A previous study showed that short-term administration of proteins derived from orf virus dampened inflammation and promoted epithelialisation of open wounds in horses. Here, we investigated the impact of orf virus interleukin-10 and vascular endothelial growth factor-E on the development and resolution of EGT. Excisional wounds were created on the forelimb of four horses, and bandages were maintained until full healing to induce EGT formation. Matching body wounds were created to ensure EGT was limited to the limb, and to differentiate the effects of the viral proteins on normal healing and on EGT formation. Viral proteins or the hydrogel vehicle control were administered topically to site-matched wounds at day 1, with repeat administration at day 8. Wound healing and EGT formation were monitored macroscopically. Wound margin samples were harvested at 2, 7 and 14 days, and at full healing, with histology used to observe epithelialisation, immunofluorescence used to detect inflammatory cells, angiogenesis and cell death, and qPCR to measure expression of genes regulating inflammation and angiogenesis. Limb wounds developed EGT, and exhibited slower healing than body wounds. Viral protein treatment did not accelerate healing at either location nor limit EGT formation in limb wounds. Treatment of limb wounds did however increase epithelialisation and angiogenesis, without dampening inflammatory cell infiltration or gene expression. The healed wounds also had less occlusion and death of blood vessels and fewer epidermal rete ridges following viral protein treatment. These findings indicate that the viral protein treatment does not suppress wound inflammation or EGT formation, but does promote vascular and epidermal repair and EGT resolution.	[Wise, Lyn M.; Stuart, Gabriella S.; Real, Nicola C.; Lateef, Zabeen] Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand; [Wise, Lyn M.; Stuart, Gabriella S.; Real, Nicola C.; Mercer, Andrew A.] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand; [Bodaan, Christa J.; Riley, Christopher B.; Theoret, Christine L.] Massey Univ, Sch Vet Sci, Palmerston North, New Zealand; [Theoret, Christine L.] Univ Montreal, Comparat Tissue Healing Lab, Dept Biomed Vet, Montreal, PQ, Canada	University of Otago; University of Otago; Massey University; Universite de Montreal	Wise, LM (corresponding author), Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand.; Wise, LM (corresponding author), Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand.	lyn.wise@otago.ac.nz	Mercer, Andrew A/G-6635-2015; Theoret, Christine/C-7320-2015	Theoret, Christine/0000-0002-7893-2495; Lateef, Zabeen/0000-0001-5987-7665; Mercer, Andrew/0000-0003-3697-1071; Riley, Christopher/0000-0001-8679-7986; Wise, Lyn/0000-0003-0646-8424	New Zealand Equine Research Foundation [RM 18049]; Health Research Council of New Zealand [13/774]	New Zealand Equine Research Foundation; Health Research Council of New Zealand(Health Research Council of New Zealand)	This study was supported by contract #RM 18049 from the New Zealand Equine Research Foundation (http://www.nzerf.co.nz/) and by contract #13/774 from the Health Research Council of New Zealand (http://www.hrc.govt.nz/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balaji S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124302; Beer H D, 2000, Vitam Horm, V59, P217, DOI 10.1016/S0083-6729(00)59008-6; Bennett JR, 2016, VIRUS RES, V213, P230, DOI 10.1016/j.virusres.2015.12.015; Berry DB, 2003, AM J VET RES, V64, P88, DOI 10.2460/ajvr.2003.64.88; Bodaan CJ, 2016, WOUND REPAIR REGEN, V24, P966, DOI 10.1111/wrr.12488; Bussieres G, 2008, RES VET SCI, V85, P294, DOI 10.1016/j.rvsc.2007.10.011; Celeste CJ, 2013, VET SURG, V42, P147, DOI 10.1111/j.1532-950X.2012.00966.x; Celeste CJ, 2011, WOUND REPAIR REGEN, V19, P89, DOI 10.1111/j.1524-475X.2010.00639.x; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Dart AJ, 2009, AUST VET J, V87, P215, DOI 10.1111/j.1751-0813.2009.00428.x; Deschene K, 2011, WOUND REPAIR REGEN, V19, P250, DOI 10.1111/j.1524-475X.2010.00663.x; DiPietro LA, 2016, J LEUKOCYTE BIOL, V100, P979, DOI 10.1189/jlb.4MR0316-102R; Dubuc V, 2006, CAN J VET RES, V70, P206; Ducharme-Desjarlais M, 2005, AM J VET RES, V66, P1133, DOI 10.2460/ajvr.2005.66.1133; Fronza M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112297; Galeano M, 2003, DIABETOLOGIA, V46, P546, DOI 10.1007/s00125-003-1064-1; Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153; Gordon A, 2008, WOUND REPAIR REGEN, V16, P70, DOI 10.1111/j.1524-475X.2007.00326.x; Hanft J. R., 2008, J WOUND CARE, V17, P30, DOI [DOI 10.12968/JOWC.2008.17.1.27917, 10.12968/jowc.2008.17.1.27917, DOI 10.12968/jowc.2008.17.1.27917]; Hashimoto Ichiro, 2002, Journal of Medical Investigation, V49, P61; Helmbold P, 2006, J INVEST DERMATOL, V126, P1419, DOI 10.1038/sj.jid.5700275; Hosack LW, 2008, BIOMATERIALS, V29, P2336, DOI 10.1016/j.biomaterials.2008.01.033; HOWARD RD, 1993, AM J VET RES, V54, P2150; Hsu KC, 2017, WOUNDS, V29, P154; Johnson KE, 2014, ADV WOUND CARE, V3, P647, DOI 10.1089/wound.2013.0517; Jumper N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172955; Kavasi RM, 2017, FOOD CHEM TOXICOL, V101, P128, DOI 10.1016/j.fct.2017.01.012; Kieran I, 2013, WOUND REPAIR REGEN, V21, P428, DOI 10.1111/wrr.12043; King A, 2014, ADV WOUND CARE, V3, P315, DOI 10.1089/wound.2013.0461; KISCHER CW, 1992, J SUBMICR CYTOL PATH, V24, P281; KNIGHTON DR, 1981, SURGERY, V90, P262; Lawlor KT, 2015, INT J MOL SCI, V16, P28098, DOI 10.3390/ijms161226078; Lee HB, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103048; Lepault E, 2005, WOUND REPAIR REGEN, V13, P520, DOI 10.1111/j.1067-1927.2005.00073.x; Limandjaja GC, 2017, BRIT J DERMATOL, V176, P116, DOI 10.1111/bjd.14844; Litwiniuk M, 2016, WOUNDS, V28, P78; Ma XY, 2015, INT J MOL MED, V35, P1246, DOI 10.3892/ijmm.2015.2135; Mills Stuart J, 2013, Cells, V2, P621, DOI 10.3390/cells2030621; O'Brien L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003826.pub3; Ogawa R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030606; Paquet-Fifield S, 2009, J CLIN INVEST, V119, P2795, DOI 10.1172/JCI38535; Peranteau WH, 2008, J INVEST DERMATOL, V128, P1852, DOI 10.1038/sj.jid.5701232; Petrey AC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00101; Roth A, 2005, ARTHRITIS RES THER, V7, pR677, DOI 10.1186/ar1725; Serban MA, 2008, CURR PROTOC CELL BIO; SHAKESPEARE V, 1991, BRIT J PLAST SURG, V44, P219, DOI 10.1016/0007-1226(91)90131-3; SMITH JE, 1979, AM J PHYSIOL, V236, pH725, DOI 10.1152/ajpheart.1979.236.5.H725; Sorensen MA, 2014, WOUND REPAIR REGEN, V22, P647, DOI 10.1111/wrr.12207; Sullivan TP, 2001, WOUND REPAIR REGEN, V9, P66, DOI 10.1046/j.1524-475x.2001.00066.x; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; Theoret C, 2017, EQUINE WOUND MANAGEM, P550; Theoret CL, 2016, NEW ZEAL VET J, V64, P90, DOI 10.1080/00480169.2015.1091396; Theoret CL, 2013, VET SURG, V42, P783, DOI 10.1111/j.1532-950X.2013.12055.x; Theoret CL, 2013, WOUND REPAIR REGEN, V21, P365, DOI 10.1111/wrr.12018; Theoret CL, 2002, VET SURG, V31, P266, DOI 10.1053/jvet.2002.32394; Ud-Din S, 2014, EXP DERMATOL, V23, P615, DOI 10.1111/exd.12457; Wakelin KA, 2016, VET DERMATOL, V27, P434, DOI 10.1111/vde.12370; Wietecha MS, 2013, CURR TOP MICROBIOL, V367, P3, DOI 10.1007/82_2012_287; Wilmink JM, 1999, EQUINE VET J, V31, P61, DOI 10.1111/j.2042-3306.1999.tb03792.x; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200; Wise LM, 2007, VIRUS RES, V128, P115, DOI 10.1016/j.virusres.2007.04.018; Wise LM, 2018, ADV WOUND CARE, V7, P283, DOI 10.1089/wound.2016.0721; Wise LM, 2014, WOUND REPAIR REGEN, V22, P356, DOI 10.1111/wrr.12169; Wise LM, 2012, CELL MICROBIOL, V14, P1376, DOI 10.1111/j.1462-5822.2012.01802.x; Yates CC, 2010, AM J PATHOL, V176, P1743, DOI 10.2353/ajpath.2010.090564; Zhang Qunzhou, 2006, Exp Cell Res, V312, P145, DOI 10.1016/j.yexcr.2005.10.006; Zheng Y, 2007, ARTERIOSCL THROM VAS, V27, P503, DOI 10.1161/01.ATV.0000256459.06671.3c; Zheng YJ, 2006, ARTERIOSCL THROM VAS, V26, P2019, DOI 10.1161/01.ATV.0000233336.53574.a1	69	17	17	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2018	13	5							e0197223	10.1371/journal.pone.0197223	http://dx.doi.org/10.1371/journal.pone.0197223			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF7AA	29763436	Green Published, Green Submitted, gold			2023-01-03	WOS:000432118800030
J	Abegaz, TM; Birru, EM; Mekonnen, GB				Abegaz, Tadesse Melaku; Birru, Eshetie Melese; Mekonnen, Gashaw Binega			Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria	PLOS ONE			English	Article							CONVERTING-ENZYME-INHIBITORS; VENTRICULAR SYSTOLIC DYSFUNCTION; RANDOMIZED CONTROLLED-TRIALS; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE PATIENTS; ADVERSE DRUG-REACTIONS; ELDERLY-PATIENTS; STOPP/START CRITERIA; OLDER-ADULTS; STROKE PREVENTION	Background There was a paucity of data on the magnitude of potentially inappropriate prescriptions (PIPs) among Ethiopian elderly cardiovascular patients. Objective The aim of this study was to assess PIPs and associated factors in the elderly population with cardiovascular disorders using the START/STOPP screening criteria. Methods A hospital-based cross-sectional study was conducted at medical wards of a teaching hospital in Ethiopia from 1 December 2016-30 May 2017. Included patients were hospitalized elderly patients aged 65 years or older with cardiovascular disorders; their medications were evaluated using the START/STOPP screening criteria from admission to discharge. Multivariable logistic regression was applied to identify factors associated with inappropriate medications. One Way Analysis Of Variance (ANOVA) was carried out to test significant differences on the number of PIPs per individual diagnosis. Results Two hundred thirty-nine patients were included in the analysis. More-than a third of the patients were diagnosed with heart failure, 88 (36.82%). A total of 221 PIPs were identified in 147 patients, resulting in PIP prevalence of 61.5% in the elderly population. Of the total number of PIPs, occurrence of one, two and three PIPs accounted for 83 (56.4%), 52 (35.4%), and 12(8.2%) respectively. One way ANOVA test showed significant differences on the mean number of PIPs per individual diagnosis (f = 5.718, p<0.001). Angiotensin Converting Enzyme Inhibitors (ACEIs) were the most common inappropriately prescribed medications, 32(14.5%). Hospital stay, AOR: 1.086 (1.016-1.160), number of medications at discharge, AOR: 1.924 (1.217-3.041) and the presence of co-morbidities, AOR: 3.127 (1.706-5.733) increased the likelihood of PIP. Conclusion Approximately, two-thirds of elderly cardiovascular patients encountered potentially inappropriate prescriptions. ACEIs were the most commonly mis-prescribed medications. Longer hospital stay, presence of comorbidities and prescription of large number of medications at discharge have been correlated with the occurrence of inappropriate medication. It is essential to evaluate patients' medications during hospital stay using the STOPP and START tool to reduce PIPs.	[Abegaz, Tadesse Melaku; Mekonnen, Gashaw Binega] Univ Gondar, Sch Pharm, Dept Clin Pharm, Coll Med & Hlth Sci, Gondar, Ethiopia; [Birru, Eshetie Melese] Univ Gondar, Sch Pharm, Dept Pharmacol, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar	Abegaz, TM (corresponding author), Univ Gondar, Sch Pharm, Dept Clin Pharm, Coll Med & Hlth Sci, Gondar, Ethiopia.	abegaztadesse981@gmail.com	mekonnen, Gashaw Binega/AAO-3178-2020	mekonnen, Gashaw Binega/0000-0002-2650-8668				Abegaz TM, EPIDEMIOLOGY TARGET; Ahmed A, 2002, SOUTHERN MED J, V95, P703; Ahmed A, 2002, J GERONTOL A-BIOL, V57, pM138, DOI 10.1093/gerona/57.2.M138; Akao M, 2014, CIRC J, V78, P2166, DOI 10.1253/circj.CJ-14-0344; Ambrosio G, 2011, HEART, V97, P209, DOI 10.1136/hrt.2010.207365; Arif SA, 2010, ANN PHARMACOTHER, V44, P1604, DOI 10.1345/aph.1P128; Bajorek B., 2011, THERAPEUTIC ADV DRUG; Bangalore S, 2007, J AM COLL CARDIOL, V50, P563, DOI 10.1016/j.jacc.2007.04.060; Bauersachs J, 2003, Minerva Cardioangiol, V51, P155; Bejan-Angoulvant T, 2010, J HYPERTENS, V28, P1366, DOI 10.1097/HJH.0b013e328339f9c5; BRUGTS JJ, 2009, BMJ-BRIT MED J, V338, DOI DOI 10.1136/BMJ.B2376; Bucci C, 2008, CAN J CARDIOL, V24, P629, DOI 10.1016/S0828-282X(08)70651-2; Chang CB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094350; Cheng JWM, 2009, AM J GERIATR PHARMAC, V7, P233, DOI 10.1016/j.amjopharm.2009.10.001; Chiatti C, 2012, DRUG SAFETY, V35, P73, DOI 10.1007/BF03319105; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Dalleur O, 2014, DRUG AGING, V31, P291, DOI 10.1007/s40266-014-0157-5; Danchin N, 2006, ARCH INTERN MED, V166, P787, DOI 10.1001/archinte.166.7.787; Desai AS, 2007, J AM COLL CARDIOL, V50, P1959, DOI 10.1016/j.jacc.2007.07.067; Flaker GC, 2006, AM HEART J, V152, P967, DOI 10.1016/j.ahj.2006.06.024; Fleg JL, 2011, NAT REV CARDIOL, V8, P13, DOI 10.1038/nrcardio.2010.162; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gallagher PF, 2008, AGE AGEING, V37, P96, DOI 10.1093/ageing/afm116; Galvin R, 2014, EUR J CLIN PHARMACOL, V70, P599, DOI 10.1007/s00228-014-1651-8; Getachew H, 2016, CLIN INTERV AGING, V11, P819, DOI 10.2147/CIA.S107394; Hamano J, 2014, J GEN FAM MED, V15, P117, DOI 10.14442/general.15.117; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Hedna K, 2015, EUR J CLIN PHARMACOL, V71, P1525, DOI 10.1007/s00228-015-1950-8; Holmes DR, 2009, J AM COLL CARDIOL, V54, P95, DOI 10.1016/j.jacc.2009.03.044; Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064; Knijff-Dutmer EAJ, 2003, QJM-INT J MED, V96, P513, DOI 10.1093/qjmed/hcg090; Lahoud R, 2012, AM J CARDIOL, V109, P159, DOI 10.1016/j.amjcard.2011.08.024; Lang PO, 2010, AGE AGEING, V39, P373, DOI 10.1093/ageing/afq031; Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x; Mills E, 2010, QJM; Misganaw A, 2014, J HEALTH POPUL NUTR, V32, P1; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082359; O'Connor M., 2013, THESIS; O'Connor MN, 2012, DRUG AGING, V29, P437, DOI 10.2165/11632610-000000000-00000; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Onder G, 2005, EUR J CLIN PHARMACOL, V61, P453, DOI 10.1007/s00228-005-0928-3; Onder G, 2013, AGE AGEING, V42, P284, DOI 10.1093/ageing/aft038; Papademetriou V, 2004, J AM COLL CARDIOL, V44, P1175, DOI 10.1016/j.jacc.2004.06.034; Poggio R, 2010, POSTGRAD MED J, V86, P136, DOI 10.1136/pgmj.2008.072058; Marquez PHP, 2017, DRUG AGING, V34, P453, DOI 10.1007/s40266-017-0452-z; Rancourt Carol, 2004, BMC Geriatr, V4, P9, DOI 10.1186/1471-2318-4-9; Rasmussen JN, 2007, JAMA-J AM MED ASSOC, V297, P177, DOI 10.1001/jama.297.2.177; Rollason V, 2003, DRUG AGING, V20, P817, DOI 10.2165/00002512-200320110-00003; San-Jose A, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0038-8; Scott I, 2009, INTERN MED J, V39, P347, DOI 10.1111/j.1445-5994.2009.01966.x; Sehgal Vishal, 2013, J Family Med Prim Care, V2, P194, DOI 10.4103/2249-4863.117423; Shah Kartik Nitinbhai, 2016, J Basic Clin Pharm, V7, P110, DOI 10.4103/0976-0105.189434; Sonnerstam E, 2016, DRUG AGING, V33, P889, DOI 10.1007/s40266-016-0408-8; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Tangeman HJ, 2003, ANN PHARMACOTHER, V37, P701, DOI 10.1345/aph.1C286; Tosato M, 2014, AGE AGEING, V43, P767, DOI 10.1093/ageing/afu029; Williams B, 2004, BMJ-BRIT MED J, V328, P634, DOI 10.1136/bmj.328.7440.634; Wright SP, 2003, EUR J HEART FAIL, V5, P201, DOI 10.1016/S1388-9842(02)00201-5; Yang P, 2016, THER CLIN RISK MANAG, V12, P1517, DOI 10.2147/TCRM.S116789; Yeomans ND, 2011, EXPERT REV GASTROENT, V5, P447, DOI [10.1586/egh.11.42, 10.1586/EGH.11.42]	61	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2018	13	5							e0195949	10.1371/journal.pone.0195949	http://dx.doi.org/10.1371/journal.pone.0195949			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE6AF	29723249	Green Published, gold, Green Submitted			2023-01-03	WOS:000431305100011
J	Lewis, G				Lewis, Glyn			Transcranial magnetic stimulation for depression	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSION; EFFICACY; THERAPY; SAFETY; CARE		[Lewis, Glyn] UCL, Div Psychiat, London W1T 7NF, England	University of London; University College London	Lewis, G (corresponding author), UCL, Div Psychiat, London W1T 7NF, England.	glyn.lewis@ucl.ac.uk	Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245				Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2; Button KS, 2015, PSYCHOL MED, V45, P3269, DOI 10.1017/S0033291715001270; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Herwig U, 2007, BRIT J PSYCHIAT, V191, P441, DOI 10.1192/bjp.bp.106.034371; Hovington CL, 2013, ANN MED, V45, P308, DOI 10.3109/07853890.2013.783993; Levkovitz Y, 2015, WORLD PSYCHIATRY, V14, P64, DOI 10.1002/wps.20199; Liston C, 2014, BIOL PSYCHIAT, V76, P517, DOI 10.1016/j.biopsych.2014.01.023; National Institute for Health and Care Excellence, 2004, DEPR MAN DEPR PRIM S; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Wiles N, 2013, LANCET, V381, P375, DOI 10.1016/S0140-6736(12)61552-9	13	5	7	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 28	2018	391	10131					1639	1640		10.1016/S0140-6736(18)30863-8	http://dx.doi.org/10.1016/S0140-6736(18)30863-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE7NC	29726325				2023-01-03	WOS:000431419100005
J	Bianchi, CM; Huneau, JF; Barbillon, P; Lluch, A; Egnell, M; Fouillet, H; Verger, EO; Mariotti, F				Bianchi, Clelia M.; Huneau, Jean-Francois; Barbillon, Pierre; Lluch, Anne; Egnell, Manon; Fouillet, Helene; Verger, Eric O.; Mariotti, Francois			A clear trade-off exists between the theoretical efficiency and acceptability of dietary changes that improve nutrient adequacy during early pregnancy in French women: Combined data from simulated changes modeling and online assessment survey	PLOS ONE			English	Article							NUTRITION AWARENESS; PHYSICAL-ACTIVITY; RISK-FACTORS; ADULTS; FOOD; INTERVENTION; FEASIBILITY; ENERGY	Background During pregnancy, the diet of a mother-to-be should be adapted to meet increases in nutrient requirements. We analyzed the theoretical efficiency and acceptability of different types of tailored dietary changes for pregnant women. Methods The nutrient adequacy of the diet was evaluated using the PANDiet score, by comparing the nutrient intakes of 344 non-pregnant premenopausal women (18-44y) with dietary reference intakes for the first trimester of pregnancy. Simulations were performed to evaluate the theoretical efficiency of three types of ten successive tailored dietary changes in improving nutrient adequacy, with graded difficulty in implementation. The acceptability (declared intention to use in the diet) of most efficient dietary changes was evaluated during an online randomized study including 115 French pregnant women (22-41y). Results Modifying the amount consumed of foods (type-1) did not modify the food repertoire and resulted in the smallest theoretical efficiency (increase in the PANDiet score of 9.8 +/- 0.2 points), but changes were the most acceptable (probability of the intention to use: 0.30-0.78). Conversely, replacing food items by items from the same group or eaten at the same time (type-3) broadened the food repertoire (3.6 +/- 1.3 food subgroups added) and resulted in the greatest theoretical efficiency (+23.9 +/- 0.3) but changes were the least acceptable (0.07-0-23). Replacing food items within the same subgroup (type-2) slightly broadened the food repertoire (+8.0 +/- 1.3 foods) and resulted in moderate theoretical efficiency (+14.8 +/- 0.2) and intermediate acceptability (0.11-0.35). Conclusion A clear trade-off exists between the theoretical efficiency and acceptability of dietary changes, with a graded broadening of the food repertoire.	[Bianchi, Clelia M.; Huneau, Jean-Francois; Egnell, Manon; Fouillet, Helene; Mariotti, Francois] Univ Paris Saclay, INRA, AgroParisTech, UMR PNCA, Paris, France; [Barbillon, Pierre] Univ Paris Saclay, INRA, AgroParisTech, UMR MIA, Paris, France; [Lluch, Anne] Danone Nutr Res, Ctr Daniel Carasso, Global Nutr Dept, Palaiseau, France; [Verger, Eric O.] Univ Montpellier, SupAgro, IRD, NUTRIPASS, Montpellier, France	AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Danone Nutricia; Institut Agro; Montpellier SupAgro; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Mariotti, F (corresponding author), Univ Paris Saclay, INRA, AgroParisTech, UMR PNCA, Paris, France.	francois.mariotti@agroparistech.fr	Verger, Eric/J-9163-2016; Fouillet, Helene/K-7314-2012; Barbillon, Pierre/O-7790-2019; Mariotti, François/F-9651-2017	Verger, Eric/0000-0002-8689-8290; Fouillet, Helene/0000-0003-3932-251X; Barbillon, Pierre/0000-0002-7766-7693; Mariotti, François/0000-0002-4516-3853	Fonds Francais Alimentation Sante; Danone Nutricia Research	Fonds Francais Alimentation Sante; Danone Nutricia Research(Danone Nutricia)	This study was carried out within the framework of the ECAP project (http://alimentation-sante.org/aap2013-projet2-2/) supported by grants from the Fonds Francais Alimentation & Sante (FFAS: http://alimentation-sante.org) and from Danone Nutricia Research. The Fonds Francais Alimentation & Sante (FFAS) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One of the authors of this manuscript is A Lluch who is employed by Danone Nutricia Research. A Lluch contributed to writing the manuscript, offered critical comments, read and approved the final manuscript.	Abu-Saad K, 2010, EPIDEMIOL REV, V32, P5, DOI 10.1093/epirev/mxq001; Afssa (Agence Francaise de Securite Sanitaire des Aliments), 2001, APP NUTR CONS POP FR; Arnault N, 2005, TABLE COMPOSITION AL; Ax E, 2016, BRIT J NUTR, V115, P95, DOI 10.1017/S0007114515004110; Barker DJP, 2003, EUR J EPIDEMIOL, V18, P733, DOI 10.1023/A:1025388901248; Bellisle F, 2014, BRIT J NUTR, V112, P1674, DOI 10.1017/S0007114514002670; Bernard JY, 2013, J NUTR, V143, P1481, DOI 10.3945/jn.113.178640; Bianchi CM, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1078-6; Bianchi CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149858; Black AE, 2000, INT J OBESITY, V24, P1119, DOI 10.1038/sj.ijo.0801376; Blumfield ML, 2013, NUTR REV, V71, P118, DOI 10.1111/nure.12003; Blumfield ML, 2012, NUTR REV, V70, P322, DOI 10.1111/j.1753-4887.2012.00481.x; Bresson J, 2001, APPORTS NUTR CONSEIL; Brug J, 1999, PATIENT EDUC COUNS, V36, P145, DOI 10.1016/S0738-3991(98)00131-1; Caron P, 2006, ANN ENDOCRINOL-PARIS, V67, P281, DOI 10.1016/S0003-4266(06)72599-9; Castetbon K, 2009, BRIT J NUTR, V102, P733, DOI 10.1017/S0007114509274745; de Vries H, 1999, PATIENT EDUC COUNS, V36, P99; De-Regil LM, 2016, J NUTR; Devine CM, 2000, SOC SCI MED, V50, P567, DOI 10.1016/S0277-9536(99)00314-7; Dodd JM, 2014, BMC MED, pcited 2019 Jun 18 12; Dubuisson C, 2010, BRIT J NUTR, V103, P1035, DOI 10.1017/S0007114509992625; Gazan R., 2016, BR J NUTR, P1; Hawkins M, 2015, DIABETIC MED, V32, P108, DOI 10.1111/dme.12601; King JC, 2016, J NUTR S, VS1, pS8; Krebs P, 2010, PREV MED, V51, P214, DOI 10.1016/j.ypmed.2010.06.004; Lairon D, 2005, AM J CLIN NUTR, V82, P1185, DOI 10.1093/ajcn/82.6.1185; Larque E, 2012, BRIT J NUTR, V107, pS77, DOI 10.1017/S0007114512001481; Maillot M, 2009, J NUTR, V139, P1721, DOI 10.3945/jn.109.107318; Meldrum SJ, 2012, PROSTAG LEUKOTR ESS, V86, P233, DOI 10.1016/j.plefa.2012.03.006; Pouchieu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070733; Refsum H, 2001, BRIT J NUTR, V85, pS109, DOI 10.1079/BJN2000302; Shay CM, 2012, AM J CLIN NUTR, V96, P483, DOI 10.3945/ajcn.111.025056; Szwajcer E, 2012, FAM PRACT, V29, pi82, DOI 10.1093/fampra/cmr107; Szwajcer EM, 2007, EUR J OBSTET GYN R B, V135, P58, DOI 10.1016/j.ejogrb.2006.11.012; Tulchinsky TH, 2010, PUBLIC HEALTH REV, V32, P243, DOI 10.1007/BF03391600; USDA, 2003, DIET NUTR PREV CHRON; Vandelanotte C, 2004, HEALTH PROMOT INT, V19, P463, DOI 10.1093/heapro/dah408; Verger EO, 2014, J NUTR, V144, P929, DOI 10.3945/jn.113.188284; Verger EO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042155; Weinrich N.K., 2011, HANDS ON SOCIAL MARK, V2nd ed.; Whitaker KM, 2016, MIDWIFERY, V34, P211, DOI 10.1016/j.midw.2015.11.005; Willett WC, 2013, ANNU REV PUBL HEALTH, V34, P77, DOI 10.1146/annurev-publhealth-031811-124646	43	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2018	13	4							e0194764	10.1371/journal.pone.0194764	http://dx.doi.org/10.1371/journal.pone.0194764			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GC4GL	29641596	Green Published, gold, Green Submitted			2023-01-03	WOS:000429742900045
J	Olson, CA; Vuong, HE; Yano, JM; Liang, QXY; Nusbaum, DJ; Hsiao, EY				Olson, Christine A.; Vuong, Helen E.; Yano, Jessica M.; Liang, Qingxing Y.; Nusbaum, David J.; Hsiao, Elaine Y.			The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet	CELL			English	Article							AKKERMANSIA-MUCINIPHILA; AMINO-ACIDS; METABOLISM; SPECTROSCOPY; DIVERSITY; INCREASES; GLUTAMATE; NUTRIENT; MODEL; GABA	The ketogenic diet (KD) is used to treat refractory epilepsy, but the mechanisms underlying its neuroprotective effects remain unclear. Here, we show that the gut microbiota is altered by the KD and required for protection against acute electrically induced seizures and spontaneous tonic-clonic seizures in two mousemodels. Mice treated with antibiotics or reared germ free are resistant to KD-mediated seizure protection. Enrichment of, and gnotobiotic co-colonization with, KD-associated Akkermansia and Parabacteroides restores seizure protection. Moreover, transplantation of the KD gut microbiota and treatment with Akkermansia and Parabacteroides each confer seizure protection to mice fed a control diet. Alterations in colonic lumenal, serum, and hippocampal metabolomic profiles correlate with seizure protection, including reductions in systemic gammaglutamylated amino acids and elevated hippocampal GABA/glutamate levels. Bacterial crossfeeding decreases gamma-glutamyltranspeptidase activity, and inhibiting gamma-glutamylation promotes seizure protection in vivo. Overall, this study reveals that the gut microbiota modulates host metabolism and seizure susceptibility in mice.	[Olson, Christine A.; Vuong, Helen E.; Yano, Jessica M.; Liang, Qingxing Y.; Nusbaum, David J.; Hsiao, Elaine Y.] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Hsiao, EY (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA.	ehsiao@ucla.edu	Olson, Christine/ABB-8296-2021	Olson, Christine/0000-0002-5382-1393; Nusbaum, David/0000-0001-6605-6187; Vuong, Helen/0000-0001-7837-8239	UCLA Department of Integrative Biology & Physiology and Division of Life Sciences; Alfred P. Sloan Foundation Fellowship [FG-201606433]; Army Research Office Multidisciplinary University Research Initiative [W911NF-17-1-0402]; Mallinckrodt Foundation [20181433]; NIH Ruth L. Kirschstein Award [T32GM065823]; UPLIFT: UCLA Postdoctoral Longitudinal Investment in Faculty Award [K12GM106996]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM106996, T32GM065823] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD017924] Funding Source: NIH RePORTER	UCLA Department of Integrative Biology & Physiology and Division of Life Sciences; Alfred P. Sloan Foundation Fellowship(Alfred P. Sloan Foundation); Army Research Office Multidisciplinary University Research Initiative(MURI); Mallinckrodt Foundation; NIH Ruth L. Kirschstein Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UPLIFT: UCLA Postdoctoral Longitudinal Investment in Faculty Award; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors acknowledge Julianne McGinn and Tomiko Rendon for generating and caring for the germ-free animals; Kristie Yu, Sandy Wong, and Gauri Shastri for assistance with initial experiments and data analysis; Thomas Fung, Geoffrey Pronovost, Gregory Donaldson, Xia Yang, Carlos Cepeda, and Kim McDowell for helpful advice; and Bruce Tempel and Marie Francoise-Chesselet for sharing mice and reagents. This work was supported by funds from UCLA Department of Integrative Biology & Physiology and Division of Life Sciences (to E.Y.H.), Alfred P. Sloan Foundation Fellowship (FG-201606433 to E.Y.H.), Army Research Office Multidisciplinary University Research Initiative (W911NF-17-1-0402 to E.Y.H.), Mallinckrodt Foundation (20181433 to E.Y.H.), NIH Ruth L. Kirschstein Award (T32GM065823 to C.A.O.), and UPLIFT: UCLA Postdoctoral Longitudinal Investment in Faculty Award (K12GM106996 to H.E.V.).	Baraban SC, 2009, P NATL ACAD SCI USA, V106, P15472, DOI 10.1073/pnas.0900141106; Barton ME, 2001, EPILEPSY RES, V47, P217, DOI 10.1016/S0920-1211(01)00302-3; Beloosesky Y, 2000, AM J MED SCI, V319, P338, DOI 10.1097/00000441-200005000-00012; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Buffington SA, 2016, CELL, V165, P1762, DOI 10.1016/j.cell.2016.06.001; Calderon N, 2017, NEUROSCI LETT, V642, P158, DOI 10.1016/j.neulet.2017.02.014; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Castellano I, 2012, CELL MOL LIFE SCI, V69, P3381, DOI 10.1007/s00018-012-0988-3; Cooper AJL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6020016; Crawford PA, 2009, P NATL ACAD SCI USA, V106, P11276, DOI 10.1073/pnas.0902366106; Dahlin M, 2005, EPILEPSY RES, V64, P115, DOI 10.1016/j.eplepsyres.2005.03.008; Dao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Derrien M, 2008, APPL ENVIRON MICROB, V74, P1646, DOI 10.1128/AEM.01226-07; Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155; Dutton SBB, 2011, EPILEPSIA, V52, P2050, DOI 10.1111/j.1528-1167.2011.03211.x; Erakovic V, 2001, EPILEPSIA, V42, P181, DOI 10.1046/j.1528-1157.2001.4220181.x; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; EWEN LM, 1973, AM J CLIN PATHOL, V59, P2; Fenoglio-Simeone KA, 2009, EPILEPSIA, V50, P2027, DOI 10.1111/j.1528-1167.2009.02163.x; Flynn JM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005846; Freeman John M, 2010, Adv Pediatr, V57, P315, DOI 10.1016/j.yapd.2010.08.003; Hartman AL, 2010, EPILEPSIA, V51, P1395, DOI 10.1111/j.1528-1167.2010.02577.x; Hornik CP, 2016, J PEDIATR-US, V178, P125, DOI 10.1016/j.jpeds.2016.07.011; Janik R, 2016, NEUROIMAGE, V125, P988, DOI 10.1016/j.neuroimage.2015.11.018; KIMBALL AW, 1957, RADIAT RES, V7, P1, DOI 10.2307/3570549; Klein MS, 2016, J PROTEOME RES, V15, P1143, DOI 10.1021/acs.jproteome.5b01025; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Manz W, 1996, MICROBIOL-SGM, V142, P1097, DOI 10.1099/13500872-142-5-1097; Newell C, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0099-3; Reikvam DH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017996; Remely M, 2015, WIEN KLIN WOCHENSCHR, V127, P394, DOI 10.1007/s00508-015-0755-1; Rogawski MA, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a022780; Samala R, 2008, EPILEPSY RES, V81, P119, DOI 10.1016/j.eplepsyres.2008.05.001; Sariego-Jamardo A, 2015, PEDIATR NEUROL, V53, P422, DOI 10.1016/j.pediatrneurol.2015.07.013; Sato SM, 2016, ELIFE, V5, DOI [10.7554/eLife.12917, 10.7554/eLife.19109]; Simeone KA, 2016, EPILEPSIA, V57, pE178, DOI 10.1111/epi.13444; Smith MI, 2013, SCIENCE, V339, P548, DOI 10.1126/science.1229000; Smith QR, 2000, J NUTR, V130, p1016S, DOI 10.1093/jn/130.4.1016S; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Stafstrom CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00059; Sutter R, 2015, NEUROLOGY, V85, P1332, DOI 10.1212/WNL.0000000000002023; van der Stel AX, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00567; Vuong HE, 2017, ANNU REV NEUROSCI, V40, P21, DOI 10.1146/annurev-neuro-072116-031347; Wang ZYJ, 2003, MAGNET RESON MED, V49, P615, DOI 10.1002/mrm.10429; Yudkoff M, 2001, J NEUROSCI RES, V66, P931, DOI 10.1002/jnr.10083; Zuberi SM, 1999, BRAIN, V122, P817, DOI 10.1093/brain/122.5.817	50	375	400	23	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	2018	173	7					1728	+	1741.e13	10.1016/j.cell.2018.04.027	http://dx.doi.org/10.1016/j.cell.2018.04.027			27	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL3CC	29804833	Green Accepted, Bronze			2023-01-03	WOS:000437004000020
